<SEC-DOCUMENT>0001104659-22-032475.txt : 20220310
<SEC-HEADER>0001104659-22-032475.hdr.sgml : 20220310
<ACCEPTANCE-DATETIME>20220310164439
ACCESSION NUMBER:		0001104659-22-032475
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		89
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220310
DATE AS OF CHANGE:		20220310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Astria Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001454789
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37467
		FILM NUMBER:		22729668

	BUSINESS ADDRESS:	
		STREET 1:		100 HIGH STREET
		STREET 2:		28TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
		BUSINESS PHONE:		617-349-1971

	MAIL ADDRESS:	
		STREET 1:		100 HIGH STREET
		STREET 2:		28TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CATABASIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20090127
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>atxs-20211231x10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8042.36810 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/10/2022 9:03:11 PM -->
      <!-- iXBRL Library version: 1.0.8042.36816 -->
      <!-- iXBRL Service Job ID: e630cc02-3e1b-49c9-a16c-87f5a4fa8205 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:atxs="http://astria.com/20211231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" xs:nil="true" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_juG4ut0hekGfoUSdZJmpGw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" xs:nil="true" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" name="us-gaap:CommitmentsAndContingencies" id="Hidden_tc6QGG0HtUmKZEu4MT14KA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" xs:nil="true" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" name="us-gaap:PreferredStockValue" id="Hidden_5kAH2yohTU6HuCucgbOHZw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" xs:nil="true" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" name="us-gaap:PreferredStockValue" id="Hidden_M6aGybrk0kCZ6fzfhotz1g"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" xs:nil="true" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" id="Hidden_Z8KsiGkTJUyr-8iQxbhdkw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" xs:nil="true" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" id="Hidden_0JRGWDpqhUmL33rExGbsHA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_8asCuAWAkUShdS5MbDUCCQ">24.58</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" sign="-" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_yKFj6vewikWA4NmcagA9rg">12.20</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_JnG-Fi9RzU2i2IWCBQbMGQ">8925173</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_Aew1gIv4ckO-S3lSCxJoeA">3058578</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_0h6_9E_LE0OXUd1tw9ln2A">13016955</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_EaPdklywJU--bluP72dbOw">31455</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_BLlqcGRUw0yW9_W_BgHGVA">3347386</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_28JKwy45H0aXmXOk1zkCAQ">13016955</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:EntityCentralIndexKey" id="Tc_CDu0k5ax3kKqXcnnJrfoCA_2_1">0001454789</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:DocumentFiscalYearFocus" id="Tc_86DV3SgFiEWJnuiyotif0g_3_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:DocumentFiscalPeriodFocus" id="Tc__45avv7UGUqaWv-qS9pxxQ_4_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:AmendmentFlag" id="Tc_2W1VK_W7vE-aL1bEraS3kQ_5_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_11_30_2019_KyDCpKfGVkmxJYefd9nrVQ" decimals="-5" name="us-gaap:OperatingLeaseLiability" id="Hidden_HFiUTo3gw02FAUw2F3J6Qg">1700000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" id="Hidden_Q8KxfYwEQ06Q-XDWVRjAVA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" id="Hidden_h7pU9TMEukuhqRukKT1nSg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" id="Hidden_Spms05oTPUG_D656yLZ_hg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_Bn4szbYkh0yrrFWsgmb0bw" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_olLejnU3yUWT4pjn9P3eRQ">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_8_19_2021_To_8_19_2021_8Dfl9PCzRU-S7OwH_sgU5g" name="us-gaap:StockholdersEquityNoteStockSplit" id="Hidden_dLw7GAoMFEC93XKwCZhThQ">0.1667</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_CW-XStj-10mcG6SC9sfguw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_POM-32zJNUucIU9QC11d1A">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="atxs-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_u1VQyUC_pkKu65bhuNk4jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_sf3s1jFkZ0aGtBYOQC3ukQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_atxs_WeightedAverageExpectedVolatilityMember_nIDhOwmhF0mlBky65Ot7_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">atxs:WeightedAverageExpectedVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_BS6PVDaxDkyvam1jdK_ZbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_Ts_1LVNTNk69yxGtcPF9Zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_atxs_WeightedAverageExpectedVolatilityMember_RP6DX7K3TUWlKsT4sun6pQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">atxs:WeightedAverageExpectedVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_Ulx_E0qOrUKkre8jvxb7rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_StatementScenarioAxis_atxs_WarrantsAssumedInMergerMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_iJkNUaamoUSxxm1X7f0uqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">atxs:WarrantsAssumedInMergerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_StatementScenarioAxis_atxs_SharesIssuedInMergerMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_VaYAgt65X062dsLicMLsSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">atxs:SharesIssuedInMergerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_StatementScenarioAxis_atxs_SharesIssuedIn2021FinancingMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_r3IXNsELnUOmAyLBZVInLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">atxs:SharesIssuedIn2021FinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_30_2020_To_1_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_UnderwritingPublicOffering2020Member__qJWTgwHU0y6BreieN-tEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:UnderwritingPublicOffering2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-30</xbrli:startDate><xbrli:endDate>2020-01-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_30_2020_To_1_30_2020_srt_CounterpartyNameAxis_atxs_OppenheimerCo.IncMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_UnderwritingPublicOffering2020Member_ps7Jmy_qxEGruAZux02SWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atxs:OppenheimerCo.IncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:UnderwritingPublicOffering2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-30</xbrli:startDate><xbrli:endDate>2020-01-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u8JhPH-1RUqa-roQlJ-Ngw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_19_2021_To_8_19_2021_8Dfl9PCzRU-S7OwH_sgU5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-19</xbrli:startDate><xbrli:endDate>2021-08-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_m9ULvgi4IE-US35BpN7rWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__NFtVVnk7EGtmJVTvFdECA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VJIc1ZjzpUal4qapZMqgqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kD4Wl26uSEaueUAirWvXnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_N1dQ51RP6UuuD2JViSzVmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3YdF7rgdCkqzCRGFJN0xrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember_GQ8u_bZ2vk2rapCqnMoYiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_UnderwritingPublicOffering2020Member_c40JqESgcEiBixt1r0S-6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:UnderwritingPublicOffering2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Xk2KOEZoqU-rq0ONLV8kug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dRehDxBmQEyeX74Fi2n2Og"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember__jh8k2B4zk-VJ3ifpBRqMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pMusOm4pFUy12JHZQXtkNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_o2nWgMXB4EmLCnwUmgGn8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_30_2020_To_1_30_2020_us-gaap_SubsidiarySaleOfStockAxis_atxs_UnderwritingPublicOffering2020Member_AJ3obUkYbkW3WPPRYNkRqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:UnderwritingPublicOffering2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-30</xbrli:startDate><xbrli:endDate>2020-01-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_NonredeemablePreferredStockMember_h2GakjGikkGGLKMSx_TpBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonredeemablePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_NonredeemablePreferredStockMember_c0KfkkESqEyr8mt4ZudgVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonredeemablePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_Bn4szbYkh0yrrFWsgmb0bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember_a9otGjsdyEWhX3Pzq_Pbxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">atxs:AgreementAndPlanOfMergerQuellisBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_jf1HFRlRWE2wdm5GzthVPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_atxs_PublicOfferingCommonStockAndWarrantsMember_S4V25J-LO0yw2cDuPVRuDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:PublicOfferingCommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember_FsZU2jcCL0ag97BH1_5Ixw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxPeriodAxis_atxs_TaxYears2023Through2039Member_PESuIbi88Em2aHygNgW-mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">atxs:TaxYears2023Through2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_atxs_TaxYears2023Through2039Member_nyPtDfbQzUmCkbPiwwfF7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">atxs:TaxYears2023Through2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_atxs_IndefiniteTaxYearsMember_lPRNGMy2XEaPTJLtd05Mcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">atxs:IndefiniteTaxYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_5XqYaukrUUaJdZ71ko0png"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_elNRkz91iE-s8vhvuVnSvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_28_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dDqegR-RH0S_9dr4Q4C-Mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2019_KyDCpKfGVkmxJYefd9nrVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xuUxeI6afE2LnVQerSEWkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_t8Fc6FbRA0iGWOKhF-GZew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember_hXCdIxgZCEKI8TXwJzmvOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atxs:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember__UO0W7ZwwECRTisRxchBwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atxs:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember_vZQWF0XPxEqvnvbV5-zrbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atxs:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember_xAFJqmrv7kOgE5MRCew76A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atxs:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_DpksmxD47kGvcyVVnTBAsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N1cnyjsfXUyGLlzflAry7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_phPEO_62_0ef87zim7j66g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember_U49V0Lt_9kyE9hrhO0s63A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atxs:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_FkRLjZQMv0avRCk8lVRJrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember_Cc8ygbB1FkS65q1Hq4bUmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atxs:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_3t5AteWmBk6sQ6YdA-0C-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vK3sQCnrnUaOL4SPp0j-GA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VkwrOZo6Skee0mxwt5XNmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cNQZPiUZ_UeK1Pbzt5CTIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember_aICBK5MKZkuZVxp05YnVBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_EmployeeStockPurchasePlan2015Member_qvrFhdUehU6nDMNnX5A56A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:EmployeeStockPurchasePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_CommonStockOptionsReservedMember_wmV-DoZ1iEel9yGD2br-TA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:CommonStockOptionsReservedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_CommonStockOptionsOutstandingMember_7Vl-PK_cx0mTb1TT5TzDIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:CommonStockOptionsOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember_kmFzwlwoEUWBR8fU7IbkTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_EmployeeStockPurchasePlan2015Member_5SuvAJwIjkuX5pWVQNdilA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:EmployeeStockPurchasePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_CommonStockOptionsReservedMember_TAf-v0nKi0qS_WfrM_WRtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:CommonStockOptionsReservedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_CommonStockOptionsOutstandingMember_Yjog7Avv4UWNzFd78N6wtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:CommonStockOptionsOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_LGPUGn5hf0Wh2Qca8q1eow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_5FuYIQyMO0KrQWYAQrHRTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_atxs_WarrantsIssuedIn2021Member_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_yasr1KjcWk2xnQzdAy_KxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atxs:WarrantsIssuedIn2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_atxs_WarrantsIssuedIn2019Member_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_kZt19R6SjEmokrt5Mie7PA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atxs:WarrantsIssuedIn2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_atxs_WarrantsIssuedIn2018Member_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_-DDXhDsqjEaom3XeTK93Aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atxs:WarrantsIssuedIn2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_atxs_WarrantsIssuedIn2015Member_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_okImnMTN40m3e7LsnREh1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atxs:WarrantsIssuedIn2015Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_2_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BiFXZ622XUu96mNlkBimYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_By6IRPDdpEuZ5F3lwOK5ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">atxs:AgreementAndPlanOfMergerQuellisBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_uWtVDAckP0qWnkjhGrfdWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">atxs:AgreementAndPlanOfMergerQuellisBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_IIoZrvHZ90SylTKjxv1ZnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_rPxgg34LwEO0WW2sJngFGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_pkomaENPeEK2hWjtfDxw1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_kwexEh1NbUCeMgI-knFDkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_ADdWV8SUt0GFgLe1JLOiEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Ds6LSP_EK0qTg90-h5fSyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_nIJM4yXrw0GzaRxtnzccAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ar5rUSj2SE2rATotgrqFBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_OSaVkTaBE0adbR5AtRVk7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_EQBCa0WuakeegbdgZGvTIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_x-MiuZtIH0yax5u7pxoruw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_2fwTF9OAO0KdmBRB8Fzb2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_atxs_SeriesXPreferredStockMember_9HMukFq3bkmw6Lq9raeXDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atxs:SeriesXPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_atxs_CommonStockWarrantsMember_eZiUsBdsv0CpnkEmFJMYiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atxs:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_q91ttEudQ0mAGYdugRr9ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_atxs_CommonStockWarrantsMember_n7ERVEbeHkmVQE0vpdaYVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atxs:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9rTkA9cmjESbAdI_CIGCcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_P4mw2Fw8x0WkHCAyeJfKmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_CpiCowz5gUmCO8VqNzzcCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_8dpBZ3kAYkmlo-2evH5QBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ekfbhdx9h0WtXJ92zEMKrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2021_To_2_28_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_nDMEtpbiBUq1iy12eCKFQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_28_2021_To_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_yxGtZ11D_EqlCL7qM9oOug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">atxs:AgreementAndPlanOfMergerQuellisBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-28</xbrli:startDate><xbrli:endDate>2021-01-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_pvhZzT4yNEGZB0AEHw1BHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_4_2022_KOiL2_gOU0--dFQOFVb1-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_WeightedAverageMember_Q8_JfLkSZkujoq1ijmIZaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember_VoS4WBR9UkK6OOydZ60sAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">atxs:AgreementAndPlanOfMergerQuellisBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_28_2021_To_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_MBblrX_TzUq0Y8HTkRLDIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">atxs:AgreementAndPlanOfMergerQuellisBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-28</xbrli:startDate><xbrli:endDate>2021-01-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2-DGee-q5EegQ2k0m7z03g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_atxs_JefferiesMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember_SsM7_C8YNk-Wd6_cC-Nh_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atxs:JefferiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember_BsZDsx3vsEuRWOxqvJFk-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zp2xevi_xEmHwwPp0gd3NQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_Q0-uw695P0e1UfMQTMe-mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_28_2021_To_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yGEdHdBZkEuZlEVGeuF7Gg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">atxs:AgreementAndPlanOfMergerQuellisBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-28</xbrli:startDate><xbrli:endDate>2021-01-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_atxs_JefferiesMember_V_6BHty4gE2XeCiNbcgUQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atxs:JefferiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_uO-Pfxl910eVDz5-n8_42g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_DHwk8E2QikOhwrNFkk342g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_CollateralAxis_us-gaap_CollateralPledgedMember_us-gaap_InvestmentTypeAxis_atxs_ReverseRepurchaseAgreementsMember_eiP--rMiZU-1gbUFnuyFRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:CollateralPledgedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">atxs:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_InvestmentTypeAxis_atxs_ReverseRepurchaseAgreementsMember_aL_h_TEmN0mRrvtYQElzYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">atxs:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_30_2021_To_6_30_2021_srt_CounterpartyNameAxis_atxs_JefferiesMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember_oBnDRsRG00CrcvXjnale3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atxs:JefferiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-30</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mm2r7tKTwEKwrvs2FxtSqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_srt_CounterpartyNameAxis_atxs_JefferiesMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember__zmdZLIxRES1KpnGo6-lqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atxs:JefferiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_stYiOzYUG0mKnmIJCrQu3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">atxs:AgreementAndPlanOfMergerQuellisBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001454789</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_series_lxqxSSbLPkuOU9DD2aDsAA"><xbrli:measure>atxs:series</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_instrument_UhpnDIC4ZkS1xbkw5nvJeQ"><xbrli:measure>atxs:instrument</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_segment_VaIUUonErEmKwL0Ka000VA"><xbrli:measure>atxs:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_r9qJ3cWOSk6WrNQbeKvS6w"><xbrli:measure>atxs:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Y_7dFwAQRg-k-TRf_n8MTBtg"><xbrli:measure>atxs:Y</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;padding-top:1pt;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_420b3393_ba28_47bf_9e80_5accb2c76e40"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:15pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:15pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Washington, DC  20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:3pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:15pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:DocumentType" id="Narr_8tZKma1dPES08Lq9t0avuA"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><a id="_494f7af5_10df_43f6_bcf4_0534e56c15f2"></a><a id="Tc_XnLnRZadPEqsQht0eAppYQ_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:5.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:94.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:5.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:DocumentAnnualReport" id="Tc_i_esSVN1ukOMQaCRNvjqRg_1_0"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:7pt;font-weight:bold;">For the fiscal year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:DocumentPeriodEndDate" id="Narr_ia79y4Fs9EKelD3A1wnnsQ"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:CurrentFiscalYearEndDate" id="Narr_i4p9ZM1Tmk-BYF14Hsz4lw"><b style="font-size:7pt;font-weight:bold;">December 31</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">, 2021</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">or</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><a id="_b51bc4c9_41cd_407b_aa82_bb977716fba1"></a><a id="Tc_v97CP2LhvUmUv-0rOMYGDw_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:5.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:94.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:5.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:DocumentTransitionReport" id="Tc_g8c6GptXWU-6cPbOOErdqg_1_0"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:7pt;font-weight:bold;">Commission File Number: </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:EntityFileNumber" id="Narr_u_3p1XSeG0qZL-3MBKIIwQ"><b style="font-size:7pt;font-weight:bold;">001-37467</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:15pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:EntityRegistrantName" id="Narr_Y-k60w7220Os08YYAx1glw"><b style="font-weight:bold;">Astria Therapeutics,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><a id="_08c09a2e_051f_4521_bc51_a333a69f9762"></a><a id="Tc_DsT25AtArUSPUVDQ8AXg6Q_1_0"></a><a id="Tc_jb8MHS0Zs06wDZE9KDUcMQ_1_2"></a><a id="Tc_7ZfYQv5WV0iAFqPvDfdCXw_3_0"></a><a id="Tc_lLh9HJR6n0m11Zmn8bk0NQ_4_0"></a><a id="Tc_0Tr6fcah0kuKM3e1vb7J5g_5_0"></a><a id="Tc_2j_EeuKKwUuZ75lJG-RoNw_5_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:EntityIncorporationStateCountryCode" id="Tc__X3qYDZstk6t218MaiJ1NA_0_0"><b style="font-size:7pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:EntityTaxIdentificationNumber" id="Tc_d5lqHRAqn0iirHjaG0pyHA_0_2"><b style="font-size:7pt;font-weight:bold;">26-3687168</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;">(State or other jurisdiction of<br />incorporation or organization)</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;">(IRS Employer<br />Identification No.)</p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;line-height:1.19;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;line-height:1.19;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:EntityAddressAddressLine1" id="Narr_3b_gbn9fEE6RA7MH3gZQbQ"><b style="font-size:7pt;font-weight:bold;">100 High Street </b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:EntityAddressAddressLine2" id="Narr_2E5ZD2CV5EivTaUc8MrxBA"><b style="font-size:7pt;font-weight:bold;">Floor 28</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:2pt;line-height:1.19;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:EntityAddressCityOrTown" id="Narr_-Awlm5ppOEusDZavmo03iw"><b style="font-size:7pt;font-weight:bold;">Boston</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:EntityAddressStateOrProvince" id="Narr_9iRiPmdoWUev0-kRNsEn0Q"><b style="font-size:7pt;font-weight:bold;">Massachusetts</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:EntityAddressPostalZipCode" id="Tc_ND8ZTFSOsk2HPxrY6HDGzQ_4_2"><b style="font-size:7pt;font-weight:bold;">02110</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;">Registrant&#8217;s telephone number,&#160;including area code </span><b style="font-size:7pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:CityAreaCode" id="Narr_cknEF3aXmUmyvoS64O1GFg"><b style="font-size:7pt;font-weight:bold;">617</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:LocalPhoneNumber" id="Narr_E7LOJv5h3k-hWquPhNZtHQ"><b style="font-size:7pt;font-weight:bold;">349-1971</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-indent:18pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><a id="_69847537_e670_4d75_9e47_5e552ce5a39a"></a><a id="Tc_iGpAlGZIyESmfdNb3pHkOg_2_0"></a><a id="Tc_DrmZNoVBGUah-oevcNa3OA_2_2"></a><a id="Tc_Bn0cAL9guEy-NjMsehNZjg_2_4"></a><a id="Tc_kmoTvMm9mUatyGGe2fNPWA_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:35.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:26.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:35.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:35.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:26.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:35.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:35.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:35.4%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:Security12bTitle" id="Tc_pkmf3q3dqUKgSwkiJQXhLA_3_0"><b style="font-size:7pt;font-weight:bold;">Common Stock, $0.001 par value per share</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:26.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:TradingSymbol" id="Tc_AqbGliVgzk-GSP2trlcbNg_3_2"><b style="font-size:7pt;font-weight:bold;">ATXS</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.3%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:SecurityExchangeName" id="Narr_N0pyATb2oU6xLSuLtbW-4A"><b style="font-size:7pt;font-weight:bold;">Nasdaq</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;"> Global Market</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-indent:18pt;margin:0pt;">Securities registered pursuant to Section 12(g) of the Act:<b style="font-weight:bold;"> None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;white-space:pre-wrap;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-size:7pt;">&#160;Yes&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:7pt;">&#8999;</span><span style="font-size:7pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_Sw5h8oiuX0GN_kwr4u4ltA"><span style="font-size:7pt;">No</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;white-space:pre-wrap;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-size:7pt;"> Yes&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:7pt;">&#8999;</span><span style="font-size:7pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:EntityVoluntaryFilers" id="Narr_nIBRPIcXIU-gYW6osmkmoA"><span style="font-size:7pt;">No</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:EntityCurrentReportingStatus" id="Narr__FsznA16XUaOdGM5v84bxQ"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;"> &#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span><span style="font-size:7pt;">&#160;&#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:EntityInteractiveDataCurrent" id="Narr_noZzfUQwMku0E2Nk6L0W8g"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;</span><span style="font-family:'Times New Roman';font-size:7pt;">&#8999;</span><span style="font-size:7pt;">&#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;">Large&#160;accelerated&#160;filer <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;">Accelerated&#160;filer <span style="font-family:'Times New Roman';">&#9723;</span></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:EntityFilerCategory" id="Narr_vNWHLWNFz0OIwvklw2SJBw"><span style="font-size:7pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:7pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;">Smaller&#160;reporting&#160;company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:EntitySmallBusiness" id="Narr_QZFmNb5OjEO9M3OX4D8y9g"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;">Emerging growth company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:EntityEmergingGrowthCompany" id="Narr_N-1PHKfTaEKDFXDAnSkZgg"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric><span style="font-size:7pt;">&#160;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has &#64257;led a report on and attestation to its management&#8217;s assessment of the e</span><span style="font-size:7pt;">&#64256;</span><span style="font-size:7pt;">ectiveness of its internal control over &#64257;nancial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting &#64257;rm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:IcfrAuditorAttestationFlag" id="Narr_W88Pw2ZlikeA6pKZ5l70CA"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;Yes&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:EntityShellCompany" id="Narr_u_2VGF5O10WpY7ZOiErj_A"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric><span style="font-size:7pt;">&#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-indent:18pt;margin:0pt;">Aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, based on the last sale price for such stock on June 30, 2021:&#160;&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_6_30_2021_pvhZzT4yNEGZB0AEHw1BHA" decimals="0" name="dei:EntityPublicFloat" id="Narr_9T0qxuTTKk6SFgyFROQtOw">129,863,570</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-indent:18pt;margin:0pt;">As of March 4, 2022, there were <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_4_2022_KOiL2_gOU0--dFQOFVb1-A" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_E-MJA07B006OQ4VAqJo7jQ">13,016,955</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.001 per share, outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:2pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-indent:18pt;margin:0pt;">Portions of the registrant&#8217;s definitive proxy statement relating to its 2022 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The registrant intends to file such proxy statement with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Annual Report on Form 10-K relates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3a2226cd_96e2_4cd2_a72b_f231ca8b1387"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times';font-weight:bold;">TABLE OF CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:98.72%;"><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;"><a href="#PARTI_333156"><b style="font-style:normal;font-weight:bold;">PART I</b></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item1Business_209525"><span style="font-style:normal;font-weight:normal;">Item 1. Business</span></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item1A_245229"><span style="font-style:normal;font-weight:normal;">Item 1A. Risk Factors</span></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">24</p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_647014"><span style="font-style:normal;font-weight:normal;">Item 1B. Unresolved Staff Comments</span></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">68</p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item2Properties_654044"><span style="font-style:normal;font-weight:normal;">Item 2. Properties</span></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">68</p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item3LegalProceedings_185277"><span style="font-style:normal;font-weight:normal;">Item 3. Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">68</p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item4MineSafetyDisclosures_208551"><span style="font-style:normal;font-weight:normal;">Item 4. Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">68</p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#PARTII_570594"><b style="font-style:normal;font-weight:bold;">PART II</b></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">69</p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item6Reserved_659568"><span style="font-style:normal;font-weight:normal;">Item 6. Reserved</span></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">69</p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">70</p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">80</p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item 8. Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">80</p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">80</p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item9AControlsandProcedures_521927"><span style="font-style:normal;font-weight:normal;">Item 9A. Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">80</p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item9BOtherInformation_174599"><span style="font-style:normal;font-weight:normal;">Item 9B. Other Information</span></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">81</p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item9CDisclosureRegardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">Item 9C: Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">81</p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#PARTIII_908662"><b style="font-style:normal;font-weight:bold;">PART III</b></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item10_839238"><span style="font-style:normal;font-weight:normal;">Item 10. Directors, Executive Of&#64257;cers and Corporate Governance</span></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">82</p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item11ExecutiveCompensation_18724"><span style="font-style:normal;font-weight:normal;">Item 11. Executive Compensation</span></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">82</p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item12_979061"><span style="font-style:normal;font-weight:normal;">Item 12. Security Ownership of Certain Bene&#64257;cial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">82</p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">82</p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item14PrincipalAccountantFeesandServices"><span style="font-style:normal;font-weight:normal;">Item 14. Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">82</p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#PARTIV_833106"><b style="font-style:normal;font-weight:bold;">PART IV</b></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item15_889501"><span style="font-style:normal;font-weight:normal;">Item 15. Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">83</p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item16Form10KSummary_747493"><span style="font-style:normal;font-weight:normal;">Item 16. Form 10-K Summary</span></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">86</p></td></tr><tr><td style="vertical-align:top;width:91.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#SIGNATURES_944344"><span style="font-style:normal;font-weight:normal;">SIGNATURES</span></a></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">87</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><span style="display:inline-block;width:234pt;"></span><span style="display:inline-block;width:5.6pt;"></span>-i</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a2d24ac1_aaba_4e51_a621_4e3140caf892"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary of the Material Risks Associated with Our Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investing in our common stock involves a high degree of risk because our business is subject to numerous risks and uncertainties. The principal factors and uncertainties that make investing in our common stock risky include, among others:</i></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are heavily dependent on the success of our product candidate, STAR-0215 for the treatment of hereditary angioedema, or HAE, which is in the preclinical stage of development, and has only produced results in preclinical and nonclinical settings. We cannot give any assurance that we will generate clinical or other data for STAR-0215 or for any other future product candidates that is consistent with its preclinical data or sufficiently supportive to receive regulatory approval, which will be required before any product candidate can be commercialized.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will need substantial additional funding. If we are unable to raise capital when needed or on acceptable terms, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have never generated any revenue from product sales and may never be profitable.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any future product candidate we may seek to develop.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our preclinical programs may experience delays or may never advance to clinical trials. We cannot predict if the United States Food and Drug Administration, or FDA, or comparable foreign regulatory authorities will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of our programs. As a result, we cannot be sure that we will be able to submit initial investigational new drug application, or INDs, or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications, including clinical trial application submissions in the European Union, will result in the FDA or comparable foreign regulatory authorities allowing clinical trials to begin or that we can meet the requirements imposed by such authorities for beginning such trials on a timely basis or at all.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical trials are costly, time consuming, difficult to enroll and inherently risky, and we may fail to demonstrate safety and efficacy on the timelines that we expect or to the satisfaction of applicable regulatory authorities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:4.75pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">STAR-0215 or any future product candidates may cause adverse events or undesirable side effects or have other unexpected properties that could delay or halt clinical trials, delay or prevent their regulatory approval, limit the commercial viability of an approved label, or result in significant negative consequences following marketing approval, if any.</span></td><td style="width:1pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:4.75pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face substantial competition from other pharmaceutical and biotechnology companies, and our operating results may suffer if we fail to compete effectively.</span></td><td style="width:1pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will need to maintain a cell line for STAR-0215 and any other future biologic candidate that generates sufficient material for preclinical, nonclinical and clinical studies, and also build and maintain sufficient preclinical, clinical and commercial manufacturing drug substance and drug product capacity, in each case, through third party manufacturers, for STAR-0215 and any other future product candidate that advances into such stages, on the timetables and in a manner that, in each case, are consistent with our expected development timetables and financial projections, the failure of which could materially harm our operating results and require us to raise capital sooner than we expect.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">ii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our forecasts of cash usage and how long we expect our existing cash, cash equivalents and short-term investments to fund operating expenses may not be accurate and we may therefore use our cash and cash equivalents more rapidly than we expect, which could force us to delay, reduce or eliminate our product development programs or commercialization efforts, if any, and therefore materially harm our operating results, and we could be required to raise capital sooner than we expect.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have historically incurred significant losses, have a limited operating history on which to assess our business, and anticipate that we will continue to incur significant losses for the foreseeable future.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The ongoing COVID-19 pandemic, and future </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variants or outbreaks </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of other highly infectious or contagious diseases, could seriously harm our research, preclinical development, development or manufacturing efforts, increase our costs and expenses and have a material adverse effect on our business, financial condition and results of operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The price of our stock has been and is likely to continue to be volatile, and investors could lose all or part of their investment.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The summary risk factors described above should be read together with the text of the full risk factors below, in the section entitled &#8220;<i style="font-style:italic;">Risk Factors</i>&#8221; in Part&#160;I, Item&#160;1A of this Annual Report on Form&#160;10-K and the other information set forth in this Annual Report on Form&#160;10-K, including under the heading &#8220;<i style="font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</i>&#8221; and our consolidated financial statements and the related notes, as well as in other documents that we file with the Securities and Exchange Commission. The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not precisely known to us, or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, results of operations and future growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">iii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3f02e849_e46e_4aa5_8716_8102feb8d460"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SPECIAL NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form&#160; 10-K contains forward-looking statements,&#160;which reflect our current views with respect to, among other things, our operations and financial performance, strategy, future financial condition and clinical development programs. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements.&#160;All statements, other than statements of historical facts, contained in this Annual Report on Form&#160;10-K, including statements regarding our strategy, &#160;future operations, &#160;future financial position, future revenue, projected costs, prospects, plans and objectives of management, clinical development programs, regulatory filings and expected market growth are forward-looking statements. The words &#160;&#8220;anticipate,&#8221; &#160;&#8220;believe,&#8221; &#160;&#8220;continue,&#8221; &#160;&#8220;could,&#8221; &#160;&#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include but are not limited to those described under the heading &#8220;<i style="font-style:italic;">Summary of Material Risks Associated with our Business</i>&#8221; and the &#8220;<i style="font-style:italic;">Risk Factors</i>&#8221; in Part I, Item 1A of this Annual Report on Form 10-K and include, among other things, statements about:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding the timing of our planned filing of an IND for STAR-0215, and the timing, nature, goals and results of our planned Phase 1a and Phase 1b/2 clinical trials of STAR-0215, including that favorable results from such trials could establish proof of concept for the differentiation of STAR-0215 as a potential treatment for HAE;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations about the unmet medical need for HAE, the potential differentiating attributes of STAR-0215 as a potential treatment for HAE, along with the potential market impact of such differentiation, the potential of STAR-0215 to be a best-in-class and the most patient friendly treatment for HAE, and the nature and anticipated growth of the global HAE market and HAE therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations that we have identified a cell line for STAR-0215 and the ability of such cell line to generate sufficient material for our planned STAR-0215 preclinical and clinical studies and the master cell bank, and our plans and timetable for initiating current Good Manufacturing Practices manufacturing of STAR-0215;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding our ability to expand our pipeline;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential benefits of any future acquisition, in-license, collaboration or preclinical development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our manufacturing plans, capabilities and strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our intellectual property position and strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing, including additional financing to fund our long-term operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments relating to our competitors and our industry; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of government laws and regulations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report on Form&#160;10-K, particularly in the &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K, that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments that we may make or enter into.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">iv</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">You should read this Annual Report on Form&#160;10-K with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward- looking statement, whether as a result of new information, future events or otherwise, except as required by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REFERENCES TO ASTRIA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as otherwise indicated herein or as the context otherwise requires, references in this Annual Report on Form&#160;10-K to &#8220;Astria,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Astria Therapeutics,&#160;Inc. and its consolidated subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">v</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_00e03d2f_c48b_4c99_88f6_4ccb0e130c84"></a><a id="PARTI_333156"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;I</b></p><a id="Item1Business_209525"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;1. Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics. Our mission is to bring hope with life-changing therapies to patients and families that are affected by rare and niche allergic and immunological diseases. Our lead product candidate is STAR-0215, formerly known as QLS-215, a potential best-in-class monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema, or HAE, a rare, debilitating and potentially life-threatening disease. STAR-0215 has the potential to be the most patient-friendly chronic treatment option for HAE, based on the preclinical data generated to date and the existing HAE treatment landscape.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2021, we acquired Quellis Biosciences,&#160;Inc., or Quellis, including the STAR-0215 program, and announced a private placement that, upon closing in February&#160;2021, resulted in gross proceeds to us of approximately $110.0 million before deducting placement agent and other offering expenses, which we refer to as the February&#160;2021 Financing. In November&#160;2020, after we stopped the development of our edasalonexent program as a potential treatment for Duchenne Muscular Dystrophy, we decided to explore and evaluate strategic options. The acquisition of Quellis was the result of our evaluation of strategic options.</p><a id="_Hlk97688921"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">HAE is a rare, debilitating and potentially life-threatening disease. The treatment options for patients with HAE have improved, however, there is remaining unmet medical need and the global market for HAE therapy is strong and growing. The vision for our lead program, STAR-0215, is to develop a best-in-class monoclonal antibody inhibitor of plasma kallikrein able to provide long-acting, effective attack prevention for HAE with dosing once every three&#160;months or longer. Targeted plasma kallikrein inhibition can prevent HAE attacks by suppressing the pathway that generates bradykinin and causes excessive swelling. STAR-0215 is currently in preclinical development and we expect to submit an Investigational New Drug application, or IND, for STAR-0215 in mid-2022 and plan to initiate a Phase 1a clinical trial shortly thereafter with initial results anticipated by&#160;year end 2022. We believe that this clinical trial has the opportunity to establish proof of concept for the differentiated profile of STAR-0215. We expect the Phase 1a clinical trial to be conducted in healthy volunteers and evaluate several single escalating dose cohorts with subcutaneous, or SC, administration. Our goals for this trial with STAR-0215 are to demonstrate safety and tolerability, establish prolonged half-life, demonstrate the duration of inhibition of plasma kallikrein activity and to refine dose and dosing regimen for studies in HAE patients. Assuming positive data from the Phase 1a trial, we plan to initiate a Phase 1b/2 trial in patients with HAE in 2023. We expect the Phase 1b/2 trial will be a randomized, placebo-controlled, global multi-center trial. The primary goals for this trial in HAE patients are to demonstrate safety and tolerability, establish prolonged half-life, demonstrate inhibition of plasma kallikrein activity, and provide an initial assessment of the impact of STAR-0215 on HAE attack rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August&#160;4, 2021, our Board of Directors approved a reverse stock split of our outstanding shares of common stock at a ratio of one-for-six (1:6). The reverse stock split became effective on August&#160;19, 2021. The reverse stock split was approved by our stockholders at our Annual Meeting of Stockholders on June&#160;2, 2021. All share and per share amounts of the common stock included in this Annual Report on Form&#160;10-K, including in the accompanying consolidated financial statements, have been retrospectively adjusted to give effect to the reverse stock split for all periods presented, including reclassifying an amount equal to the reduction in par value to additional paid-in capital. As of March&#160;4, 2022, we had 13,016,955 shares of outstanding common stock and approximately 31,455 shares of outstanding Series&#160;X Preferred Stock, which we issued in the Quellis acquisition and the February&#160;2021 Financing, which are convertible into an aggregate of 5,242,501 shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2021, we formally changed our name to Astria Therapeutics,&#160;Inc. from Catabasis Pharmaceuticals,&#160;Inc. The name &#8220;Astria&#8221; originates from the Greek word for star, demonstrating our commitment to patients who serve as our guiding stars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Product Candidate</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">STAR-0215</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">STAR-0215 is a monoclonal antibody that was designed to inhibit plasma kallikrein for the treatment of HAE. Plasma kallikrein is a critical component of the plasma contact system, which causes pathologic vascular permeability in Type I and Type II HAE. STAR-0215 is a humanized monoclonal antibody that was developed through a hybridoma screening and antibody optimization process. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">Following humanization and optimization for affinity and overall properties, the antibody was modified to increase its plasma half-life. This process resulted in STAR-0215, a humanized monoclonal antibody having the following desirable features: high affinity and kallikrein inhibitory activity, selectivity for plasma kallikrein compared to pre- kallikrein, reduced chemistry, manufacturing and controls or, CMC, liabilities and long plasma half-life. Based on these characteristics and preclinical experiments with STAR-0215, including in vitro potency results and long plasma half-life in non-human primates, we believe that STAR-0215 has the potential to be a best-in-class and the most patient-friendly monoclonal antibody inhibitor of plasma kallikrein that could combine the benefits of infrequent dosing with the inhibition of attacks over long periods of time. We believe that we can establish clinical proof of concept early in the development program with a Phase 1a clinical trial in normal healthy volunteers and a Phase 1b/2 trial in patients with HAE. If we achieve these goals, we believe that we can develop a differentiated, best-in-class new preventative therapy for HAE with a well-understood monoclonal antibody modality to provide patients with improved outcomes and quality of life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Overview of HAE</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">HAE is a rare, autosomal dominant genetic disorder. The disease is characterized by recurrent, unpredictable, debilitating and potentially life-threatening edema in the skin, abdomen and airway. The vast majority of HAE cases (Type I and Type II) are caused by defects in the C1 esterase inhibitor gene. Deficiencies in the C1 esterase inhibitor gene result in overproduction of bradykinin, a key mediator of vasodilation and angioedema. In several other types of HAE, which are a small minority of cases, other mutations (e.g., in the Factor XII gene) can cause HAE. The estimated prevalence of Type I and Type II HAE range from 1 in 10,000 to 1 in 50,000 with fewer than 8,000 patients in the United States and 15,000 patients in Europe with HAE. There are active and knowledgeable HAE patient advocacy organizations in the United States and internationally.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Patients with HAE are typically diagnosed by the age of 20 with the average age of disease onset around 11. The severity and frequency of swelling attacks is highly variable even between family members. At the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit in October&#160;2021, we presented findings indicating a substantial need for new HAE treatments, and that HAE patients are open to trying new therapies that could reduce their disease and treatment burdens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The Role of Plasma Kallikrein in Hereditary Angioedema</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Plasma kallikrein is an enzyme that cleaves high molecular weight kininogen, or HMWK, to release bradykinin. Normally, circulating C1 esterase inhibitor (C1INH) limits the activation of plasma kallikrein from its precursor prekallikrein, and thereby prevents the release of excess bradykinin from the cleavage of HMWK by plasma kallikrein. In HAE associated with C1INH deficiency, plasma kallikrein is hyperactive, resulting in excessive bradykinin release. Bradykinin activates the bradykinin receptor (B2R) in endothelial cells, resulting in increased vascular permeability and release of fluid into subcutaneous tissue spaces, or angioedema. Thus, unchecked plasma kallikrein activity is a critical component that causes pathologic vascular permeability and vasodilation in HAE, leading to excessive tissue swelling, a primary clinical symptom.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Unaddressed Market Opportunity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There are two treatment approaches to managing the unpredictable and recurrent edema attacks typically experienced by people with HAE. On-demand treatments are administered at the onset of an attack to reduce the severity and duration of the attack, and preventative treatments, which is the treatment approach that we are pursuing with STAR-0215, are taken chronically to reduce the frequency and severity of future attacks. In the United States, the United States Food and Drug Administration, or FDA, has approved four therapies for on-demand treatment of HAE: BERINERT&#174; (C1 esterase inhibitor [human]), FIRAZYR&#174; (icatibant injection), KALBITOR&#174; (ecallantide) and RUCONEST&#174; (C1 esterase inhibitor [recombinant]). For long-term preventative treatment of HAE, the FDA has approved the following four therapies: CINRYZE&#174; (C1 esterase inhibitor [human]), HAEGARDA&#174; (C1 esterase inhibitor subcutaneous [human]), TAKHZYRO&#174; (lanadelumab-flyo) and ORLADEYO&#174; (berotralstat).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">With the exception of KALBITOR, these therapies are also approved and commercially available outside of the United States. The approved preventative therapies have provided HAE patients with treatment options but have limitations in dosing frequency, side effects and/or efficacy. CINRYZE and HAEGARDA are administered twice a week; CINRYZE by intravenous, or IV, infusion and HAEGARDA by SC injection. TAKHZYRO is dosed twice a&#160;month by SC injection. Dosing every four weeks may be considered in some patients. With these injectable therapies, patients have reported a desire for less burdensome administration. ORLADEYO is an oral capsule taken daily with food, and data from its approved label, while not comparative data, suggest a lower&#160;percentage reduction in attack rate than other available therapies. Historically, androgens and antifibrinolytic treatments have also been used as preventative treatment but they are associated with side effects such as hypertension, acne, hirsutism, rashes, amenorrhea, liver enzyme elevations </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">and increased risk of thrombosis and their overall use has been declining with the ability of more-tolerable, HAE-specific therapies. Although there has been progress with recent innovation in therapies for HAE and, as described in the section entitled &#8220;Competition&#8221; in this Business section, there are a significant number of product candidates for HAE in clinical and preclinical development, we believe that there is remaining unmet medical need for potent and long duration of action preventative therapies to provide patients with lower burden of treatment and improved outcomes and quality of life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preclinical Results</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our vision for STAR-0215 is supported by preclinical data showing potent inhibition of the production of bradykinin by plasma kallikrein and a long plasma half-life that could potentially enable patients to dose less frequently. Multiple experiments have confirmed that STAR-0215 is approximately 10-fold more potent than lanadelumab, a monoclonal antibody inhibitor of plasma kallikrein commercialized under the name TAKHZYRO and an approved preventative treatment for HAE, in inhibiting bradykinin production. In cynomolgus monkey studies, lanadelumab was observed to have a half-life of approximately 10&#160;days, which is consistent with what has been reported in FDA review documents and publications for lanadelumab in non-human primates. STAR-0215 was administered at the same dose as lanadelumab and the observed half-life was approximately 34&#160;days, which is about a three to four-fold longer half-life than observed for lanadelumab. We believe this could translate to a half-life of several&#160;months for STAR-0215 in humans. If this longer half-life is demonstrated in clinical trials, it has the potential to enable dosing once every three&#160;months or longer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We presented new preclinical data from the STAR-0215 program at the American College of Allergy, Asthma and Immunology, or ACAAI, Annual Scientific Meeting in November&#160;2021, demonstrating the high potency of STAR-0215 for binding to and inhibition of plasma kallikrein on a different site than lanadelumab and supporting the ability of YTE technology to extend half-life. YTE modifications in STAR-0215 are designed to enable a longer duration of action. In cynomolgus monkeys dosed with STAR-0215, the YTE modifications protected STAR-0215 from antibody clearance leading to a more than three-fold increase in plasma half-life compared to an antibody without the YTE modifications. Additional preclinical data presented at the American Academy of Allergy, Asthma, and Immunology, or AAAAI, Annual Meeting in February&#160;2022 demonstrated how STAR-0215 binds to plasma kallikrein. The preclinical data to date suggest that at equal doses STAR-0215 would have a significantly longer duration of action than lanadelumab and could result in STAR-0215 being an effective preventative therapy for patients with HAE due to inhibition of the pathologic activity of plasma kallikrein for an extended time period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preclinical and Clinical Development Plans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2021, we initiated IND-enabling activities and began Good Manufacturing Practices, or GMP, manufacturing of STAR-0215. We plan to submit an IND for STAR-0215 in mid-2022 and plan to initiate the Phase 1a clinical trial shortly thereafter, with initial results anticipated by&#160;year end 2022. Subsequently, assuming positive data from the Phase 1a clinical trial, we plan to initiate a Phase 1b/2 trial in patients with HAE in 2023. We believe that these clinical trials have the opportunity to establish proof of concept for the differentiated profile of STAR-0215.</p><a id="_Hlk97688933"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our objective for our planned early clinical trials is to establish clinical proof of concept to support the profile that we anticipate for STAR-0215 in terms of activity and half-life. We expect the Phase 1a clinical trial to be conducted in healthy volunteers and to evaluate several single escalating dose cohorts with subcutaneous administration. The primary goals for the Phase 1a trial are to demonstrate safety and tolerability, establish the prolonged half-life of STAR-0215, to demonstrate inhibition of plasma kallikrein activity, and refine dose and dosing regimen for studies in HAE patients. We also expect that results from the Phase 1a trial, if favorable, will enable us to design and initiate our planned Phase 1b/2 clinical trial in patients with HAE. We expect the Phase 1b/2 trial will be a randomized, placebo-controlled, global multi-center trial. The primary goals for this trial in HAE patients are to demonstrate safety and tolerability, establish prolonged half-life, demonstrate inhibition of plasma kallikrein activity, and provide an initial assessment of the impact of STAR-0215 on HAE attack rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Competition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The development and commercialization of new drugs is highly competitive. If we successfully develop and commercialize STAR-0215, we and any future collaborators will face competition from pharmaceutical and biotechnology companies worldwide. Many of the entities developing and marketing potentially competing products have significantly greater financial resources and expertise than we do in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing. Even if we are able to successfully develop and commercialize STAR-0215, our commercial opportunity will </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer side effects, are more convenient or are less expensive than STAR-0215.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The key competitive factors affecting the success of STAR-0215, if approved, are likely to be its efficacy, safety, convenience, price and the availability of coverage and reimbursement from government and other third-party payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA has approved four therapies for on-demand treatment of HAE: BERINERT, FIRAZYR, KALBITOR and RUCONEST. For long-term preventative treatment of HAE, the FDA has also approved four therapies: CINRYZE, HAEGARDA, TAKHZYRO and ORLADEYO. There are four main manufacturers of therapies for HAE: CSL Behring (BERINERT and HAEGARDA), Takeda (FIRAZYR, KALBITOR, CINRYZE and TAKHZYRO), Pharming (RUCONEST) and BioCryst (ORLADEYO). With the exception of KALBITOR, these therapies are also approved and commercially available outside of the United States (HAEGARDA is marketed as BERINERT SC outside of the United States). Historically, androgens and antifibrinolytic treatments have also been used as preventative treatment for HAE, however their use is declining with the availability of more-tolerable, HAE-specific therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On-demand and preventative HAE therapies target one of three primary mechanisms. BERINERT and HAEGARDA, RUCONEST and CINRYZE are C1 INH replacement therapies. FIRAZYR is a Bradykinin 2 receptor antagonist, and KALBITOR, TAKHZYRO and ORLADEYO target plasma kallikrein. TAKHZYRO is a monoclonal antibody and KALBITOR and ORLADEYO are small molecule inhibitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On-demand therapies are taken as needed; BERINERT and RUCONEST are IV infusions approved for adult and pediatric patients, FIRAZYR is a SC injection, approved for adults 18 and older, and KALBITOR is a series of 3 SC injections, approved for patients 12&#160;years and older. KALBITOR must be administered by a healthcare professional to monitor for the risk of anaphylactic reactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Preventative therapies are taken chronically. CINRYZE is an IV infusion and HAEGARDA is an SC injection; both are administered twice a week and are approved for adult and pediatric patients 6&#160;years and older. TAKHZYRO is an SC injection generally administered every two weeks; however dosing every four weeks may be considered in some patients. TAKHZYRO is approved for patients 12&#160;years and older.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ORLADEYO is an oral capsule taken once daily with food for patients 12&#160;years and older. Given that TAKHZYRO is an approved monoclonal antibody inhibitor of plasma kallikrein, if STAR-0215 is approved, we expect that it will compete most directly with TAKHZYRO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are aware of additional programs in development for HAE, which are focused largely on preventative approaches. For example, in Phase 3 development for preventative treatment are CSL Behring garadacimab (CSL312), a factor XIIa-inhibitory monoclonal antibody (FXIIa mAb), and Ionis Pharmaceuticals, Inc.&#8217;s donidalorsen (IONIS-PKK-LRx), an antisense inhibitor of prekallikrein synthesis. KalVista Pharmaceuticals, Inc. has two oral small molecule plasma kallikrein inhibitors: sebetralstat (KVD900) for on-demand treatment of HAE, and KVD824 for preventative treatment, both of which are in Phase 2 development. Pharvaris is also developing two oral treatments, PHVS416, in Phase 2 for on-demand treatment, and PHVS719, in Phase 1 for preventative treatment, that are small molecule inhibitors of B2R. Intellia Therapeutics has begun Phase 1/2 trials for NTLA-2002, a CRISPR knockout of the prekallikrein gene KLKB1. BioMarin Pharmaceutical Inc. has begun Phase 1/2 trials for BMN 311, a C1INH gene therapy. In preclinical development for preventative treatment are KalVista&#8217;s oral FXIIa inhibitor, Spark Therapeutics C1-INH gene therapy (SPK-10000), Regenxbio Inc.&#8217;s plasma kallikrein mAb gene therapy, and Orchard Therapeutics plc and Pharming&#8217;s ex vivo hematopoietic stem cell gene therapy (OTL-105).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We strive to protect the proprietary technologies that we believe are important to our business. This includes plans to pursue and maintain patent protection intended to cover the composition of matter of STAR-0215, its method of use, and other related technologies and inventions that are important to our business. In addition to seeking patent protection, we also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Our commercial success depends in part upon our ability to obtain and maintain patent and other proprietary protection for commercially important technologies, inventions and know-how related to our business, defend and enforce our intellectual property </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">rights, in particular, our patent rights, preserve the confidentiality of our trade secrets and operate without infringing valid and enforceable intellectual property rights of others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We own one International (PCT) patent application directed to our product candidate STAR-0215 and its use in treating various disorders including HAE. If nationalized, any national stage applications, if granted, would expire in 2042, assuming all maintenance fees are paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The patent positions for biopharmaceutical companies like us are generally uncertain and can involve complex legal, scientific and factual issues. In addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that our STAR-0215 product candidate will be protected or remain protectable by enforceable patents, even if issued. We cannot predict whether the patent application we are currently pursuing will issue as a granted patent in any particular jurisdiction or whether the claims of any granted patent will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties. The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries where we may elect to file, the patent term is 20&#160;years from the earliest date of filing a non-provisional patent application. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the United States Patent and Trademark Office, or USPTO, in granting a patent. A United States patent term may be shortened, if a patent is terminally disclaimed by its owner, over another patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, the term of a patent covering an FDA-approved drug may be eligible for a patent term extension under The Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five&#160;years beyond the expiration of the patent, but cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval. Only one patent among those eligible for an extension may be extended. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. It is possible that an issued United States patent covering STAR-0215 may be entitled to a patent term extension. If our STAR-0215 product candidate receives FDA approval, we intend to apply for a patent term extension, if available, to extend the term of the patent that covers the approved product candidate. We also intend to seek patent term extensions in any jurisdictions where they are available. However, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to patent protection, we may rely on other forms of regulatory and legislative non-patent exclusivity protection that are typically triggered by marketing approval of a product. In the U.S., these include orphan drug exclusivity, pediatric exclusivity, new chemical entity exclusivity and, for biologics such as STAR-0215, reference product exclusivity. The European Union and many other key markets outside the United States have comparable forms of such exclusivity. However, there is no guarantee that we will obtain any of these forms of exclusivity protection for STAR-0215 or any future product candidate. We also rely on trade secret protection for our proprietary information that is not amenable to, or that we do not consider appropriate for, patent protection, including, for example, certain aspects of our manufacturing processes. However, trade secrets can be difficult to protect. Although we take steps to protect our proprietary information, including restricting access to our premises and our confidential information, as well as entering into agreements with our employees, consultants, advisors, contract research organizations, and potential collaborators, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Manufacturing and Supply</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not own or operate manufacturing facilities. We currently rely on third-party manufacturers and suppliers for the antibodies used to make STAR-0215, and we expect to continue to do so to meet our nonclinical, clinical and commercial activities. We currently have no plans to build our own clinical or commercial scale manufacturing capabilities, and have hired qualified individuals with significant manufacturing experience to oversee our relationships with our contract manufacturing partners. Our third-party manufacturers are required to manufacture STAR-0215 and any future product candidates under current GMP, or cGMP, requirements and other applicable laws and regulations. We have also adopted good inventory management and warehousing practices to minimize supply chain risks related to the manufacture of STAR-0215.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have concluded cell line development for STAR-0215; a stable clone was identified and a master cell bank produced. We believe we have scaled the process appropriately and are in the process of manufacturing sufficient material to cover nonclinical and clinical needs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Human Capital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, we had 29 full-time employees, 11 of whom were primarily engaged in research and development activities. A total of 10 of our full-time employees have Ph.D. degrees. None of our employees is represented by a labor union and we believe our relations with our employees are good.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. Our cash compensation, which consists of base salary and annual bonuses based upon bonus targets, are market-based and are designed to attract, retain and motivate our employees. The principal purposes of our equity incentive plans are also to attract, retain and motivate employees, selected consultants and the members of our board of directors through the granting of stock-based compensation awards, which have primarily consisted of stock options, and to align such awards with the interests of our stockholders. We provide a comprehensive benefits package to help employees manage health, well-being, finances, and life outside of work, including health insurance, dental and vision insurance, life insurance, short-term and long-term disability insurance, paid sick leave, a 401(k)&#160;plan, a health savings account program, and paid vacation time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We value the health, safety and wellbeing of our employees and their families. In response to the COVID-19 pandemic, we implemented, and continue to implement, safety measures that we have determined are in the best interest of our employees, along with measures designed to protect the health of all those entering our office.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Government Regulation and Product Approval</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, sales, pricing, reimbursement, post-approval monitoring and reporting, and import and export of drugs and biologics. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Review and Approval of Drugs and Biologics in the United States</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA approves and regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and related regulations. Biological products are licensed for marketing under the Public Health Service Act, or PHSA, and subject to regulation under the FDCA and related regulations. A company, institution, or organization which takes responsibility for the initiation and management of a clinical development program for such products is referred to as a sponsor. A sponsor seeking approval to market and distribute a new drug or biological product in the United States must typically secure the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of preclinical laboratory tests in compliance with the FDA&#8217;s good laboratory practice, or GLP, regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">design of a clinical protocol and submission to the FDA of an IND, which must take effect before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices, or GCPs, to establish the safety and efficacy of the proposed drug product for each proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of a new drug application, or NDA, for a drug candidate product and a biological licensing application, or BLA, for a biological product requesting marketing for one or more proposed indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">review of the request for approval by an FDA advisory committee, where appropriate or if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance with cGMPs to assure the product&#8217;s identity, strength, quality and purity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payment of user fees and securing FDA approval of the NDA or BLA; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, and the potential requirement to conduct post-approval studies.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preclinical Studies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Before a sponsor begins testing a compound with potential therapeutic value in humans, the product candidate enters the preclinical testing stage. Preclinical studies include laboratory evaluation of the purity and stability of the manufactured substance or active pharmaceutical ingredient and the formulated product, as well as in vitro and animal studies to assess the safety and activity of the product candidate for initial testing in humans and to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations and standards and the United States Department of Agriculture&#8217;s Animal Welfare Act, if applicable. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, and long-term toxicity studies, may continue after the IND is submitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The IND and IRB Processes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An IND is a request for FDA authorization to administer an investigational product candidate to humans. Such authorization must be secured prior to interstate shipment and administration of any new drug or biologic that is not the subject of an approved NDA or BLA. In support of a request for an IND, sponsors must submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, are submitted to the FDA as part of an IND. The FDA requires a 30-day waiting period after the filing of each IND before clinical trials may begin. This waiting period is designed to allow the FDA to review the IND to determine whether human research subjects will be exposed to unreasonable health risks. At any time during this 30-day period, or thereafter, the FDA may raise concerns or questions about the conduct of the trials as outlined in the IND and impose a clinical hold or partial clinical hold. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following commencement of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on that trial. Clinical holds are imposed by the FDA whenever there is concern for patient safety and may be a result of new data, findings, or developments in clinical, nonclinical, and/or chemistry, manufacturing, and controls, or CMCs. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30&#160;days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When a foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain regulatory requirements of the FDA in order to use the study as support for an IND or application for marketing approval. Specifically, the studies must be conducted in accordance with GCP, including undergoing review and receiving approval by an independent ethics committee, or IEC, and seeking and receiving informed consent from subjects. GCP requirements encompass both ethical and data integrity standards for clinical studies. The FDA&#8217;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical studies, as well as the quality and integrity of the resulting data. They further help ensure that non-IND foreign studies are conducted in a manner comparable to that required for IND studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the foregoing IND requirements, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the trial at least annually. The IRB must review and approve, among other things, the trial protocol and informed consent information to be provided to trial subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The FDA&#8217;s primary objectives in reviewing an IND are to assure the safety and rights of patients and to help assure that the quality of the investigation will be adequate to permit an evaluation of the drug&#8217;s effectiveness and safety and of the biological product&#8217;s safety, purity and potency. Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board, or DSMB, or committee. This group provides authorization for whether a trial may move </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">forward at designated check points based on access that only the group maintains to available data from the trial. Suspension or termination of development during any phase of clinical trials can occur if it is determined that the participants or patients are being exposed to an unacceptable health risk. Other reasons for suspension or termination may be made based on evolving business objectives and/or competitive climate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Expanded Access to an Investigational Drug for Treatment Use</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Expanded access, sometimes called &#8220;compassionate use,&#8221; is the use of investigational new drug products outside of clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. FDA regulations allow access to investigational drugs under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings); intermediate-size patient populations; and larger populations for use of the drug under a treatment protocol, or Treatment IND Application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">When considering an IND for expanded access to an investigational product with the purpose of treating a patient or a group of patients, the sponsor and treating physicians or investigators will determine suitability when all of the following criteria apply: patient(s)&#160;have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the expanded use of the investigational drug for the requested treatment will not interfere with the initiation, conduct, or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential development of the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There is no obligation for a sponsor to make its drug products available for expanded access; however, as required by the 21st&#160;Century Cures Act, or Cures Act, passed in 2016, sponsors are required to make policies for evaluating and responding to requests for expanded access for patients publicly available upon the earlier of initiation of a Phase&#160;2 or Phase&#160;3 clinical trial, or 15&#160;days after the investigational drug or biologic receives designation as a breakthrough therapy, fast track product, or regenerative medicine advanced therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, on May&#160;30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients, but the manufacturer must develop an internal policy and respond to patient requests according to that policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Human Clinical Studies in Support of an NDA or BLA</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written trial protocols detailing, among other things, the inclusion and exclusion criteria, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol, and any subsequent material amendment to the protocol, must be submitted to the FDA as part of the IND, and progress reports detailing the status of the clinical trials must be submitted to the FDA annually. The clinical investigation of an investigational drug or biological product is generally divided into four phases. Although the phases are usually conducted sequentially, they may overlap or be combined. The four phases of an investigation are as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">&#9679;</span><span style="font-style:italic;font-weight:bold;">Phase&#160;1. </span>&#160;Phase&#160;1 studies include the initial introduction of an investigational new drug or biological product into humans. These studies are designed to evaluate the safety, dosage tolerance, metabolism and pharmacologic actions of the investigational drug or biological product in humans, the side effects associated with increasing doses, and if possible, to gain early evidence on effectiveness.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">&#9679;</span><span style="font-style:italic;font-weight:bold;">Phase&#160;2. </span>&#160;Phase&#160;2 includes the controlled clinical trials conducted to preliminarily or further evaluate the effectiveness of the investigational drug or biological product for a particular indication(s)&#160;in patients with the disease or condition under trial, to determine dosage tolerance and optimal dosage, and to identify possible adverse side effects and safety risks associated with the drug or biological product. Phase&#160;2 clinical trials are typically well-controlled, closely monitored, and conducted in a limited patient population.</div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">&#9679;</span><span style="font-style:italic;font-weight:bold;">Phase&#160;3. </span>&#160;Phase&#160;3 clinical trials are generally controlled clinical trials conducted in an expanded patient population generally at geographically dispersed clinical trial sites. They are performed after preliminary evidence suggesting effectiveness of the drug or biological product has been obtained, and are intended to further evaluate dosage, clinical effectiveness and safety, to establish the overall benefit-risk relationship of the investigational drug or biological product, and to provide an adequate basis for product approval.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">&#9679;</span><span style="font-style:italic;font-weight:bold;">Phase&#160;4. </span>&#160;Post-approval studies may be conducted after initial marketing approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A clinical trial may combine the elements of more than one phase and the FDA often requires more than one Phase 3 trial to support marketing approval of a product candidate. A company&#8217;s designation of a clinical trial as being of a particular phase is not necessarily indicative that the study will be sufficient to satisfy the FDA requirements of that phase because this determination cannot be made until the protocol and data have been submitted to and reviewed by the FDA. Moreover, as noted above, a pivotal trial is a clinical trial that is believed to satisfy FDA requirements for the evaluation of a product candidate&#8217;s safety and efficacy such that it can be used, alone or with other pivotal or non-pivotal trials, to support regulatory approval. Generally, pivotal trials are Phase 3 trials, but they may be Phase 2 trials if the design provides a well-controlled and reliable assessment of clinical benefit, particularly in an area of unmet medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or in vitro testing that suggest a significant risk in humans exposed to the drug; and any clinically important increase in the case of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Finally, sponsors of clinical trials are required to register and disclose certain clinical trial information on a public registry (clinicaltrials.gov) maintained by the U.S. National Institutes of Health, or NIH. In particular, information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. The NIH&#8217;s Final Rule on registration and reporting requirements for clinical trials became effective in 2017, and both NIH and the FDA have recently signaled the government&#8217;s willingness to begin enforcing those requirements against non-compliant clinical trial sponsors. The failure to submit clinical trial information to clinicaltrials.gov, as required, is a prohibited act under the FDCA with violations subject to potential civil monetary penalties of up to $10,000 for each day the violation continues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Manufacturing and Other Regulatory Requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Concurrent with clinical trials, companies often complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the candidate product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality, purity, and potency of the final drug. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Specifically, the FDA&#8217;s regulations require that pharmaceutical products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. Manufacturers and other entities involved in the manufacture and distribution of approved pharmaceuticals are required to register their establishments with the FDA and some state agencies, and they are subject to periodic unannounced inspections by the FDA for compliance with cGMPs and other requirements. Inspections must follow a &#8220;risk-based schedule&#8221; that may result in certain establishments being inspected more frequently. Manufacturers may also have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated. Changes to the manufacturing process, specifications or container closure system for an approved product are strictly regulated and often require prior FDA approval before being implemented. The FDA&#8217;s regulations also require, among other things, the investigation and correction of any deviations from cGMP and the imposition of reporting and documentation requirements upon the sponsor and any third-party manufacturers involved in producing the approved product.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pediatric Studies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Pediatric Research Equity Act of 2003, an application or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the sponsor plans to conduct, including study objectives and design, any deferral or waiver requests and other information required by regulation. The sponsor, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other and agree upon a final plan. The FDA or the sponsor may request an amendment to the plan at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For investigational products intended to treat a serious or life-threatening disease or condition, the FDA must, upon the request of a sponsor, meet to discuss preparation of the initial pediatric study plan or to discuss deferral or waiver of pediatric assessments. In addition, the FDA will meet early in the development process to discuss pediatric study plans with sponsors, and the FDA must meet with sponsors by no later than the end-of-phase 1 meeting for serious or life-threatening diseases and by no later than ninety&#160;days after the FDA&#8217;s receipt of the study plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may, on its own initiative or at the request of the sponsor, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric trials begin. The law now requires the FDA to send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments required under PREA, have failed to seek or obtain a deferral or deferral extension or have failed to request approval for a required pediatric formulation. It further requires the FDA to publicly post the PREA Non-Compliance letter and sponsor&#8217;s response. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation, although FDA has recently taken steps to limit what it considers abuse of this statutory exemption in PREA by announcing that it does not intend to grant any additional orphan drug designations for rare pediatric subpopulations of what is otherwise a common disease. The FDA also maintains a list of diseases that are exempt from PREA requirements due to low prevalence of disease in the pediatric population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Submission and Review of an NDA or BLA by the FDA</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to obtain approval to market a drug or biological product in the United States, a marketing application must be submitted to the FDA that provides data establishing the safety and effectiveness of the proposed drug product for the proposed indication, and the safety, purity and potency of the biological product for its intended indication. The application includes all relevant data available from pertinent preclinical and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s CMCs and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the investigational drug product and the safety, purity and potency of the biological product to the satisfaction of the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The application is the vehicle through which sponsors formally propose that the FDA approve a new product for marketing and sale in the United States for one or more indications. Every new product candidate must be the subject of an approved NDA or BLA before it may be commercialized in the United States. Under federal law, the submission and review of most applications is subject to an application user fee, which may be substantial (for example, for federal fiscal year 2022 this application fee is approximately $3.1 million), and the sponsor of an approved application is also subject to an annual program fee, currently more than $369,000 per eligible prescription product. Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee for products with orphan designation and a waiver for certain small businesses. If an application is withdrawn prior to the FDA acceptance for filing, 75% of these fees may be refunded to the sponsor. If an application is withdrawn after filing, a lower portion of these fees may be refunded in certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Following submission of an NDA or BLA, the FDA conducts a preliminary review of all applications within 60&#160;days of receipt and must inform the sponsor at that time or before whether an application is sufficiently complete to permit substantive review. In pertinent part, FDA&#8217;s regulations state that an application &#8220;shall not be considered as filed until all pertinent information and data have been received&#8221; by the FDA. In the event that FDA determines that an application does not satisfy this standard, it will issue a Refuse to File, or RTF, determination to the applicant. Typically, an RTF will be based on administrative incompleteness, such as clear omission of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">information or sections of required information; scientific incompleteness, such as omission of critical data, information or analyses needed to evaluate safety and efficacy or provide adequate directions for use; or inadequate content, presentation, or organization of information such that substantive and meaningful review is precluded. The FDA may request additional information rather than accept an application for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs and BLAs. Under that agreement, 90% of applications seeking approval of New Molecular Entities, or NMEs, are meant to be reviewed within ten&#160;months from the date on which FDA accepts the NDA for filing, and 90% of applications for NMEs that have been designated for &#8220;priority review&#8221; are meant to be reviewed within six&#160;months of the filing date. The review process and the Prescription Drug User Fee Act, or PDUFA, goal date may be extended by the FDA for three additional&#160;months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Before approving an application, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. These pre-approval inspections may cover all facilities associated with an NDA or BLA submission, including drug component manufacturing (e.g., active pharmaceutical ingredients), finished drug product manufacturing, and control testing laboratories. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may refer an application for a novel product to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The FDA&#8217;s Decision on an NDA or BLA</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA reviews an application to determine, among other things, whether the product is safe and whether it is effective for its intended use(s), with the latter determination being made on the basis of substantial evidence. The term &#8220;substantial evidence&#8221; is defined under the FDCA as &#8220;evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the product involved, on the basis of which it could fairly and responsibly be concluded by such experts that the product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling or proposed labeling thereof.&#8221; &#160;The FDA has interpreted this evidentiary standard to require at least two adequate and well-controlled clinical investigations to establish effectiveness of a new product. Under certain circumstances, however, FDA has indicated that a single trial with certain characteristics and additional information may satisfy this standard.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After evaluating the application and all related information, including the advisory committee recommendations, if any, and inspection reports of manufacturing facilities and clinical trial sites, the FDA will issue either a Complete Response Letter, or CRL, or an approval letter. To reach this determination, the FDA must determine that the drug is effective and that its expected benefits outweigh its potential risks to patients. This &#8220;benefit-risk&#8221; assessment is informed by the extensive body of evidence about the product&#8217;s safety and efficacy in the NDA or BLA. This assessment is also informed by other factors, including: the severity of the underlying condition and how well patients&#8217; medical needs are addressed by currently available therapies; uncertainty about how the premarket clinical trial evidence will extrapolate to real-world use of the product in the post-market setting; and whether risk management tools are necessary to manage specific risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">A CRL indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A CRL generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. The CRL may require additional clinical or other data, additional pivotal Phase 3 clinical trial(s)&#160;and/or other significant and time- consuming requirements related to clinical trials, preclinical studies or manufacturing. If a CRL is issued, the applicant will have one&#160;year to respond to the deficiencies identified by the FDA, at which time the FDA can deem the application withdrawn or, in its discretion, grant the applicant an additional six&#160;month extension to respond. The FDA has committed to reviewing resubmissions in response to an issued CRL in either two or six&#160;months depending on the type of information included. Even with the submission of this additional information, however, the FDA ultimately may decide that the application does not satisfy </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">the regulatory criteria for approval. The FDA has taken the position that a CRL is not final agency action making the determination subject to judicial review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An approval letter, on the other hand, authorizes commercial marketing of the product with specific prescribing information for specific indications. That is, the approval will be limited to the conditions of use (e.g., patient population, indication) described in the FDA-approved labeling. Further, depending on the specific risk(s)&#160;to be addressed, the FDA may require that contraindications, warnings or precautions be included in the product labeling, require that post-approval trials, including Phase 4 clinical trials, be conducted to further assess a product&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing trials or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Ensuring Innovation Act, which was signed into law in April&#160;2021, the FDA must publish action packages summarizing its decisions to approve new drugs and biologics within 30&#160;days of approval of such products. To date, CRLs are not publicly available documents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Expedited Review Programs </span></p><a id="_Hlk94094360"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA is authorized to expedite the development of candidate products and review of applications in several ways. None of these expedited programs changes the standards for approval but each may help expedite the development or approval process governing product candidates.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Fast Track designation</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">.  The sponsor of a product candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after the filing of the IND.  Candidate products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. In addition to other benefits, such as the ability to have greater interactions with the FDA, the FDA may initiate review of sections of a Fast Track application before the application is complete, a process known as rolling review. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Breakthrough therapy designation. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To qualify for the breakthrough therapy program, product candidates must be intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence must indicate that such product candidates may demonstrate substantial improvement on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient development program, intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review and rolling review. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Priority review.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> A product candidate is eligible for priority review if it treats a serious condition and, if approved, it would be a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention compared to marketed products. FDA aims to complete its review of priority review applications within six months as opposed to 10 months for standard review. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Accelerated approval. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Drug or biologic products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval. Accelerated approval means that a product candidate may be approved on the basis of adequate and well controlled clinical trials establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity and prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug or biologic product candidate receiving accelerated approval perform adequate and well controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials. </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Regenerative advanced therapy.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> With passage of the 21st Century Cures Act, or the Cures Act, in December 2016, Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">condition</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative advanced therapy designation include early interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Post-Approval Regulation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Drugs and biologics manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, manufacturers and other entities involved in the manufacture and distribution of approved products are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of the product, suspension of the approval, or complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters or holds on post-approval clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of products; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. In September&#160;2021, the FDA published final regulations which describe the types of evidence that the agency will consider in determining the intended use of a drug or biologic. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. If a company is found to have promoted off-label uses, it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Generic Drugs and Regulatory Exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">In 1984, with passage of the Hatch-Waxman Act, Congress established an abbreviated regulatory scheme authorizing the FDA to approve generic drugs that are shown to contain the same active ingredients as, and to be bioequivalent to, drugs previously approved </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">by the FDA pursuant to NDAs. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application, or ANDA, to the agency. An ANDA is a comprehensive submission that contains, among other things, data and information pertaining to the active pharmaceutical ingredient, bioequivalence, drug product formulation, specifications and stability of the generic drug, as well as analytical methods, manufacturing process validation data and quality control procedures. ANDAs are &#8220;abbreviated&#8221; because they generally do not include preclinical and clinical data to demonstrate safety and effectiveness. Instead, in support of such applications, a generic manufacturer may rely on the preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference-listed drug, or RLD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Hatch-Waxman Act, the FDA may not approve an ANDA until any applicable period of non-patent exclusivity for the RLD has expired. The FDCA provides a period of five&#160;years of non-patent data exclusivity for a new drug containing a new chemical entity. For the purposes of this provision, a new chemical entity, or NCE, is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. This interpretation was confirmed with enactment of the Ensuring Innovation Act in April&#160;2021. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. In cases where such NCE exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five&#160;years unless the submission is accompanied by a Paragraph IV certification, in which case the applicant may submit its application four&#160;years following the original product approval. The FDCA also provides for a period of three&#160;years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Biosimilars and Regulatory Exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">When a biological product is licensed for marketing by FDA with approval of a BLA, the product may be entitled to certain types of market and data exclusivity barring FDA from approving competing products for certain periods of time. In March&#160;2010, the Patient Protection and Affordable Care Act was enacted in the United States and included the Biologics Price Competition and Innovation Act of 2009, or the BPCIA. The BPCIA amended the PHSA to create an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. To date, the FDA has approved a number of biosimilars and the first interchangeable biosimilar product was approved on July&#160;30, 2021 and a second product previously approved as a biosimilar was designated as interchangeable in October&#160;2021. The FDA has also issued numerous guidance documents outlining its approach to reviewing and licensing biosimilars and interchangeable biosimilars under the PHSA, including a draft guidance issued in November&#160;2020 that seeks to provide additional clarity to manufacturers of interchangeable biosimilars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the BPCIA, a manufacturer may submit an application for licensure of a biologic product that is &#8220;biosimilar to&#8221; or &#8220;interchangeable with&#8221; a previously approved biological product or &#8220;reference product.&#8221; In order for the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity, and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product, and (for products administered multiple times) that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four&#160;years following the date of approval of the reference product. The FDA may not approve a biosimilar product until 12&#160;years from the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full application for such product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. There have been recent government proposals to reduce the 12-year reference product exclusivity period, but none has been enacted to date. At the same time, since passage of the BPCIA, many states have passed laws or amendments to laws, which address pharmacy practices involving biosimilar products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Orphan Drug Designation and Exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Under the Orphan Drug Act, the FDA may designate a drug product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition, generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a drug product available in the United States for treatment of the disease or condition will be recovered from sales of the product. A company must request orphan drug designation before submitting an NDA or BLA for the candidate product. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">use. Orphan drug designation does not shorten the PDUFA goal dates for the regulatory review and approval process, although it does convey certain advantages such as tax benefits and exemption from the PDUFA application fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not approve another sponsor&#8217;s marketing application for the same drug for the same indication for seven&#160;years, except in certain limited circumstances. Orphan exclusivity does not block the approval of a different product for the same rare disease or condition, nor does it block the approval of the same product for different indications. If a drug or biologic designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if the company with orphan drug exclusivity is not able to meet market demand or the subsequent product with the same drug for the same condition is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care. This is the case despite an earlier court opinion holding that the Orphan Drug Act unambiguously required the FDA to recognize orphan drug exclusivity regardless of a showing of clinical superiority. Under Omnibus legislation signed by President Trump on December&#160;27, 2020, the requirement for a product to show clinical superiority applies to drugs and biologics that received orphan drug designation before enactment of FDARA in 2017, but have not yet been approved or licensed by FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2021, the Court of Appeals for the 11th Circuit held that, for the purpose of determining the scope of market exclusivity, the term &#8220;same disease or condition&#8221; in the statute means the designated &#8220;rare disease or condition&#8221; and could not be interpreted by the FDA to mean the &#8220;indication or use.&#8221; Thus, the court concluded, orphan drug exclusivity applies to the entire designated disease or condition rather than the &#8220;indication or use.&#8221; It is unclear how this court decision will be implemented by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pediatric Exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six&#160;months of regulatory exclusivity, including orphan drug exclusivity. For drug products, the six&#160;month regulatory exclusivity may be attached to the term of any existing patent or regulatory exclusivity available under the Hatch-Waxman provisions of the FDCA. For biologic products, the six&#160;month period may be attached to any existing regulatory exclusivities but not to any patent terms. This six-month exclusivity may be granted if an NDA or BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six&#160;months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Patent Term Restoration and Extension</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent restoration of up to five&#160;years for patent term lost during product development and the FDA regulatory review. The restoration period granted on a patent covering a product is typically one-half the time between the effective date of the IND and the submission date of an application, plus the time between the submission date of an application and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14&#160;years from the product&#8217;s approval date. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension or restoration in consultation with the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Review and Approval of Drug Products in the European Union</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of drug products. Whether or not it obtains FDA approval for a product, the company would need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">trials or marketing of the product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical Trial Approval in the European Union</span></p><a id="_Hlk95293372"></a><a id="_Hlk96008903"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 31, 2022, the new Clinical Trials Regulation (EU) No 536/2014 became effective in the European Union and replaced the prior Clinical Trials Directive 2001/20/EC. The new regulation aims at simplifying and streamlining the authorization, conduct and transparency of clinical trials in the European Union. Under the new coordinated procedure for the approval of clinical trials, the sponsor of a clinical trial to be conducted in more than one Member State of the European Union, or EU Member State, will only be required to submit a single application for approval. The submission will be made through the Clinical Trials Information System, a new clinical trials portal overseen by the EMA and available to clinical trial sponsors, competent authorities of the EU Member States and the public. </p><a id="_Hlk95293547"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The new regulation did not change the preexisting requirement that a sponsor must obtain prior approval from the competent national authority of the EU Member State in which the clinical trial is to be conducted. If the clinical trial is conducted in different EU Member States, the competent authorities in each of these EU Member States must provide their approval for the conduct of the clinical trial. Furthermore, the sponsor may only start a clinical trial at a specific study site after the applicable ethics committee has issued a favorable opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Parties conducting certain clinical trials must, as in the United States, post clinical trial information in the EU at the EudraCT website: https://eudract.ema.europa.eu.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">PRIME Designation in the European Union</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIority MEdicines, or PRIME, scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small- and medium-sized enterprises, or SMEs, may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, a dedicated agency contact and rapporteur from the CHMP or Committee for Advanced Therapies, or CAT, are appointed early in PRIME scheme facilitating increased understanding of the product at EMA&#8217;s Committee level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pediatric Studies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the European Economic Area, or EEA, companies developing a new medicinal product must agree upon a Pediatric Investigation Plan, or PIP, with the EMA&#8217;s pediatric committee, or PDCO, and must conduct pediatric clinical trials in accordance with that PIP, unless a waiver applies (e.g., because the relevant disease or condition occurs only in adults). The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which marketing authorization is being sought. The marketing authorization application for the product must include the results of pediatric clinical trials conducted in accordance with the PIP, unless a waiver applies, or a deferral has been granted by the PDCO of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults, in which case the pediatric clinical trials must be completed at a later date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Marketing Authorization</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the EEA, medicinal products can only be commercialized after obtaining a marketing authorization. Marketing authorizations for medicinal products may be obtained through several different procedures founded on the same basic regulatory process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The centralized procedure provides for the grant of a single marketing authorization that is valid for all European Union Member States. The centralized procedure is compulsory for medicinal products produced by certain biotechnological processes, products designated as orphan medicinal products, and products with a new active substance indicated for the treatment of certain diseases. It is optional for those products that are highly innovative or for which a centralized process is in the interest of patients. Under the centralized procedure in the European Union, the maximum timeframe for the evaluation of a marketing authorization application, or MAA, is 210&#160;days, excluding clock stops, when additional written or oral information is to be provided by the sponsor in response to questions </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">asked by the CHMP. Accelerated evaluation may be granted by the CHMP in exceptional cases. These are defined as circumstances in which a medicinal product is expected to be of a &#8220;major public health interest.&#8221; Three cumulative criteria must be fulfilled in such circumstances: the seriousness of the disease, such as severely disabling or life-threatening diseases, to be treated; the absence or insufficiency of an appropriate alternative therapeutic approach; and anticipation of high therapeutic benefit. In these circumstances, the EMA ensures that the opinion of the CHMP is given within 150&#160;days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The decentralized procedure provides for approval by one or more other concerned European Union Member States of an assessment of an application for marketing authorization conducted by one European Union Member State, known as the reference European Union Member State. In accordance with this procedure, a sponsor submits an application for marketing authorization to the reference European Union Member State and the concerned European Union Member States. This application is identical to the application that would be submitted to the EMA for authorization through the centralized procedure. The reference European Union Member State prepares a draft assessment and drafts of the related materials within 120&#160;days after receipt of a valid application. The resulting assessment report is submitted to the concerned European Union Member States which, within 90&#160;days of receipt, must decide whether to approve the assessment report and related materials. If a concerned European Union Member State cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the European Commission, whose decision is binding on all European Union Member States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Now that the United Kingdom (which comprises Great Britain and Northern Ireland) has left the European Union, Great Britain will no longer be covered by centralized marketing authorizations (under the Northern Irish Protocol, centralized marketing authorizations will continue to be recognized in Northern Ireland). All medicinal products with a current centralized marketing authorization were automatically converted to Great Britain marketing authorizations on January&#160;1, 2021. For a period of two&#160;years from January&#160;1, 2021, the Medicines and Healthcare products Regulatory Agency, or MHRA, the UK medicines regulator, may rely on a decision taken by the European Commission on the approval of a new marketing authorization in the centralized procedure, in order to more quickly grant a new Great Britain marketing authorization. A separate application will, however, still be required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulatory Requirements After Marketing Authorization</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following marketing authorization of a medicinal product in the European Union, the holder of the authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include compliance with the European Union&#8217;s stringent pharmacovigilance or safety reporting, as well as rules&#160;potentially requiring post-authorization studies and additional monitoring obligations. In addition, the manufacturing of authorized medicinal products, for which a separate manufacturer&#8217;s license is mandatory, must also be conducted in strict compliance with the applicable European Union laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice. These requirements include compliance with European Union cGMP standards when manufacturing medicinal products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the European Union with the intention to import the active pharmaceutical ingredients into the European Union. Finally, the marketing and promotion of authorized drugs, including industry-sponsored continuing medical education and advertising directed toward the prescribers of drugs and/or the general public, are strictly regulated in the European Union notably under Directive 2001/83EC, as amended, and European Union Member State laws. Direct-to-consumer advertising of prescription medicines is prohibited across the European Union.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulatory Data Protection in the European Union</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the European Union, new chemical entities approved on the basis of a complete independent data package qualify for eight&#160;years of data exclusivity upon marketing authorization and an additional two&#160;years of market exclusivity pursuant to Regulation (EC) No 726/2004, as amended, and Directive 2001/83/EC, as amended. Data exclusivity prevents regulatory authorities in the European Union from referencing the innovator&#8217;s data to assess a generic (abbreviated) application for a period of eight&#160;years. During the additional two-year period of market exclusivity, a generic marketing authorization application can be submitted, and the innovator&#8217;s data may be referenced, but no generic medicinal product can be marketed until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of eleven&#160;years if, during the first eight&#160;years of those ten&#160;years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to authorization, is held to bring a significant clinical benefit in comparison with existing therapies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pediatric Exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Products that are granted a marketing authorization with the results of the pediatric clinical trials conducted in accordance with the PIP are eligible for a six&#160;month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval) even where the trial results are negative. In the case of orphan medicinal products, a two&#160;year extension of the orphan market exclusivity may be available. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Orphan Drug Designation and Exclusivity in the European Union</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Regulation (EC) No 141/2000 and Regulation (EC) No.&#160;847/2000 provide that a product can be designated as an orphan medicinal product by the European Commission if its sponsor can establish that the product is intended for the diagnosis, prevention or treatment of: (1)&#160;a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the European Union when the application is made, or (2)&#160;a life-threatening, seriously debilitating or serious and chronic condition in the European Union and that without incentives the medicinal product is unlikely to be developed. For either of these conditions, the sponsor must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the European Union or, if such method exists, the medicinal product will be of significant benefit to those affected by that condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once authorized, orphan medicinal products are entitled to ten&#160;years of market exclusivity in all European Union Member States and, in addition, a range of other benefits during the development and regulatory review process, including scientific assistance for trial protocols, authorization through the centralized marketing authorization procedure covering all member countries and a reduction or elimination of registration and marketing authorization fees. However, marketing authorization may be granted to a similar medicinal product with the same orphan indication during the ten-year period with the consent of the marketing authorization holder for the original orphan medicinal product or if the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities. Marketing authorization may also be granted to a similar medicinal product with the same orphan indication if the product is safer, more effective or otherwise clinically superior to the original orphan medicinal product. The period of market exclusivity may, in addition, be reduced to six&#160;years if it can be demonstrated on the basis of available evidence that the original orphan medicinal product is sufficiently profitable not to justify maintenance of market exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same drug or biologic for the same indication is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. This is the case despite an earlier court opinion holding that the Orphan Drug Act unambiguously required the FDA to recognize orphan exclusivity regardless of a showing of clinical superiority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Brexit and the Regulatory Framework in the United Kingdom</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:14pt 0pt 0pt 0pt;">The United Kingdom&#8217;s withdrawal from the EU took place on January 31, 2020. The EU and the U.K. reached an agreement on their new partnership in the Trade and Cooperation Agreement, or the Agreement, which was applied provisionally beginning on January 1, 2021 and which entered into force on May 1, 2021. The Agreement focuses primarily on free trade by ensuring no tariffs or quotas on trade in goods, including healthcare products such as medicinal products. Thereafter, the EU and the U.K. will form two separate markets governed by two distinct regulatory and legal regimes. As such, the Agreement seeks to minimize barriers to trade in goods while accepting that border checks will become inevitable as a consequence that the U.K. is no longer part of the single market. As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or the MHRA, became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic law whereas Northern Ireland continues to be subject to EU rules under the Northern Ireland Protocol. The MHRA will rely on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended), or the HMR, as the basis for regulating medicines. The HMR has incorporated into the domestic law the body of EU law instruments governing medicinal products that pre-existed prior to the U.K.&#8217;s withdrawal from the EU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:14pt 0pt 0pt 0pt;">Furthermore, while the Data Protection Act of 2018 in the United Kingdom that &#8220;implements&#8221; and complements the European Union&#8217;s General Data Protection Regulation, or GDPR, has achieved Royal Assent on May&#160;23, 2018 and is now effective in the United Kingdom, it is still unclear whether transfer of data from the EEA to the United Kingdom will remain lawful under GDPR. The Trade and Cooperation Agreement provides for a transitional period during which the United Kingdom will be treated like a European </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Union member state in relation to processing and transfers of personal data for four&#160;months from January&#160;1, 2021. This may be extended by two further&#160;months. After such period, the United Kingdom will be a &#8220;third country&#8221; under the GDPR unless the European Commission adopts an adequacy decision in respect of transfers of personal data to the United Kingdom. The United Kingdom has already determined that it considers all of the European Union 27 and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the United Kingdom to the European Union/EEA remain unaffected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General Data Protection Regulation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many countries outside of the United States maintain rigorous laws governing the privacy and security of personal information. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the EEA, and the processing of personal data that takes place in the EEA, is subject to the GDPR, which became effective on May&#160;25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, and it imposes heightened requirements on companies that process health and other sensitive data, such as requiring in many situations that a company obtain the consent of the individuals to whom the sensitive personal data relate before processing such data. Examples of obligations imposed by the GDPR on companies processing personal data that fall within the scope of the GDPR include providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, appointing a data protection officer, providing notification of data breaches and taking certain measures when engaging third-party processors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GDPR also imposes strict rules&#160;on the transfer of personal data to countries outside the EEA, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20&#160;million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR is a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance. In July&#160;2020, the Court of Justice of the European Union, or the CJEU, invalidated the EU-U.S. Privacy Shield framework, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the United States. The CJEU decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses, for transfers of personal data from the EEA to the United States. Following the withdrawal of the U.K. from the EU, the U.K. Data Protection Act 2018 applies to the processing of personal data that takes place in the U.K. and includes parallel obligations to those set forth by GDPR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pharmaceutical Coverage, Pricing and Reimbursement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, the product. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product candidate could reduce physician utilization once the product is approved and have a material adverse effect on sales, results of operations and financial condition. Additionally, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The containment of health care costs also has become a priority of federal, state and foreign governments and the prices of products have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare Reform</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. There have been a number of federal and state proposals during the last few&#160;years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and biologics and other medical products, government control and other changes to the health care system in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the ACA. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. In August&#160;2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the&#160;years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal&#160;year, which went into effect in April&#160;2013 and will remain in effect through 2031. Pursuant to the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, and subsequent legislation, these Medicare sequester reductions have been suspended through the end of March&#160;2022. From April&#160;2022 through June&#160;2022 a 1% sequester cut will be in effect, with the full 2% cut resuming thereafter. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since enactment of the ACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017, which was signed by President Trump on December&#160;22, 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. In December&#160;2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA, and therefore because the mandate was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court heard this case and in June&#160;2021, dismissed this action after finding that the plaintiffs do not have standing to challenge the constitutionality of the ACA. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results. The Trump Administration also took executive actions to delay implementation of the ACA, including directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On January&#160;28, 2021, however, President Biden revoked those orders and issued a new Executive Order which directs federal agencies to reconsider rules&#160;and other policies that limit Americans&#8217; access to health care, and consider actions that will protect and strengthen that access. Under this Order, federal agencies are directed to re-examine: policies that undermine protections for people with pre-existing conditions, including complications related to COVID-19; demonstrations and waivers under Medicaid and the ACA that may reduce coverage or undermine the programs, including work requirements; policies that undermine the Health Insurance Marketplace or other markets for health insurance; policies that make it more difficult to enroll in Medicaid and the ACA; and policies that reduce affordability of coverage or financial assistance, including for dependents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pharmaceutical Prices</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. In 2020, President Trump issued several executive orders intended to lower the costs of prescription products and certain provisions in these orders have been incorporated into regulations. These regulations include an interim final rule&#160;implementing a most favored nation model for prices that would tie Medicare Part&#160;B payments </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries, effective January&#160;1, 2021. That rule, however, has been subject to a nationwide preliminary injunction and, on December&#160;29, 2021, CMS issued a final rule&#160;to rescind it. With issuance of this rule, CMS stated that it will explore all options to incorporate value into payments for Medicare Part&#160;B pharmaceuticals and improve beneficiaries&#8217; access to evidence-based care.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, in October&#160;2020, HHS and the FDA published a final rule&#160;allowing states and other entities to develop a Section&#160;804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. The final rule&#160;is currently the subject of ongoing litigation, but at least six states (Vermont, Colorado, Florida, Maine, New Mexico, and New Hampshire) have passed laws allowing for the importation of drugs from Canada with the intent of developing SIPs for review and approval by the FDA. Further, on November&#160;20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part&#160;D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule&#160;has been delayed by the Infrastructure Investment and Jobs Act to January&#160;1, 2026 in response to ongoing litigation. The rule&#160;also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed until January&#160;1, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2021, acting pursuant to an executive order signed by President Biden, the Department of Health and Human Services, or HHS, released its plan to reduce pharmaceutical prices. The key features of that plan are to: (a)&#160;make pharmaceutical prices more affordable and equitable for all consumers and throughout the health care system by supporting pharmaceutical price negotiations with manufacturers; (b)&#160; improve and promote competition throughout the prescription pharmaceutical industry by supporting market changes that strengthen supply chains, promote biosimilars and generic drugs, and increase transparency; and (c)&#160;foster scientific innovation to promote better healthcare and improve health by supporting public and private research and making sure that market incentives promote discovery of valuable and accessible new treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. A number of states, for example, require drug manufacturers and other entities in the drug supply chain, including health carriers, pharmacy benefit managers, wholesale distributors, to disclose information about pricing of pharmaceuticals. In addition, regional healthcare organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription pharmaceutical and other healthcare programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular drug candidate to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states, and parallel trade, i.e., arbitrage between low-priced and high-priced member states, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare Law and Regulation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Health care providers and third-party payors play a primary role in the recommendation and prescription of drug products that are granted marketing approval. Arrangements with providers, consultants, third-party payors and customers are subject to broadly applicable fraud and abuse, anti-kickback, false claims laws, patient privacy laws and regulations and other health care laws and regulations that may constrain business and/or financial arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Restrictions under applicable federal and state health care laws and regulations, include the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal health care program such as Medicare and Medicaid; the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious or fraudulent or knowingly making, using or causing to made or used a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government; the Foreign Corrupt Practices Act, or FCPA, which prohibits companies and their intermediaries from making, or offering or promising to make, improper payments to non-United States officials for the purpose of obtaining or retaining business or otherwise seeking favorable treatment; and the federal transparency requirements known as the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, within the United States Department of Health and Human Services, information related to payments and other transfers of value made by that entity to physicians, other healthcare providers and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. Additionally, some state and local laws require the registration of pharmaceutical sales representatives in the jurisdiction. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Federal and State Data Privacy Laws</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There are multiple privacy and data security laws that may impact our business activities, in the United States and in other countries where we conduct trials or where we may do business in the future. These laws are evolving and may increase both our obligations and our regulatory risks in the future. In the health care industry generally, under the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, the U.S. Department of Health and Human Services, or HHS, has issued regulations to protect the privacy and security of protected health information, or PHI, used or disclosed by covered entities including certain healthcare providers, health plans and healthcare clearinghouses. HIPAA also regulates standardization of data content, codes and formats used in healthcare transactions and standardization of identifiers for health plans and providers. HIPAA also imposes certain obligations on the business associates of covered entities that obtain protected health information in providing services to or on behalf of covered entities. HIPAA may apply to us in certain circumstances and may also apply to our business partners in ways that may impact our relationships with them. Our clinical trials are regulated by the Common Rule, which also includes specific privacy-related provisions. In addition to federal privacy regulations, there are a number of state laws governing confidentiality and security of health information that may be applicable to our business. In addition to possible federal civil and criminal penalties for HIPAA violations, state attorneys general are authorized to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state attorneys general (along with private plaintiffs) have brought civil actions seeking injunctions and damages resulting from alleged violations of HIPAA&#8217;s privacy and security rules. State attorneys general also have authority to enforce state privacy and security laws. New laws and regulations governing privacy and security may be adopted in the future as well.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">At the state level, California has enacted legislation that has been dubbed the first &#8220;GDPR-like&#8221; law in the United States. Known as the California Consumer Privacy Act, or CCPA, it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA went into effect on January&#160;1, 2020 and requires covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, effective starting on January&#160;1, 2023, the California Privacy Rights Act, or CPRA, will significantly modify the CCPA, including by expanding consumers&#8217; rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA and the CPRA. The CCPA and CPRA could impact our business activities depending on how it is interpreted and exemplifies the vulnerability of our business to not only cyber threats but also the evolving regulatory environment related to personal data and individually identifiable health information. These provisions may apply to some of our business activities. In addition, other states, including Virginia and Colorado, already have passed state privacy laws and other states will likely be considering similar laws in the near future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our current or future business activities, including certain clinical research, sales and marketing practices and the provision of certain items and services to our customers, could be subject to challenge under one or more of such privacy and data security laws. The heightening compliance environment and the need to build and maintain robust and secure systems to comply with different privacy compliance and/or reporting requirements in multiple jurisdictions could increase the possibility that a healthcare company may fail to comply fully with one or more of these requirements. If our operations are found to be in violation of any of the privacy or data security laws or regulations described above that are applicable to us, or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal, civil and administrative penalties, damages, fines, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a consent decree or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any product candidates we may develop, once approved, are sold in a foreign country, we may be subject to similar foreign laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Corporate Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our executive offices are located at 100 High Street, 28th Floor, Boston, Massachusetts, 02110, and our telephone number is (617)&#160;349-1971. Our website address is www.astriatx.com. The information contained on, or that can be accessed through, our website is not a part of this Annual Report on Form&#160;10-K. We have included our website address in this Annual Report on Form&#160;10-K solely as an inactive textual reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Available Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K and any amendments to these reports filed or furnished pursuant to Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934, as amended, or the Exchange Act, are available free of charge on our website located at www.astriatx.com as soon as reasonably practicable after they are filed with or furnished to the Securities and Exchange Commission, or the SEC. These reports are also available at the SEC&#8217;s Internet website at www.sec.gov. Our website and the information contained therein or connected thereto are not intended to be incorporated into this Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A copy of our Corporate Governance Guidelines, Code of Business Conduct and Ethics and the charters of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee are posted on our website, www.astriatx.com, under &#8220;Investors&#8201;&#8212;&#8201;Corporate Governance&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c52dee0f_725b_4d46_b0f5_a235131cb8f6"></a><a id="_Hlk96483826"></a><a id="Item1A_245229"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;1A.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We operate in a dynamic and rapidly changing business environment that involves risks and substantial uncertainty. The following discussion addresses risks and uncertainties that could cause, or contribute to causing, actual results to differ from expectations in material ways. In evaluating our business, investors should pay particular attention to the risks and uncertainties described below and in other sections of this Annual Report on Form&#160;10-K and in our subsequent filings with the SEC. These risks and uncertainties, or other events that we do not currently anticipate or that we currently deem immaterial also may affect our results of operations, cash flows and financial condition. The trading price of our common stock could also decline due to any of these risks, and you could lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the Discovery, Development and Commercialization of Our Product Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business is entirely dependent on the success of STAR-0215 as a potential treatment for HAE, a program that is in preclinical development.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our business is entirely dependent on the success of STAR-0215, which is in the preclinical stage of development, and has only produced results in preclinical and nonclinical settings. We acquired STAR-0215 in connection with our acquisition of Quellis in January&#160;2021. We cannot give any assurance that we will generate clinical or other data for STAR-0215 sufficiently supportive to receive regulatory approval, which will be required before it can be commercialized. We have not filed an IND with the FDA for STAR-0215. We may experience issues surrounding preliminary trial execution, such as delays in filing our planned IND, delays in FDA acceptance of our planned IND, delays in filings with other regulatory authorities, include potential CTA filings in the EU, feedback from FDA and other EU regulatory authorities on our Phase 1b/2 trial design, revisions in our Phase 1a and Phase 1b/2 trial designs, and finalization of trial protocols, difficulties with patient recruitment and enrollment, quality and provision of materials and supplies necessary to manufacture sufficient quantities of drug product to meet our clinical trial needs on a timely basis, or early safety signals. STAR-0215 will require significant preclinical and clinical development, regulatory review and approval, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Until late 2020, we were largely focused on discovering and developing novel small molecule drugs by applying our SMART Linker drug discovery platform. With the acquisition of Quellis, we shifted our focus to STAR-0215. Unlike our prior product candidates, which were small molecules, STAR-0215 is a humanized monoclonal antibody. As a result, we face different regulatory, manufacturing, and research and discovery requirements and demands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The success of our business, including our ability to finance our company and generate any revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of STAR-0215, which may never occur. Given that STAR-0215 is in preclinical development, it will be&#160;years before we are able to demonstrate safety and efficacy of STAR-0215 sufficient to warrant approval for commercialization, and we may never be able to do so. If we are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize STAR-0215, we may not be able to generate sufficient revenue to continue our business and our business would be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials and we may be unsuccessful in identifying any new product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Our lead product candidate, STAR-0215, is still in the preclinical stage, and its risk of failure is high. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support our planned IND in the United States, or similar applications in other jurisdictions, including CTA submissions in the EU. Such studies are complex and may be subject to delays or increased costs due to our dependence upon third parties to assist us with such studies and the ability to source raw materials and the appropriate animals, including non-human primates, so that we can conduct such testing. In the event that the FDA or comparable foreign regulatory authorities require us to complete additional preclinical studies or we are required to satisfy other FDA requests or other requests of comparable foreign regulatory authorities prior to commencing clinical trials, the start of our planned clinical trials may be delayed or take longer to complete. Even after we receive and incorporate guidance from the FDA or comparable foreign regulatory authorities, such authorities may not agree that we have satisfied their requirements to commence any clinical trial or change their position on the acceptability of our trial design or the clinical endpoints selected, which may require us to complete additional preclinical studies or clinical trials or impose stricter approval conditions than we currently expect. We cannot be certain of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA or comparable foreign regulatory authorities will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of our programs. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications, including CTA submissions in the EU, will result in the FDA or comparable foreign regulatory authorities allowing clinical trials to begin or that we can meet the requirements imposed by such authorities for beginning such trials on a timely basis or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, any future research programs to identify new product candidates will require substantial technical, financial and human resources, and we may be unsuccessful in our efforts to identify new product candidates. If we are unable to identify suitable additional compounds for preclinical and clinical development, our ability to develop product candidates and obtain product revenues in future periods could be compromised, which could result in significant harm to our financial position and adversely impact our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Results of preclinical studies and early clinical trials may not be predictive of results of future clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of clinical trials do not necessarily predict success in future clinical trials. Many companies in the pharmaceutical and biotechnology industries, including us, have suffered significant setbacks in late-stage clinical trials after achieving positive results in preclinical studies or early development, and we cannot be certain that we will not face similar setbacks. The design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. In addition, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for the product candidates. Even if we, or any future collaborators, believe that the results of clinical trials for our product candidates warrant marketing approval, the FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. If we fail to receive positive results in preclinical studies or clinical trials of STAR-0215 or any other future product candidate, the development timeline and regulatory approval and commercialization prospects for such product candidate, and, correspondingly, our business and financial prospects would be negatively impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have limited financial and managerial resources and are focused on the preclinical and clinical development of STAR-0215 as a potential treatment for HAE, a rare disease with unmet medical need. We would expect that development of any other future product candidate would also be for specific indications that we identify as most likely to succeed, in terms of both their potential for marketing approval and commercialization. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that may prove to have greater commercial potential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on STAR-0215 and future research and development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to the product candidate.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome. If clinical trials of a product candidate fail to satisfactorily demonstrate safety and efficacy to the FDA and other comparable foreign regulators, we, or any future collaborators, may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We, and any future collaborators, are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining approval from the FDA of a BLA, which would be required for approval of STAR-0215, or NDA. Comparable foreign regulatory authorities, such as the European Medicines Agency, or the EMA, require similar approvals. We, and any future collaborators, may never receive such approvals. We, and any future collaborators, must complete extensive preclinical development and clinical trials to demonstrate the safety and efficacy in humans of any product candidate that we may choose to develop before we, or they, will be able to obtain these approvals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical testing is expensive, difficult to design and implement, can take many&#160;years to complete and is inherently uncertain as to outcome. We cannot guarantee that any clinical trials we initiate will be conducted as planned or completed on schedule, or at all. In addition, in the case of STAR-0215, for which we are designing our clinical studies with the goal of demonstrating that it can be dosed in HAE patients every three&#160;months or longer, clinical trials will necessarily be longer given the length of time between doses in the trials. Further, the clinical development of product candidates is susceptible to the risk of failure at any stage of drug development, including failure to demonstrate efficacy in a clinical trial or across a broad population of patients, the occurrence of adverse events that are severe or medically or commercially unacceptable, failure to comply with protocols or applicable regulatory requirements and determination by the FDA or any comparable foreign regulatory authority that a product candidate may not continue development or is not approvable. It is possible that even if a product candidate that we choose to develop has a beneficial effect, that effect will not be detected during clinical evaluation as a result of one or more of a variety of factors, including the size, duration, design, measurements, conduct or analysis of our clinical trials. Conversely, as a result of the same factors, our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any. Similarly, in any clinical trials we conduct, we may fail to detect toxicity of or intolerability caused by a product candidate, or mistakenly believe that a product candidate is toxic or not well tolerated when that is not in fact the case.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have not previously submitted an NDA or BLA to the FDA or similar drug approval filings to comparable foreign regulatory authorities for any of our product candidates. Moreover, our prior programs were not biologics and this lack of experience may impede our ability to successfully complete clinical development of STAR-0215 or any future biologic product candidates we pursue and obtain FDA approval in a timely manner, if at all. Any inability to complete clinical development successfully could result in additional costs to us, or any future collaborators, and impair our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties. Moreover, if (1)&#160;we, or any future collaborators, are required to modify our trial designs, such as required modifications with respect to patient populations, endpoints, comparators or trial duration, (2)&#160;we, or any future collaborators, are required to conduct additional clinical trials or other testing of a product candidate beyond the trials and testing that we, or they contemplate, (3)&#160;we, or any future collaborators, are unable to successfully complete clinical trials of a product candidate or other testing, (4)&#160;the results of these trials or tests are unfavorable, uncertain or are only modestly favorable, or (5)&#160;there are unacceptable safety concerns associated with a product candidate, we, or any future collaborators, may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be delayed in obtaining marketing approval for such product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not obtain marketing approval at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain marketing approval for indications or patient populations that are not as broad as intended or desired;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain marketing approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including boxed warnings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be subject to additional post-marketing testing or other requirements, such as a REMS program; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be required to remove the product from the market after obtaining marketing approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Given our early stage of development, it will be&#160;years before we are able to demonstrate the safety and efficacy of a treatment sufficient to warrant approval for commercialization, and we may never be able to do so. Our failure to successfully complete clinical </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">trials of a product candidate and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market any product candidate would significantly harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Adverse events or undesirable side effects caused by, or other unexpected properties of, any future product candidate may be identified during development that could delay or prevent their marketing approval or limit their use.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Adverse events or undesirable side effects caused by, or other unexpected properties of, any future product candidate could cause us, any future collaborators, an institutional review board or regulatory authorities to interrupt, delay or halt clinical trials of one or more of such product candidates and could result in a more restrictive label or the delay or denial of marketing approval by the FDA or comparable foreign regulatory authorities. If any such product candidate is associated with adverse events or undesirable side effects or has properties that are unexpected, we, or any future collaborators, may need to abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that initially showed promise in clinical or earlier stage testing have later been found to cause undesirable or unexpected side effects that prevented further development of the compound.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we, or any future collaborators, experience any of a number of possible unforeseen events in connection with clinical trials of any future product candidate, potential marketing approval or commercialization of such product candidate could be delayed or prevented.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We, or any future collaborators, may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent marketing approval or commercialization of any future product candidate, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials may produce unfavorable or inconclusive results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or any future collaborators, may decide, or regulators may require us or them, to conduct additional clinical trials or abandon product development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients required for clinical trials may be larger than we, or any future collaborators, anticipate, patient enrollment in these clinical trials may be slower than we, or any future collaborators, anticipate, particularly with respect to STAR-0215, which is being developed as a potential treatment for HAE, an indication which has a significant number of approved products and products in clinical development, or participants may drop out of these clinical trials at a higher rate than we, or any future collaborators, anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of planned clinical trials may be greater than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our third-party contractors or those of any future collaborators, including those manufacturing such product candidate or components or ingredients thereof or conducting clinical trials on our behalf or on behalf of any future collaborators, may fail to comply with regulatory requirements or meet their contractual obligations to us or any future collaborators in a timely manner or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators or institutional review boards may not authorize us, any future collaborators or our or their investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or any future collaborators, may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients that enroll in a clinical trial may misrepresent their eligibility to do so or may otherwise not comply with the clinical trial protocol, resulting in the need to drop the patients from the clinical trial, increase the needed enrollment size for the clinical trial or extend the clinical trial&#8217;s duration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or any future collaborators, may have to delay, suspend or terminate clinical trials for various reasons, including a finding that the participants are being exposed to unacceptable health risks, undesirable side effects or other unexpected characteristics of the product candidate, or travel bans or other restrictions imposed by applicable governmental authorities due to the ongoing COVID-19 pandemic;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators or institutional review boards may require that we, or any future collaborators, or our or their investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or their standards of conduct, a finding that the participants are being exposed to unacceptable health risks, undesirable side effects or other unexpected characteristics of the product candidate or findings of undesirable effects caused by a chemically or mechanistically similar drug or drug candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree or subsequently find fault with our, or any future collaborators&#8217;, clinical trial designs or our or their interpretation of data from preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may fail to approve or subsequently find fault with the manufacturing processes or facilities of third-party manufacturers with which we, or any future collaborators, enter into agreements for clinical and commercial supplies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the supply or quality of raw materials or manufactured product candidates or other materials necessary to conduct clinical trials may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply, due to, among other things, the ongoing COVID-19 pandemic; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient to obtain marketing approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, we are planning to conduct clinical trials outside of the United States, which are subject to the risks set forth above, and certain additional risks, such as unforeseen global instability, including political instability or geopolitical events, including civil or political unrest (such as the ongoing conflict between Russia and Ukraine), terrorist activity, unstable governments and legal systems, natural disasters or instability from an outbreak of pandemic or contagious disease, such as the ongoing COVID-19 pandemic, in or around any countries in which we conduct clinical trials. Such additional risks could affect our ability to enroll patients in clinical trials in these countries, prevent patients already enrolled from completing such clinical trials, and/or cause other trial delays or otherwise adversely impact such clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Product development costs for us, or any future collaborators, will increase if we, or they, experience delays in testing or pursuing marketing approvals and we, or they, may be required to obtain additional funds to complete clinical trials and prepare for possible commercialization of any future product candidate. We do not know whether any preclinical tests or clinical trials will begin as planned, will need to be restructured, or will be completed on schedule or at all. Significant preclinical or clinical trial delays also could shorten any periods during which we, or any future collaborators, may have the exclusive right to commercialize product candidates or allow our competitors, or the competitors of any future collaborators, to bring products to market before we, or any future collaborators, do and impair our ability, or the ability of any future collaborators, to successfully commercialize product candidates and may harm our business and results of operations. In addition, many of the factors that lead to clinical trial delays may ultimately lead to the denial of marketing approval of any future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we, or any future collaborators, experience delays or difficulties in the enrollment of patients in clinical trials, our or their receipt of necessary regulatory approvals could be delayed or prevented.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We, or any future collaborators, may not be able to initiate or continue clinical trials for STAR-0215 or any other future product candidate if we, or they, are unable to locate and enroll, and maintain the enrollment of, a sufficient number of eligible patients to participate in clinical trials as required by the FDA or comparable foreign regulatory authorities, such as the EMA. Patient enrollment is a significant factor in the timing of clinical trials, and is affected by many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and nature of the patient population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the severity of the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the proximity of patients to clinical sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the eligibility criteria for the trial;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the design of the clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efforts to facilitate timely enrollment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competing clinical trials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the drug being studied in relation to other available therapies, including any existing or newly approved drugs that may be approved for the indications we are investigating.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ability to successfully complete any future clinical trial for STAR-0215 as a potential treatment for HAE or for any other future product candidate for the potential treatment of any rare disease or any other indication will be dependent upon our ability to enroll, and maintain the enrollment of, a sufficient number of patients with such disease, which will be subject to a number of risks and uncertainties. For example, rare diseases, including HAE, have small patient populations and often have only a limited number of specialist physicians that regularly treat such patients. Further, these specialized sites typically treat a range of diseases and, at any point in time, may have constrained resources and capacity to handle clinical trials. In addition, in the case of HAE, the indication on which we are currently focused, approved products are available for the rare disease, and additional products may become commercially available during the STAR-0215 clinical development, and therefore patients and their healthcare providers may feel satisfied with their treatments. As a result, patients may not feel the need to participate in a clinical trial for another product candidate for the same disease or the criteria for the trial may not allow patients on such other therapies to enroll in the trial. Additionally, in the case of HAE, diagnosis is often delayed from onset of symptoms and patients that might be eligible for enrollment in our trials may not have been diagnosed and therefore are unaware of such eligibility. Finally, other companies are and will be conducting clinical trials in HAE or may have announced plans for future clinical trials for HAE that are seeking, or are likely to seek, to enroll patients with the disease and patients are generally only able to enroll in a single trial at a time. The small population of patients, competition for these patients and the limited trial sites and their constrained resources may make it difficult for us to enroll enough patients, and to maintain the enrollment of enough patients, to complete clinical trials for any such future product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The clinical trials that we may conduct may also have inclusion criteria that further limit the population of patients that we are able to enroll. These inclusion criteria could further limit the available patient pool and present challenges to clinical trial enrollment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our inability, or the inability of any future collaborators, to enroll a sufficient number of patients for any clinical trials, including potential clinical trials for STAR-0215 as a potential treatment for HAE, that we or they may determine to pursue could result in significant delays or may require us or them to abandon one or more clinical trials altogether. Enrollment delays in any such clinical trials may result in increased development costs for the applicable product candidates, delay or halt the development of and approval processes for any future product candidates and jeopardize our, or any future collaborators&#8217;, ability to commence sales of and generate revenues from any future product candidates, which could cause the value of our company to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business disruptions could delay completion of future clinical trials, seriously harm our future revenue and financial condition and increase our costs and expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our operations, and those of third-party research institution collaborators, contract research organizations, or CROs, contract manufacturing operations, and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics such as the ongoing COVID-19 pandemic, and other natural or man-made disasters or business interruptions, for which we may be partly uninsured, as well as impacts of geopolitical events, including civil or political unrest (such as the ongoing conflict between Russia and Ukraine), terrorist activity and unstable governments and legal systems. In addition, to the extent we determine to pursue development of future product candidates, we expect that we will rely on third-party research institution collaborators for conducting research and development of such product candidates, and they may be affected by government shutdowns or withdrawn funding. The occurrence of any of these business disruptions could delay completion of any clinical trials for such product candidates, seriously harm our operations and financial condition and increase our costs and expenses.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The COVID-19 pandemic has had, and continues to have, significant impacts worldwide, and may delay the initiation of future clinical trials, disrupt or increase the costs of regulatory or manufacturing activities, or have other adverse effects on our business and operations. In addition, this ongoing pandemic has adversely impacted economies worldwide and may disrupt the financial markets, both of which could result in adverse effects on our business and operations and ability to raise capital.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The COVID-19 pandemic has had, and continues to have, significant impacts worldwide causing many governments to implement measures to slow the spread of the outbreak through quarantines, travel restrictions, heightened border scrutiny, and other measures. The outbreak and government measures taken in response, including widespread emergency orders requiring business and residents to curtail non-essential activities, have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. The development of STAR-0215 or any other future product candidates could be negatively impacted by the COVID-19 pandemic for a variety of reasons, including delays of the initiation, recruitment and overall timing of clinical trials, delays at FDA and other regulatory authorities, who have been diverting resources to help address the pandemic since its inception and are likely to continue to do so, the disruption or delays of regulatory or manufacturing activities, including due to facility shut downs, capacity constraints at third party manufacturers due to the focus on vaccines and other treatments for COVID-19, and increased costs or the inability to source key raw materials that are being diverted for COVID-19 efforts, or other adverse effects that negatively impact our business or operations. The future progression and unpredictability of the pandemic and its effects on our business and operations are highly uncertain and will depend on future developments that cannot be predicted with confidence, such as the widespread use and distribution of the vaccines, the ultimate geographic spread of the disease, the duration of the outbreak, additional surges in the number of cases or deaths from COVID-19, travel restrictions and actions to contain the outbreak or treat its impact, such as social distancing and quarantines or lock-downs in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The pandemic also caused an initial significant disruption in the financial markets, and may cause future such disruptions, which could impact our ability to raise additional funds through public offerings and may also impact the volatility of our stock price and trading in our stock. Moreover, it is possible the pandemic will continue to significantly impact economies worldwide, which could result in adverse effects on our business and operations. We cannot be certain what the overall impact of the COVID-19 pandemic will be on our business and it has the potential to adversely affect our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any future product candidate we may seek to develop.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have never obtained marketing approval for a product candidate. We have not yet succeeded and may never succeed in demonstrating efficacy and safety for any of our product candidates in a Phase&#160;3 clinical trial or in obtaining marketing approval thereafter. For example, although we discovered and evaluated numerous compounds using our SMART Linker drug discovery platform, no product created using the SMART Linker drug discovery platform was ever approved for sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are able to advance STAR-0215 or any other future product candidate into late-stage development, it is possible that the FDA, EMA or other applicable foreign regulatory authority may refuse to accept for substantive review any applications that we submit for marketing approval of such product candidates or may conclude after review of our data that our applications are insufficient to obtain marketing approval of such product candidate. If the FDA, EMA or other applicable foreign regulatory authority does not accept or approve any applications that we submit for marketing approval, they may require that we conduct additional clinical or nonclinical studies, or conduct manufacturing validation studies, and submit that data before they will reconsider our applications. Depending on the extent of these or any other required studies, approval of any application that we submit may be delayed by several&#160;years or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA, EMA or other applicable foreign regulatory authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing STAR-0215 or any future product candidate, generating revenues and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for any future product candidates, which could significantly harm our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If any future product candidate receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability, or that of any future collaborators, to market the drug could be compromised.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials of product candidates are conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that clinical trials for STAR-0215 and any other future product candidate, or those of any future collaborator, may indicate an apparent positive effect of such product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If, following approval of a product candidate, we, or others, discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, any of the following adverse events could occur:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw their approval of the drug or seize the drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or any future collaborators, may be required to recall the drug, change the way the drug is administered or conduct additional clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or any future collaborators, may be required to create a Medication Guide outlining the risks of the previously unidentified side effects for distribution to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or any future collaborators, could be sued and held liable for harm caused to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may become the subject of government investigations, which would be expensive to manage and potentially result in the imposition of fines, injunctions or the imposition of civil or criminal penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the drug may become less competitive; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of these events could have a material and adverse effect on our operations and business and could adversely impact our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if STAR-0215 or any future product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success and the market opportunity for the product candidate may be smaller than we estimate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if STAR-0215 or any future product candidate of ours is approved by the appropriate regulatory authorities for marketing and sale, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, physicians are often reluctant to switch their patients from existing therapies even when new and potentially more effective or convenient treatments enter the market. Further, patients often acclimate to the therapy that they are currently taking and do not want to switch unless their physicians recommend switching products or they are required to switch therapies due to lack of reimbursement for existing therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Efforts to educate the medical community and third-party payors on the benefits of future product candidates may require significant resources and may not be successful. If STAR-0215 or any other future product candidate of ours is approved but does not achieve an adequate level of market acceptance, we may not generate significant revenues and we may not become profitable. The degree of market </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">acceptance of STAR-0215 or any other future product candidates of ours, if approved for commercial sale, will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and safety of the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential advantages of the product compared to existing approved treatments or alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical indications for which the product is approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy and whether there is an existing standard of care;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations or warnings, including distribution or use restrictions, contained in the product&#8217;s approved labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability, or the ability of any future collaborators, to offer the product for sale at competitive prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product&#8217;s convenience and ease of administration compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try, and of physicians to prescribe, the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of sales, marketing, market access and distribution support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval of other new products for the same indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the standard of care for the targeted indications for the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of market introduction of our approved products as well as competitive products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability and amount of reimbursement from government payors, managed care plans and other third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse publicity about the product or favorable publicity about competitive products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product liability claims.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The potential market opportunities for product candidates are difficult to estimate precisely. Any estimates we make as to the potential market opportunities for STAR-0215 or any future product candidates of ours will be predicated on many assumptions, including industry knowledge and publications, third-party research reports and other surveys. These assumptions will involve the exercise of significant judgment on the part of our management, will be inherently uncertain and the reasonableness of these assumptions may not have been assessed by an independent source. If any such assumptions prove to be inaccurate, the actual markets for any such future product candidate could be smaller than our estimates of the potential market opportunities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to establish sales, marketing and distribution capabilities or enter into sales, marketing and distribution arrangements with third parties, we may not be successful in commercializing any future product candidates that we may develop if and when those product candidates are approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently do not have a formal sales, marketing or distribution infrastructure. To achieve commercial success for any approved product, we would need to either develop a sales and marketing organization or outsource these functions to third parties. We expect to use a combination of focused in-house sales and marketing capabilities and third-party collaboration, licensing and distribution arrangements to sell any products that receive marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">We generally expect that we would seek to retain full commercialization rights for products that we can commercialize with a specialized sales force and to retain co-promotion or similar rights when feasible in indications requiring a larger commercial </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">infrastructure. The development of sales, marketing and distribution capabilities will require substantial resources, will be time-consuming and could delay any product launch. If the commercial launch of a product for which we recruit a sales force and establish marketing and distribution capabilities is delayed or does not occur for any reason, we could have prematurely or unnecessarily incurred these commercialization costs. This may be costly, and our investment could be lost if we cannot retain or reposition our sales and marketing personnel. In addition, we may not be able to hire or retain a sales force that is sufficient in size or has adequate expertise in the medical markets that we plan to target. If we are unable to establish or retain a sales force and marketing and distribution capabilities, at such time as we need to, our operating results may be adversely affected. If a potential partner has development or commercialization expertise that we believe is particularly relevant to a product, then we may seek to collaborate with that potential partner even if we believe we could otherwise develop and commercialize the product independently.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may collaborate with third parties for commercialization of any products that require a large sales, marketing and product distribution infrastructure. We intend to potentially commercialize product candidates through collaboration, licensing and distribution arrangements with third parties. As a result of entering into arrangements with third parties to perform sales, marketing and distribution services, our product revenues or the profitability of these product revenues may be lower, perhaps substantially lower, than if we were to directly market and sell products in those markets. Furthermore, we may be unsuccessful in entering into the necessary arrangements with third parties or may be unable to do so on terms that are favorable to us. In addition, we may have little or no control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we do not establish sales, marketing and distribution capabilities, either on our own or in collaboration with third parties, we will not be successful in commercializing any product candidates that receive marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We face substantial competition from other pharmaceutical and biotechnology companies, and our operating results may suffer if we fail to compete effectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The development and commercialization of new drug products is highly competitive. We expect that we, and any future collaborators, will face significant competition from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide with respect to any product candidates that we, or they, may seek to develop or commercialize in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are developing STAR-0215 for the potential treatment of HAE. The key competitive factors affecting the success of STAR-0215, if approved, are likely to be its efficacy, safety, convenience, price and the availability of coverage and reimbursement from government and other third-party payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA has approved four therapies for on-demand treatment of HAE: BERINERT, FIRAZYR, KALBITOR and RUCONEST. For long-term preventative treatment of HAE, the FDA has also approved four therapies: CINRYZE, HAEGARDA, TAKHZYRO and ORLADEYO. There are four main manufacturers of therapies for HAE: CSL Behring (BERINERT and HAEGARDA), Takeda (FIRAZYR, KALBITOR, CINRYZE and TAKHZYRO), Pharming (RUCONEST) and BioCryst (ORLADEYO). With the exception of KALBITOR, these therapies are also approved and commercially available outside of the United States (HAEGARDA is marketed as BERINERT SC outside of the United States). Historically, androgens and antifibrinolytic treatments have also been used as preventative treatment for HAE, however their use is declining with the availability of more-tolerable, HAE-specific therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On-demand and preventative HAE therapies target one of three primary mechanisms. BERINERT and HAEGARDA, RUCONEST and CINRYZE are C1 INH replacement therapies. FIRAZYR is a Bradykinin 2 receptor antagonist, and KALBITOR, TAKHZYRO and ORLADEYO target plasma kallikrein. TAKHZYRO is a monoclonal antibody and KALBITOR and ORLADEYO are small molecule inhibitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On-demand therapies are taken as needed; BERINERT and RUCONEST are IV infusions approved for adult and pediatric patients, FIRAZYR is a SC injection, approved for adults 18 and older, and KALBITOR is a series of 3 SC injections, approved for patients 12&#160;years and older. KALBITOR must be administered by a healthcare professional to monitor for the risk of anaphylactic reactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Preventative therapies are taken chronically. CINRYZE is an IV infusion and HAEGARDA is an SC injection; both are administered twice a week and are approved for adult and pediatric patients 6&#160;years and older. TAKHZYRO is an SC injection generally administered every two weeks; however dosing every four weeks may be considered in some patients. TAKHZYRO is approved for patients 12&#160;years and older.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ORLADEYO is an oral capsule taken once daily with food for patients 12&#160;years and older. Given that TAKHZYRO is an approved monoclonal antibody inhibitor of plasma kallikrein, if STAR-0215 is approved, we expect that it will compete most directly with TAKHZYRO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are aware of additional programs in development for HAE, which are focused largely on preventative approaches. For example, in Phase 3 development for preventative treatment are CSL Behring garadacimab (CSL312), a factor XIIa-inhibitory monoclonal antibody (FXIIa mAb), and Ionis Pharmaceuticals&#8217; donidalorsen (IONIS-PKK-LRx), an antisense inhibitor of prekallikrein synthesis. KalVista Pharmaceuticals has two oral small molecule plasma kallikrein inhibitors: sebetralstat (KVD900) for on-demand treatment of HAE, and KVD824 for preventative treatment, both of which are in Phase 2 development. Pharvaris is also developing two oral treatments, PHVS416, in Phase 2 for on-demand treatment, and PHVS719, in Phase 1 for preventative treatment, that are small molecule inhibitors of B2R. Intellia has begun Phase 1/2 trials for NTLA-2002, a CRISPR knockout of the prekallikrein gene KLKB1. BioMarin has begun Phase 1/2 trials for BMN 311, a C1INH gene therapy. In preclinical development for preventative treatment are KalVista&#8217;s oral FXIIa inhibitor, Spark Therapeutics C1-INH gene therapy (SPK-10000), Regenxbio&#8217;s plasma kallikrein mAb gene therapy, and Orchard Therapeutics and Pharming&#8217;s ex vivo hematopoietic stem cell gene therapy (OTL-105).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The enrollment and retention of patients in clinical trials for STAR-0215 may be disrupted or delayed as a result of clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of STAR-0215 in relation to commercially available therapies and other programs in development, including approved products as well as any other new products that may be approved in the future for the treatment of HAE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our competitors may succeed in developing, acquiring or licensing technologies and drug products that are more effective, have fewer or more tolerable side effects or are less costly than any product candidates that we may develop, which could render any future product candidates obsolete and noncompetitive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we, or any future collaborators, may develop. Our competitors also may obtain FDA or other marketing approval for their products before we, or any future collaborators, are able to obtain approval for ours, which could result in our competitors establishing a strong market position before we, or any future collaborators, are able to enter the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our potential future competitors may have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining marketing approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">STAR-0215 and any other future biologic product candidates will be regulated as biological products, or biologics, and therefore they may be subject to competition from biologic products that are biosimilar to or interchangeable with an FDA-licensed reference biologic product.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, was enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable with&#8221; based on its similarity to an approved biologic. Under the BPCIA, a reference biological product is granted 12&#160;years of data exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four&#160;years after the date of first licensure of the reference product. In addition, the licensure of a biosimilar product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still develop and receive approval of a competing biologic, so long as its BLA does not rely on the reference product, the sponsor&#8217;s data or submit the application as a biosimilar application. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty, and any new policies or processes adopted by the FDA could have a material adverse effect on the future commercial prospects for our biological products.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that STAR-0215 and any of our future product candidates, we develop as a biologic product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider subject product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products will depend on a number of marketplace and regulatory factors that are still developing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Nonetheless, the approval of biosimilars to our product candidates, would have a material adverse impact on our business due to increased competition and pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the FDA or comparable foreign regulatory authorities approve generic versions of any future products that receive marketing approval through the NDA pathway, or such authorities do not grant such products appropriate periods of data exclusivity before approving generic versions of our products, our sales could be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once an NDA is approved, the product covered thereby becomes a &#8220;reference-listed drug&#8221; in the FDA&#8217;s publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; commonly known as the Orange Book. Manufacturers may seek approval of generic versions of reference-listed drugs through submission of abbreviated new drug applications, or ANDAs, in the United States. In support of an ANDA, a generic manufacturer need not conduct clinical trials to assess safety and efficacy. Rather, the applicant generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration and conditions of use or labeling as the reference-listed drug and that the generic version is bioequivalent to the reference-listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference-listed drug and companies that produce generic products are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a significant&#160;percentage of the sales of any branded product or reference-listed drug is typically lost to the generic product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may not approve an ANDA for a generic product until any applicable period of non-patent exclusivity for the reference-listed drug has expired. The Federal Food, Drug, and Cosmetic Act, or FDCA, provides a period of five&#160;years of non-patent exclusivity for a new drug containing a new chemical entity, or NCE. Specifically, in cases where such exclusivity has been granted, an ANDA may not be submitted to the FDA until the expiration of five&#160;years unless the submission is accompanied by a Paragraph IV certification that a patent covering the reference-listed drug is either invalid or will not be infringed by the generic product, in which case the applicant may submit its application four&#160;years following approval of the reference-listed drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Generic drug manufacturers may seek to launch generic products following the expiration of any applicable exclusivity period we obtain if our products are approved, even if we still have patent protection for such products. Competition that any such products of ours may face from generic versions of such products could materially and adversely impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made in those product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product liability lawsuits against us could divert our resources, cause us to incur substantial liabilities and limit commercialization of any products that we may develop.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We face an inherent risk of product liability claims as a result of the clinical testing of product candidates despite obtaining appropriate informed consents from our clinical trial participants. We will face an even greater risk if we or any future collaborators commercially sell any product that we may or they may develop. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of any future product candidates. Regardless of the merits or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for any future product candidates or products that we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation and significant negative media attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant costs to defend resulting litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize any products that we may develop.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although we maintain general liability insurance of $5.0&#160;million in the aggregate and clinical trial liability insurance of $10.0&#160;million in the aggregate, this insurance may not fully cover potential liabilities that we may incur. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. We will need to increase our insurance coverage if and when we begin selling any product candidate that receives marketing approval. In addition, insurance coverage is becoming increasingly expensive. If we are unable to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the development and commercial production and sale of any future product candidates, which could adversely affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Financial Position and Need for Additional Capital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will need substantial additional funding. If we are unable to raise capital when needed or on acceptable terms, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Developing biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes&#160;years to complete. We are continuing to conduct preclinical and nonclinical studies, and ramp up manufacturing of clinical supplies, of STAR-0215, and plan to initiate Phase 1a clinical trial in the second half of 2022 and a Phase 1b/2 clinical trial in 2023, and expect that our expenses will increase substantially as a result. In addition, we may in the future initiate new research, preclinical and clinical development efforts, and seek marketing approval, for other product candidates, and would expect our expenses to increase in connection with each of these activities. If we obtain marketing approval for any of our product candidates, we may incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of a future collaborator, and these activities would require substantial additional funding. In addition, while we may seek one or more collaborators for future development of our product candidates, we may not be able to enter into a collaboration for any of our product candidates on suitable terms or at all. In any event, our existing cash, cash equivalents and short-term investments will not be sufficient to fund all of the efforts that we plan to undertake or to fund the completion of development of any of our product candidates. Furthermore, we have incurred and will continue to incur significant additional costs associated with operating as a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, we will be required to obtain substantial additional funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources. We do not have any committed external source of funds. Adequate additional funding may not be available to us on acceptable terms, on a timely basis or at all, impacting our ability to execute on our strategic plans. Our failure to raise capital on acceptable terms as and when needed may force us to delay, reduce or eliminate our research and development programs or any future efforts to seek approval for and commercialize products, and would have a material adverse effect on our business, results of operations, financial condition and ability to pursue our business strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that our existing cash, cash equivalents and short-term investments are sufficient to support operating expenses through 2023. Our estimate as to how long we expect our cash, cash equivalents and short-term investments to be able to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. Our future funding requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to meet our overall timing expectations for STAR-0215;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress, timing, costs and results of clinical trials of, and research, preclinical and clinical development, and manufacturing efforts for, STAR-0215 any future product candidates, including potential future clinical trials and all activities necessary to initiate and conduct clinical trials;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to enter into and the terms and timing of any additional collaborations, licensing or other arrangements that we may establish;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and characteristics of future product candidates that we pursue and their development requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the outcome, timing and costs of seeking regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of commercialization activities for any of our product candidates that receive marketing approval to the extent such costs are not the responsibility of any future collaborators, including the costs and timing of establishing product sales, marketing, market access, distribution, supply chain and manufacturing capabilities, and scaling up the manufacturing of drug substance and drug product to clinical and commercial scale, securing all raw materials necessary to conduct such scale-up and successfully completing all other activities related thereto;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subject to receipt of marketing approval, revenue, if any, received from commercial sales of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if we obtain marketing approval of any of our products, our ability to successfully compete against other approved products that are approved or used as treatments for the indications for which our products are approved, including with respect to STAR-0215 in HAE;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our headcount growth and associated costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against intellectual property related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of the COVID-19 pandemic on our operations, business and prospects; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of operating as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have incurred significant losses since inception. We expect to incur losses for at least the next several&#160;years and may never achieve or maintain profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our net losses were $194.9 million (including $164.4 million of in-process research and development expenses) and $37.3 million for the&#160;years ended December&#160;31, 2021 and December&#160;31, 2020, respectively. As of December&#160;31, 2021, we had an accumulated deficit of $455.8&#160;million. We have not generated any revenues from product sales, have not completed the development of any product candidate and may never have a product candidate approved for commercialization. We have financed our operations to date primarily through private placements of preferred stock before we became a public company and our private placement of preferred stock in the February&#160;2021 Financing, registered offerings of our common stock, and our at-the-market programs, and have devoted substantially all of our financial resources and efforts to research and development, including preclinical studies and clinical development programs. Our net losses may fluctuate significantly from quarter to quarter and&#160;year to&#160;year. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect to continue to incur significant expenses and operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital. We anticipate that we will continue to incur significant expenses and operating losses and we may incur increased expenses if and to the extent we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiate and continue research and preclinical and clinical development efforts for STAR-0215 and any future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to identify and develop any future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory and marketing approvals for STAR-0215 and any future product candidate that successfully completes clinical trials, in the United States and other markets;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish sales, marketing, market access, distribution, supply chain and other commercial infrastructure in the future to commercialize products for which we may obtain marketing approval, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require the manufacture of larger quantities of STAR-0215 and any other future product candidates for clinical development and potentially commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain, expand and protect our intellectual property portfolio; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire and retain additional personnel or add information systems, equipment or physical infrastructure to support our operations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To become and remain profitable, we or any potential future collaborators must develop and eventually commercialize at least one product candidate with significant market potential. This will require that we or our collaborators be successful in a range of challenging activities, including completing preclinical studies and clinical trials of one or more product candidates, obtaining marketing approval for one or more these product candidates, manufacturing, marketing and selling those products for which we or our collaborators may obtain marketing approval and satisfying any post-marketing requirements. We or our collaborators may never succeed in any or all of these activities and, even if we or our collaborators do succeed, we or our collaborators may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause investors to lose all or part of their investments in us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will need to raise additional capital to develop and commercialize STAR-0215 or to acquire, develop and commercialize any future product candidates or to pursue other strategic options. To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, our existing stockholders&#8217; ownership interests may be substantially diluted, and the terms of these securities could include liquidation or other preferences and anti-dilution protections that could adversely affect your rights as a common stockholder. For example, in connection with the acquisition of Quellis and our February&#160;2021 Financing, we issued an aggregate of 86,077 shares of Series&#160;X, of which 53,532 shares of Series&#160;X Preferred Stock automatically converted into 8,921,966 shares of our common stock upon the stockholder approval of the conversion of the Series&#160;X Preferred Stock into common stock in June&#160;2021 and an additional 1,090 shares have subsequently converted into 181,698 shares of common stock. The remaining 31,455 &#160;shares of Series&#160;X Preferred Stock are convertible into 5,242,501 shares of common stock at the election of the holders thereof, subject to certain beneficial ownership limitations. In addition, our June&#160;2018 and February&#160;2019 registered offerings of common stock and common stock warrants and our January&#160;2020 registered offering of common stock were highly dilutive to existing stockholders&#8217; ownership interests. Further, exercise of the common stock warrants sold in our June&#160;2018 and February&#160;2019 offerings, and the warrants that we assumed in the acquisition of Quellis, could result in additional dilution upon exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Debt financing, if available, would result in periodic payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, creating liens, redeeming stock or declaring dividends, that could adversely impact our ability to conduct our business. In addition, securing additional financing could require a substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities, which may adversely affect our management&#8217;s ability to oversee the development of any future product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we raise additional funds through collaborations or marketing, distribution, licensing or royalty arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Dependence on Third Parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may seek to establish collaborations and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The development and commercialization of product candidates require substantial cash to fund expenses. We may seek one or more collaborators for the development and commercialization of STAR-0215 or any future product candidates. Likely collaborators may include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Collaborations are complex and time-consuming to negotiate and document. Further, there have been a significant number of business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. In addition, any collaboration agreements that we enter into in the future may contain, restrictions on our ability to enter into potential collaborations or to otherwise develop specified compounds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We face significant competition in seeking appropriate collaborators and strategic partners. Whether we reach a definitive agreement for a collaboration or strategic partnership will depend, among other things, upon our assessment of the other party&#8217;s resources and expertise, the terms and conditions of the proposed transaction and the proposed party&#8217;s evaluation of a number of factors. Those factors may include the potential differentiation of ours or a partner&#8217;s product candidate from competing product candidates, design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities and the regulatory pathway for any such approval, the potential market for the product candidate, the costs and complexities of manufacturing and delivering the product to patients and the potential of competing products. The collaborator or strategic partner may also be considering alternative transaction types and structures that may be more attractive than the one with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop the product candidate or bring it to market and generate product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we enter into collaborations with third parties for the development and commercialization of a product candidate, our prospects with respect to such product candidate will depend in significant part on the success of those collaborations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we enter into collaborations for the development and commercialization of a product candidate, we will have limited control over the amount and timing of resources that our collaborators will dedicate to the development or commercialization of such product candidates. Our ability to generate revenues from these arrangements will depend on any future collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. In addition, any future collaborators may have the right to abandon research or development projects and terminate applicable agreements, including funding obligations, prior to or upon the expiration of the agreed upon terms. Collaborations involving product candidates pose a number of risks, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not perform their obligations as expected;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue development and commercialization of a product candidate or may elect not to continue or renew development or commercialization programs, based on clinical trial results, changes in the market or competitive landscape, changes in the collaborators&#8217; strategic focus or available funding or external factors, such as an acquisition, that divert resources or create competing priorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborations may be terminated and, if terminated, may result in negative publicity for our product candidate and the need for additional capital to pursue further development or commercialization of the applicable product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, all of the risks related to product development, regulatory approval and commercialization described in this &#8220;Risk Factors&#8221; section would apply to the activities of our collaborators. Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If any future collaborator of ours is involved in a business combination or a sale or other transaction involving our collaboration, it or the party with which it entered into a business combination, sale or other transaction could decide to delay, diminish or terminate the development or commercialization of any product candidate licensed to it by us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We expect to rely on third parties to conduct our clinical trials. If they do not perform satisfactorily, our business could be significantly harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not plan to independently conduct clinical trials of STAR-0215 or any future product candidates. We would expect to rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct clinical trials of any such product candidate. Any of these third parties could terminate its engagement with us under certain circumstances or encounter, for example, business challenges, such as a loss of business, the COVID-19 pandemic or the impacts of geopolitical events, including civil or political unrest (such as the ongoing conflict between Russia and Ukraine), or enter into transactions, such as business combinations, that temporarily or permanently impact the amount or type of resources that they are able or willing to devote to our engagement. We might not be able to enter into alternative arrangements or do so on commercially reasonable terms. In addition, there is a natural transition period when a new CRO begins work. As a result, delays would likely occur, which could materially impact our ability to meet our expected clinical development timelines and harm our business, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, our reliance on these third parties for clinical development activities would limit our control over these activities, but we would remain responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards. For example, notwithstanding the obligations of a CRO for a trial of a product candidate, we would remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA and most other comparable regulatory authorities outside the United States require us to comply with standards, commonly referred to as current Good Clinical Practices, or cGCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. The FDA and other comparable regulatory authorities outside the United States enforce these cGCPs through periodic inspections of trial sponsors, principal investigators, clinical trial sites and institutional review boards. If we or any of our third-party contractors fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or other comparable regulatory authorities outside the United States may require us to perform additional clinical trials before approving a product candidate, which would delay the marketing approval process. We cannot be certain that, upon inspection, the FDA or other comparable regulatory authorities outside the United States will determine that any of our clinical trials comply with cGCPs. Many of these risks are heightened by the COVID-19 pandemic. We are also required to register clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Other regions, including the EU, have similar requirements. The failure to comply with these registration and posting requirements can result in fines, adverse publicity and civil and criminal sanctions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, the third parties that may conduct clinical trials on our behalf would not be our employees, and except for remedies available to us under our agreements with such contractors, we would not be able to control whether or not they devote sufficient time, skill and resources to our development programs, a risk that could be exacerbated during the ongoing COVID-19 pandemic as any such third parties try to address the impact of the ongoing pandemic on their own businesses and financial condition. Any such contractors may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could impede their ability to devote appropriate time to our clinical programs. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we may not be able to obtain, or may be delayed in obtaining, marketing approvals for the applicable product candidates. If that occurs, we would not be able to, or may be delayed in our efforts to, successfully commercialize such product candidates. In such an event, our financial results and the commercial prospects for any product candidates that we seek to develop could be harmed, our costs could increase and our ability to generate revenues could be impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also expect to rely on other third parties to store and distribute drug supplies for any future clinical trials we may pursue. Any performance failure on the part of any such distributors or impacts from geopolitical events, including civil or political unrest (such as the ongoing conflict between Ukraine and Russia), terrorist activity and unstable governments and legal systems could delay clinical development or marketing approval of any future product candidates or commercialization of any resulting products, producing additional losses and depriving us of potential product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The manufacturing of pharmaceutical products and, in particular, biologics, is complex and we do not have our own clinical manufacturing capabilities. We will rely on third parties to produce clinical and commercial supplies of any future product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently have no manufacturing facilities and plan to rely on third-party contract manufacturers to manufacture all of our preclinical product candidate supplies and clinical trial product supplies. We do not own, nor do we plan to own, &#160;any manufacturing facilities. There can be no assurance that our preclinical and clinical development product supplies from third parties will not be limited or interrupted, or be of satisfactory quality or continue to be available at acceptable prices. Additionally, the process of manufacturing pharmaceutical products and, in particular, biologics is complex, highly regulated, and subject to multiple risks. Manufacturing biologics is highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, other supply disruptions and higher costs. If microbial, viral or other contaminations are discovered at the facilities of our third-party contract manufacturers, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials, result in higher costs of drug product and adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the contract manufacturers we engage are unable to supply us with sufficient clinical grade quantities of our product candidates, and we are unable to timely establish an alternate supply from one or more third-party contract manufacturers, we will experience delays in our development efforts as we seek to locate and qualify new manufacturers. In particular, any replacement of our third-party contract manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements or capacity could be limited at each of the qualified replacements. We expect to obtain drug product and drug substance from single third-party contract manufacturers, which exacerbates these and other related risks for us. Additionally, contract manufacturers may rely on single source suppliers for certain of the raw materials for our preclinical and clinical product supplies. If current or future suppliers are delayed or unable to supply sufficient raw materials to manufacture product for our preclinical studies and clinical trials, we may experience delays in our development efforts as materials are obtained or we locate and qualify new raw material manufacturers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The manufacturing process for a clinical candidate is subject to FDA and foreign regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with their standards, such as cGMPs. In the event that any of our manufacturers fail to comply with such requirements or to perform their obligations to us in relation to quality, &#160;timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third-party, which we may not be able to do on reasonable terms, if at all. The transfer of the manufacturing of biologic products to a new contract manufacturer and any additional process development that may be necessary can be lengthy and involve significant additional costs. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer would negatively affect our ability to develop product candidates in a timely manner or within budget.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, our reliance on third-party manufacturers exposes us to risks beyond our control, including the:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to meet our drug specifications and quality requirements consistently;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to initiate or continue preclinical studies or clinical trials of product candidates under development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay or inability to procure or expand sufficient manufacturing capacity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing and drug quality issues, including related to scale-up of manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to comply with cGMP and similar foreign standards;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reliance on a limited number of sources, and in some cases, potentially single sources for drug components and raw materials, such that if we are unable to secure a sufficient supply of these drug components and raw materials, we will be unable to manufacture and sell our future product candidate in a timely fashion, in sufficient quantities or under acceptable terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of qualified backup suppliers for those components and raw materials that are purchased from a sole or single source supplier;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to negotiate manufacturing agreements with third parties under commercially reasonable terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disruption of operations by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier, the issuance of an FDA Form&#160;483 notice or warning letter or geopolitical events, including civil or political unrest (such as the ongoing conflict between Ukraine and Russia), terrorist activity and unstable governments and legal systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">carrier disruptions or increased costs that are beyond our control;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to deliver our drugs under specified storage conditions and in a timely manner; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible misappropriation of our proprietary information, including our trade secrets and know-how.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Some of these events could be the basis for FDA action, including injunction, recall, seizure or total or partial suspension of production, any of which could result in a failure to begin our clinical trials or having to stop ongoing clinical trials. In addition, &#160;our third-party manufacturers and suppliers are subject to numerous environmental, health and safety laws and regulations, including those governing the handling, use, storage, treatment and disposal of waste products, and failure to comply with such laws and regulations could result in significant costs associated with civil or criminal fines and penalties for such third parties. Based on the severity of the regulatory action, our clinical or commercial supply of drug and packaging and other services could be interrupted or limited, &#160;which could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, our contract manufacturers are or may be engaged with other companies to supply and manufacture materials or products for such companies, which also exposes our suppliers and manufacturers to regulatory risks for the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may also affect the regulatory clearance of a contract supplier&#8217;s or manufacturer&#8217;s facility, which could impact the contract supplier&#8217;s or manufacturer&#8217;s ability to manufacture for us.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain and maintain sufficient patent protection for product candidates, or if the scope of the patent protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to commercialize such product candidates successfully may be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to STAR-0215 and any future product candidates. If we do not adequately protect our intellectual property, competitors may be able to erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. To protect our proprietary position, we have filed an International (PCT) patent application directed to STAR-0215 and intend to file patent applications in the United States and abroad related to STAR-0215 and future novel product candidates and related technologies that are important to our business. The patent application and approval process is expensive and time-consuming. We may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Failure to protect or to obtain, maintain or extend adequate patent and other intellectual property rights could materially adversely affect our ability to develop and market our products and product candidates. The enforcement, defense and maintenance of such patents and other intellectual property rights may be challenging and costly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We cannot be certain that any patent application directed to STAR-0215 or any future product candidate will be issued in a form that provides us with adequate protection to prevent competitors from developing competing products. As a biopharmaceutical company, our patent position is uncertain because it involves complex legal and factual considerations. The standards applied by USPTO, and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biopharmaceutical patents. Consequently, patents may not issue from any applications that are currently pending or that we file in the future. As such, we do not know the degree of future protection that we will have for STAR-0215 and its use. The scope of patent protection that the USPTO and foreign patent offices will grant with respect to STAR-0215 is uncertain. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. For example, it is possible that the USPTO and foreign patent offices will not allow broad antibody claims that specifically cover our STAR-0215 product candidate and antibodies closely related to it. As a result, upon receipt of FDA approval, or regulatory approval in foreign jurisdictions, competitors may be free to market antibodies almost identical to ours, including biosimilar antibodies, thereby decreasing our market share. However, a competitor cannot submit to the FDA an application for a biosimilar product based on STAR-0215 or any future biologic products until four&#160;years following the date of approval of our &#8220;reference product,&#8221; and the FDA may not approve such a biosimilar product until 12&#160;years from the date on which the reference product was approved. See the section of this Annual Report on Form&#160;10-K entitled &#8220;Business&#8201;&#8212;&#8201;Government Regulation and Product Approval&#8201;&#8212;&#8201;Biosimilars and Regulatory Exclusivity&#8221; for more details regarding biosimilar regulatory exclusivities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our pending International patent application and any future patent applications we file cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Assuming the other requirements for patentability are met, currently, patents are granted to the party who was the first to file a patent application. However, prior to March&#160;16, 2013, in the United States, patents were granted to the party who was the first to invent the claimed subject matter. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, our patents or pending patent applications may be challenged in the courts or patent offices in the United States and abroad. For example, we may be subject to a third party preissuance submission of prior art to the USPTO, or become involved in post-grant review procedures, oppositions, derivations, reexaminations, inter partes review or interference proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing antibodies or compounds similar or identical to our product candidates, or limit the duration of the patent protection of our product candidates. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Patent applications may not result in patents being issued which protect any current and future product candidates, in whole or in part, or which effectively prevent others from commercializing competitive products. Changes in either the patent laws or interpretation </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. In addition, the laws of foreign countries may not protect our rights to the same extent or in the same manner as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if patent applications that we file issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner. Our competitors may also seek approval to market their own products similar to or otherwise competitive with any of our future products. Alternatively, our competitors may seek to market biosimilar versions of any approved products by submitting an application for a biosimilar product under the BPCIA. In these circumstances, we may need to defend or assert our patents, or both, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our patents invalid or unenforceable, or that our competitors are competing in a non-infringing manner. Thus, even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we do not obtain protection under the Hatch-Waxman Act and similar non-United States legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Patents have a limited duration. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest United States non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates, their manufacture, or use are obtained, once the patent life has expired, we may be open to competition from competitive products, including biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our United States patents, if issued, may be eligible for limited patent term extension under the Hatch-Waxman Act, or under similar legislation in other countries. The Hatch-Waxman Act permits a patent term extension of up to five&#160;years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. The patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, and only one patent applicable to an approved drug may be extended. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner than we expect. As a result, our revenue from applicable products could be reduced, possibly materially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our development and commercialization rights to STAR-0215 and future product candidates and technology may be subject, in part, to the terms and conditions of licenses granted to us by others.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may become reliant upon licenses to certain patent rights and proprietary technology from third parties that are relevant to our STAR-0215 product candidate and possible future product candidates. These and other licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we choose to develop or commercialize our technology and products in the future. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories included in all of our licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Such license agreements would likely impose various development obligations, payment of royalties and fees based on achieving certain milestones, as well as other obligations. In addition, our licensors, in the future, may allege that we have materially breached our obligations under a certain license agreement and may therefore terminate that license agreement. If we fail to comply with our obligations under these agreements, the licensor may have the right to terminate the license. The termination of any such license agreements or failure to adequately protect such license agreements could prevent us from commercializing product candidates covered by the licensed intellectual property. Furthermore, our competitors may obtain the freedom to seek regulatory approval of, and to market products competitive with ours.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Disputes may arise regarding intellectual property subject to a licensing agreement, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of rights granted under the license agreement and other interpretation related issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sublicensing of patent and other rights under any collaboration relationships we might enter into in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ownership of inventions and know how resulting from the joint creation or use of intellectual property by our licensors and us; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the priority of invention of patented technology.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for&#160;years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">An intellectual property litigation could lead to unfavorable publicity that could harm our reputation and cause the market price of our common stock to decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the course of any patent litigation, there could be public announcements of the results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our products, programs, or intellectual property could be diminished. In such event, the market price of our common stock may decline.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing current and future product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our commercial success depends, in part, on our ability to develop, manufacture, market and STAR-0215, as well as any future product candidates, without infringing the intellectual property and other proprietary rights of third parties. If any third-party patents or patent applications are found to cover STAR-0215 or any future product candidates or their methods of use, we may not be free to manufacture or market such product candidates as planned without obtaining a license, which may not be available on commercially reasonable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In spite of our efforts to avoid obstacles and disruptions arising from third-party intellectual property, it is impossible to establish with certainty that our programs directed to STAR-0215 and any future product candidates will be free of claims by third-party intellectual property holders. Even with modern databases and on-line search engines, literature searches are imperfect and may fail to identify relevant patents and published applications. Even when a third-party patent is identified, we may conclude upon a thorough analysis, that we do not infringe the patent or that the patent is invalid. If the third-party patent owner disagrees with our conclusion and we continue with the business activity in question, patent litigation may be initiated against us. Alternatively, we might decide to initiate litigation in an attempt to have a court declare the third-party patent invalid or non-infringed by our activity. In either scenario, patent litigation typically is costly and time-consuming, and the outcome is uncertain. The outcome of patent litigation is subject to uncertainties that cannot be quantified in advance, for example, the credibility of expert witnesses who may disagree on technical interpretation of scientific data. Ultimately, in the case of an adverse outcome in litigation, we could be prevented from commercializing a product or using certain aspects of our technology platform as a result of patent infringement claims asserted against us. This could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There is a substantial amount of intellectual property litigation in the biopharmaceutical industry, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to STAR-0215 or any future product candidates, including interference proceedings before the USPTO. Third parties may assert infringement claims against us based on existing or future intellectual property rights. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. The biopharmaceutical industry has produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that any current or future product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could significantly harm our business and operating results. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are found to infringe a third party&#8217;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing any future product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our involvement in litigation, and in, e.g., any interference, derivation, reexamination, inter partes review, opposition or post-grant proceedings or other intellectual property proceedings in the United States, or other jurisdictions, may divert management time from focusing on business operations, could cause us to spend significant amounts of money and may have no guarantee of success. Any current and potential intellectual property litigation also could force us to do one or more of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stop selling, manufacturing or using our products in the United States or other jurisdictions that use the subject intellectual property;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain from a third party asserting its intellectual property rights, a license to sell or use the relevant technology, which license may not be available on reasonable terms, or at all, or may be non-exclusive thereby giving our competitors access to the same technologies licensed to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">redesign those products or processes that use any allegedly infringing or misappropriated technology, which may result in significant cost or delay to us, or which redesign could be technically infeasible; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pay damages, including the possibility of treble damages in a patent case if a court finds us to have willfully infringed certain intellectual property rights.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Along with patent protection, we also rely on trade secret protection for our proprietary information that is not amenable to, or that we do not consider appropriate for, patent protection, including, for example, certain aspects of our manufacturing processes. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, consultants, independent contractors, CROs, advisors, contract manufacturers, suppliers and other third parties. We also enter into confidentiality and invention or patent assignment agreements with employees and certain consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Trade secrets and confidential know-how are difficult to maintain as confidential. Although we use reasonable efforts to protect our trade secrets, any party with whom we have executed a confidentiality agreement may breach that agreement and disclose our proprietary information, including our trade secrets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. Accordingly, we may not be able to obtain adequate remedies for such breaches, despite any legal action that we might take against persons making such unauthorized disclosures. In addition, courts outside the United States sometimes are less willing than United States courts to protect trade secrets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such third party, or those to whom they communicate such technology or information, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our business and competitive position could be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Those with whom we collaborate on research and development related to current and future product candidates may have rights to publish data and other information to which we have rights. In addition, we sometimes engage individuals or entities to conduct research relevant to our business. The ability of these individuals or entities to publish or otherwise publicly disclose data and other information generated during the course of their research is subject to certain contractual limitations. These contractual provisions may be insufficient or inadequate to protect our confidential information. If we do not apply for patent protection prior to such publication, or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes to the patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act, or the Leahy-Smith Act, signed into law in September&#160;2011, could increase those uncertainties and costs. The Leahy-Smith Act included a number of significant changes to United States patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, for example, via post grant review and inter partes review proceedings at the USPTO. In addition, the Leahy-Smith Act transformed the United States patent system into a &#8220;first to file&#8221; system. The first-to-file provisions, however, only became effective in March&#160;2013. However, the Leahy-Smith Act and its implementation could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could harm our business, results of operations and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The United States Supreme Court has ruled on several patent cases, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Additionally, there have been proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact our ability to enforce our proprietary technology. Depending on future actions by the Congress, the United States courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to make antibodies that are the same as or similar to STAR-0215 or future product candidates but that are not covered by the claims of patents that we own or have rights to;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or our licensors or any current or future strategic partners might not have been the first to conceive or reduce to practice the inventions covered by our pending patent application;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or our licensors or any future strategic partners might not have been the first to file patent applications covering certain of our inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that our pending patent rights will not lead to issued patents, or that patents, if granted, may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third parties performing manufacturing or testing for us using our products or technologies could use the intellectual property of others without obtaining a proper license;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop additional technologies that are patentable; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third parties may allege that our development and commercialization of STAR-0215 or future products may infringe their intellectual property rights, the outcome of which may have an adverse effect on our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering any future product candidates, our competitive position would be adversely affected.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may obtain only limited geographical protection with respect to certain patent rights, which may diminish the value of our intellectual property rights in those jurisdictions and prevent us from enforcing our intellectual property rights throughout the world.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive. Accordingly, we may not file for patent protection in all national and regional jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant proceeding of each national/regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant patent offices, while granted by others. It is also quite common that depending on the country, the scope of patent protection may vary for the same product candidate or technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The requirements for patentability may differ in certain countries, particularly in developing countries. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection, but where patent enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued or licensed patents or where any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by changes in foreign intellectual property laws. Additionally, laws of some countries outside of the United States and Europe do not afford intellectual property protection to the same extent as the laws of the United States and Europe. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, including India, China and other developing countries, do not favor the enforcement of patents and other intellectual property rights. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired and our business, results of operations and financial condition may be adversely affected. Consequently, we may not be able to prevent third parties from practicing our inventions in certain countries outside the United States and Europe. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, if our ability to enforce our patents to stop infringing activities in those jurisdictions is inadequate. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and resources from other aspects of our business. Furthermore, while we intend to protect our intellectual property rights in major markets for our products, we may not be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property or claiming ownership of what we regard as our own intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many of our employees, including our senior management, were previously employed at other biopharmaceutical companies, including our competitors or potential competitors. Some of these employees, including members of our senior management, executed proprietary rights, non-disclosure and non-competition agreements, or similar agreements, in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such third party. Litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">In addition, while we typically require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">agreement with each party who in fact develops intellectual property that we regard as our own, which may result in claims by or against us related to the ownership of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our senior management and scientific personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Regulatory Approval and Other Legal Compliance Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we complete the necessary preclinical studies and clinical trials, the regulatory approval process is expensive, time consuming and uncertain and may prevent us or any future collaborators from obtaining approvals for the commercialization of STAR-0215 or any future product candidates. As a result, we cannot predict when or if, and in which territories, we, or any future collaborators, will obtain marketing approval to commercialize a product candidate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of biopharmaceutical products are subject to extensive regulation by the FDA and comparable foreign regulatory authorities, which regulations differ from country to country. We, and any future collaborators, are not permitted to market our product candidates in the United States or in other countries until we, or they, receive approval of a BLA from the FDA, which would be required for approval of STAR-0215, or NDA or marketing approval from applicable regulatory authorities outside the United States. Product candidates in the development phase are subject to the risks of failure inherent in drug development. We have not submitted an application for or received marketing approval for any of our product candidates in the United States or in any other jurisdiction. We have no experience as a company in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party clinical research organizations to assist us in this process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The process of obtaining marketing approvals, both in the United States and abroad, is lengthy, expensive and uncertain. It may take many&#160;years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information, including manufacturing information, to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. The FDA or other regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, changes in or the enactment or promulgation of additional statutes, regulations or guidance during preclinical or clinical development, or comparable changes in the regulatory review process for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we, or any future collaborators, ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any delay in obtaining or failure to obtain required approvals could negatively affect our ability or that of any future collaborators to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed abroad. Any approval we may be granted for our product candidates in the United States would not assure approval of our product candidates in foreign jurisdictions and any of our product candidates that may be approved for marketing in a foreign jurisdiction will be subject to risks associated with foreign operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to market and sell our products in the European Union and other foreign jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. We, and any future collaborators, may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may file for marketing approvals but not receive necessary approvals to commercialize our products in any market.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In many countries outside the United States, a product candidate must also be approved for reimbursement before it can be sold in that country. In some cases, the price that we intend to charge for our products, if approved, is also subject to approval. Obtaining non-United States regulatory approvals and compliance with non-United States regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries. In addition, if we fail to obtain the non-United States approvals required to market our product candidates outside the United States or if we fail to comply with applicable non-United States regulatory requirements, our target markets will be reduced and our ability to realize the full market potential of our product candidates will be harmed and prospects may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, we could face heightened risks with respect to seeking marketing approval in the United Kingdom as a result of the 2020 withdrawal of the United Kingdom from the European Union, commonly referred to as Brexit. The United Kingdom and European Union entered into a Trade and Cooperation Agreement in connection with Brexit that sets out certain procedures for approval and recognition of medical products in each jurisdiction. Since the regulatory framework for pharmaceutical products in the United Kingdom covering the quality, safety, and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales, and distribution of pharmaceutical products is derived from European Union directives and regulations, the consequences of Brexit the impact the future regulatory regime that applies to products and the approval of product candidates in the United Kingdom remains unclear. As of January&#160;1, 2021, the Medicines and Healthcare products Regulatory Agency, or the MHRA, became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic law, whereas Northern Ireland will continue to be subject to European Union rules&#160;under the Northern Ireland Protocol. The MHRA will rely on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended), or the HMR, as the basis for regulating medicines. The HMR has incorporated into the domestic law of the body of European Union law instruments governing medicinal products that pre-existed prior to the United Kingdom&#8217;s withdrawal from the European Union. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, &#160;may force us to restrict or delay efforts to seek regulatory approval in the United Kingdom for any product candidates, which could significantly and materially harm our business, or prevent us from commercializing any product candidate in the United Kingdom and/or the European Union and restrict our ability to generate revenue and achieve and sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect that we will be subject to additional risks in commercializing any of our product candidates that receive marketing approval outside the United States, including tariffs, trade barriers and regulatory requirements; economic weakness, including inflation, or political instability in particular foreign economies and markets (such as the ongoing conflict between Ukraine and Russia); compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; and workforce uncertainty in countries where labor unrest is more common than in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We, or any future collaborators, may not be able to obtain orphan drug designation or orphan drug exclusivity for any future product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. We, or any future collaborators, may seek orphan drug designations and may be unable to obtain such designations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if we, or any future collaborators, obtain orphan drug designation for a product candidate, we, or they, may not be able to obtain orphan drug exclusivity for that product candidate. Generally, a product with orphan drug designation only becomes entitled to orphan drug exclusivity if it receives the first marketing approval for the indication for which it has such designation, in which case the FDA or the EMA will be precluded from approving another marketing application for the same drug for that indication for the applicable exclusivity period. The applicable exclusivity period is seven&#160;years in the United States and ten&#160;years in Europe. The European exclusivity period can be reduced to six&#160;years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or the EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Even if we, or any future collaborators, obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because FDA has taken the position that, under certain circumstances, another drug with the same active moiety can be approved for the same condition. Specifically, the FDA&#8217;s regulations provide that it can approve another drug with the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">same active moiety for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2017, the Congress passed the FDA Reauthorization Act of 2017, or FDARA, which among other things, codified the FDA&#8217;s pre-existing regulatory interpretation to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. Under Omnibus legislation signed by President Trump on December&#160;27, 2020, the requirement for a product to show clinical superiority applies to drugs and biologics that received orphan drug designation before enactment of FDARA in 2017, but have not yet been approved or licensed by FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. This may be particularly true in light of a decision from the Court of Appeals for the 11<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Circuit in September&#160;2021 finding that, for the purpose of determining the scope of exclusivity, the term &#8220;same disease or condition&#8221; means the designated &#8220;rare disease or condition&#8221; and could not be interpreted by the Agency to mean the &#8220;indication or use.&#8221;&#160; Thus, the court concluded, orphan drug exclusivity applies to the entire designated disease or condition rather than the &#8220;indication or use.&#8221; We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, to obtain orphan drug designation in the European Union, we would need to demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the European Union or, if such method exists, the medicinal product will be of significant benefit to those affected by that condition. There is no assurance that we would be able to meet that standard for STAR-0215 or any other product candidate. In particular, there is no assurance that STAR-0225 will be able to show, to the satisfaction of European Union regulatory authorities, that it of significant benefit to HAE patients given the currently available commercial products for HAE in the European Union and the additional products that are ahead of STAR-0215 in clinical development for HAE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any product candidate for which we obtain marketing approval would remain subject to ongoing regulation and could be subject to restrictions or withdrawal from the market, and we may be subject to substantial penalties if we fail to comply with regulatory requirements, when and if any of our product candidates are approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any product candidate for which we obtain marketing approval will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to quality control and manufacturing, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and recordkeeping. In addition, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine, including the requirement to implement a risk evaluation and mitigation strategy. Accordingly, if we receive marketing approval for one or more of our product candidates, we will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. If we fail to comply with these requirements, we could have the marketing approvals for our products withdrawn by regulatory authorities and our ability to market any products could be limited, which could adversely affect our ability to achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We must also comply with requirements concerning advertising and promotion for any product candidate for which we obtain marketing approval. Promotional communications with respect to prescription products are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. In September&#160;2021 the FDA published final regulations which describe the types of evidence that the FDA will consider in determining the intended use of a drug or biologic. Thus, we will not be able to promote any products we develop for indications or uses for which they are not approved. The FDA and other agencies, including the Department of Justice, or the DOJ, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. Violations of the Federal Food, Drug, and Cosmetic Act and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription products may lead to investigations and enforcement actions alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, later discovery of previously unknown adverse events or other problems with our products or their manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on such products, manufacturers or manufacturing processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the labeling or marketing of a product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on distribution or use of a product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct post-marketing studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of the products from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that we submit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">damage to relationships with collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unfavorable press coverage and damage to our reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, restitution or disgorgement of profits or revenues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of marketing approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to permit the import or export of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">litigation involving patients using our products.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Non-compliance with European Union requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the European Union&#8217;s requirements regarding the protection of personal information can also lead to significant penalties and sanctions. Further, the marketing and promotion of authorized drugs, including industry-sponsored continuing medical education and advertising directed toward the prescribers of drugs and/or the general public, are strictly regulated in the European Union, notably under Directive 2001/83EC, as amended, and are also subject to European Union Member State laws. Direct-to-consumer advertising of prescription medicines is prohibited across the European Union.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, assuming we, or any future collaborators, receive marketing approval for one or more of our product candidates, we, and any future collaborators, and our and their contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. If we, and any future collaborators, are not able to comply with post-approval regulatory requirements, our or any future collaborators&#8217; ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may seek certain designations for our product candidates, including Breakthrough Therapy, RMAT Therapy, Fast Track and Priority Review designations in the U.S., and PRIME Designation in the European Union, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may seek certain designations for one or more of our product candidates that could expedite review and approval by the FDA. A Breakthrough Therapy and Regenerative Medicine Advanced Therapy, or RMAT, product is defined as a product that is intended, alone or in combination with one or more other products, to treat a serious condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For products that have been designated as Breakthrough and RMAT therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may also designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#8217;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may also seek a priority review designation for one or more of our product candidates. If the FDA determines that a product candidate offers major advances in treatment or provides a treatment where no adequate therapy exists, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six&#160;months, rather than the standard review period of ten&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These designations are within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for these designations, the FDA may disagree and instead determine not to make such designation. Further, even if we receive a designation, the receipt of such designation for a product candidate may not result in a faster development or regulatory review or approval process compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualifies for these designations, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the European Union, we may seek PRIME designation for some of our product candidates in the future. PRIME is a voluntary program aimed at enhancing the EMA&#8217;s role to reinforce scientific and regulatory support in order to optimize development and enable accelerated assessment of new medicines that are of major public health interest with the potential to address unmet medical needs. The program focuses on medicines that target conditions for which there exists no satisfactory method of treatment in the European Union or even if such a method exists, it may offer a major therapeutic advantage over existing treatments. PRIME is limited to medicines under development and not authorized in the European Union and the applicant intends to apply for an initial marketing authorization application through the centralized procedure. To be accepted for PRIME, a product candidate must meet the eligibility criteria in respect of its major public health interest and therapeutic innovation based on information that is capable of substantiating the claims. The benefits of a PRIME designation include the appointment of a Committee for Medicinal Products for Human Use rapporteur to provide continued support and help to build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review, meaning reduction in the review time for an opinion on approvability to be issued earlier in the application process. PRIME enables an applicant to request parallel EMA scientific advice and health technology assessment advice to facilitate timely market access. Even if we receive PRIME designation for any of our product candidates, the designation may not result in a materially faster development process, review or approval compared to conventional EMA procedures. Further, obtaining PRIME designation does not assure or increase the likelihood of EMA&#8217;s grant of a marketing authorization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We and our contract manufacturers are subject to significant regulation. The manufacturing facilities on which we rely may not continue to meet regulatory requirements, which could materially harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">All entities involved in the preparation of product candidates for clinical trials or commercial sale, including any contract manufacturers, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP. These regulations govern manufacturing processes and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We or our contract manufacturers must supply all necessary documentation in support of a BLA or NDA on a timely basis and must adhere to the FDA&#8217;s current Good Laboratory Practice and cGMP regulations enforced through its facilities inspection program. Our facilities and quality systems and the facilities and quality systems of some or all of our contract manufacturers must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of any product candidate. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or the associated quality systems for compliance with the regulations applicable to the activities being conducted. If these facilities do not pass a pre-approval plant inspection, FDA approval of the products will not be granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The regulatory authorities also may, at any time following approval of a product for sale, audit our manufacturing facilities or those of our contract manufacturers. If any such inspection or audit identifies failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility, which may lead to temporary or permanent supply shortages. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we of our third-party manufacturers fail to maintain regulatory compliance, the FDA can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new product, or revocation of a pre-existing approval. Any such consequence would severely harm our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inadequate funding for the FDA, the SEC and other government agencies, including from government shut downs, or other disruptions to these agencies&#8217; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent&#160;years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In addition, government funding of the SEC and other government agencies, including government agencies and regulatory authorities outside the United States, on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several&#160;years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Separately, in response to the COVID-19 pandemic, since March&#160;2020 when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been working to resume routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis. The FDA has developed a rating system to assist in determining when and where it is safest to conduct prioritized domestic inspections. As of May&#160;2021, certain inspections, such as foreign preapproval, surveillance, and for-cause inspections that are not deemed mission-critical, remain temporarily postponed. In April&#160;2021 the FDA issued guidance for industry formally announcing plans to employ remote interactive evaluations, using risk management methods, to meet user fee commitments and goal dates and in May&#160;2021 announced plans to continue progress toward resuming standard operational levels. Should the FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">FDA does not determine a remote interactive evaluation to be adequate, the FDA has stated that it generally intends to issue a complete response letter or defer action on the application until an inspection can be completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2020 and 2021 a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. As of May&#160;26, 2021, the FDA noted it was continuing to ensure timely reviews of applications for medical products during the ongoing COVID-19 pandemic in line with its user fee performance goals and conducting mission critical domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA quality standards. However, the FDA may not be able to continue its current pace and review timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the ongoing COVID-19 pandemic and travel restrictions, the FDA is unable to complete such required inspections during the review period. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities. If a prolonged government shutdown or other disruption occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Current and future legislation may increase the difficulty and cost for us to obtain reimbursement for any of our product candidates that do receive marketing approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we may receive for any approved products. If reimbursement of our products is unavailable or limited in scope, our business could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2010, President Obama signed into law the ACA. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. In August&#160;2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the&#160;years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal&#160;year, which went into effect in April&#160;2013 and will remain in effect through 2031 under the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act. Pursuant to subsequent legislation, however, these Medicare sequester reductions have been suspended through the end of March&#160;2022. From April&#160;2022 through June&#160;2022 a 1% sequester cut will be in effect, with the full 2% cut resuming thereafter. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since enactment of the ACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act, or TCJA, in 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. Further, in December&#160;2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA and therefore because the mandate was repealed as part of the TCJA, the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court heard this case and in June&#160;2021, dismissed this action after finding that the plaintiffs do not have standing to challenge the constitutionality of the ACA. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Trump Administration also took executive actions to delay implementation of the ACA, including directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers or manufacturers of pharmaceuticals or medical devices. On January&#160;28, 2021, however, President Biden revoked those orders and issued a new executive order which directs federal agencies to reconsider rules&#160;and other policies that limit Americans&#8217; access to health care, and consider actions that will protect and strengthen that access. Under this order, federal agencies are directed to re-examine: policies that undermine </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">protections for people with pre-existing conditions, including complications related to COVID-19; demonstrations and waivers under Medicaid and the ACA that may reduce coverage or undermine the programs, including work requirements; policies that undermine the Health Insurance Marketplace or other markets for health insurance; policies that make it more difficult to enroll in Medicaid and the ACA; and policies that reduce affordability of coverage or financial assistance, including for dependents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop or commercialize product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to considerable legislative and executive actions and could impact the prices we obtain for our products, if and when licensed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The prices of prescription pharmaceuticals have been the subject of considerable discussion in the United States. There have been several recent Congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. In 2020 President Trump issued several executive orders intended to lower the costs of prescription products and certain provisions in these orders have been incorporated into regulations. These regulations include an interim final rule&#160;implementing a most favored nation model for prices that would tie Medicare Part&#160;B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries, effective January&#160;1, 2021. That rule, however, has been subject to a nationwide preliminary injunction and, on December&#160;29, 2021, CMS issued a final rule&#160;to rescind it. With issuance of this rule, CMS stated that it will explore all options to incorporate value into payments for Medicare Part&#160;B pharmaceuticals and improve beneficiaries&#8217; access to evidence-based care.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, in October&#160;2020, HHS and the FDA published a final rule&#160;allowing states and other entities to develop a Section&#160;804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. The final rule&#160;is currently the subject of ongoing litigation, but at least six states (Vermont, Colorado, Florida, Maine, New Mexico, and New Hampshire) have passed laws allowing for the importation of drugs from Canada with the intent of developing SIPs for review and approval by the FDA. Further, on November&#160;20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part&#160;D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule&#160;has been delayed by the Infrastructure Investment and Jobs Act to January&#160;1, 2026 in response to ongoing litigation. The rule&#160;also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed until January&#160;1, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2021, acting pursuant to an executive order signed by President Biden, the Department of Health and Human Services, or HHS, released its plan to reduce pharmaceutical prices. The key features of that plan are to: (a)&#160;make pharmaceutical prices more affordable and equitable for all consumers and throughout the health care system by supporting pharmaceutical price negotiations with manufacturers; (b)&#160; improve and promote competition throughout the prescription pharmaceutical industry by supporting market changes that strengthen supply chains, promote biosimilars and generic drugs, and increase transparency; and (c)&#160;foster scientific innovation to promote better healthcare and improve health by supporting public and private research and making sure that market incentives promote discovery of valuable and accessible new treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In markets outside of the United States and the European Union, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. In many countries, including those of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control and access. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we or our collaborators may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to certain healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, fines, disgorgement, exclusion from participation in government healthcare programs, curtailment or restricting of our operations, and diminished profits and future earnings.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Healthcare providers, third-party payors and others will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our future arrangements with healthcare providers and third-party payors will expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any products for which we obtain marketing approval. Potentially applicable United States federal and state healthcare laws and regulations include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Anti-Kickback Statute</span>. &#160;The federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">False Claims Laws</span>. &#160;The federal false claims laws, including the civil False Claims Act, impose criminal and civil penalties, including those from civil whistleblower or qui tam actions against individuals or entities for knowingly presenting, or causing to be presented to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">HIPAA</span>. &#160;The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing or attempting to execute a scheme to defraud any healthcare benefit program. In addition, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or the HITECH Act, also imposes obligations on certain types of individuals and entities, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">False Statements Statute</span>. &#160;The federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transparency Requirements</span>. &#160;The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the HHS information related to physician and healthcare provider payments and other transfers of value and physician ownership and investment interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Analogous State and Foreign Laws</span>. &#160;Analogous state laws and regulations, such as state anti-kickback and false claims laws, and transparency laws, may apply to sales or marketing arrangements, and claims involving healthcare items or services reimbursed by non-governmental third party payors, including private insurers, and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, in addition to requiring manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures. Many state laws also govern the privacy and security of health information in some circumstances, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. Foreign laws also govern the privacy and security of health information in many circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the European Union. Payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Efforts to ensure that our business arrangements with third parties, and our business generally, will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, and reputational harm, any of which could substantially disrupt our operations. If any of the physicians or other providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we operate or plan to operate has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the European Union, including personal health data, is subject to the European Union General Data Protection Regulation, or the GDPR, which took effect across all member states of the EEA in May&#160;2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including strict rules&#160;on the transfer of personal data to countries outside the European Union, including the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result, there is increased scrutiny on the extent to which clinical trial sites located in the EEA should apply the GDPR to transfers of personal data from such sites to countries that are considered to lack an adequate level of data protection, such as the United States. The GDPR also permits data protection authorities to require destruction of improperly gathered or used personal information and/or impose substantial fines for violations of the GDPR, which can be up to four&#160;percent of global revenues or 20&#160;million Euros, whichever is greater, and it also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR provides that European Union member states may make their own laws and regulations limiting the processing of personal data, including genetic, biometric or health data. Assisting parties with whom we exchange personal data in complying with the GDPR, or complying with the GDPR ourselves, may cause us to incur substantial operational costs or require us to change our business practices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Similar initiatives are either in place or under way in the United States. There are a broad variety of data protection laws that are applicable to our activities, and a wide range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered at both the state and federal levels. For example, the California Consumer Privacy Act, which went into effect on January&#160;1, 2020, is creating similar risks and obligations as those created by GDPR, though the Act does exempt certain information collected as part of a clinical trial subject to the Federal Policy for the Protection of Human Subjects (the Common Rule). Many other states are considering similar legislation. A broad range of legislative measures also have been introduced at the federal level. Accordingly, failure to comply with federal and state laws (both those currently in effect and future legislation) regarding privacy and security of personal information could expose us to fines and penalties under such laws. There also is the threat of consumer class actions related to these laws and the overall protection of personal data. Even if we are not determined to have violated these laws, government investigations into these issues </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Given the breadth and depth of changes in data protection obligations, preparing for and complying with such requirements is rigorous and time intensive and requires significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data collected in the European Union. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our clinical trials, could require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business, and could lead to government enforcement actions, private litigation and significant fines and penalties against us and could have a material adverse effect on our business, financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to United States and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to the United States Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, the United States domestic bribery statute contained in 18 U.S.C. &#167;&#160;201, the United States Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, third-party intermediaries, joint venture partners and collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. We may have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. In addition, we may engage third party intermediaries to promote our clinical research activities abroad and/or to obtain necessary permits, licenses, and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives, contractors, partners and agents, even if we do not explicitly authorize or have actual knowledge of such activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Noncompliance with anti-corruption and anti-money laundering laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension and/or debarment from contracting with certain persons, the loss of export privileges, reputational harm, adverse media coverage and other collateral consequences. If any subpoenas, investigations or other enforcement actions are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management&#8217;s attention and resources and significant defense and compliance costs and other professional fees. In certain cases, enforcement authorities may even cause us to appoint an independent compliance monitor which can result in added costs and administrative burdens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. Further, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order, or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of European Union Member States and the UK Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment. Payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization, and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines, or imprisonment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could significantly harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts, which could adversely affect our business, financial condition, results of operations or prospects. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our employees, independent contractors, CROs, consultants, commercial partners, vendors and principal investigators may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, CROs, consultants, commercial partners, vendors and, if we commence clinical trials, our principal investigators. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the European Union and other jurisdictions, provide accurate information to the FDA, the European Commission and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately, or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. Even with appropriate policies and procedures, it is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent such activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations and prospects, including the imposition of significant fines or other sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we, or any future collaborators, are able to commercialize any product candidate that we, or they, develop, the product may become subject to unfavorable pricing regulations, third-party payor reimbursement practices or healthcare reform initiatives that could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The commercial success of any future product that we may develop will depend substantially, both domestically and abroad, on the extent to which the costs of such product will be paid by third-party payors, including government health administration authorities and private health coverage insurers. If coverage and reimbursement is not available, or reimbursement is available only to limited levels, we, or any future collaborators, may not be able to successfully commercialize such product. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us, or any future collaborators, to establish or maintain pricing sufficient to realize a sufficient return on our or their investments. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement for products can differ significantly from payor to payor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved drugs. Marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. Many countries outside the United States, including many countries in the European Union, require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted and can be lengthy, involve extensive negotiations and potentially result in price caps, significant discounts or other budgetary control measures, which could correspondingly impact pricing and reimbursement in other markets through so-called informal or formal reference pricing schemes. These reviews and negotiations could ultimately result in a pricing and reimbursement structure for a drug that a company deems inadequate and therefore </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">elects not launch in such markets. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we, or any future collaborators, might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time periods, which may negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability or the ability of any future collaborators to recoup our or their investment in one or more product candidates, even if any future product candidates obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Therefore, our ability, and the ability of any future collaborators, to commercialize any product will depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available from third-party payors. Third-party payors decide which medications they will cover and establish reimbursement levels. The healthcare industry is acutely focused on cost containment, both in the United States and elsewhere. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability or that of any future collaborators to sell any products we develop profitably. These payors may not view our products, if any, as cost-effective, and coverage and reimbursement may not be available to our customers, or those of any future collaborators, or may not be sufficient to allow our products, if any, to be marketed on a competitive basis. Cost-control initiatives could cause us, or any future collaborators, to decrease the price we, or they, might establish for products, which could result in lower than anticipated product revenues. If the prices for any future products decrease or if governmental and other third-party payors do not provide coverage or adequate reimbursement, our prospects for revenue and profitability will suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There may also be delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the indications for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Reimbursement rates may vary, by way of example, according to the use of the drug and the clinical setting in which it is used. Reimbursement rates may also be based on reimbursement levels already set for lower cost drugs or may be incorporated into existing payments for other services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, increasingly, third-party payors are requiring higher levels of evidence of the benefits and clinical outcomes of new technologies and are challenging the prices charged. For example, to obtain reimbursement or pricing approval in some countries, we, or any future collaborators, may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies. We cannot be sure that coverage will be available for any product candidate that we, or any future collaborator, commercialize and, if available, that the reimbursement rates will be adequate. Further, the net reimbursement for drug products may be subject to additional reductions if there are changes to laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. An inability to promptly obtain coverage and adequate payment rates from both government-funded and private payors for any product candidate for which we, or any future collaborator, obtain marketing approval could significantly harm our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Taxation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in tax law could adversely affect our business and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The rules&#160;dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us and our stockholders. Many such changes have been made and changes are likely to continue to occur in the future. For example, the TCJA was enacted in 2017 and significantly reformed the Internal Revenue Code of 1986, as amended, or the Code. The TCJA, among other things, contained significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, a limitation of the tax deduction for net interest expense to 30% of adjusted earnings (except for certain small businesses), a limitation of the deduction for net operating losses to 80% of current&#160;year taxable income and an elimination of net operating loss carrybacks (though any net operating losses generated in taxable&#160;years beginning after December&#160;31, 2017 may be carried forward indefinitely), and the modification or repeal of many business deductions and credits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">As part of Congress&#8217; response to the COVID-19 pandemic, the Families First Coronavirus Response Act, or the FFCR Act, was enacted on March&#160;18, 2020, the CARES Act was enacted on March&#160;27, 2020, and COVID-19 relief provisions were included in the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">Consolidated Appropriations Act, 2021 or CAA, which was enacted on December&#160;27, 2020. All contain numerous tax provisions. In particular, the CARES Act, among other things, suspends the 80% limitation on the deduction for net operating losses in taxable&#160;years beginning before January&#160;1, 2021, permits a 5-year carryback of net operating losses arising in taxable&#160;years beginning after December&#160;31, 2017 and before January&#160;1, 2021, and generally caps the limitation on the deduction for net interest expense at 50% of adjusted taxable income for taxable&#160;years beginning in 2019 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is also likely that Congress will enact additional legislation in connection with the COVID-19 pandemic, and as a result of the changes in the U.S. presidential administration and control of the U.S. Senate, additional tax legislation may also be enacted. For example, President Biden has proposed to increase the U.S. corporate income tax rate from its current 21%, implement a minimum tax on book income and increase taxation of international business operations, among numerous other corporate tax reform proposals. It cannot be predicted whether, when, in what form, or with what effective dates, new tax laws may be enacted, or regulations and rulings may be enacted, promulgated or issued under existing or new tax laws, which could result in an increase in the combined company&#8217;s or the combined company&#8217;s stockholders&#8217; tax liability or require changes in the manner in which the combined company operates in order to minimize or mitigate any adverse effects of changes in tax law or in the interpretation thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our ability to use net operating losses and research and development credits to offset future taxable income may be subject to certain limitations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In general, under Sections&#160;382 and 383 of the Code, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change net operating losses or tax credits, or NOLs or credits, to offset future taxable income or taxes. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock increases its ownership by more than 50&#160;percentage points over its lowest ownership&#160;percentage within a specified testing period. As a result of the shares issued in January&#160;and February&#160;2021 related to the acquisition of Quellis and the concurrent private placement of Series&#160;X Preferred Stock, we have likely experienced an ownership change, as defined by Section&#160;382. If we have experienced an ownership change, as defined by Section&#160;382, at any time since inception, utilization of the federal and state net operating loss carryforwards or research and development tax credit carryforwards would be subject to annual limitation under Sections&#160;382 and 383. Under Section&#160;382, the annual limitation is determined by first multiplying the value of our stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. We are planning to complete a study to confirm an ownership change occurred in 2021 and assess whether there have been multiple ownership changes since inception, as well as the resulting amount of the limitation on our net operating loss carryforwards and research and development tax credit carryforwards. In addition, our NOLs or credits may also be impaired under state law. Accordingly, we may not be able to utilize a material portion of our NOLs or credits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Employee Matters, Managing Growth and Information Technology</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our future success depends on our ability to retain our senior management and key employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are highly dependent on our executive officers and key employees. If we are unable to retain our executive officers or other key employees, replacing them may be difficult and costly, and may take an extended period of time because of the nature of our current business strategy and the limited number of individuals in our industry with the relevant breadth of skills and experience. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate replacements for our executive officers or key employees on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We rely on consultants and advisors, including financial, legal, scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by other entities and may have commitments under consulting or advisory contracts with those entities that may limit their availability to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Security breaches and other disruptions to our information technology systems could compromise our information, disrupt our business and expose us to liability, which would cause our business and reputation to suffer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">In the ordinary course of our business, we collect, process and store sensitive data, including intellectual property, as well as our proprietary business information, employee data and personally identifiable information of clinical trial participants in accordance with informed consents covering such information. We also rely to a large extent on information technology systems to operate our business. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have outsourced elements of our confidential information processing and information technology structure, and as a result, we are managing independent vendor relationships with third parties who may or could have access to our confidential information. The secure maintenance of this information is important to our operations and business strategy. Despite our security measures, our information technology infrastructure, and that of our vendors and third-party providers, may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. We, our vendors and third-party providers could be susceptible to third party attacks on our and their information security systems, which attacks are of ever-increasing levels of sophistication and are made by groups and individuals with a wide range of motives and expertise, including organized criminal groups, hacktivists, nation states and others. Additionally, the risk of cyber-attacks or other privacy or data security incidents may be heightened as a result of our moving increasingly towards a remote working environment, which may be less secure and more susceptible to hacking attacks. While we have invested in information technology security measures and the protection of confidential information, there can be no assurance that our efforts will prevent service interruptions or security breaches. For example, we have detected common types of attempts to attack our information technology systems and data using means that have included phishing. Any service interruptions or security breaches of our information technology systems may substantially impair our ability to operate our business and could compromise our networks, or those of our vendors and third-party providers, and the information stored could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure, or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, disrupt our operations, and damage our reputation, any of which could adversely affect our business. Although we maintain cyber liability insurance of $1.0&#160;million in the aggregate it may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our principal stockholders own a significant&#160;percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our holders of 5% or more of our capital stock and their respective affiliates beneficially own in excess of 20.0% of our outstanding common stock. These stockholders, acting together or on their own, may be able to impact matters requiring stockholder approval. For example, they may be able to impact elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that investors may feel are in their best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with each investor&#8217;s interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The price of our common stock has been and is likely to continue to be highly volatile, which could result in substantial losses for our stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our stock price has been and is likely to continue to be highly volatile. For example, when we announced our acquisition of Quellis, our stock price increased by approximately 70% in one day. In the twelve&#160;months ending February&#160;28, 2022, the last business day in February, our stock price has traded at a high of $22.01 and a low of $3.83.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The stock market in general and the market for smaller pharmaceutical and biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, our investors may lose some or all of their investments. The market price for our common stock may be influenced by many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and results of clinical trials of STAR-0215 or any future product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commencement or termination of collaborations for any development programs we may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure or discontinuation of any of any development programs we may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of existing or new competitive products or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of clinical trials of product candidates of competitors;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory or legal developments in the United States and other countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the recruitment or departure of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of expenses related to a product candidate or clinical development program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of any additional efforts to develop additional product candidates or products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated changes in estimates as to financial results or recommendations by securities analysts that cover our stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcement or expectation of additional financing efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcement of collaborations, licenses, acquisitions or other comparable forms of transactions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our common stock by us, our insiders or other stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the structure of healthcare payment systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market conditions in the pharmaceutical and biotechnology sectors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic, industry and market conditions, including political instability, or instability from an outbreak of pandemic or contagious disease, such as the ongoing COVID-19 pandemic; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the other factors described in this &#8220;Risk Factors&#8221; section.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, securities class action litigation has often been brought against a company following a decline in the market price of its securities. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a public company we have incurred and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, or SOX, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Market and other applicable securities rules&#160;and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We expect that our management and other personnel will continue to devote a substantial amount of time towards maintaining compliance with these requirements. These requirements increase our legal and financial compliance costs and make some activities more time-consuming and costly. These rules&#160;and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Pursuant to Section&#160;404 of SOX, we are required to furnish reports by our management on our internal control over financial reporting with our Annual Reports on Form&#160;10-K with the SEC. If we cease to be a smaller reporting company with less than $100&#160;million in annual revenue, we will also be required to include attestation reports on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with SOX Section&#160;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, engage outside consultants and adopt a detailed work plan to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section&#160;404 of SOX. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">A significant portion of our total outstanding shares may be sold into the market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. As of February&#160;28, 2022, we had outstanding 13,016,955 shares of common stock and 31,455 shares of our Series&#160;X Preferred Stock, which are convertible into 5,242,501 shares of our common stock. Pursuant to our obligations under a registration rights agreement entered into in connection with the acquisition of Quellis and the February&#160;2015 Financing, we have registered under the Securities Act of 1933, as amended, or the Securities Act, 15,399,967 shares of our common stock issued to the former Quellis stockholders or issued or issuable upon conversion of the Series&#160;X Preferred Stock. As a result, such shares are freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule&#160;144 under the Securities Act. Any significant sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of February&#160;28, 2022, we also had outstanding warrants to purchase 1,530,380 shares of common stock at a weighted average exercise price of $41,84 per share, with expiration dates between March&#160;30, 2022 and December&#160;14, 2030. We have registered the issuance of shares upon exercise of these warrants under registration statements. As a result, the shares issuable upon exercise of these warrants can be freely sold in the public marked upon issuance, subject to volume limitations applicable to affiliates. Sales of these shares could cause the market price of our common stock to decline significantly. Furthermore, if our stock price rises, the holders of these warrants may be more likely to exercise their warrants and sell a large number of shares, which could negatively impact the market price of our common stock and reduce or eliminate any appreciation in our stock price that might otherwise occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, we have an ongoing sales agreement with Jefferies LLC, pursuant to which we could issue and sell shares of common stock under an at-the-market offering program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We do not anticipate paying any cash dividends on our capital stock in the foreseeable future, accordingly, stockholders must rely on capital appreciation, if any, for any return on their investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have never declared nor paid cash dividends on our capital stock. We currently plan to retain all of our future earnings, if any, to finance the operation, development and growth of our business. Any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be investors&#8217; sole source of gain for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The trading market for our common stock will likely depend, in part, on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. There can be no assurance that analysts will cover us or provide favorable coverage. If one or more analysts downgrade our stock or change their opinion of our stock, our share price would likely decline. In addition, if one or more analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Relating to our Certificate of Incorporation and Bylaws</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which our investors might otherwise receive a premium for </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a classified board of directors such that all members of the board are not elected at one time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allow the authorized number of our directors to be changed only by resolution of our board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limit the manner in which stockholders can remove directors from the board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on at stockholder meetings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limit who may call a special meeting of stockholder meetings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, as of February&#160;28, 2022, there are 31,455 shares of our Series&#160;X Preferred Stock outstanding that we issued in connection with the acquisition of Quellis and the February&#160;2021 Financing. Except as otherwise required by law, the Series&#160;X Preferred Stock does not have voting rights. However, as long as any shares of Series&#160;X Preferred Stock are outstanding, we may not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series&#160;X Preferred Stock, (i)&#160;alter or change adversely the powers, preferences or rights given to the Series&#160;X Preferred Stock or alter or amend the Certificate of Designation that authorized the Series&#160;X Preferred Stock, amend or repeal any provision of, or add any provision to, our Certificate of Incorporation or bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of preferred stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series&#160;X Preferred Stock, (ii)&#160;issue further shares of Series&#160;X Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series&#160;X Preferred Stock, or (iii)&#160;enter into any agreement with respect to any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three&#160;years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. This could discourage, delay or prevent someone from acquiring us or merging with us, whether or not it is desired by, or beneficial to, our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our certificate of incorporation designates the state courts in the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal court for the District of Delaware, as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against the company and our directors and officers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or employees to our company or our stockholders, any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our certificate </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">of incorporation or bylaws, or any action asserting a claim against us governed by the internal affairs doctrine. These exclusive forum provisions may limit the ability of our stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or our directors, officers, or employees, which may discourage such lawsuits against us and our directors, officers, and employees. Alternatively, if a court were to find the choice of forum provisions contained in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could materially adversely affect our business, financial condition, and operating results. This exclusive forum provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act, which provides for exclusive jurisdiction of the federal courts. It could apply, however, to a suit that falls within one or more of the categories enumerated in the exclusive forum provision and asserts claims under the Securities Act, inasmuch as Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules&#160;and regulations thereunder; provided, that with respect to claims under the Securities Act, our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules&#160;and regulations thereunder.</p><a id="_a860bbac_33ff_4bb1_8926_48dcc8d538f6"></a><a id="Item1BUnresolvedStaffComments_647014"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;1B. Unresolved Staff Comments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_f3c84a02_ea03_44dd_ab97_79ea7f368ed7"></a><a id="Item2Properties_654044"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;2. Properties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our offices are located in Boston, Massachusetts and consist of approximately 11,000 square feet of subleased office space under a lease that expires in July&#160;2022. We believe that our existing facilities are sufficient for our needs for the foreseeable future. On January&#160;28, 2022, we entered into a sublease agreement, or the Sublease Agreement, with Grant Thornton LLP, or the Sublandlord, pursuant to which we will sublease approximately 17,136 square feet of office space located in Boston, Massachusetts. The term of the Sublease Agreement will commence on the latest to occur of (i)&#160;May&#160;1, 2022, (ii)&#160;the receipt of the landlord&#8217;s consent to the Sublease Agreement and (iii)&#160;the date on which the Sublandlord delivers full and exclusive possession of the premises to us as set forth in the Sublease Agreement, and will end on July&#160;31, 2024 (or on such earlier date as the term may sooner cease or expire as set forth in the Sublease Agreement). If the landlord fails to deliver its consent within 45&#160;days after the execution of the Sublease Agreement, we have the right to terminate the Sublease Agreement, in accordance with the terms set forth therein.</p><a id="_b6d24618_2f7d_469c_a949_7e87caf06901"></a><a id="Item3LegalProceedings_185277"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;3. Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time we may become subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, as of the date of this Annual Report on Form&#160;10-K, we do not believe we are party to any claim or litigation, the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p><a id="_c73de5db_c7bd_492a_b779_3dfabf6bca15"></a><a id="Item4MineSafetyDisclosures_208551"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;4. Mine Safety Disclosures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8dbdd939_07f8_42e7_9938_63fb6c909b3f"></a><a id="PARTII_570594"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;II</b></p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Market Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September&#160;9, 2021, following our name change to Astria Therapeutics,&#160;Inc., our common stock, $0.001 par value per share, commenced trading under the symbol &#8220;ATXS&#8221; on the Nasdaq Global Select Market. Prior to September&#160;9, 2021, our common stock was publicly traded on the Nasdaq Global Market under the symbol &#8220;CATB&#8221; since June&#160;25, 2015. Prior to that time, there was no public market for our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Holders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March&#160;4, 2022, there were approximately 26 holders of record of our common stock. This number of holders of record does not include beneficial owners of our common stock whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Dividends</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have never declared nor paid cash dividends on our common stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. We do not intend to pay cash dividends in respect of our common stock in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Sales of Unregistered Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We did not sell or issue any equity securities that were not registered under the Securities Act during the period covered by this Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Purchases of Equity Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We did not purchase any of our registered equity securities during the period covered by this Annual Report on Form&#160;10-K.</p><a id="_03d43052_bc1c_4a6d_89db_60cff80eb3e7"></a><a id="Item6Reserved_659568"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item&#160;6.</b> <b style="font-weight:bold;">Reserved</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_baa48b83_f306_4d7d_9cb3_4972fd597fcd"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should review the &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. This section provides additional information regarding our businesses, current developments, results of operations, cash flows, financial condition, contractual commitments and critical accounting policies and estimates that require significant judgement and have the most potential impact on our consolidated financial statements. This discussion and analysis is intended to better allow investors to view the Company from the management&#8217;s perspective.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics. Our mission is to bring hope with life-changing therapies to patients and families that are affected by rare and niche allergic and immunological diseases. Our lead product candidate is STAR-0215 (formerly known as QLS-215), a potential best-in-class monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema, or HAE, a rare, debilitating and potentially life-threatening disease. STAR-0215 has the potential to be the most patient-friendly chronic treatment option, based on the data generated to date and the existing HAE treatment landscape.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2021 we acquired Quellis Biosciences,&#160;Inc., or Quellis, including the STAR-0215 program, and announced a private placement that, upon closing in February&#160;2021, resulted in gross proceeds to us of approximately $110.0 million before deducting placement agent and other offering expenses. In November&#160;2020, after we stopped the development of our edasalonexent program as a potential treatment for Duchenne Muscular Dystrophy, or DMD, we decided to explore and evaluate strategic options. The acquisition of Quellis was the result of our evaluation of strategic options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2021, we formally changed our name to Astria Therapeutics,&#160;Inc. from Catabasis Pharmaceuticals,&#160;Inc. The name &#8220;Astria&#8221; originates from the Greek word for star, demonstrating our commitment to patients who serve as our guiding stars.</p><a id="_Hlk97688943"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">HAE is a rare, debilitating and potentially life-threatening disease. The treatment options for patients with HAE have improved, however, there is remaining unmet medical need and the global market for HAE therapy is strong and growing. The vision for our lead program, STAR-0215, is to develop a best-in-class monoclonal antibody inhibitor of plasma kallikrein able to provide long-acting, effective attack prevention for HAE with dosing once every three months or longer. Targeted plasma kallikrein inhibition can prevent HAE attacks by suppressing the pathway that generates bradykinin and causes excessive swelling. STAR-0215 is currently in preclinical development and we expect to submit an Investigational New Drug application, or IND, for STAR-0215 in mid-2022 and plan to initiate a Phase 1a clinical trial shortly thereafter with initial results anticipated by year end 2022. We believe that this clinical trial has the opportunity to establish proof of concept for the differentiated profile of STAR-0215. We expect the Phase 1a clinical trial to be conducted in healthy volunteers and evaluate several single escalating dose cohorts with subcutaneous administration. Our goals for this trial with STAR-0215 are to demonstrate safety and tolerability, establish prolonged half-life, demonstrate the duration of inhibition of plasma kallikrein activity and to refine dose and dosing regimen for studies in HAE patients. Assuming positive data from the Phase 1a trial, we plan to initiate a Phase 1b/2 trial in patients with HAE in 2023. We expect the Phase 1b/2 trial will be a randomized, placebo-controlled, global multi-center trial. The primary goals for this trial in HAE patients are to demonstrate safety and tolerability, establish prolonged half-life, demonstrate inhibition of plasma kallikrein activity, and provide an initial assessment of the impact of STAR-0215 on HAE attack rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Our vision for STAR-0215 is supported by preclinical data showing potent inhibition of the production of bradykinin by plasma kallikrein and a long plasma half-life that could potentially enable patients to dose less frequently. Multiple experiments have confirmed that STAR-0215 is approximately 10-fold more potent than lanadelumab, a monoclonal antibody inhibitor of plasma kallikrein commercialized under the name TAKHZYRO and an approved preventative treatment for HAE, in inhibiting bradykinin production. In cynomolgus monkey studies, lanadelumab was observed to have a half-life of approximately 10 days, which is consistent with what has been reported in United States Food and Drug Administration, or FDA, review documents and publications for lanadelumab in non-human primates. STAR-0215 was administered at the same dose as lanadelumab and the observed half-life was approximately 34 days, which is about a three to four-fold longer half-life than observed for lanadelumab. We believe this could translate to a half-life of several </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">months for STAR-0215 in humans. If this longer half-life is demonstrated in clinical trials, it has the potential to enable dosing once every three months or longer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">January&#160;2021 Quellis Acquisition and February&#160;2021 Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2021, we acquired Quellis pursuant to an Agreement and Plan of Merger, or the Merger Agreement, by and among us, Cabo Merger Sub I,&#160;Inc., a Delaware corporation and our wholly owned subsidiary, or the First Merger Sub, Cabo Merger Sub II, LLC, a Delaware limited liability company and our wholly owned subsidiary, or the Second Merger Sub, and Quellis, or the Quellis Acquisition. Pursuant to the Merger Agreement, the First Merger Sub merged with and into Quellis, pursuant to which Quellis was the surviving entity and became a wholly owned subsidiary of ours, or the First Merger. Immediately following the First Merger, Quellis merged with and into the Second Merger Sub, pursuant to which the Second Merger Sub was the surviving entity, or the Second Merger and, together with the First Merger, the Merger. Under the terms of the Merger Agreement, at the closing of the Merger, we issued to the Quellis stockholders 555,444 shares of our common stock, and 50,504 shares of newly designated Series&#160;X Preferred Stock (as described below). In addition, we assumed outstanding Quellis stock options, which became options for 55,414 shares of our common stock, and assumed a warrant exercisable for Quellis common stock, which became a warrant to purchase 2,805 shares of Series&#160;X Preferred Stock at an exercise price of $341.70 per share, and a warrant to purchase 30,856 shares of our common stock at an exercise price of $2.10 per share. Upon stockholder approval of the Conversion Proposal (as defined below) on June&#160;2, 2021, the warrant to purchase Series&#160;X Preferred Stock was converted into the right to purchase 467,500 shares of our common stock, at a per share exercise price of $2.10 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We concluded that the Quellis Acquisition was not the acquisition of a business, as substantially all of the fair value of the non-monetary assets acquired was concentrated in a single identifiable asset, STAR-0215.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We determined that the cost to acquire the Quellis assets was $170.7 million, based on the fair value of the equity consideration issued and including direct costs of the acquisition of $1.8 million. The net assets acquired in connection with the Quellis Acquisition were recorded at their estimated fair values as of January&#160;28, 2021, which is the date the Quellis Acquisition was completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the estimation of fair value of the asset purchase consideration, we used the carrying value of the cash and cash equivalents, prepaid expenses, accounts payable and accrued liabilities as the most reliable indicator of fair value based on the associated short-term nature of the balances. The remaining fair value was attributable to the acquired in-process research and development, or IPR&amp;D. As STAR-0215 had not, at the time of the Quellis Acquisition, received regulatory approval in any territory, the cost attributable to the IPR&amp;D was expensed in our consolidated statements of operations and comprehensive loss for the year ended December 31, 2021, as the acquired IPR&amp;D had no alternative future use, as determined by us in accordance with United States generally accepted accounting principles, or U.S. GAAP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January 2021, we also entered into a Stock Purchase Agreement, or the Purchase Agreement, with certain institutional and accredited investors pursuant to which, we sold an aggregate of 35,573 shares of Series X Preferred Stock for an aggregate purchase price of $110.0 million, or the February 2021 Financing. Our stockholders approved the conversion of the Series X Preferred Stock into shares of common stock in accordance with Nasdaq Listing Rule 5635(a), or the Conversion Proposal, at our annual stockholders meeting on June 2, 2021. On the fourth business day after the approval of the Conversion Proposal, each share of Series X Preferred Stock automatically converted into 166.67 shares of common stock, subject to certain beneficial ownership limitations, including that a holder of Series X Preferred Stock is prohibited from converting shares of Series X Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (as of December 31, 2021, these percentages are set at 4.99% to 9.99% and can be adjusted by the holder to a number between 4.99% and 19.99%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. Shares of Series X Preferred Stock not converted automatically are thereafter subject to conversion at the option of the holder, subject to certain beneficial ownership limitations. As of December 31, 2021, 54,622 shares of Series X Preferred Stock were converted into 9,103,664 shares of common stock and 31,455 shares of Series X Preferred Stock remained outstanding. Each share of Series X Preferred Stock is convertible into 166.67 shares of common stock and therefore the number of shares of underlying common stock issuable upon conversion of the outstanding shares Series X Preferred Stock is 5,242,501. Outstanding shares of Series X Preferred Stock are subject to conversion at the option of the holder.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Reverse Stock Split</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 4, 2021, our Board of Directors approved a reverse stock split of our outstanding shares of common stock at a ratio of one-for-six (1:6). The reverse stock split became effective on August 19, 2021. The reverse stock split was approved by our stockholders at our Annual Meeting of Stockholders on June 2, 2021. All share and per share amounts of the common stock included in this Annual Report on Form 10-K, including in the accompanying consolidated financial statements, have been retrospectively adjusted to give effect to the reverse stock split for all periods presented, including reclassifying an amount equal to the reduction in par value to additional paid-in capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Financial Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our business is almost entirely dependent on the success of STAR-0215, which is in the preclinical stage of development, and has only produced results in preclinical and nonclinical settings. Our net losses were $194.9 million (including $164.6 million of in-process research and development expenses) and $37.3 million for the years ended December 31, 2021 and December 31, 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $455.8 million. We have financed our operations to date primarily through private placements of preferred stock before we became a public company and our private placement of preferred stock in the February 2021 Financing, registered offerings of our common stock and our at-the-market programs, and have devoted substantially all of our financial resources and efforts to research and development, including preclinical studies and clinical development programs. As of December 31, 2021, we had $125.5 million in cash, cash equivalents and short-term investments. We expect that our existing cash, cash equivalents and short-term investments are sufficient to support our operating expenses through 2023. Advancing the development of STAR-0215 or any future product candidates will require a significant amount of capital. Our existing cash and cash equivalents will not be sufficient to fund STAR-0215 or any future product candidates through regulatory approval. We will need to obtain substantial additional funding to complete the development and commercialization of STAR-0215 or any future product candidates, support our continuing operations, future clinical trials and expansion of our pipeline. Furthermore, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional financing to fund our long-term operations sooner than planned. See the section titled &#8220;Liquidity, Capital Resources and Capital Requirements&#8221; below for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, we have not generated any revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts, and the development of our product candidates, which include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee-related expenses including salaries, benefits and stock-based compensation expense;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred under agreements with third parties, including contract research organizations, or CROs, that conduct clinical trials and research and development and preclinical activities on our behalf;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of consultants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of lab supplies and acquiring, developing and manufacturing study materials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">We typically use our employee, consultant and infrastructure resources across our development programs. We track outsourced development costs by product candidate or development program, but we do not allocate personnel costs, other internal costs or external </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">consultant costs to specific product candidates or development programs. We record our research and development expenses net of any research and development tax incentives we are entitled to receive from government authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The following table summarizes our research and development expenses by program (in thousands). All of the programs with respect to which we incurred research and development expenses during the&#160;years ended December&#160;31, 2020 have been discontinued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">STAR-0215</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,172</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Edasalonexent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 631</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,344</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other research programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">911</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Costs not directly allocated to programs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Employee expenses including cash compensation, benefits and stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,488</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,101</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Facilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 338</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 515</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Consultants and professional expenses, including stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 862</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,134</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 150</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 496</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total costs not directly allocated to programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,838</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,245</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,552</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25,590</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on the results of the Phase 3 PolarisDMD trial of edasalonexent for the treatment of DMD, in October 2020 we stopped all activities related to the development of edasalonexent, including the ongoing GalaxyDMD open-label extension trial, and wound down substantially all activities related to edasalonexent by mid-2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect to incur significant research and development expenses in the year ending December 31, 2022, and in future periods in connection with the preclinical and clinical activities related to the development of STAR-0215. Because of this, we expect that our research and development expenses over the next several quarters will be higher than the prior year periods. Development of STAR-0215 and any future product candidates is highly uncertain and we cannot reasonably estimate at this time the nature, timing and costs of the efforts that would be necessary to complete the development of any such product candidates. We are also unable to predict when, if ever, material net cash inflows would commence from STAR-0215 or any other product candidates. This is due to the fact that we would need to raise substantial additional capital to fund the clinical development of any such product candidates and the numerous risks and uncertainties associated with developing and commercializing product candidates, including the uncertainties of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing an appropriate safety profile with IND-enabling toxicology studies;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful enrollment in, and completion of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the FDA and foreign regulatory approval processes or perspectives that may delay or prevent the approval of new products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt of marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">launching commercial sales, if we are able to obtain marketing approval, whether alone or in collaboration with others; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a continued acceptable safety profile following approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A change in the outcome of any of these variables with respect to the development of STAR-0215 or any future product candidate would significantly change the costs and timing associated with the development of that product candidate.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in executive, finance, accounting, commercial, business development, legal and human resources functions. Other significant costs include facility costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters, and fees for accounting and consulting services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We anticipate that in the near term our general and administrative expenses will remain relatively consistent with their current levels, although as we continue to develop STAR-0215 and potentially expand our pipeline to include other product candidates, our general and administrative expenses may increase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Acquired In-process Research and Development Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Acquired IPR&amp;D expense resulted from the Quellis Acquisition in January 2021. The acquisition cost allocated to acquire IPR&amp;D with no alternative future use was recorded as expense at the acquisition date and no additional IPR&amp;D expense relating to the Quellis Acquisition is expected to be reported in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reduction in Workforce</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December 2020, following the decision to stop development of edasalonexent, we announced that we were reducing our workforce during the quarter ended December 31, 2020. The reduction of workforce resulted in total expenses for employee severance and employee benefits of $0.6 million, of which $0.2 million was recorded during the year ended December 31, 2021. As of December 31, 2021, all severance related to the reduction of workforce has been paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Income (Expense)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other income (expense), net consists of interest income earned on our cash, cash equivalents and short-term investments and net amortization expense on short-term investments, and gains and losses related to foreign currency fluctuations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with U.S. GAAP. We believe that several accounting policies are important to understanding our historical and future performance. We refer to these policies as critical because these specific areas generally require us to make judgments and estimates about matters that are uncertain at the time we make the estimate, and different estimates&#8212;which also would have been reasonable&#8212;could have been used. On an ongoing basis, we evaluate our estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe that the following accounting policy is the most critical to aid you in fully understanding and evaluating our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Quellis Acquisition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January 2021, we acquired Quellis pursuant to the Merger Agreement. We concluded that the Quellis Acquisition was not the acquisition of a business, as substantially all of the fair value of the non-monetary assets acquired was concentrated in a single identifiable asset, STAR-0215.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We determined that the cost to acquire the Quellis assets was $170.7 million, based on the fair value of the equity consideration issued and including direct costs of the acquisition of $1.8 million. The net assets acquired in connection with the Quellis Acquisition were recorded at their estimated fair values as of January 28, 2021, which is the date the Quellis Acquisition was completed. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the estimation of fair value of the asset purchase consideration, we used the carrying value of the cash and cash equivalents, prepaid expenses, accounts payable and accrued liabilities as the most reliable indicator of fair value based on the associated short-term nature of the balances. The remaining fair value was attributable to the acquired in-process research and development, or IPR&amp;D. As STAR-0215 had not, at the time of the Quellis Acquisition, received regulatory approval in any territory, the cost attributable to the IPR&amp;D was expensed in the Company&#8217;s consolidated statements of operations and comprehensive loss for the year ended December 31, 2021, as the acquired IPR&amp;D had no alternative future use, as determined by the Company in accordance with United States generally accepted accounting principles, or U.S. GAAP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accrued Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of the process of preparing our financial statements, we are required to estimate our accrued expenses. This process involves reviewing contracts, identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The estimate of accrued research and development expense is dependent, in part, upon the receipt of timely and accurate reporting from CROs and other third-party service providers. The significant estimates in our accrued research and development expenses include the costs incurred for services performed by CROs in connection with research and development activities for which we have not yet been invoiced. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We base our expenses related to CROs on our estimates of the services received and efforts expended pursuant to contracts with CROs that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our CROs will exceed the level of services provided and result in a prepayment of the research and development expense. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting expense amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of the&#160;Years Ended December&#160;31, 2021 and 2020</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The following table summarizes our results of operations for the&#160;years ended December&#160;31, 2021 and 2020, together with the dollar change in those items (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period-to-</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period&#160;Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,552</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25,590</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (10,038)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,807</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,845</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,962</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Acquired in-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 164,617</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 164,617</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 194,976</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 37,435</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 157,541</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (194,976)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (37,435)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (157,541)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 64</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 135</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (71)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (194,912)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (37,300)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (157,612)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Research and development expenses decreased by $10.0 million to $15.6 million for the year ended December 31, 2021 from $25.6 million for the year ended December 31, 2020, a decrease of 39%. The decrease in research and development expenses was attributable </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">to stopping all development activities associated with our edasalonexent program, partially offset by costs to support our preclinical development of the STAR-0215 program. The $10.0 million decrease in research and development expenses was primarily attributable to a $16.7 million decrease in costs to support our edasalonexent program, a $1.6 million decrease in employee related expenses, a $0.3 million decrease in consulting expense, and a $0.5 million decrease in the research and development portion of facilities and other office expenses. These decreases were partially offset by a $8.2 million increase in costs to support preclinical development of the STAR-0215 program, and a $0.9 million increase in other research and platform programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administrative Expenses</i></p><a id="_Hlk97688893"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses increased by $3.0 million to $14.8 million for year ended December 31, 2021 from $11.8 million for the year ended December 31, 2020, an increase of 25%. The increase in general and administrative expenses was attributable to a $2.5 million increase in employee expenses, $1.4 million of which was specifically related to stock compensation, a $0.7 million increase in recruiting expense, a $0.4 million increase in insurance expense, a $0.1 million increase in the general and administrative portion of facilities and general office expenses and a $0.1 million increase in our Delaware franchise fee, partially offset by a decrease in professional services of $0.8 million largely related to a decrease in activities related to preparation for commercialization of edasalonexent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Income (Expense), Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other income (expense), net decreased by $71 thousand for the&#160;year ended December&#160;31, 2021 compared to the&#160;year ended December&#160;31, 2020, which was attributable to a decrease in interest and investment income due to lower interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From our inception through December 31, 2021, we raised an aggregate of $426.0 million through private placements of preferred stock before we became a public company and our private placement of preferred stock in the February 2021 Financing, registered offerings of our common stock and our at-the-market programs. As of December 31, 2021, we had $125.5 million in cash, cash equivalents and short-term investments. We expect that our existing cash, cash equivalents and short-term investments are sufficient to support our operating expenses through 2023. Advancing the development of STAR-0215 and other product candidates will require a significant amount of capital. Our existing cash and cash equivalents will not be sufficient to fund any of our product candidates through regulatory approval. Furthermore, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional financing to fund our long-term operations sooner than planned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will need to obtain substantial additional funding to complete the development and commercialization of STAR-0215 or any future product candidates, support our continuing operations, future clinical trials and expansion of our pipeline. In addition, STAR-0215 or any future product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of product candidates that we do not expect to be commercially available for years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of our stockholders. Market volatility, inflation, interest rate fluctuations and concerns related to the COVID-19 pandemic may have a significant impact on the availability of funding sources and the terms on which any funding may be available. If we fail to raise capital as, and when, needed, we may be unable to continue our operations at planned levels and be forced to modify our business strategies and reduce or terminate our operations. Although we will continue to pursue these plans, there is no assurance that we will be successful in obtaining sufficient funding on terms acceptable to us to fund continuing operations when needed or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">February&#160;2021 Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 28, 2021, we entered into the Purchase Agreement and sold an aggregate of 35,573 shares of Series X Preferred Stock on the February 1, 2021 closing date for gross proceeds of approximately $110.0 million, and net proceeds of $104.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">January&#160;2020 Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">On January 30, 2020, we entered into an underwriting agreement with Oppenheimer &amp; Co. Inc. relating to an underwritten public offering, or the January 2020 Financing, of 881,666 shares of common stock at a price to the public of $30.00 per share, including </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">115,000 shares issued upon the exercise in full by Oppenheimer &amp; Co. Inc. of its overallotment option. This resulted in gross proceeds of $26.5 million, and net proceeds of $24.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">At-the-Market Offerings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have entered into various sales agreements with Cowen and Company LLC, or Cowen, pursuant to which we could issue and sell shares of common stock, under at-the-market offering programs. On May 20, 2021, we terminated our sales agreement with Cowen. On June 30, 2021, we entered into an Open Market Sale Agreement<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> with Jefferies LLC, or Jefferies, pursuant to which we can issue and sell shares of common stock, of up to $25.0 million under at-the-market offering programs (collectively, with the Cowen at-the-market offering program, the ATM Programs). We pay the sales agent commissions of 3% of the gross proceeds from any common stock sold through the ATM Programs. As of December 31, 2021, we have not sold any shares of common stock pursuant to the Jefferies agreement and $25.0 million of common stock remains available for sale under the Jefferies agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2020, we sold an aggregate of 392,288 shares of common stock pursuant to our ATM Programs, at an average offering price of $42.76 per share, for gross proceeds of $16.8 million, resulting in net proceeds of $16.3 million after deducting sales commissions and offering expenses. There was no activity from the ATM Programs during the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Funding Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our primary uses of capital are for compensation and related expenses, manufacturing costs for preclinical and clinical materials, third party preclinical research and development services, legal and other regulatory expenses and general overhead. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, we had an accumulated deficit of $455.8 million. We have been primarily involved with research and development activities and have incurred operating losses and negative cash flows from operations since our inception.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, we had available cash, cash equivalents and short-term investments of $125.5 million. &#160;We expect that our existing cash, cash equivalents and short-term investments are sufficient to support our operating expenses through 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our estimate as to how long we expect our cash, cash equivalents and short-term investments to be able to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of biotechnology products, we are unable to estimate the exact amount of our operating capital requirements. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. Our future funding requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress, timing, costs and results of clinical trials of, and research and preclinical development efforts for, STAR-0215 and any future product candidates, including potential future clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to enter into and the terms and timing of any additional collaborations, licensing or other arrangements that we may establish;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and characteristics of future product candidates that we pursue and their development requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the outcome, timing and costs of seeking regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of commercialization activities for any of our product candidates that receive marketing approval to the extent such costs are not the responsibility of any future collaborators, including the costs and timing of establishing product sales, marketing, market access, distribution, supply chain and manufacturing capabilities, and scaling up the manufacturing of drug substance and drug product to clinical and commercial scale, securing all raw materials necessary to conduct such scale-up and successfully completing all other activities related thereto;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if we obtain marketing approval of any of our product candidates, revenue, if any, received from commercial sales of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if we obtain marketing approval of any of our product candidates, our ability to successfully compete against other approved products that are approved or used as treatments for the indications for which our products are approved, including with respect to STAR-0215 in HAE;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our headcount growth and associated costs;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against intellectual property related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress, timing, costs and results of clinical trials of, and research and preclinical development efforts for, STAR-0215 and any future product candidates, including potential future clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of the COVID-19 pandemic on our operations, business and prospects; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of operating as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes&#160;years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, STAR-0215 or any future product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of medicines that we do not expect to be commercially available for&#160;years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders&#8217; ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. Debt financing, if available, would result in periodic payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of the&#160;Years Ended December&#160;31, 2021 and 2020</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The following table provides information regarding our cash flows for the&#160;years ended December&#160;31, 2021 and 2020 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (30,151)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (32,485)</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net cash (used in) provided by investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (12,555)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,300</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 104,284</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40,860</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net increase in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 61,578</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,675</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Cash Used in Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities was $30.2 million for the year ended December 31, 2021 and consisted primarily of a net loss of $194.9 million adjusted for the non-cash portion of acquired IPR&amp;D of $164.6 million, stock-based compensation expense of $3.4 million, and a net increase in net assets of $3.3 million, which resulted primarily from a decrease in accounts payable of $2.0 million, and a decrease in accrued expenses of $1.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities was $32.5 million for the&#160;year ended December&#160;31, 2020 and consisted primarily of a net loss of $37.3 million adjusted for non-cash items of $1.4 million, and a net decrease in operating assets of $3.4 million, which resulted primarily from a decrease in prepaid expenses and other current assets of $1.3 million and a decrease in the right of use asset of $0.2 million as well as increases in accrued expenses and accounts payable of $1.9 million.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Cash</i> <i style="font-style:italic;">(Used in) Provided by Investing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities was $12.6 million for the year ended December 31, 2021 and consisted of purchases of short-term investments of $78.0 million, partially offset by proceeds from maturities of short-term investments of $59.0 million and cash acquired in the Quellis Acquisition of $6.4 million. Net cash provided by investing activities was $6.3 million for the year ended December 31, 2020 and consisted of proceeds from maturities of short-term investments of $69.1 million, which were partially offset by purchases of short-term investments of $62.8 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Cash Provided by Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities was $104.3 million during the year ended December 31, 2021, which was attributable to net proceeds of $104.3 million from the February 2021 Financing. Net cash provided by financing activities was $40.9 million during the year ended December 31, 2020, which was primarily attributable to net proceeds of $24.6 million from the January 2020 Financing and net proceeds of $16.3 million from our ATM Programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Material Cash Requirements from Known Contractual Obligations </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The following table summarizes our significant contractual obligations as of payment due date by period at December 31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:42.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Payments&#160;due&#160;by&#160;period</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">More than 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">1 - 3 Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating lease obligations (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 438</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 438</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Payments under vendor agreements (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 766</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 766</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total contractual cash obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,204</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,204</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(1)</span>Represents future minimum lease payments under our non-cancelable operating lease. The minimum lease payments above do not include any related common area maintenance charges or real estate taxes.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(2)</span>Represents future milestone payments under vendor agreements if certain clinical milestones related to the planned Phase 1a clinical trials of the STAR-0215 program are met.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, our only material contractual obligations were our facility lease pursuant to which we will make payments of $0.4 million until it&#8217;s expiration in June of 2022 and to certain vendors to which we will make payments of $0.8 million if certain clinical milestones related to the planned Phase 1a clinical trials of STAR-0215 are met. In January 2022, we entered into a sublease as described in <i style="font-style:italic;">Item 2. Properties</i>, to which we will make payments of $1.4 million from May 2022 through June 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We enter into agreements in the normal course of business with vendors for preclinical research studies and other services and products for operating purposes. We have not included these payments in the table of contractual obligations above since the contracts are cancelable at any time by us, generally upon 60 days&#8217; prior written notice, and therefore we believe that our non-cancelable obligations under these agreements are not material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_963b613c_51db_49ac_9005_3acc25a3d07e"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;7A. Quantitative and Qualitative Disclosures about Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates. As of December 31, 2021, we had cash, cash equivalents and short-term investments of $125.5 million and, as of December 31, 2020, we had cash, cash equivalents and short-term investments of $44.9 million. Our cash equivalents as of December 31, 2021 consisted of money market funds and U.S. reverse repurchase agreements. Our cash equivalents as of December 31, 2020 consisted of money market funds. Our short-term investments as of December 31, 2021 and 2020 consisted of U.S. reverse repurchase agreements. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of our investment portfolio and interest income. Inflation generally affects us by increasing our research and development costs. We believe that inflation has not had a material effect on our financial statements included elsewhere in this Annual Report on Form 10-K. However, our operations may be adversely affected by inflation in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021 and December&#160;31, 2020, we had no material liabilities that would require us to purchase foreign currency.</p><a id="_6596d520_499f_40b3_a1cf_db28cec446a2"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;8. Financial Statements and Supplementary Data</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements together with the report of our independent registered public company accounting firm (PCAOB ID: <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:AuditorFirmId" id="Narr_MCCE0FylsUSMcDrwov5Ing">42</ix:nonNumeric>), required to be filed pursuant to this Item 8 are appended to this Annual Report on Form 10-K. An index of those consolidated financial statements is found in Item 15 of this Annual Report on Form 10-K.</p><a id="_8f88d483_fae1_4bfb_a887_a4b839d048da"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There has been no change of accountants nor any disagreements with accountants on any matter of accounting principles or practices or financial disclosure required to be reported under this Item.</p><a id="_7e82b6dd_2035_45ae_bf7f_bf71959c99ee"></a><a id="Item9AControlsandProcedures_521927"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;9A. Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We maintain disclosure controls and procedures (as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934, or the Exchange Act) that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1)&#160;recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules&#160;and forms and (2)&#160;accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Annual Report on Form&#160;10-K. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer have concluded based upon the evaluation described above that, as of December&#160;31, 2021, our disclosure controls and procedures were effective at the reasonable assurance level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;promulgated under the Exchange Act as a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2021. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, in Internal Control&#8212;Integrated Framework (2013). Based on its assessment, our management believes that, as of December&#160;31, 2021, our internal control over financial reporting was effective based on those criteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form&#160;10-K does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting in accordance with an exemption established for smaller reporting companies with annual revenue of less than $100 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the three&#160;months ended December&#160;31, 2021, there have been no changes in our internal control over financial reporting, as such term is defined in Rules&#160;13a-15(f)&#160;and 15(d)-15(f)&#160;promulgated under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><a id="_9d47be71_c12c_4179_8190_3046e3d019b6"></a><a id="Item9BOtherInformation_174599"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;9B. Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not Applicable.</p><a id="_7969019e_f263_48cd_a655_6dc6a7dab9af"></a><a id="Item9CDisclosureRegardingForeignJurisdic"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not Applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_70504e3f_d4e8_4c6f_b971_b7fec797cb77"></a><a id="PARTIII_908662"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;III</b></p><a id="Item10_839238"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;10. Directors, Executive Of&#64257;cers and Corporate Governance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item&#160;is set forth under the captions &#8220;Proposal No.&#160;1&#160;&#8212; Election of Class&#160;I Directors&#160;&#8212; Information Regarding Directors,&#8221; &#8220;Corporate Governance,&#8221; &#8220;Executive Officers,&#8221; &#8220;Corporate Governance&#160;&#8212; Code of Business Conduct and Ethics&#8221; and &#8220;Compensation Governance&#160;&#8212; Committees of the Board of Directors&#160;&#8212; Audit Committee&#8221; &#160;in our definitive proxy statement for our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120&#160;days of December&#160;31, 2021, and is incorporated into this Annual Report on Form&#160;10-K by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are also required under Item&#160;405 of Regulation S-K to provide information concerning delinquent filers of reports under Section&#160;16 of the Securities and Exchange Act of 1934, as amended. If applicable, this information will be set forth under the caption &#8220;Delinquent Section&#160;16(a)&#160;Reports&#8221; in our definitive proxy statement for the 2022 Annual Meeting of Stockholders to be filed with the SEC no later than 120&#160;days after the end of our fiscal&#160;year and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have adopted a code of ethics, our Code of Business Conduct and Ethics, that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions. Our Code of Business Conduct and Ethics, as well as our corporate governance guidelines and the charters for the audit, compensation, nominating and corporate governance, and science and technology committees of our Board of Directors, are each accessible under the &#8220;Corporate Governance&#8221; heading of the &#8220;For Investors&#8221; section of our website, http://www.astriatx.com. We also intend to disclose in the same location on our website, any amendments to, or waivers from, our Code of Business Conduct and Ethics that are required to be disclosed pursuant to the disclosure requirements of Item&#160;5.05 of Form&#160;8-K.</p><a id="_5f28b0f5_5f16_4fad_894f_420aa7c70549"></a><a id="Item11ExecutiveCompensation_18724"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;11. Executive Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item&#160;is set forth under the captions &#8220;Executive Officers,&#8221; &#8220;Executive Compensation,&#8221; and &#8220;Corporate Governance&#160;&#8212; Director Compensation&#8221; in our definitive proxy statement for our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120&#160;days of December&#160;31, 2021, and is incorporated into this Annual Report on Form&#160;10-K by reference.</p><a id="_c9470b69_0df4_46ab_bb5d_71e04f43089c"></a><a id="Item12_979061"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;12. Security Ownership of Certain Bene&#64257;cial Owners and Management and Related Stockholder Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item&#160;is set forth under the captions &#8220;Securities Authorized for Issuance under Equity Compensation Plans&#8221; and &#8220;Principal Stockholders&#8221; in our definitive proxy statement for our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120&#160;days of December&#160;31, 2021, and is incorporated into this Annual Report on Form&#160;10-K by reference</p><a id="_8acd0865_8b76_4eec_8781_a46bdc4da3aa"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item&#160;is set forth under the captions &#8220;Corporate Governance&#160;&#8212; Director Independence&#8221; and &#8220;Certain Relationships and Related Person Transactions&#8221; in our definitive proxy statement for our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120&#160;days of December&#160;31, 2021, and is incorporated into this Annual Report on Form&#160;10-K by reference.</p><a id="_c1083b46_ee4a_4ada_b968_73e474c8dad3"></a><a id="Item14PrincipalAccountantFeesandServices"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;14. Principal Accountant Fees and Services</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item&#160;is set forth under the caption &#8220; Ratification of the Appointment of Ernst&#160;&amp; Young LLP as Astria&#8217;s Independent Registered Public Accounting Firm for the Fiscal&#160;Year Ending December&#160;31, 2022&#8221; in our definitive proxy statement for our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120&#160;days of December&#160;31, 2021, and is incorporated into this Annual Report on Form&#160;10-K by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_caf3c1b8_d1a3_4884_93a3_79cde1459d35"></a><a id="PARTIV_833106"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;IV</b></p><a id="Item15_889501"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;15.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibits and Financial Statement Schedules</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)(1)&#160;Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">The financial statements listed below are filed as part of this Annual Report on Form&#160;10-K and are incorporated herein by reference.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 0pt;"></td><td style="vertical-align:bottom;width:92.55%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ReportofIndependentRegisteredPublicAccou"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">F-1</p></td></tr><tr><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"></td><td style="vertical-align:bottom;width:92.55%;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ConsolidatedBalanceSheets_999017"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets at December&#160;31, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">F-3</p></td></tr><tr><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"></td><td style="vertical-align:bottom;width:92.55%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ConsolidatedStatementsofOperations_66416"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations for the&#160;years ended December&#160;31, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"></td><td style="vertical-align:bottom;width:92.55%;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ConsolidatedStatementsComprehensiveLoss_"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Comprehensive Loss for the&#160;years ended December&#160;31, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"></td><td style="vertical-align:bottom;width:92.55%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ConsolidatedStatementsofStockholdersEqui"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Stockholders&#8217; Equity for the&#160;years ended December&#160;31, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"></td><td style="vertical-align:bottom;width:92.55%;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ConsolidatedStatementsofCashFlows_205385"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the&#160;years ended December&#160;31, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">F-7</p></td></tr><tr><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"></td><td style="vertical-align:bottom;width:92.55%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#a1OrganizationandOperations_348641"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">F-8</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)(2)&#160;Financial Statement Schedules</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">All financial schedules have been omitted because the required information is either presented in the consolidated financial statements filed as part of this Annual Report on Form&#160;10-K or the notes thereto or is not applicable or required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">(a)(3)&#160;Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 9pt 0pt;">The exhibits required for this Annual Report on Form&#160;10-K by Item&#160;601 of Regulation&#160;S-K and Item&#160;15(b)&#160;of Form&#160;10-K are listed in the following Exhibit&#160;Index:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXHIBIT&#160;INDEX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:bottom;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br /><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:88.29%;border-bottom:1px solid #000000;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description of Exhibit</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:9.18%;border-top:1px solid #000000;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;">&#8201;&#8201;2.1**</span></p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:88.29%;border-top:1px solid #000000;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000110465921009065/tm214487d1_ex2-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Agreement and Plan of Merger, dated January&#160;28, 2021, by and among Catabasis Pharmaceuticals,&#160;Inc., Cabo Merger Sub I,&#160;Inc., Cabo Merger Sub II, LLC and Quellis Biosciences,&#160;Inc. (incorporated by reference to Exhibit&#160;2.1 to the Registrant&#8217;s Current Report on Form&#160;8-K (File No.&#160;001-37467) filed with the SEC on January&#160;29, 2021)</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:9.18%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;">&#8201;&#8201;3.1</span></p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:88.29%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000110465921113879/tm2126977d1_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit&#160;3.2 to the Registrant&#8217;s Current Report on Form&#160;8-K (File No.&#160;001-37467) filed with the SEC on September&#160;8, 2021)</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:9.18%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;">&#8201;&#8201;3.2</span></p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:88.29%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0001454789/000110465921113879/tm2126977d1_ex3-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit&#160;3.3 to the Registrant&#8217;s Current Report on Form&#160;8-K (File No.&#160;001-37467) filed with the SEC on September&#160;8, 2021)</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:9.18%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;">&#8201;&#8201;4.1</span></p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:88.29%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000110465918041160/a18-14696_6ex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-37467) filed with the SEC on June 20, 2018)</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:9.18%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;">&#8201;&#8201;&#8194;4.2</span></p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:88.29%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000110465919006087/a19-3947_4ex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-37467) filed with the SEC on February 6, 2019)</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:9.18%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;">&#8201;&#8201;&#8194;4.3</span></p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:88.29%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="atxs-20211231xex4d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Registered Securities</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:9.18%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">10.1+</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:88.29%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000110465921034984/tm211035d2_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated as of January&#160;28, 2021, by and among the Registrant and each purchaser identified therein (incorporated by reference to Exhibit&#160;10.3 to the Registrant&#8217;s Annual Report on Form&#160;10-K (File No.&#160;001-37467) filed with the SEC on March&#160;11, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:1.89pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:1.89pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:1.89pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:1.89pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000104746915004732/a2223775zex-10_19.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Warrant to purchase shares of Series&#160;B Preferred Stock issued on March&#160;31, 2015 to Square 1 Bank (incorporated by reference to Exhibit&#160;10.19 to the Registrant&#8217;s Registration Statement on Form&#160;S-1 (File No.&#160;333-204144) filed with the SEC on May&#160;13, 2015)</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000104746915004732/a2223775zex-10_20.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Warrant to purchase shares of Series&#160;B Preferred Stock issued on March&#160;31, 2015 to Midcap Financial Trust (incorporated by reference to Exhibit&#160;10.20 to the Registrant&#8217;s Registration Statement on Form&#160;S-1 (File No.&#160;333-204144) filed with the SEC on May&#160;13, 2015)</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000104746915004732/a2223775zex-10_21.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Warrant to purchase shares of Series&#160;B Preferred Stock issued on March&#160;31, 2015 to Flexpoint MCLS Holdings, LLC (incorporated by reference to Exhibit&#160;10.21 to the Registrant&#8217;s Registration Statement on Form&#160;S-1 (File No.&#160;333-204144) filed with the SEC on May&#160;13, 2015)</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.5</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000110465921034984/tm211035d2_ex10-9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Warrant to Purchase Shares of Series&#160;X Preferred Stock issued on January&#160;28, 2021 to Viridian LLC (incorporated by reference to Exhibit&#160;10.9 to the Registrant&#8217;s Annual Report on Form&#160;10-K (File No.&#160;001-37467) filed with the SEC on March&#160;11, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.6</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000110465921034984/tm211035d2_ex10-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Warrant to Purchase Shares of Common Stock issued on January&#160;28, 2021 to Viridian LLC (incorporated by reference to Exhibit&#160;10.10 to the Registrant&#8217;s Annual Report on Form&#160;10-K (File No.&#160;001-37467) filed with the SEC on March&#160;11, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.7*</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000104746915004732/a2223775zex-10_4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated 2008 Equity Incentive Plan, as amended (incorporated by reference to Exhibit&#160;10.4 to the Registrant&#8217;s Registration Statement on Form&#160;S-1 (File No.&#160;333-204144) filed with the SEC on May&#160;13, 2015)</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.8*</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000104746915004732/a2223775zex-10_5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Incentive Stock Option Agreement under Amended and Restated 2008 Equity Incentive Plan (incorporated by reference to Exhibit&#160;10.5 to the Registrant&#8217;s Registration Statement on Form&#160;S-1 (File No.&#160;333-204144) filed with the SEC on May&#160;13, 2015)</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.9*</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000104746915004732/a2223775zex-10_6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Nonstatutory Stock Option Agreement under Amended and Restated 2008 Equity Incentive Plan (incorporated by reference to Exhibit&#160;10.6 to the Registrant&#8217;s Registration Statement on Form&#160;S-1 (File No.&#160;333-204144) filed with the SEC on May&#160;13, 2015)</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;">&#8201;10.10*</span></p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000110465920072654/tm2022204d1_ex99-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated 2015 Stock Incentive Plan (incorporated by reference to Exhibit 99.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-37467) filed with the SEC on December 15, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.11*</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000104746915005184/a2224803zex-10_8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Incentive Stock Option Agreement under 2015 Stock Incentive Plan (incorporated by reference to Exhibit&#160;10.8 to the Registrant&#8217;s Registration Statement on Form&#160;S-1 (File No.&#160;333-204144) filed with the SEC on June&#160;3, 2015)</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;">&#8201;10.12*</span></p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000104746915005184/a2224803zex-10_9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Nonstatutory Stock Option Agreement under 2015 Stock Incentive Plan (incorporated by reference to Exhibit&#160;10.9 to the Registrant&#8217;s Registration Statement on Form&#160;S-1 (File No.&#160;333-204144) filed with the SEC on June&#160;3, 2015)</span></a></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.13*</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000104746915005184/a2224803zex-10_22.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2015 Employee Stock Purchase Plan (incorporated by reference to Exhibit&#160;10.22 to the Registrant&#8217;s Registration Statement on Form&#160;S-1 (File No.&#160;333-204144) filed with the SEC on June&#160;3, 2015)</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.14*</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000110465922025658/tm227201d1_ex99-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2022 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 99.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-37467) filed with the SEC on February 22, 2022)</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.15*</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000110465922025658/tm227201d1_ex99-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Nonstatutory Stock Option Agreement under the 2022 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 99.2 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-37467) filed with the SEC on February 22, 2022)</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.16*</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000104746915004732/a2223775zex-10_10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement, dated as of April&#160;7, 2010, by and between the Registrant and Jill C. Milne, as amended (incorporated by reference to Exhibit&#160;10.10 to the Registrant&#8217;s Registration Statement on Form&#160;S-1 (File No.&#160;333-204144) filed with the SEC on May&#160;13, 2015)</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.17*</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000110465920124372/tm2029578d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Executive Severance Benefits Plan effective October&#160;7, 2020 (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Quarterly Report on Form&#160;10-Q (File No.&#160;001-37467) filed with the SEC on November&#160;12, 2020)</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.18*</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000104746915004732/a2223775zex-10_13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Indemnification Agreement by and between the Registrant and each of its executive officers and directors (incorporated by reference to Exhibit&#160;10.13 to the Registrant&#8217;s Registration Statement on Form&#160;S-1 (File No.&#160;333-204144) filed with the SEC on May&#160;13, 2015)</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.19</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="atxs-20211231xex10d19.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Sublease Agreement, dated as of January 28, 2022, by and between Grant Thornton LLP and the Registrant</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;">&#8201;&#8201;10.20</span></p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000110465919060826/a19-17598_1ex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Sublease Agreement, dated as of September 9, 2019, by and between Allied Minds, LLC and the Registrant (Incorporated by reference to Exhibit 10.1 to the to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-37467) filed with the SEC on November 7, 2019)</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.21*</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000110465921035040/tm219302d3_ex99-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Quellis Biosciences, Inc. 2019 Stock Incentive Plan (incorporated by reference to Exhibit 99.1 to the Registrant&#8217;s Registration Statement on Form S-8 (File No. 333-254151) filed with the SEC on March 11, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.22</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1454789/000110465921087607/tm2120854d2_ex1-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Open Market Sale Agreement</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">SM</sup><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, dated as of June 30, 2021, by and between the Company and Jefferies LLC (incorporated by reference to Exhibit 1.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-37467) filed with the SEC on June 30, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">21.1</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="atxs-20211231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries of the Registrant</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">23.1</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="atxs-20211231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Ernst&#160;&amp; Young LLP, independent registered public accounting firm</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">24.1</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#SIGNATURES_944344"><span style="font-style:normal;font-weight:normal;">Power of Attorney (see signature page&#160;of this Annual Report on Form&#160;10-K)</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">31.1</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="atxs-20211231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer pursuant to Rule&#160;13a-14(a)/Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as amended</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">31.2</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="atxs-20211231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer pursuant to Rule&#160;13a-14(a)/Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as amended</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">32.1</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="atxs-20211231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">32.2</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="atxs-20211231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">101.INS</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">XBRL Instance Document</p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">XBRL Taxonomy Extension Schema Document</p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">XBRL Taxonomy Calculation Linkbase</p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">XBRL Taxonomy Labels Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">XBRL Taxonomy Presentation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Taxonomy Extension Definition Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:0.06%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.12%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">Exhibit 104</p></td><td style="vertical-align:top;width:2.51%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.03%;margin:0pt;padding:2.15pt 0pt 0.85pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) </p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">Management contract or compensatory plan arrangement.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;">**</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;">Exhibits and/or schedules have been omitted pursuant to Item&#160;601(a)(5)&#160;of Regulation&#160;S-K. The Registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the </p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Registrant may request confidential treatment pursuant to Rule&#160;24b-2 of the Exchange Act for any exhibits or schedules so furnished. A list identifying the contents of all omitted exhibits and schedules can be found on page&#160;iii of Exhibit&#160;2.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">+ &#160;Certain portions of this exhibit (indicated by &#8220;[***]&#8221;) have been omitted because they are both (i)&#160;not material and (ii)&#160;would be competitively harmful if publicly disclosed.</p><a id="_1330d230_7380_40e1_bf3d_9d6d90689591"></a><a id="Item16Form10KSummary_747493"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;16. Form&#160;10-K Summary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_ff270729_ddd5_4938_bbb6_db32faf68de5"></a><a id="ReportofIndependentRegisteredPublicAccou"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">To the Stockholders and the Board of Directors of Astria Therapeutics,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying consolidated balance sheets of Astria Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) as of December&#160;31, 2021 and 2020, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity, and cash flows for each of the two&#160;years in the period ended December&#160;31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for each of the two&#160;years in the period ended December&#160;31, 2021, in conformity with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules&#160;and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.&#160;The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Audit Matter</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1)&#160;relates to accounts or disclosures that are material to the financial statements and (2)&#160;involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="margin-left:0pt;"><a id="_Hlk54011019"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:14.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:83.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:36pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;line-height:1.19;margin-bottom:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Determination of accounting acquirer and assessment of accounting model in the merger with Quellis Biosciences, Inc.</span></p></td></tr><tr><td style="vertical-align:top;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Description of the Matter</i></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:36pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-bottom:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">As discussed in Notes 1 and 3 to the consolidated financial statements, the Company executed a Merger Agreement and acquired Quellis Biosciences, Inc. (&#8220;Quellis&#8221;) on January 28, 2021. The merger was accounted for as an asset acquisition, with the Company being identified as the accounting acquirer.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Evaluating the Company&#39;s accounting treatment of the merger required especially subjective auditor judgment. Specifically, a high degree of auditor judgment was required to evaluate the Company&#39;s determination of the accounting acquirer and assessment of the transaction as an asset acquisition. </span></p></td></tr><tr><td style="vertical-align:top;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">How We Addressed the Matter in Our Audit</i></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:36pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-bottom:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our audit procedures to test the Company&#8217;s determination of the accounting acquirer in the Quellis acquisition included, among others, the review of management&#8217;s accounting memorandum that documented the factors the Company considered in determining the accounting acquirer, including voting interests held by the former shareholder groups and the composition of the board of directors and senior management of the combined Company. &#160;In addition, we inspected the Company&#8217;s Merger Agreement and assessed the terms in the agreement and compared them to the Company&#8217;s accounting memorandum. We tested the Company&#8217;s determination of the accounting acquiror including the assessment of the voting interests of the various shareholder groups held in the Company post transaction and the composition of the board of directors and senior management of the combined entities. Additionally, we evaluated the composition and amounts of the assets acquired and liabilities assumed in the transaction and whether Quellis contained processes in place to generate outputs in the assessment of the transaction as an asset acquisition.</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:AuditorName" id="Narr_03pRYAv_-E-zvMASyERCKw">Ernst&#160;&amp; Young LLP</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">We have served as the Company&#8217;s auditor since 2010.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="dei:AuditorLocation" id="Narr_bVuGvl8DDkaz-7rqWaXlsA">Boston, Massachusetts</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">March&#160;10, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="font-size:3pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7e57afee_4d16_4406_a6b9_87af0ac79bcd"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Astria Therapeutics, Inc</b>.</p><a id="ConsolidatedBalanceSheets_999017"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Consolidated Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(in thousands, except share and per share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman Bold';visibility:hidden;">&#8203;</span></p><a id="_98a3142e_ee04_41bf_a0a3_ccd30303a78b"></a><a id="Tc_SZA0ejHQdkmSbEtVx-ZhTw_1_2"></a><a id="Tc_h_ukcJS_jkyHJKpQDifUgQ_1_5"></a><a id="Tc_l54xGOcCq0Cu3jR241kcaA_2_2"></a><a id="Tc_vWkdpRB_v0GP4T2SciDDqQ_2_5"></a><a id="Tc_YO1FQpBZyECzyaPucP0xJg_3_0"></a><a id="Tc_0bgtsI6_q0CRz9jWe2892w_4_0"></a><a id="Tc_YCXlKzXG1EOUZWYOROHUXA_5_0"></a><a id="Tc_CNp3uf64-keHJKO5yscaSg_5_2"></a><a id="Tc_p5VrogM7J0einiBU6cMx6g_5_5"></a><a id="Tc_5EgxKNR3nEmIFaWATw9Sjw_6_0"></a><a id="Tc_kUze_ghmK0S9-n8C4_r2JQ_7_0"></a><a id="Tc_fUqRjcnl40-5fNBUnLXJIw_8_0"></a><a id="Tc_jtF0habCWkiiUqvCrtomfA_9_0"></a><a id="Tc_V0yNxlX49kq7EGoV_pncug_10_0"></a><a id="Tc_vk9P9AqdMkGUfg5uFYEm7g_11_0"></a><a id="Tc_GBNE55RPMEmtyUyWt0l0JQ_11_2"></a><a id="Tc_iqbUZ6v4Y0mSqJdPnVbqTw_11_5"></a><a id="Tc__a9_sWA2mUCm4L2Srti0ag_12_0"></a><a id="Tc_wtPbaMM_jUGFD15tLxuTvg_13_0"></a><a id="Tc_1apgqgsdAUS9MettwhDQLA_14_0"></a><a id="Tc_QbvK_s5O0ESJRrGPUylpWw_14_2"></a><a id="Tc_FdSSusYFQEWlBmMKt4lkkQ_14_5"></a><a id="Tc_UMRkxWg9-kWA5fRYOi9qZw_15_0"></a><a id="Tc_j5gJpPnjQ0eRBW1wTZH7xw_16_0"></a><a id="Tc_oOPops5znkiBc_uDkedwgw_17_0"></a><a id="Tc_ClPtVcnQSUqkNzoxtPgY6w_18_0"></a><a id="Tc_eDjLR9s-7kC9l9vBMVGGTQ_18_3"></a><a id="Tc_2zbw0B_w80qFIEfn8zEBbQ_19_0"></a><a id="Tc_A2yBXr-09ka9uwksOjXtLA_20_0"></a><a id="Tc_V3xtPfmBuESny7BDV-5PSA_21_0"></a><a id="Tc_9mbelhdWgkeJ51eFhMB_Ig_22_0"></a><a id="_f56dc82b_070c_4fc2_8ec3_1c45c48a116c"></a><a id="_f56dc82b_070c_4fc2_8ec3_1c45c48a116c_2"></a><a id="_f56dc82b_070c_4fc2_8ec3_1c45c48a116c_3"></a><a id="Tc_i2Nhq47M6E-5fJ4psYO7bQ_23_0"></a><a id="Tc_4cLbSKubLU6EjHIjFpg2fQ_23_6"></a><a id="Tc_muV6DupOR0mYWQPKa90hEQ_24_0"></a><a id="Tc_4MiuPrUrd0WqE3MvAsXUGQ_25_0"></a><a id="Tc_bMdnWwJ0mUe6jYubNMIFwQ_26_0"></a><a id="Tc_mfkO-PwBbEWeQagZlemPXQ_27_0"></a><a id="Tc_zokZ8nd4RUKh6Wf7Nzz3ZA_28_0"></a><a id="Tc_8VNyElrRCUGZHJ-H-3-v3Q_29_0"></a><a id="Tc__9YpGFmoJUqtJb0Bqzrxbg_29_2"></a><a id="Tc_Z4mE5m0t10uLtj_1vRYU6Q_29_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:middle;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_8SklCD2Pbk28nq6G28nFxg_5_3">86,508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_SfPw4_SFwkqrxWnsksSGxg_5_6">24,930</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_BwYHxPMpBUup-dv3GBjEHg_6_3">39,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="Tc_D7tMGG-4Qkq068U4i6vkOg_6_6">20,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_6gi7Jh1ziUSbUAbZwHUpGQ_7_3">1,567</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_iXx0RzSbkU6CChy8tscjkQ_7_6">1,395</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_Z_9t1O_7qUaCrkWk0QfntQ_8_3">127,075</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_Wwk2G2ISd0OXMqZtGXrkng_8_6">46,325</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_Y7YdnUV5iUmbGsXoQ6K8lw_9_3">394</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_zr-QKpxmo0mx-g8TbMczDQ_9_6">966</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_Y5P5B1hff0CT-GyUGA-4cw_10_3">45</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_tDa-L6E1o06K8LSmjYZv1Q_10_6">165</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_30OrE6_YlUmsn9xBGBtp2w_11_3">127,514</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_cAZVlB53b0aN0cZle_nhEg_11_6">47,456</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and stockholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_wkJ6o3E6oEyfIwokCCkh_A_14_3">1,557</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_vsQzU1xYDE6g-vIByBex2w_14_6">1,544</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_lFiMHVtLEkuw5WdvZFioJQ_15_3">3,281</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_3BHI5onhOEaGKFwBDsrkJg_15_6">4,197</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Current portion of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_fvmexcAz8UuyfkU-x3WePw_16_3">365</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_FaYprY1FckGBEabTXn1x7w_16_6">649</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_np0RJv0KgUOL-nujAxnsGg_17_3">5,203</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_08xyQzbZ3km1-RtStVcvSw_17_6">6,390</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Long-term portion of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_sK146jJxr02P4w8b-G8Sjw_18_6">397</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_CZ4IJX1k_EyOeppZ0DIcaA_19_3">5,203</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_Rk-lixB14kK9RpSeg5pzXQ_19_6">6,787</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Commitments (Note 7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_nKRKj1T3TUKfxsDgDsZLlg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_LT7fQGS6-Uqe1hKNX8rHPg">0.001</ix:nonFraction></ix:nonFraction> par value per share, <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_NonredeemablePreferredStockMember_c0KfkkESqEyr8mt4ZudgVg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_H_FjblRHiUCeom9e34GgOg"><ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_NonredeemablePreferredStockMember_h2GakjGikkGGLKMSx_TpBQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_rLGxlpjoZEOV_O8TAp6IGg">4,908,620</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_NgFRpMrXVk6aDc5Tlz7Xlw"><ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_ZNhExe4CCki4ow62CFcTvw">no</ix:nonFraction></ix:nonFraction> shares issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_5kAH2yohTU6HuCucgbOHZw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_M6aGybrk0kCZ6fzfhotz1g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Series X redeemable convertible preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_Bn4szbYkh0yrrFWsgmb0bw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_8ZZWdHwMRkqW2CxitoJ2Mw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr__NmbzgfFcECPj_yUTbwccA">0.001</ix:nonFraction></ix:nonFraction> par value per share, <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_Bn4szbYkh0yrrFWsgmb0bw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_2tuszKKYY0WjL1-xnSNoFQ"><ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_lsmcQuV3QEK6swr4RMiktA">91,380</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_PTQ5NUjvQU66jn0XCZs8QA">31,455</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_EaPdklywJU--bluP72dbOw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and outstanding as of December 31, 2021 and <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_Bn4szbYkh0yrrFWsgmb0bw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_WsVXJ8wtU0yu2mo48nExnA">no</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_olLejnU3yUWT4pjn9P3eRQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and outstanding as of December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockValue" scale="3" id="Tc_Y-3DJja1lEikWubbsJluvg_23_3">96,398</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_cKq37aKUUUyKCKG0qwznkQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_VNIDz_M44EGdYacMwGRQLw">0.001</ix:nonFraction></ix:nonFraction> par value per share, <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Vg9zD-XNwkS0eURHz9Pi-g"><ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_gzmldISqVEyDX-j3B4vpsg">150,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_8qSO6XnBskCT9fZbtUX7gg">13,016,955</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_4NUUlSW-j0S-EbEBa1jUpw">3,347,386</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_BLlqcGRUw0yW9_W_BgHGVA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_28JKwy45H0aXmXOk1zkCAQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at December 31, 2021 and December 31, 2020, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_CPUIFNpYg06OyGko7Rqhxg_24_3">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_3HWJiLfUkEmbSeGEICk-jw_24_6">4</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_yKrb7B-X5EaSCYkH5E2Skg_25_3">481,709</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_Fn2O_1wa5UOPFW7gy1hpTg_25_6">301,562</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_Z8KsiGkTJUyr-8iQxbhdkw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_0JRGWDpqhUmL33rExGbsHA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:middle;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_ptVcob1pYEyvN3txKSRu1A_27_3">455,809</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_ABjJj30NwkWnDSqd1QGvog_27_6">260,897</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_1faM2BXhhE6Q-RR1JPffWw_28_3">122,311</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_qI-GFEhHTUK3D_je3LZEfA_28_6">40,669</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_GsZ07QBWmUGRIuKz5to3ZQ_29_3">127,514</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_IcpTfSa_BEaS_GHGswgvvQ_29_6">47,456</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5dbac7b4_5b13_42f0_8f84_dafa433761df"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Astria Therapeutics, Inc</b>.</p><a id="ConsolidatedStatementsofOperations_66416"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(in thousands, except share and per share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_b4eccf6f_bf36_4548_b0ec_89e04cb9e673"></a><a id="Tc_4Euwo2jHWke_0WS1GkPeDw_1_2"></a><a id="Tc_N1cdoGDDjUW3hYb6-rMgRA_2_2"></a><a id="Tc_Ixfktf_4FEe63GxKrakrHA_2_5"></a><a id="Tc_dkaWYHAdYEmpRlSdlfXsPA_3_0"></a><a id="Tc_wBqg0d8gqEakFG4QDYiFog_4_0"></a><a id="Tc_Qz0Wj3werEaC0o4uxGkKDg_4_2"></a><a id="Tc_T6qCScd9eEaZumKL6F-NkA_4_5"></a><a id="Tc_up-xMKlgfEqetM5_M1jWrg_5_0"></a><a id="Tc_RnSC5HoOX06ZuDgKfPgqZw_6_0"></a><a id="Tc_Dm6oeFCGzU-Y5WC6b1IU8A_6_6"></a><a id="Tc__2nLg9Xqk0-onBqYMQEJmw_7_0"></a><a id="Tc_mJBm6iBvQE-JgpMvhUDqIw_8_0"></a><a id="Tc_lX54DubaEUSwj9MoRLZSAA_9_0"></a><a id="Tc_rFd4GFGtDEaO-uoBisPwLA_10_0"></a><a id="Tc_6Gc0dAs31USfrJQWfSo6LQ_11_0"></a><a id="Tc_nN5rPnyTH0eDOtLiIQHPnA_12_0"></a><a id="Tc_hohvc76ZqEu77M6CYQ-Scg_13_0"></a><a id="Tc_af-EvzrtLEq2b4MsSEFVVw_14_0"></a><a id="Tc_JwwU6pAYBkezhUOMHHwHog_14_6"></a><a id="Tc_tJSArg9QNU2bXl3ktYL2zw_15_0"></a><a id="Tc_eRmYXNlINUyig6jE2vHX7A_15_2"></a><a id="Tc_pVJ0EAqvrkSD8am4heJoxw_15_5"></a><a id="Tc_JZnumnlmH0eb7N97HytPEA_16_0"></a><a id="Tc_5iUtuyxq40WRVP5-57k6Dg_17_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_QRgZ7mXCF0uXNgdluRp9Fw_4_3">15,552</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_hCT1Dd01Rk29OrgN3OBQng_4_6">25,590</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_rMa50_FR70enpFpTaJ2c3w_5_3">14,807</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_D4XcUtkTCkWo69sfYTQNIA_5_6">11,845</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Acquired in-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" id="Tc_UDNyzKYP9UOmOQKw0d1uWA_6_3">164,617</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_mOYn3Y-f_062X6k4snIFhg_7_3">194,976</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_Mpiev2xzXU-9K79xxJJAag_7_6">37,435</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_0jYk4WwI5UOeBGghwyr2Mw_8_3">194,976</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_ogyCpfpM9U6ZCeZx1IcBdw_8_6">37,435</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Interest and investment income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_vtr_JNfMPEaSYH9KM0xG5w_10_3">122</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_ge23q-2oD0W7P1RXxqsb2A_10_6">236</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Other expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_Bwx8AjzB90yF3aMGuTpiJg_11_3">58</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_4c3W3QOHwkqdLm_Kz44BAg_11_6">101</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_ZLtREk79KkuQurNSd78wPg_12_3">64</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_JQXO9r25TkyiP67yAvoeFg_12_6">135</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_uIGxt2VNj0aP_xHa0jjIFQ_13_3">194,912</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_-QivLC38WkmpYzbodX0x8Q_13_6">37,300</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Dividend on convertible preferred stock related to beneficial conversion feature and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="atxs:DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts" scale="3" id="Tc_eBD-UgsPkEeUl4Z-FHK4xA_14_3">24,437</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss attributable to common shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_ebymizkxHki5Ckt08mf97A_15_3">219,349</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_D_xw5DwTakSTwVFq4b0rYw_15_6">37,300</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss per share<span style="font-family:'Calibri','Helvetica','sans-serif';">&#8212;</span>basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="-sec-ix-hidden:Hidden_8asCuAWAkUShdS5MbDUCCQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_dXBdT-jPP02rz6cVjNOkmg_16_3">24.58</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="-sec-ix-hidden:Hidden_yKFj6vewikWA4NmcagA9rg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_msxw68r_Ik2eHgQl0eqsXQ_16_6">12.20</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Weighted-average common shares outstanding used in net loss per share<span style="font-family:'Calibri','Helvetica','sans-serif';">&#8212;</span>basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_v4FE-eP840e1O3yrafwGFw_17_3">8,925,173</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_nuRL9EypKU-EjlrFG2hjKQ_17_6">3,058,578</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_11e88c78_0bf7_4bdf_9c09_3a7ddc83c150"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Astria Therapeutics, Inc</b>.</p><a id="ConsolidatedStatementsComprehensiveLoss_"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Consolidated Statements Comprehensive Loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_9f273892_89ab_4403_b9c4_42b741f65514"></a><a id="Tc_Vapbk1RkG0qVKXLa1SdFlg_1_2"></a><a id="Tc_V3lun1NxTEKlDhsHL5fL1g_2_2"></a><a id="Tc_6jECUmDLkU-aHOtB5VnUYg_2_5"></a><a id="Tc_i-27xk8GcEOe-ocz77bU-Q_3_0"></a><a id="Tc_IkCbPpFHt0euhnm2amEyLQ_3_2"></a><a id="Tc_jXyMFo91lk2IbTH5pjvxWg_3_5"></a><a id="Tc_zGwNYhvBkkmgDZs1nx-OHA_4_0"></a><a id="Tc_84Ez7xjC1kOhDQHpQ6-MDA_5_0"></a><a id="Tc_GN6cC63s3kOo_U7PqNcNOA_6_0"></a><a id="Tc_hmNUDGKoAU-hb3iGLsjEMQ_7_0"></a><a id="Tc_jOMseET_bU-Zq0rM801Lpg_7_2"></a><a id="Tc_BOBfHlWw50WHOXoyrdH05w_7_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_-P4ZQm3zSkaSxVHilxbxTQ_3_3">194,912</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_gqCKgIj8206uxzaTjVFbkA_3_6">37,300</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other comprehensive income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Gain on short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="Tc_F8gXkWZ1NEGDFxlAL_MJrw_5_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="Tc_jtjgUzGs8kmW45YqsCZdpw_5_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total other comprehensive income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="Tc_FBqQOxCpkECbwh53bF1nPg_6_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="Tc_T-bd-Wvj9Em8nFdyuuu4lg_6_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_d3N2dRXhMEeJYbsECXMLpA_7_3">194,912</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_w9HtmgYzOkixK2eakqeVKA_7_6">37,300</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6894e33f_ce38_42b2_b4f8_ce2dcaf49267"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Astria Therapeutics, Inc.</b></p><a id="ConsolidatedStatementsofStockholdersEqui"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Consolidated Statements of Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_bec6e760_b416_4c55_8388_de28a18d6f96"></a><a id="Tc_WbdNdlJmN0ysTsYoxCX8LA_1_2"></a><a id="Tc_0sN8F9wbFEut2s6b8stC_g_1_7"></a><a id="Tc_c0KLjMeb3U-SKz1R1NnvJg_1_19"></a><a id="Tc_6bdux66r1keRwC5h1IChOA_1_22"></a><a id="Tc_luF376zark2xI6RILh9glg_2_7"></a><a id="Tc_0HE6n-97ZUeJ_amHLFCusw_2_13"></a><a id="Tc_0bmD-h22UESNDslCzF9AUQ_2_16"></a><a id="Tc_UvYlFRX7dU-es90hrnqOsw_2_19"></a><a id="Tc_HbhHjQ330EanaXdY9cDjRg_2_22"></a><a id="Tc_YresmbgK50Ksn4GpN4jD7g_3_2"></a><a id="Tc_OMD9WuX_Z0KeijIkEHjJzQ_3_4"></a><a id="Tc_isy49CnR1kC6uCJJ8nzG1A_3_7"></a><a id="Tc_7hlOuCDigkm_SbZxO4484g_3_10"></a><a id="Tc_-yrvzAPO70CHCCSek7eOGA_3_13"></a><a id="Tc_qKO-mF_l3kuXZHbAoCQseg_3_16"></a><a id="Tc_aDT2_3maak-e43UbIH_0sw_3_19"></a><a id="Tc_GP-L-JxhqEuDrgfWAv_6IA_3_22"></a><a id="Tc_M4K31u1EDEeUnSoB1xE2pw_4_0"></a><a id="Tc_N1b9nsTFDEqMisDRmzLYaw_4_2"></a><a id="Tc_h5zgpA7IUEy2qNN0WplgPg_4_4"></a><a id="Tc_dqs8KzCbwE6BMI_2fqB93Q_4_5"></a><a id="Tc_4RdsvqkTl0iN6K4ZPNAdwg_4_10"></a><a id="Tc_xC-WJuHtAkWOHWypyFeG9w_4_13"></a><a id="Tc_QNNXKnIReESqyAG0umo5mA_4_16"></a><a id="Tc_WNrIJrD810Sca-8olLcIEQ_4_19"></a><a id="Tc_uYQe8t9bLUqsREiouS7qLw_4_20"></a><a id="Tc_VEcoyVtC1UmaxFzVTju0cg_4_22"></a><a id="Tc_1W-SGmbNtk-j-3RElQuQHQ_5_0"></a><a id="Tc_a4iXH-gp2U2QWjU3NCsEgg_5_2"></a><a id="Tc_Hi_RV2pQOEeRVg6rmCSDmw_5_5"></a><a id="Tc_OAllRWbv8UqtCmHeAGN-gA_5_17"></a><a id="Tc_W8Rfcz9Z40SSZT6MGQrKRQ_5_20"></a><a id="Tc_83aK29w8NUqZUuBd_YsQrA_6_0"></a><a id="Tc_-rFKFpq0xUizZXX0EMhNhg_6_2"></a><a id="Tc_JRUEE4XrDkGANlmJYmnqVA_6_5"></a><a id="Tc_jUXZH-3CjkSB2sOrW7FEog_6_11"></a><a id="Tc_Tgeks4lyt0q09NZVoYvafw_6_17"></a><a id="Tc_3_l7DAoGt02ae1kKHY8Alw_6_20"></a><a id="Tc_1Z-vgNOhQUeDlOr0cYx7LA_7_0"></a><a id="Tc_CL8bU8g4906QYvxxu81AHw_7_2"></a><a id="Tc_MQkHldKy4EOW595UgKDwiQ_7_5"></a><a id="Tc_qp_DqLOBlkaL7BGgDLUvIQ_7_17"></a><a id="Tc_kKSS5z6SIU6vcSebTUeFCw_7_20"></a><a id="Tc_nVkda-7At0OGhxBu4f8hnw_8_0"></a><a id="Tc_uL9EzwiW0ku05oohEEmt2A_8_2"></a><a id="Tc_T-xJ6_MfC0uLhGaEREgcrw_8_5"></a><a id="Tc_zGd8MRXzaUW54XKD337fNQ_8_8"></a><a id="Tc_F40ngXHKg02Y3peixtRvyg_8_11"></a><a id="Tc_nx4KyrKkB0GW9Gc7BUgmRQ_8_17"></a><a id="Tc_zJrXspeguEqZxeqdgF4jNA_8_20"></a><a id="Tc_93smMi_OQ02jlNQonCn4Wg_9_0"></a><a id="Tc_NcIoABwmPEaM0JJv-i_LJQ_9_2"></a><a id="Tc_JA-jEMjmj06WPSsmiFaVmA_9_5"></a><a id="Tc_pL5tUYWmAkuig3DC7Lf1hQ_9_8"></a><a id="Tc_BYWdkVpxt0CzgCQN9uZmIw_9_11"></a><a id="Tc_RDXTFW1G3E-369nSSHWhAA_9_14"></a><a id="Tc_-mk3bV4ZD0ays1aDWDHs-g_9_20"></a><a id="Tc_F16plb-nNkOp90-9u89hkQ_10_0"></a><a id="Tc_Iae39VOFeU2Q2ZUm8B7w8w_10_2"></a><a id="Tc_wC0bgsbi6UmE98se4551sw_10_4"></a><a id="Tc_oRyuvWGYBUWi-zmYOZDbMg_10_5"></a><a id="Tc_Wp8h7oyGVUqGOPvzX1jG9Q_10_10"></a><a id="Tc_q4B8wIDuOE6CrepvudUxJg_10_13"></a><a id="Tc_ESyFVDKfW0GzRm8iVZNRrg_10_16"></a><a id="Tc__fkhR--xA0SerseALluKoQ_10_19"></a><a id="Tc_LXT9K4iSHEWXl6iFTywGwg_10_20"></a><a id="Tc_h-l6gpprnky053X7Uc3Zfg_10_22"></a><a id="Tc_eOO9WdM7-Uu9CbXFYW66aQ_11_0"></a><a id="Tc_GJO1y-nGUUiZqYgoN69DjA_11_8"></a><a id="Tc_UhGqT1ae2kqY7_VzT8AheA_11_11"></a><a id="Tc_8crLxhtqxEC3RtUheV7G1Q_11_17"></a><a id="Tc_rkMlHuSHPkut71EGJn-wnQ_11_20"></a><a id="Tc_Z5dxhh2kr0GafCXkgPo35Q_12_0"></a><a id="Tc_ddLYLVscfUahCogFJX0LbA_12_11"></a><a id="Tc_pG_OA63tIUWScky7VQ8N2w_12_17"></a><a id="Tc_V3Ypmpmc9UK9XEv4lCZ-vQ_12_20"></a><a id="Tc_PuFwoHTx1UKP6d707m-A7A_13_0"></a><a id="Tc_kNrVJ5JqekCDPRtlx085WQ_13_17"></a><a id="Tc_-XgyJcq3OUS7vaVEk1ovhg_13_20"></a><a id="Tc__jtoRIjRwUuWKXsDY3-2sg_13_23"></a><a id="Tc__0qpQvuwYUW9uQobjrp_qA_14_0"></a><a id="Tc_B_Yydro50Em6T4bhfoR2pg_14_2"></a><a id="Tc_v3vWBVPzM0e2L4ZAqda1ig_14_5"></a><a id="Tc_9_5xNcJDtkSVInguinivew_14_8"></a><a id="Tc_CrA_UAyogEmzfSETgiv0Kw_14_11"></a><a id="Tc_F21dE7n9PUe00I-bh8xYVg_14_17"></a><a id="Tc_Ipl2y9_aZEuuUfl-9J9opg_14_20"></a><a id="Tc_UcDYT14Rtku_KKN5AJiu3g_15_0"></a><a id="Tc_ELYijvDC6Ee91ZklmQL2Aw_15_23"></a><a id="Tc_RPv_UhAyqEuToIa2zGy2zg_16_0"></a><a id="Tc_fmM3VaEa9EWqymS3zwzHZw_16_11"></a><a id="Tc_3QtLeH7eP0S1CJDTZ5LPlw_16_17"></a><a id="Tc_4JbzGYn6JUiBE29q0BGrEQ_16_20"></a><a id="Tc_pQWZRS-gSEOtXLyVTin6dw_17_0"></a><a id="Tc_U6zGTgQakEKWDDjAa7UpfQ_17_2"></a><a id="Tc_cghmVogJp0uugb5AW_WNHA_17_5"></a><a id="Tc_4ZTkg8t_yEW_cI6kSFI-IQ_17_8"></a><a id="Tc_HJkbIVWNJEK3xKPwwoCSEQ_17_11"></a><a id="Tc_6SrRUYvW6Uyf3SPWtPffTQ_17_17"></a><a id="Tc__uTEbuo0vkGL6P1aWy6a1w_17_20"></a><a id="Tc_S1gTPmIUEEu6kTHS1iPISA_18_0"></a><a id="Tc_aR8LVzEQ7Uq7FIUQjLl9Fg_18_2"></a><a id="Tc_8Etu1Vu070ql9dCzbmu4ZA_18_5"></a><a id="Tc_aGlItScVvUGEw-_YF4Carg_18_11"></a><a id="Tc_uoP_JuLvTkyGgN4Otif_Kg_18_14"></a><a id="Tc_TmrKnOPEmUCGnj1OMF9kNQ_18_17"></a><a id="Tc_Qvg-PoBDCE-YTFHOglxNaQ_18_20"></a><a id="Tc_6aJ2XCgzXkKlxVrA6_b17A_18_23"></a><a id="Tc_5UfGrCam2kWhKyEM1Oz4Uw_19_0"></a><a id="Tc_Jc_S-EYUIU2RHu95D9FJsw_19_8"></a><a id="Tc_z8frACtDMkS8v9ClFU_abA_19_11"></a><a id="Tc_9m7GUEj59EC6BAo-_an2Rw_19_17"></a><a id="Tc_9DuunPsQ_Ui1yIwsCs6zFA_19_20"></a><a id="Tc_Jpqpgjh1yUiXfxodlly35w_20_0"></a><a id="Tc_--O_ewS_IUKgSaL4kazGVQ_20_2"></a><a id="Tc_orXWW8btaUWGedlKFe4Vvw_20_5"></a><a id="Tc_V6qHJkbib0mBIUWjUGWofw_20_8"></a><a id="Tc_cqULwC5RHkmOZUjtdnW0vw_20_11"></a><a id="Tc_ch-k4_KwWkeXYcwz2b3Vnw_20_14"></a><a id="Tc_oNYePnmq7UW3PPJBnUGk5g_20_20"></a><a id="Tc_Bs6hgYCufEKzDh1eaZvrjw_21_0"></a><a id="Tc_fQQmMpka3E-rnkB5Li6e6w_21_4"></a><a id="Tc_yQr4-nUOYkqXmadQmC7KOA_21_10"></a><a id="Tc__VVJ4hJmO0OH4hmIJjOw4A_21_13"></a><a id="Tc_ipgW9-KuLECsUZGCnwksjQ_21_16"></a><a id="Tc_c87MlZjDo0mosCwMKQmJMQ_21_19"></a><a id="Tc_D2pYxeotsUyhox6W62G5eQ_21_20"></a><a id="Tc_hP5a9u47m0uzQcLCHW24CQ_21_22"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.048851013%;padding-left:0pt;padding-right:0pt;width:100.09%;"><tr style="height:1pt;"><td style="vertical-align:top;width:29.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series X Preferred Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:14.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional Paid -&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Par&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">in Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Loss) Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:top;width:29.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cNQZPiUZ_UeK1Pbzt5CTIg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_iM0EdfLpvkGeLi62u6KP4Q_4_8">2,072,266</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cNQZPiUZ_UeK1Pbzt5CTIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_YTS2afuq4EuMi3MgRDDuSQ_4_11">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3YdF7rgdCkqzCRGFJN0xrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_xzR-f8pDkkiCHlZeJWohXQ_4_14">259,315</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_N1dQ51RP6UuuD2JViSzVmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_nzjKoVCNRkOLlfilb1wWBw_4_17">223,597</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2019_IIoZrvHZ90SylTKjxv1ZnQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Z_mErjdq9Ealhh0CjBuPCw_4_23">35,720</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:29.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Issuance of common stock in public offering, net of $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_atxs_PublicOfferingCommonStockAndWarrantsMember_S4V25J-LO0yw2cDuPVRuDA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_5cI0MkgtekqWvrgGP5DQJA">1.9</ix:nonFraction> million in issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zp2xevi_xEmHwwPp0gd3NQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_2r18L8EnRU-44Yy0ticvHA_5_8">881,666</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zp2xevi_xEmHwwPp0gd3NQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_shdWlvdCm0GB6OazWgALPg_5_11">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2-DGee-q5EegQ2k0m7z03g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_R9TSoYieAUSZZw-x2hnPtw_5_14">24,558</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_TJ0QhMgbwE6lXAkoF8uwFQ_5_23">24,559</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:29.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Issuance of common stock for at-the-market offerings, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember_FsZU2jcCL0ag97BH1_5Ixw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_72wbelq5ykqUoRu8r1JDrw">0.5</ix:nonFraction> million</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zp2xevi_xEmHwwPp0gd3NQ" decimals="INF" format="ixt:numdotdecimal" name="atxs:StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings" scale="0" id="Tc_leVB_jwHxkyxOdwmW0aTpA_6_8">392,288</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2-DGee-q5EegQ2k0m7z03g" decimals="-3" format="ixt:numdotdecimal" name="atxs:StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings" scale="3" id="Tc_3BdI1nVucE2nf1m_VR4kww_6_14">16,268</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="atxs:StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings" scale="3" id="Tc_rv1W76V-UUecaN95z7_dSw_6_23">16,268</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:29.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Proceeds from exercises of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zp2xevi_xEmHwwPp0gd3NQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_zL7SpuWGZEydqJM0lk4Fvg_7_8">1,166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zp2xevi_xEmHwwPp0gd3NQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_saF8FfmIbUarjF-5KqsqwA_7_11">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2-DGee-q5EegQ2k0m7z03g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_JJL8wKDnr0m5tyw37im3qg_7_14">31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_TXs8XHssN0uDk65KDt13XA_7_23">32</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:29.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2-DGee-q5EegQ2k0m7z03g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_2ZEac2x24067P_52e51YxQ_8_14">1,390</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_ObdJdvVIvkeXzmZt9q9oNw_8_23">1,390</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:29.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_t8Fc6FbRA0iGWOKhF-GZew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_NW81FoRTkk-2em_vD21r4w_9_17">37,300</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_P-oBIQrzkUygAdN1eYLy9Q_9_23">37,300</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:29.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VkwrOZo6Skee0mxwt5XNmg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_boiMt74q30WpPFyW1477cA_10_8">3,347,386</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VkwrOZo6Skee0mxwt5XNmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_3XrCVwYFXEmTcPUkc4bvuw_10_11">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kD4Wl26uSEaueUAirWvXnQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_t6drCvPq8E-7LINBTnMWng_10_14">301,562</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VJIc1ZjzpUal4qapZMqgqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_N7xvfAS-NEmuFs5hEccUaQ_10_17">260,897</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_CuWBixH3yk6cj2Ykkcl6Zg_10_23">40,669</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:29.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Issuance of preferred stock and common stock in a private offering of public equity, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_jf1HFRlRWE2wdm5GzthVPQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_U5if2hxUskW80GB4n80yIA_11_2">35,573</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_jf1HFRlRWE2wdm5GzthVPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_GrXInVdWxE2LUBI2pcNkNA_11_5">84,696</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ekfbhdx9h0WtXJ92zEMKrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_dcDADuXgdUaEKQ8rKCZJDA_11_14">19,565</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_fZ0kZJ9CTkWNEc8ElFwe7Q_11_23">104,261</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:29.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Issuance of preferred stock and common stock upon acquisition of Quellis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_jf1HFRlRWE2wdm5GzthVPQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="Tc_bWWDdcc5C0yseXsT8tTmDQ_12_2">50,504</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_jf1HFRlRWE2wdm5GzthVPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="Tc_tR-6L4vqlUu2nkHjHe4ymA_12_5">156,185</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u8JhPH-1RUqa-roQlJ-Ngw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="Tc_p-asHhdwRUiAHl1fXFjsDQ_12_8">555,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ekfbhdx9h0WtXJ92zEMKrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="Tc_TT1RpKNwrEST-DFxniOzSQ_12_14">8,098</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="Tc_1PGvEuH4okmVlEq1Ujpfzw_12_23">164,283</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:29.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Issuance of common stock upon the conversion of preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_jf1HFRlRWE2wdm5GzthVPQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" sign="-" scale="0" id="Tc_QeHjqhCnw0Sgh-QrJqcPiw_13_2">54,622</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_jf1HFRlRWE2wdm5GzthVPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" sign="-" scale="3" id="Tc_QgjLYI-pv0iFkkcS42hlvA_13_5">168,920</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u8JhPH-1RUqa-roQlJ-Ngw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_0_ZIz4FJkEG-DA8ADAXxAg_13_8">9,103,664</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u8JhPH-1RUqa-roQlJ-Ngw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_4dzl5_BwtECydhwABeJ_fQ_13_11">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ekfbhdx9h0WtXJ92zEMKrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_zgJpIhBoS0SdXPE-QPJODw_13_14">168,911</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:29.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Fair value adjustment to acquired Quellis warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ekfbhdx9h0WtXJ92zEMKrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_08AVlAGcPkuVcy0cbFPR0Q_14_14">1,157</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_KEbGNqzLHEuKyjVhSxa5CA_14_23">1,157</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:29.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Accretion of preferred stock discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_jf1HFRlRWE2wdm5GzthVPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockAccretionOfRedemptionDiscount" sign="-" scale="3" id="Tc_yA5_kH2Pw02McNfT1jjLXQ_15_5">24,437</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ekfbhdx9h0WtXJ92zEMKrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockAccretionOfRedemptionDiscount" scale="3" id="Tc_Ubth5HGxtUK12q2x2WUoPg_15_14">24,437</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:29.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Proceeds from exercises of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u8JhPH-1RUqa-roQlJ-Ngw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_fYEeaxYxu0i5EJTSykirLA_16_8">10,470</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ekfbhdx9h0WtXJ92zEMKrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_njtipbpsc02h9IU1cCZMOg_16_14">23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_fw3PwtniH0uFNHHh8_MyTg_16_23">23</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:29.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Reclassification of equity classified warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ekfbhdx9h0WtXJ92zEMKrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="3" id="Tc_foockEwQpU6QE7L7ztbEDA_17_14">3,468</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="3" id="Tc_TdhySrQSekW65BISCTF-9Q_17_23">3,468</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:29.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Fractional shares eliminated pursuant to reverse stock split</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u8JhPH-1RUqa-roQlJ-Ngw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" sign="-" scale="0" id="Tc_k65bfwycvEymQcvrxJpSyg_18_8">9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:29.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ekfbhdx9h0WtXJ92zEMKrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_3e-uICOteU-RMQPvQ1ipgg_19_14">3,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_bo8g_ueT6k6K9qGKWZSeXg_19_23">3,362</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:29.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xuUxeI6afE2LnVQerSEWkg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ENABGel5ckaCNZroE5ORJA_20_17">194,912</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Uok--MSZmUW1WTmbaXzcXQ_20_23">194,912</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:29.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_3t5AteWmBk6sQ6YdA-0C-w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_anrkw_BYWEObKXucXGouHQ_21_2">31,455</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_3t5AteWmBk6sQ6YdA-0C-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_enBZh9zpP0a3DupZDJltwQ_21_5">96,398</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vK3sQCnrnUaOL4SPp0j-GA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_afXn0AJ7eE6WQamZIQsr4Q_21_8">13,016,955</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vK3sQCnrnUaOL4SPp0j-GA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_MKWL0-WHikGwRTomVEl_Zw_21_11">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__NFtVVnk7EGtmJVTvFdECA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_v3mMpOv1D0GZYPVOapepcg_21_14">481,709</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_m9ULvgi4IE-US35BpN7rWA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_uDb65a6B6kCYnHAmuvUOXQ_21_17">455,809</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_8sL4AkZUX0O7gPohPXldew_21_23">122,311</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7eeefcad_6f41_4a3d_bb54_81adabf1ae9a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Astria Therapeutics, Inc</b>.</p><a id="ConsolidatedStatementsofCashFlows_205385"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Consolidated Statements of Cash Flows </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_69466c45_f513_4588_8494_20a5422c1833"></a><a id="Tc_lLde2GJJhEu_gckscTjmWg_1_2"></a><a id="Tc_CKF4X9s5-UyZweQaMadq-w_2_2"></a><a id="Tc_fTK-ZiDbeEmhRpe_SazCaA_2_5"></a><a id="Tc_z-TuUvxnSUa1sGrHr6TELg_3_0"></a><a id="Tc_SaDK35gjqUmyzwPlWyaAqw_4_0"></a><a id="Tc_0P53Ir7_QUyM-VguyQxSOA_4_2"></a><a id="Tc_3XtVmdMqXkWEWHtu6EqHkQ_4_5"></a><a id="Tc_D8VCg1LET0y69fodgXJ_kA_5_0"></a><a id="Tc_vpKHeXemu0mqGqh7UJlNkQ_6_0"></a><a id="Tc_9lC7jgOPlUOXVKufr4tZgA_6_6"></a><a id="Tc_QtoZe8SjCUOFOTOu_ZX42A_7_0"></a><a id="Tc_RKgjScLofUSyppp1CI_47Q_8_0"></a><a id="Tc_AAliOOpXIkuqlP4zxzKuVw_8_6"></a><a id="Tc_elMo8KYrcEy3xrNIG7AYYw_9_0"></a><a id="Tc_OPjeofNmNkOPFH3lHbEZPw_10_0"></a><a id="Tc_FCS9lSB3m06eugnkml8qRA_11_0"></a><a id="Tc_Rjie88x54kG1HbboAJvw8A_12_0"></a><a id="Tc_tpkLBBv030KH_7mnImBZaw_13_0"></a><a id="Tc_B2zUj-4qu0iWejVWlVhNfw_14_0"></a><a id="Tc_2I6KWkZ3pkijgQIixl7fIQ_15_0"></a><a id="Tc_yJ6VWQGnwEOPC6uEQiKl1A_16_0"></a><a id="Tc_TEmM6IE32UeyJrONjHSgOg_17_0"></a><a id="Tc_FW6QxDZvt0C_UfWlQTXDzg_18_0"></a><a id="Tc_RaORIJmm1kyyFc-0qrDnQg_19_0"></a><a id="Tc_HbLLjZLSekWs6Td8rT7rFw_19_6"></a><a id="Tc_iZKdpE5HzUq0KipPtBWxYQ_20_0"></a><a id="Tc_vEI1sVw58UeFcAbwOaejnw_21_0"></a><a id="Tc_hMOM5BApDkGxnEoMb5l_fQ_22_0"></a><a id="Tc_IVJNG0RNP0SA3YGpoiPl6w_23_0"></a><a id="Tc_uVczUaEsUUyPS6A2ucpg7w_23_3"></a><a id="Tc__CGTe3QokEydCKt_7_FWfA_24_0"></a><a id="Tc_5YrLHsyzB0qTEY9xm-oBmQ_24_6"></a><a id="Tc_4m7lui0ZQ0e10H80N3meYw_25_0"></a><a id="Tc_3z3F1KjIqkiKxGLJGShYsA_25_3"></a><a id="Tc_PB8L7qqUEEmh879T-6SKFw_26_0"></a><a id="Tc_AXMaLenmJkisyHbCLwVMHQ_27_0"></a><a id="Tc_VFXoJ-9iyUSxGNn3s7vC1w_28_0"></a><a id="Tc_mNumCV4D90--oEOCsKgicA_29_0"></a><a id="Tc_t_HTg5nd6UqvmJHeDOGnzw_30_0"></a><a id="Tc_75gNI8maOEGBPZ5kfRPHFA_30_2"></a><a id="Tc_CG7SVpUpE0Wi6htKJezU_A_30_5"></a><a id="Tc_p0ub4rUkkUWiG6INZtvd2Q_31_0"></a><a id="Tc_8pbbFjP49E20drZtfQ6O9w_32_0"></a><a id="Tc_F0Ejsn41c02n4SYaiVlN1A_32_2"></a><a id="Tc_L1dlEYv1KkS8GHPltHEaFw_32_5"></a><a id="Tc_OxzZxrFYBEe0FI_qX3Hwiw_32_6"></a><a id="Tc_0pA_AK6oUEWmyzRzDM7jHA_33_0"></a><a id="Tc_HXSbkHOfL0eVTKGVFhghjQ_33_2"></a><a id="Tc_7bMJPaMj8kGhSjE3vFFvEA_33_5"></a><a id="Tc_HtMmlitCKUK4FqDr9bjrJQ_33_6"></a><a id="Tc_HWRh-ljhzUGKfRpLTwzFAw_34_0"></a><a id="Tc_RT1V-PpCCEORhxSemZb6sg_34_2"></a><a id="Tc_KJ-dQAtGTUGI5XnG2Q4zHA_34_5"></a><a id="Tc_wEkNYPfTdEainkPaDxdX2Q_34_6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Operating&#160;activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_-JgXfnqG7US_fm3F0e0eTw_4_3">194,912</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_mOTs1mpWH0Kt4dqT-pMR0A_4_6">37,300</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Reconciliation of net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Non-cash portion of acquired in-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="atxs:NonCashPortionOfAcquiredResearchAndDevelopment" scale="3" id="Tc_qd5FTp6vmkubrzpjfZAmTg_6_3">164,612</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_OJPnER9C7E2MwSa9TV3dqA_7_3">3,362</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_GHQwHp716kmuBYoP1-RQjQ_7_6">1,390</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Net gain on warrants inherited in acquisiton of Quellis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="atxs:GainLossOnWarrantInherited" scale="3" id="Tc_vl8wdIKjbk2DVcZLr0oLqA_8_3">71</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Other non-cash items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" sign="-" scale="3" id="Tc_QaQ2-eZwrk6z8IsP7tli3g_9_3">21</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" sign="-" scale="3" id="Tc_aoR8905VVUOj1UAKbERtSQ_9_6">58</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Changes in assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_fFzycP32XUisroI7BWzFuw_11_3">85</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_8d00lj2oI0GzovVmQoZGiA_11_6">1,257</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Right-of-use asset- operating</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="atxs:IncreaseDecreaseInRightOfUseAssetOperating" sign="-" scale="3" id="Tc_oaOkpsOTIki_4TZ8Um-hUA_12_3">109</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="atxs:IncreaseDecreaseInRightOfUseAssetOperating" scale="3" id="Tc__Wlvs1w6kUaT-sdlaDgByw_12_6">176</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_MroKQyMscUOJKIeDhyLgQw_13_3">1,965</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_awgXwsPWeUi5eyR3YRF3-g_13_6">347</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_57Fx8xDnpEW3FMZPvVsTrg_14_3">1,316</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="Tc_CqyXMNy870q_2YN0QO3_qA_14_6">1,587</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_-gKQBFoqxUO4dcVfxPwKQA_15_3">30,151</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_6Z2OMKATs0yz2jABtoi28Q_15_6">32,485</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Purchases of short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" id="Tc_5FBnl1fX0EOcrgJM2SqaIg_17_3">78,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" id="Tc_JUPSMeRN00-hQrhgPS1Jnw_17_6">62,777</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Sales and maturities of short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" scale="3" id="Tc_9JrlSEGxoUOkQk3UL9BE9w_18_3">59,000</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" scale="3" id="Tc_8K0Ar24DE0C1vgDoUxpAAQ_18_6">69,110</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cash acquired in acquisition of Quellis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAcquiredFromAcquisition" scale="3" id="Tc__k28kJONs0CJav6d7zEXIQ_19_3">6,466</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_qKYdE-TqcE6UNlAi9wbVLQ_20_3">21</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_SYdzmOS9pketve1Bb8VWig_20_6">33</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net cash (used in) provided by investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_6gbu7frBW0qOjOpmHb_a5w_21_3">12,555</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_37t2EAd15k2Fyp_r44wwBQ_21_6">6,300</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Proceeds from underwritten public offering, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="Tc_lUfcMDXe70Ci-uB_0496_A_23_6">24,559</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Proceeds from private offering of public equity, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="3" id="Tc_TDIPq0he1EyRZwE4ThAT9Q_24_3">104,261</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Proceeds from at-the-market offering, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="atxs:ProceedsFromIssuanceOfAtMarketOffering" scale="3" id="Tc_ewL8w1z7e06L6oVYU7eDDw_25_6">16,270</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Proceeds from exercise of common stock options </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_UNLH3EDSLEmN1OFEuOGy3g_26_3">23</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_51zeycRB8UqQCQ1jklhd7Q_26_6">31</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_3jyHuRrS-0WAgT9dPyfmsQ_27_3">104,284</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_wD1Gj5m5DkyoJ-nJVLf2Ww_27_6">40,860</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net increase in cash, cash equivalents and restricted cash </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_EqOTzhM36Uujl839b1C5jQ_28_3">61,578</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_8stb1wmju0ilbi9RGxHcQA_28_6">14,675</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cash, cash equivalents and restricted cash, beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_5k_0sYvK70a4k0O1mrsJyg_29_3">25,051</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2019_IIoZrvHZ90SylTKjxv1ZnQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_z-sK_YQK8UKLY5ixhVQsbA_29_6">10,376</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cash, cash equivalents and restricted cash, end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_FQ1i6NrQBUyJEVlVC4B5uw_30_3">86,629</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_GpQL-z4jGkC2Zbwd7vcomA_30_6">25,051</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Supplemental disclosure of non-cash transactions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Conversion of Series X Preferred Stock into common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="Tc_wzKnysDu8EOSbjvoGKNuRQ_32_3">168,920</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Non-cash dividend on convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="atxs:DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts" scale="3" id="Tc_7EJCQjgS30OVV_HH3UvCtg_33_3">24,437</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Reclassification of warrant liability to additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="atxs:ReclassificationOfEquityClassifiedWarrants" scale="3" id="Tc_j84Gx0lF5U6JsTu6q8RYFQ_34_3">3,468</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="NotestoConsolidatedFinancialStatements_2"></a><a id="a1OrganizationandOperations_348641"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:NatureOfOperations" id="Tb_omThe7HkL0iPjuyHVr0WGQ" continuedAt="Tb_omThe7HkL0iPjuyHVr0WGQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">Astria Therapeutics, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">Notes to Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">1.</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Organization and Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The Company</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Astria Therapeutics, Inc. (the &#8220;Company&#8221;), formerly known as Catabasis Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics. Its mission is to bring hope with life-changing therapies to patients and families that are affected by rare and niche allergic and immunological diseases. On October 26, 2020, the Company announced that the Phase 3 PolarisDMD trial of the Company&#8217;s previous lead product candidate, edasalonexent, for the treatment of Duchenne Muscular Dystrophy (&#8220;DMD&#8221;) did not meet its primary and secondary endpoints. Based on these results, the Company announced that it was stopping activities related to the development of edasalonexent, including the Company&#8217;s ongoing open-label extension trial. On January 28, 2021, the Company acquired Quellis Biosciences, Inc. (&#8220;Quellis&#8221;). The Company&#8217;s lead product candidate, which was acquired in the Quellis acquisition, is STAR-0215 (formerly known as QLS-215), a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema, or HAE, a rare, debilitating and potentially life-threatening disease. The Company was incorporated in the State of Delaware on June 26, 2008.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Reverse Stock Split</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">On August 19, 2021, the Company effected a reverse stock split of its outstanding shares of common stock at a ratio of <span style="-sec-ix-hidden:Hidden_dLw7GAoMFEC93XKwCZhThQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-for-six (1:6) pursuant to a Certificate of Amendment to its Certificate of Incorporation filed with the Secretary of State of the State of Delaware. Pursuant to the reverse stock split, every six shares of the Company&#8217;s issued and outstanding shares of common stock were automatically combined into one issued and outstanding share of common stock, without any change in the par value per share of the common stock. Amounts of common stock resulting from the reverse stock split were rounded down to the nearest whole share and any resulting fractional shares were cancelled for cash. The number of authorized shares of the Company&#8217;s common stock remained unchanged. The reverse stock split affected all issued and outstanding shares of the Company&#8217;s common stock, and the respective numbers of shares of common stock underlying the Company&#8217;s outstanding Series X Preferred Stock, outstanding stock options, outstanding warrants and the Company&#8217;s equity incentive plans were proportionately adjusted. All share and per share amounts of the common stock included in the accompanying consolidated financial statements have been retrospectively adjusted to give effect to the reverse stock split for all periods presented, including reclassifying an amount equal to the reduction in par value to additional paid-in capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:6pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Agreement and Plan of Merger</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">On January 28, 2021, the Company acquired Quellis (the &#8220;Quellis Acquisition&#8221;). &#160;Under the terms of that certain agreement and plan of merger, dated January 28, 2021 (the &#8220;Merger Agreement&#8221;), the Company issued to the stockholders of Quellis <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_28_2021_To_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yGEdHdBZkEuZlEVGeuF7Gg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="Narr_cF-apuP8qk2wQCZ5iJ2jqA">555,444</ix:nonFraction> shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_By6IRPDdpEuZ5F3lwOK5ig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_FILZA6BnHEWa-kW85NPNnA">0.001</ix:nonFraction> per share, and <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_28_2021_To_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_MBblrX_TzUq0Y8HTkRLDIA" decimals="INF" format="ixt:numdotdecimal" name="atxs:TemporaryEquityStockIssuedInAcquisitionSharesNewIssues" scale="0" id="Narr_skVMU9iyr0uc-8HLZX-Iww">50,504</ix:nonFraction> shares of newly designated Series X redeemable convertible preferred stock (&#8220;Series X Preferred Stock&#8221;) (as described below). The Series X Preferred Stock had a conversion value on the closing date of $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_28_2021_To_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_MBblrX_TzUq0Y8HTkRLDIA" decimals="-5" format="ixt:numdotdecimal" name="atxs:TemporaryEquityConversionValue" scale="6" id="Narr_uymKsIOe5kOGwXyppKEyLw">122.7</ix:nonFraction> million. In addition, the Company assumed options granted under the Quellis stock option plan, which became options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_28_2021_To_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yGEdHdBZkEuZlEVGeuF7Gg" decimals="INF" format="ixt:numdotdecimal" name="atxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross" scale="0" id="Narr_GHTODk-Yr0Gi73QnRbi3Wg">55,414</ix:nonFraction> shares of the Company&#8217;s common stock, a warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_uWtVDAckP0qWnkjhGrfdWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_dj-Z-zs4KEaJsO5dcwRwpg">2,805</ix:nonFraction> shares of Series X Preferred Stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_uWtVDAckP0qWnkjhGrfdWg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_KdSlEYlBkk6oh9JkNhGiJQ">341.70</ix:nonFraction> per share, and a warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_By6IRPDdpEuZ5F3lwOK5ig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_UrYtbt85A0SkGfe71B1ZQg">30,856</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_By6IRPDdpEuZ5F3lwOK5ig" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_wJhTyXWopE6Qn85bPc-3Zw">2.10</ix:nonFraction> per share, which warrants are exercisable until December 14, 2030. Upon stockholder approval of the Conversion Proposal (as defined below) on June 2, 2021, the warrant to purchase Series X Preferred Stock was converted into the right to purchase <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_6_2_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BiFXZ622XUu96mNlkBimYA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_4qrEwP84002O8zWIFd0_OA">467,500</ix:nonFraction> shares of the Company&#8217;s common stock, at a per share exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="As_Of_6_2_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BiFXZ622XUu96mNlkBimYA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr__qfE3knn30mCmGjeVDAJFA">2.10</ix:nonFraction> per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:6pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Purchase Agreement and Series X Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Concurrent with the Quellis Acquisition, the Company entered into a Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain institutional and accredited investors. Pursuant to the Purchase Agreement, the Company sold an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember_VoS4WBR9UkK6OOydZ60sAw" decimals="INF" format="ixt:numdotdecimal" name="atxs:TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodSharesNewIssues" scale="0" id="Narr_meOgCrIHGkmLyo0ZnRlvNw">35,573</ix:nonFraction> shares of Series X Preferred Stock for gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember_VoS4WBR9UkK6OOydZ60sAw" decimals="-5" format="ixt:numdotdecimal" name="atxs:TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodGrossValue" scale="6" id="Narr_EORrffLbHEeI4K6bz6AGgw">110.0</ix:nonFraction> million, and net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember_VoS4WBR9UkK6OOydZ60sAw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="Narr_x-ifgQsUP0muqCLrlWSfgw">104.3</ix:nonFraction> million (the &#8220;February 2021 Financing&#8221;). Each share of Series X Preferred Stock is convertible into </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_c7qf1T1Qg0qy6hQffpGRZA_1_2"></a><a id="Tc_O5ecmJUXJEyEZoKpciJomg_2_2"></a><a id="Tc_0iZFuzGf-0ac78Z2rURWvA_3_2"></a><a id="Tc_wHQC8PZ3jEmxVGOBY-wZFw_4_2"></a><a id="Tc_AGu3aOgb_UuJnmKv48D0Vw_5_2"></a><a id="Tc_IIhnxl-4rECP4pewBUepaA_6_0"></a><a id="Tc_ij9oOVcCU0-GDtBDLbasLg_7_0"></a><a id="Tc_IT0E53RaaUGaxYQ8l5Y3ow_8_0"></a><a id="Tc_owz49b3eDkaJwiKrwdivDg_9_0"></a><ix:continuation id="Tb_omThe7HkL0iPjuyHVr0WGQ_cont1" continuedAt="Tb_omThe7HkL0iPjuyHVr0WGQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember_a9otGjsdyEWhX3Pzq_Pbxw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_DsFRiYw_SUiZxRlhFaVZTw">166.67</ix:nonFraction> shares of common stock. In accounting for the Purchase Agreement, the Company recorded a beneficial conversion feature of $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember_VoS4WBR9UkK6OOydZ60sAw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="6" id="Narr_MRamrd18J0uMFNvSwLqABQ">19.6</ix:nonFraction> million and issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember_VoS4WBR9UkK6OOydZ60sAw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_36BL7ys9dUujIT1WZsHv8g">5.7</ix:nonFraction> million. The combined total was treated as a discount to the value of Series X Preferred Stock, See Note 2 &#8211; &#8220;Summary of Significant Accounting Policies&#8221; for further discussion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">As a result of the Quellis Acquisition and the February 2021 Financing, the Company issued the following Series X Preferred Stock or warrants to purchase Series X Preferred Stock:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="atxs:ScheduleOfPreferredStockOrWarrantsToPurchasePreferredStockTableTextBlock" id="Tb_b0LO9163dEuJX_aNe2qHAA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series&#160;X</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;Preferred&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock at</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Shares issued in merger</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_srt_StatementScenarioAxis_atxs_SharesIssuedInMergerMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_VaYAgt65X062dsLicMLsSw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_RC1_ER7vG0WT-LtXJZb1dw_6_2">50,504</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Shares issued in February 2021 Financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_srt_StatementScenarioAxis_atxs_SharesIssuedIn2021FinancingMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_r3IXNsELnUOmAyLBZVInLA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_ht-QvX50wE-wf5Ftw2f7Rw_7_2">35,573</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Warrants assumed in merger</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_srt_StatementScenarioAxis_atxs_WarrantsAssumedInMergerMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_iJkNUaamoUSxxm1X7f0uqw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_gCVrFOdQYEm9xUuFJ9ZgUg_8_2">2,805</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_B02xcma4s0GpSFOo6RCOQA_9_2">88,882</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">At its 2021 Annual Meeting of Stockholders on June 2, 2021, the Company&#8217;s stockholders approved the conversion of the Company&#8217;s Series X Preferred Stock into shares of the Company&#8217;s common stock in accordance with Nasdaq Listing Rule 5635(a) (the &#8220;Conversion Proposal&#8221;). Following stockholder approval of the Conversion Proposal, each share of Series X Preferred Stock then outstanding automatically converted into <ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_CrmQNCtCOEK5xAJRMPfW-w">166.67</ix:nonFraction> shares of the Company&#8217;s common stock, subject to certain beneficial ownership limitations, including that a holder of Series X Preferred Stock is prohibited from converting shares of Series X Preferred Stock into shares of the Company&#8217;s common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (as of December 31, 2021, these percentages are set at <ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_uO-Pfxl910eVDz5-n8_42g" decimals="4" format="ixt:numdotdecimal" name="atxs:PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially" scale="-2" id="Narr_KlWtm--hFES-zc66Oikq_w">4.99</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_DHwk8E2QikOhwrNFkk342g" decimals="4" format="ixt:numdotdecimal" name="atxs:PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially" scale="-2" id="Narr_nqrIficQ1kydrcOHXgrNeQ">9.99</ix:nonFraction>% and can be adjusted by the holder to a number between <ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_uO-Pfxl910eVDz5-n8_42g" decimals="4" format="ixt:numdotdecimal" name="atxs:PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter" scale="-2" id="Narr_FsKh0P7drkqwZKgfPOFWjQ">4.99</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_DHwk8E2QikOhwrNFkk342g" decimals="4" format="ixt:numdotdecimal" name="atxs:PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter" scale="-2" id="Narr_LjThl_ir_UOkRkTAqs5FLQ">19.99</ix:nonFraction>%) of the total number of shares of the Company&#8217;s common stock issued and outstanding immediately after giving effect to such conversion. As of December 31, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_Q0-uw695P0e1UfMQTMe-mg" decimals="INF" format="ixt:numdotdecimal" name="atxs:StockIssuedDuringPeriodSharesIncreaseDecreaseDueToConversionOfPreferredSharesIntoCommonShares" scale="0" id="Narr_Mx_iXg5irUKNHwrzPVlgIA">54,622</ix:nonFraction> shares of Series X Preferred Stock were converted into <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_Q0-uw695P0e1UfMQTMe-mg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Narr_dhyRg_UTDkCOSAD9eyQQgQ">9,103,664</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_fDgNXeQj8kyyxA794AuKXQ">31,455</ix:nonFraction> shares of Series X Preferred Stock remained outstanding. Each share of Series X Preferred Stock is convertible into <ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_eNMA6ngkX0KGxkjxXQSUPg">166.67</ix:nonFraction> shares of common stock. At December 31, 2021, the number of shares of common stock issuable upon conversion of the remaining outstanding shares of Series X Preferred Stock is <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_D8qkl3qj1068AqMtqB5kNQ">5,242,501</ix:nonFraction>. Outstanding shares of Series X Preferred Stock are subject to conversion at the option of the holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Prior to stockholder approval of the Conversion Proposal, the terms of the Series X Preferred Stock included a cash redemption feature. This cash redemption feature resulted in substantial doubt about the Company&#8217;s ability to continue as a going concern as disclosed in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2020 (the &#8220;2020 Annual Report on Form 10-K&#8221;). Upon stockholder approval of the Conversion Proposal, the cash redemption feature was eliminated and, consequently, there is no longer substantial doubt about the Company&#8217;s ability to continue as a going concern for at least twelve months subsequent to the issuance of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Holders of Series X Preferred Stock are entitled to receive dividends, subject to certain beneficial ownership limitations, on shares of Series X Preferred Stock equal, on an as-if-converted-to-common-stock basis, and in the same form as dividends actually paid on shares of the Company&#8217;s common stock. Except as otherwise required by law, the Series X Preferred Stock does not have voting rights. However, as long as any shares of Series X Preferred Stock are outstanding, the Company may not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series X Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to the Series X Preferred Stock or alter or amend the Certificate of Designation that authorized the Series X Preferred Stock, amend or repeal any provision of, or add any provision to, the Company&#8217;s Certificate of Incorporation or bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of preferred stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series X Preferred Stock, (ii) issue further shares of Series X Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series X Preferred Stock, or (iii) enter into any agreement with respect to any of the foregoing.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_omThe7HkL0iPjuyHVr0WGQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">January 2020 Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">On January 30, 2020, the Company entered into an underwriting agreement with Oppenheimer &amp; Co. Inc. relating to an underwritten public offering (the &#8220;January 2020 Financing&#8221;) of <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_30_2020_To_1_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_UnderwritingPublicOffering2020Member__qJWTgwHU0y6BreieN-tEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_ME42qQhStUWK4xCwOqRJhg">881,666</ix:nonFraction> shares of common stock at a price to the public of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="As_Of_1_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_UnderwritingPublicOffering2020Member_c40JqESgcEiBixt1r0S-6w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_-Q2blSzO-Ea5cCPJ2G2D4A">30.00</ix:nonFraction> per share, including <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_30_2020_To_1_30_2020_srt_CounterpartyNameAxis_atxs_OppenheimerCo.IncMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_UnderwritingPublicOffering2020Member_ps7Jmy_qxEGruAZux02SWA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_ieNYXzWoNUeadRwl5GhGIA">115,000</ix:nonFraction> shares issued upon the exercise in full by Oppenheimer &amp; Co. Inc. of its overallotment option. This resulted in gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_30_2020_To_1_30_2020_us-gaap_SubsidiarySaleOfStockAxis_atxs_UnderwritingPublicOffering2020Member_AJ3obUkYbkW3WPPRYNkRqg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_ssdR-fS3XEamBSWmsbF2Tw">26.5</ix:nonFraction> million, and net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_30_2020_To_1_30_2020_us-gaap_SubsidiarySaleOfStockAxis_atxs_UnderwritingPublicOffering2020Member_AJ3obUkYbkW3WPPRYNkRqg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_gE57oynMOkmInEMDYTSP-A">24.6</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company has entered into various sales agreements with Cowen and Company LLC (&#8220;Cowen&#8221;), pursuant to which the Company could issue and sell shares of common stock under at-the-market offering programs. On May 20, 2021, the Company terminated its sales agreement with Cowen. On June 30, 2021, the Company entered into an Open Market Sale Agreement<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> with Jefferies LLC (&#8220;Jefferies&#8221;), pursuant to which the Company can issue and sell shares of common stock of up to $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_6_30_2021_srt_CounterpartyNameAxis_atxs_JefferiesMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember__zmdZLIxRES1KpnGo6-lqg" decimals="-5" format="ixt:numdotdecimal" name="atxs:CommonStockSaleAgreementValue" scale="6" id="Narr_yoSW5gQgbkCtAmn_hy3qOQ">25.0</ix:nonFraction> million under at-the-market offering programs (collectively, with the Cowen at-the-market offering program, the &#8220;ATM Programs&#8221;). The Company pays the sales agent commissions of <ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_6_30_2021_To_6_30_2021_srt_CounterpartyNameAxis_atxs_JefferiesMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember_oBnDRsRG00CrcvXjnale3w" decimals="INF" format="ixt:numdotdecimal" name="atxs:PercentageOfCommissionPaidToUnderwriterBasedOnProceedsFromOffering" scale="-2" id="Narr_PnT4nyjsUUiOuc9Lrx63bQ">3</ix:nonFraction>% of the gross proceeds from any common stock sold through the ATM Programs. As of December 31, 2021, the Company has <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_atxs_JefferiesMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember_SsM7_C8YNk-Wd6_cC-Nh_w" decimals="0" format="ixt-sec:numwordsen" name="atxs:StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings" scale="0" id="Narr_SMCw0KLcZUKx1sBODcB6ow">no</ix:nonFraction>t sold any shares of common stock pursuant to the Jefferies agreement and, as a result, $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_atxs_JefferiesMember_V_6BHty4gE2XeCiNbcgUQg" decimals="-5" format="ixt:numdotdecimal" name="atxs:RemainingAvailableUnderCurrentSalesAgreement" scale="6" id="Narr_w24dkpw46USzFqXTkKGD2w">25.0</ix:nonFraction> million of common stock remains available for sale under the Jefferies agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">During the year ended December 31, 2020, the Company sold an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember_BsZDsx3vsEuRWOxqvJFk-g" decimals="INF" format="ixt:numdotdecimal" name="atxs:StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings" scale="0" id="Narr_a4SbFcW6ekW-x0c12dLjlQ">392,288</ix:nonFraction> shares of common stock pursuant to the ATM Programs, at an average price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember_GQ8u_bZ2vk2rapCqnMoYiQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_k1USilPPaUCCn9Qmgfrsbg">42.76</ix:nonFraction> per share, for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember_BsZDsx3vsEuRWOxqvJFk-g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_i_k2IgrWDkeOL__GxTmrSQ">16.3</ix:nonFraction> million after deducting sales commissions and offering expenses. There was no activity from the ATM Programs during the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">As of December 31, 2021, the Company had an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_J3U-Xzs3BkWpCekbvK7eGw">455.8</ix:nonFraction> million and had available cash, cash equivalents and short-term investments $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="Narr_Dsvw2oLR1UaOJ6_mD9eXrg">125.5</ix:nonFraction> million. The Company has been primarily involved with research and development activities and has incurred operating losses and negative cash flows from operations since its inception. The Company has not generated any product revenues and has financed its operations primarily through public offerings and private placements of its equity securities. There can be no assurance that the Company will be able to obtain additional debt, equity or other financing or generate product revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company&#8217;s business, results of operations, and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company is subject to a number of risks similar to other life science companies, including, but not limited to, successful discovery and development of its drug candidates, raising additional capital, development by its competitors of new technological innovations, protection of proprietary technology and regulatory approval and market acceptance of the Company&#8217;s products. The Company has been primarily involved with research and development activities and has incurred operating losses and negative cash flows from operations since its inception. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="font-family:'Times';font-weight:bold;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_XNOl5AW4M0S-sbmIjF14kg" continuedAt="Tb_XNOl5AW4M0S-sbmIjF14kg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">2. &#160;&#160;&#160;Summary of Significant Accounting Policies&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_2aFOwgm1oU2yoosU0Si8RQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation and Principles of Consolidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Astria Securities Corporation and Quellis Biosciences, LLC, successor in interest to Quellis. All intercompany balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented.&#160;&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><a id="_07b3fe5c_b939_4416_8c2a_40efae67206c"></a><a id="Tc_898j-UqE5E61CVJyhhWqdw_1_2"></a><a id="Tc_T6MHYAgNXEStmQehPj3pug_2_2"></a><a id="Tc_Fobixus5Vkyt7CsEIJtVPQ_2_5"></a><a id="Tc_YAvvRy1mCkK-VEB3ehfxOg_3_0"></a><a id="Tc_11FzHJaolU6tk_1lVaMPxA_3_2"></a><a id="Tc_jm4xNaKRLEeWHhTd4ECEZg_3_5"></a><a id="Tc_XL2kK1ANXEyYRFswgzYA0A_4_0"></a><a id="Tc_wLERw09SvUCvON8q6_LbmA_5_0"></a><a id="Tc_MbVJglEPZ0moC3a61EHP9g_5_2"></a><a id="Tc_LnHUcqDV_0GvGJiyT0j5Sw_5_5"></a><ix:continuation id="Tb_XNOl5AW4M0S-sbmIjF14kg_cont1" continuedAt="Tb_XNOl5AW4M0S-sbmIjF14kg_cont2"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:UseOfEstimates" id="Tb_a9YwEaCsAUOFIZj6Wa529A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company utilizes certain estimates to record expenses relating to research and development contracts. These contract estimates, which are primarily related to the length of service of each contract and the amount of service provided as of each measurement date, are determined by the Company based on input from internal project management, as well as from service providers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="atxs:OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock" id="Tb__dLt46hV50y59pgBNb8u9Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Off-Balance Sheet Risk and Concentrations of Credit Risk </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company has no off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements. Financial instruments that subject the Company to credit risk primarily consist of cash, cash equivalents, short-term investments and restricted cash. The primary objectives for the Company&#8217;s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company&#8217;s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="Tb_9s2treraRkCYGUV9veShSg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents and Restricted Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="Tb_C8VbTGmc2kKI0MZERkOPHg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The reconciliation of cash, cash equivalents and restricted cash reported within the applicable balance sheet that sum to the total of the same such amount shown in the statement of cash flows is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_Op00F5IuAkuW_wOi-2m3Hw_3_3">86,508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_V0FR3b535U6dQOSHPHuZxg_3_6">24,930</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Restricted cash (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="Tc_KwDvCtkuwEGeRjEmCeX6TA_4_3">121</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="Tc_pbbkK7M240C2oVrnX3fsKQ_4_6">121</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_folvLW4v4ESd-eNInbWmww_5_3">86,629</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_tJvPt1GjXEui07spbfWbCQ_5_6">25,051</ix:nonFraction></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-left:46.8pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:46.8pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Included in prepaid expenses and other current assets at December 31, 2021 and other long-term assets at December 31, 2020.</span></td></tr></table></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:InvestmentPolicyTextBlock" id="Tb_5tkIViyfqUO-VEmT-ckqRA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Short-Term Investments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company classifies all corporate debt securities with a remaining maturity of greater than three months and reverse repurchase agreements with a remaining maturity of greater than one business day at the time of purchase as short-term investments. Short-term investments are recorded at fair value, with the unrealized gains and losses reported in other comprehensive loss. The amortized cost of debt securities is adjusted for the amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest and investment income. Realized gains and losses, interest, dividends and declines in value judged to be other-than-temporary are included in interest and investment income. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The cost of securities sold is based on the specific identification method for purposes of recording realized gains and losses. To determine whether an other-than-temporary impairment exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the investment outweighs evidence to the contrary. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_keduC77Ed0Kzz1_oiYvpJA" continuedAt="Tb_keduC77Ed0Kzz1_oiYvpJA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three broad levels as follows: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3 inputs are unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk33515187"></a><ix:continuation id="Tb_XNOl5AW4M0S-sbmIjF14kg_cont2" continuedAt="Tb_XNOl5AW4M0S-sbmIjF14kg_cont3"><ix:continuation id="Tb_keduC77Ed0Kzz1_oiYvpJA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The carrying amounts reflected in the balance sheets for cash equivalents, restricted cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values at December 31, 2021 and 2020, due to their short-term nature. There have been no changes to the valuation methods during the years ended December 31, 2021 and 2020. The Company evaluates transfers between levels at the end of each reporting period. There were <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" scale="3" id="Narr_cpm_Y0z3Tku9kakWzI4rgA">no</ix:nonFraction> <span style="-sec-ix-hidden:Hidden_Q8KxfYwEQ06Q-XDWVRjAVA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">transfers</span></span> <span style="-sec-ix-hidden:Hidden_h7pU9TMEukuhqRukKT1nSg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span></span> <span style="-sec-ix-hidden:Hidden_Spms05oTPUG_D656yLZ_hg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assets</span></span> or liabilities between levels during the years ended December 31, 2021 and 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company&#8217;s investment portfolio may include fixed income securities that do not always trade on a daily basis. As a result, the pricing services used by the Company apply other available information as applicable through processes such as benchmark yields, benchmarking of like securities, sector groupings and matrix pricing to prepare valuations. The Company validates the prices provided by its third party pricing services by obtaining market values from other pricing sources and analyzing pricing data in certain instances. The Company also invests in certain reverse repurchase agreements which are collateralized by deposits in the form of United States Government Securities and Obligations for an amount no less than <ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_CollateralAxis_us-gaap_CollateralPledgedMember_us-gaap_InvestmentTypeAxis_atxs_ReverseRepurchaseAgreementsMember_eiP--rMiZU-1gbUFnuyFRA" decimals="INF" format="ixt:numdotdecimal" name="atxs:PercentageOfInvestmentAmountToCollateralizedDepositsValue" scale="-2" id="Narr_WPKuU23ffECqScEd-M8OEw">102</ix:nonFraction>% of their value. The Company does not record an asset or liability for the collateral as the Company is not permitted to sell or re-pledge the collateral. The collateral has at least the prevailing credit rating of United States Government Treasuries and Agencies. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at <ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_InvestmentTypeAxis_atxs_ReverseRepurchaseAgreementsMember_aL_h_TEmN0mRrvtYQElzYg" decimals="INF" format="ixt:numdotdecimal" name="atxs:PercentageOfInvestmentAmountToCollateralizedDepositsValue" scale="-2" id="Narr_mKhzV9vTQUq-rihj2lmbgg">102</ix:nonFraction>% of the value of the reverse repurchase agreements on a daily basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company accounted for warrants to purchase its stock pursuant to Accounting Standards Codification (&#8220;ASC&#8221;) Topic 470, Debt, and ASC Topic 480, Distinguishing Liabilities from Equity, and classifies warrants for common stock and preferred stock as liabilities or equity. The warrants classified as liabilities are reported at their estimated fair value and any changes in fair value are reflected in research and development expense. The warrants classified as equity are reported at their estimated fair value with no subsequent remeasurement.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_vtY94lv_Tky0gwv1vWpNcQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. The Company has not recognized any significant impairment charges from inception through December&#160;31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_aQrqDkvMkkC9CW34JKqyDQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Research and development costs are expensed as incurred. Research and development costs include salaries and personnel-related costs, stock-based compensation, consulting fees, fees paid for contract research services, the costs of laboratory equipment and facilities and other external costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred. The deferred amounts are expensed as the related goods are delivered or the services are performed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_qGllelNhLUqJtlHoaCbUUA" continuedAt="Tb_qGllelNhLUqJtlHoaCbUUA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company accounts for its stock-based compensation awards in accordance with ASC Topic&#160;718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation (</i>&#8220;ASC&#160;718&#8221;). ASC&#160;718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statements of operations based on their grant date fair values. For granted stock options, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model.&#160; The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Company&#8217;s common stock consistent with the expected term of the option, risk-free interest rates and expected dividend yields of the Company&#8217;s common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">For awards subject to service-based vesting conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><a id="_a270b892_5d2c_47da_8a9e_8c633684d3a5"></a><a id="Tc_ako0j5kg8UOn9i0PVpYViQ_1_2"></a><a id="Tc_l-1jQWw8oky435b4C7rezw_2_2"></a><a id="Tc_OpouP81ZMUyZW5L1J0iLlQ_2_5"></a><a id="Tc_FZCMwPbOCEWKqTFg0_3dIg_3_0"></a><a id="Tc_rb1n0Km_l0CDbj8MamhCqA_3_2"></a><a id="Tc_C4MmHD4pNE6Ib1HOVNXy8A_3_5"></a><a id="Tc_h5vsQejt0kW22bt60bRM1Q_4_0"></a><a id="Tc_B2pPGerA4UiUg7hqAflCQQ_5_0"></a><a id="Tc_e-OWnutCZEuyxI87cB2YsA_5_2"></a><a id="Tc_GRxsfQAvok-A1qJ3hdWQbQ_5_5"></a><a id="_Hlk1722198"></a><a id="Tc_GDe8Ibbik0Cxe0mBGKK4nw_1_2"></a><a id="Tc_EcFSB85O0UyeJ0akvPA8Pg_2_2"></a><a id="Tc_TFIBBPseQk-jRd__88K0MA_2_4"></a><a id="Tc_j9hQnQP02US3o53jXMhSmA_3_0"></a><a id="Tc_Lr69F2WNkUKiIiXlHDoNxw_4_0"></a><a id="Tc_MSgbc3de3Uu8I9jXOPC7Fg_5_0"></a><a id="Tc_g7S97RC-nk2vdYZGYGqCxA_5_4"></a><ix:continuation id="Tb_XNOl5AW4M0S-sbmIjF14kg_cont3" continuedAt="Tb_XNOl5AW4M0S-sbmIjF14kg_cont4"><ix:continuation id="Tb_qGllelNhLUqJtlHoaCbUUA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company expenses restricted stock awards based on the fair value of the award on a straight-line basis over the associated service period of the award. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_t_7n1zQIL0mXkjbzPpiMsQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">During the years ended December 31, 2021 and 2020, the Company recorded stock-based compensation expense for employee and non-employee stock options and restricted stock, which was allocated as follows in the statements of operations (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9rTkA9cmjESbAdI_CIGCcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_57sGiVkc2U26T6oTtNiO8Q_3_3">1,132</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_CpiCowz5gUmCO8VqNzzcCQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_KxqfeGS160a8PUTqAm4OCg_3_6">599</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_P4mw2Fw8x0WkHCAyeJfKmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_va6m5FcqjUOU_4lnE9SbGA_4_3">2,230</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_8dpBZ3kAYkmlo-2evH5QBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_-PrV82bb3UagpP9IfGT-7Q_4_6">791</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_BJ9zZ41_-UqtgahpfBqEHg_5_3">3,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_fq3Hj-7mYUeVRRHD_FZwPg_5_6">1,390</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="3" id="Narr_pzSSX6DYAUGda0mTD0gUrQ"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="3" id="Narr_smveeqB4IUSglVnaukMO-w">No</ix:nonFraction></ix:nonFraction> related tax benefits were recognized for the years ended December 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_IB3cf1SSX0y0v_8g-5QPbg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss Per Share </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Basic net loss per share is calculated by dividing net loss by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the Company&#8217;s dilutive net loss per share calculation, stock options and warrants to purchase the Company&#8217;s common stock were considered to be common stock equivalents but were excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive; therefore, basic and diluted net loss per share were the same for all periods presented. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: </p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_2rlqik4AUUyDiUMeSsUEcg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_2fwTF9OAO0KdmBRB8Fzb2g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_xX0SDGKV00WjtrUhGYo05A_3_2">1,346,733</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_q91ttEudQ0mAGYdugRr9ow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_5unntZQ0ZUC6HnSR3zMNxg_3_4">227,945</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_atxs_CommonStockWarrantsMember_eZiUsBdsv0CpnkEmFJMYiw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_da3HGjYW-EeimZAk3JnZGQ_4_2">1,530,380</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_atxs_CommonStockWarrantsMember_n7ERVEbeHkmVQE0vpdaYVw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_XOmSq_t4xkSzlk7hxk-WEQ_4_4">1,032,292</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Series X Preferred Stock (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_atxs_SeriesXPreferredStockMember_9HMukFq3bkmw6Lq9raeXDQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_vf9ygsner06i_9Jwk1Qdzg_5_2">5,242,501</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_YgNW9CiW_EOgIIZsAK7Xqw_6_2">8,119,614</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_o4jUrW6t2UK8-fdFIRbm7A_6_4">1,260,236</ix:nonFraction></p></td></tr></table></ix:nonNumeric><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-left:46.8pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:46.8pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Shown as common stock equivalents</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_2dke4P9CW0-WY71-T39wbQ" continuedAt="Tb_2dke4P9CW0-WY71-T39wbQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company provides deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company&#8217;s financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. A valuation allowance is provided to reduce the deferred tax assets to the amount that will more likely than not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC Topic&#160;740, <i style="font-style:italic;">Expenses&#8212;Income Taxes</i>. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company did not have any uncertain tax positions for any periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk97688838"></a><ix:continuation id="Tb_XNOl5AW4M0S-sbmIjF14kg_cont4" continuedAt="Tb_XNOl5AW4M0S-sbmIjF14kg_cont5"><ix:continuation id="Tb_2dke4P9CW0-WY71-T39wbQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Company assesses the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where it has operations to determine the potential effect its business and any assumptions it has made about its future taxable income. The Company cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on its business if they were to be enacted. Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the currently available option to deduct research and development expenditures and requires taxpayers to amortize them over five years. The U.S. Congress is considering legislation that would defer the amortization requirement to future periods, however, the Company has no assurance that the provision will be repealed or otherwise modified.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_lRELF4dtlEOY1iwoYCKr7Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Segment Information </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, the Company&#8217;s chief executive officer, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business in one operating segment. The Company operates in <ix:nonFraction unitRef="Unit_Standard_segment_VaIUUonErEmKwL0Ka000VA" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_kIEla1ZcF0a3HNDTKwpKMg">one</ix:nonFraction> geographic segment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_RZAZO9amh0SXkSTfEsI6Xw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_msrhB4QCzUqfaHNydBtAEA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company determines if an arrangement is a lease at inception. Operating leases are included in&#160;right-of-use&#160;(&#8220;ROU&#8221;) lease assets, current portion of lease obligations, and long-term lease obligations on the Company&#8217;s balance sheets. The Company does not currently hold any financing leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">ROU lease assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease obligations represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s facility leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company&#8217;s ROU lease assets also include any lease payments made and excludes lease incentives. If the Company&#8217;s facility lease includes options to terminate the lease which would affect the lease period when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments under facility leases are recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="Tb_cQhALg56A0qGWTEMYWpBtg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Acquired In-Process Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire in-process research and development (&#8220;IPR&amp;D&#8221;) with no alternative future use is charged to expense at the acquisition date. Refer to Note 3, &#8220;Acquisition of Quellis&#8221; for a more detailed description of the accounting policy utilized for the recent asset acquisition.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times';line-height:1.19;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_XNOl5AW4M0S-sbmIjF14kg_cont5"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="atxs:PreferredStockDiscountPolicyTextBlock" id="Tb_iWihsg4s9EeksuuncSuWIw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Preferred Stock Discount</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">As discussed above, in February 2021, the Company issued Series X Preferred Stock in a private placement transaction. It was determined that this transaction resulted in recognition of a beneficial conversion feature, which was valued based on the difference between the price of the shares of common stock on the date of commitment and the conversion price on the closing date, resulting in a total value of $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_nDMEtpbiBUq1iy12eCKFQQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="6" id="Narr_Ol9eLdZV4E6xlGzF6vC60g">19.6</ix:nonFraction> million. Additionally, the Company incurred total issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_nDMEtpbiBUq1iy12eCKFQQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_iRpmWfCJrkK-DCxIlI0qZg">5.7</ix:nonFraction> million related to the private placement. Both of these features were recorded as a discount on Series X Preferred Stock recognized at the close of the transaction. These features are analogous to preferred dividends and are recorded as a non-cash return to holders of Series X Preferred Stock through additional paid in capital. The discount related to the beneficial conversion feature is recognized through the earliest possible date of conversion, which occurred upon the shareholder approval of the conversion in June 2021. The issuance costs are recognized as a dividend at the time of conversion to common shares. As of December 31, 2021, $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mm2r7tKTwEKwrvs2FxtSqQ" decimals="-5" format="ixt:numdotdecimal" name="atxs:NonCashReturnRelatedToCommonStock" scale="6" id="Narr_IGta-22iOkqSyccf3YC5zg">24.4</ix:nonFraction> million of the above amounts were accounted for as a non-cash dividend related to shares of Series X Preferred Stock, and $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_Q0-uw695P0e1UfMQTMe-mg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="6" id="Narr_QpOwa5HYxU2PCGEcFMOUIg">0.9</ix:nonFraction> million remained to be recognized upon future conversion.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times';line-height:1.19;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_YsYI9FreWkOsx94MQTA7Fw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements -Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">In December 2019, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740)</i>. This standard includes amendments within the scope of Topic 740 to reduce complexity and improve areas of U.S. GAAP. This amendment was effective for annual reporting periods beginning after December 15, 2020. Adoption of the standard did not have a material impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements - Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">In June 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, <i style="font-style:italic;">Financial Instruments-Credit Losses</i> (Topic 326). This standard requires a financial asset to be presented at amortized cost basis at the net amount expected to be collected. It also requires that credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. In November 2019, the FASB issued an amendment making this ASU effective for annual reporting periods beginning after December 15, 2022 for smaller reporting companies. Early adoption is permitted. The Company is currently evaluating the impact that this standard will have on its consolidated financial statements as well as the timing of when this standard will be adopted.</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f59dc166_7983_4e86_884c_0271497f0297"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="Tb_QSMmwgFlXUaiMUf8GgvhXw" continuedAt="Tb_QSMmwgFlXUaiMUf8GgvhXw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3. &#160;&#160;&#160;Acquisition of Quellis</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">On January 28, 2021, the Company completed the Quellis Acquisition in accordance with the terms of the Merger Agreement as discussed in Note 1, &#8220;Organization and Operations&#8221;. Under the terms of the Merger Agreement, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_28_2021_To_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yGEdHdBZkEuZlEVGeuF7Gg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="Narr__K29DFoW_EazfC9Tj0ejOg">555,444</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_28_2021_To_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_MBblrX_TzUq0Y8HTkRLDIA" decimals="INF" format="ixt:numdotdecimal" name="atxs:TemporaryEquityStockIssuedInAcquisitionSharesNewIssues" scale="0" id="Narr_HUV7JeOLnk272oldScYk9Q">50,504</ix:nonFraction> shares of Series X Preferred Stock. Each share of Series X Preferred Stock is convertible into <ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_uWtVDAckP0qWnkjhGrfdWg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_yxQYHCwUGUyma5FzJodDZw">166.67</ix:nonFraction> shares of Common Stock, subject to certain conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company concluded that the Quellis Acquisition was not the acquisition of a business, as substantially all of the fair value of the non-monetary assets acquired was concentrated in a single identifiable asset, STAR-0215.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_70df2ff7_7c1a_4ad6_a29b_82e718535487"></a><a id="Tc_N-iJTZ4ilk63PmqqfYyeGg_1_0"></a><a id="Tc_XK6GbNqInUSi0r0Bu8Pybw_1_2"></a><a id="Tc_PHgVviHcCEaK3SMPxVgPmA_2_0"></a><a id="Tc_-zBwdiGLf0m5ddkTIduxqw_3_0"></a><a id="Tc_LwnoHCj-v0uO88oqz9S--Q_4_0"></a><a id="Tc_fagNIN6HbUKc3dIzzhlKTg_5_0"></a><a id="Tc_N7-4WfdnmkCN2fz5ZU_AiA_6_0"></a><a id="Tc_9lrSPyVSzEuV-gb60BqzGQ_6_2"></a><ix:continuation id="Tb_QSMmwgFlXUaiMUf8GgvhXw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company determined that the cost to acquire the Quellis assets was $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_stYiOzYUG0mKnmIJCrQu3Q" decimals="-5" format="ixt:numdotdecimal" name="atxs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities" scale="6" id="Narr_-LX6AvP3ikSaOzvDjx8Psg">170.7</ix:nonFraction> million, based on the fair value of the equity consideration issued and including direct costs of the acquisition of $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_28_2021_To_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_yxGtZ11D_EqlCL7qM9oOug" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AcquisitionCosts" scale="6" id="Narr_szYGpOnEmUmL9-aVhA4nZA">1.8</ix:nonFraction> million. The net assets acquired in connection with the Quellis Acquisition were recorded at their estimated fair values as of January 28, 2021, which is the date the Quellis Acquisition was completed. The following table summarizes the net assets acquired based on their estimated fair values as of January 28, 2021 (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="Tb_IJpduOBHd0SDedudTGK3Pw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Acquired IPR&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_stYiOzYUG0mKnmIJCrQu3Q" decimals="-3" format="ixt:numdotdecimal" name="atxs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment" scale="3" id="Tc_bs2fy1NNDkKhxBJU3w4H7w_1_3">164,612</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_stYiOzYUG0mKnmIJCrQu3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="Tc_siMFJ3l90kqVZ4GJpzP5PA_2_3">8,307</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_stYiOzYUG0mKnmIJCrQu3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="Tc_u8q6Ln9HT0GgTF0iAMtyFA_3_3">136</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_stYiOzYUG0mKnmIJCrQu3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" id="Tc_PCNZs7b_K0S4HHodSkqFSw_4_3">1,974</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_stYiOzYUG0mKnmIJCrQu3Q" decimals="-3" format="ixt:numdotdecimal" name="atxs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" scale="3" id="Tc_ko33URsVF0-Mo9NRV_pjNw_5_3">400</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net acquired tangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_stYiOzYUG0mKnmIJCrQu3Q" decimals="-3" format="ixt:numdotdecimal" name="atxs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities" scale="3" id="Tc_VYIArfWoR0mrneO0K580oQ_6_3">170,681</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:28.8pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">In the estimation of fair value of the asset purchase consideration, the Company used the carrying value of the cash and cash equivalents, prepaid expenses, accounts payable and accrued liabilities as the most reliable indicator of fair value based on the associated short-term nature of the balances. The remaining fair value was attributable to the acquired IPR&amp;D. As STAR-0215 had not, at the time of the Quellis Acquisition, received regulatory approval in any territory, the cost attributable to the IPR&amp;D was expensed in the Company&#8217;s consolidated statements of operations and comprehensive loss for the year ended December 31, 2021 as the acquired IPR&amp;D had no alternative future use, as determined by the Company in accordance with U.S. GAAP.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_a62334a4_d828_4408_bd94_2709598691e7"></a><a id="Tc_feszId4a-USl1J7M-P-7vw_1_2"></a><a id="Tc_iQgZGlqG3EGvnMPX4oJHHg_2_2"></a><a id="Tc_F7DXYkjkvUyaT9VJb4Er6g_2_5"></a><a id="Tc_0Z9GFYKIsUKahIVnYLK0hg_2_8"></a><a id="Tc_RKDzwGZVzU66FFvaWlaWWw_3_2"></a><a id="Tc_geVcr3v1mkSAyBm17E_DRA_3_5"></a><a id="Tc_Uhd1BM6cqEmJ_l3QWD_pGw_3_8"></a><a id="Tc_MAt_S2ihIU21MIezuE2hPg_4_2"></a><a id="Tc_wWTW17zulkGML3TrWk36RA_4_5"></a><a id="Tc_xfMsKUAegkmH7qYBaFezcA_4_8"></a><a id="Tc_y0wqe4BwPk-u-14J0j71bQ_5_2"></a><a id="Tc_irvbrPJZskCeiNtIA0I0zA_5_5"></a><a id="Tc_q4uzY7qUjkmv1BwZnuK3mQ_5_8"></a><a id="Tc_CwAAOA-OvUWqIPEs3i-TLw_5_11"></a><a id="Tc_W9ZkpFxVtkeHqa_9KZWxKw_6_0"></a><a id="Tc_ujarYAzB_kCU9tY9FC2RXA_7_0"></a><a id="Tc_gebslIMjHkOKjPXQb2r51Q_8_0"></a><a id="Tc_1jcsl1tNoECBDV3kSBmniw_8_2"></a><a id="Tc_B5Ny3x86ikC372wyJeArLQ_8_5"></a><a id="Tc_nNiafqC8KkaS_nU6QdCuPQ_8_6"></a><a id="Tc_wB6T-JI8WUufYfGQCBPOqA_8_8"></a><a id="Tc_TjYe9p9q2EKw-lHvB21pCg_8_9"></a><a id="Tc_Z3P_gCmKe0eqj8cJOD8uNQ_8_11"></a><a id="Tc_8FRSwhuus0uIVhu1mBwp2w_9_0"></a><a id="Tc_Z0lzJXTviUamnyNMHCly4Q_9_3"></a><a id="Tc_JlKnZDhiwUGWXyEgymYZfA_9_6"></a><a id="Tc_OfhMI3Cgt0yLujlSopXurw_9_9"></a><a id="Tc_pBxuQ6ycRUm1WcQCpQBv9w_9_12"></a><a id="Tc_d33j7uBy-EiG7UJa9HWmSA_10_0"></a><a id="Tc_1cSOYn_pdUabFjRCJK7DPg_11_0"></a><a id="Tc_yXeEvmD_EEa412Vxi6Oscg_11_3"></a><a id="Tc_xZITWSirrUupL4XxbYlPog_11_9"></a><a id="Tc_0noa8KUZ-EeydN4Y6s5rVw_12_0"></a><a id="Tc_rsBfKu3j2ESJLf439rL4Eg_12_2"></a><a id="Tc_K-4n5G1hxkiSvSdMF8je6g_12_5"></a><a id="Tc_CtRCSdEdG0Kv70liGrQlQg_12_8"></a><a id="Tc_x9TwukhBLUeYLpDYHhvWtA_12_9"></a><a id="Tc_vpVNpbgo8UGT1XN3QPlg2A_12_11"></a><a id="_2938f744_d70d_4bc4_b8a7_99085a5f0d2c"></a><a id="Tc_UrgHc9UH3EyYRsVgScxSjQ_1_2"></a><a id="Tc_INiUPdY7_0-xcl0iAMw49g_2_2"></a><a id="Tc_N7AJ2zSUzk6TXWxGplEDeA_2_5"></a><a id="Tc_Q5M3vIvAuk2P3Sn7QylJSg_2_8"></a><a id="Tc_o2V3Sk2lrEWQrWQwHCVF_Q_3_2"></a><a id="Tc_RFf5qAr4tEyxRIzIYMofxg_3_5"></a><a id="Tc_-rJ_fwLYOUCSZHzXgMJivg_3_8"></a><a id="Tc_A5bz2AW6fkO8jmoD7zEd8g_4_2"></a><a id="Tc_eN7XyhGI9Uqh_wzNZE8P4w_4_5"></a><a id="Tc_8IoECAPk1UO4U7-myn1xLg_4_8"></a><a id="Tc_LsgEW_km0U-mQT5LmU_M0Q_5_2"></a><a id="Tc_pvcE0Sg34Ueh3evv9yjbgA_5_5"></a><a id="Tc_41FjX1-FnkaMX-trNycTbg_5_8"></a><a id="Tc_lZMXwNsQkk-PPLwLYf1mbg_5_11"></a><a id="Tc_ogZlVC5f-kqJQdy9SAc3Fg_6_0"></a><a id="Tc_gvNw9vtahkiSC7ifAE_PLg_7_0"></a><a id="Tc_pRtBLflrKU-0B-dZpT7Yzw_8_0"></a><a id="Tc_JkNUjX2re0Ky0t5XC7wCgg_8_2"></a><a id="Tc_hr8rvofMzUa3c9GxXHZbxw_8_5"></a><a id="Tc_PLMI52z6akW984t8xB_WvA_8_6"></a><a id="Tc_aF0p8MW_qE-FMagIQ2Q8NQ_8_8"></a><a id="Tc_-_d7sxq7LkGthJ_55DoY1g_8_9"></a><a id="Tc_RFAGfwWZyU-VgJGwtNPUdg_8_11"></a><a id="Tc_0Ld8n2XdpUisaPpD0njbYQ_9_0"></a><a id="Tc_muJvcybHmEOCyFTrEqetAQ_10_0"></a><a id="Tc_YuGBos3PsUqXJ0-gfCWi7A_10_3"></a><a id="Tc_I-Uqqbr-0U61-8Tyyh0YwQ_10_9"></a><a id="Tc_YZ3-QCU3D0W7EqY2kC2v4w_11_0"></a><a id="Tc_8geY6ZrtN0So6bCeTFGibA_11_2"></a><a id="Tc_gS2P1Zz6-UOCgjazs8XfKQ_11_5"></a><a id="Tc_DWs8y4dhzk69mkWUpAO7yw_11_8"></a><a id="Tc_U4JnvuC2FU2Wk2V9lE4oiA_11_9"></a><a id="Tc_vq9kARrTFE6mruDroZBMkQ_11_11"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_dW5D1xkJ20OZBpPfClEVGQ" continuedAt="Tb_dW5D1xkJ20OZBpPfClEVGQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">4. &#160;&#160;&#160;Financial Instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The following tables present information about the Company&#8217;s financial assets and liabilities that have been measured at fair value, and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value. Below is a summary of assets and liabilities measured at fair value on a recurring basis (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_gNuAENhEjEOCFEgrpyQDBw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">in&#160;Active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_rPxgg34LwEO0WW2sJngFGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_ejJF7_pGLU6rG7cu8qWdKg_8_3">1,853</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_pkomaENPeEK2hWjtfDxw1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_iF8NY5Z2gk2MCXG-ghsoPQ_8_12">1,853</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Reverse repurchase agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 5.75pt;">Short-term investments:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Reverse repurchase agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember_hXCdIxgZCEKI8TXwJzmvOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_QYrg_AegckOb_7S9W7y34A_11_6">39,000</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember__UO0W7ZwwECRTisRxchBwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_fHVUb9RCeUOcDUZwdB8dsQ_11_12">39,000</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Total </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_nIJM4yXrw0GzaRxtnzccAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_LCGmWgRFoUuYSC8yisHDyw_12_3">1,853</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Ds6LSP_EK0qTg90-h5fSyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_B8lipiEYf0ORqEy0OaA50w_12_6">39,000</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ar5rUSj2SE2rATotgrqFBg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_nnjtR_VoEEmqj07bE3027Q_12_12">40,853</ix:nonFraction> </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">in&#160;Active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_kwexEh1NbUCeMgI-knFDkQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_TAA908MwTEeX4F1UXCrQHw_8_3">22,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_ADdWV8SUt0GFgLe1JLOiEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_cgtD6ezwDUOgsEE_qMwPPw_8_12">22,999</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Short-term investments:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Reverse repurchase agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember_vZQWF0XPxEqvnvbV5-zrbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_vLy2BWpIbkW2jYh6Mj9ZhA_10_6">20,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember_xAFJqmrv7kOgE5MRCew76A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_MR8G242zn0G_VTIPast7ww_10_12">20,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_EQBCa0WuakeegbdgZGvTIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_ZapNEft3wUKY3XvvCeTUbQ_11_3">22,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_OSaVkTaBE0adbR5AtRVk7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_z4y6lNLy70WdhunU-yzAWA_11_6">20,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_x-MiuZtIH0yax5u7pxoruw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_mzgi4BwW8EOPd55KzWkQvw_11_12">42,999</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2021 and 2020, cash equivalents approximated their fair value due to their short-term nature.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5d519702_5e73_478f_9985_4bb1bda27d38"></a><a id="Tc_FTZNC9mqqEyGNo9rUX_bWg_1_2"></a><a id="Tc_E_m93TsMy0uifInn1E-g6w_2_0"></a><a id="Tc_gctBz-5xe0eYfgR3Dv0hHg_2_2"></a><a id="Tc_Ef5DAkWfMk6xmsz8Z2MI6g_3_0"></a><a id="Tc_0yMcZwv2OkuZg7x7VxaF7g_4_0"></a><a id="Tc_vQk7r21bxEiBcJ10YmNpiQ_5_0"></a><a id="Tc_rrbQ2HPLOEyw6tWl2AEkSA_6_0"></a><a id="Tc_7awm74H9-E-P8LF95RiH6g_6_2"></a><a id="Tc_y5L9rZf1vEiVVQtp0WTqHw_1_2"></a><a id="Tc_QX6dUrnE2UGKoAOU3DF6Fw_2_2"></a><a id="Tc_8dYf0sfQrEWkRfv4bUlVqw_4_0"></a><a id="Tc_0E2GkwIPokWkRQW7h_v9rg_4_2"></a><a id="Tc_qg_HUXTd2kqDnM14nUTTNg_4_3"></a><a id="Tc_jWcKMp2siEqUi1LUsypAhQ_5_0"></a><a id="Tc_ItBLZwWuj0avTYBQJJqVSg_5_2"></a><a id="Tc_tOxxBwnU9EK3qgQsHLbOTA_6_0"></a><a id="Tc_fBQP6YA60UqL7aEvj957uw_6_2"></a><a id="Tc_Qkx5REI7eEC9RJ4EBjzOJQ_6_3"></a><a id="Tc_KK8CdrV8uUixMs9n-342oA_7_0"></a><a id="Tc_dug8na9BlEm5KyJ4U8cUjQ_7_3"></a><ix:continuation id="Tb_dW5D1xkJ20OZBpPfClEVGQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">In connection with the Quellis Acquisition, the Company issued a warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_uWtVDAckP0qWnkjhGrfdWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_kqFTwJKg-E6TqmemqWZ1Sg">2,805</ix:nonFraction> shares of Series X Preferred Stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_uWtVDAckP0qWnkjhGrfdWg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_UaUA36OAn0O9BR4C_5Esqg">341.70</ix:nonFraction> per share. Upon stockholder approval of the Conversion Proposal, and reflecting the reverse stock split, the warrant became a warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_6_2_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BiFXZ622XUu96mNlkBimYA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_zv6xCPpmmE-p0NhwgYEztg">467,500</ix:nonFraction> shares of common stock at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="As_Of_6_2_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BiFXZ622XUu96mNlkBimYA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_RDH3PNrMsUmerFC7K5YQXA">2.10</ix:nonFraction>. This was originally accounted for as a liability until stockholder approval of the Conversion Proposal on June 2, 2021, at which point the warrant was reclassified to permanent equity. The warrant liability was valued based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The Company estimated the fair value of the warrant liability using Black-Scholes option-pricing models and assumptions that are based on the individual characteristics of the warrants on the valuation date, as well as assumptions including the fair value per share of the underlying security, the remaining contractual term of the warrant, risk-free interest rate, expected dividend yield and expected volatility of the price of the underlying security (in thousands).</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Tb_e4noWd8WK0m4TP9tN3av7g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times';line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Balance at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_3hVszi-haEizFq7jk2_Y4Q_2_3">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Issuance of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="Tc_a2losiSOoUGmSA5Qzb1lbw_3_3">4,332</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">(Decrease) increase in the fair value of the warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" sign="-" scale="3" id="Tc_6OgQNsnRtUmOaj1_lLDaHg_4_3">864</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:80.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Reclassification of warrant liability to additional paid in-capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-3" format="ixt:numdotdecimal" name="atxs:ReclassificationOfEquityClassifiedWarrants" scale="3" id="Tc_T_KDhAqSuUazQWywSK6rAA_5_3">3,468</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:80.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_yFRWEiOGbkugLExjZR-Feg_6_3">&#8212;</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><span style="font-family:'Times';line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The fair value of the warrants was based on the following assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_WzZMD00xoUq6XxErY881LA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times';line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Weighted-average expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_item_r9qJ3cWOSk6WrNQbeKvS6w" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_atxs_WeightedAverageExpectedVolatilityMember_nIDhOwmhF0mlBky65Ot7_w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Narr_LGGHwD3AFkCO5XLWhpPIfQ">89.1</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_item_r9qJ3cWOSk6WrNQbeKvS6w" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_atxs_WeightedAverageExpectedVolatilityMember_RP6DX7K3TUWlKsT4sun6pQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Narr_6lzpd1dkt0uQBPgi3yoWhQ">89.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_Y_7dFwAQRg-k-TRf_n8MTBtg" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_sf3s1jFkZ0aGtBYOQC3ukQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_HWx4v47bZkawkc1KJfnhzg">9.54</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_Y_7dFwAQRg-k-TRf_n8MTBtg" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_Ts_1LVNTNk69yxGtcPF9Zw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_H8QbXoc-Y027gPdINytjTw">9.88</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_item_r9qJ3cWOSk6WrNQbeKvS6w" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_u1VQyUC_pkKu65bhuNk4jw" decimals="5" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Narr_G0hIeSwk-k6wn8BDEL31Ow">1.064</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_item_r9qJ3cWOSk6WrNQbeKvS6w" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_BS6PVDaxDkyvam1jdK_ZbA" decimals="5" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Narr_r0eJlpQIYUKmtyXwanhpaQ">1.725</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_item_r9qJ3cWOSk6WrNQbeKvS6w" contextRef="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_Ulx_E0qOrUKkre8jvxb7rg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_16B_KM6l5EOZChoowa2_7w_7_2">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times';font-size:1pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times';line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_cf7564c6_486a_4c83_bd6e_04b2a54be477"></a><a id="Tc_JDBHONL4Jk-NSHFuaYixKA_1_5"></a><a id="Tc_Cv1gxmtTkEaRnGfmTvBjjw_1_8"></a><a id="Tc_OFa3JFNyQ02yQZSXepmlxA_2_2"></a><a id="Tc_G-XCx8SicEWgTbwYlQjzFA_2_5"></a><a id="Tc_q-ytHnSyZUeF90RRRUznpg_2_8"></a><a id="Tc_aYVSEplxWk-YYy6jMmdlhQ_3_2"></a><a id="Tc_LcBmOfJM8ki3Qax4NMQu5g_3_5"></a><a id="Tc_cNllXWvFN0i5pkmORNAo7A_3_8"></a><a id="Tc_LDNUdo9Yb0map9lDJPuDOQ_3_11"></a><a id="Tc_9R8l7WxNWk6goFMlTBAnSw_4_0"></a><a id="Tc_gKI_fQx7uk-g9cHUG4QLkw_5_0"></a><a id="Tc_dCOHkhQTvUqjNjWTI8l6XA_5_2"></a><a id="Tc_UjjhIFGLP0-aZGAMIt8Uww_5_5"></a><a id="Tc_fh2mI7HurESj23LOgKaIyw_5_6"></a><a id="Tc_Z0ZGHwgjgkm3NSxiUQi7pw_5_8"></a><a id="Tc_VN3RNyRpPEWXhN3natwglA_5_9"></a><a id="Tc_WJkSTuIbiE22h8R7pvknXw_5_11"></a><a id="Tc_rKJA0cJPuEW7f5363b3oqQ_6_0"></a><a id="Tc_QvQSiTKfvE-hkZE65rw0ng_6_2"></a><a id="Tc_xCVJVC-7Fk2bdDyMi8dQzA_6_5"></a><a id="Tc_oK373gwHzUyilyMdM0RDHA_6_6"></a><a id="Tc_OAbVGf3zx0qz-Gd4NkbOmA_6_8"></a><a id="Tc_laGpKIsULEW0tx8CIkmH8g_6_9"></a><a id="Tc_3gioD3y2-EGjP_2cUaj9-g_6_11"></a><a id="_0b0be2f0_f824_41ba_9659_28b8417fcb06"></a><a id="Tc_t_d3pqucP0269QrqX8Zf2g_1_5"></a><a id="Tc_CV-FODg5rUumRYaOK7mfWg_1_8"></a><a id="Tc_-IhPsU-gVEWVy3KLIH0wmg_2_5"></a><a id="Tc_2djWvHqbAECepIRKecudaw_2_8"></a><a id="Tc_D9xHUSP2pUSIsywO8C0Zzw_3_2"></a><a id="Tc_ftcUwiU53UiAQhGyuWvdWw_3_5"></a><a id="Tc__Wrbax9o-06g6N3t6kiU8Q_3_8"></a><a id="Tc_XVa1aC9HSUe14prOBmwmTw_3_11"></a><a id="Tc_EMmDRAOt7kCoP6NITXKzcQ_4_0"></a><a id="Tc_g2H7TNjmwUuV_V_wOIl9Ww_5_0"></a><a id="Tc_QjVvzznwV0mw-7JYGjrkFQ_5_2"></a><a id="Tc_0VBd9QyvWUS0XpnMtZDc-g_5_5"></a><a id="Tc_fmyGtkYy9UqMYW_SANj1vQ_5_6"></a><a id="Tc_tIIWkr8CtEaIjyc85REm6Q_5_8"></a><a id="Tc_v1f9AIzD-USc73XkPs8sMg_5_9"></a><a id="Tc_5WvExR-cOkqsb5Sqr_6O9g_5_11"></a><a id="Tc_KSwd2IyHj0etMOiGfM9Qjg_6_0"></a><a id="Tc_bTwh6i_tVECU5oPtN9WAsA_6_2"></a><a id="Tc_R-OTtm11bkOu5j8UXJj8pg_6_5"></a><a id="Tc_zuiR9TVT_kC51zxlVJJjhw_6_6"></a><a id="Tc_VnSugiqzKE2oI9HiM3b8ow_6_8"></a><a id="Tc_B6HkSL66_UmP8YkJulqVJg_6_9"></a><a id="Tc_tzR3vGhbDUGIAhfHcdFNlA_6_11"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="atxs:ShortTermInvestmentsTextBlock" id="Tb_fZH0JJ6350-IXvXS8eLFzA" continuedAt="Tb_fZH0JJ6350-IXvXS8eLFzA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">5.&#160;&#160;&#160;&#160;Short-Term Investments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:MarketableSecuritiesTextBlock" id="Tb_xZBYd1Mrk0GQAZld0K48EA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The following tables summarize the short-term investments held at December 31, 2021 and 2020 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Reverse repurchase agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember_U49V0Lt_9kyE9hrhO0s63A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss" scale="3" id="Tc_ZiCiOP_NikOXty0xxV4v6g_5_3">39,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember_U49V0Lt_9kyE9hrhO0s63A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" scale="3" id="Tc_EKZJdoRNdUe4YRaitH0Dfg_5_12">39,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_phPEO_62_0ef87zim7j66g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss" scale="3" id="Tc_GLfrKW7X3kyogkP8ErxHOA_6_3">39,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_phPEO_62_0ef87zim7j66g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" scale="3" id="Tc_QmAGBkQErUKAp9OSR7tFjA_6_12">39,000</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Reverse repurchase agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember_Cc8ygbB1FkS65q1Hq4bUmQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss" scale="3" id="Tc_0N91ntOmT06PlNqn6pHn7Q_5_3">20,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember_Cc8ygbB1FkS65q1Hq4bUmQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" scale="3" id="Tc_y0O2YW6go0WzCfy3oo_uNw_5_12">20,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_FkRLjZQMv0avRCk8lVRJrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss" scale="3" id="Tc_--DA5f8I_UWWRAzkkMVZ6w_6_3">20,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_FkRLjZQMv0avRCk8lVRJrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" scale="3" id="Tc_u56POnmy1EOGWwrUtAKwUw_6_12">20,000</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The contractual maturities of all short-term investments held at December 31, 2021 and 2020 were one year or less. There were <ix:nonFraction unitRef="Unit_Standard_instrument_UhpnDIC4ZkS1xbkw5nvJeQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="Narr_urGYfoEq6EGZVuwUlyjYPg">no</ix:nonFraction> short-term investments in an unrealized loss position at December 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Gross realized gains and losses on the sales of short-term investments are included in other income, net. Unrealized holding gains or losses for the period that have been included in accumulated other comprehensive income, as well as gains and losses reclassified out of accumulated other comprehensive income into other income, net were not material to the Company&#8217;s consolidated results of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_fZH0JJ6350-IXvXS8eLFzA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">During the years ended December 31, 2021 and 2020 all proceeds included in the Company&#8217;s cash flows related to maturities of underlying securities. The gains on proceeds of maturities of short-term investments were not material to the Company&#8217;s consolidated results of operations for the years ended December 31, 2021 and 2020.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_99f412ea_bd68_4409_b9e5_25149dc531c0"></a><a id="Tc_nNZ4mqGTeUKEYZ1a7qu9OQ_1_2"></a><a id="Tc_59rVQlFW4E6F9Q2XrigpIQ_1_5"></a><a id="Tc_VosGw39m-0--RBEzLBo6AQ_2_2"></a><a id="Tc_UzY4CwhfWUe7CYOVJf75ww_2_5"></a><a id="Tc_TcdzfeZ95kenk0V-MPelWQ_3_0"></a><a id="Tc_RdrLQoYxOkS08jGQBJHJbw_3_2"></a><a id="Tc_GglB7hk9oEOv3gdvUm0OYg_3_5"></a><a id="Tc_zBGHnnulyEKwhIrI22BhEA_4_0"></a><a id="Tc_N_m1IlukPk-N5yuCkaQv7A_5_0"></a><a id="Tc_qdrNIJGgd0ynAXM1WBs9Rw_5_6"></a><a id="Tc_xhwNgrsvVUCQZEaWwOMzPA_6_0"></a><a id="Tc_ItqdPBkbm0eLRx_LkWIPHg_7_0"></a><a id="Tc_8c0g5VTn2kyCVEKoS1E8vA_7_3"></a><a id="Tc_hXBwVQl2c0W7ChqEEFLdmA_8_0"></a><a id="Tc_33Twha7jGEesmjYL_vLqJA_8_2"></a><a id="Tc_vnSpDQ2iBEuJeehTwvElxw_8_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_MWC_N256qka_GUQYr2fZ_A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">6.&#160;&#160;&#160;&#160;Accrued Expenses</b></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_qHDeEq9_H02g6GmrZr5-wg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Accrued expenses consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_7-sYNR-UX0mIiwPwmgmaDA_3_3">1,958</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_A4D6-tvhN0W7WfJOq03pqQ_3_6">1,719</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued contracted costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="atxs:AccruedContractedResearchCostsCurrent" scale="3" id="Tc_uZfoqA5h0E6i7FKDYZbnGg_4_3">760</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="atxs:AccruedContractedResearchCostsCurrent" scale="3" id="Tc_Vq9S68l-lEiv8XaY3GxkKw_4_6">1,726</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_WQ88vFa7yUa2RN8EQh59Eg_5_3">295</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_yprTyGRWGkqgsVSIgO2jpQ_6_3">268</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_ouu2A80PfkyC3QUsphgBFA_6_6">356</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued severance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="atxs:AccruedSeveranceCurrent" scale="3" id="Tc_3Pl_FifSR0q2j3Ghlqxsdw_7_6">396</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_1BadB2SqyEqzPteTBN5GpA_8_3">3,281</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_b2Jk5XUK-E-LNnF7bNiJbQ_8_6">4,197</ix:nonFraction> </p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_OxpZi-t0dkWe-tk9LhLadg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">7. &#160;&#160;&#160;Commitments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">In November 2019, the Company entered into a sublease for office space which was classified as an operating lease. At inception of the lease, the Company recognized a lease <span style="-sec-ix-hidden:Hidden_HFiUTo3gw02FAUw2F3J6Qg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liability</span></span> and right-of-use asset of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_11_30_2019_KyDCpKfGVkmxJYefd9nrVQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_aa7Pa0pgUkiFWP_SL3wViQ">1.7</ix:nonFraction> million. The lease liability represents the present value of the remaining lease payments, discounted using the Company&#8217;s estimated incremental borrowing rate of <ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="As_Of_11_30_2019_KyDCpKfGVkmxJYefd9nrVQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Narr_k2VgQLfT8UeSzC3VpP4ptw">7.49</ix:nonFraction>%. The ROU asset represents the lease liability adjusted for any prepaid and accrued rent payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The lease is scheduled to expire in 2022. Future minimum payments required under the non-cancelable operating leases as of December 31, 2021 are $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="Narr_10rDyaujUU2y5gQdXXXv3Q">0.4</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Rent expense was $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr__V7l6r4jSEidArxRgwDxdA">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_2mHHxODVEUqzfYAMDZvAjA">0.8</ix:nonFraction> million for the years ended December 31, 2021 and 2020, respectively. Lease payments were $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="Narr_w0JrIsEVnE-iPx6hVuMZMQ">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="Narr_hWblTa2wjESO2g-HP_XIhg">1.5</ix:nonFraction> million for the years ended December 31, 2021 and 2020, respectively.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:PreferredStockTextBlock" id="Tb_r8gybHFNBk-Xj2mWRk9EWA" continuedAt="Tb_r8gybHFNBk-Xj2mWRk9EWA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">8.&#160;&#160;&#160;Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times';font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Preferred Stock </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Under the Company&#8217;s amended and restated certificate of incorporation, the Company has <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_ht1zfOOlGkaWh4B4VCN9xQ">5,000,000</ix:nonFraction> shares of preferred stock authorized for issuance, with a $<ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_UZaVqo1RbkWELvZv9bqrZQ">0.001</ix:nonFraction> par value per share. Preferred stock may be issued from time to time in <ix:nonFraction unitRef="Unit_Standard_series_lxqxSSbLPkuOU9DD2aDsAA" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="INF" format="ixt-sec:numwordsen" name="atxs:NumberOfPreferredStockSeries" scale="0" id="Narr__VP5Fv7C_k2f8CTLTn0B8Q">one</ix:nonFraction> or more series, each series to have such terms as stated or expressed in the resolutions providing for the issue of such series adopted by the board of directors of the Company. Preferred stock which may be redeemed, purchased or acquired by the Company may be reissued except as otherwise provided by law. As of December 31, 2021, the Company had <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_DkObyfSIekiIQkY2Gfmm_Q">31,455</ix:nonFraction> shares of Series X Preferred Stock outstanding. Each share of Series X Preferred Stock is convertible into <ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_quxm002mV0SdG3Yrnk30oA">166.67</ix:nonFraction> shares of common stock and therefore the number of shares of underlying common stock issuable upon conversion of the Series X Preferred Stock is <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_qDkLaGbwxUezfxf64fcSjA">5,242,501</ix:nonFraction>. Refer to Note 1 &#8211; &#8220;Organization and Operations&#8221; regarding the Company&#8217;s issuance of Series X Preferred Stock in January 2021 and February 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b3b4ad61_0413_40db_946f_706492d366dc"></a><a id="Tc_scKFXu9EgEmn3AD2Sdyh9g_1_0"></a><a id="Tc_2FqEXoNpYU6UQtriD3duyw_1_2"></a><a id="Tc_5K151lay1EK0tTYIKgtTDw_1_4"></a><a id="Tc_jypDJ2zpn023Rz9_A3_pvg_1_6"></a><a id="Tc_PzQ5SgAZlUyYtZDJPZSYLg_1_9"></a><a id="Tc_jhy9yASeTU2RSTshnVSw_Q_2_0"></a><a id="Tc_ZFXi3gmhq0a7BsiTC4b8zw_2_2"></a><a id="Tc_zMGawtlTYEy3oh5aNo71gw_2_6"></a><a id="Tc_xc8tjVuOjkyMuxdOpHvvrw_2_9"></a><a id="Tc_rffJm2AakU2qElyNOheBxg_3_0"></a><a id="Tc_JmZfutg3UUOK9tkgoIunBg_3_2"></a><a id="Tc_Sx6kwBKdyEWUpwiXJMW3JA_3_6"></a><a id="Tc_ovIs5GaGOU-QNmDCnVmWwA_3_9"></a><a id="Tc_L1CV7svqZU-OhB3M96Umjg_4_0"></a><a id="Tc_taBvzY9kj0--13W7mBNLww_4_2"></a><a id="Tc_c2pyHd6HUkqndzNw5OJeXA_4_6"></a><a id="Tc_Xm5HAeKIDUqpSJtYoRKMNw_4_9"></a><a id="Tc_uNlJ9KOwcUurszXSFQ-IoQ_5_0"></a><a id="Tc_Sh3QTDrGQECWaRqD8wEcDA_5_2"></a><a id="Tc_0RopWpmmNEqWGV8FNxWR0Q_5_6"></a><a id="Tc_U46b3xSKg0ywuPecNuRPnw_5_9"></a><a id="Tc_HM9vompfsEOXtztG7jp-5w_6_0"></a><a id="Tc_L8csmoMNl0KMZV1p5CFw6g_7_0"></a><a id="Tc_0xF9x264u0W7kUlvmZeNEw_7_6"></a><a id="Tc_qGhXLb9Bq0S5cz2h6eb6kw_8_0"></a><a id="_f6b37fce_e9e2_4593_9ec7_772c14e82d60"></a><a id="Tc_H7U9Zhph90mNJYvZksykew_1_2"></a><a id="Tc_Lk_fJWrwD02JGb6Koz7xpw_1_4"></a><a id="Tc_ZH-5X2e7wUakDvqdZLNLNA_2_2"></a><a id="Tc_o0Ao2_eQjE-EKLXXkRerZA_2_4"></a><a id="Tc_4sjodrvtmUGXTPo9kZqhuQ_3_0"></a><a id="Tc_Y6hKcXUpPEqPOgCen_cCvw_3_4"></a><a id="Tc_K4l-1dIEI0SY-RM2StEJJw_4_0"></a><a id="Tc_tBLxUOKbsE28l9e_jnkbEA_5_0"></a><a id="Tc_uhhu-1aNHUeaNO9YRKhOKg_6_0"></a><a id="Tc_NaoPZI2HwkSkI52uTWYCWg_7_0"></a><a id="Tc_qy0rpxLD40a1BnWbxR5Wvg_8_0"></a><ix:continuation id="Tb_r8gybHFNBk-Xj2mWRk9EWA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Outstanding Warrants</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_9DI--S7A0E-X9D3zNHpn_g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The following table presents information about warrants that are issued and outstanding at December 31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Year Issued</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity&#160;Instrument</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants&#160;Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date&#160;of&#160;Expiration</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_atxs_WarrantsIssuedIn2015Member_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_okImnMTN40m3e7LsnREh1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_gV_bFvbyUEqYKg6DlUsPJg_2_4">204</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_atxs_WarrantsIssuedIn2015Member_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_okImnMTN40m3e7LsnREh1Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_8Yz-SQutBUqrvGq5EIcpog_2_7">732.72</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3/30/2022</p></td></tr><tr><td style="vertical-align:bottom;width:32.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_atxs_WarrantsIssuedIn2018Member_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_-DDXhDsqjEaom3XeTK93Aw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_gZt7OXdwMEeeNAy_w1tYwg_3_4">699,962</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_atxs_WarrantsIssuedIn2018Member_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_-DDXhDsqjEaom3XeTK93Aw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_Q71mjZejsUuW9KFCsqY3pw_3_7">72.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">6/21/2023</p></td></tr><tr><td style="vertical-align:bottom;width:32.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_atxs_WarrantsIssuedIn2019Member_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_kZt19R6SjEmokrt5Mie7PA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_71yxC1uUakesH_JFBfcO7g_4_4">331,858</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_atxs_WarrantsIssuedIn2019Member_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_kZt19R6SjEmokrt5Mie7PA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_r9N6YD1JgECI28ijMMxhSQ_4_7">37.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2/7/2024</p></td></tr><tr><td style="vertical-align:bottom;width:32.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_atxs_WarrantsIssuedIn2021Member_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_yasr1KjcWk2xnQzdAy_KxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc__nDvxvT1DEi-pa_5Z4GW3w_5_4">498,356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_atxs_WarrantsIssuedIn2021Member_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_yasr1KjcWk2xnQzdAy_KxA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_a9zXd_PX9UGp4LwXkHiBbA_5_7">2.10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">12/14/2030</p></td></tr><tr><td style="vertical-align:bottom;width:32.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_LGPUGn5hf0Wh2Qca8q1eow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc__uUi08ce6ka0hCa86yRJfA_6_4">1,530,380</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:32.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Weighted average exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_5FuYIQyMO0KrQWYAQrHRTw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_KOPk6Z_30EWLmNOx9cFvbw_7_7">41.84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:32.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Weighted average life in years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_WeightedAverageMember_Q8_JfLkSZkujoq1ijmIZaA" format="ixt-sec:duryear" name="atxs:WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm" id="Tc_rQqVVEZYakWm2c6Z6TfV1w_8_9"> 4.05</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">As of December 31, 2021, the Company had <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_HJcLDxCdRUK4jLT42a52Uw">150,000,000</ix:nonFraction> shares of common stock authorized for issuance, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_DYdxQbnyH0ipkchEJ7G6RA">0.001</ix:nonFraction> par value per share, with <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_yAKTLf2PZEa0bs9MJHV7bA">13,016,955</ix:nonFraction> shares issued and <span style="-sec-ix-hidden:Hidden_0h6_9E_LE0OXUd1tw9ln2A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>. &#160;The voting, dividend and liquidation rights of holders of common stock are subject to and qualified by the rights, powers and preferences of the holders of any outstanding preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Reserved for Future Issuance</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Company has reserved for future issuance the following shares of common stock:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:ScheduleOfStockByClassTextBlock" id="Tb_b4y9nCTj0E6QWTMWD7-EiQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;"> December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;"> December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Series X Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_sOm9n5DduUa0agj5wT8qrQ_3_2">5,242,501</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Warrants for the purchase of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember_aICBK5MKZkuZVxp05YnVBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_-ew7vdgHJE6fdJ3BAawYuw_4_2">1,530,380</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember_kmFzwlwoEUWBR8fU7IbkTQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_yepDWw5EFUWHR9xQ1OM7ew_4_4">1,032,291</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Options outstanding to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_CommonStockOptionsOutstandingMember_7Vl-PK_cx0mTb1TT5TzDIQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_yfaTcXNE9EGntfvKdgEYxw_5_2">1,346,733</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_CommonStockOptionsOutstandingMember_Yjog7Avv4UWNzFd78N6wtA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_RY2WKxVa5kGcF6dKW-xp5w_5_4">227,846</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Options available for future issuance to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_CommonStockOptionsReservedMember_wmV-DoZ1iEel9yGD2br-TA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_vBvSGetEJ0-1K1nFDgo9Ag_6_2">1,633,736</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_CommonStockOptionsReservedMember_TAf-v0nKi0qS_WfrM_WRtg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_zCvOQQef306byqTZ_Fp4Wg_6_4">322,695</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Shares reserved for the employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_EmployeeStockPurchasePlan2015Member_qvrFhdUehU6nDMNnX5A56A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_BwR9lmsmoESRIAL-2OMWZQ_7_2">30,904</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_EmployeeStockPurchasePlan2015Member_5SuvAJwIjkuX5pWVQNdilA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_frt5etSUyk-1ELBmu9nS-w_7_4">24,825</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_ikORBBzrWkie8M1Z05Ur7w_8_2">9,784,254</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_q4-LSgTTvUuD-HF9bNOEOw_8_4">1,607,657</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">As of December 31, 2021, the Company also had <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_YWuoWZBz6EWMy_n8Iwuseg">31,455</ix:nonFraction> shares of Series X Preferred Stock outstanding. Each share of Series X Preferred Stock outstanding is convertible into <ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_tqLNaUdHBEOImNMAxeR7ew">166.67</ix:nonFraction> shares of the Company&#8217;s common stock, subject to certain beneficial ownership limitations at the holder&#8217;s option. See Note 1 &#8211; &#8220;Organization and Operations&#8221; for additional detail.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_rkV1KwPrMEqiMsFjXsyF5w" continuedAt="Tb_rkV1KwPrMEqiMsFjXsyF5w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">9. Stock Incentive Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Prior to the Company&#8217;s initial public offering in June 2015 (the &#8220;IPO&#8221;), the Company granted awards to eligible participants under its 2008 Equity Incentive Plan. In May 2015, the Company&#8217;s board of directors adopted and, in June 2015, the Company&#8217;s stockholders approved the 2015 Stock Incentive Plan, as amended and amended and restated since the IPO (&#8220;2015 Plan&#8221;), which became effective immediately prior to the effectiveness of the IPO. Subsequent to the IPO, option grants have been awarded to eligible participants only under the 2015 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The 2015 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units, stock appreciation rights and other stock-based awards. The Company&#8217;s employees, officers, directors and consultants and advisors are eligible to receive awards under the 2015 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Terms of stock option agreements, including vesting requirements, are determined by the Company&#8217;s board of directors, subject to the provisions of the applicable stock incentive plan. Options granted by the Company generally vest ratably over <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N1cnyjsfXUyGLlzflAry7w" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_GWxU2cDCLEWvrL1DD0VDCw">four years</ix:nonNumeric>, with a <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N1cnyjsfXUyGLlzflAry7w" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Narr_vnCmuenM60WRthxZZbR2pg">one-year</ix:nonNumeric> cliff, and options are exercisable from the date of grant for a period of <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N1cnyjsfXUyGLlzflAry7w" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_aRNejPiA2UmsISTYyWmj_Q">ten years</ix:nonNumeric>. For options granted through December 31, 2021, the exercise price or purchase price, as applicable, equaled the estimated fair value of the common stock as determined by the Company&#8217;s board of directors on the date of grant.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1a865cc1_10d5_488f_ac55_5ecbdf0640e9"></a><a id="Tc_aBHOxFrAIUOMtSLbjZ8_vg_1_7"></a><a id="Tc_hVOs3jYhU0S7_-hlsIbeLA_2_7"></a><a id="Tc_A7K8cP4LYU6aI9cSRa0-Qw_3_4"></a><a id="Tc_3LzWTBULdkuV1Eeud20DZA_3_7"></a><a id="Tc_YYkhTjxcY02PAUbob67eWw_3_9"></a><a id="Tc_-JMFBlTFdkGnas3-sNXiKw_4_4"></a><a id="Tc_nPiMxUPAk02nnAUKFmiGlA_4_7"></a><a id="Tc_U5QkI5GK606S5cvoyNR22w_4_9"></a><a id="Tc_XBkLRTwpPUG_ndHmXoA7Sw_5_2"></a><a id="Tc_3vc33TFirUmadUoAr62qiw_5_4"></a><a id="Tc_XT8FmGnyfEOXvuzglBoQow_5_7"></a><a id="Tc_ubebNrq9UkOxojtca3lPug_5_9"></a><a id="Tc_UegQQmAos0eQGYsPUU5omA_6_0"></a><a id="Tc_SnS9YH70CUqlPBjQaj2SJg_6_4"></a><a id="Tc_JuPkTNKafEqc8WBCaWETRQ_6_9"></a><a id="Tc_HjubsTTMtUu09pm2B9LYCA_6_10"></a><a id="Tc_BvrTtB9Jkky7R0MpYB7wpA_7_0"></a><a id="Tc__iiEojHWekGyXDlgRp_irQ_7_4"></a><a id="Tc_cqgpl4zZS0WoYFP0Q-w8vg_8_0"></a><a id="Tc_xMTf8JEDfk6TaBEVOkfgWg_8_4"></a><a id="Tc_zcvlhXxekEa2t1bdObgy8A_9_0"></a><a id="Tc_VlHw6mfug0Sc00FxJYU_TQ_9_4"></a><a id="Tc_qD7dUdA3hky76mtu42m_4A_10_0"></a><a id="Tc_mb2ye44VxkWCfc3m0YGbew_10_4"></a><a id="Tc_-WNUYMbSN0G5yKSxRov79w_11_0"></a><a id="Tc_QzsLvO53DkK4fLtAIYxuKw_11_4"></a><a id="Tc_5QX5NhhFZkqTdSgyvnB91Q_12_0"></a><a id="Tc_7W6iGtPgikivE7fLifnEPQ_12_4"></a><a id="Tc_qeaQu3Fx0UenB9z524aEJg_12_9"></a><a id="Tc_I8pw62BQkkeCLtldouvnbg_13_0"></a><a id="Tc_ocOliqdHO0mHuHmPtMZ3Lg_13_4"></a><a id="Tc_ytGf88A-t0Cq59o6CYk5Rw_13_9"></a><a id="_a778345f_8864_43bb_b5cb_0b591396535e"></a><a id="Tc_RHULecfCnEqC6nUVfsrakg_1_2"></a><a id="Tc_R51uOR48k0Wmm1q1lJhikw_2_2"></a><a id="Tc_SkI30nE4n0qDgJWMMSgaWg_2_4"></a><a id="Tc_Br2ajiQh-EeM5qIMz8DhwA_3_0"></a><a id="Tc_9XKKfz_jV0KqTHxF6Uf0Lg_3_2"></a><a id="Tc_ueltdrr6DkOZA97JMFKIqg_3_4"></a><a id="Tc_GQ9zmRhr2UWvTz5aspYPDQ_4_0"></a><a id="Tc_7Bfp6NsoXUSNCbsccsxGkQ_4_2"></a><a id="Tc_m4cC1SyHqkicfkN-39rLnw_4_4"></a><a id="Tc_Dn0WzZJgb02gsuk9hH_JOg_5_0"></a><a id="Tc_GOBjpO7njESEvzB_tBCmSQ_5_2"></a><a id="Tc_mXBSymrYTUi9gJfgz72iFw_5_4"></a><a id="Tc_JpoWzoWy-E2ng6SQaUp8aA_6_0"></a><ix:continuation id="Tb_rkV1KwPrMEqiMsFjXsyF5w_cont1" continuedAt="Tb_rkV1KwPrMEqiMsFjXsyF5w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">A summary of the Company&#8217;s stock option activity and related information for employees and non-employees follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_C5PeJ1Y27kWED6OHJrd4nA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average&#160;Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term&#160;(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outstanding at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_SKqAPrO9S0O0MRYJ79uomQ_6_2">227,846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_wgO8-DkfyESxjf0UWhyrLg_6_5">68.25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_ciNtMqhPUUmBUQEgziSZvA_6_7"> 8.13</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_MTFEmDDjl0uTmB8aFkmDAA_7_2">1,156,646</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_frNfIIa3v0eUUf8vuGACDg_7_5">15.91</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Assumed in Quellis Acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="INF" format="ixt:numdotdecimal" name="atxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross" scale="0" id="Tc_5iYJVk_2sEeH8oLWfE6Ufw_8_2">55,414</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="2" format="ixt:numdotdecimal" name="atxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageExercisePrice" scale="0" id="Tc_52ZHvgIXFkuhE71vIrrtgw_8_5">1.73</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_7qWynpdfc0OMgYJNAJDBPw_9_2">10,470</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_N5VpfHuVp0aBhIYDcQQHzw_9_5">2.10</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Cancelled or forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="Tc_HlJ0BD5puUqatd2hpBxqZg_10_2">81,196</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_QgO8m0hLwUWFtyiFJ7o12A_10_5">48.13</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Tc_yXE24xwskke41sO_Uy1pZA_11_2">1,507</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_AnQFkNFTY0eWGPOiul4SHw_11_5">100.85</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_YRMy9ncmB0S7DTpWAyw4sg_12_2">1,346,733</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_RwCENR2lNEyCMiUeg0l8mA_12_5">22.25</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_k3uOuouF3kGBUTqnV_VJoQ_12_7">9.02 </ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_3DsDo4bPr0KD4qxW23NH_g_12_10">168,181</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vested and exercisable at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="Tc_OvlDYshhPEqPY1fGOptC8w_13_2">135,412</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="Tc_UnAtTxzunkqtEU7Bn6Meiw_13_5">72.76</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="Tc_RQHPa57lbUyEeE4VbMdvKw_13_7">7.19 </ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="Tc_dQhEyfob_EmZY6X_JedUTg_13_10">77,798</ix:nonFraction> </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The total intrinsic value of options exercised in the years ended December 31, 2021 and 2020 was $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N1cnyjsfXUyGLlzflAry7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Narr_FyHiYLX9w0Cj2NeRy89t5g">45</ix:nonFraction> thousand and $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Xk2KOEZoqU-rq0ONLV8kug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Narr_cAl_bb3vv0uoaCVFBWKc2A">29</ix:nonFraction> thousand, respectively. The weighted-average grant date fair value of options granted to employees and non-employees for the years ended December 31, 2021 and 2020 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N1cnyjsfXUyGLlzflAry7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_TI2np-E0Wk62_44U0kPLSw">9.82</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Xk2KOEZoqU-rq0ONLV8kug" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_9RsKgG6m3EWu38mVghVtjQ">3.81</ix:nonFraction>, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">At December 31, 2021, the total unrecognized compensation expense related to unvested stock option awards was $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_DpksmxD47kGvcyVVnTBAsA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_kvw1OZ1yxkWuVPe43tCJdg">10.8</ix:nonFraction> million. The Company expects to recognize that cost over a weighted-average period of approximately <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N1cnyjsfXUyGLlzflAry7w" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_4D7PnAu4t0qMbl-ZIr2rqw">2.9</ix:nonNumeric> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The fair value of stock options granted to employees and non-employees was estimated using the Black-Scholes option-pricing model based on the following assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_G7FDm3TvqkyRcZxbuUQdyw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:36.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Weighted-average expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dRehDxBmQEyeX74Fi2n2Og" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="Narr_5NdYP56XFka0neb55rFuAA">69.28</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember__jh8k2B4zk-VJ3ifpBRqMA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="Narr_qQXuc5ibPkKhdxfayKB2bg">71.32</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pMusOm4pFUy12JHZQXtkNQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="Narr_TZ6nP6p23k6d_Qh9RwkICA">75.51</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_o2nWgMXB4EmLCnwUmgGn8g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="Narr_ktgD588EFU-k7H4UXJt43Q">82.08</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dRehDxBmQEyeX74Fi2n2Og" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_i0_6qWIEFESbAmQK6d9y4Q">5</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember__jh8k2B4zk-VJ3ifpBRqMA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_n37L2Ybt80qNGm-RINaOow">6.25</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pMusOm4pFUy12JHZQXtkNQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_Xetajwq_sE28wqnQT6vo6Q">5.50</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_o2nWgMXB4EmLCnwUmgGn8g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_5qvgreZDgEyCVGa35erR7g">6.25</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dRehDxBmQEyeX74Fi2n2Og" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_t0XYB6ANzUyQskJWFvhRyQ">0.42</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember__jh8k2B4zk-VJ3ifpBRqMA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_lwgDdkn2NUuxvwm2Lei6Vg">1.36</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pMusOm4pFUy12JHZQXtkNQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_MdXr8TFEEU-4fMzuiIE2jQ">0.37</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_o2nWgMXB4EmLCnwUmgGn8g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_xMK5EhArDUartqXfCyWx2A">1.51</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_cJ3CgYnDGUi3QmsEwhi6Lw_6_2">0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_wfihcv0fTUWjIJtbt_xWvw_6_4">0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Volatility</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Due to the lack of company-specific historical and implied volatility data of its common stock, the Company does not have relevant historical data to support its expected volatility. As such, the Company has used a weighted average of expected volatility based on the volatilities of a representative group of publicly traded biopharmaceutical companies. For purposes of identifying representative companies, the Company considered characteristics such as number of product candidates in early stages of product development, area of therapeutic focus, and length of trading history. The expected volatility was determined using an average of the historical volatilities of the representative group of companies for a period equal to the expected term of the option grant. The Company intends to continue to consistently apply this process using the same representative companies until a sufficient amount of historical information regarding the volatility of the Company&#8217;s own share price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_rkV1KwPrMEqiMsFjXsyF5w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Expected Term</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company uses the &#8220;simplified method&#8221; to estimate the expected term of stock option grants. Under this approach, the weighted-average expected life is presumed to be the average of the contractual term (ten years) and the vesting term (generally four years) of the Company&#8217;s stock options, taking into consideration multiple vesting tranches. The Company utilizes this method due to lack of historical exercise data and the plain-vanilla nature of the Company&#8217;s share-based awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Risk-Free Rate</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The risk-free rate was based on the yield curve of United States Treasury securities with periods commensurate with the expected term of the options being valued.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_aeccbf6c_47f6_4b34_8eef_d0ee2c2c5bbd"></a><a id="Tc_lFIPw0hF80m7APb4SW2N9g_1_2"></a><a id="Tc_ba7Z8ST0v0O46dkGBAQ0rw_2_2"></a><a id="Tc_9ushXQOcqU6D3BLjfGhZaw_2_4"></a><a id="Tc_CCu9uNq35EqUEhXFM5xgDA_3_0"></a><a id="Tc_FqjmX5FklEOmQhKxZaPBgA_3_3"></a><a id="Tc_RT4vANDo40eX8N7UmI_JDg_3_5"></a><a id="Tc_xcMUdvBLZEaqZsqw55Ec6g_4_0"></a><a id="Tc_IW2KG7mhokGEkmu3d_keng_5_0"></a><a id="Tc_XP1RdHUSF0KqL3CTi1Tkyw_6_0"></a><a id="Tc_t2pRmQYNEU6e6LQhmD5zzQ_6_4"></a><a id="Tc_XJD2PkgSpUysB-Px01NVjQ_7_0"></a><a id="Tc_W4kYqvEtMEi3XtwhnchCRw_8_0"></a><a id="Tc_l4_gFlA_o0y-mLYqqDRMoA_9_0"></a><a id="Tc_OvYFTvcKCkqcSNgLyNcXcQ_10_0"></a><a id="Tc_fOHzkCYyIk-_QOlCidbEXQ_10_3"></a><a id="Tc_tp7mOj1aiEOdVeLBF9BMGg_10_5"></a><a id="_37107141_7c52_4e3e_8d44_c12898ad9171"></a><a id="Tc_9ilvsXSA1kC8vDh7-HSRYw_1_2"></a><a id="Tc_9vIf3GXZuUK9G_qYvm2XxQ_2_2"></a><a id="Tc_lR70uHC47kGlQtjwVYOj0w_2_5"></a><a id="Tc_t7hYSj_BF0GRfaISNBQDPw_3_0"></a><a id="Tc_QdHgNLrz-EukEv5YW6-tpQ_4_0"></a><a id="Tc_v4l3pO0l-0-WSI-3ikJxOw_4_2"></a><a id="Tc_56f8_VrfJUylzB4WdZme7w_4_5"></a><a id="Tc_TESTHQ-jek6BKGOOnvcnmw_5_0"></a><a id="Tc_Aby4bgu28EGkNJSDYJgAtA_6_0"></a><a id="Tc_0DvzWg1rZ0GNtOWaeH675Q_7_0"></a><a id="Tc_7RYtEM4RDkSC-RsFQtbo0g_8_0"></a><a id="Tc_bJ7gmlWIJE2Oz_Glbe9ZYA_9_0"></a><a id="Tc_XO4US4_xPEG0TCwi6YWehw_10_0"></a><a id="Tc_87m2jPHy3Eu8Hpcb8n6KUg_11_0"></a><a id="Tc_J7NdubM-qkm_bC5RCGTTeQ_12_0"></a><a id="Tc_PUeWTDGJVEmo39nf6fiHLg_13_0"></a><a id="Tc_UPP5ghNnW0mt8SsAeBD-Cg_14_0"></a><a id="Tc_CPweTjgwcEW0KPwGuOe1-A_14_2"></a><a id="Tc_xDHTUW0rXk-jdUhe9qLRjQ_14_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_H_D1Lyi1hUKAbrtKuyJ4Aw" continuedAt="Tb_H_D1Lyi1hUKAbrtKuyJ4Aw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">10. &#160;&#160;&#160;Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">For the years ended December 31, 2021 and 2020, the Company did not record a provision for federal or state income taxes as it has incurred cumulative net operating losses since inception.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">A reconciliation of the U.S. statutory income tax rate to the Company&#8217;s effective tax rate is as follows for the years ended December 31, 2021 and 2020:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_7-KzmH_j3UWicq4y118wcQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Federal income tax (benefit) at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_rRZfHuBxmE-gnfp2UX3eOg_3_2">21.00</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_aSHxo3oh8kiqVzW4MOIRCA_3_4">21.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" scale="-2" id="Tc_D4PKRzo8ZUahr3V1ZzuA_A_4_2">0.25</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" scale="-2" id="Tc_MrrMCWAcvEOO81iK46Fedg_4_4">0.41</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Federal research and development credits and adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="Tc_YAl9cOvVG0y1FjxPYnW2lA_5_2">0.44</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="Tc_HdeRVCpLREakzRr-mpP_fQ_5_4">2.78</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Nondeductible research costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="Tc_i-Aw0NLFSkCU5BZNp2a4Ow_6_2">17.75</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">State income tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_iRsgKDPP4kWsovvlY65Tvg_7_2">0.82</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_pRKf_QXkOU-IRXfqiwIZ5g_7_4">6.03</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="Tc_2bsHNZB6XEq34D_K77sGZg_8_2">0.01</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="Tc_EdeoR-ezc0uNT1oL9aTeow_8_4">0.37</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_WG8qs2YXrE2cGp2oQCWzdA_9_2">4.27</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_tsFI4XdyCEOobcRBlVaQDA_9_4">29.77</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="4" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_RrMRTlfmqkeMM3RabdkXxQ_10_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="4" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_xrARKlLLLUaD348LW_mTFA_10_4">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_PwtgeIJO_0WUy40UUhmsag" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company&#8217;s deferred tax assets consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Deferred tax assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_thAZGxdCq0-F7b4qWd81ng_4_3">75,849</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_4BuPfKhy1UynbDs5LeEFdQ_4_6">65,373</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" scale="3" id="Tc_QPH2tcUZDEO-USnNLMztYQ_5_3">10,063</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" scale="3" id="Tc_s2TxZ7OpbEemZsB26kjunw_5_6">9,273</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Capitalized research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_UYndZ5WxEUeh_mn4cnrcUQ_6_3">139</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_7hnq8ZTku0SjqF80243G9g_6_6">482</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Capitalized legal expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" scale="3" id="Tc_MNyT-wB5AUys2pKnQ3KjaA_7_3">1,048</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" scale="3" id="Tc_HQPrAwB4dE6DtFH2pPW8QA_7_6">1,070</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="atxs:DeferredTaxAssetsLeaseLiability" scale="3" id="Tc_K2FUREceh0qKtbbJEGTYYQ_8_3">99</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="atxs:DeferredTaxAssetsLeaseLiability" scale="3" id="Tc_fftcyLR-6U6NeCCdzaNn9Q_8_6">284</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_MXj9c2J3hkeQy1jN03eJpg_9_3">1,977</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_GTGgrpQxkUuZA4ySbsgYAg_9_6">1,648</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_8XWHXBt5JEypgtfGdsu-BA_10_3">89,175</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_A_aY-CmUPUO4q8H-w-ZU7w_10_6">78,130</ix:nonFraction> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Deferred tax liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">ROU asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="atxs:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" id="Tc_1gMwyyBFV0-421eIqQul8w_12_3">107</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="atxs:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" id="Tc_IOu6E2adlkCzTA5vxMG51Q_12_6">262</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_fAcJf82DPUGxW7J7YMDavA_13_3">89,068</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_FdRifXvQsUW3oQbgeiigiw_13_6">77,868</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="Tc_AvR4MZrHpUmDD7K56v71vg_14_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="Tc_FOOv3DCSV0eqD7xmcy6SRA_14_6">&#8212;</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company recorded an increase to the valuation allowance of $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_512XCHamW0OCe5mCN-3tDg">11.2</ix:nonFraction> million during the year ended December 31, 2021 due primarily to the federal and state net operating losses and tax credits generated. The Company recorded an increase to the valuation allowance of $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_LuTL3tD2UEGwWeAuMTswaw">11.1</ix:nonFraction> million during the year ended December 31, 2020 which was also primarily due to the federal and state net operating losses and tax credits generated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_H_D1Lyi1hUKAbrtKuyJ4Aw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences representing net future deductible amounts become deductible. Due to the Company&#8217;s history of losses and expectation of future losses, the deferred tax assets were fully offset by a valuation allowance at December 31, 2021 and 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">As of December 31, 2021, the Company had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_elNRkz91iE-s8vhvuVnSvw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_ixncRcg-S0ykui3-70teBg">279.4</ix:nonFraction> million of federal and $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_5XqYaukrUUaJdZ71ko0png" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_oks06ihO6UO7l2arv_4aow">271.8</ix:nonFraction> million of state net operating loss respectively, which may be available to offset future taxable income. Federal net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_atxs_TaxYears2023Through2039Member_nyPtDfbQzUmCkbPiwwfF7A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_3xq4aA-JPUeAI0gYY9Tpew">150.6</ix:nonFraction> million and state net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxPeriodAxis_atxs_TaxYears2023Through2039Member_PESuIbi88Em2aHygNgW-mg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_BjI-a79Ki06fhB8TP2brRg">271.8</ix:nonFraction> million will expire at various dates from 2028 through 2041. Federal net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_atxs_IndefiniteTaxYearsMember_lPRNGMy2XEaPTJLtd05Mcg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_5_Kg20_0e0aFbZbaKMn0Rg">128.8</ix:nonFraction> million can be carried forward indefinitely. The Company had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_elNRkz91iE-s8vhvuVnSvw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_DzsAPy4Dok6qjCQ3pC5RUw">8.1</ix:nonFraction> million of federal and $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_5XqYaukrUUaJdZ71ko0png" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_zVA7Z0kAEEu9FufMink6aQ">2.4</ix:nonFraction> million of state tax credit carryforwards available to reduce future tax liabilities as of December 31, 2021, which will expire at varying times through the year 2041.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), provides for a limitation of the annual use of net operating losses and other tax attributes (such as research and development tax credit carryforwards) following certain ownership changes (as defined by the Code) that could limit the Company&#8217;s ability to utilize these carryforwards. At this time, the Company has not completed a study to assess whether an ownership change under Section 382 of the Code has occurred, or whether there have been multiple ownership changes since the Company&#8217;s formation, due to the costs and complexities associated with such a study. The Company may have experienced various ownership changes, as defined by the Code, as a result of past financing transactions. Accordingly, the Company&#8217;s ability to utilize the aforementioned carryforwards may be limited. Additionally, U.S. tax laws limit the time during which these carryforwards may be applied against future taxes. Therefore, the Company may not be able to take full advantage of these carryforwards for federal or state income tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">As of December 31, 2021 and 2020, the Company did not have any significant unrecognized tax benefits. The Company had not accrued interest or penalties related to uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The federal and state income tax returns are generally subject to tax examinations for the tax years ended December 31, 2018 through December 31, 2021. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state taxing authorities to the extent utilized in a future period. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" id="Tb_8GTh2ocIyEagXeEtp2L5sQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">11.&#160;&#160; Defined Contribution Benefit Plan </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company sponsors a 401(k) retirement plan, in which substantially all of its employees are eligible to participate. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company did not provide any contributions to this plan during the years ended December 31, 2021 or 2020.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g" name="us-gaap:SubsequentEventsTextBlock" id="Tb_2VIRgvmNX0OImU0En7cMAA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">12.&#160;&#160; Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Operating Lease </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">On January 28, 2022, the Company entered into a sublease agreement (the &#8220;Sublease&#8221;) with Grant Thornton LLP (the &#8220;Sublandlord&#8221;), for office space. &#160;The Sublease will commence on the latest to occur of (i) May 1, 2022, (ii) the receipt of the landlord&#8217;s consent to the Sublease and (iii) the date on which the Sublandlord delivers full and exclusive possession of the premises to the Company as set forth in the Sublease and will end on July 31, 2024. The Sublease will increase the future minimum payments described in Note 7 from approximately $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_7e7qdCjybEKUxSl2FPkQ9g">0.4</ix:nonFraction> million to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ" contextRef="As_Of_1_28_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dDqegR-RH0S_9dr4Q4C-Mw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_gpfraDknvEGcQm0ZlwmtiQ">1.8</ix:nonFraction> million.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_204e83b4_65d6_4a55_bb53_3bf7dde478ad"></a><a id="_cp_blt_2_1132"></a><a id="_cp_blt_2_1130"></a><a id="_cp_blt_2_1128"></a><a id="SIGNATURES_944344"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><span style="font-size:6pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.89%;"><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;">Astria Therapeutics,&#160;Inc.</p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;">Date: March 10, 2022</p></td><td style="vertical-align:top;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;">By: </p></td><td style="vertical-align:top;width:46.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;">/s/ Jill C. Milne</p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;">Jill C. Milne</p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;">President and Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">We, the undersigned directors and officers of Astria Therapeutics,&#160;Inc. (the &#8220;Company&#8221;), hereby severally constitute and appoint Jill C. Milne and Noah Clauser, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of us might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant in the capacities and on the dates indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_cp_text_4_649"></a><a id="_cp_text_4_651"></a><a id="_cp_text_1_653"></a><a id="_cp_text_1_659"></a><a id="_cp_text_1_661"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:45.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:23.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.38%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">/s/ Jill C. Milne</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.38%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">President and Chief Executive Officer and Director <br />(Principal Executive Officer)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">March 10, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Jill C. Milne</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">/s/ Noah Clauser</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.38%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Chief Financial Officer and Treasurer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">March 10, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Noah Clauser</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">(Principal Financial Officer, Principal Accounting <br />Officer)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">/s/ Kenneth Bate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.38%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Kenneth Bate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Chairman</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">March 10, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">/s/ Joanne Beck</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.38%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Joanne Beck</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">March 10, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">/s/ Frederick C. Callori</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.38%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Frederick C. Callori</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">March 10, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">/s/ Hugh Cole</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.38%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Hugh Cole</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">March 10, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">/s/ Michael Kishbauch</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.38%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Michael Kishbauch</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">March 10, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">/s/ Gregg Lapointe</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.38%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Gregg Lapointe</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">March 10, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">/s/ Jonathan Violin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.38%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Jonathan Violin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">March 10, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>atxs-20211231xex4d3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/10/2022 09:04:27 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 4.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES REGISTERED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">As of December 31, 2021, Astria Therapeutics, Inc. (&#8220;we&#8221;, &#8220;us&#8221; or the &#8220;Company&#8221;) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;): our common stock, $0.001 par value per share.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital stock. This description is based upon, and is qualified by reference to, our restated certificate of incorporation, our amended and restated by-laws and applicable provisions of Delaware corporate law. You should read our restated certificate of incorporation and amended and restated by-laws, which are filed as exhibits to the Annual Report on Form 10-K of which this exhibit is a part, for the provisions that are important to you.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.25pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Our authorized capital stock consists of 150,000,000 shares of common stock, $0.001 par value per share, and 5,000,000 shares of preferred stock, $0.001 par value per share.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.25pt;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Voting Rights.</i><font style="font-size:11pt;">&#160;&#160;&#160;&#160;Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, except that unless otherwise required by law, holders of our common stock are not entitled to vote on any amendment to our restated certificate of incorporation that relates solely to the terms of one or more outstanding series of preferred stock, if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more such other series, to vote thereon pursuant to our restated certificate of incorporation. Holders of our common stock do not have cumulative voting rights.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.25pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">An election of directors will be decided by a plurality of the votes cast by the stockholders entitled to vote on the election at a duly held stockholders&#8217; meeting at which a quorum is present. All other questions will be decided by a majority in voting power of the votes cast by the holders of all of the shares of stock present or represented and voting affirmatively or negatively on such matter at a duly held meeting of stockholders at which a quorum is present, except when a different vote is required by law, our restated certificate of incorporation or our amended and restated by-laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.25pt;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Dividends.</i><font style="font-size:11pt;">&#160;&#160;&#160;&#160;Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend or other rights of then outstanding preferred stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.25pt;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Liquidation and Dissolution.</i><font style="font-size:11pt;">&#160;&#160;&#160;&#160;In the event of our liquidation or dissolution, the holders of common stock are entitled to receive all assets of the Company available for distribution to our stockholders after the payment of all debts and other liabilities and subject to any preferential or other rights of any then outstanding preferred stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.25pt;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Other Rights.</i><font style="font-size:11pt;">&#160;&#160;&#160;&#160;Holders of common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Effects of Authorized but Unissued Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Our authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval, subject to any limitations imposed by the listing requirements of the Nasdaq Global Market. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could make it more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise. In addition, if we issue preferred stock, the issuance could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Provisions of Our Restated Certificate of Incorporation and Amended and Restated By-laws and Delaware Law That May Have Anti-Takeover Effects</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Delaware law, our restated certificate of incorporation and our amended and restated by-laws contain provisions that could have the effect of delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.25pt;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Staggered Board; Removal of Directors.</i><font style="font-size:11pt;">&#160;&#160;&#160;&#160;Our restated certificate of incorporation and our amended and restated by-laws divide our board of directors into three classes with staggered three-year terms. In addition, a director is only able to be removed for cause and only by the affirmative vote of the holders of at least 75% of the votes that all of our stockholders would be entitled to cast in an annual election of directors. Any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, is only able to be filled by vote of a majority of our directors then in office. The classification of our board of directors and the limitations on the removal of directors and filling of vacancies could make it more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of our company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.25pt;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Stockholder Action by Written Consent; Special Meetings.</i><font style="font-size:11pt;">&#160;&#160;&#160;&#160;Our restated certificate of incorporation provides that any action required or permitted to be taken by our stockholders must be effected at a duly called annual or special meeting of our stockholders and may not be effected by any consent in writing by our stockholders. Our restated certificate of incorporation and our amended and restatd by-laws also provide that, except as otherwise required by law, special meetings of our stockholders can only be called by our chairman of the board, our chief executive officer or our board of directors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.25pt;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Advance Notice Requirements for Stockholder Proposals.</i><font style="font-size:11pt;">&#160;&#160;&#160;&#160;Our amended and restated by-laws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of persons for election to our board of directors. Stockholders at an annual meeting are only able to consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors or by a stockholder of record on the record date for the meeting who is entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder&#8217;s intention to bring such business before the meeting. These provisions could have the effect of delaying until the next stockholder meeting stockholder actions that are favored by the holders of a majority of our outstanding voting securities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.25pt;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Delaware Business Combination Statute.</i><font style="font-size:11pt;">&#160;&#160;&#160;&#160;We are subject to Section 203 of the General Corporation Law of the State of Delaware. Subject to certain exceptions, Section 203 prevents a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with any &#8220;interested stockholder&#8221; for </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">three years following the date that the person became an interested stockholder, unless the interested stockholder attained such status with the approval of our board of directors or unless the business combination is approved in a prescribed manner. A &#8220;business combination&#8221; includes, among other things, a merger or consolidation involving us and the &#8220;interested stockholder&#8221; and the sale of more than 10% of our assets. In general, an &#8220;interested stockholder&#8221; is any entity or person beneficially owning 15% or more of our outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity or person.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.25pt;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Amendment of Certificate of Incorporation and By-laws.</i><font style="font-size:11pt;">&#160;&#160;&#160;&#160;The General Corporation Law of the State of Delaware provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#8217;s certificate of incorporation or by-laws, unless a corporation&#8217;s certificate of incorporation or by-laws, as the case may be, requires a greater percentage. Our amended and restated by-laws may be amended or repealed by a majority vote of our board of directors or the affirmative vote of the holders of at least 75% of the votes that all of our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 75% of the votes that all of our stockholders would be entitled to cast in any annual election of directors is required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our restated certificate of incorporation described in this section and above under &#8220;&#8212;</font><i style="font-size:11pt;font-style:italic;">Staggered Board; Removal of Directors</i><font style="font-size:11pt;">&#8221; and &#8220;&#8212;</font><i style="font-size:11pt;font-style:italic;">Stockholder Action by Written Consent; Special Meetings</i><font style="font-size:11pt;">.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.25pt;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Exclusive Forum Selection.</i><font style="font-size:11pt;">&#160;&#160;&#160;&#160;Our restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware (or if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for (1) any derivative action or proceeding brought on behalf of the Company, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or employees to the Company or our stockholders, (3) any action asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware or our restated certificate of incorporation or our amended and restated by-laws, or (4) any action asserting a claim against the Company governed by the internal affairs doctrine. Although our restated certificate of incorporation contains the choice of forum provision described above, it is possible that a court could rule&#160;that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>3
<FILENAME>atxs-20211231xex10d19.htm
<DESCRIPTION>EXHIBIT 10.19
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/10/2022 09:04:37 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.19</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXECUTION VERSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:180.95pt;margin:0pt 0pt 0pt 227.85pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SUBLEASE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">THIS SUBLEASE AGREEMENT (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Sublease Agreement</u>&#8221;) made as of January 28, 2022 (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Effective Date</u>&#8221;), by and between <b style="font-weight:bold;">Grant Thornton LLP, </b>an Illinois limited liability partnership (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Sublandlord</u>&#8221;), and <b style="font-weight:bold;">Astria Therapeutics, Inc., </b>a Delaware corporation (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Subtenant</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">W I T N E S S E T H:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">WHEREAS, Sublandlord is the tenant under that certain Lease dated December 31, 2012 by and between BROOKFIELD PROPERTIES 75 STATE CO. LLC, a Delaware limited liability company as landlord (hereinafter referred to as &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Landlord</u>&#8221;), and Sublandlord, as tenant (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Lease</u>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">WHEREAS, pursuant to the Lease, Landlord leased to Sublandlord certain premises (the &#8220;Premises&#8221;), a portion of which Premises consists of approximately 17,136 rentable square feet of office space located on the fourteenth (14th) floor of that certain office building located at 75 State Street, Boston, Massachusetts 02110 (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Building</u>&#8221;) as more particularly described on <u style="text-decoration:underline;text-decoration-color:#000000;">Exhibit A</u> attached hereto and hereby made a part hereof (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Subleased Premises</u>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">WHEREAS, Sublandlord wishes to sublease the Subleased Premises to Subtenant, and Subtenant wishes to sublease the Subleased Premises from Sublandlord, subject to and in accordance with the terms hereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">NOW, THEREFORE, for and in consideration of the premises, the rents reserved hereunder, and certain other good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">1.</font></font><u style="text-decoration:underline;text-decoration-color:#000000;">Subleased Premises</u>. Sublandlord hereby subleases the Subleased Premises to Subtenant, and Subtenant hereby subleases the Subleased Premises from the Sublandlord, subject to the terms and conditions of this Sublease Agreement. Sublandlord represents to Subtenant that, to the best of Sublandlord&#8217;s knowledge and belief, the floor plans attached hereto are accurate and complete in all material respects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">2.</font></font><u style="text-decoration:underline;text-decoration-color:#000000;">Term of Sublease; Early Access</u>. The term of this Sublease Agreement shall commence on the latest to occur of (i) May 1, 2022, (ii) receipt of Landlord&#8217;s consent to this Sublease Agreement pursuant to Section 14 of this Sublease Agreement (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Landlord&#8217;s Consent</u>&#8221;), and (iii) the date on which Sublandlord delivers full and exclusive possession of the Subleased Premises to Subtenant in the Delivery Condition (as that term is hereinafter defined) (the last to occur of (i), (ii) and (iii) above being referred to herein as the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Commencement Date</u>&#8221;), and shall end on July 31, 2024 (or on such earlier date as such term may sooner cease or expire as hereinafter provided). For purposes of this Sublease Agreement, &#8220;Delivery Condition&#8221; means the Subleased Premises are vacant, broom clean, free of all personal property, equipment, furniture (other than the <u style="text-decoration:underline;text-decoration-color:#000000;">Available Furniture</u> (as hereinafter defined)) and debris, with all HVAC and air handling systems in good working order and condition. &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Available Furniture</u>&#8221; shall mean the furniture listed on Exhibit C attached hereto. Notwithstanding the foregoing, the Commencement Date shall not be deemed to have occurred unless and until Subtenant has had reasonable access to the Subleased Premises for at least fourteen (14) days immediately prior to the anticipated Commencement Date, for the sole purpose of taking measurements, installing furniture, fixtures,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXECUTION VERSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">equipment and telephone/data lines and systems provided (i) Subtenant may not use the Subleased Premises during such access period for the purpose of conducting its business, (ii) Subtenant shall have obtained any necessary approvals and/or consents for proposed alterations to the extent required by the Lease, and (iii) all other provisions of this Sublease Agreement (exclusive of obligations to pay Rent or Electrical Costs, but expressly including, but not limited to, insurance coverage) shall apply to all such activities. Sublandlord shall use commercially reasonable efforts to cause the Commencement Date to occur on or before May 1, 2022. If for any reason the Commencement Date does not occur on or before May 15, 2022, Subtenant shall be entitled to two (2) additional days of abated Rent for each day in the period commencing on May 15, 2022 and ending on the day immediately preceding the Commencement Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Lease</u>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font>Subtenant acknowledges that it has reviewed and is familiar with all of the terms, covenants and conditions of the Lease. Sublandlord represents and warrants to Subtenant as follows: (i) the Lease attached hereto as Exhibit B is a true and correct copy thereof, (ii) the Lease has not been amended, modified or supplemented and is in full force and effect, (iii) Sublandlord holds the tenant&#8217;s interest under the Lease and has not subleased all or any portion of the Subleased Premises, nor has Sublandlord transferred, assigned, pledged, hypothecated, mortgaged, encumbered or granted a security interest in all or any portion of the Lease, and (iv) to Sublandlord&#8217;s knowledge neither Landlord nor Sublandlord is in default under the Lease (and no circumstances exist which, with the passage of time or giving of notice, or both, could ripen into a default by Landlord or Sublandlord under the Lease), and (v) there are no alterations or improvements or other work in the Subleased Premises which are required to be removed, nor is there any restoration of the Subleased Premises required at the expiration or earlier termination of this Sublease Agreement or the Lease. Sublandlord covenants as follows: (v) to reasonably cooperate with Subtenant in obtaining any required consents, approvals from Landlord, (w) to use reasonable efforts to cause Landlord to perform or fulfill its obligations under the Lease; (x) to timely perform all of its obligations under the Lease; (y) not to modify or amend the Lease without Subtenant&#8217;s prior written consent should such modification or amendment alter or affect this Sublease or Subtenant&#8217;s rights, benefits, obligations or liabilities hereunder, and (z) not to voluntarily cancel or terminate the Lease. Except as provided herein, all of the terms, covenants and conditions of the Lease are incorporated herein and made a part hereof as if fully set forth herein but only to the extent the same pertain to the Subleased Premises, any related uses of the Building or appurtenances to the Subleased Premises (including, but not limited to, common areas and parking areas). From and after the Commencement Date, Subtenant assumes and agrees to perform, observe, and comply with all of the terms, covenants and conditions on Sublandlord&#8217;s part to be performed, observed and complied with under the Lease, as &#8220;Tenant&#8221; thereunder subject to the terms of this Sublease Agreement. As between Sublandlord and Subtenant, in the event of a conflict between the terms of the Lease and the terms of this Sublease Agreement, the terms of this Sublease Agreement will control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font>This Sublease Agreement is expressly made subject to and subordinate to all of the terms, covenants and conditions of the Lease and to all mortgages, deeds of trust, deeds to secure debt, leases and other documents of record as of the Effective Date. This subsection (b) shall be self-operative. Subtenant shall, within ten (10) days after written request from Sublandlord, execute and deliver to Sublandlord such certificates and other instruments as Sublandlord may reasonably request to confirm such subordination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font>Subtenant&#8217;s obligation to pay Rent (as that term is hereinafter defined), Electrical Charges, Real Estate Taxes, and Operating Expenses and any additional charges with</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXECUTION VERSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">respect to the Subleased Premises shall be limited to the amounts specified in this Sublease Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font>Subtenant shall in no case have any rights in respect of the Subleased Premises greater than Sublandlord&#8217;s rights under the Lease as it relates to the Subleased Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font>Subtenant agrees that Sublandlord shall not be required to perform any of the covenants and obligations of Landlord under the Lease. This is a sublease and Subtenant shall look solely to Landlord for the furnishing of the services and the performance of repairs and the obligations of Landlord under the Lease. In no event shall Sublandlord be liable for the non-performance of any obligation of the Landlord under the Lease including but not limited to any default by Landlord under the Lease. Subtenant understands that the supplying of heat, light, water, air conditioning, electricity and other utilities, janitorial, cleaning, window washing and elevator services, the provision of any other services, the construction or replacement of any improvements, and building maintenance and repair are the obligations of Landlord and that Sublandlord has no control with respect to the same, shall have no responsibility in connection therewith, and shall not be liable in any way with respect to the failure of or interference with any of such services or facilities. Sublandlord, at Subtenant&#8217;s sole cost and expense, shall promptly send such notices to (but shall not be obligated to file suit against) Landlord as Subtenant may reasonably require, and reasonably cooperate with Subtenant, to secure Landlord&#8217;s performance under the Lease. If, however, Sublandlord shall at Subtenant&#8217;s direction commence any proceeding or take any other action to enforce the obligations of Landlord insofar as such obligations relate to the Subleased Premises, or if Subtenant takes any such action pursuant to this Section or if Subtenant delivers or receives any notice or communication under this Sublease Agreement, Subtenant agrees to indemnify, defend (with legal counsel acceptable to Sublandlord), and hold harmless Sublandlord from and against any liabilities, actual costs or actual expenses (including reasonable attorneys&#8217; fees) which Sublandlord may incur in connection therewith or by reason thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font>Sublandlord shall not have the right to modify the Lease in any manner that would impact the rights or obligations of the Subtenant without Subtenant&#8217;s consent, which consent shall not be unreasonably withheld, conditioned or delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(g)</font></font>Sublandlord shall perform its obligations as Tenant under the Lease to the extent necessary to avoid any adverse impact upon this Sublease, the Subleased Premises or Subtenant&#8217;s use and enjoyment of the Subleased Premises or rights, obligations or liabilities hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Whenever the consent or approval of Sublandlord is required, Subtenant agrees to promptly request such written consent or approval from Landlord and Subtenant agrees to (1) promptly provide any information or additional documentation reasonably requested by Landlord, at its sole cost and expense, (2) be solely responsible for any additional reasonable obligations or liabilities related or attributable to said request or consent (if granted by Landlord), and (3) be solely responsible for any reasonable costs and expenses related or attributable to such request or consent (if granted by Landlord) (including, but not limited to, Sublandlord&#8217;s reasonable attorneys&#8217; fees related to any additional documentation memorializing the same, increased insurance obligations, or surrender obligations), all of which shall be memorialized in a written amendment to the Sublease Agreement if such consent is granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Occupancy</u>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font>Subtenant shall use and occupy the Subleased Premises solely for the Permitted Use as defined in the Lease and by Section 5.1 Permitted Use of the Lease and in</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXECUTION VERSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">accordance with the rules and regulations as provided in the Lease, including, but not limited to, the exhibits to the Lease, as the same may be from time to time amended by Landlord upon delivery of same to Subtenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font>Subtenant covenants that it will occupy the Subleased Premises in accordance with the terms of the Lease and will not take any action or allow any of its employees, representatives, agents, affiliates or contractors to take any action that would create a default by Sublandlord under any provision of the Lease or any of the rules and regulations as provided in the Lease including, but not limited to, the exhibits to the Lease, as the same may be from time to time amended by Landlord, and upon delivery to Subtenant, with respect to the Subleased Premises, Building or Property, or render Sublandlord liable for any loss, cost, damage or liability in connection with any provisions of the Lease. Subtenant further covenants and agrees to indemnify, defend and hold Sublandlord harmless from and against any loss, cost (including, but not limited to, any reasonable legal expenses, fees and costs incurred by counsel selected by Sublandlord), expense, lien, claim or liability arising out of, by reason of, or resulting from, Subtenant&#8217;s failure to perform or observe any of the terms and conditions of the Lease. Any other provision in this Sublease Agreement to the contrary notwithstanding, Subtenant shall pay to Sublandlord as additional rent hereunder any and all sums which Sublandlord may be required to pay the Landlord arising out of, by reason of, or resulting from Subtenant&#8217;s failure to perform or observe one of more of the terms and conditions of the Lease. Except arising as a result of the negligence or tortious act or omission of Subtenant, or any of Subtenant&#8217;s agents, officers, contractors, employees, servants, invitees or another person (other than Sublandlord) claiming by or through or under Subtenant, Sublandlord covenants and agrees to indemnify, defend and hold Subtenant harmless from and against any loss, cost (including, but not limited to, any reasonable legal expenses, fees and costs incurred by counsel selected by Subtenant, expense, lien, claim or liability arising out of, by reason of, or resulting from, Sublandlord&#8217;s failure to perform or observe any of the terms and conditions of the Lease and any breach of or default under this Sublease Agreement. Any other provision in this Sublease Agreement to the contrary notwithstanding, Sublandlord shall pay to Subtenant by offset of rent due hereunder any and all sums which Subtenant may be required to pay Landlord arising out of, by reason of, or resulting from Sublandlord&#8217;s failure to perform or observe one of more of the terms and conditions of the Lease or this Sublease Agreement. The provisions here of shall survive the expiration or earlier termination of this Sublease Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font>If any &#8220;Tenant&#8217;s Default&#8221; described in Section 13. 1 of the Lease shall occur in respect of Subtenant or Subtenant&#8217;s property, or if Subtenant shall default in the payment of Rent, Electrical Costs, or additional rent hereunder or in the performance or observance of any of the terms, covenants and conditions of this Sublease Agreement or of the Lease on the part of Subtenant to be performed or observed, Sublandlord shall be entitled to exercise any and all remedies available at law or in equity and/or any or all of the rights and remedies reserved by Landlord in the Lease, including but not limited to those rights and remedies provided by Sections 6.3 Landlord&#8217;s Recapture Right, 11.1 Landlord&#8217;s Right and 13.2 Landlord&#8217;s Default of the Lease, which Sections are hereby incorporated herein by reference as if fully set forth herein and as if Sublandlord were the &#8220;Landlord&#8221; and Subtenant were the &#8220;Tenant.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font>If Subtenant shall default in the performance of any of its obligations hereunder, and such default shall remain uncured beyond applicable notice and cure periods, Sublandlord at its option may perform such obligations and, if necessary, enter the Subleased Premises for such purpose. Subtenant shall pay to Sublandlord, upon demand, the amount of all reasonable costs and expenses reasonably incurred by Sublandlord in the performance of any such obligations. Any action taken by Sublandlord pursuant to this Section shall not constitute a waiver of any of Sublandlord&#8217;s other rights and remedies hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 73.9pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXECUTION VERSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Security Deposit; Rent; Electrical Costs</u>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font>Subtenant has deposited with Sublandlord the sum of One Hundred Sixty-Two Thousand Seven Hundred Ninety-Two and No/100 Dollars ($162,792.00) in the form of a letter of credit issued by Pacific Western Bank substantially in the form attached hereto as Exhibit D in favor of Sublandlord (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Security Deposit</u>&#8221;) to secure Subtenant&#8217;s performance of its obligations hereunder. If Subtenant defaults hereunder and such default remains uncured beyond any applicable notice or cure period, then Sublandlord may, without prejudice to Sublandlord&#8217;s other remedies, apply part or all of the Security Deposit to the extent reasonably necessary cure Subtenant&#8217;s default. If Sublandlord so uses part or all of the Security Deposit, Subtenant shall, within thirty (30) days after written demand, pay Sublandlord or provide a letter of credit to Sublandlord in the amount necessary to restore the Security Deposit to its original amount. If Sublandlord assigns its interest in the Lease, the Security Deposit shall be transferred to the assignee and Sublandlord shall be relieved of any further liability in relation to the Security Deposit with respect to matters first arising after the date of such assignment. Upon the termination of this Sublease Agreement, Sublandlord may use the Security Deposit to cure any existing and continuing defaults of Subtenant. In the event all or any portion of the Security Deposit remains after paying to cure such default, the remaining amount shall be returned to Subtenant within sixty (60) days after the expiration or earlier termination of this Sublease Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font>Subtenant shall pay to Subland)lord (or at the direction of Sublandlord, and Landlord provided to Subtenant in writing, Subtenant shall pay directly to Landlord) a fixed annual base rent beginning on that date which is thirty (30) days following the Commencement Date (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Rent Commencement Date</u>&#8221;) in the amounts set forth below and after the first such payment, on the twenty fifth (25th) day of the month preceding the month for which the installment is due (e.g., the installment of base rent for June is payable on May 25), subject to appropriate proration for any partial month during the term of this Sublease Agreement (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Rent</u>&#8221;):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:26.4pt;"><td style="vertical-align:bottom;width:25.25%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><div style="height:26.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">RENTAL PERIOD*</b></p></div></div></td><td style="vertical-align:bottom;width:24.92%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><div style="height:26.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ANNUAL BASIC RENT</b></p></div></div></td><td style="vertical-align:bottom;width:25.04%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><div style="height:26.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">MONTHLY PAYMENT</b></p></div></div></td><td style="vertical-align:bottom;width:24.78%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><div style="height:26.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PER SQUARE FOOT</b></p></div></div></td></tr><tr><td style="vertical-align:top;width:25.25%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From the Commencement Date through the day immediately preceding the Rent Commencement Date</p></td><td style="vertical-align:top;width:24.92%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$0</p></td><td style="vertical-align:top;width:25.04%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$0</p></td><td style="vertical-align:top;width:24.78%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$0</p></td></tr><tr style="height:26.3pt;"><td style="vertical-align:top;width:25.25%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><div style="height:26.3pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From June 1, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">through May 31, 2023</p></div></div></td><td style="vertical-align:top;width:24.92%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><div style="height:26.3pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$651,168.00</p></div></div></td><td style="vertical-align:top;width:25.04%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><div style="height:26.3pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$54,264.00</p></div></div></td><td style="vertical-align:top;width:24.78%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><div style="height:26.3pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$38.00</p></div></div></td></tr><tr style="height:26.4pt;"><td style="vertical-align:top;width:25.25%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><div style="height:26.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From June 1, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">through May 31, 2024</p></div></div></td><td style="vertical-align:top;width:24.92%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><div style="height:26.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$670,703.04</p></div></div></td><td style="vertical-align:top;width:25.04%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><div style="height:26.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$55,891.92</p></div></div></td><td style="vertical-align:top;width:24.78%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><div style="height:26.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$39.14</p></div></div></td></tr><tr style="height:26.4pt;"><td style="vertical-align:top;width:25.25%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><div style="height:26.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From June 1, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">through July 31, 2024</p></div></div></td><td style="vertical-align:top;width:24.92%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><div style="height:26.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$115,125.36</p></div></div></td><td style="vertical-align:top;width:25.04%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><div style="height:26.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$57,562.68</p></div></div></td><td style="vertical-align:top;width:24.78%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><div style="height:26.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$40.31</p></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">*the Rental Periods may be adjusted in accordance with the establishment of the Commencement Date, it being the intent of the parties hereto that each Rental Period after the Rent Commencement Date shall be for the number of months set forth in the &#8220;Rental Period&#8221; column.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font>Subtenant shall be responsible for all electrical costs including air handling units and other HVAC equipment associated with the furnishing of electricity to the Subleased Premises and to any exterior Subtenant signage (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Electrical Costs</u>&#8221;). Electrical Costs shall (1) accrue commencing on the Commencement Date, (2) be payable in monthly installments at the same time Rent payments are due, and (3) be based on the separate sub-meters for the Subleased Premises and invoices provided to Subtenant by the applicable utility provider.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXECUTION VERSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font>Subtenant shall not be obligated to pay to Sublandlord any amounts in addition to the Rent, Electrical Charges (if not paid directly to the utility provider), Operating Expenses, and Real Estate Taxes except as set forth in this Sublease Agreement. For the avoidance of doubt, Subtenant will not be obligated to pay any amounts attributable to increases in the Real Estate Taxes and Operating Expenses during the term of the Sublease Agreement, which shall be governed by Article VIII Real Estate Taxes of the Lease and Article IX Operating Expenses of the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font>Subtenant shall also pay to Sublandlord, within 30 days following written request, any actual additional charges payable by Sublandlord to Landlord related to Subtenant&#8217;s operations hereunder (e.g., any review fees, indemnities, and any charges incurred as a result of Subtenant&#8217;s After Hours Request (as hereinafter defined)). Subtenant shall not be obligated to pay any fee with respect to obtaining Landlord consent of the transaction contemplated by this Sublease Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font>All Rent, except as set forth in subsection (e) immediately above, and Electrical Charges, shall be payable without demand, and without offset, counterclaim or setoff in immediately available United States funds. The obligation to pay Rent and Electrical Charges shall be independent of Sublandlord&#8217;s obligations hereunder and shall survive the termination of this Sublease Agreement. If the Rent Commencement Date is on a day other than the first day of a calendar month, Rent and Electrical Charges for such fractional monthly period shall be prorated. All Rent and Electrical Charges shall be paid via electronic payment or by check per the instructions below or at such other place or in such manner as Sublandlord may designate by written notice to Subtenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:90%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:60%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Wiring/ACH Instructions:</p></td><td style="vertical-align:bottom;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BMO Harris Bank N.A.</p></td></tr><tr><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chicago, Illinois</p></td></tr><tr><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ABA (routing/transit) #: [ABA (routing/transit #] </p></td></tr><tr><td style="vertical-align:top;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Swift Code (for non-US clients): [Swift Code (for non-US clients)</p></td></tr><tr><td style="vertical-align:top;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Account Name: [Account Name]</p></td></tr><tr><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Account Number: [Account Number]</p></td></tr><tr><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Wire Reference Required: [Wire Reference]**</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Check Instructions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:90%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.82%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Lockbox Address*</p></td><td style="vertical-align:top;width:50.17%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">UPS/Overnight Delivery Only Address</p></td></tr><tr><td style="vertical-align:top;width:49.82%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">GRANT THORNTON LLP</p></td><td style="vertical-align:top;width:50.17%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Conduent c/o BMO Harris</p></td></tr><tr><td style="vertical-align:top;width:49.82%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">33562 Treasury Center</p></td><td style="vertical-align:top;width:50.17%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Grant Thornton LLP - [Lockbox number]</p></td></tr><tr><td style="vertical-align:top;width:49.82%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Chicago, IL 60694-3500</p></td><td style="vertical-align:top;width:50.17%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">141 W. Jackson Boulevard, Suite 1000</p></td></tr><tr><td style="vertical-align:top;width:49.82%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.17%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Chicago, IL 60604</p></td></tr><tr><td style="vertical-align:top;width:49.82%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.17%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">(877) 895-3278</p></td></tr><tr><td style="vertical-align:top;width:49.82%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Check remittance reference required: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">[Check remittance reference]**</p></td><td style="vertical-align:top;width:50.17%;border-bottom:1px solid #010101;border-left:1px solid #010101;border-right:1px solid #010101;border-top:1px solid #010101;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Check remittance reference required: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">[Check remittance reference]**</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">*The address in the Lockbox Address column should only be used when using the U.S. Postal Service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">**Unidentified payments will be delayed in application to outstanding balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">6.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Insurance; Waivers</u>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXECUTION VERSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font>During the term of this Sublease Agreement, Subtenant shall maintain commercial general liability insurance, physical damage insurance, comprehensive automobile insurance, builders all risk insurance, and all other insurance Landlord may reasonably require, all in accordance with the terms, conditions and provisions of the Lease. Subtenant shall name Sublandlord (and such other entities as are required by Landlord and of which Subtenant has received prior notice) as an additional insured on each such insurance policy and shall provide Sublandlord with certificates of insurance certifying said coverage prior to taking possession of the Subleased Premises, all in accordance with the insurance provision of the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font>Whether the loss or damage is due to the negligence of either Sublandlord or Subtenant, their agents or employees, or any other cause, Sublandlord and Subtenant do each hereby release and relieve the other, their agents, and their employees from responsibility for, and waive their entire claim of recovery for, any loss or damage to the real or personal property of either located anywhere in the Building, to the extent that such loss or damage arises out of or is incident to the occurrence of any of the perils which are actually covered by their respective insurance policies in effect at such time or which were required to be in effect at such time by the terms of this Sublease Agreement. Each party shall use commercially reasonable efforts to cause its insurance carriers to consent to the foregoing waiver of rights of subrogation against the other party. Notwithstanding the foregoing, no such release shall be effective unless the aforesaid insurance policy or policies shall expressly permit such a release or contain a waiver of the carrier&#8217;s right to be subrogated. In the event that any insurance carrier denies its consent to the foregoing waiver of rights of subrogation, the affected party shall promptly advise the other party hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">7.</font></font><u style="text-decoration:underline;text-decoration-color:#000000;">Late Payments</u>. Other remedies for nonpayment of rent notwithstanding, if Rent and/or Electrical Charges due hereunder is not received by Sublandlord on or before the date the same is due and such nonpayment continues for five (5) business days following written notice, then (i) such delinquent sums shall bear interest at a rate equal to twelve percent (12%) per annum, commencing with the due date and continuing through the day preceding the date on which payment of such delinquent sum with interest thereon is paid and (ii) in consideration of the administrative and other expenses incurred by Sublandlord as a result of the late payments, Subtenant shall pay to Sublandlord a late charge equal to $500.00 for the third (3rd) such late payment in any twelve (12) month period. Sublandlord and Subtenant agree that such late charge is intended to compensate Sublandlord for additional administrative charges and other damages incurred by Sublandlord on account of such late payment and not as a penalty. Sublandlord and Subtenant agree that the actual damages to be suffered by Sublandlord in such event shall be difficult, if not impossible to ascertain, and that such late charge is a reasonable estimate of such charges and damages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">8.</font></font><u style="text-decoration:underline;text-decoration-color:#000000;">Sublandlord&#8217;s Improvements; Subtenant Alterations; Sublandlord Representations</u>. Subtenant acknowledges and agrees that it is leasing the Subleased Premises on an &#8220;AS-IS, WHERE IS&#8221; basis, without any representations or warranties of any kind, except as set forth herein. The Available Furniture is available for Subtenant&#8217;s use during the term of the Sublease. Subtenant shall not be responsible for any damage to or loss of the Furniture and shall leave the Furniture in the Subleased Premises at the end of the Term in its then &#8220;as is&#8221; condition. Subtenant further acknowledges and agrees that it is solely responsible for the maintenance, repair, and/or replacement of any air conditioning handling units or other HVAC equipment located in the Subleased Premises during the term of this Sublease Agreement and, upon the expiration or early termination of this Sublease Agreement, shall deliver the same to Sublandlord in good and operable condition. To Sublandlord&#8217;s knowledge the HVAC systems are in good working order and condition. Subtenant shall not make any alterations, modifications or improvements to the Subleased Premises except in accordance with the Lease and this Sublease Agreement. All</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXECUTION VERSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">alterations, decorations, installations, additions or improvements in or to the Subleased Premises shall be made in a good, workmanlike and lien-free manner at Subtenant&#8217;s sole cost and expense and shall comply with all of the terms and conditions of the Lease, this Sublease Agreement and/or any conditions related to any consent granted by Landlord with respect to any such Alterations. At the written request of Landlord, delivered at the time Landlord approves the same, any such alterations, decorations, installations, additions or improvements made by Subtenant shall be removed by the Subtenant upon the termination of this Sublease Agreement, and Subtenant shall repair any damage caused by such removal, at Subtenant&#8217;s cost and expense. Subtenant, at Subtenant&#8217;s sole cost and expense, shall cause the Subleased Premises and any signage returned to Sublandlord at the expiration or earlier termination of the Sublease Agreement in substantially the same condition, reasonable wear and tear and damage by casualty excluded, Subtenant shall, at its sole cost and expense, remove all furniture, fixtures, and equipment from the Subleased Premises, and Subtenant shall, at its sole cost and expense, remove any Lines (as defined in the Lease) in accordance with Section 14.27 of the Lease should Landlord elect to have such items removed from the Premises. For avoidance of doubt, Subtenant shall not be responsible for the removal of Sublandlord made Alterations to the Premises (including GT&#8217;s Initial Work) which constitute &#8220;above standard office improvements&#8221; (as such phrase is defined in the Lease).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Sublandlord represents and warrants the following is true and correct as of the date hereof (and shall be deemed repeated as of the Commencement Date):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font>Sublandlord is the tenant under the Lease and has the capacity to enter into this Sublease Agreement with Subtenant, subject to Landlord&#8217;s consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font>The Lease attached hereto as <u style="text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u> is a true, correct, and complete copy of the Lease, is in full force and effect, and has not been further modified, amended, or supplemented except as expressly set out therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font>Sublandlord has not received any notice, and has no actual knowledge, of any default by Sublandlord or Landlord under the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">9.</font></font><u style="text-decoration:underline;text-decoration-color:#000000;">Casualty or Eminent Domain</u>. The effect of a partial or total destruction of the Subleased Premises by fire or other casualty and the effect of taking all or any part of the Subleased Premises for any public or quasi-public use by virtue of the exercise of the power of eminent domain, or by private purchase in lieu thereof, shall be subject to and governed by Article XII Casualty: Eminent Domain of the Lease, respectively. Without limiting the generality of the foregoing, in the event that the Lease is terminated pursuant to either of said sections, this Sublease Agreement shall terminate contemporaneously therewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">10.</font></font><u style="text-decoration:underline;text-decoration-color:#000000;">Assignment and Subletting.</u> The Assignment and/or Subletting of the Sublease by the Subtenant shall be governed by Article VI Assignment and Subletting of the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">11.</font></font><u style="text-decoration:underline;text-decoration-color:#000000;">Sublandlord</u>. The term &#8220;Sublandlord&#8221; as used in this Sublease Agreement means only the Tenant under the Lease at the time in question, so that if the Lease shall be assigned, such assignor shall be thereupon released and discharged from all covenants, conditions and agreements of Sublandlord hereunder, but such covenants, conditions and agreements shall be binding upon each successor assignee until thereafter assigned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">12.</font></font><u style="text-decoration:underline;text-decoration-color:#000000;">Indemnity</u>. Subject to the waiver of subrogation provisions of this Sublease Agreement, Subtenant shall indemnify, defend (with legal counsel reasonably acceptable to Sublandlord), and hold harmless Sublandlord, its direct and indirect subsidiaries and affiliates and its respective officers, directors, shareholders and employees (individually and collectively,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXECUTION VERSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Sublandlord Indemnitee</u>&#8221;) against and save them harmless from and against all claims, losses, reasonable costs, damages, expenses and liabilities, including, without limitation, reasonable attorneys&#8217; fees and disbursements, which Sublandlord Indemnitee may incur or pay out (including, without limitation, to Landlord) by reason of (i) any accidents, damages or injuries to persons or property occurring by reason of or directly related to Subtenant&#8217;s (or Subtenant&#8217;s officers&#8217;, partners&#8217;, employees&#8217;, agents&#8217;, customers&#8217; and/or invitees&#8217;) use or occupancy of the Subleased Premises, and occurring in, on or about the Subleased Premises or the Building (except to the extent the same shall have been caused by Sublandlord&#8217;s negligence or willful misconduct) which expressly includes the fitness room, (ii) any default hereunder on Subtenant&#8217;s part, (iii) any work done by Subtenant after the date hereof in or to the Subleased Premises except if done by Sublandlord, (iv) any negligent or willful act or omission on the part of Subtenant and/or its officers, partners, employees, agents, customers and/or invitees, or any person claiming through or under Subtenant, either prior to, during or after the term of this Sublease Agreement, (v) actions taken by Sublandlord at Subtenant&#8217;s request pursuant to Section 3 of this Sublease Agreement, or (vi) any holding over by Subtenant in the Subleased Premises beyond the expiration or sooner termination of this Sublease Agreement, including any such liability with respect to the entire Lease arising out of such holding over by Subtenant. Such obligation shall not be construed to negate, abridge or otherwise reduce any other right or obligation of indemnity that would otherwise exist as to Subtenant and the indemnification obligations under this Section and shall not be limited in any way by restriction on the amount or type of damages, compensation or benefits payable by or for Subtenant under any worker&#8217;s compensation acts, disability benefit acts or other employee benefit acts. Subject to the waiver of subrogation provisions of this Sublease Agreement, if any action or proceeding shall be brought against Sublandlord Indemnitee by reason of any such claim as to which Subtenant is obligated to indemnify Sublandlord, Subtenant, upon notice from Sublandlord Indemnitee at Subtenant&#8217;s expense, shall resist and defend such action or proceeding and employ counsel satisfactory to Sublandlord Indemnitee in Sublandlord Indemnitee&#8217;s reasonable discretion. Notwithstanding the foregoing, Sublandlord Indemnitee may retain its own attorneys to participate or assist in defending any claim, action or proceeding involving potential liability of $1,000,000 or more, and Subtenant shall pay the reasonable fees and disbursements of such attorney. Subtenant shall pay to Sublandlord within thirty (30) business days after demand all sums which may be owing to Sublandlord by reason of this Section. Subtenant&#8217;s obligations under this Section shall survive the expiration of this Sublease Agreement. Sublandlord shall indemnify, defend (with legal counsel selected by Subtenant), and hold harmless Subtenant from and against all losses, costs, damages, expenses and liabilities, including, without limitation, reasonable attorneys&#8217; fees and disbursements, which Subtenant may incur or pay out (including, without limitation, to Landlord) by reason of any breach or default hereunder or under the Lease on Sublandlord&#8217;s part.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">13.</font></font><u style="text-decoration:underline;text-decoration-color:#000000;">Broker&#8217;s Commission</u>. Subtenant represents to Sublandlord that the only brokers with whom it has dealt in connection with this transaction are Cushman and Wakefield U.S. Inc., representing Sublandlord and Perry CRE, representing Subtenant (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Brokers</u>&#8221;). Sublandlord will pay or cause to be paid to Brokers a market fee commission pursuant to the terms of separate commission agreements approved by Sublandlord, payable 100% upon mutual execution of the Sublease. Sublandlord agrees to indemnify Subtenant and hold Subtenant harmless from and against the claims of any broker or agent claiming to have dealt with Sublandlord. Subtenant agrees to indemnify Sublandlord and hold Sublandlord harmless from and against any and all claims of any broker or agent claiming to have dealt with Subtenant, other than Brokers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">14.</font></font><u style="text-decoration:underline;text-decoration-color:#000000;">Conditions to Agreement of Sublease</u>. This Sublease Agreement is expressly contingent upon the written consent of the Landlord to the transaction contemplated hereby in a form reasonably satisfactory to Sublandlord and Subtenant. Sublandlord shall use commercially reasonable efforts to obtain Landlord&#8217;s Consent promptly after the date hereof and will advise</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXECUTION VERSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Subtenant if Sublandlord receives Landlord&#8217;s Consent or if Landlord delivers written notice of its rejection of such request for consent to the transaction contemplated hereby. If Landlord fails to deliver Landlord&#8217;s Consent within forty-five (45) days after the execution and delivery of this Sublease Agreement, Subtenant shall have the right, exercisable no later than sixty (60) days after the execution and exchange of this Sublease Agreement (as to which time is of the essence), but not after such Landlord&#8217;s Consent has been received, to cancel this Sublease Agreement by notice to Sublandlord. Upon the giving of such notice of cancellation, this Sublease Agreement shall terminate and come to an end, and the parties shall not have any further rights or obligations hereunder, except that Sublandlord will forthwith return any Rent amounts and Security Deposits paid to it by Subtenant on account of this Sublease Agreement and except that the parties&#8217; obligations under Section 12 hereof shall survive such termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">15.</font></font><u style="text-decoration:underline;text-decoration-color:#000000;">Notices</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font>Any and all notices which are or may be required to be given pursuant to the terms of this Sublease Agreement shall be in writing and shall be sent by United States certified or registered mail, postage prepaid, return receipt requested, by hand delivery, or by a nationally recognized overnight air courier service to the parties hereto at the respective addresses set forth below. In addition to the foregoing any notices given pursuant to this Section 15 shall also be given by electronic transmission via the email(s) provided below. Notice shall be considered to have been given upon the earlier to occur of actual receipt or two (2) business days after posting if delivered via United States mail or one (1) business day after posting if delivered via courier service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:90%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If to Sublandlord:</p></td><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Grant Thornton LLP</p></td></tr><tr><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">171 N. Clark Street, Suite 200</p></td></tr><tr><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chicago, Illinois 60601</p></td></tr><tr><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attn: Office of the General Counsel - Dept. of Risk, Regulatory </p></td></tr><tr><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">and Legal Affairs</p></td></tr><tr><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">with email copy only to: </p></td><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Doug Carroll</p></td></tr><tr><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Doug.Carroll@us.gt.com</p></td></tr><tr><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If to Subtenant:</p></td><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Astria Therapeutics, Inc., </p></td></tr><tr><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 37pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">100 High Street, 28th Floor</p></td></tr><tr><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 37pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Boston, MA 02110</p></td></tr><tr><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 37pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attn: Legal Department</p></td></tr><tr><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">with email copy only to: </p></td><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven L. Charlip, LLC</p></td></tr><tr><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">69 Old Connecticut Path</p></td></tr><tr><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Wayland, MA 01778</p></td></tr><tr><td style="vertical-align:bottom;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attn: Steven L. Charlip</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font>Sublandlord and Subtenant agree to promptly furnish the other any notices or demands that either receives relating to the Lease. Either party shall be entitled to change such address on written notice to the other.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font>The time limits provided in the Lease for the giving of notices, making demands, performance of any act, condition or covenant, or the exercise of any right, remedy or option, are changed, for the purposes of determining the deadlines for Subtenant and Sublandlord to perform their obligations under this Sublease Agreement that are incorporated into this Sublease Agreement from the Lease, by lengthening or shortening the same in each instance by one-half, but in any event at least two (2) business days, as appropriate, so that notices may be given, demands</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXECUTION VERSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">made, or any act, condition or covenant performed, or any right, remedy or option hereunder exercised, by Sublandlord or Subtenant, as the case may be, within the time limit relating thereto contained in the Lease and, if notice is required, measured from the earlier of the date on which notice is given to Subtenant by any of Sublandlord or Landlord. Subtenant and Sublandlord shall promptly deliver to each other copies of all material notices, requests or demands which relate to the Subleased Premises or the use or occupancy thereof promptly after receipt of same from Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">16.</font></font><u style="text-decoration:underline;text-decoration-color:#000000;">Binding Effect</u>. The covenants, conditions and agreements contained herein shall be binding upon and inure to the benefit of Sublandlord and Subtenant and their respective successors and assigns, as permitted hereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">17.</font></font><u style="text-decoration:underline;text-decoration-color:#000000;">Governing Law</u>. This Sublease Agreement is entered into in The Commonwealth of Massachusetts, and its validity and interpretation shall be constructed in accordance with the laws of that state.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">18.</font></font><u style="text-decoration:underline;text-decoration-color:#000000;">Parking</u>. Sublandlord will provide Subtenant with 10 parking spaces through the term of the Sublease Agreement at the market rate being charged by Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">19.</font></font><u style="text-decoration:underline;text-decoration-color:#000000;">Access After Hours; Utilities</u>. Subtenant understands and agrees that the hours of operation for the Building are as follows: 8:00AM-6:00PM on each Monday through Friday and 8:00AM-1:00 PM on Saturdays (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Building Hours</u>&#8221;), except for the holidays outlined in the Lease. In the event that Subtenant desires the use of the heating, ventilation, lighting and air-conditioning system in the Subleased Premises outside of the Hours of Operation, Subtenant shall deliver Sublandlord a written request for such use not less than sixty (60) hours prior to the requested date of usage (an &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">After Hours Request</u>&#8221;). In the event an After Hours Request is made on less than (48) hours&#8217; notice, the Sublandlord shall act in good faith to accommodate such After Hours Request. Subtenant shall pay Sublandlord for all reasonable charges of Landlord incurred by Sublandlord due to Subtenant&#8217;s After-Hours Request within ten (10) days after delivery of a written request by Sublandlord to Subtenant for such payment which is governed by Section 7.4 Building Services of the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">20.</font></font><u style="text-decoration:underline;text-decoration-color:#000000;">Waiver of Breach</u>. Failure of Sublandlord or Subtenant to declare an event of default or default hereunder immediately upon its occurrence, or delay in taking any action in connection with such a default or event of default, shall not constitute a waiver of such a default or event of default, but Sublandlord and Subtenant shall have the right to declare the default or event of default at any time and take such action as authorized by law or under this Sublease Agreement. Acceptance by Sublandlord of any Rent or Electrical Charges after it has become due, or acceptance of less than the full amount due, shall not constitute or be construed as a waiver of any of Sublandlord&#8217;s rights and remedies hereunder, nor excuse any delay or partial payment upon any subsequent occasion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">21.</font></font><u style="text-decoration:underline;text-decoration-color:#000000;">No Estate</u>. This Sublease Agreement shall create the relationship of landlord and tenant only between Sublandlord and Subtenant and no estate shall pass out of Sublandlord. Subtenant shall have only usufruct, not subject to levy and sale and not assignable in full or in part by Subtenant except as provided herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">22.</font></font><u style="text-decoration:underline;text-decoration-color:#000000;">Holding Over</u>. If Subtenant remains in possession after expiration or termination of the term of this Sublease Agreement, without Sublandlord&#8217;s or Landlord&#8217;s written consent, Subtenant shall become a tenant-at -sufferance, and there shall be no renewal of this Sublease Agreement by operation of law. During the period of such holding over, all provisions of this Sublease Agreement shall be and remain in effect except that the monthly rental due hereunder</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXECUTION VERSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(inclusive of Electrical Charges) shall be equal to the amounts owed by Sublandlord to the Landlord under the Lease on account of such holding over, including without limitation any damages claimed by the Landlord or any other party; provided that if Subtenant and another subtenant or occupant of a portion of the Premises other than the Subleased Premises are holding over in the Premises following the expiration or earlier termination of the Lease, then Sublandlord shall equitably allocate the amount of holdover rent payable by Subtenant and such other party or parties and Subtenant shall pay its share thereof as so equitably allocated by Sublandlord. The inclusion of the preceding sentence in this Sublease Agreement shall not be construed as Sublandlord&#8217;s consent to Subtenant holding over.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">23.</font></font><u style="text-decoration:underline;text-decoration-color:#000000;">Time of Essence</u>. Time is of the essence in this Sublease Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">24.</font></font><u style="text-decoration:underline;text-decoration-color:#000000;">Miscellaneous</u>. Subtenant shall pay and be liable for all rental, sales and use taxes, and other similar taxes, if any levied or imposed by any city, state, county or other governmental authority. Such payments shall be paid concurrently with the payment of rental or other sum due hereunder upon which the tax is based. The content of each and every exhibit which is referenced in this Sublease Agreement is incorporated into this Sublease Agreement as fully as if set forth in the body of this Sublease Agreement. This Sublease Agreement contains the entire agreement of the parties hereto as to the Subleased Premises, and no representations, inducements, promises or agreements, oral or otherwise, between the parties, not embodied herein, shall be of any force or effect. If any term, covenant or condition of this Sublease Agreement or the application thereof to any person, entity or circumstance shall, to any extent, be invalid or unenforceable, the remainder of this Sublease Agreement, or the application of such term, covenant or condition to persons, entities or circumstances other than those which or to which used may be held invalid or unenforceable, shall not be affected thereby, and each term, covenant or condition of this Sublease Agreement shall be valid and enforceable to the fullest extent pem1itted by law. The circulation of one or more drafts of this Sublease Agreement shall not constitute a reservation of the Subleased Premises or an offer to lease the Subleased Premises to Subtenant. Neither party shall be bound hereunder until such time as both parties have signed this Sublease Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">25.</font></font><u style="text-decoration:underline;text-decoration-color:#000000;">Sublandlord Default</u>. Sublandlord shall in no event be in default in the performance of any of Sublandlord&#8217;s obligations under this Sublease Agreement unless and until Sublandlord shall fail to perform such monetary obligations required under this Sublease Agreement (if any) within ten (10) days of written notice from Subtenant to Sublandlord or any other obligation of Sublandlord under this Sublease Agreement within thirty (30) days of written notice from Subtenant to Sublandlord; provided that Subtenant hereby acknowledges and agrees that in no event shall Sublandlord be in default hereunder or have any liability hereunder caused by, attributable to, or otherwise related to Landlord&#8217;s failure to perform any of its obligations under the Lease (including, but not limited to, Section 13.2 Landlord&#8217;s Default of the Lease). In the event a Sublandlord default hereunder is not cured within the applicable cure period set forth above, Subtenant may, but without any obligation to do so, make such payments and do such work or otherwise perform Sublandlord&#8217;s covenants, all on behalf of and at the expense of Sublandlord, as the case may be. Subtenant shall not have the right to cure Landlord&#8217;s defaults under the Lease. Sublandlord agrees to pay Subtenant the actual costs, fees and expenses incurred in curing Sublandlord&#8217;s default under this Sublease Agreement upon the presentation of reasonable supporting documentation thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">26.</font></font>Execution in Counterparts. This Agreement can be executed in counterparts, each of which shall be an original and, upon the delivery to the Title Company of one or more of the Agreement signed by all parties, together will constitute a fully executed and binding contract. The exchange of executed signature pages by facsimile or Portable Document Format (PDF)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXECUTION VERSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">transmission or other electronic means such as DocuSign shall constitute effective delivery of such signature pages and may be used in lieu of the original signature pages for all purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 80.25pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[Signatures on Following Page]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 223.4pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXECUTION VERSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">IN WITNESS WHEREOF, Sublandlord and Subtenant have caused this Sublease Agreement to be executed by their duly authorized officers and have caused their corporate seals to be affixed all as of the day and year first written above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SUBLANDLORD:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GRANT THORNTON LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: <img src="atxs-20211231xex10d19001.jpg" alt="Graphic" style="display:inline-block;height:35.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:137.23pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 73.9pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Name: Mark McNamee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Title: National Managing Director, Administration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 9.05pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SUBTENANT:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ASTRIA THERAPEUTICS, INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:16.55pt;text-indent:-16.55pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:16.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">By:</font></font><img src="atxs-20211231xex10d19002.jpg" alt="Graphic" style="display:inline-block;height:35.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:84.73pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Name: Ben Harshbarger </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Title: Chief Legal Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Exhibit A</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Subleased Premises </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Attach drawing)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="atxs-20211231xex10d19003.jpg" alt="Graphic" style="display:inline-block;height:339.7pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:326.95pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="atxs-20211231xex10d19004.jpg" alt="Graphic" style="display:inline-block;height:51.74pt;width:26.24pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Exhibit B</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Copy of Lease </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Attached)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.44pt 297.35pt;"><b style="font-size:11.5pt;font-weight:bold;">TENANT:</b><font style="display:inline-block;width:20.29pt;"></font><b style="font-size:11.5pt;font-weight:bold;">GRANT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 369.5pt;"><b style="font-size:11.5pt;font-weight:bold;">THORNTON LLP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;">LEASE OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11.5pt;font-weight:bold;">75 STATE STREET</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11.5pt;font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PAGE</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ARTICLE </b>I <b style="font-weight:bold;">BASIC PROVISIONS</b></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">1</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46pt;">1.1</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTRODUCTION</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46pt;">1.2</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BASIC DATA</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46pt;">1.3</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ADDITIONAL DEFINITIONS</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ARTICLE </b>II <b style="font-weight:bold;">PREMISES AND APPURTENANT RIGHTS</b></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">5</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46pt;">2.1</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LEASE OF PREMISES</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46pt;">2.2</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">APPURTENANT RIGHTS AND RESERVATIONS</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46pt;">2.3</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">125 HIGH STREET PREMISES</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ARTICLE </b>III <b style="font-weight:bold;">BASIC RENT</b></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">11</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46pt;">3.1</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PAYMENT</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">11</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ARTICLE IV COMMENCEMENT DATE, RENT COMMENCEMENT DATE AND CONDITION</b></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 45pt;">4.1</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COMMENCEMENT DATE AND RENT COMMENCEMENT DATE</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">13</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 45pt;">4.2</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CONDITION OF THE PREMISES</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">13</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ARTICLE V USE OF PREMISES</b></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">16</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 45pt;">5.1</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PERMITTED USE</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">16</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 45pt;">5.2</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT&#8217;S INITIAL WORK</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 45pt;">5.3</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXTRA HAZARDOUS USE</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">23</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 45pt;">5.4</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INSTALLATIONS AND ALTERATIONS BY TENANT</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">23</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 45pt;">5.5</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">HAZARDOUS MATERIALS</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">25</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ARTICLE VI ASSIGNMENT AND SUBLETTING</b></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">27</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 45pt;">6.1</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROHIBITION</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 45pt;">6.2</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXCESS PAYMENTS</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 45pt;">6.3</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD&#8217;S RECAPTURE RIGHT</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 45pt;">6.4</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MISCELLANEOUS PROVISIONS</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">33</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 45pt;">6.5</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FURTHER REQUIREMENTS</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ARTICLE VII RESPONSIBILITY FOR REPAIRS AND CONDITION OF PREMISES; SERVICES TO BE FURNISHED BY LANDLORD</b></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 47pt;">7.1</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD REPAIRS</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">7.2</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT&#8217;S AGREEMENT</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">35</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 47pt;">7.3</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FLOOR LOAD - HEAVY MACHINERY</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">37</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 47pt;">7.4</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BUILDING SERVICES</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">37</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 47pt;">7.5</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ELECTRICITY</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">40</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 47pt;">7.6</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERRUPTION OF SERVICE</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">41</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">i</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ARTICLE VIII REAL ESTATE TAXES</b></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">42</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 47pt;">8.1</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PAYMENTS ON ACCOUNT OF REAL ESTATE TAXES</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">42</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">8.2</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ABATEMENT</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">44</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 47pt;">8.3</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ALTERNATE TAXES</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">44</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ARTICLE IX OPERATING EXPENSES</b></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">44</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 47pt;">9.1</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DEFINITIONS</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">44</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 47pt;">9.2</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT&#8217;S PAYMENTS</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">45</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ARTICLE X INDEMNITY AND PUBLIC LIABILITY INSURANCE</b></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">46</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 47pt;">10.1</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INDEMNITY</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">46</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 47pt;">10.2</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LIABILITY INSURANCE</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">47</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 47pt;">10.3</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT&#8217;S PROPERTY DAMAGE INSURANCE</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">47</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46pt;">10.4</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INSURANCE REQUIREMENTS</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">48</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46pt;">10.5</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INJURY CAUSED BY THIRD PARTIES</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">48</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 47pt;">10.6</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD&#8217;S INSURANCE</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">48</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46pt;">10.7</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">WAIVER OF SUBROGATION</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">49</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ARTICLE XI LANDLORD&#8217;S ACCESS TO PREMISES</b></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">49</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46pt;">11.1</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD&#8217;S RIGHTS</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">49</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ARTICLE XII CASUALTY; EMINENT DOMAIN</b></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">49</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46pt;">12.1</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CASUALTY</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">49</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46pt;">12.2</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EMINENT DOMAIN</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">53</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ARTICLE XIII DEFAULT</b></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">54</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46pt;">13.1</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT&#8217;S DEFAULT</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">54</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46pt;">13.2</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD&#8217;S DEFAULT</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">59</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ARTICLE XIV MISCELLANEOUS PROVISIONS</b></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">59</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.1</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTENTIONALLY OMITTED</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">59</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.2</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">WAIVER</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">59</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.3</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COVENANT OF QUIET ENJOYMENT</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">59</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.4</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD&#8217;S LIABILITY</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">60</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.5</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NOTICE TO MORTGAGEE OR GROUND LESSOR</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">61</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.6</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ASSIGNMENT OF RENTS AND TRANSFER OF TITLE</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">61</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.7</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RULES AND REGULATIONS</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">61</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.8</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ADDITIONAL CHARGES</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">62</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.9</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INVALIDITY OF PARTICULAR PROVISIONS</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">62</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.10</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROVISIONS BINDING, ETC.</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">62</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">ii</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.11</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RECORDING</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">62</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.12</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NOTICES</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">62</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.13</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">WHEN LEASE BECOMES BINDING</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">63</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.14</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PARAGRAPH HEADINGS AND INTERPRETATION OF SECTIONS</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">63</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.15</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RIGHTS OF MORTGAGEE OR GROUND LESSOR</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">64</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.16</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">STATUS REPORT</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">66</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.17</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTENTIONALLY OMITTED</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">66</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.18</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">REMEDYING DEFAULTS</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">66</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.19</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">HOLDING OVER</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">66</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.20</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTENTIONALLY OMITTED</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">67</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.21</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SURRENDER OF PREMISES</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">67</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.22</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTENTIONALLY OMITTED</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">68</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.23</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BROKERAGE</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">68</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.24</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GOVERNING LAW</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">68</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.25</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CONFIDENTIAL INFORMATION</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">68</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.26</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ANTI-TERRORISM</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">69</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">14.27</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TELECOMMUNICATIONS LINES AND EQUIPMENT</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">69</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ARTICLE XV EXTENSION OPTIONS</b></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">70</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">15.1</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">OPTIONS TO EXTEND</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">70</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ARTICLE XVI EXPANSION OPTION</b></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">73</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">16.1</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXPANSION OPTION</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ARTICLE XVII RIGHT OF FIRST OFFER</b></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">76</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">17.1</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RIGHT OF FIRST OFFER</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">76</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">17.2</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">OFFER SPACE BASIC RENT</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">79</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ARTICLE XVIII CONTRACTION OPTION</b></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">80</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">18.1</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT&#8217;S CONTRACTION OPTION</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">80</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ARTICLE XIX TERMINATION OPTION</b></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">81</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">19.1</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TERMINATION OPTION</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">81</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ARTICLE XX ROOF RIGHTS</b></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">82</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">20.1</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GENERALLY</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">82</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">20.2</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INSURANCE PREMIUMS</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">83</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">20.3</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NO REPRESENTATIONS, SERVICES OR OBLIGATIONS</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">83</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">20.4</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COMPLIANCE WITH LEGAL REQUIREMENTS</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">83</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">20.5</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ADDITIONAL COVENANTS</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">84</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">20.6</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RESERVED RIGHTS OF LANDLORD</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">84</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">20.7</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FORCE MAJEURE</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">85</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">20.8</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DISCLOSURE</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">85</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.1pt;">20.9</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GOOD FAITH AND FAIR DEALING</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">85</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXHIBIT A</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.2pt;">(Plan of Premises) </p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-1</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">iii</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXHIBIT B</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.2pt;">(Items Included in Operating Expenses)</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">B-1</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXHIBIT C</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.2pt;">(Cleaning Specifications)</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">C-1</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXHIBIT D</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.2pt;">(Tenant&#8217;s Work Requirements)</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">D-1</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXHIBIT E</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.2pt;">(Contractor&#8217;s Insurance Requirements) </p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">E-1</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXHIBIT F</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.2pt;">(Building Standards) </p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-1</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXHIBIT G</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.2pt;">(Tenant Plan Requirements) </p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">G-1</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXHIBIT H</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.2pt;">(Commencement Letter) </p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">H-1</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXHIBIT I</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.2pt;">(HVAC Specifications)</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">I-1</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXHIBIT J</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.2pt;">(Form of SNDA)</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1-l</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXHIBIT K</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.2pt;">(Landlord&#8217;s Premises Work)</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">K-1</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXHIBIT L</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.2pt;">(List of Tenant Competitors) </p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">L-1</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXHIBIT M</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.2pt;">(High Street Lessor Consent Requirements) </p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">M-1</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXHIBIT N</p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.2pt;">(Assignment Agreement) </p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">N-1</p></td></tr><tr><td style="vertical-align:bottom;width:17.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXHIBIT O</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0-1</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.2pt;">(Example of Tenant&#8217;s Share of Remaining High Street Rent Obligations)</p></td><td style="vertical-align:bottom;width:5.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">iv</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">LEASE</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11.5pt;">THIS INSTRUMENT IS A LEASE, dated as of December 31</font><sup style="font-size:8.62pt;vertical-align:top;">st</sup><font style="font-size:11.5pt;">, 2012, in which the Landlord and the Tenant are the parties hereinafter named, and which relates to space in the building (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Building&#8221;) </b><font style="font-size:11.5pt;">located at 75 State Street, Boston, Massachusetts. The parties to this instrument hereby agree with each other as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;">ARTICLE I </b><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">BASIC PROVISIONS</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">1.1</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">INTRODUCTION</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.3pt;margin:0pt 0pt 10pt 10.4pt;"><font style="font-size:11.5pt;">The following set forth basic data and, where appropriate, constitute definitions of the terms hereinafter listed.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">1.2</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">BASIC DATA</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Landlord: </b><font style="font-size:11.5pt;">BROOKFIELD PROPERTIES 75 STATE CO. LLC, a Delaware limited liability company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Landlord&#8217;s Original Address: </b><font style="font-size:11.5pt;">c/o Brookfield Financial Properties, L.P., Three World Financial Center, 200 Vesey Street, New York, New York 10281-1021.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Tenant: </b><font style="font-size:11.5pt;">GRANT THORNTON LLP, an Illinois limited liability partnership</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Tenant&#8217;s Original Address: </b><font style="font-size:11.5pt;">Grant Thornton LLP 1901 S. Myers Road, Suite 455, Oakbrook Terrace, Illinois 60181, Attn: Russell G. Wieman, with a copy to Grant Thornton LLP, 175 West Jackson, Suite 2000, Chicago, Illinois 60684-2687, Attn: Executive Director of Procurement, with a copy to Grant Thornton LLP, 175 West Jackson, Suite 2000, Chicago, Illinois 60684-2687, Attn: Office of the General Counsel</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Basic Rent: </b><font style="font-size:11.5pt;">The Basic Rent, net of Additional Rent, is as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 80.7pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:22.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:23.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:29.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:24.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:30.2pt;"><td style="vertical-align:top;width:22.56%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.2pt;text-indent:-0.2pt;margin:0pt 0pt 0pt 6.7pt;"><b style="font-size:11.5pt;font-weight:bold;">RENTAL PERIOD</b></p></td><td style="vertical-align:top;width:23.17%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.35pt;text-indent:-0.35pt;margin:0pt 0pt 0pt 6.6pt;"><b style="font-size:11.5pt;font-weight:bold;">ANNUAL<br>BASIC RENT</b></p></td><td style="vertical-align:top;width:29.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.05pt;margin:0pt 0pt 0pt 7.15pt;"><b style="font-size:11.5pt;font-weight:bold;">MONTHLY<br>PAYMENT</b></p></td><td style="vertical-align:top;width:24.62%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.2pt;margin:0pt 0pt 0pt 6.7pt;"><b style="font-size:11.5pt;font-weight:bold;">PER SQUARE <br>FOOT</b></p></td></tr><tr style="height:58.55pt;"><td style="vertical-align:top;width:22.56%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 0pt 6.45pt;"><font style="font-size:11.5pt;">From the Commencement Date through 6/30/13</font></p></td><td style="vertical-align:top;width:23.17%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;">$0</font></p></td><td style="vertical-align:top;width:29.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;">$0</font></p></td><td style="vertical-align:top;width:24.62%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;">$0</font></p></td></tr><tr style="height:44.6pt;"><td style="vertical-align:top;width:22.56%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.75pt 6.5pt;"><font style="font-size:11.5pt;">From July 1,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.1pt;margin:0pt 0pt 0pt 6.3pt;"><font style="font-size:11.5pt;">2013 through 1/31/18</font></p></td><td style="vertical-align:top;width:23.17%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6.55pt;"><font style="font-size:11.5pt;">$1,861,605.00*</font></p></td><td style="vertical-align:top;width:29.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6.8pt;"><font style="font-size:11.5pt;">$155,133.75*</font></p></td><td style="vertical-align:top;width:24.62%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6.6pt;"><font style="font-size:11.5pt;">$45.00</font></p></td></tr><tr style="height:30.7pt;"><td style="vertical-align:top;width:22.56%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.1pt;text-indent:-0.1pt;margin:0pt 0pt 0pt 6.25pt;"><font style="font-size:11.5pt;">From 2/01/18 through 1/31/21</font></p></td><td style="vertical-align:top;width:23.17%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6.35pt;"><font style="font-size:11.5pt;">$1,985,712.00</font></p></td><td style="vertical-align:top;width:29.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6.6pt;"><font style="font-size:11.5pt;">$165,476.00</font></p></td><td style="vertical-align:top;width:24.62%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6.6pt;"><font style="font-size:11.5pt;">$48.00</font></p></td></tr><tr style="height:30.9pt;"><td style="vertical-align:top;width:22.56%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.15pt;margin:0pt 0pt 0pt 6.1pt;"><font style="font-size:11.5pt;">From 2/01/21 through 07/31/24</font></p></td><td style="vertical-align:top;width:23.17%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6.35pt;"><font style="font-size:11.5pt;">$2,109,819.00</font></p></td><td style="vertical-align:top;width:29.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6.8pt;"><font style="font-size:11.5pt;">$175,818.25</font></p></td><td style="vertical-align:top;width:24.62%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6.6pt;"><font style="font-size:11.5pt;">$51.00</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 117.25pt;"><font style="font-size:11.5pt;">*subject to abatement pursuant the provisions of </font><b style="font-size:11.5pt;font-weight:bold;">Section 3.l(a).</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Rent Commencement Date: </b><font style="font-size:11.5pt;">July 1, 2013.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Additional Rent: </b><font style="font-size:11.5pt;">All charges and sums which Tenant is obligated to pay to Landlord pursuant to the provisions of this Lease, including without limitation, Escalation Charges.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Commencement Date: </b><font style="font-size:11.5pt;">The date this Lease is executed and delivered by both parties and Landlord delivers possession of the Premises in the Delivery Condition (as defined in </font><b style="font-size:11.5pt;font-weight:bold;">Section 4.2(a)).</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Premises: </b><font style="font-size:11.5pt;">Agreed to be 41,369 rentable square feet consisting of the entire 13</font>th <font style="font-size:11.5pt;">floor of the Building containing 24,233 rentable square feet (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Thirteenth Floor Premises&#8221;) </b><font style="font-size:11.5pt;">as shown on the floor plan attached hereto as </font><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit A-1,</b><font style="font-size:11.5pt;"> and a portion of the 14</font>th <font style="font-size:11.5pt;">floor of the Building containing 17,136 rentable square feet (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Fourteenth Floor Premises&#8221;) </b><font style="font-size:11.5pt;">as shown on the floor plan attached hereto as </font><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit A-2.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Permitted Uses: </b><font style="font-size:11.5pt;">Executive or professional business offices of the type generally found in first-class office buildings in the downtown Boston area, but specifically excluding (i) medical or dental offices, (ii) utility company offices, (iii) employment agencies (other than executive or professional search firms that operate in the Premises on an &#8220;off-the-street&#8221; basis), (iv) retail banking or retail brokerage offices that operate in the Premises on a so-called &#8220;off-the-street&#8221; basis (i.e. not by appointment) (except that offices for executives or employees of the named Tenant or its successor for the provision of financial services, tax planning, accounting and advisory services to clients and customers generally on an appointment basis as opposed to regularly providing such services to the general public on an off-the-street basis shall be permitted), (v) non-profit organizations and (vi) governmental or quasi-governmental offices.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Escalation Factor: </b><font style="font-size:11.5pt;">Agreed to be 5.2%.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 79.65pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Term or Term of this Lease: </b><font style="font-size:11pt;">The period commencing on the Commencement Date, and expiring at the close of the day on July 31, 2024, unless earlier terminated or extended as herein provided.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Base Operating Expenses: </b><font style="font-size:11pt;">Operating Expenses for the calendar year ending December 31, 2013.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Base Taxes: </b><font style="font-size:11pt;">Taxes (as defined in </font><b style="font-size:11.5pt;font-weight:bold;">Section 8.1) </b><font style="font-size:11pt;">finally assessed for the tax fiscal year ending June 30, 2014, as the same may be reduced by the proportional amount of any abatement applicable to any tax fiscal year included within the aforesaid tax fiscal year.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:48.4pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:left;">CPI:</b></font><font style="font-size:11pt;">Shall mean &#8220;The Consumer Price Index (New Series) (Base Period 1982 84=100) (all items for all urban consumers for Boston-Brockton-Nashua (CPI U) Area)&#8221; as published by the Bureau of Labor Statistics of the United States Department of Labor or if the same is discontinued, a replacement index published by the Department of Labor or other applicable Governmental Authority, appropriately adjusted. In the event that the CPI is converted to a different standard reference base or otherwise revised, the determination of those increases provided for herein to be made with reference to the CPI shall be made with the use of such conversion factor, formula or table for converting the CPI as may be published by the Bureau of Labor Statistics or, if said Bureau shall not publish the same, then with the use of such conversion factor, formula or table as may be published by Prentice Hall, Inc., or any other nationally recognized publisher of similar statistical information reasonably selected by Landlord and reasonably approved by Tenant. If the CPI ceases to be published, and there is no successor thereto, such other index as Landlord shall reasonably designate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Security Deposit: </b><font style="font-size:11pt;">None.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Brokers:</b><font style="display:inline-block;width:28.57pt;"></font><font style="font-size:11pt;">Richards Barry Joyce &amp; Partners, LLC and UGL Services Equis Operations Co.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">1.3</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">ADDITIONAL DEFINITIONS</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 18pt;"><b style="font-size:11.5pt;font-weight:bold;">Agent: </b><font style="font-size:11pt;">Brookfield Financial Properties L.P., or such other person or entity from time to time designated by Landlord.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 18pt;"><b style="font-size:11.5pt;font-weight:bold;">Bankruptcy Code: </b><font style="font-size:11pt;">As defined in </font><b style="font-size:11.5pt;font-weight:bold;">Section 13.1. Building Garage: </b><font style="font-size:11pt;">As defined in </font><b style="font-size:11.5pt;font-weight:bold;">Section 2.2(c).</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 18pt;"><b style="font-size:11.5pt;font-weight:bold;">Business Days: </b><font style="font-size:11pt;">All days except Saturday, Sunday, New Year&#8217;s Day, Martin Luther King&#8217;s Birthday, Presidents&#8217; Day, Patriot&#8217;s Day, Memorial Day, Bunker Hill Day, Independence Day, Labor Day, Columbus Day, Veterans&#8217; Day, Thanksgiving Day, Christmas Day (and the following day when any such day occurs on Sunday) and such other days as observed by both the federal and state governments as legal holidays.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 18pt;"><b style="font-size:11.5pt;font-weight:bold;">Default of Tenant: </b><font style="font-size:11pt;">As defined in </font><b style="font-size:11.5pt;font-weight:bold;">Section 13.1.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Environmental Condition: </b><font style="font-size:11.5pt;">Any disposal, release or threat of release of Hazardous Materials on, from or about the Building or the Property.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Environmental Laws: </b><font style="font-size:11.5pt;">Any federal, state and/or local statute, ordinance, bylaw, code, rule and/or regulation now or hereafter enacted, pertaining to any aspect of the environment or human health, including, without limitation, Chapter 21C, Chapter 21D, and Chapter 21E of the General Laws of Massachusetts and the regulations promulgated by the Massachusetts Department of Environmental Protection, the Comprehensive Environmental Response, Compensation and Liability Act of 1980, 42 U.S.C. &#167; 9601 et seq., the Resource Conservation and Recovery Act of 1976, 42 U.S.C. &#167; 6901 et seq., the Toxic Substances Control Act, 15 U.S.C. &#167;2061 et seq., the Federal Clean Water Act, 33 U.S.C. &#167;1251, and the Federal Clean Air Act, 42 U.S.C. &#167;7401 et seq.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Escalation Charges: </b><font style="font-size:11.5pt;">The amounts prescribed in </font><b style="font-size:11.5pt;font-weight:bold;">Sections 8.1 </b><font style="font-size:11.5pt;">and </font><b style="font-size:11.5pt;font-weight:bold;">9.2. Event of Bankruptcy: </b><font style="font-size:11.5pt;">As defined in </font><b style="font-size:11.5pt;font-weight:bold;">Section 13.1.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Force Majeure: </b><font style="font-size:11.5pt;">Collectively and individually, strikes or other labor trouble, fire or other casualty, acts of God, governmental preemption of priorities or other controls in connection with a national or other public emergency or shortages of fuel, supplies or labor resulting therefrom, or any other cause, whether similar or dissimilar, which in any case is beyond the reasonable control of the party required to perform an obligation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Hazardous Materials: </b><font style="font-size:11.5pt;">Shall mean each and every element, compound, chemical mixture, contaminant, pollutant, material, waste or other substance which is defined, determined or identified as hazardous or toxic under any Environmental Law, including, without limitation, any &#8220;oil,&#8221; &#8220;hazardous material,&#8221; &#8220;hazardous waste,&#8221; &#8220;hazardous substance&#8221; or &#8220;chemical substance or mixture,&#8221; as the foregoing terms (in quotations) are defined in any Environmental Laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Initial Liability Insurance: </b><font style="font-size:11.5pt;">$5,000,000 per occurrence (combined single limit) for property damage, bodily injury or death.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Laws: </b><font style="font-size:11.5pt;">Means all present and future statutes, laws, codes, regulations, ordinances, orders, rules, bylaws, administrative guidelines, requirements, directives and actions of any federal, state or local governmental or quasi-governmental authority, and other legal requirements of whatever kind or nature that are applicable to the Property, (including Environmental Laws and the Americans With Disabilities Act of 1990, as the same may be amended from time to time (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;ADA&#8221;)) </b><font style="font-size:11.5pt;">and any amendments, modifications or changes to any of the foregoing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Operating Expenses: </b><font style="font-size:11.5pt;">As defined in </font><b style="font-size:11.5pt;font-weight:bold;">Section 9.1. Operating Year: </b><font style="font-size:11.5pt;">As defined in </font><b style="font-size:11.5pt;font-weight:bold;">Section 9.1.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><b style="font-size:11.5pt;font-weight:bold;">Property: </b><font style="font-size:11.5pt;">The Building and the land parcels on which it is located (including adjacent sidewalks and plazas).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 81.5pt;"><b style="font-size:11.5pt;font-weight:bold;">Tax Year: </b><font style="font-size:11pt;">As defined in </font><b style="font-size:11.5pt;font-weight:bold;">Section 8.1.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.25pt;text-indent:-0.25pt;margin:0pt 0pt 10pt 81.25pt;"><b style="font-size:11.5pt;font-weight:bold;">Taxes: </b><font style="font-size:11pt;">As determined in accordance with </font><b style="font-size:11.5pt;font-weight:bold;">Section 8.1.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.25pt;text-indent:-0.25pt;margin:0pt 0pt 10pt 81.25pt;"><b style="font-size:11.5pt;font-weight:bold;">Tenant&#8217;s Plans: </b><font style="font-size:11pt;">As defined in </font><b style="font-size:11.5pt;font-weight:bold;">Section 5.2.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 81.25pt;"><b style="font-size:11.5pt;font-weight:bold;">Tenant&#8217;s Removable Property: </b><font style="font-size:11pt;">As defined in </font><b style="font-size:11.5pt;font-weight:bold;">Section 5.2.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;">ARTICLE </b><font style="font-size:12pt;">II</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">PREMISES AND APPURTENANT RIGHTS</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">2.1</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">LEASE OF PREMISES</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">Landlord hereby demises and leases to Tenant for the Term of this Lease and upon the terms and conditions hereinafter set forth, and Tenant hereby accepts from Landlord, the Premises.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">2.2</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">APPURTENANT RIGHTS AND RESERVATIONS</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11pt;">Tenant shall have, as appurtenant to the Premises, the non-exclusive right to use, and permit its invitees to use, in common with others, public or common lobbies, hallways, stairways (exclusive of fire stairs which are available for emergency egress only) and elevators and common walkways necessary for access to the Building, and if the portion of the Premises on any floor includes less than the entire floor, the common toilets, corridors and elevator lobby on such floor; but such rights shall always be subject to reasonable rules and regulations from time to time established by Landlord pursuant to </font><b style="font-size:11.5pt;font-weight:bold;">Section 14.7 </b><font style="font-size:11pt;">and to the right of Landlord, subject to the terms and conditions of this Lease, to designate and change from time to time areas and facilities so to be used. Tenant shall have the non-exclusive right, in common with Landlord and others entitled thereto, to access telephone/data closets and shafts and conduits in the Building, plenum areas and other pathways in the Building, in order to install Lines (as defined in Section 14.27) and to obtain tel/data connections and services for the Premises, subject to Landlord&#8217;s right to reasonably designate the location of and reasonably approve such installations and connections and to Landlord&#8217;s reasonable rules and regulations relative to the access to and the use of such areas within the Building</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:43.65pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11pt;">Excepted and excluded from the Premises are the ceiling, floor, perimeter walls and exterior windows (except the inner surfaces of each thereof), and any space in the Premises used for shafts, stacks, pipes, conduits, fan rooms, ducts, electric or other utilities, sinks or other Building facilities, but the entry doors to the Premises are a part thereof. Landlord shall have the right to place in the Premises (but in such manner as to reduce to a minimum interference with Tenant&#8217;s use of the Premises) interior storm windows, sun control devices, and utility lines, equipment, stacks, pipes, conduits, ducts and the like. In the event that Tenant shall install any hung ceilings or walls in the Premises, Tenant shall install and maintain, as Landlord may require, proper access panels therein to afford access to any facilities above the ceiling or within or behind the walls. Landlord agrees to use reasonable efforts to refrain from installing or maintaining any new conduits or pipes containing liquid in the plenum area above any hung ceilings in the Premises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:43.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11pt;">Subject to the provisions of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 2.2(c), </b><font style="font-size:11pt;">Landlord shall make available to Tenant on an unreserved, non-exclusive basis, up to twenty-five (25) monthly parking passes in the parking garage in the Building (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Building Garage&#8221;). </b><font style="font-size:11pt;">The parking</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:1.35pt;margin:0pt 0pt 0.94pt 9.95pt;"><font style="font-size:11.5pt;">privileges granted herein are for use by employees of Tenant and other occupants of the Premises, Tenant&#8217;s contractors, agents and invitees, are non-transferable (other than to an assignee or subtenant permitted or consented to by Landlord pursuant to the applicable provisions of </font><b style="font-size:11.5pt;font-weight:bold;">Section 6.1 </b><font style="font-size:11.5pt;">hereof). Tenant shall pay, as Additional Rent, the prevailing market rate in the Building (exclusive of discounts included in tenant concession packages) for such parking spaces from time to time in effect at the Building Garage, which monthly parking rate for unreserved parking passes is currently $490 per parking pass per month, subject to increase from time to time during the Term in accordance with the terms of this Lease. In no event shall Tenant be charged a monthly parking rate in excess of the monthly rate charged to the general public in the Building Garage. From and after April 1, 2014, Tenant shall have the right to relinquish any of its parking passes to Landlord from time to time upon at least one (1) full calendar month&#8217;s prior written notice. In the event Tenant relinquishes any parking passes during the Term, Landlord will have no further obligation to provide the relinquished parking passes to Tenant and the number of parking passes Landlord is obligated to provide to Tenant under this Lease will be reduced by the number of parking passes Tenant has relinquished and Tenant&#8217;s obligation to pay the monthly parking rate for such relinquished parking pass(es) shall terminate upon the effective date of such relinquishment. </font><font style="font-size:11pt;">If, </font><font style="font-size:11.5pt;">as of April 1, 2014, Tenant has failed to subscribe for all twenty-five (25) parking passes, then Landlord shall only be required to provide Tenant (and Tenant will only be obligated to pay for) with the number of parking passes then being utilized by Tenant as of such date. Landlord has entered into a management agreement or lease with an entity for the Building Garage </font><b style="font-size:11.5pt;font-weight:bold;">(&#8220;Building Garage Operator&#8221;). </b><font style="font-size:11.5pt;">Subject to the availability of parking passes controlled by Landlord in the Building Garage and Landlord&#8217;s anticipated needs for parking rights for future tenants, Landlord agrees to use reasonable efforts to satisfy requests by Tenant to re-subscribe for any of the original twenty-five (25) parking passes relinquished by Tenant during the Term. Landlord reserves the right to require Tenant to enter into a reasonable parking agreement directly with the Building Garage Operator for its parking passes and to pay the Building Garage Operator the monthly charge established hereunder, and Landlord shall have no liability for claims arising through acts or omissions of the Building Garage Operator solely in the event of Landlord&#8217;s gross negligence. It is understood and agreed that the identity of the Building Garage Operator may change from time to time during the Term. In connection therewith, any parking lease or agreement entered into between Tenant and a Building Garage Operator shall be freely assignable by such Building Garage Operator to any successors thereto. Landlord or the Building Garage Operator shall have the right from time to time to promulgate reasonable rules and regulations regarding the Building Garage, any parking passes and the use thereof, including, but not limited to, rules and regulations controlling the flow of traffic to and from various parking areas, the angle and direction of parking and the like. Landlord or the Building Garage Operator shall have the right to reasonably designate from time to time certain areas and spaces within the Building Garage that Tenant may use and certain areas and spaces that are off limits so long as such restrictions do not materially decrease Tenant&#8217;s parking rights under this Lease. Tenant shall comply with and cause its employees to comply with all such rules and regulations as well as all reasonable additions and amendments thereto, so long as such additions and amendments do not materially increase Tenant&#8217;s obligations under this Lease or materially decrease Tenant&#8217;s parking rights under this Lease. Landlord reserves for itself the right to alter the Building Garage as Landlord or the Building Garage Operator sees fit, and in such case to change the Building Garage including the reduction in area of the same; provided there is no material adverse effect on</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:1.35pt;margin:0pt 0pt 0pt 8.2pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">Tenant&#8217;s parking rights under this </font><b style="font-size:11.5pt;font-weight:bold;">Section 2.2(c). </b><font style="font-size:11.5pt;">In no event may Tenant assign its rights hereunder with respect to the use of such parking passes to any third party, except in connection with an assignment of this Lease or sublease effected in accordance with the provisions of </font><b style="font-size:11.5pt;font-weight:bold;">Article VI. </b><font style="font-size:11.5pt;">Landlord shall not be (i) responsible for money, jewelry, automobiles or other personal property lost in or stolen from the Building Garage regardless of whether such loss or theft occurs when the Building Garage or other areas therein are locked or otherwise secured or (ii) liable for any loss, injury or damage to persons using the Building Garage or automobiles or other property therein, it being agreed that, to the fullest extent permitted by law, the use of the Building Garage shall be at the sole risk of Tenant and its employees. Landlord and the Building Garage Operator shall have the right to temporarily close the Building Garage or certain areas therein in order to perform necessary repairs, maintenance and improvements to the Building Garage and Landlord agrees to use reasonable efforts to minimize the duration of any such temporary closures. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Tenant is denied use of any parking passes in the Building Garage on a Business Day on account of any casualty or other closure of the Building Garage, Tenant shall receive a credit for such Business Day towards the monthly parking fee. The Building Garage Operator may elect to provide parking cards or keys to control access to the Building Garage, and in such event, Landlord or the Building Garage Operator shall provide Tenant with one card or key for each parking pass that Tenant has subscribed for hereunder free of charge, provided that the Building Garage Operator shall have the right to require Tenant or its employees to pay a reasonable fee for any lost or damaged cards or keys.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">2.3</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">125 HIGH STREET PREMISES.</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:45.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11.5pt;">Landlord and Tenant hereby acknowledge that Tenant is the subtenant under that certain sublease dated as of April 27, 2009, as affected by that certain Assignment, Assumption and Consent dated December 1, 2011 and that certain Consent to Assignment of Sublease dated April 19, 2012 (collectively, the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;High Street Sublease&#8221;) </b><font style="font-size:11.5pt;">between Tenant, as subtenant, and Riversource Investments, LLC and Ameriprise Financial, Inc. (together with its successors and/or assigns, the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;High Street Sublessor&#8221;), </b><font style="font-size:11.5pt;">jointly and severally as sublandlord, governing Tenant&#8217;s occupancy of that certain premises consisting of 13,920 rentable square feet on the 21</font><sup style="font-size:8.62pt;vertical-align:top;">st</sup><font style="font-size:11.5pt;"> floor in the building located at 125 High Street, Boston, MA (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;High Street Premises&#8221;), </b><font style="font-size:11.5pt;">as affected by that certain Consent to Sublease dated May 21, 2009 between Tenant, the High Street Sublessor and 125 High Street, L.P. (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Master Lessor&#8221;). </b><font style="font-size:11.5pt;">The High Street Sublease is subject and subordinate to that certain Lease dated August 7, 2007 (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Master Lease&#8221;) </b><font style="font-size:11.5pt;">between Master Lessor and the High Street Sublessor with respect to certain premises consisting of 18,166 rentable square feet on the 21</font><sup style="font-size:8.62pt;vertical-align:top;">st</sup><font style="font-size:11.5pt;"> floor of the 125 High Street, Boston, Massachusetts building. Tenant represents and warrants to Landlord, as of the date of this Lease, that (i) Tenant has delivered to Landlord a true, correct and complete copies of the High Street Sublease and Consent to Sublease (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Sublease Documents&#8221;) </b><font style="font-size:11.5pt;">and the Master Lease, (ii) the Sublease Documents and Master Lease are in full force and effect and have not been terminated, revoked, rescinded, amended or modified as of the date of this Lease, (iii) the High Street Sublease expires on March 31, 2018 (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;High Street Expiration Date&#8221;) </b><font style="font-size:11.5pt;">and (iv) Tenant has not assigned the High Street Sublease or sublet all or any portion of the High Street Premises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:44.85pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11.5pt;">Subject to the terms and conditions of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 2.3 </b><font style="font-size:11.5pt;">and provided and on condition that both as of the date of delivery of the Assignment Election Notice (as hereinafter defined) and as of the High Street Assignment Date (as hereinafter defined): (y) this Lease is in full force and effect and has not been terminated, and (z) Tenant has not assigned the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.65pt;margin:0pt 0pt 0pt 7.8pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:1.65pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">High Street Sublease or sublet any part of the High Street Premises, Tenant shall have an option to assign all of Tenant&#8217;s right, title and interest as subtenant under the High Street Sublease to Landlord or Landlord&#8217;s designee (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;High Street Assignment Option&#8221;) </b><font style="font-size:11.5pt;">effective as of the High Street Assignment Date (as hereinafter defined), provided, however, Tenant shall not assign to Landlord and Landlord will not be obligated to assume Tenant&#8217;s obligations under Section 25 of the High Street Sublease. Tenant shall also transfer and assign to Landlord all of Tenant&#8217;s right, title and interest in the Furniture identified in Section 22 of the Sublease and all other furniture of Tenant in the High Street Premises as of the date of this Lease (collectively the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Surrendered Furniture&#8221;), </b><font style="font-size:11.5pt;">free from all liens, claims, demands and encumbrances. Tenant shall exercise the High Street Assignment Option, if at all, by a written notice (hereinafter called the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Assignment Election Notice&#8221;) </b><font style="font-size:11.5pt;">from Tenant to Landlord given on or before June 30, 2013 (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Assignment Option Expiration Date&#8221;), </b><font style="font-size:11.5pt;">time being of the absolute essence with respect to the giving of the Assignment Election Notice. Prior to the Assignment Option Expiration Date, Tenant may (but shall have no obligation to Landlord to) market the High Street Premises to find a subtenant or transferee for the High Street Premises and/or to negotiate with the High Street Sublessor to cause the High Street Sublessor to exercise the early termination option under the Master Lease. Tenant shall, at all times during the term of the High Street Sublease, maintain in full force and effect the Letter of Credit (as defined in Section 25 of the High Street Sublease) in the amount of$139,200.00 and if Tenant breaches its obligation to maintain the Letter of Credit under the High Street Sublease (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;High Street L/C&#8221;) </b><font style="font-size:11.5pt;">in full force and effect, including any obligations to renew, extend or replace the Letter of Credit under the High Street Sublease, such breach shall be an immediate Default of Tenant under this Lease. Landlord agrees to reimburse or credit to Tenant fifty percent (50%) of the annual costs incurred by Tenant to maintain the High Street L/C.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:44.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Tenant timely exercises the High Street Assignment Option, Tenant shall use reasonable efforts to obtain, at Tenant&#8217;s sole cost and expense, a written consent agreement executed by Tenant, the High Street Sublessor and the Master Lessor in the form attached hereto as </font><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit M</b><font style="font-size:11.5pt;"> or other form reasonably acceptable to Landlord (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;High Street Consent&#8221;) </b><font style="font-size:11.5pt;">and fully executed, original counterparts of any other consents and approvals required under the High Street Sublease and the Master Lease, any ancillary High Street lease or sublease documents, including any subordination, nondisturbance and attornment agreements, and under applicable Laws to effectuate the assignment of the High Street Sublease to Landlord (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Other Assignment Approvals&#8221;) </b><font style="font-size:11.5pt;">all in form and substance reasonably acceptable to Landlord. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Tenant fails to deliver (or fails to timely deliver) the Assignment Election Notice by the Assignment Option Expiration Date, such failure shall not constitute a default under this Lease but the provisions of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 2.3 </b><font style="font-size:11.5pt;">shall be null and void and of no further force or effect and Landlord shall not be required to accept an assignment of the High Street Sublease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:43.85pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(d)</font></font><font style="font-size:11.5pt;">Landlord shall not be required to accept an assignment of the High Street Sublease from Tenant unless and until the later date to occur of (such later date, the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;High Street Assignment Date&#8221;): </b><font style="font-size:11.5pt;">(i) January 1, 2014, (ii) the date Tenant fully vacates the High Street Premises and surrenders possession thereof to Landlord in the Surrender Condition, (iii) the date Tenant delivers to Landlord an original counterpart of an Assignment and Assumption Agreement in the form attached hereto as </font><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit N</b><font style="font-size:11.5pt;"> executed by Tenant (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Assignment Agreement&#8221;) </b><font style="font-size:11.5pt;">and an estoppel in form reasonably acceptable to Landlord from the High Street Sublessor, and (iv) the date Tenant delivers to Landlord fully executed, original counterparts of the High Street Consent executed by Tenant, the High Street Sublessor and the Master Lessor</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.55pt;margin:0pt 0pt 0pt 7.4pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">and any Other Assignment Approvals. The </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Surrender Condition&#8221; </b><font style="font-size:11.5pt;">shall mean that the High Street Premises is delivered to Landlord vacant, broom clean, free of any property or debris, free of any right or claim of right of use or occupancy by any other party and otherwise in the condition required under the High Street Sublease for sun-ender of the High Street Premises at the end of the High Street lease term, including, without limitation, Tenant&#8217;s performance of any obligations under the High Street Sublease requiring the removal of Tenant&#8217;s trade fixtures, equipment and other personal property and restoration of any damage or affected areas of the High Street Premises, except that Tenant shall not remove any of the Surrendered Furniture. Tenant hereby represents and warrants to Landlord that Tenant has not received any notice from the High Street Sublessor or Master Lessor that requires Tenant to remove any alterations, improvements or installations (including wiring or cabling) upon the expiration or earlier termination of the High Street Sublease. Landlord will exercise reasonable efforts to lease the High Street Premises to a new tenant with the Surrendered Furniture in place, however, a new tenant for all or any portion of the High Street Premises requires that Landlord remove the Furniture prior to delivery of the High Street Premises then Tenant shall be responsible to pay to Landlord, within thirty (30) days following receipt of an invoice, 50% of the total out-of-pocket costs incurred by Landlord to remove and dispose of such Surrendered Furniture.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:45.85pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(e)</font></font><font style="font-size:11.5pt;">From and after the High Street Assignment Date, the monthly Basic Rent payable by Tenant under this Lease shall be increased by an amount equal to the monthly amortization (on a straight line basis over the remainder of the Initial Term through July 31, 2024, together with interest thereon at the High Street Applicable Rate (as hereinafter defined)) of fifty percent (50%) of the total &#8220;Fixed Rent&#8221;, &#8220;Subtenant&#8217;s Tax Payment&#8221;, &#8220;Subtenant&#8217;s Operating Payment,&#8221; &#8220;Subtenant&#8217;s Insurance Payment,&#8221; &#8220;Electricity Additional Rent,&#8221; and any &#8220;Condenser Water Charge,&#8221; that are payable by the tenant under the High Street Sublease during the period commencing on the High Street Assignment Date through the High Street Expiration Date (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Tenant&#8217;s Share of the Remaining High Street Rent Obligations&#8221;). </b><font style="font-size:11.5pt;">The term &#8220;Tenant&#8217;s Share of Remaining High Street Rent Obligations&#8221; shall not include any late charges, interest, indemnity amounts or other sums (including parking charges) other than total &#8220;Fixed Rent&#8221;, &#8220;Subtenant&#8217;s Tax Payment&#8221;, &#8220;Subtenant&#8217;s Operating Payment,&#8221; &#8220;Subtenant&#8217;s Insurance Payment,&#8221; &#8220;Electricity Additional Rent,&#8221; and any &#8220;Condenser Water Charge,&#8221; that are payable by the tenant under the High Street Sublease during the period commencing on the High Street Assignment Date through the High Street Expiration Date. For purposes of this Section 2.3, the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;High Street Applicable Rate&#8221; </b><font style="font-size:11.5pt;">shall mean 4%, provided, however, if at any time during the Initial Term the rate publicly announced from time to time by Bank of America, National Association, or its successor bank at its headquarters as its Prime Rate (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Prime Rate&#8221;) </b><font style="font-size:11.5pt;">increases above a baseline rate of 3.25%, the High Street Applicable Rate shall be adjusted to the Prime Rate then in effect plus .75% but in no event in excess of 6%. </font><font style="font-size:11pt;">If, </font><font style="font-size:11.5pt;">prior to July 31, 2024, this Lease is terminated on account of a Default of Tenant, the Tenant&#8217;s Share of the Remaining High Street Rent Obligations, if any, shall immediately increase to 100% of the total fixed rent and additional rent that was paid or is payable by Landlord (as assignee of Tenant) at any time under the High Street Sublease, together with interest at the High Street Applicable Rate, and shal1 immediately become due and payable as Basic Rent under this Lease, provided, however, Landlord shall credit to Tenant&#8217;s obligations under this </font><b style="font-size:11.5pt;font-weight:bold;">Section 2.3 </b><font style="font-size:11.5pt;">the net proceeds, if any, received by Landlord from any leasing or subleasing of the High Street Premises, after deducting all expenses in connection with such leasing or subleasing, including, without limitation, brokerage commissions, legal expenses, attorneys&#8217; fees, advertising, alteration costs and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:73.3pt;margin:0pt 0pt 0pt 8.6pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.25pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">expenses of preparation for the High Street Premises for lease. By way of example only of the foregoing, </font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit O</b><font style="font-size:11.5pt;"> attached hereto sets forth an example of the manner of calculation of Tenant&#8217;s Share of the Remaining High Street Rent Obligations payment to Landlord.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:47.1pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(f)</font></font><font style="font-size:11.5pt;">Tenant shall make estimated monthly payments to Landlord on account of Tenant&#8217;s Share of the Remaining High Street Rent Obligations together with and as part of Tenant&#8217;s payment of the Basic Rent under this Lease based upon the amounts of total &#8220;Fixed Rent&#8221;, &#8220;Subtenant&#8217;s Tax Payment&#8221;, &#8220;Subtenant&#8217;s Operating Payment,&#8221; &#8220;Subtenant&#8217;s Insurance Payment,&#8221; &#8220;Electricity Additional Rent,&#8221; any &#8220;Condenser Water Charge,&#8221; and parking charges billed to Tenant or Landlord, as applicable, as of the High Street Assignment Date under the High Street Sublease and the High Street Applicable Rate in effect as of the date Landlord notifies Tenant in writing of Tenant&#8217;s estimated monthly payment pursuant to this </font><b style="font-size:11pt;font-weight:bold;">Section 2.3(e). </b><font style="font-size:11.5pt;">The monthly amount to be paid to Landlord shall be sufficient to provide Landlord by the end of each calendar year with a sum equal to Tenant&#8217;s required payments, as estimated by Landlord from time to time during each calendar year, on account of Tenant&#8217;s Share of the Remaining High Street Rent Obligations for such calendar year. As promptly as reasonably possible after the end of each calendar year, Landlord shall submit to Tenant a reasonably detailed accounting of Tenant&#8217;s Share of the Remaining High Street Rent Obligations (the </font><b style="font-size:11pt;font-weight:bold;">&#8220;Landlord&#8217;s Reconciliation Statement&#8221;) </b><font style="font-size:11.5pt;">together with an estimate of the monthly payment payable by Tenant for the succeeding calendar year for Tenant&#8217;s Share of the Remaining High Street Rent Obligations. If the estimated payments theretofore made for such calendar year by Tenant on account of Tenant&#8217;s Share of the Remaining High Street Rent Obligations exceed Tenant&#8217;s required payment on account thereof for such calendar year, according to Landlord&#8217;s Reconciliation Statement, Landlord shall, provided Tenant is not then in Default under this Lease, credit the amount of any overpayment against subsequent rental obligations of Tenant with respect to Basic Rent, provided that, if the required payments on account thereof for such calendar year are greater than the estimated payments (if any) theretofore made on account of Tenant&#8217;s Share of the Remaining High Street Rent Obligations for such calendar year, Tenant shall pay such amounts to Landlord within thirty (30) days after delivery of Landlord&#8217;s Reconciliation Statement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:46.15pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(g)</font></font><font style="font-size:11.5pt;">Tenant&#8217;s obligation to pay the Tenant&#8217;s Share of the Remaining High Street Rent Obligation to Landlord shall constitute Basic Rent due and payable under this Lease and if Tenant fails to timely pay the same to Landlord, Landlord shall have the same rights and remedies under this Lease as for the non-payment of Basic Rent beyond the applicable grace period (if any). From and after the date of this Lease, Tenant shall not modify or amend the High Street Sublease without Landlord&#8217;s prior written consent, which consent shall not be unreasonably withheld, provided, however, Landlord&#8217;s consent to any amendment or modification to the High Street Sublease which adversely affects Landlord, the High Street Premises or any of the rights or obligations of Landlord, as assignee under the High Street Sublease, shall be in Landlord&#8217;s sole and absolute discretion. The foregoing shall not limit Tenant&#8217;s right (without Landlord&#8217;s consent) to terminate the High Street Sublease so long as Tenant has not exercised the High Street Assignment Option.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:46.1pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(h)</font></font><font style="font-size:11.5pt;">From and after the High Street Assignment Date, Landlord or its designee shall have the right to assign the High Street Sublease or to sublease all or any p01tion of the High Street Premises without any requirement to obtain the consent or approval of Tenant or to provide notice to Tenant. The amount of the Tenant&#8217;s Share of the Remaining High Street Rent</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.05pt;margin:0pt 0pt 0pt 9.6pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">Obligations payable by Tenant under </font><b style="font-size:11.5pt;font-weight:bold;">Section 2.3(e) </b><font style="font-size:11.5pt;">shall not be adjusted, credited or reduced in any way on account of any assignment of the High Street Sublease or sublease of the High Street Premises by Landlord or its designee, and Landlord shall have the right to retain 100% of any revenue received from such assignment or sublease without compensation to Tenant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:45.2pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(i)</font></font><font style="font-size:11.5pt;">Tenant agrees to defend, indemnify and hold Landlord harmless from and against any and all claims, demands, liability, costs and expenses (including reasonable attorneys&#8217; fees and disbursements), damages or loss (including loss of rental income) occasioned on account of, or in connection with, (i) any default under the High Street Sublease by Tenant or any party claiming by, through, or under Tenant (excluding Landlord or any of Landlord&#8217;s subtenants, assignees, or any of their respective partners, members, principals, directors, officers, agents, employees, licensees or contractors) or (ii) any act, omission, negligence or willful misconduct of Tenant or any party claiming by, through or under Tenant (excluding Landlord or any of Landlord&#8217;s subtenants, assignees, or any of their respective partners, members, principals, directors, officers, agents, employees, licensees or contractors) which results in any claims against Landlord. Landlord agrees to defend, indemnify and hold Tenant harmless from and against any and all claims, demands, liability, costs and expenses (including reasonable attorneys&#8217; fees and disbursements), damages or losses occasioned on account of, or in connection with, (y) any default under the High Street Sublease by Landlord or any party claiming by, through, or under Landlord (including, but not limited to, Landlord&#8217;s subtenants, assignees, or any of their respective partners, members, principals, directors, officers, agents, employees, licensees or contractors) accruing from and after the High Street Assignment Date or (z) any act, omission, negligence or willful misconduct of Landlord, any party claiming by, through or under Landlord (including, but not limited to, Landlord&#8217;s subtenants, assignees, or any of their respective partners, members, principals, directors, officers, agents, employees, licensees or contractors) occurring from and after the High Street Assignment Date which results in any claims against Tenant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;">ARTICLE III </b><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">BASIC RENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:44.1pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">3.1</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">PAYMENT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:43.85pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11.5pt;">Except as otherwise set forth herein, Tenant agrees to pay to Landlord, or as directed by Landlord, commencing on the Rent Commencement Date without offset, abatement (except as otherwise expressly set forth in this Lease), deduction or demand, the Basic Rent. Notwithstanding the foregoing, and provided and only so long as no Default of Tenant exists or occurs at any time during the Abatement Period (as hereinafter defined), the Basic Rent and Escalation Charges due under this Lease will be abated during the period commencing on the Rent Commencement Date through March 31, 2014 (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Abatement Period&#8221;). </b><font style="font-size:11.5pt;">The foregoing rent abatement shall apply only to and affect the Basic Rent and Escalation Charges due under this Lease with respect to the Premises and Tenant shall be obligated to pay the Electricity Charges and all other Additional Rent which accrue and are due under this Lease with respect to the Premises from and after the Commencement Date. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">at any time during the Abatement Period there occurs any Default of Tenant under this Lease, Tenant&#8217;s right to abate the Basic Rent under this </font><b style="font-size:11.5pt;font-weight:bold;">Section 3.l(a) </b><font style="font-size:11.5pt;">for the Abatement Period shall be suspended until such time that Tenant cures such Default of Tenant. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">this Lease is terminated due to any Default of Tenant under this Lease during the Abatement Period, any and all Basic Rent and any Escalation</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.7pt;margin:0pt 0pt 0pt 7.3pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.45pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">Charges, if any, which had been abated prior to Tenant&#8217;s default pursuant to this </font><b style="font-size:11.5pt;font-weight:bold;">Section 3.l(a) </b><font style="font-size:11.5pt;">shall immediately become due and payable. Landlord and Tenant agree that all amounts due from Tenant under or in respect of this Lease, whether labeled Basic Rent, Escalation Charges, additional charges or otherwise, shall be considered as rental reserved under this Lease for all purposes, including without limitation regulations promulgated pursuant to the Bankruptcy Code, and including further without limitation Section 502(b) thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:46.9pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11.5pt;">The Basic Rent and regularly recurring payments of Additional Rent shall be payable in equal monthly installments, in advance, on the first day of each and every calendar month during the Term of this Lease, either by wire transfer of immediately available federal funds to the account of Landlord pursuant to the wiring instructions set forth below in paragraph (c) of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 3.1 </b><font style="font-size:11.5pt;">or by good and sufficient check (subject to collection) drawn on a bank which is a member of the Boston or New York Clearing House Association sent to the lockbox address for Landlord set forth in paragraph (d) of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 3.1, </b><font style="font-size:11.5pt;">or pursuant to such other written instructions as Landlord may deliver to Tenant in accordance with this Lease, at least thirty (30) days before the date such payments are due under this Lease, without notice or demand and, except as otherwise provided in this Lease, without offset or counterclaim. All other sums due under this Lease shall be paid to Landlord at Landlord&#8217;s Original Address, or at such other place as Landlord shall from time to time designate by at least thirty (30) days&#8217; written notice to Tenant. Landlord and Tenant agree that all amounts due from Tenant under or in respect of this Lease, whether labeled Basic Rent, Escalation Charges, additional charges or otherwise, shall be considered as rental reserved under this Lease for all purposes, including without limitation regulations promulgated pursuant to the Bankruptcy Code, and including further without limitation Section 502(b) thereof. Basic Rent for any partial month shall be pro rated on a daily basis, and if Basic Rent commences on a day other than the first day of a calendar month, the first payment which Tenant shall make to Landlord shall be payable on the date Basic Rent commences and shall be equal to a proportionate part of the monthly installment of Basic Rent for the partial month in which Basic Rent commences.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:46.3pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11.5pt;">Landlord&#8217;s wiring instructions for payments of Basic Rent and Additional Rent are presently set forth below:</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:46.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Account Name:</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">BROOKFIELD PROPERTIES 75 STATE CO. LLC</font></p></td></tr><tr><td style="vertical-align:top;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Account Number:</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">[account number]</font></p></td></tr><tr><td style="vertical-align:top;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Bank Name:</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">JPMORGAN CHASE</font></p></td></tr><tr><td style="vertical-align:top;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Bank ABA#:</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">[Bank ABA number]</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:45.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(d)</font></font><font style="font-size:11.5pt;">Landlord&#8217;s lockbox address for payments of Basic Rent and Additional Rent is set forth below:</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:46.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">JP Morgan Chase for</font></p></td></tr><tr><td style="vertical-align:top;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Brookfield Properties 75 State Co. LLC</font></p></td></tr><tr><td style="vertical-align:top;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Newark Post Office</font></p></td></tr><tr><td style="vertical-align:top;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">P.O. Box 10458</font></p></td></tr><tr><td style="vertical-align:top;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:53.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Newark, NJ 07193-0458</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11.5pt;font-weight:bold;">ARTICLE IV</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">COMMENCEMENT DATE, RENT COMMENCEMENT DATE AND CONDITION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:46.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">4.1</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">COMMENCEMENT DATE AND RENT COMMENCEMENT DATE</u><font style="font-size:11.5pt;"> </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">The Commencement Date shall be as set forth in </font><b style="font-size:11.5pt;font-weight:bold;">Section 1.2 </b><font style="font-size:11.5pt;">of this Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">Except as expressly set forth in </font><b style="font-size:11.5pt;font-weight:bold;">Section 4.2 </b><font style="font-size:11.5pt;">of this Lease, Tenant acknowledges and agrees that Landlord has no obligation to perform any improvements to the Premises or the Building to prepare the same for Tenant&#8217;s occupancy. Promptly following the occurrence of the Commencement Date, Landlord and Tenant hereby agree to execute a Commencement Date Letter in the form attached hereto as </font><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit H</b><font style="font-size:11.5pt;"> to confirm the Commencement Date. Failure to execute said letter shall not affect the Commencement Date as determined in accordance with the terms of this Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:45.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">4.2</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">CONDITION OF THE PREMISES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:45.1pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11.5pt;">Except as otherwise expressly set forth in this Lease, the Premises are being leased by Tenant in their AS IS condition existing on the date hereof, WITHOUT REPRESENTATION OR WARRANTY by Landlord, and Tenant hereby agrees that Landlord shall have no obligation to furnish, render or supply any work, labor, services, materials, fixtures, equipment or decoration to make the Premises suitable for Tenant&#8217;s occupancy, except that Landlord shall deliver possession of the Premises to Tenant vacant, broom clean, and free of all property, tenants or occupants and with Landlord&#8217;s Premises Work (as hereinafter defined) substantially completed (the </font><b style="font-size:11.5pt;font-weight:bold;white-space:pre-wrap;">&#8220;Delivery Condition&#8221;).   </b><font style="font-size:11.5pt;">Landlord shall perform, at Landlord&#8217;s cost and expense, (i) the work described on </font><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit K</b><font style="font-size:11.5pt;"> attached hereto (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Landlord&#8217;s Premises Work&#8221;) </b><font style="font-size:11.5pt;">to the Premises, and (ii) the Landlord&#8217;s Base Building Work (as hereinafter defined). Landlord agrees to perform the Landlord&#8217;s Premises Work in a good and workmanlike manner and using Building Standard materials.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:44.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11.5pt;">Landlord will exercise commercially reasonable efforts to deliver the Premises to Tenant in the Delivery Condition, including with Landlord&#8217;s Premises Work substantially completed, on January 31, 2013, subject to delays resulting from Tenant Delay (as hereinafter defined) and Force Majeure (as so extended, the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Target Commencement Date&#8221;). </b><font style="font-size:11.5pt;">Notwithstanding the foregoing, if Landlord is unable to deliver the Premises to Tenant with Landlord&#8217;s Premises Work substantially completed on or before the Target Commencement Date (as the same may be extended), Landlord shall have no liability to Tenant on account thereof and no such failure to give possession to Tenant on the Target Commencement Date shall in any way affect the validity of this Lease or the obligations of Tenant hereunder or, except as expressly set forth in </font><b style="font-size:11.5pt;font-weight:bold;">Section 4.2(c) </b><font style="font-size:11.5pt;">below, give rise to any claim for damages by Tenant or a claim for resc1ss10n.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:43.3pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Landlord does not deliver possession of the Premises to Tenant with Landlord&#8217;s Premises Work substantially complete and otherwise in the Delivery Condition within fourteen (14) days following the Target Commencement Date (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;First Outside Date&#8221;), </b><font style="font-size:11.5pt;">subject to a day for day postponement of such First Outside Date on account of any delays resulting from Tenant&#8217;s Delay and/or Force Majeure, then Tenant shall be entitled to a credit equal to one day of Basic Rent for each day following the First Outside Date until the earlier of the date the Commencement Date occurs or the Second Outside Date (as hereinafter defined). </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Landlord does not deliver possession of the Premises to Tenant with Landlord&#8217;s Premises Work substantially complete and otherwise in the Delive1y Condition within ninety (90) days following the Target Commencement Date (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Second Outside Date&#8221;), </b><font style="font-size:11.5pt;">subject to a day for day</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.2pt;margin:0pt 0pt 0pt 7.8pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">postponement of such Second Outside Date on account of any delays resulting from Tenant&#8217;s Delay and/or Force Majeure, then Tenant shall have the option, by delivery of written notice to Landlord not later than ten (10) days following such Second Outside Date (time being of the essence with respect to the giving of such notice by Tenant), as so extended, to elect either to (i) receive a credit equal to two days of Basic Rent for each day following the Second Outside Date until the date the Commencement Date occurs, or (ii) terminate this Lease. If Tenant fails to make an election within such ten-day period, Tenant shall be deemed to have elected to receive additional credits pursuant to foregoing clause (i). If Tenant elects to terminate this Lease then this Lease shall terminate thirty (30) days after the giving of Tenant&#8217;s termination notice, provided, however, that if Landlord delivers the Premises to Tenant in the condition required under this Lease within thirty (30) days following Landlord&#8217;s receipt of such termination notice, such termination notice shall be void and without further force or effect and this Lease shall continue in full force and effect (but Tenant shall receive the alternative credits against Basic Rent, including credits equal to two days of Basic Rent for each day following the Second Outside Date until the Commencement Date occurs). The foregoing rent credits and/or termination right shall be Tenant&#8217;s sole and exclusive remedy at law or in equity or otherwise for the failure of Landlord to cause the Commencement Date to occur by the First Outside Date or the Second Outside Date, as the case may be.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:45.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(d)</font></font><font style="font-size:11pt;">Tenant acknowledges and agrees that, subject to Landlord&#8217;s performance of the Landlord&#8217;s Premises Work and the Landlord&#8217;s Base Building Work and Landlord&#8217;s other obligations under </font><b style="font-size:11.5pt;font-weight:bold;">Section 4.2(a) </b><font style="font-size:11pt;">and </font><b style="font-size:11.5pt;font-weight:bold;">Section 5.5, </b><font style="font-size:11pt;">Tenant has inspected the Premises and the common areas of the Building, and has found the same to be satisfactory for the Permitted Uses. Landlord&#8217;s Premises Work shall be deemed &#8220;substantially complete&#8221; or &#8220;substantially completed&#8221; for purposes of this Lease when (i) Landlord&#8217;s Premises Work has been completed except only for those minor details or adjustments and minor items which, in accordance with good construction practice should be performed after or simultaneous with the performance of Tenant&#8217;s Initial Work (as hereinafter defined) (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Landlord&#8217;s Punchlist Items&#8221;), </b><font style="font-size:11pt;">may not then be completed and provided such incomplete items do not impede or delay the performance of Tenant&#8217;s Initial Work or Tenant&#8217;s occupancy of the Premises, and (ii) Landlord has obtained all appropriate approvals, documents or other permissions, if applicable, from the City of Boston Inspectional Services Department with respect to the completion of the Landlord&#8217;s Premises Work (except that the foregoing requirement shall be deemed waived if Landlord&#8217;s failure to obtain such governmental approval is the result of an act, omission or fault of Tenant). Upon receipt of a written request from Tenant, Landlord will provide Tenant copies of any governmental approvals or signoffs for Landlord&#8217;s Premises Work. Landlord shall complete Landlord&#8217;s Punchlist Items as soon as reasonably practicable following the Commencement Date, subject to Tenant providing Landlord with reasonable and timely access to the applicable portions of the Premises and to delays resulting from Tenant&#8217;s Delay and/or Force Majeure. Except to the extent Tenant notifies Landlord in writing within the forty-five (45) day period described in </font><b style="font-size:11.5pt;font-weight:bold;">Section 4.2(h) </b><font style="font-size:11pt;">specifying the respects in which Landlord&#8217;s Premises Work has not been substantially completed, Tenant shall be deemed to have accepted the Landlord&#8217;s Premises Work, subject to completion of the Landlord&#8217;s Punchlist Items. For purposes of this Lease, </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Tenant Delay&#8221; </b><font style="font-size:11pt;">shall mean any delay occurring after the date of this Lease in the design, permitting or performance of the Landlord&#8217;s Premises Work or Landlord&#8217;s Base Building Work to the extent that such delay is caused by any act or, where there is a duty to act under this Lease, any failure to act by Tenant or Tenant&#8217;s contractors, architects, engineers, or anyone else</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:73.8pt;margin:0pt 0pt 0pt 7.65pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">engaged by or on behalf of Tenant in connection with the construction of the Tenant&#8217;s Initial Work, including, without limitation, delays resulting from accommodating any scheduling requests made by Tenant, delays caused by Tenant&#8217;s failure to grant necessary access to any portion of the Premises to Landlord or Landlord&#8217;s employees, agents or contractors or any delay caused by the performance of any work in the Premises by any contractors of Tenant. Landlord&#8217;s Premises Work shall be deemed substantially complete as of the date when Landlord&#8217;s Premises Work would have been substantially complete but for any such Tenant Delay as reasonably determined by Landlord in the exercise of its good faith business judgment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:46.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(e)</font></font><font style="font-size:11pt;">Landlord shall upgrade the common corridor, elevator lobby and common area restrooms on the 14</font><sup style="font-size:8.25pt;vertical-align:top;">th</sup><font style="font-size:11pt;"> floor of the Building using building standard materials and similar to the recently constructed common area corridor and restrooms on the 18</font><sup style="font-size:8.25pt;vertical-align:top;">th</sup><font style="font-size:11pt;"> floor of the Building (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Landlord&#8217;s Base Building Work&#8221;). </b><font style="font-size:11pt;">Landlord agrees to diligently perform the Landlord&#8217;s Base Building Work following the execution and delivery of this Lease and receipt of all permits therefor and Landlord will exercise commercially reasonable efforts to substantially complete Landlord&#8217;s Base Building Work on or before the later date to occur of (y) sixty (60) days following the Commencement Date, and (z) April 30, 2013, subject to delays resulting from Tenant Delay (as hereinafter defined) and Force Majeure (as so extended, the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Base Building Work Completion Date&#8221;). </b><font style="font-size:11pt;">Landlord&#8217;s Base Building Work shall be performed in a good and workmanlike manner and in compliance with applicable Laws. Notwithstanding the foregoing, Landlord&#8217;s Base Building Work shall be deemed substantially complete for purposes of this Lease when (i) Landlord&#8217;s Base Building Work has been completed except only those minor details or adjustments and minor items which, in accordance with good construction practice should be performed after completion of Landlord&#8217;s Base Building Work or Tenant&#8217;s Initial Work (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Base Building Punchlist Items&#8221;), </b><font style="font-size:11pt;">may not then be completed and provided such incomplete items do not impede or delay Tenant&#8217;s right to lawfully occupy the Premises and will not impede Tenant&#8217;s use of the Premises, and (ii) Landlord has obtained all appropriate approvals, documents or other permissions, if applicable, from the City of Boston Inspectional Services Department with respect to the completion of the Landlord&#8217;s Base Building Work (except that the foregoing requirement shall be deemed waived if Landlord&#8217;s failure to obtain such governmental approval is the result of an act, omission or fault of Tenant). Landlord shall complete the Base Building Punchlist Items as soon as reasonably practicable, subject to delays resulting from Tenant Delay and/or Force Majeure. If Landlord does not substantially complete the Landlord&#8217;s Base Building Work on or before the Base Building Work Completion Date, subject to a day for day postponement of such date on account of any delays resulting from Tenant&#8217;s Delay and/or Force Majeure, then Tenant shall be entitled to a credit equal to </font><font style="font-size:12pt;">&#189; </font><font style="font-size:11pt;">day of Basic Rent for each day following such date until the Landlord&#8217;s Base Building Work is substantially complete.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:43.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(f)</font></font><font style="font-size:11pt;">If Tenant is unable to obtain or is delayed in obtaining any building permits or approvals for Tenant&#8217;s Initial Work or a ce1iificate of occupancy for the Premises solely as the result of any Landlord&#8217;s Premises Work, Landlord&#8217;s Base Building Work, any of the common areas of the Building, the structural elements of the Building or the base building systems serving the Building not being in compliance with applicable Laws and the compliance with such Laws was not triggered by the performance of Tenant&#8217;s Initial Work, Landlord shall be responsible to remedy such violation, at Landlord&#8217;s expense (and without including such costs in Operating Expenses), as soon as reasonably practicable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.45pt;margin:0pt 0pt 0pt 8.05pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(g)</font></font><font style="font-size:11pt;">Tenant acknowledges and agrees that Tenant has entered into this Lease and agrees to accept possession of the Premises and to perform the obligations of Tenant hereunder with knowledge that Landlord&#8217;s Base Building Work will be performed while Tenant is performing the Tenant&#8217;s Initial Work and the performance of such Landlord&#8217;s Base Building Work may result in noise, dust and other disturbances. Tenant hereby agrees that its obligations to pay all Basic Rent, Escalation Charges and Additional Rent under the Lease shall not be diminished, reduced or affected by the performance of Landlord&#8217;s Base Building Work after the Commencement Date, nor shall Tenant have any right to make a claim for constructive eviction, or to terminate this Lease or otherwise claim a defense to the full and timely performance of its obligations under this Lease as a result of the performance of Landlord&#8217;s Base Building Work after the Commencement Date and, with respect to the Corridor Finish Work, while Tenant is in occupancy of the Premises. Landlord and Tenant shall reasonably cooperate with each other to coordinate the performance of Landlord&#8217;s Base Building Work and Tenant&#8217;s Initial Work, provided, however, such reasonable efforts shall not require Landlord to perform such Landlord&#8217;s Base Building Work after hours or on an overtime or premium pay basis.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(h)</font></font><font style="font-size:11pt;">Except to the extent Tenant notifies Landlord in writing by not later than forty-five (45) days following the date that Landlord has substantially completed the Base Building Work, the taking of possession of the Premises by Tenant for the commencement of its business operations shall be deemed an acceptance of and substantial completion by Landlord of Landlord&#8217;s Base Building Work, subject to Landlord&#8217;s obligation to complete any punchlist items.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.8pt;margin:0pt 0pt 12pt 188.6pt;"><b style="font-size:11.5pt;font-weight:bold;">ARTICLE V<br></b><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">USE OF PREMISES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">5.1</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">PERMITTED USE</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11pt;">Tenant agrees that the Premises shall be used and occupied by Tenant only for Permitted Uses and for no other purpose.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11pt;">Tenant agrees to conform to the following provisions during the Term of this Lease:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(i)</font><font style="display:inline-block;width:25.62pt;"></font><font style="font-size:11pt;">Tenant shall cause all freight to be delivered to or removed from the Building and the Premises in accordance with reasonable rules and regulations established by Landlord in accordance with </font><b style="font-size:11.5pt;font-weight:bold;">Section 14.7;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(ii)</font><font style="display:inline-block;width:22.56pt;"></font><font style="font-size:11pt;">Tenant will not place on the exterior of the Premises (including both interior and exterior surfaces of doors and interior surfaces of windows) or on any part of the Building outside the Premises, any signs, symbol, adve1tisement or the like. Landlord will not withhold consent for signs or lettering on the entry doors to the Premises and in the elevator lobby of any partial floor in which the Premises is situated provided such signs conform to Building standards adopted by Landlord in its sole discretion and Tenant has submitted to Landlord a plan or sketch of the sign (including size, color, material, location and method of affixation) to be placed on such entry doors and Landlord has approved such plan or sketch. If Landlord provides a directory in the main lobby of the Building, Landlord agrees to provide Tenant with its prop01tionate share of listings on such directory. Excluding any signage rights of tenants in the Building under leases executed prior to the date of this Lease (including the rights under</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:63.75pt;margin:0pt 0pt 0pt 43.15pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5.3pt 36pt;"><font style="font-size:11.5pt;">existing leases of such tenants to transfer or change their signage) and provided and only so long as Grant Thornton LLP or any successor to Grant Thornton LLP (a </font><b style="font-size:11pt;font-weight:bold;">&#8220;GT </b><b style="font-size:11.5pt;font-weight:bold;">Successor&#8221;) </b><font style="font-size:11.5pt;">is the Tenant under this Lease and is satisfying the Occupancy Condition (as defined in </font><b style="font-size:11.5pt;font-weight:bold;">Section 15.1), </b><font style="font-size:11.5pt;">if, at any time during the Term, Landlord hereafter grants signage rights in the main lobby of the Building (other than lobby directory signage) to any competitor of Tenant identified on </font><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit L</b><font style="font-size:11.5pt;"> attached hereto or any successor in interest to any such competitor (a </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Tenant Competitor&#8221;) </b><font style="font-size:11.5pt;">leasing less rentable square footage in the Building than Tenant leases under this Lease at the time such signage rights are granted to a Tenant Competitor, Landlord shall grant comparable signage rights in such Building lobby to Tenant;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(iii)</font><font style="display:inline-block;width:18.75pt;"></font><font style="font-size:11.5pt;">Tenant shall not perform any act or carry on any practice which may cause any offensive odors or loud noise or constitute a nuisance or a menace to, or otherwise interfere with the business of, any other tenant or tenants or other persons in the Building; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(iv)</font><font style="display:inline-block;width:19.4pt;"></font><font style="font-size:11.5pt;">Subject to the terms of </font><b style="font-size:11.5pt;font-weight:bold;">Section 7.2, Section 4.2(a) </b><font style="font-size:11.5pt;">and </font><b style="font-size:11.5pt;font-weight:bold;">Section 5.5 </b><font style="font-size:11.5pt;">of this Lease, Tenant shall, in its use of the Premises, comply with the requirements of all applicable governmental laws, rules and regulations, including without limitation the Americans With Disabilities Act of 1990.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">5.2</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">TENANT&#8217;S INITIAL WORK.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11.5pt;">Following the Commencement Date, Tenant shall undertake, at Tenant&#8217;s sole cost and expense (except for the Landlord&#8217;s Contribution as hereinafter provided), the making of leasehold improvements to the Thirteenth Floor Premises (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Tenant&#8217;s Initial 13</b><sup style="font-size:8.62pt;font-weight:bold;vertical-align:top;">th </sup><b style="font-size:11.5pt;font-weight:bold;">Floor Work&#8221;) </b><font style="font-size:11.5pt;">and to the Fourteenth Floor Premises (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Tenant&#8217;s Initial 14</b><sup style="font-size:8.62pt;font-weight:bold;vertical-align:top;">th </sup><b style="font-size:11.5pt;font-weight:bold;">Floor Work&#8221;) </b><font style="font-size:11.5pt;">in accordance with plans and specifications approved by Landlord in accordance with subsection (b) of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 5.2. </b><font style="font-size:11.5pt;">Tenant&#8217;s Initial 13</font><sup style="font-size:8.62pt;vertical-align:top;">th</sup><font style="font-size:11.5pt;"> Floor Work and Tenant&#8217;s Initial 14</font><sup style="font-size:8.62pt;vertical-align:top;">th</sup><font style="font-size:11.5pt;"> Floor Work are collectively referred to in this Lease as </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Tenant&#8217;s Initial Work.&#8221; </b><font style="font-size:11.5pt;">Tenant shall diligently undertake and prosecute the construction of the Tenant&#8217;s Initial Work in accordance with such plans and specifications and all other provisions of this Lease relating to Tenant&#8217;s alterations, additions and improvements so as to promptly substantially complete the Tenant&#8217;s Initial Work.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11.5pt;">Tenant shall, at Tenant&#8217;s sole cost and expense, cause construction drawings for the Tenant&#8217;s Initial Work </font><b style="font-size:11.5pt;font-weight:bold;">(&#8220;Construction Drawings&#8221;) </b><font style="font-size:11.5pt;">to be completed and submitted to Landlord for review and approval, which Construction Drawings shall contain complete information and dimensions necessary for the construction and finishing of the Premises and for the engineering in connection therewith and comply with the provisions of </font><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit G</b><font style="font-size:11.5pt;"> (Tenant&#8217;s Plan Requirements) attached hereto. Within ten (10) Business Days after receipt of the complete set of final Construction Drawings for the applicable Tenant&#8217;s Initial Work, Landlord shall return such Construction Drawings to Tenant with its objections, suggested modifications and/or approval (which suggested objections and suggested modifications are herein referred as </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Landlord Modifications&#8221;), </b><font style="font-size:11.5pt;">provided such ten (10) Business Day period shall be extended for an additional reasonable period (not to exceed an additional five (5) Business Days) if Landlord notifies Tenant in writing (which notice may be sent electronically) that Tenant&#8217;s Construction Drawings are being sent to a third party consultant for review. The Construction Drawings shall thereafter be revised by Tenant to reflect the applicable changes and Tenant shall deliver revised Construction Drawings to Landlord within ten (10) Business Days</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.45pt;margin:0pt 0pt 0pt 8.5pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">after its receipt of Landlord&#8217;s response. Landlord shall grant its approval or disapproval thereto, and/or state any further objections or proposed modifications, within five (5) Business Days after receipt thereof. After the first submission and resubmission, Landlord and Tenant agree to deliver revised submissions or objections within a five (5) Business Day period. Promptly upon Landlord&#8217;s approval of the Construction Drawings for the applicable Tenant&#8217;s Initial Work, Tenant shall submit an application for, and diligently pursue issuance of, a building permit (and any other approvals required) for the performance of Tenant&#8217;s Initial Work. Tenant shall provide Landlord with copies of all written comments, responses, approvals, disapprovals and/or other correspondence received from all applicable governmental authorities in connection with such application, and shall otherwise keep Landlord informed regarding the processing of Tenant&#8217;s building permit application. No deviation from the Construction Drawings (other than de minimis or immaterial deviations and minor substitutions of materials) shall be made by Tenant except by written change order approved by Landlord </font><b style="font-size:11.5pt;font-weight:bold;">(&#8220;Change Order&#8221;). </b><font style="font-size:11.5pt;">Tenant shall be responsible for the payment of any and all costs to complete the Tenant&#8217;s Initial Work except to the extent Tenant is entitled to receive Landlord&#8217;s Contribution (as hereinafter defined) under this </font><b style="font-size:11.5pt;font-weight:bold;">Section 5.2. </b><font style="font-size:11.5pt;">All Tenant&#8217;s Initial Work shall be performed by contractors and subcontractors which have been approved by Landlord, which approval will not be unreasonably withheld or delayed. All contractors and subcontractors performing the Tenant&#8217;s Initial Work shall be financially sound and able to complete the portion of the Tenant&#8217;s Initial Work for which they are responsible in a prompt and timely fashion. In connection with the performance of the Tenant&#8217;s Initial Work by Tenant or Tenant&#8217;s contractors, Tenant shall comply with, and shall cause Tenant&#8217;s contractors and all subcontractors to comply with, the provisions of </font><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit D</b><b style="font-size:11.5pt;font-weight:bold;"> (Tenant&#8217;s Work Requirements), </b><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit E</b><b style="font-size:11.5pt;font-weight:bold;"> (Contractor&#8217;s Insurance Requirements), </b><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit F</b><b style="font-size:11.5pt;font-weight:bold;"> (Building Standards) </b><font style="font-size:11.5pt;">and </font><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit G</b><b style="font-size:11.5pt;font-weight:bold;"> (Tenant Plan Requirements) </b><font style="font-size:11.5pt;">of this Lease, as the same may be amended from time to time. As part of Tenant&#8217;s Initial Work, Tenant shall install building standard window blinds or other style of window blinds reasonably approved by Landlord, including mecco shades, on all windows in the Premises and, during the Term of this Lease, Tenant shall be responsible to maintain, repair and replace all such window blinds in the Premises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11.5pt;">In consideration of Tenant&#8217;s fulfillment of all of its obligations under this </font><b style="font-size:11.5pt;font-weight:bold;">Section 5.2 </b><font style="font-size:11.5pt;">to perform the Tenant&#8217;s Initial Work in and to the Premises and the performance of all of its financial and other obligations under this Lease and subject to the terms of this </font><b style="font-size:11pt;font-weight:bold;">Section 5.2, </b><font style="font-size:11pt;">Landlord agrees to provide the Landlord&#8217;s Contribution to reimburse Tenant for the hard and, to the extent permitted herein, soft costs incurred by Tenant in connection with the design, construction and installation of the Tenant&#8217;s Initial Work in and to the Premises (the </font><b style="font-size:11pt;font-weight:bold;">&#8220;Total Costs&#8221;), </b><font style="font-size:11pt;">including, without limitation, costs of construction, repairing or replacing HVAC equipment or components thereof, and alterations and improvements to the restrooms within the Premises. Landlord shall reimburse Tenant for the Total Costs paid by Tenant for the Tenant&#8217;s Initial 13</font><sup style="font-size:8.25pt;vertical-align:top;">th</sup><font style="font-size:11pt;"> Floor Work up to One Million Nine Hundred Thirty Eight Thousand Six Hundred Forty and 00/100 Dollars ($1,938,640.00) ($80.00 per rentable square foot of the Thirteenth Floor Premises) (the </font><b style="font-size:11pt;font-weight:bold;">&#8220;Landlord&#8217;s 13</b><sup style="font-size:8.25pt;font-weight:bold;vertical-align:top;">th</sup><b style="font-size:11pt;font-weight:bold;"> Floor Contribution&#8221;). </b><font style="font-size:11pt;">Landlord shall reimburse Tenant for the portion of the Total Costs solely attributable to Tenant&#8217;s Initial 14</font><sup style="font-size:8.25pt;vertical-align:top;">th </sup><font style="font-size:11pt;">Floor Work up to One Million One Hundred Ninety-Nine Thousand Five Hundred Twenty and 00/100 Dollars ($1,199,520.00) ($70.00 per rentable square foot of the Fourteenth Floor Premises) (the </font><b style="font-size:11pt;font-weight:bold;">&#8220;Landlord&#8217;s 14</b><sup style="font-size:8.25pt;font-weight:bold;vertical-align:top;">th </sup><b style="font-size:11pt;font-weight:bold;">Floor Contribution&#8221;). </b><font style="font-size:11pt;">Landlord&#8217;s 13</font><sup style="font-size:8.25pt;vertical-align:top;">th </sup><font style="font-size:11pt;">Floor Contribution and Landlord&#8217;s 14</font><sup style="font-size:8.25pt;vertical-align:top;">th </sup><font style="font-size:11pt;">Floor Contribution are hereinafter collectively referred to as the </font><b style="font-size:11pt;font-weight:bold;">&#8220;Landlord&#8217;s</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72.25pt;margin:0pt 0pt 0pt 9.65pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;">Contribution&#8221;. </b><font style="font-size:11.5pt;">Tenant acknowledges and agrees that Landlord&#8217;s total financial obligation with respect to the permitting, purchase, construction, and installation of Tenant&#8217;s Initial Work shall be limited solely to Landlord&#8217;s Contribution and Tenant shall be entirely responsible for any such excess costs. If the Total Costs of Tenant&#8217;s Initial Work shall be less than Landlord&#8217;s Contribution, then the amount of Landlord&#8217;s Contribution shall be reduced accordingly. Notwithstanding anything to the contrary in this </font><b style="font-size:11.5pt;font-weight:bold;">Section 5.2, </b><font style="font-size:11.5pt;">Tenant may utilize up to twenty percent (20%) of Landlord&#8217;s Contribution towards reimbursement of &#8220;soft&#8221; costs incurred by Tenant for architectural and design costs, permit and filing fees, construction management, signage, cabling, furniture, moving and security system expenses. Landlord and Tenant acknowledge and agree that Landlord is providing Landlord&#8217;s Contribution to Tenant for the primary purpose of constructing and improving the Premises with &#8220;qualified long-term real property&#8221; for use in Tenant&#8217;s trade or business pursuant to and in accordance with the provisions of Section 110 of the Internal Revenue Code, to the extent the applicable elements of Tenant&#8217;s Initial Work qualify as such &#8220;qualified long-term property&#8221; under the applicable provisions of the Internal Revenue Code and excluding any portion of the Landlord&#8217;s Contribution applied by Tenant to &#8220;soft&#8221; costs or to Basic Rent. The Landlord&#8217;s Contribution shall be payable on a percentage of completion basis, not more than once during each calendar month, and any amount so funded will be paid to Tenant within thirty (30) days following Landlord&#8217;s receipt of all of the following items and provided there is no uncured Default of Tenant or any condition of which Tenant has been given written notice and which, with the passage of time, would constitute a Default of Tenant under this Lease:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(i)</font><font style="display:inline-block;width:25.15pt;"></font><font style="font-size:11.5pt;">a payment request (a </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Funding Request&#8221;), </b><font style="font-size:11.5pt;">seeking that percentage of the Landlord&#8217;s Contribution (less the applicable holdback amount specified below) which corresponds to the percentage of completion achieved as of the date of such payment request of Tenant&#8217;s Initial Work:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(ii)</font><font style="display:inline-block;width:21.95pt;"></font><font style="font-size:11.5pt;">a certificate of Tenant&#8217;s architect to Landlord and any other party reasonably designated by Landlord (such as Landlord&#8217;s mortgagee, if any) specifying the percentage of completion of Tenant&#8217;s Initial Work to the Funding Request submitted, performed in or to the applicable portion of the Premises in accordance with the Construction Drawings therefor approved by Landlord which Tenant has achieved as of the date of such certificate (and in any payment request seeking final payment, such certificate shall include a certification by the Tenant&#8217;s architect that the applicable portion of the Tenant&#8217;s Initial Work for the Premises has been Substantially Completed in accordance with the plans, and that all punch list items noted by the parties have also been fully completed);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(iii)</font><font style="display:inline-block;width:18.75pt;"></font><font style="font-size:11.5pt;">a copy of the final certificate of use and occupancy (or its equivalent) issued to Tenant by the applicable governmental authority with respect to the Thirteenth Floor Premises or the Fourteenth Floor Premises, as applicable (final payment of the corresponding portion of Landlord&#8217;s Contribution only);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(iv)</font><font style="display:inline-block;width:19.4pt;"></font><font style="font-size:11.5pt;">a copy of complete as-built plans and specifications for the Tenant&#8217;s Initial Work to the Premises and one set of blueprints showing all items of Tenant&#8217;s Initial Work (final payment of the corresponding portion of Landlord&#8217;s Contribution only), which shall be submitted to Landlord in hard-copy paper form (together with a PDF scanned copy of all paper plans) and on disk in Auto-CAD Version 2000;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(v)</font><font style="display:inline-block;width:22.59pt;"></font><font style="font-size:11.5pt;">evidence that Tenant has funded the Tenant Contribution (as hereinafter defined), if any, associated with such payment request (and each prior payment request made by Tenant), as determined pursuant to </font><b style="font-size:11.5pt;font-weight:bold;">Section 5.2(d), </b><font style="font-size:11.5pt;">below; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(vi)</font><font style="display:inline-block;width:19.4pt;"></font><font style="font-size:11.5pt;">duly executed lien waivers from all contractors, sub-contractors and suppliers performing work or supplying material for the Tenant&#8217;s Initial Work and acknowledging payment of all amounts due in connection with the portion of Tenant&#8217;s Initial Work to the Premises represented by the Funding Request, provided, however, that Tenant shall deliver final lien waivers with its submission of the final Funding Request for the Tenant&#8217;s Initial Work.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">Upon receipt and approval of all such items, Landlord shall, within thirty (30) days following receipt of the Funding Request, disburse the amount of Landlord&#8217;s Contribution requested to be funded to Tenant. Landlord shall have the right to hold back ten percent (10%) of the amount requested until such time as, in addition to Tenant&#8217;s satisfaction of the requirements otherwise applicable to a final payment under clauses (i) - (vi) above of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 5.2(c), </b><font style="font-size:11.5pt;">Landlord has received a certificate from Tenant&#8217;s architect that all punch list items have been corrected or completed. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Tenant fails to properly requisition the full Landlord&#8217;s Contribution on or before the second (2</font><sup style="font-size:8.62pt;vertical-align:top;">nd</sup><font style="font-size:7.5pt;">) </font><font style="font-size:11.5pt;">anniversary of the Rent Commencement Date (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Reimbursement Deadline&#8221;), </b><font style="font-size:11.5pt;">then Tenant shall be deemed to have waived any right to the balance thereof except that, provided there is no uncured Default of Tenant, Tenant may elect by notice to Landlord delivered on or before the Reimbursement Deadline to apply any undisbursed amount of the Landlord&#8217;s Contribution to the Basic Rent next due under this Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">If, </font><font style="font-size:11.5pt;">as of the date when a disbursement of the Landlord&#8217;s Contribution is due hereunder (and provided Tenant has delivered to Landlord all documentation required under this </font><b style="font-size:11.5pt;font-weight:bold;">Section 5.2(c) </b><font style="font-size:11.5pt;">and Landlord has not notified Tenant that Landlord reasonably disputes the accuracy or completeness of the applicable Funding Request), the applicable disbursement of the Landlord&#8217;s Contribution is not timely paid by Landlord, then provided no Default of Tenant has occurred and is continuing, Tenant may deliver a second notice (an </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Offset Notice&#8221;) </b><font style="font-size:11.5pt;">to Landlord at Landlord&#8217;s addresses set forth in this Lease (or to such other notice address as Landlord may specify in a written notice to Tenant upon not less than thirty (30) days&#8217; prior notice), which notice shall specify the Funding Request that has not been timely paid, the date upon which it was received by Landlord and state conspicuously in bold type and in all capital letters at the top of the first page of such notice and on the envelope containing such notice </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;THIS IS A TIME SENSITIVE OFFSET NOTICE AND LANDLORD SHALL BE DEEMED TO ACCEPT SUCH OFFSET IF IT FAILS TO RESPOND TO THIS SECOND REQUEST FOR DISBURSEMENT WITHIN FIVE (5) BUSINESS DAYS AFTER RECEIPT&#8221; </b><font style="font-size:11.5pt;">and if Tenant shall deliver such second notice to Landlord as aforesaid and Landlord fails to disburse the amount of the Landlord&#8217;s Contribution expressly referenced in the Offset Notice, subject to Landlord&#8217;s right to dispute such Funding Request as hereinafter provided, within such five (5) Business Day period, then Tenant shall have the right to have such unpaid amount of Landlord&#8217;s Contribution credited against the next installment(s) of Basic Rent and/or Escalation Charges thereafter due under this Lease. Within the thirty (30) day period following receipt of a Funding Request or within the additional 5-Business Day period described above, Landlord may</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.65pt;margin:0pt 0pt 0pt 43.75pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">dispute in good faith the Funding Request by written notice to Tenant setting forth the basis upon which Landlord reasonably disputes the accuracy or completeness of any Funding Request. If Landlord disputes the accuracy or completeness of any Funding Request, Landlord and Tenant shall reasonably cooperate with each other to resolve such dispute as expeditiously as possible, but Landlord will have no obligation to disburse any disputed amount of such Funding Request and Tenant will not have any right to credit the disputed amount of the Funding Request against the Basic Rent and/or Escalation Charges until the dispute has been resolved to Landlord&#8217;s satisfaction or by arbitration as provided below. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">the parties are unable to resolve such funding dispute within fourteen (14) days following the date of Landlord&#8217;s dispute notice to Tenant, such dispute may be submitted by either party to arbitration in Boston, Massachusetts for expedited proceedings under the Fast Track Procedures provisions (currently, Rules F-1 through F- 13) of the Arbitration Rules of the Construction Industry of the American Arbitration Association (the </font><b style="font-size:11pt;font-weight:bold;">&#8220;AAA&#8221;), </b><font style="font-size:11.5pt;">with both parties agreeing to waive the $75,000 qualification in such rules. In any case where the parties utilize such expedited arbitration: (1) the parties will have no right to object if the arbitrator so appointed was on the list submitted by the AAA and was not objected to in accordance with Rule 54 (except that any objection shall be made within four (4) days from the date of mailing), (2) the Notice of Hearing shall be given four (4) days in advance of the hearing, (3) the first hearing shall be held within five (5) Business Days after the appointment of the arbitrator, and (4) each party in such arbitration shall pay its own attorneys&#8217; fees and other costs of such arbitration and the losing party shall pay the costs charged by the AAA and/or the arbitrator. Judgment upon any award rendered in any arbitration held pursuant to this </font><b style="font-size:11.5pt;font-weight:bold;">Section 5.2(c) </b><font style="font-size:11.5pt;">may be entered in any court having jurisdiction, and in connection therewith, the arbitrators shall be bound by the provisions of this Lease, and shall not add to, subtract from or otherwise modify such provisions, and the sole remedy which may be awarded by the arbitrators in any proceeding pursuant to this </font><b style="font-size:11.5pt;font-weight:bold;">Section 5.2(c) </b><font style="font-size:11.5pt;">is an order compelling Landlord to pay any portion of the Landlord&#8217;s Contribution which Landlord was withholding pursuant to the foregoing provisions of this Section, and, except for the costs and fees described in clause (4) above, the arbitrators may not award damages or grant any monetary award or other form of relief.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:44.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(d)</font></font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">at any time Landlord in good faith determines that Total Costs will exceed Landlord&#8217;s Contribution, Landlord shall only be required to disburse the Landlord&#8217;s Contribution towards submitted Funding Requests on a pari passu basis with Landlord reimbursing to Tenant only the amount of the Funding Request </font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">multiplied</u><font style="font-size:11.5pt;"> by a fraction, the numerator of which is the amount of Landlord&#8217;s Contribution and the denominator of which is Landlord&#8217;s good faith estimate of Total Costs for the Tenant&#8217;s Initial Work, and the amount of each Funding Request due from Tenant is herein referred to as the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Tenant Contribution.&#8221; </b><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Tenant fails to pay any portion of the Tenant Contribution as and when required, Landlord shall have the right to withhold any further funding of Landlord&#8217;s Contribution pending Tenant&#8217;s delivery of evidence reasonably satisfactory to Landlord that Tenant has made such Tenant Contribution and any such withholding by Landlord shall not be deemed a delay or default by Landlord under this Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:44.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(e)</font></font><font style="font-size:11.5pt;">The Landlord&#8217;s 13</font><sup style="font-size:8.62pt;vertical-align:top;">th</sup><font style="font-size:11.5pt;"> Floor Contribution and Landlord&#8217;s 14</font><sup style="font-size:8.62pt;vertical-align:top;">th</sup><font style="font-size:11.5pt;"> Floor Contribution are separate allowances to be used and applied primarily to Tenant&#8217;s Initial 13</font><sup style="font-size:8.62pt;vertical-align:top;">th</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.05pt;margin:0pt 0pt 0pt 8.2pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">Floor Work and Tenant&#8217;s Initial 14</font><sup style="font-size:8.62pt;vertical-align:top;">th</sup><font style="font-size:11.5pt;"> Floor Work, respectively, provided, however, so long as Tenant has substantially completed a Class </font><font style="font-size:11pt;">A </font><font style="font-size:11.5pt;">office installation in the applicable portion of the Premises (i.e. the Thirteenth Floor Premises and the Fourteenth Floor Premises), Tenant may utilize any excess of the Landlord&#8217;s 13</font><sup style="font-size:8.62pt;vertical-align:top;">th </sup><font style="font-size:11.5pt;">Floor Contribution or the Landlord&#8217;s 14</font><sup style="font-size:8.62pt;vertical-align:top;">th</sup><font style="font-size:11.5pt;"> Floor Contribution, as applicable, towards the costs to perform Tenant&#8217;s Initial Work in the other portion of the Premises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(t)</font></font><font style="font-size:11.5pt;">The Tenant&#8217;s Initial Work may not commence nor may Tenant permit Tenant&#8217;s contractor or any other contractors and/or subcontractors to commence any work until all required insurance has been obtained, and until Tenant&#8217;s certificates of such insurance have been delivered to Landlord. Landlord shall have the right to require Tenant, and Tenant shall have the duty, to stop work in the Premises immediately if any of the insurance coverage Tenant is required to carry herein lapses during the course of such work, in which event the Tenant&#8217;s Initial Work may not be resumed until the required insurance is obtained and satisfactory evidence of same is provided to Landlord.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(g)</font></font><font style="font-size:11.5pt;">Landlord will have the right to inspect the performance of the Tenant&#8217;s Initial Work by Tenant&#8217;s contractor and any subcontractor(s), and Tenant agrees to cooperate with Landlord to facilitate such inspections, including notifying Landlord prior to any and all government inspections of the Tenant&#8217;s Initial Work so that Landlord&#8217;s construction manager may (if he or she so desires) be present for such inspections. Landlord shall use reasonable and diligent efforts not to interfere unreasonably with the performance of the Tenant&#8217;s Initial Work during the course of any inspections by Landlord pursuant to this subparagraph.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(h)</font></font><font style="font-size:11.5pt;">Upon substantial completion of the Tenant&#8217;s Initial Work, Tenant shall deliver to Landlord a written notice (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Completion Notice&#8221;) </b><font style="font-size:11.5pt;">certifying that the Tenant&#8217;s Initial Work is substantially complete. Within five (5) days after Tenant delivers the Completion Notice, Tenant and a representative of Landlord shall jointly inspect the Premises with Tenant&#8217;s architect and Tenant&#8217;s contractor. </font><font style="font-size:11pt;">If, </font><font style="font-size:11.5pt;">as a result of the aforementioned joint inspection, either Landlord or Tenant discovers minor deviations or variations from the Construction Drawings of a nature commonly found on a &#8220;punch list&#8221; (as that term is used in the construction industry), Tenant shall promptly notify Tenant&#8217;s contractor of such deviations; provided, however, that in the event of a dispute, Landlord (or Landlord&#8217;s Representative) and Tenant (or Tenant&#8217;s contractor) shall negotiate in good faith, using their reasonable discretion, to determine which items constitute punch list items. Tenant&#8217;s construction contract for the Tenant&#8217;s Initial Work will require that Tenant&#8217;s Contractor cause all such punch list items to be remedied as soon as is practicable after the date of such joint inspection, and Tenant will use all reasonable and diligent efforts to enforce such obligation. </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Substantial Completion&#8221;, &#8220;Substantially Complete&#8221; </b><font style="font-size:11.5pt;">and phrases of a similar nature shall mean, with regard to Tenant&#8217;s Initial Work, </font><font style="font-size:11pt;">(1</font><font style="font-size:11.5pt;">)completion of Tenant&#8217;s Initial Work in accordance with the Construction Drawings therefor (as modified by any approved change orders thereto), other than de minimis or immaterial deviations and minor substitutions of materials, other non-substantial items of construction, mechanical adjustment or decoration that remain to be performed (i.e. so-called </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;punchlist items&#8221;) </b><font style="font-size:11.5pt;">which will not unreasonably interfere with Tenant&#8217;s ability to lawfully take occupancy of the Premises or to conduct its business therein; and (2)Tenant has obtained all governmental inspection and other approvals required to be obtained by Tenant in connection with such construction (including without limitation, a permanent or temporary certificate of occupancy or its equivalent permitting lawful occupancy the Premises), subject only to a final inspection necessary to</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:73.85pt;margin:0pt 0pt 0pt 8.05pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">convert a temporary certificate of occupancy to a final certificate of occupancy, and subject to Tenant&#8217;s obligation to complete all such work.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(i)</font></font><font style="font-size:11pt;">Tenant and its contractors performing the Tenant&#8217;s Initial Work shall provide copies of warranties for the Tenant&#8217;s Initial Work and the materials and equipment which are incorporated into the Building and Premises in connection therewith, as well as provide to Landlord all operating and maintenance manuals for all equipment (other than Tenant&#8217;s office equipment) incorporated into the Building and/or Premises as part of the Tenant&#8217;s Initial Work. Tenant shall enforce all such warranties. Without limitation, all aspects of the Tenant&#8217;s Initial Work shall be warranted to be free from defects in design and workmanship for a period of not less than one (1) year from Substantial Completion of the Tenant&#8217;s Initial Work.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(j)</font></font><font style="font-size:11pt;">Tenant shall reimburse Landlord on demand, as Additional Rent, for any actual, out-of-pocket third-party costs (including engineers&#8217; and architects&#8217; fees and expenses but excluding in-house personnel of Landlord or its parent company) incurred by Landlord in connection with review and approval of the Construction Drawings, Change Orders, and any inspections or other oversight by Landlord during the performance of Tenant&#8217;s Initial Work. Except for such out-of-pocket expenses, Landlord will not charge Tenant any construction management or supervisory fee in connection with Tenant&#8217;s Initial Work, unless Landlord and Tenant otherwise agree that Landlord will manage the performance of Tenant&#8217;s Initial Work on Tenant&#8217;s behalf.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(k)</font></font><font style="font-size:11pt;">In accordance with </font><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit D,</b><font style="font-size:11pt;"> Tenant shall have access, on a non-exclusive, first-come, first-serve basis, to freight elevators serving the Building during Tenant&#8217;s performance of Tenant&#8217;s Initial Work and Tenant&#8217;s move-in to the Premises and Tenant shall pay as an overtime charge for use of such freight elevators and loading docks during non&#173; Business Hours, at Landlord&#8217;s then building standard rate from time to time charged to the tenants in the Building for such after-hours usage (which standard charge currently includes use of both the freight elevators and loading areas), which shall constitute Additional Rent under this Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">5.3</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">EXTRA HAZARDOUS USE.</u><font style="font-size:11pt;"> Tenant covenants and agrees that Tenant will not do or permit anything to be done in or upon the Premises, or bring in anything or keep anything therein, which shall increase the rate of property or liability insurance on the Premises or the Property above the standard rate applicable to Premises being occupied for the Permitted Uses. If the premium or rates payable with respect to any policy or policies of insurance carried by or on behalf of Landlord with respect to the Property increases as a result of any act or activity on or use of the Premises during the Term or payment by the insurer of any claim arising from any act or neglect of Tenant, its employees, agents, contractors or invitees, Tenant shall pay such increase, from time to time, within thirty (30) days after demand therefor by Landlord, as Additional Rent.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">5.4</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">INSTALLATIONS AND ALTERATIONS BY TENANT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11pt;">Tenant shall not make any alterations, additions (including, for the purposes hereof, wall-to-wall carpeting), or improvements (the foregoing referred to as </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Alterations&#8221;) </b><font style="font-size:11pt;">in or to the Premises (including Tenant&#8217;s Initial Work), without Landlord&#8217;s prior written consent, provided, however, Tenant may make Cosmetic Alterations (as hereinafter defined) to the Premises without Landlord&#8217;s consent so long as Landlord is notified in writing at</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">least ten </font><font style="font-size:11pt;">(10</font><font style="font-size:11.5pt;">) days prior to commencement of any such Cosmetic Alterations. Tenant is not required to notify Landlord prior to hanging pictures or similar decorations in the Premises. For purposes hereof, </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Cosmetic Alterations&#8221; </b><font style="font-size:11.5pt;">shall mean non-structural alterations to the Premises which (1) do not affect any area of the Building outside of the Premises, (2) are not visible from the exterior of the Premises or the Building, (3) do not affect or involve the Building&#8217;s electrical, plumbing, mechanical or fire/life safety systems or any other systems of the Building, and (4) cost less than $50,000 in any consecutive 12-month period and do not require the issuance of a building permit. Any such Alteration (other than picture hanging and other similar decorations) shall (i) be in accordance with the provisions of </font><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit D</b><b style="font-size:11.5pt;font-weight:bold;"> (Tenant&#8217;s Work Requirements), </b><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit E</b><b style="font-size:11.5pt;font-weight:bold;"> (Contractor&#8217;s Insurance Requirements), </b><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit F</b><b style="font-size:11.5pt;font-weight:bold;"> (Building Standards) </b><font style="font-size:11.5pt;">and </font><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit G</b><b style="font-size:11.5pt;font-weight:bold;"> (Tenant Plan Requirements) </b><font style="font-size:11.5pt;">of this Lease (unless otherwise approved by Landlord), (ii) be made at Tenant&#8217;s sole expense, and shall be performed at such times and in such manner as Landlord may from time to time reasonably designate and (iii) upon the expiration or earlier termination of the Term of this Lease, become part of the Premises and the property of Landlord (except as otherwise set forth in </font><b style="font-size:11.5pt;font-weight:bold;">Section 5.4(b</b><font style="font-size:11.5pt;">). Prior to commencing any Alterations to the Premises, Tenant shall obtain all state, local and other necessary permits and shall carry during the continuation of such Alterations such insurance (naming Landlord, Agent, any Superior Mortgagee, Superior Lessor and any other parties reasonably designated by Landlord as additional insureds) and obtain such payment, performance and lien bonds as Landlord shall reasonably require or other security reasonably designated by Landlord. Landlord agrees that the original named Tenant under this Lease, Grant Thornton LLP or its successor, will not be required to obtain any payment, performance or lien bonds or other security for the performance of Tenant&#8217;s Initial Work. Tenant acknowledges and agrees that any review or approval by Landlord of any plans and/or specifications with respect to any Alterations is solely for Landlord&#8217;s benefit, and without any representation or warranty whatsoever to Tenant with respect to the adequacy, correctness or efficiency thereof or otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:44.75pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11.5pt;">All articles of personal property and all business fixtures, machinery and equipment and furniture owned or installed by Tenant solely at its expense in the Premises </font><b style="font-size:11.5pt;font-weight:bold;">(&#8220;Tenant&#8217;s Removable Property&#8221;) </b><font style="font-size:11.5pt;">shall remain the property of Tenant and may be removed by Tenant at any time prior to the expiration of this Lease, provided that Tenant, at its expense, shall repair any damage to the Building caused by such removal. Notwithstanding anything in this Lease to the contrary, Landlord shall have the right to require Tenant to remove any and all Alterations made to the Premises (including Tenant&#8217;s Initial Work) which constitute above&#173; standard office improvements, repair any damage caused by such removal and restore the Premises and the Building to its condition prior to the installation of such above standard office improvements. For purposes of this Lease, the term </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;above standard office improvements&#8221; </b><font style="font-size:11.5pt;">shall mean improvements for an area of similar size as the Premises which are unusual or extraordinary for normal office and administrative usage in the downtown Boston area, including without limitation, curved walls, circular rooms, internal stairways, data centers, slab cuts, kitchens, cafeterias, raised flooring, private showers or executive bathrooms, safes or vault areas, fitness or daycare facilities, print shops, emergency generators, UPS systems and equipment, vertical and horizontal transportation systems, and areas involving special electrical or fire suppression systems. Tenant may, at the time Tenant submits a request for Landlord&#8217;s approval for any Alterations (including Tenant&#8217;s Initial Work), request in a separate written notice delivered to Landlord and specifically referring to this </font><b style="font-size:11.5pt;font-weight:bold;">Section 5.4(b) </b><font style="font-size:11.5pt;">that Landlord specify whether the Alterations shown on the plans constitute above standard office improvements which</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:73.25pt;margin:0pt 0pt 0pt 7.2pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:1.25pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Tenant will be required to remove at the expiration or earlier termination of the Term. If Tenant makes such request to Landlord, Landlord agrees to notify Tenant within fifteen (15) Business Days after receipt of such request if Landlord considers any such Alterations to be above standard office improvements which must be removed at the end of the Term. In addition, Tenant may, not more than twice during the Term, deliver to Landlord a written request that Landlord confirm whether or not there are any above standard office improvements in the Premises which Tenant is required to remove and Landlord agrees to notify Tenant within fifteen (15) Business Days after receipt of such request if Landlord considers any such Alterations to be above standard office improvements which must be removed at the end of the Term. If Tenant fails to request either at the time of plan submission to Landlord or at such other time during the Term that Landlord specify whether any Alterations Tenant proposes to make constitutes above&#173; standard office improvements, Landlord may notify Tenant at any time prior to the date that is thirty (30) days prior to the expiration of the Term, of Landlord&#8217;s determination that any such Alterations constitute above standard office improvements and Tenant shall so remove such above standard office improvements at the expiration or earlier termination of this Lease and repair any damage caused by the installation or removal of such above standard office improvements.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11pt;">Notice is hereby given that Landlord shall not be liable for any labor or materials furnished or to be furnished to Tenant upon credit, and that no mechanic&#8217;s or other lien for any such labor or materials shall attach to or affect the reversion or other estate or interest of Landlord in and to the Premises, the Building or the Property. To the maximum extent permitted by applicable Law, at such time as any contractor commences to perform work on behalf of Tenant, Landlord may require that such contractor (and any subcontractors) furnish a written statement acknowledging the provisions set forth in the previous sentence. Whenever and as often as any mechanic&#8217;s or similar lien shall have been filed against the Property based upon any act or interest of Tenant or of anyone claiming through Tenant, Tenant, at its expense, shall procure the satisfaction or discharge of record of all such liens and encumbrances within thirty (30) days after Tenant shall have received notice of the filing thereof by bonding (acceptable to Landlord), deposit or payment as will remove or satisfy the lien; or in default thereof, Landlord may cause any such lien or liens to be removed of record by payment of bond or otherwise, as Landlord may elect, and Tenant will reimburse Landlord for all costs and expenses incidental to the removal of any such lien or liens incurred by Landlord. Tenant shall indemnify and save harmless Landlord of and from all claims, reasonable counsel fees, loss, damage and expenses whatsoever by reason of any liens, charges or payment of any kind whatsoever that may be incurred or become chargeable against Landlord or the Building of which the Premises are a part, or Tenant&#8217;s Alterations or any part thereof, by reason of any work done or to be done or materials furnished or to be furnished to or upon the Premises in connection with Tenant&#8217;s Alterations.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(d)</font></font><font style="font-size:11pt;">In the course of any work being performed by Tenant (including without limitation, &#8220;field installations&#8221; of Tenant&#8217;s Removable Prope1iy) other than by Tenant&#8217;s employees, Tenant agrees to employ union labor compatible with that being employed by Landlord for work in or to the Building, and not to employ or permit the use of any labor or otherwise take any action which might result in a labor dispute involving personnel providing services or construction in the Building pursuant to arrangements made by Landlord.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">5.5</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">HAZARDOUS MATERIALS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:46.9pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11.5pt;">Tenant may use chemicals such as adhesives, lubricants, ink, solvents, cleaning fluids all of the kind and in amounts and in the manner customarily found and used in business offices in order to conduct its business at the Premises and to maintain and operate the business machines located in the Premises provided that the same are stored and maintained strictly in accordance with all applicable Laws. Tenant may also use and maintain in the Premises standard batteries associated with IDF or data rooms in the Premises, provided Tenant notifies Landlord in writing of the brand, size, and serial numbers of any such batteries and any such batteries are stored, maintained and disposed of strictly in accordance with all applicable Laws. Except for the foregoing, Tenant shall not use, store, handle, treat, transport, release or dispose of any other Hazardous Materials on or about the Premises or the Property. Landlord represents to Tenant that, as of the date of this Lease and without any investigation or testing by or on behalf of Landlord, Landlord has no knowledge of (i) any Environmental Condition at the Property, nor (ii) the presence in or on the Premises of any Hazardous Materials in amounts and/or under conditions which are in violation of existing applicable Environmental Laws. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">any Hazardous Materials (including any asbestos or asbestos-containing material) are discovered in the Premises during the performance of Tenant&#8217;s Initial Work, in such amounts or at such levels which, under applicable Law, requires removal or remediation, and such Hazardous Materials are not the result of any Environmental Condition caused by any wrongful act or omission of Tenant or its agents, employees or contractors, then, as Tenant&#8217;s sole remedy and Landlord&#8217;s sole obligation with respect to such Hazardous Materials or Environmental Condition, Landlord shall, at Landlord&#8217;s sole cost and expense (and without including such costs in Operating Expenses), take any such action required by any governmental authority to clean up, remove, treat or abate (including, without limitation, subsequent monitoring requirements) such Hazardous Materials or remedy such Environmental Condition, in either case, in accordance with applicable Environmental Laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:45.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11.5pt;">Landlord shall be responsible to remove, remediate or abate, if and to the extent required by, and in accordance with, applicable Laws (x) Hazardous Materials located in the common areas, the structural elements or the base building systems of the Building, (y) Hazardous Materials that are present in the Building (including the Premises) as the result of the actions of Landlord or any Landlord Party, or (z) Hazardous Materials which Landlord reasonably determines to have been in, at or on the Premises prior to the Commencement Date. Notwithstanding the foregoing, Landlord&#8217;s obligation to remove, remediate or abate Hazardous Materials in clause (x) above of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 5.5(b) </b><font style="font-size:11.5pt;">shall not apply to requirements of Environmental Laws resulting from the use of Hazardous Materials, or additions, alterations or improvements in the Premises by Tenant or anyone claiming by, through or under Tenant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:45.2pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11.5pt;">Any handling, treatment, transportation, storage, disposal or use of Hazardous Materials by Tenant in or about the Premises or the Property and Tenant&#8217;s use of the Premises shall comply with all applicable Environmental Laws. Tenant shall, within ten (10) Business Days of Landlord&#8217;s written request therefor, disclose in writing all Hazardous Materials that are being used by Tenant in the Premises, the nature of such use and the manner of storage and disposal. Without Landlord&#8217;s prior written consent, Tenant shall not conduct any sampling or investigation of soil or groundwater on the Property to determine the presence of any constituents therein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:44.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(d)</font></font><font style="font-size:11.5pt;">Tenant shall indemnify, defend upon demand with counsel reasonably acceptable to Landlord, and hold Landlord harmless from and against, any liabilities, losses</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.25pt;margin:0pt 0pt 0pt 8.2pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">claims, damages, interest, penalties, fines, attorneys&#8217; fees, experts&#8217; fees, court costs, remediation costs, and other expenses which result from the use, storage, handling, treatment, transportation, release, threat of release or disposal of Hazardous Materials in or about the Premises or the Property by Tenant or Tenant&#8217;s agents, employees, contractors or invitees. The provisions of this </font><b style="font-size:11pt;font-weight:bold;">paragraph (d) </b><font style="font-size:11.5pt;">shall survive the expiration or earlier termination of this Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:46.65pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(e)</font></font><font style="font-size:11.5pt;">Tenant shall give written notice to Landlord as soon as reasonably practicable of (i) any communication actually received by Tenant from any governmental authority concerning Hazardous Materials which relates to the Premises or the Property, and (ii) any Environmental Condition of which Tenant is aware.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">ARTICLE VI </b><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">ASSIGNMENT AND SUBLETTING</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">6.1</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">PROHIBITION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11.5pt;">Tenant covenants and agrees that whether voluntarily, involuntarily, by operation of law or otherwise neither this Lease nor the term and estate hereby granted, nor any interest herein or therein, will be assigned, mortgaged, pledged, encumbered or otherwise transferred and that neither the Premises nor any part thereof will be encumbered in any manner by reason of any act or omission on the part of Tenant, or used or occupied or permitted to be used or occupied, by anyone other than Tenant, or for any use or purpose other than a Permitted Use, or be sublet (which term, without limitation, shall include granting of concessions, licenses and the like) in whole or in part. Tenant shall not offer or advertise the Premises for assignment or subletting without Landlord&#8217;s prior written approval of Tenant&#8217;s offering or advertising materials, which approval will not be unreasonably withheld or delayed. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Tenant (or any subtenant) is a corporation, the provisions of this </font><b style="font-size:11pt;font-weight:bold;">Section 6.t(a) </b><font style="font-size:11.5pt;">shall apply to a transfer (however accomplished, whether in a single transaction or in a series of related or unrelated transactions) of stock (or any other mechanism such as, by way of example, the issuance of additional stock, a stock voting agreement or change in class(es) of stock) which results in a change of control of Tenant (or such subtenant) as if such transfer of stock (or other mechanism) which results in a change of control of Tenant (or such subtenant) were an assignment of this Lease except that the transfer of the outstanding capital stock of Tenant or any subtenant by persons or parties through the &#8220;over the counter market&#8221; or through any recognized stock exchange, (other than those deemed &#8220;insiders&#8221; within the meaning of the Securities Exchange Act of 1934, as amended) shall not be deemed an assignment of this Lease. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Tenant (or such subtenant) is a partnership, joint venture or limited liability company (herein called a </font><b style="font-size:11pt;font-weight:bold;">&#8220;LLC&#8221;), </b><font style="font-size:11.5pt;">the provisions of this </font><b style="font-size:11pt;font-weight:bold;">Section 6.l(a) </b><font style="font-size:11.5pt;">shall apply with respect to a transfer (by one or more transfers) of an interest in the distributions of profits and losses of such partnership, joint venture or LLC (or other mechanism, such as, by way of example, the creation of additional general partnership or limited partnership interests) which results in a change of control of such partnership, joint venture or LLC, as if such transfer of an interest in the distributions of profits and losses of such partnership, joint venture or LLC which results in a change of control of such partnership, joint venture or LLC were an assignment of this Lease. The foregoing shall not apply to a mere name change of Tenant without any other change in the ownership of interests in Tenant or to a conversion or change of Tenant into another type of entity (e.g., the conversion of a corporation into a limited liability company) so long as the conversion does not further limit</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:73.95pt;margin:0pt 0pt 0pt 8.2pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.25pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">any liability of Tenant to Landlord under this Lease or reduce the tangible net worth of Tenant from the tangible net worth of Tenant immediately prior to such conversion.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11.5pt;">The provisions of </font><b style="font-size:11.5pt;font-weight:bold;">paragraph (a) </b><font style="font-size:11.5pt;">shall not apply to (and Landlord consent shall not be required in connection with) the following transfers: </font><font style="font-size:11pt;">(I) </font><font style="font-size:11.5pt;">transfers to an entity into or with which Tenant is merged or consolidated, or (2) transfers to any entity which purchases all or substantially all of Tenant&#8217;s voting stock, partnership interests or other membership interests, or (3) transfers to an entity to which all or substantially all of Tenant&#8217;s assets are transferred (the transferee in clauses (1), (2) or (3) being referred to as a </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Tenant Successor&#8221;); </b><font style="font-size:11.5pt;">or (4) transfers (including, without limitation, subleases or other occupancy agreements) to any entity which controls or is controlled by Tenant or is under common control with Tenant (the transferee in clause (4) being referred to as a </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Tenant Affiliate&#8221;); </b><font style="font-size:11.5pt;">provided that in any of such events:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(i)</font><font style="display:inline-block;width:25.15pt;"></font><font style="font-size:11.5pt;">with respect to a Tenant Successor, the Tenant Successor is a reputable entity of good character and has a net worth computed in accordance with generally accepted accounting principles consistently applied at least equal to the greater of (1) the net worth of Tenant immediately prior to such merger, consolidation or transfer, or (2) the net worth of Tenant herein named on the date of this Lease,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(ii)</font><font style="display:inline-block;width:21.95pt;"></font><font style="font-size:11.5pt;">with respect to a Tenant Affiliate such Tenant Affiliate has a net worth which, in Landlord&#8217;s reasonable judgment, is sufficient to meet the financial and other obligations of Tenant under this Lease;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(iii)</font><font style="display:inline-block;width:18.75pt;"></font><font style="font-size:11.5pt;">proof reasonably satisfactory to Landlord of such net worth shall have been delivered to Landlord at least ten </font><font style="font-size:11pt;">(I </font><font style="font-size:11.5pt;">0) days prior to the effective date of any such transaction; provided, however, that if, due to securities regulations or other applicable laws or a written confidentiality agreement, Tenant is unable to provide prior notice of such transaction, then Tenant shall provide such notice to Landlord within ten</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(10) days after the date of such transaction,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(iv)</font><font style="display:inline-block;width:19.4pt;"></font><font style="font-size:11.5pt;">the assignee agrees directly with Landlord, by written instrument in form satisfactory to Landlord, to be bound by all the obligations of Tenant hereunder including, without limitation, the covenant against further assignment and subletting, and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(v)</font><font style="display:inline-block;width:22.59pt;"></font><font style="font-size:11.5pt;">such merger, consolidation or transfer shall be for a good business purpose and not principally for the purpose of transferring this Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">For purposes of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 6.l(b</b><font style="font-size:11.5pt;">), the term </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;control&#8221; </b><font style="font-size:11.5pt;">shall mean, in the case of a corporation, ownership or voting control, directly or indirectly, of at least fifty percent (50%) of all the voting stock, and in the case of a joint venture or partnership or similar entity, ownership, directly or indirectly, of at least fifty percent (50%) of all the general or other partnership (or similar) interests therein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11.5pt;">Provided that Tenant is not in default of any of Tenant&#8217;s obligations under this Lease beyond applicable notice and cure periods and subject to Landlord&#8217;s rights pursuant to </font><b style="font-size:11.5pt;font-weight:bold;">Section 6.3 </b><font style="font-size:11.5pt;">below, Landlord&#8217;s consent to a proposed assignment or sublease shall not be unreasonably withheld, conditioned or delayed, provided and upon condition that:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(i)</font><font style="display:inline-block;width:25.15pt;"></font><font style="font-size:11.5pt;">In Landlord&#8217;s reasonable judgment the proposed assignee or subtenant is engaged in a business which is in keeping with the then standards of the Building and Property and the proposed use is limited to the Permitted Use;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(ii)</font><font style="display:inline-block;width:21.95pt;"></font><font style="font-size:11.5pt;">The proposed assignee or subtenant is a reputable person or entity with sufficient financial worth considering the responsibility involved, based on evidence provided by Tenant (and others) to Landlord, as determined by Landlord in its reasonable discretion;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(iii)</font><font style="display:inline-block;width:18.75pt;"></font><font style="font-size:11.5pt;">Neither (A) the proposed assignee or sublessee nor (B) any person or entity which, directly or indirectly, controls, is controlled by, or is under common control with, the proposed assignee or sublessee, is then an occupant of any part of the Property;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(iv)</font><font style="display:inline-block;width:19.4pt;"></font><font style="font-size:11.5pt;">The proposed assignee or sublessee is not a person or entity with whom Landlord is then, or during the preceding six (6) months has been, actively negotiating to lease space at the Property;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(v)</font><font style="display:inline-block;width:22.59pt;"></font><font style="font-size:11.5pt;">The proposed sublease or assignment shall be in form reasonably satisfactory to Landlord and shall comply with the applicable provisions of this </font><b style="font-size:11.5pt;font-weight:bold;">Article VI;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(vi)</font><font style="display:inline-block;width:19.4pt;"></font><font style="font-size:11.5pt;">Except for listings with a commercial real estate broker, Tenant shall not have advertised or publicized in any way the availability of the Premises without prior notice to and approval by Landlord, which approval shall not be unreasonably withheld, conditioned or delayed;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(vii)</font><font style="display:inline-block;width:16.2pt;"></font><font style="font-size:11.5pt;">With respect to and after taking into account the proposed sublease, there will not be more than three (3) different occupants (including Tenant) in possession of the Premises; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(viii)</font><font style="display:inline-block;width:13.01pt;"></font><font style="font-size:11.5pt;">there shall not be any Default of Tenant (defined in </font><b style="font-size:11.5pt;font-weight:bold;">Section 13.t) </b><font style="font-size:11.5pt;">in existence and there shall not have been two (2) or more Defaults of Tenant during the Term.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">Tenant covenants and agrees that it shall be reasonable for Landlord to condition any consent to a proposed assignment of this Lease (except an assignment permitted without Landlord&#8217;s consent pursuant to </font><b style="font-size:11.5pt;font-weight:bold;">Section 6.l(b)) </b><font style="font-size:11.5pt;">on Tenant depositing with Landlord the estimated Tenant&#8217;s Share of the Remaining High Street Rent Obligations reasonably estimated by Landlord to be payable by Tenant for the remainder of the term of the High Street Sublease, provided, however, such deposit shall be subject to reconciliation of payments actually due in accordance with </font><b style="font-size:11.5pt;font-weight:bold;">Section 2.3 </b><font style="font-size:11.5pt;">of this Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(d)</font></font><font style="font-size:11.5pt;">Tenant shall request Landlord&#8217;s consent to a proposed assignment or sublease pursuant to this </font><b style="font-size:11.5pt;font-weight:bold;">Article VI </b><font style="font-size:11.5pt;">by submitting a written request therefore (a </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Consent Request Notice&#8221;) </b><font style="font-size:11.5pt;">which notice shall set forth (i) in the case of a proposed subletting, the area proposed to be sublet, and, in the case of a proposed assignment such notice shall set forth Tenant&#8217;s intention to assign this Lease, (ii) the term of the proposed subletting including the proposed dates of the commencement and the expiration of the term of the proposed sublease or the effective date of the proposed assignment, as the case may be, (iii) the rents, work contributions, and all other economic and financial terms (collectively, the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Economic Terms&#8221;), </b><font style="font-size:11.5pt;">and all other material provisions that are proposed to be included in the transaction, (iv) in reasonable detail, the identity of the proposed assignee or subtenant, the nature of its business and its proposed use of the Premises, (v) current financial information with respect to the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:73pt;margin:0pt 0pt 0pt 7.7pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">proposed assignee or subtenant, including, without limitation, its most recent financial report and (vi) such other information as Landlord may reasonably request.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(e)</font></font><font style="font-size:11pt;">If, this Lease be assigned, or if the Premises or any part thereof be sublet or occupied by anyone other than Tenant, whether or not in violation of the terms and conditions of this Lease, Landlord may, at any time and from time to time after a Default of Tenant, collect rent and other charges from the assignee, subtenant or occupant, and apply the net amount collected to the rent and other charges herein reserved, but no such assignment, subletting, occupancy, collection or modification of any provisions of this Lease shall be deemed a waiver of this covenant, or the acceptance of the assignee, subtenant or occupant as a tenant or a release of Tenant from the further performance of covenants on the part of Tenant to be performed hereunder. Any consent by Landlord to a particular assignment, subletting or occupancy or other act for which Landlord&#8217;s consent is required under </font><b style="font-size:11.5pt;font-weight:bold;">paragraph (a) </b><font style="font-size:11pt;">of </font><b style="font-size:11.5pt;font-weight:bold;">Section 6.1 </b><font style="font-size:11pt;">shall not in any way diminish the prohibition stated in </font><b style="font-size:11.5pt;font-weight:bold;">paragraph (a) </b><font style="font-size:11pt;">of </font><b style="font-size:11.5pt;font-weight:bold;">Section 6.1 </b><font style="font-size:11pt;">as to any further such assignment, subletting or occupancy or other act or the continuing liability of the original named Tenant. No assignment or subletting hereunder shall relieve Tenant from its obligations hereunder and Tenant shall remain fully and primarily liable therefor. No such assignment, subletting, or occupancy shall affect or be contrary to Permitted Uses. Any consent by Landlord to a particular assignment, subletting or occupancy shall be revocable, and any assignment, subletting or occupancy shall be void </font><i style="font-size:11.5pt;font-style:italic;">ab initio, </i><font style="font-size:11pt;">if, with respect to an assignment, the same shall fail to require that such assignee or occupant agree therein to be independently bound by and upon all of the covenants, agreements, terms, provisions and conditions set forth in this Lease on the part of Tenant to be kept and performed, or, with respect to a sublease, the same shall fail to require that the sublease is subject and subordinate to the terms of this Lease and the subtenant agrees to be bound by and upon all of the covenants, agreements, terms, provisions and conditions set forth in this Lease in so far as they relate to the subleased premises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">6.2</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">EXCESS PAYMENTS.</u><font style="font-size:11pt;"> Except for transfers permitted without Landlord&#8217;s prior consent pursuant to </font><b style="font-size:11.5pt;font-weight:bold;">Section 6.l(b), </b><font style="font-size:11pt;">if Tenant assigns this Lease or sublets the Premises or any portion thereof to any party other than a Permitted Transferee, Tenant shall pay to Landlord, as Additional Rent, fifty percent (50%) of the amount received by Tenant, if any, by which (a) any and all compensation received by Tenant as a result of such assignment or subletting, net of brokerage fees, the costs of leasehold improvements or improvement allowances, reasonable legal fees and other reasonable costs of subletting actually incurred by Tenant (expressly excluding any lease takeover arrangements) in connection with such assignment or subletting (prorated over the term of the assignment or subletting), exceeds (b) in the case of an assignment, the Basic Rent, Electricity Charges, Escalation Charges and all other charges due under this Lease, and in the case of a subletting, the portion of the Basic Rent, Electricity Charges, Escalation Charges and all other charges allocable to the portion of the Premises subject to such subletting. Such payments shall be made on the date the corresponding payments under this Lease are due. Notwithstanding the foregoing, the provisions of this Section shall impose no obligation on Landlord to consent to an assignment of this Lease or a subletting of all or a portion of the Premises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">6.3</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">LANDLORD&#8217;S RECAPTURE RIGHT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11pt;">Except for any assignment or sublease which does not require Landlord&#8217;s consent pursuant to </font><b style="font-size:11.5pt;font-weight:bold;">Section 6.l(b) </b><font style="font-size:11pt;">hereof, a Consent Request Notice shall be deemed an irrevocable offer from Tenant to Landlord whereby Landlord (or Landlord&#8217;s designee) may, at its</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.2pt;margin:0pt 0pt 0pt 8.05pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.65pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">option, (a) sublease such space from Tenant upon the terms and conditions hereinafter set forth (if the proposed transaction is a sublease of all or part of the Premises), (b) have this Lease assigned to it or its designee or terminate this Lease (if the proposed transaction is an assignment or a sublease of all or substantially all of the Premises or a sublease of a portion of the Premises which, when aggregated with other subleases then in effect, covers all or substantially all of the Premises), or (c) terminate this Lease with respect to the space covered by the proposed sublease (if the proposed transaction is a sublease of part of the Premises for substantially all of the then Term). Said option may be exercised by Landlord by notice to Tenant at any time within thirty (30) days after the date (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Recapture Notice Date&#8221;) </b><font style="font-size:11.5pt;">that is the later to occur of </font><font style="font-size:11pt;">(i) </font><font style="font-size:11.5pt;">the date that such notice has been given by Tenant to Landlord and (ii) the date that Landlord shall have received all other information required to be furnished to Landlord by Tenant pursuant to the provisions of this </font><b style="font-size:11.5pt;font-weight:bold;">Article VI; </b><font style="font-size:11.5pt;">and Tenant shall not assign this Lease or sublet such space to any person prior to the Recapture Notice Date. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Landlord exercises its right to terminate this Lease in the case of a proposed assignment or sublease, this Lease shall terminate as of the date (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Recapture Date&#8221;) </b><font style="font-size:11.5pt;">which is the later of (y) sixty (60) days after the date of Landlord&#8217;s election, and (z) the proposed effective date of such assignment or sublease, as if such date were the last day of the Term of this Lease. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Landlord exercises the rights under this Section to terminate this Lease in connection with a proposed sublease of a portion of the Premises, this Lease shall be deemed amended to eliminate the proposed sublease premises from the Premises as of the Recapture Date, and thereafter all Basic Rent, Electricity Charges and Escalation Charges shall be appropriately prorated to reflect the reduction of the Premises as of the Recapture Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Landlord does not initially exercise its rights under this </font><b style="font-size:11.5pt;font-weight:bold;">Section 6.3 </b><font style="font-size:11.5pt;">within the time period set forth in </font><b style="font-size:11.5pt;font-weight:bold;">subparagraph (a) </b><font style="font-size:11.5pt;">above, and, thereafter, Tenant wishes to enter into an assignment or sublease on terms and conditions that are not &#8220;substantially similar&#8221; to the terms and conditions set forth in the original notice given to Landlord requesting consent to an assignment or sublease (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Consent Request Notice&#8221;), </b><font style="font-size:11.5pt;">Tenant shall give Landlord a revised notice and Landlord shall again have all of Landlord&#8217;s rights under this </font><b style="font-size:11.5pt;font-weight:bold;">Section 6.3 </b><font style="font-size:11.5pt;">with respect thereto as Landlord had with respect to the original Consent Request Notice. The terms and conditions of the fully-executed transfer document shall be deemed &#8220;substantially similar&#8221; to the terms and conditions set forth in the original Consent Request Notice delivered to Landlord if (i) the economic terms of such proposed sublet or assignment on an aggregate basis differ by 5% or less on a net effective basis in favor of the assignee or sublessee, as applicable, from the terms contained in such Consent Request Notice, and (ii) the restoration obligations of the proposed transferee of the proposed sublet or assignment are substantially the same as those set forth in such Consent Request Notice. In addition, if Tenant does not enter into the proposed assignment or sublease upon the same terms as set forth in the Consent Request Notice and obtain Landlord&#8217;s consent thereto as required under this </font><b style="font-size:11.5pt;font-weight:bold;">Article VI </b><font style="font-size:11.5pt;">within one hundred eighty (180) days following the expiration of the thirty (30) day period for Landlord to exercise Landlord&#8217;s rights under this </font><b style="font-size:11.5pt;font-weight:bold;">Section 6.3, </b><font style="font-size:11.5pt;">then Landlord&#8217;s rights under this </font><b style="font-size:11.5pt;font-weight:bold;">Section 6.3 </b><font style="font-size:11.5pt;">shall revive with respect to the same or any alternative proposed assignment or sublease which Tenant proposes to enter into after such 180-day period expires and Tenant shall again have to comply with the provisions of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 6.3 </b><font style="font-size:11.5pt;">with respect thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Landlord exercises its option to sublet the Premises, such sublease to Landlord or its designee (as subtenant) shall be at the lower of (x) the rental rate per rentable square foot of Basic Rent and Escalation Charges then payable pursuant to this Lease or (y) the rentals set forth in the proposed sublease, and shall be for the same term as that of the proposed</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.2pt;margin:0pt 0pt 0pt 8.3pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">subletting, provided, however, that if the proposed sublease term will expire with less than nine (9)</font><font style="display:inline-block;width:12.58pt;"></font><font style="font-size:11.5pt;"> months remaining in the Term then in effect, Landlord may elect to sublease such space from Tenant for the remainder of the Term and Tenant will have no right to exercise any extension option with respect to such subleased space, and:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(i)</font><font style="display:inline-block;width:25.15pt;"></font><font style="font-size:11.5pt;">The sublease shall be expressly subject to all of the covenants, agreements, terms, provisions and conditions of this Lease except such as are irrelevant or inapplicable, and except as otherwise expressly set forth to the contrary in this section;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(ii)</font><font style="display:inline-block;width:21.95pt;"></font><font style="font-size:11.5pt;">Such sublease shall be upon the same terms and conditions as those contained in the proposed sublease, including any work allowances, tenant concessions and construction obligations of Tenant set forth therein, except such as are irrelevant or inapplicable and except as otherwise expressly set forth to the contrary in this Section;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(iii)</font><font style="display:inline-block;width:18.75pt;"></font><font style="font-size:11.5pt;">Such sublease shall give the sublessee the unqualified and unrestricted right, without Tenant&#8217;s permission, to assign such sublease or any interest therein and/or to sublet the space covered by such sublease or any part or parts of such space and to make any and all changes, alterations, and improvements in the space covered by such sublease; </font><i style="font-size:11.5pt;font-style:italic;">provided </i><font style="font-size:11.5pt;">that, unless Tenant agrees otherwise, Landlord or its assignee or subtenant will, at their respective sole cost and expense, restore the sublet premises to substantially its condition on the commencement of such sublease and Tenant shall not, in any event, be obligated to remove any alterations, decorations and installations made by Landlord or its designee or any subtenant or assignee thereof;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(iv)</font><font style="display:inline-block;width:19.4pt;"></font><font style="font-size:11.5pt;">Such sublease shall provide that any assignee or further subtenant of Landlord or its designee, may, at the election of Landlord, be permitted to make alterations, decorations and installations in such space or any part thereof and shall also provide in substance that any such alterations, decorations and installations in such space therein made by any assignee or subtenant of Landlord or its designee may be removed, in whole or in part, by such assignee or subtenant, at its option, prior to or upon the expiration or other termination of such sublease </font><i style="font-size:11.5pt;font-style:italic;">provided </i><font style="font-size:11.5pt;">that, unless Tenant agrees otherwise, Landlord or its assignee or subtenant will, at their respective sole cost and expense, restore the sublet premises to substantially its condition on the commencement of such sublease and Tenant shall not, in any event, be obligated to remove any alterations, decorations and installations made by Landlord or its designee or any subtenant or assignee thereof; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(v)</font><font style="display:inline-block;width:22.59pt;"></font><font style="font-size:11.5pt;">Such sublease shall also provide that (A) the parties to such sublease expressly negate any intention that any estate created under such sublease be merged with any other estate held by either of said parties, and (B) any assignment or subletting by Landlord or its designee (as the subtenant) may be for any purpose or purposes that Landlord, in Landlord&#8217;s uncontrolled discretion, shall deem suitable or appropriate. Performance by Landlord or its designee under such sublease shall be deemed performance by Tenant of a similar obligation under this Lease related to such space, and any default under any such sublease shall not give rise to a default under a similar obligation in this Lease, nor shall Tenant be liable for any default under this Lease or be deemed to be in default hereunder if such default is occasioned by or arises from</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:63.6pt;margin:0pt 0pt 0pt 44pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.25pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">any act or omission of the subtenant under such sublease or is occasioned by or arises from any act or omission of any occupant under or pursuant to any such sublease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(vi)</font></font><font style="font-size:11.5pt;">Such sublease shall include an agreement of Landlord to indemnify and save harmless Tenant and the Tenant Parties (as hereinafter defined) from and against all claims, loss, cost, damage or expense arising from any accident, injury or damage to any person, or to the property of any person, where such accident, damage or injury results or is claimed to have resulted from the acts, omissions, breach, negligence or willful misconduct of any subtenant or assignee of Landlord under such sublease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">6.4</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">MISCELLANEOUS PROVISIONS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11.5pt;">With respect to each and every sublease or subletting authorized by Landlord under the provisions of this Lease, it is further agreed:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11.5pt;">(i)</font><font style="display:inline-block;width:33.75pt;"></font><font style="font-size:11.5pt;">No subletting shall be for a term (including any renewal or extension options contained in the sublease) ending later than one day prior to the expiration date of this Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11.5pt;">(ii)</font><font style="display:inline-block;width:30.1pt;"></font><font style="font-size:11.5pt;">No sublease shall be valid, and no subtenant shall take possession of the Premises or any part thereof, until an executed counterpart of such sublease (and all ancillary documents executed in connection with, with respect to or modifying such sublease) has been delivered to Landlord.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11.5pt;">(iii)</font><font style="display:inline-block;width:27.01pt;"></font><font style="font-size:11.5pt;">Each sublease shall provide that it is subject and subordinate to this Lease and to any matters to which this Lease is or shall be subordinate, and that in the event of termination, reentry or dispossess by Landlord under this Lease Landlord may, at its option, take over all of the right, title and interest of Tenant, as sublessor, under such sublease, and such subtenant shall, at Landlord&#8217;s option, attorn to Landlord pursuant to the then executory provisions of such sublease, except that Landlord shall not be (A) liable for any previous act or omission of Tenant under such sublease, (B) subject to any credit, offset, claim, counterclaim, demand or defense which such subtenant may have against Tenant, (C) bound by any previous modification of such sublease or by any previous prepayment of more than one </font><font style="font-size:11pt;">(1) </font><font style="font-size:11.5pt;">month&#8217;s rent, </font><font style="font-size:11pt;">in </font><font style="font-size:11.5pt;">either case, not approved by Landlord in writing, (D) bound by any covenant of Tenant to undertake or complete any construction of the Premises or any portion thereof, (E) required to account for any security deposit of the subtenant other than any security deposit actually delivered to Landlord by Tenant, (F) bound by any obligation to make any payment to such subtenant or grant any credits, except for services, repairs, maintenance and restoration provided for under the sublease to be performed after the date of such attornment, (G) responsible for any monies owing by Landlord to the credit of Tenant or (H) required to remove any person occupying the Premises or any part thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11.5pt;">(iv)</font><font style="display:inline-block;width:26.65pt;"></font><font style="font-size:11.5pt;">Each sublease shall provide that the subtenant may not assign its rights thereunder or further sublet the space demised under the sublease, in whole or in part, except in compliance with all of the terms and provisions of this </font><b style="font-size:11.5pt;font-weight:bold;">Article VI.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.45pt;margin:0pt 0pt 0pt 78.7pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11pt;">Except for any subletting by Tenant to Landlord or its designee pursuant to the provisions of this </font><b style="font-size:11.5pt;font-weight:bold;">Article VI, </b><font style="font-size:11pt;">each subletting shall be subject to all of the covenants, agreements, terms, provisions and conditions contained in this Lease. Notwithstanding any such subletting to Landlord or any such subletting to any other subtenant and/or acceptance of rent or additional rent by Landlord from any subtenant, Tenant shall and will remain fully liable for the payment of the Basic Rent, Escalation Charges, Electricity Charges and all other additional charges due and to become due hereunder and for the performance of all the covenants, agreements, terms, provisions and conditions contained in this Lease on the part of Tenant to be performed and all acts and omissions of any licensee or subtenant or anyone claiming under or through any subtenant which shall be in violation of any of the obligations of this Lease, and any such violation shall be deemed to be a violation by Tenant. Tenant further agrees that notwithstanding any such subletting, no other and further subletting of the Premises by Tenant or any person claiming through or under Tenant (except as provided in </font><b style="font-size:11.5pt;font-weight:bold;">Section 6.3 </b><font style="font-size:11pt;">hereof) shall or will be made except upon compliance with and subject to the provisions of this Article.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11pt;">If Landlord shall give or decline to give its consent to any proposed assignment or sublease, or if Landlord shall exercise any of its options under </font><b style="font-size:11.5pt;font-weight:bold;">Section 6.3 </b><font style="font-size:11pt;">hereof, Tenant shall indemnify, defend and hold harmless Landlord against and from any and all loss, liability, damages, costs and expenses (including, but not limited to, reasonable counsel fees) resulting from any claims that may be made against Landlord by the proposed assignee or sub lessee or by any brokers or other persons claiming a commission or similar compensation in connection with the proposed assignment or sublease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">6.5</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">FURTHER REQUIREMENTS.</u><font style="font-size:11pt;"> Tenant shall reimburse Landlord on demand, as Additional Rent, for any out-of-pocket costs (including reasonable attorneys&#8217; fees and expenses) incurred by Landlord in connection with any request for Landlord&#8217;s consent to any actual or proposed assignment or sublease or other act described in </font><b style="font-size:11.5pt;font-weight:bold;">Section 6.1, </b><font style="font-size:11pt;">whether or not consummated and whether or not Landlord&#8217;s consent is required, including the costs of making investigations as to the acceptability of the proposed assignee or subtenant. Any sublease to which Landlord gives its consent shall not be valid unless and until Tenant and the sublessee execute a consent agreement in form and substance satisfactory to Landlord in its reasonable discretion and a fully executed counterpart of such sublease has been delivered to Landlord. The terms of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 6.5 </b><font style="font-size:11pt;">shall not apply to an assignment or sublease pursuant to </font><b style="font-size:11.5pt;font-weight:bold;">Section 6.l(b).</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11.5pt;font-weight:bold;">ARTICLE VII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">RESPONSIBILITY FOR REPAIRS AND CONDITION OF PREMISES; SERVICES TO</b><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"><br></b><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">BE FURNISHED BY LANDLORD</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">7.1</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">LANDLORD REPAIRS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11pt;">Except as otherwise provided in this Lease, Landlord agrees to keep in good order, condition and repair the roof, public areas, exterior walls and structure of the Building (including all plumbing, mechanical and electrical systems installed by Landlord, but specifically excluding any supplemental heating, ventilation or air conditioning equipment or systems installed at Tenant&#8217;s request or installed (whether or not by or on behalf of Tenant) as a result of requirements in excess of building standard design criteria), except that Landlord shall in no event be responsible to Tenant for the repair of glass in the Premises, the doors leading to the Premises, or any condition in the Premises or the Building caused by any act or neglect of</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.25pt;margin:0pt 0pt 0pt 8pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">Tenant, or its invitees or contractors. Landlord shall not be responsible to make any improvements or repairs to the Building unless expressly provided in this Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:46.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11.5pt;">Except as otherwise provided in </font><b style="font-size:11.5pt;font-weight:bold;">Section 7.6(b) </b><font style="font-size:11.5pt;">of this Lease, Landlord shall never be liable for any failure to make repairs which, under the provisions of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 7.1 </b><font style="font-size:11.5pt;">or elsewhere in this Lease, Landlord has undertaken to make unless Tenant has given notice to Landlord of the need to make such repairs or Landlord otherwise has documented, actual knowledge of the need for such repair, and Landlord has failed to commence to make such repairs within a reasonable time (or immediately in the event of an emergency which threatens public safety) after receipt of such notice, or fails to proceed with reasonable diligence to complete such repairs.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:46.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11.5pt;">Except with respect to Tenant&#8217;s obligations under </font><b style="font-size:11.5pt;font-weight:bold;">Section 7.2(b) </b><font style="font-size:11.5pt;">of this Lease to comply with applicable Laws, Landlord shall, as part of Operating Expenses to the extent permitted pursuant to </font><b style="font-size:11.5pt;font-weight:bold;">Article IX </b><font style="font-size:11.5pt;">and </font><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</b><font style="font-size:11.5pt;"> of this Lease, maintain the common areas of the Building, the structural elements of the Building and the base building systems serving the Building in general in compliance with applicable Laws. Landlord agrees to operate the Building, including with respect to building security, as a first-class office building comparable to other Class A, multi-tenant office buildings located in the financial district of Boston, Massachusetts.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">7.2</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">TENANT&#8217;S AGREEMENT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11.5pt;">Tenant will keep neat and clean and shall maintain the Premises (including components of the base building systems which exclusively serve the Premises) and every part thereof in good order, condition and repair, excepting only those repairs for which Landlord is responsible under the terms of this Lease, reasonable wear and tear of the Premises, and damage by fire or other casualty or as a consequence of the exercise of the power of eminent domain; and shall surrender the Premises, at the end of the Term, in such condition.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11.5pt;">Without limitation but subject to Landlord&#8217;s obligations in </font><b style="font-size:11.5pt;font-weight:bold;">Sections 4.2(a), 7.1 </b><font style="font-size:11.5pt;">and </font><b style="font-size:11.5pt;font-weight:bold;">5.5 </b><font style="font-size:11.5pt;">of this Lease, Tenant shall continually during the Term of this Lease maintain the Premises in accordance with all present and future Laws and the standards recommended by the Boston Board of Fire Underwriters applicable to any work, installation, occupancy, use or manner of use by Tenant of the Premises or any part thereof, and shall, at Tenant&#8217;s expense, obtain all permits, licenses and the like required by applicable Law. Tenant shall not be obligated to make structural repairs or alterations to the Premises in order to comply with such Laws unless the need for such repairs or alterations arises from (i) the specific manner and nature of Tenant&#8217;s use or occupancy of the Premises, as distinguished from mere general office use, (ii) the manner of conduct of Tenant&#8217;s business or operation of its installations, equipment or other property therein, (iii) any cause or condition created by or at the instance of the Tenant, including, without limitation, Tenant&#8217;s Initial Work and/or any other Alterations made by Tenant, or (iv) a breach by Tenant of any provisions of this Lease. Tenant shall also be responsible for the cost of compliance with all present and future Laws in respect of the Building to the extent arising from any of the causes set forth in </font><b style="font-size:11.5pt;font-weight:bold;">clauses (i) </b><font style="font-size:11.5pt;">through </font><b style="font-size:11.5pt;font-weight:bold;">(iv) </b><font style="font-size:11.5pt;">of the preceding sentence, in which event Tenant shall be responsible to perform, at Tenant&#8217;s sole cost and expense, such repairs or alterations, whether or not such compliance requires work which is structural or non-structural, ordinary or extraordinary, foreseen or unforeseen. Without limitation of any of Tenant&#8217;s obligation, Tenant shall comply, at Tenant&#8217;s cost and expense, with</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.9pt;margin:0pt 0pt 0pt 8.5pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.6pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">all Laws, including, without limitation, the ADA, with respect to the restrooms on any full floor of the Premises (whether or not any such restroom is existing as of the date of this Lease and whether or not Tenant has retrofitted or altered the same), as well as any Laws that require the installation, modification, or maintenance within the Premises of (y) any fire-rated partitions, gas, smoke or fire detector or alarm, any emergency signage or lighting system, or any sprinkler or other system to extinguish fires, and (z) any handicap facilities. To the extent that the Premises constitute a &#8220;Place of Public Accommodation&#8221; within the meaning of the ADA, Tenant shall be responsible, subject to the requirements of </font><b style="font-size:11pt;font-weight:bold;">Section 5.2, </b><font style="font-size:11pt;">for making the Premises comply with such Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.7pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:35.3pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11pt;">Notwithstanding the provisions of </font><b style="font-size:11pt;font-weight:bold;">Article XII </b><font style="font-size:11pt;">and subject to the provisions of </font><b style="font-size:11pt;font-weight:bold;">Section 10.</b><font style="font-size:11pt;">7 of this Lease, to the maximum extent this provision may be enforceable according to Law, Tenant shall be responsible for the cost of repairs which may be made necessary by reason of damage to the Building caused by any act or neglect of Tenant, or its contractors or invitees (including any damage by fire or other casualty arising therefrom). </font><font style="font-size:11.5pt;">In </font><font style="font-size:11pt;">the event that the premium or rates payable with respect to any policy or policies of insurance purchased by Landlord or Agent with respect to the Property increases as a result of payment by the insurer of any claim arising from the any act or neglect of Tenant, or its contractors or invitees, Tenant shall pay, as Additional Rent, such increase, from time to time, within thirty (30) days after written demand therefor by Landlord and supporting documentation with respect thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:73.2pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:34.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(d)</font></font><font style="font-size:11pt;">Tenant, at its expense, after notice to Landlord, may contest, by appropriate proceedings prosecuted diligently and in good faith, the validity, or applicability to the Premises, of any law or requirement of any public authority, </font><i style="font-size:11.5pt;font-style:italic;">provided </i><font style="font-size:11pt;">that (i) Landlord shall not be subject to criminal penalty or to prosecution for a crime, or any other fine or charge, nor shall the Premises, or any part thereof, or the Building, or any part thereof, be subjected to any lien (unless Tenant shall remove such lien by bonding or otherwise) or encumbrance, by reason of non-compliance or otherwise by reason of such contest; (ii) before the commencement of such contest, Tenant shall furnish to Landlord a cash deposit or other security in amount, form and substance reasonably satisfactory to Landlord and shall indemnify Landlord against the cost thereof and against all liability for damages, interest, penalties and expenses (including reasonable attorneys&#8217; fees and expenses), resulting from or incurred in connection with such contest or non-compliance, (iii) such non-compliance or contest shall not constitute or result in any violation of any Superior Lease or Superior Mortgage (as such terms are defined in </font><b style="font-size:11pt;font-weight:bold;">Section 14.15), </b><font style="font-size:11pt;">or if any such Superior Lease and/or Superior Mortgage shall permit such non&#173; compliance or contest on condition of the taking of action or furnishing of security by Landlord, such action shall be taken and such security shall be furnished at the expense of Tenant, (iv) such non-compliance or contest shall not prevent Landlord from obtaining any and all permits and licenses in connection with the operation of the Building; and (v) Tenant shall keep Landlord advised as to the status of such proceedings. Without limiting the application of the above, Landlord shall be deemed subject to prosecution for a crime if Landlord or Agent, or any officer, director, partner, shareholder or employee of Landlord or Agent, as an individual, is charged with a crime of any kind or degree whatever, whether by service of a summons or otherwise, unless such charge is withdrawn before Landlord or Agent, or such officer, director, partner, shareholder or employee of Landlord or Agent (as the case may be) is required to plead to answer thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:73.2pt;margin:0pt 0pt 0pt 7.75pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.8pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:35.2pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(e)</font></font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">repairs or other obligations are required to be made or performed by Tenant pursuant to the terms hereof, Landlord may demand that Tenant make the same promptly, and if Tenant refuses or neglects to commence such repairs within ten (I 0) Business Days after receipt of a written demand from Landlord and thereafter fails to complete the same within the applicable time period therefore set forth in </font><b style="font-size:11.5pt;font-weight:bold;">Article XIII </b><font style="font-size:11.5pt;">of this Lease (except in the case of emergency, including without limitation, notice of an unsafe condition in the Premises, in which event Landlord may make such repairs immediately and without notice), Landlord may (but shall not be required to do so) enter upon the Premises and perform such repair or other obligation notwithstanding the fact that no specific provision for such substituted performance by Landlord is made in this Lease with respect to such default. In performing such obligation, Landlord may make any payment of money or perform any other act reasonably necessary to perform such repair or other obligation. All sums so paid by Landlord (together with interest at the rate set forth in Section 14.18) and all costs and expenses in connection with the performance of any such act by Landlord shall be deemed to be Additional Rent under this Lease and shall be payable to Landlord immediately on demand. Landlord may exercise the foregoing rights without waiving any other of its rights or releasing Tenant from any of its obligations under this Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">7.3</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">FLOOR LOAD - HEAVY MACHINERY</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.9pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:35.1pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11.5pt;">Tenant shall not place a load upon any floor in the Premises exceeding 80 lbs. per square foot or the maximum which such floor is allowed by Law to carry. Landlord reserves the right to prescribe the weight and position of all business machines and mechanical equipment, including safes, which shall be placed so as to distribute the weight. Business machines and mechanical equipment shall be placed and maintained by Tenant at Tenant&#8217;s expense in settings sufficient, in Landlord&#8217;s judgment, to absorb and prevent vibration, noise and annoyance. Tenant shall not move any safe, heavy machinery, heavy equipment, freight, bulky matter or fixtures into or out of the Building without Landlord&#8217;s prior consent, which consent may include a requirement to provide insurance, naming Landlord and Agent as an insured, in such amounts as Landlord may deem reasonable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.2pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:35.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">any such safe, machinery, equipment, freight, bulky matter or fixtures requires special handling, Tenant agrees to employ only persons holding a Master Rigger&#8217;s License to do such work, and that all work in connection therewith shall comply with Laws. Any such moving shall be at the sole risk and hazard of Tenant, and Tenant will exonerate, indemnify and save Landlord harmless against and from any liability, loss, injury, claim or suit resulting directly or indirectly from such moving.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">7.4</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">BUILDING SERVICES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.7pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:35.3pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11.5pt;">Landlord shall, on Business Days from 8:00 a.m. to 6:00 p.m. and on Saturdays from 8:00 a.m. to 1:00 p.m. (the &#8220;Building Hours&#8221;), furnish heating and cooling </font><b style="font-size:11.5pt;font-weight:bold;">(&#8220;HVAC&#8221;) </b><font style="font-size:11.5pt;">as normal seasonal changes may require to provide reasonably comfortable space temperature and ventilation for occupants of the Premises under normal business operation in accordance with the specifications set forth on </font><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit </b><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">I</u><font style="font-size:11.5pt;"> attached hereto. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Tenant shall require HVAC outside of Building Hours, Landlord shall, upon reasonable advance notice from Tenant, furnish such service and Tenant shall pay therefor Landlord&#8217;s then standard charges as may from time to time be in effect. As of the date of this Lease, the current charge for overtime HVAC is $47 per hour per floor for heat and $80 per hour per floor for cooling, each of which charge is</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 8.5pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.85pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">subject to increase from time to time from and after the Effective Date, but in no event shall the charge to Tenant for overtime heat or overtime cooling increase in any calendar year during the Term from that charged to Tenant in the prior calendar year by more than the annual percentage increase in the CPI from the preceding calendar year. In the event Tenant introduces into the Premises personnel or equipment which overloads the capacity of the Building system or in any other way interferes with the system&#8217;s ability to perform adequately its proper functions, supplementary systems may, if and as needed, at Landlord&#8217;s option, be provided by Landlord, at Tenant&#8217;s expense. In the event Tenant introduces into the Premises personnel or equipment which exceeds the occupancy or electrical load levels specified on </font><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit </b><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">I</u><font style="font-size:11.5pt;"> or in any other way interferes with the system&#8217;s ability to perform adequately its proper functions, including, without limitation, Tenant&#8217;s design, layout or occupancy level of the Premises in a manner which inhibits the HVAC system&#8217;s ability to perform in accordance with the specifications on </font><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit </b><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">I</u><font style="font-size:11.5pt;"> and Tenant fails to correct such interference or overloading within ten (10) days after written notice to Tenant, supplementary systems may, if and as needed, at Landlord&#8217;s option, be provided by Landlord, at Tenant&#8217;s expense, and Landlord shall not be deemed to be in default of Landlord&#8217;s obligation under this </font><b style="font-size:11.5pt;font-weight:bold;">Section 7.4 </b><font style="font-size:11.5pt;">to provide HVAC service to the Premises in accordance with </font><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit </b><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">I</u><font style="font-size:11.5pt;"> to the extent resulting from such interference or overloading by Tenant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11.5pt;">Landlord shall also provide:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(i)</font><font style="display:inline-block;width:25.62pt;"></font><font style="font-size:11.5pt;">Passenger elevator service in common with Landlord and other tenants in the Building, with at least one (1) such elevator serving the Premises operational, subject to Force Majeure and emergency conditions, on a 24 hours a day, seven (7) days per week basis.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(ii)</font><font style="display:inline-block;width:21.95pt;"></font><font style="font-size:11.5pt;">Hot water for lavatory purposes and cold water (at temperatures supplied by the City of Boston) for drinking, lavatory and toilet purposes at a central service area on each floor. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Tenant uses water for any purpose other than for ordinary lavatory and drinking purposes, Landlord may assess a reasonable charge for the additional water so used or install a water meter and thereby measure Tenant&#8217;s water consumption for all purposes. In the latter event, Tenant shall pay the cost of the meter and the cost of installation thereof and shall keep such meter and installation equipment in good working order and repair. Tenant agrees to pay for water consumed, as shown on such meter, together with the sewer charge based on such meter charges, as and when bills are rendered, and in default in making such payment Landlord may pay such charges and collect the same from Tenant as an additional charge.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(iii)</font><font style="display:inline-block;width:18.75pt;"></font><font style="font-size:11.5pt;">Cleaning and janitorial services to the Premises on Business Days (excluding any private and/or executive bathrooms and showers, data centers, pantries, and kitchenettes), provided the same are kept in order by Tenant and no extra services are necessary by reason of any special area of the Premises or any special installations made by Tenant, substantially in accordance with the cleaning standards set forth in </font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit C</u><font style="font-size:11.5pt;"> attached hereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(iv)</font><font style="display:inline-block;width:19.4pt;"></font><font style="font-size:11.5pt;">Free access to the Premises on Business Days during Building Hours and access at all other times subject to reasonable security restrictions from time to time in effect, and subject always to restrictions based on emergency conditions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(v)</font><font style="display:inline-block;width:22.59pt;"></font><font style="font-size:11.5pt;">Subject to Force Majeure and emergency conditions, Landlord or Landlord&#8217;s prope11y manager, as part of Operating Expenses, currently provides one or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:58.85pt;margin:0pt 0pt 0pt 48.3pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">more uniformed attendants in or about the lobby of the Building on a 24 hours per day, 7 days per week basis, security turnstiles with a card access system, a visitor I.D. check-in and closed circuit television monitors. Landlord expressly reserves the right, from time to time during the Term, to increase, reduce, modify or change the level and types of security services in effect at the Building, provided, however, Landlord shall, throughout the Term, provide security services to the Building materially consistent with security services being provided at comparable Class A, multi-tenant high rise office towers in the financial district of Boston, Massachusetts.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.3pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:35.7pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11.5pt;">Tenant shall have access, on a non-exclusive, first come, first serve basis, to the freight elevator and loading area serving the Building during the Term and during Tenant&#8217;s performance of Tenant&#8217;s Initial Work and Tenant&#8217;s move in to the Premises and Tenant shall pay the overtime charge for use of such freight elevators and loading areas outside of the Building&#8217;s standard freight hours (which standard charge currently includes use of both the freight elevators and loading areas), at Landlord&#8217;s then building standard rate from time to time charged to the tenants in the Building for such services, which shall constitute Additional Rent under this Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:73.5pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:34.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(d)</font></font><font style="font-size:11.5pt;">Landlord or Agent currently provides one or more uniformed attendants in or about the lobby of the Building. Such attendant(s) serve functions such as assisting visitors and invitees of tenants and others in the Building, monitoring fire control and alarm equipment, and summoning emergency services to the Building as and when needed. Tenant expressly acknowledges and agrees that: (i) such attendants are not police officers, they are unarmed, and they are not trained in situations involving potentially physical confrontation; and (ii) such attendants have been provided as an amenity to tenants of the Building for the sole purposes set forth above, and not for the purpose of securing any individual tenant premises or guaranteeing the physical safety of Tenant&#8217;s Premises or of Tenant&#8217;s employees, agents, contractors or invitees. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">and to the extent that Tenant desires to provide additional security for the Premises or for such persons or their property, Tenant shall be responsible for so doing, after having first consulted with Landlord and after obtaining Landlord&#8217;s consent, which shall not be unreasonably withheld. Except to the extent resulting from the gross negligence or willful misconduct of Landlord or Landlord&#8217;s agents, employees or contractors, Landlord expressly disclaims any and all responsibility and/or liability for the physical safety of Tenant&#8217;s property, and for that of Tenant&#8217;s employees, agents, contractors and invitees, and, without in any way limiting the operation of Article X hereof, Tenant, for itself and its agents, contractors, invitees and employees, hereby expressly waives any claim, action, cause of action or other right which may accrue or arise as a result of any damage or injury to the person or property of Tenant or any such agent, invitee, contractor or employee. Tenant acknowledges that the Building is located in an urban area, and that crimes against property and persons do occasionally occur. Tenant agrees that, as between Landlord and Tenant, it is Tenant&#8217;s responsibility to advise its employees, agents, contractors and invitees as to necessary and appropriate safety precautions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.65pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:35.35pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(e)</font></font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Landlord or any affiliate of Landlord has elected or at any time during the Term elects to qualify as a real estate investment trust (a </font><b style="font-size:12pt;font-weight:bold;">&#8220;REIT&#8221;), </b><font style="font-size:11.5pt;">any services required or permitted to be performed by Landlord pursuant to this Lease (whether set forth in this </font><b style="font-size:11pt;font-weight:bold;">Article VII </b><font style="font-size:11.5pt;">or elsewhere in this Lease), the charge or cost of which may be treated as impe1missible tenant service income under the Laws governing a REIT, may be performed by a taxable REIT subsidiary that is affiliated with either Landlord or Landlord&#8217;s property manager or by an independent contractor of Landlord or Landlord&#8217;s property manager (the </font><b style="font-size:11pt;font-weight:bold;">&#8220;Service Provider&#8221;).</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.65pt;margin:0pt 0pt 0pt 7.3pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">If </font><font style="font-size:11.5pt;">Tenant is subject to a charge under this Lease for any service, then, at Landlord&#8217;s direction, Tenant will pay such charge either to Landlord for further payment to the Service Provider or directly to the Service Provider, and, in either case, (i) Landlord will credit such payment against any charge for such service made by Landlord to Tenant under this Lease, and (ii) such payment to the Service Provider will not relieve Landlord from any obligation under this Lease concerning the provision of such service.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">7.5</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">ELECTRICITY</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:73.65pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:34.35pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11.5pt;">Tenant acknowledges that Landlord is the owner of all wires, risers, conduits and other electrical equipment used to provide electrical service to the Building, and Tenant agrees that it shall obtain any electrical service that Tenant requires for the Premises directly from the utility company over Landlord&#8217;s existing wires, risers, conduits and other electrical equipment, and Tenant shall timely make all payments for such electrical service invoiced by the utility company. Tenant agrees that its &#8220;connected load&#8221; requirement shall not exceed five (5) watts at 277/480 volts per square foot, of which two (2) watts per square foot will be transformed to 120/208 volts. Tenant further agrees that its use of the Premises will not exceed such requirement and that its total connected lighting load will not exceed the maximum from time to time permitted under applicable governmental regulations. In order to assure that the foregoing requirements are not exceeded and to avert possible adverse effect on the Building&#8217;s electrical system, Tenant shall not, without Landlord&#8217;s prior consent, connect any fixtures, appliances or equipment to the Building&#8217;s electrical distribution system other than typewriters, pencil sharpeners, desk top calculators, dictaphones, photocopiers, personal computers, standard pantry appliances, word processors, radios and other similar small electrical equipment normally found in business offices and not drawing more than 15 amps at 120/208 volts.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:73.5pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:34.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11.5pt;">Landlord shall, at Landlord&#8217;s expense, within sixty (60) days after final approval of Tenant&#8217;s Construction Drawings for Tenant&#8217;s Initial Work, install a separate meter (a </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Tenant&#8217;s Meter&#8221;) </b><font style="font-size:11.5pt;">in the Premises to measure Tenant&#8217;s consumption of electricity in the Premises (excluding the main air handler and fan boxes). Such Tenant&#8217;s Meter shall measure tenant electricity consumption in the Premises only and in no other space in the Building. Landlord&#8217;s installation of the Tenant&#8217;s Meter shall be performed simultaneously and in coordination and cooperation with Tenant&#8217;s performance of Tenant&#8217;s Initial Work. Tenant&#8217;s Construction Drawings shall separately indicate the locations for such Tenant&#8217;s Meter (which location shall be within the existing electrical closet(s) serving the Premises) and clearly indicate that Landlord is to install the same. From and after the date such Tenant&#8217;s Meter for the Premises has been installed and made operational, Tenant shall timely make all payments for such electrical service invoiced by the utility company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:73pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:35pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11.5pt;">Until the Tenant&#8217;s Meter is installed in the Premises as provided in </font><b style="font-size:11.5pt;font-weight:bold;">Section 7.S(b) </b><font style="font-size:11.5pt;">above, Tenant&#8217;s electrical usage for the Premises shall be governed by the terms of this </font><b style="font-size:11.5pt;font-weight:bold;">paragraph (c). </b><font style="font-size:11.5pt;">Tenant shall, from and after the date Tenant first enters the Premises for any purpose (including the performance of Tenant&#8217;s Initial Work) until the earlier of (y) the day immediately preceding the date the Tenant&#8217;s Meter measuring electrical supply to the Premises is installed and operational (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Pre-Meter Period&#8221;), </b><font style="font-size:11.5pt;">or (z) the date Tenant commences occupancy of the Premises for the conduct of business, pay for electrical consumption for the Premises at the estimated rate of One and 25/100 Dollars ($1.25) per rentable square foot of Premises per annum (prorated for periods of less than one year). Notwithstanding the foregoing,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:73pt;margin:0pt 0pt 0pt 6.75pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.75pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">in the event that the Tenant&#8217;s Meter measuring electrical supply to the Premises has not been installed and rendered operational as of the date Tenant commences occupancy of the Premises for the conduct of business, or if during the Term of the Lease such Tenant&#8217;s Meter is damaged, broken or for any reason not operational, Tenant shall pay for electrical consumption for the Premises at the estimated rate charged of $2.50 per rentable square foot of the Premises per annum, which rate is subject to increase from time to time during the Term to reflect Landlord&#8217;s actual cost to provide such electricity charged by the provider thereof until Tenant&#8217;s Meter is installed and/or rendered operational, as the case may be and Tenant pays electricity charges to the utility company in accordance with </font><b style="font-size:11.5pt;font-weight:bold;">paragraph (b) </b><font style="font-size:11.5pt;">above of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 7.5. </b><font style="font-size:11.5pt;">Tenant shall pay any such electricity charges due to Landlord under this </font><b style="font-size:11.5pt;font-weight:bold;">paragraph (c) </b><font style="font-size:11.5pt;">within thirty (30) days after rendition of bills therefor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.55pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(d)</font></font><font style="font-size:11.5pt;">Landlord shall furnish and install all replacement lighting, tubes, lamps, bulbs and ballasts required in the Premises, and Tenant shall pay to Landlord or its designated contractor upon demand Landlord&#8217;s then established reasonable charges therefor, and in such event, Tenant shall pay to Landlord or its designated contractor upon demand the then established reasonable charges therefor of Landlord or its designated contractor, as the case may be, at the Building&#8217;s standard rates.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.45pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:35.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(e)</font></font><font style="font-size:11.5pt;">Landlord shall have the right, in its sole discretion, to select any entity or entities which it desires to have as the electrical service provider to the Building (including the Premises), and Tenant shall not have the right to select the same or participate in the selection of the same, except and to the extent that any Laws mandate that Tenant shall have any such right(s).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">7.6</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">INTERRUPTION OF SERVICE</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:73.15pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:34.85pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11.5pt;">Landlord reserves the right to curtail, suspend, interrupt and/or stop the supply of water, sewage, electrical current, cleaning, and other services, and to curtail, suspend, interrupt and/or stop use of entrances and/or lobbies serving access to the Building, or other portions of the Property, without thereby incurring any liability to Tenant, when necessary by reason of accident or emergency, or for repairs, alterations, replacements or improvements in the judgment of Landlord reasonably exercised, desirable or necessary, or when prevented from supplying such services or use due to any act or neglect of Tenant or Tenant&#8217;s agents employees, contractors or invitees or any person claiming by, through or under Tenant or by Force Majeure, including, but not limited to, strikes, lockouts, difficulty in obtaining materials, accidents, laws or orders, or inability, by exercise of reasonable diligence, to obtain electricity, water, gas, steam, coal, oil or other suitable fuel or power. No diminution or abatement of rent or other compensation, nor any direct, indirect or consequential damages shall or will be claimed by Tenant as a result of, nor shall this Lease or any of the obligations of Tenant be affected or reduced by reason of, any such interruption, curtailment, suspension or stoppage in the furnishing of the foregoing services or use, irrespective of the cause thereof. Failure or omission on the part of Landlord to furnish any of the foregoing services or use as provided in this paragraph shall not be construed as an eviction of Tenant, actual or constructive, nor entitle Tenant to an abatement of rent, nor to render the Landlord liable in damages, nor release Tenant from prompt fulfillment of any of its covenants under this Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.4pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:35.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11.5pt;">Notwithstanding the foregoing, if (i) an intem1ption or curtailment, suspension or stoppage of an Essential Service (as said term is hereinafter defined) shall occur,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.4pt;margin:0pt 0pt 0pt 8.05pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.95pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">except any of the same due to any act or neglect of Tenant or Tenant&#8217;s agents employees, contractors or invitees or any person claiming by, through or under Tenant (any such interruption of an Essential Service being hereinafter referred to as a </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Service Interruption&#8221;), </b><font style="font-size:11.5pt;">and (ii) such Service Interruption is within the reasonable control of Landlord to remedy (and Landlord is not impeded by reason of any Force Majeure), and (iii) as a result of such Service Interruption, the Premises becomes Untenantable so that for the Eligibility Period {as hereinafter defined) Tenant is unable to and does not in fact conduct its business in the affected portion of the Premises during the entirety of the Eligibility Period by reason of such Untenantability, then there shall be an abatement of one day&#8217;s Basic Rent for each day during which such Service Interruption continues after the Eligibility Period until such date that the Premises or the affected portion thereof shall be rendered tenantable {or such earlier date, if any, as Tenant shall reoccupy the Premises or the affected portion thereof for the conduct of its business); provided, however, that if any part of the Premises is reasonably useable for Tenant&#8217;s normal business operations or if Tenant conducts all or any part of its operations in any portion of the Premises notwithstanding such Service Interruption, then the amount of each daily abatement of Basic Rent shall only be proportionate to the nature and extent of the interruption of Tenant&#8217;s normal operations or ability to use the Premises. For the purposes hereof, the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Eligibility Period&#8221; </b><font style="font-size:11.5pt;">shall be defined as seven (7) days after Landlord&#8217;s receipt of written notice from Tenant of the condition causing Untenantability in the Premises and, for purposes of this Lease, </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Untenantable&#8221; </b><font style="font-size:11.5pt;">shall mean that the Premises or the affected portion thereof is inaccessible and/or reasonably unusable for general office use. The rights granted to Tenant under this </font><b style="font-size:11.5pt;font-weight:bold;">paragraph {b) </b><font style="font-size:11.5pt;">shall be Tenant&#8217;s sole and exclusive remedy resulting from a failure of Landlord to provide Essential Services. For purposes hereof, the term </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Essential Services&#8221; </b><font style="font-size:11.5pt;">shall mean the following services in accordance with Landlord&#8217;s obligations under this Lease: all reasonable means of access to the Premises, passenger elevator service, water and sewer/septic service, HVAC and electricity. A Service Interruption will not be deemed to have occurred if the Service Interruption results from Tenant&#8217;s introduction into the Premises of personnel or equipment which overloads the capacity of the Building systems or in any other way interferes with any building system&#8217;s ability to perform its proper functions, including, without limitation, Tenant&#8217;s design, layout or occupancy level of the Premises in a manner which inhibits the HVAC system&#8217;s ability to perform properly.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;">ARTICLE VIII<br></b><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">REAL ESTATE TAXES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">8.1</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">PAYMENTS ON ACCOUNT OF REAL ESTATE TAXES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:73.25pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:34.75pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11.5pt;">For the purposes of this Article, the term &#8220;Tax Year&#8221; shall mean the twelve-month period commencing on the July 1 immediately preceding the Commencement Date and each twelve-month period thereafter falling wholly or partly within the Term of this Lease; and the term &#8220;Taxes&#8221; shall mean (i) all taxes, assessments (special or otherwise), levies, fees and all other government levies, exactions and charges of every kind and nature, general and special, ordinary and extraordinary, foreseen and unforeseen, which are, at any time prior to or during the Term, imposed or levied upon or assessed against the Property or any portion thereof, or against any Basic Rent, Additional Rent or other rent of any kind or nature payable to Landlord by anyone on account of the ownership, leasing or operation of the Property, or which arise on account of or in respect of the ownership, development, leasing, operation or use of the Property or any portion thereof; (ii) all gross receipts taxes or similar taxes imposed or levied</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:73.25pt;margin:0pt 0pt 0pt 6.5pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:1.55pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">upon, assessed against or measured by any Basic Rent, Additional Rent or other rent of any kind or nature or other sum payable to Landlord by anyone on account of the ownership, development, leasing, operation, or use of the Property or any portion thereof; (iii) all value added, use and similar taxes at any time levied, assessed or payable on account of the ownership, development, leasing, operation, or use of the Property or any portion thereof; and (iv) reasonable expenses of any proceeding for abatement of any of the foregoing items included in Taxes, but the amount of special taxes or special assessments included in Taxes shall be limited to the amount of the installment (plus any interest, other than penalty interest, payable thereon) of such special tax or special assessment required to be paid during the year in respect of which such Taxes are being determined. There shall be excluded from Taxes (1) all income, capital levy, capital stock, gift, franchise, margin, estate, succession, inheritance and transfer taxes of Landlord, (2 ) all taxes or assessments initiated as a means of financing improvements to the Property (provided, however, the foregoing shall not prohibit such taxes from being included in Operating Expenses if and to the extent the cost of the underlying improvements would otherwise be included in Operating Expenses under the terms of this Lease), and (3) any fines, late charges, interest or penalties resulting from any late payment of Taxes by Landlord; provided, however, that if at any time during the Term the present system of ad valorem taxation of real property shall be changed so that a capital levy, franchise, income, profits, sales, rental, use and occupancy, or other tax or charge shall in whole or in part be substituted for, or added to, such ad valorem tax and levied against, or be payable by, Landlord with respect to the Property or any portion thereof, such tax or charge shall be included in the term &#8220;Taxes&#8221; for the purposes of this Article.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:73.2pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:34.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11pt;">In the event that for any reason, Taxes during any Tax Year shall exceed Base Taxes, Tenant shall pay to Landlord, as an Escalation Charge, an amount equal to (i) the excess of Taxes over Base Taxes for such Tax Year multiplied by (ii) the Escalation Factor, such amount to be apportioned for any fraction of a Tax Year in which the Commencement Date falls or the Term of this Lease ends. If the Base Taxes do not reflect a fully assessed Building, then the Base Taxes shall be equitably adjusted and grossed up as if the Building were a fully assessed building.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:73.3pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:34.7pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11pt;">Estimated payments by Tenant on account of Taxes shall be made monthly on the first (1</font><sup style="font-size:8.25pt;vertical-align:top;">st</sup><font style="font-size:7pt;">) </font><font style="font-size:11pt;">day of each and every calendar month during the Term of this Lease and otherwise in the manner herein provided for the payment of Basic Rent. The monthly amount so to be paid to Landlord shall be sufficient to provide Landlord by the time real estate tax payments are due a sum equal to Tenant&#8217;s required payments, as estimated by Landlord from time to time, on account of Taxes for the then current Tax Year. Promptly after receipt by Landlord of bills for such Taxes, Landlord shall advise Tenant of the amount thereof and the computation of Tenant&#8217;s payment on account thereof. f estimated payments theretofore made by Tenant for the Tax Year covered by such bills exceed the required payments on account thereof for such Tax Year, Landlord shall credit the amount of overpayment against subsequent obligations of Tenant on account of Taxes (or refund such overpayment if the Term of this Lease has ended and Tenant has no further obligation to Landlord); but if the required payments on account thereof for such Tax Year are greater than estimated payments theretofore made on account thereof for such Tax Year, Tenant shall make payment to Landlord within thirty (30) days after being so advised by Landlord. If the Taxes comprising the Base Taxes are reduced as a result of an appropriate proceeding or otherwise, the Taxes as so reduced shall, for all purposes be deemed to be the Base Taxes and Landlord shall give notice to Tenant of the amount by</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:73.3pt;margin:0pt 0pt 0pt 6.95pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">which the tax payments previously made were less than the tax payments required to be made under this Article VIII, and Tenant shall pay the amount of the deficiency within thirty (30) days after demand therefor. Upon request from Tenant, Landlord agrees to provide Tenant with a copy of any tax bill for the Property in Landlord&#8217;s possession.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(d)</font></font><font style="font-size:11pt;">Upon written request and to the extent not readily available via the City of Boston&#8217;s website, Landlord shall provide to Tenant copies of all bills for Taxes and evidence of payment of such Taxes.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">8.2</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">ABATEMENT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:37.1pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">If </font><font style="font-size:11pt;">Landlord shall receive any tax refund or reimbursement of Taxes or sum in lieu thereof with respect to any Tax Year, then out of any balance remaining thereof after deducting Landlord&#8217;s expenses reasonably incurred in obtaining the same, Landlord shall pay to Tenant, provided there does not then exist a Default of Tenant, an amount equal to such refund or reimbursement or sum in lieu thereof (exclusive of any interest) multiplied by the Escalation Factor; provided, that in no event shall Tenant be entitled to receive more than the amount of any payments actually made by Tenant on account of Taxes for such Tax Year pursuant to Section 8.1 or to receive any payment if Taxes for any Tax Year are less than Base Taxes.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">8.3</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">ALTERNATE TAXES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.55pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:35.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11pt;">If some method or type of taxation shall replace the current method of assessment of real estate taxes in whole or part, or the type thereof, or if additional types of taxes are imposed upon the Property or Landlord in lieu of existing Taxes or in lieu of increase in existing Taxes, Tenant agrees that such replacement or additional taxes shall be deemed to be and shall be Taxes hereunder and Tenant shall pay an equitable share of the same as an additional charge computed in a fashion consistent with the method of computation herein provided, to the end that Tenant&#8217;s share thereof shall be, to the maximum extent practicable, comparable to that which Tenant would bear under the foregoing provisions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.25pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:35.75pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11pt;">If a tax (other than a Federal or State net income tax) is assessed on account of the rents or other charges payable by Tenant to Landlord under this Lease, Tenant agrees to pay the same as an additional charge within thirty (30) days after billing therefor, unless applicable law prohibits the payment of such tax by Tenant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;">ARTICLE IX<br></b><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">OPERATING EXPENSES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">9.1</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">DEFINITIONS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.2pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">For the purposes of this Article, the following terms shall have the following respective meanings:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">Operating Year: Each twelve-month period ending on December 31 in which any part of the Term of this Lease shall fall.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">Operating Expenses: The aggregate costs or expenses incurred by Landlord with respect to the operation, administration, cleaning, repair, maintenance and management of the Property including, without limitation, those items enumerated in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;"> annexed hereto, provided that, if during any portion of the Operating Year for which</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.05pt;margin:0pt 0pt 0pt 44.3pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">Operating Expenses are being computed (including the Operating Year for Base Operating Expenses), the Building was not operated or less than all of the leasable area of the Building was occupied by tenants or if Landlord is not supplying all tenants with the services and utilities being supplied hereunder, actual Operating Expenses incurred shall be reasonably projected by Landlord to the estimated Operating Expenses that would have been incurred if the Building were fully occupied for such Operating Year and such services and utilities were being supplied to all tenants, and such projected amount shall, for the purposes hereof, be deemed to be the Operating Expenses for such Operating Year. The foregoing shall not entitle Landlord to collect an amount exceeding one hundred percent </font><font style="font-size:11pt;">(I </font><font style="font-size:11.5pt;">00%) of the Operating Expenses incurred by Landlord with respect to the pertinent Operating Year (plus any imputed management fee), notwithstanding the operation of the foregoing &#8220;gross up&#8221; provisions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">9.2</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">TENANT&#8217;S PAYMENTS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11.5pt;">In the event that Operating Expenses for any Operating Year shall exceed Base Operating Expenses, Tenant shall pay to Landlord, as an Escalation Charge, an amount equal to (i) the excess of Operating Expenses for such Operating Year over Base Operating Expenses, multiplied by (ii) the Escalation Factor, such amount to be apportioned for any Operating Year in which the Commencement Date falls or the Term of this Lease ends.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11.5pt;">Estimated payments by Tenant on account of Operating Expenses shall be made monthly on the first (I </font><sup style="font-size:8.62pt;vertical-align:top;">st </sup><font style="font-size:11.5pt;">day of each and every calendar month during the Term of this Lease and otherwise in the manner herein provided for the payment of Basic Rent. The monthly amount so to be paid to Landlord shall be sufficient to provide Landlord by the end of each Operating Year with a sum equal to Tenant&#8217;s required payments, as estimated by Landlord from time to time during each Operating Year, on account of Operating Expenses for such Operating Year. After the end of each Operating Year, Landlord shall submit to Tenant a reasonably detailed accounting of Operating Expenses for such Operating Year. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">estimated payments theretofore made for such Operating Year by Tenant exceed Tenant&#8217;s required payment on account thereof for such Operating Year, according to such statement, Landlord shall credit the amount of overpayment against subsequent obligations of Tenant hereunder (or refund such overpayment if the Term of this Lease has ended and Tenant has no further obligation to Landlord); but, if the required payments on account thereof for such Operating Year are greater than the estimated payments (if any) theretofore made on account thereof for such Operating Year, Tenant shall make payment to Landlord within thirty (30) days after being so advised by Landlord in writing. Landlord&#8217;s failure to render or delay in rendering an Operating Expense statement with respect to any Operating Year shall not prejudice Landlord&#8217;s right thereafter to render the same with respect thereto nor shall the rendering of an Operating Expense statement for any Operating Year prejudice Landlord&#8217;s right thereafter to render a corrected Operating Expense statement for such Operating Year, provided that Landlord renders the Operating Expense statement in question or the corrected Operating Expense statement, as the case may be, within two (2) years after the end of the applicable Operating Year.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">there are elements of Building repair and maintenance which would have been included in Base Operating Expenses except that such repair and maintenance is covered under construction or installation warranties or service contracts (excluding warrantied repairs of defects that do not constitute ordinary repair and maintenance), then the costs which</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.75pt;margin:0pt 0pt 0pt 9.4pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.05pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">would have been incurred but for such warranties or service contracts shall be included in Base Operating Expenses, less the reasonable costs incurred by Landlord in enforcing such warranties and less the cost of any such service contracts.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(d)</font></font><font style="font-size:11pt;">Any such accounting by Landlord shall be binding and conclusive upon Tenant and Tenant shall not have any right to review or audit such accounting, unless within ninety (90) days after the giving by Landlord of such accounting Tenant shall notify Landlord that Tenant disputes the correctness of such accounting, specifying the particular respects in which the accounting is claimed to be incorrect. If Tenant timely sends such dispute notice to Landlord, Tenant may, at Tenant&#8217;s sole cost and expense, undertake a review or audit of such of Landlord&#8217;s books as are directly relevant to the Operating Expense accounting for the Operating Year in question, provided and on condition that (i) there is no Default of Tenant under this Lease, (ii) Tenant has made all payments of Escalation Charges billed or invoiced by Landlord as of the date of the audit, (iii) the audit is performed by a qualified employee of Tenant or an independent certified public accounting firm or other professional auditing firm whose fee or other compensation is fixed by contract and is in no manner computed or determined based upon the results of the audit, (iv) both Tenant and any of its designated audit firms execute and deliver to Landlord a confidentiality agreement in form and substance reasonably acceptable to Landlord whereby such parties expressly agree to maintain the results of such audit in strict confidence (except that the results may be disclosed in any arbitration pursuant to this subsection (d)), and (v) such audit is commenced and completed and the results thereof delivered to Landlord within ninety (90) days following the date Landlord makes its books available to Tenant. If Tenant fails to timely deliver a dispute notice to Landlord, or fails to complete its audit and deliver the results thereof to Landlord within the applicable ninety (90) day period, then, in either of such events, Landlord&#8217;s accounting shall be binding and conclusive upon Tenant for all purposes of this Lease. If such dispute has not been settled by mutual agreement of the parties, either party may submit the dispute to expedited arbitration in accordance with the expedited commercial arbitration rules of the American Arbitration Association within ninety (90) days after the date Tenant delivers its results to Landlord. The decision of the arbitrators shall be final and binding on Landlord and Tenant and judgment thereon may be entered in any court of competent jurisdiction. Pending resolution by agreement or arbitration, Tenant shall make all payments shown by such accounting to be without prejudice to Tenant&#8217;s position.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11.5pt;font-weight:bold;">ARTICLE X</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">INDEMNITY AND PUBLIC LIABILITY INSURANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;font-style:normal;font-weight:normal;text-align:left;">10.1</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">INDEMNITY</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11pt;">To the maximum extent this agreement may be made effective according to Law and subject to the release of liability and waiver of claims set forth in </font><b style="font-size:11.5pt;font-weight:bold;">Section 10.7 </b><font style="font-size:11pt;">to the extent applicable in any case, Tenant agrees to indemnify and save harmless Landlord and Landlord&#8217;s managing agent, beneficiaries, partners, subsidiaries, affiliates, officers, directors, agents, employees, and any Superior Lessor and Superior Mortgagee (the &#8220;Landlord Parties&#8221;) from and against all claims, loss, cost, damage or expense of whatever nature arising from: (a) any accident, injury or damage whatsoever to any person, or to the property of any person, occurring in or about the Premises; (b) any accident, injury or damage occurring outside of the Premises but on the Property where such accident, damage or injury results or is claimed to have resulted from an act, omission, negligence or willful misconduct of Tenant or Tenant&#8217;s agents or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.75pt;margin:0pt 0pt 0pt 8.65pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.65pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">employees or independent contractors; or (c) the conduct or management of the Premises or of any business therein, or any thing or work whatsoever done, or any condition created (other than by Landlord) in or about the Premises; and, in any case, occurring after the date of this Lease until the end of the Term of this Lease and thereafter so long as Tenant is in occupancy of any part of the Premises. The foregoing indemnity shall not apply to any such claims, losses, costs, damages or expenses arising from the negligence or willful misconduct of Landlord or any Landlord Parties. This indemnity and hold harmless agreement shall include indemnity against all losses, costs, damages, expenses and liabilities incurred in or in connection with any such claim or proceeding brought thereon, and the defense thereof, including, without limitation, reasonable attorneys&#8217; fees and costs at both the trial and appellate levels. The provisions of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 10.l(a) </b><font style="font-size:11.5pt;">shall survive the expiration or earlier termination of this Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:73.2pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:34.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11.5pt;">To the maximum extent this agreement may be made effective according to law and subject to the release of liability and waiver of claims set forth in </font><b style="font-size:11.5pt;font-weight:bold;">Section 10.</b><font style="font-size:11.5pt;">7 to the extent applicable in any case, Landlord agrees to indemnify and save harmless Tenant and Tenant&#8217;s partners, members, shareholders, officers and directors (collectively, the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Tenant Parties&#8221;) </b><font style="font-size:11.5pt;">from and against all claims of any third party arising from any accident, injury or damage whatsoever to any person, or to the property of any person, where such accident, damage or injury results or is claimed to have resulted from the gross negligence or willful misconduct of Landlord or Landlord&#8217;s agents, employees or contractors, together with reasonable attorneys&#8217; fees incurred in connection with each such claim or action brought thereon; provided, however, in no event shall this indemnity apply to the extent any such claim arises from the negligence or willful misconduct of Tenant or any of the Tenant Parties and the provisions of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 10.1(b) </b><font style="font-size:11.5pt;">shall not be deemed to be made by the holder of any mortgage or ground lessor now or hereafter on the Building (whether or not such holder shall be a mortgagee in possession of or shall have exercised any rights under a conditional, collateral or other assignment of leases and/or rents respecting, the Building or such ground lessor shall have exercised any of its rights under a ground lease affecting the Building). This indemnity and hold harmless agreement shall include indemnity against all losses, costs, damages, expenses and liabilities incurred in or in connection with any such claim or any proceeding brought thereon, and the defense thereof, including, without limitation, reasonable attorneys&#8217; fees and costs at both the trial and appellate levels. The provisions of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 10.l(b) </b><font style="font-size:11.5pt;">shall survive the expiration or earlier termination of this Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">I 0.2</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">LIABILITY INSURANCE</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">Tenant agrees to maintain in full force from the date upon which Tenant first enters the Premises for any reason, throughout the Term of this Lease, and thereafter so long as Tenant is in occupancy of any part of the Premises, a policy of commercial general liability and property damage insurance (including broad form contractual liability, independent contractor&#8217;s hazard and completed operations coverage) under which Tenant is named as an insured and Landlord, Agent (and such other persons as are in privity of estate with Landlord as may be set out in a notice from time to time) are named as additional insureds. Each such policy shall be written on an &#8220;occurrence&#8221; basis, and shall be in at least the amounts of the Initial Liability Insurance specified in </font><b style="font-size:11.5pt;font-weight:bold;">Section 1.3. </b><font style="font-size:11.5pt;">Tenant shall provide Landlord with a duplicate original or certificate of its insurance coverages.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">10.3</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">TENANT&#8217;S PROPERTY DAMAGE INSURANCE</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:45pt;text-indent:-45pt;margin:0pt 0pt 0pt 35.85pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:37.1pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">To the maximum extent this agreement may be made effective according to Law, neither Landlord nor Landlord&#8217;s insurers shall have any responsibility or liability for any loss of or damage to Tenant&#8217;s Removable Property. Tenant shall carry special form/cause of loss insurance (formerly known as &#8220;all-risk&#8221; property insurance) on a &#8220;replacement cost&#8221; basis, insuring Tenant&#8217;s Removable Property, Tenant&#8217;s Initial Work, Alterations, and any other leasehold improvements and fixtures located in the Premises, whether made by or on behalf of Tenant or any party claiming by, through or under Tenant pursuant to this Lease or otherwise existing in the Premises as of the Commencement Date (collectively, the </font><b style="font-size:11pt;font-weight:bold;">&#8220;Improvements&#8221;), in </b><font style="font-size:11.5pt;">an amount equal to the full replacement cost of Tenant&#8217;s Removable Property and all such Improvements. Landlord, the Landlord Parties and such other persons as Landlord shall request in a written notice to Tenant shall be named as additional insureds on each such policy. The provisions of this </font><b style="font-size:11pt;font-weight:bold;">Section 10.3 </b><font style="font-size:11.5pt;">shall be applicable from and after the execution of this Lease and until the end of the Term of this Lease, and during such further period as Tenant may use or be in occupancy of any part of the Premises or of the Building. In addition, Tenant, at Tenant&#8217;s expense, shall maintain at all times during the Term of this Lease (i) business interruption and extra expense insurance with limits not less than one hundred percent (100%) of all charges payable by Tenant under this Lease for a period of twelve (12) months, and (ii) workers&#8217; compensation insurance in accordance with the laws of the state in which the Premises are located with employers&#8217; liability insurance in an amount not less than $1,000,000.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">10.4</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">INSURANCE REQUIREMENTS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">The insurance companies issuing the policies required to be carried by Tenant and Landlord hereunder (the </font><b style="font-size:11pt;font-weight:bold;">&#8220;Insurers&#8221;) </b><font style="font-size:11.5pt;">must be licensed and authorized to do business in the Commonwealth of Massachusetts, must have been in business for at least five (5) years, must carry an A.M. Best Company, Inc. policy holder rating of A- or better, an A.M. Best Company, Inc. financial category rating of Class VIII or better and must be otherwise reasonably satisfactory to Landlord. Notwithstanding Landlord&#8217;s right to approve the Insurers and to establish credit rating standards for the Insurers, Landlord will not be responsible for the solvency of any of Tenant&#8217;s Insurers.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">10.5</u><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:15.88pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u>INJURY CAUSED BY THIRD PARTIES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">To the maximum extent this agreement may be made effective according to law, Tenant agrees that Landlord and the Landlord Parties shall not be responsible or liable to Tenant, or to those claiming by, through or under Tenant, for any loss or damage that may be occasioned by or through the acts or omissions of persons occupying adjoining premises or any part of the premises adjacent to or connecting with the Premises or any part of the Property or otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">10.6</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">LANDLORD&#8217;S INSURANCE</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.35pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">Landlord agrees to maintain in full force and effect, at all times during the Term of this Lease, (i) special form/cause of loss property insurance covering the Building in an amount equal to at least the replacement value of the Building (exclusive of footings and foundation) and subject to commercially reasonable deductible; and (ii) commercial general liability insurance with respect to the Building in an amount not less than amounts required to be carried by Tenant under this Lease for such liability coverage. Landlord may satisfy such insurance requirements by including the Property in a so-called &#8220;blanket&#8221; insurance policy.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.35pt;margin:0pt 0pt 0pt 8.55pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">10.7</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">WAIVER OF SUBROGATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.9pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">Insofar as, and to the extent that, the following provision shall not make it impossible to secure insurance coverage obtainable from responsible insurance companies doing business in the locality in which the Property is located (even though extra premium may result therefrom) Landlord and Tenant: (a) mutually agree that, with respect to any damage to property, the parties each hereby waive all rights and claims against each other for such losses, and waive all rights of subrogation of their respective insurers, for damage to their respective properties as a result of the acts or omissions of the other party or the other party&#8217;s employees, to the extent any such claims are covered (or would have been covered) by the insurance required to be maintained by Landlord and Tenant, respectively, pursuant to this Lease, or other property insurance that either party may carry at the time of an occurrence and exclusive of any commercially reasonable deductibles maintained by the applicable party under this Lease; and (b) mutually agree that any property damage insurance carried by either shall provide for the waiver by the insurance carrier of any right of subrogation against the other.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;">ARTICLE XI<br></b><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">LANDLORD&#8217;S ACCESS TO PREMISES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">11.1</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">LANDLORD&#8217;S RIGHTS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:37.55pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">After reasonable notice (except in emergencies when no such notice shall be required), Landlord, its agents and representatives, shall have the right to enter the Premises (i) to inspect the same, (ii) to exercise such rights as may be permitted hereunder, (iii) to make repairs or alterations to the Building or other tenant spaces therein, (iv) to make repairs or perform other obligations if Tenant fails to do so as required hereunder (but the Landlord shall have no duty whatsoever to make any such inspections, repairs, alterations, additions or improvements except as otherwise expressly provided in this Lease), (v) to deal with emergencies, (vi) to post such notices as may be permitted or required by law to prevent the perfection of liens against Landlord&#8217;s interest in the Building, (vii) to exhibit the Premises to prospective tenants during the twenty-four (24) months preceding expiration of the term of this Lease (except that during the initial Term and provided Tenant has not committed in writing to lease replacement space in another building in the Boston area, such 24 month period shall be reduced to fifteen (15) months to correspond with the deadline for Tenant&#8217;s exercise of Tenant&#8217;s extension option) and at any reasonable time during the Term to show the Premises to prospective purchasers, lessors and mortgagees, or (viii) for any other purpose as Landlord may deem necessary or desirable; provided, however, Landlord shall use reasonable efforts not to unreasonably interfere with Tenant&#8217;s use of or access to the Premises. Tenant shall not be entitled to any abatement of rent or other charges nor shall Landlord be deemed guilty of an eviction, actual or constructive, or any violation of Tenant&#8217;s quiet enjoyment of the Premises on account of Landlord&#8217;s access to the Premises pursuant to the provisions of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 11.1 </b><font style="font-size:11.5pt;">or any other provision of this Lease or applicable Laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;">ARTICLE XII<br></b><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">CASUALTY; EMINENT DOMAIN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">12.1</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">CASUALTY</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:44.95pt;text-indent:-44.95pt;margin:0pt 0pt 0pt 36.05pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:74pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:34pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">the Building or the Premises shall be partially or totally damaged or destroyed by fire or other casualty (each, a </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Casualty&#8221;) </b><font style="font-size:11.5pt;">and if this Lease is not terminated as provided below, then (i) Landlord shall repair and restore the Building and the Premises (but excluding Tenant&#8217;s Removable Property and Improvements </font><b style="font-size:11.5pt;font-weight:bold;">(&#8220;Landlord&#8217;s Restoration Work&#8221;) </b><font style="font-size:11.5pt;">with reasonable dispatch (but Landlord shall not be required to perform the same on an overtime or premium pay basis) after notice to Landlord of the Casualty and the settlement of any insurance claims with respect to such Casualty, and (ii) Tenant shall repair and restore in accordance with </font><b style="font-size:11.5pt;font-weight:bold;">Section 5.2 </b><font style="font-size:11.5pt;">all of Tenant&#8217;s Removable Property and the Improvements </font><b style="font-size:11.5pt;font-weight:bold;">(&#8220;Tenant&#8217;s Restoration Work&#8221;) </b><font style="font-size:11.5pt;">with reasonable dispatch after the Casualty. Notwithstanding anything to the contrary contained herein, if in Landlord&#8217;s sole discretion, it would be appropriate for safety reasons, health reasons or the efficient operation or restoration of the Building or the Premises for Landlord to perform such portion of Tenant&#8217;s Restoration Work on behalf of Tenant which are structural or are related to Building systems, and Landlord is electing to perform similar restoration work for at least 80% of the tenants in the Building whose leased premises were similarly affected by the Casualty, then (a) Landlord shall give Tenant a written notice specifying the portion of Tenant&#8217;s Restoration Work to be performed by Landlord (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Specified Restoration Work&#8221;), </b><font style="font-size:11.5pt;">and (b) Landlord and Tenant shall agree upon the Restoration Plans (as hereinafter defined) and the budget in accordance with this </font><b style="font-size:11.5pt;font-weight:bold;">Section12.l(a) </b><font style="font-size:11.5pt;">and thereafter Landlord shall perform the Specified Restoration Work with reasonable dispatch after the final approval of the Restoration Plans and the budget, subject to Tenant&#8217;s obligations under this </font><b style="font-size:11.5pt;font-weight:bold;">Article XII </b><font style="font-size:11.5pt;">to pay the costs of such Specified Restoration Work. In the event Landlord elects to perform any Specified Restoration Work under this </font><b style="font-size:11.5pt;font-weight:bold;">Section 12.l(a), </b><font style="font-size:11.5pt;">Landlord shall, at Tenant&#8217;s cost, promptly thereafter prepare the construction drawings for the Specified Restoration Work (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Restoration Plans&#8221;) </b><font style="font-size:11.5pt;">and a budget therefor. Tenant shall have the right, within ten (10) Business Days following submission by Landlord, to approve the Restoration Plans, which approval shall not be withheld if the layout and quality of finishes and materials proposed in such plans are consistent with Tenant&#8217;s Initial Work in the Premises (or Tenant&#8217;s initial improvements to any additional space in the Building leased to Tenant), and to approve the budget therefor, which budget approval shall not be unreasonably withheld or delayed. Any disapproval by Tenant of any submission by Landlord of the Restoration Plans shall be accompanied by a specific statement of the reasons therefor and Tenant shall respond to any resubmission by Landlord of the Restoration Plans within five (5) Business Days after such resubmission by Landlord. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Tenant fails to respond to a request by Landlord for approval of any portion of the Restoration Plans or the budget for the Specified Restoration Work within the time periods set forth in this </font><b style="font-size:11.5pt;font-weight:bold;">Section 12.l(a), </b><font style="font-size:11.5pt;">Tenant&#8217;s approval thereof will be deemed given. Landlord and Tenant shall reasonably cooperate with each other to coordinate the scheduling and performance of Landlord&#8217;s Restoration Work, any Specified Restoration Work and Tenant&#8217;s Restoration Work in order to not unreasonably interfere with the timely progress by both pa1iies of their respective restoration work and Landlord agrees to provide Tenant with not less than ten (10) days prior written notice of the substantial completion date of any Specified Restoration Work.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.4pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:35.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">all or part of the Premises shall be rendered Untenantable (as defined in </font><b style="font-size:11.5pt;font-weight:bold;">Section 7.6(b)) </b><font style="font-size:11.5pt;">by reason of a Casualty, the Basic Rent and Escalation Charges shall be abated in the proportion that the Untenantable area of the Premises bears to the total area of the Premises, for the period from the date of the Casualty to the earliest of (i) the date Landlord shall have substantially completed its repair and restoration of that portion of the Premises Landlord is</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.4pt;margin:0pt 0pt 0pt 8.3pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.45pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">required by this Lease to repair and restore (provided, that if Landlord would have completed its repair and restoration at an earlier date but for Tenant having failed to cooperate with Landlord in effecting such repairs or restoration or collecting insurance proceeds, then the Premises shall be deemed to have been repaired and restored on such earlier date and the abatement shall cease), or (ii) the date Tenant or any subtenant reoccupies a portion of the Premises for Tenant&#8217;s normal business purposes (in which case the Basic Rent and Escalation Charges allocable to such reoccupied portion shall be payable by Tenant from the date of such occupancy). Notwithstanding any provision contained in this Lease to the contrary, (x) there shall be no abatement with respect to any portion of the Premises which has not been rendered Untenantable by reason of a Casualty and which is accessible, whether or not other portions of the Premises are Untenantable, and (y) any abatement of Basic Rent or Escalation Charges applicable to any portion of the Premises which was rendered Untenantable by reason of a Casualty shall cease on the earliest of the dates referred to in clauses (i), or (ii) of the preceding sentence provided such portion is accessible, whether or not other portions of the Premises remain Untenantable. Landlord&#8217;s determination of the date such repair and restoration to the Premises shall have been substantially completed or the date the Premises is made tenantable shall be controlling unless Tenant disputes same by notice to Landlord given within ten (10) days after such determination by Landlord, and pending resolution of such dispute, Tenant shall pay Basic Rent and Escalation Charges in accordance with Landlord&#8217;s determination. Notwithstanding the foregoing, if by reason of any act or omission by Tenant, any subtenant or any of their respective partners, directors, officers, servants, employees, agents or contractors, Landlord, any Superior Lessor or any Superior Mortgagee shall be unable to collect all of the insurance proceeds (including, without limitation, rent insurance proceeds) applicable to the Casualty, then, without prejudice to any other remedies which may be available against Tenant, there shall be no abatement of Basic Rent or of Escalation Charges. Nothing contained in this </font><b style="font-size:11.5pt;font-weight:bold;">Section 12.1 </b><font style="font-size:11.5pt;">shall relieve Landlord or Tenant from any liability that may exist as a result of any Casualty.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11.5pt;">If by reason of a Casualty (i) the Building shall be totally damaged or destroyed, (ii) the Building shall be so damaged or destroyed (whether or not the Premises are damaged or destroyed) that repair or restoration shall require more than fifteen (15) months or the expenditure of more than 20% percent of the full insurable value of the Building (which, for purposes of this Section </font><font style="font-size:11pt;">12.1(</font><font style="font-size:11.5pt;">c), shall mean replacement cost less the cost of footings, foundations and other structures below the street and first floors of the Building) immediately prior to the Casualty, or (iii) more than 30% of the Premises shall be damaged or destroyed (as estimated in any such case by a reputable contractor, architect or engineer designated by Landlord), then in any such case Landlord may terminate this Lease by notice given to Tenant within 180 days after the Casualty, provided, however, Landlord may terminate this Lease pursuant to this </font><b style="font-size:11.5pt;font-weight:bold;">paragraph (c) </b><font style="font-size:11.5pt;">only if Landlord shall also elect to terminate at least 80% percent of the leases in the Building for premises affected by the casualty in a similar or greater manner as the Premises was affected (expressly excluding any leases for similarly affected premises under which Landlord does not have a termination right under the circumstances of the casualty at issue). If this Lease is te1minated as a result of a Casualty, Landlord shall be entitled to retain for its benefit and Tenant shall promptly pay over to Landlord the proceeds of insurance maintained by Tenant on the Improvements.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(d)</font></font><font style="font-size:11.5pt;">Within ninety (90) days after the occurrence of any Casualty affecting the Premises, Landlord shall deliver to Tenant a written estimate from a reputable contractor, architect or engineer designated by Landlord as to the probable length of time that will be</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:71.8pt;margin:0pt 0pt 0pt 8.2pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:2.15pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">necessary to substantially complete Landlord&#8217;s Restoration Work. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">such time estimate exceeds fifteen (15) months from the date of such Casualty, Tenant shall have the right to terminate this Lease by giving notice to Landlord thereof within ten ( I 0) Business Days after receipt of such estimate. </font><font style="font-size:12pt;">In </font><font style="font-size:11.5pt;">addition, as to any Casualty occurring within the last two (2) years of the Term of this Lease and as to which the estimated time for substantial completion of Landlord&#8217;s Restoration Work would leave less than nine (9) months remaining in the Term of this Lease (taking into account any extension of the Term that has been validly exercised by Tenant), Tenant shall have the right to terminate this Lease by delivering written notice to Landlord of such election within ten ( I 0) Business Days after receipt of Landlord&#8217;s estimate. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">the Premises or the Building are substantially damaged by fire or other casualty, and this Lease is not otherwise terminated hereunder, and if Landlord&#8217;s Restoration Work shall not be substantially completed within ninety (90) days after the time period set forth in Landlord&#8217;s estimate for substantial completion of Landlord&#8217;s Restoration Work, as such date may be extended as a result of delays caused by events of Force Majeure (but in no event exceeding more than an additional four (4) months as a result of such Force Majeure delays), Tenant shall have the right to terminate this Lease by delivering at least thirty (30) days prior written notice to Landlord of such election which notice must be delivered within ten </font><font style="font-size:11pt;">(I </font><font style="font-size:11.5pt;">0) Business Days after the expiration of such time period, provided, however, that if Landlord completes such restoration prior to the end of such thirty (30) day notice period, Tenant&#8217;s notice of termination shall be deemed rescinded, and this Lease shall continue in full force and effect. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Tenant is entitled pursuant to the terms of this </font><b style="font-size:11.5pt;font-weight:bold;">paragraph (d) </b><font style="font-size:11.5pt;">to terminate this Lease and Tenant fails to deliver a termination notice to Landlord within the ten </font><font style="font-size:11pt;">(I </font><font style="font-size:11.5pt;">0) Business Day period set forth herein, Tenant will be deemed to have waived Tenant&#8217;s rights under this </font><b style="font-size:11.5pt;font-weight:bold;">paragraph (d) </b><font style="font-size:11.5pt;">to terminate the Lease on account of such Casualty.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(e)</font></font><font style="font-size:11.5pt;">Landlord shall not carry any insurance on Tenant&#8217;s Removable Property or on the Improvements and shall not be obligated to repair or replace Tenant&#8217;s Removable Property or the Improvements (whether or not installed by or at the expense of Landlord). Tenant shall look solely to its insurance for recovery of any damage to or loss of Tenant&#8217;s Removable Property or any Improvements. In the event of a partial or total destruction of the Premises, within thirty (30) days after receiving a notice from Landlord, Tenant shall remove any and all of Tenant&#8217;s Removable Property from the portion of the Premises destroyed, and if Tenant does not so remove Tenant&#8217;s Removable Property, Landlord, at Tenant&#8217;s expense, may discard the same or may remove Tenant&#8217;s Removable Property to a public warehouse for deposit or retain the same in its own possession and at its discretion may sell the same at either public auction or private sale, the proceeds of which shall be applied first to the expenses of removal, storage and sale, second to any sums owed by Tenant to Landlord, with any balance remaining to be paid to Tenant; if the expenses of such removal, storage and sale shall exceed the proceeds of any sale, Tenant shall pay such excess to Landlord upon demand. Tenant shall be solely responsible for arranging for any visits to the Premises by Tenant&#8217;s insurance adjuster that may be desired by Tenant prior to the removal of Tenant&#8217;s Removable Property by Tenant or Landlord, as provided in this Section 12.l(d), or the performance by Landlord of Landlord&#8217;s Restoration Work or the Specified Restoration Work and Landlord shall be under no obligation to delay the performance of same, nor shall Landlord have any liability to Tenant in the event that Tenant fails to do so. Tenant shall promptly permit Landlord access to the Premises for the purpose of performing Landlord&#8217;s Restoration Work and, if applicable, the Specified Restoration Work.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:1.15pt;margin:0pt 0pt 0pt 7.25pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:71.3pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36.7pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(f)</font></font><font style="font-size:11pt;">This </font><b style="font-size:11pt;font-weight:bold;">Section 12.1 </b><font style="font-size:11pt;">shall be deemed an express agreement governing any damage or destruction of the Premises by fire or other casualty, and any law providing for a contingency in the absence of an express agreement, now or hereafter in force, shall have no application.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">12.2</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">EMINENT DOMAIN</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11pt;">If the Premises or Tenant&#8217;s access to or use of the Premises shall be affected by any exercise of the power of eminent domain, Basic Rent and Escalation Charges payable by Tenant shall be justly and equitably abated and reduced according to the nature and extent of the loss of use thereof suffered by Tenant. In no event shall Landlord have any liability for damages to Tenant for inconvenience, annoyance or interruption of business arising from such exercise of the power of eminent domain.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11pt;">If any part of the Building is taken by any exercise of the right of eminent domain, then Landlord shall have the right to terminate this Lease (even if Landlord&#8217;s entire interest in the Premises may have been divested) by giving notice of Landlord&#8217;s election so to do within ninety (90) days after the occurrence of the effective date of such taking, whereupon this Lease shall terminate thirty (30) days after the date of such notice with the same force and effect as if such date were the date originally established as the expiration date hereof; provided, however, Landlord may terminate this Lease pursuant to this </font><b style="font-size:11pt;font-weight:bold;">paragraph (b) </b><font style="font-size:11pt;">only if Landlord shall also elect to terminate at least 80% percent of the leases in the Building for premises affected by the taking in a similar or greater manner as the Premises was affected (expressly excluding any leases for similarly affected premises under which Landlord does not have a termination right under the circumstances of the taking at issue)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11pt;">If this Lease shall not be terminated pursuant to paragraph (b), Landlord shall thereafter use due diligence to restore the Premises (excluding any alterations, additions or improvements made by Tenant pursuant to Article V) to proper condition for Tenant&#8217;s use and occupation, provided that Landlord&#8217;s obligation shall be limited to the amount of compensation recoverable by Landlord from the taking authority. If, for any reason, such restoration shall not be substantially completed within six (6) months after the expiration of the ninety (90)-day period referred to in paragraph (b) (which six-month period may be extended for such periods of time as Landlord is prevented from proceeding with or completing such restoration for any cause beyond Landlord&#8217;s reasonable control, but in no event for more than an additional three (3) months), Tenant shall have the right to terminate this Lease by giving notice to Landlord thereof within thirty (30) days after the expiration of such period (as so extended). Upon the giving of such notice, this Lease shall cease and come to an end thirty (30) days after the giving of such notice, without further liability or obligation on the part of either party unless, within such thirty (30) day period, Landlord substantially completes such restoration. Such right of termination shall be Tenant&#8217;s sole and exclusive remedy at law or in equity for Landlord&#8217;s failure so to complete such restoration.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(d)</font></font><font style="font-size:11pt;">Landlord shall have and hereby reserves and excepts, and Tenant hereby grants and assigns to Landlord, all rights to recover for damages to the Property and the leasehold interest hereby created, and to compensation accrued or hereafter to accrue by reason of such taking, and by way of confirming the foregoing, Tenant hereby grants and assigns, and covenants with Landlord to grant and assign to Landlord, all rights to such compensation. Nothing contained herein shall be construed to prevent Tenant from prosecuting in any</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.5pt;margin:0pt 0pt 0pt 7pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">condemnation proceedings a claim for the value of any of Tenant&#8217;s Removable Property installed in the Premises by Tenant at Tenant&#8217;s expense and for relocation expenses, provided that such action shall not affect the amount of compensation otherwise recoverable by Landlord from the taking authority.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;">ARTICLE XIII<br></b><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">DEFAULT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">13.1</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">TENANT&#8217;S DEFAULT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:46pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">at any time subsequent to the date of this Lease any one or more of the following events (herein referred to as a &#8220;Default of Tenant&#8221;) shall happen:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(i)</font><font style="display:inline-block;width:25.15pt;"></font><font style="font-size:11.5pt;">Tenant shall fai1 to pay the Basic Rent, Escalation Charges, additional charges or other charges hereunder when due and such failure sha11 continue for five (5) Business Days after notice to Tenant from Landlord; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(ii)</font><font style="display:inline-block;width:21.95pt;"></font><font style="font-size:11.5pt;">Tenant shall neglect or fail to perform or observe any other covenant herein contained on Tenant&#8217;s part to be performed or observed and Tenant shall fail to remedy the same as soon as practicable and in any event within thirty (30) days after notice to Tenant specifying such neglect or failure, or if such failure is of such a nature that Tenant cannot reasonably remedy the same within such thirty (30) day period, and the continuance of which for the period required for cure wi11 not (w) subject Landlord or any Superior Lessor or any Superior Mortgagee (as such terms are defined in </font><b style="font-size:11.5pt;font-weight:bold;">Section 14.15) </b><font style="font-size:11.5pt;">to prosecution for a crime of any other fine or charge, (x) subject the Premises, or any part thereof, or the Building, or any part thereof, to being condemned or vacated, (y) subject the Building, or any part thereof, to any lien or encumbrance which is not removed or bonded within the time period required under this Lease, or (z) result in a default under any Superior Lease or under any Superior Mortgage (as such terms are defined in </font><b style="font-size:11.5pt;font-weight:bold;">Section 14.15), </b><font style="font-size:11.5pt;">if Tenant shall not (A) within said thirty (30) day period advise Landlord of Tenant&#8217;s intention to take a11 steps reasonably necessary to remedy such default, (B) duly commence within said thirty (30) day period, and thereafter diligently prosecute to completion a11 steps reasonably necessary to remedy the default and (</font><font style="font-size:11pt;">C) </font><font style="font-size:11.5pt;">complete such remedy within a reasonable time after the date of said notice of Landlord; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(iii)</font><font style="display:inline-block;width:18.75pt;"></font><font style="font-size:11.5pt;">Tenant&#8217;s leasehold interest in the Premises shall be taken on execution or by other process of law directed against Tenant; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(iv)</font><font style="display:inline-block;width:19.4pt;"></font><font style="font-size:11.5pt;">Tenant shall make an assignment for the benefit of creditors or shall be adjudicated insolvent, or sha11 file any petition or answer seeking any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief for itself under any present or future Federal, State or other statute, law or regulation for the relief of debtors (other than the Bankruptcy Code, as hereinafter defined), or shall seek or consent to or acquiesce in the appointment of any trustee, receiver or liquidator of Tenant or of a11 or any substantial part of its properties, or shall admit in writing its inability to pay its debts generally as they become due; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(v)</font><font style="display:inline-block;width:22.59pt;"></font><font style="font-size:11.5pt;">An Event of Bankruptcy (as hereinafter defined) sha11 occur with respect to Tenant; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(vi)</font><font style="display:inline-block;width:19.4pt;"></font><font style="font-size:11.5pt;">A petition shall be filed against Tenant under any law (including, but not limited to, the Bankruptcy Code) seeking any reorganization, arrangement, composition, readjustment, liquidation, dissolution, or similar relief under any present or future Federal, State or other statute, law or regulation and shall remain undismissed or unstayed for an aggregate of sixty (60) days (whether or not consecutive), or if any trustee, conservator, receiver or liquidator of Tenant or of all or any substantial part of its properties shall be appointed without the consent or acquiescence of Tenant and such appointment shall remain unvacated or unstayed for an aggregate of sixty (60) days (whether or not consecutive); or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(vii)</font><font style="display:inline-block;width:16.2pt;"></font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Landlord gives Tenant the notice specified in subsection (a)(i) above twice in any calendar year (whether or not Tenant cures such failure within the applicable cure period therefor) with respect to any recurring monthly payments of Basic Rent or Escalation Charges, and Tenant shall thereafter in the same calendar year fail to pay any recurring monthly payments of Basic Rent or Escalation Charges when due;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.4pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">then in any such case Landlord may terminate this Lease by notice to Tenant, specifying a date not less than five (5) days after the giving of such notice on which this Lease shall terminate and this Lease shall come to an end on the date specified therein as fully and completely as if such date were the date herein originally fixed for the expiration of the Term of this Lease, and Tenant will then quit and surrender the Premises to Landlord, but Tenant shall remain liable as hereinafter provided.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:71.55pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11.5pt;">For purposes of clause (a)(v) above, an &#8220;Event of Bankruptcy&#8221; means the filing of a voluntary petition by Tenant, or the entry of an order for relief against Tenant, under Chapter 7, 11, or 13 of the Bankruptcy Code, and the term &#8220;Bankruptcy Code&#8221; means 11 U.S.C. </font><font style="font-size:11pt;">&#167;</font><font style="font-size:11.5pt;">101, </font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">et seq</u><font style="font-size:11.5pt;">. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">an Event of Bankruptcy occurs, then the trustee of Tenant&#8217;s bankruptcy estate or Tenant as debtor-in-possession may (subject to final approval of the court) assume this Lease, and may subsequently assign it, only if it does the following within one hundred twenty (120) days after the date of the filing of the voluntary petition, or the entry of the order for relief (or such additional time as a court of competent jurisdiction may grant if consent of Landlord is not required under the Bankruptcy Code, for cause, upon a motion made within the original one hundred twenty (120) day period):</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(i)</font><font style="display:inline-block;width:25.15pt;"></font><font style="font-size:11.5pt;">file a motion to assume the Lease with the appropriate court;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11.5pt;">(ii)</font><font style="display:inline-block;width:21.95pt;"></font><font style="font-size:11.5pt;">satisfy all of the following conditions, which Landlord and Tenant acknowledge to be commercially reasonable:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11.5pt;">(A)</font><font style="display:inline-block;width:20.04pt;"></font><font style="font-size:11.5pt;">cure all Defaults of Tenant under this Lease or provide Landlord with Adequate Assurance (as defined below) that it will (x) cure all monetary Defaults of Tenant hereunder within ten (10) days from the date of the assumption; and (y) cure all nonmonetary Defaults of Tenant hereunder within thirty (30) days from the date of the assumption;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11.5pt;">(B)</font><font style="display:inline-block;width:20.67pt;"></font><font style="font-size:11.5pt;">compensate Landlord and any other person or entity, or provide Landlord with Adequate Assurance that within ten (10) days after the date of the assumption, it will compensate Landlord and such other person or entity, for any pecuniary loss that Landlord and such other person or entity incurred as a result of any Default of Tenant, the trustee, or the debtor-in-possession;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.65pt;margin:0pt 0pt 0pt 78.95pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11pt;">(C)</font><font style="display:inline-block;width:21.34pt;"></font><font style="font-size:11pt;">provide Landlord with Adequate Assurance of Future Performance (as defined below) of all of Tenant&#8217;s obligations under this Lease; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11pt;">(D)</font><font style="display:inline-block;width:20.73pt;"></font><font style="font-size:11pt;">deliver to Landlord a written statement that the conditions herein have been satisfied.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.2pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:35.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11pt;">For purposes only of the foregoing </font><b style="font-size:11pt;font-weight:bold;">paragraph (b), </b><font style="font-size:11pt;">and in addition to any other requirements under the Bankruptcy Code, any future federal bankruptcy law and applicable case law, &#8220;Adequate Assurance&#8221; means at least meeting the following conditions, which Landlord and Tenant acknowledge to be commercially reasonable, entering an order segregating sufficient cash to pay Landlord and any other person or entity under </font><b style="font-size:11pt;font-weight:bold;">paragraph (b) </b><font style="font-size:11pt;">above.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(d)</font></font><font style="font-size:11pt;">For purposes only of </font><b style="font-size:11pt;font-weight:bold;">paragraph (b</b><font style="font-size:11pt;">), and in addition to any other requirements under the Bankruptcy Code, any future federal bankruptcy law and applicable case law, &#8220;Adequate Assurance of Future Performance&#8221; means at least meeting the following conditions, which Landlord and Tenant acknowledge to be commercially reasonable:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(i)</font><font style="display:inline-block;width:25.62pt;"></font><font style="font-size:11pt;">the trustee or debtor-in-possession depositing with Landlord, as security for the timely payment of rent and other monetary obligations, an amount equal to the sum of two (2) months&#8217; Basic Rent plus an amount equal to two (2) months&#8217; installments on account of Operating Expenses and Taxes, computed in accordance with </font><b style="font-size:11pt;font-weight:bold;">Articles VIII </b><font style="font-size:11pt;">and </font><b style="font-size:11pt;font-weight:bold;">IX;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(ii)</font><font style="display:inline-block;width:22.56pt;"></font><font style="font-size:11pt;">the trustee or the debtor-in-possession agreeing to pay in advance, on each day that the Basic Rent is payable, the monthly installments on account of Operating Expenses and Taxes, computed in accordance with </font><b style="font-size:11pt;font-weight:bold;">Articles VIII </b><font style="font-size:11pt;">and </font><b style="font-size:11pt;font-weight:bold;">IX </b><font style="font-size:11pt;">hereof;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(iii)</font><font style="display:inline-block;width:19.5pt;"></font><font style="font-size:11pt;">the trustee or debtor-in-possession providing adequate assurance of the source of the rent and other consideration due under this Lease;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(iv)</font><font style="display:inline-block;width:20.12pt;"></font><font style="font-size:11pt;">Tenant&#8217;s bankruptcy estate and the trustee or debtor-in-possession providing Adequate Assurance that the bankruptcy estate (and any successor after the conclusion of the Tenant&#8217;s bankruptcy proceedings) will continue to have sufficient unencumbered assets after the payment of all secured obligations and administrative expenses to assure Landlord that the bankruptcy estate (and any successor after the conclusion of the Tenant&#8217;s bankruptcy proceedings) will have sufficient funds to fulfill Tenant&#8217;s obligations hereunder; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(e)</font></font><font style="font-size:11pt;">If the trustee or the debtor-in-possession assumes the Lease under paragraph (b) above and applicable bankruptcy law, it may assign its interest in this Lease only if the proposed assignee first provides Landlord with Adequate Assurance of Future Performance of all of Tenant&#8217;s obligations under the Lease, and if Landlord determines, in the exercise of its reasonable business judgment, that the assignment of this Lease will not breach any other lease, or any mortgage, financing agreement, or other agreement relating to the Property by which Landlord or the Property is then bound (and Landlord shall not be required to obtain consents or waivers from any third party required under any lease, mo1tgage, financing agreement, or other such agreement by which Landlord is then bound).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.45pt;margin:0pt 0pt 0pt 7.1pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(f)</font></font><font style="font-size:11pt;">For purposes only of </font><b style="font-size:11.5pt;font-weight:bold;">paragraph (e) </b><font style="font-size:11pt;">above, and in addition to any other requirements under the Bankruptcy Code, any future federal bankruptcy law and applicable case law, &#8220;Adequate Assurance of Future Performance&#8221; means at least the satisfaction of the following conditions, which Landlord and Tenant acknowledge to be commercially reasonable:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(i)</font><font style="display:inline-block;width:25.62pt;"></font><font style="font-size:11pt;">the proposed assignee submitting a current financial statement, audited by a certified public accountant, that allows a net worth and working capital in amounts determined in the reasonable business judgment of Landlord to be sufficient to assure the future performance by the assignee of Tenant&#8217;s obligation under this Lease; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(ii)</font><font style="display:inline-block;width:22.56pt;"></font><font style="font-size:11pt;">if requested by Landlord in the exercise of its reasonable business judgment, the proposed assignee obtaining a guarantee (in form and substance satisfactory to Landlord) from one or more persons who satisfy Landlord&#8217;s standards of creditworthiness;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(g)</font></font><font style="font-size:11pt;">If this Lease shall have been terminated as provided in this Article, or if any execution or attachment shall be issued against Tenant or any of Tenant&#8217;s property whereupon the Premises shall be taken or occupied by someone other than Tenant, then Landlord may re-enter the Premises, either by summary proceedings, ejectment or otherwise, and remove and dispossess Tenant and all other persons and any and all property from the same, as if this Lease had not been made.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(h)</font></font><font style="font-size:11pt;">In the event of any termination, Tenant shall pay the Basic Rent, Escalation Charges and other sums payable hereunder up to the time of such termination, and thereafter Tenant, until the end of what would have been the Term of this Lease in the absence of such termination, and whether or not the Premises shall have been relet, shall be liable to Landlord for, and shall pay to Landlord, as liquidated current damages: (i) the Basic Rent, Escalation Charges and other sums that would be payable hereunder if such termination had not occurred, less the net proceeds, if any, of any reletting of the Premises, after deducting all reasonable expenses in connection with such reletting, including, without limitation, all repossession costs, brokerage commissions, legal expenses, attorneys&#8217; fees, advertising, expenses of employees, alteration costs and expenses of preparation for such reletting; and (ii) if, in accordance with </font><b style="font-size:11.5pt;font-weight:bold;">Section 3.l(a), </b><font style="font-size:11pt;">Tenant commenced payment of the full amount of Basic Rent on any day other than the Commencement Date, the amount of Basic Rent that would have been payable during the period beginning on the Commencement Date and ending on the day Tenant commenced payment of the full amount of Basic Rent under such </font><b style="font-size:11.5pt;font-weight:bold;">Section 3.l(a). </b><font style="font-size:11pt;">Tenant shall pay the portion of such current damages referred to in clause (i) above to Landlord monthly on the days which the Basic Rent would have been payable hereunder if this Lease had not been terminated, and Tenant shall pay the portion of such current damages referred to in clause (ii) above to Landlord upon such termination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(i)</font></font><font style="font-size:11pt;">At any time after such termination, whether or not Landlord shall have collected any such current damages, as liquidated final damages and in lieu of all such current damages beyond the date of such demand, at Landlord&#8217;s election Tenant shall pay to Landlord an amount equal to the excess, if any, of the Basic Rent, Escalation Charges and other sums as hereinbefore provided which would be payable hereunder from the date of such demand assuming that, for the purposes of this paragraph, annual payments by Tenant on account of Taxes and Operating Expenses would be the same as the payments required for the immediately</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.75pt;margin:0pt 0pt 0pt 8.7pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.25pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">preceding Operating or Tax Year for what would be the then unexpired Term of this Lease if the same remained in effect, over the then fair net rental value of the Premises for the same period, which excess amount shall be discounted to present value using a discount rate equal to the average yield to maturity of United States treasury instruments having a maturity comparable to the time period between the date of such termination or reentry and the expiration date of this Lease plus one percent (1 %).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:71.9pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36.1pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(j)</font></font><font style="font-size:11pt;">In case of any Default by Tenant, re-entry, expiration and dispossession by summary proceedings or otherwise, Landlord may (i) re-let the Premises or any part or parts thereof, either in the name of Landlord or otherwise, for a term or terms which may at Landlord&#8217;s option be equal to or less than or exceed the period which would otherwise have constituted the balance of the Te1m of this Lease and may grant concessions or free rent to the extent that Landlord considers advisable and necessary to re-let the same and (ii) may make such reasonable alterations, repairs and decorations in the Premises as Landlord in its sole judgment considers advisable and necessary for the purpose of reletting the Premises; and the making of such alterations, repairs and decorations shall not operate or be construed to release Tenant from liability hereunder as aforesaid. Landlord shall in no event be liable in any way whatsoever for failure to re-let the Premises, or, in the event that the Premises are re-let, for failure to collect the rent under such re-letting. Tenant hereby expressly waives any and all rights of redemption granted by or under any present or future laws in the event of Tenant being evicted or dispossessed, or in the event of Landlord obtaining possession of the Premises, by reason of the violation by Tenant of any of the covenants and conditions of this Lease. The foregoing notwithstanding, in the event of termination of this Lease or repossession of the Premises after a Default of Tenant, and provided Tenant has cooperated with Landlord in timely surrendering possession of the Premises as required herein after such termination or repossession, Landlord agrees to use commercially reasonable efforts to mitigate its damages hereunder, provided, however, Landlord&#8217;s obligation to use commercially reasonable efforts to mitigate its damages shall be deemed satisfied by Landlord&#8217;s marketing of the Premises in a manner similar to the manner in which Landlord markets other premises within the Building, and provided further, that Landlord shall not be obligated to show preference for reletting the Premises over any other vacant space in the Building or to lease the Premises for a rental less than the current fair market rent then prevailing for comparable office space in comparable Class A, multi-tenant high rise office towers in the financial district of Boston, Massachusetts.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.45pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:35.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(k)</font></font><font style="font-size:11pt;">If a Guarantor of this Lease is named in </font><b style="font-size:11.5pt;font-weight:bold;">Section 1.2, </b><font style="font-size:11pt;">the happening of any of the events described in </font><b style="font-size:11.5pt;font-weight:bold;">paragraphs (a)(iv)-(a)(vi) </b><font style="font-size:11pt;">of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 13.1 </b><font style="font-size:11pt;">with respect to the Guarantor shall constitute a Default of Tenant hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.25pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:35.75pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(1)</font></font><font style="font-size:11pt;">The specified remedies to which Landlord may resort hereunder are not intended to be exclusive of any remedies or means of redress to which Landlord may at any time be entitled lawfully, and Landlord may invoke any remedy (including the remedy of specific performance) allowed at law or in equity as if specific remedies were not herein provided for.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.45pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:35.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(m)</font></font><font style="font-size:11pt;">Notwithstanding anything to the contrary contained in this Lease, with respect to any legal proceedings or actions, if either party places the enforcement of this Lease or any part thereof in the hands of an attorney, or files suit upon the same, in any case, as a result of a breach by the other party of its covenants under this Lease, or if Landlord places the recovery of possession of the Premises in the hands of an attorney, the prevailing party in any such proceeding or action shall be entitled to recover its reasonable out-of-pocket attorneys&#8217; fees and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.45pt;margin:0pt 0pt 0pt 9.6pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.05pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">disbursements, and court costs. As used herein, the term &#8220;prevailing party&#8221; shall mean the party who substantially prevails in the matter at issue including a party who dismisses an action for recovery hereunder in exchange for payment of sums allegedly due, performance of covenants allegedly breached or consideration substantially equal to the relief sought in the action. The provisions of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 13.l(m) </b><font style="font-size:11.5pt;">shall not apply to any arbitration conducted pursuant to the terms of this Lease. The provisions of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 13.l(m) </b><font style="font-size:11.5pt;">shall survive the expiration or earlier termination of this Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">13.2</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">LANDLORD&#8217;S DEFAULT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:37.55pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">Landlord shall in no event be in default in the performance of any of Landlord&#8217;s obligations hereunder unless and until Landlord shall have failed to perform such obligations within thirty (30) days after written notice from Tenant, or if such failure is of such a nature that Landlord cannot reasonably remedy the same within such thirty (30) day period, Landlord shall fail to commence promptly (and in any event within such thirty (30) day period) to remedy the same and to prosecute such remedy to completion with diligence and continuity. Notwithstanding anything herein to the contrary, this Lease shall be construed as though Landlord&#8217;s covenants contained herein are independent and not dependent, and Tenant hereby waives the benefit of any law, statute, ruling or judgment to the contrary.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;">ARTICLE XIV<br></b><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">MISCELLANEOUS PROVISIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">14.1</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">INTENTIONALLY OMITTED</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">14.2</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">WAIVER</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11.5pt;">Failure on the part of Landlord or Tenant to complain of any action or non-action on the part of the other, no matter how long the same may continue, shall never be a waiver by Tenant or Landlord, respectively, of any of the other&#8217;s rights hereunder. Further, no waiver at any time of any of the provisions hereof by Landlord or Tenant shall be construed as a waiver of any of the other provisions hereof, and a waiver at any time of any of the provisions hereof shall not be construed as a waiver at any subsequent time of the same provisions. The consent or approval of Landlord or Tenant to or of any action by the other requiring such consent or approval shall not be construed to waive or render unnecessary Landlord&#8217;s or Tenant&#8217;s consent or approval to or of any subsequent similar act by the other.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11.5pt;">No payment by Tenant, or acceptance by Landlord, of a lesser amount than shall be due from Tenant to Landlord shall be treated otherwise than as a payment on account of the earliest installment of any payment due from Tenant under the provisions hereof. The acceptance by Landlord of a check for a lesser amount with an endorsement or statement thereon, or upon any letter accompanying such check, that such lesser amount is payment in full, shall be given no effect, and Landlord may accept such check without prejudice to any other rights or remedies which Landlord may have against Tenant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">14.3</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">COVENANT OF QUIET ENJOYMENT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">Tenant, subject to the terms and provisions of this Lease, on payment of the Basic Rent, Escalation Charges and additional charges and observing, keeping and performing all of the other terms and provisions of this Lease on Tenant&#8217;s part to be observed, kept and perfo1med, shall lawfully, peaceably and quietly have, hold, occupy and enjoy the Premises during the term</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.45pt;margin:0pt 0pt 0pt 5.1pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.25pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">hereof, without hindrance or ejection by any persons lawfully claiming under Landlord to have title to the Premises superior to Tenant; the foregoing covenant of quiet enjoyment is in lieu of any other covenant, express or implied.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">14.4</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">LANDLORD&#8217;S LIABILITY</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11.5pt;">Tenant specifically agrees to look solely to Landlord&#8217;s then equity interest in the Property at the time owned (including, without limitation, the rents, issues, profits, income, receipts, revenues and proceeds thereof), for recovery of any judgment from Landlord; it being specifically agreed that neither Landlord (original or successor) nor any partner of Landlord (nor any principal of any such partner) shall ever be personally liable for any such judgment, or for the payment of any monetary obligation to Tenant. The provision contained in the foregoing sentence is not intended to, and shall not, limit any right that Tenant might otherwise have to obtain injunctive relief against Landlord or Landlord&#8217;s successors in interest, or to take any action not involving the personal liability of Landlord (original or successor).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11.5pt;">To the maximum extent permitted by Law and subject to the provisions of </font><b style="font-size:11.5pt;font-weight:bold;">Section 7.6(b) </b><font style="font-size:11.5pt;">and Section 10.7 of this Lease, with respect to any services or utilities to be furnished by Landlord to Tenant, Landlord shall in no event be liable for failure to furnish the same when prevented from doing so by strike, lockout, breakdown, accident, order or regulation of or by any governmental authority, or failure of supply, or failure whenever and for so long as may be necessary by reason of the making of repairs or changes which Landlord is required or is permitted by this Lease or by law to make or in good faith deems necessary, or inability by the exercise of reasonable diligence to obtain supplies, parts or employees necessary to furnish such services, or because of war or other emergency, or for any other cause beyond Landlord&#8217;s reasonable control, or for any cause due to any act or neglect of Tenant or Tenant&#8217;s servants, agents, employees, licensees or any person claiming by, through or under Tenant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11.5pt;">Except for Tenant&#8217;s liability under </font><b style="font-size:11.5pt;font-weight:bold;">Section 14.19 </b><font style="font-size:11.5pt;">of this Lease, in no event shall either party be liable to the other for any loss of business or any other indirect, punitive or consequential damages suffered by such party from whatever cause. Landlord hereby acknowledges that Tenant is an Illinois limited liability partnership and agrees not to seek to recover from any partner, principal, retired or former partner or principal, or the constituent members of any partners of Tenant, but instead shall look solely to the assets of Tenant in connection with the enforcement of any claim hereunder. Landlord fu1ther agrees that negative capital accounts shall not be considered an asset of Tenant. Notwithstanding anything to the contrary herein, Landlord hereby waives any lien rights or possessory interest that it may have concerning Tenant&#8217;s personal property, including, Tenant&#8217;s furniture, movable fixtures, equipment, supplies and Tenant&#8217;s work papers, electronic and other files, and Tenant&#8217;s client files and papers.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(d)</font></font><font style="font-size:11.5pt;">Where provision is made in this Lease for Landlord&#8217;s consent and Tenant shall request such consent and Landlord shall fail or refuse to give such consent, Tenant shall not be entitled to any damages for any withholding by Landlord of its consent, it being intended that Tenant&#8217;s sole remedy shall be an action for specific performance or injunction, and that such remedy shall be available only in those cases where Landlord has expressly agreed in writing not to unreasonably withhold its consent. Furthermore, whenever Tenant requests Landlord&#8217;s consent or approval (whether or not provided for herein), Tenant shall pay to Landlord, on</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.7pt;margin:0pt 0pt 0pt 7.65pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">demand, as an additional charge, any expenses incurred by Landlord (including without limitation legal fees and costs, if any) in connection therewith without limitation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(e)</font></font><font style="font-size:11.5pt;">With respect to any repairs or restoration which are required or permitted to be made by Landlord, the same may be made during Building Hours and, except as otherwise expressly set forth in this Lease, Landlord sha11 have no liability for damages to Tenant for inconvenience, annoyance or interruption of business arising therefrom.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">14.5</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">NOTICE TO MORTGAGEE OR GROUND LESSOR</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">After receiving notice from any person, firm or other entity that it holds a mortgage or a ground lease which includes the Premises, no notice from Tenant to Landlord shall be effective unless and until a copy of the same is given to such holder or ground lessor (provided Tenant shall have been furnished with the name and address of such holder or ground lessor), and the curing of any of Landlord&#8217;s defaults by such holder or ground lessor shall be treated as performance by Landlord.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">14.6</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">ASSIGNMENT OF RENTS AND TRANSFER OF TITLE</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11.5pt;">With reference to any assignment by Landlord of Landlord&#8217;s interest in this Lease, or the rents payable hereunder, conditional in nature or otherwise, which assignment is made to the holder of a mortgage on property which includes the Premises, Tenant agrees that the execution thereof by Landlord, and the acceptance thereof by the holder of such mortgage shall never be treated as an assumption by such holder of any of the obligations of Landlord hereunder unless such holder shall, by notice sent to Tenant, specifically otherwise elect and that, except as aforesaid, such holder shall be treated as having assumed Landlord&#8217;s obligations hereunder only upon foreclosure of such holder&#8217;s mortgage and the taking of possession of the Premises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:12pt;">In </font><font style="font-size:11.5pt;">no event shall the acquisition of Landlord&#8217;s interest in the Property by a purchaser which, simultaneously therewith, leases Landlord&#8217;s entire interest in the Property back to the seller thereof be treated as an assumption by operation of law or otherwise, of Landlord&#8217;s obligations hereunder, but Tenant shall look solely to such seller-lessee, and its successors from time to time in title, for performance of Landlord&#8217;s obligations hereunder. In any such event, this Lease shall be subject and subordinate to the lease to such seller-lessee, provided that such subordination shall be conditioned upon the execution and delivery by and between Tenant and any such purchaser-lessor of an SNDA (as hereinafter defined) as provided in </font><b style="font-size:11pt;font-weight:bold;">Section 14.15(d). </b><font style="font-size:11.5pt;">For all purposes, such seller-lessee, and its successors in title, shall be the Landlord hereunder unless and until Landlord&#8217;s position shall have been assumed by such purchaser-lessor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11.5pt;">Except as provided in </font><b style="font-size:11.5pt;font-weight:bold;">paragraph (b) </b><font style="font-size:11.5pt;">of this Section, in the event of any transfer of title to the Property by Landlord and upon the written assumption by the transferee of all of Landlord&#8217;s obligations under this Lease, Landlord shall thereafter be entirely freed and relieved from the performance and observance of all covenants and obligations hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">14.7</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">RULES AND REGULATIONS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">Tenant shall abide by rules and regulations from time to time reasonably established by Landlord (together with such reasonable changes thereto whether by modification, elimination or addition so long as any additions or modifications do not materially increase Tenant&#8217;s obligations or materially decrease Tenant&#8217;s rights under this Lease) as Landlord at any time or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.05pt;margin:0pt 0pt 0pt 7.2pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.7pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">times hereafter may make and communicate to Tenant in writing, which, in Landlord&#8217;s reasonable judgment, shall be necessary for the reputation, safety, care and appearance of the Property, or the preservation of good order therein, or the operation or maintenance of the Property, it being agreed that such rules and regulations will be established and applied by Landlord in a non-discriminatory fashion, such that all rules and regulations shall be generally applicable to other tenants of the Building. Landlord agrees to use reasonable efforts to ensure that any such rules and regulations are uniformly enforced, but Landlord shall not be liable to Tenant for violation of the same by any other tenant or occupant of the Building, or persons having business with them. In the event that there shall be a conflict between such rules and regulations and this Lease, the provisions of this Lease shall prevail.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">14.8</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">ADDITIONAL CHARGES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Tenant shall fail to pay when due any sums under this Lease designated as an Escalation Charge or additional charge, Landlord shall have the same rights and remedies as Landlord has hereunder for failure to pay Basic Rent.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">14.9</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">INVALIDITY OF PARTICULAR PROVISIONS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.9pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">any term or provision of this Lease, or the application thereof to any person or circumstance shall, to any extent, be invalid or unenforceable, the remainder of this Lease, or the application of such term or provision to persons or circumstances other than those as to which it is held invalid or unenforceable, shall not be affected thereby, and each term and provision of this Lease shall be valid and be enforced to the fullest extent permitted by law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">14.10</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">PROVISIONS BINDING, ETC.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.7pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">Except as herein otherwise provided, the terms hereof shall be binding upon and shall inure to the benefit of the successors and assigns, respectively, of Landlord and Tenant (except in the case of Tenant, however, only such assigns as may be permitted hereunder) and, if Tenant shall be an individual, upon and to his heirs, executors, administrators, successors and permitted assigns. The reference contained to successors and assigns of Tenant is not intended to constitute a consent to assignment by Tenant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">14.11</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">RECORDING</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.35pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">Tenant agrees not to record this Lease, but, if the Term of this Lease (including any extended term) is seven (7) years or longer, each party hereto agrees, on the request of the other, to execute a so-called notice of lease in recordable form, complying with applicable law and reasonably satisfactory to Landlord&#8217;s attorneys. In no event shall such document set forth the rent or other charges payable by Tenant under this Lease; and any such document shall expressly state that it is executed pursuant to the provisions contained in this Lease, and is not intended to vary the terms and conditions of this Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">14.12</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">NOTICES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.45pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">Whenever, by the terms of this Lease, notices shall or may be given either to Landlord or to Tenant, such notice shall be in writing and shall be sent by registered or certified mail (return receipt requested), posted in a United States post office station, or letterbox in the continental</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.45pt;margin:0pt 0pt 0pt 7.55pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-0.15pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">United States, or by a nationally recognized overnight commercial courier or delivery service, postage or delivery charges prepaid, and verification of delivery requested:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.35pt;text-indent:-0.35pt;margin:0pt 0pt 12pt 35.65pt;"><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">intended for Landlord, addressed to Landlord c/o Brookfield Financial Properties L.P., 250 Vesey Street, New York, NY 10281-1023 and marked &#8220;ATTN: Senior Vice President/Director of Leasing&#8221; (or to such other address or addresses as may from time to time hereafter be designated by Landlord by like notice), with a copy sent to the same address and marked &#8220;ATTN: General Counsel&#8221;, provided, however, any notices to Landlord sent prior to February 1, 2013 shall be sent to Landlord at Landlord&#8217;s Original Address set forth in </font><b style="font-size:11.5pt;font-weight:bold;">Section 1.2 </b><font style="font-size:11.5pt;">of this Lease to the attention of the foregoing parties; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.1pt;text-indent:-0.1pt;margin:0pt 0pt 12pt 35.9pt;"><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">intended for Tenant, addressed to Tenant at Grant Thornton LLP 1901 S. Myers Road, Suite 455, Oakbrook Terrace, Illinois 60181, Attn: Russell G. Wieman, with a copy to Grant Thornton LLP, 175 West Jackson, Suite 2000, Chicago, Illinois 60684-2687, Attn: Executive Director of Procurement, with a copy to Grant Thornton LLP, 175 West Jackson, Suite 2000, Chicago, Illinois 60684-2687, Attn: Office of the General Counsel (or to such other address or addresses as may from time to time hereafter be designated by Tenant by like notice).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.05pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">Notwithstanding anything in this </font><b style="font-size:11.5pt;font-weight:bold;">Section 14.12 </b><font style="font-size:11.5pt;">or this Lease to the contrary, invoices, bills and statements may be rendered by delivering them to Tenant at the Premises without the necessity of a receipt and without providing a copy to any other person or address. All such notices shall be effective three (3) Business Days after the date of deposit in the United States Mail or on the next Business Day following deposit with such nationally recognized overnight courier or delivery service within the Continental United States, provided in any case that the sender has tracking information of delivery to or refusal to accept delivery (which refusal shall be the equivalent of a delivery) at the specified location.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:44.35pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">14.13</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">WHEN LEASE BECOMES BINDING</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.7pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">The submission of this document for examination and negotiation does not constitute an offer to lease, or a reservation of, or option for, the Premises, and this document shall become effective and binding only upon the execution and delivery hereof by both Landlord and Tenant. All negotiations, considerations, representations and understandings between Landlord and Tenant are incorporated herein and this Lease expressly supersedes any proposals or other written documents relating hereto. This Lease may be modified or altered only by written agreement between Landlord and Tenant, and no act or omission of any employee or agent of Landlord shall alter, change or modify any of the provisions hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:43.85pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">14.14</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">PARAGRAPH HEADINGS AND INTERPRETATION OF SECTIONS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.7pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">The paragraph headings throughout this instrument are for convenience and reference only, and the words contained therein shall in no way be held to explain, modify, amplify or aid in the interpretation, construction or meaning of the provisions of this Lease. The provisions of this Lease shall be construed as a whole, according to their common meaning (except where a precise legal interpretation is clearly evidenced), and the provisions hereof shall not be construed or interpreted for or against either party, regardless of any rules of construction or interpretation. Use in this Lease of the words &#8220;including,&#8221; &#8220;such as&#8221; or words of similar import, when followed</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.7pt;margin:0pt 0pt 0pt 7.1pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.85pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">by any general term, statement or matter, shall not be construed to limit such term, statement or matter to the specified item(s), whether or not language of non-limitation, such as &#8220;without limitation&#8221; or &#8220;including, but not limited to,&#8221; or words of similar import, are used with reference thereto, but rather shall be deemed to refer to all other terms or matters that could fall within a reasonably broad scope of such term, statement or matter. Tenant represents that (a) it has had the opportunity to review this Lease and the terms and conditions herein set forth with sophisticated legal counsel of Tenant&#8217;s choosing, and (b) it has had the opportunity to discuss and negotiate such terms and conditions with Landlord or Landlord&#8217;s counsel, and (c) this Lease as executed represents the results of such review, discussions and negotiations.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">14.15</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">RIGHTS OF MORTGAGEE OR GROUND LESSOR</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11pt;">Subject to </font><b style="font-size:11.5pt;font-weight:bold;">Sections 14.l5(c) </b><font style="font-size:11pt;">and </font><b style="font-size:11.5pt;font-weight:bold;">14.15 (d) </b><font style="font-size:11pt;">below, this Lease, and all rights of Tenant hereunder, are and shall be subject and subordinate to any ground lease of the Property, and all renewals, extensions, modifications and replacements thereof, and to all mortgages which may now or hereafter affect the Property and/or any of such leases, whether or not such mortgages shall also cover other lands and/or buildings and/or leases, to each and every advance made or hereafter to be made under such mortgages, and to all renewals, modifications, replacements and extensions of such leases and such mortgages and all consolidations of such mortgages. Subject to </font><b style="font-size:11.5pt;font-weight:bold;">Sections 14.l5(c) </b><font style="font-size:11pt;">and </font><b style="font-size:11.5pt;font-weight:bold;">14.l5(d) </b><font style="font-size:11pt;">below, this Section shall be self-operative and no further instrument of subordination shall be required. </font><font style="font-size:12pt;">In </font><font style="font-size:11pt;">confirmation of such subordination, but subject to </font><b style="font-size:11.5pt;font-weight:bold;">Sections 14.l5(c) </b><font style="font-size:11pt;">and </font><b style="font-size:11.5pt;font-weight:bold;">14.l5(d) </b><font style="font-size:11pt;">below, Tenant shall promptly execute, acknowledge and deliver any instrument that Landlord, the lessor under any such lease or the holder of any such mortgage or any of their respective successors in interest may reasonably request to evidence such subordination. Any lease to which this Lease is, at the time referred to, subject and subordinate is herein called </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Superior Lease&#8221; </b><font style="font-size:11pt;">and the lessor of a Superior Lease or its successor in interest at the time referred to, is herein called </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Superior Lessor&#8221;; </b><font style="font-size:11pt;">and any mortgage to which this lease is, at the time referred to, subject and subordinate, is herein called </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Superior Mortgage&#8221; </b><font style="font-size:11pt;">and the holder of a Superior Mortgage, or its successor in interest at the time referred to, is herein called </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Superior Mortgagee.&#8221;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11pt;">Subject to </font><b style="font-size:11.5pt;font-weight:bold;">Sections 14.l5(c) </b><font style="font-size:11pt;">and </font><b style="font-size:11.5pt;font-weight:bold;">14.l5(d) </b><font style="font-size:11pt;">below, if any Superior Lessor or Superior Mortgagee or the nominee or designee of any Superior Lessor or Superior Mo1igagee shall succeed to the rights of Landlord under this Lease, whether through possession or foreclosure action or delivery of a new lease or deed, or otherwise, then at the request of such party so succeeding to Landlord&#8217;s rights (herein called </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Successor Landlord&#8221;) </b><font style="font-size:11pt;">and upon such Successor Landlord&#8217;s written agreement to accept Tenant&#8217;s attornment, Tenant shall attorn to and recognize such Successor Landlord as Tenant&#8217;s landlord under this Lease and shall promptly execute and deliver any instrument that such Successor Landlord may reasonably request to evidence such attornment. Upon such attornment, this Lease shall continue in full force and effect as a direct lease between the Successor Landlord and Tenant upon all of the terms, conditions and covenants as are set forth in this Lease, except that the liability of the Successor Landlord (unless formerly the landlord under this Lease or its nominee or designee) shall be limited in the manner set forth in Section 6 of the SNDA form attached hereto as </font><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit </b><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">J;</b><font style="font-size:11pt;"> provided, however, the Successor Landlord shall be bound by and recognize Tenant&#8217;s right to offset against Rent the amount of any po1iion of the Landlord&#8217;s Contribution that is due and payable under the Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.75pt;margin:0pt 0pt 0pt 9.3pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11.5pt;">Landlord shall, subject to satisfaction of Tenant&#8217;s obligations under this </font><b style="font-size:11.5pt;font-weight:bold;">Section 14.l5(c), </b><font style="font-size:11.5pt;">deliver to Tenant, within fourteen (14) days following the date of this Lease, a Subordination, Non Disturbance and Attornment Agreement (an </font><b style="font-size:11pt;font-weight:bold;">&#8220;SNDA&#8221;) </b><font style="font-size:11.5pt;">in the form attached hereto as </font><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit J</b><font style="font-size:11.5pt;"> executed by the existing Superior Mortgagee. Concurrent with the execution and delivery of this Lease, Landlord and Tenant shall execute, acknowledge and deliver to Landlord six (6) execution counterparts of the SNDA in the form attached hereto as </font><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit </b><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">J,</b><font style="font-size:11.5pt;"> and Landlord agrees to forward same to the existing Superior Mortgagee for signature.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(d)</font></font><font style="font-size:11.5pt;">With respect to future Superior Mortgages and Superior Leases, the provisions of </font><b style="font-size:11.5pt;font-weight:bold;">Sections 14.l5(a) </b><font style="font-size:11.5pt;">and </font><b style="font-size:11.5pt;font-weight:bold;">14.l5(b) </b><font style="font-size:11.5pt;">hereof shall be conditioned upon the execution and delivery by and among Tenant, Landlord and any such Superior Mortgagee or Superior Lessor, as applicable, of an SNDA in the then customary form of such Superior Mortgagee or Superior Lessor, provided that (i) such form contains only commercially reasonable terms, including, without limitation, customary nondisturbance protections for Tenant (it being understood and agreed that the terms of the SNDA attached hereto on </font><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit </b><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">J</b><font style="font-size:11.5pt;"> shall be deemed to be commercially reasonable and contains customary nondisturbance protections), and (ii) if the Landlord&#8217;s Contribution has not been fully disbursed pursuant to </font><b style="font-size:11.5pt;font-weight:bold;">Section 5.2(c) </b><font style="font-size:11.5pt;">at the time of execution of such future SNDA, such SNDA contains the agreement of the Superior Mortgagee or Superior Lessor to recognize and be bound by Tenant&#8217;s express offset rights under </font><b style="font-size:11.5pt;font-weight:bold;">Section 5.2(c) </b><font style="font-size:11.5pt;">of this Lease. Tenant agrees to execute such SNDA on the then customary form of such Superior Mortgagee or Superior Lessor meeting such criteria and return the same to Landlord within ten (10) Business Days after Landlord&#8217;s written request therefor, and in the event that Tenant shall fail to execute, acknowledge and return any such SNDA pursuant to this </font><b style="font-size:11.5pt;font-weight:bold;">Section 14.l5(d) </b><font style="font-size:11.5pt;">within such ten (10) Business Day period, then (x) the provisions of </font><b style="font-size:11.5pt;font-weight:bold;">Sections 14.l5(a) </b><font style="font-size:11.5pt;">and </font><b style="font-size:11.5pt;font-weight:bold;">(b) </b><font style="font-size:11.5pt;">shall apply and (y) this Lease shall be subordinate to such future Superior Mortgages and Superior Leases (as applicable) and to all renewals, extensions, modifications and replacements thereof, notwithstanding the fact that such Superior Mortgagee or Superior Lessor, as the case may be, and Tenant have not executed and exchanged an SNDA. Tenant shall be liable to pay the reasonable fees charged by the Superior Mortgagee and Superior Lessor including, without limitation, reasonable attorney&#8217;s fees, in connection with obtaining such SNDA. Tenant may request customary and reasonable modifications to such SNDA from the Superior Mortgagee and Superior Lessor (as the case may be) except that Landlord&#8217;s obligations under this </font><b style="font-size:11.5pt;font-weight:bold;">Section 14.l5(d) </b><font style="font-size:11.5pt;">shall be deemed fully satisfied when Landlord delivers an SNDA (meeting the criteria set forth above) executed by its Superior Mortgagee or Superior Lessor, as applicable, on its standard form regardless of the acceptability to such Superior Mortgagee or Superior Lessor of Tenant&#8217;s requested modifications.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(e)</font></font><font style="font-size:11.5pt;">Landlord represents and warrants to Tenant that, as of Effective Date, there is no Superior Lease affecting the Building and there is no Superior M01igage affecting the Building except for that certain Mortgagor Assignment and Modification Agreement Supplementing and Amending Mortgage and Other Documents dated as of September 18, 2008 between Brookfield Properties 75 State Mezz LP, as original mortgagor, Brookfield Prope1iies 75 State Co. LLC, as Mortgagor, and Deutsche Bank AG, New York Branch, as Administrative Agent, and recorded with the Suffolk County Registry of Deeds in Book 44052, Page 299, and modifying that certain Mortgage, Security Agreement, Assignment of Leases and Rents and Fixture Filings executed by Original Mortgagor dated as of June 10, 2008 and recorded with the Suffolk Registry of Deeds in Book 43657, Page 21.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.75pt;margin:0pt 0pt 0pt 8.8pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">14.16</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">STATUS REPORT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">Recognizing that both parties may find it necessary to establish to third patiies, such as accountants, banks, mortgagees, ground lessors, or the like, the then current status of performance hereunder, either party, on the request of the other made from time to time, will promptly furnish to Landlord, or the holder of any mortgage or ground lease encumbering the Premises, or to Tenant, as the case may be, a statement of the status of any matter pertaining to this Lease, including, without limitation, acknowledgments that (or the extent to which) each party is in compliance with its obligations under the terms of this Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">14.17</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">INTENTIONALLY OMITTED</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">14.18</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">REMEDYING DEFAULTS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.95pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">Landlord shall have the right, but shall not be required, to pay such sums or do any act which requires the expenditure of monies which may be necessary or appropriate by reason of the failure or neglect of Tenant to perform any of the provisions of this Lease which continues beyond applicable notice and cure periods (or such shorter period in the event of an emergency, including without limitation, an unsafe condition), and in the event of the exercise of such right by Landlord, Tenant agrees to pay to Landlord forthwith upon demand all such sums, together with interest thereon at a rate equal to 3% over the so-called base rate in effect from time to time at Citibank, N.A. (but not in excess of the maximum rate permitted by law), as an additional charge. Any payment of Basic Rent, Escalation Charges, additional charges or other sums payable hereunder not paid within five (5) Business Days of when due shall, at the option of Landlord, bear interest at a rate equal to 3% over the so-called base rate in effect from time to time at Citibank, N.A. (but not in excess of the maximum rate permitted by law) from the due date thereof and shall be payable forthwith on demand by Landlord, as an additional charge.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">14.19</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">HOLDING OVER</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11.5pt;">Any holding over by Tenant after the expiration of the Term of this Lease shall be treated as a daily tenancy at sufferance at a rate equal to (y) for the first thirty (30) days of such holdover, an amount equal to one hundred fifty percent (150%) of the Basic Rent, Escalation Charges and other additional charges due under this Lease during the period immediately preceding the holdover by Tenant, and (z) thereafter, at the greater of (i) two (2) times the Basic Rent, Escalation Charges, Electricity Charges and additional charges then in effect, or (ii) fair market rent, prorated on a daily basis, and shall otherwise be on the terms and conditions set forth in this Lease as far as applicable. Without limiting the foregoing, Tenant shall also be responsible for, and indemnify and hold Landlord harmless from and against, all lost, cost and damage suffered by Landlord as a result of any such holding over, provided that Tenant shall only be responsible for (and obligated to indemnify and hold Landlord harmless from and against) loss of rental, loss of a tenant or other consequential damages if such holdover continues for more than thirty (30) days. Upon receipt of a written request from Tenant received during the last nine (9) months of the then Term of this Lease, Landlord agrees to inform Tenant if Landlord has entered into any new lease for any portion of the Premises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11.5pt;">Provided and on the condition that (i) Grant Thornton LLP or a GT Successor is the named Tenant under this Lease and is satisfying the Occupancy Condition, (ii) there is no Default of Tenant in existence at time of delivery of the Holdover Intention Notice or as of the expiration or earlier termination of the Term of this Lease, and (iii) Landlord has not</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:71.95pt;margin:0pt 0pt 0pt 9.6pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:2.45pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">delivered to Tenant a Qualifying Deal Notice (as hereinafter defined), Tenant may deliver to Landlord, not less than one hundred twenty (120) days prior to the then expiration of the Term of this Lease, written notice (a </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Holdover Intention Notice&#8221;) </b><font style="font-size:11.5pt;">indicating that Tenant desires to continue in possession of the Premises after the expiration of the Term for a period of, at Tenant&#8217;s election, either fourteen (14) days, thirty (30) days or sixty (60) days (as so designated by Tenant in its Holdover Intention Notice, a </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Temporary Holdover Period&#8221;) </b><font style="font-size:11.5pt;">beyond the expiration or earlier termination of this Lease. Landlord shall have ten (10) Business Days following receipt of Tenant&#8217;s Holdover Intention Notice to deliver to Tenant a Qualifying Deal Notice or to otherwise reasonably approve or disapprove in writing Tenant&#8217;s proposed Temporary Holdover Period. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Landlord approves the Temporary Holdover Period, Tenant may remain in the Premises for the Temporary Holdover Period on all of the same terms and conditions of this Lease in effect immediately prior to the effectiveness of such period, except that Tenant shall pay to Landlord an amount equal to one hundred twenty-five percent (125%) of the Basic Rent due under this Lease during the period immediately preceding the holdover by Tenant. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Landlord disapproves Tenant&#8217;s Holdover Intention Notice, Landlord shall set forth a reasonable basis for such disapproval and in such event Tenant shall have no right under this </font><b style="font-size:11.5pt;font-weight:bold;">Section 14.19(b) </b><font style="font-size:11.5pt;">to continue in occupancy of the Premises after the expiration or earlier termination of the Term of this Lease and any continued occupancy by Tenant shall be governed by </font><b style="font-size:11.5pt;font-weight:bold;">Section 14.19(a) </b><font style="font-size:11.5pt;">above of this Lease. Landlord may, at any time during the Term, whether prior to or within ten (10) Business Days after Tenant delivers a Holdover Intention Notice, deliver to Tenant a written notice (a </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Qualifying Deal Notice&#8221;) </b><font style="font-size:11.5pt;">that Landlord has entered into or is actively negotiating one or more leases or letters of intent for all or any portion of the Premises which is for a term that is scheduled to commence within six (6) months after the expiration of this Lease. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Landlord delivers a Qualifying Deal Notice to Tenant prior to or within ten (10) Business Days after Tenant delivers a Holdover Intention Notice, this </font><b style="font-size:11.5pt;font-weight:bold;">Section 14.19(b) </b><font style="font-size:11.5pt;">shall immediately be null and void and of no further force or effect, provided, however, Landlord&#8217;s failure to deliver a Qualifying Deal Notice shall not limit Landlord&#8217;s right under this </font><b style="font-size:11.5pt;font-weight:bold;">Section 14.19(b) </b><font style="font-size:11.5pt;">to reasonably disapprove of Tenant&#8217;s Holdover Intention Notice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.45pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:44.85pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11.5pt;">Nothing in this </font><b style="font-size:11.5pt;font-weight:bold;">Section 14.19 </b><font style="font-size:11.5pt;">or elsewhere in this Lease shall be construed as Landlord&#8217;s consent or agreement to any holdover in the Premises by Tenant or anyone claiming by, through or under Tenant after the expiration or earlier termination of the Term of this Lease and nothing herein shall prevent Landlord from immediately exercising Landlord&#8217;s rights under this Lease or at law to commence summary process or other legal proceedings against Tenant on account of any holding over in any portion of the Premises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">14.20</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">INTENTIONALLY OMITTED</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">14.21</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">SURRENDER OF PREMISES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">Upon the expiration or earlier termination of the Term of this Lease, Tenant shall peaceably quit and surrender to Landlord the Premises in neat and clean condition and in good order, condition and repair, together with all alterations, additions and improvements which may have been made or installed in, on or to the Premises prior to or during the Term of this Lease, excepting only (a) ordinary wear and use and (b) those instances of damage by fire or other casualty for which, under other provisions of this Lease, Tenant has no responsibility of repair or restoration. Tenant shall remove all of Tenant&#8217;s Removable Property and, to the extent required by Landlord pursuant to </font><b style="font-size:11.5pt;font-weight:bold;">Section 5.4, </b><font style="font-size:11.5pt;">all Alterations made by or on behalf of Tenant; and shall repair any damages to the Premises or the Building caused by such removal. Any Tenant&#8217;s</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.5pt;margin:0pt 0pt 0pt 8.45pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.5pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">Removable Property which shall remain in the Building or on the Premises after the expiration or termination of the Term of this Lease shall be deemed conclusively to have been abandoned, and either may be retained by Landlord as its property or may be disposed of in such manner as Landlord may see fit, at Tenant&#8217;s sole cost and expense.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">14.22</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">INTENTIONALLY OMITTED</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">14.23</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">BROKERAGE</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.85pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">Tenant warrants and represents that Tenant has dealt with no broker in connection with the consummation of this Lease other than Brokers and, in the event of any brokerage claims against Landlord predicated upon prior dealings with Tenant, Tenant agrees to defend the same and indemnify Landlord against any such claim (except any claim by Brokers). Landlord warrants and represents that Landlord has dealt with no broker in connection with the consummation of this Lease other than the Brokers and, in the event of any brokerage claims against Tenant predicated upon prior dealings with Landlord, Landlord agrees to defend the same and indemnify Tenant against any such claim (including any claim by Brokers). Landlord shall be responsible for the payment of any commissions due to the Brokers in connection with this Lease pursuant to a separate agreement with such Brokers.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">14.24</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">GOVERNING LAW</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.1pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">This Lease shall be governed exclusively by the provisions hereof and by the laws of the Commonwealth of Massachusetts, as the same may from time to time exist.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">14.25</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">CONFIDENTIAL INFORMATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11.5pt;">Tenant agrees that this Lease and the terms contained herein will be treated as strictly confidential and except as required by law (or except with the written consent of Landlord) Tenant shall not disclose the same to any third party except for Tenant&#8217;s employees, brokers, agents, partners, lenders, accountants and attorneys and like parties who have been advised of the confidentiality provisions contained herein and agree to be bound by the same. In the event Tenant is required by law to provide this Lease or disclose any of its terms, Tenant shall give Landlord prompt notice of such requirement prior to making disclosure so that Landlord may seek an appropriate protective order. If failing the entry of a protective order Tenant is compelled to make disclosure, Tenant shall only disclose portions of the Lease which Tenant is required to disclose and will exercise reasonable efforts to obtain assurance that confidential treatment will be accorded to the information so disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11.5pt;">Landlord will not, and will use reasonable efforts to cause Landlord&#8217;s agents not to, reveal to any person, association or company, any confidential information provided to Landlord by Tenant concerning the business or finances of Tenant. For purposes of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 14.25(b), </b><font style="font-size:11.5pt;">confidential information shall not include information that (i) is or becomes generally available to the public other than as a result of a disclosure by Landlord or any Landlord agent, or (ii) was available to Landlord on a non-confidential basis prior to its disclosure to Landlord by Tenant or its representatives). Notwithstanding the foregoing, Landlord may disclose such financial information as may be provided by Tenant to Landlord to actual or prospective lenders or purchasers of the Property and/or actual or prospective investors in Landlord or any of its affiliates and to Landlord&#8217;s consultants, attorneys, insurers, auditors and accountants, so long as any person or entity to whom Landlord discloses such information agrees</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.2pt;margin:0pt 0pt 0pt 9.85pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-0.3pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">to keep such information confidential. In addition, Landlord and its agents may disclose any information (a) to the extent required by any Law or order of any public authority or court, and (b) in connection with any litigation between Landlord and Tenant or otherwise related to this Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:46.85pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">14.26</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">ANTI-TERRORISM</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:37.45pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Tenant represents, warrants and covenants to Landlord that (i) neither Tenant nor any of its partners, members, principal stockholders or any other constituent entity either in control of the operation or management of Tenant or having a controlling financial interest in Tenant has been or will be designated or named as a terrorist, &#8220;Specifically Designated and Blocked Person,&#8221; or other banned or blocked person, entity, nation or transaction pursuant to any law, order, rule or regulation that is enforced or administered by the Office of Foreign Assets Control or on the most current list published by the U.S. Treasury Department Office of Foreign Assets Control at its official website, http://www.treas.gov/ofac/tl 1 sdn.pdf or at any replacement website or other replacement official publication of such list (such list, or any such replacement official publication of such list, the </font><b style="font-size:11pt;font-weight:bold;">&#8220;OFAC List&#8221;)), </b><font style="font-size:11pt;">or by any Executive Order or the United States Treasury Department; and (ii) Tenant has not engaged, and will not engage, in this transaction, directly or indirectly, on behalf of, or instigating or facilitating, and will not instigate or facilitate, this transaction, directly or indirectly, on behalf of, any such person, group, entity or nation. A breach of any Tenant representation, warranty and covenant contained in this Section shall be an immediate and material Default of Tenant under this Lease without notice or cure rights. Tenant hereby agrees to defend, indemnify and hold harmless Landlord from and against any and all claims, damages, losses, risks, liabilities and expenses (including reasonable attorneys&#8217; fees and costs) arising from or related to Tenant&#8217;s breach of any of the foregoing representations, warranties and/or covenants.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:45.65pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">14.27</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">TELECOMMUNICATIONS LINES AND EQUIPMENT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11pt;">Tenant shall not install, maintain, replace, remove and use communications or computer wires, cables and related devices (collectively, the </font><b style="font-size:11pt;font-weight:bold;">&#8220;Lines&#8221;) </b><font style="font-size:11pt;">at the Building in or serving the Premises without Landlord&#8217;s prior written consent, which consent may not be unreasonably withheld, provided, however, the foregoing will not require Landlord&#8217;s consent for Tenant&#8217;s use of cell phones, so-called PDA&#8217;s or the like in the Building which do not require installation of Lines. Tenant shall have the right, at no additional charge from Landlord, to tie-in to the existing telecommunications risers and disconnects on the floor to obtain telecommunications service from existing providers serving the Building. Tenant shall locate all electronic telecommunications equipment within the Premises and shall coordinate the location of all Lines with Landlord. Any request for consent shall contain such information as Landlord may reasonably request. Landlord&#8217;s approval of, or requirements concerning, the Lines or any equipment related thereto, the plans, specifications or designs related thereto, the contractor or subcontractor, or the work performed hereunder, shall not be deemed a warranty as to the adequacy or appropriateness thereof, and Landlord hereby disclaims any responsibility or liability for the same. If Landlord consents to Tenant&#8217;s proposal, Tenant shall pay all of Tenant&#8217;s and Landlord&#8217;s third party costs in connection therewith (including without limitation all costs related to new Lines) and shall use, maintain and operate the Lines and related equipment in accordance with and subject to all laws governing the Lines and equipment and at Tenant&#8217;s sole</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.75pt;margin:0pt 0pt 0pt 8.95pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.75pt;margin:0pt 0pt 0pt 8.95pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11.5pt;">risk and expense. Tenant shall comply with all of the requirements of this Lease concerning alterations in connection with installing the Lines. Tenant shall submit drawings or sketches to Landlord of all such Lines installed by or on behalf of Tenant. Landlord reserves the right to require that Tenant remove any Lines located in or serving the Premises which are installed in violation of these provisions, or which are at any time in violation of any laws or present a dangerous or potentially dangerous condition (whether such Lines were installed by Tenant or any other party), within three days after written notice. Landlord shall make available to Tenant sufficient space in the Building for Tenant to install, at Tenant&#8217;s sole cost and expense, one, 4 inch conduit to connect Tenant&#8217;s Lines from the Premises to the telecom closet on the floors on which the Premises is located (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Tenant&#8217;s Conduit&#8221;). </b><font style="font-size:11.5pt;">Tenant&#8217;s installation of the Tenant&#8217;s Conduit shall constitute an Alteration which is subject to all of the terms and provisions of </font><b style="font-size:11.5pt;font-weight:bold;">Section 5.4 </b><font style="font-size:11.5pt;">of this Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:46.3pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11.5pt;">Landlord may (but shall not have the obligation to) (i) install and relocate Lines at the Building; and (ii) monitor and control the installation, maintenance, replacement and removal of, the allocation and periodic re-allocation of available space (if any) for, and the al location of excess capacity (if any) on, any Lines now or hereafter installed at the Building by Landlord, Tenant or any other party. Landlord reserves the right to require Tenant to appropriately insulate the Lines and any associated equipment (including without limitation riser cables), and take such other remedial action at Tenant&#8217;s sole cost and expense as Landlord may require in its sole discretion to prevent excessive electromagnetic fields, radio frequency or radiation from emanating from Tenant&#8217;s Lines and other equipment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:45.85pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11.5pt;">On or before the expiration or sooner termination of the Term of this Lease and unless Landlord otherwise elects in writing to Tenant not later than thirty (30) days prior to expiration of the Term, Tenant shall remove all Lines installed by or on behalf of Tenant and restore the Premises and the Building and risers to their condition existing prior to the installation of such Lines </font><b style="font-size:11.5pt;font-weight:bold;">(&#8220;Wire Restoration Work&#8221;), </b><font style="font-size:11.5pt;">at Tenant&#8217;s sole cost and expense. In the event Landlord elects to retain such Lines, Tenant covenants that Tenant shall have good right to surrender such Lines, free of all liens and encumbrances. In the event Tenant fails or refuses to pay all costs of the Wiring Restoration Work within ten (10) days of Tenant&#8217;s receipt of Landlord&#8217;s notice requesting Tenant&#8217;s reimbursement for or payment of such costs, Landlord may apply all or any portion of the Security Deposit toward the payment of such unpaid costs relative to the Wiring Restoration Work. The retention or application of such Security Deposit by Landlord pursuant to this clause does not constitute a limitation on or waiver of Landlord&#8217;s right to seek further remedy under law or equity. The provisions of this clause shall survive the expiration or sooner termination of the Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11.5pt;font-weight:bold;">ARTICLE XV</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5.65pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXTENSION OPTIONS</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">15.1</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">OPTIONS TO EXTEND</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:44.9pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11.5pt;">For purposes hereof the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Occupancy Condition&#8221; </b><font style="font-size:11.5pt;">shall mean that Tenant has not assigned this Lease (except for assignments permitted without Landlord&#8217;s consent pursuant to </font><b style="font-size:11.5pt;font-weight:bold;">Section 6.l(b) </b><font style="font-size:11.5pt;">of this Lease) or sublet more than twenty-five percent (25%) of the Premises, exclusive of subleases permitted without Landlord&#8217;s consent pursuant to </font><b style="font-size:11.5pt;font-weight:bold;">Section 6.l(b) </b><font style="font-size:11.5pt;">of this Lease. Provided that, at the time of each such exercise and at the commencement of an Extended Term (as hereinafter defined), (i) this Lease is in full force and effect, and (ii) no</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11.5pt;">Default of Tenant shall have occurred and be continuing, and (iii) Grant Thornton LLP (or a GT Successor) is satisfying the Occupancy Condition (any of which conditions described in clauses (i), (ii), and/or (iii) may be waived by Landlord in writing at any time in Landlord&#8217;s sole discretion), Tenant shall have the right and option to extend the Term of this Lease with respect to all or a full floor of the Premises for two extended terms (each an </font><b style="font-size:11pt;font-weight:bold;">&#8220;Extended Term&#8221; </b><font style="font-size:11.5pt;">and collectively the </font><b style="font-size:11pt;font-weight:bold;">&#8220;Extended Terms&#8221;) </b><font style="font-size:11.5pt;">of five (5) years each by giving written notice to Landlord not later than fifteen (15) months prior to the expiration date of the Term of this Lease then in effect. The effective giving of such notice of extension by Tenant in accordance with this </font><b style="font-size:11pt;font-weight:bold;">Section 15.1 </b><font style="font-size:11.5pt;">shall automatically extend the Term of this Lease for the applicable Extended Term, and no instrument of renewal or extension need be executed. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Tenant exercises an extension option under this </font><b style="font-size:11pt;font-weight:bold;">Section 15.1 </b><font style="font-size:11.5pt;">for less than all of the Premises, the portion of the Premises as to which such Extended Term will apply must consist of a full floor of the Premises then leased by Tenant (any such floor, a </font><b style="font-size:11pt;font-weight:bold;">&#8220;Non-Extension Floor&#8221;) </b><font style="font-size:11.5pt;">and Tenant shall be responsible, at Tenant&#8217;s sole cost and expense, to remove any internal staircases located on any Non-Extension Floor, install a Building Standard floor/ceiling deck in the opening where such staircase was located and restore the portion of the Premises affected by the removal of such internal staircase to building standard condition and shall perform all other Alterations necessary to lawfully separate the Non-Extension Floor(s) and all utilities serving the same from the remainder of the Premises. In the event that Tenant fails timely to give such notice to Landlord, this Lease shall automatically terminate at the end of the Term then in effect, and Tenant shall have no further option to extend the Term of this Lease and this </font><b style="font-size:11pt;font-weight:bold;">Article XV </b><font style="font-size:11.5pt;">shall be deemed of no further force and effect. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Tenant timely exercises its option(s) to extend the Term of this Lease pursuant to this </font><b style="font-size:11pt;font-weight:bold;">Article XV, </b><font style="font-size:11.5pt;">the Extended Terms shall commence on August 1, 2024 and August 1, 2029, respectively, and shall end on July 31, 2029 and July 31, 2034, respectively. Each Extended Term shall be on all the terms and conditions of this Lease, except: (i) during the second Extended Term, Tenant shall have no further option to extend the Term, (ii) the Basic Rent for each Extended Term shall be the Fair Market Rental Value (as hereinafter defined in </font><b style="font-size:11pt;font-weight:bold;">paragraph (b) </b><font style="font-size:11.5pt;">below) of the Premises as of the Commencement Date of the applicable Extended Term, determined in the manner set forth in </font><b style="font-size:11pt;font-weight:bold;">paragraph (b) </b><font style="font-size:11.5pt;">below, and (iii) Landlord shall not be required to furnish any materials or perform any work to prepare the Premises for Tenant&#8217;s occupancy during any Extended Term and Landlord shall not be required to provide any work allowance or reimburse Tenant for any Alterations made or to be made by Tenant, or to grant Tenant any rent concession. Tenant&#8217;s right under this </font><b style="font-size:11pt;font-weight:bold;">Article XV </b><font style="font-size:11.5pt;">shall be personal to the originally named Tenant under this Lease and shall not apply in favor of or be exercisable by any assignee of this Lease (other than a permitted transferee pursuant to </font><b style="font-size:11pt;font-weight:bold;">Section </b><b style="font-size:11.5pt;font-weight:bold;">6.l(b) </b><font style="font-size:11.5pt;">of this Lease), nor any sublessee of all or any portion of the Premises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:43.9pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11.5pt;">Provided Tenant has timely exercised its rights hereunder to extend the Term of this Lease pursuant to </font><b style="font-size:11pt;font-weight:bold;">paragraph (a) </b><font style="font-size:11.5pt;">above and the conditions for Tenant&#8217;s exercise have been satisfied, Landlord shall provide Tenant, at least six (6) months prior to the commencement of the applicable Extended Term, with Landlord&#8217;s good faith estimate of the Fair Market Rental Value of the Premises for the upcoming Extended Term. If Tenant disagrees with Landlord&#8217;s estimate of the Fair Market Rental Value as set forth in Landlord&#8217;s notice referred to above, Tenant shall notify Landlord within thirty (30) days after its receipt of Landlord&#8217;s notice setting forth Tenant&#8217;s estimate of the Fair Market Rental Value of the Premises and the parties agree to act in good faith to attempt to reach agreement on the Fair Market Rental Value of the Premises for the Extended Term. </font><font style="font-size:10.5pt;">If </font><font style="font-size:11.5pt;">Tenant fails to notify Landlord that Tenant disagrees with</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.2pt;margin:0pt 0pt 0pt 7.55pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Landlord&#8217;s estimate and setting forth Tenant&#8217;s Fair Market Rental Value estimate within such thirty (30) day period then Tenant will be deemed to have accepted Landlord&#8217;s estimate of the Fair Market Rental Value for the Premises during the Extended Term. If Tenant has timely given its dispute notice and the parties are unable to reach agreement thereon within thirty (30) days after the delivery of such notice by Tenant, then either party may submit the determination of the Fair Market Rental Value of the Premises to arbitration by giving notice to the other party naming the initiating party&#8217;s arbitrator within ten (10) Business Days after the expiration of such thirty (30) day period. Within fifteen (15) days after receiving a notice of initiation of arbitration, the responding party shall appoint its own arbitrator by notifying the initiating party of the responding party&#8217;s arbitrator. If the second arbitrator shall not have been so appointed within such fifteen (15) day period, the initiating party shall deliver written notice of such failure to the responding party and the responding party shall have a period of ten (10) days after receipt of such notice to appoint its arbitrator and deliver written notice thereof to the initiating party. If the responding party fails to notify the initiating party of its designated arbitrator within the foregoing additional ten (10) day period, then the second arbitrator shall be chosen in the same manner as described below with respect to the selection of the third arbitrator. Upon the selection (or appointment, as the case may be) of the second arbitrator, the two arbitrators thus appointed shall, within fifteen (15) days after the responding party&#8217;s notice of appointment of the second arbitrator, appoint a third arbitrator. If the two initial arbitrators are unable timely to agree on the third arbitrator, then either may, on behalf of both, request such appointment by the Boston office of JAMS/ENDISPUTE, or its successor, or, on its failure, refusal or inability to act, by a court of competent jurisdiction. The Fair Market Rental Value of the Premises for the Extended Term shall be determined by the method commonly known as &#8220;baseball arbitration&#8221;, whereby Landlord&#8217;s selected arbitrator and Tenant&#8217;s selected arbitrator shall each set forth its respective determination of the Fair Market Rental Value of the Premises, and the third arbitrator must select one or the other (it being understood that the third arbitrator shall be expressly prohibited from selecting a compromise figure). Landlord&#8217;s selected arbitrator and Tenant&#8217;s selected arbitrator shall deliver their determinations of the Fair Market Rental Value of the Premises to the third arbitrator within five (5) Business Days of the appointment of the third arbitrator and the third arbitrator shall render his or her decision within ten (10) days after receipt of both of the other two determinations of the Fair Market Rental Value of the Premises. The third arbitrator&#8217;s decision shall be binding on both Landlord and Tenant. All arbitrators shall be commercial real estate brokers who are independent from the parties and who have had at least ten (10) years&#8217; experience in Class A office building leasing transactions in the financial district of Boston, Massachusetts. Each party shall pay the fees of its own arbitrator, and the fees of the third arbitrator shall be shared equally by the parties. In the event Tenant initiates the aforesaid arbitration process and as of the Commencement Date of the Extended Term the amount of the Fair Market Rental Value of the Premises has not been determined, Tenant shall continue to pay Rent at the rate and on the terms in effect, including Escalation Charges, as of the last month of the Term then in effect and when the determination has actually been made, an appropriate retroactive adjustment shall be made as of the Commencement Date of the Extended Term if necessary. In the event that such determination shall result in an overpayment by Tenant of any Basic Rent, such overpayment shall be paid or credited by Landlord to Tenant promptly after such dete1mination has been made, and if such determination shall result in an underpayment by Tenant of any Basic Rent, Tenant shall pay any such amounts to Landlord promptly following such determination. For purposes of this </font><b style="font-size:11.5pt;font-weight:bold;">Article XV, </b><font style="font-size:11pt;">the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Fair Market Rental Value&#8221; </b><font style="font-size:11pt;">shall</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:2.25pt;margin:0pt 0pt 0pt 8.3pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">mean the fixed annual rent that a willing tenant would pay and a willing landlord of comparable first class office towers in Boston, Massachusetts would accept for the Premises during the Extended Term, taking into account all then relevant factors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:71.3pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:47.35pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11pt;">The termination of this Lease during the initial Term or the first Extended Term, respectively, shall also terminate and render void any option or right on Tenant&#8217;s part to extend this Lease for the Extended Term(s), and nothing contained in this </font><b style="font-size:11.5pt;font-weight:bold;">Article XV </b><font style="font-size:11pt;">shall prevent Landlord from exercising any right granted to or reserved by Landlord in this Lease to terminate this Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11.5pt;font-weight:bold;">ARTICLE XVI</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXPANSION OPTION</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">16.1</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">EXPANSION OPTION</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11pt;">Subject to the terms and conditions of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 16.1 </b><font style="font-size:11pt;">and provided and on the condition that both at the time of delivery of the Tenant&#8217;s Expansion Notice (as hereinafter defined) and as of the Expansion Premises Commencement Date (as hereinafter defined), (x) this Lease is in full force and effect, (y) no Default of Tenant shall have occurred and be continuing, and (z) Grant Thornton LLP (or a GT Successor) is satisfying the Occupancy Condition (any of which conditions described in clauses (x), (y), and (z) may be waived by Landlord in writing at any time in Landlord&#8217;s sole discretion), Tenant shall have a one-time right to expand the Premises to include additional space in the Building located in an area and configuration to be designated by Landlord and containing not less than 4,000 nor more than 7,000 rentable square feet of space (as so designated by Landlord, the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Expansion Premises&#8221;) </b><font style="font-size:11pt;">for a term commencing on a date designated by Landlord and falling between February 1, 2018 and December 31, 2018. Tenant shall give Landlord written notice (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Tenant&#8217;s Expansion Notice&#8221;) </b><font style="font-size:11pt;">on or before 5:00 pm EST on February 1, 2017 (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Expansion Option Expiration Date&#8221;), </b><font style="font-size:11pt;">time being of the absolute essence, of its election to expand the Premises in accordance with this </font><b style="font-size:11.5pt;font-weight:bold;">Section 16.1. </b><font style="font-size:11pt;">If Tenant shall fail to timely deliver Tenant&#8217;s Expansion Notice electing to so expand the Premises by the Expansion Option Expiration Date, Tenant shall be deemed to have waived such right, and Landlord shall thereafter have no further obligation to Tenant with respect to this </font><b style="font-size:11.5pt;font-weight:bold;">Article XVI.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11pt;">If Tenant timely delivers the Tenant&#8217;s Expansion Notice electing to lease the Expansion Premises, then, on the date on which Landlord delivers vacant possession of such Expansion Premises to Tenant (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Expansion Premises Commencement Date&#8221;), </b><font style="font-size:11pt;">the Expansion Premises shall become part of the Premises, upon all of the terms and conditions set forth in this Lease, except that (i) Tenant shall have no further option to expand the Premises pursuant to this </font><b style="font-size:11.5pt;font-weight:bold;">Article XVI, </b><font style="font-size:11pt;">(ii) the Basic Rent for the Expansion Premises shall be the Expansion Premises Fair Market Rental Value (as hereinafter defined) as of the Expansion Premises Commencement Date (as hereinafter defined), determined in the manner set forth in </font><b style="font-size:11.5pt;font-weight:bold;">paragraph (c) </b><font style="font-size:11pt;">below, (iii) Tenant&#8217;s lease of the Expansion Premises shall be co-terminous with the Term of this Lease for the Premises (including being subject to </font><b style="font-size:11.5pt;font-weight:bold;">Article XV </b><font style="font-size:11pt;">of this Lease), and shall be on an &#8220;as is&#8221; basis, except as expressly set forth in this </font><b style="font-size:11.5pt;font-weight:bold;">Section 16.l(b), </b><font style="font-size:11pt;">(iv) Landlord shall not be required to furnish any materials or perform any work to prepare the Expansion Premises for Tenant&#8217;s occupancy, except that Landlord shall, at Landlord&#8217;s expense, deliver the Expansion Premises to Tenant vacant, broom clean and separately metered for electrical service and Landlord shall install any necessary partition walls and common corridors</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.75pt;margin:0pt 0pt 0pt 8.2pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">necessary to demise the Expansion Premises, and (v) Landlord shall not be required to provide any work allowance or reimburse Tenant for any Alterations made or to be made by Tenant (including any of the improvement allowances set forth in </font><b style="font-size:11.5pt;font-weight:bold;">Section 5.2 </b><font style="font-size:11pt;">of this Lease which shall not be applicable to the Expansion Premises), or to grant Tenant any rent concession with respect to Tenant&#8217;s lease of the Expansion Premises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11pt;">If Tenant timely exercises its option pursuant to this </font><b style="font-size:11.5pt;font-weight:bold;">Section 16.1, </b><font style="font-size:11pt;">Landlord shall, at least six (6) months prior to the Anticipated Inclusion Date (as hereinafter defined), deliver a written notice to Tenant (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Landlord&#8217;s Expansion Notice&#8221;) </b><font style="font-size:11pt;">which sets forth (i) the location and rentable square footage of the Expansion Premises (which Expansion Premises shall be measured in accordance with Landlord&#8217;s then standard method of measurement of space in the Building), including delivery of a floor plan of such Expansion Premises,, (ii) the anticipated commencement date (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Estimated Expansion Commencement Date&#8221;) </b><font style="font-size:11pt;">for the inclusion of the Expansion Premises (which shall be between February 1, 2018 and December 31, 20 l 8), (iii) the Base Operating Expenses and Base Taxes for the Expansion Premises, and (iv) Landlord&#8217;s determination of the Expansion Premises Fair Market Rental Value for the Expansion Premises (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Landlord&#8217;s Expansion Offer Determination&#8221;). </b><font style="font-size:11pt;">The Basic Rent with respect to the Expansion Premises shall be the Expansion Premises Fair Market Rental Value for such Expansion Premises, determined as of the Estimated Expansion Commencement Date, and shall be set forth in Landlord&#8217;s Expansion Notice. Tenant shall deliver written notice to Landlord </font><b style="font-size:11.5pt;font-weight:bold;">(&#8220;Tenant&#8217;s Expansion Rent Notice&#8221;) </b><font style="font-size:11pt;">within thirty (30) days after Landlord&#8217;s delivery of Landlord&#8217;s Expansion Notice whether Tenant accepts, rejects or disputes Landlord&#8217;s Expansion Offer Determination, and if Tenant disputes Landlord&#8217;s Expansion Offer Determination, the Tenant&#8217;s Expansion Rent Notice shall set forth Tenant&#8217;s good faith determination of the Expansion Premises Fair Market Rental Value for the Expansion Premises </font><b style="font-size:11.5pt;font-weight:bold;">(&#8220;Tenant&#8217;s Expansion Offer Determination&#8221;). </b><font style="font-size:11pt;">If Tenant rejects the Landlord&#8217;s Expansion Notice, Tenant will not be obligated to lease the Expansion Premises and this Section </font><font style="font-size:10.5pt;">16.1 </font><font style="font-size:11pt;">shall be of no further force or effect. If Tenant fails to send Tenant&#8217;s Expansion Rent Notice within such thirty (30) day period, or fails to object to Landlord&#8217;s Expansion Offer Determination in Tenant&#8217;s Expansion Rent Notice and to set forth therein Tenant&#8217;s Expansion Offer Determination, then Tenant shall be deemed to have accepted Landlord&#8217;s Expansion Offer Determination as the Expansion Premises Fair Market Rental Value for the Expansion Premises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(d)</font></font><font style="font-size:11pt;">If Tenant timely so elects to lease the Expansion Premises, but objects to Landlord&#8217;s Expansion Offer Determination and in Tenant&#8217;s Expansion Rent Notice sets forth Tenant&#8217;s Expansion Offer Determination, and the parties do not agree on the Expansion Premises Fair Market Rental Value within thirty (30) days after delivery of such Tenant&#8217;s Expansion Offer Determination from Tenant, then either party may initiate the arbitration procedure set forth in </font><b style="font-size:11.5pt;font-weight:bold;">Section 15.l(b) </b><font style="font-size:11pt;">of this Lease to determine the Expansion Premises Fair Market Rental Value by giving notice to the other within ten (10) Business Days after the end of such thirty (30) day period, provided, however, references to the &#8220;Fair Market Rental Value of the Premises&#8221; or &#8220;Fair Market Rental Value of the Premises for the Extended Term&#8221; in such </font><b style="font-size:11.5pt;font-weight:bold;">Section 15.l(b) </b><font style="font-size:11pt;">shall be deemed references, respectively, to the Expansion Premises Fair Market Rental Value or the Expansion Premises Fair Market Rental Value for the remainder of the Term of this Lease following the Expansion Premises Commencement Date. If neither party timely submits the dispute for arbitration within such additional ten (10) Business Day period, Landlord&#8217;s determination of Expansion Premises Fair Market Rental Value shall be binding on the parties. If either party submits the dete1mination of the Expansion Premises Fair Market Rental Value to</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.95pt;margin:0pt 0pt 0pt 7.5pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">arbitration and as of the Expansion Premises Commencement Date the amount of the Expansion Premises Fair Market Rental Value has not been determined, Tenant shall pay the amount set forth in Landlord&#8217;s Expansion Offer Determination as the Basic Rent for the Expansion Premises and when the determination has actually been made, an appropriate retroactive adjustment shal1 be made as of the Expansion Premises Commencement Date, if necessary. In the event that such determination shall result in an overpayment by Tenant of any Basic Rent, such overpayment shall be paid or credited by Landlord to Tenant promptly after such determination has been made, and if such determination shall result in an underpayment by Tenant of any Basic Rent, Tenant shall pay any such amounts to Landlord promptly following such determination. For purposes of this </font><b style="font-size:11.5pt;font-weight:bold;">Article XVI, </b><font style="font-size:11pt;">the term </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Expansion Premises Fair Market Rental Value&#8221; </b><font style="font-size:11pt;white-space:pre-wrap;">shall mean the fixed annual rent that a willing tenant would pay and a willing landlord of comparable  first class office towers in Boston, Massachusetts would accept for comparable expansion premises and for a comparable term, taking into account all then relevant factors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(e)</font></font><font style="font-size:11pt;">If the Expansion Premises is not available for Tenant&#8217;s occupancy on the Estimated Expansion Commencement Date as a result of the holding over of the prior tenant or for any other reason beyond Landlord&#8217;s reasonable control, Landlord shall not be subject to any liability whatsoever for such failure or inability to deliver possession and the exercise of said option shall remain effective, but the Expansion Premises Commencement Date will be postponed and the Basic Rent and Additional Rent shall not commence with respect to the Expansion Premises, until the Expansion Premises is delivered to Tenant in the condition required under this </font><b style="font-size:11.5pt;font-weight:bold;">Article XVI. </b><font style="font-size:11pt;">Notwithstanding the foregoing, if Landlord does not deliver possession of the Expansion Premises to Tenant in the condition required by this </font><b style="font-size:11.5pt;font-weight:bold;">Article XVI </b><font style="font-size:11pt;">on or before January 1, 2019, Landlord may provide Tenant with written notice identifying substitute space in the Building reasonably comparable to the original Expansion Premises which is available for delivery to Tenant by not later than February 28, 2019 as substitute expansion space (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Substitute Expansion Space&#8221;). </b><font style="font-size:11pt;">Tenant shall have the right to reasonably approve the Substitute Expansion Space proposed by Landlord and, if approved, the Substitute Expansion Space shall become the Expansion Premises and Landlord shall deliver the same to Tenant in the condition required under </font><b style="font-size:11.5pt;font-weight:bold;">Section 16.1 </b><font style="font-size:11pt;">for the Expansion Premises not later than February 28, 2019. Tenant shall have a period of ten (10) Business Days to approve or disapprove of the Substitute Expansion Space and if Tenant fails to respond within such ten (10) Business Day period, Tenant will be deemed to have approved the Substitute Expansion Space as the Expansion Premises. If Tenant does not approve the Substitute Expansion Space designated by Landlord, Tenant shall set forth Tenant&#8217;s reasonable basis for such disapproval and Tenant shall have the option expressly set forth in such notice to elect to cancel the exercise of its option to lease the Expansion Premises and such cancellation of Tenant&#8217;s exercise of its option to lease the Expansion Premises shall be effective thirty (30) days thereafter, provided, however, that if Landlord delivers the Expansion Premises to Tenant in the condition required under this Lease within thirty (30) days following Landlord&#8217;s receipt of such cancellation notice, such cancellation notice shall be void and without further force or effect and Tenant&#8217;s exercise of its option to lease the Expansion Premises shall continue in full force and effect. The foregoing right of cancellation shall be Tenant&#8217;s sole and exclusive remedy at law or in equity or otherwise for the failure of Landlord to deliver possession of the Expansion Premises to Tenant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><font style="font-size:11pt;">Once incorporated into the Premises, Tenant&#8217;s rights and obligations with respect to the Expansion Premises shall be subject to and with the benefit of all of the terms and conditions of this Lease, except that the rentable area of the Premises, Basic Rent and the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72.25pt;margin:0pt 0pt 0pt 7.5pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">Escalation Factor shall be revised to reflect the addition of the Expansion Premises to the Premises upon the Expansion Premises Commencement Date. Promptly after determination of the Expansion Premises Fair Market Rental Value, or if Tenant has accepted Landlord&#8217;s determination of the Expansion Premises Fair Market Rental Value, Landlord and Tenant agree to enter into an amendment to this Lease memorializing the addition of the Expansion Premises to this Lease and the amendment to the applicable defined terms hereunder, but failure of the parties to execute such an amendment shall have no effect on the effectiveness of the expansion of the Premises to include the Expansion Premises, and the economic terms associated therewith, as set forth above.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(g)</font></font><font style="font-size:11pt;">The rights created by this </font><b style="font-size:11.5pt;font-weight:bold;">Section 16.1 </b><font style="font-size:11pt;">shall be personal to the originally named Tenant under this Lease and shall not apply in favor of or be exercisable by any assignee of this Lease (other than an assignee that is permitted without Landlord&#8217;s consent pursuant to </font><b style="font-size:11.5pt;font-weight:bold;">Section 6.1(b) </b><font style="font-size:11pt;">of this Lease), nor any sublessee of all or any portion of the Premises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.3pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;">ARTICLE XVII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">RIGHT OF FIRST OFFER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">17.1</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">RIGHT OF FIRST OFFER</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11pt;">Tenant acknowledges and agrees that the 14</font><sup style="font-size:8.25pt;vertical-align:top;">th</sup><font style="font-size:11pt;"> Floor ROFO Space (as hereinafter defined) is currently available for lease and the term </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Initial 14</b><sup style="font-size:8.62pt;font-weight:bold;vertical-align:top;">th </sup><b style="font-size:11.5pt;font-weight:bold;">Floor Lease Up&#8221; </b><font style="font-size:11pt;">shall refer to the initial leases (and any extensions or renewals thereof) entered into by Landlord with third party tenants for all or any portion of the 14</font><sup style="font-size:8.25pt;vertical-align:top;">th </sup><font style="font-size:11pt;">Floor ROFO Space following the date of this Lease (any such tenant or occupant of leases entered into as part of the Initial 14</font><sup style="font-size:8.25pt;vertical-align:top;">1</sup><font style="font-size:11pt;"> Floor Lease-Up being a Superior Occupant for purposes of this </font><b style="font-size:11.5pt;font-weight:bold;">Article XVII </b><font style="font-size:11pt;">with respect to the 14</font><sup style="font-size:8.25pt;vertical-align:top;">th </sup><font style="font-size:11pt;">Floor ROFO Space leased by such tenant or occupant). The parties agree that the provisions of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 17.1 </b><font style="font-size:11pt;">shall not apply until after the 14</font><sup style="font-size:8.25pt;vertical-align:top;">th</sup><font style="font-size:11pt;"> Floor ROFO Space has been leased by Landlord to Superior Occupants as part of the Initial 14</font><sup style="font-size:8.25pt;vertical-align:top;">th </sup><font style="font-size:11pt;">Floor Lease Up, provided, however, the foregoing shall be deemed waived as to any portion of the 14</font><sup style="font-size:8.25pt;vertical-align:top;">th</sup><font style="font-size:11pt;"> Floor ROFO Space that has not been leased as part of the Initial 14</font><sup style="font-size:8.25pt;vertical-align:top;">th </sup><font style="font-size:11pt;">Floor Lease Up as of the 2</font><sup style="font-size:8.25pt;vertical-align:top;">nd </sup><font style="font-size:11pt;">anniversary of the Commencement Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11pt;">Subject to the terms and conditions of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 17.1 </b><font style="font-size:11pt;">and the rights of the Superior Occupant (as hereinafter defined) and provided the ROFO Conditions are satisfied both on the date Tenant notifies Landlord that Tenant accepts Landlord&#8217;s offer to lease the applicable Available ROFO Space and on the commencement date of this Lease for the applicable Available ROFO Space, before Landlord leases any Available ROFO Space to any unrelated third party other than the Superior Occupant(s), Landlord will first offer by written notice to Tenant </font><b style="font-size:11.5pt;font-weight:bold;">(&#8220;Landlord&#8217;s Offer Notice&#8221;) </b><font style="font-size:11pt;">to lease such Available ROFO Space to Tenant. As used in this </font><b style="font-size:11.5pt;font-weight:bold;">Section 17.1, &#8220;Available ROFO Space&#8221; </b><font style="font-size:11pt;">shall mean and refer to (1) any leaseable space on the twelfth (12</font><sup style="font-size:8.25pt;vertical-align:top;">th</sup><font style="font-size:11pt;">) floor of the Building (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;12</b><sup style="font-size:8.62pt;font-weight:bold;vertical-align:top;">th</sup><b style="font-size:11.5pt;font-weight:bold;"> Floor ROFO Space&#8221;), </b><font style="font-size:11pt;">and/or (2) any leasable space on the fourteenth (14</font><sup style="font-size:8.25pt;vertical-align:top;">th</sup><font style="font-size:11pt;">) floor of the Building (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;14</b><sup style="font-size:8.62pt;font-weight:bold;vertical-align:top;">th</sup><b style="font-size:11.5pt;font-weight:bold;"> Floor ROFO Space&#8221;), </b><font style="font-size:11pt;">which, in any case, Landlord determines will become available for lease after (i) all Superior Occupants have declined or failed to exercise their rights to lease such space, (ii) the expiration or termination of the lease with the then tenant, subtenant or other occupant of such space and the failure of such tenant or occupant in such space to exercise any extension or renewal rights granted to such party, and (iii) the failure of Landlord to grant any tenant,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 0pt 7.85pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11.5pt;">subtenant or other occupant of the space the right to renew or continue its term of occupancy whether or not such rights are expressly granted by a lease or other written instrument and whether or not such right to renew or continue its term of occupancy is subsequently memorialized in a lease or written instrument (any such party described in clauses (ii) and (iii) being an </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Existing Tenant&#8221;). </b><font style="font-size:11.5pt;">Landlord&#8217;s Offer Notice shall specify the rentable square footage and location of the Available ROFO Space (together with a floor plan of such space), and the anticipated commencement date and specified rent commencement date therefor. Tenant shall notify Landlord within thirty (30) days after the date of Landlord&#8217;s Offer Notice, time being of the absolute essence, that (A) Tenant elects to lease all (but not less than all) of the Available ROFO Space identified in and Landlord&#8217;s Offer Notice, or (B) Tenant rejects Landlord&#8217;s offer to lease the Available ROFO Space. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Tenant fails to timely notify Landlord of Tenant&#8217;s election, Tenant shall be deemed to have given notice that Tenant rejects Landlord&#8217;s offer and Landlord shall thereafter be entitled to lease such Available ROFO Space to any third party on such terms and conditions and for such rent as Landlord determines in its sole discretion.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(c)</font></font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Tenant timely delivers its acceptance notice electing to lease the Available ROFO Space, then, on the date on which Landlord delivers vacant possession of such Available ROFO Space to Tenant (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Offer Space Commencement Date&#8221;), </b><font style="font-size:11.5pt;">the Available ROFO Space shall become part of the Premises, upon all of the terms and conditions set forth in this Lease, except that (i) the Basic Rent for the Available ROFO Space shall be the Offer Space Fair Market Rental Value (as hereinafter defined) for such Available ROFO Space as of the Anticipated Inclusion Date (as hereinafter defined), determined in the manner set forth in </font><b style="font-size:11.5pt;font-weight:bold;">Section 17.2 </b><font style="font-size:11.5pt;">below, (ii) the Escalation Factor with respect to such Available ROFO Space shall be a fraction, expressed as a percentage, the numerator of which is the number of rentable square feet in the Available ROFO Space and the denominator of which is the number of rentable square feet in the Building, (iii) the Base Operating Expenses under this Lease for the Available ROFO Space shall be the Operating Expenses incurred during the calendar year in which the Anticipated Inclusion Date falls and the Base Taxes under this Lease for the Available ROFO Space shall be the Taxes incurred for tax fiscal year in which the Anticipated Inclusion Date falls, (iv) Tenant shall accept the Available ROFO Space in its &#8220;as is&#8221; condition on the Offer Space Commencement Date and Landlord shall not be required to furnish any materials or perform any work to prepare the Available ROFO Space for Tenant&#8217;s occupancy, except that Landlord shall, at Landlord&#8217;s expense, deliver the Available ROFO Space to Tenant vacant, broom clean and separately metered for electrical service and Landlord shall install any necessary partition walls and common corridors necessary to demise the Available ROFO Space, (v) Landlord shall not be required to provide any work allowance or reimburse Tenant for any Alterations made or to be made by Tenant (including any of the improvement allowances set forth in </font><b style="font-size:11.5pt;font-weight:bold;">Section 5.2 </b><font style="font-size:11.5pt;">of this Lease which shall not be applicable to the Available ROFO Space), or to grant Tenant any rent concession with respect to Tenant&#8217;s lease of the Available ROFO Space, and (vi) Tenant&#8217;s lease of the Available ROFO Space shall be co-terminous with the Term of this Lease for the Premises (including being subject to </font><b style="font-size:11.5pt;font-weight:bold;">Article XV </b><font style="font-size:11.5pt;">of this Lease). </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">the Available ROFO Space is not available for Tenant&#8217;s occupancy on the date estimated by Landlord as the Anticipated Inclusion Date (as hereinafter defined) therefor for any reason, including, but not limited to, the holding over of the prior tenant, then Landlord and Tenant agree that Landlord shall have no liability to Tenant on account thereof and no such failure to give possession to Tenant on such date shall in any way affect the validity of this Lease or the obligations of Tenant hereunder or give rise to any claim for damages by Tenant or a claim for rescission and the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.55pt;margin:0pt 0pt 0pt 8.05pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">exercise of Tenant&#8217;s option to lease the applicable Available ROFO Space shall remain effective, but the Offer Space Commencement Date will be postponed until the Available ROFO Space is delivered to Tenant in the condition required under this </font><b style="font-size:11.5pt;font-weight:bold;">Section 17.1. </b><font style="font-size:11pt;">Notwithstanding the foregoing, if Landlord does not deliver possession of the Available ROFO Space to Tenant in the condition required by this </font><b style="font-size:11.5pt;font-weight:bold;">Article XVII </b><font style="font-size:11pt;">within eight (8) months following the Anticipated Inclusion Date for any reason, then Tenant may, within ten (10) business days after such date, cancel the exercise of its option to lease the Available ROFO Space by giving to Landlord a written cancellation notice and such cancellation of Tenant&#8217;s exercise of its option to lease the Available ROFO Space shall be effective thirty (30) days thereafter, provided, however, that if Landlord delivers the Available ROFO Space to Tenant in the condition required under this Lease within thirty (30) days following Landlord&#8217;s receipt of such cancellation notice, such cancellation notice shall be void and without further force or effect and Tenant&#8217;s exercise of its option to lease the Available ROFO Space shall continue in full force and effect. The foregoing right of cancellation shall be Tenant&#8217;s sole and exclusive remedy at law or in equity or otherwise for the failure of Landlord to deliver possession of the Available ROFO Space to Tenant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(d)</font></font><font style="font-size:11pt;">The term </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Superior Occupant&#8221; </b><font style="font-size:11pt;">for purposes of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 17.1 </b><font style="font-size:11pt;">shall mean (i) with respect to the 12</font><sup style="font-size:8.25pt;vertical-align:top;">th</sup><font style="font-size:11pt;"> Floor ROFO Space, New Boston Fund, Inc. and any parent, affiliate, or subsidiary of New Boston Fund, Inc. or any successors or assigns to any of the foregoing (collectively, </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;New Boston&#8221;), </b><font style="font-size:11pt;">and (ii) with respect to the 14</font><sup style="font-size:8.25pt;vertical-align:top;">th </sup><font style="font-size:11pt;">Floor ROFO Space, any tenant or occupant of leases entered into as part of the Initial 14</font><sup style="font-size:8.25pt;vertical-align:top;">th</sup><font style="font-size:11pt;"> Floor Lease-Up, including any extension rights or renewals of such leases, entered into as part of the Initial 14</font><sup style="font-size:8.25pt;vertical-align:top;">th </sup><font style="font-size:11pt;">Floor Lease Up. Landlord shall have the right to negotiate with and to lease any Available ROFO Space at any time to the Superior Occupant(s) or extend or renew the lease or occupancy of any Superior Occupant(s) before Landlord will have any obligation to offer the applicable Available ROFO Space to Tenant pursuant to this </font><b style="font-size:11.5pt;font-weight:bold;">Section 17.1.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(e)</font></font><font style="font-size:11pt;">The right under this </font><b style="font-size:11.5pt;font-weight:bold;">Section 17.1 </b><font style="font-size:11pt;">granted to Tenant is a one-time right as to the Available ROFO Space (or such portion thereof as may be offered by Landlord to Tenant if the entire Available ROFO Space is not then being offered to Tenant under this </font><b style="font-size:11.5pt;font-weight:bold;">Section 17.1) </b><font style="font-size:11pt;">to be effective only once during the Term, so that after Landlord delivers to Tenant a Landlord&#8217;s Offer Notice for any particular space within the Available ROFO Space and Tenant elects not to lease the Available ROFO Space offered to Tenant, either by express rejection or failure to deliver an acceptance notice to Landlord within the required time period, Tenant&#8217;s rights hereunder shall forever terminate as to the Available ROFO Space that was so offered to Tenant (but not as to the balance of the Available ROFO Space that was not previously offered to Tenant) and, thereafter, Landlord shall have no further obligation to offer to Tenant such previously offered Available ROFO Space.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(f)</font></font><font style="font-size:11pt;">For purposes of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 17.1, </b><font style="font-size:11pt;">the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;ROFO Conditions&#8221; </b><font style="font-size:11pt;">shall mean the following conditions are satisfied in full as of the date of both (1) Landlord&#8217;s Offer Notice with respect to the Availab1e ROFO Space, and (2) the Anticipated Inclusion Date with respect to the Available ROFO Space: (i) this Lease is in full force and effect, (ii) no Default of Tenant shall have occurred and be continuing, (iii) the Grant Thornton LLP or any GT Successor and/or any assignee permitted without Landlord&#8217;s consent pursuant to </font><b style="font-size:11.5pt;font-weight:bold;">Section 6.l(b) </b><font style="font-size:11pt;">of this Lease, is satisfying the Occupancy Condition (provided that the foregoing requirements of clauses (ii) and (iii) of this sentence may be waived by Landlord in its sole discretion, at any time), and (iv) there remains at least thirty-six (36) full calendar months remaining in the then Term of this Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.1pt;margin:0pt 0pt 0pt 8.05pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(g)</font></font><font style="font-size:11.5pt;">The rights created by this </font><b style="font-size:11.5pt;font-weight:bold;">Section 17.1 </b><font style="font-size:11.5pt;">shall be personal to the originally named Tenant under this Lease and shall not apply in favor of or be exercisable by any assignee of this Lease (other than an assignee that is permitted without Landlord&#8217;s consent pursuant to </font><b style="font-size:11.5pt;font-weight:bold;">Section 6.1(b) </b><font style="font-size:11.5pt;">of this Lease), nor any sublessee of all or any portion of the Premises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">17.2</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">OFFER SPACE BASIC RENT</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11.5pt;">The Basic Rent with respect to any Available ROFO Space leased by Tenant pursuant to this </font><b style="font-size:11.5pt;font-weight:bold;">Article XVII </b><font style="font-size:11.5pt;">(individually or collectively for purposes of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 17.2, </b><font style="font-size:11.5pt;">the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Offer Space&#8221;) </b><font style="font-size:11.5pt;">shall be the Offer Space Fair Market Rental (as hereinafter defined) for such Offer Space, which Basic Rent shall be determined as of the date estimated by Landlord in Landlord&#8217;s offer notice as the anticipated commencement date (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Anticipated Inclusion Date&#8221;) </b><font style="font-size:11.5pt;">for such Offer Space and shall be set forth in a written notice (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Offer Rent Notice&#8221;) </b><font style="font-size:11.5pt;">given to Tenant on the later to occur of (x) the date which is no later than one hundred eighty (180) days prior to the Anticipated Inclusion Date for such Offer Space, or (y) the date Landlord sends Landlord&#8217;s Offer Notice to Tenant. Landlord&#8217;s determination of the Offer Space Fair Market Rental as set forth in the Offer Rent Notice is hereinafter referred to as </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Landlord&#8217;s Offer Determination.&#8221; &#8220;Offer Space Fair Market Rental&#8221; </b><font style="font-size:11.5pt;">of the applicable Offer Space for purposes of this </font><b style="font-size:11.5pt;font-weight:bold;">Article XVII </b><font style="font-size:11.5pt;">means the fixed annual rent that a willing tenant would pay and a willing landlord of comparable first class office towers in Boston, Massachusetts would accept for comparable expansion premises and for a comparable term, taking into account all then relevant factors. Tenant shall deliver written notice to Landlord </font><b style="font-size:11.5pt;font-weight:bold;">(&#8220;Tenant&#8217;s Rent Notice&#8221;) </b><font style="font-size:11.5pt;">within thirty (30) days after Landlord&#8217;s delivery of the Offer Rent Notice whether Tenant accepts or disputes Landlord&#8217;s Offer Determination, and if Tenant disputes Landlord&#8217;s Offer Determination, the Tenant&#8217;s Rent Notice shall set forth Tenant&#8217;s good faith determination of the Offer Space Fair Market Rental for the applicable Offer Space, which shall constitute the minimum that Tenant can claim as the Offer Space Fair Market Rental for such space in any arbitration thereof </font><b style="font-size:11.5pt;font-weight:bold;">(&#8220;Tenant&#8217;s Minimum Offer Determination&#8221;). </b><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Tenant fails to send Tenant&#8217;s Rent Notice within such thirty (30) day period, or fails to object to Landlord&#8217;s Offer Determination in Tenant&#8217;s Rent Notice and to set forth therein Tenant&#8217;s Minimum Offer Determination, then Tenant shall be deemed to have accepted Landlord&#8217;s Offer Determination as the Offer Space Fair Market Rental for the applicable Offer Space.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11.5pt;">If Tenant timely so elects to lease the applicable Offer Space in accordance with the provisions of </font><b style="font-size:11.5pt;font-weight:bold;">Section 17.1, </b><font style="font-size:11.5pt;">but objects to Landlord&#8217;s Offer Determination and in Tenant&#8217;s Rent Notice sets forth Tenant&#8217;s Minimum Offer Determination, and the parties do not agree on the Offer Space Fair Market Rental for the applicable Offer Space within thirty </font><font style="font-size:11pt;">(30) days after delivery of such Tenant&#8217;s Minimum Offer Determination from Tenant, then either party may initiate the arbitration procedure set forth in </font><b style="font-size:11pt;font-weight:bold;">Section 15.l(b) </b><font style="font-size:11pt;">of this Lease to determine the Offer Space Fair Market Rental of the applicable Offer Space by giving notice to the other within ten (10) Business Days after the end of such thirty (30) day period, provided, however, for purposes of any arbitration procedure, references in </font><b style="font-size:11pt;font-weight:bold;">Section 15.1(b) </b><font style="font-size:11pt;">to &#8220;Premises&#8221; shall be deemed to refer instead to the applicable Offer Space and references to &#8220;Fair Market Rental Value&#8221; shall be deemed to refer instead to the Offer Space Fair Market Rental defined in this </font><b style="font-size:11pt;font-weight:bold;">Section 17.2. </b><font style="font-size:11pt;">If neither party timely submits the dispute for arbitration within such ten (10) Business Day period, Landlord&#8217;s Offer Determination shall be binding on the parties. If either party has initiated the arbitration process as provided herein, upon determination of the Offer Space Fair Market Rental of the applicable Offer Space, or if Tenant has accepted (or is deemed</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72.5pt;margin:0pt 0pt 0pt 7.95pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11.5pt;">to have accepted) Landlord&#8217;s Offer Determination, Landlord and Tenant shall, within thirty (30) days, execute an amendment to this Lease to memorialize the incorporation of the applicable Offer Space into the Premises upon the terms contained in Landlord&#8217;s Offer Notice, and otherwise on substantially the same terms and conditions as contained in this Lease, provided, however, failure of the parties to execute such an amendment shall have no effect on the effectiveness of the expansion of the Premises to include the applicable Offer Space and the economic terms associated therewith as set forth above. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">either party submits the determination of the Offer Space Fair Market Rental Value to arbitration and as of the commencement date of this Lease for such Offer Space the amount of the Offer Space Fair Market Rental Value has not been determined, Tenant shall pay the amount set forth in Landlord&#8217;s Offer Determination as the Basic Rent for the applicable Offer Space and when the determination has actually been made, an appropriate retroactive adjustment shall be made as of the commencement date for such Offer Space if necessary. In the event that such determination shall result in an overpayment by Tenant of any Basic Rent, such overpayment shall be paid or credited by Landlord to Tenant promptly after such determination has been made, and if such determination shall result in an underpayment by Tenant of any Basic Rent, Tenant shall pay any such amounts to Landlord promptly following such determination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11.5pt;font-weight:bold;">ARTICLE XVIII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">CONTRACTION OPTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">18.1</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">TENANT&#8217;S CONTRACTION OPTION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(a)</font></font><font style="font-size:11.5pt;">Subject to the terms and conditions of this Article XVIII, Tenant shall have a one-time option, during the initial Term only (hereinafter called the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Contraction Option&#8221;), </b><font style="font-size:11.5pt;">to exclude from the Premises, effective as of a date specified by Tenant and falling between July 1, 2018 and July 1, 2020 (as so specified by Tenant, the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Contraction Date&#8221;), </b><font style="font-size:11.5pt;">all or any contiguous portion of any partial floor of the Premises leased by Tenant (a </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Partial Floor Premises&#8221;), </b><font style="font-size:11.5pt;">as designated by Tenant in its Contraction Notice (the portion so designated by Tenant for exclusion, the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Reduction Premises&#8221;), </b><font style="font-size:11.5pt;">provided and on condition that (a) Tenant gives Landlord written notice of such election (hereinafter called the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Contraction Notice&#8221;) </b><font style="font-size:11.5pt;">not later than the date that is twelve (12) months prior to the effective Contraction Date as hereinabove provided, (b) Tenant pays to Landlord the Termination Payment (determined as set forth in </font><b style="font-size:11.5pt;font-weight:bold;">Section 19.1 </b><font style="font-size:11.5pt;">of this Lease as if Tenant had exercised its early termination option but prorated for the Reduction Premises only) not later than the date that is thirty (30) days prior to the effective Contraction Date, and (c) to the extent Tenant elects to exclude from the Premises less than the entire Partial Floor Premises on any floor, both the Reduction Premises and the remaining portion of the Partial Floor Premises that will continue to be a part of the Premises (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Adjusted Partial Floor Premises&#8221;) </b><font style="font-size:11.5pt;">must consist of an Acceptable Configuration (as hereinafter defined) which is reasonably approved by Landlord. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Tenant timely notifies Landlord of its election to partially reduce the Premises pursuant to this </font><b style="font-size:11.5pt;font-weight:bold;">Section 18.1, </b><font style="font-size:11.5pt;">then the rentable square footage of the Premises and all of the pertinent economic terms set forth under this Lease shall be adjusted to reflect the exclusion of the Reduction Premises from the Premises. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Tenant exercises the Contraction Option, Tenant shall, at Tenant&#8217;s sole cost and expense, on or before the Contraction Date, perform all work necessary to lawfully demise and separate the Reduction Premises from the remainder of the Premises and, if Tenant exercises its Contraction Option with respect to less than the entire Partial Floor Premises, to lawfully demise</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:73.4pt;margin:0pt 0pt 0pt 7.75pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11.5pt;">and separate the Adjusted Partial Floor Premises from the Reduction Premises and the remainder of the Premises, including without limitation, removal of any internal staircase in the Reduction Premises and installation of a building standard floor/ceiling deck and restore the affected portions of the Premises to building standard condition acceptable to Landlord. For all purposes of this Lease, an </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Acceptable Configuration&#8221; </b><font style="font-size:11.5pt;">shall mean a contiguous and commercially reasonable, independently leasable configuration containing not less than 4,000 square feet of rentable floor area, which contains reasonable means of ingress, egress or access to the Common Areas and/or core areas of the Building (such as access to bathrooms, telephone and electrical closets, etc.) and contains a reasonably proportionate ratio of linear feet of exterior window line to the rentable area of the Premises as a whole.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(b)</font></font><font style="font-size:11.5pt;">Landlord and Tenant agree to enter into an amendment to this Lease memorializing Tenant&#8217;s exercise of the Contraction Option, but failure of the parties to execute such an amendment shall have no effect on the effectiveness of Tenant&#8217;s exercise of the Contraction Option as set forth above. In the event Tenant exercises its Contraction Option pursuant to the provisions of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 18.1, </b><font style="font-size:11.5pt;">the Term of this Lease for the Reduction Premises shall expire as of the Contraction Date as fully and completely as if such date were the date originally fixed herein for the expiration of the Term of this Lease for the Reduction Premises and Tenant shall surrender the Reduction Premises to Landlord in the condition required under this Lease, provided, however, in addition to such surrender obligations, Tenant shall remove from the Reduction Premises any above-standard improvements designated by Landlord pursuant to </font><b style="font-size:11.5pt;font-weight:bold;">Section 5.4 </b><font style="font-size:11.5pt;">of this Lease and repair any damage to the Reduction Premises caused by such removal and restore the affected portion of the Premises to is condition prior to the installation of such improvements. Tenant shall remain liable to satisfy any and all obligations of Tenant under the Lease with respect to the Reduction Premises which accrue up to the Contraction Date, and any such obligations shall survive the Contraction Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11.5pt;font-weight:bold;">ARTICLE XIX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">TERMINATION OPTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">19.1</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">TERMINATION OPTION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11.5pt;">Tenant shall have a one-time right to terminate the Term of this Lease effective as of July 31, 2021 (hereafter referred to as the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Early Termination Date&#8221;), </b><font style="font-size:11.5pt;">provided and on condition that (a) Tenant gives Landlord written notice of such election (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Early Termination Notice&#8221;) </b><font style="font-size:11.5pt;">by not later than July 1, 2020, (b) both as of the date of Tenant&#8217;s exercise of such option and as of the Early Termination Date, this Lease is in full force and effect and there is no Default of Tenant under this Lease, (c) Tenant pays to Landlord, not later than thirty (30) days prior to the Early Termination Date, the Termination Payment (as hereinafter defined). As used herein, the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Termination Payment&#8221; </b><font style="font-size:11.5pt;">shall be an amount equal to the sum of (i) Landlord&#8217;s unamortized costs and expenses (with such amortization calculated on a straight line basis over the original lease term with interest at the rate of Eight Percent (8%) per annum incurred in connection with this Lease (including any amendments thereto executed pursuant to </font><b style="font-size:11.5pt;font-weight:bold;">Articles XVI or XVII), </b><font style="font-size:11.5pt;">which costs shall consist of Landlord&#8217;s Contribution and any other improvement allowances or concessions paid for by Landlord, the Basic Rent which was waived during the Abatement Period and any other free rent periods, and all Landlord&#8217;s legal fees and brokerage commissions incurred in connection with this Lease and any such amendments, plus (ii) an amount equal to three (3) months of the then fully escalated rental (i.e. Basic Rent and Escalation Charges)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:37.7pt;margin:0pt 0pt 0pt 7.35pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">payable under this Lease. Tenant&#8217;s obligation to pay the Termination Payment is in addition to and not in lieu of Tenant&#8217;s obligation to pay all Basic Rent and Additional Rent due under the Lease through (and including) the Early Termination Date. In the event of any termination of this Lease pursuant to the provisions of this </font><b style="font-size:11.5pt;font-weight:bold;">Section 19.1, </b><font style="font-size:11pt;">the Term of the Lease shall expire as of the Early Termination Date as fully and completely as if such date were the date originally fixed herein for the expiration of the Term of this Lease. Tenant shall remain liable to satisfy any and all obligations of Tenant under the Lease which accrue up to the Early Termination Date, and any such obligations shall survive the Early Termination Date. The right created by this </font><b style="font-size:11.5pt;font-weight:bold;">Section 19.1 </b><font style="font-size:11pt;">shall be personal to the originally named Tenant under this Lease and shall not apply in favor of or be exercisable by any assignee of this Lease (except with respect to an assignment permitted without Landlord&#8217;s consent pursuant to </font><b style="font-size:11.5pt;font-weight:bold;">Section 6.l(b)), </b><font style="font-size:11pt;">nor any sublessee of all or any portion of the Premises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11.5pt;font-weight:bold;">ARTICLE XX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">ROOF RIGHTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">20.1</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">GENERALLY.</u><font style="font-size:11pt;"> Subject to and so long as (i) compliance with all rules, regulations, statutes and codes of any governmental authority having jurisdiction thereover, (ii) compliance with any covenants, conditions and restrictions applicable to the Building, (iii) a Default of Tenant is not in existence and continuing, and (iv) at Landlord&#8217;s election, any cable or other service provider installing, servicing or maintaining the equipment installed by Tenant on the roof or providing cable service to the Premises enters into Landlord&#8217;s required license agreement for similar installations and services provided to tenants in the Building, Tenant shall have the right of access to and the non-exclusive use of the area of the roof of the Building in an area reasonably designated by Landlord (the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Tenant&#8217;s Roof Area&#8221;) </b><font style="font-size:11pt;">for the installation of one (1) satellite dish or antenna, in size and dimension reasonably acceptable to Landlord, for the supply of cable television and/or telecommunication services solely to the Premises (collectively, the </font><b style="font-size:11.5pt;font-weight:bold;">&#8220;Tenant&#8217;s Rooftop Equipment&#8221;), </b><font style="font-size:11pt;">free of any license fee for the use thereof, and provided further that the installation and maintenance of any aspect of Tenant&#8217;s Rooftop Equipment shall not void any roof or other warranty applicable to the Building and that all such installations shall be located and screened in a manner reasonably approved in writing by Landlord, which approval will not be unreasonably withheld provided Tenant has complied with all the conditions of this </font><b style="font-size:11.5pt;font-weight:bold;">Article XX. </b><font style="font-size:11pt;">Tenant may use Tenant&#8217;s Roof Area for Tenant&#8217;s own use or the use of its permitted subtenants (and not for resale purposes) and only for the purpose set forth in this </font><b style="font-size:11.5pt;font-weight:bold;">Article XX. </b><font style="font-size:11pt;">The location, height, diameter, design and installation of the satellite dish or other cable television equipment shall be subject to Landlord&#8217;s approval, which shall be in Landlord&#8217;s reasonable discretion. Tenant shall use and maintain Tenant&#8217;s Rooftop Equipment so as not to cause any interference with other users of the roof, including Landlord, or damage to or interference with the operation of the Building or Building systems. Tenant&#8217;s Rooftop Equipment, including any Lines installed in connection therewith, shall constitute Tenant&#8217;s Removable Property. Tenant shall cooperate reasonably with Landlord and any other tenant or person now or hereafter having equipment, installations, lines or machinery on the roof of the Building so as not to cause (or to eliminate) any interference or adverse effect caused to such rooftop installations. If at any time during the term of this Lease, Tenant shall cease to actively use the Tenant&#8217;s Rooftop Equipment for a period of time in excess of two (2) years, or if Tenant fails to install any Tenant&#8217;s Rooftop Equipment in Tenant&#8217;s Roof Area on or before the second anniversary of the Commencement Date, then the license granted to Tenant pursuant to this</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:1pt;margin:0pt 0pt 0pt 8.35pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;">Article XX </b><font style="font-size:11.5pt;">shall automatically terminate and expire and Tenant shall have no further right to use space on the roof of the Building upon the expiration of said two (2) year period or upon such second anniversary of the Commencement Date, as applicable, and Tenant shall, at its sole cost and expense, remove Tenant&#8217;s Rooftop Equipment, if any, from Tenant&#8217;s Roof Area within 60 days after receipt of notice from Landlord to so remove Tenant&#8217;s Rooftop Equipment, unless, prior the expiration of said 60-day period, Tenant re-commences its use (or initiates its use, as applicable) of Tenant&#8217;s Rooftop Equipment. Tenant shall have the right to access telephone/data closets and shafts and conduits in the Building, plenum areas and other pathways in the Building, in order to connect the Tenant&#8217;s Rooftop Equipment to the Premises, subject to Landlord&#8217;s right to reasonably approve such connections and to Landlord&#8217;s reasonable rules and regulations relative to the access to and the use of such areas within the Building.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">20.2</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">INSURANCE PREMIUMS.</u><font style="font-size:12pt;"> If </font><font style="font-size:11.5pt;">the rate of any insurance carried by Landlord is increased as a result of Tenant&#8217;s Rooftop Equipment, then Tenant will pay to Landlord within thirty (30) days after Landlord delivers to Tenant a certified statement from Landlord&#8217;s insurance carrier stating that the rate increase was caused by Tenant&#8217;s Rooftop Equipment, a sum equal to the difference between the original premium and the increased premium resulting from the Tenant&#8217;s Rooftop Equipment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">20.3</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">NO REPRESENTATIONS, SERVICES OR OBLIGATIONS</u><font style="font-size:11.5pt;"> Landlord has not made any representations or promises pertaining to the suitability of the Building&#8217;s rooftop or Tenant&#8217;s Roof Area for Tenant&#8217;s Rooftop Equipment. Tenant, for the purpose of this paragraph and its right to rooftop access hereunder, accepts the rooftop and Tenant&#8217;s Roof Area in its &#8220;AS IS&#8221; condition. Other than as set forth in this </font><b style="font-size:11.5pt;font-weight:bold;">Article XX, </b><font style="font-size:11.5pt;">Landlord shall not have any obligations with respect to Tenant&#8217;s Rooftop Equipment or compliance with any Laws (including the obtaining of any required permits or licenses, or the maintenance thereof) relating thereto and Landlord shall have no obligation to provide any services or other utilities to Tenant&#8217;s Roof Area and Tenant shall be responsible to procure and pay for all electrical service and any other utility service required for Tenant&#8217;s Rooftop Equipment in accordance with the applicable provisions of this Lease. Landlord makes no representation that Tenant&#8217;s Rooftop Equipment will be able to receive or transmit communication signals without interference or disturbance (whether or not by reason of the installation or use of similar equipment by others on the roof) and Tenant agrees that Landlord shall not be liable to Tenant therefor. Tenant acknowledges and agrees that the privileges granted Tenant under this </font><b style="font-size:11.5pt;font-weight:bold;">Article XX </b><font style="font-size:11.5pt;">shall not, now or at any time after the installation of the Tenant&#8217;s Rooftop Equipment, be deemed to grant Tenant a leasehold or other real property interest in the Building or any portion thereof, including the Building&#8217;s roof. The license granted to Tenant in this </font><b style="font-size:11.5pt;font-weight:bold;">Article XX </b><font style="font-size:11.5pt;">shall automatically terminate and expire upon the expiration or earlier termination of this Lease (including renewals) and the termination of such license shall be self-operative and no further instrument shall be required to effect such termination. Notwithstanding the foregoing, upon request by Landlord, Tenant, at Tenant&#8217;s reasonable expense, shall promptly execute and deliver to Landlord, in recordable form, any certificate or other document reasonably required by Landlord confirming the termination of Tenant&#8217;s right to use the Tenant&#8217;s Roof Area.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">20.4</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">COMPLIANCE WITH LEGAL REQUIREMENTS.</u><font style="font-size:11.5pt;"> Tenant will obtain prior to installation, any and all necessary licenses, approvals, permits, etc., necessary for the installation, maintenance and use of any equipment installed pursuant to this </font><b style="font-size:11.5pt;font-weight:bold;">Article XX. </b><font style="font-size:11.5pt;">Tenant&#8217;s Rooftop Equipment shall not in any way conflict with any applicable Laws now in force or which may</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.5pt;margin:0pt 0pt 0pt 7.65pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">hereafter be enacted. Tenant will, at its sole cost and expense, promptly comply or ensure that Tenant&#8217;s Rooftop Equipment complies with all laws, statutes, ordinances, governmental rules or regulations, or requirements of any board of fire insurance underwriters or other similar bodies now or hereafter constituted relating to or affecting Tenant&#8217;s roof use. Tenant shall indemnify and hold Landlord harmless from and against any and all loss, cost (including reasonable attorneys&#8217; fees incurred in defending Landlord), damage or liability arising out of any violations of said laws, statutes, ordinances, rules or regulations.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">20.5</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">ADDITIONAL COVENANTS.</u><font style="font-size:11pt;"> Tenant&#8217;s use of Tenant&#8217;s Roof Area shall be exercised: (a) in such manner as will not create any hazardous condition or interfere with or impair the operation of the heating, ventilation, air conditioning, plumbing, electrical, fire protection, life safety, public utilities or other systems or facilities in the Building; (b) in compliance with all applicable laws, codes and regulations and subject to and in accordance with the terms of this Lease applicable to the performance of Alterations; (c) in such a manner as will not directly or indirectly interfere with, delay, restrict or impose any expense, work or obligation upon Landlord in the use or operation of the Building; (d) at Tenant&#8217;s cost, including the cost of repairing all damage to the Building and any personal injury and/or property damage attributable to the installation, inspection, adjustment, maintenance, removal or replacement of any equipment or apparatus on the roofs approved hereunder; and (f) in a manner which will not void or invalidate any roof warranty then in effect with respect to the roof of the Building. Tenant&#8217;s Rooftop Equipment shall be used solely in the ordinary course of Tenant&#8217;s business operations and Tenant may not sublease, license or otherwise permit third parties (other than Tenant Successors or Tenant Affiliates) to establish communications transmission facilities as part of Tenant&#8217;s roof use. Tenant shall (i) be solely responsible for any damage caused as a result of Tenant&#8217;s Rooftop Equipment, (ii) promptly pay any tax, license, permit or other fees or charges imposed pursuant to any Laws or insurance requirements relating to the installation, maintenance or use of Tenant&#8217;s Rooftop Equipment, (iii) promptly comply with all precautions and safeguards reasonably required by Landlord&#8217;s insurance company and all governmental authorities, and (iv) perform all necessary repairs or replacements to, or maintenance of, the Tenant&#8217;s Rooftop Equipment, provided, however, that if Tenant&#8217;s failure to so repair, replace or maintain the Tenant&#8217;s Rooftop Equipment jeopardizes the property of Landlord or any other tenant located on the roof or within the Building, Landlord may, at Landlord&#8217;s option and after ten (10) days&#8217; written notice to Tenant (except in an emergency), elect to perform such repairs, replacements or maintenance at Tenant&#8217;s sole reasonable cost and expense unless Tenant has commenced such repairs within ten (10) days following Tenant&#8217;s receipt of such notice and Tenant diligently prosecutes such repairs to completion.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">20.6</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">RESERVED RIGHTS OF LANDLORD.</u><font style="font-size:11pt;"> If any of Tenant&#8217;s Rooftop Equipment installed by Tenant in connection with Tenant&#8217;s roof use, including any Lines, interferes with or disturbs use of the roof, including the use by Landlord or other tenants or occupants of the Building of their communications equipment, or the operation of the Building or the Building systems, then following demand by Landlord, Tenant shall promptly relocate, at Tenant&#8217;s sole cost and expense, all or a portion of Tenant&#8217;s Rooftop Equipment to another area on the roof reasonably designated by Landlord. Notwithstanding anything in this </font><b style="font-size:11.5pt;font-weight:bold;">Article XX </b><font style="font-size:11pt;">to the contrary, Landlord shall have the right, at any time upon thirty (30) days&#8217; prior written notice, to require Tenant to relocate any of its installations located on the roof to such location as is reasonably designated by Landlord. Such relocation shall be at Landlord&#8217;s sole cost and expense, unless Landlord&#8217;s reason for requiring such relocation is a result of Tenant&#8217;s failure to</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.95pt;margin:0pt 0pt 0pt 8.7pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11.5pt;">comply with the terms of this </font><b style="font-size:11pt;font-weight:bold;">Article XX, </b><font style="font-size:11.5pt;">in which event such relocation shall be at Tenant&#8217;s sole cost and expense.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">20.7</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">FORCE MAJEURE.</u><font style="font-size:11.5pt;"> Whenever a period of time is prescribed for the taking of an action by Landlord or Tenant (other than any monetary obligations hereunder), the period of time for the performance of such action shall be extended by the number of days that the performance is actually delayed due to acts or events of Force Majeure, but the unavailability of funds or the shortage of administrative personnel shall not be deemed a cause beyond the reasonable control of either party for this purpose.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">20.8</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">DISCLOSURE.</u><font style="font-size:11.5pt;"> Landlord acknowledges that this Lease (and any amendments hereto and SNDA&#8217;s, estoppels and confirmation certificates executed in connection with this Lease) may be reviewable by industry and/or governmental regulatory authorities. Within ten (10) business days following a request, Landlord shall comply with any requests from such industry or regulatory authorities to provide copies of any such lease documentation to any such industry or regulatory authorities designated by Tenant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">20.9</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">GOOD FAITH AND FAIR DEALING.</u><font style="font-size:11.5pt;"> Landlord and Tenant shall have the duty to exercise their rights and remedies, and perform their respective obligations hereunder, in good faith.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;">[Signatures Commence on Following Page]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">IN WITNESS WHEREOF, Landlord and Tenant have caused this Lease to be duly executed, under seal, by persons hereunto duly authorized, in multiple copies, each to be considered an original hereof, as of the date first set forth above.</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:31.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:14.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:41.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:41.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">LANDLORD:</u></p></td><td colspan="3" style="vertical-align:top;width:46.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">BROOKFIELD PROPERTIES 75 STATE CO. LLC</font></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:41.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Attest:</font></p></td><td style="vertical-align:top;width:31.67%;border-bottom:1.0pt dashed #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:41.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Jeremiah B. Larkin</font></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.67%;border-top:1.0pt dashed #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:41.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Name: Jeremiah B. Larkin</font></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:41.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Title: Senior Vice President, Director of Leasing</font></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:41.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">TENANT:</u></p></td><td colspan="3" style="vertical-align:top;width:46.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">GRANT THORNTON LLP</font></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:46.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Attest:</font></p></td><td style="vertical-align:top;width:31.67%;border-bottom:1.0pt dashed #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">By:</font></p></td><td style="vertical-align:top;width:40.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Russell Wieman</font></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:46.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Name: Russell Wieman</font></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:46.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Title: CFO</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.44pt 0pt;"><font style="font-size:11.5pt;">EXHIBIT A</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11.5pt;">(Floor Plan of the Premises)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:19.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:19.5pt;font-weight:bold;">75 STATE STREET</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">0013</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12.5pt;font-weight:bold;">12/4/2012</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;"><img src="atxs-20211231xex10d19005.jpg" alt="Graphic" style="display:inline-block;height:436.75pt;width:453.05pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:19.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:19.5pt;font-weight:bold;">75 STATE STREET</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">0014</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12.5pt;">11/26/2012</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.4pt;"><font style="font-size:12.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;"><img src="atxs-20211231xex10d19006.jpg" alt="Graphic" style="display:inline-block;height:415pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:430.65pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.5pt 0pt;"><font style="font-size:11.5pt;">EXHIBIT B</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11.5pt;">(Items Included in Operating Expenses)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11.5pt;">Without limitation, Operating Expenses shall include:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:34.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">All expenses (including any sales or use tax) incurred by Landlord or Landlord&#8217;s agents which shall be directly related to employment of personnel, including amounts incurred for wages, salaries and other compensation for services, payroll, social security, unemployment and similar taxes, workmen&#8217;s compensation insurance, disability benefits, pensions, hospitalization, retirement plans and group insurance, uniforms and working clothes and the cleaning thereof, and expenses imposed on Landlord or Landlord&#8217;s agents pursuant to any collective bargaining agreement for the services of employees of Landlord or Landlord&#8217;s agents in connection with the operation, administration, repair, maintenance, cleaning, management and protection of the Property and all common areas (including, without limitation, cost incurred by Landlord or any designee of Landlord for operating, cleaning, maintaining and providing utilities to the roof terrace and fitness facility at the Building), and its mechanical systems including, without limitation, day and night supervisors, property manager, accountants, bookkeepers, janitors, carpenters, engineers, mechanics, electricians and plumbers and personnel engaged in supervision of any of the persons mentioned above; provided that, if any such employee is also employed on other property of Landlord, such compensation shall be suitably prorated among the Property and such other properties;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:34.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">The cost incurred by Landlord of services, materials and supplies furnished or used in the operation, administration, repair, maintenance, cleaning, management and protection of the Property, including, without limitation, fees, if any, imposed upon Landlord, or charged to the Property, by the state or municipality in which the Property is located on account of the need of the Property for increased or augmented public safety services;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:34.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">The cost of replacements for tools and other similar equipment used in the repair, maintenance, cleaning and protection of the Property, provided that, in the case of any such equipment used jointly on other property of Landlord, such costs shall be suitably prorated among the Property and such other properties;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:34.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Where the Property is managed by Landlord or an affiliate of Landlord, management fees at reasonable rates for self-managed buildings consistent with the type of occupancy and the service rendered, which management fees shall not exceed four percent (4%) of gross annual income for the Building, whether or not actually paid, or where managed by other than Landlord or an affiliate thereof, the amounts accrued for management, together with, in either case, amounts accrued for legal and other professional fees relating to the Property, but excluding such fees and commissions paid in connection with services rendered for securing or renewing leases and for matters not related to the normal administration and operation of the Building and in no event in excess of four percent (4%) of gross annual income for the Building;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:35.8pt;text-indent:-35.8pt;margin:0pt 0pt 0pt 7.65pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">B-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">Premiums for insurance against damage or loss to the Building from such hazards as shall from time to time be generally required by institutional mortgagees in the Boston area for similar properties, including, but not by way of limitation, insurance covering loss of rent attributable to any such hazards, and public liability insurance and premiums for fidelity bonds covering persons having custody or control over funds or other property of Landlord relating to the Property;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">If, during the Term of this Lease, Landlord shall make a capital expenditure which is (a) required by any Laws (or any amendments, regulations, orders or rulings thereto) that are enacted, or first interpreted to apply to the Building, after the Commencement Date, (b) reasonably intended to reduce Operating Expenses or create an operating efficiency or savings for the Building, (c) in Landlord&#8217;s reasonable judgment, associated with protecting life or the safety and/or security of the Building, (d) incurred to perform replacements which in Landlord&#8217;s reasonable judgment are made in lieu of repairs and provided such replacements are comparable in quality and utility as the item being replaced, the total cost of which capital expenditure is not properly includable in Operating Expenses for the Operating Year in which it was made, there shall nevertheless be included in such Operating Expenses for the Operating Year in which it was made and in Operating Expenses for each succeeding Operating Year the annual charge-off of such capital expenditure on a straight-line basis. Annual charge-off shall be determined by dividing the original capital expenditure </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">plus</u><font style="font-size:11pt;"> an interest factor, reasonably determined by Landlord as being the interest rate then being charged for long-term mortgages by institutional lenders on like properties within the locality in which the Building is located, by the number of years of useful life of the improvement made with the capital expenditure; and the useful life shall be determined reasonably by Landlord in accordance with generally accepted accounting principles consistently applied and in effect at the time of making such expenditure;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">Legal and other professional and consulting fees incurred in connection with the maintenance, management and operation of the Property, including in connection with the preparation of statements required in connection with payments by tenants and occupants of the Building on account of Taxes and Operating Expenses, except as hereinafter excluded; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">Costs incurred by Landlord for electricity, fuel, water and sewer use charges, and all other utilities supplied to the Property, except for those paid for directly by tenants of the Property, and the fair market rental value of the space in the Building used as the fitness facility;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">9.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">All other expenses reasonably paid or incurred in connection with the operating, cleaning and maintenance of the Building or said common areas and facilities of the Building consistent with other high quality Class A buildings in the Financial District of Boston.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Notwithstanding anything to the contrary set forth in the Lease, Operating Expenses shall not include the following:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.05pt;text-indent:-0.05pt;margin:0pt 0pt 0pt 7.25pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">B-2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(i)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Advertising, promotional and marketing costs, including leasing commissions, attorneys&#8217; fees (in connection with the negotiation and preparation of letters, deal memos, letters of intent, leases, subleases and/or assignments), space planning costs, and other costs and expenses incurred in connection with lease, sublease and/or assignment negotiations and transactions with present or prospective tenants or other occupants of the Building;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(ii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Costs associated with the operation of the business of the entity which constitutes Landlord as the same are distinguished from the costs of operation of the Building, including accounting and legal matters, costs of defending any lawsuits with any mortgagee, costs of selling, syndicating, financing, mortgaging or hypothecating any of Landlord&#8217;s interest in the Building, costs incurred in connection with any disputes between Landlord and its employees, between Landlord and Building management, or between Landlord and other tenants or occupants;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(iii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Costs which may be considered capital improvements, capital repairs, capital charges or any other capital costs except for the annual charge-off as permitted in item (6) above of this Exhibit B;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(iv)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Costs paid directly by other tenants of the Building;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(v)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Costs incurred by Landlord due to the violation by Landlord or any tenant of the terms and conditions of any lease of space in the Building;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(vi)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Taxes and costs of contesting or appealing Taxes if already included in the determination of Taxes;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(vii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">costs (including permit, license, and inspection fees) incurred in renovating, improving, decorating, painting or redecorating vacant space or space for tenants;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(viii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">depreciation and amortization on the Building, except as expressly permitted in item (6) above of this Exhibit B;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(ix)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">amounts paid to Landlord or to subsidiaries or affiliates of Landlord for goods and/or services in the Building (excluding the management fee which is determined pursuant to item (4) above of this Exhibit B) to the extent the same exceeds the costs of such goods and/or services rendered by unaffiliated third parties on a competitive basis;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(x)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">interest on debt or amortization payments on mortgages or deeds of trust or any other debt for borrowed money except to the extent included in the annual charge-off permitted in item (6) above of this Exhibit B;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(xi)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">items and services for which Tenant reimburses Landlord or pays third parties or that Landlord provides selectively to one or more tenants of the Building other than Tenant;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(xii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">costs incurred, in excess of the deductible, in connection with repairs or other work needed to the Building because of fire, windstorm, or other casualty or cause insured against by Landlord or required to be insured against by Landlord under the terms of this</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">B-3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><font style="font-size:11.5pt;">Lease and costs of restoration following any condemnation (except for fees and expenses incurred in pursuing and collecting an award from the taking authority);</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(xiii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">costs incurred to remedy structural defects in original construction materials or installations in the Building;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(xiv)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">any costs, fines or penalties incurred because Landlord violated any governmental rule or authority or defaulted under any agreement;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(xv)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">any costs incurred to cause the Building to comply with any governmental law, code, order, ordinance regulation or other legal requirement enacted prior to the date of this Lease, provided, however, that costs to comply with any reinterpretation, amendment or modification of such Laws or rules and regulations promulgated thereunder which are enacted after the Commencement Date shall be included in Operating Expenses; Costs of removing, encapsulating or otherwise abating any asbestos or other Hazardous Materials, except with respect to any materials which are determined by Law to be hazardous after the Commencement Date; provided, however, that the foregoing shall not be deemed to prohibit Landlord from including in Operating Expenses the costs of preventive measures taken by Landlord to prevent or limit the formation, accumulation or dispersion of mold or Hazardous Materials in or about the Building, including, without limitation, the use of filtration and/or chemical application;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(xvii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Costs of Landlord&#8217;s Premises Work and Landlord&#8217;s Base Building Work or other work to satisfy Landlord&#8217;s obligations under Section 4.2 or to deliver any Expansion Premises or Available ROFO Space for Tenant&#8217;s occupancy;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(xviii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Contributions to charitable or political organizations;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(xix)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Reserves of any kind, including reserves for bad debts, rent loss or for future improvements, repairs or additions;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(xx)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">the cost of any electricity for lights and plugs (exclusive of building systems) furnished to the Premises or any other leasable space in the Building and the cost of HVAC services supplied outside of Building Hours to the Premises or any other leasable space in the Building;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(xxi)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">the cost of installing, operating and maintaining (in excess of costs that would be incurred for operating and maintaining same as office space) any specialty service by or on behalf of Landlord, such as a luncheon club, athletic or recreational club, observation areas, broadcasting facility, childcare or similar facility;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(xxii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">the cost of the acquisition or installation of any sculpture, paintings or other objects of art which are of the quality and nature of &#8220;fine art,&#8221; rather than decorative artwork customarily found in first class office buildings in the financial district of Boston, Massachusetts which are similar to the Building, and/or special maintenance and cleaning costs in connection therewith;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">B-4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(xxiii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">salaries, fringe benefits and other compensation paid to any executive or employee of Landlord and/or Landlord&#8217;s managing agent above the grade of &#8220;building manager&#8221; (as such term is commonly understood in the property management industry) or equivalent position for the Building, provided, however, all wages, salaries and other compensation otherwise allowed to be included in Operating Expenses shall exclude any allocable portion of such costs related to any employee&#8217;s time devoted to other buildings or properties other than the Building;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(xxiv)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">any cost or expense which is applicable to or incurred for the Building Garage or any costs of personnel used to park cars, collect money or provide special security, and garage management fees;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(xxv)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">any cost or expense which is applicable to or incurred for the retail space in the Building, including, without limitation, the costs of cleaning services to any such retail space, and the cost of any other services or utilities provided to any retail space, to the extent that the level of those services or utilities (as the case may be) exceed the level of services or utilities (as the case may be) to which Tenant is entitled under this Lease;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(xxvi)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">rentals for items which if purchased, rather than rented, would constitute a capital expenditure to the extent that such payments exceed the amount which could have been included in Operating Expenses had Landlord purchased such equipment rather than leasing such equipment;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(xxvii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Tenant appreciation events;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(xxviii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Costs for which Landlord is reimbursed by insurance, condemnation awards, warranty, guaranty, indemnity, other tenants or otherwise;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(xxix)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Costs related to causing the Building to be registered or re-certified under &#8220;LEED&#8221;, &#8220;Energy Star&#8221; or &#8220;Green Globes&#8221; certification requirements, or any other similar certification requirements; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">(xxx)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Any rental payments and related costs pursuant to any ground lease of land underlying all or any portion of the Building or Property, and any costs related to any reciprocal easement agreement, and/or covenant, condition and restriction agreement.</font></p></td></tr></table><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">B-5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.69pt 0pt;"><font style="font-size:11.5pt;">EXHIBIT C</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11.5pt;">(Cleaning Specifications)</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-size:11.5pt;font-weight:bold;">A.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">General</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">All stone, ceramic, tile, marble, terrazzo and other unwaxed flooring to be swept nightly on Business Days, using approved dust-down preparation; wash flooring once a month.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">All linoleum, rubber, asphalt tile and other similar types of flooring (that may be waxed) to be swept nightly on Business Days, using approved dust-down preparation. Waxing, if any, shall be done at Tenant&#8217;s expense.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">All carpeting and rugs to be carpet swept or vacuum cleaned nightly on Business Days, as may be required.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">Hand dust and wipe clean all furniture, files, fixtures and window sills nightly on Business Days;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">Dust interior of all waste paper disposal cans and baskets nightly on Business Days; damp dust as necessary.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">Wash clean all water coolers nightly on Business Days;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">Dust all door and other ventilating louvers within reach, as necessary.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">Dust all telephones as necessary.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">9.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">Sweep all private stairway structures nightly on Business Days.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">10.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">Wipe clean all bright work weekly.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">11.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">Interior and exterior of metal elevator car and hatch doors, including saddles, to be properly cleaned and treated as necessary.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">12.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">Vacuum clean and change filters in air conditioning units semi-annually.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-size:11.5pt;font-weight:bold;">B.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Lavatories (Building)</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Sweep and wash all lavatory floors nightly on Business Days, wash and polish all mirrors, powder shelves, bright work and enameled surfaces in lavatories, weekly.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Scour, wash and disinfect all basins, bowls and urinals throughout all lavatories nightly on Business Days.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Wash all toilet seats nightly on Business Days.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36.2pt;text-indent:-36.2pt;margin:0pt 0pt 0pt 42.64pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">C-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Hand dust and clean all partitions, tile wall dispensers and receptacles in all lavatories nightly on Business Days.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Empty paper towel receptacles and transport wastepaper from the demised premises nightly on Business Days.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Fill toilet tissue holders nightly on Business Days (tissue to be furnished by Landlord).</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Empty sanitary disposal receptacles nightly on Business Days.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Wash interior of waste cans and receptacles at least once a week.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">9.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Thoroughly wash all wall tile and stall surfaces as often as necessary but in no event less than once every two weeks.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">l 0.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Fill soap dispensers and paper towel dispensers (dispensers, soap and paper towels to be furnished by Landlord at Landlord&#8217;s expense).</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-size:11.5pt;font-weight:bold;">C.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">High Dusting</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><font style="font-size:11.5pt;">Do all high dusting quarterly, which includes the following:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">I.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Dust clean all vertical surfaces, such as walls, partitions, doors and bucks and other surfaces not reached in nightly cleaning.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Dust clean all pipes, ventilating and air conditioning louvers, ducts, high moldings and other high areas not reached in nightly cleaning.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Dust all lighting fixtures, including glass or plastic enclosures (exterior only).</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-size:11.5pt;font-weight:bold;">D.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Window Cleaning</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">I.</font></font><font style="font-size:11.5pt;">All windows to be cleaned inside and outside, five times a year.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">2.</font></font><font style="font-size:11.5pt;">Tenants&#8217; entrance doors and lobby glass to be cleaned daily on Business Days.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">All other interior glass and a normal amount of partition glass, glass doors and fan lights are to be cleaned twice a year.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Mail chute glass to be kept in a clean condition at all times.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-size:11.5pt;font-weight:bold;">E.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Day Porters</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">I.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Service, during Business Days, all public and operating space throughout the Building.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11.5pt;">Keep elevator cars clean and neat during the day on Business Days.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">C-2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:46.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11.5pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11.5pt;">Insert toilet tissue in lavatories (tissue to be furnished by Landlord) as necessary on Business Days.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:46.3pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">Keep staircases policed as necessary on Business Days.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:45.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">Fill soap dispensers and paper towel dispensers on Business Days (dispensers, soap and paper towels to be furnished by Landlord at Landlord&#8217;s expense).</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:45.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11.5pt;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11.5pt;">Police all Buildings&#8217; men&#8217;s and ladies&#8217; toilets during the daytime portion of Business Days.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:9.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.65pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><b style="font-size:11.5pt;font-weight:bold;">F.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exterminating Services</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.1pt;margin:0pt 0pt 0.15pt 45.25pt;"><font style="font-size:11.5pt;">Provide exterminating services by a licensed operator once a month throughout public space and vacant tenant space in the Building.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:8.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><b style="font-size:11pt;font-weight:bold;">G.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Additional Cleaning Services</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.2pt 45.25pt;"><font style="font-size:11.5pt;">Any services not listed above will be solely at Tenant&#8217;s expense including, without limitation, the following services:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:62pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:1.1pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:1.1pt;margin-top:0pt;"><font style="font-size:11.5pt;">Washing and/or waxing non-carpeted flooring; spot cleaning and shampooing carpeting.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:61.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.85pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.85pt;margin-top:0pt;"><font style="font-size:11.5pt;">The cleaning, maintaining and furnishing of lavatory supplies for private (non-core) lavatories.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:61.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:1.39pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:1.39pt;margin-top:0pt;"><font style="font-size:11.5pt;">Washing and relamping of all light fixtures.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:61.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:1.45pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:1.45pt;margin-top:0pt;"><font style="font-size:11.5pt;">Cleaning any interior glass other than windows, mail chutes and directories.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:61.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:1.45pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:1.45pt;margin-top:0pt;"><font style="font-size:11.5pt;">Exterminating in Tenant&#8217;s Premises (to be done by Landlord&#8217;s contractor).</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:61.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11.5pt;">Any cleaning and related rubbish removal for computer rooms, training rooms, copy centers/rooms, cafeterias, kitchens, pantries or any other areas used for the preparation, distribution, or consumption of food.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18.25pt;text-indent:-18.25pt;margin:0pt 0pt 0pt 61.5pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">C-3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.44pt 0pt;"><font style="font-size:11.5pt;">EXHIBIT D</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;">(Tenant&#8217;s Work Requirements)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:10.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">A.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">General</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:46.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:34.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;"><font style="font-size:10.5pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;"><font style="font-size:11.5pt;">All alterations, installations or improvements (&#8220;Alterations&#8221;) to be made by Tenant in, to or about the Premises (excluding Cosmetic Alterations) shall be made in accordance with the requirements of this Exhibit and by union contractors or mechanics approved by Landlord.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:46.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:34.95pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;"><font style="font-size:11.5pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;"><font style="font-size:11.5pt;">Tenant shall, prior to the commencement of any work, submit for Landlord&#8217;s written approval, complete plans for the Alterations, which plans meet the requirements set forth in Exhibit G. Drawings are to be complete with full details and specifications for all of the Alterations.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:46.05pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">Alterations must comply with the Building Code in effect for the City of Boston and the requirements, rules and regulations and any other governmental agencies having jurisdiction.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:45.4pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">No work shall be permitted to commence without the Landlord being furnished with a valid permit from the Boston Building Department and/or other agencies having jurisdiction.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:45.25pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:11.5pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:11.5pt;">All demolition, removals or other categories of work that may inconvenience other tenants or disturb Building operations, must be scheduled and performed before 7:00 a.m. or after 6:00 p.m. and Tenant shall provide the Building manager with at least 48 hours&#8217; notice prior to proceeding with such work.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:44.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">All inquiries, submissions, approvals and all other matters shall be processed through the Building manager.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:44.65pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11.5pt;">7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11pt;">In </font><font style="font-size:11.5pt;">the event that Tenant shall desire to have such work performed under the City of Boston&#8217;s &#8220;fast-track&#8221; building permit process, and if Landlord executes an Owner&#8217;s Design Affidavit, then Tenant shall execute such indemnity agreement(s) as Landlord may reasonably request, holding Landlord harmless from loss or damage arising therefrom.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:7.85pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;"><font style="font-size:11.5pt;">B.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;"><font style="font-size:11.5pt;">Prior to Commencement of Work</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:44.1pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">Tenant shall submit to the Building manager a request to pe1form the work. The request shall include the following enclosures:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:79.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11.5pt;">(i)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11.5pt;">A list of Tenant&#8217;s contractors and/or subcontractors for Landlord&#8217;s approval.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36.15pt;text-indent:-36.15pt;margin:0pt 0pt 0pt 79.95pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">D-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:81.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11.5pt;">(ii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11.5pt;">Four complete sets of plans and specifications properly stamped by a registered architect or professional engineer and meeting the requirements set forth in Exhibit G.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:81.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;"><font style="font-size:11.5pt;">(iii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;"><font style="font-size:11.5pt;">A properly executed building permit application form.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:81.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11.5pt;">(iv)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11.5pt;">Four executed copies of the Insurance Requirements agreement in the form of Exhibit E from Tenant&#8217;s contractor.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:81.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11.5pt;">(v)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11.5pt;">Contractor&#8217;s and subcontractor&#8217;s insurance certificates including an indemnity in accordance with the Insurance Requirements agreement.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:46.1pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">Landlord will return the following to Tenant:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:80.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:11.5pt;">(i)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:11.5pt;">Two sets of plans approved or a disapproval with specific comments as to the reasons therefor (such approval or comments shall not constitute a waiver of Building Department approval or approval of other governmental agencies).</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:80.65pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">(ii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">Two fully executed copies of the Insurance Requirements agreement.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:46.1pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:34.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">Tenant shall obtain a building permit from the Building Department and necessary permits from other governmental agencies. Tenant shall be responsible for keeping current all permits. Tenant shall submit copies of all approved plans and permits to Landlord and shall post the original permit on the Premises prior to the commencement of any work. All work, if performed by a contractor or subcontractor, shall be subject to reasonable supervision and inspection by Landlord&#8217;s representative. Such supervision and inspection, to the extent that the work may affect the Building&#8217;s mechanical and electrical systems, shall be at Tenant&#8217;s sole expense and Tenant shall pay Landlord&#8217;s reasonable charges for such supervision and inspection.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:7.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:10.5pt;">C.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11.5pt;">Requirements and Procedures</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:44pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">All structural and floor loading requirements shall be subject to the prior approval of Landlord&#8217;s structural engineer.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:43.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5.5pt;margin-top:0pt;"><font style="font-size:11.5pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5.5pt;margin-top:0pt;"><font style="font-size:11.5pt;">All mechanical (HVAC, plumbing and sprinkler) and electrical requirements shall be subject to the approval of Landlord&#8217;s mechanical and electrical engineers and all mechanical and electrical work shall be performed by contractors approved by Landlord. When necessary, Landlord will require engineering and shop drawings, which drawings must be approved by Landlord before work is started. Drawings are to be prepared by Tenant and all approvals shall be obtained by Tenant.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:43.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11.5pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11.5pt;">Elevator service for construction work shall be charged to Tenant at standard Building rates which will include the cost of operators and supervisory staff. Prior arrangements for elevator use shall be made at least 48 hours in advance with Building manager by Tenant. No material or equipment shall be carried</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:35.25pt;text-indent:-35.25pt;margin:0pt 0pt 0pt 43.44pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">D-2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.15pt;margin:0pt 0pt 0pt 80.7pt;"><font style="font-size:11.5pt;">under or on top of elevators. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">an operating engineer or master mechanic is required by any union regulations, such engineer or master mechanic shall be paid for by Tenant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:44.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:11.5pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">shutdown of risers and mains for electrical, HVAC, sprinkler and plumbing work is required, such work shall be supervised by Landlord&#8217;s representative. No work will be performed in Building&#8217;s mechanical or electrical equipment rooms without Landlord&#8217;s approval and under Landlord&#8217;s supervision.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:44.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">Tenant&#8217;s contractor shall:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:80.4pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;"><font style="font-size:11.5pt;">(i)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;"><font style="font-size:11.5pt;">have a responsible superintendent or foreman on the Premises at all times;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:79.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">(ii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">police the job at all times, continually keeping the Premises orderly;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:79.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.9pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;"><font style="font-size:11.5pt;">(iii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;"><font style="font-size:11.5pt;">maintain cleanliness and protection of all areas, at all times, including elevators and lobbies.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:79.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.65pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;"><font style="font-size:11.5pt;">(iv)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;"><font style="font-size:11.5pt;">protect the front and top of all peripheral HVAC units and thoroughly clean them at the completion of work;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:79.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11.5pt;">(v)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11.5pt;">block off supply and return grills, diffusers and ducts to keep dust from entering into the Building air conditioning system; and</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:79.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">(vi)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">avoid the disturbance of other tenants.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:43.65pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;"><font style="font-size:11.5pt;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;"><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Tenant&#8217;s contractor is negligent in any of its responsibilities and if, after notice to Tenant no corrective action is taken, Landlord may, but shall not be obligated to, engage other contractors to perform the Alterations. Tenant shall be charged for corrective work.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:43.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.95pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.44pt;margin-top:0pt;"><font style="font-size:11.5pt;">7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.44pt;margin-top:0pt;"><font style="font-size:11.5pt;">All equipment and installations must be equal to the standards set forth in Exhibit</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.15pt;text-indent:-0.15pt;margin:0pt 0pt 0.4pt 79pt;"><font style="font-size:11.5pt;">F. Any deviation from such standards will be permitted only if indicated or specified on the plans and specifications and approved by Landlord.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:43.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.85pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">A properly executed air balancing report signed by a professional engineer shall be submitted to Landlord upon the completion of all HVAC work for approval.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:42.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">9.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><font style="font-size:11.5pt;">Upon completion of the Alterations and prior to taking occupancy, Tenant shall submit to Landlord a permanent certificate of occupancy and final approval by the other governmental agencies having jurisdiction.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:42.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.9pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;"><font style="font-size:11.5pt;">10.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.1pt;margin-top:0pt;"><font style="font-size:11.5pt;">Tenant shall submit to Landlord a final &#8220;as-built&#8221; set of drawings in autocad format and one set of blueprints showing all items of the Alterations in full detail.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:42.3pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11.5pt;">11.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11.5pt;">Additional and differing provisions in the Lease, if any, will be applicable and will take precedence.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36.15pt;text-indent:-36.15pt;margin:0pt 0pt 0pt 42.29pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">D-3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:47.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:34.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">12.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">Any plan or design approval rights reserved to or exercised by Landlord hereunder are for the sole and exclusive benefit of Landlord to ensure compatibility of such work with Building systems and Building standards, and such approval does not constitute any representation or warranty whatsoever as to the adequacy, correctness, efficiency or compliance with applicable law of such plan or design or the work shown thereon.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:34.5pt;text-indent:-34.5pt;margin:0pt 0pt 0pt 47.44pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">D-4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1.29pt 0pt;"><font style="font-size:11pt;">EXHIBIT E</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">(Contractor&#8217;s Insurance Requirements)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Building: 75 State Street, Boston, Massachusetts</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.4pt 0pt;"><font style="font-size:11pt;">Tenant:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.3pt 0pt;"><font style="font-size:11pt;">Premises:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.1pt 0pt;"><font style="font-size:11pt;">The undersigned contractor or subcontractor (&#8220;Contractor&#8221;) has been hired by the tenant or occupant (hereinafter called &#8220;Tenant&#8221;) of the Building named above or by Tenant&#8217;s contractor to perform certain work (&#8220;Work&#8221;) for Tenant in the Premises identified above. Contractor and Tenant have requested the undersigned landlord (&#8220;Landlord&#8221;) to grant Contractor access to the Building and its facilities in connection with the performance of the Work and Landlord agrees to grant such access to Contractor upon and subject to the following terms and conditions:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:34.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:10.5pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11pt;">Contractor agrees to indemnify and save harmless the Landlord (and, if Landlord is a general or limited partnership, each of the partners thereof), Brookfield Financial Properties L.P. and their respective officers, employees and agents and their affiliates, subsidiaries and partners, and each of them, from and with respect to any claims, demands, suits, liabilities, losses and expenses, including reasonable attorneys&#8217; fees, arising out of or in connection with the Work (and/or imposed by law upon any or all of them) because of personal injuries, including death at any time resulting therefrom and loss of or damage to property, including consequential damages, whether such injuries to person or property are claimed to be due to negligence of the Contractor, Tenant, Landlord or any other party entitled to be indemnified as aforesaid except to the extent specifically prohibited by law (and any such prohibition shall not void this Agreement but shall be applied only to the minimum extent required by law).</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:34.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11pt;">Contractor shall provide and maintain at its own expense, until completion of the Work, the following insurance:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:33.85pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;"><font style="font-size:11pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;"><font style="font-size:11pt;">Workmen&#8217;s Compensation and Employers, Liability Insurance covering each and every workman employed in, about or upon the Work, as provided for in each and every statute applicable to Workmen&#8217;s Compensation and Employers&#8217; Liability Insurance.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:33.85pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;"><font style="font-size:11pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;"><font style="font-size:11pt;">Commercial General Liability Insurance including coverages for Products/Completed Operations, Broad Form Property Damage and Contractual Liability (to specifically include coverage for the indemnification clause of this Agreement), all listing Landlord as an additional insured, for not less than the following limits:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.29pt 144pt;"><font style="font-size:11pt;">Personal Injury:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.29pt 144pt;"><font style="font-size:11pt;">$5,000,000 per person</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:13pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.29pt 144pt;"><font style="font-size:11pt;">$5,000,000 per occurrence</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 151.75pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">E-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.29pt 144pt;"><font style="font-size:11.5pt;">Property Damage:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.29pt 144pt;"><font style="font-size:11.5pt;">$5,000,000 per occurrence</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.29pt 144pt;"><font style="font-size:11.5pt;">$5,000,000 aggregate</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11.5pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11.5pt;">Commercial Automobile Liability Insurance (covering all owned, non-owned and/or hired motor vehicles to be used in connection with the Work) for not less than the following limits:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.29pt 144pt;"><font style="font-size:11.5pt;">Bodily Injury:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 144pt;"><font style="font-size:11.5pt;">$5,000,000 per person</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 144pt;"><font style="font-size:11.5pt;">$5,000,000 per occurrence</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.29pt 144pt;"><font style="font-size:11.5pt;">Property Damage:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.29pt 144pt;"><font style="font-size:11.5pt;">$5,000,000 per occurrence</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.4pt 144pt;"><font style="font-size:11.5pt;">$5,000,000 aggregate</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Contractor shall furnish a certificate from its insurance carrier or carriers to the Building office before commencing the Work, showing that it has complied with the above requirements regarding insurance.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;"><font style="font-size:11.5pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.34pt;margin-top:0pt;"><font style="font-size:11.5pt;">Contractor shall require all of its subcontractors engaged in the Work to provide the following insurance:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;"><font style="font-size:11.5pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;"><font style="font-size:11.5pt;">Commercial General Liability Insurance including Protective and Contractual Liability coverages with limits of liability at least equal to the limits stated in paragraph 2(b), except that such limits may be reduced to $1,000,000 for subcontractors so long as Contractor&#8217;s insurance coverage for the project expressly covers all liabilities arising out of acts or omissions of the subcontractors with limits at least equal to the coverage amounts required under paragraph 2(b).</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;"><font style="font-size:11.5pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;"><font style="font-size:11.5pt;">Commercial Automobile Liability Insurance (covering all owned, non-owned and/or hired motor vehicles to be used in connection with the Work) with limits of liability at least equal to the limits stated in paragraph 2(c), except that such limits may be reduced to $1,000,000 for subcontractors so long as Contractor&#8217;s insurance coverage for the project expressly covers all liabilities arising out of acts or omissions of the subcontractors with limits at least equal to the coverage amounts required under paragraph 2(c).</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Contractor&#8217;s insurance policies shall name the Landlord, Agent, Landlord&#8217;s property manager and Landlord&#8217;s mortgagee(s) as additional insureds and such other parties as may be reasonably requested by Landlord as additional insureds. Contractor shall not materially decrease or cancel its insurance coverage without ten (10) days&#8217; prior written notice to Landlord.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.2pt;margin:0pt 0pt 0pt 7.2pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">E-2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.25pt 0pt;"><font style="font-size:11pt;">Upon the request of Landlord, Contractor shall require all of its subcontractors engaged in the Work to execute an Insurance Requirements agreement in the same form as this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.4pt 0pt;"><font style="font-size:11pt;">Agreed to and executed this</font><font style="display:inline-block;width:47.91pt;"></font><font style="font-size:11pt;">day of</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:99.9%;"><tr style="height:1pt;"><td style="vertical-align:top;width:51.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:51.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:48.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Contractor:</font></p></td></tr><tr><td style="vertical-align:top;width:51.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:51.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:51.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:51.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">By:</font></p></td><td style="vertical-align:top;width:44.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">E-3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1.04pt 0pt;"><font style="font-size:11pt;">EXHIBIT F</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">(Building Standards)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">A.</u></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">PARTITIONS</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.75pt 0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:70.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10.5pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">All interior partitions are to be constructed of 2-1/2&#8221; metal studs, 16&#8221; on center, with one layer of 5/8&#8221;-thick gypsum wallboard on each side, properly taped and spackled. Partitions shall be anchored to the integrated ceiling modular grid or to the slab above, as may be required. Sound partitions shall have a minimum 3&#8221;-thick sound attenuation blanket throughout. Sound baffles above the integrated ceiling shall not interfere with the functioning of the return air plenum. Firecode gypsum board shall be used where required by code.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11pt;">All demising and/or corridor partitions are to be constructed of 2-1/2&#8221; metal studs, 16&#8221; on center, with one layer of 5/8&#8221;-thick gypsum wallboard on each side with the space between studs filled with a minimum 3&#8221;-thick sound attenuation blanket throughout. Studs and the inside layer of gypsum wallboard on each side shall run from floor to underside of metal deck or concrete slab. Open space between the metal deck corrugations and the studs and wallboard shall be filled with a compressible mineral fiber filler. Wallboard shall be proper taped and spackled, including the portion above the integrated ceiling. Firecode gypsum board shall be used where required by code. Fire and sound rated transfer grills shall be installed, above the integrated ceiling, where required to insure proper operation of the return air plenum.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11.5pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11pt;">All partitions intersecting a curtain wall mullion shall terminate at the perimeter fin tube enclosure. The space between the end of the partition and the mullion shall be filled from the top of the enclosure to the underside of the gypsum wallboard soffit with the building standard partition closure. Demising partitions intersecting the curtain wall mullion shall have the space above the gypsum wallboard soffit to the underside of the spandrel beam closed off with the same materials as the partition itself.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:10.5pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11pt;">All dwarf interior partitions shall be constructed of 2-1/2&#8221; metal studs, 16&#8221; on center, with one layer of 5/8&#8221;-thick gypsum wallboard on each side, suitably cross-braced and properly taped and spackled. The top of the partition shall be capped with a solid 4&#8221; X 1-1/3&#8221; plastic laminate-faced wood cap.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11.5pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11pt;">Private toilet partitions must meet the requirements for an interior partition except that water resistant wallboard shall be used under all ceramic tile.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.55pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:17.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">B.</u></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">FLOOR COVERINGS</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.44pt 72pt;"><font style="font-size:11pt;">Resilient flooring, if installed, after floor preparation, and with the approval of Landlord, shall be vinyl composition tile, 12&#8221; </font><font style="font-size:11.5pt;">X </font><font style="font-size:11pt;">12&#8221; </font><font style="font-size:11.5pt;">X </font><font style="font-size:11pt;">1/8&#8221;-thick conforming to F.S. SS-T-312 Type IV. Base shall be vinyl 4&#8221;-high minimum, coved at resilient</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 79.8pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.4pt 72pt;"><font style="font-size:11.5pt;">and square edged at carpet, 0.080&#8221;-thick, including premolded end stops and external comers.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.55pt 0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><u style="font-size:10.5pt;text-decoration:underline;text-decoration-color:#000000;">C.</u></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">CERAMIC WALL AND FLOOR TILE</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:11pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:11.5pt;">Executive toilets and pantries requiring ceramic wall and floor tile shall be the building standard or any other Landlord-approved equal.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:10.5pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:11.5pt;">Marble thresholds shall be the same as the base building toilets.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">D.</u></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">DOORS AND FRAMES</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:11pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:11.5pt;">All interior doors shall be flush solid core 1-3/4&#8221;-thick; solid wood particle board or wood stave core construction; mahogany finish to match building standard; premium grade; fire rated where required.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:10.5pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:11.5pt;">All interior hollow metal doors shall be 1-3/4&#8221;-thick; honeycomb core or resin impregnated, rot and vermin resistant material conforming to Type II, heavy-duty, Style 2, full flush hollow steel construction of the Steel Door Institute; fire rated where required.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:11pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:11.5pt;">All interior frames shall be 16 gauge hollow metal conforming to SDI-100 (latest issue). All frames shall be welded one piece construction except that three-piece frames may be used in interior tenant drywall partitions.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:10.5pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:11.5pt;">Tenant entrance frames shall meet the requirements of the landlord&#8217;s minimum standard or better.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:8.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">E.</u></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">HARDWARE</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:11pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:11.5pt;">All locks shall be keyed and mastered to the Building system. Four individual keys for each lock must be furnished to the building manager.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:10.5pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:11.5pt;">Special hardware, other than building standard, must be approved by Landlord.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:11pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:11.5pt;">Card key or other security type system must be approved by Landlord.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">F.</u></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">EQUIPMENT</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:11pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:11.5pt;">All equipment requiring hook up to the building systems shall be submitted to Landlord for approval. Separate metering may be required.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">G.</u></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">VENETIAN BLINDS AND CURTAINS</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:11pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.2pt;margin-top:0pt;"><font style="font-size:11.5pt;">All interior venetian blinds shall be by the same manufacturer, and of the same style and width as those installed by Landlord on the perimeter of the Building. The color need not match the perimeter blinds.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:71.55pt;text-align:justify;text-indent:-71.55pt;margin:0pt 0pt 0pt 8.29pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11.5pt;">No curtains will be permitted as they will interfere with proper functioning of the heating &amp; cooling system.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.55pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">H.</u></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">COMPUTER ROOM FLOORS AND SUPPLEMENTAL AIR-CONDITIONING</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:71.3pt;text-indent:-71.3pt;margin:0pt 0pt 0.15pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:71.3pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">1.</font></font><font style="display:inline-block;width:10.25pt;"></font><font style="font-size:11.5pt;">All computer room flooring and supplemental air-conditioning equipment must meet the minimum standards established by Landlord and its architect and structural, mechanical and electrical engineers.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.55pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">I.</u></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.4pt;margin-top:0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">ELECTRICAL</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.55pt 0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11.5pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11.5pt;">All materials and equipment shall be manufactured, tested, installed in accordance with the latest editions of applicable publications of the Massachusetts Electrical Code, Commonwealth of Massachusetts State Building Code, ASTM, UL, IPCEA, NEMA, IEEE, ANSI, NFPA and OSHA.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11.5pt;">Rigid conduit and/or electrical metallic tubing (EMT) shall be used throughout and shall be independently supported from the structure.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11.5pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11.5pt;">All electrical devices, panelboards, outlets, switches and related accessories shall be approved by Landlord before they may be installed.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11.5pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11.5pt;">All lighting fixtures (other than those in the integrated ceiling) shall be approved by Landlord before they may be installed.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11.5pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11.5pt;">All conduit runs, raceways, etc., must be maintained at a height of a minimum of nine (9&#8221;) inches above the integrated ceiling.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11.5pt;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11.5pt;">All wire and cable shall comply with the requirements of the base building specifications.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11pt;">7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11.5pt;">There shall be no exposed wire, wire molding or conduit.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:12pt;">8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11.5pt;">On multi-tenanted floors, available circuits shall be allocated on the basis of the rentable floor area.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11pt;">9.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11.5pt;">Tenant shall submit for Landlord&#8217;s approval its electrical power and lighting plans and specifications before proceeding with the installation.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.55pt 0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:14.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">J.</u></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">TELEPHONE</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.55pt 0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11.5pt;">Tenant shall make arrangements with Verizon regarding its requirements for service. Tenant shall coordinate its utilization of all empty conduit provided for its use by Landlord.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11.5pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.15pt;margin-top:0pt;"><font style="font-size:11.5pt;">Landlord has provided plywood backboards for the use of the telephone company in all telephone rooms and closets.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:71.55pt;text-indent:-71.55pt;margin:0pt 0pt 0pt 7.59pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">Telephone outlets in walls and partitions shall be flush boxes with bushed hole in cover.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">Telephone raceways and outlets shall conform to the conduit and outlet articles of the specifications for the base building.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">All raceways and conduit runs shall be independently supp01ied from the structure.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">All raceways and conduit runs, etc. must be maintained at a height of a minimum of nine (9&#8221;) inches from the integrated ceiling.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">No telephone wire shall run loose or exposed.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">The telephone company shall not cause any labor dispute that might cause a disruption of the base building work.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">9.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">Floor outlets are subject to Landlord approval as to type and location.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">K.</u></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">SPRINKLERS</u></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">Alterations to the system to accommodate Tenant&#8217;s space plan shall be performed, at Tenant&#8217;s expense, by a sprinkler contractor approved by Landlord.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">All additional and/or relocated sprinkler heads shall be the same as those installed in the base building except for pendant type heads.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">L.</u></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">PLUMBING</u></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">There are no wet columns in tenant areas, all waste, vent, hot and cold water lines for additional facilities must be carried back to the central core area of the building.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:10.5pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">All additional piping required for Tenant facilities must be independently supported from the structure and a minimum clearance of nine (9&#8221;) inches must be maintained between the underside of the piping and hangers and the integrated ceiling.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">No exposed plumbing of any kind is permitted.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:10.5pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">All piping must conform to the requirements of the base building specifications.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">All pipe covering shall conform to the requirements of the base building specifications.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:10.5pt;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">All Tenant-added plumbing fixtures shall be by the same manufacture, and of the same style and trim as the base building fixtures.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Pantry and/or lunch room fixtures, etc. are subject to Landlord&#8217;s approval, and the need for such facilities must be demonstrated.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">All toilet accessories must be by the same manufacture as the base building accessories.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">9.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">All connections to the Building piping must be made at the time designated by Landlord.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="font-size:10.5pt;text-decoration:underline;text-decoration-color:#000000;">M.</u></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">HEATING, VENTILATING AND AIR-CONDITIONING</u></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:10.5pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">All costs involved in altering the system shall be paid by the tenant.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:10.5pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Tenant shall pay the cost of rotating the fixtures, etc. to suit its floor plan.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Special HVAC requirements for computer rooms, etc. shall be submitted to Landlord for approval together with all design requirements for review by the base building consultants well in advance of the anticipated start date of Tenant work (45 days minimum).</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:10.5pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Systems added by Tenant shall conform to the requirements of the base building specifications.</font></p></td></tr></table><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.44pt 0pt;"><font style="font-size:11.5pt;">EXHIBIT G</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:11.5pt;">(Tenant Plan Requirements)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">Whenever Tenant shall be required by the terms of the Lease to submit plans to Landlord in connection with any improvement or alteration to the Premises, such plans shall include at least the following:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Floor plan indicating location of partitions and doors (details required of partition and door types).</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:10.5pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Location of standard electrical convenience outlets and telephone outlets.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Location and details of special electrical outlets; </font><i style="font-size:11.5pt;font-style:italic;">e.g., </i><font style="font-size:11.5pt;">photocopiers, etc.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Reflected ceiling plan showing layout of standard ceiling and lighting fixtures. Partitions to be shown lightly with switches located indicating fixtures to be controlled.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Locations and details of special ceiling conditions, lighting fixtures, speakers, etc.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:10.5pt;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Location and specifications of floor covering, paint or paneling with paint colors referenced to standard color system.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:10.5pt;">7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Finish schedule plan indicating wall covering, paint, or paneling with paint colors referenced to standard color system.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Details and specifications of special millwork, glass partitions, rolling doors and grilles, blackboards, shelves, etc.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:10.5pt;">9.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Hardware schedule indicating door number keyed to plan, size, hardware required including butts, latchsets or locksets, closures, stops, and any special items such as thresholds, soundproofing, etc. Keying schedule is required.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:10.5pt;">10.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Verified dimensions of all built-in equipment (file cabinets, lockers, plan files, etc.)</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">11.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Location and weights of storage files.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">12.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Location of any special soundproofing requirements.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">13.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Location and details of special floor areas exceeding 50 pounds of live load per square foot.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:71.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">14.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">All structural, mechanical, plumbing and electrical drawings, to be prepared by the base building consulting engineers, necessary to complete the Premises in accordance with Tenant&#8217;s Plans.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">G-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:70.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">15.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">All drawings to be uniform size (30&#8221; x 46&#8221;) and shall incorporate the standard project electrical and plumbing symbols and be at a scale of 1/8&#8221; </font><font style="font-size:12.5pt;">= </font><font style="font-size:11.5pt;">l&#8217; or larger.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:70.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">16.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">All drawing shall be stamped by an architect (or, where applicable, an engineer) licensed in the Commonwealth of Massachusetts and without limiting the foregoing, shall be sufficient in all respects for submission to the City of Boston Inspectional Services Department in connection with a building permit application.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:70.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">17.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Landlord&#8217;s approval of the plans, drawings, specifications or other submissions in respect of any work, addition, alteration or improvement to be undertaken by or on behalf of Tenant shall create no liability or responsibility on the part of Landlord for their completeness, design sufficiency or compliance with requirements of any applicable laws, rules or regulations of any governmental or quasi-governmental agency, board or authority.</font></p></td></tr></table><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">G-2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1.29pt 0pt;"><font style="font-size:11pt;">EXHIBIT H</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">(Commencement Letter)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:13pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1.29pt 0pt;"><i style="font-size:11pt;font-style:italic;">BROOKFIELD FINANCIAL PROPERTIES L.P.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.6pt 0pt;"><i style="font-size:11pt;font-style:italic;">One Liberty Plaza</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11.5pt;font-style:italic;">New York, NY 10006</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">[Name of Contact]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">[Name of Tenant]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">75 State Street</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Boston, MA 02109</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:50%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:51.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1.29pt 0pt;"><font style="font-size:11pt;">RE:</font></p></td><td style="vertical-align:top;width:51.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.29pt 0pt;"><font style="font-size:11pt;">[Name of Tenant]</font></p></td></tr><tr><td style="vertical-align:top;width:48.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1.29pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.29pt 0pt;"><font style="font-size:11pt;">[Floor] 75 State Street, Boston</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Dear [Name of Contact]:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:13pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.7pt;margin:0pt;"><font style="font-size:11pt;white-space:pre-wrap;">Reference is made to that certain Lease, dated as of            , 20 , between BROOKFIELD PROPERTIES 75 STATE CO. LLC as Landlord and ________ as Tenant, with respect to space on the ______ floor of 75 State Street, Boston, Massachusetts.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:37pt;margin:0pt 0pt 0pt 7.9pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.7pt;margin:0pt;"><font style="font-size:11pt;">In accordance with Section </font><font style="font-size:10.5pt;">4.1 </font><font style="font-size:11pt;">of the Lease, this is to confirm that the Commencement Date of the te1m of such Lease occurred on</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:27.38pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-size:11pt;">, the Rent Commencement Date shall be [and that the Initial Term of such Lease shall expire on</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-size:11pt;">.] If the foregoing is in accordance with your understanding, would you kindly execute this letter in the space provided below, and return the same to us for execution by Landlord, whereupon it will become a binding agreement between us.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:46.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;">Very truly yours,</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">BROOKFIELD PROPERTIES 75 STATE CO. LLC</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;">By:</font></p></td><td style="vertical-align:top;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;">_______________________________________</font><font style="display:inline-block;width:1.5pt;"></font><font style="font-size:11pt;">&#160;&#160;&#160;&#160;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 36pt;"><font style="font-size:11pt;">Name:</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 36pt;"><font style="font-size:11pt;">Title:</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;">Accepted and Agreed:</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;">[Name of Tenant]</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;">By:</font></p></td><td style="vertical-align:top;width:44.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;">Name:</font></p></td><td style="vertical-align:top;width:44.16%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;">Tilte:</font></p></td><td style="vertical-align:top;width:44.16%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;">Date:</font></p></td><td style="vertical-align:top;width:44.16%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.34pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">H-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:11.5pt;">EXHIBIT I</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">(Heating, Ventilating and Air-Conditioning Specifications)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">The base building HVAC system (the </font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">&#8220;System&#8221;)</u><font style="font-size:11.5pt;"> shall be designed to maintain the following conditions provided Tenant&#8217;s air distribution duct work is designed in accordance with S.M.A.C.N.A. (Sheet Metal and Air Conditioning National Association, Inc.) standards for variable air volume systems:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">In the summer, the System shall be nominally designed to maintain a maximum of 76&#176;F (+/- 2 degrees) dry bulb temperature and 50% relative humidity when the outdoor weather conditions do not exceed 89&#176;F dry bulb and 74&#176;F wet bulb.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">In the winter, the System shall be nominally designed to maintain a minimum 72&#176;F (+/- 2 degrees) </font><font style="font-size:11pt;">dry </font><font style="font-size:11.5pt;">bulb when the outdoor temperature is not less than 6&#176;F.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">The design conditions described herein are based upon an occupancy of not more than one person per 100 usable square feet, a combined lighting and standard electrical load not to exceed 2.5 watts per usable square foot, and the use of venetian blinds on each window drawn to a 45&#176; angle in the exposure subject to direct solar radiation. The basis for design of the Tenant&#8217;s air distribution system shall be a maximum of 57&#176;F supply air temperature entering the Premises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.35pt;margin:0pt 0pt 0pt 8.6pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">I-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;">EXHIBIT J</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;">(Form of Subordination, Non-Disturbance and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;">Attornment Agreement)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.4pt 0pt;"><b style="font-size:10.5pt;font-weight:bold;">RECORDING REQUESTED BY AND WHEN RECORDED, RETURN TO:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:11.5pt;">Latham </font><font style="font-size:11pt;">&amp; </font><font style="font-size:11.5pt;">Watkins</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:11.5pt;">LLP 633 West Fifth Street</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:11.5pt;">Suite 4000</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.25pt 0pt;"><font style="font-size:11.5pt;">Los Angeles, CA 90071</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.25pt 0pt;"><font style="font-size:11.5pt;">Attn: Donald </font><font style="font-size:11pt;">I. </font><font style="font-size:11.5pt;">Berger, Esq.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0.05pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="50.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;">(Space above this line for Recorder&#8217;s use only)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SUBORDINATION, NON-DISTURBANCE AND</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">ATTORNMENT AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.15pt 0pt;"><font style="font-size:11.5pt;">NOTICE: THIS SUBORDINATION, NON-DISTURBANCE AND ATTORNMENT AGREEMENT RESULTS IN YOUR LEASEHOLD ESTATE IN THE PREMISES BECOMING SUBJECT TO AND OF LOWER PRIORITY THAN THE LIEN OF SOME OTHER OR LATER SECURITY INSTRUMENT.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">This SUBORDINATION, NON-DISTURBANCE AND ATTORNMENT AGREEMENT (this &#8220;Agreement&#8221;) dated as of the</font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:9.26pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="display:inline-block;width:36pt;"></font><font style="font-size:11.5pt;">day of</font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:6.94pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-size:11.5pt;">, 20_, by and among DEUTSCHE BANK AG, NEW YORK BRANCH having an address at 60 Wall Street, New York, New York 10005, in its capacity as administrative agent (in such capacity, together with its successors and assigns, </font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">&#8220;Mortgagee&#8221;),</u><font style="font-size:11.5pt;"> BROOKFIELD PROPERTIES 75 STATE STREET CO. LLC, a Delaware limited liability company, having an office and place of business at c/o Brookfield Financial Properties L.P., Three World Financial Center, 200 Vesey Street, New York, NY 10281 </font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">(&#8220;Landlord&#8221;)</u><font style="font-size:11.5pt;"> and GRANT THORNTON LLP, an Illinois limited liability partnership, and having an office and place of business at 1901 S. Myers Road, Suite 455, Oakbrook Terrace, Illinois 60181 (the </font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">&#8220;Tenant&#8221;).</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">RECITALS:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:43.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">A.</font></font><font style="font-size:11.5pt;">Tenant has entered into a certain lease dated as of December</font><font style="display:inline-block;width:27.24pt;"></font><font style="font-size:11.5pt;">, 2012 (the </font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">&#8220;Lease&#8221;),</u><font style="font-size:11.5pt;"> with Landlord, with respect to that certain premises consisting of 24,233 rentable square feet on the 13</font><font style="font-size:7.5pt;">th </font><font style="font-size:11.5pt;">floor and 17,136 rentable square feet on a portion of the 14</font><font style="font-size:7.5pt;">th </font><font style="font-size:11.5pt;">floor (the </font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">&#8220;Premises&#8221;)</u><font style="font-size:11.5pt;"> and located in the building located on the real property commonly known as 75 State Street, Boston, MA (the </font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">&#8220;Property&#8221;)</u><font style="font-size:11.5pt;"> and more particularly described in </font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</u><font style="font-size:11.5pt;"> attached hereto; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.65pt;margin:0pt 0pt 0pt 6.55pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">J-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:44.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">B.</font></font><font style="font-size:11.5pt;">Mortgagee has made or is about to make a mortgage loan (the </font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">&#8220;Loan&#8221;)</u><font style="font-size:11.5pt;"> to Landlord secured by a deed of trust (the </font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">&#8220;Mortgage&#8221;)</u><font style="font-size:11.5pt;"> of certain prope1iy that includes the Premises; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:44.65pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">C.</font></font><font style="font-size:11.5pt;">The parties desire to set f01ih the terms of their agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">NOW, THEREFORE, in consideration of the Premises and of the sum of ONE DOLLAR ($1.00) to each party hereto paid by the other, the receipt hereof is hereby acknowledged, the parties hereto do hereby covenant and agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:37.45pt;margin:0pt 0pt 0.44pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:42.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">1.</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">Subordination</u><font style="font-size:11.5pt;">. Notwithstanding anything to the contrary contained in the Lease, the Lease and the leasehold estate created thereby are and shall at all times be subject and subordinate to the Mortgage and to all renewals, modifications, consolidations, replacements and extensions thereof, to the full extent of the principal sum secured thereby, interest thereon and any other sum due Mortgagee thereunder. The Mortgage shall take precedence over the Lease and shall be entitled to the same rights and privileges, both in law and in equity, as the Mortgage would have had if it had been executed, delivered, and recorded prior to the execution, delivery, and recording, or any of them, of the Lease or any notice thereof. Tenant and Landlord agree that notwithstanding anything to the contrary contained in the Lease, Tenant will not subordinate the Lease or its interest in the Premises to any other mortgage or encumbrance without the prior written consent of Mortgagee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:37.45pt;margin:0pt 0pt 0.44pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:42.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">2.</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">Attornment.</u><font style="font-size:11pt;"> If </font><font style="font-size:11.5pt;">Mortgagee (or its nominee or designee) shall succeed to the rights of Landlord under the Lease through possession or foreclosure action, delivery of a deed or otherwise, or another person purchases the Property or the portion thereof containing the Premises upon or following foreclosure of the Mortgage or in connection with any bankruptcy case commenced by or against Landlord (Mortgagee, its nominees and designees, and such purchaser, and their respective successors and assigns, each being a &#8220;Successor-Landlord&#8221;), then, Tenant shall attorn to and recognize Successor-Landlord as Tenant&#8217;s landlord under the Lease. Upon such attornment, the Lease shall continue in full force and effect as, or as if it were, a direct lease between Successor-Landlord and Tenant upon all terms, conditions and covenants as are set forth in such Lease. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">such Lease shall have terminated by operation of law or otherwise as a result of or in connection with a bankruptcy case commenced by or against Landlord or a foreclosure action or proceeding or delivery of a deed in lieu of foreclosure or otherwise, upon request of Successor-Landlord, Tenant shall promptly execute and deliver a direct lease with Successor-Landlord which direct lease shall be on the same terms and conditions as the Lease (subject, however, to the provisions of clauses (a)-(g) of Section 6 hereof) and shall be effective as of the day such Lease shall have terminated as aforesaid.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:37.45pt;margin:0pt 0pt 0.44pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:41.75pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">3.</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">No Constructive Eviction.</u><font style="font-size:11.5pt;"> Tenant agrees that foreclosure of, or any other legal action in connection with, the Mortgage shall not be a constructive eviction of Tenant except at the option of Mortgagee, which option shall arise only if Tenant is in default under the Lease beyond the expiration of any applicable grace period. Tenant shall have no right to appear in any such foreclosure action.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.4pt;margin:0pt 0pt 0pt 6.75pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">J-2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.7pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:44.75pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">4.</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">SNDA</u><font style="font-size:11.5pt;">. Tenant agrees to enter into a subordination, non-disturbance and attornment agreement with any person which shall succeed Mortgagee as lender with respect to the Property, or any portion thereof, provided such agreement is in the same form as this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.7pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:44.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">5.</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">Non-Disturbance.</u><font style="font-size:11.5pt;"> Mortgagee shall not, in the exercise of its rights arising, or which may arise, out of the Mortgage, disturb Tenant, interfere with Tenant, or deprive Tenant of its possession or its right to possession of the Premises (or any part thereof) under the Lease, or any right or privilege granted to or inuring to the benefit of Tenant under the Lease, or join Tenant in summary or foreclosure proceedings, provided the Lease is then in full force and effect. Provided Tenant is not in default (beyond all applicable notice and cure periods) under the Lease, Successor Landlord shall be bound to Tenant under all of the terms and conditions of the Lease and shall perform all obligations of landlord under the Lease (except to the extent expressly provided otherwise in Section 6 of this Agreement). Notwithstanding anything to the contrary set forth in this Agreement, if Tenant is in default under the Lease beyond the expiration of any applicable notice and cure period, Mortgagee shall have the absolute and unconditional right to exercise and enforce or cause Landlord to exercise and enforce any rights of Landlord under such Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.7pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:43.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">6.</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">Mortgagee&#8217;s Liability.</u><font style="font-size:11.5pt;"> Mortgagee, whether or not it succeeds to the interest of Landlord under the Lease, shall not be</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:34.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">liable for any act, omission, neglect or default of any prior landlord, including the present Landlord; provided however, Successor Landlord shall continue to be bound by any Offset Right that Tenant may have relating to any event or occurrence before the date of attornment of (i) the basis of such Offset Right remains uncured after the date of attornment and (ii) either Lender or Successor Landlord was provided with notice and opportunity to cure the same in accordance with Section 9 below and pursuant to the terms and conditions of the Lease. </font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">&#8220;Offset Right&#8221;</u><font style="font-size:11.5pt;"> means any right of Tenant to any offset for non-payment of any Landlord&#8217;s Contribution (as defined in the Lease) or Space Planning Allowance (as defined in the Lease), or any other offset, defense, claim, counterclaim, reduction, deductions or abatement against Tenant&#8217;s payment of Rent or performance of Tenant&#8217;s other obligations under the Lease, arising (whether under the Lease or other applicable law, including 11 U.S.C. </font><font style="font-size:11pt;">&#167; </font><font style="font-size:11.5pt;">365(h)) from Landlord&#8217;s breach or default under the Lease, or rejection of the Lease in bankruptcy from Landlord&#8217;s breach or default under the Lease; or</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:34.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">liable or responsible for or with respect to the retention, application and/or return to Tenant of any security deposit paid to any prior Landlord, including the present Landlord, whether or not still held by such prior Landlord unless and until Mortgagee or such other purchaser has actually received for its own account as Landlord the full amount of such security deposit; or</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:34.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">subject to any offsets, counterclaims or defenses which Tenant might have against any prior landlord, including the present Landlord; provided, however, Successor</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">J-3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11pt;">Landlord shall continue to be bound by any Offset Right that Tenant may have relating to any event or occurrence before the date of attornment if (i) the basis of such Offset Right remains uncured after the date of attornment and (ii) either Lender or Successor Landlord was provided with notice and opportunity to cure the same in accordance with Section 9 below and pursuant to the terms and conditions of the Lease; or</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">(d)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">bound by any rent or additional rent that Tenant might have paid for more than the current month and one succeeding month to any prior landlord, including the present Landlord; or</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">(e)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">bound by any obligation to make any payment to Tenant which was required to be made prior to the time Mortgagee succeeded to any prior landlord&#8217;s interest; or</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">(f)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">bound by any assignment, surrender, termination, cancellation, amendment, or modification of the Lease made after the date hereof (other than any assignment, surrender, te1mination, cancellation, amendment or modification of the Lease that pertains to any right of Tenant under the express terms of the Lease, including, but not limited to, Tenant&#8217;s renewal, expansion and termination rights set forth in the Lease), if consent is required pursuant to the Mortgage or other loan documents by and between Landlord and Lender dated as of the date of the Mortgage. Tenant represents and warrants that, as of the date hereof, it has not sublet the Premises to any sublessee; has not assigned any of its rights under the Lease; has no right to lease or occupy any part of the Property subject to the lien of the Mortgage other than the Premises and any expansion or right of first offer rights expressly set forth in the Lease and the non-exclusive right to use of the common areas of the Property subject to the lien of the Mortgage; and has no extension or renewal rights other than as expressly set forth in the Lease, including amendments thereto; or</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">(g)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">liable to Tenant beyond the Successor Landlord&#8217;s interest in the Property and the rents, income, receipts, revenues, issues and profits arising from such Property; or</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">(h)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">required to remove any person occupying the Premises or any part thereof except if such person claims by or through Successor-Landlord.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.7pt;margin:0pt 0pt 0.3pt 0pt;"><font style="font-size:11pt;">Notwithstanding anything to the contrary contained herein, Mortgagee and any Successor Landlord shall be bound by and recognize Tenant&#8217;s right under Section 5.2(c) of the Lease to offset against Rent the amount of any Allowances that are due and payable under the Lease. </font><b style="font-size:11pt;font-weight:bold;">&#8220;Allowances&#8221; </b><font style="font-size:11pt;">mean the Landlord&#8217;s Contribution and the Space Planning Allowance (as such terms are defined in the Lease and herein collectively referred to as the </font><b style="font-size:11pt;font-weight:bold;">&#8220;Allowances&#8221;) </b><font style="font-size:11pt;">due under the Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:43.1pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">7.</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Payment of Rent.</u><font style="font-size:11pt;"> Tenant acknowledges being advised by Landlord that the Lease and the rent and all sums due thereunder have been or will be assigned to Mortgagee pursuant to an Assignment of Leases and Rents from Landlord to Mortgagee, as security for the obligations</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.25pt;margin:0pt 0pt 0pt 6.75pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">J-4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.7pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:11.5pt;">secured by the Mortgage. Landlord hereby directs Tenant that if Mortgagee notifies Tenant in writing of an event of default under the Mortgage and demands that Tenant pay its rent and all other sums due under the Lease to Mortgagee, Tenant will honor such demand and pay to Mortgagee the rent and all other sums due under the Lease from and after the date of receipt of such notice, on each due date under the Lease, until directed otherwise in writing by Mortgagee or by a court of competent jurisdiction. Tenant shall make such payments to Mortgagee without any further direction or consent from Landlord and despite the fact that no receiver of rents may have been appointed by a court. Landlord hereby irrevocably authorizes and directs Tenant to make such payments to Mortgagee despite the receipt of any contrary instructions from Landlord or any other party, except a court of competent jurisdiction. Payment of rent by Tenant in accordance with the provisions of this Section shall constitute performance by Tenant under the Lease as to all amounts paid.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.7pt;margin:0pt 0pt 0.4pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:43.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">8.</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">Insurance and Condemnation Proceeds.</u><font style="font-size:11.5pt;"> Tenant agrees that, notwithstanding any provision hereof to the contrary, the terms of the Mortgage shall continue to govern with respect to the disposition of any insurance proceeds or eminent domain awards, and any obligations of Landlord to restore the real estate of which the Premises are a part shall, insofar as they apply to Mortgagee, be limited to insurance proceeds or eminent domain awards received by Mortgagee after the deduction of all costs and expenses incu1Ted in obtaining such proceeds or awards, provided, however, the foregoing shall not limit Tenant&#8217;s express termination rights under the Lease in the event of any such casualty or condemnation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.7pt;margin:0pt 0pt 0.4pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:43pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">9.</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">Notice of Default and Cure Rights.</u><font style="font-size:11.5pt;"> This Agreement shall serve as notice to Tenant of the Mortgage, and pursuant to the Lease,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11.5pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11.5pt;">Intentionally Deleted.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11.5pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;"><font style="font-size:11.5pt;">In the event of a default by Landlord under the Lease which would give Tenant the right, immediately or after the lapse of a period of time, to cancel or terminate the Lease, Tenant shall not exercise such right (i) until Tenant has given written notice of such default, act or omission to Mortgagee and (ii) unless Mortgagee has failed, within ten (10) business days after Mortgagee receives such notice, to cure or remedy, or to cause Lenders to cure or remedy, the default, or if such default shall be one that is reasonably capable of being remedied by Lenders or Mortgagee but is not reasonably capable of being remedied by Lenders or Mortgagee within such ten (10) business day period, until a reasonable period for remedying such default, act or omission shall have elapsed following the giving of such notice and following the time when Mortgagee shall have become entitled under the M01igage to remedy the same (which reasonable period shall in no event be less than the period to which Landlord would be entitled under the Lease or otherwise, after similar notice, to effect such remedy), provided that Mortgagee shall with due diligence pursue the right to remedy such default and shall with due diligence commence and continue to, remedy, or cause to be remedied, such default, act or omission before the expiration of said ten (10) business day period.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.05pt;margin:0pt 0pt 0pt 78.6pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">J-5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11.5pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11.5pt;">Notwithstanding the foregoing, Mortgagee shall not have any obligation hereunder to remedy such default, act or omission.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0.2pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:45.85pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:justify;">10.</font></font><font style="font-size:11.5pt;">Notice of Mortgage. To the extent that the Lease shall entitle Tenant to notice of the existence of any mortgage and the identity of any mortgagee, this Agreement shall constitute such notice to Tenant with respect to the Mortgage and Mortgagee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0.2pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:45.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:justify;">11.</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">Successor-Landlord Liability.</u><font style="font-size:11.5pt;"> Notwithstanding anything herein or in the Lease to the contrary, in the event that a Successor-Landlord shall acquire title to the Property or a portion thereof, Successor-Landlord shall have no obligation, nor incur any liability, beyond Successor&#173; Landlord&#8217;s then interest, if any, in the Property, and Tenant shall look exclusively to such interest, if any, of Successor-Landlord in the Property for the payment and discharge of any obligations imposed upon Successor-Landlord hereunder or under the Lease. Tenant agrees that, with respect to any money judgment which may be obtained or secured by Tenant against Successor-Landlord, Tenant shall look solely to the estate or interest owned by Successor&#173; Landlord in the Property (including, without limitation, the rents, issues and profits therefrom), and Tenant will not collect or attempt to collect any such judgment out of any other assets of Successor-Landlord.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0.2pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:44.7pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:justify;">12.</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">Intentionally Deleted.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0.2pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:44.65pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:justify;">13.</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">No Obligation.</u><font style="font-size:11.5pt;"> Except as specifically provided in this Agreement, Mortgagee shall not, by virtue of this Agreement, the Mortgage or any other instrument to which Mortgagee may be a party, be or become subject to any liability or obligation to Tenant under the Lease or otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0.2pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:44.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:justify;">14.</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">Modifications</u><font style="font-size:11.5pt;">. No modification, amendment, waiver, or release of any provision of this Agreement or of any right, obligation, claim, or cause of action arising thereunder shall be valid or binding for any purpose whatsoever unless in writing and duly executed by the party against which the same is sought to be asserted.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0.2pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:44.3pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:justify;">15.</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">Hazardous Substances.</u><font style="font-size:11.5pt;"> Tenant shall neither suffer nor itself manufacture, store, handle, transp01i, dispose of, spill, leak, dump any toxic or hazardous waste, waste product or substance (as they may be defined in any federal or state statute, rule or regulation pertaining to or governing such wastes, waste products or substances) on the property mortgaged to Mortgagee at any time during the term, or extended term, of the Lease in contravention of any applicable federal or state statute or regulation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.8pt;margin:0pt 0pt 0pt 7.2pt;"><font style="display:inline-block;text-indent:0pt;width:35.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">16.</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">Landlord&#8217;s Acknowledgments.</u><font style="font-size:11.5pt;"> Landlord, as landlord under the Lease and trustor under the Mortgage, agrees for itself and its heirs, successors and assigns, that: (a) this Agreement does not (i) constitute a waiver by M01igagee of any of its rights under the Mortgage, and/or (ii) in any way release Landlord from its obligation to comply with the terms, provisions, conditions, covenants, agreements and clauses of the Mortgage; and (b) the provisions of the Mortgage and Lease remain in full force and effect and must be complied with by Landlord.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.8pt;margin:0pt 0pt 0pt 7.2pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">J-6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.7pt;margin:0pt 0pt 0.1pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:45.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">17.</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Successors and Assigns.</u><font style="font-size:11pt;"> The terms of this Agreement shall be binding upon and inure to the benefit of, and be enforceable by, the respective successors and permitted assigns of the pa1iies hereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.7pt;margin:0pt 0pt 0.1pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:44.65pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">18.</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Authority.</u><font style="font-size:11pt;"> Each party to this Agreement represents and warrants to each other party hereto that the execution and delivery of this Agreement has been duly authorized and that this Agreement shall be binding upon said party in accordance with its terms.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.7pt;margin:0pt 0pt 0.1pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:44.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">19.</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Notices.</u><font style="font-size:11pt;"> Any notice required or permitted to be given by Tenant to Landlord shall be simultaneously given also to M01igagee. Performance by Mortgagee shall satisfy any conditions of the Lease requiring performance by Landlord, and M01igagee shall have a reasonable time to complete such performance as provided in Section 9 hereof. Any notice which any party hereto may be required or may desire to give hereunder shall be deemed to have been given if delivered personally or if mailed, postage prepaid, by United States registered or certified mail, return receipt requested, or by overnight express courier addressed as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.7pt;margin:0pt 0pt 0.1pt 0pt;"><font style="font-size:11pt;">If to Mortgagee:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">Deutsche Bank AG, New York Branch</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">200 Crescent Court, Suite 550</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">Dallas, Texas 75201</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">Attention: Gerard K. Dupont</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 36pt;"><font style="font-size:11pt;">with a copy to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">Latham </font><font style="font-size:11.5pt;">&amp; </font><font style="font-size:11pt;">Watkins LLP</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">633 West Fifth Street, Suite 4000</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">Los Angeles, CA 90071</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">Attention: Donald I. Berger, Esq.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.15pt 36pt;"><font style="font-size:11pt;">If to Landlord:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.3pt 108pt;"><b style="font-size:11.5pt;font-weight:bold;">Prior to February 1, 2013:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 108pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.15pt;margin:0pt 0pt 0.3pt 108pt;"><font style="font-size:11pt;">c/o Brookfield Financial Properties </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.15pt;margin:0pt 0pt 0.3pt 108pt;"><font style="font-size:11pt;">L.P. Three World Financial Center</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 0.05pt 108pt;"><font style="font-size:11pt;">200 Vesey Street, 11</font><sup style="font-size:8.25pt;vertical-align:top;">th</sup><font style="font-size:11pt;"> Floor </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 0.05pt 108pt;"><font style="font-size:11pt;">New York, New York 10281</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.05pt;margin:0pt 0pt 0.1pt 108pt;"><font style="font-size:11pt;">Attention: Senior Vice President, Finance </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.05pt;margin:0pt 0pt 0.1pt 108pt;"><font style="font-size:11pt;">Attention: General Counsel <br>Facsimile No.: (212)417-7195</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 108pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.3pt 108pt;"><b style="font-size:11.5pt;font-weight:bold;">After February 1, 2013:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.2pt;text-indent:-0.2pt;margin:0pt 0pt 0.3pt 107.8pt;"><font style="font-size:11pt;">c/o Brookfield Financial Prope1iies L.P.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.2pt;text-indent:-0.2pt;margin:0pt 0pt 0.3pt 107.8pt;"><font style="font-size:11pt;">250 Vesey Street</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">New York, NY 10281-1023</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 115.2pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">J-7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">Attention: Senior Vice President, Finance </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">Attention: General Counsel</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-size:11pt;">Facsimile No.: (212) 417-7195</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">With a copy to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.2pt;text-indent:-0.2pt;margin:0pt 0pt 0pt 107.8pt;"><font style="font-size:11pt;">Goodwin Procter LLP </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.2pt;text-indent:-0.2pt;margin:0pt 0pt 0pt 107.8pt;"><font style="font-size:11pt;">Exchange Place</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 108pt;"><font style="font-size:11pt;">53 State Street</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.2pt;margin:0pt 0pt 0.44pt 108pt;"><font style="font-size:11pt;">Boston, Massachusetts 02109 </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.2pt;margin:0pt 0pt 0.44pt 108pt;"><font style="font-size:11pt;">Attention: Samuel Richardson, Esq.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.2pt;margin:0pt 0pt 0.44pt 108pt;"><font style="font-size:11pt;">Facsimile No.: (617) 227-8591</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 108pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 36pt;"><font style="font-size:11pt;">If to Tenant:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.04pt 108pt;"><font style="font-size:11pt;">Grant Thornton LLP</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 0.5pt 108pt;"><font style="font-size:11pt;">1901 S. Myers Road, Suite 455</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 0.5pt 108pt;"><font style="font-size:11pt;">Oakbrook Terrace, Illinois 60181</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 0.5pt 108pt;"><font style="font-size:11pt;">Attn: Russell G. Wieman</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 108pt;"><font style="font-size:11pt;">with a copy to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.04pt 108pt;"><font style="font-size:11pt;">Grant Thornton LLP</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.04pt 108pt;"><font style="font-size:11pt;">175 West Jackson, Suite 2000</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.29pt 108pt;"><font style="font-size:11pt;">Chicago, Illinois 60684-2687</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.05pt;text-indent:-0.05pt;margin:0pt 0pt 0.05pt 107.95pt;"><font style="font-size:11pt;">Attn: Executive Director of Procurement </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.05pt;text-indent:-0.05pt;margin:0pt 0pt 0.05pt 107.95pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;"><font style="font-size:11pt;">with a copy to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.29pt 108pt;"><font style="font-size:11pt;">Grant Thornton LLP</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.04pt 108pt;"><font style="font-size:11pt;">175 West Jackson, Suite 2000</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.29pt 108pt;"><font style="font-size:11pt;">Chicago, Illinois 60684-2687</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;">Attn: Office of the General Counsel</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 115.7pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.2pt 0pt;"><font style="font-size:11pt;">or at such other addresses or to the attention of such other persons as may from time to time be designated by the party to be addressed by written notice to the other parties in the manner herein provided. Notices, demands and requests given in the manner aforesaid shall be deemed sufficiently served or given for all purposes hereunder when received or when delivery is refused or when the same are returned to sender for failure to be called for.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0.25pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:43.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">20.</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Governing Law.</u><font style="font-size:11pt;"> This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0.25pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:43.1pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">21.</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Counterparts.</u><font style="font-size:11pt;"> This document may be executed in counterparts and any pa1ty may execute any counterpart, each of which shall be deemed to be an original and all of which, taken together, shall be deemed to be one and the same document.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.15pt;margin:0pt 0pt 0pt 7.25pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">J-8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">[SIGNATURES APPEAR ON NEXT PAGE]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 150.2pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">J-9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">IN WITNESS WHEREOF, </b><font style="font-size:10.5pt;">the parties have caused this Agreement to be duly executed as of the date first above written.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:48.95pt;text-indent:-48.95pt;margin:0pt 0pt 0.34pt 0pt;"><font style="font-size:10.5pt;">NOTICE: THIS SUBORDINATION, NON-DISTURBANCE AND ATTORNMENT AGREEMENT CONTAINS A PROVISION WHICH ALLOWS THE PERSON OBLIGATED ON THE LEASE TO OBTAIN A LOAN, A PORTION OF WHICH MAY BE EXPENDED FOR OTHER PURPOSES THAN IMPROVEMENT OF THE PROPERTY.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:6.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td colspan="3" style="vertical-align:bottom;width:39.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">MORTGAGEE:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.5pt;">DEUTSCHE</font><font style="font-size:10.5pt;letter-spacing:0.65pt;"> </font><font style="font-size:10.5pt;">BANK</font><font style="font-size:10.5pt;letter-spacing:0.8pt;"> </font><font style="font-size:10.5pt;">AG,</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.5pt;">NEW</font><font style="font-size:10.5pt;letter-spacing:0.3pt;"> </font><font style="font-size:10.5pt;">YORK</font><font style="font-size:10.5pt;letter-spacing:0.6pt;"> </font><font style="font-size:10.5pt;">BRANCH</font></p></td><td colspan="2" style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.3pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="3" style="vertical-align:bottom;width:39.85%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td colspan="3" style="vertical-align:bottom;width:39.85%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.5;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;">Its:</p></td><td colspan="3" style="vertical-align:bottom;width:39.85%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.3pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:39.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:39.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="3" style="vertical-align:bottom;width:39.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td colspan="3" style="vertical-align:bottom;width:39.85%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.5;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;">Its:</p></td><td colspan="3" style="vertical-align:bottom;width:39.85%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.3pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.3pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:39.85%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.3pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">LANDLORD:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;">BROOKFIELD 75 STATE STREET CO.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.5pt;">LLC,</font></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.3pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;">a Delaware limited liability company</p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.3pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.3pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.3pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.3pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.3pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="3" style="vertical-align:bottom;width:39.85%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td colspan="3" style="vertical-align:bottom;width:39.85%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.5;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;">Its:</p></td><td colspan="3" style="vertical-align:bottom;width:39.85%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.3pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.3pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:39.85%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.3pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.3pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:39.85%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.3pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;vertical-align:super;">TENANT:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;">GRANT</font><font style="font-size:10.5pt;letter-spacing:0.4pt;"> </font><font style="font-size:10.5pt;">THORNTON</font><font style="font-size:10.5pt;letter-spacing:1.4pt;"> </font><font style="font-size:10.5pt;">LLP,</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">an Illinois limited liability partnership</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:39.18%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td colspan="2" style="vertical-align:bottom;width:39.18%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.5;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:bottom;width:39.18%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.3pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">J-10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:9.5pt;white-space:pre-wrap;">STATE OF  <br></font><u style="font-size:9.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:171.05pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-size:9.5pt;">) ss.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:9.5pt;">COUNTY OF</font><u style="font-size:9.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:17.9pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-size:9.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-size:9.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.25pt 0pt;"><font style="font-size:9.5pt;">On</font><u style="font-size:9.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:92.74pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-size:9.5pt;">20_, before me, the undersigned notary public in and for said County and State, personally appeared</font><font style="display:inline-block;width:18.7pt;"></font><font style="display:inline-block;width:104.35pt;"></font><font style="font-size:9.5pt;">of Deutsche Bank AG, New York</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.5pt 0pt;"><font style="font-size:9.5pt;">Branch</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.3pt 144pt;"><font style="font-size:9.5pt;">personally known to me</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.3pt 144pt;"><i style="font-size:9.5pt;font-style:italic;">[or]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.3pt 144pt;"><font style="font-size:9.5pt;">proved to me on the basis of satisfactory evidence</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><font style="font-size:9.5pt;">to be the person(s) whose name(s) </font><u style="font-size:9.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:31.82pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-size:9.5pt;">subscribed to the within instrument and acknowledged to me that </font><u style="font-size:9.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:17.64pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-size:9.5pt;">executed the same in </font><u style="font-size:9.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:26.23pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:9.5pt;">authorized capacity(ies) and that, by </font><u style="font-size:9.5pt;text-decoration:underline;text-decoration-color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;</u><font style="font-size:9.5pt;">signature(s) on the instrument, the person(s) or the entity(ies) upon behalf of which the person(s) acted executed the instrument. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:9.5pt;">WITNESS my hand and official seal.</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.9%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><i style="font-size:9.5pt;font-style:italic;">My commission expires on</i></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">J-11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:9.5pt;">STATE OF <br></font><u style="font-size:9.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:172pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-size:9.5pt;"> ) ss.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><font style="font-size:9.5pt;">COUNTYOF</font><u style="font-size:9.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:120.27pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:9.5pt;">On</font><u style="font-size:9.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:94.04pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-size:9.5pt;">20_, before me, the undersigned notary public in and for said County and State, personally appeared </font><u style="font-size:9.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:15.03pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-size:9.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:105.65pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-size:9.5pt;white-space:pre-wrap;">  </font><u style="font-size:9.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:79.4pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-size:9.5pt;">of Brookfield 75 State Street Co. LLC,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.3pt 144pt;"><font style="font-size:9.5pt;">personally known to me</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.3pt 144pt;"><i style="font-size:9.5pt;font-style:italic;">[or]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.3pt 144pt;"><font style="font-size:9.5pt;">proved to me on the basis of satisfactory evidence</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><font style="font-size:9.5pt;">to be the person(s) whose name(s) </font><u style="font-size:9.5pt;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">              </u><font style="display:inline-block;width:14.82pt;"></font><font style="font-size:9.5pt;">subscribed to the within instrument and acknowledged to me that </font><u style="font-size:9.5pt;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">             </u><font style="font-size:9.5pt;"> executed the same in </font><u style="font-size:9.5pt;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">             </u><font style="font-size:9.5pt;"> authorized capacity(ies) and that, by </font><u style="font-size:9.5pt;text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">             </u><font style="font-size:9.5pt;"> signature(s) on the instrument, the person(s) or the entity(ies) upon behalf of which the person(s) acted executed the instrument. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.25pt;margin:0pt 0pt 0.5pt 9.6pt;"><font style="font-size:9.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.5pt 0pt;"><font style="font-size:9.5pt;">WITNESS my hand and official seal.</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.9%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><i style="font-size:9.5pt;font-style:italic;">My commission expires on</i></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 269.1pt;"><font style="font-size:9.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">J-12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 5.59pt 0pt;">STATE OF<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:119.6pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u>)ss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;">COUNTY OF<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:110.1pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u>)</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;">On<u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:98.15pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="white-space:pre-wrap;">,20_, before me, the undersigned notary public in and for said County and State, personally appeared  </font><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:27.2pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:109.15pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="white-space:pre-wrap;">  </font><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:103.55pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u>of Grant Thornton <font style="font-size:10pt;">LLP,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 5.75pt 144pt;">personally known to me</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 5.75pt 144pt;"><i style="font-style:italic;">[or]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 5.75pt 144pt;">proved to me on the basis of satisfactory evidence</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 5.75pt 0pt;"><font style="white-space:pre-wrap;">to be the person(s) whose name(s)  </font><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:28.24pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u> executed the same in subscribed to the within instrument and acknowledged to me that authorized capacity(ies) and that, by<u style="text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">           </u> signature(s) on the instrument, the person(s) or the entity(ies) upon behalf of which the person(s) acted executed the instrument.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 5.75pt 0pt;">WITNESS my hand and official seal.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.9%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><i style="font-size:9.5pt;font-style:italic;">My commission expires on</i></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="font-size:11.5pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">J-13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.3pt 0pt;"><b style="font-size:11.5pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Legal Description of the Property</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">J-14</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">EXHIBIT K</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">LANDLORD&#8217;S PREMISES WORK</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11.5pt;">Landlord, at its cost, shall deliver the Premises to Tenant in core and shell condition, vacant, broom clean and otherwise in compliance with all applicable Laws for demolished space and with the following work performed in a good and workmanlike manner:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:4.09pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:4.09pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">Construct a building standard demising wall to lawfully demise the 14</font><sup style="font-size:8.62pt;vertical-align:top;">th </sup><font style="font-size:11.5pt;">Floor Premises;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:4.09pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:4.09pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">Remove the one (1) internal staircase indicated on the plan attached to this Exhibit K and install a Building Standard floor/ceiling deck (the other internal staircase to remain in the Premises in its as is condition);</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:4.09pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:4.09pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">Remove partitions, components, equipment and fixtures;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:4.09pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:4.09pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">Remove electrical, telephone and data cabling and devices (other than base building wiring and cabling);</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:4.09pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:4.09pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">Remove existing floor finishes and prepare subfloor to accept Tenant finishes. The areas of the Premises cross-marked on the floor plan attached hereto as Schedule K shall be level concrete floors with a maximum of&#188;&#8221; (non-cumulative) total variation of 10&#8217; non&#173; cumulative;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:4.09pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:4.09pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">Remove existing ceilings, lighting and other ceiling mounted devices and existing window blinds;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:4.09pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:4.09pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">Bring all plumbing back to the core; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">Sheetrock and finish tape all structural columns to be ready to accept Tenant finishes.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Tenant acknowledges and agrees that the main HVAC trunk line servicing the Premises shall remain as currently configured and will not be demolished, removed or re-located as part of Landlord&#8217;s Premises Work.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">K-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="atxs-20211231xex10d19008.jpg" alt="Graphic" style="display:inline-block;height:416.8pt;left:0%;padding-bottom:0.2pt;position:relative;top:0pt;width:540pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.6pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">K-2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">EXHIBIT L</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1.04pt 0pt;"><font style="font-size:11pt;">LIST OF TENANT COMPETITORS</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:11pt;">PWC </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:11pt;">KPMG</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Deloitte </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">E&amp;Y</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">CBIZ Tofias </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">McGladery</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">KLR (Kahn Litwin Renza) </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">BDO</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 9.6pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">L-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">EXHIBIT M</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">HIGH STREET LESSOR CONSENT</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.5pt 0pt;"><font style="font-size:11.5pt;">125 High Street, L.P.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.1pt 0pt;"><font style="font-size:11.5pt;">c/o Tishman Speyer Properties 45 Rockefeller Plaza</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;">New York, NY 10111</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.15pt 0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;"> </u><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:68.98pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-size:11.5pt;">,20_</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.15pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:38.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:59.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:38.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Riversource Investments, LLC</font></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:59.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Riversource Investments, LLC</font></p></td></tr><tr><td style="vertical-align:top;width:38.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Ameriprise Financial, Inc.</font></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Ameriprise Financial, Inc.</font></p></td></tr><tr><td style="vertical-align:top;width:38.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">c/o CB Richard Ellis, Inc.</font></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">c/o Ameriprise Lease Administration</font></p></td></tr><tr><td style="vertical-align:top;width:38.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">775 Ameriprise Financial Center</font></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">One South Wacker Drive, Suite 800</font></p></td></tr><tr><td style="vertical-align:top;width:38.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Minneapolis, Minnesota 55474</font></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Chicago, IL 60606-3392</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:38.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:59.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:38.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Grant Thornton LLP</font></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:38.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">175 W. Jackson Boulevard, 20</font><sup style="font-size:8.62pt;vertical-align:top;">th </sup><font style="font-size:11.5pt;">Floor</font></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:38.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.1pt 0pt;"><font style="font-size:11.5pt;">Chicago, IL 60604</font></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:38.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Attn: Risk, Regulatory and Legal Affairs</font></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:38.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:59.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:38.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Brookfield Properties 75 State Co. LLC</font></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:38.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">c/o Brookfield Financial Properties L.P.</font></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:38.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">250 Vesey Street</font></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:38.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">New York, NY 10281-1023</font></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:38.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Attention: Senior Vice President, Finance</font></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:38.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Attention: General Counsel</font></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.44pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:44pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">RE:</font></font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">CONSENT TO ASSIGNMENT OF SUBLEASE</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.44pt 43.95pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:93.33%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:14.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:82.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">&#8220;Building&#8221;:</font></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">&#160;&#160;</font></p></td><td style="vertical-align:bottom;width:82.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">High Street Tower - 125 High Street, Boston, Massachusetts</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">&#8220;Premises&#8221;:</font></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:82.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">13,920 square feet of Gross Rental Area on the 21</font><sup style="font-size:8.62pt;vertical-align:top;">st </sup><font style="font-size:11.5pt;">floor of the Building</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">&#8220;Landlord&#8221;</font></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:82.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">125 High Street, L.P., a Delaware limited partnership</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">&#8220;Tenant&#8221;:</font></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:82.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Riversource Investments, LLC, a Minnesota limited liability company and Ameriprise Financial, Inc., a Delaware corporation, jointly and severally</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">&#8220;Assignor&#8221;:</font></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:82.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Grant Thornton LLP, an Illinois limited liability partnership</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">&#8220;Assignee&#8221;:</font></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:82.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Brookfield Properties 75 State Co. LLC, a Delaware limited liability company</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">&#8220;Lease&#8221;:</font></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:82.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Lease, between Landlord and Tenant, dated as of August 7, 2007, as same has heretofore been or may hereafter be amended, modified, extended or restated from time to time</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">&#8220;Sublease&#8221;:</font></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:82.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Sublease, between Tenant, as sublessor, and Assignor, as sublessee, dated as of April 27, 2009, as modified, amended and supplemented by the</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:93.33%;"><tr><td style="vertical-align:bottom;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:82.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Consent to Sublease, that certain Assignment, Assumption and Consent dated December 1, 2011 between CCR LLP, as assignor, and Grant Thornton LLP, as assignee, and that certain Consent to Assignment of Sublease dated April 19, 2012 between CCR LLP, Grant Thornton LLP, Riversource Investments, LLC, Ameriprise Financial, Inc. and 125 High Street, L.P.</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.69pt 0pt;"><font style="font-size:11.5pt;">&#8220;Consent to Sublease&#8221;:</font></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:82.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Consent to Sublease, between Landlord, Tenant and Assignor.</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">&#8220;Assignment and&#160;Assumption Agreement&#8221;:</font></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:82.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;white-space:pre-wrap;">Assignment and Assumption Agreement dated as of_______ 20__  (the &#8220;Effective Date&#8221;), a copy of which is attached hereto as </font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</u><font style="font-size:11.5pt;"> and incorporated herein by this reference.</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:82.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;">Ladies and Gentlemen:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.4pt;margin:0pt 0pt 0.2pt 0pt;"><font style="font-size:11.5pt;">You have requested our consent to the Assignment and Assumption Agreement. Such consent is hereby granted on the terms and conditions, and in reliance upon the representations and warranties, set forth in this letter agreement (this &#8220;Agreement&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Assignor represents and warrants to Assignee, Landlord and Tenant that (a) the Sublease is in full force and effect; (b) the Sublease has not been assigned (excepting only pursuant to the Assignment and Assumption Agreement), encumbered, amended, modified, extended or supplemented; (c) Assignor knows of no defense or counterclaim to the enforcement of the obligations of the Assignor under the Sublease; (d) Assignor is not entitled to any reduction, offset or abatement of the rent payable under the Sublease; (e) Assignor is not in default of any of its obligations or covenants, and has not breached any of its representations or warranties under the Sublease, </font><font style="font-size:11pt;">(f) </font><font style="font-size:11.5pt;">a true and complete copy of the Assignment and Assumption Agreement is attached hereto as </font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit A;</u><font style="font-size:11.5pt;"> (g) the Assignment and Assumption Agreement and the 75 State Lease (as hereinafter defined) constitute the entire agreement between Assignor and Assignee with respect to the Sublease, the Premises, and/or the assignment of the Sublease, and (h) the Sublet Premises (as hereinafter defined) has not been further sublet in whole or in part.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Landlord&#8217;s obligations are governed only by the Lease, the Consent to Sublease and this Agreement. Landlord shall not be bound or estopped by any provision of the Sublease and/or the Assignment and Assumption Agreement.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">All of the terms, conditions, agreements, representations and warranties contained in the Consent to Sublease are hereby incorporated by this reference into this Agreement as if fully and completely set forth herein, except that notices to Assignee shall be sent to Assignee&#8217;s notice address and to the attention of the parties set forth above for Assignee in this Consent to Assignment of Sublease. This consent to the Assignment and Assumption Agreement is upon and subject</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:35.45pt;text-indent:-35.45pt;margin:0pt 0pt 0pt 42.95pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.75pt;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11.5pt;">to all of the terms, conditions, agreements, representations and warranties set forth in the Consent to Sublease and all of said terms, conditions, agreements, representations and warranties are hereby remade and reaffirmed as of the date hereof; provided, however, the Assignee shall be substituted for and replace the Assignor in all respects and all references contained in the Consent to Sublease to the &#8220;Subtenant&#8221; shall be deemed to be references to the Assignee. Without limiting the foregoing, from and after the Effective Date, Assignee hereby assumes and agrees to perform in a timely fashion all of the agreements, obligations, liabilities, duties, and covenants of Assignor (as subtenant) under the Consent to Sublease and hereby remakes and reaffirms, on its own behalf, all of the agreements, obligations, liabilities, duties, and covenants of Assignor under and pursuant to the Consent to Sublease. Except as expressly set forth herein, the terms and conditions of the Consent to Sublease shall be and remain unmodified and in full force and effect in accordance with its terms.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Assignor and Assignee each agrees:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">(i)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">notwithstanding any provision contained in this Agreement to the contrary, the liability of the Landlord for its obligations (whether under the Lease, the Consent to Sublease, this Agreement, or otherwise) shall be limited to the interests of Landlord in the Real Property. In no event shall any partner, member, manager, shareholder, director, officer, principal, employee, agent, or owner of Landlord, direct or indirect, disclosed or undisclosed, be personally liable for any debts, liabilities or obligations of Landlord, or for any claims against Landlord, arising out of or resulting from the Lease, the Consent to Sublease the Premises, or this Agreement. Any such debts, obligations, liabilities or claims shall be satisfied solely out of the interests of Landlord in the Real Property. In no event shall any personal judgment be sought or obtained against any partner, member, manager, shareholder, director, officer, principal, employee, agent, or owner of Landlord, direct or indirect, disclosed or undisclosed; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">(ii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">the obligations of Landlord under this Agreement, the Consent to Sublease and the Lease shall not be binding upon Landlord after the sale, conveyance, assignment or transfer by Landlord of its interest in the Real Property, and Assignor and Assignee shall look solely to the transferee for the satisfaction of such obligations. Any such transferee shall be deemed to have assumed all of Landlord&#8217;s obligations under this Agreement and the Consent to Sublease.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Except for amounts paid to Assignor by Assignee pursuant to that certain Lease dated December_, 2012 (the &#8220;75 State Street Lease&#8221;) between Assignee, as landlord, and Assignor, as tenant, Assignor and Assignee each represents and warrants that no other rent or other consideration is being paid or is payable to Assignor for the right to use or occupy the Premises or for the use, sale or rental</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:35.8pt;text-indent:-35.8pt;margin:0pt 0pt 0pt 42.14pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11pt;">by Assignee of fixtures, leasehold improvements, equipment, furniture, or other personal property.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">Tenant fu11her certifies to Assignee, as of the date hereof, as follows:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.4pt;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-indent:0pt;width:35.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(i)</font></font><font style="font-size:11pt;">A true, correct and complete copy of the Lease, the Sublease and the Consent to Sublease are attached hereto as </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B,</u><font style="font-size:11pt;"> and the Sublease sets forth the entire agreement between Tenant and Assignor with respect to the subleasing of the Sublet Premises, the Lease, the Sublease and the Consent to Sublease are in full force and effect and have not been modified, supplemented, amended or assigned in any way whatsoever except as described on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;"> hereto (excepting only pursuant to the Assignment and Assumption Agreement).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-indent:0pt;width:35.7pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(ii)</font></font><font style="font-size:11pt;">Notwithstanding anything to the contrary in the Consent to Sublease, the subleased premises pursuant to the Sublease consists of 13,920 square feet of Gross Rental Area on the 21</font><sup style="font-size:8.25pt;vertical-align:top;">st </sup><font style="font-size:11pt;">floor of the Building (the &#8220;Sublet Premises&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.05pt;text-indent:-0.05pt;margin:0pt 0pt 12pt 71.95pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(iii)</font></font><font style="font-size:11pt;">The term of the Sublease expires on March 31, 2018 and Tenant has not exercised its termination option pursuant to Article 32 of the Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.6pt;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-indent:0pt;width:35.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(iv)</font></font><font style="font-size:11pt;">The monthly Fixed Rent presently payable under the terms of the Sublease is $46,400 and has been paid in full through</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:35.25pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-size:11pt;">_</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.5pt;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-indent:0pt;width:35.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(v)</font></font><font style="font-size:11pt;">All additional rent including without limitation, &#8220;Subtenant&#8217;s Tax Payment&#8221;, &#8220;Subtenant&#8217;s Operating Payment,&#8221; &#8220;Subtenant&#8217;s Insurance Payment,&#8221; &#8220;Electricity Additional Rent,&#8221; any &#8220;Condenser Water Charge&#8221; and any parking charges that are payable by Assignor under the terms of the Sublease have been paid in full through </font><font style="font-size:12.5pt;">-------</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.55pt;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-indent:0pt;width:35.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(vi)</font></font><font style="font-size:11pt;">Tenant has not delivered nor received any outstanding notice of default under the Lease or the Sublease and, to the best of Tenant&#8217;s knowledge, there are no defaults under the Lease or the Sublease and no event has occurred which, with the giving of notice or the lapse of time, or both, would constitute a default under the Lease or the Sublease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.6pt;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-indent:0pt;width:35.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(vii)</font></font><font style="font-size:11pt;">The current addresses for notices to be sent to Tenant under the Sublease is set forth below:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11pt;">With a copy to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.1pt;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-indent:0pt;width:35.9pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(viii)</font></font><font style="font-size:11pt;">Tenant acknowledges and agrees that, as of the date of this Consent to Assignment of Sublease, Assignor has not installed or perfo1med any Specialty Alterations in or to the Sublet Premises that require removal at the expiration or earlier termination of the term of the Sublease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.1pt;margin:0pt 0pt 0pt 79.15pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11pt;">Tenant acknowledges that Assignee has or will hereafter acquire an interest in the Sublease and the Sublet Premises, and Assignee is relying upon the certifications of Tenant set forth in this paragraph 6 in connection therewith.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">This Agreement constitutes the entire agreement of the parties with respect to Landlord&#8217;s consent to the Assignment and Assumption Agreement. This Agreement may not be amended, modified, altered or changed except in writing signed by the Landlord. This Agreement shall be construed and governed by the laws of the Commonwealth of Massachusetts, without regard to principles of conflicts of laws. Assignor and Assignee each represents that it is duly authorized to execute and deliver this Agreement, and that it has full power and authority to enter into this Agreement.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">Landlord&#8217;s rights and remedies under this Agreement shall be in addition to every other right or remedy available to it under the Lease, at law, in equity or otherwise, and Landlord shall be able to assert its rights and remedies at the same time as, before, or after its assertion of any other right or remedy to which it is entitled without in any way diminishing such other rights or remedies. Nothing contained herein shall be deemed to diminish or relieve the Tenant of its primary responsibility and liability under the Lease. The invalidity or unenforceability of any provision of this Agreement shall not impair the validity and enforceability of any other provision of this Agreement.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">9.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">This Agreement shall bind and inure to the benefit of the parties and their respective successors and assigns, except that it shall not inure to the benefit of any successor or assign of Assignee whose status was acquired in violation of the Lease, the Sublease, the Consent to Sublease and/or this Agreement.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">10.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">Assignor and Assignee, jointly and severally, indemnify Landlord against, and hold it harmless from, all costs, damages and expenses, including reasonable attorneys&#8217; fees and disbursements, arising out of any claims for brokerage commissions, finders fees or other compensation in connection with the Assignment and Assumption Agreement or procuring possession of the Premises by Assignee. If any action or proceeding is brought against Landlord by reason of any such claim, then Assignor and Assignee, at their sole expense, shall defend any such claim with counsel reasonably acceptable to Landlord and settle any such claim at their expense; however, any stipulation, settlement agreement, consent order, judgment or decree entered into in connection therewith shall be subject to the prior written approval of the Landlord in all respects. The provisions of this paragraph 10 shall survive the expiration or earlier termination of the Lease and/or the Sublease.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">11.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">Assignor and Assignee, jointly and severally, indemnify Landlord against, and hold it harmless from any and all losses, costs, expenses, claims and liabilities including, but not limited to, reasonable counsel fees, arising from the use, occupancy, conduct or management of the Premises by Assignee, or its agents,</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:35.55pt;text-indent:-35.55pt;margin:0pt 0pt 0pt 42.35pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11.5pt;">employees, contractors, representatives, invitees or visitors, or Assignee&#8217;s business activities therein. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">any action or proceeding is brought against Landlord by reason of any such claim, Assignor and Assignee, upon written notice from Landlord, shall, at the sole cost and expense of Assignor and Assignee, resist or defend such action or proceeding using counsel reasonably approved by Landlord; however, any stipulation, settlement agreement, consent order, judgment or decree entered into in connection therewith shall be subject to the prior written approval of the Landlord in all respects. The provisions of this paragraph 11 shall survive the expiration or earlier termination of the term of the Sublease and/or the Lease. The indemnity and any right granted to Landlord pursuant to this paragraph shall be in addition to, and not in limitation of, Landlord&#8217;s rights under the Lease.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">12.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">In no event shall the Sublease or the Assignment and Assumption Agreement be modified, amended or supplemented, nor shall the Sublease or the rights of Assignee thereunder be assigned or sub-sublet, without the prior written consent of the Landlord in each instance in accordance with the applicable terms of the Lease. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">Assignee desires Landlord&#8217;s consent to any such action it must specifically and separately request such consent. Tenant shall give Landlord prompt written notice if the Sublease terminates prior to the expiration of its stated term.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">13.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Notwithstanding the provisions of Section 22 of the Sublease to the contrary, Tenant hereby conveys to Assignee all of Tenant&#8217;s right, title and interest in the Furniture described in Section 22 of the Sublease and agrees that Assignor and/or Assignee may remove any or all of the Furniture at any time and from time to time following the date of this Consent to Assignment of Sublease.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">14.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11.5pt;">Neither the execution and delivery of this Agreement, the Consent to Sublease or the Sublease, nor any acceptance of rent or other consideration from Assignee by Landlord or Landlord&#8217;s agent shall operate to waive, modify, impair, release or in any manner affect Tenant&#8217;s liabilities and obligations under the Lease.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">14.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">there shall be any conflict or inconsistency between the terms, covenants and conditions of the Consent to Sublease as supplemented by this Agreement and the Sublease, then the terms, covenants and conditions of the Consent to Sublease as supplemented by this Agreement shall prevail.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">15.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Each of the parties hereby irrevocably and unconditionally waives its right to a jury trial in any cause of action arising out of, or relating to, this Agreement. All disputes arising, directly or indirectly, out of or relating to this Agreement, and all actions to enforce this Agreement, shall be dealt with and adjudicated in the state courts of the Commonwealth of Massachusetts or the federal courts for the Commonwealth of Massachusetts and for that purpose each party hereby expressly and irrevocably submits itself to the jurisdiction of such courts. To the maximum extent permitted under applicable law, this consent to personal</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:35.15pt;text-indent:-35.15pt;margin:0pt 0pt 0pt 44pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11.5pt;">jurisdiction shall be self-operative and no further instrument or action, shall be necessary in order to confer jurisdiction upon it in any such court.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">16.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Tenant agrees to pay, upon demand, Landlord&#8217;s reasonable out-of-pocket fees and disbursements incurred in connection with and related to the preparation and execution of this Agreement.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">17.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">This Agreement may be executed in counterparts, each of which shall be deemed an original, and all such counterparts shall together constitute one and the same instrument. This Agreement shall be effective upon execution and delivery by all of the parties hereto.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:35.35pt;text-indent:-35.35pt;margin:0pt 0pt 0pt 45.9pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.15pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.15pt 10.5pt;"><font style="font-size:11pt;">Executed as an instrument under seal as of the date and year set forth above.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:27.5pt;text-indent:36pt;margin:0.15pt 202.3pt 12pt 153.35pt;"><font style="font-size:11pt;">Very</font><font style="font-size:11pt;letter-spacing:0.75pt;"> </font><font style="font-size:11pt;">truly</font><font style="font-size:11pt;letter-spacing:0.45pt;"> </font><font style="font-size:11pt;">yours,</font><font style="font-size:11pt;letter-spacing:0.05pt;"> </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 165.6pt;"><font style="font-size:11pt;">125</font><font style="font-size:11pt;letter-spacing:0.55pt;"> </font><font style="font-size:11pt;">HIGH</font><font style="font-size:11pt;letter-spacing:1.1pt;"> </font><font style="font-size:11pt;">STREET,</font><font style="font-size:11pt;letter-spacing:1.25pt;"> </font><font style="font-size:11pt;">L.P.,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 165.6pt;"><font style="font-size:11pt;">a</font><font style="font-size:11pt;letter-spacing:0.6pt;"> </font><font style="font-size:11pt;">Delaware</font><font style="font-size:11pt;letter-spacing:1.15pt;"> </font><font style="font-size:11pt;">limited</font><font style="font-size:11pt;letter-spacing:0.95pt;"> </font><font style="font-size:11pt;">partnership</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:34.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt;"><font style="font-size:11pt;">By:</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:bottom;width:62.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">TST</font><font style="font-size:11pt;letter-spacing:0.65pt;"> </font><font style="font-size:11pt;">125</font><font style="font-size:11pt;letter-spacing:0.35pt;"> </font><font style="font-size:11pt;">High</font><font style="font-size:11pt;letter-spacing:0.65pt;"> </font><font style="font-size:11pt;">GP,</font><font style="font-size:11pt;letter-spacing:0.95pt;"> </font><font style="font-size:11pt;">L.L.C.,</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#160;</font></p></td></tr><tr><td style="vertical-align:bottom;width:34.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:62.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">a</font><font style="font-size:11pt;letter-spacing:0.2pt;"> </font><font style="font-size:11pt;">Delaware</font><font style="font-size:11pt;letter-spacing:1.05pt;"> </font><font style="font-size:11pt;">limited</font><font style="font-size:11pt;letter-spacing:1.05pt;"> </font><font style="font-size:11pt;">liability</font><font style="font-size:11pt;letter-spacing:0.95pt;"> </font><font style="font-size:11pt;">company,</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:34.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:62.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">its</font><font style="font-size:11pt;letter-spacing:0.2pt;"> </font><font style="font-size:11pt;">sole</font><font style="font-size:11pt;letter-spacing:0.35pt;"> </font><font style="font-size:11pt;">general</font><font style="font-size:11pt;letter-spacing:0.35pt;"> </font><font style="font-size:11pt;">partner</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0pt 153.35pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt;"><font style="font-size:11pt;">By:</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:bottom;width:56.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#160;</font></p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:56.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.5;margin:0pt 121.2pt 0pt 0pt;"><font style="font-size:11pt;">Name:</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:56.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:11pt;">Its:</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0pt 153.35pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:43.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">RIVERSOURCE</font><font style="font-size:11pt;letter-spacing:2.85pt;"> </font><font style="font-size:11pt;">INVESTMENTS,</font><font style="font-size:11pt;letter-spacing:2.55pt;"> </font><font style="font-size:11pt;">LLC,</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:bottom;width:53.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">AMERIPRISE</font><font style="font-size:11pt;letter-spacing:2.55pt;"> </font><font style="font-size:11pt;">FINANCIAL,</font><font style="font-size:11pt;letter-spacing:2.25pt;"> </font><font style="font-size:11pt;">INC.,</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#160;</font></p></td></tr><tr><td style="vertical-align:bottom;width:43.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">a</font><font style="font-size:11pt;letter-spacing:0.75pt;"> </font><font style="font-size:11pt;">Minnesota</font><font style="font-size:11pt;letter-spacing:1.4pt;"> </font><font style="font-size:11pt;">limited</font><font style="font-size:11pt;letter-spacing:1.2pt;"> </font><font style="font-size:11pt;">liability</font><font style="font-size:11pt;letter-spacing:0.95pt;"> </font><font style="font-size:11pt;">company</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:53.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">a</font><font style="font-size:11pt;letter-spacing:0.25pt;"> </font><font style="font-size:11pt;">Delaware</font><font style="font-size:11pt;letter-spacing:1.05pt;"> </font><font style="font-size:11pt;">corporation</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0pt 153.35pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">By:</font></p></td><td colspan="2" style="vertical-align:top;width:44.29%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:2.75%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">By</font></p></td><td colspan="2" style="vertical-align:top;width:45.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#160;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Name:</font></p></td><td style="vertical-align:top;width:36.05%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:2.75%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.5;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.5;margin:0pt;"><font style="font-size:11pt;">Name</font></p></td><td style="vertical-align:bottom;width:38.94%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.5;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Title:</font></p></td><td style="vertical-align:top;width:36.05%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:2.75%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.3pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:11pt;">Title:</font></p></td><td style="vertical-align:bottom;width:38.94%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.3pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:47.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:11pt;">Hereunto</font><font style="font-size:11pt;letter-spacing:0.95pt;"> </font><font style="font-size:11pt;">duly</font><font style="font-size:11pt;letter-spacing:0.45pt;"> </font><font style="font-size:11pt;">authorized</font></p></td><td style="vertical-align:bottom;white-space:normal;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.29;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:45.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.29;margin:0pt;"><font style="font-size:11pt;">Hereunto</font><font style="font-size:11pt;letter-spacing:0.95pt;"> </font><font style="font-size:11pt;">duly</font><font style="font-size:11pt;letter-spacing:0.45pt;"> </font><font style="font-size:11pt;">authorized</font></p></td><td style="vertical-align:bottom;white-space:normal;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.55pt 0pt 0pt 0pt;"><font style="font-size:11pt;letter-spacing:-0.05pt;">BROOKFIELD PROPERTIES</font><font style="font-size:11pt;letter-spacing:0.05pt;"> </font><font style="font-size:11pt;">75</font><font style="font-size:11pt;letter-spacing:-0.6pt;"> </font><font style="font-size:11pt;">STATE</font><font style="font-size:11pt;letter-spacing:-0.4pt;"> </font><font style="font-size:11pt;">CO.</font><font style="font-size:11pt;letter-spacing:-0.7pt;"> </font><font style="font-size:11pt;">LLC</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:3.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:3.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><font style="font-size:11pt;">By:</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:44.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#160;&#160;&#160;&#160;</font></p></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#160;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.5;margin:0pt;"><font style="font-size:11pt;">Name</font></p></td><td style="vertical-align:bottom;width:40.6%;border-bottom:1.0pt solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.5;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:11pt;">Title:</font></p></td><td style="vertical-align:bottom;width:40.6%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.3pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:95.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:11pt;">Hereunto</font><font style="font-size:11pt;letter-spacing:0.95pt;"> </font><font style="font-size:11pt;">duly</font><font style="font-size:11pt;letter-spacing:0.45pt;"> </font><font style="font-size:11pt;">authorized</font></p></td><td style="vertical-align:top;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.3pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.3pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="4" style="vertical-align:bottom;width:50.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:11pt;letter-spacing:-0.05pt;">GRANT</font><font style="font-size:11pt;letter-spacing:-0.65pt;"> </font><font style="font-size:11pt;">THORNTON</font><font style="font-size:11pt;letter-spacing:-0.2pt;"> </font><font style="font-size:11pt;">LLP,</font><font style="font-size:11pt;letter-spacing:-0.65pt;"> </font><font style="font-size:11pt;">an</font><font style="font-size:11pt;letter-spacing:-0.75pt;"> </font><font style="font-size:11pt;">Illinois</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="4" style="vertical-align:bottom;width:50.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:11pt;">limited</font><font style="font-size:11pt;letter-spacing:0.3pt;"> </font><font style="font-size:11pt;">liability</font><font style="font-size:11pt;letter-spacing:0.15pt;"> </font><font style="font-size:11pt;">partnership</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">By:</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:44.26%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:11pt;">/s/ Russell Weiman</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt 0pt 0pt 7.2pt;"><font style="font-size:11pt;">Name:</font></p></td><td style="vertical-align:bottom;width:40.6%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:11pt;">Russell Weiman</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt 0pt 0pt 7.2pt;"><font style="font-size:11pt;">Title:</font></p></td><td style="vertical-align:bottom;width:40.6%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:11pt;">CFO</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="6" style="vertical-align:top;width:99.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt 0pt 0pt 7.2pt;"><font style="font-size:11pt;">Hereunto</font><font style="font-size:11pt;letter-spacing:0.25pt;"> </font><font style="font-size:11pt;">duly</font><font style="font-size:11pt;letter-spacing:0.05pt;"> </font><font style="font-size:11pt;">authorized</font></p></td><td style="vertical-align:top;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:15.25pt;text-align:justify;text-indent:-15.25pt;margin:0pt 0pt 0pt 8.15pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;">Assignment and Assumption Agreement</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.45pt 0pt;"><font style="font-size:11.5pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.34pt 0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;">Lease, Sublease and Consent to Sublease</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">M-10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">EXHIBIT N</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">ASSIGNMENT AGREEMENT</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">ASSIGNMENT AND ASSUMPTION OF SUBLEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.9pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">This ASSIGNMENT AND ASSUMPTION OF SUBLEASE (this </font><b style="font-size:11pt;font-weight:bold;">&#8220;Assignment&#8221;), </b><font style="font-size:11.5pt;">is made as of </font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:22.32pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-size:11.5pt;">,2014 by and between GRANT THORNTON LLP., having an address at </font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:90.89pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:31.95pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-size:11.5pt;">,and </font><b style="font-size:11pt;font-weight:bold;">(&#8220;Assignor&#8221;), </b><font style="font-size:11.5pt;">BROOKFIELD PROPERTIES 75 STATE CO. LLC, having an address of c/o</font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:39.74pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><b style="font-size:11pt;font-weight:bold;">(&#8220;Assignee&#8221;).</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">WITNESSETH</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">A.</font></font><font style="font-size:11.5pt;">WHEREAS, (i) Riversource Investments, LLC, a Minnesota limited liability company and Ameriprise Financial, Inc., a Delaware corporation (jointly and severally, </font><b style="font-size:11pt;font-weight:bold;">&#8220;Tenant&#8221;), </b><font style="font-size:11.5pt;">as sublandlord, and Assignor, as subtenant, are parties to that certain Sublease dated April 27, 2009, as modified, amended and supplemented by the Consent to Sublease, that certain Assignment, Assumption and Consent dated December </font><b style="font-size:10.5pt;font-weight:bold;">1, </b><font style="font-size:11.5pt;">2011 between CCR LLP, as assignor, and Grant Thornton LLP, as assignee, and that certain Consent to Assignment of Sublease dated April 19, 2012 between CCR LLP, Grant Thornton LLP, Riversource Investments, LLC, Ameriprise Financial, Inc. and 125 High Street, L.P. (the </font><b style="font-size:11pt;font-weight:bold;">&#8220;Sublease&#8221;) </b><font style="font-size:11.5pt;">of certain premises consisting of 13,920 rentable square feet on the 21</font><sup style="font-size:8.62pt;vertical-align:top;">st</sup><font style="font-size:11.5pt;"> floor (together with certain appurtenant rights, as more fully described in the Lease, the </font><b style="font-size:11pt;font-weight:bold;">&#8220;Sublet Premises&#8221;) </b><font style="font-size:11.5pt;">in the building located, commonly known as and numbered 125 High Street, Boston, Massachusetts (the </font><b style="font-size:11pt;font-weight:bold;">&#8220;Building&#8221;), </b><font style="font-size:11.5pt;">upon and subject to the terms and conditions set forth in the Sublease, and (ii) Tenant, as tenant, and 125 High Street, L.P., as landlord (the </font><b style="font-size:11pt;font-weight:bold;">&#8220;Landlord&#8221;), </b><font style="font-size:11.5pt;">are parties to that certain Lease dated August 7, 2007 (the </font><b style="font-size:11pt;font-weight:bold;">&#8220;Lease&#8221;) </b><font style="font-size:11.5pt;">pursuant to which Tenant leases approximately 18,166 rentable square feet in the Building, of which the Sublet Premises is a part.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">B.</font></font><font style="font-size:11.5pt;">WHEREAS, Assignor desires to assign to Assignee all of its right, title and interest in, to and under the Sublease; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:justify;">C.</font></font><font style="font-size:11.5pt;">WHEREAS, Assignee desires to assume all of Assignor&#8217;s obligations under the Sublease commencing on the Effective Date (as defined below), upon the terms and conditions hereinafter set forth.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">NOW THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth, and other valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto hereby agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">1.</font></font><font style="font-size:11.5pt;">Conditioned upon Assignee&#8217;s receipt of a fully executed written consent of Landlord and Tenant in the f01m attached hereto as </font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit A,</u><font style="font-size:11.5pt;"> Assignor hereby assigns and transfers to Assignee, effective as of </font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:19.55pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-size:11.5pt;">,2014 (the </font><b style="font-size:11pt;font-weight:bold;">&#8220;Effective Date&#8221;), </b><font style="font-size:11.5pt;">all of Assignor&#8217;s right, title and interest in, to and under the Sublease, together with all of the rights,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.55pt;margin:0pt 0pt 0pt 5.85pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">N-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.6pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11.5pt;">privileges and appurtenances with respect to the leasehold estate created thereby, and all of Assignor&#8217;s right, title and interest in and to any remaining leasehold improvements and furniture (including the Furniture described in Section 22 of the Sublease) located in the Sublet Premises, upon all of the te1ms and conditions herein set forth, to have and to hold the same unto Assignee, as permitted by the Sublease for the tenn of the Sublease, subject to all of the terms, covenants and conditions of the Sublease. Capital terms used but not defined herein shall have the meanings ascribed to such terms in the Sublease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">2.</font></font><font style="font-size:11.5pt;">Assignee hereby accepts the foregoing assignment and expressly assumes and agrees to fully and punctually pay, perform and observe all of the te1ms, covenants, conditions and obligations of the Sublease required to be paid, performed and observed on the part of the Subtenant under the Sublease and which arise or accrue from and after the Effective Date, excluding Assignor&#8217;s obligation under Section 25 of the Sublease to maintain the Letter of Credit. Assignor expressly covenants and agrees that Assignor shall continue to maintain the Letter of Credit pursuant to and in accordance with the terms and conditions of Section 22 of the Sublease and Assignee shall reimburse Assignor for 50% of the reasonable costs incurred by Assignor to maintain such Letter of Credit for the remainder of the term of the Sublease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">3.</font></font><font style="font-size:11.5pt;">Assignee shall indemnify and hold Assignor harmless from and against any and all demands, claims, actions, losses, damages, liabilities, litigation and costs and expenses thereof including, without limitation reasonable attorneys&#8217; fees and disbursements of any kind and nature whatsoever (collectively, </font><b style="font-size:11pt;font-weight:bold;">&#8220;Assignor Claims&#8221;), </b><font style="font-size:11.5pt;">which may be imposed on, asserted against or otherwise incurred by Assignor by or on behalf of any person or entity whatsoever due to or arising from the failure or alleged failure of Assignee, to undertake, perform, pay, discharge or observe any of the covenants, terms and conditions of the Sublease from and after the Effective Date, excluding the obligation retained by Assignee pursuant to Section 2 of this Assignment to maintain the Letter of Credit in accordance with Section 25 of the Sublease. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">any action or proceeding is brought against Assignor by reason of any Assignor Claim, Assignee, upon notice from Assignor, shall defend such action or proceeding, and Assignee shall pay all expenses in respect of defending against such action or proceeding.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">4.</font></font><font style="font-size:11.5pt;">Assignor shall indemnify and hold Assignee harmless from and against any and all demands, claims, actions, losses, damages, liabilities, litigation and costs and expenses thereof including, without limitation, reasonable attorneys&#8217; fees and disbursements of any kind and nature whatsoever (collectively, </font><b style="font-size:11pt;font-weight:bold;">&#8220;Assignee Claims&#8221;), </b><font style="font-size:11.5pt;">which may be imposed on, asserted against or otherwise incurred by Assignee by or on behalf of any person or entity whatsoever due to or arising from the failure or alleged failure of Assignor to undertake, perform, pay, discharge or observe any of the covenants, terms and conditions of the Sublease prior to the Effective Date or any Assignee Claims arising out of Assignor&#8217;s failure to maintain the Letter of Credit in accordance with the terms of Section 2 of this Assignment. </font><font style="font-size:11pt;">If </font><font style="font-size:11.5pt;">any action or proceeding is brought against Assignee by reason of any Assignee Claim, Assignor, upon notice from Assignee, shall defend such action or proceeding, and Assignor shall pay all expenses in respect of defending against such action or proceeding.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">5.</font></font><font style="font-size:11.5pt;">Assignor hereby acknowledges, agrees, certifies and represents to Assignee as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.9pt;margin:0pt 0pt 0pt 6.95pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">N-2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">(i)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">A true, complete and accurate copy of the Lease, Sublease and Consent to Sublease, is attached hereto as </font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11.5pt;">. and the Sublease sets forth the entire agreement between Tenant and Assignor with respect to the subleasing of the Sublet Premises, the Lease, the Sublease and the Consent to Sublease are in full force and effect and have not been modified, supplemented, amended or assigned in any way whatsoever except as described on </font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11.5pt;"> hereto;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">(ii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">The term of the Sublease and expires on March 31, 2018;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">(iii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Notwithstanding anything to the contrary in the Consent to Sublease, the subleased premises pursuant to the Sublease consists of 13,920 square feet of Gross Rental Area on the 21</font><sup style="font-size:8.62pt;vertical-align:top;">st</sup><font style="font-size:11.5pt;"> floor of the Building (the &#8220;Sublet Premises&#8221;);</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">(iv)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">The term of the Sublease expires on March 31, 2018 and Assignor has not received notice that Tenant has exercised its termination option pursuant to Article 32 of the Lease.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(v)</font></font><font style="font-size:11.5pt;">The monthly Fixed Rent presently payable under the terms of the Sublease is $46,400 and has been paid in full through</font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:207.2pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-size:11.5pt;">_</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">(vi)</font></font><font style="font-size:11.5pt;">All additional rent including without limitation, &#8220;Subtenant&#8217;s Tax Payment&#8221;, &#8220;Subtenant&#8217;s Operating Payment,&#8221; &#8220;Subtenant&#8217;s Insurance Payment,&#8221; &#8220;Electricity Additional Rent,&#8221; any &#8220;Condenser Water Charge&#8221; and any parking charges that are payable by Assignor under the terms of the Sublease have been paid in full through</font><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:58.11pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-size:11.5pt;">_</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">(vii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Assignor has not delivered nor received any outstanding notice of default under the Lease or the Sublease and, to the best of Assignor&#8217;s knowledge, there are no defaults under the Lease or the Sublease and no event has occurred which, with the giving of notice or the lapse of time, or both, would constitute a default under the Lease or the Sublease.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">(viii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11.5pt;">Assignor acknowledges and agrees that, as of the date of this Assignment, Assignor has not installed or performed any Specialty Alterations in or to the Sublet Premises that require removal at the expiration or earlier termination of the term of the Sublease.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">6.</font></font><font style="font-size:11.5pt;">Assignor hereby acknowledges and agrees that Assignor will hereafter execute and deliver to Assignee any further assignments, instruments of transfer, bills of sale, releases or conveyances which may reasonably be deemed necessary by Assignee to fully vest in Assignee all of the Assignor&#8217;s right, title and interest in and to the Lease, the Furniture and any other furniture and leasehold improvements in the Sublet Premises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36.45pt;margin:0pt 0pt 0pt 6.45pt;"><font style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">N-3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">7.</font></font><font style="font-size:11.5pt;">This Assignment may not be amended, modified or terminated except by an instrument, in writing, executed by the parties hereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">8.</font></font><font style="font-size:11.5pt;">This Assignment may be executed in several counterparts, and all so executed shall constitute one Assignment, binding on each of the parties hereto, notwithstanding that each of the parties are not signatories to the original or the same counterpart.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">9.</font></font><font style="font-size:11.5pt;">This Assignment shall be binding upon and shall inure to the benefit of the parties hereto and their respective successor and assigns.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;text-align:left;">10.</font></font><font style="font-size:11.5pt;">This Assignment shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-size:11pt;font-style:italic;">[signature page follows]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">N-4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:37.05pt;margin:0pt 0pt 0.05pt 9.9pt;"><font style="font-size:11.5pt;">IN WITNESS WHEREOF, the parties hereto have duly executed this Assignment as of the day and year first above written.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11.5pt;font-weight:bold;">ASSIGNOR:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-0.05pt;margin:0pt;"><font style="font-size:11.5pt;">GRANT THORNTON LLP, an Illinois<br>limited liability partnership</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:3.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:44.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><font style="font-size:11pt;">By:</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:44.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#160;&#160;&#160;&#160;</font></p></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#160;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.5;margin:0pt;"><font style="font-size:11pt;">Name</font></p></td><td style="vertical-align:bottom;width:40.6%;border-bottom:1.0pt solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.5;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:11pt;">Title:</font></p></td><td style="vertical-align:bottom;width:40.6%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:10.3pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:95.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:11pt;">Hereunto</font><font style="font-size:11pt;letter-spacing:0.95pt;"> </font><font style="font-size:11pt;">duly</font><font style="font-size:11pt;letter-spacing:0.45pt;"> </font><font style="font-size:11pt;">authorized</font></p></td><td style="vertical-align:top;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin:0pt;"><b style="font-weight:bold;text-decoration:none;text-decoration-color:#000000;">ASSIGNEE:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.44pt 0pt 0pt 0pt;"><font style="letter-spacing:-0.05pt;text-decoration:none;text-decoration-color:#000000;">BROOKFIELD</font><font style="letter-spacing:0.1pt;text-decoration:none;text-decoration-color:#000000;"> </font><font style="letter-spacing:-0.05pt;text-decoration:none;text-decoration-color:#000000;">PROPERTIES</font><font style="letter-spacing:0.2pt;text-decoration:none;text-decoration-color:#000000;"> </font><font style="text-decoration:none;text-decoration-color:#000000;">75</font><font style="letter-spacing:-0.65pt;text-decoration:none;text-decoration-color:#000000;"> </font><font style="text-decoration:none;text-decoration-color:#000000;">STATE</font><font style="letter-spacing:-0.6pt;text-decoration:none;text-decoration-color:#000000;"> </font><font style="text-decoration:none;text-decoration-color:#000000;">CO.</font><font style="letter-spacing:-0.4pt;text-decoration:none;text-decoration-color:#000000;"> </font><font style="text-decoration:none;text-decoration-color:#000000;">LLC</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:3.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:44.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">By:</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:44.27%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:11pt;">/s/ Russell Weiman</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt 0pt 0pt 7.2pt;"><font style="font-size:11pt;">Name:</font></p></td><td style="vertical-align:bottom;width:40.6%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:11pt;">Russell Weiman</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt 0pt 0pt 7.2pt;"><font style="font-size:11pt;">Title:</font></p></td><td style="vertical-align:bottom;width:40.6%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt;"><font style="font-size:11pt;">CFO</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="6" style="vertical-align:top;width:99.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.3pt;margin:0pt 0pt 0pt 7.2pt;"><font style="font-size:11pt;">Hereunto</font><font style="font-size:11pt;letter-spacing:0.25pt;"> </font><font style="font-size:11pt;">duly</font><font style="font-size:11pt;letter-spacing:0.05pt;"> </font><font style="font-size:11pt;">authorized</font></p></td><td style="vertical-align:top;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">N-5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.15pt 0pt;"><font style="font-size:11.5pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><u style="font-size:11.5pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;">Copy of Consent to Assignment of Sublease</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">N-6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.84pt 0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.3pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:13pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Lease, Sublease and Consent to Sublease</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">N-7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.55pt 0pt;"><font style="font-size:11pt;">EXHIBIT O</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;">Tenant&#8217;s Share of the Remaining High Street Rent Obligations</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">O-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Exhibit C</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Available Furniture</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:80%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">75 State Street</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Boston, MA 02109</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1/28/2022</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">14th Floor Furniture Inventory</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:79.92%;"><tr><td colspan="2" style="vertical-align:top;width:75%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Description</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Quantity</p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Guest Seating</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">23</p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Task Chairs</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">105</p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Workstations</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">74</p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Cobi Chairs</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">23</p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Executive Seating Table</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">42 Inch Oval</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12</p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Conference Room Table</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">72 Inch x 36 inch</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Team RoomTable</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">24 Inch Round</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Team RoomTable</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">36 Inch Round</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Conference Room Table</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">48 Inch x 24 Inch</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">File Cabinets</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">3 High</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">69</p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Conference Room Seating</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">16</p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">52 Inch Display - Wall Mounted</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Room 14047</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Cisco SX20 VC Codec &amp; Camera</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Room 14047</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">8&#8221; Cisco Touch Panel Controller</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Room 14047</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Table Mounted Microphones</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Room 14047</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Ceiling Mounted Speakers</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Room 14047</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">43&#8221; Displays - Wall Mounted</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Room 14079</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Steelcase Media:Scape Table</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Room 14079</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Exhibit D</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Security Deposit Letter of Credit</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="atxs-20211231xex10d19009.jpg" alt="Graphic" style="display:inline-block;height:40.69pt;width:73.76pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">STANDBY LETTER OF CREDIT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">DRAFT of Standby Letter of Credit</p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Draft for discussion purposes only</b></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">begin format</p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">BENEFICIARY:</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Letter of Credit number: 2010100000XX</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BENEFICIARY</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: xx/xx/xx</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BENEFICIARY</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BENEFICIARY</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BENEFICIARY</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Attn</b>: Building Manager</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ladies and Gentlemen:</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At the request and for the account of APPLICANT NAME AND ADDRESS, we hereby establish our standby letter of credit number 2010100000XX in your favor in the amount of &#160;&#160;&#160;&#160;U.S. dollars and &#160;&#160;&#160;&#160;&#160;cents (USD&#160;&#160;&#160;&#160;) (hereinafter the &#8220;maximum amount&#8221;) available with us at our office listed below, by payment of your draft(s) drawn on us at sight accompanied by the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">1.&#160;The original of this letter of credit and all amendments (if any).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">2.&#160;Statement purportedly signed by the beneficiary stating the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">&#8220;This demand is pursuant to the lease dated xx/xx/xx by and between the applicant and the beneficiary.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Partial drawings under this letter of credit are permitted. We shall, after each presentation of this letter of credit, return the same to you, making this letter of credit to show the amount paid by us and the date of such payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Each draft must be marked &#8220;Drawn under Pacific Western Bank Letter of Credit number 2010100000XX.&#8221; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This letter of credit expires at our office listed below at 5 p.m. eastern time on</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Notwithstanding the foregoing, this letter of credit shall be automatically extended for a period of one year unless at least thirty (30) calendar days prior to any expiration date we have sent written notice to your above address by courier that we elect not to renew this letter of credit for such additional period. <b style="font-weight:bold;">In any event, this letter of credit will not be extended beyond FINAL EXPIRY DATE.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Notwithstanding any provision herein to the contrary, our aggregate obligation to honor such drafts shall not exceed the maximum amount, as reduced by prior draws or automatic reductions hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If any instructions accompanying a drawing under this letter of credit request that payment is to be made by transfer to an account with us or at another bank, we and/or such other bank may rely on an account number specified in such instructions even if the number identifies a person or entity different from the intended payee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:3.0pt solid #134890;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">475 Fifth Avenue, 18<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Floor, N.Y. 10017</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="atxs-20211231xex10d19010.jpg" alt="Graphic" style="display:inline-block;height:40.49pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:73.49pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><font style="font-size:9.5pt;">This Letter of Credit is transferable one or more times, but in each instance to a single transferee and only in the full amount available to be drawn under the Letter of Credit at the time of such transfer. Any such transfer may be effected only through ourselves and only upon presentation to us at our below-specified office of a duly executed instrument of transfer in the format attached hereto as Exhibit A together with the original of this letter of credit. Each transfer shall be evidenced by our endorsement on the reverse of the original of this letter of credit, and we shall deliver the original of this letter of credit so endorsed to the transferee. Without prejudice to the foregoing, such transfer shall be permitted without our approval, provided that such transfer is not in favor of any person or entity identified on a then-current list of specially Designated Nationals and Blocked Persons provided by the Office of Foreign Assets Control of the U.S. Department of the Treasury. All charges in connection with any transfer under this letter of credit shall be paid by the beneficiary at the time written notice of a transfer is submitted.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 104.6pt;"><font style="font-size:9.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><font style="font-size:9.5pt;">This letter of credit shall be promptly surrendered to us by you (or any subsequent transferee) upon expiration.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><font style="font-size:9.5pt;">Except so far as otherwise expressly stated, this documentary credit is subject to Uniform Customs and Practice for Documentary Credits, 2007 revision, International Chamber of Commerce Publication No. 600.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><font style="font-size:9.5pt;">We engage with you that each draft drawn under and in compliance with the terms of this letter of credit will be duly honored on delivery of the specified documents, if presented at this office during regular business hours: 475 Fifth Avenue, 18</font><sup style="font-size:7.12pt;vertical-align:top;">th</sup><font style="font-size:9.5pt;"> Floor, New York, N.Y. 10017 Attn:Trade Finance Dept.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 237.6pt;">Very truly yours,</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 237.6pt;">Pacific Western Bank</p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">end format</p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-size:9pt;">Agreed </font><font style="font-size:9.5pt;">to </font><font style="font-size:8.5pt;">and </font><font style="font-size:9pt;">accepted by:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="0.75" width="25.0%" style="background-color:#000000;color:#000000;height:1px;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><font style="font-size:9.5pt;">APPLICANT</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:3.0pt solid #134890;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">475 Fifth Avenue, 18<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Floor, N.Y. 10017</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>atxs-20211231xex21d1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/10/2022 09:04:43 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;21.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Subsidiaries of the Registrant</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:49.49%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Entity</b></p></td><td style="vertical-align:bottom;width:2.01%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:48.48%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Jurisdiction&#160;of&#160;Incorporation</b></p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Astria Securities Corporation</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:48.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delaware</p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Quellis Biosciences, LLC</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delaware</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>atxs-20211231xex23d1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/10/2022 09:04:45 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit&#160;23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">We consent to the incorporation by reference in the following Registration Statements:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">1)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">Registration Statement (Form S-1 Nos. 333-225410 and 333-225734) of Astria Therapeutics, Inc.,</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">2)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">Registration Statement (Form S-3 No. 333-231441 and 333-254174) of Astria Therapeutics, Inc., and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">3)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">Registration Statement (Form S-8 Nos. 333-206394, 333-210229, 333-216793, 333-223721, 333-229643, 333-239114, 333-254151, and 333-258633) pertaining to the equity incentive plans of Astria Therapeutics, Inc.;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">of our report dated March 10, 2022, with respect to the consolidated financial statements of Astria Therapeutics, Inc. included in this Annual Report (Form 10-K) of Astria Therapeutics, Inc. for the year ended December 31, 2021.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Ernst &amp; Young LLP</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Boston, Massachusetts</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">March 10, 2022</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>atxs-20211231xex31d1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/10/2022 09:04:49 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">I, Jill C. Milne, certify that:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">1.</font>I have reviewed this Annual Report on Form 10-K of Astria Therapeutics, Inc.;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">2.</font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">3.</font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">4.</font>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:18pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:18pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:18pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">5.</font>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</div><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:18pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 10, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jill C. Milne</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jill C. Milne</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>atxs-20211231xex31d2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/10/2022 09:04:53 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;text-indent:0pt;margin:0pt;"><b style="font-family:'Times';font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Times';font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.79;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">I, Noah C. Clauser, certify that: </p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.79;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">1.</font>I have reviewed this Annual Report on Form 10-K of Astria Therapeutics, Inc.; </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">2.</font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">3.</font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">4.</font>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:18pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:18pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:18pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </div><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">5.</font>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </div><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:18pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">Date: March 10, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt;"><font style="line-height:1.37;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="line-height:1.37;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:12pt;text-indent:-12pt;margin:0pt;">/s/ Noah C. Clauser</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="line-height:1.37;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">Noah C. Clauser</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="line-height:1.37;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">Chief Financial Officer and Treasurer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="line-height:1.37;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>atxs-20211231xex32d1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/10/2022 09:04:58 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with this Annual Report on Form 10-K of Astria Therapeutics, Inc. (the &#8220;Company&#8221;) for the year ended December&#160;31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Jill C. Milne, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that, to her knowledge on the date hereof:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">(1)</font>The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">(2)</font>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 10, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.9%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">/s/ Jill C. Milne&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jill C. Milne</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>atxs-20211231xex32d2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/10/2022 09:05:03 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with this Annual Report on Form 10-K of Astria Therapeutics, Inc. (the &#8220;Company&#8221;) for the year ended December&#160;31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Noah C. Clauser Chief Financial Officer and Treasurer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that, to his knowledge on the date hereof:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">(1)</font>The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">(2)</font>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 10, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">/s/ Noah C. Clauser</p></td></tr><tr><td style="vertical-align:top;width:49.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Noah C. Clauser</p></td></tr><tr><td style="vertical-align:top;width:49.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer and Treasurer</p></td></tr><tr><td style="vertical-align:top;width:49.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>atxs-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/10/2022 9:03:25 PM-->
<!--Modified on: 3/10/2022 9:03:25 PM-->
<xsd:schema targetNamespace="http://astria.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:attributeFormDefault="unqualified" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:atxs="http://astria.com/20211231" xmlns:dei="http://xbrl.sec.gov/dei/2021q4">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://astria.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/StatementConsolidatedStatementsComprehensiveLoss" id="StatementConsolidatedStatementsComprehensiveLoss">
        <link:definition>00300 - Statement - Consolidated Statements Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00500 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesCashAndCashEquivalentsAndRestrictedCashDetails" id="DisclosureSummaryOfSignificantAccountingPolicesCashAndCashEquivalentsAndRestrictedCashDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Polices - Cash and Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails" id="DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails">
        <link:definition>40302 - Disclosure - Acquisition of Quellis - Net assets acquired based on their estimated fair values (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureFinancialInstrumentsDetails" id="DisclosureFinancialInstrumentsDetails">
        <link:definition>40401 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureShortTermInvestmentsDetails" id="DisclosureShortTermInvestmentsDetails">
        <link:definition>40501 - Disclosure - Short-Term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>40601 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureIncomeTaxesReconciliationDetails" id="DisclosureIncomeTaxesReconciliationDetails">
        <link:definition>41001 - Disclosure - Income Taxes - Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>00400 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>00405 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureOrganizationAndOperations" id="DisclosureOrganizationAndOperations">
        <link:definition>10101 - Disclosure - Organization and Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureFinancialInstruments" id="DisclosureFinancialInstruments">
        <link:definition>10401 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureShortTermInvestments" id="DisclosureShortTermInvestments">
        <link:definition>10501 - Disclosure - Short-Term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>10601 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureCommitments" id="DisclosureCommitments">
        <link:definition>10701 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10801 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureStockIncentivePlans" id="DisclosureStockIncentivePlans">
        <link:definition>10901 - Disclosure - Stock Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11001 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureDefinedContributionBenefitPlan" id="DisclosureDefinedContributionBenefitPlan">
        <link:definition>11101 - Disclosure - Defined Contribution Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11201 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices" id="DisclosureSummaryOfSignificantAccountingPolicesPolices">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Polices (Polices)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureFinancialInstrumentsTables" id="DisclosureFinancialInstrumentsTables">
        <link:definition>30403 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureShortTermInvestmentsTables" id="DisclosureShortTermInvestmentsTables">
        <link:definition>30503 - Disclosure - Short-Term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>30603 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>30803 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureStockIncentivePlansTables" id="DisclosureStockIncentivePlansTables">
        <link:definition>30903 - Disclosure - Stock Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31003 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails" id="DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails">
        <link:definition>40101 - Disclosure - Organization and Operations - Reverse Stock Split, Agreement and Plan of Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails" id="DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails">
        <link:definition>40102 - Disclosure - Organization and Operations - Stock Purchase Agreement and Series X Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureOrganizationAndOperationsJanuary2020FinancingDetails" id="DisclosureOrganizationAndOperationsJanuary2020FinancingDetails">
        <link:definition>40103 - Disclosure - Organization and Operations - January 2020 Financing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails" id="DisclosureOrganizationAndOperationsLiquidityDetails">
        <link:definition>40104 - Disclosure - Organization and Operations - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails" id="DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails">
        <link:definition>40202 - Disclosure - Summary of Significant Accounting Polices - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails">
        <link:definition>40203 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails">
        <link:definition>40204 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreferredStockDiscountDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPreferredStockDiscountDetails">
        <link:definition>40206 - Disclosure - Summary of Significant Accounting Policies - Preferred Stock Discount (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureAcquisitionOfQuellisDetails" id="DisclosureAcquisitionOfQuellisDetails">
        <link:definition>40301 - Disclosure - Acquisition of Quellis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails" id="DisclosureFinancialInstrumentsWarrantLiabilityDetails">
        <link:definition>40402 - Disclosure - Financial Instruments - Warrant liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureFinancialInstrumentsFairValueOfWarrantsDetails" id="DisclosureFinancialInstrumentsFairValueOfWarrantsDetails">
        <link:definition>40403 - Disclosure - Financial Instruments - Fair value of warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureCommitmentsDetails" id="DisclosureCommitmentsDetails">
        <link:definition>40701 - Disclosure - Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureStockholdersEquityPreferredStockDetails" id="DisclosureStockholdersEquityPreferredStockDetails">
        <link:definition>40801 - Disclosure - Stockholders' Equity - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails" id="DisclosureStockholdersEquityCommonStockWarrantsDetails">
        <link:definition>40802 - Disclosure - Stockholders' Equity - Common Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureStockholdersEquityCommonStockDetails" id="DisclosureStockholdersEquityCommonStockDetails">
        <link:definition>40803 - Disclosure - Stockholders' Equity - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails" id="DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails">
        <link:definition>40804 - Disclosure - Stockholders' Equity - Shares Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureStockIncentivePlansSummaryOfPlansDetails" id="DisclosureStockIncentivePlansSummaryOfPlansDetails">
        <link:definition>40901 - Disclosure - Stock Incentive Plans - Summary of Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails" id="DisclosureStockIncentivePlansStockOptionActivityDetails">
        <link:definition>40902 - Disclosure - Stock Incentive Plans - Stock option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureStockIncentivePlansStockBasedCompensationExpenseDetails" id="DisclosureStockIncentivePlansStockBasedCompensationExpenseDetails">
        <link:definition>40903 - Disclosure - Stock Incentive Plans - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesDeferredTaxAssetsDetails">
        <link:definition>41002 - Disclosure - Income Taxes - Deferred tax assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" id="DisclosureIncomeTaxesOperatingLossCarryforwardsDetails">
        <link:definition>41003 - Disclosure - Income Taxes - Operating Loss Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41201 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureAcquisitionOfQuellis" id="DisclosureAcquisitionOfQuellis">
        <link:definition>10301 - Disclosure - Acquisition of Quellis</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureOrganizationAndOperationsTables" id="DisclosureOrganizationAndOperationsTables">
        <link:definition>30103 - Disclosure - Organization and Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureAcquisitionOfQuellisTables" id="DisclosureAcquisitionOfQuellisTables">
        <link:definition>30303 - Disclosure - Acquisition of Quellis (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails">
        <link:definition>40205 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="atxs-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="atxs-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="atxs-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="atxs-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:element id="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_AccruedContractedResearchCostsCurrent" name="AccruedContractedResearchCostsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="atxs_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_EmployeeStockPurchasePlan2015Member" name="EmployeeStockPurchasePlan2015Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock" name="OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="atxs_NumberOfPreferredStockSeries" name="NumberOfPreferredStockSeries" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="atxs_AtMarketOfferingMember" name="AtMarketOfferingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_ProceedsFromIssuanceOfAtMarketOffering" name="ProceedsFromIssuanceOfAtMarketOffering" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="atxs_PercentageOfCommissionPaidToUnderwriterBasedOnProceedsFromOffering" name="PercentageOfCommissionPaidToUnderwriterBasedOnProceedsFromOffering" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="atxs_CommonStockReservedForFutureIssuanceAbstract" name="CommonStockReservedForFutureIssuanceAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_AccruedSeveranceCurrent" name="AccruedSeveranceCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="atxs_OppenheimerCo.IncMember" name="OppenheimerCo.IncMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_ShortTermInvestmentsTextBlock" name="ShortTermInvestmentsTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="atxs_RemainingAvailableUnderCurrentSalesAgreement" name="RemainingAvailableUnderCurrentSalesAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="atxs_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm" name="WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="atxs_ReverseRepurchaseAgreementsMember" name="ReverseRepurchaseAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_CommonStockOptionsReservedMember" name="CommonStockOptionsReservedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_CommonStockOptionsOutstandingMember" name="CommonStockOptionsOutstandingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_PercentageOfInvestmentAmountToCollateralizedDepositsValue" name="PercentageOfInvestmentAmountToCollateralizedDepositsValue" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="atxs_IncreaseDecreaseInRightOfUseAssetOperating" name="IncreaseDecreaseInRightOfUseAssetOperating" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="atxs_SummaryOfSignificantAccountingPolicesLineItems" name="SummaryOfSignificantAccountingPolicesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_SummaryOfSignificantAccountingPolicesTable" name="SummaryOfSignificantAccountingPolicesTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_IndefiniteTaxYearsMember" name="IndefiniteTaxYearsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_UnderwritingPublicOffering2020Member" name="UnderwritingPublicOffering2020Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="atxs_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="atxs_TaxYears2023Through2039Member" name="TaxYears2023Through2039Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_WarrantsIssuedIn2015Member" name="WarrantsIssuedIn2015Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_WarrantsIssuedIn2018Member" name="WarrantsIssuedIn2018Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_WarrantsIssuedIn2019Member" name="WarrantsIssuedIn2019Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_PublicOfferingCommonStockAndWarrantsMember" name="PublicOfferingCommonStockAndWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember" name="SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember" name="AgreementAndPlanOfMergerQuellisBiosciencesIncMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember" name="StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_SeriesXPreferredStockMember" name="SeriesXPreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_SharesIssuedInMergerMember" name="SharesIssuedInMergerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_SharesIssuedIn2021FinancingMember" name="SharesIssuedIn2021FinancingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_WarrantsAssumedInMergerMember" name="WarrantsAssumedInMergerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially" name="PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter" name="PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="atxs_NonCashPortionOfAcquiredResearchAndDevelopment" name="NonCashPortionOfAcquiredResearchAndDevelopment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="atxs_WarrantsIssuedIn2021Member" name="WarrantsIssuedIn2021Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageExercisePrice" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues" name="TemporaryEquityStockIssuedInAcquisitionSharesNewIssues" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodSharesNewIssues" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="atxs_StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings" name="StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings" name="StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="atxs_ScheduleOfPreferredStockOrWarrantsToPurchasePreferredStockTableTextBlock" name="ScheduleOfPreferredStockOrWarrantsToPurchasePreferredStockTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="atxs_JefferiesMember" name="JefferiesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_ReclassificationOfEquityClassifiedWarrants" name="ReclassificationOfEquityClassifiedWarrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="atxs_PreferredStockDiscountPolicyTextBlock" name="PreferredStockDiscountPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="atxs_NonCashReturnRelatedToCommonStock" name="NonCashReturnRelatedToCommonStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="atxs_GainLossOnWarrantInherited" name="GainLossOnWarrantInherited" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts" name="DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="atxs_SeriesXRedeemableConvertiblePreferredStockMember" name="SeriesXRedeemableConvertiblePreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodGrossValue" name="TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodGrossValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="atxs_AgreementAndPlanOfMergerAbstract" name="AgreementAndPlanOfMergerAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract" name="StockPurchaseAgreementAndSeriesXPreferredStockAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_January2020FinancingAbstract" name="January2020FinancingAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="atxs_CommonStockSaleAgreementValue" name="CommonStockSaleAgreementValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="atxs_StockIssuedDuringPeriodSharesIncreaseDecreaseDueToConversionOfPreferredSharesIntoCommonShares" name="StockIssuedDuringPeriodSharesIncreaseDecreaseDueToConversionOfPreferredSharesIntoCommonShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="atxs_TemporaryEquityConversionValue" name="TemporaryEquityConversionValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="WeightedAverageExpectedVolatilityMember" id="atxs_WeightedAverageExpectedVolatilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>atxs-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/10/2022 9:03:25 PM-->
<!--Modified on: 3/10/2022 9:03:25 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://astria.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://astria.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#StatementConsolidatedStatementsComprehensiveLoss" roleURI="http://astria.com/role/StatementConsolidatedStatementsComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://astria.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureSummaryOfSignificantAccountingPolicesCashAndCashEquivalentsAndRestrictedCashDetails" roleURI="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesCashAndCashEquivalentsAndRestrictedCashDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails" roleURI="http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureFinancialInstrumentsDetails" roleURI="http://astria.com/role/DisclosureFinancialInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureShortTermInvestmentsDetails" roleURI="http://astria.com/role/DisclosureShortTermInvestmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://astria.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureIncomeTaxesReconciliationDetails" roleURI="http://astria.com/role/DisclosureIncomeTaxesReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://astria.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637825430037015088" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_637825430037015088" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637825430037015088" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637825430037015088" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637825430037015088" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_637825430037025084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637825430037015088" xlink:to="us-gaap_ShortTermInvestments_637825430037025084" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637825430037025084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637825430037015088" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637825430037025084" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637825430037025084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637825430037025084" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637825430037025084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_637825430037025084" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637825430037025084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637825430037025084" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637825430037025084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637825430037025084" xlink:to="us-gaap_LiabilitiesCurrent_637825430037025084" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637825430037025084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637825430037025084" xlink:to="us-gaap_AccountsPayableCurrent_637825430037025084" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637825430037025084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637825430037025084" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637825430037025084" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637825430037025084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637825430037025084" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637825430037025084" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637825430037025084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637825430037025084" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637825430037025084" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637825430037035087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_637825430037035087" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637825430037035087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637825430037035087" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637825430037035087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637825430037035087" xlink:to="us-gaap_PreferredStockValue_637825430037035087" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637825430037035087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637825430037035087" xlink:to="us-gaap_CommonStockValue_637825430037035087" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637825430037035087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637825430037035087" xlink:to="us-gaap_AdditionalPaidInCapital_637825430037035087" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637825430037035087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637825430037035087" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637825430037035087" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637825430037035087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637825430037035087" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637825430037035087" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://astria.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637825430037035087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss_637825430037035087" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637825430037045083" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637825430037035087" xlink:to="us-gaap_OperatingIncomeLoss_637825430037045083" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637825430037045083" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637825430037045083" xlink:to="us-gaap_OperatingExpenses_637825430037045083" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_637825430037045083" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637825430037045083" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_637825430037045083" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637825430037045083" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637825430037045083" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637825430037045083" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_637825430037045083" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637825430037045083" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_637825430037045083" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637825430037045083" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637825430037035087" xlink:to="us-gaap_NonoperatingIncomeExpense_637825430037045083" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637825430037045083" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637825430037045083" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637825430037045083" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_637825430037045083" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637825430037045083" xlink:to="us-gaap_InvestmentIncomeInterest_637825430037045083" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts" xlink:label="atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts_637825430037055196" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts_637825430037055196" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://astria.com/role/StatementConsolidatedStatementsComprehensiveLoss" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637825430037055196" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_637825430037055196" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637825430037055196" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637825430037055196" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_637825430037055196" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637825430037055196" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_637825430037055196" order="1" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://astria.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637825430037055196" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637825430037055196" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637825430037055196" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637825430037055196" xlink:to="us-gaap_ProfitLoss_637825430037055196" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_GainLossOnWarrantInherited" xlink:label="atxs_GainLossOnWarrantInherited_637825430037055196" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637825430037055196" xlink:to="atxs_GainLossOnWarrantInherited_637825430037055196" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_NonCashPortionOfAcquiredResearchAndDevelopment" xlink:label="atxs_NonCashPortionOfAcquiredResearchAndDevelopment_637825430037055196" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637825430037055196" xlink:to="atxs_NonCashPortionOfAcquiredResearchAndDevelopment_637825430037055196" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_637825430037055196" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637825430037055196" xlink:to="us-gaap_OtherNoncashIncomeExpense_637825430037055196" order="4" use="optional" weight="-1" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637825430037065087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637825430037055196" xlink:to="us-gaap_ShareBasedCompensation_637825430037065087" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637825430037065087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637825430037055196" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637825430037065087" order="6" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_IncreaseDecreaseInRightOfUseAssetOperating" xlink:label="atxs_IncreaseDecreaseInRightOfUseAssetOperating_637825430037065087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637825430037055196" xlink:to="atxs_IncreaseDecreaseInRightOfUseAssetOperating_637825430037065087" order="7" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637825430037065087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637825430037055196" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637825430037065087" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637825430037065087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637825430037055196" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637825430037065087" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637825430037065087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637825430037065087" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637825430037065087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637825430037065087" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637825430037065087" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637825430037065087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637825430037065087" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637825430037065087" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ProceedsFromIssuanceOfAtMarketOffering" xlink:label="atxs_ProceedsFromIssuanceOfAtMarketOffering_637825430037065087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637825430037065087" xlink:to="atxs_ProceedsFromIssuanceOfAtMarketOffering_637825430037065087" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637825430037075090" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637825430037065087" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637825430037075090" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637825430037075090" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637825430037075090" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_637825430037075090" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637825430037075090" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_637825430037075090" order="1" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_637825430037075090" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637825430037075090" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_637825430037075090" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition_637825430037075090" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637825430037075090" xlink:to="us-gaap_CashAcquiredFromAcquisition_637825430037075090" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637825430037075090" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637825430037075090" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637825430037075090" order="4" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Polices - Cash and Cash Equivalents and Restricted Cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637146016367598930" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637825430037075090" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637146016367598930" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637825430037075090" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_637825430037085084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637146016367598930" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_637825430037085084" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Acquisition of Quellis - Net assets acquired based on their estimated fair values (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities" xlink:label="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_637825430037085084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_637825430037085084" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_637825430037085084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_637825430037085084" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_637825430037085084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_637825430037085084" order="3" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:label="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_637825430037085084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities" xlink:to="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_637825430037085084" order="4" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment" xlink:label="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment_637825430037085084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities" xlink:to="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment_637825430037085084" order="5" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://astria.com/role/DisclosureFinancialInstrumentsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Financial Instruments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_637146062458924571" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637825430037085084" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure_637146062458924571" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637825430037085084" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure_637825430037095085" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure_637146062458924571" xlink:to="us-gaap_InvestmentsFairValueDisclosure_637825430037095085" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://astria.com/role/DisclosureShortTermInvestmentsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Short-Term Investments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue_637825430037095085" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue_637825430037095085" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://astria.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637825430037095085" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637825430037095085" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AccruedContractedResearchCostsCurrent" xlink:label="atxs_AccruedContractedResearchCostsCurrent_637825430037095085" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="atxs_AccruedContractedResearchCostsCurrent_637825430037095085" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637825430037095085" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637825430037095085" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AccruedSeveranceCurrent" xlink:label="atxs_AccruedSeveranceCurrent_637825430037095085" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="atxs_AccruedSeveranceCurrent_637825430037095085" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637825430037095085" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637825430037095085" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://astria.com/role/DisclosureIncomeTaxesReconciliationDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Income Taxes - Reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637825430037095085" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637825430037095085" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_637825430037105085" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_637825430037105085" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_637825430037105085" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_637825430037105085" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637825430037105085" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637825430037105085" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637825430037105085" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637825430037105085" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637825430037105085" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637825430037105085" order="6" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637825430037105085" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637825430037105085" order="7" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>atxs-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/10/2022 9:03:25 PM-->
<!--Modified on: 3/10/2022 9:03:25 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://astria.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://astria.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails" roleURI="http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails" roleURI="http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureOrganizationAndOperationsJanuary2020FinancingDetails" roleURI="http://astria.com/role/DisclosureOrganizationAndOperationsJanuary2020FinancingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureOrganizationAndOperationsLiquidityDetails" roleURI="http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails" roleURI="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" roleURI="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" roleURI="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPreferredStockDiscountDetails" roleURI="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreferredStockDiscountDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureAcquisitionOfQuellisDetails" roleURI="http://astria.com/role/DisclosureAcquisitionOfQuellisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails" roleURI="http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureFinancialInstrumentsDetails" roleURI="http://astria.com/role/DisclosureFinancialInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureFinancialInstrumentsWarrantLiabilityDetails" roleURI="http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureFinancialInstrumentsFairValueOfWarrantsDetails" roleURI="http://astria.com/role/DisclosureFinancialInstrumentsFairValueOfWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureShortTermInvestmentsDetails" roleURI="http://astria.com/role/DisclosureShortTermInvestmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureStockholdersEquityPreferredStockDetails" roleURI="http://astria.com/role/DisclosureStockholdersEquityPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureStockholdersEquityCommonStockWarrantsDetails" roleURI="http://astria.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails" roleURI="http://astria.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureStockIncentivePlansSummaryOfPlansDetails" roleURI="http://astria.com/role/DisclosureStockIncentivePlansSummaryOfPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureStockIncentivePlansStockOptionActivityDetails" roleURI="http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureStockIncentivePlansStockBasedCompensationExpenseDetails" roleURI="http://astria.com/role/DisclosureStockIncentivePlansStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" roleURI="http://astria.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://astria.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://astria.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="atxs-20211231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:definitionLink xlink:role="http://astria.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_1" xlink:title="us-gaap_BusinessAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:title="us-gaap_BusinessAcquisitionAcquireeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BusinessAcquisitionAxis_1" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BusinessAcquisitionAxis_1 To us-gaap_BusinessAcquisitionAcquireeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralAxis" xlink:label="us-gaap_CollateralAxis_1" xlink:title="us-gaap_CollateralAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralDomain" xlink:label="us-gaap_CollateralDomain_1" xlink:title="us-gaap_CollateralDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CollateralAxis_1" xlink:to="us-gaap_CollateralDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CollateralAxis_1 To us-gaap_CollateralDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_1" xlink:title="us-gaap_FairValueByLiabilityClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByLiabilityClassAxis_1" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByLiabilityClassAxis_1 To us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_1" xlink:title="us-gaap_CashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis_1" xlink:title="us-gaap_InvestmentTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_1" xlink:title="us-gaap_InvestmentTypeCategorizationMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_InvestmentTypeAxis_1" xlink:to="us-gaap_InvestmentTypeCategorizationMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_InvestmentTypeAxis_1 To us-gaap_InvestmentTypeCategorizationMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis_1" xlink:title="us-gaap_TaxPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_1" xlink:title="us-gaap_TaxPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxPeriodAxis_1" xlink:to="us-gaap_TaxPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxPeriodAxis_1 To us-gaap_TaxPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_1" xlink:title="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_1" xlink:title="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_1" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_1 To srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_1" xlink:title="us-gaap_LeaseContractualTermAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_1" xlink:title="us-gaap_LeaseContractualTermDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LeaseContractualTermAxis_1" xlink:to="us-gaap_LeaseContractualTermDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LeaseContractualTermAxis_1 To us-gaap_LeaseContractualTermDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://astria.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SeriesXRedeemableConvertiblePreferredStockMember" xlink:label="atxs_SeriesXRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atxs_SeriesXRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonredeemablePreferredStockMember" xlink:label="us-gaap_NonredeemablePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonredeemablePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SeriesXRedeemableConvertiblePreferredStockMember" xlink:label="atxs_SeriesXRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atxs_SeriesXRedeemableConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SeriesXRedeemableConvertiblePreferredStockMember" xlink:label="atxs_SeriesXRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atxs_SeriesXRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings" xlink:label="atxs_StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="atxs_StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings" xlink:label="atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="atxs_StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings" xlink:to="atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_PreferredStockAccretionOfRedemptionDiscount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="extended" xlink:title="00405 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_PublicOfferingCommonStockAndWarrantsMember" xlink:label="atxs_PublicOfferingCommonStockAndWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atxs_PublicOfferingCommonStockAndWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AtMarketOfferingMember" xlink:label="atxs_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atxs_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Organization and Operations - Reverse Stock Split, Agreement and Plan of Merger (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember" xlink:label="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SeriesXRedeemableConvertiblePreferredStockMember" xlink:label="atxs_SeriesXRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atxs_SeriesXRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AgreementAndPlanOfMergerAbstract" xlink:label="atxs_AgreementAndPlanOfMergerAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atxs_AgreementAndPlanOfMergerAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="atxs_AgreementAndPlanOfMergerAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="atxs_AgreementAndPlanOfMergerAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues" xlink:label="atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="atxs_AgreementAndPlanOfMergerAbstract" xlink:to="atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_TemporaryEquityConversionValue" xlink:label="atxs_TemporaryEquityConversionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="atxs_AgreementAndPlanOfMergerAbstract" xlink:to="atxs_TemporaryEquityConversionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="atxs_AgreementAndPlanOfMergerAbstract" xlink:to="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="atxs_AgreementAndPlanOfMergerAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="atxs_AgreementAndPlanOfMergerAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails" xlink:type="extended" xlink:title="40102 - Disclosure - Organization and Operations - Stock Purchase Agreement and Series X Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SeriesXRedeemableConvertiblePreferredStockMember" xlink:label="atxs_SeriesXRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atxs_SeriesXRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember" xlink:label="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember" xlink:label="atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SharesIssuedInMergerMember" xlink:label="atxs_SharesIssuedInMergerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="atxs_SharesIssuedInMergerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SharesIssuedIn2021FinancingMember" xlink:label="atxs_SharesIssuedIn2021FinancingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="atxs_SharesIssuedIn2021FinancingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_WarrantsAssumedInMergerMember" xlink:label="atxs_WarrantsAssumedInMergerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="atxs_WarrantsAssumedInMergerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract" xlink:label="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodSharesNewIssues" xlink:label="atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract" xlink:to="atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodGrossValue" xlink:label="atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodGrossValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract" xlink:to="atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodGrossValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially" xlink:label="atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract" xlink:to="atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter" xlink:label="atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract" xlink:to="atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_StockIssuedDuringPeriodSharesIncreaseDecreaseDueToConversionOfPreferredSharesIntoCommonShares" xlink:label="atxs_StockIssuedDuringPeriodSharesIncreaseDecreaseDueToConversionOfPreferredSharesIntoCommonShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract" xlink:to="atxs_StockIssuedDuringPeriodSharesIncreaseDecreaseDueToConversionOfPreferredSharesIntoCommonShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/DisclosureOrganizationAndOperationsJanuary2020FinancingDetails" xlink:type="extended" xlink:title="40103 - Disclosure - Organization and Operations - January 2020 Financing (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_UnderwritingPublicOffering2020Member" xlink:label="atxs_UnderwritingPublicOffering2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atxs_UnderwritingPublicOffering2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_OppenheimerCo.IncMember" xlink:label="atxs_OppenheimerCo.IncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="atxs_OppenheimerCo.IncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_January2020FinancingAbstract" xlink:label="atxs_January2020FinancingAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atxs_January2020FinancingAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="atxs_January2020FinancingAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="atxs_January2020FinancingAbstract" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="atxs_January2020FinancingAbstract" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="atxs_January2020FinancingAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails" xlink:type="extended" xlink:title="40104 - Disclosure - Organization and Operations - Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_JefferiesMember" xlink:label="atxs_JefferiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="atxs_JefferiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AtMarketOfferingMember" xlink:label="atxs_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atxs_AtMarketOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_CommonStockSaleAgreementValue" xlink:label="atxs_CommonStockSaleAgreementValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atxs_CommonStockSaleAgreementValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_PercentageOfCommissionPaidToUnderwriterBasedOnProceedsFromOffering" xlink:label="atxs_PercentageOfCommissionPaidToUnderwriterBasedOnProceedsFromOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atxs_PercentageOfCommissionPaidToUnderwriterBasedOnProceedsFromOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings" xlink:label="atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_RemainingAvailableUnderCurrentSalesAgreement" xlink:label="atxs_RemainingAvailableUnderCurrentSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atxs_RemainingAvailableUnderCurrentSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Polices - Fair Value of Financial Instruments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SummaryOfSignificantAccountingPolicesTable" xlink:label="atxs_SummaryOfSignificantAccountingPolicesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="atxs_SummaryOfSignificantAccountingPolicesTable" xlink:to="us-gaap_InvestmentTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ReverseRepurchaseAgreementsMember" xlink:label="atxs_ReverseRepurchaseAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="atxs_ReverseRepurchaseAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralAxis" xlink:label="us-gaap_CollateralAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="atxs_SummaryOfSignificantAccountingPolicesTable" xlink:to="us-gaap_CollateralAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralDomain" xlink:label="us-gaap_CollateralDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralPledgedMember" xlink:label="us-gaap_CollateralPledgedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CollateralDomain" xlink:to="us-gaap_CollateralPledgedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="atxs_SummaryOfSignificantAccountingPolicesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SummaryOfSignificantAccountingPolicesLineItems" xlink:label="atxs_SummaryOfSignificantAccountingPolicesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="atxs_SummaryOfSignificantAccountingPolicesLineItems" xlink:to="atxs_SummaryOfSignificantAccountingPolicesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract" xlink:label="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="atxs_SummaryOfSignificantAccountingPolicesLineItems" xlink:to="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_PercentageOfInvestmentAmountToCollateralizedDepositsValue" xlink:label="atxs_PercentageOfInvestmentAmountToCollateralizedDepositsValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract" xlink:to="atxs_PercentageOfInvestmentAmountToCollateralizedDepositsValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" xlink:type="extended" xlink:title="40204 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SeriesXPreferredStockMember" xlink:label="atxs_SeriesXPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="atxs_SeriesXPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_CommonStockWarrantsMember" xlink:label="atxs_CommonStockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="atxs_CommonStockWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreferredStockDiscountDetails" xlink:type="extended" xlink:title="40206 - Disclosure - Summary of Significant Accounting Policies - Preferred Stock Discount (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SeriesXRedeemableConvertiblePreferredStockMember" xlink:label="atxs_SeriesXRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atxs_SeriesXRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_NonCashReturnRelatedToCommonStock" xlink:label="atxs_NonCashReturnRelatedToCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="atxs_NonCashReturnRelatedToCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/DisclosureAcquisitionOfQuellisDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Acquisition of Quellis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SeriesXRedeemableConvertiblePreferredStockMember" xlink:label="atxs_SeriesXRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atxs_SeriesXRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember" xlink:label="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember" xlink:label="atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues" xlink:label="atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities" xlink:label="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquisitionCosts" xlink:label="us-gaap_AcquisitionCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AcquisitionCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Acquisition of Quellis - Net assets acquired based on their estimated fair values (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember" xlink:label="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment" xlink:label="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:label="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities" xlink:label="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/DisclosureFinancialInstrumentsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Financial Instruments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ReverseRepurchaseAgreementsMember" xlink:label="atxs_ReverseRepurchaseAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="atxs_ReverseRepurchaseAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueNetAssetLiabilityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueNetAssetLiabilityAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueNetAssetLiabilityAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueNetAssetLiabilityAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Financial Instruments - Warrant liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember" xlink:label="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SeriesXRedeemableConvertiblePreferredStockMember" xlink:label="atxs_SeriesXRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atxs_SeriesXRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ReclassificationOfEquityClassifiedWarrants" xlink:label="atxs_ReclassificationOfEquityClassifiedWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="atxs_ReclassificationOfEquityClassifiedWarrants" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/DisclosureFinancialInstrumentsFairValueOfWarrantsDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Financial Instruments - Fair value of warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_WeightedAverageExpectedVolatilityMember" xlink:label="atxs_WeightedAverageExpectedVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="atxs_WeightedAverageExpectedVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/DisclosureShortTermInvestmentsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Short-Term Investments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="us-gaap_ScheduleOfInvestmentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ShortTermInvestmentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ReverseRepurchaseAgreementsMember" xlink:label="atxs_ReverseRepurchaseAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="atxs_ReverseRepurchaseAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfInvestmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/DisclosureStockholdersEquityPreferredStockDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Stockholders' Equity - Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SeriesXRedeemableConvertiblePreferredStockMember" xlink:label="atxs_SeriesXRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atxs_SeriesXRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_NumberOfPreferredStockSeries" xlink:label="atxs_NumberOfPreferredStockSeries" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="atxs_NumberOfPreferredStockSeries" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Stockholders' Equity - Common Stock Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_WarrantsIssuedIn2015Member" xlink:label="atxs_WarrantsIssuedIn2015Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="atxs_WarrantsIssuedIn2015Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_WarrantsIssuedIn2018Member" xlink:label="atxs_WarrantsIssuedIn2018Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="atxs_WarrantsIssuedIn2018Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_WarrantsIssuedIn2019Member" xlink:label="atxs_WarrantsIssuedIn2019Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="atxs_WarrantsIssuedIn2019Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_WarrantsIssuedIn2021Member" xlink:label="atxs_WarrantsIssuedIn2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="atxs_WarrantsIssuedIn2021Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_CommonStockWarrantsMember" xlink:label="atxs_CommonStockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atxs_CommonStockWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="atxs_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atxs_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Stockholders' Equity - Shares Reserved for Future Issuance (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SeriesXRedeemableConvertiblePreferredStockMember" xlink:label="atxs_SeriesXRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atxs_SeriesXRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember" xlink:label="atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_CommonStockOptionsOutstandingMember" xlink:label="atxs_CommonStockOptionsOutstandingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atxs_CommonStockOptionsOutstandingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_CommonStockOptionsReservedMember" xlink:label="atxs_CommonStockOptionsReservedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atxs_CommonStockOptionsReservedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_EmployeeStockPurchasePlan2015Member" xlink:label="atxs_EmployeeStockPurchasePlan2015Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atxs_EmployeeStockPurchasePlan2015Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/DisclosureStockIncentivePlansSummaryOfPlansDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Stock Incentive Plans - Summary of Plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Stock Incentive Plans - Stock option activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageExercisePrice" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/DisclosureStockIncentivePlansStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Stock Incentive Plans - Stock-Based Compensation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Income Taxes - Operating Loss Carryforwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_TaxYears2023Through2039Member" xlink:label="atxs_TaxYears2023Through2039Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="atxs_TaxYears2023Through2039Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_IndefiniteTaxYearsMember" xlink:label="atxs_IndefiniteTaxYearsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="atxs_IndefiniteTaxYearsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://astria.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingSubleaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingSubleaseDescriptionAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingSubleaseDescriptionAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LesseeOperatingSubleaseDescriptionAbstract" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>atxs-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/10/2022 9:03:25 PM-->
<!--Modified on: 3/10/2022 9:03:25 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SeriesXRedeemableConvertiblePreferredStockMember" xlink:label="atxs_SeriesXRedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_SeriesXRedeemableConvertiblePreferredStockMember" xlink:to="atxs_SeriesXRedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_SeriesXRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding redeemable convertible Series X preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_SeriesXRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series X redeemable convertible preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_SeriesXRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series X Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Investments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term portion of operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments (Note 7)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.001 par value per share, 150,000,000 shares authorized; 13,016,955 and 3,347,386 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonredeemablePreferredStockMember" xlink:label="us-gaap_NonredeemablePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonredeemablePreferredStockMember" xlink:to="us-gaap_NonredeemablePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonredeemablePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonredeemablePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, outstanding (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Par value of common stock (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, authorized (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, beginning of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, outstanding (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense (Excluding Acquired in Process Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development in Process</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired in-process research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest and investment income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expense, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts" xlink:label="atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts" xlink:to="atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of dividend on convertible preferred stock related to beneficial conversion feature and issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend On Convertible Preferred Stock Related To Beneficial Conversion Feature And Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend on convertible preferred stock related to beneficial conversion feature and issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash dividend on convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to common shareholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share - basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share - diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding used in net loss per share - basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding used in net loss per share - diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other comprehensive income:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deficit Accumulated</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Shareholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock, net of issuance costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings" xlink:label="atxs_StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings" xlink:to="atxs_StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity impact of the value of new stock issued in At-the-Market offerings during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues, At the Market Offerings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for at-the-market offerings, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings" xlink:label="atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings" xlink:to="atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new stock issued in At-the-Market offerings during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues, At the Market Offerings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for at-the-market offerings, net of issuance costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of preferred stock and common stock upon acquisition of Quellis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon acquisition of Quellis (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon acquisition of Quellis (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon the conversion of preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon the conversion of preferred stock (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common shares issued from conversion of Series X preferred shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value adjustment to acquired Quellis warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:to="us-gaap_PreferredStockAccretionOfRedemptionDiscount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Accretion of Redemption Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of preferred stock discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercises of options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercises of options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification of equity classified warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Reverse Stock Splits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fractional shares eliminated pursuant to reverse stock split</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_PublicOfferingCommonStockAndWarrantsMember" xlink:label="atxs_PublicOfferingCommonStockAndWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_PublicOfferingCommonStockAndWarrantsMember" xlink:to="atxs_PublicOfferingCommonStockAndWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_PublicOfferingCommonStockAndWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to a public offering of common stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_PublicOfferingCommonStockAndWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock and warrants in public offering</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AtMarketOfferingMember" xlink:label="atxs_AtMarketOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_AtMarketOfferingMember" xlink:to="atxs_AtMarketOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to At-the-Market Offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ATM</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_NonCashPortionOfAcquiredResearchAndDevelopment" xlink:label="atxs_NonCashPortionOfAcquiredResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_NonCashPortionOfAcquiredResearchAndDevelopment" xlink:to="atxs_NonCashPortionOfAcquiredResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_NonCashPortionOfAcquiredResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of non-cash portion of acquired IP R&amp;D.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_NonCashPortionOfAcquiredResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash Portion of Acquired Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_NonCashPortionOfAcquiredResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash portion of acquired in-process research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_GainLossOnWarrantInherited" xlink:label="atxs_GainLossOnWarrantInherited" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_GainLossOnWarrantInherited" xlink:to="atxs_GainLossOnWarrantInherited_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_GainLossOnWarrantInherited_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of gain (loss) on warrant inherited during acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_GainLossOnWarrantInherited_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain Loss On Warrant Inherited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_GainLossOnWarrantInherited_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net gain on warrants inherited in acquisiton of Quellis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Noncash Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-cash items</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_IncreaseDecreaseInRightOfUseAssetOperating" xlink:label="atxs_IncreaseDecreaseInRightOfUseAssetOperating" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_IncreaseDecreaseInRightOfUseAssetOperating" xlink:to="atxs_IncreaseDecreaseInRightOfUseAssetOperating_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_IncreaseDecreaseInRightOfUseAssetOperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the reporting period in the aggregate amount of right-of-use-asset-operating.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_IncreaseDecreaseInRightOfUseAssetOperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Right Of Use Asset Operating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_IncreaseDecreaseInRightOfUseAssetOperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use asset-operating</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale, Maturity and Collection of Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales and maturities of short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Acquired from Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash acquired in acquisition of Quellis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from underwritten public offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from issuance of private placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from private offering of public equity, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ProceedsFromIssuanceOfAtMarketOffering" xlink:label="atxs_ProceedsFromIssuanceOfAtMarketOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_ProceedsFromIssuanceOfAtMarketOffering" xlink:to="atxs_ProceedsFromIssuanceOfAtMarketOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_ProceedsFromIssuanceOfAtMarketOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow associated with the amount received from entity's At-the-market offering of stock to the public.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_ProceedsFromIssuanceOfAtMarketOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of At the Market Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_ProceedsFromIssuanceOfAtMarketOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from at-the-market offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of common stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of non-cash transactions:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Amount Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Series X Preferred Stock into common stock</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ReclassificationOfEquityClassifiedWarrants" xlink:label="atxs_ReclassificationOfEquityClassifiedWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_ReclassificationOfEquityClassifiedWarrants" xlink:to="atxs_ReclassificationOfEquityClassifiedWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_ReclassificationOfEquityClassifiedWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in additional paid in capital (APIC) resulting from reclassification of equity classified warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_ReclassificationOfEquityClassifiedWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification Of Equity Classified Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="atxs_ReclassificationOfEquityClassifiedWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification of warrant liability to additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atxs_ReclassificationOfEquityClassifiedWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification of warrant liability to additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition of Quellis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition of Quellis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ShortTermInvestmentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Investments</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ShortTermInvestmentsTextBlock" xlink:label="atxs_ShortTermInvestmentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_ShortTermInvestmentsTextBlock" xlink:to="atxs_ShortTermInvestmentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_ShortTermInvestmentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of the short-term investments. Short-term investments may include current marketable securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_ShortTermInvestmentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Investments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_ShortTermInvestmentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Incentive Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Incentive Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Benefit Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Benefit Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation and Principles of Consolidation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock" xlink:label="atxs_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock" xlink:to="atxs_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for off-balance sheet risk and concentrations of credit risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Off-Balance Sheet Risk and Concentrations of Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Off-Balance Sheet Risk and Concentrations of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents and Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In Process Research and Development, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired In-Process Research and Development</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_PreferredStockDiscountPolicyTextBlock" xlink:label="atxs_PreferredStockDiscountPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_PreferredStockDiscountPolicyTextBlock" xlink:to="atxs_PreferredStockDiscountPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_PreferredStockDiscountPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for preferred stock discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_PreferredStockDiscountPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Discount Policy Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_PreferredStockDiscountPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ScheduleOfPreferredStockOrWarrantsToPurchasePreferredStockTableTextBlock" xlink:label="atxs_ScheduleOfPreferredStockOrWarrantsToPurchasePreferredStockTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_ScheduleOfPreferredStockOrWarrantsToPurchasePreferredStockTableTextBlock" xlink:to="atxs_ScheduleOfPreferredStockOrWarrantsToPurchasePreferredStockTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_ScheduleOfPreferredStockOrWarrantsToPurchasePreferredStockTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure preferred stock or warrants to purchase preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_ScheduleOfPreferredStockOrWarrantsToPurchasePreferredStockTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Preferred Stock Or Warrants To Purchase Preferred Stock [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_ScheduleOfPreferredStockOrWarrantsToPurchasePreferredStockTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of common stock warrants outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restrictions on Cash and Cash Equivalents [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of anti-dilutive common stock equivalents excluded from calculation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of net assets acquired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of assets and liabilities measured fair value on recurring basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of warrant liability was valued based on significant inputs not observable in the market, which represents a Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value of the warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of short term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_CommonStockReservedForFutureIssuanceAbstract" xlink:label="atxs_CommonStockReservedForFutureIssuanceAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_CommonStockReservedForFutureIssuanceAbstract" xlink:to="atxs_CommonStockReservedForFutureIssuanceAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_CommonStockReservedForFutureIssuanceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_CommonStockReservedForFutureIssuanceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reserved for Future Issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of common stock reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Series X preferred stock or warrants to purchase</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of assumptions made based on the Black-Scholes option pricing model</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of U.S. statutory income tax rate to effective tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Acquiree [Domain]</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember" xlink:label="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember" xlink:to="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to acquisition of Quellis Biosciences, Inc, pursuant to agreement and plan of merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quellis Biosciences, Inc</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split ratio</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AgreementAndPlanOfMergerAbstract" xlink:label="atxs_AgreementAndPlanOfMergerAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_AgreementAndPlanOfMergerAbstract" xlink:to="atxs_AgreementAndPlanOfMergerAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_AgreementAndPlanOfMergerAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_AgreementAndPlanOfMergerAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement and Plan of Merger [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_AgreementAndPlanOfMergerAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement and Plan of Merger</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues" xlink:label="atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues" xlink:to="atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new shares classified as temporary equity issued in an acquisition during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued in an Acquisition, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of preferred stock upon acquisition of Quellis (in shares)</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_TemporaryEquityConversionValue" xlink:label="atxs_TemporaryEquityConversionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_TemporaryEquityConversionValue" xlink:to="atxs_TemporaryEquityConversionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_TemporaryEquityConversionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The conversion value of temporary equity shares on the merger closing date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_TemporaryEquityConversionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Conversion Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_TemporaryEquityConversionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion value on closing date</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross" xlink:to="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross number of share options (or share units) assumed in acquisition during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Assumed in Acquisition, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options assumed in Quellis Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumed in Quellis Acquisition (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares which may be purchased with warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase number of shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of warrants (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember" xlink:label="atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember" xlink:to="atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to stock purchase agreement with institutional and accredited investors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SharesIssuedInMergerMember" xlink:label="atxs_SharesIssuedInMergerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_SharesIssuedInMergerMember" xlink:to="atxs_SharesIssuedInMergerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_SharesIssuedInMergerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to shares issued in merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_SharesIssuedInMergerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued in merger</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SharesIssuedIn2021FinancingMember" xlink:label="atxs_SharesIssuedIn2021FinancingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_SharesIssuedIn2021FinancingMember" xlink:to="atxs_SharesIssuedIn2021FinancingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_SharesIssuedIn2021FinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to shares issued in 2020 financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_SharesIssuedIn2021FinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued in February 2021 Financing</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_WarrantsAssumedInMergerMember" xlink:label="atxs_WarrantsAssumedInMergerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_WarrantsAssumedInMergerMember" xlink:to="atxs_WarrantsAssumedInMergerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_WarrantsAssumedInMergerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to warrants assumed in merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_WarrantsAssumedInMergerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants assumed in merger</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract" xlink:label="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract" xlink:to="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Purchase Agreement and Series X Preferred Stock [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Purchase Agreement and Series X Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodSharesNewIssues" xlink:label="atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodSharesNewIssues" xlink:to="atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new shares classified as temporary equity issued in a private offering during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued in a Private Offering During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of preferred stock in a private offering of public equity, net of issuance costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodGrossValue" xlink:label="atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodGrossValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodGrossValue" xlink:to="atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodGrossValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodGrossValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross value of new stock classified as temporary equity issued in a private offering during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodGrossValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued In Private Offering During Period, Gross Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodGrossValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds from issuance of preferred stock in a private offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beneficial conversion feature</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series X Preferred Stock at Transaction Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series X redeemable convertible preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Convertible, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares of common stock into which each share of Series X Preferred Stock may be converted</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially" xlink:label="atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially" xlink:to="atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of beneficial ownership common stock issued and outstanding immediately after giving effect to such conversion initially considered for prohibiting from converting shares of Series X Preferred Stock into shares of the Company's common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Ownership on Common Stock Issued and Outstanding Immediately After Conversion, Initially</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, percentage of beneficial ownership initially, after conversion</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter" xlink:label="atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter" xlink:to="atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of beneficial ownership common stock issued and outstanding immediately after giving effect to such conversion thereafter considered for prohibiting from converting shares of Series X Preferred Stock into shares of the Company's common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Ownership on Common Stock Issued and Outstanding Immediately After Conversion, Thereafter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, percentage of beneficial ownership thereafter, after conversion</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_StockIssuedDuringPeriodSharesIncreaseDecreaseDueToConversionOfPreferredSharesIntoCommonShares" xlink:label="atxs_StockIssuedDuringPeriodSharesIncreaseDecreaseDueToConversionOfPreferredSharesIntoCommonShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_StockIssuedDuringPeriodSharesIncreaseDecreaseDueToConversionOfPreferredSharesIntoCommonShares" xlink:to="atxs_StockIssuedDuringPeriodSharesIncreaseDecreaseDueToConversionOfPreferredSharesIntoCommonShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_StockIssuedDuringPeriodSharesIncreaseDecreaseDueToConversionOfPreferredSharesIntoCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) in number of shares issued during the period upon the conversion of preferred shares into common shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_StockIssuedDuringPeriodSharesIncreaseDecreaseDueToConversionOfPreferredSharesIntoCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Increase (Decrease) Due to Conversion of Preferred Shares into Common Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_StockIssuedDuringPeriodSharesIncreaseDecreaseDueToConversionOfPreferredSharesIntoCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Series X preferred shares converted during period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common shares issuable upon conversion of preferred stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_UnderwritingPublicOffering2020Member" xlink:label="atxs_UnderwritingPublicOffering2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_UnderwritingPublicOffering2020Member" xlink:to="atxs_UnderwritingPublicOffering2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_UnderwritingPublicOffering2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents sale of stock by a underwritten public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_UnderwritingPublicOffering2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">January 2020 Financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_OppenheimerCo.IncMember" xlink:label="atxs_OppenheimerCo.IncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_OppenheimerCo.IncMember" xlink:to="atxs_OppenheimerCo.IncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_OppenheimerCo.IncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Oppenheimer &amp; Co. Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_OppenheimerCo.IncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Oppenheimer &amp; Co. Inc</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_January2020FinancingAbstract" xlink:label="atxs_January2020FinancingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_January2020FinancingAbstract" xlink:to="atxs_January2020FinancingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_January2020FinancingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_January2020FinancingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">January 2020 Financing [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_January2020FinancingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">January 2020 Financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds from sale of stock in public offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from public offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_JefferiesMember" xlink:label="atxs_JefferiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_JefferiesMember" xlink:to="atxs_JefferiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_JefferiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Jefferies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_JefferiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Jefferies</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_CommonStockSaleAgreementValue" xlink:label="atxs_CommonStockSaleAgreementValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_CommonStockSaleAgreementValue" xlink:to="atxs_CommonStockSaleAgreementValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_CommonStockSaleAgreementValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The aggregate value of common stock authorized to be issued under the terms of an open market sale agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_CommonStockSaleAgreementValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Sale Agreement, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_CommonStockSaleAgreementValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum aggregate value of common shares which can be issued under the agreement</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_PercentageOfCommissionPaidToUnderwriterBasedOnProceedsFromOffering" xlink:label="atxs_PercentageOfCommissionPaidToUnderwriterBasedOnProceedsFromOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_PercentageOfCommissionPaidToUnderwriterBasedOnProceedsFromOffering" xlink:to="atxs_PercentageOfCommissionPaidToUnderwriterBasedOnProceedsFromOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_PercentageOfCommissionPaidToUnderwriterBasedOnProceedsFromOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of commission paid to underwriters based on proceeds from offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_PercentageOfCommissionPaidToUnderwriterBasedOnProceedsFromOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Commission Paid to Underwriter based on Proceeds from Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_PercentageOfCommissionPaidToUnderwriterBasedOnProceedsFromOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of commission paid to underwriter based on proceeds from common stock</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_RemainingAvailableUnderCurrentSalesAgreement" xlink:label="atxs_RemainingAvailableUnderCurrentSalesAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_RemainingAvailableUnderCurrentSalesAgreement" xlink:to="atxs_RemainingAvailableUnderCurrentSalesAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_RemainingAvailableUnderCurrentSalesAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of remaining available under its current sales agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_RemainingAvailableUnderCurrentSalesAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining Available Under Current Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_RemainingAvailableUnderCurrentSalesAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining available under sales agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, and Short-term Investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restrictions on Cash and Cash Equivalents [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash and Cash Equivalents Items [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents and Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash And Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SummaryOfSignificantAccountingPolicesTable" xlink:label="atxs_SummaryOfSignificantAccountingPolicesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_SummaryOfSignificantAccountingPolicesTable" xlink:to="atxs_SummaryOfSignificantAccountingPolicesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_SummaryOfSignificantAccountingPolicesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of information about significant accounting policies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_SummaryOfSignificantAccountingPolicesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Polices [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments [Domain]</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ReverseRepurchaseAgreementsMember" xlink:label="atxs_ReverseRepurchaseAgreementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_ReverseRepurchaseAgreementsMember" xlink:to="atxs_ReverseRepurchaseAgreementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_ReverseRepurchaseAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments represented by an agreement between the entity and another party for the reverse repurchase transactions of identical or substantially the same securities at a date certain for a specified price. Such agreements are generally short-term in nature.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_ReverseRepurchaseAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse repurchase agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralAxis" xlink:label="us-gaap_CollateralAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollateralAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collateral Held [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralDomain" xlink:label="us-gaap_CollateralDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollateralDomain" xlink:to="us-gaap_CollateralDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollateralDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collateral Held [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralPledgedMember" xlink:label="us-gaap_CollateralPledgedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollateralPledgedMember" xlink:to="us-gaap_CollateralPledgedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollateralPledgedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Securities and Obligations</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SummaryOfSignificantAccountingPolicesLineItems" xlink:label="atxs_SummaryOfSignificantAccountingPolicesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_SummaryOfSignificantAccountingPolicesLineItems" xlink:to="atxs_SummaryOfSignificantAccountingPolicesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_SummaryOfSignificantAccountingPolicesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_SummaryOfSignificantAccountingPolicesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Polices [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract" xlink:label="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract" xlink:to="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Transfers Between Level 1 and Level 2, Description and Policy [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value assets, transfers from Level 1 to Level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value assets, transfers from Level 2 to Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value liabilities, transfers from Level 1 to Level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value liabilities, transfers from Level 2 to Level 1</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_PercentageOfInvestmentAmountToCollateralizedDepositsValue" xlink:label="atxs_PercentageOfInvestmentAmountToCollateralizedDepositsValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_PercentageOfInvestmentAmountToCollateralizedDepositsValue" xlink:to="atxs_PercentageOfInvestmentAmountToCollateralizedDepositsValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_PercentageOfInvestmentAmountToCollateralizedDepositsValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of investment in reverse repurchase agreements which are collateralized by deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_PercentageOfInvestmentAmountToCollateralizedDepositsValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Investment Amount To Collateralized Deposits Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_PercentageOfInvestmentAmountToCollateralizedDepositsValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of investment amount to collateralized deposits value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Incentive Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Tax Benefit from Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax benefits recognized from stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_CommonStockWarrantsMember" xlink:label="atxs_CommonStockWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_CommonStockWarrantsMember" xlink:to="atxs_CommonStockWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_CommonStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security that gives the holder the right to purchase shares of common stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_CommonStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock warrants</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SeriesXPreferredStockMember" xlink:label="atxs_SeriesXPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_SeriesXPreferredStockMember" xlink:to="atxs_SeriesXPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_SeriesXPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to series X preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_SeriesXPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series X Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_SeriesXPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series X Preferred Stock (1)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive common stock equivalents excluded from computation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_NonCashReturnRelatedToCommonStock" xlink:label="atxs_NonCashReturnRelatedToCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_NonCashReturnRelatedToCommonStock" xlink:to="atxs_NonCashReturnRelatedToCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_NonCashReturnRelatedToCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of Non Cash Return Related To Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_NonCashReturnRelatedToCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Cash Return Related To Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_NonCashReturnRelatedToCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non cash return</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition of Quellis</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities" xlink:label="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities" xlink:to="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount recognized as of the acquisition date for the identifiable assets acquired other than intangible assets in excess of (less than) the aggregate liabilities assumed other than deferred tax liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other than Intangible Assets And Deferred Tax Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost to acquire the assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net acquired tangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquisitionCosts" xlink:label="us-gaap_AcquisitionCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquisitionCosts" xlink:to="us-gaap_AcquisitionCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquisitionCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition Costs, Period Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AcquisitionCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition costs</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment" xlink:label="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment" xlink:to="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Acquired Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Acquired Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired IPR&amp;D</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:label="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:to="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of accrued liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Hierarchy [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiabilityAbstract" xlink:to="us-gaap_FairValueNetAssetLiabilityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Net Asset (Liability) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of assets measured at fair value on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative warrant liability was valued based on significant inputs not observable in the market, which represents a Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of warrant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Decrease) increase in the fair value of the warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_WeightedAverageExpectedVolatilityMember" xlink:label="atxs_WeightedAverageExpectedVolatilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_WeightedAverageExpectedVolatilityMember" xlink:to="atxs_WeightedAverageExpectedVolatilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_WeightedAverageExpectedVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Weighted-average expected volatility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_WeightedAverageExpectedVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and rights outstanding, measurement input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="us-gaap_ScheduleOfInvestmentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_ScheduleOfInvestmentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInvestmentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Investments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfInvestmentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Investments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale and Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale and Held-to-Maturity, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of short term investments in unrealized loss position</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Related Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AccruedContractedResearchCostsCurrent" xlink:label="atxs_AccruedContractedResearchCostsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_AccruedContractedResearchCostsCurrent" xlink:to="atxs_AccruedContractedResearchCostsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_AccruedContractedResearchCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date for contracted research costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_AccruedContractedResearchCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Contracted Research Costs, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_AccruedContractedResearchCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued contracted costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued professional fees</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AccruedSeveranceCurrent" xlink:label="atxs_AccruedSeveranceCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_AccruedSeveranceCurrent" xlink:to="atxs_AccruedSeveranceCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_AccruedSeveranceCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for severance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_AccruedSeveranceCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Severance, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_AccruedSeveranceCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued severance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Description [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated incremental borrowing rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future minimum payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Number of Shares, Par Value and Other Disclosures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_NumberOfPreferredStockSeries" xlink:label="atxs_NumberOfPreferredStockSeries" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_NumberOfPreferredStockSeries" xlink:to="atxs_NumberOfPreferredStockSeries_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_NumberOfPreferredStockSeries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of series that may be used to issue preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_NumberOfPreferredStockSeries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Preferred Stock Series</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_NumberOfPreferredStockSeries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum number of series used to issue preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_WarrantsIssuedIn2015Member" xlink:label="atxs_WarrantsIssuedIn2015Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_WarrantsIssuedIn2015Member" xlink:to="atxs_WarrantsIssuedIn2015Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_WarrantsIssuedIn2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to warrants issued in 2015.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_WarrantsIssuedIn2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Issued in 2015</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_WarrantsIssuedIn2018Member" xlink:label="atxs_WarrantsIssuedIn2018Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_WarrantsIssuedIn2018Member" xlink:to="atxs_WarrantsIssuedIn2018Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_WarrantsIssuedIn2018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to warrants issued in 2018.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_WarrantsIssuedIn2018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Issued in 2018</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_WarrantsIssuedIn2019Member" xlink:label="atxs_WarrantsIssuedIn2019Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_WarrantsIssuedIn2019Member" xlink:to="atxs_WarrantsIssuedIn2019Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_WarrantsIssuedIn2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to warrants issued in 2019.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_WarrantsIssuedIn2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Issued in 2019</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_WarrantsIssuedIn2021Member" xlink:label="atxs_WarrantsIssuedIn2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_WarrantsIssuedIn2021Member" xlink:to="atxs_WarrantsIssuedIn2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_WarrantsIssuedIn2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to warrants issued in 2021.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_WarrantsIssuedIn2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Issued In 2021</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_WeightedAverageMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="atxs_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="atxs_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual life of warrant, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants And Rights Outstanding Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atxs_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average life (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember" xlink:label="atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember" xlink:to="atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to shares reserved for warrants issued for the purchase of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants for the purchase of common Stock</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_CommonStockOptionsOutstandingMember" xlink:label="atxs_CommonStockOptionsOutstandingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_CommonStockOptionsOutstandingMember" xlink:to="atxs_CommonStockOptionsOutstandingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_CommonStockOptionsOutstandingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to the options outstanding to purchase common stock that has been reserved for future issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_CommonStockOptionsOutstandingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options outstanding to purchase common Stock</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_CommonStockOptionsReservedMember" xlink:label="atxs_CommonStockOptionsReservedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_CommonStockOptionsReservedMember" xlink:to="atxs_CommonStockOptionsReservedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_CommonStockOptionsReservedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to the options reserved to purchase common stock that has been reserved for future issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_CommonStockOptionsReservedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options available for future issuance to purchase common stock</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_EmployeeStockPurchasePlan2015Member" xlink:label="atxs_EmployeeStockPurchasePlan2015Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_EmployeeStockPurchasePlan2015Member" xlink:to="atxs_EmployeeStockPurchasePlan2015Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_EmployeeStockPurchasePlan2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the 2015 Employee Stock Purchase Plan ("2015 ESPP").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_EmployeeStockPurchasePlan2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares reserved for the employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cliff period for vesting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, beginning of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled or forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expired (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and exercisable (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of year (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, beginning of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageExercisePrice" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageExercisePrice" xlink:to="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise per share of share options assumed in acquisition during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Assumed in Acquisition, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumed in Quellis Acquisition (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled or forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expired (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and Exercisable (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and Exercisable</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award Options Outstanding Aggregate Intrinsic Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional disclosures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intrinsic value of options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value of options granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense related to unvested stock option awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average amortization period over which cost is expected to be recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumptions used to calculate fair value of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of the U.S. statutory income tax rate to the Company's effective tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal income tax (benefit) at statutory rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Deduction, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal research and development credits and adjustments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nondeductible research costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State income tax, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation Other Adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, General Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal Settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized legal expenses</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_DeferredTaxAssetsLeaseLiability" xlink:label="atxs_DeferredTaxAssetsLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_DeferredTaxAssetsLeaseLiability" xlink:to="atxs_DeferredTaxAssetsLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount, before allocation of valuation allowance, of deferred tax asset attributable to lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atxs_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="atxs_DeferredTaxLiabilitiesRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="atxs_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax liability attributable to right of use asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Right of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="atxs_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ROU asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Period [Domain]</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_TaxYears2023Through2039Member" xlink:label="atxs_TaxYears2023Through2039Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_TaxYears2023Through2039Member" xlink:to="atxs_TaxYears2023Through2039Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_TaxYears2023Through2039Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Identified as tax years 2023 through 2039.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_TaxYears2023Through2039Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Years 2023 through 2039</label>
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_IndefiniteTaxYearsMember" xlink:label="atxs_IndefiniteTaxYearsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atxs_IndefiniteTaxYearsMember" xlink:to="atxs_IndefiniteTaxYearsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atxs_IndefiniteTaxYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No expiration date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atxs_IndefiniteTaxYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No expiration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingSubleaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingSubleaseDescriptionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingSubleaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingSubleaseDescriptionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingSubleaseDescriptionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Sublease, Description [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingSubleaseDescriptionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sublease</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>atxs-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/10/2022 9:03:25 PM-->
<!--Modified on: 3/10/2022 9:03:25 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://astria.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://astria.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://astria.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://astria.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#StatementConsolidatedStatementsComprehensiveLoss" roleURI="http://astria.com/role/StatementConsolidatedStatementsComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://astria.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureOrganizationAndOperations" roleURI="http://astria.com/role/DisclosureOrganizationAndOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureAcquisitionOfQuellis" roleURI="http://astria.com/role/DisclosureAcquisitionOfQuellis" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureFinancialInstruments" roleURI="http://astria.com/role/DisclosureFinancialInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureShortTermInvestments" roleURI="http://astria.com/role/DisclosureShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureAccruedExpenses" roleURI="http://astria.com/role/DisclosureAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureCommitments" roleURI="http://astria.com/role/DisclosureCommitments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureStockholdersEquity" roleURI="http://astria.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureStockIncentivePlans" roleURI="http://astria.com/role/DisclosureStockIncentivePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureIncomeTaxes" roleURI="http://astria.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureDefinedContributionBenefitPlan" roleURI="http://astria.com/role/DisclosureDefinedContributionBenefitPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureSubsequentEvents" roleURI="http://astria.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureSummaryOfSignificantAccountingPolicesPolices" roleURI="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureOrganizationAndOperationsTables" roleURI="http://astria.com/role/DisclosureOrganizationAndOperationsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureAcquisitionOfQuellisTables" roleURI="http://astria.com/role/DisclosureAcquisitionOfQuellisTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureFinancialInstrumentsTables" roleURI="http://astria.com/role/DisclosureFinancialInstrumentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureShortTermInvestmentsTables" roleURI="http://astria.com/role/DisclosureShortTermInvestmentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureAccruedExpensesTables" roleURI="http://astria.com/role/DisclosureAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureStockholdersEquityTables" roleURI="http://astria.com/role/DisclosureStockholdersEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureStockIncentivePlansTables" roleURI="http://astria.com/role/DisclosureStockIncentivePlansTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureIncomeTaxesTables" roleURI="http://astria.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails" roleURI="http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails" roleURI="http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureOrganizationAndOperationsJanuary2020FinancingDetails" roleURI="http://astria.com/role/DisclosureOrganizationAndOperationsJanuary2020FinancingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureOrganizationAndOperationsLiquidityDetails" roleURI="http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureSummaryOfSignificantAccountingPolicesCashAndCashEquivalentsAndRestrictedCashDetails" roleURI="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesCashAndCashEquivalentsAndRestrictedCashDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails" roleURI="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" roleURI="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" roleURI="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" roleURI="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPreferredStockDiscountDetails" roleURI="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreferredStockDiscountDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureAcquisitionOfQuellisDetails" roleURI="http://astria.com/role/DisclosureAcquisitionOfQuellisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails" roleURI="http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureFinancialInstrumentsDetails" roleURI="http://astria.com/role/DisclosureFinancialInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureFinancialInstrumentsWarrantLiabilityDetails" roleURI="http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureFinancialInstrumentsFairValueOfWarrantsDetails" roleURI="http://astria.com/role/DisclosureFinancialInstrumentsFairValueOfWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureShortTermInvestmentsDetails" roleURI="http://astria.com/role/DisclosureShortTermInvestmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://astria.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureCommitmentsDetails" roleURI="http://astria.com/role/DisclosureCommitmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureStockholdersEquityPreferredStockDetails" roleURI="http://astria.com/role/DisclosureStockholdersEquityPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureStockholdersEquityCommonStockWarrantsDetails" roleURI="http://astria.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureStockholdersEquityCommonStockDetails" roleURI="http://astria.com/role/DisclosureStockholdersEquityCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails" roleURI="http://astria.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureStockIncentivePlansSummaryOfPlansDetails" roleURI="http://astria.com/role/DisclosureStockIncentivePlansSummaryOfPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureStockIncentivePlansStockOptionActivityDetails" roleURI="http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureStockIncentivePlansStockBasedCompensationExpenseDetails" roleURI="http://astria.com/role/DisclosureStockIncentivePlansStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureIncomeTaxesReconciliationDetails" roleURI="http://astria.com/role/DisclosureIncomeTaxesReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureIncomeTaxesDeferredTaxAssetsDetails" roleURI="http://astria.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" roleURI="http://astria.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="atxs-20211231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://astria.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://astria.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637825430037775594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637825430037775594" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637825430037775594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_637825430037775594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637825430037785569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637825430037785569" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637825430037785569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637825430037785569" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637825430037785569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637825430037785569" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637825430037785569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637825430037785569" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637825430037785569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637825430037785569" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637825430037785569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637825430037785569" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637825430037785569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637825430037785569" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637825430037785569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637825430037785569" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637825430037785569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_637825430037785569" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637825430037785569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637825430037785569" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637825430037785569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637825430037785569" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637825430037785569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637825430037785569" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637825430037785569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637825430037785569" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637825430037795289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637825430037795289" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637825430037795289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637825430037795289" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637825430037795289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637825430037795289" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637825430037795289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637825430037795289" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637825430037795289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_637825430037795289" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637825430037795289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_637825430037795289" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637825430037795289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637825430037795289" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637825430037795289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637825430037795289" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637825430037795289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637825430037795289" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637825430037795289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637825430037795289" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637825430037795289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637825430037795289" order="26" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637825430037805478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637825430037805478" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637825430037805478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637825430037805478" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_637825430037805478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_637825430037805478" order="29" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637825430037805478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637825430037805478" order="30" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637825430037805478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637825430037805478" order="31" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637825430037805478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637825430037805478" order="32" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637825430037805478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637825430037805478" order="33" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_637825430037805478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_637825430037805478" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName_637825430037805478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_637825430037805478" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_637825430037815501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_637825430037815501" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_637825430037815501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_637825430037815501" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637825430037815501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_637825430037815501" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637825430037815501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637825430037815501" xlink:to="us-gaap_StatementClassOfStockAxis_637825430037815501" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637825430037815501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637825430037815501" xlink:to="us-gaap_ClassOfStockDomain_637825430037815501" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SeriesXRedeemableConvertiblePreferredStockMember" xlink:label="atxs_SeriesXRedeemableConvertiblePreferredStockMember_637825430037815501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637825430037815501" xlink:to="atxs_SeriesXRedeemableConvertiblePreferredStockMember_637825430037815501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637825430037815501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637825430037815501" xlink:to="us-gaap_StatementLineItems_637825430037815501" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637825430037815501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637825430037815501" xlink:to="us-gaap_AssetsAbstract_637825430037815501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637825430037815501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637825430037815501" xlink:to="us-gaap_AssetsCurrentAbstract_637825430037815501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637825430037815501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637825430037815501" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637825430037815501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_637825430037825517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637825430037815501" xlink:to="us-gaap_ShortTermInvestments_637825430037825517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637825430037825517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637825430037815501" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637825430037825517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637825430037825517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637825430037815501" xlink:to="us-gaap_AssetsCurrent_637825430037825517" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637825430037825517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637825430037815501" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637825430037825517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637825430037825517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637825430037815501" xlink:to="us-gaap_OtherAssetsNoncurrent_637825430037825517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637825430037825517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637825430037815501" xlink:to="us-gaap_Assets_637825430037825517" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637825430037825517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637825430037815501" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637825430037825517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637825430037825517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637825430037825517" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637825430037825517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637825430037825517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637825430037825517" xlink:to="us-gaap_AccountsPayableCurrent_637825430037825517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637825430037825517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637825430037825517" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637825430037825517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637825430037825517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637825430037825517" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637825430037825517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637825430037825517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637825430037825517" xlink:to="us-gaap_LiabilitiesCurrent_637825430037825517" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637825430037835465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637825430037825517" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637825430037835465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637825430037835465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637825430037825517" xlink:to="us-gaap_Liabilities_637825430037835465" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637825430037835465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637825430037825517" xlink:to="us-gaap_CommitmentsAndContingencies_637825430037835465" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637825430037835465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637825430037825517" xlink:to="us-gaap_StockholdersEquityAbstract_637825430037835465" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637825430037835465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637825430037835465" xlink:to="us-gaap_PreferredStockValue_637825430037835465" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637825430037835465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637825430037835465" xlink:to="us-gaap_CommonStockValue_637825430037835465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637825430037835465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637825430037835465" xlink:to="us-gaap_AdditionalPaidInCapital_637825430037835465" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637825430037835465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637825430037835465" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637825430037835465" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637825430037835465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637825430037835465" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637825430037835465" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637825430037835465" xlink:to="us-gaap_StockholdersEquity_637825430037845469" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637825430037825517" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637825430037845469" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_637825430037845469" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637825430037845469" xlink:to="us-gaap_StatementClassOfStockAxis_637825430037845469" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637825430037845469" xlink:to="us-gaap_ClassOfStockDomain_637825430037845469" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonredeemablePreferredStockMember" xlink:label="us-gaap_NonredeemablePreferredStockMember_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637825430037845469" xlink:to="us-gaap_NonredeemablePreferredStockMember_637825430037845469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SeriesXRedeemableConvertiblePreferredStockMember" xlink:label="atxs_SeriesXRedeemableConvertiblePreferredStockMember_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637825430037845469" xlink:to="atxs_SeriesXRedeemableConvertiblePreferredStockMember_637825430037845469" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637825430037845469" xlink:to="us-gaap_StatementLineItems_637825430037845469" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637825430037845469" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637825430037845469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637825430037845469" xlink:to="us-gaap_PreferredStockSharesAuthorized_637825430037845469" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637825430037845469" xlink:to="us-gaap_PreferredStockSharesIssued_637825430037845469" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637825430037845469" xlink:to="us-gaap_PreferredStockSharesOutstanding_637825430037845469" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637825430037845469" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637825430037845469" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637825430037845469" xlink:to="us-gaap_CommonStockSharesAuthorized_637825430037845469" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637825430037845469" xlink:to="us-gaap_CommonStockSharesIssued_637825430037845469" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637825430037845469" xlink:to="us-gaap_CommonStockSharesOutstanding_637825430037845469" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_637825430037845469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637825430037845469" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_637825430037845469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637825430037845469" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637825430037845469" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637825430037845469" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_637825430037845469" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637825430037845469" xlink:to="us-gaap_OperatingExpenses_637825430037845469" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_637825430037845469" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_637825430037845469" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637825430037845469" xlink:to="us-gaap_InvestmentIncomeInterest_637825430037845469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637825430037845469" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637825430037845469" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637825430037845469" xlink:to="us-gaap_NonoperatingIncomeExpense_637825430037845469" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_637825430037845469" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts" xlink:label="atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts_637825430037845469" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637825430037845469" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_637825430037845469" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_637825430037845469" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637825430037845469" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637825430037845469" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/StatementConsolidatedStatementsComprehensiveLoss" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss_637825430037845469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_637825430037845469" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_637825430037845469" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_637825430037845469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_637825430037845469" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637825430037845469" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_637825430037845469" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637825430037845469" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637825430037845469" xlink:to="us-gaap_StatementEquityComponentsAxis_637825430037845469" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637825430037845469" xlink:to="us-gaap_PreferredStockMember_637825430037845469" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637825430037845469" xlink:to="us-gaap_CommonStockMember_637825430037845469" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637825430037845469" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637825430037845469" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637825430037845469" xlink:to="us-gaap_RetainedEarningsMember_637825430037845469" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637825430037845469" xlink:to="us-gaap_EquityComponentDomain_637825430037845469" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637825430037845469" xlink:to="us-gaap_StatementClassOfStockAxis_637825430037845469" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SeriesXRedeemableConvertiblePreferredStockMember" xlink:label="atxs_SeriesXRedeemableConvertiblePreferredStockMember_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637825430037845469" xlink:to="atxs_SeriesXRedeemableConvertiblePreferredStockMember_637825430037845469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637825430037845469" xlink:to="us-gaap_ClassOfStockDomain_637825430037845469" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637825430037845469" xlink:to="us-gaap_StatementLineItems_637825430037845469" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637825430037845469" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637825430037845469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637825430037845469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637825430037845469" xlink:to="us-gaap_StockholdersEquity_637825430037845469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637825430037902364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637825430037845469" xlink:to="us-gaap_CommonStockSharesIssued_637825430037902364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637825430037903466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637825430037845469" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637825430037903466" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637825430037904131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_637825430037903466" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637825430037904131" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings" xlink:label="atxs_StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings_637825430037905095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637825430037845469" xlink:to="atxs_StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings_637825430037905095" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings" xlink:label="atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings_637825430037905095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings_637825430037905095" xlink:to="atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings_637825430037905095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_637825430037905095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637825430037845469" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_637825430037905095" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_637825430037905095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions_637825430037905095" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_637825430037905095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637825430037905095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637825430037845469" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637825430037905095" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637825430037905095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637825430037905095" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637825430037905095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_637825430037905095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637825430037845469" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_637825430037905095" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount_637825430037905095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637825430037845469" xlink:to="us-gaap_PreferredStockAccretionOfRedemptionDiscount_637825430037905095" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637825430037905095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637825430037845469" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637825430037905095" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637825430037905095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637825430037845469" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637825430037905095" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_637825430037905095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637825430037845469" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_637825430037905095" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_637825430037915486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637825430037845469" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_637825430037915486" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637825430037915486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637825430037845469" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637825430037915486" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637825430037915486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637825430037845469" xlink:to="us-gaap_NetIncomeLoss_637825430037915486" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637825430037915486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637825430037845469" xlink:to="us-gaap_StockholdersEquity_637825430037915486" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637825430037915486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637825430037845469" xlink:to="us-gaap_CommonStockSharesIssued_637825430037915486" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="extended" xlink:title="00405 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637825430037915486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637825430037915486" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637825430037915486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637825430037915486" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637825430037915486" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637825430037915486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637825430037915486" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637825430037915486" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_PublicOfferingCommonStockAndWarrantsMember" xlink:label="atxs_PublicOfferingCommonStockAndWarrantsMember_637825430037925476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637825430037915486" xlink:to="atxs_PublicOfferingCommonStockAndWarrantsMember_637825430037925476" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AtMarketOfferingMember" xlink:label="atxs_AtMarketOfferingMember_637825430037925476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637825430037915486" xlink:to="atxs_AtMarketOfferingMember_637825430037925476" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637825430037925476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637825430037915486" xlink:to="us-gaap_StatementLineItems_637825430037925476" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637825430037925476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637825430037925476" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637825430037925476" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637825430037925476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637825430037925476" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637825430037925476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637825430037925476" xlink:to="us-gaap_ProfitLoss_637825430037925476" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637825430037925476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637825430037925476" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637825430037925476" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_NonCashPortionOfAcquiredResearchAndDevelopment" xlink:label="atxs_NonCashPortionOfAcquiredResearchAndDevelopment_637825430037925476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637825430037925476" xlink:to="atxs_NonCashPortionOfAcquiredResearchAndDevelopment_637825430037925476" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637825430037925476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637825430037925476" xlink:to="us-gaap_ShareBasedCompensation_637825430037925476" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_GainLossOnWarrantInherited" xlink:label="atxs_GainLossOnWarrantInherited_637825430037925476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637825430037925476" xlink:to="atxs_GainLossOnWarrantInherited_637825430037925476" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_637825430037925476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637825430037925476" xlink:to="us-gaap_OtherNoncashIncomeExpense_637825430037925476" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637825430037925476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637825430037925476" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637825430037925476" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637825430037925476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637825430037925476" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637825430037925476" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_IncreaseDecreaseInRightOfUseAssetOperating" xlink:label="atxs_IncreaseDecreaseInRightOfUseAssetOperating_637825430037935485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637825430037925476" xlink:to="atxs_IncreaseDecreaseInRightOfUseAssetOperating_637825430037935485" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637825430037935485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637825430037925476" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637825430037935485" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637825430037935485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637825430037925476" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637825430037935485" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637825430037935485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637825430037925476" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637825430037935485" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637825430037935485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637825430037935485" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_637825430037935485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637825430037935485" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_637825430037935485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_637825430037935485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637825430037935485" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_637825430037935485" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition_637825430037935485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637825430037935485" xlink:to="us-gaap_CashAcquiredFromAcquisition_637825430037935485" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637825430037935485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637825430037935485" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637825430037935485" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637825430037935485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637825430037935485" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637825430037935485" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637825430037935485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637825430037935485" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637825430037945587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637825430037935485" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637825430037945587" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637825430037945587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637825430037935485" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637825430037945587" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ProceedsFromIssuanceOfAtMarketOffering" xlink:label="atxs_ProceedsFromIssuanceOfAtMarketOffering_637825430037945587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637825430037935485" xlink:to="atxs_ProceedsFromIssuanceOfAtMarketOffering_637825430037945587" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637825430037945587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637825430037935485" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637825430037945587" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637825430037945587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637825430037935485" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637825430037945587" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637825430037945587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637825430037945587" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637825430037945587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637825430037945587" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378254300379455871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378254300379455871" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_637825430037945587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_637825430037945587" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1_637825430037945587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637825430037945587" xlink:to="us-gaap_ConversionOfStockAmountConverted1_637825430037945587" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts" xlink:label="atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts_637825430037955465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637825430037945587" xlink:to="atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts_637825430037955465" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ReclassificationOfEquityClassifiedWarrants" xlink:label="atxs_ReclassificationOfEquityClassifiedWarrants_637825430037955465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637825430037945587" xlink:to="atxs_ReclassificationOfEquityClassifiedWarrants_637825430037955465" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureOrganizationAndOperations" xlink:type="extended" xlink:title="10101 - Disclosure - Organization and Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_637825430038005482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_637825430038005482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637825430038005482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637825430038005482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureAcquisitionOfQuellis" xlink:type="extended" xlink:title="10301 - Disclosure - Acquisition of Quellis" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_637825430038005482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract_1" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_637825430038005482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureFinancialInstruments" xlink:type="extended" xlink:title="10401 - Disclosure - Financial Instruments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637825430038005482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637825430038005482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureShortTermInvestments" xlink:type="extended" xlink:title="10501 - Disclosure - Short-Term Investments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ShortTermInvestmentsTextBlock" xlink:label="atxs_ShortTermInvestmentsTextBlock_637825430038015147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="atxs_ShortTermInvestmentsTextBlock_637825430038015147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="10601 - Disclosure - Accrued Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_637825430038015147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_637825430038015147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureCommitments" xlink:type="extended" xlink:title="10701 - Disclosure - Commitments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637825430038015147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637825430038015147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10801 - Disclosure - Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock_637825430038015147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_PreferredStockTextBlock_637825430038015147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureStockIncentivePlans" xlink:type="extended" xlink:title="10901 - Disclosure - Stock Incentive Plans" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637146178117517641" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637825430038015147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637146178117517641" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637825430038015147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11001 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637825430038015147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637825430038015147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureDefinedContributionBenefitPlan" xlink:type="extended" xlink:title="11101 - Disclosure - Defined Contribution Benefit Plan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_637825430038025511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_637825430038025511" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11201 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637825430038025511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_637825430038025511" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Polices (Polices)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637825430038025511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637825430038025511" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637825430038025511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_637825430038025511" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock" xlink:label="atxs_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock_637825430038025511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="atxs_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock_637825430038025511" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_637825430038025511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_637825430038025511" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock_637825430038025511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock_637825430038025511" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_637825430038025511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_637825430038025511" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637825430038025511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637825430038025511" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637825430038025511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637825430038025511" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637825430038025511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637825430038025511" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637825430038025511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637825430038025511" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637825430038025511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637825430038025511" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_637825430038035461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_637825430038035461" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_637825430038035461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_637825430038035461" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_637825430038035461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_637825430038035461" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_637825430038035461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_637825430038035461" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_PreferredStockDiscountPolicyTextBlock" xlink:label="atxs_PreferredStockDiscountPolicyTextBlock_637825430038035461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="atxs_PreferredStockDiscountPolicyTextBlock_637825430038035461" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637825430038035461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637825430038035461" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureOrganizationAndOperationsTables" xlink:type="extended" xlink:title="30103 - Disclosure - Organization and Operations (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ScheduleOfPreferredStockOrWarrantsToPurchasePreferredStockTableTextBlock" xlink:label="atxs_ScheduleOfPreferredStockOrWarrantsToPurchasePreferredStockTableTextBlock_637825430038035461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="atxs_ScheduleOfPreferredStockOrWarrantsToPurchasePreferredStockTableTextBlock_637825430038035461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Summary of Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_637825430038035461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_637825430038035461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637825430038045516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637825430038045516" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637825430038045516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637825430038045516" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureAcquisitionOfQuellisTables" xlink:type="extended" xlink:title="30303 - Disclosure - Acquisition of Quellis (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_637825430038045516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract_2" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_637825430038045516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureFinancialInstrumentsTables" xlink:type="extended" xlink:title="30403 - Disclosure - Financial Instruments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_635728554159523084" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_637825430038045516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_635728554159523084" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_637825430038045516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_637825430038045516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_635728554159523084" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_637825430038045516" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637825430038045516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_635728554159523084" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637825430038045516" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureShortTermInvestmentsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Short-Term Investments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock_637825430038045516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock_637825430038045516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="30603 - Disclosure - Accrued Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637825430038045516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637825430038045516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30803 - Disclosure - Stockholders' Equity (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_CommonStockReservedForFutureIssuanceAbstract" xlink:label="atxs_CommonStockReservedForFutureIssuanceAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_637825430038055498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_CommonStockReservedForFutureIssuanceAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock_637825430038055498" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_637825430038055498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_CommonStockReservedForFutureIssuanceAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_637825430038055498" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureStockIncentivePlansTables" xlink:type="extended" xlink:title="30903 - Disclosure - Stock Incentive Plans (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637825430038055498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637825430038055498" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637825430038055498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637825430038055498" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31003 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637825430038065644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637825430038065644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637825430038065644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637825430038065644" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Organization and Operations - Reverse Stock Split, Agreement and Plan of Merger (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_637825430038065644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_637825430038065644" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637825430038065644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637825430038065644" xlink:to="us-gaap_BusinessAcquisitionAxis_637825430038065644" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637825430038065644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637825430038065644" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637825430038065644" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember" xlink:label="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_637825430038065644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637825430038065644" xlink:to="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_637825430038065644" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637825430038075585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637825430038065644" xlink:to="us-gaap_StatementEquityComponentsAxis_637825430038075585" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637825430038075585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637825430038075585" xlink:to="us-gaap_EquityComponentDomain_637825430038075585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637825430038075585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637825430038075585" xlink:to="us-gaap_CommonStockMember_637825430038075585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637825430038075585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637825430038065644" xlink:to="us-gaap_StatementClassOfStockAxis_637825430038075585" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637825430038075585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637825430038075585" xlink:to="us-gaap_ClassOfStockDomain_637825430038075585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SeriesXRedeemableConvertiblePreferredStockMember" xlink:label="atxs_SeriesXRedeemableConvertiblePreferredStockMember_637825430038075585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637825430038075585" xlink:to="atxs_SeriesXRedeemableConvertiblePreferredStockMember_637825430038075585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_637825430038075585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637825430038065644" xlink:to="us-gaap_ClassOfStockLineItems_637825430038075585" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_637825430038075585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637825430038075585" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_637825430038075585" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AgreementAndPlanOfMergerAbstract" xlink:label="atxs_AgreementAndPlanOfMergerAbstract_637825430038075585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637825430038075585" xlink:to="atxs_AgreementAndPlanOfMergerAbstract_637825430038075585" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_637825430038075585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_AgreementAndPlanOfMergerAbstract_637825430038075585" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_637825430038075585" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637825430038075585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_AgreementAndPlanOfMergerAbstract_637825430038075585" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637825430038075585" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues" xlink:label="atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues_637825430038075585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_AgreementAndPlanOfMergerAbstract_637825430038075585" xlink:to="atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues_637825430038075585" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_TemporaryEquityConversionValue" xlink:label="atxs_TemporaryEquityConversionValue_637825430038085504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_AgreementAndPlanOfMergerAbstract_637825430038075585" xlink:to="atxs_TemporaryEquityConversionValue_637825430038085504" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross_637825430038085504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_AgreementAndPlanOfMergerAbstract_637825430038075585" xlink:to="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross_637825430038085504" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637825430038085504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_AgreementAndPlanOfMergerAbstract_637825430038075585" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637825430038085504" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637825430038085504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_AgreementAndPlanOfMergerAbstract_637825430038075585" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637825430038085504" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails" xlink:type="extended" xlink:title="40102 - Disclosure - Organization and Operations - Stock Purchase Agreement and Series X Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_637825430038085504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_637825430038085504" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637825430038085504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637825430038085504" xlink:to="us-gaap_StatementClassOfStockAxis_637825430038085504" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637825430038095800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637825430038085504" xlink:to="us-gaap_ClassOfStockDomain_637825430038095800" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SeriesXRedeemableConvertiblePreferredStockMember" xlink:label="atxs_SeriesXRedeemableConvertiblePreferredStockMember_637825430038095800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637825430038095800" xlink:to="atxs_SeriesXRedeemableConvertiblePreferredStockMember_637825430038095800" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637825430038095800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637825430038085504" xlink:to="us-gaap_BusinessAcquisitionAxis_637825430038095800" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637825430038095800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637825430038095800" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637825430038095800" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember" xlink:label="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_637825430038095800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637825430038095800" xlink:to="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_637825430038095800" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637825430038095800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637825430038085504" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637825430038095800" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637825430038095800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637825430038095800" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637825430038095800" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember" xlink:label="atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember_637825430038095800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637825430038095800" xlink:to="atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember_637825430038095800" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637825430038095800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637825430038085504" xlink:to="srt_StatementScenarioAxis_637825430038095800" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637825430038095800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637825430038095800" xlink:to="srt_ScenarioUnspecifiedDomain_637825430038095800" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SharesIssuedInMergerMember" xlink:label="atxs_SharesIssuedInMergerMember_637825430038095800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637825430038095800" xlink:to="atxs_SharesIssuedInMergerMember_637825430038095800" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SharesIssuedIn2021FinancingMember" xlink:label="atxs_SharesIssuedIn2021FinancingMember_637825430038095800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637825430038095800" xlink:to="atxs_SharesIssuedIn2021FinancingMember_637825430038095800" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_WarrantsAssumedInMergerMember" xlink:label="atxs_WarrantsAssumedInMergerMember_637825430038095800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637825430038095800" xlink:to="atxs_WarrantsAssumedInMergerMember_637825430038095800" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637825430038105507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637825430038085504" xlink:to="srt_RangeAxis_637825430038105507" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637825430038105507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637825430038105507" xlink:to="srt_RangeMember_637825430038105507" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637825430038105507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637825430038105507" xlink:to="srt_MinimumMember_637825430038105507" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637825430038105507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637825430038105507" xlink:to="srt_MaximumMember_637825430038105507" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_637825430038105507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637825430038085504" xlink:to="us-gaap_ClassOfStockLineItems_637825430038105507" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract" xlink:label="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract_637825430038105507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637825430038105507" xlink:to="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract_637825430038105507" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodSharesNewIssues" xlink:label="atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodSharesNewIssues_637825430038105507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract_637825430038105507" xlink:to="atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodSharesNewIssues_637825430038105507" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodGrossValue" xlink:label="atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodGrossValue_637825430038105507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract_637825430038105507" xlink:to="atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodGrossValue_637825430038105507" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637825430038105507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract_637825430038105507" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637825430038105507" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_637825430038105507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract_637825430038105507" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_637825430038105507" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637825430038105507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract_637825430038105507" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637825430038105507" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637825430038115507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract_637825430038105507" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637825430038115507" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_637825430038115507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract_637825430038105507" xlink:to="us-gaap_TemporaryEquitySharesIssued_637825430038115507" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_637825430038115507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract_637825430038105507" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_637825430038115507" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially" xlink:label="atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially_637825430038115507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract_637825430038105507" xlink:to="atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially_637825430038115507" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter" xlink:label="atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter_637825430038115507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract_637825430038105507" xlink:to="atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter_637825430038115507" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_StockIssuedDuringPeriodSharesIncreaseDecreaseDueToConversionOfPreferredSharesIntoCommonShares" xlink:label="atxs_StockIssuedDuringPeriodSharesIncreaseDecreaseDueToConversionOfPreferredSharesIntoCommonShares_637825430038115507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract_637825430038105507" xlink:to="atxs_StockIssuedDuringPeriodSharesIncreaseDecreaseDueToConversionOfPreferredSharesIntoCommonShares_637825430038115507" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637825430038115507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract_637825430038105507" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637825430038115507" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637825430038115507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract_637825430038105507" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637825430038115507" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637825430038125521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract_637825430038105507" xlink:to="us-gaap_PreferredStockSharesOutstanding_637825430038125521" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureOrganizationAndOperationsJanuary2020FinancingDetails" xlink:type="extended" xlink:title="40103 - Disclosure - Organization and Operations - January 2020 Financing (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_637825430038125521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_637825430038125521" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637825430038125521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637825430038125521" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637825430038125521" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637825430038125521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637825430038125521" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637825430038125521" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_UnderwritingPublicOffering2020Member" xlink:label="atxs_UnderwritingPublicOffering2020Member_637825430038125521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637825430038125521" xlink:to="atxs_UnderwritingPublicOffering2020Member_637825430038125521" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637825430038125521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637825430038125521" xlink:to="srt_CounterpartyNameAxis_637825430038125521" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637825430038125521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637825430038125521" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637825430038125521" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_OppenheimerCo.IncMember" xlink:label="atxs_OppenheimerCo.IncMember_637825430038125521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637825430038125521" xlink:to="atxs_OppenheimerCo.IncMember_637825430038125521" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637825430038125521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637825430038125521" xlink:to="us-gaap_StatementEquityComponentsAxis_637825430038125521" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637825430038135479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637825430038125521" xlink:to="us-gaap_EquityComponentDomain_637825430038135479" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637825430038135479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637825430038135479" xlink:to="us-gaap_CommonStockMember_637825430038135479" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_637825430038135479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637825430038125521" xlink:to="us-gaap_ClassOfStockLineItems_637825430038135479" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_January2020FinancingAbstract" xlink:label="atxs_January2020FinancingAbstract_637825430038135479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637825430038135479" xlink:to="atxs_January2020FinancingAbstract_637825430038135479" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637825430038135479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_January2020FinancingAbstract_637825430038135479" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637825430038135479" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637825430038135479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_January2020FinancingAbstract_637825430038135479" xlink:to="us-gaap_SharesIssuedPricePerShare_637825430038135479" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_637825430038135479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_January2020FinancingAbstract_637825430038135479" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_637825430038135479" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637825430038135479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_January2020FinancingAbstract_637825430038135479" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637825430038135479" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails" xlink:type="extended" xlink:title="40104 - Disclosure - Organization and Operations - Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_637544317721104493" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_637825430038135479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_637544317721104493" xlink:to="us-gaap_ScheduleOfStockByClassTable_637825430038135479" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637825430038135479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637825430038135479" xlink:to="us-gaap_StatementEquityComponentsAxis_637825430038135479" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637825430038145509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637825430038135479" xlink:to="us-gaap_EquityComponentDomain_637825430038145509" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637825430038145509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637825430038145509" xlink:to="us-gaap_CommonStockMember_637825430038145509" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637825430038145509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637825430038135479" xlink:to="srt_CounterpartyNameAxis_637825430038145509" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637825430038145509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637825430038145509" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637825430038145509" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_JefferiesMember" xlink:label="atxs_JefferiesMember_637825430038145509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637825430038145509" xlink:to="atxs_JefferiesMember_637825430038145509" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637825430038145509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637825430038135479" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637825430038145509" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637825430038145509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637825430038145509" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637825430038145509" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AtMarketOfferingMember" xlink:label="atxs_AtMarketOfferingMember_637825430038145509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637825430038145509" xlink:to="atxs_AtMarketOfferingMember_637825430038145509" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_637825430038145509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637825430038135479" xlink:to="us-gaap_ClassOfStockLineItems_637825430038145509" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_CommonStockSaleAgreementValue" xlink:label="atxs_CommonStockSaleAgreementValue_637825430038145509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637825430038145509" xlink:to="atxs_CommonStockSaleAgreementValue_637825430038145509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_PercentageOfCommissionPaidToUnderwriterBasedOnProceedsFromOffering" xlink:label="atxs_PercentageOfCommissionPaidToUnderwriterBasedOnProceedsFromOffering_637825430038145509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637825430038145509" xlink:to="atxs_PercentageOfCommissionPaidToUnderwriterBasedOnProceedsFromOffering_637825430038145509" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings" xlink:label="atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings_637825430038145509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637825430038145509" xlink:to="atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings_637825430038145509" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_RemainingAvailableUnderCurrentSalesAgreement" xlink:label="atxs_RemainingAvailableUnderCurrentSalesAgreement_637825430038145509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637825430038145509" xlink:to="atxs_RemainingAvailableUnderCurrentSalesAgreement_637825430038145509" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637825430038145509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637825430038145509" xlink:to="us-gaap_SharesIssuedPricePerShare_637825430038145509" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637825430038155473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637825430038145509" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637825430038155473" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637825430038155473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637825430038145509" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637825430038155473" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_637825430038155473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637825430038145509" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_637825430038155473" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Polices - Cash and Cash Equivalents and Restricted Cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637146016366736481" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637825430038155473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637146016366736481" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637825430038155473" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_637825430038155473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637146016366736481" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_637825430038155473" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637825430038155473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637146016366736481" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637825430038155473" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Polices - Fair Value of Financial Instruments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637146017813345805" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SummaryOfSignificantAccountingPolicesTable" xlink:label="atxs_SummaryOfSignificantAccountingPolicesTable_637825430038155473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637146017813345805" xlink:to="atxs_SummaryOfSignificantAccountingPolicesTable_637825430038155473" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis_637825430038165585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_SummaryOfSignificantAccountingPolicesTable_637825430038155473" xlink:to="us-gaap_InvestmentTypeAxis_637825430038165585" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_637825430038165585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis_637825430038165585" xlink:to="us-gaap_InvestmentTypeCategorizationMember_637825430038165585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ReverseRepurchaseAgreementsMember" xlink:label="atxs_ReverseRepurchaseAgreementsMember_637825430038165585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_637825430038165585" xlink:to="atxs_ReverseRepurchaseAgreementsMember_637825430038165585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralAxis" xlink:label="us-gaap_CollateralAxis_637825430038165585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_SummaryOfSignificantAccountingPolicesTable_637825430038155473" xlink:to="us-gaap_CollateralAxis_637825430038165585" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralDomain" xlink:label="us-gaap_CollateralDomain_637825430038165585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollateralAxis_637825430038165585" xlink:to="us-gaap_CollateralDomain_637825430038165585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralPledgedMember" xlink:label="us-gaap_CollateralPledgedMember_637825430038165585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollateralDomain_637825430038165585" xlink:to="us-gaap_CollateralPledgedMember_637825430038165585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637825430038165585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_SummaryOfSignificantAccountingPolicesTable_637825430038155473" xlink:to="srt_RangeAxis_637825430038165585" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637825430038165585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637825430038165585" xlink:to="srt_RangeMember_637825430038165585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637825430038165585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637825430038165585" xlink:to="srt_MinimumMember_637825430038165585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SummaryOfSignificantAccountingPolicesLineItems" xlink:label="atxs_SummaryOfSignificantAccountingPolicesLineItems_637825430038165585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_SummaryOfSignificantAccountingPolicesTable_637825430038155473" xlink:to="atxs_SummaryOfSignificantAccountingPolicesLineItems_637825430038165585" order="4" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract" xlink:label="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract_637825430038165585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_SummaryOfSignificantAccountingPolicesLineItems_637825430038165585" xlink:to="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract_637825430038165585" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_637825430038165585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract_637825430038165585" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_637825430038165585" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_637825430038165585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract_637825430038165585" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_637825430038165585" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_637825430038175505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract_637825430038165585" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_637825430038175505" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_637825430038175505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract_637825430038165585" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_637825430038175505" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_PercentageOfInvestmentAmountToCollateralizedDepositsValue" xlink:label="atxs_PercentageOfInvestmentAmountToCollateralizedDepositsValue_637825430038175505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract_637825430038165585" xlink:to="atxs_PercentageOfInvestmentAmountToCollateralizedDepositsValue_637825430038175505" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637825430038175505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637825430038175505" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637825430038175505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637825430038175505" xlink:to="us-gaap_IncomeStatementLocationAxis_637825430038175505" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637825430038175505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637825430038175505" xlink:to="us-gaap_IncomeStatementLocationDomain_637825430038175505" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637825430038175505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637825430038175505" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637825430038175505" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637825430038175505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637825430038175505" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637825430038175505" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637825430038175505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637825430038175505" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637825430038175505" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637825430038175505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637825430038175505" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637825430038175505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_637825430038185558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637825430038175505" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_637825430038185558" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" xlink:type="extended" xlink:title="40204 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637825430038185558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637825430038185558" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637825430038185558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637825430038185558" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637825430038185558" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637825430038185558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637825430038185558" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637825430038185558" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637825430038185558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637825430038185558" xlink:to="us-gaap_EmployeeStockOptionMember_637825430038185558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_CommonStockWarrantsMember" xlink:label="atxs_CommonStockWarrantsMember_637825430038185558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637825430038185558" xlink:to="atxs_CommonStockWarrantsMember_637825430038185558" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SeriesXPreferredStockMember" xlink:label="atxs_SeriesXPreferredStockMember_637825430038185558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637825430038185558" xlink:to="atxs_SeriesXPreferredStockMember_637825430038185558" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637825430038185558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637825430038185558" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637825430038185558" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637825430038185558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637825430038185558" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637825430038185558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended" xlink:title="40205 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_637825430038195517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments_637825430038195517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreferredStockDiscountDetails" xlink:type="extended" xlink:title="40206 - Disclosure - Summary of Significant Accounting Policies - Preferred Stock Discount (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637825430038195517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637825430038195517" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637825430038195517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637825430038195517" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637825430038195517" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637825430038195517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637825430038195517" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637825430038195517" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_637825430038195517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637825430038195517" xlink:to="us-gaap_PrivatePlacementMember_637825430038195517" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637825430038195517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637825430038195517" xlink:to="us-gaap_StatementClassOfStockAxis_637825430038195517" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637825430038195517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637825430038195517" xlink:to="us-gaap_ClassOfStockDomain_637825430038195517" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SeriesXRedeemableConvertiblePreferredStockMember" xlink:label="atxs_SeriesXRedeemableConvertiblePreferredStockMember_637825430038195517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637825430038195517" xlink:to="atxs_SeriesXRedeemableConvertiblePreferredStockMember_637825430038195517" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637825430038195517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637825430038195517" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637825430038195517" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_637825430038195517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637825430038195517" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_637825430038195517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637825430038195517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637825430038195517" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637825430038195517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_NonCashReturnRelatedToCommonStock" xlink:label="atxs_NonCashReturnRelatedToCommonStock_637825430038195517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637825430038195517" xlink:to="atxs_NonCashReturnRelatedToCommonStock_637825430038195517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1_637825430038195517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637825430038195517" xlink:to="us-gaap_ConversionOfStockAmountConverted1_637825430038195517" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureAcquisitionOfQuellisDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Acquisition of Quellis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637825430038205486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637825430038205486" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637825430038205486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637825430038205486" xlink:to="us-gaap_StatementClassOfStockAxis_637825430038205486" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637825430038205486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637825430038205486" xlink:to="us-gaap_ClassOfStockDomain_637825430038205486" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SeriesXRedeemableConvertiblePreferredStockMember" xlink:label="atxs_SeriesXRedeemableConvertiblePreferredStockMember_637825430038205486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637825430038205486" xlink:to="atxs_SeriesXRedeemableConvertiblePreferredStockMember_637825430038205486" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637825430038205486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637825430038205486" xlink:to="us-gaap_BusinessAcquisitionAxis_637825430038205486" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637825430038205486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637825430038205486" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637825430038205486" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember" xlink:label="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_637825430038205486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637825430038205486" xlink:to="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_637825430038205486" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637825430038205486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637825430038205486" xlink:to="us-gaap_StatementEquityComponentsAxis_637825430038205486" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637825430038205486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637825430038205486" xlink:to="us-gaap_EquityComponentDomain_637825430038205486" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637825430038205486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637825430038205486" xlink:to="us-gaap_CommonStockMember_637825430038205486" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637825430038215563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637825430038205486" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637825430038215563" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637825430038215563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637825430038215563" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637825430038215563" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember" xlink:label="atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember_637825430038215563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637825430038215563" xlink:to="atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember_637825430038215563" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_637825430038215563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637825430038205486" xlink:to="us-gaap_BusinessAcquisitionLineItems_637825430038215563" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_637825430038215563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637825430038215563" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_637825430038215563" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues" xlink:label="atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues_637825430038215563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637825430038215563" xlink:to="atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues_637825430038215563" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_637825430038215563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637825430038215563" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_637825430038215563" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities" xlink:label="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities_637825430038215563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637825430038215563" xlink:to="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities_637825430038215563" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquisitionCosts" xlink:label="us-gaap_AcquisitionCosts_637825430038215563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637825430038215563" xlink:to="us-gaap_AcquisitionCosts_637825430038215563" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Acquisition of Quellis - Net assets acquired based on their estimated fair values (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637825430038215563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637825430038215563" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637825430038225503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637825430038215563" xlink:to="us-gaap_BusinessAcquisitionAxis_637825430038225503" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637825430038225503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637825430038225503" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637825430038225503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember" xlink:label="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_637825430038225503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637825430038225503" xlink:to="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_637825430038225503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_637825430038225503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637825430038215563" xlink:to="us-gaap_BusinessAcquisitionLineItems_637825430038225503" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment" xlink:label="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment_637825430038225503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637825430038225503" xlink:to="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment_637825430038225503" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_637825430038225503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637825430038225503" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_637825430038225503" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_637825430038225503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637825430038225503" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_637825430038225503" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_637825430038225503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637825430038225503" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_637825430038225503" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:label="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_637825430038225503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637825430038225503" xlink:to="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_637825430038225503" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities" xlink:label="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities_637825430038225503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637825430038225503" xlink:to="atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities_637825430038225503" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureFinancialInstrumentsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Financial Instruments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_637146062457901596" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637825430038225503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_637146062457901596" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637825430038225503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_637825430038225503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637825430038225503" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_637825430038225503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637825430038225503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_637825430038225503" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637825430038225503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_637825430038235476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_637825430038225503" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_637825430038235476" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_637825430038235476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637825430038225503" xlink:to="us-gaap_FinancialInstrumentAxis_637825430038235476" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637825430038235476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_637825430038235476" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637825430038235476" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_637825430038235476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637825430038235476" xlink:to="us-gaap_MoneyMarketFundsMember_637825430038235476" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ReverseRepurchaseAgreementsMember" xlink:label="atxs_ReverseRepurchaseAgreementsMember_637825430038235476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637825430038235476" xlink:to="atxs_ReverseRepurchaseAgreementsMember_637825430038235476" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637825430038235476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637825430038225503" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637825430038235476" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637825430038235476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637825430038235476" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637825430038235476" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_637825430038235476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637825430038235476" xlink:to="us-gaap_FairValueInputsLevel1Member_637825430038235476" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_637825430038235476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637825430038235476" xlink:to="us-gaap_FairValueInputsLevel2Member_637825430038235476" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637825430038235476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637825430038225503" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637825430038235476" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract_637825430038235476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637825430038235476" xlink:to="us-gaap_FairValueNetAssetLiabilityAbstract_637825430038235476" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637825430038235476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetAssetLiabilityAbstract_637825430038235476" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637825430038235476" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure_637825430038235476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetAssetLiabilityAbstract_637825430038235476" xlink:to="us-gaap_InvestmentsFairValueDisclosure_637825430038235476" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_637825430038235476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetAssetLiabilityAbstract_637825430038235476" xlink:to="us-gaap_AssetsFairValueDisclosure_637825430038235476" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Financial Instruments - Warrant liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_637825430038245502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_637825430038245502" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637825430038245502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_637825430038245502" xlink:to="us-gaap_BusinessAcquisitionAxis_637825430038245502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637825430038245502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637825430038245502" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637825430038245502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember" xlink:label="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_637825430038245502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637825430038245502" xlink:to="atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_637825430038245502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637825430038245502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_637825430038245502" xlink:to="us-gaap_StatementEquityComponentsAxis_637825430038245502" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637825430038245502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637825430038245502" xlink:to="us-gaap_EquityComponentDomain_637825430038245502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637825430038245502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637825430038245502" xlink:to="us-gaap_CommonStockMember_637825430038245502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637825430038245502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_637825430038245502" xlink:to="us-gaap_StatementClassOfStockAxis_637825430038245502" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637825430038245502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637825430038245502" xlink:to="us-gaap_ClassOfStockDomain_637825430038245502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SeriesXRedeemableConvertiblePreferredStockMember" xlink:label="atxs_SeriesXRedeemableConvertiblePreferredStockMember_637825430038245502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637825430038245502" xlink:to="atxs_SeriesXRedeemableConvertiblePreferredStockMember_637825430038245502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_637825430038245502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_637825430038245502" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_637825430038245502" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637825430038245502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_637825430038245502" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637825430038245502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637825430038255478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_637825430038245502" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637825430038255478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_637825430038255478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_637825430038245502" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_637825430038255478" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_637825430038255478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_637825430038255478" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_637825430038255478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_637825430038255478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_637825430038255478" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_637825430038255478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_637825430038255478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_637825430038255478" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_637825430038255478" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ReclassificationOfEquityClassifiedWarrants" xlink:label="atxs_ReclassificationOfEquityClassifiedWarrants_637825430038255478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_637825430038255478" xlink:to="atxs_ReclassificationOfEquityClassifiedWarrants_637825430038255478" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6378254300382554781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_637825430038255478" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6378254300382554781" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureFinancialInstrumentsFairValueOfWarrantsDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Financial Instruments - Fair value of warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637825430038265583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637825430038265583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_637825430038265583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637825430038265583" xlink:to="us-gaap_MeasurementInputTypeAxis_637825430038265583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637825430038265583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_637825430038265583" xlink:to="us-gaap_MeasurementInputTypeDomain_637825430038265583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_WeightedAverageExpectedVolatilityMember" xlink:label="atxs_WeightedAverageExpectedVolatilityMember_637825430038265583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637825430038265583" xlink:to="atxs_WeightedAverageExpectedVolatilityMember_637825430038265583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_637825430038265583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637825430038265583" xlink:to="us-gaap_MeasurementInputExpectedTermMember_637825430038265583" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_637825430038265583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637825430038265583" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_637825430038265583" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_637825430038265583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637825430038265583" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_637825430038265583" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637825430038265583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637825430038265583" xlink:to="srt_RangeAxis_637825430038265583" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637825430038265583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637825430038265583" xlink:to="srt_RangeMember_637825430038265583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637825430038265583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637825430038265583" xlink:to="srt_MinimumMember_637825430038265583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637825430038265583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637825430038265583" xlink:to="srt_MaximumMember_637825430038265583" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637825430038265583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637825430038265583" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637825430038265583" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_637825430038265583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637825430038265583" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_637825430038265583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureShortTermInvestmentsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Short-Term Investments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="us-gaap_ScheduleOfInvestmentsTable_637825430038275584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfInvestmentsTable_637825430038275584" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_637825430038275584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable_637825430038275584" xlink:to="us-gaap_FinancialInstrumentAxis_637825430038275584" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637825430038275584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_637825430038275584" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637825430038275584" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember_637825430038275584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637825430038275584" xlink:to="us-gaap_ShortTermInvestmentsMember_637825430038275584" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ReverseRepurchaseAgreementsMember" xlink:label="atxs_ReverseRepurchaseAgreementsMember_637825430038275584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsMember_637825430038275584" xlink:to="atxs_ReverseRepurchaseAgreementsMember_637825430038275584" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems_637825430038275584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable_637825430038275584" xlink:to="us-gaap_ScheduleOfInvestmentsLineItems_637825430038275584" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss_637825430038275584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems_637825430038275584" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss_637825430038275584" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue_637825430038275584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems_637825430038275584" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue_637825430038275584" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_637825430038275584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems_637825430038275584" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_637825430038275584" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637825430038275584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637825430038275584" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AccruedContractedResearchCostsCurrent" xlink:label="atxs_AccruedContractedResearchCostsCurrent_637825430038285480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="atxs_AccruedContractedResearchCostsCurrent_637825430038285480" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637825430038285480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637825430038285480" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637825430038285480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637825430038285480" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_AccruedSeveranceCurrent" xlink:label="atxs_AccruedSeveranceCurrent_637825430038285480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="atxs_AccruedSeveranceCurrent_637825430038285480" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637825430038285480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637825430038285480" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureCommitmentsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Commitments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_635748989977006451" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_637825430038285480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_635748989977006451" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_637825430038285480" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637825430038285480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_637825430038285480" xlink:to="us-gaap_OperatingLeaseLiability_637825430038285480" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637825430038285480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_637825430038285480" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637825430038285480" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637825430038285480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_637825430038285480" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637825430038285480" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637825430038285480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_637825430038285480" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637825430038285480" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_637825430038285480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_637825430038285480" xlink:to="us-gaap_OperatingLeaseExpense_637825430038285480" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_637825430038285480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_637825430038285480" xlink:to="us-gaap_OperatingLeasePayments_637825430038285480" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureStockholdersEquityPreferredStockDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Stockholders' Equity - Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_637825430038295573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_637825430038295573" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637825430038295573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637825430038295573" xlink:to="us-gaap_StatementClassOfStockAxis_637825430038295573" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637825430038295573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637825430038295573" xlink:to="us-gaap_ClassOfStockDomain_637825430038295573" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SeriesXRedeemableConvertiblePreferredStockMember" xlink:label="atxs_SeriesXRedeemableConvertiblePreferredStockMember_637825430038295573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637825430038295573" xlink:to="atxs_SeriesXRedeemableConvertiblePreferredStockMember_637825430038295573" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_637825430038295573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637825430038295573" xlink:to="us-gaap_ClassOfStockLineItems_637825430038295573" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_637825430038295573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637825430038295573" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_637825430038295573" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637825430038295573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_637825430038295573" xlink:to="us-gaap_PreferredStockSharesAuthorized_637825430038295573" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637825430038295573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_637825430038295573" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637825430038295573" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637825430038295573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_637825430038295573" xlink:to="us-gaap_PreferredStockSharesIssued_637825430038295573" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637825430038295573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_637825430038295573" xlink:to="us-gaap_PreferredStockSharesOutstanding_637825430038295573" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_NumberOfPreferredStockSeries" xlink:label="atxs_NumberOfPreferredStockSeries_637825430038295573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_637825430038295573" xlink:to="atxs_NumberOfPreferredStockSeries_637825430038295573" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_637825430038295573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_637825430038295573" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_637825430038295573" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637825430038295573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_637825430038295573" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637825430038295573" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Stockholders' Equity - Common Stock Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_637825430038305526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_637825430038305526" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637825430038305526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_637825430038305526" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637825430038305526" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637825430038305526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637825430038305526" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637825430038305526" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_WarrantsIssuedIn2015Member" xlink:label="atxs_WarrantsIssuedIn2015Member_637825430038305526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637825430038305526" xlink:to="atxs_WarrantsIssuedIn2015Member_637825430038305526" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_WarrantsIssuedIn2018Member" xlink:label="atxs_WarrantsIssuedIn2018Member_637825430038305526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637825430038305526" xlink:to="atxs_WarrantsIssuedIn2018Member_637825430038305526" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_WarrantsIssuedIn2019Member" xlink:label="atxs_WarrantsIssuedIn2019Member_637825430038305526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637825430038305526" xlink:to="atxs_WarrantsIssuedIn2019Member_637825430038305526" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_WarrantsIssuedIn2021Member" xlink:label="atxs_WarrantsIssuedIn2021Member_637825430038305526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637825430038305526" xlink:to="atxs_WarrantsIssuedIn2021Member_637825430038305526" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637825430038305526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_637825430038305526" xlink:to="us-gaap_StatementClassOfStockAxis_637825430038305526" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637825430038305526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637825430038305526" xlink:to="us-gaap_ClassOfStockDomain_637825430038305526" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_CommonStockWarrantsMember" xlink:label="atxs_CommonStockWarrantsMember_637825430038305526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637825430038305526" xlink:to="atxs_CommonStockWarrantsMember_637825430038305526" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637825430038305526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_637825430038305526" xlink:to="srt_RangeAxis_637825430038305526" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637825430038305526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637825430038305526" xlink:to="srt_RangeMember_637825430038305526" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember_637825430038315591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637825430038305526" xlink:to="srt_WeightedAverageMember_637825430038315591" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_637825430038315591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_637825430038305526" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_637825430038315591" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_637825430038315591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637825430038315591" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_637825430038315591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637825430038315591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637825430038315591" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637825430038315591" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="atxs_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm_637825430038315591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637825430038315591" xlink:to="atxs_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm_637825430038315591" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureStockholdersEquityCommonStockDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Stockholders' Equity - Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_637825430038315591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_637825430038315591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637825430038315591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_637825430038315591" xlink:to="us-gaap_CommonStockSharesAuthorized_637825430038315591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637825430038315591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_637825430038315591" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637825430038315591" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637825430038315591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_637825430038315591" xlink:to="us-gaap_CommonStockSharesIssued_637825430038315591" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637825430038315591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_637825430038315591" xlink:to="us-gaap_CommonStockSharesOutstanding_637825430038315591" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Stockholders' Equity - Shares Reserved for Future Issuance (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_637825430038325147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_637825430038325147" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637825430038325147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637825430038325147" xlink:to="us-gaap_StatementClassOfStockAxis_637825430038325147" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637825430038325147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637825430038325147" xlink:to="us-gaap_ClassOfStockDomain_637825430038325147" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SeriesXRedeemableConvertiblePreferredStockMember" xlink:label="atxs_SeriesXRedeemableConvertiblePreferredStockMember_637825430038325147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637825430038325147" xlink:to="atxs_SeriesXRedeemableConvertiblePreferredStockMember_637825430038325147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember" xlink:label="atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember_637825430038325147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637825430038325147" xlink:to="atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember_637825430038325147" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_CommonStockOptionsOutstandingMember" xlink:label="atxs_CommonStockOptionsOutstandingMember_637825430038325147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637825430038325147" xlink:to="atxs_CommonStockOptionsOutstandingMember_637825430038325147" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_CommonStockOptionsReservedMember" xlink:label="atxs_CommonStockOptionsReservedMember_637825430038325147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637825430038325147" xlink:to="atxs_CommonStockOptionsReservedMember_637825430038325147" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_EmployeeStockPurchasePlan2015Member" xlink:label="atxs_EmployeeStockPurchasePlan2015Member_637825430038325147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637825430038325147" xlink:to="atxs_EmployeeStockPurchasePlan2015Member_637825430038325147" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_637825430038325147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637825430038325147" xlink:to="us-gaap_ClassOfStockLineItems_637825430038325147" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637825430038325147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637825430038325147" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637825430038325147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureStockIncentivePlansSummaryOfPlansDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Stock Incentive Plans - Summary of Plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637825430038335895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637825430038335895" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637825430038335895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637825430038335895" xlink:to="us-gaap_AwardTypeAxis_637825430038335895" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637825430038335895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637825430038335895" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637825430038335895" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637825430038335895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637825430038335895" xlink:to="us-gaap_EmployeeStockOptionMember_637825430038335895" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637825430038335895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637825430038335895" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637825430038335895" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637825430038335895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637825430038335895" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637825430038335895" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_637825430038335895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637825430038335895" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_637825430038335895" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637825430038335895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637825430038335895" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637825430038335895" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Stock Incentive Plans - Stock option activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637146133100441210" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637825430038345511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637146133100441210" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637825430038345511" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637825430038345511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637825430038345511" xlink:to="us-gaap_AwardTypeAxis_637825430038345511" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637825430038345511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637825430038345511" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637825430038345511" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637825430038345511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637825430038345511" xlink:to="us-gaap_EmployeeStockOptionMember_637825430038345511" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637825430038345511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637825430038345511" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637825430038345511" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637825430038345511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637825430038345511" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637825430038345511" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637825430038345511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637825430038345511" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637825430038345511" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637825430038345511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637825430038345511" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637825430038345511" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross_637825430038345511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637825430038345511" xlink:to="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross_637825430038345511" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637825430038345511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637825430038345511" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637825430038345511" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_637825430038345511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637825430038345511" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_637825430038345511" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_637825430038355494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637825430038345511" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_637825430038355494" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637825430038355494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637825430038345511" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637825430038355494" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_637825430038355494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637825430038345511" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_637825430038355494" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637825430038355494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637825430038345511" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637825430038355494" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637825430038355494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637825430038355494" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637825430038355494" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637825430038355494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637825430038355494" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637825430038355494" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageExercisePrice" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageExercisePrice_637825430038355494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637825430038355494" xlink:to="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageExercisePrice_637825430038355494" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637825430038355494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637825430038355494" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637825430038355494" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_637825430038365625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637825430038355494" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_637825430038365625" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_637825430038365625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637825430038355494" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_637825430038365625" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637825430038365625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637825430038355494" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637825430038365625" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_637825430038365625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637825430038355494" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_637825430038365625" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_637825430038365625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637825430038345511" xlink:to="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_637825430038365625" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637825430038365625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_637825430038365625" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637825430038365625" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_637825430038365625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_637825430038365625" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_637825430038365625" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:label="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_637825430038365625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637825430038345511" xlink:to="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_637825430038365625" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637825430038365625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_637825430038365625" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637825430038365625" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_637825430038365625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_637825430038365625" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_637825430038365625" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637825430038375477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637825430038345511" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637825430038375477" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637825430038375477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637825430038375477" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637825430038375477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637825430038375477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637825430038375477" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637825430038375477" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637825430038375477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637825430038375477" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637825430038375477" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637825430038375477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637825430038375477" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637825430038375477" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureStockIncentivePlansStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Stock Incentive Plans - Stock-Based Compensation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637825430038375477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637825430038375477" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637825430038375477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637825430038375477" xlink:to="us-gaap_AwardTypeAxis_637825430038375477" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637825430038385463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637825430038375477" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637825430038385463" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637825430038385463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637825430038385463" xlink:to="us-gaap_EmployeeStockOptionMember_637825430038385463" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637825430038385463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637825430038375477" xlink:to="srt_RangeAxis_637825430038385463" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637825430038385463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637825430038385463" xlink:to="srt_RangeMember_637825430038385463" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637825430038385463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637825430038385463" xlink:to="srt_MinimumMember_637825430038385463" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637825430038385463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637825430038385463" xlink:to="srt_MaximumMember_637825430038385463" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637825430038385463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637825430038375477" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637825430038385463" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637825430038385463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637825430038385463" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637825430038385463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_637825430038385463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637825430038385463" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_637825430038385463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637825430038385463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637825430038385463" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637825430038385463" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637825430038385463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637825430038385463" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637825430038385463" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637825430038385463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637825430038385463" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637825430038385463" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureIncomeTaxesReconciliationDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Income Taxes - Reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637825430038395470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637825430038395470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637825430038395470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637825430038395470" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637825430038395470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_637825430038395470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637825430038395470" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_637825430038395470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637825430038395470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637825430038395470" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637825430038395470" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_637825430038395470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637825430038395470" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_637825430038395470" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637825430038395470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637825430038395470" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637825430038395470" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637825430038395470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637825430038395470" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637825430038395470" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637825430038395470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637825430038395470" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637825430038395470" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637825430038395470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637825430038395470" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637825430038395470" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Income Taxes - Deferred tax assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_637825430038395470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_637825430038395470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637825430038395470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_637825430038395470" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637825430038395470" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_637825430038395470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_637825430038395470" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_637825430038395470" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637825430038395470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_637825430038395470" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637825430038395470" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_637825430038405652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_637825430038395470" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_637825430038405652" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_DeferredTaxAssetsLeaseLiability" xlink:label="atxs_DeferredTaxAssetsLeaseLiability_637825430038405652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_637825430038395470" xlink:to="atxs_DeferredTaxAssetsLeaseLiability_637825430038405652" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_637825430038405652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_637825430038395470" xlink:to="us-gaap_DeferredTaxAssetsOther_637825430038405652" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637825430038405652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_637825430038395470" xlink:to="us-gaap_DeferredTaxAssetsGross_637825430038405652" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_637825430038405652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_637825430038405652" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="atxs_DeferredTaxLiabilitiesRightOfUseAsset_637825430038405652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_637825430038405652" xlink:to="atxs_DeferredTaxLiabilitiesRightOfUseAsset_637825430038405652" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637825430038405652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_637825430038405652" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637825430038405652" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_637825430038405652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_637825430038405652" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_637825430038405652" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637825430038405652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637825430038405652" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Income Taxes - Operating Loss Carryforwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_637825430038405652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_637825430038405652" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_637825430038405652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637825430038405652" xlink:to="us-gaap_IncomeTaxAuthorityAxis_637825430038405652" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637825430038415487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_637825430038405652" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637825430038415487" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_637825430038415487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637825430038415487" xlink:to="us-gaap_DomesticCountryMember_637825430038415487" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_637825430038415487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637825430038415487" xlink:to="us-gaap_StateAndLocalJurisdictionMember_637825430038415487" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis_637825430038455467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637825430038405652" xlink:to="us-gaap_TaxPeriodAxis_637825430038455467" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_637825430038455467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis_637825430038455467" xlink:to="us-gaap_TaxPeriodDomain_637825430038455467" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_TaxYears2023Through2039Member" xlink:label="atxs_TaxYears2023Through2039Member_637825430038455467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain_637825430038455467" xlink:to="atxs_TaxYears2023Through2039Member_637825430038455467" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="atxs-20211231.xsd#atxs_IndefiniteTaxYearsMember" xlink:label="atxs_IndefiniteTaxYearsMember_637825430038455467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain_637825430038455467" xlink:to="atxs_IndefiniteTaxYearsMember_637825430038455467" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_637825430038465201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637825430038405652" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_637825430038465201" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_637825430038465201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637825430038465201" xlink:to="us-gaap_OperatingLossCarryforwards_637825430038465201" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_637825430038465201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637825430038465201" xlink:to="us-gaap_TaxCreditCarryforwardAmount_637825430038465201" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://astria.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_637825430038465201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_637825430038465201" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637825430038465201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637825430038465201" xlink:to="us-gaap_SubsequentEventTypeAxis_637825430038465201" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637825430038465201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637825430038465201" xlink:to="us-gaap_SubsequentEventTypeDomain_637825430038465201" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637825430038465201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637825430038465201" xlink:to="us-gaap_SubsequentEventMember_637825430038465201" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_637825430038465201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637825430038465201" xlink:to="us-gaap_SubsequentEventLineItems_637825430038465201" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingSubleaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingSubleaseDescriptionAbstract_637825430038465201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637825430038465201" xlink:to="us-gaap_LesseeOperatingSubleaseDescriptionAbstract_637825430038465201" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637825430038475512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingSubleaseDescriptionAbstract_637825430038465201" xlink:to="us-gaap_OperatingLeaseLiability_637825430038475512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>atxs-20211231xex10d19001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 atxs-20211231xex10d19001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P +<# 2(  A$! Q$!_\0
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M>'O$7A^WT??'YDL\^IQLL2D'!)P >G0'/-4]/U]/AWJ8:.[6_P# .H2DVUW
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MBEA(P8W0,OY'BEB@B@B6**)(XU&%1%  ^@J2B@!%554*H  Z 4M%% !1110
&4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>atxs-20211231xex10d19002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 atxs-20211231xex10d19002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P '$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V&[\07,E_
M-8:)IW]H3P$+<2O*(H86Z[2V"2WL <9YQ3/M?BW_ *!.E?\ @:__ ,;I?!"
M>#]/FZR7"&XE8]6=V+,3^)KH*UDU%\J6QG%.2O<XWQ%J/B.W\,7L\\,5BZO
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ML>]><>'OA/J^EZB-6N/%]V-1N3+]O:",$2JV,;6;D,,?>(..P%3+\+;BU'B
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@+64W-N#&TB?,L@&=K DY.0!G/<T ;%%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>atxs-20211231xex10d19003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 atxs-20211231xex10d19003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '% ;0# 2(  A$! Q$!_\0
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M,/X).JG@\=(V5&B^T0>8(?,,3I*-LD$@ZQ2#LP_(CD>P!%S]:/8"@_7M1WH
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MR.^?0C!K%\*Z)J=GXELKBYL+B*)'.7>,X'!Z\<?7]10!ZE_2DZ>M'MC\#10
M<T>W/XT>^/>@=!0 $9!!Y!J4K+=3Q7%O,L.K0@)#,S;5N%'2*0]B/X7[=#D&
MHO\ /2@@$8/3TQ0!.#%J$,ES;Q-#/"2MU:,A5HF'WB%[8[CMU''(@[?6IL37
M5Q%<VTPAU>(!89F?:MRHZ12'L?[KGIT.0:4&*_AEN;>)H9H6*W5HR[6A8?>^
M7MCN.W4<$8 (._;-&.?_ *U5-3:9-*N6MV<2A#L,8);/M@'G\*99->M?W@NU
M50HCV+&28QUR5) YZ9Y_*@"]]?QH^OXYH],?2CZ?GB@ Y]NE'7W^M%'YT &,
MU:1Y;B9YH4$MY*%6XMRP1=04#"_-_#.H^Z_\70]<U5_^M01D8(S0 ]DC,*7%
MM(9;60D1R,FU@PX9'7JKJ>"I^O2F?@*M*\L\TD\,8EO)0!<6S-M74% POS?P
MSJ/NO_%]UNM0,D;1)<6TAEM925CD9=K!A]Y'7JKKT*T ,_3O2CZ=:2L:XEU,
M7-R(PWV<740S\Q<+\N0H"X*GYLGG]: -D=,?2CKU_&E.,X["D_\ UXH /_UT
M?SH]Z9+*L,$DK@[(U+-@9.!R<#OTH GAF>"42QXW %2&&0P/56'<$?Y])9H8
MWB:ZM0?*Z21DY,)/;W4]C^!YZ\VOBS2W0.GVQE(R&2T<@]>G'M_GM+#XPL;:
M82Q+>A@,<V;D,#U4C'(/]1^ !K=1_C1U/3/%9=QXHT;>K6ZWRJXR8S:2$QG.
M,9Q\P[@]<=>>L7_"4Z8,96]'_;I)_A]?R/X@&R>_T[UQGC?5M.O/#9BMK^WF
ME,R$(CAB1SS_ )_^M6G>>*=+^QS(_P!J3S(VC7?:N!DC '3_ #S7E@TV^!&;
M&YQG_GDW^% 'W-HLB2Z%I\D;!T>VC967H05&"*O5\SVG@[XP)9P):3:Q%;+&
MHB1-85%5,# "^;P .V!_2IO^$0^-'_/SK7_@\7_X[0!])45\V_\ "(?&C!_T
MK6O_  >+_P#'?\_R#X0^-'_/UK?_ (.U]?\ KK0!])5DV7BCP]J5VEK8Z[IE
MU<R9V0P7<;NV!DX .3P"?PKP/_A$/C1_S\ZU_P"#Q?\ X[7GNE66I:CJ4-KI
M$<TE^^[REA.&. 2<'Z9H ^U**R?"T%S;>$=%@O5=;J*P@299#E@XC4,"?7.:
MUJ "BBB@ HHHH **** "BBB@ HHHH R?%)QX1UG_ *\9O_0#7S;X'LKC2K+4
MK&Y 6>"[PX5@PSL'_P!;_/3Z1\5?\BCK/_7E-_Z :\#TX_\ $WU_G/\ IW_M
M-: -+\,?A11^/%&/_K@4 'O3XI3 S$*CHZF.2.0925#U5AW!IG7O1WH E1X]
M-AV,99=#E<*&9LR6,AX"L3U']UCPP&UL$ TMQ!);. Q#*PW)(OW9!ZC^HZ@\
M4R*9H78@1NCJ4DCD&Y)$/56'<'_/2E1H]-A".9)=$ED"J6.9;*0\!6)ZCLK'
MAA\K8(!H C]11VJ6XMWMI%5F5E<;DD7[KKTR/U!'4'BHNOX\4 '3_P"O1^/;
M'6@>M'XT ':@_P"-%!X_K0 '!X(R#^M3$275Q%<6\@AU:(*L4S-M6X4=(I#V
M(_A<].AR.D/KS1C@\ CTH G5H]0@DN;:%H9XB1=VC+AHF'4[>V.X[=1QT@_E
M4V);JXBGMY5BU:(*D4S-M6X4=(I#V/\ =<].AR#PX&/4(9+FVB:*>$D75HR[
M6B8=?E[ =QVZCCH 5_Q_&CIVQ1]#UP*!0 =:*./;K1U]* #T_E1^5%'/]* $
M.".]6O-:5Y;E$C>ZD4?:8'?8E^BCCYCPDZC[K_Q#Y6JMGOGWI5;:ZL,94Y&5
M##CU!ZT .98FACN;:0S6DI(CDV[3D=49?X7'0@_7D=69YJ>1-AGU'3[=9%D"
M_;]/WX$@' =6/0C/RMV^ZV5(-1LL;P1W-M*9K68D1R;=IR.J,O57'0C^AS0
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M".L_]>4W_H!KY]T.[@O[[7+NU?S8);W,<@4C<-B^M?0?BC_D4M9P<?Z#-_Z
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M#@_V+$?^14KJ?'7_ " (,_\ 00M/_1Z4 +XC_P"1D\+<_P#+[+_Z)>E\?_\
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MISUKUV@ HHHH **** "OE;X/_P#)4]%_[;_^B)*^GM4G>UTB]N(VVO% [JV
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M!%].]'_ZZ?)%Y8C9)$EAE0/#-&<I*AZ,O]1U!X-,H *.]':CUH *#WHH_E0
M8Y_^M7'^+M.N-3U[28())80D,LDL\2%VAC!&Y]JG. .2!SUKL/Z5BW,CQ>.=
M$EB<I+'!,RNG53@<_P"?_K4 84?PZOK22..;7 ;1EWHULQ*R(P)#(>A!_P :
MFG\"R-$?(UV[,W 4R$XP,>AST _*NW#P1(FR/;:32XFMD'_'M(W_ "WA_P"F
M9(^>//'5?2DG@>WDV.0<C<KJ<JZGH0>XH X6#P?KMO#+#%X@ BE&'4AB&&,=
M_8G_ #T=I_@K4K*Z$C:_*BJC*#"#D9  X;C''Z#\.SSWH'U&: .8U'PMJ-W:
M&%/$=VQWJV)AA>,^G?G]/RI:?X*U"SU2TNY]52X6WD#[#N]LXST_^L*[3J*.
M] "]_P :QO%>?^$4U'C_ )9#^8K8[5C^*_\ D5=1_P"N7;ZB@#T?PG/H6F>
M_"<<_AW^T+V\L0ZK;622.=H!9F)Q_>%=1;^)DM8A#;>$M<AB!.%CLD51] &K
MR[0OB%H6F:)X/F@U*RENM.L'MKFVF=XBI<)_%L(."M=%_P +PTWTTO\ \#V_
M^-4 =I#XJ2^GGT]M-U*PNC:23Q&ZA"!@N <$$\@L*YWX.>)=1USP!)?ZY>M<
M2V]Q*AGD !V* >2.N,GFN6U'XKZ5<7EUK!NM-CFMM+G@M[=)GE,TKE2H/R#
M^4_G7/\ P0MT\4Z9J/AV_P!7NHK*!S<'3[<^7]H5QM;>XY*YV_+F@#N[;PGJ
M/Q#B_MO4/$.I6NEW%Z+FTTT!2GE(P\MCD9&<%OQ%>JTR&&*V@C@A18XHU"(B
MC 50, "GT %%%% !1110!%=6\=Y:36TN?+FC:-L'!P1@_P Z\@TGX VMCJUK
M=7NO/=002"0PI:^46(Y7YMYQS@GCG';K7LE% &9K>APZ[;V\4MS=6S6\ZW$4
MMLX5U< @=01T)[5G#PG./^9I\0?]_P"+_P"-UTE% '.?\(I/G_D:=?\ ^_\
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MNSL[8'8$G@4G_"Q/!G_0T:3_ .!2?XU;T[QCX;UB]2ST[7+"[NG!*PPSJS$
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M?/(BY  Z 8% '#?%\3)-X+6>16G%VXD91@,WEC) ^M<VQR2?2NH^,_\ Q_\
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MN1T/!)]>P-9.K6,>N>*]:M8=0M(9$AL)T>91*FZ.21@"N1D''K7.V&B3Z/\
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M_9-9'AN>"ZU37Y[>198GNEVR+T;"_3FM?4C_ ,2F]]?L\G4_[)]Z *_AK4?
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MVYKE]&DU5OC3HRW]QK36ACNFM(=4C"E$$8^88ZDDG.1D#%:]KJWBY/&<<_\
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MB@ KR#X7_P#)5?B%_P!?0_\ 0WKU^OGO3]:O?#^M_%?4],$9OH)5,0;D#,C
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M%J30:=="[L)[7S[H2ILC8QJ-C J#G(ZYQGI]* -6&X\937"VRWMEYQ4,5*<
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M6H?&3PN?$.AP:6Z6EWY*Q70GWC:,DX'&./SH ]>HHHH **** "BBB@ HHHH
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MI=&*M%EP=P(Y!^7&1ZUV]<=\3KN"T\%3//.\(^T08>-=SC$JDE1@Y( )Z=J
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M2ZA,Z2,WE?\ +$*<%N.AXY'%>V?#JQMK3X<:%!#$%BDLDD=6YW,XW,3GU)-
M&'X+2&X^)7CYF2.5?M-KM8@-_P LO6N&^(%JTOQ8OK>"9K>(Z=;M*D3,GF*'
M)(^4C\\'%>RZ#X3T3PS+>2:/8I:M>.'FVLQ#$9QP3QU/ KQWX@WUI8_%Z]>[
MN8H$;38%4R-@$[CQ_G]* ,FYT&\FN8;Y]5+V>Q8I1!#Y<N0=VUG!XR1G(P&
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MK^7,BARL!<E!@_[.!ZB@!?&^N^%_%_A*ZT:#Q+:6\MR$DAE*LRDJP8=!RN0
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MX0V,JFYL =.PKJ1>:LQP/B'XB)_[!$?^-7_".DZ.=/\  DMQIUB0^CSR3-)
MN&PJ'<Q(]SR?>L)=>DU_2M(N;GP7HMKI>I:I#!;7-KL,@*3 $LNW[N%(S[CU
MH LK>ZY-JVFV47Q&U:);N1U::[T^*)$ 0MD$GD\ 8K<TJYUS2?B9H6DR^-)-
M>LKZWN))4,<:A"B\?=SW^G2M&[MO#VB^+];N+S1+>: 6UE&D,5FLC%W>0 *N
M.I./RK&M[W2;WXS^'!I6D2Z;Y$%Y%.KV8@W.$!QQUP"/SH ]0U__ )%S4_\
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M']N^,9 ^L:BRQZ3?1NZQ01-%/*@W'9(I^Z">>/ZUTGC_ /Y$N]_ZZ0?^CDH
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M.VM]:MXVM3E)2Z,2=I&2,X_BS2F<MG'B>V /0>7$>OX_[2_E[TYH-?6[-J?
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M/7_A,H<_^ Z5'H\>GV]EXAUG49]12"PB#L+*Y:(L/,FSPI )^OK4FO?\C%I
M P/^$RAX)_Z=D_S_ (5'HNFW&LPZ]IG]IV%I9W40BGCNHBS.#+-RIW+C'X\T
M 1:5+I/C+Q#%I<1\6Z'=?9_M6GWUS=R"20='V*V1MQCG/-=;;_"RUMDA@_X2
M7Q"VGQQ&.2R^VXCE!!SG !&<Y(!%8D/AB_\ #44NN?\ "6Z?J.HV%K((9KN(
MDK&%_P!6JB3:H^7' KT[3;I[W1[2[<*KSVZ2L!T!90?RYH \$T.WC/@/P]:@
MND7VF[C&QRK ?:XAPW4'WKI_$6JZ5HVLSZ6+/Q;=0PR)'>WB7LWV>"-E!+E@
M3G:"#CBN9TC?_P (-H/ER)$_VJ]VR.,JI^UQ8)&>@KL+[P1J.H:I?7=QXXM?
ML]\ZM=6"1[()=J; &Q)G!'49YXSG% %^S^$UO#$KP>+O$>5@\JUD%V 8(R0<
M+@=#@=?054\*:3_8GQFU*R-_>WS+H<3-<7DOF2.3+W/;Z"NL\&WUS/;ZC87#
MV;KIMU]EB>SCV1E BL!MR<8W8ZUB6/\ R7K5O^P%#_Z-H Z?1O#=KHNK:SJ$
M$TKR:K.L\JN1A"%VX7V^M<OJ%R=7U/QC?0QC['8Z3)IWFY/[R4*SN![+N ^M
M:7C31_%6J1C^Q-6CAM5*F2S3]S+./XE$_.S/&"%_&J6F7>CS_#+6;;2+-[$V
MMK<QW5E-GS8)MC%@Y/+$YSN[]: .,\(6^J#P[X:LH[*[<WM@98G37Y8UVH%S
ME OR_>& ./RJ[+J6%_T>X%Y()8XS%:^+)'<%W"@D = 2,U!X3UV,V?@6QMUF
MAOCI-Q!;-=6SK"\Q12HW8Y'R\D=JQ[+P9JF@VFFQZWX?L+,:;J,<XU>&5"]T
M[3J%4]PFUCP?04 =9;V/B#_A+[=+:P+7.E 7$J7>MR3HZRHZ *&7@C!YQ_.I
M;N?5I_C-X3_M6QM[0BSO/+$%P9=WRC.?E&.U6->CNM2\0Z\FDF6XE$.GM(EG
M<B.1HQ+(74/G@D ]ZYW2+"^L_C/H9O++4K=)([QK<7UWY_[O8N /F;;@[CU[
MB@#VNLGQ3_R*6L\X_P!!F_\ 0#6M61XJ_P"11UG_ *\9O_0#0!8T/GP_IO\
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MJ>0=V>@' ]*UO%'B8>*/!VK:;HNE:M/=7,)AC9+?Y5<],L#\OKFLKP[X6O\
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M5<0W/QVU62WFCE0Z%%\\;!A_K>F16QX4^''A_P '6]_;Z?'/-%?!1.ETXD#
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M*_'33O%7B:RT2#1;N"2[<J)'E4A<*3R!]*X7XHP_$U/!I/BNYTN33/M$>1;
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M?75['XOG$UWL,S&SA(.P8&!CBI/ 22Q:;JL<]S]IE75;D//@#S#NZX' ^@H
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MAJ6&9Y$U.W=!\D4UC(KSGTC&/F/M6OX;\;:/XH=XK(W,-RBES;W5NT4FWIN
M/49.,BN-LKF75A;WFJ^/;>UOM/NYUCB,,";2K-'EE//*_P ZU= G\_XAH?\
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M\]ZODRI ]S@%0RG"\#H"?UKY,UOP-X@T""[N;VR_T2UN3:R7,;AD\ST'?]*
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MZ9P>F<T ?0FD_P#(&L?^O>/_ -!%7*IZ1_R!;#_KWC_]!%7* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \L_:!_Y)BW!_
MX_8?_9JN^&K5=%^(%M96=O=26]WH44TT\T[R>4RN0HRV<9R>..E4OV@?^28M
MP?\ C]A_]FJUX=@AT+XC66FV=O+Y5]H*32R23/(49'( ^8G&=W3CI0!Z37B7
MCC6I7\=:E:ZMXGO-#@LK)Y=/CA38)&PN&[^=DEQMXQMK<\?>-?$.@>-+#3=/
M>WBTZ: -+))#N8,2W0D@8^4=?6LF'Q,VMZ-]NUGQ%I$-[%YPCBETG>\6,@%6
M)X) !R/6@#J-._X]_AUGO"3T_P"G8UR7Q*O+>RU7Q-/_ ,)'<Z7J,%O;365K
M#.(Q<R!6Z@CY_3&:T["P\0F#P*1KUN#)$3#FP'[L?9R>?FYXX[5%>[K3QEJT
M&N>(M*6<+:RHUSI D!.U@&4;CM(]<T >I:1-+<Z+83SDM-);QNY(QEBH)X[<
MUA^)(=2BU_2-3L=,DOX[>*XCE2*5$9=X7:?F(!^Z:\OU?XH^*;&*X:RU"TN_
M+O/(CD^PD*\7'[S:&W>O3BO<K.1I;*"1R&=XU9B%*Y)'H>1]#0!SO@CPTNA>
M![32+R#YG5WN89&$@W.2S+Z$<XJIXBTGP9X9T274;SP]8M%%@)##;(7=B<!5
M'J379UXY\9+MM5E_L P6DH@19X8GD;S9IG215"A< !<$Y)Q0!J>#KO3;SQW!
M-IGA\:1%)H[2\"/$JM(F/N$@$8.0>1FGS$?\*3OR4\Q<SY7/WQ]H;(R?7I7G
M7PIGUC3O$DQ8:9!?QV9MI1?2>2H163:!L7!;GKR3FN@NM7U5?A%J,;R:"]KM
MG9T2\;SF'G$D*,8)/;VQ0!UN@KX+UC6;K1Y/#%C9:E;(LIA=(G#*W0JR$C/M
MU%=IIVA:3I$DDFG:;:VCR@!VAB52P'J1UZU\S^&[W4-+UB'7=6TB%)I;RV:V
MF<*,IG C4(,*<-DL>N,5]44 >7_$?68-.\>>$H6UM=*$BW*W,ZLH9(BHQG<"
M "RXSBL#7M=L7U_2EL?B%%<QPI+.9+J\BC6*0 *OS+&>2'88QS^%=]XR^&7A
MWQS=V]WJR7*W$"&-9()=I*]<'((X))_&N#\/?#'PI!\2XDT7?>V6EP,]\;ET
MGB:63(CCQC&0 S'\* (TUP17T]ZGCS2!<SJL<C_VNOS!<[>/)P,;C5>_UD2"
MXO#XYTI[HVDEN&&K*24/)4#R<') ]*[?7-3^'WA[6O[)O=!MFNU@^TLL&EB0
M)%T+DJO &#FJ\>A>';G4O%4T&D:8]N=.MY;=EM4V@-'(=R\<9X/;I0!L?"C_
M ));X>XQ_HW_ +,:V;CPGX>N[F6YN-$L))Y3NDD:!2SGW..:QOA/_P DL\/_
M /7M_P"S&NKO;N'3[&XO+ABL,$;2R$#.%49/\J /&M3NK"\U._M]*\&6EO8:
M9JL%JVJ1LBNDHE0G"8SMP<9&>O2O1K[_ )*1HW _Y!UU_P"AQ5Y7<I.-=O;N
MUM/%%EI6I:E!=&.YMD%M+*94^8MRP!'0?2O5+[_DI&C_ /8.NO\ T.*@#SFR
MO-.L-2LH]6\&V=QIVHZK<6HU65XV=Y6E<CY.NWC&2>WY^J6_A/P]:W,5Q!HE
MA'-"VZ.18%!0^H..*\;^SR7&LVLNH6'B74-%L=2GNF@@M4:U2197^8,?F8 <
MD<_6O=+"\AU'3[:]MB3!<1++&2,':PR..W% ')>*[/5_[:N+G3])DOX[G2);
M+,<R)LD9LC(8CCWKJ=(MY+31K&VE 62&WCC< Y (4 U<KCOB9X@U?PUX4%_H
MBQ-=FX2/]]&74*02<@?3]: ,'XR:E>V=KH=LE_+IVFW%ZHO+N)BC*N1\H8?=
MR"QYX^6L_19+>7P'X\-MJTVK6RO)'%>S8W2(L*@#/1L#C=WZU4M/&%[X@F>S
MUS5]+M[0013)]KTT3JTAR",9P"/?GFE2+4;SPUXUGT[7K*2P0;"(M."JX$"\
M*,_+@<=#TH ZCQX]HMIX9_M#5GTFU><I)>1RB-D!@;@,00,].GY5+\);J]NO
M"ER;J[N+RWCOYXK*YG.YI;=6PK;OXN_-8OBRSU&#_A'&US7]/>R:Y.#/I89$
M/DM@E2Q!_P#K^U9M[XVU#19H;'1M;TZZLQ:O(!;Z:(5B<'A "V.<DX'- 'M%
M?./CZX&G_#/6=#E:]N;B/Q!(S73P-Y;Y8MR_(SR!C/:O8?AOX@OO$W@VWU+4
MVS>N[K*HMS"$(/W0#U&,<UXYXXFGT_X6ZOHEU'=S7,>OR,]WY3&%LL2/G/?!
M'% 'T)I/_(&L<]?L\?\ Z"*N53TC_D"V'_7O'_Z"*N4 %%%% !1110 4444
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M /H.:;_X%)_C0!SA^%6AM<K<FZOS,J%%8M'T/)XV8ZU%_P *A\._8VM//O\
MR&))7S$SR<]=F>M4OBOXRBL? %[<:!K]NFH++$%-M<(7 +#( !STS7A_AGQQ
MX[\1>)=/T=/%=[$UY,(P[/P,_04 ?15O\-=$@OK6Z>2ZG-M*)HXY"FS<,XR
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MT.""T3QKYFGP(4CM4WQ*!SW'-:-YX(\=SO";7Q@UH$;,@$\LGF#TR>G?IZT
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MT44 .T_]GW0=-N3/'J5Q.2NW9=V\4J?7!7KQUK3_ .%,Z/C[]I_X+(/\***
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4H **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>atxs-20211231xex10d19004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 atxs-20211231xex10d19004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% ",# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>atxs-20211231xex10d19005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 atxs-20211231xex10d19005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" <<!V$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH Y?2;C7=1UK7TFOH((;#58XK>!(A(##Y$3LK,=I.X2;A@ H_\
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M%S&MY/+/WRR-Y2KQQ\I7G!&X9R+$3^,&O%AE@T..U$4B-=)-,[M)@>7((=H
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ME<,&\J0[P-[!MF48+A/O _,P![']L\8?] +0_P#P<S?_ "+1]L\8?] +0_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O'_P!H[_DGFG_]A6/_ -%2U[!7C_[1W_)/-/\
M^PK'_P"BI: /F"BBB@#[_HHHH **** "BBB@ HHHH **** "BBB@ HHHH *C
M,C"X2(0R%&1F,H*[5((PIYSDY)& 1\IR1QF2B@ HHHH **** "BBB@ HHHH
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M"*5(W! -AEV-'=ZM:>'K>2\+1V@@19;J6Y=V6VC46JR1W++(_FW1C(\LG).
M 2,E\NSM8+B6VU_Q#<010:9Q9_VJ\4HTZ-VMY%%P7VR)=D$*IRP4!<EV):0
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MP 2[KG*K@@Y/'(J._P#$N@Z4^S4=;TVS<.4VW%TD9W!58CYB.=KH<>C*>XH
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M=6WE?;-GD;995\G]S)%@^7#D="2=VYEIZ'HBZ03>ZE<1WUWJ#P,UU>PM!]J
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M*'HW_8*O_P#T;:4 =!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ."Z'_XFO/U^&NOV\$8O/B#XK>:WWR7K6]U.5>'>Q0P@*=TA1"IC!8AG#9(
M62GK'@K5=$027/CSQK*WVCBWLIY)WEBW3LJ1DE=TK1QQ@A0VPAF8;#N4 ],_
MX03P?_T*FA_^"Z'_ .)KSOPUJGAS1KW1([GP_=WFIWGA?2IS-:6/VD[4?;N*
MJI=2I$;%LG(B0##*H:,?#/6!I-HFK^//$9\10^9*BP7SO#)(8YQ&MN9=F9-J
MDL-V=N\':&#"/3?A)969CCM/%/B!9[1[B6"/3]2B'G11R3H(XL[2DJ&4!R1L
M#3.N?G)4 Z2+QCX:MUMGF\"ZY8)^Z"O+X?91$YEBB1/E!^8>7"PVYXC0 EPJ
MU7C\<^'UV&Q^'/B.XCCVA9+;0%VQNGE@IR1AHVAC0^C0K@D*IKEX_ ,L>L26
M.A>./$86UBN+-Y(K]/WDD:[K:UBQ(HW(#-N0D$>6QQ$LBM6HWPWMKFXG8^-O
M%UW+'<>67%^@^VO$99([>%G(S+$P!+'*A@^-I#^6 = WC72(IKT)\/\ Q.VQ
MPXD30"!=,LQ=2N<'.]WE!<+@[CPQP8]2\7:%?VLRWOPZ\1WZO+%.T,OAXOYD
MABP7^?@L@ C)//0+N7D<WJ'PUTVRMS-=^.?$!TU'O!>7#:DNV2%A.\\,:*&9
MI0T2&4$8;:YQD86GH_P[U&_B?4[KQAXCB::[>YL(TU!?/F8+M\IM[+MNTBBF
MC?/RC*_-A'6@#K+;QAI2V$EM!\+O$\5I!;R1^1_8<:+Y4CJ)$5"PW!F*EE4'
M.,D8!(L:EXCT^]M[M=1^&/B"\B2X:29)=*MYM\J!(]X7S#O.UE 89RH."0K8
MY\?"JRA2-(?&7B>9(W$42P:C$!<^0TS16L.6&)860'YOE!#$!>=F'KG@6WT=
MHK?2/&'B.?5H8IS8A;LD3"&*["6\ 123)$5".,@ 2L!M,@6@#T0>,HFOWQ\.
M_$_VA+U5,ITZ$?OV0Q"0/YF"-BE3(#M"X!8 C/+Z:_P4M;>T%GI4<T<EPK0-
M+I5W<>;(X>-5#/&Q<$I( G(W(2!N7(D?X:V=G!;-9^,]<A:S_=PS"87,=RUN
M\\D4(@R2\D!1<H%VD(P50Q8K)>>%_&^EH;^?XEW< L4ENK^633S+$(MURRNB
MXVL=K#=%SMX.2%B% &/J5CX/UZ_U4>&=*M(+=O#E_.TGD26<;SE+8Q[A(B1[
M%4QR+R5!?>0IP[7/B.EQ??&WP?96S^9-%:2W"11,/.4@2-N43*T ;]W\IP"6
M7YF4!&7+G\%Z]>ZE*-1\=ZE/IMM;FPU:[*.1-&TNT0VAVD-*XAA255R?,."9
M2Q2MR+X;Z[%JRZMK/C"^U&_M)9+AY&L1<)!"T@=6MHY(Y%$Q\D@K& 5WIC(4
M+* ;'PZMXCX?>UBMY[A4U6\;-_ ZF[V7:D7$[O"#]H0 ;1GDJ02"I\JXT6@Z
M3H,>K:EI5I9V@LHVE%]9I&7A$<41-QLAPDZI)+&L*G#!F4#!(3G[GP8WA_2;
MF*3Q%K-G%#>B=95VW?FO),K0S.HM T\YGCB!CW$JIQOPV&CT;P?K-[+:ZQJ'
MB#Q';33ZA]JEM)[=,K [2"W9XQ$\;W"LL+$L/W2!1A!&A !H"R>^O)]:UUIX
M$M90=.A>T:,EP(HQ?2_N=LMVR.GE1;/E(\L+O#[)/AKIZ_\ "-QRBSNV>XO;
MF0Q:D6+3".\XGN?W9"72<@ '+[!D_*/*KZ)X0N['3?)75M92UM[A+MQ):(<V
MZ1;;9XD\C+SJL,"-'(I*LK,$#>4]7-1U2ST*\G\/:=HL\MT^;FXB@0$1[ \B
M7*/+$3<W<@C!"_/EX6RPV,Q #6C]@M;#2[>SGN]9N8ECBL;B[^>YVQ1R&:ZE
M0 1W.+21(I Q^9=P) ;98\/:$\$L\HO(-3U.XEMWN9[JU93,B-#,6N%V_N;A
M/-D\E,KA#$"&\O*EAX9.E:CJHN!/.1ONY+U;.$[S(2XFC18#FY1K>$,B_(VV
M.7:7;;6Q?R)'>7MO=6WV?[1LF9TC60,ZB8QR0#RBTURJV\3&,@[0J;=VWY@
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M<!E7&3\JY(KL+S_DH>C?]@J__P#1MI0!T%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7C_[1W_)/-/\
M^PK'_P"BI:]@KQ_]H[_DGFG_ /85C_\ 14M 'S!1110!]_T444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MAMK>&1EBNIX6N72VBV.62<LBHY8%7VA N6VC/A@N;M#JL\\DD$;M:VF97V"
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>/_M'?\D\T_P#["L?_ **EKV"O'_VCO^2>:?\ ]A6/_P!%2T ?,%%%
M% 'W_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 >'ZSX6O[GX;>)-3N+N"\9)=5\R#[-)A0+LLS1
M9N!Y?SP*Y!W#"* A;>9:?PG@M/LNH7<YDO+%M'L4D,=B\SPJ99%DMHX_(_>Q
M2,CF0J.I;EV!EKL/%#->?!;Q27BC8K<:B-J0+C"7DH!VK&PR N2VT'.6+H<R
M#C_AGJM]="V:Q-W=WC:/8VB7\]AM%BBW,R&,!8R)("% )#[F(R2@5W@ .P\1
M:I+HTH6RT^.XU"&W2#4Y9?.,MK;- [)''=[$;RGDA8&X=R(W)9AV6QHNGK:V
M%[>ZA+)J.H3)]BNQ=;E4('0)920RW+(96$C*CY(;?N+/OW2Z&E6!T6UD_LRR
MC^V;V<FYMI-L#22I']FB=8%)@_=%0YSY:)"Q5HPH&AYK1VZI92VFFO"B6T*2
MJI@L"P@VV\T23@/*=PV%<  @ \_O "-=2\G+6OGR0VL420R2R8QO\G%K*LLZ
MN;EQC:TBKM\U0226#\_>;_%>F"RM[WS-&^:U#QSMOU%$D+M;Q/\ :-LS/#$H
M:5F^7]X.KR+#7-W?Z[K45SH.ISVFF:=BTF:]N)$225)K9H;9\S%A,^&#2%"P
M6;RV4R!E'01VMAI^DO;V]A!';I$EL]FQC8*#';H+2<&?;)<.FU$=B0 5&2#^
M\ +$$]OIEF(M-/\ H^F8L8(LE!$%,*BV=9)5W32?\LI& &'4Y(;,F7K>O0:1
M89EN+N6"W=],80B4SRN[Y6%5-P)6G\N-5$F"29TE4A-]2:EXIM] \LR39:VB
M2+[+YYN+N)W\GR[5X1*3-<2@2E9,_+M)^8%BU?P_I>HQZGI^H:OK6=;\J.T-
ML'5X+-1'')):%6E:1YG&9#+N+'RE8G:-K@$>E:/->36^J:Z8^;?[%&L^I&Z@
MMU:;RY;28;D$TK[A'O(?+1J&!:,--L&Y*V1V22)#<(EG'Y]U(1NV21_9VGCE
M?RYQ,,--CDLB#>X!$@O$@:%R/+N+79;6WVAU8J\L0Q:7$^965BXC8OQN+0@&
M0G#<_=ZP[ZCIUAH]K]KO9(I;2^F6X8/'$AW?8VE$^&NPGF8;S&965FPB2,Z@
M$?B'7;G77.@0)&LERCV6HM,SQ"S2X68)#*H8JDK&.)$F'F@ERP7;(BR;%A86
M-FD]G:"TO)[A[FRN%OEV+.%::6.U<,Q;>1.SF79(9$5W;.]31HFF0^'[?-M<
M1WE_L2!;I6'^GR(/W\6UI\-.6AG?)VA&F<_,3,6N2FPM?(MII['^PEBN+=I)
MIHQ 47?YEL8@40;%C&&*OA(IE;:<LP!7D-O%H[W]S;P2QBT:UD:1C,7B1I&E
MM[G,ACW(B-'YLDI7S'D^Z&*OS^S_ (3:\NYKV>^G\/B62"+3;F'[,^HR*+H/
M;['91NC(5T<!#P ^7BW1D-C=>-+.V:\CG;2/*>V^P3-/Y5Y+&;R,QS,VZ2/R
MRL3"9E5F;!9=^Q8^HNKKR_M;7EO//8S2FS*7J9^VY\W]TD9VQQ*698UDD_UN
M ISF-V +$Z?;]3/E3[8)I3!)<6</,T:QS*;=ID8O&T<N]]_R $J@^8M6'KVM
M165O:J8(]2U._=K=K&$0S_VF<3J]GOPI6*!WRTCH JC!RS,*K^(=?:TL)]-C
M:36=5U!&LK81JK17=RCDR0&!_D$ $FUY 6(175W$B*6N:/X="ZF]]JEMYTU]
MOL96=IK@>0D>T6Q$T1(A)$K-(67S75'R1*$4 IZ3H=VCI-J5UINI:A+;FS>X
MFD1XKT!;D/IRE@T@2-E5VD;?(^UMV=I"[&HWMC';ZA<3-'<1*[VMRT\/^L.)
MCY%UB ^5;HLBL)#QM8,20V9+D<EPUTGVJVG2:WVK+?)&)&5Y98W-O%^Z!>'&
MU7DVKA54DEE=H^/GNKS7+I[/2+?RM)TS;:WDVG(?.AN$E@#Z=:LODO'&0@)F
M.4PW)0+\H :SJ,NO2ZG':ZA?6%AI\2_VI>6.P:A-<%G:+3HI%'E[HRX!"LQ+
M.J9RS$[FDZ=INC:-!::591VL%VDT4EM9RK&SM&K@0*1/@70&0TH)SY#[F7"E
M;%G;K8O8V=HT=O)IB00R0"-KAK>)UB001DQAW@;:S>=N&'BRV51T6.WU*STB
MSDNQ_HEAI\7F-YL@"-YA97@:9I_*>Y%Q$=TC$XW[<Y=G(!'>Z_#]@O;R6^C4
M;#:S00R@RO-O9A:1".X^6Z6/<AV\L[QL#A-@S[.X/B;5QJ5YJ$:Z?OB:S7$@
MMY8S/;36_F*)L1W'0KD*76XC.T[7C6.&W&M:I;RZC>^3IGE&#3TDU&93*([E
M8R9X3,&%P-\:1ODNLGS2!9/+C7I)KF:9 7DCC>=UM[X/=&$6ZNPV0925O+N-
MMPA#)G>4 RFZ,J 1K-_HL8C>=X;J)[=8!=YF_=1,#;"0W'_'SO\ -)D4](F#
M$%5>N?\ %?C-[;^SM-L%^VZ_J45W'%8P2,&4'*!&\J;"R)($#2E@ L-P593A
M38\2:UJ,&G7,,'V&[U:_S"NG7$2O&JX7;;3(;K8LA-PH:4':P*K@EHE:/P[I
M]IIE[=22W\8U#5GM;BXN9[Q]\?E/$([1D8QRY$<L*AV!9S(3*HW*C@%?0],F
MTA-9E:XDN=0O;@#5=0=BKRG<52S5C/$4G_> 1RK''&5:,A>5K<N[NP$5U"FI
MP7%O'+%IX@DN(YTNR%96L6$LQW7!RQ+'83NBW%PC EW/;VEK--+<SPLMI]G,
M<FHD- B1)*\#DW(!N2GF,)@1M49+8&7Y^ZN=1\7WD]G(M]'HL<L\#I.%A?46
MQNFL$V7$8+(4<"4 J=C*6*K(9@"N7B\:WDT%GK$]QX=M]^FR+:7+J^J-$#*;
M96DN,'<C(#*!ND\N;+HA&[J)M0N)H+AY;Z".2YP!"KA'>(.T;6L>VZPMRLCK
M&TP(7<\8Y(&VQ=W$5I9W21W$\L$GE65O+'.[A]I9&@\PS#;<%E=/-8Q_/)$I
M+,N*S]4\0V=C+=Q?VS!>R7%VMFD*W@CEERQ5K:'RY!LN(VE4[]J?*T:NP(,J
M@$FN:\; W(D>.<72&VMFAN)(UO9O,FC6TC97(@G5FB!DZM\YP!&3'3TRR^VP
M7E[K#_;[Z[N[B,*)]R_NWE M+(L8C%(AMXW,FU=S)NW' 9(]-T=I;^TUF^FD
M&H7"+IVV"Y4LMN4=9+)93-N>6&1&F>88<[&"]U70FN0B:C>K)'+>WEN42*6Z
MC@EF56D06:R1RX26.XF"&4#CS$7+/\X +%ZT.LV\Z//)<6T[W%G-!'B-=05!
M=1M:QJ\@*2J1EI!MW; 0=OW,OQ!J;ZJLFG6XGGM[N4VM[,L+".YB66=&LX$:
M0?Z0=C*\@ 4(&D+* F(_$-W=Z_<:CH=A<QS1NGV:[F@E3R[E2;A9+*-7?$=T
MD1\S<.I1?,")@5J?8HM-L[L:?9_Z5-%);(K2/:O?[#=.L,;M)O6;<6=IR#OW
M%P3G* $D$$.GI-963R2V+H\2.M\#+>2[KEI((L.FR=&&3*27;G>Q92X-=U=;
M#2[^^DN(Y(]DD+3+<-!!*1YX6 2B7%M*&"HTS8!8JH^;:$CU74=+TZ6ZOM2N
M-*FANHGMIR6R+F*)IP8&5W$<>QI40R.VUG<H0A9*Y^"PUCQ!/=:UJ]I?7=K^
M\&E:5<1O;M/\CR"*:,Y2'!9X&D;_ %JJHR$9A. 4[72;WQ;JE[KGBK3]2MM&
MN4$4%A)#*TL]NGVPF.XBC VNK,DB-M)&(U5F=BQ[351OO+J"]O)[>1K1XTN;
M>TVOY<@G8I:L"9#< 11LP&X'RD(0%N([HK;I<W*F[NH-ER)GTR%I)KLAIV%N
M)0[.AB_>#&4'F,@1DYCK/U#5[DDZ5H/ES3Z@]Y&B+;O! "DDZ2N&C(='25X?
M,=F 89,67;;0!)XFUW[)$;>.>>YFU#S[?&F2_OY8XUN-RVJ>80+B(A-[$ '&
M!EMJ"OI>F6\$]U->+!<ZO=_O+A[+,<,DH2Y1K>Q<RKY<RL)V=LALR2$[=_R1
MP:;::+I<VI731ZGJ!=WU6]0N9Y<_:8XXK>5 BFX5Y/(&W8VW"[4RBC8UW488
M-+OYI]2D1)DDM1-92 /.W[]5M[53*=MTK  G;\Q &.,1@$DDB:A$EQ<1^9,^
M]41955V<+< V\!$^([E!N5Y%(SAN0!^[P]1U35]6UN\L-+NX_LZO<:?=W=K=
MA2Q5/,6"WC9AMO%5F&\-Y8"EFR0(XCQ#J#:EJALH;R2 1.\;:D@6-)93YT26
MEH99 HNMLDF94/RM&%88)1="RL=(TQ%T[3;>,);V\EI#]D)C$T9:X)MK>0S#
M;<!H@97R"2@+8X* $EAIMGH]FUCILN+#RFLX;2TF$:2[#<DQ6Y\X,ER/^6DC
M'YMF?E(8I'K'B>QL[>:=KJ2^2=!'_P 2^3_CZ1@S1P6Y$X"7&R6)\@AI5Y0'
M $<>NW7V>UFO;J]@=I(GL#>63>7,^8I0\%DIE;%S]HC4XP,C8IWM'D9<$-WX
MCUEM4UV"26#?<06-E%,@BS$TFU$#2JR:@K))F9"8PB':W.X !8V46KW\NI7B
MQZAI]Z[SZ7#:S0B!"$=S%"$G 6^\WS6:<%AA&VNF2%Z2?4(KAT9M6@BM[Z6;
M3VF8O"ID2X*"&/,RLLQ7SEWH"69 V0%5&+J6\E^U[;^";SY3#']G)3SXT\W=
M;0_Z2-MRNU\R_*.G'R';R^KZW>W^K7^FZ)- ^MW4OV>6XM_+Q';022D6S8N]
MRW#+YK*PV%@Q_P!649X@"QK?B:]U"=M&T,^=JMW%+'=M#>1I]E"I.RVRXG81
M7><+OP0=KOAEB*KH6%C8:%!<0IJ'VJ2:(P/,)XXY;M$>2/R8V$JD7 GE!>5O
MO2SGE2P$<EK:VGARW:T2ZN[VX2XB2>07#R7%_, [QQ?Z[(G"^4SNP"&, $+&
M,1V'U"QM[*\7^U(YH+9)+6>1+_!D$:3-Y".UQF.X10K/(Q!(&21C,8 :I?S1
MI?3/>VB6FPHURMR5%PJ-<&6WB'GH(9T1.9MPY!) "87EP+[QK?W5QJT<DGAN
M6XN+>VT]AY+:@($F41^4\H,<N]Y&W'EOLR,1 4!:2^6\\;>9>7,7F:3']JAL
MK"20VLFIR+]H0P@%E>WD CPS'<63.!$&FC/6,["XGD^W27B/<?N1',J&<QF5
M_LL>)57S4=&W$J T8"/NVLP ![Y;E[R,3222;Y+62.-V@><A9F6"%6F4QSA=
MKF3@.I5@=N"F/KWB9;&)X;$7>J7>IO+9V<<<[+)-+%.ZRPA%*>2$4L/M"YP$
MW.25021ZOXC&C;;:W2?4KI=\4%I!<3"XN'MM\@A*/)N5MAB=I?G\Y 05^>(,
M:/I+V<\][?M!>:E=6BV<EU;7C,\Q1)E>RM&>4/$R-$'9V?+L7)VD90 KV^B0
M:=%JU_/-/]JGM)((9])GB:0*JS@Z=9IM!7R1&K J%9W7+8VLHZ2\\FU<I*L=
MJ^^62)88@QA9EN6\ZV_<GS;AEW%XQNP"3SG]Y&\4\,LM]+<3B1OM$!O8+&4S
MF,-.ZQ^4%*_NMJ>7(P</E@%S+EN7UW4+C4M1F\/Z%<P/)!=O/?76EPAO[-ML
MR^:RE59DO9-\D>U=Y.UG C+' !)J^KM/JD]CH/E@Z?<2R7FH6ENKE95\Z4VU
MG"Y9'O&1Y!(X' +%ADA5W-,T9-%LUT>TTF=X;#3_ +.ABD6,F)C+DPS!4/VB
M0QQ-("R*I9&#9&6IV&GPZ587<=A!(L&E6[F"/38!<1HJ/>(HMMY(^V8($I8-
MDX4CYLC0UNXMM'LKN[NI([$6B3W:Q0VZ.0=ERQDMG=57[0R[G<'>  01AB[
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MG>J&0JNZ4IM(()1="2RN+:)(PVW[)OFGD6T$KH&6X'VB#;"%:Y=F4NH5@-S
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQQ-;-]LF'D(BH2\4AW%Y<G[C,S*WW #TQ(TTZ6*XN)/L4,7V>R5(XEV6;LT
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MWF&VV=EF9K=B+HA9@EJ!\H7#+)B2(S[TCGUQKZ_ET72'DDU;8;*>>"15EMX
MFXVK2M<G?>(N\I*=R[Q)C $S+N:/8_V18/:-<3W-U>;Q=H;G%RTGD>8+;<;D
MD7&'RK[F(BB56<[$D( :/:V]C8/:VVJ?VC"=ZQR6UT5>\$L&_P M3]H ^TD(
MDQEP@/F,RA2[L-"74T\B*\NI_+:65$$8NEC\^57E*6D>+C:+A755<YVO@J<C
MA(]7U)HDG<W48@=)1-=K,J12)$TQ:VB_TE#%<!0V9> /+).-H"\^<>-KVXOY
M6D_L1TFL(TM98X3KRJ]QNA5EFR0GEH48LF09^ DAV@&.9E\>:69[K4Y+#PNU
MNBVJRLT\FI1?O(G4PM(S^?$\L2*XW;Y0KXDS&J>B21/;7B2BU@6&TE>ZGA6V
M:4(C"X_>P%8P6N'++O4%L!F Y8,\:7]II+VZI+&MN7:UC%I \D3K$MPWV>**
M-VV2QK'\QV_-MV@9PJ9=Y<6&C:C;VE[=?9+I(G(E#QON=S,$FBC$1'VMR7.P
M(OF>;(!YOEX4 CUB>V\)6$TTT$:S,X96@B3SYKN1VC66 "WVRW4D9<LO0%54
M@(S/5?2?#K6NJ76JZA821:E';O*+F"V4&W27S<RHB*Z37S>7'YI50""@7(&'
MCTW2[@VL/B6\TK[)?V^GRRPZ=IMD$:QBDBPGE[XCYUV%@BB()557 V@8W[E\
MEMH\,WE6,=O(B,T%O90IO4I#.L;VNZ+$EP8HU4QDD*J@?='S@%B:T87%U:'3
MI+E(D:Y MT6V53*;G)MWSG[0<A7)=!\X<%=Q!Y_6;C6O$-Q%IMC)(K[);FXN
M+6W*R640+>5'"957R[R6&95;>X\L!F"C<"8_$%U/>:MJ'A[1+>"VOX+22YN[
MN))9TL%DDD EB$>"MVT<DK[ @9_,!\PA,/J:?I]C8)+:Z99R6]GI]OLB>T/G
MQ6H1KM/,MQY;%[K.1*I!/S $N1A@"2#2[/3='2TL;;S],L=T4$.GP@X8M/$4
MA=9/,CN 759)7;;]X_)ERIJEWI>GZ=>7=S=P/:VOVFX:*UM_+R0+HR"WD# B
MYP'#D.2-C';'O)HU&[TZTB:[\^QL(X);B2>>,M*(E5;LM); IY9N00[2*%9@
M-X;<-I/+I8W'BJ<ZYK$?]FV5S+(8K6-@9@\:7:K,B)N;[>B",%,':(\\NJK$
M 6+>P_MNZO\ 5KVTOI=+L/-N[;3X8]WG,);S]Y'L\LQW>6QLQN3Y-Y,I#1=9
M>00V[FVEBCG=WE>*WA46A#.MRV;9^-UPRE@Y$BX&7^3.&KZS)+#+*]]#'</&
M\C*D!F$TL'D7!1;49 6Z^\IV-N* L2NY57+U[Q$FARB+3[2#4]0$LEQ9VD-N
MJI*X:Y:<08RQN JLDI+<;PP4LWE. 'B3Q0^DZ<]C;Q3ZGK5[:7-O:B&Z9OM1
M@$P8J(M@693M,@41GYBJ,[1JM&FZ$FESR7SS0:OK6H;[;4=61UMYKX(DP\BV
M"R 13(8HPV"@PA8G<IVU_#NA6^DRSRSS?:]8N+0V]S-;.0DYW73/;6<K2!EF
M5U)=BV3L#OAV9QN7ZMJ5A=K-+&+Z1Y8+2XLIU.2KW"[+</(-ET(0X9^ &/)9
M4*@ N7$[R^>4,]VLOF0.UD6"RA?/_<QD2X@F4@*TK;06PN0<!.+U*[N_%KZL
MSW-VOAE[>:U<V4J%]59%G=([)4=@3L;+MN_>&((44+(M6+JZ7Q3J2WK7<8TR
M%Y1:W5IJ#12:@$E1$6U7S@L;[W>W>4@%PZA&"R_)T"QJCRJGEB!$DL;6/3[M
MHDN8E67_ $>&,3*L5Q&8\%_1."N2(@ OL1:7-:6#2;)4:PB&ERQQ%E7SU$-L
M'F"1SP@;F;'(C( X 2GXB\1#2UN+F2Y\^W.+:5+=9@;PO++&D%JR2G;<IM?=
MA<L=F3&!E"_O++1HGN;^Z^THWF:?:S6WF--,@67_ $2)_/+"YWQ#=)\N]@B_
M? VY^DZ=>7-XVKZCJ<\LZ^?IUO:6MR=C0H)D>TADE=)&N-\"R/.VTGRUVD*&
M( #3[6X>6WU_7?\ 1KBUM)+:"X@E%XE@"SQ>1&6D9I+TN45Y/+8/L\L DG.Y
M?Q*!=VE[%'8H[R_9_L3,9(P\=PQGMR( 6NFS(6C4L0/FR<D/'-';PP7$[7,\
M$ Q97.I02&1YX8781P(1*\GG%YFC+ &1F20#:S1D8_B;6+RTEMK;1-/G.J7=
MI<W=G +,B"TRS W>3;F3[1B;+1?[3+@NR"0 L>(;UTO)K#2H(#JUK%=7D,5N
M6864I#J+A56'$LA%TKR1%BP# JDA8%[%CH*:/>1S7-CNU!<WMSJ%O:JX=U!6
M:6)5B9EFF5(1)$-N0Y\LLRLQKZ/X6B\.:=/')HUC>7%GMN0"CM&603,DT0$#
M&.1I"V8(MRQ!R4&6P]R6V&G/)I[1QVR2N+BYF^RQN;F0+<.L\ 6(>;>;H8I'
M4HP4*-H/4@%QK>6RQ;2V\X\J*6=;N*!)/+8><'N(@D/-R_F*60J%/F-LW[7#
M<6ZZEXY2\TV:"TM_#<*237E[I.Z42L[3-FPD6,^8Y5O+G)!W%G544D[BZM[;
MQ5=7,-LT=OX8N[BYFNI;:-,W;^5/%NL7BCWR2GRY&E#9)  4O&QW]I:Z+Y=Y
M]FMK&#3([;>L"6;9AAC<2;+B)7@\M;C)D#(O&V0ERXV"@ %O+;>;;26\Z_9(
MC.;N.!'V,_VD&X@"P_/<MP9$V[1YG&[)#Y_B'4O[!TYKJZB@M)DEB,%K:P^<
MS33"0.;5C",W+/))P0X94!81B5F!KVKV>DV8O!)!%&EW(BQ6< F?SG-R@-H?
M+PUV\A =#N"_/G@EFS['0(K!H[[4;."VOSEUM1O+QI-$?/$,T:^9)=XB)9]T
MKOY61Y0E^4 DTVUOG&J>)=12275'228V>F_O%T\+')&!#\ACN+P&/RW9N1G;
MPF%?I+BW\KS_ /1_(\GS)_\ 1H/,^S;O/_TB#]R?,N'W?,G.-W?/[S/O8$TJ
M)9'$YNX(IB$@"L\KE9W6:W1HA&]VP$A9$"_ZU]VY0F<?6;JX&L/9:9^XNK;4
M"DUS;1 1VZ,IN6>.*2-_,NVB>=,0A]PD+R8RJJ 6-3O]1;Q+%86=K8PW<F9[
MF6$+,8IEMP-D#O&BF[='8#S&($4(<KM8K5S2],@T+PT8;&/4A9VVF*K6,,4H
M>6!1.5:+"Q%+J0L&?'S @ @$J]%GH)\/Z,FFV:1H-*1?)FCMY'86^V5?-C78
MR"Z&^0MM5S)@;@HE4)H:A!I]B]T]U%&MN'#EHUFB, D65<P[<A[AY9) 3'LD
M(E4')V[P"GJ\Z:-9W\MY/!:>1+Y]M)!:*1$C&5Y9HPX -P(S.7 :3A-^SYS&
MW-W N?&$M]J>IB2SMX4QIMBTSK,DX@G8?NMGF0WB!O,W*LBE&0JKE%DJQ8V3
M>)KV$7<L;>&KA%6SM[J%42_??!=&:2,>6&ED"2N"NY<,V](V61).D,Y73!,3
M]HM!Y(@M[DPS"&6&1%\EG:7+W+2;E#ERJNBY^8$R $FI--<:7JTT4]W*@MYD
MEFTS+.ZKYZ^5;KYAV7"-M!<K\Q &.T>/XHUUM(U86.C)'=Z]J+SK!;6K+"7*
MPP[UD=F:,3JI257D0CRTV8^8%H]7\366FZGHUE;P3ZAJ+RHFF1/'([HGEHTR
MR!WW"X$1X>4)M^T+D[?.:H_!^E0^'[*PNAJ4>L:Q-;M'>W-O=ADNV"&=(8T:
M54\TB3S!(5^8"1VVF4L0"QH6G0V-J\IO9$UB[0+<ZO*H9(&,JPB!=\KIY^(U
MB.&DRT*&7>=H?81&+V:K8R78NGCE9IH5C$H583]IN<Q*4G4H B#DG' "DQ5R
MT-KI<@TJ>2!(T*0LF%>%I?);RI4GD&ZZD9]RO*O!?YP<GS.?G@OO'&J7EEIM
M[':Z4MQOO;^U@V.)T\LI&%8JZ7 C?:S.)%0PQ,H212J $=K!=>*IY]-TA_*T
MZWNV74;NZM8)&BG*;;F'RF#)]H)SEXU\EEN9N&8 MTFG:6MC;Z?:6%A'-;R.
MD\GVQ61K@ 0L;J<F#/VH. 0K%2W+$Y7"$=G EO;JNGQR:3I-O;2Z?936DK,B
M #$N7C9_/15<+$OS#^(YD797G-C8:7>9CDMH%M_[2FN&L/+$H_=LUW+_ *-M
M%TA1F$>,D@$J,C8 2:C?V^DV"7ETL#0O$]V3?(8C=F&!)%FE M\K<*8AA  0
MBLP4F/8N/I^F17\ U.YL()(8M0:\AA6W?=(L#J'N9/)C7;>LZ[MA4MM4Q!5)
ME(CL=,N_%-UINM36T@B=([BQ$LB -F)/^)C(4A,;705XT6)P%4QN5)'(ZBS"
MW3A%MI)B7CD;[7:M$+HJMLWVB4F !9T&-JC )7'!0B( C:.5?,:UC@U7,J22
M1E$;[4UOM1Y#(J*D=R) H"L2O[A0/+^9DP]3N[MK>"WT.2/4;_5;@/$MQ&B9
M6$6Z2W,N+;$<\3)@!_NL>C%4A6/5M6N$TZ\T[35_M#79(C<1XLPG $)2[N4:
M+/VB$>5^Z0,YRA$8#*(]C1="BM)9+@P?:[K4)5NI)KJ)U-TJM"4DFWQDQ31#
M.R(%5R&(5.1& 5_#.@V6CP6^GVECEFBANI$:UD@MKD[XW-PZ-%MAN%?>5B4@
M@! <!4\NY%#=@_:3:27HFMX[A;62-$^U21R+^_D+6Z;+CRUA*JS*-P*X41[Z
M#!-_9<C3F25Y4-R)4L2KS*ODE;B5# V+J-5&V/'SE/NK]V+EX[>Y\>WLUI-H
M\ECX==\W%E([I%> .)'W,J_NITDF)=5VDR0NA:4;C  5]+6'QM+864,%I;^$
MT<QB88B.MJ8)80R%8XVBEC$!5XUQF-F'^K #=@RPO#:F:"26XE1W*G%M/=,T
M+JDJ.8XR+HQ1%2BM'Y:N^3A4H*3SVZ1+8W<CS6[7+RB&)6N'4#RICYD2@72^
M7 0D@C4;SC?Y7RU]8U-=.M8KNXCM/,O[V%[6W>T9!>DRP;-X=04NE4;$#.!E
M-[;54B( +K4[;2K6*348Y,WCVLJ-<6B,+ITE #;=L;_:C&L;>61D%%$2.8V4
MY]CI\*7$OB35IXSJ2(\ NHXQNM%8O"&4*KQ37S-''%($'\*HHP ))/#6@7^G
MW*ZMJ$\^H7;Q+-;6YBD)\I+98_F,@C47;,VTRRX9D4@+&NY4U-S0V\5S)%'.
MCO!/=17<"QM<$!UMW5FCB7[4[I; HQ 3:H 7Y2P!<D6>TW_Z%8M]ANVO1Y=G
M*=T,GF;F3:IQ<#=)D+O+]PGG#;S=U>,Q72;*XM+E[2XE^T7L,2F//F(0F"5M
MUU!K@Q[0V0"&?"[Q&:^J7=]J.J6.DZ>D=N&3S-2U>Y7RBAEV01E7$2M'J!A=
M2%(4*)-NUP5V[FDV%QHVASV\23VLT<7FRM'"#-,)-N9Y2L<@ENT"."%+AV )
M $BA0".PTVTT32]'L=*;384M'>U2>X+SQ1^7YL*.-H2-;AY9D#K\K/NE4%MH
M(T(%MA%8):V$@AN+B6Z;3KID60AIQ(;H(^6RLC(^W<I42'*[PJ5)=YCGU.2W
MU."QC&][JZBBAV6Y"09,Q9LF81@E&(V!2-ZL%7=R\7VCQ?>6S2Z?YWAZ?RI;
MJW^PB$:I(!$PNBS;@85'V<K&75V D#;O*\M@".*QN?&R1[X8_P"Q+I"ZRLCH
M^HA&M]EU+NA$6< ,(WC!)@ 5FA=ZZ""&[<1.UI(\]TX>*X2-!-&HC\K[8V^W
M14N"LB!HFZ(C!0VUD,EM#]HVHB3_ -HS1)<)<2VGE[.L/VGS#;A1<F%AF-AQ
MM"8"Y8X^L:I;Z!IT$Q@GFU*[W75E96%N1-.[B%9[B&"9&,4R"65O*R<AI"^2
M7*@!XB\26^D6LC6>G3S7DOF2Z9806QCN&<Q;I)X4D@_UVZZ <'=A [8++(A/
M"OAI+25[V=8-0N[J7S8GCC5=/:V5K?RG@VJXBV1QQ;5R"[1G)=4218]/T9;5
M[77_ !!96EY>2.;V:1HV6&U0K$6F7[0FZ)XVP,-(K&-21Q%'#'TBP(FHFPD$
M$]U^ZN"DX5?MH4P@W+D1 &:,Q\*G _=YV[DV@%-+5?L5G<ZA:1ZA/$D=Z9'T
M]E-PZ)"&NG00EHKA1N"1 Y(X[?N\>_$^L:M)H5C;23_Z1&M_?3VL6%00R1RR
MDO!L%PPV(4*L'A>,IM5V9*>IF]\1Q20:%>SG3I(K2ZO]12&-C+$51_-0)#YB
MW^U$*J%*JGEL-K,@&QI.AV^GZ=!IFGVWV6"2*W$4$%@8H2^ WVMO,@=DN%\I
ML+([X*1!R&<&@"Y!INF0B)XM&C^PVSC4"DEK(\CLT>5N2'A,C709&7;NWX;<
MQ+%5J/4[FST71]234+CR+2UV.;B> +&K*R2/= _9]AN#)-N50&5WC&T!MX6/
M7+VVTCPU=ZG>-(L"VXNC+)"D;W!408GDWP!4NE( CC. Q"C Q^[S])TZ^\27
M UN_-H4ND6;3(K>VVQ8!C7^T'9T<"X*!6B1LE4&PD_.5 )+/3KS7M6-]J5K]
MFGFB6ZL[/[&52#=( MU*[Q,GVU(A&@0EMOEM@[7.WH+>W\WR/]'\_P [RY_]
M)@\O[3M\C_2)_P!R/+N$V_*G&=O;'[NF8YGTN1YX9%>5#<!TMR[SJGD[;J53
M;?+=(J@K%MY*XP=OR9_B74;M+VYT/2;*T?7M019T69D6W@8.RPW!=HOWD^V,
M2>6<X6U;;]P;P"OJ-Y#)<6>FZ;%'->1(9I)'LP98K<F&>:Y9/L_%T)-A$*C.
M^6.1D(P%U++1/[(T&]M)%\R[.V[NY(K;<LDQE9FNT_<MNN#M$@BPX5DC0 +A
MFKZ!X:_L[1VLXYIY[C4)6U"6YFAV>?,[0LURR/"5@F1LF.'I\HSDABFHH6 0
M7QMI)W1/M2O):L))P(XD>>0+!N2X"%T6-<%AE<#I& &K^3:V^NW%PL<$$:17
M<DGE JBH,FY!,+!IT$>0GS_ZF'[NZN7GB7QE<2S7D4=KH,UZ8FM)6:.'4P#]
MF9YB8$DBG5GC"(S$L\ "@;5D%=K8>+=$M9;N..+097=[=+JUCD>\*N\HO(HA
M$KFX=8Y&,6TQLLX;#X>-NTU""XBO+AX-/@N?-ECN3:&($7 B"9D\PJJI<;C'
MM#LP(@7!3YF0 \(TIT?47(O+Z>0_$6U+"Z*IP3+AS" K1R-SNRB@[5 &58#W
M]W<>,H8X[S9&VGR&:U<M^\(D3RWC!&WY<RA]IS^\BW C9CP3P^)[2]O(-2:1
MKR7QQI[&XGLHHY;@L[N&:)@);<%<N#R#N** #(3[G-:RR_$.RO$N-\-OI4\4
ML.]/W+22PE&V_?\ G$4@R<K^ZXP<Y .@HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\?_:._Y)YI_P#V
M%8__ $5+7L%>/_M'?\D\T_\ ["L?_HJ6@#Y@HHHH ^_Z*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#S?5?-_X4UXL\GS]WFZOGR-F[;]KGW9W\;<9W8^;;G;\V*X#X6Z/<:^]N=<
MBOOLUCI]FNZZM TSH]Q-Y44),;$VCQL5D/&0-NX1@BN_N[ZW7X0^,PLGF-%+
MK,,BPJ9&C=KB? 8+DCAU8YZ*=QP.:XOX+VDT%S;S3VVI(\>CP*+HQ$&!9;Z5
MUB2,I^\BE7#F7YM@#_.O\(!ZIID%NL4-W:C9"WDA9+4&9+8,ML!#:_NL-;.%
M!9UP!R>""8Z\^O)I&COJ5V)[2.QVP,ES.LC6X+0 0SD7!5II,AEE8X17RY W
M;X]2U:V\.I9"2TD6Y#Q6L%K8Q(7A+-;+Y%N7B13;L2H:1F4 E5!#%0F/H6G7
MUY>V&O:O<QP7BI''")I_-&C(7@*VA67YVN)XY"KRM\P)  P1D DTK3WN=)M;
MJZMK&VN+2T2TTR!YFB&F)+'!_HTCEO.2Y<2",2#. JL%4L4?H#/;VUU%?RGR
MITE%N'E)F:S-S+;%K:4+*V9'9EVL/D1=O\(&^/3;A9'MI[A8[2_L4CLG:XD:
M469E6U=[5Y&D!FE<E=LH!&<9R<A\._UF>6);.W>#3]7TZT7S[N8RW!T8.ML&
M29\GS\K+)('8B,F %L^6SJ &KZMJ<^G2:-8SP6.IC3X[>>22^FD;2I+D11PQ
M2%"QFF>3=B;@HOS$'/[S05;#0\W(OO[-9I8D9W\MVM4'DS26T^'8R2,#/*96
MW;%EE<L!DM8TV*ST"#,+?9]]VJRLZAVADG>W'DW(CD_>W#;U"S$,0N"S-DM(
M7&KV]G9F:;49]-AT^6WMYI[@EQ:!C:L8)RTC"21P^/.&0@9OF!!+@$D^KKI"
M0W5U<1VEA:HD,T]U<-(;$LUL!!< 2L'E8.Q\XG"#!.0Q+<7;Z;/XPNH-9\21
MWUAHFGW<=A8Z=J5K+&\RO+!M%PA9VGWN57<9 H:%696#.HDTX7WBESJ?B,7=
MCX2L4A:&WEF\])3MC5TGWHZW, *>:MQG $F_?G/E=I;PI%/ UK%]D6.6-'2"
MW662QC*0#[(0'<1[B(V8HNP(I/RG$I (_/FT\+--+J21ATA@AD8B6)C' RVQ
M9]T4QD9'7SG?AY/+5]S9&'K.LOIS6^E1C[?JUU=QZ9#!!=,D]F#%;22Q^>8V
MD>':#(\X&\;DZ'YDT-3NO[(^QBRMX(M6EEM]-@BTU-\4.WRI#:RX_AV><PE\
ML>7$7(4$@25_#NE+IF=3U$[-87[);.UNUNB6*R_9PU@@W;?+5E4@8W;9OD+.
MQ8@!X<TR?3+Q]8UZ;RM:U*6**XN-LN+-B(Y%LXC*95\EG,@+JZJ7947YMH30
MDL0+.WT^_LX'A\U;0"*QF<6\;&&0VR^6BA[<A60R'8@"(LBN0^;$$^VS$]O:
M0%;#%K&NE0[GA8&$-:Q%TVO&75E9QY:IM (4HS)S<MSJ7B2]G@TNZDAVW#Z?
MJVL6BMYMKAUS9Q  &5U=VVW#1JL<;$Y+%R0"2>YU'Q)KFIVUBT^GQQ>787^L
MV,JSF.0^5OM(50*WR^82)Y%)B+3<*#QJ6^AFSTMH#:1L\=NM@T*B3RA&/*\J
MU^:)O.@VLRO.P8KOE(";F5([6QT[3]'M(+*2#3[&UE&GR&WW.(6D:*)[:&18
MU=E:1B3,'#+*H+9VLBR7.LZ;HE@-1NS'9Z;IZ>3/>6J*\=@RO;H;2'$6Z2)V
M!#,!\I1A\I " $=_JEGI&G6^I?OXX;&46OEZ5:B<I(!&OV&#]Q\T+NNTME")
M%5,J?E3'T7P]>:MJUMK>OVGV46$L<-G906Y9-.VR*%@CB> JZGY"]U&PQMPA
M5%+&3P_IM]KR6FI^)-&CL8($>WM-/6UR;**9H%%OY1A8.AB0!Y0PVB:5"J;2
M4Z"QD6W>&"3RUGMKA;)O[.M&8:>66"1;6/$)_<&,+OE8J,XQLRJQ@%>W%MIC
MM+%;237]NZV3_8+5'EM3MBF2RB80*OV<JV-\A4+N&6!.4S]6\<6VAI:Q6HDN
MK]W2QL+7[6DI,Y:)7M)C]H8F<$9,S J@<<L21(:MK<7A2RM=*TRWM#K@MTL]
M*AEFAEBBEV19LU9I(Y<%51RSXSN3DL4C)X?#:;-<ZA/))-J\EO%YKM?K,D2>
M<42P(:YP\X998EF*J&;<22Q<, 5] T:QL$6>34HWU&[N#97=] /^/<%LFRE8
M3R-%*6E8[T=2TH0NSNP\WI);JZ3;>&]G\ZWE):%F@&SS/*(LIE$H0S,9 (W&
M,?)EF!;S9$FF1[,Q7<=LEN\<$HNY#*8%98?]'E/VCYKAV92LAWX!QSNR_'B]
MF\0WHTZ:XCTW2P[Z/>R7EZ93/\\96R"_:"OVAHVD5I1YC8QAE<LD8 :C/<^)
M2="AU*T&EHCQ/+-<O']JB,EL8K;S%N69S*CINN-K?+.J@!W9:ZBW=M-1IX?+
MB$2+&+-&54M7+1;;4H;CRQ*T1A1-N%#;WSB7:9(M0EBO+:UBBG$B>5!$);A)
M#%N$326\H-SF2X$:O)OP<(21O.0^?J.II8Q>3+/?6ZO]FM%3[4KNSLH LF/V
M@O\ :6$I?S5*8_=LSLJ'< &LZGHVDV=U<W ^TJO_ !*_+:%YI9P#&!9R1O)O
MGFD#2-&Q! 60L?E8F3/TS3F6\-YJFISQW\MW)IQ:*YN)(+.$B)!:,TCK(LD@
M1)%G 0M(4.2&19+&FPO)Y^L:E).]Z_GV\UN+AHVL1+Y9^PHS3KB9I61DF  9
M0H78ABQT$@^T2^0VJ><MU+/!#.LNP*NY3);XCD4M, DP1U&Z,1G/(8R $<+M
M=(5DOI,ZF[1*SS*# $8E[;]U*!YX!G >/E1$-Q8Q@MS]U?3ZKJC6NF32"_F?
MR9KLO%&L:?/*VGR2139\]3'(-Z)(T229 RQD8UC5IM>,VBPM&D%\@LM3O)'+
M0V_F2,GV0;)'1+H([Y<Y4N(E(/F(%T-)TZVMXH/.AM#8S)-;W,]PZ-O$D[C[
M', Y5Y5>15\PF4LPG!VM)EP \/V\6A65C%:QR&,6XB00W$(>ZE@1XQ;2(6*>
M>J* 7C;YC P8HB*IL7K0VEAYPGD>")ULY;BTPTM\I>:"*U$QD,BRI*Z9D9E^
M<DY7<^VOJ=W#I_A^REUFYCMXXTFMY4N91]GN5!VM:O\ :74RNRJ=DIQN*%R0
MCE'YN!'\4:G?:B;/S](M,66F:=?AHGU9X([D/!/YQS(PD"R*SA]FT_=?S< $
MEA8W/C5_^$DUJUDN],NG!TZP^RN&FM@K2B%U9_+4%XK=S*VT.Z,F6B:,MU&H
MLQM]09[^.XLY'</+<*IMFB03,]M(PW)$%961Y6C'R%4^:0!A8DCFE>\C-K'>
M_:WD@W7M@46XB"S8MY'4$JBN&Q(T>PI(H&]F+'#NM<EO=1@T_3H_-U"[NUBN
M72=#(+53_I$,DD"_NI+?S^!O7DQE9'9F1@"3Q-K30W[V-A!=ZE?7SA/[-N@J
MP7$2I.K0!7 "!O+D?>^W>,LK3+'Y1KVMB=*M+F/;'J%_=W$MO<BXLY(FUJ1+
M>?9:DSAML2QI'MEWN'V/DDLQ;0_L@6(\33>7=WMY>W!>=WTZ-X[O?&8X;79P
M7BC4QY;<JY+$R >8%N:O!;RQ7]M=C>EU_H+23@PB[,BRE+:218OEA'FJJ2*2
M=YVY+Y#@%BY%N^IQ>9<3Q+J<LEH6"F&9S'')MA4B,.(\">4/O!#8VL5?%<G/
M?7.L37FD:?-'8P37&R]OH'>V2S?SHR;56CF9?MF;EF,@^5V 0J_S;(Y]1E\1
M7E]<6>H7UK"97LC>:?LCN;O(<QVL"$$%=ACN!<,QP)7*F-6?R^@^Q_V5H_V>
MPOO/M/\ CWDG\WYY=K;'BWB>,+=RS22?O@!\W##<%) *=A)INF>'X["TFM((
M(WDL;>VM+A8?)8F,FR;%SAKQAO D#<-N;C)WV-7UW3-'TN]<:C)=0;UTY?LL
M\D\H=-J_90!-O-T^^3#K@C +_<!:2\\066EW@UO4]3@MK&.)DEGEFDC !!E6
M!K5G&RXV-$P;:SL%<;4RH.7X;_M+5+BTNM8:.U.R.TMK"XE:3;Y9BF!N(GF8
MBZ95:1,9:-<EV<@4 5[-6\47%UX@UJ6.6WMW\BVTZ*=0L98GRD*M(I@U)79%
M+Y &\*IR2R[B3>:MK;/J/V2.>(1^8U_N8JDIA:W<>:6$P\Y$\Z)RQE4;B %1
MR2>WM;6Y22YG@D;RK:*&?429"\D4>ZT!-S_Q\E8P5?*X,H8%B9&;#U?Q+<RW
M5IH>ARQK<R(UJ9[RY=HK0&+:8)I(KC<UP)DB0R#)3ST&2SC> 6+SQ1=W%[/9
M6;1W=Q(Z+>"&9$2SAWE/LC,MW^ZO"SE5<8#MM'1"R:&C::OAT2PQW\E]JD21
M0/,]PS&]E$:R2(T;W&#<%(RP=MNV-XP"R(11IGD^'M+CC5KN2^B=(Y9;B42O
M/-)M;R9SYQ7[1Y:1())&" R1A/E;RZU'N/L4KI%<;ULI;:TC=Y]X596B5HY-
M\P+S8PP=@&Q*NT.2P8 C!6)(TCN9+D(XCC\NZ;-V86F9;>,M/GSU,8\QFX<*
MP;C(3CQ!-XY2.%WCE\+S6X@BAN;XJ-4FC:9EAW!Y7S&40M,C N8G.)4*E(]U
MKX[\@7 GA\*316ML#>W$Y>X9O+D2&5!*=K<$B=BC.TD 4R(?WO823>>WVD/.
MRWWGI]GCN]KAA$JO:J1<!1<!XF(9/E7RY1E22[ !)+<7%G]H-UO2;SXAYUR(
M!$7*H+5Y(9,"83$(LBJY4(R_?.Y\O6=?6SMXG6.[N]3U)Y88+"WNF#7#L&1H
M$V3L(7A\J/S)ONI\Y7#2'$GB?Q6GA^ 7B7?VB]>4QV\,#JT=Z4>5?LRQ>8S^
M8&*1L\:Y#M&6!1618]'T=4NC?:W-'+/.GV2YM[JY:XBL8I(H%%B=\Q#2NWEL
M9-I\SG(&]: *^C:%<V;Q3W=W:7^J7=O/:M>1WSQHT@4J]JA5MZNODQ_OR)92
M('W;=J"M@XFLB;=I(7D1((PLL9N+E8TD$EFTWG%VG0K,V\.NUB#N;;)D:Y)T
MNU!DD3*/9HTMU(J,S[T%N\T<KE)T>.-&F;=\Q(3YI,#G]3U)O$VJ2:;96L;$
MH]IK$^5C,J?-+_9L8\W9+<; RL^_$0,C*5+D  L7]UJNOZSJ.F:<^I1PR7"[
MKL^9% @@;_CTCEA<[3(T<Q><9*!UC8%]JKH6EEI%[H+Z=I7EWNGM;G3DVN09
MXQ',4MYI%B+1P*CH4ESE@ZD%MP,@;:VTC2S:V=Q)]E1TLK>:W1-TL2^9&+(S
M!PRNC;T1V:/:[Q L[;P]C6M8M+5#)J$]I?6[)<PBVMU>5KQ=SJ\'D[MF\,((
M][$[G=HPJ&0 @!KNH06EJEU>:U'#9W-P;.::S:5I9&$K*EO!&A8B4DLKNGS_
M +LX"G#1<>;.V\?O<74]O&GA^9)H[33TE0//.5N&6:*.0)LN)(Y3-\XVA2C'
M>6W0Z&EV%]J^I+JNJB[N+>Q=X](M[9=SHZ2GS+>=I&82.OV*+]Y(P7S)6*N2
M(W7I'C07BO\ :?MUI!B&SM7D603O$'9HU+RY>Y62 ,9)/NA<##>8] !'>SWT
M]M$\T ^W2RV]T5N986CA"220QHA97CN3')&[84$*CDD;8ZR_$7BI;.W"V[1S
M:GJKI;6^GM=M Q #AX4D$GE>>)!(C.CJ4W)G>RQK(:UJ=QI.@O;V5S)JFIW"
M)IMM%;1W)6:41RIM$AFPCK*DKR2;]ZHF&.X*]5_#.FS:?<)J]UJ^FZMJES<&
M.YUE)BL A<P>6GDB39Y\J"W *JHQM)+X7S0"QI"36,UWK-W=27NL7**)K@*8
MX%43;4L@AN3#YX?S8U*M\K??.6S)L6[W-L^E1QWUI=D.UH)3,ZHX1566/YI7
M9YPT<C@D.0(W1BI)<QV%Q9Q2HUM<06\A\L2&6<.8LM%!Y5QB8^;<,T3QK)\V
M"A7)((?E[@7'B&\CT&Q:#3H9)=M[?I="66$H%VVX8NPEOP+8,9#DPJ."QPS
M!<75YXIO(_#5I>_9X(9?(NM09COML!91:1EI9%GO5\K<TP)\K!8?,:Z2PC7[
M/'IQ\NP>1Y+=84NV+0AA'*\4I68,]TZ;Y?,7)3+'<WWI:<%GI>D16-C;Q6-I
M8OLTUM.N[G;#&CJC&V=/-9'N6,C2!@C;U!4D;@YCU/6%TOP_]LO=3CCMX+>X
M=U$K>:MM&8T>W)%UE[H.0@F!8!\C@L-P!<U#5O)L[B\U6/SI+:6-H[>.V\P(
MS%)EMGC69E-R/+0)(=J[Y8]F2Q5L/2K&;5;C2=8UBWM#JD+VT-M97)-S]CC8
MF4Q 2S*_VQ8Q'))*RYVJ-JM@YL:18S:E>P:OK4T:I;O%%96EU(98K-=\+P_:
M(Y7WKJ#+*5W@G&1UR VP;ICI<D,D=W');(;5MUXH8!_)98"1<Y^T,LBQK(S9
MWAF!"NH< !),^EQI!-(KRH+<H]P7>=4\[=:Q,+GY;I%4AI=W)7.3M^3F]=UC
M4;Z>:PT2YOGU.^WV?VD.K1V>Y)9'ML1W"QB[C$;E7 X'E*[?-YADUOQ+<WFJ
M0:?HTL9U2Y22UN[B2Y<VE@&\SRX)E@N#Y-P9/*B$G4DML)QL%S0+;3M*MH+>
MWF^:26*VN-0>[::1;A+EYC;7.R4A9B9F&X,4=W92H!CC< T-.T^WT>)X;6[G
MO%:5,3-=EI]0EA5]T6\SC=<!XCO)"J8P(R-J?)'>3M9:7/<7.I26UM;VZ1W*
MM<JK0@9Q;RR/<_+.\<\8$BLIWH'9RI5*D#(;.?[1;3N\,0L98;NZ66)T8Q,M
ML\;7)5KATE$8D<_,P))V,H;C[.XM_B'9D'S[OP^\2PP1M<E3>E")?L;QM=;O
MM"JK-YQVER Q(C4B8 T$E?Q[*FK-=3_\(Y/%<VL5K!<M"=;3=+B(1M(ODR)Y
M.=V?WB-\VQ=R+U%ZUQ+YI&I>>US++%&+%Q&LJ1;P;4!I\BX(,Q\R,IAH@6P$
MVL+<2P^7)9W$YQ*\$$9G2;SUM]RFW.^8[IGQ,X<%6&Q?-^X5;G]9\0:7HN^-
MY+'6;R:4Z/;6D;;FO@<J+24O,V9(V*EY95P%E( W2&@#0US7$TJ7;_;=\UQ>
MW8AM&L;=;IW16D$T:PJ6RT.79I BXVQ!O-*LKY^DV.Z\;7]9D@AU63STMK>S
M_>)I2L)FD6V C9;B[+QN9< MPW&T /8T?2Y[!GU+5-:\W4GB>V6YM7EN$C41
M;9;:UCDED+3(]L)&9HV9\$%2<[=A],ELXKJRCL(#'+F2"*QMT0(L*CRI%#QF
M,7 /D(JR/M(A5UVA60  \#PRRV^H:?F$?:+D-91,J0H6GS)"8U,GVEEE0.,K
MNWL8R2'!X_5+V\O;S4](\/I/+)8VEQ]NU*& SI;S()<_9A&(E^WR?:-SX*A>
MGS$&M#6K_P#M:\CT32'GM)!NOM0DLK/>^F6["9O,3*+)'=SB0#;M9UW.0N?F
M;8AT=]+B>.&*"W\F66YG>WM&E=$*W")/$[1LTMVR^4)-Q?.#Q\XW %>SL+/3
M].O(;>TGN8;")YYGM8Q+)=R 7$+O%.GEO]M8(!(<D@D*.6+5)J5W%865SJU]
MJ,C"SMY%6=7AG+O ET&:W!"JEUMR9,H5PI0 @,1)K.J6=I%?:O<W.6MXI<>3
M,)!!Y*W?SVV^/8USM#ATS\H7#9"_/S[3/XEU._UC7+6<:=9RL=+TZ*1G>[$<
M=P \2C:8[L$2_*&WIM :-&1)* *=SI4'BR:XNO$5M&GAR&X+BR3S4BD!FO%2
M1 F'^V,[(KQ=?G^8&1E2/N+FZE(ULR/)<O:(PN(=/\XR20>6[I'& X$=Q\XR
M5)8@(QV[T"%Y=DN6:YCDMYGE@N)899 9(T6Y)BMDC=G^T(5&\J 2 <<J%3#U
MKQ';Z7K%OM2#6-:DNYS86=I<&1I#M\H+Y;28MV4HZM+M9%6*<_(TI2@"/5_%
M(TD3Z/;QQWFIW[RK:6.ERQJDI-S,& VNLT4I0,9)C^[1D9@=P*M7T#2%\*Z)
M<7]U>1W>KPV7E7FJVJ---.Y>8&WM]_[L2B;9_>,DF3(@9PQL:)HL>CG[;>W,
M=QJ.HHEIJ5]9WD^V8B3R/*#-(%1XBT2K(6,S[)<+O))V(M2%\)Y1-)))=/-;
MSV<-_&S1-'&Q%K&R2(([@@F0D;L;7!?:L;  L7!51###<R75N4N+6$073"20
M)& T D:<%KC?&["0\J(Y 2IRQY.2:X\9[RRS_P!D3;K>7;J@W:DA\R?[/;>6
MZPEE")$[8.5,J>9^[+M'J=\WBZXN'759!X9EN%L9=DZVZZP5,["WM"S]2QCC
M=\@38.TH$(;I/*LY;R[:-O.599(DB@40I+-BZ9TM#YBE;G$A$DH.#M8?*0^P
M KP#3--^U+;ZI 83+)8RPVDL-NES(=XBM8MLB^5<Q((HPWREE"@Y(4Q&K>)K
M?2OM/]HWOVI7B2&1M.)#3.?,B%O!&MP9$N&F$I#!?NH5+9CW*:CXD06<\QN-
MN[,%SY4RL6<%S]@B2.Z#)>[6 W+G) _V0N7:1ZA,CZOKNIR?:)+@V=G;W$\(
M&U6FB\F#RIT1;YPI+2Y^4R%%  8  DL[;4;N6*^O[>""ZG\[R[2RG5H(FW3&
M6WA(N$/V\@R;[@ *-K 8^8G<GU"QN;B6<:I'<.UN4Q:W_EK<Q2',<<*BX 2?
M][;?O2!GS4VD;QM+O4+%[BXG?5(Y7#OISBWO_*6=V,A6UB7[0 ET,1Y<@$YX
MVY^3'USQ++I &DZ;=R:CJS)/#:M:1S/]E@$<I!;<TB7%PK6CJ%9E9F##Y 7)
M +GB?7KRSEFT_23/=ZU)_K6LW*"VA1MXPC).#($D7=A"6!7HSP(QIGA1-%EU
M"ZAM/-UFXWW%S/;HJD.S73)+ 9(]AF)F*;'8[$*AF8 &2GHVE:;X1B$YN=-A
M@2X9(I#$LXEF$\P$=N%8.L_EF96B1=@DE/EJ/WBMJ?V98"U^Q+! 6TKYK@V]
MK'(T3K%B"X11;D-<JD<>(U VK)T8>7N !G>.</))!;VK^;/;+'8-'-&9$FD$
MT"/&2;G!E62+YB0-^$W&-^;U)9O'"7,%A!''X7A>1YYK7)%VKM=1RRVDD<9?
MS0>73!\PG:#L8M,:I<WWBI-:T_3K>2UTC2[UWO&T]][SF-I7_P!&"HC+=&8!
MF#, I2)AYBR'=UE]I5NC20P6?V&WLL3JUA$0R 1!4FC"PG=,OE&(1*2#&V&#
M!E2@".:T%E=31QVUI!</<3SPBRBCA>:26)RLL?FH4:Z 1T(WX*EG? (09?B+
M6;70M#N+_48O*LGE#0S16$\8LUN/- N-JHKK-ND*R#S%; W H\@C:YJ-W8Z>
M;#4Y$DL\W",L"+MW>;)(RO%'+$-UPRF021IMEVRR#YV$6<_0M&FD$?B+5(;N
M+4OL7F1Q>22VEQRQLTCQ*L 26ZDD!:0; 1OVXP ) "OH.@ZN'37-=22WU:%)
MB85MQ*=.MW6;+V_E(8I;J215DD8*20Q78H(5NLEB>*6YMH].GA\V*621+-VV
M7";I?EB<.BPW#-(CLQQG<0&;873/N&B'GJTMB\*7<ACCMHW7<K>?YQ@:-=XN
MP#-N",['RLXC,I*\_JMS!->+I6E:AYU[%*8K^2TN8F%FN+K?*BI&&^VRHTS%
M85W!T&[Y!B0 L:KJ+W]Y=:!I/$S6CWDEY;6+ Z.)1.WF&$ 2"Y=9%4*'WL2[
M[$ (DV+'0HM"BOK:&#RXXY9+L3PQ/++'O6;_ $A"\<C2W)SY;*7?*JIPH;RS
M&=-CT32S;W31R)9.@-Q(9P\T,GF)O1E'RWC-+(&,>YY"1G9YJ[+&NFVT72[^
M>\,=O B271:*%,2E//G @B=RHN$($K.5(<KG''[L +N&*"XN+B(QPO&[HT=O
M)"ZV\Y,GE^4)"HCNIOM:L2RLI^Z?O!FYNVC_ .$HU:TOKJ/[#H4>H7/DV\R>
M6C$R/ 7#;%:*Y-P(G0';(OFR[9'+,D<CQWWB_5Y;G4IH[?P^;B&-K"Z&ZUN8
MEG98MVX BX,L;!XLK@20!]Q1HWZBSEF9X+JS^USI:V[QM:>>9"%"AD1Q*R.M
MQ(K0L3*&VA6&5WEV (Y[\:9 EW'%Y*K%-=1[K6:"&X$SDB(HI)6X+M#DM&SL
M7<(A+.%P_$FN6GAI/[#TU8Y]3G?[-I]F+QX!/O:)KB-Y?-XN-K>8)7VL3,FW
M>Q;='JGB*+1_LNFZ=+ FMZI+]GL)'F>+>I^S9^TB7<5N5A=-ID61CL'&9/*)
MX.T:X\/V?]I7ES_:'B&_W0RW0F!-R(" MNZ&XV-<^7'(NY>%*/N9L%I "QX?
MTV71=1^W2R^?J\_D1ZM?W4R0QLSE0MNR),^VX'F*ZDJZD-Y:,B,@38A2\OOL
M^GQ&>'R(C'=3/,7\N-]I^SMLN=XN1&8SYQW <L#\^*D3R9WL[65HPZ/''%#=
MRB8P,JPS>3*/./F7&U&D609V@;N>LG-EW\1RC3C+]FL+&[AANKY[YI KHR%+
M,KYQQ<_OBK3 OAT1@?,VB( SXM:U'Q]J,HM[Z!/#(E?3[Z=U6*-ED,1:V $[
M^=,VY8A,NQ5#2%-Y=".PLQM@T^VBT:?[()2XMY!E73>DBW3-(F[SE=E8K(R/
MN\Y@)&128[>)H=$TJ#3[R/3((4:S$Q*R);)O6);?!F93< A4#D2#=&XQ\^TQ
MWDR:79RZI<1SWD+10SK:RVZH;QT,.)G'D*5NR=J)$2-Q1  ISL *]U>V5G9_
M;]:L/,6SV:@99;"202(#&BW<K"U'EW*(K?NUQM&<X4;DKZ+IVJ:MJ-GK&J6\
M\"OF6'2[E?+\T*;=5NKLQIL^TA5++&P(&$"[#&S57T[2Y?%-Y!K%U%.D:XET
MHL4V7& BC4Y"L6S[08F3RXI%^7RS@ 9*=(EA#=/9O+91W3[X[N)KNV"F9E6%
M?M,O[@>5<*NX*@VY QQC]V 1VNE6[_9"UG]L8RB^C:^B.Z9_W6;F4M#F*X0%
ME2,;?E&T!0N(\?7-0N(M.CT[3[2>77=2M))K-KBT"0W%R@5H9)G:!0MR$AWB
M,A0I0JV $:C5)HEO(;&TTG^T-4U6*)V$R/9O=PH(\74TRVP\J:%NB@J5W @!
MRB T/1=+AL]C2P7EUK,I:>X*?93?2H8R\C;(@8+B(K,4B4A@5=B=^]T +EII
M-I;&WNK]8[J2:X2XBDOT=%E8R1A)Y!)&1#=*)3&JKMW8"@*JJL(L:Z/HT%W<
M+:"WC3^T=0>33FB6\"K$\EU(HBS#<*XWJG).TCK\T1JT$/V*UNIS&J!TN1/<
MV(:69MD4:W!!@_=WBLP$<>T[\;-O/[KGXEU?Q5XECM(H+N+1HW+W-T<1I?R1
M&W592ZQH\=P%9U9&7"M!M0H\?F1 %.XTRZ\=7D=L;"^C\.6T6;F![>!)M3;"
MSS)O6-1!-]H\M)%WJKLKX*F)J[18E@>R2.*.4W2%K>"^9H$NG51.)73R-L5Q
MYQ9BJA21O<AC&%0TJSFCM],MUTNT6![>*5XRA17:,6P61Q]F4+*@5@B_)_JU
M^4?\L<_5M57P_I=K?ZB8[D37"2+ U@PEU,_NA$2GE@I>*0FU>C>6QVH!F$ L
M7=W"OAU/LDD<B2.([5I(PB2W#SPKYTV+9A#<+<.Q";,;MQ9>#Y>?:VROJBZ[
MKMG(UU>/]NLK*:W98D0;"H,8#LU]%#$6SM#'>R*2J90\-^'9O[9;5-6,=UK!
M14>T:4R10Y:VF=IV"LOVI3LV[2JLD46Q451LV(#8_:#.TD<SR/;+*+L[%F<&
MW*2SJ8@(;H;UV)A2_P G]U?*  BV<I'<"-WWLC7@F1(YY3(+5I#/&@9+H( H
M4;,F0HI.TE,.]U2\O=172=+\AIH8H[[5II+4RR"/*[)7C$ VWNR.)XXRI&0X
M*82,M'<WVI7M^-!T>&TM)+A\B[OHV=8]J6[0R/YB%YKP1JSB.1HV79E@ZJDC
M;&A:+:6A%O!9QB1+B2:2T:9Y%+/);S&2Z8^8/M48*[<NV[&Y2JM^[ +%EIEC
MIEA_9\,D=NZNUM=WBW?^L=WA7,Q1HV-U,A0A\$JS'!.0'L2"WN1?37,D=G 4
M,]T0EL/L4RQP,C7!8N#.@4.K#Y H&<X0DM0VFHM\@DCLQ;^9+-<S+;Q,FY)'
MGFC**8I\O.Q"J V#O*G:$Y>QO;GQW>PV-K%=P^%416BFFF=I9F@>!T9B-LL)
MD67>A:3>WE1O@+N60 L;QXP*K)91Z=X2%PDB+<Q1F'56DD@F1W4[64.TC; I
M.YR?, *F-]RWTJW>""&.SS'/+'?$-$;?[4ZO!(;FXVPKLN RDB/C?@Y&,^7'
MH_GV"$274=O(]QON][Q&)9YF@8QO&&S%*QD945&=3NWNTCN-V'=:U;Z-X<TU
MU;^U6O\ R=0@@L[8F?4RKVSR3Q1,NR)LM)(T2KDY+AD8.P -#5-<BTG[+)>6
M<%U->1?:TLX+=UFU"2/[,?,$!B9Q,@W;4+Y4(NXX!:+'\,>&;_2O^)[J(@E\
M17^)(]EG(]I$[^5$USL\A9(9F#9D3<N_#%BH!,5SPWX>OIKBTU#Q&)-5U1$C
M>V^V1?Z.@S%))/%OB,D$H:1P$8J6,?"HBJL706*-<)")+&1I)'65OM4*JEX%
M:#;<R$1 I.JA<(P0[E90-J*Z@!#8J[P^1#)Y$KP7$<-PC$3)&J#S)WDA+K.-
MR$*S;B;>/E?WF.;FNKCQ#.=+T3_2[/4(K66YU%H@FU"BM]J\Q8UV7854Q&0<
M;K>1=JJZU(W]I7\T>A:.L:^:\=]?ZE<1-)*K":)PSF2'8EP8A&5A*?+N&/+6
M)/,V+'1H8-+AL+&&1$F19EDEA >=OW!-W.7@.VZ5@656^\1D]#Y8!'INE)'I
MW]G6=G/!&^V2.>XB4/=G%NQO9BT)VW*MNPL@!9D)(QRA?W]OI%FNHZBL TP1
M+=W%Q>H8S,4-L%FF46XVW P=B94DJH"_\\K%[-;VOVK6;F/98-$M\\$MN5C*
M1>4S7,O[CS%N$ PL98Y$2X ()3D]*T)=8U+1M6U%[0VDMP]YI=FBM;K>RB57
M6_E>-54W#0#=Y3*<X8_(-X0 L0:4;C4HKR\TF3R('%\EHUO)'YFR7<=0<Q6X
M#7CA(\0<,%+ _?91N1V.-E]J$?\ :&W;>1))I^WS-GE_Z2ZB NEVL9V! 1NV
M?*J<A+$%E<7-F(I&\R:ZQ,DQM!$90##MN)@T)"7,8 VJ0 Q3.U0-L6?<W-Q%
MJ,-O8VG]IWEU%#=+97RBU2X1#$IO)'-MQ<1MY8,>?E55(4-M6@"O?WGF?9[2
MUL;'4];GQ>:67B\ZVN\>6B7\TRP*J2(@R0C=&"J26CQ<TK1+'2DO[V&SDN))
MWCO[E[BSVO> LKK*ZK;@B>,I)MB09R0S /)N$>BZ%_9-G)<F"?6-2O=M[/)<
MQ;'OV4PL'??&!!)&=PBA+*HQR0=S)H3P[M.=MD[>;$MQYAM,R3;!!_I,B_9S
MMN4V_)'M^8J!CC$8!)<>38.Z72QS.KQ2%98@3?LJHWG';#\]PBV\A6.//"*3
MMRNSE].AN_&%Z1=6DC:#*D,_E3QIY6L;7C*7$SBW4JXB$3^6#M?*I\OERJ([
M#2D\8:BI^QSIX1O_ #[QH'B6!-2+F1?.D"0JRLN8R@9LNIBE#;XG!["UM_-@
MM"UOYTT^)Y%N(-BS['B"W$Q\D;;A45&"87YLKT0,H!'$58>1YDB/>)&N92UI
M)?"2-09781*RW"I#+A$(("C=LRNS'U'58=,M].M]DAO'M[FXM88X MS/(0SF
M>-&M@/M'E"=F7"@/*$<$2*PCUG5K?0H'OO*@U&ZDS$87F/EZA=Q.?)P5@*?:
M=MO(,+M*NL<9#?NV6QI&BWL6K+>:O:_;=1O-TH\V"-8H(HY+<)YKHK#[3A%D
MRF%=D*YVQ1% #R#PSJEP;J]T^^-]:W__  G5C)<K]H$JRN\LF8I FV,;3$S%
MT7YF"#: H*^YW4RM\2])@ DWIH]ZY)C8+AIK4##8P3\IR <CC.,C/B&GRWP\
M:ZN+NXU*UG;Q;HRRQ:E)NGN%#385O+4)CA74<(%4;2<+GW.\_P"2AZ-_V"K_
M /\ 1MI0!T%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7C_[1W_)/-/_ .PK'_Z*EKV"O'_VCO\ DGFG
M_P#85C_]%2T ?,%%%% 'W_1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 >?ZQ:Q-\*/&,*W'G6X_M
M66.6%WC8MYDKLK#@C;)O0C)5U7/1RH\\^%=\-%L='F,-W/<7NF;;80QQM/+L
MU!]T%N60($ 9GFW.6VNK#:$R._UX0S?"3Q?);VUV(F?4L017 !1EFD5V#94[
M"ZM*RDGAV4;AA:XOX(P10Z?:70>>.:6T\MI3:N7VB\^6. L&#1Y9O/9 %7S(
M3\K!WH ](T+2KS38(7U&?S+Z+9;R2V=J4CM%+Q,MM;1>60;?!VO)G=A!N(V#
MRKD/DI<6MPS1PSVJ+:))=2B1K19#;%K:8^<2\\AVE7Y_AZY_>%AY+V]I<6ZQ
MI B11QR640D6W5A;D0VY$.)+=P,M)VQ_#M_=\WJ6KZI:>=IVEZC_ ,3,110;
MKH[UT<W'RP+.!(_G2.RQ*&(<JS22$^6ZH0"Q>:OK"W5GI-BOV.^CV127<\SS
M6UB!+;CRIG9\7$DPW%#E9<2)E4WLXN:!HVF^'[>RCM!'!):(EK]HNW5Y(-XM
M0;><B7#SN%C"%1M4!% VA0\FBV%KHT%G:0RSI'%GSKR]NH)+FUGD>W<VSG#9
M:=G+M@GD_*0#'M+F:72-.GO+RY^SM9>61<S!"MM&!;&2U6>X*&7SB& E.!N/
MS$,@% $D]T+-(9CJ<FGVELB?:KF_OHW%CAK8_9I06(9Y$W?O&9F4L2&(<"N7
MTB*?Q7?Z/JE];R:9X;L+A;G2TECBA"L4@%L@3<T;(RS,HP"ZR(=KQEA&MBUC
MU7Q-J6GWGG7=GHVFO;A8R))_,G655:)T8$R@8+--( T;&/Y8WBG!Z2TL1IT6
MG%([&S;3O*TV,RM-LMX'6#=%&SX^T,SI&BO\N,C@LK*X!7T^UB@@MVLKBQTY
M+/R--,T3NRHL;PC[+N?"W&6\Z,2\,C.5"[R]9^I^(HM(U;3X8[7=JBQ):VT=
MT[M-;K-):J(YOG;>KMD&Y!949-O[Q_E>34]7ET75-'@-G'-J\B&QL@7FD*D_
M96DB+-\TR$!G:YVXC$?*LV5:OX2T&YT--/N+JTD.J+;K;7%RT+NEBA:VVV42
M DO$%R!+N<(R2.Q.YQ0!)X;T.73($NI9-FLO]FAGD@@2<:9'OAD;3PJL2L9,
MLFU@,)&5);$:$[%C9IIOV"WS]A@LXDM0Y166V/\ HP6VBFD"L\;XP3M8LV1N
M1E5:CC2VL[B*[N$N[!(7BM;3;;)&MBDIM%%I@;ED#N%&] P7YU#KM!KF]-F?
M5;RQL-+M9[&QL=/M(I;V&1KD6J3B M80O'MW;D2)S<AGV!B<KD$ $D\LWB"W
M6W@L9 MB]NM_+:N;B=)HA'BP,HE#22AI9&^T-A(B0W#J9$Z#2]+AT9+*SM+2
M2RM[1!#MMK02BV9FMR88Y64.\3G<7?8V3N9GC* 5'HFD6^G6>FF'3I]+^QQ+
M;^1$#(;,R&V9X$Q&5FC9ER\Q)(.\[AR4SY-0M_#EA+')<P64.FQ?9H[B.$W!
MTPI!:R?9%!7S+B-E#RLXP0B')4J&4 U&N+;0[=KG59(].M[5XHDGBMT2#3T(
MME-LDC*"\3OU<* !D$H4&.?TJTFU&_TSQ+KEM)HMKI[Q0:58B(QR6#3I;1^4
M0$VR(Y+*#QY8<@X;B"QIVCM'<:?K6O&2PELKA(K6VCVE=.,IACBMH]L(21")
M'1G7 &\*2YB22/8MK2&WMX]+MY9+&>RMX;8-:J)I]/5Q"J1P[X"9(&,;;I7!
MY1L_=/E@%BVL(;:XCN%LH[6>)(;1Y+6V#-;*#"5MH3Y +VY)8L_&W+?=Q^[P
M]<\1)X:^R6]G:0'5X_*@AL1;KY:"3R46T@E/E;5D;#*Y##$,WRGRMBQZOJ\-
MO<6FCZ;'&=8@N+:W^SV9 _L_FWE^SJPC0_9Y%0EF&6VJ["-UC=8Y/#VBV7AN
M>UMYI9XM27RH9)D238LCI;C[/;!HL2P[+4!F)9T6,EF!+,H!7\-^%K_3KI-;
MOKZ^?6FBMK*:XN5DGD@B\V&3[/@ I+E69'N$VJ"F[:&\QJZ3[8UK;K*ADWVR
M)$L4MPKM"6$'^C3;I\/</G".3@;ADG/[RO''#;"TFU-K32#8NZH8K@)';*L:
M,8(2T*"6!HD9WS]TJ<<Q@Q\O:7>I:W<2PZ9<QZ=9VFIBUOKTRM$SKFWB:RF+
M.S/=8X%PA/W$".#(VT T+J6;Q'<6UA9:K=Z;INGW$4%[=K>$,&!@SI[N)BSS
MLQ&9E/R_<!8L^=C2[:'2$L;73C::9I]H@M_LS $6K.UN1!+MGPT[[GPVUN9
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M^42;@JQ9E(DR1M(_>>8<_6Y8O#0RMG';9=VM8X!"JY\OR4%J?)):Z$2*$B?
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M\K^9<,!$4D>*.!A]L5N!&F-P3.<1@1@%RYGTZREMKF]?=))$)TBN$9#>J&M
M;B6(0C_2481K&@7<20HP3A,O0-&OKG6;+6]9LI)]0NK) BR1^5 $1K5FFN$V
M'R[PLH8*N0!"J;ODWU'X>TZXU/6+75-7M_M=^\44WV5U"P6CJMNWF7*[/EOU
M64A6"KN1!@1C@=(/)C2W>=8V2X>&0->1"(73;K=5FGS"-EP& "1\9( XQ^[
M*^G_ &2<PFV62[C=XU59(G$,K"0R-/*HA"0W"2).2HV_/L#[69 G/W6IZG?R
MVVD:9'''?:D\3FYOK2,?92(()!)=+M >^7RV*1(0 NUF 50:DN=2U'4M<L]
MT:*"6=O*NM6N985)ACX\N>96A39=[8H6C3! )?<FU$8ZGAG2;33[!-.M%CNP
MMP;B03H^Z=F>"7S[HO&62Z4,"%)&[@X08$0!)H6D6^F00Z;9:=.]JVR]$M\"
M?MKL\3//.S1[UN48%@K8SD8^Z1%8M;:ZD@T>W:'[3'#%&4>_>=WFB5U^>7,:
MJEP-L$HW@MN\Q0% ,E5XWLH;-[N=($MX94DDED6240(IMRANU=@YN#&J/YKK
M^Y ^8X4F3FX+6;Q*)+6_U"[T_297FM'MO*,"RK]IMB3<X$1CN+G=)A-O*3Y
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MI,R6*W C'V=\$Q/,VV8I(ZE?E1"O[X%K&D:5!9Z<T$A@M/M4J'4H)FBGC5I
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M.R %B>W@G=$M_(B^URS0JL-S$UN)DN"_F*KH?])7$LN%0C>CAR=J,./@NO\
MA,[P:U/;P6VEKBZM((D^>[DD$*(LS/L\F[50GE.'!_TB,H[(C;Y/.A\:B*74
M+^-O#[W$%I#'?70@_M57C==LL6 8YP6^T1E N]7AX4JK1]Q]N:2X6=YH[=U=
M(V$KKMM2Y@/V>95FPT[[OD8 @;AC.?W@!GPW,-SJD,C74C/:) OVF]4% S[
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M*-+%IC;_ "S9,@DN<L60X*MO(8_.&:/5/$]CX:LA=7UU);BUMVVI-)YAB")
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ_]H[_DGFG_
M /85C_\ 14M>P5X_^T=_R3S3_P#L*Q_^BI: /F"BBB@#[_HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:"580[11E,O8Y217RP8,H3*[E9+&NWTUG<2:+IL,8U1D^SZ=%:QE6TQ,J(Y
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M8A<2A)'!+Q[D4%OI]Y;2,/L$S>58[+8$!"!$ZVT*>4!-" )3YA&8P9<%!NV
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MCZAJEIH]@+&))+>>5XK.U@:=UQ+</%YD,LD<S'[1E_,,O+A9"Z"3;)N "_\
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M\J"&.YG\QEW(DDEO(!,WF7 2,MO/19 1O&_< 9\5T\FCR^9+.6AWV@0R-#)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *\?_:._Y)YI_P#V%8__ $5+
M7L%>/_M'?\D\T_\ ["L?_HJ6@#Y@HHHH ^_Z*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOLY6L.PT.;6S:S3VEI)X?MWO(M*L) 9EO=TDC)YTGE%8K4+'&8E4,O$1RQ5
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MY+LY&Y4##L+&!!]@N9=/OM/NH(D@$<$2M'8!_LQ:U3:N'C)5<R!6"A9/GCP
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M(W<E0J1!LAE8B273MWD006L$MC%%<6D$$]GL\W=O!MW(BQ#; 1J P!WXCY.
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M[_-W>HM::EHWA[PA-'->Q6]S!:-.BNL$4,NQTG.SS(H@T,<:N-WF[64D/LF
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M9##&%D\O[5'-"QW-NPI;]XQWD %CPE8KX?M_[1FN[N_UZ]MXOM=W<1M$Q"B
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M@ HHHH **** "BBB@ HHHH **** "O'_ -H[_DGFG_\ 85C_ /14M>P5X_\
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MRH(O^/94N2?/4L$*D,&8E) ".YU,)<1Z)-;R:EK6IV\:20[8]WEQ%DE$Y:!
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MN6:%R3& IK/UG5H=#L-0:Q:34#';I:1:5I;A?,4/<HD5ND<F^*5=I\R0 _+
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M5HUDH N7-I>Z_I-S+>VTEB%O1>R6\$4L?VRU69?*E<JGFK<+%""J1ON#"/>
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M$ 48."01CM+;]W\0]3W_ "^?I5IY6[CS/+EN=^WUV^9'G'3>N?O"@#H****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "O'_ -H[_DGFG_\ 85C_ /14M>P5X_\ M'?\D\T__L*Q_P#HJ6@#
MY@HHHH ^_P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH \SOE:]^"7B=GL(R[/JTK6]VR_NB+J=L
MDKN&],9&,C<HPP^\.?\ AE>2M8.8[B[F@.A6/E7/E32>7+$]RP18XR9&B#)(
MK!G7<R[$&R1%'07T5I:_!+Q/#-<2101OJR(\ERX9F%U.$!<MN8LVT8)._.#G
M)!X_X8V[:Q-8VMT+MA;:/9Q3VU]:*D]];--<-B)FDS]E0R1;L9$BQ*NW!V,
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MG<6+C:<-D 9$?-R:S<:EXF2T\,:?8S3:?=O-=%9@\*D2W$,D;(0#;S,91(9
MN77S<><(PLE?7=:EU'6IO#&F7W]J7S;Y+F1%3RXRLTLD,"MYZB.X0(PP%$CA
M =\6WS(]S3O"MCX>L+RV19+BX9!)=7_V3]X(D>9[8QQK&T<DL1VJJJHP%3Y0
M B$ IZ;H'D7FKWUS?_VC,TLC37]O!EY(U"B)V01-'+<P2VY140 +DL5W/AMB
MWL1?2B-([%MMW<&Y>V:94CB+72!H'7"I<[FQ*RD,,OD_<J.6:&WM]2NII[2.
MSL7GN/M5K"-MFN)_,GC!B<-<!BZ.NYNFXA2Y1N?O9M9\6ZS/ 9Y(-#TQ[@W=
MW9PSQSB16NHD%HWE;C*H">859@Q^51M+JX!'XB\0OK^I[=(6<PV<5S']HA+;
MV<QPM+#"A"M'?K$TQ3.=N'4Y+2"+H'T2WT=+:RMM/@\L?NUV2F*25%MYTC2V
M)ER+E8U16E)7<F?F 4!-"\MKC_B8%X9[6";$EU)9.-S(N\;H]D?FM,R)"C#C
M:I'EMN7)Y_6-6LM'L[:>_MH&\V642?V?YCAY6-PAALRC9%WYDH5GQ&S@R-QM
M81@$FN2+!X8N8FAC:+>;2*+2BS[TCDF$<=I&I.RZB55<G9@-'C("[HX[;2(K
MG6)M<U:Z^UZS)YT,=I;73O#"NV5##8R,8PEP1"/,8'<"C\(&R,^TTFXETX^(
M->AGM=2GM+E[.VLXPLUNDXGF:&V7*G[:!M+R&,;@@7!.]ZZS4;MKRPU #49(
M49'MF6S=>I>:%!!.P15N"^P$,S!&4+@;MY ([ZXBABN[I[B>Y4_:5(LYWS=8
M60-;VZ+-E;A! N2 .0Y4*7?;CZCXCOU\;PV&DI!>7:Q"264W$BP2P":</;QQ
M^9Y8NP(>&;KLESL5<5'K6O7.HZH^E:+=R+J5Y;H+NW\YXS;VW[UE$)8)Y5])
M&^\(_ $)W8"!FU+&V_LV*.)9OMK-*8_M,-W^]OVME.R-LRH/M)*%7;YE=;=@
M^T$*@!'8Z1::5<2R6MY=W8:X<QDW[L]XREV-N"9P'G1H0I=Q_JE$3$A6(DOY
M[?3K-[I[F>XABBDLV:+42@GB4R[HT,ERH6XB$>YYF.["/@@Y"6)+FWMH'MS?
M><IB: ;+TA[E%>2(0Q,T^5N%=XD>4D;F91D$C9Q=I<7WCZZ>ZU98Y?#MTADM
M[&.3Y-2B,4QAA3,@47"DS&;)&UH(2, ;P 27%C+XZU&>[UKS[C0Y)9(]/L/(
M2 3- 9T:/9++O6Y8>8-VU5$:[CLD"F'L+BXBN-1G_P!(GGF\J2#_ $:=XH[I
M29_]'@_?!%N4,7S/]X ?P@_(7&I;M.GO)_/;S8I$>&VDS)-L$Y-K L<YVW*;
M<,R_>*\'C]W3U[4EL3!#:74EX]W<3116]K,SS2H9$6>),W*'S5<NPE'$*(PP
MN/F *?B#6/)^V-IUS8ZGK=Q]IL+>&P?RY'QM"V[XN WF1O*)&D'^K02G$9;)
MDMM*FL$O[PZE)K&K727$'F"[-NEW\UPXLX-LN8GC<-\[;F0%@& !"2:=I,]O
M9P7%YJL$MY<XM;V]\^62"!04@:UMV:<212.X'SY9FD0EANV*-"YU-!%*;V?R
M9IMMM+!]J6)Y'=9&CM(L7&([D!XR7!&[*D'&"@ 75^EC]KGN->\N":4P170"
MNS']Z/L\*!B&N$D!_P"61+*%0AV4L,O689]:>\T?2X(T-I<,U^B6<4J1*RNY
M6$S(J-<3I,H;=N1 [[B"09(]4U74[Z\NX=,U2Q>.'4%M[NZC>9'B6,&4P6\2
MM)YURBY9CM"M@(R. RI<L_#ECIL2:<T-HMP=36\@CD&]6?SY7\U99D=I+@PJ
M=_S$C9\IC!#T 6+*TAM=+%O!+),E@D@-Q&HN'A9?M"-<1L(#YMTS9$B<X+-P
M<_O"]U.QTNWGU-XXVM]/>XNGAM;3SXU*"Z+O'*%4).V&#[F(!^3@R!F)[J'2
MM&EU2^M9+J#[.=0NEDMP&9;==RSG]R@^T,%@^1RFW9\O^K.<."S?Q%.^I7MK
M]HTBVBAO;9EW;[\L@5;X-% CK<+#O41C)W!,"/".P!&VE7/B>WGN[U+NUMX7
M\Q%DLG6XR@EB^W@+"C-=,B )&.(P4?#'8E=1>*+=S"L$<5P7E>WAA\M2DC+<
ML);9I(PCW#C)=&;"@DDXR9*[V+6=Q&KPW<;PV\\C7,*+*N<R?Z1&BPD"Z._)
M4(@?SW \W9@<WXBUV718K73=*T>QEO-1EBBM=/L61XY'A78[1/Y.$F@D6+)F
M78$A7&&#*H!<\3^*(]"N)=+TVPCNM4N4N"^EV=Q.K3A2TA$3H@2*<I*9G(_>
M?<4!]Z.+GAO0;C1M,OQ<17UYJ-[YLMUNF$,RP/)<2QQQO&%C,VZ1MVUQM:0G
M>%$8J/P]H*Z3:PW^K11ZE?W"27-S.NFM$"BRM*LPA6+(N&)MMR'#,8E(W&+G
M0FLA9/ @\P7R)*J*CQ@RR,L[+/#OB6(W38D+*NT8E<ON4)D );];BW^U:H8Y
M;</()&B9HFL0P80A%V^>MU)'/$I08/)V[20LF//>S:_XJO[*.^CCM;&XB@N-
M24GR(FWE1;PY8&.Z=9WB>1&;: F-K.%3/U"[F\1IJ]IHANTL[-S+?SZ?:G!7
M<;@1PQ2<IJ <X) X+;F(D"(G23:9]EBUBRTB;[%8+%';NFGKM%C'MDDD\F*(
MEOM)\P-G:HQ)$0'*$. 6-/-O9VIL+2?[!'#%;66QYB&TY&BQ%&"QDBDN-[+Q
MQE7CSN 3?7U35S9V=WJS:C/!]MB6"WAC,,AAEB)W6\:&0K)=NS3*-NY<Q*"#
ML^>QK&M6]A!>ZA=-YT^F2P@6T-L;K8[NR(L>%4_:)8Y%7;N.SS$)&TY?#\/:
M5=W%U#>ZW/&KW3R0QVD-ZFRV8Q-$RK,N9I[Q$M]KR%EP'DVGY2* )+.VG>S.
MK:[-L5(EMX!#=RW"62J1&\7RR[WO6:2:$3)ECL& "Q1MB"ZN+.S$DDN^:VQ$
MD9D&80QA*VLVZY(DN7# +(6QEL\!L/&OGP6\$=O=1VSA_)GDD>*)K=YA$660
M(S1&Z:23S5/ELIR4POF;VKW/BJQTFR@FB:2\NM[:?:6:W>3'/LC MKB3S'1I
MS(%7<<L Y.-JR/0!8UK6X_#;PVD/F7VK.@ATK3WDG4W*E5W*TAWAW'E,QD8?
M(&4,5#EVQ] \.Q%UFUR6TU&YUAS%J4MS'"Z7[PK^[B>$,5CGB*NN(]ZD0R%O
MF*E:_AW18)TNK_5)X[B_U!+6+4=1F,MN?/1H@(G@)B,<N2I@E5%8!E.,X,O0
M/>6T=O:7%V8Q8P.BHMW<(^T*,R([-.5>>!X#*TAR55&"[FW-0!3U'5+?1=)G
MU"ZU7^S9K2T-LSW=Z2%+1O)'!M\V4?:5'E,TA20N#\H8-A<?1-$N/$]U!J&J
M:?/+91;GL5:46BQN92LDEPD4K 7JEIF!1$PQ.61R%BCT6TN?&FMB_9Y(--BM
M[9;>#<\@:V*)*C3S+*KM=?O"R9+"$J7P3(DC=I% \TML )YK0Q1&VM+P,R%$
M:)O.E:2(R)<*2=J,YW; >&W% ".Z::]1M0+W<;PV_FQ0"V)$*NSJ)X]]N9/M
M BW?NL'!.PK\P8X>K:K:Z7%!;QSSZ@EU%YEG:V,<$CW9VM<&]B!A"/<"1"Y4
M-LY5L;W1&CO==TW0K*-+?3X[V[=Y+BXLEB6-KB;9YL,\H\E2+AG2W4J "CW4
M>028LV-"T&YM=;?6KFWCU#4K^X$L4UV706]LJ+%YJC[./)N'C,8>+Y0Y0X*A
M=J@%/1/![PZC!XAN(?/\3:A$RM=RLR_8X"2#(C/;\W&UT^655Z,JA(UV#H'M
M?-2%_L4]UYD4DVY5\BXG_P!'1/.9O*3RKGGR@N^/Y&8Y^7:I:Z8B6MI#8P>0
MPB#6LGV58FQY441N'!M\17"(658\ %<@@#(CY_5Y]1UO45T71+2>TA$3WUS=
MVT*JUKN+GRX"Z)Y5[,DP+>81Y:OD9)+$ KZC<WGB33$TGP]<;+*TE<ZW=I 1
M)'B1)<QJ+<$WI&YR$7]TY8$;]C#I+>QL=,LDLM+ACBTVS25;0V2>>;01(Z22
MQXA;-P9)&0HS,6"L>3O4R:7ID5M!%#!80>3-+]J2)K=XUG7?"PGN#)&SBY0=
M-S;G92QP?]73U6[ATVTM[V:2. ,CW'VRXC$4S*MNHDNBIMCBZ2,.%BP-R!\C
M"E4 +&N2+875Q<-Y=J6N(F65;1I""\3Q>;&XA(%QC*!3Y@8)%'A3,*RXK6\U
MV\U#5[ZXOK:#RIXTL;=S(^G\20M/%)'YBO<_N@/+C*^5O<89G)>2*PFU6XGU
M'4+*2TM;9YI[*TCMBWD1L6=;P1M V^\,B,VSJBR\KN8A]R]M8GGEEN++9Y?F
MS7(ME?<59'C2:-TBWM<>7&$VHP95D(RV$R 1WCS73F:*^CG2U>5Y98;,R&V4
M+<INMOE?=<!MJ.I+<*?D7?M./XC\2ZE;ZI+I^C6\CZM$AN+H1%IT%K%YC8C4
MX!G^:WW1@*S"X0!P,2I7\27\RI#;6\=WJ.IR6\\$<EO=$C;&SQ27*-'"_E7$
M2O\ ,%1,F8HOFLJJ-"+2H-&EG%U+(]\UQ-<+?EY7FD+P,/-CB9'C>X582GEH
M" @8JJ*_E$ DTK0[/PG%#'-)Y\D<KSF\G@#RWC;9S\B(V6N1']^0(6D4'J?N
M;$4%YI^[RDGN/(B ^^7^T1KYNR)/,FXF&4W2/P_&3_SSIWEM,CDQ1QVR6[RW
M$HAM3*8%9;G]_;'ROFN'9E+J=^ 2,'=E^/-PWBZ],FF+)9:0'2XMY(9%C>]E
M#R/-#;%9 HG)CNE>=)%RLIRKKLEH CW?\)[]B@43CPR)5@6Y:XQ-J8'F;8X=
M\K%56%W,TF1*X5TV@JRCJ))'73/M3W$%I:/+/YQMHF41(\BA[<K#<$M=F0L!
M*@;YPX"AF^;4@2VM$O/[!2/$:1YMK:V3RF,;-&R(PV*9=L7E8+XCV1Y '#8=
M]J%GHTL#Q&#4)+#S;E-L80RY80S*@5@CW;3,_*IP7,9\LS!F ,?X-+$G_"9*
M(KZ*8>(+@-'=2/)L7C +%F1I =VXAF8_*6)&TUWANEC\5):%Y$>>R:4*VYEE
M". 2GSX0KY@W94%O,3#'80/-_@46BM_%EI=+=KJ$.L2?:%N;U9V!(QAL'E]R
MONDVJ'XP3MPO8'4;X?%Q-,DMHSI[:$UQ!.T'S+*)PLBI)Z%3$67G[J'CN =9
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5X_^T=_R3S3_P#L*Q_^BI:]@KQ_]H[_ ))YI_\ V%8__14M
M 'S!1110!]_T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% 'F\SI9_!SQ);W%YYDS_ -MQ(\Q57G<2
MW1/  !8A68A0.AX %<W\'LQP6UDD.I,BZ/9221M:26[EC>W$@=9"X0Q 29QD
M^:N<#Y72NLN?^20^+O\ N.?^E%S7G'P[O],TC3XH;^UG,EWI5E;0V=R(1<S^
M;>3;H8%EC19;>7>'<[CM# ;B0"H!ZGJ'B*T\/:-8WEQK6FV'A^W2"-Y[:S=?
M-;:&5+=?F5HG5EY3=L5' ))W19^C:7J\FJ6>H:U:1V;V;K'9P6=H)$TR)MBF
MVC^4;BRF+?.H= !,@\K;N,FD65Y#XA;5]7O[&VU.\V0W$[H8W98G1##:+*S$
M6[R.BEB S-D@'S8FCV%M9[;,\-E!!<6T45I"ENLJI;_ZEE@3,3*868D/,B+M
M55!&8\H 5XG@EBMK*]@^QPR116LEC'-%-'!(ZQ$V*PHI#J$1F9F7*HY*D*6*
M9^JZQ>:3?65II]O]OU>'RT^SI(;EXU,),D!E,0;RRZ6^96?<K3QO)A-JO)KN
MN-HMO8K8S7<E\[I!'9R72RRP/BW86\H!88D^6,SNSF-[E""5?(-"T&;0'L B
M2&[B2."ZO/LYF2%0L"+9PY02&WPS,'#'8T9:1F.\$ DT31;?POIRW-Y+Y<UK
M%%#=W^PG[(BB#%O SQ9-H &W,6^7YF9MVYEU$LVC>S91)9"S>.)EM+=6$ *P
MC[-%F#+6['!9QM*E.H"D)3MIY;&+3;F\M/[+M=.BS<N84<6ZNHW6H944+"A>
M B6/<N+=@Y7:2<.V9M;N[:UN(H[+0[9SIAC$"EYIQ<-YMI"%C&^W"P1@L %,
M0<.I8,T(!)%!;ZW>6TKC^SM!/E6+- "L5V0(FCMD_=!)+(G>HD;!=I&1"JOM
M?H+""W\U+JW'E^1Y=BQM 9$LRK1 VUNOE;3"6#"20 $;<$CRQY4EC;36R0B>
M..%[=U@!L[4@6BLT&VW@!B^> J 'DXP5)^3&(LO5;]-&;3H8E\G4QNALM/M4
M4%W6*)OL<+-;_P#'LVT%YOEV%5R1C:@!7O[W2[7[/;1P02WE]C2H["V.8V*>
M7NME7R=LELG[WS)64F(-(J@,Q5:_A[PY>6]G/>ZOI\!U*\^SV=U$(RR6=OF$
M?8X5\ED:WVM(6*@ ?=9V*F59-&\-S0W$M]>V<:27*16]TDL!G$$+%0-.CA6/
M9]G1)!F6-\&12S@JK*-PV.^(6T^G0):IY-HZ1P[Q;QNJ>9;Q*;?#VY*Q!FZ8
M:0DIY0  "UMKPWUHD[3VS6\HA66,FX<+Y,3M#YDMOEH7*L6D+;BR(-VYMB<W
M<M=^)H8+'P\]I;VB(UM)/%;)-%%^YC9K%-]OA;>5-DBW&'4X VD%%->\,/B"
M]GT.RLX[*WEMTTR\U&SLA,]LF\Q26,*B)76 F.0BX<&,$.!@@!>DCT_RK.]L
M3I.(X8HHH58>;"&F*F6SC)A+?9OEC#/M*A7(&P1;4 +&FZ5;Z7_QY6?V6SBE
M6W@FCB+7"(GV>$1[6AW&-O)(9V9OD1&#[<&//N9(O"]JU]<W4&F6-E$Z*TEL
M\T=E(T08PHQ0&2V)V$!3&0\:1J3N6-#5?[+T2U%]J-E8VT:Q#3Y1+!BWC#1(
MJ6GF_9_^/0LQ8R' 5P!T)1<_3XKC7[FWUWQ?:_9K"#S'@M;ZV >S#VSF5)G\
MO:T+)*X))4#R(0V9&=0 9?AS0M3OO$MOX@U_3KO39+&XBATJULX(V>P@)FB>
M&1A"JR0$@!=N]D5E;*JS.>P-LR6Z6DND1R);6[6X41*T!,H -F?W /V?YX<2
M(I&(3YF-A#R2V5Q=2M]N;$+^7#?".T$KRDL2+<LT.)K;$Y7<%0IL8EB6?9CZ
MQX@@\%Z= K6_GZM\T=G;F*)8X% A>2WB?;%BW5!DS$%4$9+DE50@%C7;^W@\
MZ/3HOMUQ<RO:/926I=KEU\UWMYWD.1&PE!C 'R*WF8:$/BO8Z']CLY]3NKSS
M]4,45K->PW&\3*"8GL8I9)0Z,)=P5@8VWF(N9'60L>&_#UUIGB&35;QI[K4K
MW-M#?2B>5;2!'!:T*L5)7$;%+@C]XQ+-RRB30MH4\A2LD[S7.RQAF>X7SC$7
M/FVS.DX,DT(28^9G<@)*F1O,W@%Q[Y;E[R,3222;Y+62.-V@><A9F6"%6F4Q
MSA=KF3@.I5@=N"G+WNL3>++CR[&>3^RS>K$EY"I(U5H3-,;>V1FVQD*I_P!+
M#IF2,;>@VFH75SXOEFBTE[LV(O9+75X#O+,H@ FL0A<QAR8P#,&C1?, 1F9W
M)V$T^&P>W@L#']D^SM8JUC<A7NH[=;A4LEWR I*F_<)%;),4F[RP!0 36[6%
ME!9Z1':/!';RVD'V2X6)[P0I.L=CYC-OC=,AA(K,08I21'WDO]?_ +!O'O[F
M\^U6MQ+)$IB^<2R()=EG;QJV!-E&W.YRSX09W*L4FKZFNFI/+-)=SP3)*KH)
M6CNI45IE*0Q;HMI\R2"-)$W,YDC!_ADK+;1KC4M1&K:H=5NI#YL45J;418BS
M-)]G&),1S+)'"?M.55O)@V/DEB 1VGA]=0OX]6U?3[1]0"-9V,&HAAOA5+I%
MMR[.[O*5=FE?:\;K@H'QYE;$\EI=7 FC-I>&]>YTU?M8<?;&4W!>V=50*J(8
MR%D99/E\P 9?<YEIKAKJX6,W%S;O;SR:=>JGVIXS/MLXBQ!WQ[IBT@,1W*IX
M&Y4Q]4U/6KN]OM+T22349%<_:;Z"4JA"O</]@4HVV"?:(XS,<$!@6(?R@P!3
MU'6-9UF>XTWP^D\MXGGQZI?I$D3J2DSQ:>LJ;E6:/S /-W;(V4$EF?8VQ8Z%
MH^CV=M8VT&E3J_VC3K(K$@%RN;AVLIF$;D1H%^9LEF=&+#.0YI6BV&B6<.F6
MR_VE8P6CV"2W5S'-+J0!G+V>W<B;HB@QO!"J9% 7YS5B\U Z4MS?W]S/"L<N
MY+V.&&*6]"RW#?9"DB\1QH ?,RH*EI-ZJ':@ UN6S6SU+^TU\NPGB:WDO;UA
M;)=;C<K]FF<1[HH4R-DG&[S%VEBQW\?:Z1<?$1K+6M7TZ=M,>(_8+>] !OP8
MKB,?:3%&/)QA94?#!#.^QCO54L66E3^/+6UO-3TN"/P\D30Z7I:)*D-XPBE$
M<K?*?L\*H[*CA49SM<A?W<8["]M[.2\66:W@GNKOSK&W>\@"/><3NUK*3"2M
MN FY6&=VT'YO^6@!'=HVHQ7$NG^7??:'>R/GJJK<E)Y/,AG/V=]L2*DD:DY#
M>8P^\5<X^N:M/::]IKV=I)_:]P]TELKQ1)>Z@D,CEK7<T6R*WY202%]Q11A2
MS;JN:Q?I?:C_ &1 OVZZFBO+="47S@20)(I5>W9([=5DA?>QRX6/"R[AOCT[
MPW-#;WEQ.TDNI:JX^VDH3%=2H)M]LX>!BEJ"65)&RY1E4-@1@@%?3/"[:==.
MR6=I=SWCSI=3RZ8MO%<((FBCL54([0VZB%"7;(.U-OF>:=O07<,TIN)!:1W5
MM*CP2-<1E9+IC)(B6\J"W)^SJ9"1(">!N.Y2S,30S7#S VD=REP\]N3<1D&Z
M55?9!./LYVP!FF ;GA8R#)YI!P[Z:\O]1O\ 3M$N?M.H7&^UOM70%8X8P;EH
M[57B+>5<1[L;V4A00S!F9$8 IZAJ.IZK=76E:+-=RW,EP+?6-2LTC9[0"*67
M[';3;(U)4J4\R0YC,ZYRS'9N6MA;Z3IG]FZ0T$=BL3VD,-JY43E9)"883]H&
MVX5%F#N<$N5<M^[91';:5+I]@?L5M)$\Z?9I43SGD9$>X=K:$_N1 B;RL,Q(
M&"HQ]PF36]6T[3MVH:EJ6R&7S;+SH[MH89_]>?(3]^$BN%,8!E;;R-H*DX0
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MQ3:%8;5W[L'S,-+6;4K^XG\1748TZ-!IUMI<EP1)(S)=(;4^;-_Q]-') WG
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MW3K;W23>6@9"NWS<$[W(B["8J[S.+F2<S//'_H]TR"Y.UU-O // 2=! N6X
M(D(VEG*@%.6Y2"UBCGOI[9EV6LMNUZHDN"T4IBLU9IR4N0)(F,@8%R%(;!^7
M'U[5[R[UC4-+\/K!=:G>1&RN+^SF(>*-5NSM0;]JS0,T.264%IT#&/<I$>HZ
MY>W@?1_#EW)=275O]C-QF6-K<".Y.U7DEQ]L0>26C;9(WWF(7)AT(/#MIIVB
M3:9"DD_VI'L[F2]5_-U2(/<N\*;YD(G.^5C+PAW[E&WA "33='L]&T>32X=6
MG_TZ5[674X<>==2,TR87RVXN8\*9)BA)$9+?=)CT))$6))GMOL4,N^:V*QKO
MB=EN',D$31&1KDJ=SQLO\38W$.&D2[N[][^;3[F.XB6W4K=6$J2&7<LKI'%&
M[F..55>!_,;*R!QD 8V\>8;GQ,+_ $NV@DT_PS&DJ:F;*S>#[1%Y<B0+;;4+
MM*BK&DT;#AH5C"XW*P!8OYU\1WXBL;V.RT:W=YEO--W,TLKI=[VLG6/$D^S)
MD $G^L;:5>/<VQ_8MIH8M+2.SCL]-A0PQVZ3.^V-8[L[K0)B7[4RL&<@9*DA
M68@FKD6[R+GR_(\GS;C[?_9_VC;]GWW./)\O_EYWX\S9\^[=W\NL_P 0ZE!H
MFCW5^DT#^7+*+)+6WB/FWCM<(([<#>PN2[ .S*ZG#?(,OM (]4OH=%L$=H9(
M;I'D$,KQC=<R!YD8VRLBHMX_F&0#RL2[RJEURZ1_V5>:U>7>LRG=?R126[1V
M3%'M+<"Z2-89-QB-ZKL5=MV$RRC .YZ\6B)?ZC<ZM=7?EWLT5Q!9V=HJJ]H7
M-SYBVLN\1"[;:ID;+E6CDR=C*5Z35C&UU$;R.-'WN)0'G9_)\JYVFU*@?Z05
MR6$?SA2PR<(2 1W,]O96=[)&?,A?[0'33R5-V0;EVAMT64%;D$$NX +$'H1^
M[P_$GBZYLKB[M]*O;26X*20O=QL[K&ZF4+;Q1DF-KP%XR(\YEV.&$8V&CQ/>
M7UH]Q9^'X+0:E;N\[W7V?>D19;B0QVT/F?-?>6[.1@!PV7(#**L:?I]IX,!&
MGF2[DMWE^W'[2[S7S-'+/M6+S")+PA869F4;D;Y<+A5 )+'3=.\*:3?6-M+/
M<,OF?;&AF9KF_D,<TI1 )MPNRA1V? +#;MP HCN:AX@73)KJ[:]C<1H$&R)F
M2[<32[;:W!F"FX"QRHR@9+-&3PNRJ]W+''<11)JL<,$2&VNKVYO)U@>U!N-\
M<1\[!NHQ!\\I.Y1EC_='-Z59O\05AEUN*^TW1OGL(+*\N6S?A)9]R/&TK?OD
M2*/+L-X/G$<K')& 'FV_C*?S)[K?X4CBV6UE)<EGUI-GE(I,L@Q(DLBD.#RT
ML2N5EB(7M("LUO% ES)$E\@M8S)=,[1"(8D@++.2UQ_Q\?O$.1Y?S$^6-TAU
M*7S[25OFNU\Y)+5)$5MQ02K:E//V_:-FQMWS+M20Y17!K#U7Q#;6=O;V=I<Q
MZC*]N\-J(M52'[:) OEP([7(?S]KV[F8ACM)*X,@% %C6M<:)(98'DDO+]PM
MM9P2*\H>)E4Q;%N55G29V:5E.WRXW1S@*QCTK29TR+G58)+JYE-L+IYY9L0_
M.)+."3SPZS((OFE"H6V*S*SJQ$>@V$RW5KJ%[J5I=Z]?W"27<]Q"=EOMB++:
M01,Z20N(II&!*EL&1G'S 5J--Y-K("\_D^4EO- ;O]]#^Z41VQD-Q\MR[S B
M0'YAM!.=CD +>;[+!9ZFKSR;(GMW1KO<OROLCMB&N"AN?,*H9"6W,C@E=RXY
M^?5GU#5CI%EK7V>Q3.ER:E)<L@1S),C6\09][7N(X<2,7XRX5=X$ER[N[[7-
M6N-,T_7(XD:]>RN[VW/EJB"&0FUB!E8FZ7>',J*H&SG/EF,Z&DVT.FOIMI8&
MTL=J&W> @$HP6%D@D G.Z<6R8W8?A-P*K\C@!;Z1;.C6^GV$=L%18UMH9$CB
MTT[HI<-"&DB-P&=I581X.%!8 AFDN[F*&SNM6FA@BM5\K4+V&YM'">2A8K,&
M,0;[0$CC8H0Q7RD3"Y$E9=]XGTW3=)BFN[:2_%HZ6ZH+E9O](\Y"MJ4$LC27
MB!4()!&Y2=Z!F(R]+TM]:O+S4M>$ZWFGZ@DT<*6[2!TMA&PDFCCX%V0ZKN3&
MX1IY8>$D2 $D%I-XB$6HZE;22Z:KC4K,Q1'=>1K'Y*W+R0IO6X,;F01A5/\
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M"V/F*_?DQA.TNIX6^)>DVZRQF=-'O7>,,-RJTUJ%)'4 E6 /?:?2@#I****
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MN)1%:77DSO,(Y8XHHIE<G++Y<PDW%<!HI'95D&#T]AJ'QATZ>^*>']#Q<:A
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M$_[QI$D^6UB"7'%R5,T>8\EG0'("*ACO]7L=*M)#?W&I0H4CM8[6&XWSR/\
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MX]O+;6]Q=>7,G[M6EW,EJA:WQ;7!\]@]RPD4*Y)SDD @D. 1Z?=W+):N+Z.
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M?GY17')W5U+XEEO=/GE@3PY'A=8EFL4EEN9E:WC%O)L(_P!+W0S+F($!7A*
MEHR "QJ2)XSU'4--D>"TTB2[N;'4+B)E"2D&&-!AE8&Y$D<2AI!&0KD1"3 E
M'46;?V?!IZ6P@@\B4Q7237&U8O.=&$4F)7W7)\R-MY#[V#\IYP-26/DV20I
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M,,)S^DI/XHN+:ZGL;O3=$LWM/L\<4,3KO4VTB1V[+%N-OYBG>_W6\J)D<)O
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M/M4J2!3)OSNRC[0&6;<F>R\^X54@F5<:4?MRR;)P48+;3NS,=Q?:PED0@K<
M(&,I+226T5W<&>[N(U>1Q!="Y2$JL4A0BQN55\.Y\X^60.,CEMS>=CZOJDTI
M_L;2[N[M[N1XK"Z+W95M.5K8M$DSEI#YLCOM6>,??V F0ILD *_B34F82:)I
MMK&^H26\-O-+,5E>Q5XRL4%WNE*7#N&N=@=RGF-$&'SASL1P:1H]E>FTBC^S
MP/<I=7 4I=EF1WE1Y?W?DG;' PGD?YP$);)20U['2ETU#8Z<(Q/<I<1[[N_9
M9XG=EN?LDK1R%GE(EN'64;C$OS /N8OH-((+V/4IKV2"X^T1P3.T<;&)97BV
M6=PL;G<^Z<F-U'R @EB"WF@!+.L=[/>17L;W)N'LEG?=;NCAU>*UF'ELNQB7
M5964$+*@3<TN]N7TJR'C>]TK4;^QCTWPVUNBZ7;2".,W:AY&$#VTBNNSRXU;
MY&&X(DG)"""2$7'BJ>WN;AH/[#T[,-K%<70*7CR(H6.X8N[!CYL*+(N_S5$Q
M^:.X0-T%D38ZC$8;>".>3RK2..-H4^RIE'^QM"L@!9("9%8-)C,S* I5' +$
M=M;R0);7=CY4+Q+;QQPV1E2% \<4ULH,  MV*I\S??5G8;50$8?B74;[3[""
MW,TDGB"]N##Y-BGESW@#^8+5'**3 D4SJ;E60QE=WWBRT:UKFE:+876E&YDE
MEN[B/3-/LEMHR&._ M?L[NJ;%#C<Y$0:&6(!V.UZDL]%>QO#<:EK,$E]/*NG
MRW*LS26L+ -'8F4 /R)&(G+1R,Y@)#Y"T 'A;0GL9;37&O(+B[:5[.^EMK5M
MD21LT"65M%MS';I)\Q?C/E;FRK$IH"QE6"[M3IWEI%:0VK(D*&"Y9W+"U.+?
M<;>-6$>\+M"32$C>C%9+PPW23S7T=I]KF1+(+*X(1I&,GV2=<2QQ!U,*.X)\
MPLN "(A7/ZD)_$]Q=Z+IXNUTFV=M-O=1\Z*>= Q2&6T4[)' *F.=I&+'(VNT
M9!,8!'=W_P!LURWTGPY:V/VH:?;R7E]:#?':VK[!'8P301[T61OFWL!L1FD4
M< )L:=H*:7X<@TZTL?+A@M!93026JH9R71HHIL12B12))%EE0E 9)FQDYCN-
M;S:587-Q9:?(]Y$\DOE1$LRW$KQ2M;PR/#\T$LA)>0\)D_="_NZ?B:71_#NG
M7MY,L$5NL0L$AG9+:.7B,Q6:JT?EO"P\P%VW>4'EP5&[8 1ZEJ]IX:LM1UF]
M:2-(+@PG4I[1TE>0);KM;;:\12M%M:0!APFP\JL>/H7A1M4\01ZQK5C);OL^
MP0VIMU9;*)0Q:S"M:B-X"K.#.",Y$:L>6>XFC7&M:Q<^([[3_P!W+%MM;&XM
M@K1/,L"F.53;,6WQHJ22[F\M7DC Q&7K<;":O>SVRR7&H*@VW<\4:3HK3E8[
M8!83(+<M')F1E.%.Y6?ED  2WMW9"66WDGGF1T5EMI8KB%9$CF:WC<K%@%0Z
MB8F+:RQ*P9PU8_BKQ<UDD4>D36FHZI?.BV.V^6*WN7#&2*(8G!5PLD3LV LJ
M[4R/,11)XAUTZ#J8L-%TN>XOK>+RK-1##'! 9(PL4!9@NVW9T4D[U+2!40OM
M=(Y/#^F-HEQ+?-)&VIW%[Y>I2W5VK+&F8HH;?>&W.X0Q-&TBLSY;=Y33' !'
M96EGIBW,RG-YJ,3F2Y-^!<2[94A^RMB89F13% DH=L2%R2K.?,U/M-W,ER?,
MDE2]1DCW72++N5G+V<:QRA//4+<*90R;=L>3)L9@)J3:=I<5Y/=1XC280[YE
MQ&D>UGMI2]R5EN L4H\TMA2CDX&0_/W5XVN^(%T&#4(X= 1Y;#5FGNU,DJ1A
M(EME+2.6=WG4O(JJV)(T+B12* +#WUSXFO7BTK59)]'N7E5;[SWM/M$L3[X[
M6"17!QD3[YHXCF)0N692PU"TK6<$5L/LT,L1ABAL[A$#>490UD(Q*!',J%@)
M(G'SPDL55 K1Q6PL]&^R9C^S0)':M8$1M&D(55CL)EDG93.ZSX#J5#$)N)7"
MO'K6J6>DZ29;V6<PGRK5[!P+QY/W:XL9(S*QDN)!,[!DQG"ERRK\X >*=<32
M_, _?7[RK:%+,+"U\9-ZPV?G;]T,B?:(I=V0=NYT&-X7+MM(FO;K5)M:DM+W
M4-20V=XUF#&^V.++Z="D\@,8?!E$@^^K.W[O]V]7-*TV6343J.K2_;?M.=,M
M[*69)HX[4EUDMQNF/F7 \I9)W;?D(RINQ6Q/-MTYUWSKY42V_EF[Q)#O$'^C
M2-]H&ZY?=\DF[Y2P.><R '+^,H8M?USPA++;?;(5UN:T^UVY>,;?WRS6\D6&
M)4B)%9L%7"29,2D$X;>/;O4==U[0(M3D6\G>-;*5;](EF62V9A;VY,:\F1F\
MNXVC.8F9F 2.63XB7*:GK5IHUG-YVISW<]JUW*BQB**2"X3[-(OF)NF.]S;E
MU16###',CMH>'O#-GI_B#QO;7-A!<K=79M!.S 3W\,EIYK6D>9%*R*"K-*S$
MR<LQR-R@%-]7\"Z5X:U?2-,U[35MY=,2Q@GEND(F\H3[X7CB7>$8AV:0#=(;
MD[&SY>.@TR2[D\!Z?/J9CN$M],B%QJ-^$E^U;RPF@9PC;8-T<.Z?:ZM$2V3C
MS!8UW3=-^RW]W!9VDUW=))8F2%%CAOE>6?=9,X8F%V=BK293,S1GYC^[KF]#
MCU'Q!X>T2_\ $<?FZ>;2UCA2-%:YUN94W".:*9&WQC?)ABZ@%'FX5E:, I^!
M-,G\4>%?#]YJD=W)H=NZ6T*&**X:Y&R*-A,C*P2W66$J @R?DE<*T9E/>6EO
MOTRUW6]C=3Z;++#Y,<&T6\GF*8+;;Y)985_<MYH"G$,4F"I.,?P5?):>"_#
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M@#951G=\I;FY-4N=;MS!I=_J5MA!;7%VK/&UM%A#]B_>SLG]H%I8D\U@/O.
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M3EB<9WXDEN8M&TY9Y6^R?:LQVUWYKQR2*PB";XI0SRW8C7"JR2,QA()3>4
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M4444 ??]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;) 58M,Z,$X8*IP2.H,*VYM9&TR0););V?D6*LOV5S)"<0D1H7@Y4R'<%VP
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M+:]U1O*U-OL=G<32";%F/,@\FRMPI^:'Y]A<2,"XR_F?,JR>'M$N])0:K?\
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M;+&4O'I^BZAXBU2UOM?TN1K2=#-!IE[:P['5?*C:>]/ED?:F1@R(H7:(RFX
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M44P>\CAB>24K$5DE#1$?:XQ#(RQH&4>4-VT%-MR&*:XO8?-^UWR26\$D7VV
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MDE:V88F9S V]DR=C[2JD'&XKYF!OKUCPN9FUCQ:9XXT?^V  $<L-OV2VVG)
MY*X)'8DC)QD@'24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %>/\ [1W_ "3S3_\ L*Q_^BI:]@KQ_P#:._Y)
MYI__ &%8_P#T5+0!\P4444 ??]%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!CS?;$\967E>>;&;3Y_M'
M4QB1)(?*]E;$DW3!8#G.P8\7FTL3_&;Q1]MLH##%J&G-]IWS33P&5DC0Q2$
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MQ^<V%!DF*$%9)(>OT62YUS5+'6-5ADTNU1[2VMK6X+R/#+'DM#?;B&9V:0/
M[]"(V^5I-LO4*?L5O!+"8XWLGV1Q"&U5K9'$6-/;#@!VWH$V%1\D6XMC]X 9
M?@>>*2+6I8;2^TR,:A;Q"&.%_P!SA8QY7ENFX*<YWE%Q!)$,H(]L5?7M8_LW
M['IFA6\%UJ]Y%L>PTZ3B&&+]T8/-BB#10AS,%E)0I*1T3>$DU;4-/\.0OI-A
M!'?('&F1:?)),Z+F&V"0.CL4*.#''YWW8VG3*MOD)CTC2TL8&.IWWVZ<2I8W
M]_J$:W#L)'2%;#!19&C(*L7(0,SI+AUD=0 :&C:7;V%Y?17P^VZGJ'EG72UN
M9HV#@A(D7AC#OE<+(RR )$Z,PV#98MA;FSBM9[B")!*VGQ26"E);<DQEK2!E
MC&^,;)%:1 A18AG#QLZR3W)L[=7NY)"-/>W@:*UNI)2TD@C"VY<RJ7E,HA/F
M2JH,<H!X=VKB]1MKSQ%*EH5^R:+82OIQ%M$5EO\ +(9M.M@#&#"IA9#.53Y4
MP?E25V +#I<>*[JR-D]C#X<M)81%?0,(8HW$L$+V,#[5:2/Y9'25 ,R^3M9#
M$*W-#L;?PM;FWTRWD@@M;>",1DVRJ)B(@T,P290]Y*-@$C?(-R;>K>9H6^FB
MS1K"WL[34(M,15M2$CD:U6-HG6T"NP97*)"ZNSG+_.VT*BFGJNIV&G6<UV;^
M>.UCM$CEGN+BZC2TM@8"\<H\S<+MDE9HV*B0Y /3+ %S5-9@T"WOY6O8T32K
M<%)[J25H%3$1:&9P[$SGY"K,N[$RE5DPX;'TG3&N-2%YJEI:6%O97"PVEE<3
MK=+;/YL;*]QF4C[9+YA9'0$CS3O:0LHJOIEG/KNK:7JVJ6\<<L5[NAL+V6)2
M7$,>V6X1 #]N,6957:RI&FW$9.\=!;W"V=TPMECMYT1<I=2-M9WBB18+B99'
M!N-WV?\ >.&)1PJ!_F:@ MG9S';7_E[+9X0DMTRO';EI(62VF4W#F2Z^X5E(
MQEE*YR0V'J'B"*W\RSTNX@N+AHF6:.ZUMT^P*OV=)89Y!*X681I<2!U.Y?)D
M*ASO9I-6UZ:6RM;#2K2.[N)K=(YK;4Y"186\B1?NKN-YOWMQ(QV1JY4L68;@
M [-<\/:6FAWD\WGYN)?L\=QJ%_<*\X<B%1;72HX5IMA01NN?OG()8M, 'A_1
MXM+BCLSJ$[7L]V'DEN+QVE#A8'\F<"X/F7!BB!ROR!5;Y0A*O<:\MM->.ZS'
M%>;([.-)KA#+D+$ZV<I:?$MPP:0HQ)"[R<X),D82S@:=K^_Q#+$+=X-3NA)#
M:0K%$\EM,AF(DF9!+)YAW$*26)4 -RYEO/$LHM;V_GA\.VODZ7>[B2+B9F2&
M6U<1W)E60R,O[QBX(P,["[7 !(KW/B?5+*.WOI&\*Z=>FVGGO9G5[AFPIM)X
MC*C,%;"9E4NQ>(%'4R/)UAU+[%$&_?K);^3;PQ22>:59U1C;2GSRIN#L 620
MJN9XP"Y9MU>UU.PTW3K2.QG@CCM<:?:VOVJ,^2ZB+-BX-QM>Y.U@K9^7G)QG
MS*>K:U8^'GM;Z62[ANHT2!8HX_M,L@"Q;;&;$C&6X8RL\9!R/F;)7S/, #4?
M$:^'K65+>:[U"\@N%LM/BN"R^<[RQK]E=F< RXVLLKC/E.''F@2%L_PUH4,-
MW/?:UJ%I?ZO<VXL+N6YE$\,$/VCRC;!3,2R2%"J%E+EUD,A+,8Q)X;TJXT]M
M+N=:@L3J-GY-C;O%(&@T>)HH,VS(\V1,Y+(LB[V;>A)VD)72!VV6ZI?261@>
M&+=+,LAMP6MR;:?=*PDGD!PK\D!^#D@R &>]PUE80Z@ZR6NH1I:VTJP2+<R1
M$O;D64S-)^]E=I&596 "B4ME<EGQ]3U34M=NI/#_ (<NY+;[-</IL][)=LCQ
M@1,QB20LXEG/D9:7#20K,/D+>9BO/K*ZC<+X3\/7LFE0V"6]C<W*2-_H"2&-
M?LF\.Z&X(CE F((5@L8.]]U;%E"MIX<\FQ6.T>&W:REC1&@,<OD0PI X-RI,
M[.(O+DWG]V JN-ZR, :EI86=IIPM4M(+2Q:*WL98]3C#&.,")4M1VF4B21=Q
MD<"1R!OR5%."]72;_2+N_BDL'N$CL;@WDS2LDK)$(K1&X-P=[N_G'S-NV89&
M\[8[N\ET2"8IJ4&F:=;R^1)<S*C)8JKH+>W:%'V*KF8-O 1A"$5MK8D7'LM.
M74-1O=5OM/\ L-C#MM(=+7[.6B:,M"+25924'GQR1F,)M4+*X5E\UGF ([:Y
MA\5V$=Y/'':>$X$A M#"&CN55X98(7M=VZ-P)-B"//G$*Q!C\N.3K+>=X-1@
MBFU#[/):11V^TRM/; N8 T4DC,&>XZ;'<(2+@$*Y#U)IUM>V*&VL+6..4/"L
MN]I6@B4-&\HW.09I6\V9A,$&Y@!(<KSR^K^,['1/">FRR27<AD2WL4,^H;;C
M9(T:2"XPZ"*XQ'<@.3A6@?+J25(!8U#Q#-H6FBTDN;L7D*16EK([F:?YHHG:
M&7DQ27S".9HQAESY8) E >/PWH_V:Z2Z\07$$FM^5;)*\L>^VMV,L+F!CYK;
MKD?Z.JRN=S!("N\H^30-+>VNFU7Q!9?VEX@\IC,=[7"V$"2PS?9W*!@]QE_.
M4+&,ME4V(J8Z2%V2XM91?26Z6Z+;&*XF618"YML0W'[TE[@Y(1P2!YASNR-X
M!7NKF&TM[:\FDM(1ISQ#S=2NAMT]6$"R1S,96W7!C=]DG/W\$X<F3C]0N]7\
M3F;2[2YD@T6"WDT^^E$H,GSR!#:'S797O"4$08L54,9-S>>BH6USJ6N7%SI.
MG22:?IUJ\=G>:M<731W$DF;6$HTD4H!O T<PW,K A8@,I+ENLL=,L+&"PM;9
M8+&PL=D*64GEM#:NSVTBQSKYIWW);F.0'@R9.XD%P"2+&FS1_9&D@AM;@V?D
M^;&43S9K?)GW39>=\M(CYW8E.Y6<A7C>>RM,"Y,^V/RY66Z,EVMH4^R8@E E
M<-<L=C1E<G<2RAB6,D=[?G2]$:\O[V.&+3GC:626YD06<(>W<P3[)W:6X*?=
M;D.3@\2$/S^GV,VN7MK<:K-=Z=;VSDZ5:WDAN382%XMLETTCM_ICK.##&^X1
M@]&(Q0!8T*TOM7>PUC7'CMI+>XC6WM;YO,%A$RP$6\O[T.UQ(YC=7E\SE$;9
M&Y"UTFF:E]HGLHHO/M\Q1) ;R3+1;DCD>UF0SEWN?+5GW%?E5LY/S;XUO[2X
MMX(5O9$C9_[.+BY>3[(Q$0>WN'2<G[02&"RY^5B!DLP$G)ZS<WFK:P^E:.L#
M^9IYMFDD!::"1%+"'[2+ADEO8I%\U48 @;R)%RSD DO+R[UR&?3;33HUN&MT
MTV[)O$E+@PEWLS)YW[^5&2<,6*2*'P-@E:X7J-'TNV\.W$,5MJ$>Q',.HRML
M"SRL5\KS?GR+I_,C)D _><[@,Q;:]G9Z;X8FF6S2.?4-\IDNA&N.9HV6W=FD
M4"XE26%0[G=(41W+;0*N6,B6.](H_L-K8Q>;+-/*K1VH;RY)HKC$Y+W!&Z3S
M2, 29RV6W@!!<V][9B..^\N%,6+N;TL;0DPHUM,ZSDM<DDA9 25)ZDG]YQ]D
MS^//*%^^WPE'%$L!N@T9G,NP"WN%:Z9GDV/&4D*@F0K(IQCS:XN/^$M^W6FL
MW'E>#K/:MQ<:A/Y(C8_9F6RE'G%S(@Y:5FW>:2O"ADD["U%Q#%'>R- NIPQ)
M!%'>70D2P,BVNZREE#[GDD=05E*L?F!P>%< D2Y)LK.WOI)+.61([.15NI)1
M9,Z0EK>:5906G;)"3'&"RXY8"3/DU:RLK P7K6C1RN+2VTZ-XGC6*1TB6R-N
ML@7S6,<T8)+HICE8LJ9C&7XBO[#PUI,$<3SK=K$++3K*&:/S[2+R[4M8X20R
M-)*40"1 [1^:&R% 8W(+2Y%Q<7^M/:&:Y0VC).SWD5@;HQ_Z#)$)<,3+)"WF
M=&3<N(D$= %C1=$F9TUN]ADU*[9'/V8W!N4LUC6(?9$,DY4SB:%6,V.6C?=L
M)4C8AMIG>$I''<)<O!<.+VU*F=8U3,\A$2^5<;BA"MG(@4*$^8I7BTYK[6<+
M#&J63QQ>;(ZSL4B96$5RI=BSG(GBESN7?E@OS"7F]:NKV_U,Z9X;\^ZU<117
M-S))%'LA3RU*SW,3QQK]K9D3RXR1M\E&S&A=6 "[U66[EM]&T4?9[^:*W>ZE
MU!4\JP\UDD2>XAVA%O6F9]D2?>8AFX"A=C0=*_LNSBTG23/#>KODO+F5MSEI
MBK2>:P:1#=HK0OND5E?D( C-L-$T,:=J,!L;#;'YK7L#7"3;)$E)\V1R^9$N
MP)%4F7=N5=J; \HCL0:AML7%\<VD'DLAFC^U1Q>7, L;'<S/=[PT>$>7YX4?
M 9PC !<Z@D&G-<1:C/:M%:/#'ONE;R0@$N&6X*-]I>##_O@PCV$MQN\SG[>V
ME\;75FFIKY?AZ*[>.QL[Z))DN6MY=@\PRD7 N"L5PQ7&W:5W%MLBO&+:^\8W
MMH=8N)(M#@>U<B\3$5^0[#R;F,.J).)'";$R/,A;S$VF%!TEL$&F2WDME GE
MRQF)'F6<2NLD<8BD9I@LEV&@11(Q^1V50S[6+ %B#4O(G<?OU_LZ*%#!-)N8
M^<@"VK2-.4>Y\Q8SN8GY94 /[PN>7UOQ2]S>6WA[P]-/-J$D1,$;3M%*]F B
M2 &24%[@2(^0YCE"Q3KF-L2-7U_Q!?:AJ</@W1O/EOVM'<SP7=S%/;VK1EXV
M=2PVW"LD0/G.N[<HRHG?R^H\.Z1;^%X+B*._@DO[J[635+\L1"]RSIP83,?+
MFE648V#&=IQC8A ([>PAMKB:&ZU*,:Q,EO!JFJP0B".]P2BQ/L?,4^V="I#(
MQ+QE=RJ4%A78:3!/<>7=)$^(%D97$92:(+;2;[@K)=;TV++NP)%/3HXLERUO
M!!,T<21/]CF,FHNK1Q2B(+%(RRDK=?O$VL#)NV'#1^<,<F;ZX\2ZLUK:2>38
M1W:Q7=_<*(A.5DLE*2A<;+TXS&P"E 0@"R!O) +EY-!XFOWTJPU.[ATDV[:?
M>7LK2F,(R11_8W663_CZ+7 82LH8%0A#D2 = L"I;P6MO/'I]NK^3.LDK;H!
M*(BT$C)< FZD>3<LWS$;CU+[G-&=K*WBM#Y=E%8/'9P"1E\NVB86Y2WD47#[
MYRKA%<]P2!AAYF?>W\.FW&FW,PD%U:O%;)]IE$_[QR0EHL9NCB\,<B@SG<-I
M8EMK$  L:KXL;2Q;W%Q!(+XW#V4-L64+-/+&LD-JP25Q'*=T8\UP5'ER$;5D
M4G+T[3?[4O(-2U26>&>'$=M-/-@6-O,$1;-]TWFI=NCHYE #[W4;V4!&-.T8
M7UY!K=]<^5<-BV1;N:9CIT$@15@^:X#PWLL<D6Z1>XQC+;I-BQNYV\N^A/D?
M\>MM&M_>R_Z-"WV<F&YC:0_Z6WFR;3@D_(&;G# !+?V\FG++_:\%G86N;6\F
MN+PG[(F(E>WFD6YXN2QXERVWD=6R^/JFJZCJ5X=-TC5)S/<^;]I*.H>%5'S6
M*.K>2MVHEF=64AA]GC$FY<N;&J:QJ/VR'1]'N?L=Y'%%'+<7+K<'3XYA'&L<
MJFXQ)<^84=6?ADWA/,8$/8L--M],LY;2WL;%+>3SOM<=W=%A+/<$$6]UF1\S
M-OMQYI\W<-X"J&0, 1Z-9VUKX?EL[&WCGBMK>*&>XBE266VEMRH"R0H)5-U'
M'Y9!56WO$ 0@$8JXT^G7.G22W#^;IQV&YF*-')<-A424[(5;[6LT(C$:%64[
M3@-L04[[7M-LDMIKIY)?LR/''IEW<*KH8VMG82AW8R3Q[3*LO$84[F=5(E/-
MQZ7K/B;PHG_"1WT#V=WJJO=VT4:6\FHVT<$9*LD:/)]I5X&W1J0<I(@(4(5
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MJ^N;I(SI^]0I9@% BO\ ,DL02+H9%,G!107NI2ZC?QZ'874%O='[)<WUY*J
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M:;>ZU+.;*WV+;65\1;M;N5B0R7#Q-B.]8W"M$H'"C@([;DZ2SDM(M4#V5[)
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MRW4<MM).6R_20NR7%K*+Z2W2W1;8Q7$RR+ 7-MB&X_>DO<')"."0/,.=V1O
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M'3*F4$<#S=#1-"LQHZSM!_PD;:WY5S<SW40*:A&S0'SI0\>(O*#,8X <;5.
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M>K-KD?B#4W2T1[C4T9DM+M;J-#]CMAM$J@!B,8.. 00"<9(!VE%%% !1110
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MD61W"/ JK$8VRGG5U$%KNBL?M%E/82Q6B>7%"OF#2Y)52)4A"Q&)]N),N<E
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M5&3SVMR'N?[+B=Y3_H4P1B+A<JQV[\M&BJ$0QE0"OHEI?7$UIJFK/'->1)!
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M96&&((DSTNM+L[.U^S2P7EI!$+#3);"3R1/;3$QBU@G>Y"O<*UNC,^X'"@*
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M6\U1&A-/Q!KSV.F27%YJF%-V8=FG*S.Q$DXA2V.W]Y<ETB62-BR#8^Y0I.X
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M2!8BNY#IUI87&I6D.FW=M&R"2>2.-YXPT1=UN(]T3&:Z):!F+ [B  TC1,*
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M%VN@J0 J>4**0!A0P!8L+5;:WM(D34I4=(G5AN2:Z"BW7S[IV1"LJXP4+9=
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MEK)%?G&29$/E8MR 2'7?M386Z#2(;.&SL(]+MK&\L]3E_M$-,0)KK<8I6O9
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M3_\ L*Q_^BI:]@KQ_P#:._Y)YI__ &%8_P#T5+0!\P4444 ??]%%% !1110
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MNWE/(,@2J&R[D2V+:Z^P2Q6\E[.3'=M9QS7+>:(%+1E8I]LO,DB_ZJ1QN =
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MNR#&(U4(J!".DNI+0.CVYM+9UN)][VX><KA;O+6J["C76[>9%"LV-X;=\N0
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ME(\;6&Y5J2]@O8-.EDQ!9WY\UVOKX1[+81!X?MY=(MAF:)HSY;% 5!4%0KY
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M1110 4444 %%%% !1110 5X_^T=_R3S3_P#L*Q_^BI:]@KQ_]H[_ ))YI_\
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MMK$D=W;^&=.>.6S@MK6=Y3)NM9E\G]T)'M=P=0A3 VAAPL8A[ HUM;VJ?89
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M$Q<OK]]?:Y=1^'+"ZC<WR36FJ7+77F6^\Q7!^PQE4PLJC>3(44JL<9<2%@C
M$FL>);_4=1N--T-O/D:5K>6YCDDB29XC=.UC'EOW-P5B ,W'RMO^4^2#H6=D
M^C:=>6EC)_:#21/$MS)J3";5)U%P#"',F8[A1'&&E]%("H(U"%IIMKHFCDQ0
MSVS"*Y6YN;JXG5'WM/*Z-<#:Z*D@)6XD0_*_R$M(34FIWPLA<3ZS#'%:QHJ7
M\TT<;1WN^.=OL?F.D:B)#)'ME?"L6V$[B^0"2\URW'VJ6^\B?39?.M6:0$1W
M9B^UF2W$<CA(F18OFE<A)!D<#;MYM(SXMAMY]2%VWAN=VM=.T]S)OUN-8;AE
M9UD?]V=NUDD9E+F/>V"8O+DBL]6\8_;KS7K6<Z0V8(]*D^T0+-+RB+)&T&[R
M1Y@<3+A@PWL!M6.#H#'//J.K721WTCR9M9)MDMHLF"Z0VZ81I!&IE9VN%QAB
M&5B@*1@'/^.(;R>^T@-;7VH0MJKM!R8)&D2&Z\N!%P=OSALW(5"J&)@S%3(N
M?X=U9],L?$-E:6T^J7CZK=V[):[H[B\E\Z8,&*,JPLOF6[O=!0H21$QN1:K_
M !#B@;6O"]C:Z%I0O+B[2&UAU2.*,0JL!'V8_N3&UNIEC8[9&8NS)'A@"MSP
M18VP3Q-=?V5'?:@^NWMG?S^0FRX=V<&)P4=TM3F G!<AF8L-BDD V)M*M/M6
MHZKJES&=6N'.GQWQB>TN#)Y4B""P$[ 1$Y5E=7<2,TG08(T-7NK;3[?SY7M)
M;$7$P"V^R)I)6%T&CM-C^9]L+%48[ANRVW:Q8"29$TII()G@6T266RM0[+;3
ME)(HS':6C!857+#@AVQY0&2V?*Y^]UZXU'S]$TJ^GMC%Y-I?7D-T))X"?-*V
MBAI65+DYCC^T,Q1G+C<'1$H DOY;O4-2N])TO[)$)GECOKW2YTA8%);B5+>W
M961C>,"7D#MY:?,Q4AR&U+"PL]/TZPATW3H(81%+9B**X$<GEXG9K:W*S'%R
MKQIYC[@&*EMV4&RPEI%;RI:6!W+)%<VR3+?O%!.VZ4F$8F9UN0P+//L9CLD.
M03A:]SJ=E:6K7L\]\D:Q/8-:-=2"X!6($6H4W'S7;L=R2J"60<-AE=@"O/KU
MG;6=].FI6,-A+*XDG1A:H,EW:S"M=(T5Z=[,9"J?[0!48Q[33+WQ3++J>JK]
MCTZ;S'TO3;;RXIEN0U[DJ#*0EZH*N6. &+!EW1ATDL;/4O$!@U34Y;N.SD3R
M]-TU;QE<^1)/F&96N/FNFCVN)-P:.2 EMICP_47&J+<"Z9+^,B1);?:&:%K@
MI<F(Q0!IU*2J3Y1DPH9Y86#84)0!)<.YO'/F_:8;G[3&'M;YD,S@,K6T:&91
M',!$A#J3@QSDB(MDY>J:R;8)I6D32:C>3/)8@Q32/')Y,<TAMC+Y^8+C:%!E
M;YB6#;6"D1T[_6AIVL3:1IT7]K:O=Q"VC\EYH5DMHUN]D#71E?9<*T4V9#@L
MQQ@89XS0=)L])\Z[N+V?6=9U*6XLY]3%L()KQD^T%K:%E=3"R&$_.QVX555L
M!!& 2>'-*&C6\P9[N[N=423[3,L\<>]D$W^A08N=T<Z,9&9]SY82LTA8[EV#
M-#:F_C:[M&CG>79'9R"W\]3)(C0Q?Z0-MP)Y%#RX3<TB+PW*FH:NO]EZC>I<
M1R )<PY>X:T2X,7VD&")FE!AE0I\TV,$+N' 'E\_J%U<Z\^HV+O=W=@;BYL?
M+??;#6)56YD%I$RN!"D878TV/WI3:3A2& *]YJ1\=W&JIITT=YI$236#M#?R
M6_\ :LRGSEM8%\S8HV+MDG()=2VT!>18OEALOB#H$-BDDD;V][C[#<A(Y%MR
M@6SAC:X"QE3''YFU1N,8!PAE"]));NT26VFRXA&^U5;,M';2HBW"K;AHV8VS
M1D+NE"KRJJ.<(O#^*[O44\4:<ESI=]J#7EI=V+VKW"PM>+."_P!C6(9"^4#
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M,D;6<B@"2]EFBL)XX_+@CO+BXM9;C39RH.Y[H(L)+;(KKS#&'=PJF1]NXMM
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;$P[6MV\KYRN-G4A2<IS=PK>(=4?0&L(XM#MDBL[U[)E9XP^P&WMS'L=;7?
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M,T@?[H^8@L\<9<:Y<>)GM+?[?FPCE,CZC$X2&_E-PQ&GVWF>6LD@\M0ERAW
MQY&TL:ZB)[?3(&TV&6 6$5H+6 6]\5>X1'EA%O"&F'ES(S6Z&7=\S.%.T@;0
M @32[6U0:>^E+9IN%K+IK9: F*>4&WM@LB&;RI%;*\R*[,1M"JQX@C\J+4);
MF/[!&(I+J>[B3(BC59(GGBF1-Z7(A:,_,&!"A$R-[K)=ZNL5A<:C?W$<-H]N
MZ7&;AH\!7D9XXS%*Y$\,23;]BY=E7#*$(7G[*S76+U;VZ%V+6U22:VB2W:01
MO$]PIOMJP>7]L9Y#FWP"IRS*6554 C_LY_$-G=ZQ?6\_V2**2YM]-TY622V?
M-T1.@*%?MX9S&T8;Y7&\DMY87J-3*6,4SE?L\T/G3P6MK:K*[.5N6W6I9%!N
M7&YF4[\8((PY=B.UU%8KA)K* 746ZXC2P50(&D68F2!I8@K7!=V1MS!2,.0G
MF%#R_B37;K2(H[*PAG?4]<BNFCL+5)[4"V5;J;S828SLNSOCW@@DOMRHR&H
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M&=E ^:)\UU%S;NLXT*"7[!'/$+8S0EK=%@9+GRX[0;BHN(]BEB /E .,!54
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M5C_]%2U[!7C_ .T=_P D\T__ +"L?_HJ6@#Y@HHHH ^_Z*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B
M[S5M!T/XEW=QK.H:;93W&CVZ6TEU,B-M2:8R $G*@EXC@XW;3C.QMOA'A:&Q
MUWXO7^HW9CATZ776WOYFYW$S3!( 4+12)(Q577+%ER5.P2,/H.:T&J>/KR*:
MYOHX;32H2L5O>S1(YG>=69E5@-RB+Y6 !&XG)(0KXYX7T2&T^+VO7ULLD":;
MKMO']N>^%T\0F:5"C#:?,$S$1DDB2(NI).US0!Z^P;3;=I9VCT]+1X@)XK)3
M!IT %L9;9'(4M$^&)E"A4 );;Y8%9][J&F^&DM+2(6FG78N(;>*UM;96:*25
MHY/LMN/+0&*?RIAYK%0'!YRN$N7.K6NCRVP@MH(W2(1I;GR&FLB6M$%DD:,,
M;_,3YBY1&*%B4*BL_P +V%U]LGU35)9TU..5;22*&ZGN3IR,+5DM0'#K)N0(
MTLPQRQ.>"R@$FDZ1/ 1<3V]W9:A/;K;27EK;Q;M+3S(VALH5\ID>("9@TH!'
M[MBQ& $V%LV00!1)8_9T^S9L[=6^R%XXD$,&8/G@#$.7X :,;OE#*E/3)+>R
MTF$BVGM?[+BAMIX((S=SZ>?+MF^R1[8F:6-EVEW!)[@\ QX<EQ?7OB Z7HTD
M=G+8VXB>_M+?S8M+24)$MM FW$X^T6Y+NRJ$1'7*$?* 4[V>\OY+JQTYY] M
M+:)3>ZK&A*:;'+:1*MK KPJT:AQ'+)C8$5-S,C-M3J+/1[/3[.VTA-'\FPCB
M^SR>5 )4MMQM]ULFZ+=-#+EB\A!^ZY8J0-AHEDFEV>FVMOH\^FPP1*C"*-9#
M8.QMB;9&\LF6.0EB\H)P5<E@0-E/5-1L=$TO5M7U.:."#3+A9+C^SDVRVDK?
M99C;1ML'FI-(=SN2N?, (ZE0 U*]@T+29+G56CLHM+>W,T]O#+!'91-- 5MK
M=U@/G1%4P^#R0 1&& CKZ1HU]=ZW!K&K64FFBP>*"ULH8_,&GG9"%2W*)M>)
MUFF69R  54 @0B2H]+TK4=2UJ+5M=TN?3O+EW6UM;(I;2YC-"SJLB+^_6YSN
MDD PBB1"PR^-R 7-@-(BFMHUE1X[.>6RM7"V9,<3&*W40-FW=D 9F90O3<"H
M"@$DP33K-+B6XL='AL?*CDN)E58K-,VY:V@9HT#0N%*[\\-C R J<_XA\4W&
MG2VVDZ5-Y>L#[-%"L\XG-J)6B4172+*[.Q?:&F( 5)3M=G(62F/%]CI^O6\%
MC;Z,VJ&WAMDCM8_/2)))+<0PQS)&A2W*R!R[K@-,NSS-AC&AX;BOM(T:TN=3
MO)%UO9'97MS>'[28I66*.*&41388F619$..(V?=M>1Y& +&@Z3#I5[!?&WM+
M:]9#%<W-Q="9[)I7MG^Q.0X\QW9V*R<<D,0[R,TE@W5MIWAJ3?')IEGI]N;7
MR9+Q(S9Q 0@02.MSM\]UYCDW#8'7)!)WR+JT&F3GS]2\M;?RA/\ ;+N(KI,+
M)#B*YS/EY)"C;)#O(9SR5SNP[;4KWQ48[&.:32]-LGAM;V\%_*)(;A9(1+IY
M;S%:24L !<C((<JH)8L0".\@@UO48M*T]/LFC65W/I=[=AXC''#(8P]A@S$_
MO3LVO& 8@8HPH(<+U%O<IIL$&9O(CBECMDC**4L1*\ 6TDCADVF3YPJ.%(1<
M$DC)DIV;PZ5;Z;<7$6FZ5!IEDMM))-=AETM2+0FTD)DQ([@9$G&-J<-N^:/5
M-730-.^USZC?(T<L,4%LI6XFB.+8FQ9!(3-<2@,0YW%1(QW 8+ $D\]IH&EP
MWEM;1Q/IENEE:QLKRFS5_LP%I*(GD=I7.S#JK;1@X;_EIEVEN\^L))K,NZ2*
M5["WDE+$Z0)%@*P>8&WM<30L,S^80LF%4DMAY-#L9I?$!UK5YHX[RT2"Q@MK
MJ0W$>CL1%OA$K.IEGG65/W@4X.5+,,!NDMYWB\@N9[18O+@1KTL5B#>1^YD)
MEQ/,Q)595W -E<DY#@%.SN88;H)]JDLK>*XCLTMU41C3V:*V=+5E4-$P;!'F
M9^4RB-#EA7-ZA?2W&HR:'I4?V34[>T:%;I]D%OI*RFW,=DRQR;AYBK&GF(6;
M>28CPRQW(=9OKAX;"RO9+34HW@2Y^UR>8FCHRHH@E#NINGEEA95?[Q$VY6 9
M2]CP_IC:)I>FV-M)'IPA2%+J5[M9GMY?]$_T6;+;999%RBR +L78J* 1D L:
M;IUMH,.DQ6ADLVB>&US>6R/<.?)@3R!Y:?O 8X][2(Y"-""2R(RK&M]8>'])
MN+J23[-8Z1Y-JB,L:SZ>#':[;/>VY'5R07D,@ W#YOEWK8BODT[S;B*2>VL-
M*M'%XLZKY>G!?*G,(AAP';R)-JNI<((AC<6??R^@?;-5>*YU#S]*\(V<L%MI
MEGRS;EN+46WSC<LRLT.=XW*%GPLKY;RP"Q8:<_BW48=1N[>>QT#3\V%M:6RM
MLF#&T_U>Q LUD^QU^9<;26) ($74:9%<)%#+<6OV'R_)B2&"V!?3@RVV;6,B
M,K+"6#;Y%("XQQLW)&T*VMNR:A!IL=IOBL!$]FS1VJ2BVC-I$-B^;$[%OWG
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M=*\)"^U>_P#[2UJ:5(]3N71(7-N%7_0BH:6))OWZR@(H!\KS<%HPS5+T33_
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MN=-H)RQDF^'WAYK>95ADN;!G0NDU]<+M4B()8^2]Q&8I65;7:9"V6'*H!&M
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MBXYW;\/3=%O]3GDUO5[6>QNI;1YQ';P2+_9=M<),66UVKEKW>$:5RN?GP!R
M9+"W74;^UUR^:.*%7O!;V@C99H8)TDDE"&*-6^W"2)E=$8LB*P.7)=N@DAN[
M2RACDM)#<6B;O]"C21S-,A!GC9K=8S/YID4_<0+*TDF P4 $E[ \-XJQZ?\
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M<Z1I443Z9&\L\A",)"+]=]NPGN/+\HI&2^TLVXJYQ787%OY7G_Z/Y'D^9/\
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M,>Y0-K GV?X?6T5A:ZYI\:Y>UU61)I?*>/SI&BB=GQ(6D.2_WG=RV,AMA55
M.PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *\?\ VCO^2>:?_P!A6/\ ]%2U[!7C_P"T=_R3S3_^PK'_ .BI
M: /F"BBB@#[_ **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#E[:^MX_BGJ=@TF+J;1+2:--I^9$GN0QS
MTX,B?G[&O'+"2VLOC+X@:RAC;4AKL#V@M2CS.2)C<1A27^1XS*&;>@23RBPC
M&?+]OCF9O'5S!.(]B:9"]F6C4-EI9!/L;&2/EMMPS@?)G&1GQ2!$G^,VO7<M
MGYR6WB"PQJ "W!@<LT2Q%6,GRON()WIY9C4@*ZI%0!Z78::8;BTUOQ TD5Y;
MO%;0,YD=M/\ --NJVR;PZSERS))<@ACN(R /DT(9&M+>UNIK&[L$MK=5E@M;
M!9VLB1;'[-"43+Q'!#%$<'#?/'L45)';W%M$Y"?96L]A1K6P$B64"+;M+:0_
M*KRK(%;#(GM@,BK7/W\UQJ&IKHFG1WVE/I.V2\O;&W#I91)';2&TMB(#YJR9
M'R?*WR$E63;&P 3/=:Q>)HUM83Z='!:16VHL+6">'3A,+<FSA'DMYN57YC_J
MT63<V0$5=33-*72H8].LTDL19.D"K:63$6<4T*J4BE>%OM \\+*S\8/,API5
MK&GZ0NC):VVGV\=G9V5P;41Q6[.\$3-$5$3F++HY53+D'!D<^:#%5<_V?HEO
M:BX6[LX]'2WB5H(II/(WB&-+6!O)S<Q.1AOO,&VG 8*8P".^OM.TN\L5N[>"
MVDT_RR-ELS/9*PAC$-B!;?OXV8K&Y7#+Y@'RDJJX]MI>HW4NFZQKL7]B26<O
MV*U@@*J=':1A%&MOB)X[A94>!&+?*AWE2IRJ2>'K":>W@\3:Y9:E926CJUG8
M+;%Y-)CP L$,<<'[Q)(Y6#MC*@(I^>(NO21V/V'3D@L].@M_LDJR1000[8[6
MX81CRX2+?F%_,E#S 94._3D( $%M;Z-9B2.Q^Q0V> Z:?9&0VQ8PNT-NBP9D
MA<Y+N!G.>A'[OG]0OK?3K^U\,Z/I_DZRGD3>38P%$TZ)Y[?>4(B3S;8N"9-K
M!FY!VC+15]9N;K2=6&@^&X?LM^T4S1165I PTZ#S(@#"K1)E9FD1G)+)OC9-
MR -+%H>'/"47AFUL8[>WV7"7:RZC<VP=/+N)(H5D6",0[7MY&4;A\J)U&TQC
MRP"QX>TE/"MK:PF'-_++$E[J$D:BW@E,5NCQQ;S&WER>6BH(PRJ^!M 0(+D(
ML=)M[6X6..TBTNW6U5G'F_V; 1;%X)]LIRY50WF<JBC<QP,O'82P:-+96)TZ
MQTVZ:5XU6)8OLUG&6A+QQ%A"[K*S1C<BN!+( V=H6L<7[^(=6ATZ!_[.@TC9
M:7NHF9I#'*9!&]FESYBM(TJE/F(W(0A8>:5$0!3-W-KEPF@V.HW>G+87#6U_
MJ$&JF9K-I"%\@L\^Z5Y&WB.9D/E[D4('5_+W-*BT?08FDB:#3+72L6ZF[5(X
MM+CD6U>2V=O, DDD.'$F7 9CDG&&N:(K:?96D32QV0@2"W6U>=9(M-!2V7[&
MY$@,LK')20@D;_0@/&^NQ:/IUE<:G/\ 8YD\FU,/FO>-!(X@)M759"\]PP+%
M7"DA<L1C.\ KV]^GAO18))W^SM;Q1P0::DRS?9"(8";!0)%,]PX5C&Q!/S'L
M0'I^'-/NY+V+7?$)C@U:!Q9V\%Q<I<Q:1&7C40[O,W/<3HZGS3DG<H( PKU]
M%TJ^O+U-4\1B."\5'L426_\ -&C(7B1(%99-[7$\<FXS[MP)08P0IZ2UM[>V
M^R%;7^SUM)0MNUPA1;59/*W6I/FXDW&0J@3,2LB+@F)00 TR2*QBAL8I(+1=
M,\FPVAW:"URML1;DNZF:1@X$<FWC=@C.5?EY[Z6YGM=-\+1_86TGR].:_EV"
M/3XW1,V7F/)(LEPTL4*%E20() ,%A\UB;6M3O;Q-#M[:>QNK6TB\Z\GO)DAL
MIF%NR6IF^9;FX9ROSL,!7^[+ET?0\,Z3I>C6=GI]A#?0_P!DXM%=8]\MJ93;
M320S<NKM(S!F=%V(NX!DVY( :#90:79FRM[^>*2UNXT:ZOTB>:U:4VTLMK)(
M6_>23LY8LF5W28!RB W$NFTQ_/WQVVG6Z .AV[-)3;:_Z-)%$^TDKYC^:3B(
M'/W#S7GNX+6UAU6ZU&TLH]-=+%[\O+,( 9;82P%Y!B8,R,C3G:4(Y&Y7(Y.Q
MT[5/$=Y:7OB>WGT/PSI\MM'8:8R^7+YLHC40NB)Y<ENPN#!R P5 IV$R[@#4
MT9]2\7)IFKW-E)I^EVJ69LEGB:XN"S-;R-N;Y_/B9<8E+)L8%G0O$KIN:="D
M$2P6EU!80Z?+;V<8N8U,VGH5M#]B#'(D\P=7#G#.@&X@8+"&*PL]+GNK;^R5
ML8H-/B5"[/:>:;4"V!8,LZLX"F88QC P=S#/U/6#H=GI\-ND U,1)%%#%%"I
MMI0;7_051-_DQS;E4NS,L9=/F.8Z )+S53IB:5<7=M)!JNR.RMH#+(TL32M:
M;HGD9766(OM62Y_AR%7,AYC\.^'[S3LZG<?Z/JT_V2&=UM"WV&,?9R;*W15*
M&WR909$("9!8N4+"3PUH9T6XVW+2/?V]O:V;7,%G)_HT(,92U@9HB)8-QEW2
M9WJI7>25WK8M4.FV3I!+'&FDO!;%;6TDNY;",):,UI'B,O,CJ"3)P5W*<';\
MH!8M#-;W%NILY(XU=(4-I9%?[.CS&A@0M$/,@:2!]SJ 55HVVA,2+S=O>'Q1
MY%OH\L$5K9W<<<EW8VT-Q'IR+Y 6V@;RG697=1+O&WR@$9PNP(9+:!KN_CT_
M2;6.TM]/>'3[K5]/G6>:R6-(2ME$WE;W E(+F0,@3?N()*1ZEC =,T>PM9A?
M:8J1):K=$0R2:8\C6RQV<3&(B6,E@ID(?F,[FR 5 )+>UTS1]$M;5TM-+TO3
M7BG=;SS$MK5U<($0LD8F!997$DC$AVCDVMN3%/5];T[0+.[U'6&VQV,41CMY
M+EKMXHXS;-Y<L)F(-R9)1ME&X+F-F?!&ZQ!J-GX>LP3ID%HUI=BUG%A;"X@T
M[S#"WD1A4BE?SM\9&Q'Q(_S9"@5CZ/;//+'JOB*:"Y_LF*"*!+Z!KMK"4-&K
MI',J*MU<2-'@LF6CE 10VX@@$FD:#?76J0:GXHM--2>*RBL9/MT/G) 9/)4V
M\4C$-,7!E#.[.%:940OB7=T #3Z7;Q-'ING3PI#&D$@6:UTV7_1V2WDC651)
M+N(,;*%P-N,9&^PGDA[-D:.P2S>.*.%91'%9[EA7[+-''-L>5@_R<%5RN >-
M_+W^O&PAT'3O#EI(+U4BAMK>>21(M(C>%!''?H)AN=F(5=W/)VAW7$@ :EXD
M,=[9:;HUY);ZQ?V4442W<\COI<;/;*/M,#R%#/B:1@[[2Q58_G+#=)X>L;?P
MK]E9]0V:O>2Q?VC+?3F]N,M]G3[/*RRKOD#31A)0FQ$;E1O+/8T'PZF@RF6V
MU:>.XFEC^W7NH2K/<[RUL4MKA_-*M(4+(FU#M$@VD$DR[D-S-%<6JK)'#!"B
MP.]U=%VM&8VVVWF7S2)9W#-MDR=N5^]O^< KV4\VGV&XB19+9V189;XW#0[W
MA9;:9I)P'N) PV$DJF\*"5P9.7MM1OO%][;VT@DTOPW$XC26:Y\Y[I%>SQ;W
M/SNC";>^QBQ:16!&49O-D6Y?Q#+:F[A@MM)MXK:SDN3.UT^^9K"7[(S!R)XY
M0VPRG.[)R  3+TEG<+9V0M=-6.U.FI'90P7<C)%;$I;%;64^8P>5@ZA95#A=
MV/F.1( %AB*PM+>W:31X[)XK2..66-_LD8>W MI@)G5Y95X1^2JR#HQ^?+O?
M$45GIUDLC7TSW%HT4=E!O-[$N%E:*2+[3YKW!B:)0Z@M&VZ1BJ.0)&\0V.@/
M8Z="8[86Z)8VUD\O[V-]MH5M/+,NV>5EDXF#;8\C<2"Q:GI.D:B^CVVH:Q=0
M7.H^4]BJW5TLUJD.Z.(V,[$_/-(X^:54SYBD'*JL;@$F@QW8O;74]4U.,ZSO
M19C'.C6UG'.Y62T*-.S$^?"RAUYWF-5RD;1KN077E?99EO9[2%I;>WC:9OM$
M9QO1K:5O-?\ ?!PX,F5R[1+F0J58%\EM/:BXO/L5K#$RM+-?+YEJ42"4V\X=
MW$LC(LKF3JJ X/S;SR<NK7NK7\&GZ8T>F3(D-AJ6J2/+.MJQ12+$RK(//G\S
M<OF[EV>;M4B63D D::76=1DT30+G^S63997%^H2!K:/*NVGQ&,E)+B./SRKJ
MK")1M^\[25T&D:=:V']DIICP6D9S%$9(H)) 4^66TDD5\NPCB11LR5-IEW<#
M::>F:5I6GI';);1VFCW")91X\LI$-RJUE*%WI*3(DX9Y#D-<%$8LY(DDEEAT
MF6749H+18[3;)//J21OI;&.U_P!">YPSGS6RQE^]RI'.PT 8?CK49M(M]$OD
MM[MX+/4[/SI!=EI-.VA!Y,[&?8'D2>8-*QVD,BMG<L@\HLXI-4^)#WZ^98ZB
M+VUM;=HH()/[,^5(HWDM"I79DH@4/N@8 .6?;O[_ %>QOM1FT'6M0TJ[M[/3
M]3M5TBR\CR9K,F;>(I%"",I)%Y**VX".01QL<B5SR$,K:9\4+Q8],C4I<6=A
M''%=J4<07%@%@@+9$DJA &W.I(;<RQ%2A /3VTGQ'8:O'<0KHTMO D=O)!J"
M?9;:-FGBD@@A=(_WPB4!(V9!M>4D%B6C3+UOQ3XYL;.VL)VT-=2NXC:0V?\
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M)/+BO8/#W_(<\6?]A6/_ -(K6@#H**** "BBB@ HHHH **** "BBB@ HHHH
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M-F,1*W-*T8^'1-,T,DM_=/<"^U*.&22>U+Q^=MMQY#"1"V7/W8S*S;4!81*
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MUB5D62?"QFWNE\U@SR"9E1@KKL\G_6!(R^QO6WL%AN;Z[5-Z6A>69FDM!,\
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MNI]C[%N7,S;3'M5@_*N$3/%VUM#XXMX[J>UM!H&^%(A>L!]I\T0JQN0Y:07
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M:5!7F[S5+W6+B/3M*>2S,-O BS:M%+Y=BTAMG43"0,LUXI,;1#?U=PV"H,@
M:CK5QJ4MG8V%YJ6F6<%N1J%Q-#<B>UAD@A"6V3N$MXS2HRL&+J5QAR6#]!I%
MM8^'4@T.RN(X(-.2*W@E9/W6&:'?'+M<*;AR58,RJ3YX*A_WF:^E:?:>%K#3
M+'1H([>"1(C%/<0/;1F,O;1N+@ @-=2 G860'.5P,-NL0W"^';>UD$EW-;R6
MZR&:XMV1I0!;1 W#;3(]T03L4*I?E"N5!H D2;S98K0:;/>R6WV<)!--N%NI
M: N)G\QU:XB^68%L,P(V%CO:N3TW=XF2V2XM9+NPOGCN7AN$6(ZZ(FM8GO71
ME(AB0!76(,#*,9 &0TFG>'[CQ=/;WNJVD\-@OD,^A/= ('5(=QU!OFDGFQM9
M%8?=B3?M+D5T&FLDL&;.QGU"&2[61)IMK)J #V^Z]9RF T9W&-00&6,&,%0F
MP L1VB:E$]K=:9]IM[C8S+?VZA-00+;YN)QY/R3+RJQL%SL/  !3G]4U=)M'
MM;2.PL=3NM>B\S3XKE5>#4ANME2YN5\E6$BHPD*(N D;\C:I4\2Z]_PCWAZV
M26"?4];U")7M+6VLMDVI3(D!:Z>,P-Y4T>W<%8$ *,@D )'H'A8KKTFHZY):
M7VN:HD,Z'RI+=IX;>2WQ,X*9A=<0L81@%RVXE2HB )/#>B7BMI>JZVL\^M:E
MY-Q*DML=CXB@9_/_ '++;R1O'E GE[_)A#%F7(Z"TFM[J+3I88_MT.H^5<0R
MM;G9=@+ PN9V6#$4RA/D4E0<*.#@1QV-L1>PV\4<D\4B+>2+?6L@-VQ> K<2
MRM$!'/'L<+".@"?ZL* G'W%ZVLZH^D6K1Q21V45QKVM2PK9%D78JR2JT&^*X
M7;++$I9 H5'RRG: "/5H[_QM>2^&],D@_>Q,VIM>Q2 )'A8H[B:,01-]K9<L
MD;ML A5@/N,O::-I"V-O%:PV\<UO(\=S"L]NR-< "W+7%TS19^U!P[ ':6XR
M,J62GX<TN+1X+'1EB@G\Z);Y3<EUDU"0/"T]U.LD1:.9'92JER26P=NT%"R^
MQ6%C%?SV7[DQ1":ZOH)!)<"&9$6XNF>W#+)&@212Q RTAX5/, !8GODL-'?4
MKW3YVCBVW%TES H:01- )+F<K%M$T6QF54)#K'E-PV[,.RT^^UCQ!_:%W9QW
MLMJ[2Z?9SGR8A+&(5%S>LL>5NGB='C0Q_(@QA3R#2;.YUPCQ!KNGW:Q(ZW%E
MIMQ:/',#!)&&O+@QQ\W16-=D:@ H"BY#.1U!LVN4DMD$GF2.?WTENJF=XVA0
MW4A:#:)T*9C&-KA5(^7!0 KPM#(D-Q(\GE3W$#@7]L+<731LD7FS;K=2DY=D
M*)QN,$6PJ"P&'>75P8M,\.:1^ZUF]QN.HQ">:*.%8P;ZY7R_FF1X1'&=^QV*
M,&88VFNS'S6T71(\ZQJUI<2P0-;PJDD$C#Y[Q6@W1K&]Q,RJ1\^Q@Q9W*FY#
MX?@C>=#:QWIUNXBE?^T+&687<*K SM=%H\12J%F\N/\ =Q@L $R"  2:!X=M
M[*"TCMK:^0"7SFM[]BWVAU=#-/<L8B#<>80RD,=WD(8V5&>M".1!$YFMO.FA
MV374#1K*\CHMNQDG\F)@+E!@I&A.["E>,%*YELQ/%=,OVA8\/=23L(HPJI;2
M&ZO%,:B.X0(FQ<;L$'"KN,?-Z/N\:"RM;:UD/AR-+>:X74D5Y-9(C@.ZY8+F
M*6/$; -D3C&#Y?S  L:6&\=7#Q,T;^'V>.X_?62DZH4,/S78 7RWVQK(@^42
M1S1':5C=#TEK!O\ LBK:3Q0W,H)CNK+S-CP^5_Q\,6+O,!"^R?=LX4Y<^67C
MTVW6=[:!&CNH+)(XK6U:-H46(+:OON$$>V.X0C?&FU,!A@+R5IWFM0:7IUG>
M7VG3M]KB2Y2&ZCB22\F06Y42KY8Q>\,(XDX8QGE<#8 1WNL6GA_06U?4K&2*
MQ=([N*UN('+LJ1VY#74CJV+I61EC#.-YV+DMAER]!\,ZCJNN'6_$%MYDLLL<
M]I;3VJP%HX_LS17$TD:9%S&/-4H_!)D5-L>[,?ASPY#?7^GZCKUC=ZCJ2)%+
M"H(S8[4L2/M18J?M2D!BW#21JW&-D:]);K%>WGV:2*QF:_EBU)7CD<)J'DBS
M_P!*C9681JAP!$<[]JG< 6) )---C</;/;21WAU1(]1B^T'B]1%M5^U./*Q'
M*@";47:"<'@G*8][JDFI(VDZ$\<FK73QNDLL4$C/&C6Z/J$\1"%9875HU0X.
M^/[A"X2/4M3EUGR[;188-8FO=/1(S,R(EY'^Y<373*$=%C$I+0!<2+=# P7"
M:GANSMC;L\$\E^FH7"ZC"^I7",VHHPMG^U;?+S&8OE1$55 VKG&Y64 DT71W
MLH+.%(H)HY\WEP);1HOML[/;R-=RYC_<S*WF%8CU^7!4)\@L9CEL(?,GOKBX
ME6]$$\4,3WT0:W5I[@&!=DD&]"JKM8^6F<GA9 ;&\TNWOGDCFL)4AU'[3*?)
M2Y2/[.XNIW6)0DJA,JF0&"X. #Y?+FT/CVX07=M=_P#"+WUPTUO T4D#:K@C
M]_<21)^[B2,*(4<JTGEH6;I0 :=I#>,]4.HSV\DF@7#PS1I=VZPOK B\M//N
M&CB \H EXH7YD)).U %7K+>WEB@@_P!'GU-KB6.?_28$B:X7?!_I$_[E!'-$
M/NIPQ6/NP^0TVWE?]W+;SW/F2K.LE] D?VU1]G87$NR$>7-']Q$8*Q\KGIN3
ME]3U&PM6:.+PS/K&IZ_+Y,-E?QQP'5Q!%$6GG$L:^3Y>QPJ8 ))8*=X90"XV
MHS6-QI6BVEE'?ZC.@N5M;EBS7<,9A2.ZNY&B5X)UVA@2K#]TR<N4VW/#7AQ[
M!5N+U_[4U.^VS3W5Q;M"+M%E61))4:,^3-%YC+''D9"#IM BK^'- S>/?7L/
M]K75U+%=B[U&S\AY9(A'$TC1FV4V[1@,8DW$MO<Y_B78BM;BXO+;]UNMV\JZ
M!FC"&_*B(-+<J;8>5-'A&1592Q3!VA?E )!;33);B"..1YGAN";RU(%TJ-;[
MIYP(E\NX55(1>.0#CY<)P\ELWQ"N)].LK..#3R]O'K4UY;JL^HF(VDI21X0/
M*GC5I4*GC)(4<,8I-.O?^$VO(+?2[R>YTF&[#WEXT>Q[^1@C1L9((PD<D<4;
M]1E<VXRDQ!AZC3%1+.&VMM-@G\J6%?LL:*@=%-MLGN 8$$-Q''L<0\<#"@X&
MP DL].ABN--AM]-D:#[.KQ[XQ#!(J&T EGC$2A+A0G[M-HP(V&4Z+3N=5M]/
MM9YIY[&ZD>6,V\%U&86NI1%;,IN,0LRW8QN2-5#%=N$RN4N7EY::9;O)>122
MEG;R_.LWVWMQ$(@DL[);_)+YD86/:"'^4H')15YO1-'_ +9UC1O$6KVWV]I<
M76C-(F?E=8RT]T8K<(MPL:H$RVT[54?,OF$ L>%M ^T7D6H7[3WUU'Y9@L[^
M3>8E40LL]UB+"WZHX _B*!5W'#25N0VQFNH6ECDG=KB":(O:R1"YC,2?O+H>
M5L$ZM S# 0J4A3*;\&18?.GLP$G?=+!,RS6FQ;W**1-<$V_[N9/)8A05PR1!
MBN]5&'J6MVUE<+;:-I]IJ&IS7 ==-N[5()[YB3=)MD^41&'S'D(E0N#M)PTB
MNX!)>ZS+!%"NCO\ VW=:E*7L6TPIBX6%8!)=7,BF-2R.A7:KHKAEC(YRMCP_
MIMOI,L<9O/[5OM6Q?2WT,A\_4 C08FWAE2.&,R$"$%@8R,9RRM3T303':SZG
M=)=ZQJUZ\=Q/(]O)8F^^S2QM$[QN@$$L>"J)N59 -S$@DI8UG6;&$F:ZO8[R
M)G6\ALDDXOCYD,EL\#!WPX6)U2+Y1/(LA"@9( -2VB@N;.RM[AH-1:7[/<R3
M0K%&^I21FV*WB;) /+0A=P().% R-H?#65?&+VMO'<6DFD:G;RRW"VDC6XU=
M MHCRDJK/&$WR(8BX8E$5B5W8C@BUCQ;8_9=5:=;"[EF%W'8*ZI>PB9(Q\SR
M;K1E6/\ >0$DLLD@ \S<$V+!4CU&%$OI[MK[-V3;[5_M$*;14NA(KX"QIL5U
M&T29<B,C"D L6RR_8[(/93W]U)]GDG::S2W2\8&V#7;@J3')&.5C8JW[M@%.
MU6&/J5\EC!I,=Q)!K,][Y$\5O8JJ2:Q+&]F?M88856CP6V;BK( 2P53MKZKK
M.G6-G9ZE,\%ZNJ^3J,5C;%HGU61#9[9XQ(04D0)\MN&)DXY)SBOH&@ZH^L1:
MWKT4%WJ4OD,NG--B.X*K:JVHK'*%,4T8,@($:D#:HP?F< C\*Z'=WMZOBO6K
M2/5=6OWAE@6 (MB\&^)H[I=T2LDL23,J^83(0C@'!XZ2TELW^RRVB_VDVJ^3
M?QI(P'VV-?LB&\<-&!')&-C!%P#C(&X_)<A1KRXM98TM+F*9%GF*VRBWOG!M
MBMTLB^9M**"$5CEB!@X0/7)W5Q<:O>066A13W2WLME?7-PX ,L#"W,>HEBJH
MDB&W=!!@;B-Y0J"I *^J71\63_\ "/:/_I0U.*&=[JZBA:V:)$MI/MLJ"-6>
MX^:)! 3MP$+J$8 [GAR"QBLM(CTNUCDCU5(]3,5_/E[E EMNNY<1,/M"MY?R
MA@&+%RV[[LFB:+;Z;%IMA'+ON)]M_+%,A0:D46V62ZF62)FBF5RKA P)?!8Y
M+%9/[7LH956XCC,9N$\R6],42S;(()S<W&8P8IT5?ECPK?+NVA%W1@$>J7GV
M#P]<7-X8()I8I+B%[@;/M/E)&ZW,Q-J=ERB1EQ&$;[AX(3Y,?3+)]8UPSIH\
M _LZ62\L+2_C:S>]E;RHS?72I&5CDW)/Y99-S[B0J;"U5]*N;SQE:Z=>B&"_
MTFXB5HX)[0Q1ZS=)$J2S7C)%(D*H051#G<\8()"I766=C8ZI9!UACU.SU9([
MIOM:;HKY-ELOGR@P[8Y0JC;&-H;&< Y* $9CM[;3HK)9)VDDM!<QF6(R7-RD
M0M@;N56@9C<Q_+M0@[B%R,_<S[NX\B6W1-.\S6M1EMS!OM_+&HK&R.DMS,]J
M!%,B12MY8&Y1NVC=L*X^NZA>^>-!-I_:4FH:? ]W+-:1JCEDXO&MG@W27"_9
MW/V??DK&FU6(;R^@T313IMC+I%S+_P 37499+QDD2$*7BF027J$1,!(Q>.8(
MY;:Q1!M53@ C\/:0MK>@O;W>I7]TB27=_>V[0I=%'AE6216B!CEC,[B)%R (
M]K,#&/+U+9?[1L[*XL#!=1W?V>[2:XM\I>Q@VQ-Q+B)=EP%4^6N0. <87"1W
M2PW5W;+)!)>7-T\5S!!)B"26WCN()!)(3&K(;=I3MB)RPSNW,QV\?'<P^.-4
ML[NT$BZ#;7$874YR+<:K*?)C:;)@^2=&"Q(5V.Q=A'(FQA0!7.GM\2[^U=+.
M230@EO),E^5C^W$I"99Y!#&&BN%38J@LH=6#(?*#K)WFFA(_W$#>;:S2K<PM
M#=+YE^#]G9KM=CHJ1AW<R(JX<DMCY]KTX-+LDM=/TG?=MYCPWMO%%!%!+<1P
MRVK"69?)C$9BQ''L&#Y8Z%@ L=]XIM['2;'4I)O/M[WR[MB)S;F>)(X97NH4
M:4NL*1JY:$*S,>",%F8 +[6$CL[&_N;7[5NNXYE*7"@R@&&/[9;;9W80E6*^
M2@9Y#,JD?.V_+T&QN_$(35=9FDE%V\5[I%H)$=H5,:8NXDD<A"C74Q9'\S;^
MZ521&F\T[1;O7KA+[6KF0B5_M6G6=O>)/R3;.+^+S)'"&-BX* O&JMM4.&)F
MZ3=]N\B.80:E#=2VMTHBN-GF^7Y;&Z@!E;,*OY'R?+C#G,A=0X 13V^IK;03
MG[8T_E7S1(2!.4EB$=S WFE!"IC60QJ6.'0L-S8?'G\0RW^HVNF:-=_:]6E\
MNXN8XKA&@,>47[3A9R\<:@0RB,-B1)BI#%G>.O>:[_;.M6>DZ5/!J\TT27DH
MCES;LR36X2]3]X<0Q/%*#"L@9G&-I#&2M31M)MK>PBM9KN367O+B/49KAY4\
MS4)0]NRW46V4!8(_D&P#HJ@9X\P -#L;2RN"L,T>HWE\D%Y=WEI([37O,02X
M:3>%BBR)<0@LK(&V9 =#7\27+77AR^@@O(Y;B[TRXNE9[A4M+I4@B/GQ[BZB
M(.8E,;NJ,LDI8..6L3ZBI>&6[%I< .FH0SK<LB31(MLLMY%(7*P1(LL@,63Y
M@SR0[;N/,;>);*2XU":0:1);G40D@6V?6W@2&.2]D60&**)1Y;1POA7.UGPM
M &'\)Y=OQ0LKB33KZT^W>%(%C\]=WF^6(H_, 4?NXSY)VESSP<_.JU[!X>_Y
M#GBS_L*Q_P#I%:UY'\-;)M.^*FC"QTF.S@NO"5M-<2(587 9(R9L;AY9,@"'
M 8DJ21\Y=?6/"\*P:QXM1#(0=8#_ #R,YRUI;,>6).,G@= , 8  H Z2BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KQ_]H[_ ))YI_\ V%8__14M>P5X_P#M'?\ )/-/_P"PK'_Z*EH ^8**
M** /O^BHYYX;6WEN+B6.&")"\DDC!510,DDG@ #G-1S7]G;_ &CS[N"+[-$)
MY]\@7RHSNP[9^ZOR-R>/E/H: +%%5VO[-/,W7<"^5*D$F9 -DC[=J'T8[TP.
MIW+ZBHWU;38T=WU"T5$25V8S* JQ-ME)YX",<,?X3P<4 7**KRW]G!*T4MW!
M'(OE[D>0 CS&*1Y'^TP*CU(P.:KWFNZ/I]F+R]U6QMK4RM )IKA$0R*2&3<3
MC<"K CJ-I]* -"BJ=MJVFWMO;7%IJ%I/!=.4MY(IE99F 8D(0<,0$<D#^Z?0
MU<H **** "BBB@ HHHH **** "BHYYX;6WEN+B6.&")"\DDC!510,DDG@ #G
M- GA:X>W66,SHBN\88;E5B0I(Z@$JP![[3Z4 245'//#:V\MQ<2QPP1(7DDD
M8*J*!DDD\  <YH$\+7#VZRQF=$5WC##<JL2%)'4 E6 /?:?2@"2BJ\M_9P2M
M%+=P1R+Y>Y'D (\QBD>1_M,"H]2,#FAK^S3S-UW OE2I!)F0#9(^W:A]&.],
M#J=R^HH L4444 %%%% !1110!P_^F1_'7_ENMC/X:]Q'))'<_D642?4!_P#:
MKS2. I\;M?O3%=_N=8T^/^T460/!YCJ/)V2;CLD^Z9 R*%4[<JZQ/['->7$?
MQ#LK)1.MK/I4\LA9P8W>.6$+M7.591*^3@;@Z\MM&WQ^YN!HGQ:\9W]Q%!I]
MC:7>GW,]Q )F6 %XR9#L4#=*C2HPVE]TY )0RO0!ZA-$FC3W%S>VL$%G9XN%
MN;6V7_B76D*,(T4F/YU*K<;@F7C^T;5&U@XP].T*YUK7KC4O$NG1V\%O<2)8
MV5O [K;"23R9NL(6=+@B5G+#*(RMQYFY271C)<07%_-)IFF^'[>'^S[.6VDD
M@T^0%1'+*Q!2Y(3(=E<" ;L-D^<.HEAFM[C;]DC2"WN)-0D>&,NUN"6QY"BW
M(D>4"3S!GS%\YL,=RT 1FWO(+.:46\%EJ4>^X=[> W"6R.2[+$1"IG\QXE:2
M,8<^82&!\O//ZSJ[Z3J-KH6C6'FWUO*LK1*K3/91$RL;Q0\.ZXWH767:^[<V
MQ6WON)K-Y>Z7:OI^F2^9KZQ&UA33K:-H]+B6(OOC0Q,WEMY=N9(LR,HEC"Y)
MCWZ&E>%K?0\AH<WYE+&YB@+BS,N^)9+7=$VSY5A0Q9*11HNXD M( 4]!\-+X
M;TU+Z_BDDU"WN(FNGM[9KC[,_E(CM:#[/O*2JL2,B_*B[E0KY>*V(K":Q>#S
M;*T#V:)+-<6EL0;>&)66*.V00-N#*)08]Y>,3L%8[E)K@2K;V^I36TEFZI+/
M(MC:S22VHN 0##B!3*2Z^9)%)&2'<.V/+4-ES6DOB6ZN-@GM=!M91J<=Q#9)
M+F196>*6Q81Y9G*R/)O5RV\!-RR!R 5[^VO?%'V'3&F@L=*F\_[:;2"-FNA)
MOC$]G\DAVR"Y1Y7R0BRJ-^X2UTB6ES(B)/8QZ<+=(K%/[.=R;/+;@8#]G4NA
M(M=P.8L*P8 1L'DAM$LXHX8M,_L^'3O*G,%K;JT,(VR,[6NV$F1G+/$RX5]I
M) 4LI?+UB^AT>U9[V&3^T&218K31HPMT)FE29C:*R W ^=6E;.QC#\T?+J "
M34;^P\+6:&.*QT9K>T<%S:QM:6 !228HN8995D:2-,QY!<)D*V0<_3X[C69;
M?5]3A^S7$-W(MM'?89+$3,\D*3)]HW&8N+1RC9"[H5C1""ZEKH>HVVIV6HZW
M)!;7NE6A=)+>!1I=@ICN(U\LLR,(P@S*G+%C!\RHG'227<-@2+NYN[6.R0'S
M/-#F"W$B*#."[EA(8Y&\YE!6,29:-@Q( ->-8I'S(L\%O&8[>:X5GC1VB589
M=T^))Y&214E)(R",GGS.;U>^_M/45T".."VU,Q.EU<3_ .E1Z9YY=2)&:0+,
ML[-&(H& X"NR?*J OK]V63PMI+_V5J(M!;R%)F>#21-*%R9!(H+.-OV>,*'7
M X16*KL:-:V6A75U86OD64D=VTCL\LCJ1-+%@RF20----A@DN&"L&C!)0AP
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MCPT;8^FV-S]HM-;UJ&/2+'2W5["TB1V%A Y=6D,LD.2'QM,7[M882&8(R+M
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MA9HSMW1/0!(EQ#I?A^QN9K"[E$B6K);WJ SW4A-LB/<.8\+=*VU5!< D9+
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MJW<I%NYOQ'KTVBRG28'M)O$&H/-;6V;@PK=-Y"C$TD;H%N"%MV#;%QYR1QD
MM*H!)XB\87&E1065I<_:];O<6^DJTHMW<;;5I%G5PL<=R1(SH&CP/E&W+;'N
M>%/#Z^&+@27.IQW-Z'^R7MZUPQ5QE3%&Z&0*L\CS"0$1D_O&!+._FR'A?0H=
M$U2YO'U"2?7-4N"+FYNY07&-DJVTL2S;#.L1?:T:A55<XV\/J6EQ+#J(Q<3V
MT,<5O WVJ=)8X6)BQ;RYF9S<D.V'&%82IN\PJN0 CMKQ($%[-/8PS1+; R79
M*B,O&$20^;O6YQ(\8DC=@S#>Q)V(.3EO9O&5[_99OKN+0Y;>"'4+JX)C+2!X
M-]C*J,HCN&\W:70J")&CV,T8*4Y[Z\\3;[#28_L6G0;1J5\V5N?,;R#!;*99
M-AOP42(NY<H0K!T9M@["T6RBQ86=]/9V"6EO9PHWF)'%$?*"PN2XDBN<2#:3
MY;$3I\LAC^4 KV2V0TG2@^E?;5L-LEK9FUD!TJ%8XG F0M+FY1"H7 \QB^%"
MJ78$SV>E:'))>B#3XY_-NQ)Y(4W&WRY&NY5-L-MVJHT@BVG)1N"%RDEWJ$-D
MZ76HP7=_Y%N'NY)I!Y6GQPK#,QN4C9HS<9;S$,<>3P!A1OK#\/QZCXDU'2-4
MO8[&>%MNH1:?<(J2;<E(=0F>-&7[08<*(CA24+*5*;4 +D6C7VOZI!K-U926
MQNG2XM[*XC\DVI3<HO'&R5/M2I*B+&QPPC#'!4)%N6^F13P0(;"!?M$L=^\<
M-N]K'<R!X)&N)1Y9:.97!*QLQ+ 88GG9GPZ2L_V=TTV<)/*9D5[2W202#:/[
M18& *ESN8'8S [,G9O4QBGJTTT=U:V=A8QZMK%VZ7ME'J=H8T^6**/[7*RVR
M[)8F7E-RMA\ @F.-0 U:\AO+JUT>PBCN-;F=)XC=68$J?NHE&I2(]N )8LX
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MXM$\D;O_ &P""B%1M^R6VT8)/(7 )[D$X&<  Z2BBB@ HHHH **** "BBB@
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MQ^?::>S2VPGDS^X<P,LYE<0ET"L5=W)=L( :SJ</A_1HM7N+>,-'<2RP6**
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MO,F!)!:M<W[:EJ5M'<7=R]PD;1WJNT+HDD3VMF3(ODNRH&\Q2"VV7S%A(4*
M9?A[1;W[4NJ:HL&FW\/FV]G"US'/!H1,L?E6RIN.YIED&6!4A"L:>6"N.LRL
MENL#W,ENBHEJQENFW6H<0#R)F6?+7#[ODD!)&X8)S^\KVEQ-(CRRZA)?N;@H
MK1@VWVJ2%IBUM"AF4!UEC?)(PT056,F&<<_>2ZEKVLIHEGYEE;V5O=6\6K^>
MT4\TVYT6UBF+2;CY<6^1\2D%,E(Y$&T /-U+5$MM$T?S-*M(T6+4+FPG:?\
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M!&!*-L\:P*C$X5D4JP( $0!7TR$:'86\=G!'90:<C6\5E!-'Y:^8\#K!,AE
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M33?/\;ZU(8OW$$$L$FISV_FVDBR>0IV*!NV7*L'CDVR K#((R7;!CZ3[.O\
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M_)58:WGC*]\03:/#K_A^/R'8R31:;)Y@,8MI-AC>?D,LY!9=P48^8,P"^?\
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M:IFVW6\),8:2%U4AI2?E/)^[A([:)=%MX_.BCL=/TRWAA^T!FD:S $.Z!"\
MW6Y55+S%LCYL[=F4KZA#:6%N#-:1PF9(M,,*QO\ 9U9A%Y5IQ;E7MV)=?-=3
ML,CJN"Y50 U.2'3M+N1>Z9&EO!;QVT8C@$D4;/Y*FR0" NT$A\M=R(^<N"$*
M(*R]+TF*\O!JNKZ;/9R7'E:6+&"T=TL8HQ@6N!!MEMWWREY#^Z'R!22BN#1[
M!YK[2M9U5/[*5)8Q90B%E-B9881]E DC*)&RA8RR[3YBL%8&8Q1[B6S::)'L
M](CAN \$2&TB4+ YCC#1!O(!-N?*@0RJKD;CD((OD .?T1FC^*&N"ZBCLKEK
M*S9(H8%,L -P_F+%B,^=!)(Q=YOE*^8-P5E.R/5+F77+7^Q= N+&&Y7R;=I+
M*!+V&QM98K;,>TVX#6[AF(P?F**<A%D$/-P)J=M\4O$6F: EII^J365C#<7<
M%M'*-..^,!8(S\SP"$HC'9CS K,(DP5] T;0SX>T:*&TM(UO+=(XY'C$AV3%
M;<>3&[Q.[6[; &D)8QJH' 0", RY/"&G:/X&U#28S/96BQ2)/*+AE^S^8,B
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MFVF5EW01V%S'$C3PH\8*(7R1:*9)5(*,0LI\K"^6& ([62*!%O=,AD6PA?\
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MIS(0TP4[_*("DO #'HUHUN!JNLO)=^(-81K>>2!EX(CF9M/M724>08VB.7+
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M1)$&8F1CG.55HX-"6--3:V>2\N@\JZGK,BLE[G=,%6)$4LL\<,Y*N$ 9/*5
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MY58I,L#F,%D5I&>66NDO;A7MY[N_6.X>-[A8_L,C.TX072B*U D#)=! 0[*
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M2M)#F-YVEBMU1A*;A4#JS@ DHK!<J4$E\5;5+N:2YD,:O%8R^3=-&JI-A?+
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MVL0T5KQ.!-"D2YD=R>8U<-L8?=9L-3U&6PTR"XMH6GL;H^?/"6@CN?L$LCS
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M]O\ N6>0[P $PPP0JFMZF-#&\V\D%X[NJ&S6/%LTL>ZX=G> 8M5D,,KS@/\
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M6;6CQRV>GQVMYLCLC=6]HL@L %B9(4'EHTMJ6R&((*EC]P F( KS6C/9"/\
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MR1!8T'PW9V$%Y%%J-]?7 N_L]UKCVP>[GC9]OV99T_>'81&KR'(7# %"G[D
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M2B#8Y!14)VIE0QJUY?\ B"6#3]*TJ?2/*B^WW5[&LA>TBF9FGC5$0A+\QNC
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ML[B 1LL?F0&2YE41[$N@#%G R7W#?L*K#T$-FL[SVT(NS/>)%=F:XMV42G;
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M]S*QMPS<%<JI!R 275]*^G7<UKJ.V%LW%K-%,C-8QR"4?:YF>XV36Y.YT7
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M2F]9@#TR' Y!KQ#PC>KIIC$$4FHZTOBVY9M/69EU"Y*VSB)I)&\MQ$'9]Y=
M/F8D#YE;W?0IYIM8\3I++(Z0ZFB1*S$A%^R6[87T&YF.!W)/>O /A]-IK:WI
MUPE_:!_^$HD6V@ANE1V61!^\"$0[8MJE,($\PR*&0^4L3@'K]EIK27&)K^[U
M":_=KV"[M[A=L9!A"S6BR7#^7$JSON&&#Y93\ACC?4M6V_9([,03PW<HNIA:
MW'E?:<^4S75N!*<0AV&]#][>QRQ.)8X9CFUM+:[DGDO'6^WI))(MVHDMC)-
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ML<R(K*D9*ZGAW0K#2L/;S?;I[Z7[<]Q&\:R7CO\ 93+<P,L@VVY90TD?.XG
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M!,:@VI"2EWQGY#M(,>$R]4UJ70I[6"'3L7P_T.QTZWC0222!+:3RK5S& +3
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MGE \P1.6(55*@'2>%[2'1])OXYK:,VS7%YIMM"T0;^TO)FOY#$\<:.JQ;6.
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M&"X>*+6?FF"J\?F@1,)%A",Y3>V <;T5.PNME[J-W*DD$LK9LKJW>V7_ (F
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MC&\,(]3U73M)TR:XU(031_:YHXX-.5E/F227*+]F95W-=OG9(JN"IWME1G<
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MU*N5@51N." I!"@!8:)8Z981L;.2^07$FK*UU9[I)G9XW>XD"VX*7";W5(U
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M+10%Y,F'I<TNMZC9ZTUS_HDWV:6V@NPD<>[-J#+>F([6NY$=# GW5"H<!N
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M[E)X8G,=P LH1(M[;2K @+E<_P -^'SJ'B:RU+5],W747F7]A9W,,,3P"25
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M#;\SE1P/DY>*VE\=7E@MFT_]@0[IH6)1$OMX=)+MFCMVC$F9)<VSL/,R2Z(
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M!_TG<L0\MRSA8U"X51'727&D (J77F.EDC3LJVL<HCDW2LMY%BV^>Z+#)1>
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M)0-DB#'EELYD9MK;&C:?IGAO1HK6PL)+:W*1W4EK:Q213W3(MN#/'&93(J*
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MB#N#>6P#5T$02SGLA:M8W37,7^@1I=+;^<52U*_8]KDI:8C9Y$^8_+PK@@,
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MB 1PH6N?N=8U+Q9?R0Z/JLEGI<[S646I6[-'_:4RI,ZQ6Y(D6)$4-ON0N79
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M)+D%!!&"&FB&V($!3M=E7 7RS<FM(=/> 32R0W$:2C<BARS,L["XA3R-CW1
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M,>63<T/1K#1]'T<6VD_8K!8H0D-Y)'"LCNUKMDN4V_\ 'V&7"8!^92"REQ@
MDTW2;1$MK?2EC=X7C:1;I'(N/FM9))[M?+7;>!1N3?\ -D[NY"R7.J66A:=/
MJ!,&G-:>6;EKJXDFVQ8MO-%P4R#<["JH"SLV%*DAF%%S?:79:=/J=]) EK:>
M7-=7UTN<E1;.#<0#RRMRP"[/D)3:I&-PC/-Z)9MJUUI%]J]O) =,>VF2UO)5
M!$[Q0PAKV0@B6ZP=T05590$WE#(H !)H.E2ZG>6>K:R?L\%E+"+.UOV1WCF
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M3*7"%I58, I"",)Q*4ZRSL[.7^SWAT7[3"UV;D^=8B"220;%:\D5X$V7 ?/
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M'FD><!/G9I6F0>061BA=<??2@S(-,F73;6"14E>\6)9%O(&260W"7NU<RO\
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M0K,+>.**W11*T5O(R(7W8V!@REF>(-L:#I,/AL(ETLB7<-O%$]Z$#L-D:/\
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M:KR3S?M;BZ6/-O",G[.KMM#'Y2Q9-Q1G87[30=7TO2[.W7XIVB_9[)K"%DB
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MD@DJ0ZOO"+V$=G;K.FH:5!]E9(EMH99-,*O"C)&(H!'Y2N;<,_F-AUV,I!(
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MY<,W/Z/8W&H7FDZAJD?E-;_96@L]18,()U%M&\MY(N-]ZZ2 0A@, *2JL2
M6+"WN-0U;2]0O99]EE%!;V-OJQ , \RU,AO65CF[DW(\49X!1&(#].D$:Q6M
MO"GEL(;B%=FIW;3"T+2V[F*8M,Y>XRVZ)N0IV@$ @O8L_)M7#Q-':OOCCE::
M4,869;9?)N?WQ\VX9=H20[L @<Y_><?J^JM:V6FVN@127>L&WMY#!J2*=DX2
M,H-2.\!9Y L(B)"MYL8 ?:Q% %S5]<<RV5IIO[R[BQ;_ &?4@TD.GN6@$'VQ
M=[/),TZJ(Y ?NR/("ZH6:31-&70+AVMM2DCU:Y0I/>7P:=5<FU6.*\/GG?<;
M6 CVNJ_O'*J <-8M-,&EBW^S7$C72ND8N=3:.X^PW#1Q@FZ_?JTMQ('$:LI(
M5615"J3OL&]N7M[6X@U.33[0I;VR^?;O+<61E$*^3.&F;-PS21%7>-@@#;MP
M?+ $<\M@=.>:*ZL;2UCE5+R]N;F-_P"SW00#;.6D=9;L.B!7?.S').-LO%Z9
MJK?$*]O+6+3H]/\ #MO<:=('U"=5ENP7MCY=U$S.93*JKY<AP3L"[B'858=9
M_'U_;QRRZE;^$[>X-I+'>3Q$,Q2UV12@R'STD4L8YU=G\R=6& JLW::=(\6G
M6XTVX@TZUBM(+:RAO(F/]GEA#B"Y3[0"\S!D"< KR,G=\X!'I4MB7L([:6TL
MX]/M[5+:WF79<::DBQK]FN<S[F>4$!%*X#1@G>RKG+OO$FG:)X<L;BZD@EE2
M[CA:VN+YKI+.0/#)+#+,\I5[A7!\MF(*Y!PL:2.+%_XFETN!O+E\N^C\BQM-
M/F=)[BWDE>-5CN%^V 322 %T;(*HKDMR0U/1-'OK75-/U?59HVU!+C[/Y=Q<
M_;(M&BDP?L^^297-Q+YD8\W#]54*$VY *^A^&6NK^VU/73)+XD=!;I:+ LD&
MENJ0EI3)B<?: B*ZR2OF0%%( X7H)M.ACM--1HXYX-AP-4 7[?NMT@1KIWMR
MRSLSK%MRK,K-][!C%RSMOM$MLERL%Y=6OR1VTT63:Q[K>3;-,3,3<( CCYU$
MAPV/E#KR]_J6K75K;Z/X?B^TZW?XFFFU&&(_8F\J.6.:^2.']U<+L"1+C:=@
M)+%0  2:EJDUW?R:!8O:3SW#V\ES<W41A6WC=(!'-=8$;B\+H5BCC*$90G;M
M7&IHM@_^AA4OKEKF4WMU-=PM''>2Q_9T:69)HR\$@8%XHDPN(AR!TDT31ETR
MX>"WLI+BWU&X.I[KB-E61\VI::XWIF.XW^8Z1HJ+\IR%(RL<MO+<6JW%U;P/
MYDI:W@U*!($OU:**VWW;^2_ES-O8*BA&965"O#*H!<MK.VM#'=7 CGEO'A8W
M%_;I"UV!)#Y3SD0+LGC9ML4?!.!WR4YN&R3QS.IB:"^T9+N"Z OK13_:!5+8
M-+*%A0PL(RQ12<R[\_ZD!20)<>+7M1-%/=Z1>?9VMI[^Q'_$TBCN'=S<E(5\
MM54!X5.Q7WC=OW.B])'=VQN(HF2.='>)I9;E4C624&TV/<YB!CNOG4QQX&=H
M^[\NP L0V*S7%K.89)W=%D N$:-;H VQ-Q<+Y("7">6-BD _*<;>=G+ZKXAA
MT'PY8-;V<EU>3/"L=I?J'EN9D@AF'VM@F4O-L>R-<L2[(<,/N&LZVUA;F>VT
M^[OM4=UMHH;FU5(/MI$(0WICROGJ\46Q\(A$\>P[,R+7\!^'9K1Y=4NC=S^*
M=4MRLUY)*2^G6X6W"03,5VFX6,I(-T0+E6SQ\Q +'AW16T[69M4UV>.]US4'
MC6]+%8K6,QM:+ LR@N@N@"LB!>"TCA3MVM6Y;PV3WGF&Z@BA66(11SQR.'!%
MF5-WYF"+O(41EVW@.IPQ!%6+66X6\CDDNOLD-KLM8XYKD2B(.+4^5<YD):Y)
M+A&#,,/D[BP#<O)J&J7UY;Z?INHSQZ=I<2P:EJ%W=8$<2B$W4,TJ$C[6H"D2
M@A0)9@"&C+4 2/?S^)##9V!CMK'?:R:G>W;1*TLIDMU\F38H,5\-C+\I^3$>
M,,Z&+8T:SAT_1HK2RNX[$1I':1W8P&A7;;QQK<(Y7==/&(RI:/Y,A<$<2&F6
M>FZ9;V&EJD<8@2!-US&K+"T8M%6*YV2;&NF_=^6^.,#:"!\Y+J]CHSY2XM+2
M='@%V;NXXLT98 5O&$K;IVCC<1ROQE57=\P\P T!?+9I;N\TD(B>&U_>NTQM
MC(UNH@G"S,7G8O\ +)R%#9)(),G%Z/:_VI>:3J5U<03+;?93#;W3[TMKI1;1
M3&]D&"]_B0I&& QL!P">+&CK>,FE:YJ,7V1+#RRT=Q(9+B*1K>&-C=*C;I[N
M16V1#:"$DRP+E8ZZ07C:3I=O)+J$:"Q2&">XU2[51;(?L_F)<E9"KW#*697
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MY+;JLC1$P-%<AU*HLX #B.1/F$)^3:%62F;F_P#'MXVCV$-]:Z9:[8C<S3R
MQA192LCLKEEO8G+E6?(!1E(?+E>DT;3;&QL(D,]I,[W$<]S=36_DJUS(]O(W
MGPM("+B1R&CRH,>54 8 < KZ)H\&G65I;V:QZG/]H@NKAA!+;SB?9;(\\KLY
M\N4QL\C1L%:17*D'YR]R"^LK/0QJ%M)/_9)B&IRW,JR1BX0>3*]PK1<1Y!=F
MAV+YK[_E +EC4I(-,TZ-]5NOLGVS8[RW5M%&L3@0CSKB8(\(N$*90G:C-M0
M[0PY_1+:]\3ZQHWB&]TJ<V9Q-96ESY>V8A8]NI3R1#8)C$0BQ%20P^7:H9E
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M5B&!((ZD:#$V=PTT=G=WT<B17MQ#+92%KKFV07+DQ!8YXEB<BW0;FP"%#8
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MQ(B33K\B9C#J)4? V*91L\K8(] TJ(:M!?RW\^L7]SY4LH>9XW7RY'C::/S
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MM<ZDQ2$J]FIG5T7!(,0^9B>Y/[P CEUFTEM;1[W4K34;>6X^UNUI$[I>>5+
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M2(2[,7W: NEB=KNXNXWCF2WO'N8=080W,"*N^6)&F @1&97?&Y6C(!+LY"@
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MWF=!%<_V;%;6NG+]FCTR**+[+(-PAC98@EFS&X$;7+'&U\L%# 'APTD>GC3
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M%L8*K3\+>&/L>HMXK\0GS];U;R6'VY?*6.%C:;(Y<1A!<1R+A  I=AG /W
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M$>'HMC_:^L6>IWDD%REU*=3T^SGY^TK$MO"NH.XC 2;RV)$0 7YX^$=6:H]
MB;7-6LM8U>WC?[:Z:K8Z?%&I6<B&UC6^)9CY;HLK*8MQ P"@=DWON6;O?Z=I
M$ZI/K*R?9[OSIE:*.[.+<?:E&XI$JJ[2"%E!+IN4 KN(!8M%E\K3EELI[Z27
MRI+N26S2 73*L&+ME*_+(C!,1LR, KD*QC05S>L7,FHI%IVD74D^H:E<0K T
M2P3H/):"0ZE.8PH#A/*94WE6#0C9\Q59+K6)M0GCT[14^U3WVGM?6\IBMF>Y
M 2U,-_(K;-LBMN1$*@,R#)C5<KJ>']!.GI;*R1WKS6]N[S7=O();QHVC8W%Q
M)(C.LJ$GRH2?EP>?^>0 >&]&6PMV@6RDD>YN%OI7N8V2._E(MGDNW5D8V\JO
MNV0Y7E3P,;DL17,*)&9Q:7;S(;V,0D3C4(8FM_\ 2V,<',ZKL*HF025 )P"A
M+;J'M+Z=HUMHD^VO-<QM;O*56 &ZFE$:^3*L8E0Q' =25.%#!>7MY;OQY>M:
M7%O':Z)>VZW,(-LD1UED>)7NV#K(42/$31QN/W@*!B4R  %EIR^*196,AM'T
M>Z07;1_9FM?[?'EJES=RJ$!C(>:)XQU9DW="CIV'V%;VW6!X9)DNT21C*C0-
M<@" ?:)F6%3%<)CY%!4_*,;=O[NGHTEA-%8VME;0-;S117-DLD<<:7\$:VG^
MEL%B^22/<JJF%^Z. -I3+UG5]-T"P-K%9W<UY>(MY!:6M@JW&H,7AWW11H I
MNHR&D\OL%#, ,; "QK,]M:OIX$$<^I7Z'[,'B1+NZ4+;EI]K6^!<(R1$1MM0
M! SE1'^[K^'?!ZH8=2U6TM+C7+U()YYH;5K6.4))!*7?$(9)1(&;8Q!E.=P"
M@)#'X>\.7AO)[S5;N>[UW4;2WFD<VICMH\"%3,GF6Y$5PIB4^63\QB1F5!@1
M]!;H\^HP1+%YT;Q1W4BW5BT?VLY@"W$LGDA8[B/RWQ%C)PA^0 ;0 6'[9FSC
M2?SIHHK@32VGE^=_J0+F5FM]BW,90E8_]E<@#&SE]3DU'Q5>-HGANZV1F+?>
MZE);+L>3$2;Y65%:.]BVEEA&PC$;%E"^74FJ7%SK#BWT6.-I+=&N9[V_T=W>
M*5%@5;ET\E3]L50_EP@#<K*^0NQ3N>'](M].LX["TTZ<VYE%RK7X+&_),$CW
M<[-&62X5RVU&VDE#P  4 (]"T2QT5+"PL--M(;..WC:U\H^3J%R-T'F2R@B(
MH%*Q^8OS%_E! ("-)&?LFDO)#=_:KJXB2[DN8$WOJ$B1VZB[CCBF!,*@+OB7
ME^@!W#S(XKVVL+V."ZU:1RUN=1FC<);W,\0>W NK@A81$(@&0H1\Z*0=Q4H,
M.VM7\57D5OJGGOH]W$US%9I*QEOG81QW$XD:1O(MT\[:L<4GSJ7*ET8!P AE
M3QIJ-NVJ74$VA2796UT^*Y7_ (G4\)5)9]C2$"VC*%Q"I.[:78,2 W0:A?V[
MZ=)%</!>+<VC7F3,8H;@(+?_ $J*;S&%O"A<,<?.""Z9(R^A;W'G^1_I'VG[
M1Y<_^C3[?M>/(_TB#]\=ENN?F3G=G^+=^\Q[S7?[)TZS1IY]9NYXDN42WEV2
M:KY0MVDFMMLFT*$+,8 !YAW8&TL6 /+/AXL,'Q;\+/+!)$]SX<B,4USC?<L(
M2NY5\OY JHT8QLW+%NWMOQ)8^/T;(]^S322!WTME5@N(QMU ;5P <9!/.3EC
MSC %?X:V%]H?Q(\(&_%V$U/0F^SN%Q;N"K2A$V,H ";2X96)D+,0=ZR"3X]+
MMGU4^5.FZ72SNEDW*_R7PR@W':O&,87Y@QQSN(!X/1110!]MZ?/#-\1M?2*6
M-WATRP2558$HWF738;T.UE.#V(/>O*S([^/=6M+*V\[5[;Q*;HR:K&QM,26K
MI;&28Q;QY<O$2< ^8 C/PX]4T\3#XC:^99(V0Z98&(*A4JOF77#')W'=N.1C
M@@8XR?,UL((_B+K@AM-\R^);&6>*XCBC2-3L:.5G7C<2TQC"F-CR)6D:1(G
M/0-+\/V]A$!:QSWMQ<Q17ANM24^=>R1+MC2Y8P_N]G[EEQA]RLVTE7+D<&EG
M9 1!=VK;0PU(?,TDOEQE9R\6Y9E@ECC17;?(LA5@<;ZDEA;9MEN(Q!>)!)%<
M3VRP.\I:!!+-OA*BX0A#&"%W%MGECRPPYM;I/&\!U!_(CT,>5/.NIQ+_ *7
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M,H9FSYB;MC3=-BE@V10_:K>]NUU S7%P\K7C1O;[+DS1YCCX3<D*C:RA,>6
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MN558 4/F1NK%/,6,0[H@H1VN8W*A"ZF3P]9VEEING6^GW<C0:K;[I99-]O\
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M:0/-<(1&R6KK< Q*HMY)&C+9^<Y.0Z58-W>>4)08+R.X\F>![>],8U%]J/\
MN"9/W>%BD;RN4<,I,@!DQR]Y?CQ3+>0VSSWNB7\LEO,;:::-]2,3*?*M3)(L
M*1["RR.K S>7-M4!=P +D5_J7B;4OL<=['+INR,3ZAIERT#:ALE5C]D43D)%
M&) LTH8LV2BC(&-BQ:%K>6&PGDDM9[=WCLK?$&8HP\1BMU,BO!*G[A'SM16
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M2)&LHXO**M:HZ[UE1L#!Y(\QV )-/\.Q6&L"2]NO.N[O=#J<,B/+]IM]JI'
M$*#SXX_/CW73Y?Y2&(5V5-B&>SM=NYX+3[%+!8R?9T!^PR2?9MMK#^Y&Z%]R
M9;@C(Z8'EU[6T-EIUI<6VF3Z:UIAGL+&WA+PO((F:TB/D[6A=SEY RX9<EP
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MH9=/)R" 0'VEBP0+L((&\96NGW<^FR1>&X'AA6SMK96$X:6U:-8Q+;(WV,!
M[G@DAA@HBD]1!;-;W!G@TB.TN+=[:R:6.)1Y46;=O)MV6 E[?YI,E@N&5ON#
MYHP LIYEM[+['+:6UK';B.*Z+%[0-*%\N&-5\E9$!> 1R*&W*LB'8QRV?J'B
ME=  N)?M;Q6[Q6,=L(VEGAE:.*0V\@-Q_I,\BE0CH&V$L6)&XDU37%\/)8W#
M+=VD-NFP6T$+&(ON2);&WB*1F8N8Y61QRFT,<1/M-/3-,\R\.H^);Z"/58K2
M14A:^\Q-%M5$7FIYGF+(;AHI%+W';(Y"[0X!8T>SN#J-IJ^N101ZK:^390AK
MD7$.F)(2?*9GEW-<NAB1I<?,98MH9=^=2[N2EDENDDD<K(+.-9KJ0"V9TA/V
M>YECE8B=^B3<[2XQN+ 2V/[0:W*W%S>2*_VA(B90K?9#-)!BVF2*3#2GS $<
M A5())R3)S^I7U\@71[>;4H\((9KJ1\R6R3QDK:"19MAO-RH$EDX42)EF9QY
MH!8U+5+N\N+O18+N2*_DMV+W$UVD'V!9R@6W<Q,P%P6*K$Y3A22IE*N)+F@)
M9Z38VEG:W^/)^\]W="5XVEF19$N,38>XDF6<*X&U6#*.A#FFZ?\ V#!@#[./
MM:B9X9-C>;,]O\K-*JI=9)*F<@2[1M&Z0L:CUO6SH%OIKR_:XI(D%J8DDDD\
M^8"*7R8Y)/\ 7.T:2JK%"7;*^9$Y.0 U+Q+;:"EDKRR->,\5K;6)N4DG!9K8
M-!(K7 $LY$F[S,D(IR20?WF?;6!U:'2-0U?4HY=/#P)907,,AV2O"UO<VUTA
M=@2?F53(Q=99&0EONN:%H]M<Q1ZGJ:VCY3^RHQ/ BV]O##.T @DB#A&N'$LL
M>]%\L$LJ#:<2[D]U^X<WM[.GF2K;NQ;#6?GO !;2""4?OCY@"2*/D4@DGEI
M CD2RG2^2/\ >01+;2H\JM,HV1^5:2NT^'N&DD#([;AAV&09-[8>LZIJ4MQ%
MH.BI=W$\:2P_:[>=G!A!;Y6(F)5P86B,DK1NTBLL93>\D)KNHZU<ZM)8Z;;2
M2:G,F88YH#']DBEA5'AEGCYC3?B<2QN=[021*0R#.IIV@V&D076D0V,[VK>7
M%>ZA+:QF2Z+.-D&Q8L/"J.4)"A(T(53\K&, CLO#RZ'I.I6EH))KNYN)6O-1
M2)K:XNI9)A)&K/'$<IMF9&F3'E@,5"D'9<G%Q+>3:E:P7UM?+Y".)X1APP!%
ML&C#957VEI2LH02S!&'S;*Z6\2V<5SJ'V[39)8K>QN6^TN9H6<P!+=9 G[Y2
MSN//+%D:23:REF*<G%)#XK.ZWU"TM_#]D\>D2W%LPFBE6>15FL8D6&,JA+0H
M)P3A$B*\M(0 26.I0>,=]G:306OAF"7^S/M9MXM[^;Y9?3P8\JL.P&/S5*;F
M, 0N5W2=990K-8>5-!ILJQNUA/ MFSK9(SPJ;1(@BL8F0 F1B!]V3;Y9"K'I
MTEOIL%O$]M/8VMGY%A!<>66^S/OAB-K&98E=X781XE ;=\Y+)M2J^J:I_P (
M[%"TEG!!)^ZL=/BA.TBZ98V%C"3;A1;OY8!E)X.1\I4;0 UO6K?1].GGUUKY
MX+Z5;46C6QDFD=@)4LUB"M#+O#2QF12. J%F9=XIZ'I5S9:D?$OB&62TU!T@
MTQ55WD^Q1&6(Q6P9T;[079\23DG#$A2,%A'H'AJ_TZ6;5KQ=VL)LMP88Y($@
M*,!';0JJNILF1QEMN5P7;YQ^YZ"#2XH;,6IBGMHTQ QMBY>S\PPDV]L_E!C;
MGG+@CR\8&P(/* ![G^R_L42M!8S>;#:1Q3R^59PY\C=;P#">:Q0.8VVMA@ZY
M492N?U+Q%<12Z;;:-<WRZA<_8X8XKA0Z:3$[0LPO@\NXS2*65=QW-C:F&+,]
M?6-;>&\31_#BP2:G/$EA*PU)AI>D#&TP$0%620NFV-F1'+/A6^78+F@:+I6D
M:7)+!!)/)J3PQW\FHK&)<3?9P8+Q#(JO.5D)!VY&YCAW<^< &@Z6V@:-=6<U
MUJ5Y=LBM=WMQ>J)'GE6!6MGQ<\7#*$6-@0J!TPS'<7W(-1^SW@^U74%DTEV(
M;<7%YYAC:40RM;2J9<&X8M)Y>W<J(!C@[6CMRVQK&>YNXXT18?M%S=+FW$K1
M?Z)(8Y]S7&& 27&0'4[G8L9.3T^XO/%VHR-#<3Z?X9BEBM91J$YD:9LVI\E@
M9G659D\L)*IVE9)@4<RAR 2-<0^)+J.TM=0CTO09GCM;J6X +Z@TD42M9.SS
M9DE:)49;A ^Y6 1QM)D["VO&2XCB)DMTMTAB$MU<+(L!<PYMIOWY+W!R"KD$
M#S%P6R=\=I&EG%IT-K<_V=;V'E6RP-(K);H5@46DX\T[IFW HZ]/EY()$N?J
MVI:=HEFNHW/GI/'Y%LD<4C2W.Y3#(EG($GW3W#9<J>5 =MV59O, *^LZNF@:
M3I37;SWBV\L-LT<Z+=3AQ'%(D$B+./,NW=59)%5MN<X"Y<GAR"\:\?4-;N]E
M_;RQ6R6TTQFMM*XCVP[F<&6YDCGP9_FY8KG'RO'I.F7R7 UW5I+1]<MT6VM+
M>YN_-M])#&,+;-(6+FXF5U#388DD8!7:LG0+-,@@\F[CM3"GV?-Y(9OLS/'$
M(X)\7'[R<R,C!N<KE007#L %C>-LA9S)9&!UMMMY<+(;<%H (9]L["2>0'*/
MR0'&>21)R=[K=Q>I+HFEZK/:+%YMI=:O?2 IIJ-;O(T)<3J)[F(QCYUW;%R6
M8G>S%_J>HZO.VCZ'?WUO#'=P6=]J$UPJ+IL+I&LELLOF-YUWO0 /B0JT^W<"
M<UL:);V'A?3ET_3+7[+)911;H'2.)R7$"A)0)5CFN)2K(DP^0,&7.58. 6/#
MPBL+%8X9OLRQ7<J$7+./LS2S1LT$X>=C)<.7.V494[LK\K 22?VY:6%@M]<7
M<EE;6;I:R27I=OL>7@4Q7 ,I+RL3E9N5"MNR5.9"\U:TT"W>^N=0DMK.R=K>
M:2\F>X^S!1$0C+&3N,D:%U>5C(&E088R;*Y/3M/U3Q%?6^JZY;7VF6$4L%K;
M66I3;UA5X80PD21ML_F^9/ '/[Q6F(96/$(!8L;>X\5P/>ZQ+/9:%:?,MCJ1
M#?94C>/S([Y)&_>,\4:RHSAMGGR,22L;'K+"YF2WM&N)([2>)(H)$ENC,MHS
M"WS;S,9<RSL6^23'\0Z[OWD=K%Y%Y'=S-/#)%LM[>74%R+2.06H:V+F3]])(
MR\2 N ^5R2-K8>K>)9M,M=.M([>.+Q&7LX8K>8F1[:*26V62*29M[NCDLIG5
M2F5"D^8%W $>K^)(O#RZ7H6E1SV^J+]DALK%U<);VYEM(VCG8&13G>RB<!@,
M.JMO!W1^#M%@\-6Z7=Q/&NH0/!83M<&69M/,PM"+"/D[XMS?(VXB/>/OY<FY
MX1\/)HV^^NVG?6KGR%NY8 L[:>3Y+M9GESM9Y'=GQDJQ=WW8D.Q;I;Z1IT#A
M[[3=-T^*.)EF8_Z&@$&(L!622/:IWS%FV9DPX&XH &F;-,BAM(=3^R6\/DP0
MV$\2NEDFVV46\DBL<S<_)F3GS\XD"BN7>^2?4;+1=.DGAO;?R4U"6_59/+!,
M")+<LV%^V[X0(2!*&VAL%'#*7MU>310^'-(M_LL<41TEIYT,FEVL++ C?/)Q
M=S+(&A1<*=Q<.H );H--L[?0X-NDQ06C-=JTXNKDGR7F>W,D=PWFL9;EPQ*,
M<]57."-X!'I&G6UA;_9GAM(4CN(=TMPZ.WFD6K8NU5PKWCORL@#8^4@_-A[D
M=XNFQ/>7.I06<:;#?S72VZ"-]MN-MTR.,W!7(5DP@##*L F[/EO;#3X+8:GK
M'[O2XK>.X6_DCF^S%WMO+-V%D.;@LC,DPPBY9CD#+<_I=C>>)-1B\17?D:5#
M'+YD&FZE 9!::@QA427(:5'>8AV6%<86/RB-A(4@%SP_=7.L):7>L/=VEGIB
M.88M1WDPI T&9-1RZK]H9?WL8(P@)D^<@8W--CL+6SL=&-S!_P 2R*TA$-W)
M&YM!F#RX[A%EVM<.RDQR!< CC/\ RT+>:6'[&+=[ZQ6+?;%;V[2Y^RSORJW1
M:X8R;R\!C5#O' W*KE:R_$FN7MB]E#H:QM?65NAF%_>2M%I2E1N:^,4K>865
MD"[@=NV20OM4D $>M^)GL(K:&T/V75K;*Q_VG>-]FTU-J #47CG8,T@#&-FS
MDLO0@DFF6:^&[,WJ7T]I=#S+>\U#69;>4P9,3)]O9)U,LF/EB*M\J3 $=S8T
M?18-'LWDG?%TL3RW,VL^5-<PJ#O@GO'6?;*J/"^QA\R@J%*;9&.A]KM[+FZU
M.>R.FVFX2:I<%5M'EX07&)E6X4[E1&^;YH9,RESF@ 7498&OY!=>7)I6GR%+
M9KQ)3;*T4+K]L#2C,VY)-K;PI3=EP6R>/7^T_%MY?Z=!<?8O#%E+)I;27.H3
M?:/.E$,<\,Y>1UE;]_*(C\P$D28.T_/)-*==N(B-5DTKP[I=N[R_VO>2,&DE
M,($5Y&TP:9 WVB/EP/,1XRN(R).PLKRVTJWLK60QZ,EK;A8;>\N$_P!%MD"_
M)*!.0[LD$S))R%5'S]U@X!&TUGH\5FH?[!8:3+]E662["06,*K&H2Y'V@>8T
MBX,9(8KYB$J#G=3UKQ.WA_2X97BN[:\V""UMYBMU+"&VB-)8ENMUQ+*T3A'4
MDCG<0 Y,=QJP\,_9$O//CG7,AA;4)KEH43=PY>4+(LG^DE9'*;5",T>V!VB-
M%%_$UM=ZZT":C911M=+-=221:5$(ERV)' DWA;@&XRS*SE,R*CD %>PTM]/U
M:7Q%JD_^G6UI-:+=O<-(-+B\P/!#=(C_ +YMDX>1V;:HB5BW_+5MB348K75K
M>"XNOLZVDJP6I:\>5QF2&$QSQ+*3*SB6)DD;=M\Y2ZJ1^\DD:&4%3/)IUWI=
MN)DN;K!:QB,:$I<,TA,Z.5?<RDH?*;YQ)&'K#O-8O+Z^BL])N9[);"*=)M1G
M<RPZ8JPQ[C<.+@QSS*V]=CY8$[S\J;I0"O=:]>:S/!HNC:E]B\^T6)[B5C,V
MF6\J;8VDF2Z*2W$L@A,1!+A68G.XYZ#1;.WTJSMK6"*#2DLY8[<01W):"V(*
MJ(G E'F22^>[HY4$[XRZ[U4&/0K2Q\.63V]J\EM);N)[Y[UOGB21%DEFNF,H
M69V,3J)EW!22H!5'HDUXZ/;FXU)X[&/3$$=V9[B23[+#A,,P9P;D2&.14F'S
MAF5=A;S0 "35/$.EZ59P_P!H+/%;6,4374.H'S%@.8W1Y'Q([2 (_ENI9'D1
MD+[]N,.P$VOZO;W^MVTEO]F2U\JWN[@V<V?/4Q-=A"!*YX>)57RQ(TT1PRYH
MT?0[G6+_ $V]U*&[TVTLKT76C:--:O+';Q,A \\XV*X$<C1J"/LY=5R042ND
MC>S33DTL006MJLJQ/83S!XQ'((PUO,=KI&P-P-D*MA@J!3L)  ([2&QC%O9:
M7ID:VC7J2E%7*J1''(JW"O&7@=5(:-< +Y,*[D#*E9>NZL^EZ=>10+!J-UJ%
MI$+>UN;-D^URS!(5-Z!%A&8IM4L8E;<T9"^7N$GB/7]-T&RL+J^NK2XN+FXM
M(XS?1K;,R[':$W9,;-&!(DLBLL:;7 &% <U'I.@[=?BO=5'VOQ%<1+N65/.2
MRM1<-<?.-^%8R95,,VS8@7S!%)(P!'X.T=CJB^)[PR3>);RW$5Q%+M4V\#?9
MV,4[QPHIG1<,H*(Q#[.50.-1/(@TZY"?OM._Y?6N_*<&%A 6^V"7RY%D6!F4
M;BQ\M-S[V*J2>24P6MSY?VB^N/+%O;W]DD4EW'"Z2?.W %Q@32Q*3$%,AW(-
MC%>;EC;Q%J6RWFU*TT:"RD75-:O0L,@*RM(&5W!4RJZ;A\JBV!E7".P6( T-
M.U236=>BN'>--,TZW;^V[B\B@<":WDD$43R +ME5BTSX!1"L>P[7W/L:%80Z
M5#80V$4D;VJ1V!MC.&+?N8"7NO*0JLZ1Q84YVD%0&'F#%,7-GHVDPPV2P:+'
M!L?S;P"--/58Q;H+M3<(TV[RW1'!93M0C(0,9/$.K6FD13SW31H+5&N?*U!W
MDC@ G+^;*PD8 2-&BPX5I$.=J$*Z* 7/MR:-!]IFO-UK92_8Y6U"^5/LJL^X
MO,^\A\IY/E[E,GS+N;]X[+S]HTM[%IUUJM[/;65AY0MH-1O$BE3RU@E=KX%G
M#W!1'E1=@V*"Q9'*LE>STRXU#5HM0U)8+3R=0FN+>TU'$DL$\LDT44URHE59
M,-%"D#+NPK%%SA91TE].L*:E#J&I1Z?:HDDT4L]RT1M"[/$K3.+D,Z2,S-&!
ML"A,95E7 !8-\MA<) \TD+VR,2;AV=;:R4@-+<,9L,7\IMDC'>-Q^4[):Y^\
MU^YLK>UT?2(Y$UC[1^Y34[IYH]/+ !4OI4GD),N]_*!)!+1@ %,U8NO%)@=H
M[2.266.X^TI'++(ILXV5V=KXE\0Q%,LF\Y =0(28<&Q8V4VD6$LT6HQ_;+5'
MM;F^OR9OLX#O,SSYN,M%M9?*5F,D:R DD,^ "OI<"^'=+-S?3W=C.462>YU2
M5@D,S>>JR3O]H*2IRD:H'>0 0AV.$9-@+,;^WM(4NQ<VR2BW9KDLMK'L*1O=
M)]HW7 =HW9203V.Q@S57GFAT@2N]W::=' Y9GNI &BS'Y$$]TYN 9D8Q,!NR
MS;HQ\K1LU<O=7E[K)6ST][NR\+V:2R?;+Z25OM4L<B.5GEFC,ML%,5T@D#;X
MV1&X_=!P U"2]\2";2-*NHX_!5LDD.HZC<W\LCOF,3AF:0JYB&%5BLA5XK@;
M6'6/8L["3P]<70M9+2"=;?#WL]K!']EMXR0KW:131K(C+$5B*HIC4$''SYT/
M^);H5PQA:TTR1;=[:);B5?\ 1HP9Y%DD7S@'@Q$QC08,:[P-BEPE>>YBT>WE
MO+>\DNTT^X-K:6T]Q>JR2L/G2X?,IE+9!BW1\[HPF?,0D DU_6+?0[.$:@D[
M-<:@[6%G+$9!-(I+*KR'S<?/F5 NU\*B(C,NQN;L/#PUY_[9U72X]0O6<)%I
M^I^7&3)M8JU^((&42K 04WC"B4)M#_O'DT>V/B/49Y=;AGO;E+18XM-OWA&X
MN9I(EOXX(SM8*@=3(NQ/."JID4L_63(T[S1M8R7)NGG@$DT*A+E%5]L%R3%N
M2+<\H1@K A 2[&3:X!7O/[-U))TN%M+Q)40LM_$J"=RQ:*UN=T)\H*UQ"44_
MO"6SM.&WX^N7]]<FVL?#MO)-=ZI<+))+=6.UK0&0_P"E3PO$F#$L"+#O8%\=
M',8)D\0:G>7&K2>'M&L?M>I7L1,UU>V)\D0B2?$-RWE@+"2K*A <R+O'R%UF
M,EAH-C8:=_9][;QW<<]P%N+K5CYCZB%N&B5;B22W 8J'B:(9RQ 53L4NP!8T
MC0K;14^S6NG271D>5(YKB!%6XDA8/#]H*PAH@C*ZQ%5,:HJXY:-:DO7>WM5+
M20".X\N]CN[RP9%8QQ+NDO?W85&38DJG,)9D5/D"$DFEL]TEXR[U266Z:29A
M'"6$4<T:WJ^7F!E C*NR%D6%,OE]C\_'86_BNZ35KQ(!H5]=K<0I/";9M402
MQQQ?:F\L JA9C#&3^]5H]P!5B0".RM#XE/VV6VNW\*JC30VUU%(\FKHLD)\^
M?",6"+'&(48>;*$^9BK-GJ#$OVM)KJ*--UZTFZ=FCCN&^T","4& )O4+;&$_
M?8H%5RH9W#;JMQ:SW#1O%*]O/')<QM;_ &EB88S]I4Q[//#"%X^$<L @"!6+
M9<^JII*V-D-+GGNK^4M;VVHNJ"1XY;9 ]S,8R5DB)58W!?S!&F'=WCH -0OX
M+&"T1;6^N;Z7RH;>SF$3W<DR/--#'<%HV*QJ;=T2?<P.]WW';YM2:-HZZ>8M
M0U@QW&L7+QI>7%QNC@O)5DMT\QLPJJO&Z[8% ^8?,#EV85]#TH6E@=1:YCN]
M4NT@>\EU6*.'=<;XI88KE0Q:.<-*PCV#$:L@*OLCW;$MQ;+#/;2R1XN+)Y;F
M2[MTV-$85 N;Y&6,H<QM'L!&X!N %;R@"2Q2X-\[Q/F]CB\PH6$;2R^3&&BO
M3&K1"3_4L'7#;3A5V*V_E[J_G\2ZQ'H]E=[/#L>ZQO+N:278T++:AK602?-]
MK9V*;F(*K(X&Z4,$-1N_^$NO/[.TV?RH+&6VBOM;F/DM,Q 1(#\B;;E&GDE5
M0I6.5(L@,Y5.@L=,L+*SM+*)8(+2VEMF*7/EDVTZF,1P3E)0))/+>%(LAMIB
M1RSMLR 5]/2WB@TR)W^R6MIIXO)8]38LX0O!*9[N/:JI<;TG(<OPP=P'^<(7
M>LV6@)-<M<?V<MO%NNI[B"2=+8FW39'<LDQ$MQF-"&RQVA4R#*C/)/J1M[>7
M49IH[*2UN#+#'?W\D*V\4@PWVL-)M(:9)HXV42(N49 R@UCZ?!/J7B.'6M8L
MH[5)'C:SLKWRI6LD:<M%+<[Y!()Y&,B0JFX0[F4#EA0!'8Z;+XA@L)]>A_T2
M'98"VU:X21HH-]M(GVI1AFNYG2([,[ K#<"WRR=!#/YVCV$BIYFR[MH@FJW6
MY[9)&AF"W"$C%PORI'GS'W&-BQWN:D^R6T-O%8WKQRRJ\%I(]\R-*]MAXD^U
M8E'G"5O."9!&^928\JU<WJ_B.XFNI+&!(+&2VNXY;J?5[@-'I2&6*8_:%,C1
MNSG9Y)1A@.RJ8C$Q(!H7VM_;-1@T-+C^U-6@\IVT6=/)D5U-K*LUQ/$&1?+.
MYLJ CE]BABN#)HVC-8WMY=365WJ>J7-Q#'=7-S&L:7XA>%?M)4IMA,):3RT&
M"XCW OPXDT_2GL=.TRRDC\_5VB%^FGW]VQ\V5! KO<W 5_-DC9AM. O*83]V
MK+8DM7^QV\(BGU"XNI5NH/M4;6XNG0PRI+=/%;#R)$\L*JD#<% .3PH!8TI'
MNK.U,L7VJ:39)(]Q8M;"[>,P*US*C0YBF4H3&F>0H(. #'Q=K/-XKO[+3;*6
M2YTV\>.[O=1C8P?VHT*61-S&1\T!C9!&R*/O,%&#O>'4>.\\6:B+"SCGCTF&
M6.2ZNID,!U22,VA,C/&BO%-$!*NT&,^9&@Y"2(G0:?8^5]GM8-.@-CY4$L D
MA\K[1L\D&6=!;J(9HPB^6@(SC&%V#8 4[;1&AT:.*RL[0ZA-90A)?L:VBW)B
M6'9-+FW;R98VR8XB& QTX.RGX@URST"U@OKUL6\>R]F6[B$']HJL2E7<O;A?
MM:M$"D*LC?(I)4#:LEW<PZ(B7^HB2\1T$MJMP1'+J<I:%_WD(@1!=((D6%/O
MMM(^7!*T]!\.W^H:G9ZQK]MY]P?)OK6"5I(T:41PQ/<W$7E%8[E4 VQABHY"
M@%6E(!7\/^%KV:\COM5AGEN[N(26+SP1@VT48@2.:Y=HF9K]59V7=N7(D VJ
M3700)]FT,75OH^9)8AJ'V2YMO+-S(/)=IKGRK=MERK X1 2Q&0"1\EC3].S]
MGGGM8+J^N8H'GGDL_(^V^7Y)$\X,68YD.XQQ$_E@F/E]0>77+RX\/Z986,VJ
MWL4?]I7ES:I*D=OA##<7B-"A-SA3LM^@R2WR@8 +EUJ%W<ZHNC::([N]F>&\
M+R6R1XC3[)^^NE>,;KA&*MY2F,B(CE'\JKFE:1;Z.MK&R;[0[)(9;]S&;R22
M6 F:Z7R%47*L(Q'N)=SG.&W$6-*TO3M"TRUM88O]%EE2<'4"P-W(\D!^T7#O
M%E;G>?D0D%C@<8_=UWN;.P@ MX8!;B6.ZO)YK0"-F#VCO/=JL2M#<[7+KD!0
M%+O@+\@!(QL8TCUB6.2.,O')<S75AY1O$B:)!/=EK8-&\3%G0#:,+NR$#%.;
MT@7'BR6PU+48/]!U7FQL-0A"0W4<;1+)-=A0JRW,D*EXDVE%6+<.F18TBUO/
M%FK6&J7=ENTWS?MFG3QJ8'O%BDB0RWC^4#N<)#-%&@56\L!N$4CJ-,BN+F*&
M6XM=WVOR;I(;JV$3N%6VS+=$1E5N496VJI4':!_#N0 CM$9[>6.U\O5+O>)]
ME\JP^>X%NZO=%+<>3.BE B;<E54D$C*8^O\ B$:4;:RLK./4=7NTANX;2Y6.
M+[9MDM5$USN1#!/D%8R<+N0#!;9&)+_74T]EMH88-9U:]E5K#3&1;>6]>.*V
MD,MTS1@17$8&\ [/EV#;D+M/#WAV+1(+6ZU.Z_M#4+GRO,O+U'@6]7?;B)YU
M=#LN(\*L:$[BVX\,[E0"30_"QM[\ZG>22:AJEZ\%S]KDBDM3,L:1+YD@"8AE
M4/,JQ+MWQL5?=\[#4L3+<_8-^ESM]KB2[?[9$B;V3[-^\N<1_)<KSL1?E/EG
ME<#97MX$O-8@,0GNF_=RR^8%2-RBP$O=)Y0*7)#QNBD9 MUP8PS@\G#9ZOXD
MUFUL])NY(M(M'5_MS8E-_P"4ULOF7#@D"X B2>%RK++&Z9 7>& -";4KOQ1?
MS:!:+:"-G1]2NK$)MOE9(OWJ!SAT\J2$E,OC[KET5$NMS3+"SCLX=-C3[78&
M6&YMB;P2S7^PVSB\#;U"JLA+2  [V^?DOAZ^@VMK8?V?HNEW$$,,<0D_LZ%Y
MX=^W[(S2L&R]NRAR3 2?,\[+G+.:D3456R_MCSI%TA;<7SW)1HSJ$2I:O]KD
M>) 4=5$B^20/, Q@*. "07]OI]K?:E>/ +63;J$TUE,=U\D<5MNNXP),K"@!
M5HQOW*H^]NVOS^A^&KC5-8M-=\2:=/-=#RYK>$VX5G?;9?Z8YR!!,#%AX<_=
M1@@?#-))HFDZO?W\&L:_I\EU.7LYK2R>$0JS(D:/?3\%4N L[CRN,>3M7?L1
MUW+0)J_V6803W6FS^3=1NL*JVHD?9'BO)' 01LA!'EG!94.%(4+0!'I]M#</
M%:7$D=[<73P7PF$P6+5/)6SS>C8K>658*%C!"MCG(;<N?JQF9WT_1HX]5N]5
MMQ=)YCD177RVT:7[SJ%"&+8/D@)8[D=0I(*E]K>I#6[;1=-^US:A>6[W%LMY
M(R))L2V9+JYV8DMDW++'Y2H%D;<"%W58T#3[1+BRN(9[34)]7MTOY9)XWW:E
ML-J1=,64F$QEF*0#Y1O7!7!V@$FB6+OIRRZ?<?;VU.**]:XU&V9H;J<" B\7
M!)CP",0,5R8E">6%9SH6:YEMK:Y,%S=77^EQI-;^2;N.-K?_ $B93%E+B,%
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MZAI0NT2!(6:NHM(TM].ALDN?-C\W^RP8)%A\^) X_<JDJK%)'EM[*%8^0^U
M FTBB=;.PM-*7;:S;GLGL)V,5M$2X\TRL"C+Y<B&.'85#  91=\<=SK4-M<1
MZG<V$@N;IXX]-L(2([^\52REG5G4% )B_EM_JUR[88[4 *\NK6B64]U T<]Y
MJ=N\44$#O;/J\R(JK+;XD)1.2IEP3M"/O\M%8Y^C69O]9T_Q!J-W'>W6H(XM
M8Y?,2SGA+6TL<ENK%_)=8X?,\M@':02'.U PS]&L+[6+B*74[Z34[Z1(S)-;
M-\H0&W,=W;AQMB030L=AP+C8\@#JJ1CJ)-06*WMHKB\N[9_L\UWYI#0LP(C\
MRY'G2$1Q1?:&)AF!(VC:I\L;@ T]KF[TO3IX[^[OC=);7"W$2NJ7:?Z-NF93
ML$!P&(B5\$,Y*2'<@Y\ZQ-JMQ<:1X9GDNM89XFU'40IA\F,$)'*Z*P47"DKO
MB=4,BVTBE%7RUJOXCDU+QKXCO/#>DF.S*(!>WT09?+6*<-!(DX0[W$FX"/*;
M6AN4))*R)N6^E6$<4FEPV?G?;_\ 2B)XHUG83*R37FR6$*9MTNV2,Y"Q[1M&
MX1, 2:=IMIHHT^VL6NU6^N$G:'+_ &B^Q'#NN9\B-HG5D4R9^5@6#*SRJHDF
M<6T5M)J=Y!/"T37UN^I&:V$T\:Y3S01LAV1J'*[>7#RK&AB.:]_K-OHJQ:WJ
M5WM:VM(9'24&VDG@\TQF>5BB>8R)+N^SJHV/(1@L\1&/IEC>7\^I:GK4E]IT
M-W:&46=WF*,0%$ADNKQ_+,#7!B0$0$;$"\KDLP *\-A>>+[^/4[^TGO-(6[B
MT];>2,PR:GY$\G[Z[3[L<<693Y9">8Z_,%S'&.PLX+@RDS"^FF6[6T2YG A>
M\C1A+YDC11*45")T13M23N2)5-27R-<EI[NQDM962<2^5"MPPBAD+03*1$^Z
M4-L>.(D8\USABF*Y?7-3N1=+H^C1QS>)-62.],+6CB(@Q1HE[*)5/V<Q20KA
M,N?E *EW#( 7-4UZSTG]^]EYM\_DQV/F 6=YJUQ)]FV_,?+*X*QB50A3;L!/
MR/&*>B: L%QJ4U[<QW=W(YLEDL=UKO2(RLME9.)D\H*J1%E&0&656=R&,>A:
MZ)::9>K?1>9+JFI)A;^XC=KV1=Z21R3(OE,L22.(WC53\GDARJ*0NH]Q>33P
MR6%Q!.UQ+)/"PG)66-D1([B-!-B2&,2('0[0S9D7:VT. 4]&EBN)K-[66TF,
M5NL%O<Z8L*Q7$"S)N^S(9W$<2#"2_*&;Y-IRB"N?U2YOM2>VT#0;R2TL+I[>
M2^DTRX\Q[6+;:*BV#(5 BPV7)7Y58N5 >,/'KVM:CJT!M?#=]!!/8Q-<7.LR
M*NYUWQSR-;&6?Y8?D&Y7)7;);#_5.)1T%@NEZ9/;20:MM6WB2^N(HK_]W>1%
M INPLD[!;<&65W)^9W4,68@%P"GH$NFZ3X3TRT_M73;2WWK(/[+O%6*?R6B>
M1X&DF;]PBK()@1N?$C8!;Y] 7UMHR-)=S2+IT+V]H&MW2*W+QLH(MU2;,<41
M29I5<$[0P+,D>VC5M9/AVP-[JFI1VT%FC//F*21H9I'D1+AU6X+-;NV0D.&(
MRO*[#LPX-#U&=_[8\6WGE75KYTVG6,MPH$"_:$EDN9\2C?&CB)O*$C+'&B+E
MWYH IZ3;7?CJ_&KZT;2\THVZSVVF0A'742B1^8\3&?<J><B PRJL?^K+J)"Q
M7M)-^HQ6\(O?.AO-LL_V6=HWO$VPCS[5UN 885+*6 SGG )<%Z]SJ>Z6)[>_
M\FP,4EWN-QB5(V:13=I,TC0RPJ'5_*8$(K(V 0D9R]5U2YO;V/PUI5_)+K".
MMP7MV=1&-[QS7.XSE6BCF;'V=]QS"R;2I5T ([S6XKZ66WL6@UK4KOR;BVAM
M+EYHKGR&A(NT7SO+MXTE$H,;,OFM&%WYZR:#86T>C74\=Q)JUWJ:++<-IM\@
MGO&B6"/-M<"5'\B([D/F-O))RQ+?/8TH#2]&CNDO)+F=;>)S<3WL=PUM'MF4
M7,\WFQF>U)+R*#R-S$!<!8M2ZO;B#[68U^S+92F4B\NQNA1_-!NG FQ);Y.1
M&YCVK$Y'*HH (VUNVMWC^W7D8@G2.Y6X6\2)+XJL3--;YN"4@C52TB$8()(W
M9;?S8D_X26\GTZXD^RV&HRA;H6[^4=>;$0:2VWNKK"D,4>\KN5DDD52Y"R-)
M+./$=_YTFM26>A_9Y+N#3KF>-EN(61G%]< RB4VI+E/() ^5-P5<JNXL_F7-
MY<VB;8[B7[7+/IUUYTBQFVD2.[506\Y66.)%B,>-Z,P$@ :@"2VF9S&]K;QS
M2Z@\-Y,T-RL7VTK)#$;B(K,Q$2Q(CE,$.LD:DY+@Y;^)7L-%LKB1I]5DO?)E
MM([>1DN=6"0P2O<0QAAY2A5E)@P Y &09,-'JGBE=+MTD@OY+N]2RDO1 -SP
M*")B+UBLI)M3M<E-TA , 55? :.RTK^SOML^HF"XUA95U2]:];*6+2;D,R,6
M59+8-;1NL3,K(L(8G>J*  \/>'Y9+Q-1URX@U._N_)G)M94*7NP616ZA^8>7
M'&T8W@?ZS"L1CRXQL:==68GMT%[]NN;GR(Y[BU81C4)T2&03J4E")^[8LT9&
M^2-. R( TDNFS/-)I]K9R+:2W N/)N$.RTF$UQ.+K<K?O@\RQ'R@X*@KD*&(
MK'\2>.5TF;[+I$LDL"V_V^>Z4-<%(GFB8S@$DR6ZJ[[MG4,JQLNR0Q %?5M:
M+7MKX>TJ\DU+Q 42+4+Z.&0/'&SQ02R1XPJ1;U!D$+Y4QL %;=+%<\*Z<FC:
M3'+!;SW$S2VPGO[55D#O)'9JQM04Q]D8*-Q!78(R$ "KL-$TF7PAI<%Q<6NR
M[;<T]PTJ"%)%MBL@=MA^SVC?9864KR"478BJ$JYJEU9:%;I=2K';R:.DC6<+
MW$4&Y7$R)!*579#;MY<?ELS#+)&&^=,, 6 MS8Z7;IJ%W'8V%DD)O?L<3PI;
MRI]G94@.P#[+@2;V;. Q!90K!>;M--M_%L]E>W6DSKX?'V5+734A+1ROL#EU
M<X LM@@;80NYX!E%<%))+2PGO-4?4-1$=C9Z2A;2H)EBC2SMSYS++<PAD)@S
M%;E%(1T:  @%'D?<A-O;RN;>W@T^WTR*5;9[ABKV(W7"O)*AD7-HWE1F-0<?
M*" H12@ 6HM;V*.Q6""ZA\I(8VAA@1)+8K:F06T; AK1@WS_ #$C&U=QV;:]
MSK?D7EM<PPSW\TF$$EA!YDUVS"T;?:[V9$M"IQ(Q95# ?-N^8T_$/BF;2-4-
MDL=W!<1N\]E"\IE'/G(]S=E7;98AI8B,E64H<* @ DN- M[?S]2N3!/K]GYE
MY'>WLYC:S?\ ?D22.LQ9+)L;5A&<+G<&.\J 1Z!I9@-E)=:Q'//.B2%K!9%6
M)1):M%#8H 5^Q[2JR.H^;*EF&#MV+F4W-N-8A^R+&MOYD]YY\CK!(PMW5XI6
M:-7M0JEY I4/LQ@L6%1R/%IK);VVH?9+.TE=[>%8'1+)1%< M=;Y!FVW(VS:
M(U&R,*2H!')W5RWBV]2.QO(QHMC<3W=QJ=Q<*^;9GNP5D.0LEJTT 4Q @>5'
M&2QW'R@ OK(^,)8M,MK&T73XW1#;QB3"_N$)MV#+F*U)@ECWJB,LZ)B,/"2W
M<-Y-YJD=W;M',DSQRP;)0TL\/[HR20R"8;8-WV<LH !\M\J_FJ:IVZI9V8BM
M;Z>QM].EN)5BN=J"U3-TH>==Z[K3@>4JA<"-#G )6GK.N'PUI=Y>W*R6]TJ-
M=>7->23Q6MPV^,-*WFY-N^"40(H_=D!?-9(Z *^M:_8V&GS7T^K6ES('-S#<
M2/N@AG6TB9)D\N0O%;G(1D^9G:Y"\K(-\FGZ-+_PEMOXBU2VOC?S2R"STK[6
MC/:0AG4S2DS;957SG8!03']J9!N 3;'96C+J5_K&JO)!J=DAN;:VO&5CIT4L
MMTJS3R+*L<R!6D(3=^ZC4JOS$L^Y,);;=G5)X/LDL]VWVJ5&^SJ_VG$EQB0;
MK;D;$&UE\M<GAM@!3BFM)+V.SM;N.YU::W-Y%(LCRF17>W/VB(_:,QVN_&8=
MPWA"%R%^;+U7Q)/J>--T62"_OM7B#PV]G?2M'&R[ ]U]JBE!CMD*E-H1&=U8
M ?,:KZIJ-[#>7?AS0;B?25LY5?[7*T;Q:.F"VYPKLIMY(5F*)(!Y;*@(56BV
M:D=KI%C8"[ANI&$;FZBOI+@S30K([[+BXECF#36K"*%0&/W(E+G"$Q@%?3=/
MBL R+JDFIWEXAF^W0R0K>W4\D8E$\+F;8L#"V$:P[-I\GYMT:L:U!J%P+.<W
M%] VZ(7JWR.$@N #$1/$OVHLMO$NTRJ2 ^[(^\0QJ5Y;Z&VJ:I<74&GH)7N[
M@R9)A/E>1#-*JS_O(V\E@J*N6+1_*KHS5CV4EYJVHM>ZC)/!I-M%)'/:Z@YB
MC:-BS2W<UM(^\0R!9HXUD8B((K!&!.P IP+JOBPQ36,LEKX?N4"W.L6\\C7Y
MN'DQ*MHRR3"* 2Q1*P^YM#%2RX>N@TW2K:P2Y73$M+6_MW%K)-;V2.;%W:*9
M;5%2%#);YE+,Q*D!B2P.62Q%:'2'@OI1)#>E$LUEFNI-EY*%9$27=YOEQ,RH
MZ,6+[I2/OR.LF?K^LV7AVRC6W,B30)-;67DI%%+%N2X(C97BQ#;C[,NV7!4^
M4K-E$9F )-2EB\/VLVIW%K!!#9Q1!?(L7;[%)%%D1)(ENV;8H\JF3:#'OD .
M6VQX>E:$-6U2WO\ 7+:.QEMWQI=LEM&UQ9JOR1F(&U0M /M4;X8'R6C0N<EU
M2YI&A?V=/'XFU&""VN88I&MH9(O(CLFV2K) Y6,HD*1QPH+D#<XC^\49$/2(
MC6MQ9Q6-C(4@2>*SE,*Q*""_^C/B+,4'R1E'4$-Y2Y)^7S0".V.;.RN;"&#R
MT^SQ(]LN4MXW-MF*V80'S+=E!)?@<8R@&8N?N[JX?7'T+3]+^P7]M]AS>06H
MD%C$=J$0$V^UH=CW"*Y)8.\F46,,RY]U=W'B>^N_"NCVWV2.SB-C=)=V0CD@
MBFAE9K8.BE8XSB!8Y%!7-N2QD!C$O2:;9P644=II=O(+VSN+A[3^T)97G)DG
MG:02E02L$GEDI(Y8,=C%6=%# !X=\.0>'M+LK.&&2T-J\2SM9"4A)3M/E1[D
M+36Y:>=BSLWEEV(*E<QB2PZ5I=F]U;W=C%:O'.]K]F$RZ:Q\D.L<[+Y:P(LL
MH8C.$:0(4$158[[5=.T;1TU%Q!8C38O,LS>*T3Q0NTF(I(X5'E0LD2K'N!.X
M(&0R(%:OIVDZCJULYU"#^SH!*D6C6SV*F6P:"Y>7;(8P%\EO(M\895*JJABV
M)' ,/3T7QK=6NI75C';:1IZ%=&TIH6C-V6BBB9E81!Q8_O$'W2&#DR *!&.P
ML;5K"]ALXTC$D"+#'Y>T7"HCP*QC#HL?D-%Y)D6)5",K!=[D%2&2VMK>&[CA
MC3[!;O);1712S:R@82[3-M(V6[+'&JJ8RR^6K.I9#LR]9O9]+^RVFCI8F[L+
M18[*XO8)88[14\U9WNC&$6.W9(5\O "LZA@"J J 4Y+_ %6/4=-TOPX8WGV+
M>QQ[I'LE1[>58P98EV"U'W47:C%[<':WFF5+GAK2-'TS3I=,B;[5]N\O[7?F
M%&;4EQ!M\J((RFTV3>4=N%B7('4N+FF:19>&[>=+>2.">%#)+<W(B22%5%P(
MYKGRI$5[<*-L<>!L"C[NW]W8O+N9[(W=C<R6CVZ2WL<-]*8Q%N2YVRW>Y]XM
MV."J !D*#(&TJ@!)IFI/?10Q31^=<3>3/,]K>,J3N%MB9;4,WSVP\SYB"/ND
M;7+G/+V^I_\ "9ZQ!96E_P#-9^6VJW>EW'_'XS+!OCLIC)E+=3L:8+M;A  6
M<DU]:UE/%>HW]AH&I_9M-TN)Y9]6M[]5FN3(4D=(;EMPBMXRT33,,E0$0)C
M/6643:-I8LWO(XC8I)+F0JB60/VC$LB+,!]EP-L<6<J%7)RI* !H\<UGX?LB
MPDFM"]OB+327BW.8"&MG5PPM58R$JX/R9 Q&H4X>H>+-'L-,M=9UO4H(%/D,
M;[3[E)1=R>9;^<+0^:SBW5H\2Q[ 6'/)SNU-4NETJS:767DB?8D=O+9[FO\
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M:=NOK^T9'TG4%WY4RR,3<W$8G"1X,@B0D+RZC/2/FTMK3XA&2.QCCNO#]\D
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MDBO=I-%'I^ES$':BNT;HNUDEU*-K?8=C_((P<_*,[EQ^^\_R_L+W=U=R>?\
M9N?.\KS_ "/(\W]RUVAACW;ON^5\V%5, $D"V7V@W8@M)3(]M'<W-SY433R
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MW>U26(H9@5A7RP[J#$C,Q8$-TDUM,$U$7D<8>1S<3FUM2PC56D\B>,&)O.N
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M5#=!&@ N9]L6(YP%RB?*2 ,A2I$7G\LESXWOX(K?S)M!T^XAU*;4X;1XVU=
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M8+@B++UC4(H;Q+32K+S)I)4U5;"6W=F1,?O+MH?-4[5>1&$6P.TL;D*6;S$
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M,4\[%H@TB#S&:"U#1J'7YMY#?*V/WN'J_B6_N9;+2=!;[7K%]BX(222-,QM
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MP(VJ_46&D00:7##I5O(]G<O-O34[>4RWP?[4Y@N#)%OCB#R;A(^XG)&"6RX
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M;-\AR] TDZS97&H7JR7KZA9?88UG20,8RDSFT:Y$9W6X5X\7*$F1U)+ME$H
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M);H(8U21@SEG/ $C!Y++38IXIK[4/WE[X@E \F6-[4731K.R6<JF!6$*(O\
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MU*XU>T@L%>..]U&UVJL\,HD$,)D5R\97SX9/,R!\P88#-M+VXM(]2\R?4+2
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MKM&V9@?WLH8N$ $FG:4FDZ+8Z=IEG.;6WM,V $2I-$%A(,P$D*JER[S;2DA
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MX@Q4;6&5P-ERS9A9"^U"*-()4CO2M] L)*(EL6FNV$95+B,JQ4 J,*!QMW(
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MC$,1@UUELAG?2[>>]M-3N)$2^@N!+(#<^6MNCW,;+E(1B1QY2Y602?> :2@
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M#Y:)M&3E>HMQ8OHUBLMMIL^CWEONBL_LOF+J42+ T<S!8%Q.L,;%8%0[L8&
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M=84&22RK(FV7<I4 CFU(7PTW^S5CN]2N4-S:)B,-<,T:?9]1G93')'$$0Q2
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MW,@2Z5/M +6[EBJQL[9+0(FQQ@R7WB(:/;Q:AJ4\EU'>NC)!87<86YV!'%W
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MDDU:-(=/AM;MUG99)1"52Z5)/GN&6.8H^4CY8%@#N:OX6LX;*[DU$ZG:7OB
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M#"K[EOGCE=?M9FV-D;6M9(4<E6\G:$,85P 1W2RZ]J,&M9^P>&;+;>6,#6Z
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M/[M,A(?LJC[/N^S,Z[R^!PBM@Q\".>&&&RLY;FTM(K)$DM[B&:,)!;0A%26
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M.'K/BT[4O$VI3ZSJ^FR-I<3S06EE=QM$U]F5EA%U$(F+P*6#HS*C1?,65_\
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M@E595_<EJZ2UM?MOV1IK*<S"47&+A?+CO-OE!;F;;$,3*F,1NJ8=2 ,1I(H
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MD3( ,6TA\%$ (YH]4\;:LGAW2K^^L[<>5?ZOJ@M_).H/%);P[U#+NM9E>VN
M$P.80>0Q([#3+'3K6"RCM].@M-,26*6W66%K);J;?'&TMQ%]G14F#8\M.DC$
M$ ;59+&F>&]+LM,.B6VD02:>\LA>UN+;;#=D21>9-*#"%60,&\M%PC* 5PH'
METWU :1;PW.K"2XDN7M8H(9K:.!=4N,6^+C:8]T5QN.U8W< >3GY54N@ 7\]
MMINEP7U_!'#?ZBELAD6)/-NG'DXE8O;J6N(B9&CAVY;8<)GY4R]-T2\.H_\
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M!%C=A@DB.@"/1]'M-"L(=.F@D-Y8.;YMS/YU^P=1+>[D5W:4XD_=H[925$?
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M=D9S&"(V-LK>1\]LW[S=(Y !8C(/"1Z9';--'?B:.:\F1&>]A"2SB)YEV+&
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M-BK>0AL"DDI)9CM9)5^9R$<LX8"3I+2::$V_F7<<0@1+<B>0M]F9I(R()_\
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M?.A,@>-=C0M,L=+%O_9L<BS:>D-A.US%YD]N6CLQY3+"H60M&D9:4LP0@<E
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MA,@D(@R([D5S%<P2WWDP74,DKW.R&T?;*L;Q?/*OE,ZW,038L>=S-'T4C$0
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M8Y&%/3-!N[^XM]0U1+N;4+Y&NK?SK=(H[-5,"1R2J49/MRIE@VP9/F)PB+@
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M,I:,E0<DJVUB&,9TW[9Y3)Y_G31!TDDC\OSO^/;_ $J=3!L6YC*#RU9?X<8
MR$YN[U%O$&I2:=I<T::<UZKW^H3HL:R/YMJ1;L0B/%=*KA$/4;%&3("80"G+
M?7'B6Z71M.D^SZ)'*8+^]N%$"W(>6)+BTF1?E6XE\T2AP$<,YCVHPDQT&GV-
MOINDVMO91V,MO;W=E:Q-<L8RD0CMB&NHVV_Z3^[41_+N4M",*"U6+'2;/3-.
ML(([7&F?9$L@+R411W4;BVB!N8V0,;@JI1%VD$ J2N\ 1FX:SM[75KN2TLXF
M2WO!-JUNL#*6$,4S7+!=J7 C)1"&4'S"FS$>: !]2FT.&XN'6/3(0ZJCWP(B
M)$-N0+N<DDRG:\:S*SQC@,7<*AS[&PN;ZXTG4-6$EM#;61BTG^UE<SHY-LJ/
M> -Y<DK2JK*F]"" 0"^3%3T?2[S6=8M[RZMM_DW:WEC9W<)'V-56U0F\(D<M
M=^2<Q;R6&69B,A8^DTZYFM;A,QR:;!</\AN82V[:;:$K<R,VYKAFWI&RNRNN
M&_>8&0"2R(:STJRBGOH7GVZA!9W<TR3B!3%YB3RL9&+*\H;;E<_+&?D#DX]Y
M?)9:Q9I'I\$^I:IL2U@O(%ADU8Q+;R"ZFD$686@'F_(R@Y'R@':*)]232=.T
M.'['/<3W?D3PZ;<1JU_J)06Z>9,SJ%6:+=O89R?)5MZ*K@5] T3[%!%]OF@U
MG5M6E@OS]EG_ '<\,+VH642LN\K ""H:1C("S')<A "3PMX36VBDNKVWDN-3
MU&X2ZN9I(6M%O!%/')'/)&BD02KDE8P09.3(-Q81ZEO<[[J"-(?MWVOR[B*"
MYM/LLT_ERP1RW$ZO$/WD6$=2-FX-M"?(K5)&L-[<164T$ADE>*\B6XQ"U^L)
MM&-U+MC#)+&VU1&=N=N" N-G%I]L\;3VVF:'??:M(N=D^LZW;2&!I[B-+,I)
M&=C>3<+M!\O&S;D;@X;RP"Q9WB>/X+C1M*E^VZ8TJ2:E>WMLI34(B\)(+Q1*
MB7 B7 P0R*8\CS-Q@Z2QTNV2RATA=!DN;"X=2XO84V7R;('>[NMT>X3ALJ$8
M;G8$D  M'3LM,MY?#.E:5;007UCJL2EIOLI$,\9BB;[4ZM;ND<BE0(H7(3:%
M4?=55+_Q1I>BZ/;ZUJI@>RU.[%S;,5S'<Q%HY$GD8P+LFCB3*1D[F$84%WP0
M &I:E9Z;86FH:K%?.NI1*(],GA"&_<P*'^T*D(!N2F^-8&;8Y1  #@I3\/:+
M<ZKXE&O:O''/>(B"VMO,>(*F87+WL2Q[%O%3R6VYPQ1-JJ(U<4]*\,RZ]>6N
MH^);:"75[S9/#IVH6J(DMO$((9+BX2-.;C:\A1'9Q'YP4=&(ZR%)YKJ%18W<
MT<]Q!+NN(8D2Y2.)";F?]T&CE#,H"<-NMX\!$#D %=(EGLHE^Q2:I/=/,85U
M2Q:!;H[%1Y+DBU'DN(_,B4%0'3 ^;=\N'KVKZC?:C9Z?HL&Z[DM,R7^IQK;*
MN#LM);E9;7/F?:?-,<:8RR[L;6PL>M">YN+KP_IMM:7^K:E91W4LM_:Q&>>V
MSQ//"T$2&6)E$449<#+@N %)&II&DQ:/$MM:VN]I)6DTZ+4I7B&I,RV\SW%R
MQ1S]I5TD*@J& 1L* I*@%C1M!M]$L],T^U-]/#/=M>#[9 7-Z6*2M-=N;?,<
MR')0$J28T!;/"V+S5=+LK.75-1G@>&TBA^T37<>TNB&&17N,0@QW"&4M'#QD
MOD $_)'/)8VUPLO^B"[F2WN;F:\M,>=!&8W^T79$*^1*BQS",,57<.F1M3#2
MSU3Q'JUK]M@G;3/-$,<>K:9^\U5(Y"7DNMD06*-$>3R(W"[GVN>PH L0:&^L
MZY8W,?\ J=,NTN;6"\+.\K?(KR7@V?+,ENT7D!V\W@,Y)W!=BUBTZ.*.(R^?
M&8DLYDOI6 NUD6U0M>!HN+DJ554?YF#8X#'9<M(9IC;^9:1RB=$N"9XROVEE
MDC GG_T==DZQI$RK\OS%EP!&''/WE['I%E8W%MIUWJ+M;RBTM[P3QRZE- D#
MAYU-OQ<!;:0H6P3L&W.\^6 2:WKJ:?9QQZ?#!J6K3RPM%97"+&;UU-H3+<DQ
MH+>X4,@0,1RT>%)*HIX6\.Q6<[2RW7]KZ@WD^=-<(Z-.J):,'N@R'9<1XW1(
MV&VMD_,TCT:)X9^P:C+>ZE;?VQJVJ>98WNH2VOE1W42E ?-C*'RL(DBJ%_=2
MA%+-ETQL;'E\B.&+S))9;64M=V+!;H?NV,\V(5\NX58) HR K>7N +(H *>F
MNQLK;[$\CR1V\<DNFS7*QZA=NJ6K>9<-P5G1?E9"=K^8@=E5N,>/5=:UG69[
M#1+F[NK%719KY<HT<BM8AM^[:(YT0W#F(*L9SAD=A(@CG6?Q;=/H6CW-])IT
M6V.XU">XE_=^5+!*L8.%>*[B$I*LV<^6!)YC!O*W+..QFTL:;I>EVG]FL\<4
M-L)O+N)XX_LT9N-Q(>-[?YE(8>8&B3YD. 0"/0-+L]!TZ+3= M(#8O+!+"(K
MT+)J$:BU5KP,C !5&[>@7$A Z;\-)'K,)MXK@7-W-!,D5[!)->B%;NU46ADO
M&.U1"(PY)B&Q7^?*G?Q):ZBD\4>J37$$5C+$EXS6[+;'4$VVK?;3N</''&-R
M,C%LI@'=\JGF[.&^\9)8RZ@9+[1=\$L5E<2>0^M%&BCDO7B8XCMT!$BP  .2
M&8?,H(!)H\5QXBECU!UGEL7U""^LXC.+6;5Q&T<9O9HR.(XT$#JB[ [)N*#>
MBCI!8W-[>VZ/#')82)#=?O4>*6\E1[=A/.5A412QB/Y8_P#EIT(0(0!C;7][
M8Q2&.Y%RB7C1VD**FH/&]H5O%<.2$C.T;68EAP X5=V/K&HD/%I6G:='>Z]J
MKPWQMYHI($:6-8"E[(/,+P0(8@IC8;W90H[E@"G?75X=.@AT^W_MBXUJTBN(
MY=ACCO9&%K&+Z3;B2W\DA"4C&<2(P(*N8]#1M ^R0.T]G?:E?7EW;W4]U<?N
M6O\ :]LXN'RH,'DDL$MR1\L;#:V20:+I\$UFEXP_M6\U&6SNS<O)%;OJD:&U
M9;LH%#1K!G BX''S!FDS6I9"3[/!ODM-7GF>WE4HD$*Z@H%J&ON"Q8QGY@1M
M_A4 X1R 1B!-2L[*YMA/J%O>2V5]&4"Q"[1#%_I,S>4NV0;D?R\C<+= H WK
M7+V\_P#PFTNS2;2>^\.3W<4M[<74.T:NT;6:^:"R!8_+\MPZ;0L@1@@)+&*Q
M#<7'B/45BT6*>ZT2Z\B[NK[ _P")F,VT8F24*%MYHO*DW( K_("BAB'CZ"Q@
MMQ!8'3=/@O+4;$6,1&+S CVR&:4!4BCFA\ML1E-_[H!"F&4 %/2=!CTVRT;3
M522:WD2W<HUO.@N9($M-EQ*VP_9G18"!"QPYP"<YP:G=0Z,Z:G/:VCI<) X\
M^W"W6KM&JE0ZF%-ETC &*/)W'>-J8W1QZIJMGHWA[[;KXW^5Y-T2RBV?4VB2
MVD-TZ!=T4BN@C5'*J6V1L?G3%/PYIE]J&O1:OXBCC-Y=()M.TFZB\LB*&2-3
M>W "L@O CQCY0N!A>!G8 &C:"VN/9ZY>V\=^=219H3,5A?[-M0I<RR0VX'VQ
M VU &4*I(1LAW;<BDN+B6V<VT%S?7>GQ7-K:ZE&+>:41-$Q-R5B?;)$[AEVX
M&Z9AL&W?1;Q_VSY"PQ_:=,O;2.Y%PR>7]OSY&VY>5$5H;B-4)50%W90JR[#Y
M>/>ZT=4BCTWPXWVR^O?LDBWJVT,Z*'6)Q>W2;4\J9$BW(K8#9CVAL%8P"/4;
ME;JZM]/TG3KN]U2]N(YS/=V3 VI,7E+J,JRP*L<J&V<+&I0..1]X8L:5X>M+
M71$TC4;:.73)GMY&^W(\0U.9GMWDN;AF#,LID8*L#D%BK*=RD>7)::+9PNEM
M+8_;/[1WS?V7.P\N\C:X@::]N$>!,7"[U/EGA0-J <XN)8RI;V)GADOGO+BU
MN;J1DFA^T.@M@+ET6$F*57C3$.57:&9CPVT DT^XW7EG:R7WVFZ>)9+F*UB^
MSSWDBBSS<3CY#"R!ANA)):-P,'&RL.6[U?Q1>VEI;W.I:?:7=E]K,MO*$-],
MKP(S(H<F.WCR"PCF0R"0F,N#O:..XN/&,L&FQQ3_ -B7T3RWTMN D^IP;K9(
M9Y&VQ-#YBB96&/GCBD"!AL8;B16QMY+5+&2_M)K*!EM;2X18-011&-UK&USL
MC@4-AT( <.H)<?> )(;O[#IR[38BQ3R)H_L][Y$<]N@MMUS#^\(AMXP7S%R&
M '/SG=7G\0/:WDUO<2?:IFNX!#;6+-YNH.@"2M!F8+&J2J \63L6*0R9$N1'
M=^([&P1-5>^COK:Z0%C9ZC@WDL+0_O+5#/LC@3,WG L,!,ON7)//^'-)N==N
MM(UKQ!=W=WJ5_91S11I*Z$0&*V$DUL4E06I#2J)?O-($;8%#E* -#PSI^I7H
ML-8UB_DU._U&W 807C0#[.8T7[1: %&1")(S*C!29 '4 I&'Z2UD3[9&(H_/
M_M#9>S3V<JH+QT%JHGB_?[A"%(#+ALA2#G*B6O<7T5S+:6\L?]HQS2VMU+Y.
M_%Q\T/EW5MB1AY*2!"Z9X!WDX(\W#N-0MM?O9M'T:\CNI]002Z@UN$\B[4/9
M127,9,C?(L?F($.Y':.17#[2' *\NKWVO7$?A_1]7DU!Y45;S4+*\V+,BFS6
M6ZBD1L0RIND_T=3@[B[ [E63<\.Z7IT>AV$%M;3WUK=_9[^6Y$+(;^=?LK+>
M;C)B/D!F1_G<JQ ;!WQ^'[&&RTO33I$TETEVD-U,/,%N^J,?LFZ_!WEU"J"7
M0XWEB&!W MH>="P6\U*[M+F!72_AEBD$>Y5C@5KF%FN"$@4-)O QE7(PV290
M"NVM0Z-HS7NMZI'+9QI%<->1W0#7ZJML/M4:K(!'$&8AHE!WY& 2^U^?LM+;
M7K_4KS5H)%TM4E5--73%652R O?&"1G<))+#)M@*,&=4D*%P7J33XKCQC>:'
MJ6HK/=6-I+;SV(><6TNHF(,K7YMR/EC#RHP52A*G+;_W4==!86J3RV4LGD/F
M5[R.&QE79=NS0_Z; 3)NCC"N^] ?F\Z0'S-P:0 DM96U)U\JXCMK^5/M$;VD
MBQI>HRI$;P8617*J"4C+2 !H?,P2FS#O];_M?=IFD0P:CJ>I:?!>Q0>1]DAF
M#^6!J#R;C(JH50*BD2J4/7Y'2Q>^)89TLH+1I]0O+^T:^6*"2Y@$T1MUS<CR
MFDD@AP718RA9I2I4;@7->RTM-,T?4I99['4+J\EMK\:I=7"AKP1M%(UZQ5P!
M;PEUVP@@!8L;CYH- %S1-.L]#2<6MS'=27:1ZK=2P3W&=2.Z-GNHE3*@Y\S=
M#$&#AH58JK 5<BFLX(K:%[FQ:/RHKR2Y($D%S#&L3&\=I#N++Y00,LDA3?$[
M[@1B2/5(8"R7=W(T8>65F:[!DD6VD@BDG:166*%%8$O$/O D[0Q>.N;%O<>)
MM<A:.6>"Q:5+V1+8B!]0G3$(OH][.CV\9C@=8\\Y#L&S&)0"O)<7GBRSET/P
M_93G1+KYKZ\G)1[EF-JY<"-D2..2*?SF0;6D_?+MC8EJZ33-+L;NPMSI]A:6
MGF(Q@BMEW0VQWP>:R^9!B&6.6,E8MJAG0LRAMVPM8](ALG &FS:>KP7D[Z>2
ML.Z%+0QS%BXCMT155O*W-NC56!/S U]6U33?#>@VNL^(7DF\A$NVEMXE@GN9
M%CB3[2\1"21ONVP[%) 68*_RDA "/6]0M?"OAR^UJ0V-K-/$EQD1SQ/-)OAV
MRO'N$D4*S2N9(1O)\TDDL[*V7X:LK[4=>MO$GB59'NKMV_LG2X9O/-I$9%D:
M>*=)RIB*L-[,%R,1J-K)&\>BZ-?WWC2V\2>,+3R]3/EI;V5L9/.L95"I(ZNC
MCS+9LQ$@>8JM<,&VXE9NHANHG@6**]OI?-NX)F>U9W:\9GMG,UN7E?;:#S-K
MJN5"E@",?, #7[WT5GY%_.LT\N]S#&SI.X6,1SHHE)-IDQ,RQ,?]8H=E'G9Q
M[K7'%YIOAO0/GN)_)DW689(E1!;,MS$N\JMEL#HR!AO;**<EGJYJ>N37+IHN
ME7<D^K7Z03":U)V!75=M]'F4A;=/*DS%SO8JIXDW22:!86>B06D(NI]0?4)?
M/GOHR#)>LSI,+B/RI,K;"25E*!2H,N6^0N[@!I>S3]#O)&O?WUSLO3>S3KF[
M=/+#WV5N,?9L>23&"F$4K@AU6K%[J.V*'4@F]I8C<%(]7VP,H6!S<+(95 MD
M*JK$1ECO)"8=A)8GN(M*6:2^N)V%MY#7HCG?)W2AEN%!F/DVZLT^X-U2,C)2
M,!N7>"7Q!=0SZW=_:/#,?F7<L$\R1?VA)'*B_: A<K]@C0JZKN!. S"0L"P!
M722\\7:=-->R02>'(I8[Y8[URC3*0_\ I4D3N"++S 9%AD?<50D,%1(CU%FT
M3:M;16P\V.2+[7(;2X>)+MI)+=OM%NHE\LP@AVD7);YNC"8F6Y]GNT*V=Q?W
M;W+W"7$GE.D<EQMD@)>%3)B.W0'8Z8W$$\LS;I,?5=9*"&"&:2[U*\>WETTP
M321P7,QCQYZ[9R7M0=F^)-Q4!G96#AZ *^JZ\NAZ68-/N+2YGEM[8:=86091
M<3MY:031[;@B&S+;4*D*I(8;FWC?7TC2;&UUO^U]4NX]0NI+B6Z@>VE\QR)$
M$JSP[93(4=+9HA&JL=L810RK+),>%M$M+9[*_EADO-8O+CS;B:UN'#NH6$+)
M'/)/OFLPNPE2TFXR+\J%3&NY8W$\$#S7-Q]IMY?],6*QGEFDNL/&QN8"9BPM
MPK)F!5.#E5\P,N\ C#JEJ+BU\Q9)+=[Q?LC,R73F6/=<10QW&6B!19609+B?
M )=Y%;F[_4W\1:]<Z/83_9= BE>YU.[O[IGW1F(R>; WV@QR6^QXLQLI1/.C
M+1L&*BO-K/\ PE.HW&@6EW]DL8,:A>Z\-1Q(O+;[BR)D<);XC>([7^0W&"HV
MN&ZC1X(M.T>TT?0T@5'BAF@CB=U3:K%3<Q8F*RPEA"[1+(&VNQ<L\H5@"30[
M)=-LHM/T%;0VMO;PR6_V:9BF^1 @N!%YY#V[ NQ5F4[H78>8SAQ<M;J".\^U
M"]@&FP[[MOL[110+'())$NR5ER8V#2(Q<,'D02*J!2Q)KQUBDU?[5Y.G2>;<
MPW+;I88CMCBBD?9.0T)!>7  3:0S&-D+-R=W'>>)7M[K7IM2MM(C>:=+.<6\
M$L;;6CEG;S!&39Q*^ KIO?S#YB%2%(!&Z'QU9KJ6K/\ \2:+$_ERM#%+' Y<
MB;YU&^V#H' E5?,6!&*9B(GZS[1-97#1WFH203I;O< 7 *00,IG\VZ8F;,D!
M+1_NM[>4#%D)D%2SOKEK='::.?[.ZW6^R=[@21.)7,X43%VBD7*1Q[6V2#Y1
M(J*PQ[W7;.SLHY-)236KEWDOELM):XMS+/$FZ60;69?*<R0,(VPKB0N#,SJ&
M #7-0ALYI=&AT.,:WJ;S?9K>)1=A8WF*/+<)M(AM9=D+2;3DF1^-ZEZDT[PZ
M]A$^HWMM/JNHW<26-P\[-*A 5XVMB)(BZVGF!3Y@#N^[>Y906,>B6BQ:7=W6
MK:E:27^HV[37MR\S7=K)$WVID#QLS+'9A22C!TW@8;:<J=B6$QV_G26DD[:@
M\D%Q!+'),KR891;NQMV?[+O>9Q(V N1M^1@H ([I'TV62\5YS"97>.\F9H71
MT:ZED2YD9<"T /EH=K;=^5YV/7+ZC<_VSK&I:? T_P#8UM+*E]?7$OE/<_+>
MF2"9\$I9*2T8E*_(R%4W'YTDOFA\17M[9PW=W::=;O=Q:C>W<X!E^>[!CE01
MDM:IME"MYL2@/A6\Q/EZ18DBLQ;I:P3N8DM9M.CME 5";A$BF/EAC:!SL1EB
MX"ESN0N0 6$M;"QLTTZXXTRU^TO<VMU+'B"!S+L:0"0*+;8)$5"K<>7D+Y;8
MS]2UQ_#=A'>7?VZZ/VN>.*.0-"DMR(&<D,7)CMLI/_K0X7<K B-%:K&M:X-#
ML[F^N//M;2WEDCB:Y$S%;MRVPL=XC>W<2#&]T2,A5)5N(LO2;#4KB];Q#J^F
M7?F7%[!'9VI=LV4>\DS>8/WKHV]L))&IC$CQE4B:1J *>EZ?<7.K6FO^)[N"
M>&PB:ZT\QW81E+R!KFYCD6?#V@$B !QGRPJE00?-Z">=Q%-/:&"YU'48H#:W
M$1;9.Z*"LWR2L_V3S)(E**/EWNS;ED9ZN+?*J73W4T@%JZ27V7:W)*LB_:$#
MS9BMP8I<J>'".1N!S)R^L:_J$:7^@65](NO!)KFXN9Y80EKY;0%;A@+C]Q;[
M6XC*LS#+.K_.) "YKNN_;]8'A_2X/[1_M3R)RK'S8?L[+@W!(G&;<[1E%7#&
M-T;_ (^$8W-,-MI5A;O)<R7"7B-J-]>FZ1#<O&\"?:@WGX2 H Y105$>%.WA
M'L#38=.U0011ZE,]UJ;WTH%Z%EE8^7^^SYRYMXE*Q&,JV<)\IQEHVND\B2^\
MV"*:XM$N7O?,4).(W4+.A%SD6T8_>M'NP5G'.YG5@"Q/>/87DQU.Z_T6+R)+
MPQ;D,;X!%SD3L8K8F,H4V]0[,2F]CR<%A<^,4MI+V"1;"1Y+B*RN;MY#>RAH
M1]H,/VAHWLU=MXB#<"-"C,)=IKV<LOBF&:]OI8UT6&XEO;47JS1/<GR8XWNB
MDT^#8XN)6,2E0%"K\VYE/8).MM#%,FI1@2)->_:Y;EG@<^2I-TJM<Y%JI?:8
MN0&="-H <@%PWJ2W@\A9[NWOI89K<6UVH+(H0M<*QF&;<9B4JJC)W$JXDYR[
M[5H]!\'1:HS7=[&R((HX'GF:]N!L6W,<B22F.*4QCABP;S5W'<S!Y-4U%_"]
M@;O4+B>=TEE-O"[,B7-R8-^%<.WE6_$Y(GW!.N52-*Q]+TS5K.>+6M;FG;65
ME^TFUE6*[G-N$A1E3RR@98Q)-RD8</*P7>&87  64*S:BVNZGK4$6K&*2=7M
M+JW:1-/8LL;ACA/LT9EDDRRL9"D3M@J(1U%Y$R,$NVOIU$32WK62W"#<8BF^
M/;)D+A''E1[V#O&_!^8UY+QY8K>*&Z\ZXO\ ;)"\&YTN'"PD7,86?Y+9?XT)
M&_.,DN/-XO5]4;Q-J4>BV6O1MI-M;FZU*YAF5%D4RQEYXS+(R36^&N(C&Q*1
M[7#!RL2$ N:MXAEU1I;7P_J/V76K>)I+O6O+22VM,Q+)'N\PR".VG2'?NC8[
M2L>X%F(.YH6AZ;X:1[/2=&N["TCO1$DB1+)+%O92_)4EH)/+ARX9V'F$'RQ%
M\DEK;16.G6G]G+L:;"0:K#$]VLDD@B<NJ R%;>4J3(S2(2REBQ9Q+1+'/!%?
MWACOK.Z@E5I+E$ENSYFU&6.-$3?<VVZ>8$-@H=VP)A3& 6([>\M($$-O C6D
M2P1+' 5:"1GC?[.CB$AK8@QQEU0%%BR<L"8^/M8'\13QZ@]W]E\)6L5PEE]H
MLVBC<,@= X$46; 1*I*LRAG7:S2 (3'%I=MXJNH[O4K"/1_"]C<$XC5/*O#'
M%;L"6\@*;'; V'9L/B/[NU%7L+*.YBM[(!8[>\M;<0EH=.?R+=V"PB&)/*#-
M;^9&9#AU("1DGRV! !'=RWFF^=>NN&AZM(Q;R)'V32H+F2,!+0",EG(8G<57
M8T:1FGXBO;;1KAK-K*.:Q:W-O#&;5(UM44P"2(DQD?8V1E,DFTB/8PW%C&BF
MKZE=Z/HT;66D21:OO.GZ=:10HWE3;8V6"$^6JFU=8B[N64JJD?*P"QGA[1%T
M;6=0D>XC%W(\)GCM86W609HUCAA3R]IMS'&D;2A5/[AB3D8A )-$TJXTWS=4
MDL\ZTTL@NV,053*^S$,12%B+1G<REP=RMEI,L90+#0)>:=)#9">XTJ'9%;1X
M5;:<,%,:(L43"2V9)S$S,"$$0(&X&0#+9P026NHFQBM+&T2*Z06X9K2.1U8Q
M#,05[1D'EE]JA5@8L2P8QX=W)-XENK_2K8R"""X:RU&Y0&]$;SQ R6J,45C;
M^84WLKB1"NW;$@5T "^:Y\2:E/;Z9%=MI4+[VN;N!V\]WE@+663&76W<B191
M\QC9&5U2.-4?H(+-;***QTNWCO4TZW$-K#)*UM=6X$^$4O@$VY\H#.,LL&<3
M[N)-)M$T_P"S1)IGV&/3Y7A;[/;KM)F\M_+A"0C=;AI1F0!"&@!;(WFLO5KV
MTT70;6'79I%AMT1;JPTZP=HE58XEE\M=N&LU1WW[U?'F !E=46@ U[5['1O#
MCS?N[S08[>5;<1V^5R8'=%$2E$NK?RFVX7A?+RQ.'>*,:1+=ZM/J7B2Z\J2*
M47$D"72,EA"DD4J2 L1LA=K( Y#%L;P(29$6/0M,N;[5'UCQ-':27EW;B*]T
MY8G=[3=M@6(#;N>W=EN'8/NBSM9<A6E;<L!=&"V2\N+X3QRI/<O"L^Q)V<1M
M%&'C/F6[,)C\Y/EJR,-J^6R $>GP+;S6M@;*,&U0Q)%'NMYT*S1,[PYD(-J0
MT3%%?"*BQD,3L3#U#Q ^J:G8:%ITE]+?WF9KJ>T9D2-&CVI=)^^PULX5LK&Q
MQY@.^.<*&COK\W]O%X9TN6TQ?6Z"2.."1EBB 2);B*-7=#:MNA8(,H<.C@AI
MGAW+.U30H+^5/(@O(O/NKAKF5;CR#<NLC2HQDCV6RLLF5(0OY)(^89< S]&T
MC3K=8+^PC^VZT8I,RM.T#W[-+#*T\;K(5%LSD2LJ!U'FE0H8O&^A)<V$.DV]
MG?303Z3/$NV&!(XX)($CA+2QE9,):*-^\2%L[MN2"BO8O;^*#[%<W5W/9RO*
MT\\$<C_*T6U)7W2[5%LJ!]Q*!6WHZ8D9-W+W$G_"76<=[>R8T*2+[9Y=\_E)
M=R1%4%S]F=P19 .LK(T@+;(SM!),H!)-;:EXMN(IY+62UTN1WMIM31FG_M&W
M<PQ2QQVX+&""8J&656)58RYQO+'H+9F6_CBMXH[?^SGAMW^S0+-':EDAWV:@
M1HXB*O%(LB\ J2^U4"-(;>SN;R[BNK>#[5+Y8U!(X!*Z>:($\I08<RV\@C*M
M(W3RR,C9^ZS]1U+_ (1RS2XNHH%U*>[>"VCMX?*!NI2DJVD3M"0T<I4^9,Q'
MSY/RG C #6M6_P"$8TDW(TJ>6\A\JUT^RTV#>_F>6LDEK"?('^C[85)<9/WP
M K(JBO:>'I;2ZU&:[M/M5Q-:16*!;=!;6\8EW+8H/(W&W*S(C2A7!".6\LH!
M5?0- O(;^;4;F&"">*[2*-X[,L+/;.$\FWC-M&3&UN4B:XW'A!_#&"-016.Q
MI9(K2*S+V^E7 A;=$@++&;1$\@)-$)-L>YN5\Z< QE2I +CV\IENKP6\\MY'
M=D1S7<"+*C!@(8D:.%LV[++(#)\S1K(^2&W[.;U+4%U>XN] TC2XY;&-VTN:
M?RVVV@R@:S7R86"Q2I&NY]Y,6_+[&6-#7U^_:\>WTO2)[2""%_[,OI(K19H+
M.5UA1;".0V[*8G(*L2OR-L+8PL+[FE:!9^'O[.BMH9[1H95MFDM;,2O$K;9!
M:K(+;+VQ+.S3,0P8?,^XMM )-+\-PZ7HUKI6Z[^S0I#:7F]!<M(H5 MMN>#,
MMN3+(2_R[,L!L7*I(UXEC!)J^I:I/I\<=VB7]U-"L>PAU5+96>W7S+;=*^)>
M",YW8+%;$"_V99BXOS!9QV6$>:WM]J6,>82((LQ?-;[0/,ER -I/R 8BXO2O
M#^I>)M2L[_7%D@\/Z>\MO!IW]GLC-OEB"P- ]N%:U543:Q&X;=Y,9&V( DT"
MTU3Q#/:7NMZ9?6N@1R^1;:9]G\B:V#HBM;SH(4\VTW!=NPX(V^:&"MY?80V/
MV#[/=6^G0)?6D1M6*0[?O;3%:JZV^3;*9!\Z@;?*!8'$F*\>GZC:;'AEV?9-
ML<4,=NJ^0S>7_HB2"V.ZT.8P9%4,GE9+'!$?/Z_?2V&DPV-K;^?J4LKV5CIS
M6R OF,^9:1H]L@>R4K#ND!7*9.\%55@"Q>:@^E2Z99:=:7S:M<78B1(;1D2V
M2%HP8<B",/9*)G02L&V^8'57(^2YH.CPV-E>Q7%A([ZA<6]OJ,D%B%0,J"-H
M%C>%=UF%58U8;^)7)*X9Q7TO0#$=5OI[&.YO[Q!;WDTD4BJ9C("]K%$UN0+-
MV9BTHW$[V9B2-XU+Z-X;/4);^W@-O'$?.ENI6D$3R&-I;<,]N<VC<;Y<G:-P
MVH(P$ )+6)6U)I9HHQ,'BFDD#-/=6TIE>/RD5X-_V<DW $I(PLDFW8F"O/JS
M:V\EC<Q1Z=X:L$DL;F\$"@. LOVFTC?RU"6JA(T\[$9S#M!9F#+3O&_X324:
M;I$L$?AV+=:R3V,?F'RV8Q1P(%6-Q:,UNAD="P8DHKA(W=.LM1!$&G:VN['[
M,\4:BQM9?D,,;EK=5$"^9;A=^QB&#-*VS:P2@"2RM[RS^RO:V\$>8F@$*0&+
M$D?F[+=I!#_Q[+N8(^U"-BD>9YN*IZIJ$/A\6*P",[G^Q:?&+80SQ,;E$\K_
M %9"VIS$A<*-JJA!D:1"#6M3/AS2YM3FM[N:[C<JBQK).ZW$GE.+2%S 28)7
M&TN<!255<$*L>?8Z&(KB6[U]HX;=$>U939QQ1V4*%W^SAUBVRV;0MM)D( *
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MC'HNGVL]G"FRSU*[2V:2*PCC,.;*VC,8!60O&S.Z;&B))WJ@6/<LK*TTS1H
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MVZQX/\/?\(UHXT]M5@.K6<4=E/J9ARD-P6C=83YCC>KI);QC8JDK$JEU(C"
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M# !;$ZU<1VBW-W+9FRAWZ3=V\D;6N3"ZM)=89END!9MN\,<QGY2/,;FXK_\
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M8O>%/EO@HS/M?<I6+K+=%O[BQ9+&[ER_VE+F>%K4R/&8(VFG/E(\<^WS%5
MLD88'Y3A:]G9V.IV5C!:"2Z!MX+RTOKBWWF8%(D6\>62 J+I%#;5R21C< #\
MF/=33686QM=#M+[6KEY=2TJV>P*1S,L:$7ET[0H$N-RD$+LP9D4XR'4 T-56
MVO+BPTR;2(]0>[>&X4ZC8H(KH9A1Y9=\:;;I81.5C7D)&Q*_=4&CZ0LB&&[M
M[N^U'44\S4;V:W:U2X,;0>7(6\I7CE2-@T:)@*RR MO4R58\/^'8=-,LH@CN
M[G4;C[;)-/:"#[4HDB=)9P(0(YX@3M0;=S!G(#,Q2Q;(OV>/4YK&[9[BWAN9
M8+J%BTPC$+>=-&D1"72<A43E]BC^%?* !@0\<ITZ29%2.\>>XMY";V-5BW.\
M:(-ETC1QLJM&20@5-N7\OD[:.\^($YLVC@N/"TLIDN)0A1=:C"6P21ID12DR
M$,64!!N01#(1V2/S)O&=_=Z7>&T/AV&]$&H&0&+^U&V6BQB6545H[A&;)3$>
M6"1 ,%=D[2U.?LB7D,!FO)0\*7"[?MNSRF6>;,"[+E4C+"( ?</9,Q@$<%NM
MX(K6V:.9%<,5DC:&1 T>9I2T<:&VNF^U%MIY8#@)O=ECENDT_P"S/>^1.NH7
M=N+5+F);=KHG[,/-G+QJ!<H5=EC&TE4P%ROR2:KJT-C86$FHW$CQN\(MDN;4
M.UWAX6WO&4C*W (<I&AW<%EC=EV+A^&M#2'6);W5OL+ZV\L:_8LK'&AE6"=Q
M)L3RY+M3;O*60 L C'8IC" $GA_0=2N+A=>U5(YM8U!+:6&"[MV6.VMU-LTO
MF!45?M64'S'!)ACVA%0HO200/+$(XQ.?MD0+N0UL]RA6%&FF=8E:*X5<A4!7
M..V/W=,Q%$2:;[(SW%Q;2037L$D0FCW6JL]PNU4%UN7$8*@@A H&' Q[Z];5
M-6BT'1[*TU"^9$FOI]0M5:*&*2%$\^[C\M&%PR"2-85*Y1B6PN  "OJ%_J>M
M7M[::'8QG4D1Y9;A%CDM8WWP_+*N2C:A#Y2*JLX7 WEE!V#<TK0=.T73+6*$
M?Z++*EP+K4$8&21Y(#FX5W4O<NXRCE04.%P,;7-,M[>RT>R2SE@OK"6[BDEN
M]3)\QW5HXP)G=MYN1* 5RG!B$6(R%(D?5;'P[97%_/<QVL$"*]W#-R8@$MU/
MVF8>89+A5(V#<#(& ^; < $DDATW3+?SQY'E[;A[9[R&W=X_,A>>YF**JAHV
M:1G5&*/N(.=X Y/2-,N?&3P7%[')-H<KQ712>)X1KDL:PQM=3*%*QQ;55HX.
M/,*[FPHXT-.@'BA#8WVFQVUHSPW#:5=7,9EN55HQB[!#RM+'&MO+R5SYT<;Y
M +'I+>W\WR/]'\_SO+G_ -)@\O[3M\C_ $B?]R/+N$V_*G&=O;'[L KZ;:^;
M^]-E.S7<JW#)?+C[3Y?V=!<R@18AF C#)&-N<9(5MWEX_B?6;?1M'BDN1/J-
MU/Y5W9V%U=&W:\,36S&:0M&HMVC(WL@VIM#LR_>V6-8U.SLH+&#R8-7?4)8+
MFUAMF'VC5&C>UQ<^8H2/<@^8KRK(BG<J*P&7I&C,$@.IV4<WB*[2*97CC5$E
M"M"7O4BF0B"6%KJ4[=J%V+L4RX"@'"?"W1I]-^*&A37J0-->>&H[R-@);K"D
M!$(9@/(;8H!R67[RJ0'55G_:#_Y>O^X9_P"Y&H/A]93K\4/!DJ0P*I\-+-+(
M;:5I)5Q(@8EU)C8':@?<%*(H4A76.I/C]"L3W[J9"97TMVW2,P!VZ@OR@G"C
M"C@8&<GJ22 >!T444 ?;<=M;7GC76K6\L[2Y']F6V))K="_E2M,KP%L9:(F$
M-M.>7;G& /(-,L-(;XAOJEOID:Z@/'$]N]YJ+EH!'Y;$HI^53*SAVC 4E6"!
MFY4M['9_\E#UG_L%6'_HV[KR/09%M?%6HRM#'#YWCB>/[3(6:&<!T7R)5!&7
M#2+)"<2$.KMA%5WH ]86_ALQ 9KV.T$">7F\N0WV95CBEDAGS.?,G,:NXDYV
MJ"3D9,G%M<OXEOI+:WF_LSP[I^H)]NNG1O/$]M"OG0W,GF'/RD;;G<-CP#!)
M\IS8DM[CXB7EO:6,L]OX9LHE@N/M1$YGE AEVNK,PEX:%XYLNI,<FX2QR#=V
M$4'V**V<I]A626*423ORK;8H1%<,)LSS,"RJQ++E4SN*KN *:?V;IEE9O*UI
M86FD)''$UW*I33%V0KY,O[X@SLCL%D&<!\<AOWF?=ZE8^''T\7UK':B.X3[&
M@/VF6W$RKD31"4O)<2N+E%DC$A^^22#)NL7>JKID*75V\D1L7$=G MZTLI)A
MA8VLT?G 373@R;/OC[K9)/S9^@Z"+?5(-=U26.+5HW,6VXN([E-/\S[,H@=\
MHSW#)A5EP6(<*[2 )N *^B^$6O;C3M5U!H[F^WPM):2LLRQ&V,49:2[CC!DN
MD="<N2/FEB "EG'66]OYOD?Z/Y_G>7/_ *3!Y?VG;Y'^D3_N1Y=PFWY4XSM[
M8_=U[1/M.HB+^SX#Y,5O'Y4\_GR?(8I/])?RWVS1;]T:^:V\NS9_B7#U&\NT
M>WT33(KO4-3OWCF>YFLT4P1R+F.^N0;=$$L30%4B)4L$&?FP% ([K4;>2\_X
M1G3$^W:G=[+ETN92IE!$<C3W15!-:S*$"Q\ *9(=H^7;%H:!ISVMJT$<W]LW
MDTK7EV]\S()I_*AD2253"?L\BMY2I#QMC^;#,N!8T:WPL$$=O?7T=S+)=M/J
M4'EF9EEA/F3AH59)DY$2 ;2D0Y "E))8EM=+GF\J.XC>R< :LS1I/:#:V+J5
MH"R&,22JJ/DL"Q;<Q8J "Q+;F"SL8H[R6YM_MUM;ZDS1M<LDD7SS,8&=7A7R
M%1F)<_Q#*[ZY^TTD^++BW^62?PJ72[MHKE)$;5L&,>;<N8\E(U*K'&_S3>4&
M9F4;JDNM,O/$]]!#-83R:.LJSK#<VYM_[6DBAP9;W,:F-1((%5=I+;&/EL@4
MIN1V4+"TAN[>34C>NSJU[9 ?:%:-%>6XVVX$4JQ&2)4;;N7Y2<GY "."W@NX
MA8SV_P#;$%U*!<F\@BQ*Q6&0-=HL*F.98P0BE0I"('8,R8R]6\0K8):VMO':
M7NL7CHUM82QL7U">-HG+3A8%\B=8%A92VU4,GS#;&K5<UG53;06LL6E_;=7O
M)5-IIMV\,%S=O$\KM$Y,958X,^8DBL<E5PQW R4_"?ALVZ07<[7=_?7;QW,T
M]^DB-*(F2/RY0\"Y,2I$\;L%DD<.PV*SY )/"^@HMY/J-Z8-4UN[E66XEG@4
M%4 M659&%NK121*$*1D+O(WD*3B+<^QM=6ZQ()-]RB2K++;JC3%1!_I,VZ#"
M7"8RB$8.T9 Q^[KQ6T-[+B2.TU."5XT*3VH21I'@42-=+Y1V2B '&?+#"81L
MJ_*3S<T\OC#5I-(TVTQ#YLLNIW5W"DT+8DCC>VE0(8OM,6W*%@^%MXCN=96P
M 27DDWBZXM;+0#(D=R_VK4;R0%=L;$ INC3ROM"#[,\$@+';$&W;"&EW-.TI
M--M=*L;.SG>P/V80B:)0L@AB0+)< P^9'-@ C(QNMHEW1EMI-,M+>P^Q:;::
M9/+!)Y4YEN+<A;ASY;?:+EC"&%R/*D8?[2KO*,\8%B4I;[6N5V6HE+S7EU:J
M8Y6@\HF>X&Q#')B%PD@_=@*K9.8TH IR:A#I%N=:U81P6UN@N&EOK80R"10D
M$KS,D;*9PH*QF,@2B0JJE5#US^E:4VHZW8:IJ<LD=G8/:M8V%^ZK*T^R.)I=
M08(RFZ*R0M$NX,?E&%.[!I^C7WBV_FO]9LK1TB19+'2;^/=OE"(KRZ@(T"+<
M/$T6P'/EJY(C;8:ZB00NGFVDEI)\D$"/?H,0L&@:!;GS"9WG5I&D1?DR7PVU
MBKD C86\LL$T=Q TRRP+)]L4JDY+69\RY01J([L ((E.#RN!C(4OIK72Y;&X
MOK6>YN[B*/RM.$D!N;^YW0[I'B&V-I(1%$?,5L(-Y^55!.6MW?/?VVC:?ILF
MH7'V*.*_BUF'RO,L]DL8%Q.%??*)HGQ@;'6=BJL,R*0^'YCJD^KZD\;/J#Q2
M+=20F* 3'R#;MY,DJRPE9+:-6B!)E:2/)^7;$ 2>';74[W41?:E<>?J8XG"/
M-'&58VLXVYRUML5BGD,%:<*&D'4BQ"]GJ.W[/!/=?VGJ$&L6^9@GVZW7[-^^
M/RCRUAWQ8C^5W\A<[MS9L)<$ZC;6HB@N;IMDESI\HA,TKJ;/-S.Z+L2:%6!V
M*3N!0J> %Y>]U'5/%30^&M"U3=-RNI:C=VW^LECB@#211[P8&B,B.5 5EG\L
M 8\UE *]WJ?_  E.L7?A?0H;YV>[@FU&_E;RO/5%M!),C (8KN$^5^[ "C:V
MY2Q"CJ-!CLQ_9]IIT<$EC<1"\@6Y0%]54?9'-_(X3*S(6/# ,[88E< @\.Z5
MI8T.PT_3H]^GC[/<V0N;O#ZA$GV61;MOE\P-&0$"<+\JJ0%*;3Q!?6=AX>EU
M?6;."73#$&OK:XT\1QW\FR%UF(;<T;*L;QHDNTE]B$CY"0"/5[VVM=-N7U&R
MCN[>:W=HM.N[5#+K4HBMVCED7RP8W#KY.UD'SM&, F-3E^&K#4=6O+;Q+J]I
M_:<EQ%9MI\+QJ$>," M>NQW+',OF.RQ*5"XFV;B[2&Q:>&+S6?%MKXCU0SDQ
MW<MQ9:?<*=CPJRI%+*QC_=R(LDKQPD C<.5?SW;45+;6A!!_HE[:7]E]OMHI
MU3;K(6.)?,NE-O\ NRK-#C:<\CY<+M !8MF:;5+>V:*,B9!<+%>P*CZB$^Q_
MZ9)B,&.6(DJ(RJDD+]T*-O/W&N3SW%EH-@L>H:AJ-NLBZA##%ME=3$G]HR1,
MG C:)F0[MK_N@A?=F*34M2@UFUCT;3HH+Z^U6)+FU6[AB>&_A$4+B\O%$),:
MY3R0,*6/"[?E:/0T?1;>Q_LJU\WS[^6*.YE:Z0B35$B\G,]P98FD22)Y-R1[
MQ@[1D#(0 C\+Z6;#1H(+>TDD@#R8%]:2(VJ7FV*47DY=6D@(ECE4;P?X",_N
MP;'.EZ:MQ<+'=W-TB7<DE[%)!;W,D44!-S<$PL+1U$.53@9'][[DC7FW3I+P
M6.^$;)5FU.+[+'=.@4F>YS!O@DC%N2&*!,&/!R5"8=EI"^)+V3R;>.70WN(P
MXO;=O-U5('PXN9&BWJ87*+&CG=)Y,@?<K%E *=M!<>,)8E<?:M)DW7UG::B!
M;/KQC:-3<W)BBPL*!HA'&4R^U"PP!761:2TZ1_OKN:>=#(DT\2QF4%K<BXF3
M[.$6XBV*(U9<X3G^+9'#;W%[I,UO;^?<_;XKE7DO[86[7(\M4$DZFU"K(&"Q
MJK+AH\MB3;M%?Q)=6\$$9FTO^V9-5B$=I97EJ5^VOO,JPS?Z.?*\I<E/,(ZR
M%\%2X (]7U,6HCELK>34KJ>],D=AMCC^U2F..2,7):#=%+&-FQ?OA41W.U9&
MCC\.^%/LFM7&LWJ?VGJ>I[9C<WD6PM"DR>6'7[.HADCC2%@OREY"^0/+5EC\
M/Z%-#JESJNJ6T>H:Q>6\30W$]L4$O66))B+5/*,30@;_ +Q.TNJGR47<>UN-
MRM%%]I\R["E+F,1BYEAB?;--BVRC&2.,;AA<11,AY\MP L#]KE2,0P7+'RY9
MA*N#+(K1$2W \A?+N%B$#JAVDEBN $5QSYDE\2>5I.@W4]U:7,0N-0UBYMDC
M\QF^S.A4HB%+E(9(WC<J%&Q00S F.G>OJ?B/6?[%TJYDN;2*X6SU+594C;[5
M&K3>9!,$@79+$RL44YB97'F;A*JON:7I]Q::=%:6>G?-)+YL<5Y:@>:\0A+3
M7LF/^/@RQL%DC+9WK(%D"D@ +32TCL4LX++;!<RN\FFSNL5W,3- 'NGD #>9
M!\^'5G+XC?S"Q5JL3W]O=:.]U,\%U&FV]EBFF-N9WMV@9I8@\A\A8V4AHI O
M[P8<J"S,7%T-(LXYI;B=[=HO-MTO+N:&6:*(K, 9'V+'(J&8%)/FE6,>8^%D
M(YNW$WC!]*;4Y+N709;UI8+>Y0J==5541R.C%4B1 !+Y8/[X))((EZ4 :EL\
MOBC452_M/.TGY)HE.P-J4@)@EFB5IFV6@1HV*@ NLIY<.RR:FEZ@LZ6-JUY=
MWT\R"21P&A>Y>%K=))E'F 0(C,1) 0"3O&T\AZ<%QY]A8W5UJT\UH]HEV]TE
MW]G%] \"1R7 0NC6_E[@Y4910^X RD>67?B*=HK6TT^UGU.\U??&8T>6V5BB
MQ)-.)-[-:1QY9#&5\SS#@#=EF *^JZI?V\4S:18P7VLZA$DUDEK)(D.IF)8&
M^U;U?9%&I=E*NV956--Y&T$T;04MH'=HI]9NKV[M[N34/.79J05[9Q=%U&(U
MB);RX0P!5&P&SD1^'=,9M)AEFCDUF6[N(+M;R.);6._B\Z"=;D@+^Y,32.PA
MW+YA$K%6+L1J.MG/@1Q?;[N\\O4_)@D$<.I-#]D/VB)MS;=NV,(C.JL<[LJ?
M, !)9WK:C9"\$4=^9TCO+6V,RJFH($MG^T112[FA*-PJ%E 8@L07#CEY$FUV
M]M=,LKV/4+.Y>*ZO[NTE,9U22%[)&N(I%XB,6WY@A((^53YFXQ%Y=:KXTNX[
M+2WDFTD7$$]U>0^8(-0$=Q;*[VTN_P#T<QM#<?('R1AE#E]Z]!HFD+ICVFGZ
M;YD-G]G@E2*>X:*6]5%MHQ*PP)(WB2(*T6P(_F(&(+,% )-&TZR,5C/IEO!<
M6-U%%<PF19%2X15M D[*$$44BK&-L>SG:"IC_>8IWM^NGZ)#/K9N[PBXLF6-
MF9'OCOLQ]J6W"F2(QRD?N5 !.<@EQ4EWJNG:7HX\0S""ZTRXBMKJ2YG5A]H1
M6@VW3_*L<<RAF(0)ODV1A2-@5<_1-)U36I=-U7Q1#?3,-LUMITD>TJZ-;!;R
M3D)!-E78PJQPCLJ@MYN\ IZ#ILVI7^E:[JS1ZG<WB6^HZ?8*3&KX2WBEOY@1
ML$ZHZ$1K\J8(0LQ+UU@L'O9[7ST^WVLL3/Y.HPL?.#)!&TK[HP+>0(TR^2JJ
M'\QB=OS[8]-2>5[8W"1ZA R1NT\%M$R:HX6U*WQ<?+&4(;"9)(7<N=BBL?5K
MZ:\NK72-&ACOM0E=+B4SQE4$B112PSW_ ):));R[HUVKM(<(5(7(,8 :AJD-
MZ^G:;IKQZC+K5NLZ(L0#RQE8-FI7#*(S$8]C!0I!8[ I4@;+FC^'9X(+>*XN
MI]1^URKJ-P]VDL37<P>U=9W.P?9VCV%4M^C*J@GAML>@>'%A23[5#=WEY=W$
M-Y->7@:(Z@4:WD$SX3= 8F++';DJ,(P(()9;$TT.E":YN(8Y([M$NH3?2B+[
M9,D<69K@21*MN\:PJ^U#G:DC",LF  $<5C>VLUU>Q6EU87%ONNS>-^XN!#*%
M>6Y5H D4Z(JG;\I+!D8 0JR\W81)XMBTMYE^WV-YY%_) )U4:RZ+:Q2SSHH*
M1+ 3S &.]TZ?+\TFDB;QI>M--=1ZOX9D>".V>:P*/JBJY<M<R+$%"0NDX2,*
MFXX#\2*9.HLK2:"W@=[:34;F[>WN)O,B,2W3*+5&NI%=,02QA-RQ C.PX!;[
M@!'9W*#[19:;#/<3KLN'^TSK!<7TY\E_,<AQ)&J!HQ(C1#".BJA4!&IW][::
M?;Z0D/V24;X9;2.)'6*Y;%O!');.DK"V@#3HK+AMR-)A6!)<?5X]&O=)T:..
M2;[:D$B&4SQ7M[M>UC$TC^6H+HGF-+&26V(N["E@N7X:M4U*+0M3UOR%FNXH
MWT_3()5B1T9;&8-;QF0%(X3!\R9;=M=L88)0!EZ#IMSKMUIVL^*9Y-4DN;>R
MN(K,V[L726)(WE@VR*L<69@+B,JX81[F55D11WENUQ+/ Z:E]KCNY8[ITC<#
M[2@2 >;:D3CR[=6(9U;?NW,.0XW5[>=[N\TB28P2WUQ$+B4VI:07* 6V^2UF
M\T>5;AS&60C]X%/R-G+8^I^(K_5?L>C^&KGS-5U**WOI+@K(BQVS>4/ML2M+
M@1J5*FW8Y9B205W>8 5[[QC<7L\%CI-Q!-)/Y6H7-Y'>B)(+94M9/M3QO)NA
MA^<J;<X,B[SO4DEMC2-)M[.S73[9OM%OJ>Z]O+JUO##/J$[&WW7<)24;(?F8
MN%(Q\H4$,-U/08+;P_HUU=O%).[(MQ+=G4$:ZUA(5@Q>"5I\) ,MF-F(VL.F
MXJVQ=7XMDEO9;V2X2W222YMK:YCB%U)$T >:,O/^ZBB975XRP&6;=G.7 ">^
ML9$A74)H[F"5$U%I%?;%.(6MF^U1.9BL4$9*L4)RV"1NY+\O:P-XT>VO9[*0
M:;=/;7LVDS[8&U67; K73#S) ;>*)H6$0)RX*OR!DL8X?$<T-Q((QH<+K9V5
MOII!>_VS003RK'O81V(V*K0@E2I+M\VPUU%A$WV"TM([R,H[Q3Q#2RL*W$2/
M;E7MU,SA+=4PDB#[V6*@;AO *_GPQO;/,([FT1UU)[V2^ 63*ION;4M.QC@C
MW8>,[5V2D*6&5DS[_5KZ)+/3_#D-I<:C?N+MHEEVQ3%F;%V/+N"T-ONB\QAM
M82><J??=ZL:CK)@NK>WLII+O5M72,6A$T@M;F58O-2XB_?X2W78XD1,NP9<A
M@RF2/1-%@C>6Y+^=JVJ>9<OJMKY2W%PK7";'@8SOBWB01$QG<K(T8P26C(!8
M\.6O[BQO&U.?49KV)9WE7]S)J*EX7CN$#2EXX8A(P:(;5S(^(P&56N?:6C2V
MN)=7C:P1%NG$<JJMVFY))+I)#.66!&=/E)P$#IM</'@+S7Z(DL5I?I-<6US$
ML=V0+Q4:U;[7#^\/EQ1L6)C&[<0IS\_S<_:RP^-(5:S\P6-Y<>;=/;SB%]28
M0I"TZ1.SHUN@:'=$Y.2"KKNC,<H!&US?^+[FSM#-.EC<2^?/&B21/=QBVCBD
M:,/(\+6Z231N5RR2_-@/L)FZ33E8W"%)8S;S/]H2&PG55U L;9VO(QYF8XE=
MI-T8)#[RQWE\,65]8H;*UCFC:6^<7306C[//<R*1/&1,42)Q'++Y>29%\PX8
MK(#GZCKFFZ58:8FN7<FHP73V\B3QE6;4+A'M?+FMXTE+;-QWF-$(.UCW'F@%
MC4;[3-*TNWUS59I+BTB>.19X7DD\]S^]^T6P$S%8E62XWJ 28E(YC0!L>PTC
M4]9UF/4=;^UV5\CR-9Z='<1M<::6:,2M'*XQ/$?,CD8@X0*(0&5GC-?P_H.H
M:I>Z%K_B&6.XUA[?S)/LUQ"_GKOLS&\:Y*- @5F<?PRNSQ#+1M726=D@T[2+
M2&>"\6+[/-& %,=X$%NOVB&-9@B0JK$[0,*^UU4D+Y@!8TPO%IUEFWS8O+$@
M?3&9H7 $?D30[9,Q6Y"A6C"D98DDH&D?#U/Q#<LB:7I,DE[J]\\%\K07CNL0
M+*5?B-0UF&-O&6CP71IB1N20FO?^(K:9X(+&_CEU39;7$DQN4DEMH&6&5KB=
MU98HH,0-YL41VR;H\,GF@G4\/^&_^$>BC-S:SS7]W=B6\E@7)ENI%@>66.16
M7R[<M"S.C@;R-H&-B, 2:-I0MXI;9+F[EOTN(GOYTBCMKBZ83JPE50P$=N6%
MP"FW]X#(REBQ:0N)('T%]2O8;2\%U;Q+J<L1E%K(XC1T83$D_8\E@VU77$K%
M@ )<V(6LK:WM9YI[1K:"W5X'M_*MU^SJ+8M+;LL@*6JD!G1BQ/ R5"AN;:UO
M/&%X8+BXW:;-*XNF@<I-J$.+=&%IOVF.R8>7)(5=BS;E4L"K. $ES<>)M:CQ
M-JL>B6NJV]Y$I0&;4W6;;OBQ)M^Q1[[5RP3D9;.[+'<L7:TTB%7OK2WCFMUN
M=T4R_9(1%! 1-!ME1A9JRX9.K&3G"$DR6ES;_8].%K-/]E\V+;!8(4%X%,$0
ME@3S"8[1"P9@N 0 V61CYN?JGB;^S])AO)+G[1JBQ17S6NG76Y+IC'&/.1F=
MEBLO]8K-(H4??!#A68 -5OO[ TX1:=IN[6Y\6<%C$GD-/-"$\EH@9QBT7[S(
MA8*LK;MI$N3P[9ZC<P7%Y<WWVS4WVR1$2K*(DE='62%DG!-H9%F;:VUY(T5#
MGRU!C\/^&YH-4MM3UBWCAU:2WMU%C9N8&A6/RP4@VW&/LL?F?/&0=[@MR#&M
M:!>*\":>;Z35/,1KUK6":%OM43Q@EHU>4YM78RQ;)-^&E7:R*BL #0-^UXDD
MMC#(YN',]M;O?*#>!6A"3Q2)*P2W (+*%RP;)0EMLGG]]JUSXOU2[\+>%M=D
M<H\4U[J5C?/OBE?!:>W!N2'MP,QM""/++J5WGBKFJ>)+CQ%<W>F:)J^VVBVF
M_P!;M+D1I$?LQ$DUONF*/"A>'S$R#'G<-SNKITFDZ98V2:;96%I:26&\WT0M
M9]IDE9H3]HM%\TB.W EEWH".&V@,'^< CT;^R]%V:=;7MC#I?E#4'CMI_*4#
MB5KN,_:#Y=H6&SRPN-Q.<H23)=ZW8VNEIK&L7DD%K"XNV>.\V"["^2@N80EP
MP^SX?)A.XL77Y2Q >.]UZSTK1[J>\\00.RQ+?O,90?-5FB\NXBC2<$6RG*F,
M?-)@C+LQ,N/ID;^*[S0M>\10S_9WE6\L-.CW [\0B.]*K</^[&%&P)^[,[;\
MC=(0".W(\>>)6NY8XQ80NJ?9E>/[5-M,1*_,-DEKY5P"[ LV9I5C=XY!YG26
MJ6=O9P,M_G3=/B@N#%:70AAVD[EN4(FRMM@R@QR%EVP@(,)\Y%<H='E>6^GM
MXYM]TUPMZNZ4!HB;RW9YW6.V7.XQMD;2 5P=KY_B/Q3;Z+:V,T\,]_)=9NK6
M6TU(P1WDT<41#(HE.VV*L[.7/EJ(V+!BZE@"YK>H'10UUK4$<T:W%LUJZR21
MM)=+&S3/'\SB"+RD. S(O$PD8(Y<Y^F6,UOK-[JFJ31_VH4A.J74\A3^SXXV
M\S$6'0?8Y C;2#G=_K1)^\6,\-V4\5W'?:JLFH:Y<W$UO/)!-$&2..X#GR&$
M^X6L4C,C(V9&RJLH50E:D LWGM46:QFWW=O=QI;L%:>21'9KBW_?_)&V'8KC
M++'<\2>830!8TR;S]1TV7[3!-F)W\R$>9(WF%VW9S+LMI=F]/G3:8HTRV=B\
M/<"XUI/L5E<01:%;6D,=[?;1'#*8[=_,LG=(X\6SQ2^:L^S8I<E.615N7TYU
MN_;3(98XM-AN)X]>U6Y:1M\6P_:88TDW-!;R-$RB02*BM X'(7?U$6EK86^Z
MUL(TN+=X]@"LWV:7"[((7,!)M_WTRF0#]TLCA0H!$8!)I.G0:5]FCM[6>"WL
M)7M_^/.)'&_RUVHL46TPR,1,S*5VL!NP R)EZ[>6GA_P_)/J\5I;:?9V_P!D
M;-F\BAI"K_9@RV^U;7:J1%Q&V[(!VNGS5_$.K:+X1T:?4I[21K#3;AH[.&XB
M$?[T*7%O&)8MWD>9'"R-$7PP&-L<6!3T;2-1U#44O]6;[*]AA=/TDPK(NG;R
M$1#'$BF>W\Q%8.P38UHI1F3,I #PYX6O;^\34M>AGM;:[E:.'1G@C<6!B#Q"
M$LL6U[=H?.49VH!+QO>02#I)K=4LIKBY:.".[2=;R2]C:>*,JCYBD+QJS6H8
MSN&9T'W54['"@C_LT6 L]16TMX[>W,<G[I3]GA+N9865H55+4K;[%D8 2*O9
M@K'/U36KFU\0-INF01CQ!?VZ2SD!Y%M3& %+,P+26[22QQ_NXU"YN'W*P;:
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M^KWNI>)+W_A&?"WB.0>>D5WJ%Y9S,)X6=R/-B668G[/\@)CC*X66)D:17*D
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M'_L^ZM+:%IXK"S!B5-/\MC@!OE=I!%L*-(055D>I/#WAI[>\-QKVG?:;AO\
M1;DFW9[6),&)+>WMP=JPA)5*RX?Y6N!)Y9+"N@L+BW:5(WNO](@\N")XG-U,
MA5HDN(4=HMTD(<1!Y26.YGW&,H, %=;U+6 O'!!;M:^59PF(J$LYR\,?V+F'
M>D,C>40^QLJQ;Y (\X^LZS+'J8TGP[%/:7$'G6L%R;!&%OB.)5MH(]@#;C^\
M"N\>!%YK$PA=QJ^K.T\GAC1IOL>KQQ1P;4D;[)9EDB;[*BQ!9#N"@B3:I2-I
MW1U\ID&QI>E_V+H\45A%?--!P)+\[[E)I6AD:(R+$^Z.5R6ED4L%.[!PH\L
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M,CL&$AZR E1A<-J">"%Q9VVI26MYI]N]V6O;F6X33D98RR7N+G$CD-(R%FP
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MX3,K[GC5VC!>1D\Z3>QP"(X;1=?<R:R\<%K9(TEGI>K,U^FG*5+^?J*M+O\
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MB2.,0JQW[1AMK!MMRYMS=7 O;33XY)Y4\^"VN#)#!<<VY$MQF$F.="@" @L
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MK%#B,[L21D1Z7H-II5EHNGV>GW<MBCH\!N'?$I5(MLMT#'O65%5_+1AY8,:
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MZ EMW+8+'HV,;2@\J1+-HWLV4260LWCB9;2W5A "L(^S19@RUNQP6<;2I3J
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M%<N0K0_-H:%H\.D)86T,&LQ1:;;QVT=S=L)98?,: M;J%5@Z'RP7DY6/)",
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MCNDE#9W*26P#L'O[>RTZRNK=8(U;R;6TDMT)AA>00&.WAD6W(^S2$ &7'!(
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MRY'RNRDJ50 +"29KC3DM;W4O/?3&:*TO8R[6@D.Y7NQO!8J42)!GS#B7+/\
M.Z8<^OWERITK1[R>%8;0W,6IW^2-.199HI'NB6 ;"*1'&^Y]\9,P4J6!KFN/
MJDO]AZ+^[ON+I9=2#;--E=I/(>?<YRTCM%Y4#+NCX<I\BH+CP0Z'I<MO.]HB
M6EQ#*+C5KX.X;YD6]O&+CS S(!''ZQQ\IC]R 7-,TVS\,Z2NG64OV6.PBWF2
MZF#/#MCEC6ZNB)E\R%EC4*O&W:.%"_NK%]=?V;+=Z@;V>VCL[2Y>2"5O/%NK
M-(_VJ9!*6>,^2!&JX90SK@ D1E_J/]GRNTMU!96L/F2M+>WG-I([2K'+,/-
MDMY#D(F05(4 ?\\N7L9/[8;3]6U23=80Q"]T@WK^:]LTD4DGVV_17$84&)_*
MVE57>5 0@; "..&^\4$:EJ9DM+1K@QVOA_4Y/W<:2R.JSWT<AW2%I%_=1+@
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MCV!B<P:EJR06<$.FZE!:6D44%OIBQNKBWA8[8GFS.5FCF:)50@"3#D ABS*
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ML;2%]ZJ]T)+A7=78.$#$$%T!0&,XP_&>KS:.B0Q_9);VV3S-.MM2NBL5NL;
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M^URSW$+M+<)Y"JEPC[%B7[Q^[\N"5L0JD,%O,=-@CDDRA34$6#SY5=61YG6
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M50T[&V4"?#28MAWD(Q\P*\_::-J_BG5(Y]?ANWM)WMYDTF]A$ :UBR UU+'
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MC#9V8?Q!\2V^B:.VGNV+JZE:2W@>0RW%FZ--,MZRAG+VZO%&VT+\J @@X\L
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M5$2ON5A(%V@&7H7B8Z/JDJ7SZEK2&RL[JS@MA))=S-/^^D:U>:82R6X\M%9
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M8)9+J-C<#RK0.5WPAOGSP"H):2]UVQTZ];4]3U'39+.&RCNI98I]MPX9[?\
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M-+$YN23$LLL*G(R5MXWPQ.R2GJUCXFTW4X(;'Q7_ &C)/+]HB1]2O(X/[/\
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M&WS-S0-(M]&_L^#3=.GM[6*[G@66Y!:X9!YJE6)C8^3B&W\MBZ[D2,$_*JN
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MM]DEPCJ38Z%"D;AC*\10/&Z(6BC?:<G<Q7Y%6QJ>N7&CV;66C>0=3MXLQ07
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M>J:G\0K_ %/P_J.BP-:KEI[IDF1;S$\CP6SMY4<L<<>RX3S-O$D0SG)CDC\
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ME+1B66.XNP2DD=FDL<ICC=AEV_A7:JV-'AN=?=Y/%!C\MTM&^PW<CRP0.ZQ
MQW*L8T:XDRN(Q'MB95?;ND'F= -JZ7;V$UU'<2(D-G)%JCLX$3_9UEBN65FB
M>X8/\N<;C( H*EBP!)=068^UVK)!#]IE)DBNG#XDE\V)9;@></.ADPB)'UX5
M<#:!'A^(?$-]X=0V-N9)KR*W>YM6NI?-<2*TP>6[5)5"V\@VA'P(XR<L(PBJ
M+&K^)(=%$:V]Y))JD-N;>/37G$OV!9(XV$]_B1F*1LGS39X64_>SN.?H>C0Z
M--K,E\)+F^ND$-RETXN$D!F.+1I&E"R.8Y(5B:<+(1*#RNZ*, L:3I*Z+JEU
M?ZC=R/KCV[RO>7DK2FQB7S<M.XE2,V[.24C5(LA02FZ-FCT+K5+NQ1I?M$=G
M?3OLLM/O9$>6%I6=L2*;L)*9&B98@I79G:/E#X-0N[2PMQ-<ZC'8ADBL7-_J
MKQ+:QXB9X9")SFZ,;2.LB\\#+8P6X-'O/&.K6M_J-UY/AJTE%M!I=U*0]]-'
M(<6=U%)=X^T@J&4D$/D%_P"Y0!<TJU7Q]-;ZC*VI6W@IK?R+>+4[II$O7:;R
MV28&Z=F<,6\IPJD,5Y/EH'] :_A03V\5['"=+3:XGN1(UEB.7;/='S\R1.H5
M@K?-R&.#RE>W-C>HS&YCD@*+ITT=U=?:(H!NB5K6X3SV5[AB[+OP3R =W ?'
M\0>*X=%?3]+>*[:XO7BL+>/[:-\>]8C)!(5N"[7&W[LV-JF:/+@,S$ U+J\L
MX9[M;Z*QMK>2[-I)]JNQ*US'LEFE2X)1Q'&L;23(F_&TJ#Y88K6?IVF7&M:C
M8^(KZ"=(Y+OS+72[JU"X?))GN,VX*3)&BHA[>4JB5A*2:>GZ#>S:--+K:23S
MW%NL,T%S;RW+"VA5%;?N1TDN$DRR':R2["T:+YTC5T$6DPS'4X;5;0#47N(I
M19H/L\R^8JR22AHW07";G0@Y\TI\PP,1 $EI;RMIT.^WGFFEE\[_ $^!$DN;
MI ^%N?+A*(J&.+;,F<E$P2-OF8^O/>7LLND6=A8ZC?W$26R'4[4RQ3+&S,9;
MU1"OE*&CE$6UBKM(2JXY6/5+R[NK][2PBN[T7%DEOJ-Q+9HRQ6H0.SS)]G#&
MZ(E<); ,OSAF0!B#H:3X>6VL!!&));BZ17%Y<1,9[A%>-HY[AYHG(N(MQV(Q
MP2IPJCY8@"OI&E066E_9[)+N\GU!)8O-UFRE=]11<$B]D:%6C('F1)OR-K A
M9.%&P+%;EQ$89)6=WCG\Y&1-0B"QPS-<KY(3?QE !\XC&U@C.!&L%O-%+%>C
M=:7?V4RRW0-L\A*[8YB1$A%R9%C38&!39&PV-A3Q]Q!<?$**/RQG3U_=PW&
MXU-D5986NU\I6A7:[NBLC1EW#%67RUF +$"6?C-;&]N+O[=H E01W%WB(:SM
ME15^T%85"K%)+(L<!_UK\D  D])#8M&^G)%#=RVLUP)E^T(I$X"QLC71>$RI
M+&JGRR>284$DFY@*DNK:WU&UNYI['$=Q$9YE^Q%VC1HI8UF17@)DN&C"(T3
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M\RX,<7ELS8R\DF6D7"1R6EDYU&'5=7DL8Y+F7^R[3=J3#RX$+HL1D\PM]O\
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MW$JK"W_$QCV$!-NT<1IG$A'6&TF^VR)/;6DKRW!G")$5BF57AVRRL4;$\:J
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M2]"M:K+<VTZ2?+Y",P)=B.-FV3:VT?47NUNO#^EW$\J0:@;C4KZQ9DEDBCE
MG1(T=&6XWA?,$2[2LAD4;YD0[&D6;V&BL(CAC$DR7>FHWEW 2%(3<QB,/&<P
MF,I;F/&^,XW@!P 1Z-IBZ;I=G'-'&T=LBW"6+Q,C7"0[ EPD:J96,<3(GE2J
M[!XH1NW*)7DU'5-.T^#3KR^N9[_;+#< P3-*TRNZ017,.R,;FYC#QP[5VW#Y
M#[U#QW>KV.AHEU=>7?6UP@O/*MK?S3J$NZ'%Q#S(7/FR6T42,R; 2<LJIMIZ
M)8/JEYI6KZFG]K7$_DWZ16\+):JF&2&[+O&JR7(1QN'[OY<%8\Q1@@%?1_"A
MBGGU'Q;<P2W\6V[C96A TD[)B;PQL3'$TA&751(AECWY8#]WU$27$\JV,[^3
MJ</F2P;V!+!V"2741D67:R[I=D89@J2QJ^W> II9M_-M(M,G\YFW7SH\Q F#
M,(_M):$F)5D7S9!'M D<[L(RN1S]U+]O7_A'M&6>YU5]E[>S.V#;LTL9@NI]
M\:DW"A$D%N=B[$=,;5C! ([WQ.-2>/3=$2T@BNDDOI+J=(S:6=N%\];T%E!\
M_?/;R&-QD%<G:&$K:&B:##I::?HK:?:7%W;7'VN7[>XWW;;@'U#<8Y"9PX.%
M$GRK*F\J655DT[3K?2[.#2-'M_/9\7CK=J999"Y1EO;I9$1O.692=A="51RN
M60(MS5[R&VL(YKIY+?397,OFW,@7R5=XV6=S<Q[8Y8YG&R)F&%!(5B@C4 IW
MT5OI>DR7\UK]KA7&HBYO[8RM"4C!:\D0QH1,I=08MZD1Q8C"E?+KG]*T^\\7
MZQIVK7X@EM)8EN[?39)##,L;*L::C/+ NW[2R*1&F%"@?(RM&V+&E1WGC'4=
M.UB^TW=IYNUN;2!(#;QSR0E0NIM)]]=T?R) ^XL IR5!=>DA,R///+9R3VC)
M%<;;FR)>[\I8&^U'RXLI.,E1$R[F,*; @#4 26\:'48(VD\^2\BCN8[6ZB6/
M[2(C!NNY1Y 9+A=R )D#Y4X4YV8]]>?9[."UL+&^O-4N8I3%9"+R1*R$3)=X
ME@$4<P>6-F)"J'D8'S'C1*KZOXB32OLU@UO]MUK4Y8;FULE"^9-%!B0W=PIM
MPT<A2/!0(S9C58@&!*QZ5H1L;>X>\MI-1U2Z=-1GU&XMI&D"H&"W,8:U(2X4
M-A+7G8% '5BP!8\,^&(;.],FHW,>L:Q<O'J)>_MA";C#C%QM>(O'+"K&,1*V
MU!LR(S+QN6UK<7L444T7E_:MTIF\L;Y JQ^5=2A[8*MRK+'B,@ ?,?F\L*H%
MV2SZC>F 6LV+ORIK?R(/+1HF%Q,7B+1W$:;5"L^#Y0.$P?+X]K.7Q/K$FCZ1
M9SV^G1RI/<ZC+:I!Y\FU=]U"XM3LO5<LCABI780 K9:( S_%U^_C/1=4?3%^
MSZ0L3ZC<ZC:HVR:!870F*1K==UP5*K)&9!\L8B#C,NS/\%VL5MX-U KHD]M<
M7NGV,EQ_9D+W+>7''\DD>Q2JWK,RR!25"++%(<E'W=I/X9L;SPK+I3:#:)IX
M0R21QVOELT4B;1=A!:#%XJHW[I%&-V">5%<GX<O-8T/X>>&M2OM8T/3+&'=<
MP0SV+QHT*Q1X57:/*W#D3 D!BZW$KIOV@4 =!8:1HGA_0_#R:OI>E16]G%;2
M>8T$5K,MPOD%[WS))481[_*1U*"0M@$$$ \9I$%C)XLO;R6RD\.V%_IEE=6$
MMK^YMUEVL\=W+;)(T9"O$[!"_P JJ69"!)(FW96/Q"O+S2HM2CL9=/:[6\M[
M1&6RF)Q$_P!KN(!@NL<C;WB5U)F<\E=E6+K6/%>G^')]2N;'0[^Z@BGU=(HM
M0N6)VOA;JWD9B##L)W0(RX1QDCSO+H P_!L\^D7NG7XTN[^TKX2@N 7U.*40
M*'F5966:6,F KM<QJZHA*Y7=M9=S5/&NHPQ&SL_#M\UYJ&GRZG&LFN*8H&*[
M7E:=+@XMMKDK_JE#(-OS,#'A_9[;Q%KUM?7\>FW>KZE9*J6YN$O(K,O(BI>M
M]I8-&C"[W1VFTALIG##Y>HT3X=^&;31K.#3]%T;4YT2*0S7"+-(2ZR1"[(\U
MA) ^%=8MR@ .02X"@ R['4M9TAK[2['3/L=\VE2:U=7<]RD!DO7BF5KLJ\H_
M<ET0>4\2A2^YQ'M4-L0>*;J2\OK>UT;^SE:(:G$1J\"!(Y1<JUYD.\30_+"S
M*%8*\C/MD."P_A;P/;Q*UAHGAS B%W&ET8I'B@"O#]L;,F)K<CRWVDK_ !N2
M9"!6/H_A7PMXIUBT_L;P]I4>B6\L-TC>4)99T"E(Y)&W_P"I?RIT,1^<2QH\
MBD.Z@ CM]9U/Q8X^R64>G^'XTAU62^CNXT9)W67%V\1E:,0)-"SO!OW;T#MN
M)=3L3>)=3CT:ZCTW3+33;AK)M2M ^K1[8YYUN9#(TFXQS(2D[A>5&V-C@,WD
M6(?!/@F>WAFN=)T9[/[.\UUY44,:QJXE(NQ(LA98''F;5+/M_=%=AC8UE^(-
M'\$>%K.275-$L9+I8C(MA8V5K]IC8&?S;M8Y)&+PD,&6-MZQB-25&T[0"37O
MB)/H+SS^1&0;(7]C;S:M$0"ZW+"4DR SHQ:)/*1F"&-MHP(FDR_+U[1(M8OM
M0L(%URQT^?4;!)-1A=K$NLSRW"HHRVXRNL@*;#*D>W]V1Y&II/P_T#2WNGU7
M0--?6KA'O&@33VF@MF5959XHC(3+!DI^Z3YPTB%E3=&L6Q%X>T$6\[Z;I&FV
MS6R37.G3V,"7GV;S@TBWJINRX8Q1*BA-RM&RJ63! !7O?%M]ITVH7KQ1IIML
MD5U#,VH^;%#%--.BW3'<IF1UW,( 3C9"J<N3%S^H^+?%%]>^(+2'1[2"#14^
MU27T6K)>G39$>X:25!\KL[J&186*A0 K (Y6I-:\'>&]8^V:)I&GZ5IB:?$$
MN]0^R1O'9Q_Z0HF$K[&E;;$T<@8L$=E8,'A8G<O_  EX5L;"[DF\+:-;"%Y;
MBY62**;[#"CW$D=T50"5TD,:#R@V-OR  *P(!ARZ[JGA]+VSMO#FAVD?AN+=
M9Z?_ &ON^S2"WNG^T?+&#+YL>_\ =LP?Y=[!0V\:&H>+O$&EOJ=TNF:':VEC
M$9V1=7;R;64W$\+32;(E\[S&+MY62V83P)64'4U33O#.C/>JUCHVEW5O;F>W
M>"R60:>VVX=+I5;:K.5MP2L:%\Q ,6559>?L/!NFZQ?ZA>2^']-TB2=(Y+33
M6TQ9)+%)DDAAN94",'<LF3!E8XP"[_.-U &/=ZGK5U<7%[<:9IMA]AMWO[73
M9]2).DW,QDE-S/&T3>=/M\Z=8QS''&WR!BN>DU;Q%XBMK[6[*VTWPY;W-E%O
M@C&J1C[%<20W,QN@7@4%G&\%6(/R,S (Y>MBZ\/>'[R*263P]!;V-Q*]_=W%
MY:K$]N66Z/VJ5I=R2\M\L3C,7F LHX5<O7;'1H)DTJ'PUIL5WO,B:<NE03I"
MGG,!<@[1N,D,#%H$W2N$4)L*,] '+^)Y;Z:XUDW'A[6=+35=,W+#97&(9)<W
M0\V1V>,QVX\Y9)5:-<.P,@7/[VQ-I^JWWAK6H=4T769-4?3 ]U>7>H6R.MP!
M=HQ;?./)M0SML,:H&4.#N0D-N:=\./#^G:=J,>I65BMU)%-]J=V5(X$(=?M$
MJ)*@^SR&W25(A_JG+;6&,IE^(])\/"]T"^@M[2.RN[AK:)M0NKB4SPH]U-+-
M,N]A-;^;Y$X8G# _.R(00 7-&@O%USQ[:W5WYLUM=BXE%_,5MB9+*0;KE"[)
M]D)QM529 %0/P@P:C?7FJZU<:1IT?D:&+N>XO]8O,B2UNHYIB7D"R+NM]D'E
MQR<;"J;7$D( P[>T\2P^(+W1O#NK6ECIMG>M=:_/,EQ;-;-B57DD,L[/(DT8
M#ADD_A1OW1^<[FFZCJGA?3I!#H.E1P1VCWEG<6=YN1(%$Q:XG90@N(3)*)!%
M"G[M9<[%;RU8 ["/3;/1-)N--TJ7^Q8+6)GB'G C3_W<R"ZE5IMK0ML#!2.7
MW.PW%BE?Q!KO]@V>H:E-//91Z=YABANI?,022F01W,WER/(UNS_(B  K\QV8
M53'CIXY\-3>#;VX\^>.UL?.MI=/U9V:YAG\N<E+A99P9U<#:L63R.HVGRZ]G
M97O_  E#>)O$<GV75X(I'T[1GU*.X31X'#++=S;I(]\9;=D*?E4A1]U1& 2:
M+I^I.+CQ+K)C&KVZ3WFF0ZE<LO\ 9BS1RYFN5,F8XG*!1$N[RU0#);S'KK&A
MM]/P+>3[!'I\4IBADN"([)&\[]].@G"O;GRP(TP-@&!M /E\OJ7C&WL-6OK+
M3KB?5-6LHKN>VM_MI(MY#).9&NV$BP"W7$017;>@(& 2*QYO$'C>^UBPM8/[
M*TS[/%(^HW;7=U+_ &=YJR/Y\T;LJJK(C-'%*&\OY VS<HH Q]9&J6_B#Q7:
M^&K*<:CI.H0WPFO)L/$@M-@FENY)B'C ,A6%R/\ 6 G*K)'6Y=?VQ;W6E-X?
MT"33H=$>2[NYM7F@C**(IH6D>*.X"N&5=L9(C1!%A6$3?)R'BSP.VG^#)[W7
M+>T^V6UO))*RQ*MU$[2N(Y[B5;B1G>=L<;)%!!4&(;I!W=QX/\.QP3W3^#;'
M3KJ.*2\:)EM9?L81YV1K@/,$,<JD@*HPNTCS%\M&C *^D>)M9T;1X[5_#4]C
M)'YE[%!>:LC20"9I9/-F:22+SE*FY/E,0ZFVRY!8.E-M<UKQ!;S^()=+NXM'
MMG_M'3K>742OD1*)9%NKR+?ODB:58V1$SM6!@G  E+'P)X9O=9EU*ST?3=-T
M?3K=TM'N&6X\U-SO]MN%DDP;<^7)&AY9E8L&0*C)T$GA/P7I3ZS>0Z#:63VJ
M323F2W9C:JRN[3,HE'F6[K$JB.,=#*AQNE50"/6/&6I6D6MC^S)]-M]-B><W
M,VJ6\DUG+(I*M)&)VW[O,<1PL-NY(P" ^8<O4_B%XATJXN(WT&."_B176RNO
M$%NT=G,QG+2S.) QB(EMPJ.%0$JJE3LW7-?\/^"M!NE,?A;2C?2RKLMI;=9/
ML<9EF5[V=1(1]F <MT4#"*2N%\J/1OAWX>T.W$-]HNFF=+=KFX>Z2&:#3Y0)
M@9I"\HD>W<8"(<X$.YMK[F !'IUUK.G->W.HZ;!/JUG%;74MU=ZDDS6-V\4D
M+&98V)2WS(90GW$CDF<,I C&@/$FL:7=:E&- ^QZ?:[]0C9I7WVF^67SYKA!
M)^]C&Z1P@V[F4K$)%7SECO?!W@C1K"]N]1\/Z-IZ6B'_ %P$_P!F1798IY1Y
M@,B2_9X0(U&XLTBDMYDAK+UWP?X3\3WFKZ18Z18Z/;6O[^\U*.V2,VCJ)XPR
MN) C0DP?,H^Z001O9V@ *>I_$N34;?5$T/P[=O>65E]INKA&@O84F DF4O<[
MG7RH27DC4<LX"@1A2K=1(\.C:)>6UIX7U)T5)',VIL"'WO,TJW#,RI)%&)9R
M/,D*N4.67?#)*3> = MS=2SZ+'IMO>.UJFGI>LEK>/YER(_/"(0@;S(V1B24
M;RT0*5 >/5/A_HGV66[FFOI"O#W>HWMS']I\J*:.5;IE5=L93S,3L3_K-HS&
M%C< )?%A$5RMSX;\1FWBBEE:/4I8=DHN%EE\JYCW-Y5OPJ+*PPFUD8J%D#<_
MXAUF_P!7GNM7U#PC?2Z=86DMU;6NH6=JTDL@2X*/>QEP\=O&/.6,8RQR=Q8@
M&YIW@[1?$MQ>7B+=W&FZB@ECM[K4;W[1J.#-Y+71R1%;@1_NF*EB$0ELDHVX
M/A[H)B-A%87RPS^=:)++)-)#,D:N(DNHR4)6,N_E/V6"+$H+(" 1ZCXVU.S.
MH"#PMK,?V6W>ZM?M4T?[J<R31L]S_I'%ON92N?EVI(R_+&&6G?\ C_4=&OWL
MV\->(RP\R]M&O57&X3RB<32+-L6W57C5&;*H"KD, A-/Q5X>T?[!-;V^F:E>
MZI>W!M8[6ZU*<27SJ]T8OM2J<M OE$Q2DY(1 S(BLU7$^&NA:;9ZH+JTGE8>
M;)'->2&)+6%2WE++,S.DMNJVT&U'64IPS( ^U0#/M+O4M/BURZOO"M]/J=[:
M>9<F[FMQ"LX6Z#+<+YZ_Z$/G$;2 Y48W';%C8NO'U['/=P6WAO58)HK0WME%
MJ%Q'&Z2LDKO)<*UP"+8!T )^56#)PRJHT(_!FB#5KB%++R9C$R0">ZN;F8M)
M),SFY"RD/;2&)75'8*S&0'#.0>+UGP=H?B&]N;'3-/CL],TJW62:>ZO955G@
M>^A1;C,AS &AQY@_>(F%&%.8P#C-0U"+6+K1H%,&AV.GZW>K:&^C>U^Q2&5I
MDA(C8$*2T:NZMF+"<1X#3=W;Z?X4\27_ (AMK/3=-O;'1=,AM+&XN[XSP6HV
M7AWR2[\B+YEX1G*CRS\C(1'';Z/!I&BC2)/MVGKX?EN+F&\_LN*>:-4GNOL]
MS*S$AH0C3N%\M6W1L58%XA)F7^L:CX7M;@_VCXNL3IUO;*\XTBSQ!(TMRA62
M/Y0]N0&\H*[QH7 !R%% &_X\T;0?"VCG5M.\-Z;:/IE[;WN^&%#=6K?:SB5E
M60>9!(H<*FY=I"C Y\K#\,/H^I>)K[6[C6+%)[>*WEB^W7*3P6LD<L\)GG!N
M-TS?(NQC*YC^UQJ"RJK4R6+49+J>_P!=U/Q!I]G';O>/%>VEFYM)IXEC>6Y#
M;5GB*R&.-=GF$+)&JH8B"_X;^#?#_B?Q]XUFUNQGU":PU".2/[?M1UE9Y3()
M$B8QO\RX/53CH <4 >B/XGT&Y?[4NM:,+2UN";.YFU))C:W3K= R2_O@&B9"
M-D8;=AB,(%^3'U'Q]IL>I:<+'6--\]KBYV!M862"",RLC33-]I57!62*1(MK
M%0CHNW[R=)'\*_ T6S;X9L3LVXW*6SM\O&<GG_5+G/7+YSO?<)\*_ R1-&/#
M-B5:(PDE23M*HI().0V$7##Y@2Q!RS$@&'HOB+0=*LH;,>*M&=T0 7TVJ(\L
MMT$E1[BY'G_O(F58=B;BPR 0NP%+DOBCPQ<17,,GBG2I;>YEE$4%YJ$,J0%E
ME5FE G'FV[Y!6(Y*[Q]T "+4G^&/@BY$H?PQIH\QR[>7"$P3'Y?&W&T;><#
M#?,/F^:I(OAQX*AE61?"^E%E\S >V5A\[!FR",'!'']T<+@'% ')W,EIX]BD
MAM;2.32Q<3">>*Y>Y^WLD\T:6TCK&YCBS-'.&)_=JX,8^0NG406-C;I-IEE#
M',"CQBWG3!F0M<[;>8&$F*U4[A&W0@87(XDQ[_X(> [Y]XTJ2V/V<P#[/<.H
M!VJJR8)(WJ%ZGABS%@Q.:!\#OA\+AY3HLA1D51$;R;:I!.6'SYR<@')(^48
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MX'"6K!8Y#*'^5@%8#:4 !);V/GP6=C<Z= EHT3VN]8=S1?/F2U"&W"BV*1;
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MJDLD/V:7,$BQR?(XA:22+(D4EEWQ[))BT+)V!N;A[P7+S3Z?F6%7%R@$2#"
M6[ R%7D9IVQ)#QN558MLVO3@:2Q$26D\B2*X6.Q7R!Y:I'Y@L3&) @EV2.59
M-ORQH79E7]YAZCK=GHVHZ<NC7$%]<-+#!:F)!Y$-K*4"6^4!55+2Q'>@7:@@
M+^81&DX!)K^O364MAI6G17<>N3(;6R:2W,DEIYD"[5FD82^8/,'FLZD*1;2?
M,[1%7N:79+I,MY>SO/<7AV#[7+/;M=6^6C,>FL7)QN4Q '>V]G=RR,RLV?H&
MB6>AZ=>C[/!<3211VM\6<&,R*(H38^5(8\J4"+ TA<D2,Q.'_>])<SPV5A<W
MB2QM'IZ".VORP?:H=5DAEF/FN!OA_>R%1M4@GYD9@ %B5*0F"22WCM76UEM[
M0L5LW#0#R%B\H!HB%)\QU!5'W*51\KQ[6J^,9HXK!)+?PVUO':W5WIVXQ3%)
MHHVL8PB(SVX E/G $#S'PRH'1A=6F\2S76F;KNR\/VSII6HW<SF1IYC,D8LB
MAD=@=D[(]PIRSX8-M4!NDMT32Y],LX'@M19>39J%9;KRBR1@V48"B4KL3SF=
MBI&(W.Y RJ 2:;J$T3VT%S!::6\:1Q1PPR%[>R4K:[K67:RIYY:0K%@?=P0.
M2K9[^(8-(LKC6KHW=O!:V2NJS2RR&"!$MW-O<H\H47CF5@A.6(QDG!!-5U5M
M#LKNXNKF/3(-,LI$5-,VR6]L@2U)B8/M7[02S"#( VL"5.2IK_V=?7M[;:SK
M,,BV>FNHTG39WWB.1'2,&9I70R74A+)&V6C4_,'<L&8 DT>WN+W4X]9U.6"#
MRI8&M5E(1X)6CCC)O%5HP;N:.8(%V%8\*%SG#[%G+<)+;/-=?9?LG^B[9;D2
MH@D:W9(KA3(6-SM.Q6#N#N+_ /+0)1&WF2O!=B!(+.[2WMVN;CSPBJUN46<&
M7FXD;YHF.64,A.&8JW-ZMKZV%[:^&].CCGU=D26WBU2Z:Y2S+/$P2Y_?N6E$
MIC*NQ4 .!$78!) "YJFO7$=Y#H&F64]UJ<D44*Q2ZB(Q:1.(S)'<2+.S_:/+
M21UD56;&2F_;(2:+H?\ 8]FDC7GVC5Y);-+^_N[CRGW VH\FX\N4[YBO^K'*
M_-ABWF,TLF@Z3I6G1)&+N.XG+Q-+/J$L<KQ'ST"Q3A)0K3F99@CJN!()#\SL
MYEV(79+BUE%]);I;HML8KB99%@+FVQ#<?O27N#DA'!('F'.[(W@$<&I;+,7$
M/GAK7%N(;B3YX6S"/LTN^<"2XD/^KD)*_.#DALR<G)?2^)R=-GFDC\/VEP-/
MO9V>8,SO(D1TZ51,7>7+1DW*L5/(Y5GW5Y);[QBZ1VLL=MIMBDEA<SWR[&F2
M9;8C39':>1Q*VX))-MW!U 49W!NTT]OL/V>U@$%C8V<4%K )+C=]DSY(-K.@
ME(:8@KY;@M]_&.GF@!93;+QI2\]HT'DV8-Y=^:D*D0,(I5%PP:X<RLJR$;NF
M=PVF3'UG5TT?0[J*[>>7;%]F@2\1;PEYO+(L)84G#7%P5^ZQ'W&!+M\[/8N/
M%=GID495YVGMOW'V1Y0T]O\ *K"WEC>X#37$OE2")U#9SD;E)9X]+TEC</>Z
MW=QS7#6\>FM!=2K-;V43&$-;NAE):>?<K$L9,$JNYP%,@ :7I\RZI9:IJIM&
MOK=!"DEQ<F4:1O\ LX%G@R'S)Y%=_P!_G<Q*Y!5E6K%NUHAL7BGN[2>*X^QQ
MSW>^:2TW20226L[22.2\I3"2?=PR!"=R>9J6]QY7D?Z1Y'D^7!_I,_F?9MWD
M?Z//^^/F7#[OE?G&[OG]YR\^LWFJ?9='T^[@MYEBCM=3D342[Z4LNR/R6D\S
M]Y<ETE"2X9E954IB0O0!S_Q U7^T_#E_;Z9!.RZ;Y%A>W4EUY)MX)GA66S-R
MTCJ]P72/>Y#(J%@QSG=L:OIFG:;XO\.64DUCLDN[FU$FJJS;X9(P[VZ1L=LL
MDC2G-P,'Y0CM(Y*O'KVAVVE>$[]='LY//^SQZ9:V(9"EFDS6P:RE43 ;YF?<
MTP.X!R=_RINS_$VJ>&Y=/DO=6TSQ L>G.D;3S032-:13VD!DMY"TQR\L>8BP
MQL=P6VL1(X %8;S5/$NO^(3K.FP:=>Q6JO#J 38R;28@SA65))+I]DVY?W3E
M<PID/AZ%I=[9^+_"MW<ZM.UA+=B)+?4[R.8VYDC:=TF4;&>9[M)D5F"E9+49
M#$*!)IFL6EQ?W5W-H&I0:7:7LLZVQTUW>X9T6T9;E&NF,DLA+P@[/FD#.3Q.
MM=)<^)M+ET.SN-0TG7+ZWTCRKF*YGM_/>%8L.LLGES_O&D^SN4N5'E?O,%B/
M,! +'@: 6]SJ*7.GSPJ-0AMY-.,4TD-J(K:T$6,J^Z2-RBB3<@==TN2J+MI^
M']4MM!?68;K3[L"?72(+*[V$23[;+RT:1DRUQEBR')5BKNTC >=5<^)?"7@9
M)/M5O=V42.3#I%V9Y7,D;0J0Y/FQF6-;>)X2)%&V5.$!$C2?"^SN+6\UK7=4
M,\FIS:A]F:6\06$40E%JQ!@P-MQ)O3.%8.T0&_Y@S@&YX;TZYTR_;4-2N;0:
MM-<+$S33O)]AMW2V/V:1E^22XW>5&'=M\B['RP7RZV+832VNEW=_;2);A$6"
M*^N"B*KRV[1?:%D+/]J0C:O+996)9#( MC3+>YAN+>2-I&0HS6T9C>W66*0P
M-++<J(PJW&_S6"X7.]A@?,5Y=]1N=5EM+#PX(X(K]TM[NZDN7CN+1&@Q-')E
MSOOD6!=K?.R $.$ W2 $;W.J:MY.B>'X9[.U-I)=3WMA/YK10/L<0+*7,3WL
MN1(9'/R+*65GR7;H-(TZ+P[9V":7I]CI]AYN$;Y[9)(9#$BB5&.X7)RH!97+
M>4P)C,N%+'38-'@L+%X_L\,^RX=KRUB97F#VPS<R!OGNV?.QU(!8DX<H"22[
MM?#L4NMW4_V2PCB\R,S&>,26Y6U5I+DNA9KE=I5%;YV!V]=Q4 ISZKIFFZ)#
M<M%';6=NB7<BWZ2;+)-]M+(ER-[%KPES(A(W%CZDE\O3H);_ %C2KCQ!=^7:
M6/V:/28=1F1]EP50_P"E*75VOVC8D+M*1[MP+L:++3[C6Y6U'4+:"SM/-AAM
MK"\F&^U):!1-<R;O-%^\17RB#F/Y06W-STDUPI-G:E8R\;P*%OY&>.T DM28
MIV\QP]T=X:)CDDXP>K. %@\]O<6D3WUVB65O%;-+>S1.H>0V_P"YN-LN7NCC
M*N %'G<;L_-CQ^*;33[^TT>PCCL[FYLG-D+Z5U6WNID22.WO$#LQG=A(Y=]K
M'D*78N33USQ'<1RV%EI:07FH22_9+&WN;@3VUH4:S+F_;S"?M$<A(0JS'+J!
MN9AG4T#1U\.I)/;S1R:E/<0QWEY?W+%U5FMU$%R?.??<>6WR%0$!;Y0@?#@&
M?X:TZ[MIG.N7LDUQJ"2)J*:JJ7 @9IHL6CR1RB+#1R@1)LZR.X"AS$=BTU$6
MZ69@U*[NGLK=K4K))'*!(K6RM;W+B4(UXS$JAW* 7;@X^8FU>R6PFN)O+:ST
MQ$S)=744D=O(CQ$VTQ:YPUT&0%9&P%++\Q.=_)V8O/'EX4U";R/"MG*MJ([Q
MCB?<!&UK<1F?S%N5=P [[\NB.@3/[T -%O+?QKJ-G=0W4]OH$>72X&8X[J4F
MWB6&Z/GM(;F,;!'(Q#,Y5T&(QYG86\+Z?$BV,D%O#:16UO:6D]PRI9NJJJVU
MP5G8-)()\*P0X^0GS"L>2/4[>WV7EM//-(NVP6/[49UMW7RR;6?-P8_M+DNJ
MRL1\Q568DJ),N^UF;1;B)FFN_P"T$1(+2%YB8)&)39I\^9Y!]J82*WG8''SY
M9%=2 7+SQ59Z9!9_9[V"6[\U+.WM)+T/(K![=9;:0><WFW/S'#GY5)^=E4EG
MIZ-8-IFJ7FNWD$CZTUO# 9'NUF2T0^3C3LO<9:=C@B0A0S2AOXMIS_#]A"NJ
M6VJ:Q>:;)K$SV]G/<W$PG@MV3RS_ &<@:Z9OM DC\SS"&^8D\DXKI+>%[>Z@
MOS) ;^'R[%7NKAMME \L!-M*#/)ON65AB0??8)DX*[@ $=O%%"^I:1!#-!*E
MQ!:3L;EYB%&V4R>4S27:10R?)&SGCEB&5AEZ@VH:AK(T?1GNWD>XB%_>/;0B
M*'R6B+7$I>WP;I@@6-!N79Y<@"KM-&H7EW?$:)X;M(TOW2*::2?9=+;*)(HO
M/G8@B2ZB:&0*GFMGR&8LQ55K0T_2(;32[55T2.Z>%S>V\4B O=LOE 74SR0I
MY=YMSA6*Y);+<%D *?A_0;6"SMDTVU\Z.:6;?+)?3[Y%SLDNI)#"&BO?WDB%
M 4;EE+8C 38TN1-0EM MM]HAEW37$\D:[)WC8*LDF(@5N4,4(,;"/;N8#<8L
M+GZUJ6CZ):V&I:U% ]N95FB>\A2.2XF$4:QS/OA58[D, @4M& F]B0(R$S['
M1Y]3WZQXALYYX9HO-339[:6/SX5\L&6\AC\R*2Y"_<0*"=HX! $(!GVT_P#P
MF\L5M9VD[:+;;MD=U#B#5I&:.<272(@$.\QNZG:2?,#.H618YNH6UE>".-;*
M^F9[1W2:14:1XT=GM_GFB!^T1'R]J3;0#*Y+2,C-4DMFQM9X[6>[U$HCQVZ_
M:%G#"&52&+21F-;B)RZH&.7* R,Q4M'A^(O$+Z/]GM;.U^T:O?RM/H^GPV#0
MM()-^^57DB*P7"^<QD,A<;4)*IYI  #Q1XD?29Y8[;3OM]]J<L-_I^F);-!)
M<10(DCN6>!@;@&/!0D,$2/;M?&Z/2M";PUINM3WSW;:QK%ONO9K-5M[B<B*>
M0-!&BF/[4#N4HCL"$$A.6(:/P[X1_LWR[V_DL7\1ZYY;3W;6GE>;M_>L\:M$
M%AN%9@^QE/F?90Q56+LG6+'-(EU.UK'.]TZ7L$ L"!*L3(REQ($\NXV[(QYD
MG!B1P%PR  CN7LYO+BC@@?;+=!;>TF$?F2-Y^6AE*K_I/[N4,JNA3S)"S'"D
M\WJMQJOBR]N+2RDN[?2D3?>ZG%;R8$2/OCC@A=2PO$8.C,F=A7)'F!(XH_ML
MOBG4Y-$T^\\BU:6)-0U!XT4S3+'+\JYCC87H1+:4X!$1BQ@>7MDW-.M+%+*+
M2]-TZ2.SLK=FAL[=,&,;)!M20F.2WNF2>)F\T@X<[23O< $@>RT?1]2$*016
M%MOC\C2ED198BTJK# %94CN?.8H=A+,RKG:70)'KVN+INDO=ZA-(Z75Q+:-)
MI5TQ9@DSB*WA3))N'SL;8%(VR'>OEI1J>K0V%K(]YJ%VSM;O:AH9A(E^T<K*
M8X]ACV7A56 5-GS2$#S/*^3/T33KF[O_ /A(O$MC(MQ<HFIK8_8GE@M$1,*J
MJ.3>+^Z+2.FXCY(QA6V@!96.KZT]WJ&L37?VZ>WF\BVTZ0/%8*JR1-#!+O"+
M>*S#=*X[LB?*'*[$T"R"U>:RC"2/=2VBV^ZVDE$L9?8J/)&8KIMS_/R0$E),
M?F$"2-O+_L\D0>=#+'%--?7'F?8>T<14ROFY=+@1[PWS;BQ)&R-N;U/4FCNM
M,T?PY:QMJ6R>6+>58V :*56)9I3'->&:.;J22%F#,H+R$ CUSQ!<:A>?8+>2
M W<TH1KDL(A: B2,VD$GG/&NI@2-@C:"#S\H%7-%TNQ\-64T,EU(DDKF&5'O
M?+GNI9D9_(8_:=IOB=C&;Y<JRA,+RMSPOING:(L@LI9[=OW/F7-[,TB322R[
M)4E*S&.6[\V-U9P,KOC4;@,&X]XT=O:0+J$>CW$SI92-=7:W31$#,<(WR8%T
MZ2!\[9 =IW>8 A( 6]O,HO;BXT^2RD+M>':3<S6^Z.4"9&\E@]QC$9B#2*J*
MH4E2%?A_/U/Q>]R+."1O"6GV[7#7-K%'++J;LKR>;;*;=5\]COCFC;*GS70K
MDDF.W1_BK/9VUE9WVE>%7B>9[F0,+JZ(3[/Y@N 75I/E>%HY3DQDM\^X>7W%
MQIR26<<CK/+#'%]JM4>Q4E7!5WO"GV8E+O,DA$>/F(^Z"6V@$GV"TTI+FVM;
M*2WN$1KM3!;/,(_F>-KE9C QDNFB;)1M[,0!R"SM3N8=.T_28A<I/:KJ7F.;
MF"T9)HI&CD3[4"EN"EW*)(UVL%)8[4!(P^A<QII^F2P7LGE6\>U[B<Q*4@)D
MD9;L$0;#,9 DD@(V1XWG &7Y.#35UZ]O-3UFUDL[:73(RR7L+0B15=EDN;TM
M;+"T\:!2D3;T4J2N%(< $EO!/J]Y)?2Z']AM?-_M2VM5LY8G@;#(]U(IM&$E
MZIR5CW,K9! .U9&Z"2RU&UW_ "X^Q[F'EJK;5?S-UZFVT.Z[.9,Q+E?GY^^,
MV(M,2\L["WE@W>9NN8GEM5!MG4N1=J&MPJW+-*C,C!<$O@':V[#GOF;69=,T
M_29+2*Z0ZE>M'IJR"! V^*[ *AS<.4V>6Z,PDCW;2(_WH!3\0:G+>ZC_ &?H
MMCYLUO:3ZC-'%8I<+I<F6E@G\F2-'-W*"V(RZE68DJPR3N1Z3;:#;B%)I(;B
M-"4'E([32D.&NUD^SEIKPPI(S(-V>A&&W&33/#?]C6:Z=IL&9UE\V2XN)=SH
MSF56O%F:!O,N64_,C?*.%X4C?'J%U::5HTVIS6NFZ+ ;B34#="W<,(V41F<E
MH0(KHB481E<M@ISDE0"Q=BQTJXN-]M'8/([W3RV]KE878R1+/$_D$274F^-3
M&22<X ;^/G]+TZ'Q(%\27&FR:?:[WU.SM+:,'8LD9V7K(L3+/>$ID)EMBNO&
M[[U>VTJ;4;BVU*[TF[LC$AOHK.2W*LC$L&U"016[127Q&PK 0=O)ZG"]H^G/
M<WETD]O 9A*9 T*M '20",3>:$++<)$LD8V/R,$[ ZA "GJ>EVUJDCR6&FP"
M>X>Y18U1G2Y5F87$*>0S27!AWN00QS$J@$%GJG>:H]IJ.H:9806-SKMK*+JP
ML);=K>&4.7=F21DP+B1&G3(=@3&S84>8HS]8U+[+*FE:=%.]Y<6B3AI8>%5F
M\Q;MK=H0#=K(+B40H SB)R?F5%%C1O#G]BZ9?9T_9=7,4=S>RM'YDP9)#Y4V
M1#()KD(I=P"R^<@(7]Z7(!3\.Z7+;/J-_J?EZQ?WJ;[NYN?#\UN]S9!1&Z$>
M7E9<J,0C<'6)"$4R-)747%D6=7O_ +7</:V[+<,KR$^7ME5)XO+B'^D%=P*P
M["!*1\V(\R7D3V-X)8K6#R8)6NDA6V:0!,'SI4*1Y2X8SO\ +E_,"D#!=V7C
MXC<>-7;0;!8)/#@P-6EN;4?O'6XE,B;=D317+[49\H=OF;E*%5,H!'<Z4WC
M21Q2R+X9LTFCO+NS=9?[3+QS$S6WE)Q*&D'F;$ D:66,[Q'ANLBMO,@N;G;!
M%]GEN)/M.GQ?:%7Y[E?W,>6VW*[\R-Y;;F9EPW\)(X$ME=Q:1Y7V?S;Y1]GF
M*-%(S>8555#)<[6#[6CW'?)&I.Z1EK^)-0M_#]K'<ZG<SF=<16DR0FYN+AQ$
M47R4VB*.Y9YFP IW(#D;0?+ +D]^8)KG4)]3CN;>V>,)%"DD42-YTT3 ,F[S
MI=K!/)Y_>1K\J%UQQ^B:5?:X^GZY+;2/'</]LT>SN?F@MR5&Z_N@F$,[YWK%
M'M 9V(PS22)L66DW>K^)9-4\0V\CRV-Q'-8Z.ETDB1;SA+MT+D*ZH"FT$J&A
MF=-Q<&M 0?:Q;M87L8N+ZWE>WN9(+6602K&8TU %2 X*,BG .1)$,1C>" 6+
M7<B:*]K:ZD5WR221.BVYD#-M:XE55"ER7\SRV*$AW;87C"CC_&&HK9^%==T3
M2II&U"XT>>_>"X1E#VSHHEN94*)Y4I995$<?'F2;V3YF*2:MKEG<SZ/IVBQ^
M7J>MW;W5@L4XVQ1NF\:BJLH9<*&W0GRQ(SSJ1)DL;DFDV]MX(U6VA6.>.Y2[
MO3<W*6T]O>[W247;OY:Q%U# HC[%)4C)11* #@_@_I=OI7Q06.ULI[:.?PI;
MW):5RRS/(+=GD3(X4L6&,GYE;! ^53]H/_EZ_P"X9_[D:D^$HF_X6HC3VUI"
MY\)6N#;W!E,BA+8*SY/R.5 ^7"X 'WL[VC_:#_Y>O^X9_P"Y&@#P"BBB@#[?
M\/?\ASQ9_P!A6/\ ](K6O&/A,OV+P5I4UY%/%#=:W=I"QD\K[1NL]BQPL67;
M,SJ0D@*XV2+O4MM?V?P]_P ASQ9_V%8__2*UKQ#X8WEOX?T?2;B[$]Q;PZW>
MS6L]DYD2[D^R&,0B,E=LC;25$@5SN0(I$CE #U_7]=BTO[6MW/N\W_12]M*^
M^23YY4M8HEDRMPT.[Y]R$LT) ;(5:>GVMW(]EJ]W=2&^@1([2Q6X2>+<BS"6
MV&^8^9=*HD5I\I]U?X1*K5].T>[O=4BO-4OH_P!Z[6^G'STD:SC3S(Y+4/N\
MT7#1[F>6.0G?$03MB DZ L+E)$OYXW21S#*EYY92W69H2;2=$DV/*P?:C8.
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M!3'S&U!VHVXI'X1\-S:3,SW]G'>ZQJ+F;4;I8##:W$D,T>)&4QC9*C/(8]@
ME"&0G+ KN"P>Y:$JGF_:=DOF3PM#*Z"(123F1(T:"Y*R[<=UBVJ$RQ0 KP72
M3K8R+Y#0R2H]Q+=Q*(KQUE2)6=Q&ICNT*0D(RK\Q,8!*[XN7FNCXUOKCPY#^
MZTJ[E%O>WEU%"S7;Q0L)%9!&ICN\-;R*,G:L/*HT4D57+N%O&UQ)H3:9=KI=
MRZW>J-<*L)<YM95@E*1ADG1'4#D@QIMW%R7AW$AL],TX2;/+L8/L4HAEM!$M
MPH 1'9!;@BXR%VQ)\P:& #R]^V@ T^PM["*PLHT@BMYY86L;1X3$DT4*KM,G
MF1LXN$CV$*6W-]E4C8/,"Y\DMAIFDV\M\T%[]CE62%YX(Y)[J=8X6B$D<A64
M7[191,'G[Q RL8T+N]@TO3A>7:?;&-W;1W%H8(C()B("'N#&&#7"!-R[-H8M
M&B@L8R<?2/#>IW\MAJNJ23O?K:?9=.CNFF!@L6:+S))F S'?F-G4LK#)''"L
M0 &G>'[C7-6@U+Q#IF;O[(%BMY(0@AE\Q(YYFN40,UR%BB*LJQK@ 1EE!D7<
M>6[N4L)X=)D=[U&U&X@ELDC V-$T:R!C_P ?041QKF15!5W/^K5*KK:&6RLK
MQ[:[1!;F<6\T4B2K&Z W$I$"#RKPM,W W$[6";/,D*Y?B6[ECO)]/TR>!K^V
M\I;Z]D*2I#Y@B,5S- J#S;LM %AC0'JI. RK0!)J.ISWUU+H6A1R7&I&W6ZN
M;EK2)S$?*C:&>XCD6("Z+1!8X]P &'8 *%&AI&DVFC6"6=HL:V<EQ:W$DNK(
MY:9G?=Y[EXU+73R@)M+'9B-L XC:/1]$TO2(+>V2[\IDE5YH;U?.W3N]J[&Z
M<.5>[+[?+;<,>8-JL%YN6TK0F.^BN(X[B=X86:ZD7RW(DABG,QA41_:B?W2K
MN89C4)@%Q0!)#M?:+CR(L2P?:6NOL\F^X_T8I]H";=MR>%3860?*W/R+7)IK
M>I>*O#\D<'EP:+*D"10RR,\EY:N8UDMII)=IBNF5EV$OM<7(VEL><I;;O'(C
MN6NI++PRJ0PP)>.L_GEHX?+6YBF9OWH:>0QG#"1O*=@P2/S>HAU8PO.(VD*6
MJ1+9%WD)>-E@S!,)9%VW3,0%\W!Q*A&[]X* *>CV$NG75I87%I!.PBA8V\D:
M+<RQB4O]HF<Y66:*5@6"/@%WER6EC05V\0:8VDF]AF\V]6)[B!HA"TUYF.W1
M;E?W7%R8IXE6-E3<TNS!0JU5Y-1L?#,MO%-:0%KZ[5$T9)[8E;@-"RO,S$RR
MW9W1MN!* LFY@!YYDT7PU,MOIR^([B.]\5S64+0M*#_HD< B5G&[S8WGC>9W
M$C#+-(0,(3@ +#1+G4]9T[6-<TV2[NTN&;3X)"X@MX@V6NG\T,\4K%V*P[C@
M>2I ,)>/H$M#<O9YMHYT9X[S=<121/<LBPJ)I]J*BRJ"Q$3(<E(R"FP[:\-L
MUR^G2/9W=R9K@7&RXMUM@P18U%S=%1AI0$W1IA3ED!C4Q%X^?U7&J"3P_9K)
MJ.I2V\MX9KB*.-S^[A422KY**;A5E6,0,55HFQ*P#@4 &H:S<W&FV-AIVJ1W
MFH7MO!=_;)[=Y8S$8@XO%@,?$X:VD,=M&>3ER#AMO0:'H=II=A;65E:22P2.
M+O\ TT.6NF+PNUS<,\6Y;A6R50D9QVQ^[KZ'H-IH5O;6NGZ?=W5K=W O)A=.
M[R3L1"3=3>;&-DZR!3Y>Y>-[@%EV"OJE[8VNEC79FTVYL[1&NM^H0[!//'Y$
M8GFD6 F&X0B2,1A"Q/  *E5 +EQ!966AW$EV)_[.,37TWG"2,.@\EY+EPL0,
M%PI#NL<>W+[FP&)*<O;:5_PF&K:;J&J:7.MG-]R"1-Z:D(Y /.N9HE,:Y2))
M!&%$<N(/WCJJK')!H\VMZS%,+"[T^S:X'V,RV)@GNID;=/>S&.$")RR0NB3?
M)(81F,$J4Z2W6S:#3+ZU-B]I=>3*)KBW"+?1L\;I*[B)1'<":9G1.C,S8 9M
MT8!8%O+=V<*6UO.TE_LDE>^@2%T\HA1=\0LOV@_N66.0+]Q?E0HPK#O]3MI]
M4LQ#'::C?ZC>@V5NMHGE0.N[%W<!U$D<\212Q[/,!?R"%"'<(Y+V]_L?;::7
MI']HW=WY>H+92V7D_:]NW-Q(PA417!F:+=D/MVQL5B4LZ&D^'8K>"V76+K^T
MM3U'?MN;A'M6NE9XYBY!3=!<1JOR(K!BL"$X\I?) *?AG0KG1D.H:MIT>KZO
M>)'>WFI3P/ET#"1MB^295EC(B58"%!$2,@5A(J]( CWD,,5Q8S_Z6BR^>JD:
M@Z  R%UC"BYB:V<[5W8$7(3*F,TZ1+]8/+MOM7F8FDEEC417+QRHGF2L(@R7
M,:Q(?+*IAB5&?++1\VMS=^-+>"ST42+IMP^Z\U<%$^V*HBVSPN("!<(!&#N$
M>UE=$R8]\0!)+!<>*96M=*%];VT_EI?W\X$+W!B8JTJ 1,D=S&5@(.%)W,A"
M/!^ZV+70T@TZTT_2+:"RM9,3;?L"Q>< (O\ 2''D!8;E'PRJ5(.P@J.L4=EI
ML, LH8_#T<MG;H+NSMQ;@?+'&J0L7F7=]J41Q@!S%A92,N8B:CO+A[:S9[@^
M7#<?97>:6R9I)'S($FQ]F 6YQ' P5E?YT2((A9&8 COHK2UL@\EO:6UO]HMY
M;4+I+J(E*,L4D8,+>7=*H5 K;\F*) L9F '+_#/1E3PQI^KW%E:-IZ(UUIVF
M01M<*@61=]U-(J/YEYMP%4!2-I557+!-C2-,N]<?_A(]1MI'N[M)9H+""1)%
MM&11MD/F0K%]NCDQ"-^W")@EC&Q)X.2Q/@/0[GR8T@^Q!+>*VNLHP)EW>7Y:
M^9]L2'S=YC5"[.P[#RP#<MUBL[R2TU**^G:&7[= 9)'FN?W88/< JV-K$!/(
M@4[1*H90)BB\G\0/$\P\*ZEI5O;2:G<ZIIC7+?9KDQJD*I()+M6660+ 1'"5
MC.T/YA&79G5=35-1N+#[1I.D7'V*_662X\^Y8 K$/+CGU"2,O'&D:EISY>TK
M)(!*HQN-1^(+==+\.>)K:XCNY'^SSWMS%]H;S]00P/"\ZREA& %:'='Y9$13
MA&W0F@"QX<BAT_PX)+6XC2 I#=S7<%R(6\IX&C%\$D;8L6Q4Q Z*D?DR;0^Q
M =35)'MVNYM1N(&AL8EO+@O$TBQ2I$66[,0N"?LX,9 BV[O,3>#D;ZIPS*^C
M62WL\8E%O#>-<1WC$VX13$]Y;SRNZ218\MBI(/ER,9 QEV-AW5N_B>*>$RV-
MAI\'GWXF<LB2.5\EKTKN>-;:027+B%B/-\O<699)" "Y/]N\4IJ#2W5WIGAY
M$F:*21_,B<[KK%T\CL%EM678?).X<)PL6#)T&I3,MNK36\=MY3B\B%_<KYUJ
M0"TMQN$WSQ1M,B.@9 $$B@LK(K5[L0H;C;;1V5S9W#WT\,EP/*ME>21([W.5
M&"(7=XUD3*2S;MS-AJ^L^([30+W48A9233?:(A::9ILS^?=;'CFGD5$; ?\
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MAR#$-_S0J<GI-0UV+QW/J>FZ)JL$6G6DIEU'5([ARM@RI.(I4,A5'7,,3$*
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M2K@_9A?\PYNGS;A?M*,D>5)'EQIOPG(H L7MU]FGLK=X]^IZSN^SP&3;)>+
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ME $H4%C5KI;C2WB1Y+ZYN[<7"+%N>"X1?LP:\@5'9U$6Y72-'1F;<5RQ62M
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MXO*DABFCWV[++.K(=MQ&J*J!CD["1LR1'P\3-XM/]CZ=%IO_  CU^\<MQ=O
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M[LD#KP2EAXD@TZRO-2M8+Z2+R;R2>XMEMTD*B!7O9M\8\B:-=Y";L[5(ZC"
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M L[-.ORA9)C&%C W<[I<LQ ^50NX[]NQ0 4444 %%%% !1110 4444 %%%%
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M1F06S+;W DF!:Z;)",2 /,.[.07Y,7.I^*[R&VL[J?2=-MMEAJ=\-5F#VTP
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M,ET7@_<S!450N 1O0_+PT4>G^%!"]J([:.>]O7.H7.I3:?'&99 L0$Y5HO\
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M&W+(V]5(98]R.*XN8G6&US,=D\+7]L FH%%MV$T^V,&&8$;%! *[2VQ@@50
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M-;K+!#A#*%:W/R!=A+@E3N# X85TDNL:Q:P*EY::'!?29\F!]7<+)\\2+AC
M#R9".%.&,8YW_+L2V%G/*TLMI!)(WE[G>,$GRV+QY/\ LL2P]"<CFHX-)TVU
M$0M]/M(1$X>,1PJNQA'Y0(P."(_DS_=XZ<4 8=EXFO+CRO._X1Q?,EB"^1K9
MDS&^S+#,(RW[V#:O1O-7YERNZ3_A)9DN(H9I/#Z%[B"#']L'=N8NLB@&(9<2
M1NBK_'L;.PJ16P-)TU;=[==/M! ]NMJ\8A7:T*@A8R,8* ,P"]!N/K5B:"&Y
M0)/%'*@=7"NH8!E8,IY[A@"#V(!H Y./Q3K$NSRX/"C^9MV;?$+G=N\O;C_1
MN<^=%CU\Q/[PS)9>+II7D^UR^&(HHTC=G@UTRE59?,R085P/)620'/(3L,LO
M2+86:>7MM(%\J5YX\1@;)'W;G'HQWOD]3N;U-"V%FGE[;2!?*E>>/$8&R1]V
MYQZ,=[Y/4[F]30!S</BC4FO3:SQ^&$EV,1&FO,S[MYB4;3;C@S8C)[$D8)&T
MY?B;Q5]M\+ZI%:R>%+R&>TN,++KVQ9+<GRD?(0?><LA&]0&P!)DY7T"L_7;3
M[?X>U.S\CS_M%I+%Y.,^9N0C;]].N<??7_>7J #D_@P86^$F@F".1$V2@AW#
M'=YS[CD <%LD#L"!DXR>;\!3SP?&#6K1DQ#<VE[<!OM4KYV:G.@^0D(G+-P
M>FX$%W!Z#X)?\DAT+_MX_P#2B2N;\'00VGQ]U:T@BCBC@T>9%15 *K]J4H#T
M. I55!5<1JBKO0+(X![)1110 4444 %%%% !1110 5P?C'Q+#_;\/A9K>03A
M]+U%)P05*_VC%&RD=00=I'7.3TQSWE>-^,#,GQJCFN8XTLTTRR&Z%S)*56^6
M8$18!)+Q%, G[RX+2.D3@&A\,[5;/XF_$N)$D4->P2X?=G+F9R?F13@ELC@C
M&,,XPQ]4KS/X?Q-%\5/B2KV\<!-Q9ML2-8P04D(;"LPRP.XG.2220I)4>F4
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M"OH[0QZ;9,D\D1#V[R3WN$G20Q01B*\ D!DN'5^,C .S*DJN[+U3Q'<6EKI
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M<7"^2 EPGEC8I /RG&WG9Q\^I#6[A8+!;M(W2WEU.XE$?[]D,8$#D%$@U+S
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MSS*9%3C:R3_,2LA1@ T:WN==L(KJ]CDL[>*XCMD@O[AX9R0]O%YE\596:\=
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MXW2\EW11@RJ%MU"[HU$DFS<-FY9-.T*\@LX(A//?75]B:XN[L&,R<H_VDQM
MRQ7$;L%CB./D102?+ 2/POHT,<4$YAM-1N;AY+F:Z:$()YO/B$LCJ( ()5$,
M+"($$R*P;+1F6M"PM)OM%H9[:2]GNK>*::>6(PP7#1&W_?S1E,PW )8H@ZB,
M!F&Q?+ !K:%A'/<1VD7G7$<MF7M1 B1M<Q2MN\R(F.=W= 4)R[1JR^6VXIP<
M&F)\2O\ 1;2#9X8:69YIOLJQKJDHV+]K206ZM'<#>Y8$;7:,(NY?,*ZB-=^+
M-4B@@NXSH-R\UM<RK.BIK&W;%Y@D2-"TK1)=*R ,H$"E=F8IAV%E8J;BR AD
MEMY4$A6=&19 I647$D?DA8[CSG)VC83N9CDH%0 IW"Q1:=Y49\OS/)E5I[=_
M,N%P\QECA,01;L2"64HL;L3&NX+N793UK48K*:9?.COKS4;@I9V&G)#F=XYH
MD:X_>(1]H@&T$,Y7$&XA &V2:AK*:3H=KJ5QH]]>377D3)I_V53<WCC[.3)*
MHC %S&%9A&IZ1,> O[O+TKPM<6UU)KVK227U]<(TT?[JY#P6K1()RC(BNET2
MV =H9EB5$2)1MC +&A^&+DW]MK.L6MIJNL7MP+V1IXWC@MDV0C=$KP$PRQ[5
M14)5I NYVRH6/8LK5;&PWO:1SH[M?,JZ>T?VH!X7^T3(L)*W2XX08+LI("](
MB4Q6=OMCDCE0/(MK<Q&%F6= WVB5$6(DW3;[DE%1U/E$'9N85S^JW-WKU[<>
M&M$NK22W=/[0NIM,5"882_G1>42-B74S.<.TA $7F@*6X )-8UN<ZFF@:3#.
MU_/:)J$]U/!+!(+<1^7)<R) R22R,"L:0A4=7CSP F-#0=-_L[3A_8\L%U=7
M,JWUS*LWS2S2B2,WS(DVQX9"JN(@4 56(RX"B/0;"TTFX33M'TR2RLW>*X;3
M[=WC8QY14NG9L,"1'&IB?RRVRYR)B.;$]\LEA;[YK25XT&H1W$KLHB&^3?>1
MN9B'@^9"8A(I6%RI)WK&0"Q+J,+G]QJ4D%M-;R7BFXD#11JLC2+="42J7@)"
MAHU=L))""(E+ \G!"_C&\AF@B\K3#=SWMI8R6[0B]20&,7A1G^>$>8=\"F/S
M [2-_KEC:QONO%]YJ%S.D#Z9:Q)J%C;RK.YN4F#(ERT:,Q\OR4E06PQYI+EU
MCW@#J)(O[3ELGMVGEM9?-N+-77[1 L@9G2YE<28DCR8S%&&!&[('R P@%.XE
MM%=1!_9L<4SMJL5P)W\JU4+*?MBON0.C?N1)''MQY[EV82Y:OXNUZ;1K*:&S
M>1+W9<3QQM<%I;%=EP3>2J'?S+?=LPA7Y<@!2X2,'B'Q&NGZ67M9KN&Y9'O(
MK=RWVBUB_?&2YF5G)$&W[H:-O+;8/+=@L0CTOPW_ &5=>3<R?:=>GNYKUI;9
MO+\E9);E1/ )00VP7/S1%F5-VX LX\T DM=,:V=KS5Y(TU1;B::[NDNU4:?"
M%NTBNU65I"$96($3,T:%F(4;7SP<=U>2V-G*DL\S0^)3<W$<EB<6ZR37T9NH
MHY"Y1B<*D+#<)81\C-(-_JD4+70\NX@D+ZDD<HF@LU18WCC4BY=)4S'+O\M5
M1S(1Y<9 ^63;X1<W)UJULA]JDL-&?7;G6KS68%DMT?$L@,T>\,X?:$153*HS
M1AF9Y0$ /2]7NM1U[5K_ $/2)?LFCP2^9J;P6*M-;*))7$EL5+>9,\L$NYP"
MR,\>$$B25N6VDG3; QV>GQV4>CIOTZQ,,DD=OA[B(W :,;IWDA?<8<ELX!(9
M]U6+?26M-.32;#2X[*"2XE*6I93%:(EP[BYB;RG7S27CD6)\ 8 &-C9IWMU%
MHNCRZA<1P:?8^;+>1S32/_HD;LY>Y7S+<E+EC<$"!L@_=7^($ N:Y=VVAV%S
M?7B1V=O:N99)(E0+9B1YE^TPL\6'G;?ETR3\Q #%@)</2M"GNLZMJL$\&V(W
M45FD4KI:^9OF^U+!)'(/MOG&3Y%+>6KA<M@;ZZ:<ES$WB;4-#@TB&PB,MM:R
MP*AT^TVIBZQY#AKM1;+B,$A$"*<'[W4:C-;Z=]H-S']BCMHI[YYHK<M'9(/.
MW7,3^05:X;?EHR3P6(##.\ CO+2;89%MI(Y;.XEN0(XC$+97:Y4W$(1)1-.R
M.28V)W$JQ6,M@\_K&H+%X@FT/3M+C2^-Z+VYFTR-I5T] &<W3E(0PNID#((C
MO#84'<K%7N:[(9M6;PM96T$NIW45Q=_9FCA:"S@FD$!N1NB'F2?/(YC)^;S)
MU+'Y,W- \/+IT*QPB0SZ@YOGO6B9'6=H=LMVJ21$0SNT@7R6.T*"0.'4@%/2
MM$TZRTXQ,OVV:YSK$]]!;-<1^=A\7UN3"Z?:'/EMY*DA1]P$ [^?U9HA\2H[
MD2_V?]E\/W^KBXEC=VLVD8QBZVLN^63RU13 ZA8U4*I.T"NT+0O;HER\EN'M
MVO+N[GMA&NU0/*NI'>W""X7RHCY;;=F6)#!%KRN^U%/&_P 4(;^Z2#3_  U8
M:5>:F;B"596NH"&@-P0J$EB$B5H9 <+$593DJ0# 2&SU?+Z387TUN+224P6M
MZ(X85'VMT>Z99?)@CD27:\0,; F;;Y0PLO3WW@S6K6#[ VAZ58M>:?)9*5\3
MW:LLA>&V\P*[$-"082(L,=J(K-NV(=#X4V5YI^HZU93/!'?32FXTY%G+&&W!
MN%#20J8E,*RLZ^4J(ZR.=Z1_*5[237M(T?23=W^L1^7L&HW2+>DR2*9D5;B+
M]^Q6W)!(B4MN#A0-V48 X^;3]#N++4=4EN=9M=0:W-Q#_P 3F6XN--MU20+>
M!OM $T 23?B/S"&EE0,V2JQ_#23^V/"XUJ]U*>"TTN6=M+LDGPVEV\A,0ED>
M;"RK$@E",P8!1*/F8;$CMK?5]0^(T^H:M9VBOIEDLDB7-T&M]-D\R1XKFX'G
M-E]K73K$I(C5XE#C)=-SP3J3RZ+JUW%J<#)::A>SO)AEB9Y)Y0+M<W 4V@0N
M=G=HI"&+KD@'29N; ,6N8UE1WN;N2YNG"V9,<X-RZ&=LV[LB[(<J%Y;(*G;A
M^*-3GM;J\T?2FGCU-XGU-!<ZE+%]AQ*T?VJ1R[1M; ?/Y(Z;0#&=Y\NYKOB!
MH+U-/TBZC:>.X-RSO?+BV@5V%S<REI")(%9_*\EMC H^PC8K)8TF!M)A9KF>
M2*Z5X+[4I[N50V\PD37$H6X*K$RH8E0#;&\>X!E4$ $=E#<:-:WI,F+R&5;B
M^N;RX"LSF)HFOG03E3;G8I$),>U8G*_,J+6AJ=U_9>Z\DO9[6&**[N##<MYW
MD^7O)N2JRAY(<. 8_FQOAP(BIJ.XE6!%%[+']OL$:]1I58K;.6EB>ZD)G*B
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M-)C.]25;'EE3YNQ6?O=?$.P).L;VF69E9HW*OP%(;:C#<<@J"X9<$B-@-"@
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MNR@@%L?1]-OFU1=:UJ_D62WO8[6RL)[C>FE(-Z+YV+@B6>:*5!N.]@TR\%:
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M*9I(9"7V6R*ESM*D7!4[$V,RXP3G*+0!':6=O8KIT&9Y[2&*(QF_0V\3&66
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M]I8BQ8)@*B^=O0G RP<LQY. Z\\@#QC2O%&A>'?%4EMJVJ>5=6/C#4+J>]:
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MN?ML]];X!E2[A")=AI"1=9P8AD;3(QPQR7Z3PSX:L]"LQ]JNOMFI2RP&^O\
M4G$CB;-N4AG'G$&;)'E$9$>1C)),N'X(M-,O?!DMM=O=K UQJ;WLUXTD1CB\
MT)+'?E)5#7#1/D,X^4#('R98 C\20B#3+.>.*>%UU#3M1LX'MYKJYMU>2%6D
MO@[LSR;QY:*A$F(RBL4\P+(JW/B[6[JSBECTWPU:7"6MU<&=_-N)2B6\]C=!
MI,2RL&15F!?;M7:S,W&.GASPOXDU*[FN-+CTSP[87#C4KN_O71C>)+M,%P?/
M(D?$TSK.&/\ K(USA&1^T\/Z%I?AY8Y]%TJ#2IHY1:F.[NLBU226 O%+MG<-
M<2@AD8=0(E; "@@&6+E=.^)'ARQM+RTT]+:R>S^Q-<-,UM;%;3RXIU!94E9R
MZJP90W[KYI,"-[FK^(4T30[*&[BOI;N/%M;B[A6]>*6/R&2.XCCN LUS(P5X
MRIW#?NPJJ[''UO4/^$<\<^$U@-C';P6AL-/TR>/SIH')M0]N&5B$N#&_RR-(
M4((4A03(^IH>DM'>Q:U<7=VMU<7$,<37,JR#28 X>.WF$TID-Q*EPR%OG9#.
M57:N-P 6&DV,&MOXEUB[CM;S2KAT\RYEQ!8(Z6ZK',S2_O;AH&4&7+#<Y!+"
M.,5N:?(;' MXY[.-MULL=W+"ZZ=</M(%QLG_ 'S2L8G7[TFZ5LN!)@27=[#I
MSZ?)=W$EFEHB2-)=7H"6,+*J[;L&X_?.[+(J28<!N>=I+<W/KUQ?P6OAW1[Z
M==2B\NUN[N\N@?[/AWI&RW+Q2E9+F5XV5 C+(/,.#&020 U'Q'/?^?8:+J'D
M_9[2U=+N2263["K^2V',<S_:[A\QF,8"R9=0\G[Q3<L)XM!L([>WU*33WL4D
M2X;5+F&9;(S/&_F7P%R"\LKK(49" /.(*CO)!;V%JMU##+!:V]Q+!(C@QSR6
MD\DL,)6:,,PDN#-"2MP_F8<2;CA,27+O4EAA25;J2Q.G.(&NKZ9O(TXM#"VR
M[!N5%P[!P%<%P&<<Y!+ %.ZO[?1+&/5KQY],M=-W1S7=U,;RXLD>:U9K:4"2
M4R-,,D.#^[0IP.^7INF3ZKXCBU#79+2WN[1+9(K*[NXKUM$99XML9)8[Y;I0
M2)2 ZX !8XJ.PAN-8U&VN+R3[,MC*AT[3]1N!=_V8\A!BFOE>=96N)=Q6) 3
MY>1WKL+66XM[R/\ TK;;KLB)O+D.; L+4+:RJ)#YLTF799&9BI< ;@WS %>"
MPMX;RQLY-!G^:5+NW^VDW8:7";I9IRLC)<1*K*F7VL"JJYZ1T]7U&&RNM+MH
MK*2]U:_22ZL8)F$ U-H8H6/VD&(".<;59"4&TP@;D#%*CU#4/[-ELU7PW?/J
M5Q%*]IIDTWFBY:)K51+<R(LH692J;)&9E &6=2WRU_!GA8:+9VC7T/VS6+GR
MI+J8P3)%=ERD@FFW1<31>2X7=@[CN;8\] $GAG0ETZX2[U)Y+K4]3N"ZOJ"M
M$;X*8'\R52K!)8_+D>&(;2D>1A6$C+N6TB-9V5Q=6WE?:_L\Q34(UB,SDVP6
M2X(BVI<JV%2,'YBHQT_=R6=M,[@RQQW*7#QW$0FM3$9U5;;]_<GROEN$96**
M-F0 ,#;E.'M;G4_&7B5[73;>[M]-B2!;V[NGC N)4-H\RR)$@,5XJE5#[CL,
M3! A!9  EBU+QMK,>F6WV1]-M;U;BZOE@99))(6L\!Y56-X;SR_-SM4!0WEC
ME&*=AI^D+9:7IVGZ9;QB!$MFB6\MVQ/%%]F'FS_NE*7"JA"*2.5!(^7"1Z9I
M%O8_V396>G3R6L=HGDF<%(Y4C^R!9;E3&"MRH0>6".D;<K_#3U&X72+ ZKJ,
MD82.W>\^U7=NT5O<!7MC&UT@4%+KY51"%)!5F"=(@ 2:UJZ:%IRWUQ8>?:M%
M]KDNKU5@A<QBWVS71\G?'<;@%C1$8D@?*,#R\O1]*6ZO[+4]8EC=+1[?[#87
M;L&CEV0)Y]])LPU\4DC"QMTX"DY+K8TOPW-JGB"U\1:O9QM.R0SV5I+ 8F^0
M(IN+QUC"M=*KMLCP%3#!/XG7H+;3S.FEQ-/=RI;VZ?9S?1R2BXC5K=S+<*RI
MLN R';DY!+-@_,J@%>UGFMG=S+:17QN($9KABI*LMHL@NO*_=?:CG$8'4% O
MR[JQ]7OVGN+33M(-HVH27%M)=7]XRA8$S;LLEW;[4Q<2,J1QIM#<95H\$ U2
M?7-8O;'3]*ECEN&M]C2W#13)8[70O<W*)^[:X66(I$B#:&CE;=C*IH:-8VEK
M811/-'*%N(RUS?2/*VXO;F,70D=6:Z<"-D)0>5E5 P ) "/3=,72;'[/#-!)
MYFH+<W?]HK;C9<2S6\A6X,9^:Y^<^44 3E <X1CH%P/*%VFRPBB%S:W-XLS1
MQ6T7V9V^T^:PQ<;@[(S9*A"QY#!HTNX=-?,$4B7&P%E9@Q1MMJOV>X<S['NG
M!18W9NA') ._C[6UA\6FR1M0DC\.AXR)+B(.=2\N2R""_#@#S90BF(_>>.53
MA0"L@ :>;OQJD5W>1VD.E1W$$-Y;W;H!=W :S$D=X@"GST='6/"*'(4$+&0)
M>XL':UM[2)[Z3?;)%;-+>S*[0EA;_N;C;+A[A\Y5P,#=QG/[PMG:&XCE-])"
MD:0VPBNIE=;,DPYAF_>DR7$F\!7)8#Y<?>/F\_J6N7WANRLG6:2YO(WBTRQM
M;JZW&:1TMG\F[9"P%TP679(/W8#98X;D N:AXGL_"\5K:Q"!+_4+N"&*UD8/
M.7"VX:&5A(Q>X,;?+(QV#]V'8##/G^#]-N+/4;S5]7O-NMO*MM<>=('ALC(;
M=_(8[D\VXE5XOWB@H"J(H545&K^'- GBO'U'4]3QJYBBTR^:5I=EC&XCD-G'
M*;CS&F=YP5FW2 8"J%X4]1YMQ%+:2V]UY7V?R[5H;NY!2 2-:YBN#YC-)<E2
MWEL#CY\'.X,P!8M[/'D1?V;Y>_RY?L]RWF^9L\C][/+L?_2(]N%&]MVS.XXR
MGE_QAU?3CX&O=,EDOKK4)/)GA2:!BX7%O_I4BO&OD?Q18CPI:1P1N+A-#6O&
MJ>&_%%AX7TGP[/JM_<;9WTR6Z6:1Y6$;QR3SL799HO*(P2RA"C[P%4#G+UO&
M&O>&FTK5?AUJ5[/>O'-=W4UU&ADG(MT$RJ(AY3K&51<$*H,GF"39)@ [/3?"
M5[<6<E[IOB6>6XU>*"]2^>SC<73J5?[1+YD#;-N]?*MP5P(N&!9V2-;.[T[Q
MCIUQJ^HQZA:W23:A')?6:6WEQ1>26DG*0J4=5,1'F93=:IG:SQ^173Q+XA%Q
M)<1?"_4KB>5X%,ERUO&U[M,9BGN"(LI*A:(A1\J[I>GE';S^L_\ "8>(M9TA
M[CX:W;_9'9;J.>^C$>HON0%IRJ(C#%GQ_#GR3@J41P#,^'EH9?B%X$NH-%@L
M+>+3YHWN9)(8Y[R06^6+1J1T\Y"N5WM&0[%ARMSX_"8/?F62-D+Z68@J%2J[
M=0X8Y.X[MQR,<$#'&3/X&\*:^?B'X7U6?PC=Z3;:=9/'/<3W:R&6)HY5@+ @
M-YH!",.P"?)&H5:C_:#_ .7K_N&?^Y&@#P"BBB@#[KO]!M-0N))VENX))DCC
MG>UN'A:6.,R%$+*0R@-(S90J3P"2N0<^?P3ITUO+$FH>(('="JRQZ[>%D)'W
MANE(R.O((]0:Z2B@#G_^$-TO_GZUS_P>WO\ \>K+\3:#;:+X0UW4K"]UE+NV
MTRZ>)WUB[D"MY+X.UY",CJ#C@X(Y KM*Q_%GV/\ X0W7/[1\_P"P_P!GW'VC
M[/CS/+\MMVS/&[&<9XS0!Q^LWU_X=71QJ-I?&[O+NUL8[B'7)'CDG>667#*4
M"A2T40=A&,),RH-J!3A_!P-!8:['?B2SN[;79XYKNZF62='=X!Y'G%-DID9"
MKE2#G80,LI&Y\39O+_X0*UNKF![YO$MBY"#9YFW<'94))"@LO<XW $\UQ?P]
M\.#5-<\67UU>R"0:Q):75O)#')<;&NH'99EA4ATE$;QL<B- )" RLVT ZRQ=
M/&4]A-*D&G:'IFRV^R;5^S-+(EM^X/S#>NV1DCDC 602,I!CXGZC3A_9]G!;
M0S06<=I:"RMT=LI8R,4\J&=1.?,DVO !CD[7(<"511;VT5KIT&F^=!:0VT4=
MAB"[?R[16$"_9V;S5=IF#?NY-H8!AP"<29]YK5OX<@L[:SBV73RI;6EAO+):
M&1[?,$ZI*P7!E7;(%*1*RJH.564 KZ[XI?1(HK:QF@_M/REM+.VN9VF>"YD6
M(PVMRBRG=)+LEQ,S +MZG)+&@Z++9RG4K_4=FM22QQO<S2),=.A9K9AIKL9"
M9&8 !7QDEV?AG^>3P[I+6%Q#K&JW<;Z\;>"RGN)Y5=;!&,#&R;$N7=G=BCMN
M;YEW,_&_4\^WM9;2[E/E36WEV*23$SO:"9K4&VFQ*Q>9R4(DY X))',@!(+Y
M;-+=WFDA$3PVO[UVF-L9&MU$$X69B\[%_EDY"ALDD$F3G]0N]2U:_&@Z?<W>
MD6MLD5O?ZE-*RR6JRI%MM49G99KIB5_>\[!(,%F;)CNM3O-?O/[%TB_GTVRM
M=EIJ&J/<'?:;Q&OV17,CK-=EP 9>?+WX!+MSN:78Z;I26*6-O::<EB@M(58K
MBR65K=GMI<3'=/(V"'&>2"=V?W@ :-:6VB6\5K9/'8VD#QQ16\C)Y>GAQ;YM
MI LOSSNQ+*YW$&0\D$!R;6(](MYENYY(KFRMTA&U9[I8&E$21JZ[A)=%I<[9
M HSM=<JP;,=_K%GI5FLMUK']FK91+(YFG$KVT*&V:2"93*QEF<,%$@#$>:,'
M+ R8]A:W%Q!;:SXG_P!$GTZ5 ]H\HO;;3DC<;/.S(Q-PT<HD-P-NT*"VU0PD
M #1K6XO-6TS59?\ B6:99;EL],N)0!ILKR(J)*@DR9I89B(TX6 ,$"-D9Z2S
M86S@I/':Q1O'#';OY:Q:<K+;#[(Z1R -*V<HWS;=^!D$!XX[]X9TMT?R)(HE
MMU%Y,Q>S,J1^3YRM)BYW2*R>8KD[OD4D^8PP[+7K;5]6LH=$N))GV"*RU"<)
M<PV<HA5IK>25+A6N"R;&V@O\X9]S^61& 2:QKMY:W5CIFES^3=CR(GEFE-Q_
M9BO+:JL5V@D;S9)<N%?(;DX(7?*+'AO1TTV*":X>^;45V+-,)5NI[1Y%M/,M
MYW&3*SE%8R%?ECZ&-52CPWX>M_"\4$0;RYK?9;+=7(+)"'6T5X/,8H9VD**$
MD"X7 0!0@C-Q;P6Q@,]I:6P2]S,S>7.MC=2211B-%C"MF83R.)&PP\W+@!M@
M +%HP4V_VF>.$VZ) )F\LSVC-)&PMI9'DD+/(K0*<9W%2VX%X\<.DS>*KJSO
M)Q'I7A72DC2[2WC7:G[J%C:[@,/:N)@SR8,3)"ORHJB22Q+;0^.4M(8I(['P
MS;O]F:[MIA'%*P:")[*%E6,O:R9= P^](@X 1%;K#>)IWE2PC[+9VT026)G5
MEL#_ *-MM!;PGYI'4G807*L<+N5PI *^E6=OH<MKI4!GL888D6&TM$+) 0T'
MFJN0#/&Q=,S&,E-TQ:1"V%CU#7&T6W%E;K)']G2)I(-/A6X\AT$3"QMXPBF0
MR1+,<]8U^<A5*XCU34[?PSX>N+K%]IRVL4C0*L)D97V1S/'(AD(N9&(D9I5/
M"B;,B$,YS_#N@7EM>6^J:Q9SPR:?:&.VAM\S)I$,8B*V\2LK&XDDC++),F3\
MA12#B@"/2-#OKS5(-2\2MIMN;.XB-O8QS>?%:S_N50W3LX>:\:-TC1SE5VAA
MDLH/0'4+L7%J1/)'>6KV]K-%?3HH,4YA8RS*H53*2DD49B+IYC$#C>$+:P6&
M]TO1L1H;.R1X[)%:>UMHD>WVB0LP9Y=T4GDR$+PKG:2ISS^NZ[<RV\EKI^HQ
MV'VRWW3W%[.\+:#%.%9VN<S',[,ZB%,)MPP!VJ<@$>M:F\>N'PYI(@2^FEBB
M:YN86E33!\HCGNG\QTGN)##$8 X5Q\H8C.&V-+;^Q=.B%N)TN8I?],EU.XWM
M;PJ(3-)>2K*R-,8U!0YR%= %"*Y&?IFDV7A^S)6&QMIE\R2[EN8Y+R<RYB>$
M7.P[9KDRR)*.=PW;(@P8R#8OKRW@_?S74%E/;^9/'=:EF:#3'?R=T4Y\_;YS
M>>P3##",57Y<[P"1+<":SBFOY'M].2.R8:@\<P,RS0E7GQ)\T\BB)HC@%2Y9
MAEU2N3BO-4\5WELR77V#P\;2*.VMKS]X7281&,WP:=3*LA4K'Y3-N+,DAXD1
MI&N&\531I<K)#H$%O'<?9M5D5XGMHIHMTD[K(X8,$=XY&8B3RC]U%D-QU$4"
MVA_LH3QV%C!;QVEM"961K> R+"H=EN,L\NP^3(%#)@@_,2K $DFH2V,5N\44
M\C0[8-C7",;7*PL+>??<@27$APJ/DX,BYX)+X^L:W/I4&H1S-N2';965M%<R
MR7 0O;QMYQ28R-(YE1D=49XT8,<N_EM)X@\2V/AVW6]NY;N.X5Y/LT9N<I;3
MRB+]Q<@W CD<&8R!2P58T;:5";C3T&Q^RWD6K:U<0)J=MO\ *M[VY^T/HMN
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M#MD?,WSMR>?F/J:%\)^&T\O;X?TI?*B>"/%E&-D;[MR#CA3O?(Z'<WJ:V**
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M1S<(ZJ1%M,0.W*B4QEB-@41 %S0-#":HNI2W5I=W<UP;VU5)(TBF5OE>XA*
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M"#WK<HH Q_\ A&K#R/)^T:KM\KR<_P!K76[;OWYW>9G=GC=G=M^7.WB@>&K
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M)U["B7>H6S3E#<>84;)YQ$!$",8RSG<2NV2.?7C>S)+INFK:!\12KJ#L[+O
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M"[HC*NXN220W^IZ#0]+TSP7%<VZ:A=SW=J[27VI7OF28AEG$@\Q=XR-K28E
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M!?:O)]ET_3<"2PGU+[5%8. EPTMQ(TFZ=MIPK.1Y+!&5'7$E2:5IYUN:WO\
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MT,FU@@4.,;4!JOK6K0:%X>6XU&?=;V%I]CG@U*^BE^T*4MWDBG3(#W;1B78
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MW*]Q//+;&8V( NO+:,KS<* 5C55VR[)!NVJ4C2YJ4D.DI<PQ&.U^R/)J%U(
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M%O.#)$V^Y5TBC"ERN%1]H)5*Y-]5;QH+R^BT:1_#B)!?O8?9E:35BL:.ZR@
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M!BIW8KV2O']>EMX_AKIELC3R6;>"KIHY%@*S,56T"$["653N&]0Q3'WLJN:
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MK'B1<R7/+-MY4XX&XX*L<#=EMB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KF_B#&TOPY\2*DTD)&F7#;D"DD",
MDK\P(P0,'O@G!!P1TE<WX^,/_""ZT+C38]0@%E.[Q2@&,;(F=2_S*V-R* 4.
MX$@C&-P *_PQ=7^&7ATH\;C[$@RERTXR!@C<W((/!3HA!4<**X?X3:KJOB#4
MO$NC7%S):Z3I=Q(BVL?F>>[32W#-NGDQ*"-W7"OE$/RD.'[CX8SBY^&7AUQ+
M)+BR1-SM&Q&T;<?N^,#& #\P  ;YMU>9_!S1K>3XD>.I+C2;%/LEWY2I'(62
MW/VAW"1IM"LH:)2&(4KY:X')P >T:9H>EZ-YITZP@MFEP)&C3#,%SM4GKM4'
M:J]%7"J  !6A6&/!OAD6[V[:!ILL3NKLLULLF2H(3[P/"JQ51T53M7 XJ1_"
M?AN26ZED\/Z4\EWG[2[649,V6#G><?-\P#<]P#UH V**QU\)^&T\O;X?TI?*
MB>"/%E&-D;[MR#CA3O?(Z'<WJ:+[PGX;U.\DO+_P_I5W=28WS3V4<CM@ #+$
M9.  /PH ^9-(W'XW0N+62]CDO;PW V*9[F O,)6FA*G#^7OS$(T9E "J&8,?
MK.OE34M"TJ/XX2Z(=(CMXIGN89K(2QQIF19?*-N6W*KF-H616P/-.WY!C;])
MVWA/PW9[?LOA_2H-LJ3CRK*-<2)G8_ ^\NYL'J,G'6@#8HK+/A_3\(L?VN".
M-&2.*VO9H8T4QB/"HCA0 JC: /E.67#$DR1Z-:Q;-LM\=FW&Z_G;.WR\9R_/
M^J7.>N7SG>^X T*\/E%O)^T@ME%<01K!EA82*<3.8XIF.5CPJY+3JI+?O87;
MY#(&KUPZ!9L$!FU+Y$9!C4K@<-&(SGY^3M4$$\ALL,,2Q\3@\-VNA?M#W5M!
M)Y%I-%!=H+EIW#LTL.0TD@8,S2!B&;>I<JJLDI5HP#L/@TTK_P#"9,9;Z6$^
M(+@K)=1I'O;C)*A5=9"-NX%54?*% .X5ZA7F?PGBA&L^/IE\SSW\1W*OF !=
MH8E<2;<L<LV5W';P<+NRWIE '-^+)&8Z=9K#)*;E[A4C)5HIW%M+B&2,D"4,
M,MM9D7]WDNI"AO+_ (86M]K/PWL--B2T^PRI-!<RP\27(W7#?89F".8D^;S#
M-\I E547<VZO3/&?E$:,K^>LC7<XADAWDQM]BN?FVQXD?C=A496R00V1@\/\
M'H_M7POLH_+L;KS/.MO*1,^=S<-]FNSL?9'\^\-Q_K NWG]X =Q'IB0Q7$,,
M'GV\^ZVA@GM5C21$691:2!;?Y+9>J.=V=W4@@/E^);[3;69/M5Q)+/=7$=A#
M;N%C>\DEFE1(;A##_P >X42JK'<&5I& 9U1S8U;5K:'3M2,]I)-<S.+589HD
M\^Z)N)DB@E'E%4MY""B2/P5D.2&^8Y]CHMS?7$NK:\)#JEXCI$'L'D6")B\1
ML9T50LL"/,'W[E\W&_A(PU %QM-U'5M8TSQ!=>?'<1Q-]DT^6-5^P7@4B5/.
M$#,89%5T+D[>C)N+QE-2?3K:!+G3H3:*!;QP[!;),6BD::.*&:!$!^SH6^7#
M#(5]Q #EHS8^:TPN-.@EO)-Z2[X=R7,DD19X))/L_P#Q[A5@42@9;RU5LLNU
ML/7)]7;6;FP\,)&-8F0M'J$]B%\AG:97^T,4SY16VC$3*K;F@CWDJR[P#+\2
MW>J:G_:7AO0K/S-0OXA%J%U+-YL=F)/,C>"3]WY_EAI/,B) !$C."(HV6NHC
MT.RTNSN--MK">>%I6A-U<))<%GF,SD3J=IGMU-QC[S\NQ;:49Q':Z'I'AS1K
MF&TM(TL"DL<CWP(^TJBSCR;IWB)6WC4 )(2?E"CD8$ER_79*\LI@GM;SS+1A
M>V_E&XDW2K';S-Y1'V<F0JC8!R%P9?.P0"2YNVDL)#?)(NG_ &B:.;^T%55D
MB#S+*)0(BJ0"-0Z,2-^$#,-Q+<7;BX\<WEOJEY!Y>GIM-M%Y(EEN3*)EBFN%
M41R&R4R2QHF 9%9GDPI8UH6D_P#PFTMV\UI!/I$^Q[."[AVSZDJM++"UP50^
M3:;E81[EW/LR2=Q1^DOY1-;W=I?>7Y<22R.][/&RPQN+A0]Q"K(K6^U0%!)+
M9^8*R%@ 27'^E^?'/^\>?S($ANOW-M?8\\"W,<F]N%&YG5!O 5AN0;1EZIJ]
ME#;H98X[R\U-)((+!C%)/?R*)MUG+LC95BB+;2^XA3G>V,EZ_B#6FTZPBU&]
MDC7SG^R7+:5&LCW3EY56TC<2+*73]XF5"GS'5_E594&?::5J=S:ZAXDU6VCO
MM:G1[?[/!Y<R?9FE;&F;ERF5D4++,\> '<;OE+J 7-#\*?9[^RU_5$SJ=O$N
MG1/;Q9%G''/L1(H_LZ_*ZEO,EVJ "3'MC;*ZD5O;3V_EHVFVUBSQV-^HC1HP
M$"HME"6C59(B[NI)R06=  S?N[%^ML]_J+I+)-?,BVL?[] P!3S)+6#;(C1R
MLB>9N)!^>-BS+&%3#UG6M4U#7+JU\+-!)<6LOEMJD]M]HA@<>6);(>6NY=S_
M &8LQ+85ICD&$  !?>(-1O-1@L=,M_+U_P#=?;9'B6Y71=YM6:!MBAGCD4M\
MP/+*3N54+126GAZ'P]X5ELK32Y+V2"W$$D<F)9)9"ENOV=9'@Q)!($"O(<!
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M<290D.TK5_#VAM.8+SQ#9Z;:O:VZZ5;:=*RW$&EQ&0+Y#DS'?//#)$H<*.
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M])&'RYCQGS-S7-(BL8;*#3--O([>"V2*SNY6.#&-D,'V>62*95-X2B@.N3&
M!@;E+W-!TNS\/V=G;VEM_9ZVT4-FLUS"(PJDPGRI=L@6:9WDDVR("JN[CJ6#
MU[G6K>WT>>^N(OM5KI\L<,4,3F^DC=6MO]'F02G?=F7(1LML(#%N3N "?Q'9
MZ79S:Q<:A///!Y%BL8D$[R3$C?:F"&;RVN\ALLJJ%\Q>JJU9=EI+7&LV6J>*
MKO34N/LXTJWTV>5;F"S,C*S02-)+NENI86"[U ! ;(<%=U?3= N=9OXM7\07
M-HR(EM;6L5WO9M-0I%E#NF62&\F:2-@V9&3:!O;*YZS3KB)OL]]'<3V^8H(
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MJNE&U&SS8QIDF]L ;]K>?A<G=C*G;D [L9,DUKK4MD(5U6TAG9U#SQ61R$V
M/L#2$!]V65FW # *O@D@'S)>:7<?\+MFT::^U6_W2W<5RR1A)D@E$S2^6K(0
MW[N1G(2,;F9A&.5<_2\V@?:+6XADU?5=TT00RI<^6Z/Y31F5=H #$,#MQL#*
M&"ALD^":M\./%\OQ(OM8D>[N3)<2$7<5NRR(S*55H@V]0$+1;/W@P"OSQF.5
MH?>_L?B 3^8-8L2IBV-$VGML#A.'7$N1ER202<J%4;2&=@"1[#4V=P-:D6-G
ME Q;Q[U1U^7!(QO1ONL005^5E=OGH-EJ_P!H21=7C$8N&E>(V@(,>0%C!W9
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M<[]JD,P"$ML (]-\/O:RR&]CVS"T@TZ2^LE:.:% RE;:%4A4>3A\O,A7YBQ
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MHP69B9/#6CWE@JWFH:M/?WAVQ37<.;E(V\U4-M!N9V2-?*VRLR[GR'9PR':
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MT]Y:RK80Z:$50TLL7G+:CRV$:>4@B)E*LJQA@&9BQJOX<L=4L)X+C5=0@O\
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M.5H)4\\A[@H9&$@!(49)8#YZ\4DQM_LMU-)&%>.S\PW!7[+'*%/DS$7)9KC
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MRR0 2*6RLMT3E<Y ^88)&#SC.#C<K+@E4^*M0B%Q(SK96S& R,50%YP&";<
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MX K^"_#$UAXFU?7G>T>.Z>Y@'SF:56%]<N0K;BL:%63<@ZN.0K*=P!WE%%%
M!1110 4444 %%%% !7B_BU+C_A<\<3OY$:Q6%RBV[#9.C:A9Q_O5*\2;D.64
M\K'". I#>T5X_P")_P!_\5C<K\RQ?8[(L_#ADOM.E*@#CRP)U()^;<T@)VA
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M"%KAK4 6ZB"U18CNMY%C#$J 1SD*P(CN6]OY'D?Z/]F^S^7!_HT&[[)GR/\
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M2TMT2X2W,INA,8VVVR-!=8E^>Z+ HK9? "\G.UX[ O8V>EQPSP:?-:106?\
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M[Q1@LQ;'SXDU+>X\KR/](\CR?+@_TF?S/LV[R/\ 1Y_WQ\RX?=\K\XW=\_O
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MW;CTFE-N^#7A,^;/+^]T@;IX]C#%W , ;5^4=%..5 .6SN(!Z11110 5X_\
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MLQ8K"&7<83&X+,[B@"O;ZG>:QJ,&EZ7#/96-K%';:H;9BT>G2,8 ;* P@!V
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MLQ82H'!.QEVX;)WY=YXG71]&M;N:ZCBNX[?RELXY&OI$E91&ML5$X:><SQN
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MCM D<!/F /R !/3Y>"1@UTF@1W,6G2K=S232&]NV5G#@A#<2%%^< X"E0.V
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M$L,?VMX L$.3;![>$2-N"SXZ@O\ O&<EBX (!G^%/"6C^$]C:39[+E-D#3-
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MOY-I;KQ=JQT"*ZGT_P +6DKV]Y<S7,\LLS^9;B73YG>3B0N[ 2*SY5@J''F
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MX\-A!8_&KP&8+3[*L^GRRE9XXEO)6-NY:6Z*X<S%MP8,"N4)5B6=5]0\9?\
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MF,JQDI. .LM)-F#%)?*]O]GA*7#_ &KR/,\K="ZQN6,@558R2%MOG;@S)N%
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M/Q17DUQ';ZAOMK.XO#"S+ &GB86=JIC'^CLTKH&SE,J"3L 0 K^$_!\WA:R
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MVI=F<NQCO=<A\.637MU=W;['C@@M&(N)869+?_0RBRDS7#X9E<[MN]B6V_?
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MF3DCE4R 6(3VRL?Q+*D.E0-(VU3J%DH/D++R;J( ;6.!DD#=U7[PR0* //\
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MZ3_9HY?+5#:E$"L^%"I"=V]B0DFJW4&F6HTZ/3()M0OHA:Q:7%Y2>;Y42/\
M98C)$JO;!&EW.WW=[*HW,%6/PWIT\5[-JVHW,=]KFHI Z7UI/$PDM]Z,\=LC
MY"VJ!T!;.]R6; ;RR0 \/:'J6DO#?3M:7.H2I)"/*LVMTA9%8+:(QB8QV8V
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M )+>3[3Y%[]J^U?ZM?M]M;=-_D'9 -C;K>3&YGWMM_O?+F/'U6_ET.U#P6L
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M%C;:#I<$[0R:/9V=O$DD!1&&FD^2\D<<GDYDB<DF64N0"A.002A86*Z#I-I
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MU.Y634+L-;R-FX4'*%"QB&5S^[(W,% 7USQE_P @.V_["NF_^EL- '04444
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MY1K^$/";:+81C4+>[&IW=NL.H7UI"L'V,EXF6T@2)<+$WFN7EBP RNQ96P4
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MI\_]],7DC8.-V1N0,&;<V/K&NV=IIT&9_.N9-VEP:'?2C=*S"',,ZO(3+(2
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M&Q-/=6W KYAW&8C! ? Q\NY<EMIW1_9O$GGY_M72O)\K&W^S)-WF;,;L^?\
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MEC!6VMWD@4VCLTC+)+(8B@9<E>.Y4R26\7V?3H++3VGL5MHH[.(0KY[:<I$
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M-LEH,Q,$=Y'96O-Z##YS &^8F5MJ $EW_P 5K?3:3I__ !+=(MKOR+W5)O\
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MXW$D '!0UJ6+8^P75T(+6^MHDM29;CS_ +%YGV8O:RN9<R3.=NU\?W20<_O
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M'S =S=#\I&%QD<LV-BN?L_\ DH>L_P#8*L/_ $;=UT% !1110 4444 %%%%
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MP/-D\8H-!EL-0@EDTFVTUY+F6&RM(Y(F18)H4,0,:L]P80/ER8XDB)<;57>
M9?B#PIJ1\'Z@;K4)X)HHI)+>PM[6W@10]M):P1DK"PFN'&V-D1U \P!, 1[J
M^A:[;Z=;^(M0U.'S[>\N[66QCM$.9YY;6(2/!*D:/]IECF#;=D?);:0/,9.H
M\=:M86'@W68[>:!;+4M*N'A99(Q"Y>.9FDCV EF9WB#%RJ$RQ[6+MM;D_A7I
M]W/'KEU-!)#J5H\9,-A B6\<C684B"-BL4=X&P)2RD*<I@!S0!3^,6F7D_@:
MZU;7)H&U/S;4PV\ZE$M(R'4I;E25:9V!>1=[A5 &6\N-V](TD7#:O/%+<3O-
M;:WY<S1J$$@%@NTRF.,"3<"CG<(PKD*"1&@?B_C+!"_@;67LXH[BWC='9HE"
MV]NWVD*Q&=P:X,IN Q39\KL),D1[NH\.2+KVC6>MI#&]QJ&L&>7)8JKPJ;<O
M')$6$0*0;N6=6W-$7(D#4 =Y1110 4444 %%%% !1110!S]M9VY^(>IWI,#W
M2Z5:1*-A\R-#+<D_,1C:Q X!ZQ\@?+GH*ST1V\0S/OG6-+2,%=S&.0EWYP5V
MAEVGE&R0_P XP(S6A0!YG\79YH_#NM>1+:,\>CN#&S&)XEDGB5B9!CAE4A4W
MKO,;#;-TCI^"M'N+WP-X<GU2+R8+#3TNH;2VM 5MWQ/Y=Y'B-_.N&4H?+_A9
MBY4L5%;'Q/1XO#FORS/!)8S:)*GDW+,L2RJZ['R59/,S)\@!1F90/GX:&/P+
MY,GPYT%X%C5+?3(Y"UG$)1:MY<RM-!B$[[@L2'CYP21SG]X =!J4,T:7]O!:
M1BW5TG*I&2(E+/(UQ$HMW$EQYN6\OYLE$;Y2^#Y?X9\.MK7QI\>W"RVD7D)Y
M.;.-9+5C(1\DZ%AYA9482)@@L9#N1@AKN/%6I7.EHVGZ381MKDR37%E"EN[Q
M6HW2A[Q'6W8-+B4,\9.3NVKN9QYG/_"Q)K/XD>/;6[EDGGF>UN5F^R&'=&RN
MZF0"-%24K(FY2JDMO.#AC0!UBZ%H5K/'%J_AVQMTCNW6TN@QG6X:=&B8S.5#
M>9(H"N)-RLS1C>[D ;'_  B?AO\ M'^T?^$?TK[=YOG_ &G[%'YGF9W;]V,[
ML\YZYK8K+.FS6 1M':.*.-&'V&0D0/B,+&JD F$*47[H*X+_ "%B& !'+X3\
M-SQ-%+X?TJ2-O+W(]E&0?+4I'D8_A4E1Z X'%1R>"_"LR0I+X:T9TA39$K6$
M1"+N+87Y>!N9C@=R3WK0AU*&6]-E(LD%WL:1890,O&'*;U()##[I(!RH=-P4
ML!5B>>&UMY;BXECA@B0O))(P544#)))X  YS0!EQ>%M&MHEBL;/^SX5\P^5I
MTKVB,74*S,L14,V ,,02N 00>:KWGAW35LQ<:CJ>JA;:)C+<MJ]Q;@@$NSOY
M;H@Y)/0 #  "J +DNI37J3Q:,L<LJ.\)N9@?(BD5E# X(,A&YN%XW1LC.AZ%
MAHJV[_:KV>2^OV<2M-*6V1OM9<PQDE8AM=E^7DC[S.<L0#EW\&RZI96%K::U
MXGL;.)&,EW)JDRW5P62(JX5CE3E2"'"A3Y@$>7#KCQ:7>VUAX0N;7Q!K.HW4
M5Q(F]KZ4P:LB.\FT@LGSM&KO&QS&0@1G=2C'U2N3TFVA%OH,#6LD,\-[=7*6
M]RP,\2XF1G8Y0N<RJK/B7)D!W/N\Z@#0MM TZ:WMIXYM9"?9RB"74KQ6V.&)
MWJS@[_G."PW+@8QM&"?0=*M1+?7%[J4,<5N5DDDUBY6-(Q'M+$&3:"%YW]<_
M-G=S4D2_V1K#0I%!'8ZA*#$J28<7!65Y259@-I"(<1@DLTC,.6:B]F_M345T
MRTN9XOLLL<]Y- .%VE76$OD89_E+##?N\@A?,1B >5^-SJ5AHGCC4SJ.I'2;
M^RMWBL+NX;?;>:\D>X1;_,4,R(0I,:A97#(QB\NNT\++Y7@WP[#I<4%FG]GQ
MS6-HLF^1M\<0,TH#1*ZHTSF1<'<2K J^%K'^+UQ<67AKQ++Y4\=K/I4$0F@
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ME6!C"QE-A<:$DB6L5O<W%MYUH^VYN);B-8C(B+#_ *7/NB14FC95^0LN$5F
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M2K?=<\JRL.H93@CH*Y_QIQX:=Q]Z.[M)$/7:RW$;*=O63! /EKAGQL4AF!H
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M1P,ELA(@5+6",Q.!;%%2.20 G$>6Y7]WN2V;1S3Q*)+&1G=DNK*W61[833*
ML>8"K"0H9)=V2A.22NUEC_LQ%GW+!]B%M+Y$<EK:JSVX">5;K$#;\QA9W<MD
MB-BZY9-X')W\3>.;B33K.*2QT'9''>ZCIC*ZW!G,C31VDBP'>AF,7G.64?NS
MN4?,2 2;8O&7[JR/V;0-.M-QOM/MW9XY!\AM[!A$JO&C0;]^V0EC&4"LJ%.D
MBMCIMU',(Y+>&-"LL=M:R3M:LL5NWD6I\K'V=DA<-A1ERH7#\"Q;6;6UQ'*1
M);I"D-L(K>W5ELCF',-O^X!>!^ [DX78,;-IV9=YK-OI6G6=U:VWFL(D^S1Z
M?"9,(!;NUM9L+?$L;H&;J,[#@J$9H0"GK6LKX9T^8-ILD4B.4M8LL1#<_9(H
MXHM/'D,K ER@R%.?..UE#@6-/\.K9:S#=36$=M-9/'';I9VS""RCE8EQ; *R
M,&8+'(Q2.0 RN61&C41Z3I.HVEY]MUB#S[JSEMK.W&GV*QPV"D0@K:(X8F%A
M+(LLNY6VQX"C:-NY8VTUJD*3QQQ/:.ML);.U($*[H L4"&(_N)%4%_F;RSE=
MYV;D *=RLL4#03'R;J#?,?[,MT\R.0.#)<VT4L3;]Z7#&3!<J3L7>[$G+U"^
MN[R[&AZ%<7<$%K<1)<MI@3;81?:(HXA$IA D!$4P<;BD6)PV_:J43:L+FXL]
M/T"XCCGC2".633[6.;[!#(;7*6CL@62+:R,QVL%5P[%=L<;ZGA[1K/1M.M5T
MY-MB/*$%W:@2+M<6^1;H!(5MY2I9RS;@VYR3D2  CT+1X?#]E8:5)!':O$\<
MZ1V["412JD$3FUC*NX@8R2"1VPZF1V)^?>([N\L](2:2>Q@L;BQB\R,^4-L2
MV]NC[(&6 L;8++-&TI4,K2,JC+J 2WFEZ3:KJ,PQ9V.GF9);1_+CN@(HI5%F
M,G$96V?,2R*,)ET=7#US^EZ=<>)F&H:F^W1$\J'3-'CB$ NC%%YT%S8N'C:W
M9E).W<Q4!U9L+\@!'HMGJ_C4)XAU:[DTSP_/<.+.TO<;Y8GN8F4$YW&*=-T1
MA=V3.UE4J8U3M+2;[/.%M[F"U6"6WA^R3CRX].AD2("V C/ER3%D&WYLH)P1
ME2JR%X7LK.\NMMCIK6UW(HNTM6Q;1.5D9B2G[Q7?8TI4HJAGRX:+><?7M63P
M_%*I6>#[+*B6,26:O#;.%98(K13$C3R2J0K(K?(IE'F1X!8 N7&IVFAV5M&M
MG'%%97L!-O);/++IL4R$*$168R%G9H$,/R+O*@$1,#GZ)HRQG^T+FRM+'7+)
M$DE2.-KJ73K82>8EM;J4RR/$TZ%XS@/N5 514CL:9HBQW]U>7%Q'<ZA#>RQL
M\$+%M)END5G$ \LHXPUOEB@ZS2.WSL@U'1[**ZN+B+$-MJIG1;2Q9WMD91DQ
M 0L9FD+L791\OGRC?E,D CMB;$26,,<D<=I;R)*-,>27^S=\:R!%1@5F(*MM
M 3<BO"HB".367)J4NHWSV^C1?Z+97;7EQJ%I"DT=LLL,CJ;=?)_?2.C>8VTE
ME>Y7F5"R5'>WE]X@N+W3ENY(I8$,U]/9-Y_]E!2T>+-OLZO++*HG0L,F-E<#
MD!6V+6PM/#5JMO!926MI8)^Z-E;/</!"TJ!8H\0$R"3RR\O+.I;.2"KJ 5QH
ML.C6]O9V&EQVXTU)9+2XAM1<_P!GI@[0@,8:42B)O-56,NZ4 $AE=;E\?L/V
M^>ZA@L;&SB>[,\2[OLF?M)>XB!@(:8@J67+??;([RU]6U*STC3KF\O(OL26.
MR2[=(0L=C)*)-]Q;220A9Y"TI# 9)&?EWL4?+@TJ;4WL[^^TF.RM[6W\]+:*
MW)>P\M9$MW@'V?\ ?$+N=(7"M$96+*Q**@!)'H-QJNHR:KKMC!9Q:9]H>UM+
M2U$KV=SG<;B)C$3<M(&\P8 "L%!C>0$KL6]HEMI-ND>F?V7Y%HL[VEM;JXTU
MVCFW-;;8666;<Q4J,Y'./FPY?VUO:RO=RV/E36WF%)+2R,[V@F:4&:WQ Q>9
MR4,B<@=3D<R8>LWHT:XBTO0=.CCN426'R=)$>[3X\M-O0&W8$.!%YJ@,5WQ;
M4=G0N 1ZWK=OIOB&*PLM,QK0BCN;M;.Q,S60+O\ OXQY*FYC9[B1)-CAPKN5
M"L7(T-)\-?\ "/Z3/#'-/%?M_I-U>6T/F/;1F-5\NVW0LLG_ ![1*8U51W5(
MQY<8-*\./X;TZ]%N^-4:62\N+T6[3;%8 ?NQY>Z7?]FBWQ;S)\Q)D9]KMH72
M/ITL\XB\E5\\R-:6+336Z3-\KVY2$[V9XQ))&5;#2;BVU5#@$D]A"EQ;C[%'
M!):(+:U:WM@_]GQ.9(TDMV\@C>0(PZ?<10"?E&7Y>\NCXD0FUM=2TO3K.XED
MGN+.WD\V)G:YBWVJI"2\[^9F8-GRMV,"0,RR7=K<:_/-:VT7V/0K*+ N[2,.
MXMF1)(C8%;8AN886RKDJQ< $K"XZ"#3O[.TY+7[+!;?8HF?&G6>([7(G'GVJ
M>4V9FSS%EMH;'S9_>  VDV=ECR--@L_L$4I@^QV@;[#&_G9EML0'=,^%WQC(
M''!X\S+U"6QT*XAFO[..PVNR)<8\^2"YNB[,UC^Y=IG>1W5E.T@1@^7M/S2>
M)M2M])TZXEO[/[!;6$LUR&M(R9F=A)(D]JP7:TG$OF1L!PTA<F,9EKZ5H$\-
MU<:OJUG]FU.#[68UM/-F2PAEEG<RV^Y76:XD;!;"J=I4;%^ZX!7T73=1DBMK
MG6)8+%;3R[2VTA)E>UL+IE5Q).OG?O/WI00Q!OD5HMH4G*=1+<>7%<RI<>1'
M:2REGGGWBSDVRN9;@^<-T)5XV6/@J&0X48\N.?R8]2MY&:.">"X 3[1*&E@6
M:60,7;SLF*8JJQI@[7"':=FU.?N[VYM'M['0],M$U33[>9S$&>X32P%9BDGE
M/O>*;,0BA" @*'V?NPB@!>:Q!:W]KIVEB1-0L4S)<:CYLXTA6033?;)O.RR/
M$PV+N*&2(?-\@*26,%OH=G/Y.H01:G!%%<:A=W*F>6VE8G"WFRXWO&(Y2$#L
MRQK$6:1MH-6-+T*P\,Q3"WF\N:W\VX-S?/&TUL760/<W+K(IEAE,*OM;G<!]
MT(HBV/-<<I=00K;ZKM<7-RVZ(/QL8"0B1I#(#&C%0JRQG9F,*P!7U2[2T@E,
MFI_V6MO+YPDN;A3]F+/,!)/NFP]O(0$6/@C/&TJ#%R]DUYXAO]*GT\7WAOPQ
MITJF%I;@QF>;SXB(<+*8Y;:5'VQE<@%<+A<*]=I+SQQ@-)JNGZ/:2RS3B%RU
MS-&_G.,PEY8[BV<>6J,H<,8W5$V,=G4+]CTN",M8V.C-I]H[HD$8:.P9W9"T
M@C=2UO(?W@RJ*!"SN491L +%K%_9UA!!;M/96L'D6UG!=KM6PD,&Q%=A(HN(
MR6C4*&<^8QPQP/+IZAK2Z%8327,$EG=HDEY'9PAI?W[N(56*.((+E'ED+G<P
M8-+&6"%EV4]9U.#PYH]KF'[#-%M>UL@T5U):.S2B&.*+&]Y)0QB\M&"*B2!)
M$"!FCTO0I=!>^U[4'M+:\A?[+'L68VNEVH5VC1#M5IX@TRL^2D:@<;!    T
M/0IK?5VO]8BC75DO9+FVMH,W$6FQ2SR(=H5A(3<"29S(PV#:"RJ(56N@,YL+
M*2\:6[M8K:W,9?46DD%FS)#M#JO$R#EGE,C;3O&_!;;&8?LD4%M:6VJV5K#:
M&=DC.18 K+A8U4.)I,O@0C?&HC4@+A _+W$MQ>:Q>:-X?:?2YM'M$F>Y\@2M
MHZR+O^SI""YN6<;@44^4BI%L&Y!D L:AJFJ7.IW&C^'[V^MYK.TC^VSRI]IF
MT8&-)%5HB6%XT@CV@@NZ,7.\APHV+2ULO"VCPV%CY&G6&F7?G&"261FMK5V=
M3)(%D;>KMYC!G*JBMN89A(,=IH)T'2WTW3DCM+2Q<RVR1V\ER;&$^=NDA9D8
MRW#Y<%<D('4;6 _?2:L[Z7!<S7$D%G&EVC1&WL&F^R"9Y(_-AQ&?-N96<@CH
MGF#*L ?. (]3DT_PQI<EWJ)CTVTTUW$-U;"8FRMIMT:!"4993O"'R<;(QY?R
MD1H6Q]%TC4KN]L?$%[')97$:6D-E9/IS*NEVI<JXBC7>@>8(H89W0(_S.0HW
M%MH=[J%_;>)[JTDL+Q;<W<<"B5O['CE1C((8EB"W%Q(3*7WC*,4^5P 'ZB[M
MIH#<26L<=G/&CEY(+4R^1"\DCO)!B+,D\A1"T>6 ;:Q#X D (T7RYYH$,'V?
M2Y8Y%@M;?>U@BHX"1$1$,SQA 8@ Z+,^'(:,5EZEJXM]4AT.PCM'U8)+JDZV
MYCG&E.OE>9^[6,2.)!-*> )',C % ^Z,UR_N;*XMK#0[>.#4X'6 +'8O/#I]
MDA,K. D09A*D:1^6& +KM1MT;&C0-"AT6RN(!;207%HF93#;"06>4F;S+1_L
MJ^<Y:5R8P"J&5U4 ?(P!GZ=X?M-%N+^XG\P>)+C3'6[U.^O7/V>U0QQ[II8W
M4$D(SQN%B9UB(8HX=JZ22XEBU;S(+B>&-?/L\33I)#;7$DBLC3@S;FWYB\I%
MP560@[0X"EM<R_95VK!IL,$J6MI:$(G]G2&(JBW CN-DJL7CVQK@_O(^,X9>
M/.NOXUO)K30-7_L_0]'WPWFKKJ;>;#$H*N>9,.T@7*2N&5%4N',C%8P"NVM'
MQ)!)I^G:]!I_AFUV'4+V[O(9IK(EU9%$[32[YF8 QR@JD8)'SR*!'V%@UGHU
MFECI L;&/2XHVFMI+@*FFV[&)Y%N LK;IF43.LA&.#EL$EX[.2'0=&2%YH](
ML[)%^RV]]< MIJLLJ(UT_P!I(EB9AA%!&/E Y7*1ZMK=EIL4MS-JOV&XLMT[
MF>22X33S*JOY5W%'/\[-^\\O^ ?*J<[ X!8U;Q#9Z!Y]W=7?V.WC^T0>==7
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M)NOZIXE\(:OJFDC[)X:DE@W/'!YD>J@R,@EWF%7BD1H$1@YP0$ /W?, ._\
MA/<SR:99V[M.L,?A_3G2&265PK&2Z!8>8 1N"KT&W 4*2H4UZ17%^$(+*VUZ
M=-.BCBM#H6FO&J+$H.Z2[8G]S^[R2224^4DDCBNTH P]$F:YUWQ(THC+V][%
M:QN(U#"(6T,@0L!D@/-*1G.-YK<KG_#W_(<\6?\ 85C_ /2*UKH* "BBB@ H
MHHH **** "O+]4M9;CP7*MO<6-U9ZAI^M7\&YTC*_:"TD,^9=I15CF:-R,;3
M. ?ERP]0KQ/7[Q4^#42K<1K);^$K0'=$RB-9S&N#(IWDR>40J+A,HWFY4K@
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MW!%4C<!V'^KS]3O[?1XAJ>MK!I\RRQW-S]G0SK&564&2)_L^Z61HDV2# *1
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MX3L'NK'5M&TE/[-C36[IM2N;:%G:PGDF\E8[)A'CB!2K,0OEK.KY !2@#/\
MC%J5NW@N;3+2S^V_9O*>XE$91[4SE)5GGC"HL4TC),I79G]YDM'OV/WGA>%K
M3PMIEG.8[LKKMY'(C2*#,RW5P0RB8NS%642XW[P(RVYBNU^/^)QL9[+PQ$LD
M:VNHZ[:SW$%L?M";RFYY+6-HB)T83 LP!4MM^0L[UVF@-O-E:RRP"UEU75F:
M&>/<)I$O9'C"?+@2*5+@[LX1L(V-\8!W%%%% !1110 4444 %%%% &6-P\5/
MFUDC1K)<7"HI6<ASE'.W*F/(*@L WG/@':2-2L>Q7S_$>J3R10&2WV6\<]O)
MR8RBOY<R[O\ 6*Q9AE<!)5VG+/6Q0!Y_\4OW?AS66_UK/HER$C'RO& \>YE:
M/][M.Y=Z[6C.Q [1C)?'\-WEYIWP_P##&GVUC!<:S-I\$]K;P1&*.WC=C$;J
M.0P2 S 7"&4'( +-C!.^O\:+YT\+Z^(I)VFM_LT:R!6B>WCF)$B!DYDA<1J"
M) $+%@'9D$:=)I_AVT\-^%8;>""2TGLWC6:>PM'GDM&*%F^R[X9'E3?-(/FW
M;1-+\PV[0 2>&?"UO:Q/)-#]HU"_Q<W]XT!M')99D$\96)&29E;#1A@8]Q.2
MS,TO/_#JUV_%?QQ-]B@'[JR/VEUV3G?'NRR>4FUI,;Y!A<. ,-U'4:Q]G33M
M5DELH(ETSS+P^; 5AM7 FE6ZA=K=@\Q+*7P'V$GJ01)R_P %YK>^U'QQJD-K
ML:[UN1_/\POO3+,J97,1V[B<H[9W\X&PL >L453NM2AMG:%%DN;L)N%M  SG
M*N5SD@(&\MP&<JI(QG-1K:WEU]H%]<>7"_FQ)!:.5_=MM"L9.'$F QRA4+O(
M^8J'(!3UBYMKQVT]-(CUB=$D^1PAAA?:B%)6;.PM'<9Q@DQ[\!N%;/T_0-7T
MTPMJ>HR>(8P\<:P2*(EM0)"WF*&9C*5*P<R,T@\MV5RS;#U$$$-K;Q6]O%'#
M!$@2..-0JHH&  !P !QBI* *]A?6^IZ=;7]G)YEK=1)-"^TC<C %3@\C((ZU
M8K#GT.:TN);[1+J2WG=S+)9R2$VMPQ.3E2"8B26.Z/&6;<XDQM-BSUI9'@M;
M^"2ROY'>+R7#%'=%#$1R8"N"IW+T) ;*@HZJ :E<7H,<+6&C"41M)!KNH*DC
MD!GD5[M6DQO4;V&YB%5A\S815&4[2N/\/&]EB\'1WL\%SMT1IYG>:.9VN0MN
M@E5\EF^628%U)!\SD_,N0#<\1Q+-X?O(VMY+AV0"*..-G;S<CRR K*00^T[M
MZ;<;MZ8W#+\!PW%KH<]IJ=U]JUN"[D&J3F,*9)VPX.1PR^6\04\80*,(046Y
MH@AU:X_X299))([RW1+%9$"^7;YW;AR2#(2&/W256(,H9#4EZ+BPURVOX8//
MM[K9:782$%X0-YCD#*-S+O?:5.0-^_*!7W '!_%S=!H7BBZCNI+9#H]M#.UN
MZF1R;EA&K+NSL.95)^0 .W$WW8['P_T-4T'2KR9H[B>6RTZY:UMIF#H1&D<5
MP SCRCY8DCD )$JQ< 9:,\_\;I)KKPUKJ2&0_8KBT,)4%66*4?.K$)DQ%XU.
M&PF] 1*S+Y*>B7$4%OH_V&%H-/MX(H;H07"Q2?V9M9Y0\P:0KY(:,(!'C;M.
MQ@ &C ")S/>6T@2QOH;KRIGC@6%!>$"(F^3+.75#Y  +*5 8YD/E"N;U2^N[
MMX-$TJ&1]ME<W$FH6\:2)%',I\O48Y(D!:=LS@11JI=GDY"A7:.]UJ_\2RZA
MI&F74^CVEC+=?;]2>>17LQNO(Q*KNP66,M$,CI%T4[@&AW!:VVGV^H:;;):6
M:1W'VRZGEV.+5D"O#/*)$0S(_DDO*69Q)N ?Y2\8!8L=-AL=+AM=':1HI466
MUFM2'CN/]1MGE9!& %X B1PK1*552 $0U26QT_4F^W7&FV5I;.EY%%/)]G52
M91ON%F"KM<M+*KIEP^^,,4$K!J^O>(-,T6POEUO4+2SM(KA0_FF2:>!W>22*
M:+S$;S3N$950FV,QR ,PCVC/TZXO9;B\U+Q;!'8QZ<@U!M)-[+/]BAS,_GNR
MY2X<R191,8B6-2N&X(!3\.:;>>)+JQUFYAOK;3'VW=GILUP5CNF\V&7[?(T'
M[M9&'S?9RNTN'88W.U7/%<%I<66D6=W<W<']J7L*1.C/:2W<A2,+/*X1!%<1
M[=ZQOD-Y6T(6VB/<VRM%J!OK*>)KC9<S);V:3&UE16 F1]N)^8(R@V-*I*;E
M *JG!_$+4[F;Q=9:+HUWHPUS[0;[[(\#S_9WBM[@+<-LB)>4Q&(A#DHT4> Z
MMD '610V>E6=MI&CZ= DT_E2VUJU@(DFR8B;R>,11A9(BA8HI7_EF#M:2,+'
MH'A9H+?3]3U"PCU35KEX)+JYN-HWN!Y@N'62)7C>(O-'&JKD*45L 9CQ[7PW
MXQTVXOA)=^'V,EPE]J&H'2[JYN+A8B&A8*6*LY,9!ACQY0(,>"RU)JUAXSCT
MZYO[_5/#EE/#LOKV2WTNXV6802*;F&7=F:;RT"F-A@J I&UOG -S^W['3+=6
MUK5I(/-N$9FOW^PM<.1 X> 22+L@C5MK1X).U@VYMWF<OXBUJ&\U2+PK9:Y)
M$_VAI]7U"TUH0RVK+L9WB5[@XBVK<*T//E;=^TX7S.;U./Q9XWU%KV.PTJPM
M=,^UQ7,6KZB\GV02ETN,N I,)%NZ C<%\U@C#9B&I:^#O%>D^$UT:\\.>'Y9
M--3[<)WU(1B-"R3N+N/=MF20PB$$X ,!.=H#T =W;^#]6TS['IV@:]?>'[:U
MWB/3(XXIOM$GW'ND\V=R+<&96,3'(QG =E-1P:'J/V>*[N?'_B!+=;@7Y)N+
M-?M**,27,;;B%M?WD3^6V0JJP*$NN#4/$7B;PUI=TQ\.:-IUGI;CRHWUYF%L
MC^:JW#H%!>W).U(0 P*85<A0E.1O&L5T^IZM:V*PP;IH=-O=9:1--:261UN;
MI8XCYL:N@$>"%C50>"K2* 8<OA>^U;1/[;UO7[N\$Z03VL&J3?:+<%G@\W48
MX0R*L$:S28CD3"K@O@'8.T\ W-O>0:M-:P[([W6Y[DPVTY_TIU> //!(77=;
MJVX-UW]@@;R:Y?6WUVQU'0M,\2FQM]#_ +5_>"XU87C+;L96V70G*I+&YC)B
M<C?&L6.9.#L:-JM_I%M9Z7:7EC-JX^V&]O[V60)%!;W)AEO+D-,6D9UBB5 <
M;=K@.$!4 '27M^;I[2VLKV.ZU.9X;F-(+F0)-E8Q]K58YSMM542$QOA9&  .
MY@7\_P#!RW/_  M+Q0LFJ27-Q<)IEW++9W;LDA9X9&\L@DM -Y49C8",A6DB
M!);T33+72_#MXL<OGHR1>9<WMS+NG8QB51->3+(=T;H'*;U"+L(^5MB#S?X<
M(][XOUQ-3L\JVMPVHGU -)<-+#'+*T:3J6/RO;0-L>1U5%QN<D,P![Q6/XG^
MV#10]AYYGCN[639!G?(JSQLZ#']Y0R_,0OS?,57)&Q6/XGMOM>BB(+.9/M=J
M\1AB\TI(L\;(S+D9C5@K/@@[ V"#S0!'X+C6'P+X>B2:.=$TRV598PP5P(E^
M8;@#@]>0#Z@5N5A^"S"W@7P\UO')' =,MC&DCAV5?*7 +  $X[X&?05N4 %%
M%% !1110 4444 </XLMO,\8:+<%9UBC\I'F,6^)9#<PF)?G(0;E6?.#G<(3@
MR"W%;GBPPKH]N9XY'3^T[  (X4[OM<.TY(/ ;!([@$9&<CG_ !7=6,?C_P .
MVV^-+QD\YFC^_@3Q1QASO4*A$LX5B02<HN\2/%+U&KRJMUI$)N)())[W;&R2
M,I8K%(Y7 5E<%48$-@ $L"'5* (]$;-]KJM+!),FH8D,,>S&88BH;Y1E@A3)
MW/GKE1B--BN?\)2V]Y9ZAJ5HTYM[W4)I%2Y@,<L90B%PVX[C\\3$;L%5*IA0
M@ Z"@##\0PM+=:"\9C$D6IJX_>*LI'E2*WEACM8[6;<#D^7YA7YPI'F_P*11
MX.UJ&UADGT]-=_T:2WNF$C >5RQ*QY0*$8]"XW H/NMW'CLS3::+*.YDC$UO
M<N(X;<O.\J1%HS"<8,JL ZQ@HY*;E<"-@W!_#W5K+3?A'#KU]-8P:Q%]LN4O
M9I)'+O(TH$ET4&[:[Q;<'=O,4>"7"J #T!Y;A;-_[3NOLMQ;?9KK4A:W(49!
MB)EC9Y/W=M^ZF5E906"R$<YWX=A:-XGO[34]5>2[L?M$6HZ;9%E1IW5+=1>Q
MCS<QP+N8^2V3^\8MEF5 :)'=K>W>J7HCTY+6W:*QM;@HATB%'NEWSHCHC0,$
MCQL.&$<>2WE>;727%QY'G_Z1]F^S^9/_ *3/N^R9\_\ TB?]\-]NV/E3C;C^
M';^[ ([#R4M[2WMVC>!TBDCCLI1&MPJBW FMP)L1VZ X:/OG^+=^\P[CQ +6
M*TTS3))]1OI);4;(VFD%P-L++=*_G,Z6A"E&?YQO8E@^&$ES4]8N8KV2PT\2
M6\]L[W,D^H;S!9('8R33OYP\R)XW;RD' :,@[?+(C-+TU= LBLM_(U_;VZFY
MO;ZX9WC*).HN;C=<$FW8AF6($!2S'@[B@!'HFEH=.6/49_[6GU2**2[/VA9/
MMH @W/ V]?\ 1%:20M$5P?-8*H5@KZEM>-<W$<1,EPDR0W(EM[A56].8<S6_
M[\E($X+H1AMXQOW'?'<ZI%;6=[=&6>VCL?M$["X#L]KM-R#<2IYH:6W;8?+0
M#L", #R\/[3-XC+3321V6C6%P]["9;HR;V22=HKN8F52;,E$=$&,LHP1&@)
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MY@I,A=B51(.LNKBSU#4YYH[B"ZDM_/L8_LDX25]\>Z6U1A,NVX#0HY8A=JX
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MT]XD>Y:*]N%=K$L)_P!]<;9\/ <85 <+MXQM_=^5_">]^U^._$U_:S0>7?\
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ML::A>V2QV]Y DS W\C1F HUT%EN6,FYK5FW;%P0H.Y1@?))<7%Y::=/_ *1
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MC(QMV80 #>II-KIINM8GA:TV6Y^TR+-(Q\J(FVG19"9KEQEU:,9R.,@D2\W
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M[@JKEF*C4U6X>.SNKBYB^U+-OM8K5PT45Z^9U2WD2562-6)11+D>:Q7^$HK
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M4%RDT#O=1E6N64S;;>9?LY"VX#-MDSS\OW]_SQ@I?0:E<A?MXEE>V;-JJPW
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M#YM#Q; OA[6_"^G:9>QZ"%N+QK>-(&N((2Z7&'BCRADE8OCRPL@1F11M# 3
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MHI61=[O\YP468[,!BPCOM3A\,>'Y]8U:WCL(-+38PLE$GV=<P;+:W+0('BD
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MP3)5CS=W(GC++ 3C3=0N[C3+6>&\5&U98_-EV2O&N([8&*6-2 \A5LY4,_F
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ME>'Y_P#5(8?-N8ES(=N5?:S;57?RR[C^[DPIQ'YFQ10!EC5;PAR?#^I#:BL
M9+?YB8RY4?O>H8!#G W,,$KEAP?CG5DUKPO-?V=M/&MWX4N[J!_E$QBD,!=0
M"Q0*%V^9GYL,OE$G=CU"O%]?=!\'M.MY;S:LW@\2)#.56$&/[-\P)!'F$R*%
M!5B2 $:(DLP :%J]YJ_@'1=!LE@GU*32HP\B3%8F6))&ABMRSXCN\A3YFTJ&
MBE.6,!1>TTRP72+>>Q@N)+JWE0Q>>E\WFW\JBX$D40,H$5P-BO)*NW>YD8A2
M"5Q_ LS0?#+00EO'*;BRC@\K3+E4%T")LI#NF01W"CYY7X)*M@D@;.@N=8A+
MZH\M_:26D*/!--;WPC,C(MP[6Z#S@()XT",TA(R,_="@H 27%FYGG:>U^RK9
M2R74!LMS^2'2<&XC408DN&,C!HCO R&Y)&_D]1MIO'%QJ%BD=WIWAJT1S=&W
MM2&G:0S,\EL?*WB<?ZN:,@Y\Z9"-RY<U:VF\<7!L[:.[TSP_IUPUY=SVUJ5E
M>4&21'LV\HOY^\D3*0'5QL&27W]1+IMM$DFGC1H[:SL$%S"+:U1XK0[K@K-:
MKY)+7&0I9,87>N-Q)W@$EU:^=]KBELI[-;24W"O:KGRL^:XN;<I$3),Y;:\;
M>K AE;][GZGJ7]FZ9-<)%!<SI=S>3#IT.3&S27(+VW[E_,N]N[S$)V@ARVQ2
MQ:37M6MM 2=[RTDM@CAK;[+$CDSS-<JK6@,69+IR1O0_*!)G)&XMGV6@WUM>
MW>K:C;R/K%N\Q1HSF"PMYGD=I+();D2SX(5@Z;W9><*R[P"OI/AR[T^]NKZ_
MTFTMWD1X6M]/L$9-*M8WEE@>V;81,YE3S&786+2Q$HFP*W2?84L+R2**S\J&
MS\J[,EK8JD<:*)440J$=I)O*2.%P"/D92FTG:9/W+EIH5C$=I</<.+2(2K#M
MDGWO$1"2\\AW)(@.Y=[8(8@OAW5_+>ZM/IFE/LCLY9[BXU&RLTE2R9)-SB%
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MG.0GB"V*R8,S0.)9P[_(48*WS)QG:LGSAD#D@'N%<_XYX\#:TP^5DM'=)O\
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M*DP\V623YDS@?,QRO)ROW6XR#@8 +D-W:6J0V$%S:?N[B"W:WMY7022*R(#
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M_+SD $0<$&;%R;X'^$SJ-Q"N@ZJ+4X$=Q%?H>6+ G:QR%43*03DG[,<C_GL
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M5F9Q)F)6!(*EE8 1.&C^8. >QI8!Q(GV*33)+=X+=+FUMHW:U81QA$M<P$/
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MT'X4U4+&(I],<^=,AAGN=L+J9)%:-!YO[Q08URRJ@)"# 'H'C:1DT>Q589)
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MXB$S0^:\9DM44VX$MNPQOE8EC\Q8@J66P;.QCMTN-4GCMHIK=K6Y:\N,_)$
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M;@=P /F\_K,[^*-1UK3XS ]K9W:66I7D1:V^U0$JZV,1$NV68N?*9G:/9YS
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MT[EMK0X8IO VXSO\[\8W3W7B^PT3P_Y]G?VW]I2O.L32QVDLT=VW!$8N%FE
M:0!3M ",BR@ T =1>V_DW4OAG1M)@M;>RBEOA=BT^VVVES"5W0PQA-S7++*'
M\K(" KL##AM2VT>YT[1C$#)#J%M9<R_/>K;.%N,747[E?/N'9R9  I;=SU&_
MF[?PWXUTR*26TU32H67_ $N=9-#9I5>96,MV"C.'NP3(GE(S)MVC #*M6-5T
M_P 8Z7IEU-+XATJ!+25[V2>WT')LHFDG9IXBS[7D*,1(O+!"<;G(,H!N7FI:
M5H%Z5O\ 6;2QOYWE:%M2NHUEC&^Y*O+^^4RVX+XCCZKD9P<E.+U"]L/%D!TF
M?4OL'AV.)9'M]5U".5T=78^=<,+L2O;OYL7EX=LLL;#:F/,Q+[0-5\>>)VUB
M\L=&L])L;B<7#W5[),S6TD9/VG?*!NM2RN8_+\L#+;2AS(L^D>#=?T3P^EI=
MZ1X?M[BVUBUU0RI.J-I<"GS!+*=X,\2YN(\.X8;6VLXP5 .LCT?4K.\N/[.\
M4ZKHMO#$UXVFW\5O+%I8D$R)(S*X7[.J1,$A5F",$9A@$5A^(9KG1+4W!\::
ME++<(][;W4?V17A5)9F@EG=&)DLV\WA CY.U5"%A$=37?$GB30M.AM[S2X/M
M$,ID5WUR1FC8"XD-Q-Y2JTD)6&1S#L5=JA5#$E(J]GIWC#3=1O\ 6M1M]#;7
MD\^87+:A-Y=A;DJH$BM+E[>0I)(JD@1!)&4%L1  Q]3\)OX6-OK&IZ]?7>K"
M[LK5I]1N&N!9HMZ62YE*RJ%MI!$6\MP=KE0'!!-=!\/Y_,\%Z@T6J06T@N[R
M?[7''M-HS&X NKAWG9;J/Y0 <NN4P6<H76GXIU7Q5 EI:ZL/#]A!%J<%VRC5
M999[9?MXV7,B,RB2WP579D8)4CR]NU*^B:E<ZIX(:TM-1CCTF![ZZO=1>%W9
M;=WO"L_E2,_GQ.RE#')EQL8X8LDB '276L7^L7DFF6<O]FPZ?ON-1OGNY"+&
M4BZQ(K^8%N(1+&,HP"J%VLF=RP\?\/=)M]/\<^+]*CTW['!;ZW9);VHG*,4C
M,[(X68MYN542$$\+NDCPR(*]0N8;>"SO;6.3^SX4^T7#@W!0VAD-R6N9F6=2
M87.2J@@J>?E*_N_,_"5FW_"QO&\4=O)#)_PD=E,+6YE4/./,G=F7< I&W=,
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MA<MCQEIB^; ,Z?=GRVCS(V)+;E6V\*,\C<,EE.#MRH!L4444 %%%% !1110
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M)8VO^BJDMNQ$8#H^_(4,5ZC+T'3-2OWL=2U?2+NQL=,>VMM+TV#<[VT;K9,
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M-RS,=JAX]OF&5?,IW6J3ZU+_ &&)<:5!*EAJEW()6$4<S1H+ XE<37+$JCS
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M=CFOX;\/3:)86FJ7MM=R:U;64=C(+5"&@CWQ21V4*,"DD0R4:9G)&&)D')C
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M>FU=DXC>(,OIL.$#!%]4\9?\@.V_["NF_P#I;#0!T%%%% !7C_[1W_)/-/\
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MA699(]0UW_A'=.-_=3SQ16<2F5%E^TR'8&D^RR1&1CYWDR!_-5SDH7<B-0&
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M;<121;+;:A26Z#0QHYPQPFP*%VANHF1DN+J(V,ENENC7(EMX5D6 N;G,UO\
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M)W3(\E=JDDJ?G^]L*>@>+#"NCVYGCD=/[3L  CA3N^UP[3D@\!L$CN 1D9R
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M#99T;VRO$_C2D]SX5\3)*D9FM;VRG1A;1,PLF38F7.&4>?\ :,8RXR1@(Y-
M'2:K8_\ "08T 206NF21"TN&L>)K51L2:WLV6/,D(D$"RLR!4!8$G[L/01Q^
M1$\TNFSQQZ;LA^SVL',2[;=RMJZ;&>W7:=R;2SE2H&%"&,3VC/;P6,LEEH[7
M$*0O;L^;B0+;R0BU"Y4VYC619 H PKG@!VK'U37['3K((MM(+RW=H+"TT_EW
ME@2"5K6U\N$LUN6C,<C,!M*E2 ,!0#4GU/\ L7>$A\O^S[16EM86S';Y\@);
M00XC\[S=LBQR$'#JRCJ8Q3T[3-5NCI^IZQ'':ZA8ND$"K%)<M8H\D),89U)G
M>2([)+@-A,' _P!8QCL-'^WZG97_ (JL/EMXG@@AN[GS(M/:6.&+[/O90;MI
MA(VYV+J&78,G).Y:0M]GMS<021/'<)/*4LU5K>Y<1[EB0(X*/YLWF2!V*[Y!
MO/)0 /,AL[=;VX-W:06B(LEQ=@//9J1 3%O*,'B8#,LN]MI#'?\ +F/D[_7=
M1M=1T_2=,%C8ZBOV7S\VBSQZ'#*;:,619,;O-<,1@YP%X5<2I8U?5]4CU&32
MO#%A8MKJ2QM<3;=\.F&4Q231OMA#F.5BA##)8M*Y*"'C4T/1SHCJKP7;7<SK
M)?Z@K27!BN"MHIAB:96D>"0+R^2$$9RRE1L )-!T;^QHBCW?VF=)8UGNE?[5
M=P2,ML&A>0QEI%?;N9V"%4*8"JJE)&FAM;=GCGM+$Z8\5O.8H1)]CXMG-G;J
M(E+I*N "/FW,@52<*DD#_9[P6XL)[=;"T#R36UKN2S4"$_9;;]R#-&X1L[ 6
M&W'RDH%Y.6W;Q%?P-<-)8>$;=(;/:(U,$[S(L'DV>(U/D'S IN",D,1$8U+D
M@!IDMWXV>,"WCM?!]E>IY(BMDE,N%6$6T6Q2/('S^;(,J0[QJQC5G/6645Q;
M^4)K7[))%+%''%;VP(L;8[$\F%UC821O) &.=A6.0,WEE%%%O;Q1ZC!_H\]K
M-8Q1P?Z- YCM5D,'^CP?N0DL),7S/]Z,?W ?DS]8U;_A&_(9-*GD\F5H(8=/
M@W31PKY)6"U4P!9%=%5G7>"H67:S>5\@!7O=3.B[0S06UZOEV%O;V?DS1V$K
M;3#;0[HHBZRB--Z;PR QGY$/F+'X<T:5+V*]U>RDM=0LW MXH(YI$TN*9X]E
MM#N1HI 1O$DJ8\L'8-J!=MC1=%FM-4#ZG/)<7%BEM#;M#IQ5-/7Y%$5O^YV.
M'!<32ILP HVQ@#98.F0VU@DSZ='I)T]&CC_LBS%PUC(S@DVJFURXD63$C!<#
M;@#(9@ 2-'Y$$DP:^L5@M$B46.G^8VGX=4,5JIM29(W,1+$@X58V"A64C#N_
M.UC5$T"V6TL;C34$5[-8Q&6715E\E(H[1_)4XDB$FYMO[O)8L BJ27^U[_7O
M[)LUDTV*R2"&ZN+&(2)I9\R!X[>T<0JT@D15,H=3&@923A2C;'A_0SH-K:6E
MO:1Z?:6CO$8H!)=/;M)+ XCAE>(%X'^9I&(.TG 91'E0"30O#]OX>@AMK*.>
MUM;;9"(8U,WV-W>)WC@=H=\D,C,?,D9OEV\;-IV4]2U6QL/#\E^-0CTBTL[>
MW)U&VL_.CLXI#!B&T;R-DT3A3EAG:2I*XPJV-4;3=&TUKN^>/2!;HB?:;6V5
MY+)HX@1%:@VY\V(1O<$O@[ TG &X)S]GI=SJ6J6.N^(["TLM/L+V"#2;0*ZG
M30?*1/+4P 2B9C&/F"F$="KJP0 KVFB7VOW%OXE\06=WI%CIMN@TK3+6S\V?
M2928Q\D0MV$P*+&P;!\HEEVADW+W'V-EMUB02:>\2);++96ZNUB6$'[FWW08
M> XRSD87;SC;^[CCM;A($MY8O[,G2)8XY=-C$WV%'>-$A@9K;:T;>5N?</DX
MS\NUEYO4=<NQ;V>EZ##:#6KBW(MFT]TE73+=A"L3Q;K<"6U9O*WD#(R^W=Y1
MV $=QJUQ:Q6FD>'IIU^TQ6L&F+:R"6;3()%A'F/$0\<]NH0DW&YOF<QAEY<7
M-"T+3?#NEW\,,4;:F',5[+#MC2VDE\F1K&U<M$\:.9LQ -A6;+'=P;'AO38=
M#N&&ZT?45=8=2U*<AA;3.;9_LD18*[))YK,K%F/F'<^]V.=33)$L].LHX(_[
M/CM)8M.CM9Y5;[%$1'B.8+.5>1MJA&!+#ST^4@ON )(?)2XM;AFCAGM46T22
MZE$C6BR&V+6TQ\XEYY#M*OS_  ]<_O.3U2XUC5KR&QT2XOM&$<L5I<ZE>3N3
M8*HC>*,QM,4GFDF^0ORQ1APZ2([ANKS6=)'A[0KW_A'S8Q0V%S>JQDAT[?&B
MFS1_- GN1($7>!\BN0"'/S=!HNE:7H4%G#IT$%A'99MXA+)O^PB=[>1[:7]\
M=TTC$%6&0,KU&/, )-%:&TM46">2!(;AXC]LPIMFDEB+03J)!YD[LYV2X;(8
M-N??NER[O7K?P[:S7M[?3K!I_P#K#>W1\R%TB25;,IYH2XF:*>7#@GE(]_F,
M@8Z&I>(+?P_IT=W<23AH-EM%;;C<3*["$_9'03$S7+C)5^=H)).,E\O0XM2N
M+^VNM<N(TGT^X")#)<L\.E2,D*);DEE:YGDAG;]\S,%<X4<D, &E:8;S7K?7
M]5N(UN-.?[%8QSM)C3?WFPQ3;I\R7$T4L8WX*DJK N"A?H(;F:*XM562.&"%
M%@=[JZ+M:,QMMMO,OFD2SN&;;)D[<K][?\\=BV/L%U=""UOK:)+4F6X\_P"Q
M>9]F+VLKF7,DSG;M?']TD'/[S#FU]IWM[?0-6D\]GLX%>Y=9XM.$BQ2;9V$G
M[X31J%C<;R9&=1*-XV@$=YXJU.WGL])TNW@76Q$ENZWMQ-);Z7(Z6[K%=.&/
MFM)EUCFZE\( 27-:GAZTL='06]F\EN;-TLR]ZVXVJ.T,B6<C>;B5P)RL3#<$
M#;<DY\R/PSH%OX;L[.&VM[XS6V($NKRV,DL4<AMMT,IC;$K85565 4C6( G$
M9W7&O2ENTJWTEE'IKQ03"4R2SPY%M)]G=-SK<2R*2HD4E@9 J[F+$@$EO?O:
M:=!<WC_9&M(HTN0TS7*6 (@+Q7#"3,DF"S"8C"KEFXSOY>SM[CQ5>6UW>RSV
M.@P2^1&]P0YN8'%N!:F5V_>QRNL9,@$GF'S(P^T*\V?E_&=Y:2WL\]EX<MXH
M]-NMDS/*[RBU/V42Y+21RO)'FX!.]8\#8K&27O(5%K<6L;P1V,<*+";A/+2.
MS;-L%M("\:EXI3QN ZKM&UMH0 KZ?'-!I>G6T DT][1+:W-O:DW2V*_Z,6M9
M0'.]RI($NWY$);*]7IZYKB:)IUI*.+QY8M-LE4+<7D$\@A9;:4NY5]VTM(QE
M3Y0N"6(>H]9U4^&WT^X>VDEU H=/M#<2R2(+AUMV%FCE5,@E\MC]H?(1E.X]
M4H\-::8'CN)VDAN+%(M/%O;&1SI<;+:NMF%(=)01@R7'!QW4#Y  \/:+<V=Z
M-;OIX[C6"B64C.7N)=.@=X76R8(2)2 [$W#D,,J[!E)QH>0T%PKV]K&MQ96Z
M6\ LYU:*S=C 6LRJQ96)MD+>848A&<_NP%R6LZVKNUY>QJ;2X@LC(NZ66S>1
M;3%J)'C+3)(S M*<'YUZ$93F[Q=1U]I?#D5E_9UJ(H;;49HK-7.EP310AM/M
MV52)&8@,TF-D:,">BX +E]XF-W<1:-X6U&-[P(D#7UPTACTJ%RB 7 D?][=-
M(I5$<!\DA@!N+V-+T^TT?1GM; R+9VUO'96PCN7@81LL+>5+$9(A'>2M*^UP
MJD;E+$$[6L:<MMX>&GPV\MI [W"03_;)TCD>62.'<DY20B6\;_6!]C;@I7*[
M]YCFO$LE2?6;KR;&P\I&>YVR06Q>6W,<5R//=VN4 4B8X1?,W\]P#0-Z;3RK
M^^UC[-'9Q"*Y>\DA6. M]F)2Y"2!3<'YMC)A%$AX((W\?8:=_P )->65Y>Z?
M!8:187;VT=E?=&CE$+,MXDAWR7$DK(54A0''F%I<Q^8:/&GC)8YK^YOET2U\
MBQ$&J2*PE>*6-6BOHS+G[2TB[E*JO#+O,@;RZZR,W-T+2S>YCLW+M:M$UT\L
MD<7EHWD.ZSJQNF0>8) &V -@M]]P"Q;.T-Q'*;Z2%(TAMA%=3*ZV9)AS#-^]
M)DN)-X"N2P'RX^\?-Y?5]9.E^'[3[)-J4^I7EO;:=;I>32+)%O-N#%.HG1?M
MA69Y P*-A3\P"DG0E\3KI=K:%;J.YNOM'V."(2,PB/FP*UG,WGNKWFUCM9CC
M*NQ*J')/#VDM8WHUK5+N-]=D1+6:YN)5<6*.\,GV)\2@-*S2,5=5 RXVJJ;(
MR &EK<V6I/J%S+&-9O7C6<33NUOI\1EA8V;L)"'G_P!)D,3$#)<A0J86M2+4
MTMKRVMY9_L>WRK:%[RZ5PCN(B;24?:"TMR5!97P<!Q@M\V\CO;BVB>0KM^R;
M(8(VNQ*Z!EMS]GGW3!6N79F",68#<I+?,0_-CQ%J"7]AIUC/(L&GO%;3WU[=
MPO).VR,FR&)C'+>.\;JS-M\L$X'S!F )-5U'4=4QIFCW4]K:6\0AO+Y+Q3-;
M[MB?8E9I622]:1<>8Q_=AQ@EGRVYIW]FZ%;Z?86C6FE01NEI;V\DJA;=G$+F
MVD438DN'!=E<9QDGG)\R.PMK/0+-/[,M_LD=K%';QV2SC9;9,3?9I$-QY;7,
MAD.V3_;&XD8WQZAXDAT"W$UPMVHMDB@A3>+B0R.(C]C9!.6ENF RKX( ?.XC
M<6 +$VK-IMO-.8;O9I]N@ ,JS,A81$VCK]H)ENFXV.1C]ZN"V3OS]&M%N;VS
MU[47C6\@1;:T%VS,--B=T*PRK)+O%Y+'*BL_/( Y'^LIZ=8I=7D&IZU<>9]I
MQ90VEW;+)%91,$\N"ZW'S3<O%(XW2,5#3NHSY@$G2962W6![F2W142U8RW3;
MK4.(!Y$S+/EKA]WR2 DC<,$Y_> $EO<>5Y'^D>1Y/EP?Z3/YGV;=Y'^CS_OC
MYEP^[Y7YQN[Y_><WKGB&^MG72-%,@U);>.#S))?-;3#*L9C2X#2E)9W\N4([
M-C>8U)Q+O:Q<Z]<EX+'1+B.+4H4:(IJ8=TL@5C5(KL_: 3+)+M$<H#E@6*A@
M2[7/"FD?V-9VNF6$>P6L2K+/+/YCHV8R8;B-9,&80"(*X+*,':$3:C@%?1=&
MM]-LY%EN=M]<;8;V]DF*RQF0PG[/,ZW!=IL2%86W,8U*@,W638M[CRO(_P!(
M\CR?+@_TF?S/LV[R/]'G_?'S+A]WROSC=WS^\CL/)L+>TM[=H[*"S2*TCCEE
M#+9J1;@6TP$Q#SL#A'YQN'7/[SDR;CQL\5M<V\^F^&K&[%K(=28,]Q+#<6P^
MSR*TCK,KNLBB4$L6!7C#>< <G;:S#JO[1_A^.$VDAMK>:.:XC0">:3R)!NG/
ME1D2[0@:/!$9!48.X#USQE_R [;_ +"NF_\ I;#7D>N6TND?%'P?8Z;81O9P
M:/+]G#7<T-U<(+5HV>5(T,D4H2-5!6/<Q0#.5"Q] DMQXB\-Z+XI6PDMX[W6
M+.5T/B2YN5C4WD(7$./*)+;@4X\O _B&U0#URBBB@ KQ_P#:._Y)YI__ &%8
M_P#T5+7L%>/_ +1W_)/-/_["L?\ Z*EH ^8**** /O\ HHHH *Y_QLMXWA"^
M.GZM_9-VGER17I0LD3+(K?/@'$9QAV(*A2Q8%0:Z"N7^(MQ9V_P_UC^T+Z>Q
MM)HA;2W4$0E:)966/<4/WE^?Y@/FVYVX;% '/^.C;CXK_#@W4_DQ^;? -YQB
MR_EIL7((SEMJ[?XL[2"#@\_\"C;V'@$3S3[81=R7DW[XQBW&R1#-*6*!H2(]
MH #@.K-NR"(NL\80L_Q*^'\L)C2=+B]4.\BD;#!EU\K(9B0N X.$.-P;<!7)
M_!JYM[7X?SBWU6QF73-0\R?R<Q[$+%7FEW&+,9BRR[]VW9N^8J(HP#T0HSN5
MU"QDF$SI;7K1PK*) ZR'R7W1*9+=#,H5UR<D[]H60GC]7MM7U=+KP_IL<=A:
M"WAM+V2&U EVLUPOV4!H@1:C<J)<+&=O+8<>84N/+>:KJ,.B:;:P1PZ?%);7
M1DL28Q(2CG3RS6ZJMLT*D"15)(6(GDJ)=S3K33= L+:SM[:33++3GGA%U-$J
MM!&'68KOV%/(=%.Z0L#PH8F4DJ 27-HEI%+:V^F?:+==MD5^SJJ2HRR;()0(
M?^/9/-C4-&'QEMW"R$FIW5A!!J5YJ_\ H5@\J6MY/>Q1CY Z+'%_JRLEO)YC
MDLS'9YK#Y3N$9<7UOH7_ !--2D^Q0K+##>R[2RH[[VP\\N"]N'G0+L4;&SG"
M[U3EX-%N/$%GIFHZYH,$MC92R1Z9I;68 A+&6(+/OA#BWP(2A2-2H93(K>7O
MH DAT.]\17$NO:M:2?8W=&M]/N!*)IK@&:';*1$K1VN)B A0@I^\<*6E5^LF
MDN&O)+Z.VG\ZVEEA1;B,*<L(U2-62)S]G<[96D#$J5&[A61([JQ54UI$ADG$
M[QQ_Z0C.92S;C;L6A8FW)DY;YP@EE V! !E^)]0>.6:WTRT^W:CJ'[@6UW:,
M$D3=Y 63$!+VR%Y97;<,;D&=LRT 9_B/5$T>5-(TJ"QN9KBTEC-M=6ZP)!;1
M-(A-UE !9()&VXVD^6 ID$C$:&EZ1%I<4UYJS0&/4_-DUJ:6%R))E60.CM*A
MQ:!=P3.P*(TY<2FH['PY;6CZM T,;ZGJ5Q]KN% 2,7#E94*31QHZI:R+&^TR
M%R3*^?WH!.Q'=@7OVQ3=AX7G%[&;6,W30J\XA+!?G,&5D\L(I=R4.?\ 6;@
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MC:3!$LGDM(KS;D9_*!+"5,7-%TFSL=.N-&MX((H;*6"TN8HK$3QM'(-S6CG
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M=(U>.V+0AFG52&P$4@X6NHLK!]-L]*M[=/(_LS;:LQA:<HCF+_1T/EJSPA6
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M1C=69L_,#E0N]BN7XO\ $KV,365BT^H:A?Q746S3Y&C=DC6?"6^691<(WWV
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M]S\.6#_V=IE_JB;M573Y;F.2PA:>'3XI02TEM)Y<@GN'(C+!WD9B79258AP
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M O!-K]EJMBZ13:K:O>:BK"251$7BA'GG$@W! @ 4@R*N4=MUB+1?^)=90?\
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M#[E&I7%Z=<6.JV46IZ5H7B V>JV[7NZ*[^S(KLDF5$;3H5=BQ.Y%VLSK)N)
M<6((YX8HIWT3Q//<);AF\S4H@7<3[MI5;@1[R?GX 7R_D! _=T <O\866WUG
MP%=O%(R0Z[$6:.!I& W*<#;&22=OW0P+8X1\93T30_/&AV4=U_Q]11+#.1YI
M!D3Y7*F7YV7<#AFR6&#DYR?'_B#I$5AXW\ R1:=KBJ-;C3[7>ZB]S"/WR@*
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MN9A)YC^8^ 5\V7#<?* $<<WV*:'R9--N[)-CO8VYD%C;[ 1':,UMB8-Y4>Y
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M!M^Q552&(0*N8_#6DP^&M+C:Y62S=[B+SIYD$EU%<3_90T)E\LBX$LN=\H(
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M6E#N3;,UG,\C8G60, LRAO,$F,@9$_4:5Y6GQ6MNEC?6]K:1):P0B-R+92L
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MY498)Y^[D"9R6#L1@Y9!Q]I!_P )#>:==7+_ &+PJ8HH+$-:^3-(LX@G%J^
MT+6S )%G"L6019;),@ :9'/XSNK+4IX[Z#P]#:16\>4E:2XWRQ[HCYB%YK>0
M1H[S,%W(R#"8GW=)!=VUI<&*5([1+)[:S\VU5&6RE<V_^AIF)3Y3[H2& .=S
M9,>Q*DCM8)XGM)[*!(;?992Q0+%.+=76W)MHT6(G[.X/SF0(P W8"[67#UWQ
M-#X>%C''-'/JZW"6$=GYHEN&F:.W86L4LB F)R8VDG<D@'&-S+L +&IZ_;:(
M(+6TMHY]81Q96NFV.P212B.WD-K"6A ^SE,-)*<;!CH=H2/0M(^Q7]U>QMB_
M>6&VDNH(?-%A&DZ?\2](=BF.'RV7$@7#!FE;: F8_#WAB:RN(-4U&*,:O%<+
M!<7"V1;[+&I"Q6]DFUECMRLGS2 YVE]VUB3%N26.[3KF!].@'DQ16L4"P[HT
MWB,/:H?L_P#Q[-MC#. W#/D)Y8  "U7/V2>R,$*V4HM9!;V_G1V_^JC>UAVQ
M*6AR"2X(V/&-P*HR+RXLK/Q*L^FVL/\ HL4HT[5+Z&V!-NJ2Q;M+A,2Q2^3R
M<R%2H3.2<G98F;_A)]1.FV4L\5CI<MJEY=2Q_:YT9BH>Q215)#*8XI'G65FC
M?:<_+E=BVTRPT[18H[J""WL9)6MF3[+&!;F:>-#:1)]G7=;R/D%V + JV3D,
MH!'!I$,=A<%=$CBGV&R>*5!)L4O&5M8W\EBUFY9B6Q^[5B-J;=L4>I/8:)H\
M>J:E)]CTW394>3[=81N;-&:$I:QI%'AHP=A#HYVR1)DN%8"/4;^QT+2Y=5%O
M'87D2+I\!CL=TJRKY?EV5JC11M<0.P?D,.I*E1S'EZ1HEQ?^([#Q+JNE3Z?-
M8R_8+.ULHQC38]D2A#F!#-&3YR%U+H@DRG&Z1 "32?"D][?C5/$-C';O ZVM
MO:0V\4_V2V=(Q]DXM0)(CYDBLZDB-5VA^93726EC]FU$3_V=!:>3%;VOGVL.
MZ2WYB/V6(?9QNMN<E\_*6?A-N4CBM(=*2.]O)9+5-/0Q/,J@)8QNUNY@B @5
M'M\( 92,H%/S#YBF'K"13ZFF@:?H\$FJRVB6UW";9X[:WLVCYMOM*VX(MV"S
M;65MPE"C:5W*H 6]^]W!9Z=X<7[//=Q.D%U&C.^C$/B6,I+;C9;[K=PH<J79
M0BJBJ&CW+73U6_OK2&SN["SNG2V\V,LDL0B0;88MD96.W,:LP<2 J\SJ-DAX
MCL-,_L3[-&UY?2WTMVBZEJL5CF:]FX94<"%A]GQ(PWAE$054#=<%I;P?91IM
MQ;_:5M?L^FSF""*7[-OBB:2 KY* V[@0[F53_K3Q&L8* %B'539Q1WEQ>;O,
M\JW1;B6$/<RJLBFV7$PB%SYH;<RJJG(3G;N7S?XA^(Y[WP7K5M8:A]GTVSB^
MPF^GDEC,LA,<AM0IF:1YC$RJS2("ICF#8$C>7TFK:A=ZG?FWT_7)+2>5VM9K
MBXO4BBC\U) +!3'(R?;%DP0Z(61 N3)TDS_'-QIMA\.=1;3M0M-,2.R;2LJ%
MG>-4C4#3Y-LS;IRQ?#X;RU,G3)=@#I/ALWF:+8MYL$NS1--C_=1X:/$);8[;
M?F;Y]V-_"R+\BYWR=Q7!_#![:70;*:%XWD?1]/!=+E)056-DQC[\9#K*I3[F
M5)7YVE [R@##TJ>:3Q/X@A:61X(G@V(6+*C&,%@.H!QM)&Y>H/EKN\R;<KG]
M._=^.=>B;YF>TLYPWHI,R!.<G@QLW!"_/PH;>TG04 %%%% !1110 4444 %>
M-^+B6T2*[-S&^W0M>DE-K;R*)&D>)2#&@4H0\@++('V%6WDLIE'LE>1^(KVY
MN_#\9,4;2P^%]<L[QFF<X>$PQ.R%MS.#)'QO()4[B<C! ,OP1)?ZO\,[6RAM
MI[RWAT\1W=Q''('U,,]PD>GJ\D7RQIN4-*K8CR0"!EQZ9M&FV[2Z/!'=F)'A
MMDM?+7[0T0GVVDC+'MBBC/RJQ(PWRGG._D_AGLE^%^BNNGP7<%Q:/;3*MBOF
M780W&Z!@,1HH/221B'+-N"L^3UFHRVT-AJ$VH7$C6DB.F+J1$-P(WF>2 13*
ML03RU9=_5X\DMA0Y *=S=Z=H>AWLQ/D6$$5PLOV>]:4W*Q_:6=(F\Q66Y^5G
MD<C=G(+,5WKAS6%]XP\0)JDXNY]+L7\Z*Q5?*68*+R-60ELQW2NR C<A3:K,
M5<A(K"6DWBS6[>_U,1II;7K+9VT]T0?D2X0/$%VO'<*5W[" R!W)9G1%@V%F
M;4K=;F_MX_M#O*D<4-RI9RHN5$$#"8"*Z5,B1U./O ,0,H $M_->/.8+VTNH
MKI'BC-C<DF=0JS1QI^_3RYVADEPRYR%20LH 2L_Q)XJ73[A;&T:/5=3O7:W%
ME9W;1R3IFY4+$%D)A>-U DF(4 *QSN4(M/Q%XH\BSN-,TR^GU75]3Q%;/9R[
M#)'*99$2#:2BR1Q-'NE. J/%(V_Y4:Q;^'((&U:\FO\ [;J^JRR>;J%J(HGD
MD2*>)8+,&3]S-$H8;FR?O98\[ "/0/#PTNWN9M2O(]6U2ZN)@]W"T<7VEE%T
MHAM KH()P#([D?Q22_,<EDU+QHK26:YB'F6IBNTD&GW#H;IMTSF"WA27'VD%
M7+R\-E2!]YO+L75Q%+=7<[7$\OEQ&"22WG>*&=7EEC6WA/G!%N5D5%+\-D@?
M+N&W#U.>^UW5Y+1;J2>SWOMDC@\E',,[$VD(>52UT3;R$SY C$:L@0N7H CU
M&_U/7O$-Q;:==SP6*13V5S>0236LUQ('F(@LTE_<-,GDX>7K@DJ4QQEZ_+8_
MVCX=@M;V.:SO=3\RRFTV^\F PQ6\T2VT %T"LN2$WQB.,LZ!AGY3N6BZ=H^C
MPVUB]C%]F_XE;VEGJC1PNS,Y:UA/FC%VORGS'56<GJFXF/+^)-\MJ^@ZG--J
M5U FL"W9=*=L3DK=((XU28.LZ<HS*RAB_(?:$4 SSXC_ .$"37]*UR:2UL(+
MUOLUW";J[-W!,TTY@#JX$-T!)_K&8,0RDA@%<FAV^M>*_&;>+==CD6P2WDM]
M(LUN#;RK*T4BW%O$FY&$ZLKJ97*Y\LD* 5:+H+/1A>7&HZAJHCF&H)<V<.FP
M/&D?DN96EM8MLH'VIFC#S2$D9!53A2PV'>VU-_[02^CU&"="MJ;69 DQ5;H;
M+1A*#'<!6P\F0"%XV\[ #F_'FI6=S\-=1GO-;L9_MEH\4-Y$@>QO9%6=EB1#
M(^R0;"0X(.]8^6QY=<_H?B?6-3D\11:&/M=WJ%V8Q?7#.(9W2T?;;QF*15%Q
MLAC9ID*IEGP=JP[]CXDZW>-I.I6^C-!>3RVE[:WEV;DBSAA2.1Y(!&)CB["[
M,93)&X\*&"Q_#BU73+3Q#8Q37=RDUZ?-GDU!FGOIWMVED@B#&(Q3QY4-(P#,
M58D)MQ& 8?Q;TFSTCX9R16U[ 8_M<:27'V82G4+A7D7E@YV7"JKF67:#(0%R
M!E!Z)9V,/]IV*VJQM:V>NR>2UE9@*%6RDCVRL J@(28@RAL>7'&?F#$<7\;K
MJ"]^']^T=[!</!J$4,DD31/'N5I?W(5I2T<R*PWLB[F&!C9N"=A;QV<.I:-Y
M4<#V\NMEK&2Q00P^7_9TGED#9B11&-F59@2 0R@>4H!W%%%% !1110 4444
M%%%% &/;7.[QEJ=KNG_=Z?:28:7,8W27(^5,?*WR<MDY 48&WG8K#M9YF\=:
MM;M+(8$TRR=(RQVJS2W08@= 2%4$]]H]*W* /)_B_-;Q>'_%L=U:_P"MTJP,
M4B2%'F*W<@(&<J5C9XR0%!_>X)&Y2-3P3:VECX%TR.TNH[P7=DB27%G<.O\
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M=!J<UCJ%Q/)#IZNHTY1<S#S_ )@Z0KE0H@0[O+WONPS%=_XI:Y;BQL;3[?\
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M"_,.AX'(Z#I6Q6/X379X-T-?*@BQI]N/+MY/,C3]VO"-N;<H['<V1SD]:V*
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M"9)57S#E=X,@;'+@9'[I"/-/LE>)_&[;/X?\0YM8VE@?3Q]H"-N"9EPI4JW
M9GQ*IC#>88]Q,;(X!Z);F*.UTR.QNX&M'EA1XK9'B2X811LAM"9@JPJB[V1/
M,5E5UY;=GE]2UZXU6>;0["^GFO+KRFN9;"Z$:2J$W9L&>5#YQC,$K*&>)%)S
MO9B);%_J%_JK1:3IFH^3J&J6D(O]3L;J22%)&B.%LPY\L, 1*RY1S#\RAF(9
M=33-(LM!MYSH,D=M;:@AE@6P$0BN2PN)%^S*\A7S]I0EFS&4C0 !1A "/3]
ML_#< EN89Y[N*5M2N+Y+,7-Q'/.Z^8D1CMAYBOMD5R '5-O"J5V:$\/V&6^D
MN$GCA7?<1BTM//-E([.BR6ZK;DO(X>1Y,ERA/(*L28[FW71;!([=H].2QMX[
M.*3RVG^RVQ=E7R&,>99Y-D*^62P#",X? $G'W]I-XGU3>$DM?"FEH8H6L]-,
MDK*^U4^RYM7$MNR(H95Z[Y 2\6S< 6/[(;QN]M--;R6/ABW=;=($MU,I1E1!
M%;/'$"ENZNOFR*[@[656$8\QNH^S7T:6UM]FCTZ146(S6 \TZ?$[(B16Q-KM
M=&,2EPP'E@Y/RA"))-,2Q@>*Q@_LI;6)@O\ 9MJI^RP%Y'+0 V[!Y)"D>^+!
MQP1SM+Y>L7FF^&["8112:2;9Q9P1:=9J&7S'9U6SWV^V:68K$'C!*K@G(*[F
M *^I7\.EA;>:SCLM2C0>7'IT(DN(5CC(CBL ]J%N!M9PW_/(3/D@=(_#FC7%
ME*EW>Z?]GN+/=-);Q6PV:3$S/*L-D$MMLS.C>7,R-N.."3MJO8Z!/I\L=Y?P
M_9K_ $^(PNVC6<OD:8LC%@;" VSK*TF0)6Y9<GD#@=1=65Q%+.T+?8O+\^:2
M6TM!)-!%(V[-NWDE79VAW21%6;=+G=\J!@"NMKIVG?:(QI7V5=-\W[/+9::T
MCV/F[57[*!;X?<-SR8W[&)5MR],>^GE\2WDFDZ2\^GQV5V(]2O-/1)$M+AP/
M,%NWDEFD?[3(KR90Q>678*"1(7R.^M?V)H<7]E6NG12&[GTVQ8_8 DT,ZI P
MAP\DZ,-\7S#@'#;2)-33O#UIH]E$L>EQV4ME;L56UWW0T]6213):.\!+ROL3
M?&!R?F()8^8  T"&SM[<6-C'IT=@DK.]K$))-.D<&63[&'MV,HD,A1L8 "@*
MH8%1'JAT[0);.UDA@T>S;?;QRV:M&+(%I)5>(K!M.[R=\RNPC01C<&4DO3UF
M6Q\+V5Y<PZ7()[)V@T^WM=.PEF\R.(_LD@M2"\K>6'R656?!)X5Z^@^'XM,,
MFJ:C:QIJ<5O+%8Q6-C#'-8H)"ERUM#Y8,D0=O,1FWL4E V[F;S0"33O#$MWJ
MT%YJ^EP:=9:5=A=/TVS@25+2;S$_>1$6REHY0Q+'.(^6)#C]QT"6]Y'+:BXM
MX+=DNQ<S16T!F%NTK%08)?) ;<?,\W*[@+AV+H NZ-[9EO[21M(CMDTJW0[H
MHED^RH$R19X@8R!\&%URC!44J@W*6P]4\1)IDMG:V%O_ &A<7MVYLX[8*'4S
M-(XN;-C;B*5O*F9G9GV+@!F)=F< DUS4&M-4L]/TS2[2?Q%O>X55C4G36D\L
M-(F809+=Y7Q+("'P\I'*,(Y-(\-V]O8LRWD[7MYLN)-<T_,DA,DR,ODGRF40
MRNKS21Y*1F1N"C!A'I'A-?#NDR07-O))/L%U=MI4++]F9YI"4M,J6"!)9U(C
M<.JC*('F).PQFM+><7MG)#):ON:6QLC(J-()1]KM46*1FE=I"'1B=OS$Y4[I
M0"2&WO!]G>>W@MO*U R3PV\!E^SR/MPT$AA7>K[V$C%<CSY3YB^60>3M;F;Q
M/<:9;6-U';:1:W#V\UUIRF%KF%#%&([ QCS%M_-6(RGHN<+*RKFK#6\OB#5[
MVPT]KO2M%MD%G)=V$<PECD$YB$5FYC41)B"/SMNZ,8  'SR'J(K%;>P^P6\,
MFEVB)'$T.FHR+:W!=7#0@0CS$+2'>Q^3Y,,N#(  9^APVGAK2;:RMX(]-@M+
M@6@A29[F*U:6:',3_O=SO(TA:.0J-B2#<J\JTESK]KH.G3WFHWGV>'2?+M[J
M;]_<1VVX6Q,3Y8//(P?*S;. 3N .X/'?>(5T.WGNYC)'::59>9<--*SM;#$!
M%M)F4I-<. ^'W97*9!$@,F?IVBWT_B#3]>UZ>2UEL$2"QL[@^9#ISR"%'0SL
M4>YEE5@JO\RJY<9<@9 *?A?3[B6\T^\UBV@L;C1I6M+6WDF#1:,"((X[8$,#
M<230R ^8S,%;: H.5/46,\L7V!Y4@@F2)(KB6\NDN'TZ1OLP^Q[\AW:0'.]F
M)+!2=P*K1I\VZ>1/M.J_Z-+%!LQYC664M6^SR\OYS-NW&7#;5>3]XN,GG]3\
M1:C#]CT70;6"'Q#%%;[["W=7BTF%_*^2:,/^]7>H0O&H,<3EACCS "2]O+F>
MZ;3M'N)/[8MWCA26>)YIM%26*W4K-M+"<,&9\L[ R!20RQ.\=C0]*MO#GA_3
MXX)8[&:%[6"ZDG=+NXM97-JIM2RI\PD4*I8D;08RHV! D?A[1M.\-1(GVO8U
MA+#8/,':26WDE6R MRQCQ,LA5,R$*44JBA OR:%I<RV?V5KMOL%N/)A,%I*A
M32Y'^R*ED44%9-[,W[S:"BL0"H8&@"Q;1V>E6=D!'/I]K:_9[.(SH#-:;S;*
MELAV,'C<[0[AVPV<-QE.+TBY;Q;-!J%[;QZ7X8M4BL(UMG61)99)H4:SC*IM
MDM28XE=MO+;E5S'FKEM9V_C?,H,\/AB/-G!]A0QL8F^S(UHIC!#0^9#)YDB$
MKM*!9=HD ZBUBN+6\CCDM?)ABV11R6=L,6 Q:C[+%F/,D+G>6D"@*%(.TH"H
M 6TOV2SLI[E9])CC^SV[6R-\EI)(;94MHU6/RY8R3M,G)3<P4J"=F'?Z[IOA
M:WM+-98[>>Q1+5(H=MQ/$R"S8V%LK*LDPE1A\_.TD%B, *76HMIHMC]FD@U9
MDBL;33K*!7GTY9HX&,$2_+%(G^CS/Y[$(AB(PP5EHT33;VUU)W=HXKJUN#:E
MK$RSP:9"TMK(MFD;@;Q)&V3,% C' VJBA0"GI.F?V5K_ /:=S-]@OVBMK5HU
M7<FE027$+1V2)D^:LK/*GG@[$\LA0@3:-BWDO2D$EM;>1/:2QP-:6L<8_LTM
M;P,+)F$3[K=FVEY8QE<IQM5BEBR-P\K"V6""&TEA@CGM;42I:#= LME#A 7C
MS&X>7"A-RC&8V$?/V[7FJ6L&BZ-+]@AM?+L;ZXMHS--HL9B@5K&"8*?-D+@E
MI<D1@9;!"4 2-J$U[?LFEB2Q@TRWB5M3TNV-[%;PRI;-]DM46,!RP4/OV2!$
MVGC?MCU-.T%+?1[>UBL?[/M5B@M9;"2U6Y6S#M"TUO&1%F:.4%A)*78!AN[-
MMDTW1[3PXES=)81VB0N 3I]B\LMJK-%*UM#B$M- TCS,64#;NP NW*1WDMG8
MQ2RW5Y!8V%IY.GWICF$(TG<L)\FW=8 QCDWQ!G++M&&4H5^4 IWWV+2O#\]W
MKBW>F6?V+R+N=HHI5TM6,&+.&/R2DD3>85+JC9\L!F)5=E/3M.EU>>WUOQ#:
M_P!E:9%Y%I8:5+9INLEF2&-K?#1%7CF9]I889%4+E=TB)7T7PQ<:_K%GXE\0
M6'V&"WB-G;:6NGA6M(I%MPD)41GS(]KW".6)55DR%A8.(^LMD;2C']L\NVMX
M'AMXYT5=UJ\LD(%G !;J&MS^[7S,Y['!7*@%.UOGA^R7L1Q=&(*PFMV$B0?N
MC'97#/<8^UL9UV-(3RSX4;CNIZSXFF\,#2((GN[J\N+AK6WAN 9?+9HTD2SN
M)%FVB=B55)F#X4DG<-[M'JVNP:)_9ME=3SW5\D4=M86E]+%+]HN?]'=89]LC
M'[3E%83[1''YP))R-U?PSH5YI$MG->ZQY6M2RA[J0J9(+!':V:2P&9BJS2NZ
M$2D,\F68Y8AB ;&B6<MCJ*SWU]//=V\45I'>WTJ%;6-S!_HDBK.=UR^%8R[<
M,SK@E0J5<L]06S0+)>78-K<1VA:[#2&V,S6Q6VEVR8EE(E4+,-P4?>8G<9([
M._M],^T0AX+*.PV%;9)C.UG%+Y+"WEA20_OG8R+$$#*JA0O!VMACQ!<ZM?V&
MD6EU'9?9GBMM1N1?/,VGR,D96V)$A$TYE0@32#R^L>)&9T8 ([^[U?4K2T02
M6L=J[6=SJ9E0M9PO*B_8G<73EKB0PJ#*I+IOC^56?*ZFD02Z+H=A'$D%@VG_
M "_8+-T\J'?Y1%E+OFQ)<,9!ME^7+$$X#E9)-)FMM#L BV]IH.DZ<BQ*+BY0
M+9@O&7BN%68H97!#I+N)_>G< ?\ 6C7]IIUPVJ-+=VYLDBT^=6@>X:/>;9D@
MFVNSSS_O6V.A95\U\[CG> 1MKR:#*1?WWD6EE://)<W]TLCVR;K<FVDC24M-
M,%< 2X.-\0S(SL7P]!TN[UJXL=<\1I'%)L:V%G?RI/'IL+F-$M'1R7>>>.7<
MTC$/D(I&TE&N:3%>>;%K_BJZ@TV33ML<=M-?&2#2]K,N)G-QB6XE@N%Q(5XX
M)&2 W06XEB@@C_M2>!H98X_,N94D:V5G@;[)/^\(DF<-L63!8*WWBQW2 $:7
M)-E9V]]))9RR)'9R*MU)*+)G2$M;S2K*"T[9(28XP67'+ 28=UJ]Y'H^GVOA
M%8(?*E_LN![F8B'3)(FA!M;M0[[V?RY$60<@LBJ?W@=C5=1U'4L6.BW4\%O9
MQ"&ZN!>+O3S-D)LO,,K*UZ&W.LA/R,(E)(E9CT%E:V^@WC6FF?8;>Q7R;:28
MRDBW*"!(H'0R?--(CD"3@X$08/A<@%?1--L]%VR0R^7=GRH;J\O9A),&/D8A
MNF$W[VX;>?+895 P"C:0)-"WN/*\C_2/(\GRX/\ 29_,^S;O(_T>?]\?,N'W
M?*_.-W?/[R/[<ME;K.\TD*6B)&PE=IVM@1 ?L\RK,QEN'S\C ,?F&-V[]YR>
MFW]QXXT[RIWGTC2(=MA<+-,)?/#BW#0-(9#YJRJ_[N=1O;>""F/WX!'H>KS^
M,76:R\S2?"L;K;B&]MXHQL9;0+9F DHT4J.Q23[V9 J[5&)>LL42R^P6RV?]
MG65I$EM#/*%22T'^C;+3<Y<2^825+H<90+DN U6+>7RO(6VB^SK!Y<"V\,6]
M+%6\C-O+%%*09,'*N!MC7D_+G?CZEKG_  C_ )<$$<"7<4200V)GV0I,_DB*
MTA3:F]9-LH28@B,I)G"AD !'K.LVVAZ:9(I8[2[LG6S6.VLTN/(E,4+)86ZX
MC=Q(3$W .55QNC(4I'X?T*<WD>M:V<ZK%*(TCANY;Q])5A JVX#;P6=!F6;Y
M6^<G.T[Q8\.Z9<0K;ZAJ1\G48<VK064PE&F1/+$\5FL4<>S;Y?EAY" P !#;
M<,FA;7[VMG92W;_99H_L]K(AF:Y%H\AMA]GF(DS+,Q?Y92. V3P3Y@!P?B)&
MO_C/X&A9+22464\EO<WELK3N1 S1R3Q_(RE9 2$VH 02K9++'J>'8_*^"?A5
M?+\O-WIC8V;,YOH3G&Q.N<YP<YSN?.]N?UUTOOC1X&$"03R0;X6LKE5EN[41
MH"1.';<S#YG64R,#]Y%8C=+J>&)H+;X">')U$9BCO;)V%I'*^2-0C+84@NSY
MSD*""V=O&V@#URBBB@ KQ_\ :._Y)YI__85C_P#14M>P5X_^T=_R3S3_ /L*
MQ_\ HJ6@#Y@HHHH ^_Z*** "N;^(,;2_#GQ(J320D:9<-N0*20(R2OS C! P
M>^"<$'!'25S?Q!@AN?ASXD2>*.5!IEPX5U# ,L993SW# $'L0#0!C^.I84\9
M^ XY_LC(VIR$1W4X1"PB8*P!;EU8C;^[;YBHWQ[OG\_^%7B"V\/?":]OKB]C
MWV;RW<,$<21L&_U3%B)D%P!OC/EN5<90#.Z$GK/&MQ_Q7UZ)K[RX[#P??75N
M8(MT]G(SA6G0G;\Q48&'!^5ONALFO\)-'>U\#>'FA?[;*)9)Y'FE9ET\R!6V
MK"VS&Z+(#C)5IMRAXY&- &Q;:5>:YJ=SK.K:7Y2SRE++3+E"3OCCNX&6Y<+(
M!"Z/N&WY 7X#%BTNY<RVDNC27<WES:;*DTD"74[M!)E9F9YIE9T^SNA!4,-J
MC;QG:JEF5=X%L))+J>TMW-O)=%O-.Y0QMKAVB+1##VS<GS6V@L&VL6Y_7M;U
M*TNI]/TF:,ZH;<;M3NK=K<00I%<KYMVY@:/8)8W=-NP,7X 0$R %CQ1JD]G<
M3Z99Z?'J.K7CQV\<4WE2>?!(91NN8T0NMG$9,;N&+ @X!+/<MO#<5@UX9+7[
M9>7\LK73W*OLU"9HCM#,K/Y=LJF2,1R*P&%QE@"YHFA1:3J,MS9P>==K:26\
M-Q>1.;B\9"@9[FZ:,L,N%"*,KL!90Z[5C!<Z3HZ7>IHUC:VR>2MLSRRVJP,+
M<A+>Y!!$,8# J& 4-,/W8?#. 6+F:Q?==3W,$]C-$[SF46Q^WV9P0V\D VT0
MN&SD;C@')R?-YM+*Y\0:HCM+=W&AO<1+)-;PO&]_*/G9<OE7TTK+*V'8Y)94
M+*44V-/@U?Q+?F:]N;M;:%)8;:RN6'[V-TEA\Z^M2D1,3F$.B#)W._(7A.@L
M;95MX&MK.2QE*>3:M+;LK0NHGQ#-'$%0P1 D)ERK9!!R5=@"O8VT2IIHMKB-
MI$2-HI+!(8C=P*R%6B ?:;6-9Y$V,&8!@5.\*[Y>L:[_ &!I*(@OKF6TE2*#
M1].M/)>[D6/$:Q*F7BMMT$[?,"6\ML,T8"R6+[69]'TZ2!'GN-1@BNIK07)E
M12\8N,S7$CF-#"2$!4 )&TD>#M:)A)I.A7VBV$$ >2ZN[:XF&FS7B[=J,[DP
M,+==L<!C1-I8D!BG[M2D<= &?X>T-HT&H7#6CZU<6Z)8M93*T20!H3F#8\1:
MS0B$^60&'[T;I/-RVX;NS?RM4NC FZ(7)>.]#;H_]&9YH)C(N+9<+Y@VJ'QD
MKSAY//N/MMS'8RQ_:-[16L4[7+F/>[M)-,I_@W1N(P0%(CVI(!* O'ZYJ-]X
MHN-0TG31):Z'9)=->7=Y<[%,H-U$\4^Y]YM7(!#Q@[=A5=K+F( SY+W5_&GB
MQO#=A?7<VG0O=1ZW<Y"HLP66%HGAW9$#?N?+5&4D&0[FD5I(_0+1X8S;V.GQ
M1MI#(DMG';W861U$D;>9$1)AK<"505^7:$VA75U )C!I-E MJ9+2PB>5+=GA
ME6*R=$G+239=0;<  *O"CY-IP4*Y^NZQ#X<LK^^EGC@G5Y)PUPH412E)UBEN
MO);YX&6-(XP5+Y5!R^-H!'+J^EZ)$VH:EJ/F6LGES7-[$<C85,T4BNDA=;8R
M+.BQOOW/)L7Y, T]$\/37.L_VQXHL(WU%KA)[#3?M)DDBV-L>X8-,RX!FWK&
MI980<)EW;=GV5@U[JB^(/$ D@D5Y)].L[Y5E.FH?M$T=U?893A2)%C4G$0.T
M'>68=A-,UO<71,\ELENC3@W5XKK:DFYS/,F]28&P-JER.% 2+RR0 1K+<7-Y
M8-#=>:DFVZ:2UN0#=D"W7S88VD9?LVR20.IY!*LN7*N<^_\ $#B>WTO3I/M^
MKZA$+F 0,QA<JD92[++,?)M-R[63DR$D*&R=]/5_$!36YQHL,<>IL\OVFXOO
M,$6G_9TF"M=E9/E@E7!B4A5^=I?F;@ZFB:2^C1)!&T^H:M%$@E>ZO&$SNJSH
MLLSF60BWD()2,*VQF9MN<[ "GX>T:YM+T:AJ-E';7\2)9R7%E&X$(WP@6\$)
M1U^RE41M^_*EY3B(EPERU@2QGM(G$^E1VUV+=7 5XT+I$_V:%WB/^C.Q*[B4
M(=%C7 V*MBWFMT@LY]+C\Z&*)QITL=N0DB,^SR2R0$1VX)@*NOWEC#_,J,S<
MG%"VO73Z/I4%HVFVKW>FZG=0V:P&ZG6*,&T&U&-O;E0B>9\S8@50V0C. :&D
M&[UKQ%Y<EG'!H-H\NEK!'9)-!)B +<0;FB1D@$B*%8#:S0R*Q^:)1L:'I"Z+
M86UHEO':I:.(5^R6['[*'>%O(B+1$RQ-UDF)R6#,=O2*/1K/[+!;RV=S]LFM
MO/L+>=(OLZW'EO.!;SI'%LCCB**JR #YMVT .5DCU6ZTW2[6,"UCN7L76*PM
M3;JKM(\KK# R^3B"#S8H1'+D F-"6.W+@%/Q!JS^&[6"8K &L]C6>EPV;2%9
MQ$L?D0%8@3"XF""8!=DC!26#^4LD&AS7M[IFKW5I)9VD*6L4>GH"38R*^'C5
M!$5:(.D6&& 06EW8B@*8>@^'+R_GAUS6=/GFFGEFM=.TWRS!:6UNB7B1PSQ&
M%?W.Q_EE9"_[U5V*,[^TD:^N$:YM8I([]'NH+&6^@Y=]TOR2[(\I;YCB97#
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M<&:94$7FN%&20+#-<ZSX@L;71(KNUTFSM[B"VOE@>%;Y'"O]GBDCCV06X"Q
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M42!MMNL?*ARB LVX;@"/2XTT#1XK>SA@MX[+]U#:P[46V#M"RVLJFX*O<OO
M60G&YL]&P^'\1;B9?A]KHT[4)(X[.WELY)) 6*1XB5H9!-,"TLA.Y92K'RV.
MT%G4ON:C=V^G6<)EU.<VYE%@/(N"QOR3/$EK&S3%DN%<H7ERI)3)8 -L\O\
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M!E5$!=@&#@&A<:/]ATM;^;6O$$H2]:98(+^ZGEN4/FAK!4CNR6GC*G,BX V
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MRIE(;J)XOB9!I,UG;ZCX-2>"[@6UT^R:6(CRHQ+]F0Y7&5C4[&SE)'^95 H
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M6"B)X@N><+&Y+1J,X$9/R#"\ 8H T*X.PD6?XP7;F&-98;>ZMO-!8LZ"/3I
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M:A% KGDK&+2!P@/]T-)(P'3+L>I-'@W_ ) =S_V%=2_]+9J .@HHHH ****
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MQV[J=[/;>&=$TZ2.".PG6X-MI]O:Q)&;BYD>1FL@6MP(X&9$ E 4L &)&-S
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M!8G1[2*;S]INT8/NG8AV!D (4-Y>Y<E9KB2<W,D[NDUJ!:W31K= &8F"%?/
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MY)YI_P#V%8__ $5+0!\P4444 ??]%%% !7/^._\ DGGB7_L%77_HIJZ"N?\
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MA@FY +%GH=MI":K;3-&\<B27%Q<:C,CNI=KLO+=1JZ(;5LDI&H R[DJK;F4
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M,L,"';M8Y/5&4,2&+:QMK&W.G0Z5=S:?%;_98LP(S7B(+A?LCAT&(D4#8[L
M^]?G;<Q?/\07ZV6EZDNL&[NX+I)K:WC+- -2=OM>+(1[24(4*%E7!E/EX+<
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MS6.FS22Z?:7L]O*TR</<Q.XEL[E0A4V\D+@))@E2H+;G(4QZC=)KUY.+2_\
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MN V=VY^HFO/M7V_RK'^T_.^TP0!8L_;_ "O.5[6X8P!(8UD9D0ECNQG)RP8
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M0NR+RZ]Q\)/#5W9+:7"R211HRP_N+<-#O24/L81 @%YFE"_=5PI4*!MKO**
M./D^&V@2;P8\JV[Y'MX)$&?,V?*\9!\L.JQY!V+&JKA6D#QR?"_P\[PM&DEN
ML-[]NC2VCAB$;E2K!"L8* KY8RI!!AC<$."Y[2B@#B_^$"FCOUN8->NXA$B1
MVX52GV=%2!0$",J*/W4C% GELTBET81**W-*TF\TNUTZTCO8%M+*);<6\5L0
MC1B)5'+.S!@ZD@[B-K%2&;#C8HH \G^(6F1:/_PK/3;::=K>RUNSMHPZN=ZI
MM4,S*1&&P.A7<<G;@!P?1(-W_"5:AFZD9/L5MBW+KMC.^?+@;L@MP"2H!V#!
M;!"\/\6( VL^ ;CRI"4\1VR>8%CVKN8'!)^<$[<@+\IVG=R$KO(4<>(;UR\Y
MC-I %5F;RP0\V2H*[0QR,D,20%R% 4L :%%%% !1110 4444 %%%% !1110
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MEM!):7%]/&\YCL!<#*QHA1EDF5RI9\*5WFC5KB;Q?<7VE6^H226"WLEM>M;
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MS$6TKK%M9 C!"X3Y45ST T&PAGEM].TN"-CGS; -&GG)LN8T^U-N<M;,,"-
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MLKH?W,19RK(6V+72+'1M-N=/A\N:RMGENKC[7<>4UP6BGCE?4/,!+Q.Z,1(
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M%M!?R2>?!<6_EB3[<\8N5:R=S$H2%).%E8?-@@C+Y>PQEO,;]+GD^VQ2QO\
M;(D'FLOG?Z)<XC;;"N\[)%W*V#\QW#S>?UVZN+[SO#&C_P#$UU6ZB>UN[N]B
M 4(/-W17WE1HT491V,+)C>W(^7)< -1U+49KR?P_I,4&J:K)FWDO+Z%9$:-0
MY,>H(D*&*,AW\G;D28!SM9MUC2="BT;3M22""^UF[?S+::2^B=9-69!<,D,Y
MEC*^6$=4$X.UR N0H"&YI^CV-B^HVMN9-0O+YV>\>_\ FEOW*SH([D>21%;@
M1X1E 4XPH(.)+FK+C3M0GS!^\BGB\_4;?$<VT7!\JZ'E#;;)G(?(W ]3NS(
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MAYHF.31=!N#NU34;&"2_U"T\B2VDM0B^:?M#W%K(1$0ML9&W"3EG;EGD!0,
M5[G1);#2;W4YU@\\VEQ:E1;(B+;I'<D62F2$1PVZ'81.X(DVC<-I1:D\+6JC
MPAH=M<IJ7V^WTR%)88=UM>2D0W">1*-B&.)3O\IV907 .[/S/8\27"KINNBX
MDCD22WGB??;MN\@173 W955D6W#!T0QC<=@(=_,('+^%)[OQ%X3T2RT>6[:T
MM=,M/M]Y:LD%Y.T;,1; GRB(!Y<T0D5N7<?,0LQ(!L:Q/<^)K>]\/6%U=ZC$
M]O<6&HWT<#K^\03B.-=LJ(DX9!YFY4CD5ERRAHT/-_%6P@T;X47BZ==9M[^[
MAF>ZC,1COD>21T7F3<TBKY9:8!GD"(6+#<4[BQTBST[3O[)CC@NK%8H[=)8Y
MPLE_) )E6)!YBA+F,0Q$S9!)3HGEC9R?QMDA7P#J5TM[&D]U<06CSPQAH[Q8
MYIV6V^^Q1XCN9GP,E<=]J@'<>")89WUZ:W\SR)+V!H_,G$S;386A&9 S!SC^
M+<V>N3UKK*X_0-3T[1KO6;'4;^QMKB*[53)+<,C7/EV-LTDG[V1F.U>IR<*
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M;ZE9VF@0Z:NL75O9K;2VMLUS]FMC+!O1-D*!K,(S,)#(H+%E7:5^4 N3:_\
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MNXK0L]$,^L7FH>(+N<SP6CLMEJ:PR1V,3K<(+B[='59U?;,1&&VQ"9U4*IW
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M.<[)6/'J5=RX!P]YX(GT6SN;>V\=^*Y+QXMMK;PWDJ.]X3<-+(\(4L(3Y32
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M63#\2^)?[.O&T[0H8-4UWQ!:-):PVLWDI<KAO+F\P3#9LB3!<8:7]WL8!"$
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MR$%B$4AN4W2 '04444 %%%% !1110!XG\8#;6WA?Q"Q,<[#7;2YE@GA0H_\
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ME21D$9P?0UXO\4]-U"R\=?#M3KMW?3R:F1"]_#"5A;S8,';$D989(R">W!%
M'KFC>5_:OB'R_(W?V@GF>5OW;OLL'W]W&[&/N?+MV_Q;J/#SN8+^.2\^T-'J
M%P K%C)""Y8(Y8 ]&!7Y0 C( 7 #OR?P]GUSQ/X5.HW_ (@NX;JY2/S/L\40
M\N0I$=RK(K;08PGRE%!:25UW*\3+W&EV#:;8+:O?7=\X=W:XNV5I&+.6YV@
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MLU*P,IM"C[&E*#&TY))58MB:S>]NKAK@WT$0E$$D\2-%=D^:VQ=T0Q);E)R
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MS<LT\?Q&GF\7S^'[&1/#CVUM ;R*ZEMU\Q3Y,AN' -P8I77>_P C;L_,N\4
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M4>I:I)<&".WF3-DZ([,MP3O;8;>10KLOS%P%*#?"RGA33H;"($WLFK7^H/\
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M;K''(JN, MAY$,B,61@<)AP_UG0 4444 %%%% !1110 4444 %%%% !1110
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MM8<6HW&O>?HNFI?:7';Q6]K=W5A*'CTQWV++9PB--KR)L0>9AO*$LC;D"A&
M,N:V;Q1?S:?96<=DBVZ:9JEY:VZR?V9!(D2OIL)0%97#@EI"-L*NW3I760VG
M]CP+M%CI<,5W!#']GLL+:>:]MNMH?W:^9'*Y?,OR[68<90[9-+LK2%+%K?S(
MO[-0:=L@=Y7L?FMP;=5:++Q-Y:L97 8*0X(5@5CE:S\.Z/;&:7^RH=/^SVYN
MY8Q+#91[K96MDD=5=HY!@>800"&+%2@4 &?>76EZ3%J-[KOD?9+6)+._O3%]
MH>S3;:D63.\9DN(Y3*[%R/XCG#8(X_X?>'+_ ,1>'+.]\1//!#82W=C801V\
MC2V D>.)HBDT;B6/ =,MN$:[@Q)'[GI- LKO5=4TS7M<L9-&AM45=.M&"0C2
M&/E1B!25 F%PC@?=_=D%!M?I'!X$\)Z3!,\^B3V]G)MFU&ZN40>2P>TD\ED5
M?+:%BFYV7,<>V4 HI(4 KV_A M_9E[J7BZ^"Z9+# LMC'#&MK?GRX#% 1;X-
MNQ94*#"JR$.&);8-IMQI-KIGAPZG]NU**)K6**[M@\<"&(^7;G9$AEMY %61
MSOW"!V5$,;O!GZWX1T)-3CTU-(@GU>3R?+ACC,YM56.TA2,[T+/;C8S_ &DK
MM0HRLK[GBDT-!\!^'=(TJ6WO],@2WDEMK>[N6BD#&X%U&PMHTDA!DMFD('F,
MS%E(4DA 5 (]*\*VVB^/XK:=;N076CR07<C6B2+(?/M<P*1&JR0*L@3=Y2A$
M8KO 0+#UELEO92RZK+%!IUO:Q1VDDR6)C>R$;1[H8W:$>9:'DE\ +AF#8(\K
M/TSP_IW@_P"UW&FZ18Z:S_9H3.KMO%PWD(MLCM;DM;N0FZ7).YW. P)7+LH6
M\57_ )EM!:1^&2C:=/=6-FKM)$$AB-E!($#&U\QI6,R@?<<#RPH=@ O[<^*7
M^P'3[NVT>R<V*FS,D237&U8WLD>*'>MB#&PDD90"VW& @%=1;HL-Q8S36-W8
M2P/]@C2WA:1;4$P'RH@D6QK=Q$"96P4SMRA)6.P@6S>S1K:2W*/':K]DM6D%
MF2L+>1$1!@V[!#ND. I&,J0!'GZMJ#:!96K6^ER2W^]+*SL[.-08Y2D3_98'
M:$+]G98V+RG&T(<<@! #/\3WHT334:XTZ/R(T6UBM(!'M9C$K26:F6W""S*1
M[WFW#&QAQMVB/0-!O-'EFU"[EGCUR[V:>98[ O!8[&#10V\2(<6C*?F<NOW1
MDI(3L/#NB-IVHQW^HK.VH&6.T:\L[:XC6W9#@6D,!AVBR"$CS2=K-\V0P5EW
M-,@FB-NZF2*"V=K9P+$B2U8R0;;>V/D(&M<*P,FWH%;<-N5 (WL?(M8;2:/.
M?,LPC:?]HAM_-B3;;*J0)OM!P2Y9.8E5FZA</6-9NS<3:1H4,DVI:@XBN-0A
MN4FCMIE+2R6*R9CD8[([H@%D,9D0 QAU*&M:G/I[P^'-*DTU=:D00K)=RQ+:
MZ>DJK_H220M%-&3M0Q_(6<*"/NDQZFE^&XK+3+2!)-5M6BW0WEPC.+J?S9!(
M(Y2 XDYF<O/&X\MO,*,@9PH!);::NCZ)/%9W\EP"ZQ75[+<,[WQWR1>4KFX4
MI=9V1F4D#.Q0 %"1V+O4884OU?4I)GN+AK--\@MW5@P(M54RQXG=7?RY%"Y7
MRV8MM5GDBN+.SO+:5[B"SNG\JQ5[J<,\?$3BUF/G$RW!#2,C?-C<QYW'S.3T
MZ[E\86^F7WVZ2W\,R7$"0O<I,1?IB1/LLH^T-@JQ*-))Q-(8UVL%42 !9M;>
M-=236=3O[0>%KJX6WL!<JD9U8"64B"93C)CFB5XAC)C9E8,7DQTB_+/&C0_O
MC:/:2>7>8NW^1I%M&/G_ /'PJ,CK+O?_ );-F,.&,EIB35+":W:2U<HL$=Q)
M+'*)53(DLYCYS/+.A69PX^X0WS-^\$F7J7B:PL-.FC4P:A)-Y6GQZ3<7D<LE
MPY'EFT8M.P\Y9)5,LA4_(X!WD;@ 6/$FN_V%%>M+//J%U>7<>GQ6T$OE!Y)5
M?RK:-ED!MY &21YFY(;(_@6.GI!F@MY+_7-1CO=7O4"74=O<$O;M()$-G!M<
M):@21(@E+_O)$()#;")-)TR_MXIWU#4H);JYB^S-J8ED>VM3M6W^R0LUSYRR
M><BLSC:7(P2'V[=BZU&X$\EQ%<?9;HRV\2PSL#"'9"1:SE'<1R$OGS%"Y,D
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MW&]MN&WA_P#M:^%]K<,[K'%+8V-E,<23V[0S+);CS921<DC+SJV'2-"K;6?
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M:+>I13N/SE%K0-_;Q:G,;35X$MVB?4(S/>&8*&C)^UDFY&;09V>6% #_ ##
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M997$IP&9B,[ JGB_'OVRX\+ZZFD33PZ-:12VC3VEF8FG$9D'V0[("1#"5?\
M>@K&58Q$DEY  4_#,4VNWGC"6Q\N6/4;A9[F"U@,3:E'+:M(EJ2ZJ;>+)<?:
M6C4S;P0RMU]$O8DL8EBMK6":WFBFLK>PDMEB?4'19V2T8F,+';HBOM.#NR#G
M&?-XOPN-*N8_&-E )(-+*0Q@SS1KYD!LT(AGD5&:.!$B=%GW%665BK.^'/8:
M]K(T5)[YC=Q.' M[DI'&]_(C7+FTD+1'RX$5"?..!M;=O^\S %/7M5L[6#4+
MR,?:9K_.EVCW*AX]1N@]VBV,D>T;8T<D;_EW C+D DT['28=6UG_ (236UM+
MS4KI[K3--MYD 7:K79:TF'ENH*J"&E4G.S:-PR9BW\/-->PW^I"."2X0V&G:
M:\2HC"-[UQ;2H8GC5/L[+'YB G"OL<J^9.DN=]Y%*UM9?;&N=L1%_ T ND99
M)#!/FW.V%$D^4XY?*,0V[< 1BTAN[6,6$LESY=P(HKB50[W$MM+,1!.[P.5B
M1TPLO+D\AMQ!?G]4O5U,)X=\,V4<[W%O);72W=JUNL<!CF$5O.J1K)!$H8E"
M0C-\@0MODD0\1ZQ-)JDNC65C)J.H7%P0GVB VC2K'YDJP&7:" NR=HIU*8<1
M[3)MG8:FE>%K?2[4I'#]JEFB-K(9(##'?.L3H\4\8B(2WS&&C8[MH?9'B,JC
M@!!IFEM8W420?VP+F63S[B\M?,;4)XYGB,5R5MR%CCD9-A X5"0-D9S8U-;A
M?MM[*D#VO[V B](BCO(AYA=;IC:DQ0Q#S/+8$JX(R3OY'B33[.6*:U@:Q\JX
MB\Z6V6W@:*,S[+6X!C/EVZ(WRR %6VD\;@LG/G3G\=75U?SV\ZZ4;M8;6*X5
MDDU&2VEG<1W*A"L-LKLZ!7CWL54L=VU6 (XH;GQGK,]W=P22:2]Q-!96MU9N
MG]HI"S.4O&5"(4CN%41;P&VB161B[9T-?U+1="TN,Z]86B07SS&7S[<>1-,G
MVB9H9F-N/W0D.8V"F21CN"M\Q:3QGK4NDV82TT[^T;_597L+9;N-(DNVS./(
MN#)&JB%=V8P&W2]!D%F;GXETE[-=5T4_\)#JOB"62>WDN;>5H;AF(M9A+&8F
M,5M"'4KN;<%9T#!6;> :%YXMO;OQ&-'T_P *SZG]NE:$W%T\< GM@A:2.Z1H
M?,BCB-PFU67+A@06W8DXR#P/XQO;AIKRVC;5=8LKBQU*Z-U=1LTDAD96F;R2
M@BC\A4"1$!ODRQCD /I>E^''M(II+U_[8OKCS;83W=NRB9 LB_9'WQR/'; 1
MHP<NWF.2Q+;\/H7$B203RW5MA;F62R']H1JGVP[YT2"8B(A;<EE\MLDMO4')
M;$@!7A>SN9;ETL-\MW*L>HI-:@RRY;RWM[G9"PVQI-&4.[YU&=WE[G;#N?.\
M6/=66F+:#9<2VNJW?E%C<S%3Y^GEQ"K1Q;(XE^T\'"Q !FZ1ZJ;CQEJ.HZ+8
M+!>:8+MK>]OI;4?OGA+.=.E^3<BC<66Y4?+E0-TAW-N6NDK9);QQ:7(((+>X
ML()K9F%Y)$C2B.VWM$A2+:JLLAE7YU3YWSO< L6:Z5:Z:ECI$L=Q;K;K:QR0
MSQ^=<Q>5+)%:PRK(C!T1E=6;^!MVXEF<2:IJUG902W.H:E!%:32_9);D78@C
M=2\R>7&3./+FCZNX^8A"%&X )3UG4=-M;")-<U*.X@B25/M<DBP1W3([?NE<
M2I''=(\<9WG;@JYC"?/Y>'%->>(HK#4KRYOI;-I6M+;3'!M9M0FC5W+28.V&
M:+$X  C#30*^]5\L( 26\-WXSN+V;6H))='N;=I;?1Y)D66X5#*CQF(2@1RQ
M,8N68X=\L581K;]8]Q]HOU1+C[1(TH+?9I]HDCBG=2J+YPVM$S1^:V,./DVD
MD(M>]AM[SS1-)]L6264!8K@A;EUWXA@!G CN(S;QMOXVLKLNPLY7#U76#<VL
M>EVL\>J:GJ-NL5F+U9+9)Y5E<A_E8>5+;K&[S;41]WE@&-MB  L:OXAN1;W,
M&@F/5]6N7>>SMH97$<Y46[H_FK*5BB2.1-R,4$Q/  D^8T318;2X\Z2YDU;4
M;^W0/JWVP--?6KG+F#$B_9TCDE5\1Y79Y>"SD;33=L%U-J4MU=WUSJMQ%LF5
MV0W1ABED%I%'N3[,4DCERDF002KNS,P2Y)80/O\ -NOMWG;HY_+,4?\ :4T?
MF; F)%V7<?DKF0;!\O0;%\D N?;3*]M'<_:VEU"W6W:*))('F&U&:>-3+FW1
M/,<,6 DSL7)(C#\O_:$WBF]U8:/!:7.F.DDDCK(83K<D#C;%"K,4\H#RX99R
M") 0H 4#;8:2Y\5F]L(H;2YT6X<":_LR\$6KR_9B&BWQ%V6(,J[IBW\(AVO@
MD[&G6S0V^GP6EQ=W%HKHR&V15@NH (1'(C(X2(*/+RJE5D"SXA(88 "/3H)+
M>WACACO[>^M[9YKFV>5_M6P!?.5R^(W7=#(LOF/*RQD#)C5AR?PLF\_XE?$Q
M_M,]QC4(DWSC##:TZ[1R?E7&U>?NJ.!T'0:AKMGI>CVFJ7@@U:&XEBAAGCM
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MW_NI++*,^^?<JL\C,5C!5V&Y$<[&BZ>NDII2VFBR:>+:W$#(5:5+ R-:E[=
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M=E"[=RDJ\@8XW*H!)'IEAHNDW&G::L&DPVD3/;F7RY3I1\N:,7;;Y2!&P3@
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MK+&IPLV9%(E85&+N&ZM[>4:]'B-);AR+L"**1 91=-MN QMR)4)B9W&R6#A
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M)TN)44@M(F[&6) (CE/*G9E0"[80 ]$HKS]-1^*INIBV@^'! +N/RU^V2;C
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MF&?9IMI%;W^QKVX=S&L:/O7R9$?S0Y"D[=K;LQE%KV,-Q?7D=[K<GVF:;-K
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M  !P !QBB""&UMXK>WBCA@B0)''&H544#   X  XQ4E !1110 4444 %%%%
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M@\L@*VPON27L,5A=SV=Q(\$[K>;VO1)]E4NY%T[&X ^RL(U81H5^4,,?,P4
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MVXA4#?*"S:FD^)X?#%E=0BY\(ZA%=WKK.1J@+ZA%LEBCM'!@PB)A</MBAV[
M,!F- '?Z%HECHFC6NGV5Q:7SWEQ/;7=Q>0_O-:N56Z\Z&<F,E$#J6#DN2%*\
MYR^Y?2X^WM=+/)8F)U,E^VRVN,?:=\,RF,B*% %_?;1O!C!9\8;SO_A92S7#
M0WMYX1D\R]>VN7DU!F6^MG,XCA)%J<1(SD;VP#LW'"S*S8EYX_O-3E$M_?\
MAQEANVM+M(=2,;:FH8LMO_JBOV?>I(D<;?+F"&0$S%@#M_+G\3RR:C+'?/IM
MQ+%]BNXDEC&L1EI7B@GC5&,5L@E>-V=,2!E?<!@-N3&&U%U;P6<<\#(VGVEC
M)9"W:^D2.Y?[(Q>()]G"%1&R\?*V6;)#>;WGC>V2W2*XMO",UOONM/GEMM41
M6EL,/BV79 )$B0."K #?]F.T$RQ[Y+SXB7$T0MM4E\*7L-]=MI]Y-;ZL$-U
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MC=I)I+:=-9QWL#W#[!- \?VMHYIY4AN28V;RE;:?-)/FL23NWD2>;ZCXAN_
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M"DK(MB)3]BB*SHDMJ2C,;@IM#JI^\6;&7/F6-2-CI+W-Y>21Z>$223<IREL
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ME!@F/Q!XEN;G1+ZRL[&[M=5:W(BA>^M(W$Q=$6%B)\J6\V(DJ00LJ[6$A44
M=I17-Q>+TGL/MD.DW<D>R/[EW9G]Y(ZB.+<)]N]ED1QS@JZX.XA:$\7HR1&3
M2;N%Y7F18WN[/=NC94QQ.02TKK$ "<.0&VY!(!TE%<N?'6G)$)I8O*M_W):=
M[ZS"(DBHQ<GSONIYL0;'7S4VAPP-%MXWMKF*)UT^<-+NVH;VR)/RQLGW9R#Y
MAFB5<$\R+G:&4D R_B6ZO9)!=O=QV$-E>:B&M;EK=Y+FW17AC$@R,X,DH&"<
MP!L$(P/G?@/XSW&F^%])T"Y\-ZKJ6I):2+9FUC!^TI&<1!5 SM 61&8!L>5G
MYB6V]QXE\5:9=VMW<W5[!#I*Z)=175O)>POYDD\4$D"^7',-[,@G"X92=K[6
MPP8\WX"T*#7O@[HL<[W>+=))MZ++FT N9F\ZW$:Y>XR@4<DH"#@AF24 Z2Z^
M*6J6]YY0^'/BMX3L97%IN.QA&<D+D!@&DRN>"B@X+-LS[/XV>=J9L;OPCJMA
M)#M-XUS\HM5\L2N6!7/$:W+@8W,(EP,N0E.V\=MX?LI]'\86LEIXEL[=;J)+
M.T5DDW)(\US 5B91.%>4/N_=%D/S!6<BOX(EU#0_$%V?$-O:6%_KMNVM07&I
MVT,7V1D$Z-N9%3S91&T3LH\O"R3$["3O .D/QO\ ",<0EG358(_W.]Y;%P(_
M-5'3<?=6=AC.1"Y7(V;Y(_C1X7=YD-MK*/;OLN5;3WS;MM#,),9VE5$Q(]+>
M4C.%W=!=WC6IN IDA^S(]SF>X5OLI:21/.GS.-\!5F=4X"K"W1@BKS_B'6V.
MJ'2M,MY'O+%WNIKJ:9=NB!_.0W4KO(4<%)2Z0'!" YVC:% ,^3]H+P0EN95.
MI.X0-Y2VPW$X3Y>6 S\[#KC]T_/*;^;\8_'I&L_.\'QWQ:VNUBFGNK1?LLJ$
MEASG>&81D ';\K2<!@I74GO+G5;>72M&-H;*W0W-Y<W=PX2=XQS-=2^>[?99
M4V;$D60R1JP^1%602>-XK/PQX:DGMFOA=Z7=Z=>7<LBB:YG5+B1$ENI#(/M$
M;;,I&"K*0N=B\( 8^K>+/BI':W+16,]NMEIZ:C/(LUJ'CADBDV^8LD0.Y3%\
MRJH.Y)@,*\8CL6/B?XMZAH<>J?8[&"-HCJ GDEBC@%OS*@;<#\KJ7C(#AUVQ
M,QC&YI=3PKIUS>^%=)BUZ&.TM-%MX+JR@O'=9K&>-'!NKM'=6\H21.(U5@I1
M\%0%!3N+SR5<O*T<+V+RW<37<H<V+,MROVF7]\-T#*6"H,;1Q\N/W8!X@NI>
M,9/BSX7TCQNL:%[BUNECF%J69D\Q4;S(C'P)#*50L<;L;9#P_O\ X:G-UX5T
MBX,L<QELH7,D;2,KY0'(,GSD'KE_F]><UY?\1=?@TCQUX-235I+3[/J?FRZ=
M<O*/W4LLB-<O,)-FP '8AQM5R&&TE!T&F_$72-.TVTLFN-&*6R+#^YUJSY1(
MGY4 HN2\:J%P@VRHWRX=$ /1*\_N/#^NV/Q O]<TZ'=]LS$DS$2QQ+(MJNYH
M3+']W[+)N*G<1)%C?M*I8_X69I(@WM>Z&9!%O*)KEN<NKX=%)(SE?FC)QNY#
M^4>L:_$W3\P"2Z\/C>^V0IK]N?+ DB0MSC(VM,X[E8ER%9]J@$=G=_$JXBLW
MO;2QM9'EC$D<-JC")65@S29N3O56'W4*L0T;AB0\-7+63QX459'M(QOVJ9].
M25PFY K2,ETBE]KDMM0#,<@4$>7OKQ_$W3W 1KKP^DI<KN;7[?R@/+<[MPRV
M/,15^[G9*C8R'C0F^*6C1.,7FC%'16C7^V8"[$J&:,[241P%E&6<1D^4 Y\P
M[ "2*7XA102H!8W,DD3O$]Q9+%Y4K/$51PERV8PLDJDCYAY.?WA*[R"[^(I4
M"6TTH-)@!C:[1#F6$!F N6W_ +IYB5!&'B(#,"K/'<_$W3XGNEANO#\PB25H
M6_M^W43E5)11GD%B8QS@ ^;DX1#+'?\ Q3TNV^TM;:AX<N(X-X9O[:VD$98'
M:(B74Q[>8PY\QMF" S@ CO9/BA<W%ZUBNFVD$Z%+9);=6:VR6VL6$Q!<"2+=
MPR_NI=JG:GGW&N_B$]Y9RQV%BD*<3PR!0)01'SD2$QL#GD%P THQ(8HVGKZC
M\4;"Q@OI8[OPY<+!\T1CUZ,^:A<#.T(6#!-[LH5NB*GF%CMD?XH:0ET\27NC
M7>VXEA6&PU$SW$V(O,B$4?E@.[_=QN"AL*'9CM !)97'Q"6ZB^T6]BUJ98BZ
MR0+YFQI4\T;EGPNU')4;7YC=27PLDMCPC>7FF:#96VJZ=?"_N;N>2Y,5H?+B
MDEE,C]&8B-9)?+#$Y8*9 #&"XT#XKA6682:?.D,4KJ9VNK4(8HV*S3_Z[(CC
M( ?(##<!MSD#/C\?"38#X;U6.1]H$,UQ8QR*6\O"LC7 96_?1#:0#F1!C+"@
M#A_B3;OH7PE\(C4)?L<FF:A9MY0+/(H1' C#1LNZ15ZL'C#%&*E"5%>F74S+
MXZTF "/8^F7KDF-2V5EM0,-C('S'(!P>,YP,>7_%?QE!J?@ZVC^RW=E%]M@F
M:1KRQF61!M?_ %"S/]H&V2-_+X!W(Q( Y],U"]EB\4:9+;S?:+<>=87%K#<H
MK+.XBE1V1F4'9&DC$#+A7R%()( .@HKF[/QII\[P+=Q2:<)K=[I)+JXMRGE!
M0P<O'(Z@.OF,O/(AE/1<UT!GA6X2W:6,3NC.D98;F52 Q ZD LH)[;AZT 24
M5335M-D1'34+1D=(G5A,I#+*VV(CGD.PPI_B/ S0-6TUBX74+0E'5' F7Y6:
M0Q*#SP3(K(!W92.HQ0!<HJF-6TUBX74+0E'5' F7Y6:0Q*#SP3(K(!W92.HQ
M0^K:;&CN^H6BHB2NS&90%6)MLI// 1CAC_">#B@"Y15.75M-A>=)=0M(WMT=
MYE>908U159BW/ "R(23T#J>XH.K::I0-J%H"[LB S+\S+((F YY(D94([,P'
M4XH N45GQZ[H\NSR]5L7\S;LVW"'=N\O;CGG/G18]?,3^\,D>NZ/+L\O5;%_
M,V[-MPAW;O+VXYYSYT6/7S$_O#(!H45EQ^)=!EMQ<1ZWIKP%"XD6Z0J5 <DY
MSC&(I3G_ *9O_=.(]1\5^'](LY[J_P!:L8(8,B0F=2007&T*#DMF*0!0,DHP
M R#0!'XTC6;P+XAB>:.!'TRY5I9 Q5 8F^8[03@=> 3Z UQ?Q9\__A(?A[M_
MX]_^$@@W_P"M^]O7;T_=]-WWOF_N\;ZZ#Q-JCZSX-U2PL])U5KK4+2XM8D>S
M9-I:/",Q. JL9(_==QW!?+EV<_\ %]O*U'P+<);>?-'X@@*(EOF1N0=BRDA$
MR0/E8C<0#D!#0!TDVI1Z'XUU.2YM=2>WN[*U:.6WTZ>Z!D5IU==T:-M 7RSL
MR "S,!EV)Y=/%VMZ;JWB.:T\.7<T%U<"]@<V%_NEVPI&(0AM@ [" 98L%3S0
M?WFP@]X?$,1E"1Z;JLBMY.UQ9.H/F,BG[P!&P2(S9 P-V,F-PL?_  DRFWEF
M71]9;R[>>XV?8F#,(PA"@'&7D60%5Z\,K;65E !R\_Q \1Q6\L\7@V2X2-"2
M(S?!F?&50*]DI);#?-C:,?,R[EW9]W\1_%]O;W$</@V2YN-CM#-%;7_E@D2%
M%*-:J6(VHIY4,7!!4;MG>3>(8H?M&=-U5_)E$?R63MYB_-N=>.5&Q_\ :.T;
M0WF1;XSXF54+/H^LJ51&919,Q!+2!U^7()01,3C(8%-A<N@8 YO_ (3?Q6.O
M@G /*G[3<G<HY)XM>,(5?!PQW;%!D5HUCD\;>,6>'R/!L?W_ )T::ZS)N4^6
MJL;8!"_#;F^5 "LGEL1CJ)?$RPG!T?66P\BL4LF;:$D9-W'4%8W<;<DJ%XW2
M1J\=UXK2S@NYYM'U5(;7)DE>%43 >5-P9F VYA!W'A5EC=BJ[F4 PXO&?B47
ML%O_ ,(I)>0,B.UW"+B NI=D)$4L(V/N5?W;/P)%8OL#R+7'COQ0$CN7\'R"
M"1PFW%WF,;I@)#MMRY#>3]WRP4#Q$D^81'UG]O$ZC]A72KXS>;LPQA3* X:5
M0T@+QJ#&25!QYJKC<'5:\/BB6=HU'AS7%:6**6/? B@[XI)-I)?",IC,;!MN
M'=!T8-0!R_BB^UOQ!H>H:1/H&VTN]L;^9:2RO#$_GHQ "E7FA:%)N#M;<J(6
M8QO)V'A>QN-.T&*WO(]EUYLTDWS!MSO*[L^1P=Q8MD!,Y^Y']Q:8\81-;V]R
MFD:D]O/<2P(Z^3N_=@EF\KS/,)PLG[L*91Y;@H",&27Q4MO.L5QI-]!C+3O/
M);QK!&J1.\I+2C=&GG!69-P#*P],@'05XG\:XI+?0;_4!YEI-;ZG \8>"!HK
MZ-XXN&+*"X#P<QDR']VI9=FPQ^@7_CI-)L-1O-3T+4K..PMUN)A+<698JS[5
M "SDY)#8SC=L(&6P#Y!\4/%FBZ[X5UF2U%W%]NO;=K47EJ(O/:)%W21<,<&*
M6!@SB)RKXWNH$2@'LZW,TEQ J21WT$]E_:#/:W11KR9#%M^S*9<+%A?F!(0^
M;'EFW/7)V#:CKS)I5E>_9](:*,SSZ1>*HGD$443+IYW#R[:!BKLW)+Y3:<LI
MQ]5\8Z3XKO-.L9+K59]-N]R236FCRH^IIB(2PVC*"ZVX9&>8$E_E"J6'34TS
MXBZ$ITNT5Y%T^Y3<DUK;74$$CQ21H&@+[5C@CCC9YDSM4'&9/G) -C3/#HM-
M&TNWMX)-+-F^ WV2.>XTUI5CS!;/Y.UDRY#SG?PK[B22T<<VM0:?H:37Z?V/
M=12Q:=Y.G^5//ITDGV<I:VZF#$JE"KN%#$8(7=M&W/G^('@^#P\]]!XAL;;[
M/:*J+ISPM<VF4@(M[6.2$;XVQR6 VD8(7;B.GX5@TB9%UBPN;1'TE(88['36
M.HC2(V:)GBB2-#YSS*91).,E3E06V,: -C2M!U*ZU1-2UY([:*R>WCTRTL+=
MD?2L_9V:%"J$2HW^KDD!VA48#:'=8]17^Q3FXB&(=/\ *M;J"SA\UM-PD+^1
M;(EL7ECD!CWY(PH!&TKA8X(&>6*9]-DM7LK(;H_LRLVC%H,;+$K;$3DXPP#,
M!M  YV5GZ_J\UI>MHVC6=W;:A;6XB-Q96!EBTJU+_))&/()E,FV-3"@*_NF&
MY/++T 9^L:W<MJC:+I]E)'J4#R2:M+IJ/*FF1S;&"*R6PEE$Q(D81E)-P)\Q
M0NY=S3M)_L30Y@\<]E/#E)KNP@^U3PL?( 6 ?91YL;*B[L)M3:$4!8U$<FA^
M%]-T*WMHX=/CADMK@2/<16JM)!<2"$.L)$ #12 L'D 4*,J-BJ!%'%9V>CQ+
M<7]G!ID=OYD$)M+421:0[J"7MW^RKB-E8M)*_P BLNTY&[  2/+8P7,ER)]-
M^R116[-8PHT>F1L\8'V>26V57A*+OE))$8CX' (YNVTT>*C&L_AZ2S\+V%["
MMO;V=O&5N6:2'/E$*!+8LVZ5]R#=L1PQY2./3)+CQ[]B%W;3Z)H*VD3V=O!&
M&D+MY:%(8VBP]LJ.@=VCX,KJ',+,#V"6=O93V-G;6L%A)'YBA;/,;V)D2)6%
MLBP 3P^9(C.SC8K$,W*!4 +D=M-;O,$CCMXHG^P6_P!GM3OL(F4 &!O*PZ'%
MNQ4KL0B3+L$"C#U744T:+3EETB"36TE:#2M/LPK/$X6+]S;.\"@6[1Y,LO'E
MY9020 M?6+JP\)Q)<C2]LUGL2SM+:UC1+:ZD7<(+-C;@RK.0R.R;F7<#M4;B
MD>BZ)+H=[-J5Y9QV^I161L;I]'LYE@L8G=GC%E"+=A.69@SDEMC9[96@"3PU
MH?\ 96DK=2W4!O);18!J>A:7M$,:QK.([=!$\<D;DS.9  &=PH7=M5-B\$\=
MY+<W=I?1LDL-Q<SP/+,\*D0GRK01PL9(7>#$B'8WWF*X931JD-GON$G3[&T?
MF,@LK03SQL+B.7S8(S;L9-Y>)I& 94=5Q\P+CE]1C^TWD^GZ-9SV%GIMV;>Y
MN;/3,OI4;A]RV*K LADE C,C#>$\Y67<N64 N7RZEK;W>E:;!)86EFD5J;NS
MW0FW8J ;>RN(HVW1":*)92R#RPCY!! CZ"WMX=,F:&SL9+5+.X6%(+'31B*.
M::+ AD,:IY1"EY@ Y4LWSC8N8])TI-"LXK2WLY[1--B4$1Q+((H6+3.MNZPE
MIMSJL3*V)"$#X#E6DKZE=6^D:/&VLZ7Y< E33F@L;4W*VZ2-"HMX@;==]NZ@
M;SCAOD7<VT* 2-=6F@!KB\M;NPCBN(K4/!;O<"!FCML6]JJPD_9W*["<)^\!
M  8C;S_AG39M1O[74];:.WD5+9M.M; DK9X2TW_9"H826\@,:R,,+'\Z@LKL
MYDT.UO-9URRUS4;+R&M)5F@6U4F*T^T_.6MW2)DNEE5U69V/[MEE=2 RD=9Y
M-S;6Z_8X+2TN($2VC9K-YX[(L(!Y,*HD9D@.,E]P"E1GA2J %>&>%;^UEM[:
MTM!8NNG8=1'_ &<LJ6TGV=D#[)"^$4,A.UFC4*XWFL/7O$>J:59Z1:VB>3JU
MSY5K&OVC[4-/E)M?W-V#)F56+[6N -R"1, F0%I-<\4S:2;*"RCNY+F.XM[3
M[.)2T\.Z2R+02!W9)79)3^_+!4+*N_<^6K^'--70[+[5)/'#KD26^G&>>W::
M+3#(EF%L<+(&D3<RE&!(7<Q9BQ8N 2>%M%@TB66:?48(?$4WV0WTCR12G3U9
MHF-D<R$_OG:8A\%G+[F9W 9N@ANOL&V66]G55E@MU2X;SOL/F?9D%M,$E)DF
M<MN$C;MOF$D[?OQVVH+9BYF>\NT2R>.)DN0TOV,&.U/V9PLA-Q.^[*./,.YR
MH)^Z_/\ ]O7NI:DNF0O)::?8NFG:C>K<2R>3*\L$:VZ2AR9Y7*N#*0CQ+,I)
M1PZL 5X[&[UVWBT66WCTOP_ D5G/+,4;REQ:*VG07"3!W#.LL;R$'+#9R5KH
M-,A7[/8>6;32)=*2#3RC2,[6(<6CFSRQ*3%P OF@@C*!03DT>'H+&P&G)%96
MFE_V8GV*2 <K9&:.W<VID,@$DKRO$PE"L&P5X9LDO=5@TNR:]N8I);G17C@S
M;)+<O$[I;@VNYG5[AY?-&UB-N=C.-R#(!7O+RV\+Z-'.MQ';Q6CP6MI:K$D]
M[;#;;$:<B@MYCRJC$MOR-RGY@H88^B:;-;7MI?ZFT=I<:>\&GP1H3/%HJE[8
M1V:!AF26:*4*]P,[>@( K0TJWOH=436M=NY+>2)[>SM[ WGV^WTXO]G0))PK
MFZ?SI!YOS +)\S%<;N@LQ-8N%EDCM$B>*") A2TM%*VR_9TYC\XLV[RY IVE
MBO&-C %>ST];"XTV)+.[@2QMUM%EA+2K9@FT_P!&CW1YFB?;DS$$KL?+)_#P
M^K";Q++?:/H^G1N%22PFFL;<QK"D,!$NEK.$4H/-\MTD?$;;V!#!#&]C4-0F
M\4O:Z/8P2"X2RGM+Q5D,SQQ%4CNK'S'8[IPR%_/;:@(MP21/ENXTW3ET>)K>
M$R?)<%);R.V83L&G$D49RC>:FV9U>4MG.]B0Q=E *ZV-CX8M;K^S(8[8M<)&
M]PZ>4\DK2I]GM\B%@T&)?)##/EJ HY!*Y>IW$N@V;&YMO+@M(M\%TMPELEK,
MIBE6P23R$5;9]BIYK'!P4;#;14>J:M/X=T@:M>6DEA'8V[2I#%%$B696"!AI
MPD,3!HI&5OWJ8&Y50'=M6J>CZ)>:U?\ VW6-/^S:%%*+>"S-D2+ZW6>ZC@CF
MMR@,:Q"2%U^7&/F8D@&( C\.^&FUB]EUC7=,DL]+5UMH=,2S5$O1O=%-Q!Y0
M9HH@T21&0 @0^853<1743S7<6J0W6HSR6R+<(AN((4(MVD^S(+-6>+=+%+(Q
M8RJ%P4 )7;Q':ZK*\L=QJ@\BZ25(;J:-4)TZ:5K4I9+\I,BR"1-T@)&03E/E
M"5]0UJST.*U 2!+J*[@TR.WM\ V\SK;R?8X&, !C=%)W,4&=HW)P8P#'U+Q&
MNA:=':D>1JTFRQL;2WEMQ=VEU((7^PPYM_*^SJK19E);&0.2%H\/:'?>')3J
M%M'8OJ4\OV.<?V1<QQ0,&+?9K<*N([8EL^?M*[E+MYA<".3PGH=[86L&ISVD
M@U:VLH].$A$L1@Q*C+9)&8G#6XX4W.Z1B-[;L#*[%O:0Z2D3);1Z4]F]GIHN
MY(A,R1[K;;;0.4#R0.7=#(Y!5RQQQ\H!7COK:-)E-_=RED^PQM+J:91RP+6!
MVW(!O,;@LO! VY=R"6P]5U[5-0QHVDWWV=8)197-Z;KR)(@^P_88G>61)[_:
MI!DSA3GE2Q-7->U34KIWT#2[N2SNX$A$Y6[;S[:SD6%?):5F:+[=))N6,L3\
MN3N!;<=#1TM-)BAN+*ZM(@MZ;:YDVO<-#YDZG[).1<N6N/-G)\P[E3=)PH;Y
M@"2RCN-/NHC90V-K)'+%%//<854BDE1C:S%;AV>[_>EQ(P96:0XP922:OKB:
M7IT@FAOBL<4=M'''=J9@7$1:T/\ I0:2[*!G5QR PVER2'S[C5DM-)N+N/\
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MINGP6UPA"/$%AM)G$:F.V^2,.'$LH$F<[Y",-DHH!3ATVSTJ)U$NR2TEEO\
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M3R(;A9I@B(#*NUYX;T! P W-O?+O\W46/G;(3)-=Q/;.MM-&EV;I[=]T $>
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M<6[2-))MED"-(8_+<Y$C!65B[H ;FF>-?!-Q9/+<^(M-U-V>>-Y9X8;>XO\
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MR?,.W *AN+U-O^$GNKW0]+3S],E\V.\U"/2_W-V\\LDL-N2L19=BR"5;I2R
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MC^ZNY>@F$K[LZI/<^9+/&WV>5(_MJC[3BTAQ(/+FCXS(-K'RAEN&V%N;B6>
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M_P!D@\[S?/\ ,\L;O,V>7OS_ 'MGRYZ[>.E6** *\5A9P2K+%:01R+YFUTC
M(\Q@\F#_ +3 ,?4C)YH%A9K9PV8M(!:P[/*A$8V1[""FU>@VE5(QTP,=*L44
M 1S00W*!)XHY4#JX5U# ,K!E//<, 0>Q - @A6X>X6*,3NBH\@4;F522H)ZD
M LQ [;CZU)10!&8(6N$N&BC,Z(R)(5&Y58@L >H!*J2.^T>E8_BB"TA\(>(G
M:*T1)K*=[AIE<(_[G:3)Y?SD;5 )7YL  =!6Y67XCN9K/P_>3V]U':2(@Q<2
M*2L>2 6)PP0 $_.594^\RLJD$ \ \8WT)_:!TE;AM9 5(8C:VEX%NHI)@SB
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MD:\8_:H9D#23V_[UV2$1)<L(E&3Y3;,8RV?I^C7'B*\^W>*[3SOM/S6^DR$
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M')W,!E6;/6:5MLK.UL-.\@6LFR>'^S_L\2.F8"[V\7(^SDR.7+,7&X[=VY"
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ML [38*GS754+%/+["U_T^7S[3[=INA:+*\FG7<O[@7;;I)F3STW!-.V+$!E
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M82DFW8CY5Q\N.@V_N\/5=<N/[6?0-%\C3?[+BAN#,0!!IT22.'^TA7">7)
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MQ@%PO+OIRZU?QZ?:0R6N@Z6D^E,87:"760B2*+&-9'PZ1H'!E<YWAS&8_F8
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M"Y21 'B8;R1(NX% 0"YK/B"_T^6WL=&D@.K>5'!;VVHM(R6YD:V&VYD$Q#R
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M&.0DM*!$<H RM@+$-]S2H4T;-I;6G]FK/*;E$GE5I+6>7?&LEXWVHFY\USA
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M\\!XI&8*B  YVCC8!%GZAXBLO#UO#<SSW=Y +AHK2S2[B,Z>2'AE=G:8"6(
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M@"H,###%8U4 L:MXF_L'3K34;XZK)<B*5+6W>'RVNI@(XQ:RA0RO,\I+(T:
M;58J=@8OGZ3X>M_[6GO=>:QENS_HT*W8,XMHI)%4P3\[#<O!);Q>87+.-H =
M49I#0;#48/MGB'4D@BURXU#:-.GO%DMM-9N$5V#G,TB,B"4!F431JJ"-=AZ
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M#!#Q\T-QXL^T/J<GV"SBE%V^G7=P)X[2)=TL;:E$TZL-VYF6-,*H"!]RHH4
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MR:FTL.K00W"23"-8X[;:)T$1W7$>PK\GER3#<-PW-LW)/!\UX3IXU/69+:9
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M]IMXRTCX0E2B(<LYP S.C$ IMJR:;9P-=3?:9I/(F$]I(L8U9 ;-7O/W8)W
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MO.3'G*[?W=R9+E+(6DR213VENMQ'=16SW9M $",J.^6FG(\_:P4G!&]#D"0
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MZTZTO9XF0V<VV3[==0M,OF6\;Y6-2%9% XW8*](FHPP&:!M2DAGB>ZND34)
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M'@8.[<K2*K5V$=TU@DR7<=V!%<>=J&Z\52HW!A=J6N28;7,4G[KDD9&W 8,
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M+SQ[%?7,=Q.-+.^WAMXIS;#6<*\ALT;SGC^4IM>X1?W@WJI5%8MU#!(8K_\
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MQ'A^)M>M]/\ M"6M]/%J<'G)%$+HLUH[^8S33 RF-U*8DBCD VJI),<:R-$
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MP5(,\^6O(+2DFB:%_97FQ3P3ZI<:K+)%J%Y=Q82](V!C,IC+1JJB98D7,14
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M,.7$;4_"&C7FB1+J4B7VH:IJ,5KN:Y!AE:$+ DCW/!43)N;"%F.V/Y<NTS,
M2:%X/ATM["\U ZEJ&L.D<DDQ4)*S*L$>^>17*%XP&  ?F-YEQ*6=GV XG2WE
MALH[][AX9G:&*-;6\^:WS=A_GP8UP45G#$1G&[:K"G#=Z=++ID_GV,\=_%'<
MP/=%HS?+NM%6YDPBQK,I*!5*%B?+"M&-P'+V<-Q\19[5["ZOK32(Y8;F[NO+
M$$EV0EI(L<Z#8WV@[ RSQ814VA2VXA0"Q,]QXLE3P[IMY!<PM%%<7^MVI")=
M,C6Z^<C1@%+@&.0QL"T?[DH=Y5A#TFF6H4VY73)%M9W:=[=[&-9+R7S(-MY.
M=J+%*"&?9]\@YVADV+3\/6UO#9Z+:VLUC=PW5HMZ \!0ZF5-J6OI&*$I,I)(
M4DEBRDL"/EN2-!8)]NN8HY()T@E=KJ"4/<LC0!)741A8[@%B%B";Y"L0!79M
M4 IWEW86>G6?]JVWV^ZDB1YDN;*.+^T PMX);GR]I82!)O+$1VNVYHPK?+5/
M2=,N?$FJ:;XBU&.TFC+F[L;6*)X[>8#R42^D.TXG\O>4C<L0I0 JR.U'AW29
MM8>RUG45CO?.>*^M4="(KB2-5B_M!R(SY<KPE&2#.%QG[V6CV+"VAO;BTU*S
MCM+N"^MXIS-+:@-?JIMVBN)I!$ DL8\PI'CG((V[3L +%FC7#A6L9'#O'*K7
M<*H+T*ML?M,N(LQSH00J':28^@ !3ES?&ZM+6VTV&37;O4WMY;K$<EO'=*UO
M"5OI)-@-H08@4,>[)1@H,@)BL:C(9)3IFEF.\O\ 54=O)NA(N^9(+9EN[ID1
M6M7C"H B!26DC(V$Y6YH>E6]I+Y]O9WVH3:G=F>>XU*(H\P1HR)I]\*F)HB"
ML42  Y#  ;GC #1-#2QU%97_ --O-4BBNKAKLJGVIHC 3</'(AFBD4N=D2DQ
MIM4?NV85J6:-<.%:QD<.\<JM=PJ@O0JVQ^TRXBS'.A!"H=I)CZ  %"'R7N+6
MW98YI[I%NTCNHA&UVL9M@US,/)!2>,[0J<?P],?N^/MXU\7I:O;K:7UA?V\6
M_4#IS"+69X6 ,ET!$&B$+1,RQ%@LN]5#@;A0!'!%?^-HK&TO;7S?#E_L\V1[
M:2!]:,:H&N9?+C/V=3M1XLNA;RMI!5P8^TV,+=94L9+YW1+E8I85C:]*"#]]
M-NB41W"[<(A*@[1G;C]W'ID%O=10W=J/MT.H^3?+).#LNP%M@+F3]UB*90@*
M1KM!QG .3'C^(=13P]9VVIPZ1!J5]J$MM#'%<A;674GS$(I)6: ;;A'/RQDK
MA0[<;,( 7+W5K:Q>TC2TDU9KQX9(3#$C)J!VQE;AI/*"&=?).U4;  5VV("\
M6?X=\,W,M_#KNLF2\U.[2"X2*6![:/:J0!I9H\.([@8'[M6".88VVAH]R2:!
MH^J7'E:OJ<4$FJW_ )%PD-U:86* ?92XE(C 6Y4HV"-N]E0E0L:K%L6]O9ZS
MIT'^CP:G8ZC%'/\ Z3 /+OX\0?Z1/^Y 68 ?*G 8#MC]V 26/DWJ0O L=XDK
MK(6EB"BY:-H%::?$(\NXC9"%CXY3'R[?W?+S:BVM7\UEX3FCDU#>B:E?PHL5
MP"B1+')<DHOSHTCM]GP XA==R[7A:2ZGE\13R:+I#SL\TMNU]/*B021QJA#7
M$J&%9(KG*QF,$*"4A=#L651T&EZ=;Z?!%%:V]]Y=S+]L/E*8I+IW>%WN+@E(
M]D@8MF+(R@8!"!L0 R]"TF&QTNP6*WM+R^N;B/4[AXKH WEP_D":]@</Q$%D
M?<@50X.W 5L/J3:CY5FER;J">-_*NI7%YY*3QJ;??=0MYK;+=%+%D/#="<-E
MX_M]I<:1;:G=7L@L;I%D\Y;E[47.^!,S1;IP8HEB\US&?F!0N/F4,V'!./&D
MMB+LWW]F7&R^MX8C-:S7TD3)&URN9?W5LN^&58\AV8;P#CYP"Q;->>)KR(WH
MWZ0\K.+>*X*/J>P1PM.J&4K]B/F,QBSSM1OG\W:=BWN[R>" Y@N9KB6.;;;7
MI5;N,/ /M,!\P[(50[FBP0S';E@VZ2O<G[9Y*&[^V-?^3+;QHGF0RS1^5(MY
M$!-E+=3M+H6 8JH7YG_>QZCJD-K<6=[LCU&2\N#]ECM9PMQ=Q,861K4^<1Y2
MA8Q*N41@KR'"\. 4]1UBWT:72A:VL^H7.HR^9%;Z;<&)+XLUN\ES"//V",$E
MBAR6W.Q(0RR-)X=TN>-[6_U'4(]0U*[03S-9^4@O"5LU\^!PX80*(DWKP)"2
M=F"B&OX>%W>20:M/>1ZMJ-XB[OL]ZBP%5O )&M&64E8HU">8N/WH6$-ARZG8
MMDMKDQV9MH[BWF>'4 UNZ+'>R^9"YN;<>>2D2/AW4CYBX(+ECO +%M?+<W$<
M FDN7E2&Z)MW9%NQF$">W;SB%@7!WQ@DG<,@[QYO)Q:I<>,YY[+2;V>WLKK[
M/)<7VG(+62^38FZYM7)R&C?9%,CE]J*J@A_E:X=1F\4:I)IFGZE=FQ:W)O+N
MQD,8O9&\E!-8R>:=J0L&\P D MM*NSYK8LH8;6W@CTN"T<73V\[1V<P@6[51
M:I]H@VRG;!'& #'CYL!>C9< -.N%FM]/>P6.6WOW2]D6&1K9K@,(7-U AD)6
M(.P\R)L%M[$[B<2QWFJ:=#]CGU"7[3NV7L4EN&;[0P^SQ^?;$2MLC_?;3$,M
M)O8*'W'S*]SJEOH6G0ZIJ.J_:;4Q0RWEVUZ8_M21B+%U;QK*5$>]P'C51OW\
M;OE67+T30KO5=4M-7\2Q2/<%()+?3CLB>X:/[,1?O'N7RYT8LD@&<+B,;@!Y
M@!3\,>'$UK4=.\2:TGVF1XHY]/LUD4>:&-K*;]8]X$,GF%C*J<'./G)S+VEA
M]IEM[2);J2_\Q(II+PNZ1WA46^9XWC9DC0C<?)P!(=W\.YFDMREUY#0SP-/<
M>7<,;>98(]0 \@M<H4+R%5&U0I;# [&RI5JY>\U"*[@L[+1#!>:AJ$2:E;V+
M1O%;W,A>WE6^.&9K>%'#L8VVF1RX^9CE@"23Q#-JAT[3_#FJ1WFH2)'<R0\[
M3'));S&[8&<2QQ*LCJL!8%M^W:47-:&D::4M_L]W9W=V+FXAO99Y$D62]F46
MK"Y.Y@+<(P(^SGG$7RKA2IC\,V4$5G9RB_GU=;_%_*;I(M^I2,;9EO$5F!BC
MA&U0@ *X& 2%+7(45+>UGNDCNKA;=9YQ<6S0RZ@R"V+72P)N.]-H 5H]X<*H
M*#E@"2/B)Y4L8+FZNME]-:SQ^3)?21K;CSXDD<F+8%50C@$.$RR??;ETFG\0
M_P!E"?5]<%C)Y4\4FG/+!-K&/LT3W#)M!MK=3)DHK#<&:0?=!:2&U;Q=:Z<9
MDCU73H[@&Y-KM2#6I8I8X6N96"!=D:KO$1/[QD(7<D:L_20A++;=6MQ?7"WT
ML$OVBQ59Q>@_9HO/D/E[(_E&"$(!CWNHR/D )+6%3I=M' 9([ O;.MUITC!)
M2OD>7Y$2F0);L 5894 !CR&+UEMJ]AI5G!=/<_N;;R+>W-C81YEB<V8S9J"Q
M-L2ZA@ [9;"L"B9DU+6+;0;B2]U5I(;N2XMT*Q3I<SHTQ@016T>S>T#F*3=P
MKDQ2,JDX*\_H>C3>(;^VUCQ"([JZD0 ::7,T2PR)"\KVDAE :(M-^])$@*?N
M%RH&\ L>'8;G5];M==\1F-KID$EO;PR/(+=V2S^>S9"2\#$_O6R54DKDJ9'D
MZ28O=SW>FWEO]JC\IVN[9F:)[^5$MR#;H\FW[.=S(ZEMNX[6R&8M'%)-<V\M
MPM[J5S ][:,\EG&=LS$6I5[8[R!:XW&0?-G=+\W'S<_<ZSJ3)8>'_#L-I+J<
MEE;WC"TN6BM496M]KQ$G_CS"@AE0?.'VIEO.* %C4M6FC\2PZ/8M'JVIZG;R
MK)/$Y'V+)BAE>/;)OA@0P.S(7#-*45&+;BECPQI5EICR&PN9+F[N;C[5-=+%
M$'OFD6T::XMV9L"W;@R!0>20A!5 31=%MO#ME<Z='!=W]^B2I,55+>ZO"Z6P
M:2U;S$6*!%,:;5P%,: $%!NU%FZWD;SZA-<113"&SN]OV[9Y)$ULK7&R.$%R
M'7C?D9+#&\ D2::Y>S,5W'.D[QW$HAD.;U0L/[^V/VC]W K,I=3NW#(P=^7Y
M>>]'BRXEFA\R^T6&]*QB-(_^)M-GE+4S2@*B11LDA!V3*]QA1UJ.![CQA>6-
M^+R!]&GE2&9H2"=2.$9D@68?N[=D56GC#,<V\D84D.\FI:L9-!>R6>0/<I B
M0Z?Y@BW&.T02V1CD1_L<9<%\$=7^8=& +%O#:37K:3'!'=V+6ZP7D,,SQQ22
M1/%&5MX6EV+!&"PF5<@[E0[V#K67J?C&WL-.BF75/[9OY)3-!8:*Q9]4=0-A
MB5996BMU\MP_3<T;=02LECQ/XDM[2SF-U<3E;^+98R6<Q478SYJ2Q%+I=D<2
M$F:1C&'&#N"@"C3+&]$INM1U"?4M9FED>3[!/&H40M$[16H:4;+<.@@D!7>[
ML"Y4 &@"/PYIEW;/%/<7$=W<&W%RBVK(L4\(6-DAT[;.OE0(PB5]Z@2Y7<<$
M8W-+OOMT$3_VC!J/GR^;OT^;8MUL>%?-A_TAML,?W9$S\S;N/FPY%<6=]*MW
M'<07\%_YD$-W:3@&7S&"E+>3SLIY<<&Z0)C<5WKA@RUQ]UK]QXKNH/#6GZAY
ML=[*LM]J4%N/(NHA+L*VHDG=1_J)0T;*RR(DS@,.' +D_B>?Q#JEYIOANZN[
ML6]Q]HN+NPDBV7"CR]JVS23E6,:M'O7Y4W'<V0QAFV+#2K2WTVTTW37C6SN$
MB:9;*=TDOHTBMXUGMY%N=T<2 1ALEB0N.2P+QPVMO96=S:PPWT\,FVW86>HF
M,W]TIRYMF:ZS$RE)C*&(9SN)9R&W7-9O[1=+O+RZO9);0637[26-R\9N;6/>
MX%OLG!5UW1;I!A7#*.A 0 DU#5;>TTXZQ>7G^A^:LGFP2D)<VR!IU>$+-_"I
M+.0"9%A<;"I0#B_+E\47\6M>(YKNRT</!=6EG9B:Y_M-G1]NU"'_ '7DF1&B
M15=U+R2K&"JB31GU3Q7KA\17TO\ Q()/)EL+"&^WIJ5S%YLBF$&9?+9-B@HX
M ?87=$88C["%_)BCG;4($GU3RE;4+"#]W>,ZR",P1^9)B15$;-(RNI1!G*K^
M[ (XM-9[?;>VL<:!X["2RAA66"T@(7,<!-L#)%)B(29^51NPR^76?JNJ+H=U
M&TUK=N?M"RFTM+)I##<F)Y62SQ;8G,H$PD=G4J&8Y0MBC5Y]*\.V5IY6DQQZ
ME"C06=AIUM&7M7*;YY+,-$&E)$@!*J5)"[P@\QEIZ/H+Z9?OK&LV/V2:RWBT
MM-+M6EATZ%I\!+>-(F$C3!7:60 2*K*-J Y !)H?A%M/M6BU>&TCU">WDMKJ
M32[%3!%!++((K>%# 5,0,C2.3\P95,A9#QN7</D0376R?3VBBV32:;:>?);S
M.Z22>0IMV,RR%_G?!&8P=H;<5+:Q^QP6-O\ V=!I_P!FEB?[+I\/F06FYY1N
MA;[.-S/NVR?=V([-E?O/R]UJ%_J47]G6%I/I4-I$B:A?6-I)*^G02+&5M+-1
M DAD=1&[$I^ZW<\A0H!H7MQ<&\OK"Q,]K;Z3+ &EMK(7 TT8PB6<:VQ,DCPL
M-^<B(3#!8 BM"PTK2])BLK2.S@M6TN)YH8X8O-FM0JPF6.VS#OFC<,0\@RY9
M\?>.$DTS1H=#LHQ9PR6L-BB1M;PPAQ9QA%EE2V;R/,G$C! Y.2QR05==M5YI
MK3P]9"ZU>>.SM[)U!^SPNR0R1(,&UB:)B$>WW^8$8B,*X!SYDE %RZD31+/[
M3-;?9UL;1)&^RQJ1:)F,?9X7:)4,+&)M[,R[!M8[%VE,/1M*OM0U2SUG4TDL
M[73W6+3K*WLMALBVQ0$!AWF)XWV-D@*%+%8V^2WKZ3H5WK@L=4UZVDM!;/'-
M:0BV1Y[.ZEC&9/\ CU0,7:<2/P5CEA!R1N6/K%M_)^QR1V_V5K;R+)XK:#*6
MJG:S+ ?)R\;'RD8_*H5-V49#0!':6;6IMRPDA^S(EMB"W5OLI:2-_)@Q -\!
M5E1GX"K"O1@[+AZMJDNBSZ/H\%GY]]<[X+:!"D8T^0)@26Q-N!)&@N%1F )6
M-"=C;915?5+JXTR6'2M+XUN;RK /ID0E33 6C'FI&\;!(3&L32Q!L)^Y'!E\
MXV/#VCV^CZ6MS!=3F2Y\V>>\T^W,ZQN]M&1%:@P-FV"QJ4P?O0Q)\Y)0 %C0
MO#CZ/Y+3OYDPE1[R<6[2R1W1\K:ENS1DFW(EN0SG+9FD9GW&1AJ0PS6[P@6D
M=LEN\%N#;QDFU5E3?! /LXW0%EA!;CAI"3'Y0 KM:3%X[8VTEBL"1P!K6(YM
M%=8M@M)$3#1++$ Z2*,CYG C"J_+WEI#XUO[6QM[:-?#>GW'E2W5K$'66WD0
M1QP64T29$1*XGZ%<LN_8* *\CVWBD$0O'!H$+BRN[;2[E+@W $:,UM:LN&6(
MHF^1(^6CBCVJ)&E1>TCM$T=T@M=,\B.*51$NGVZG[-%+<1J$C_<A?+?8TDW)
M9.2"1L826EFUJ;<L)(?LR);8@MU;[*6DC?R8,0#? 5949^ JPKT8.RX^J:JN
ME:18W]@8P63[/:Q6-@UT4)@298K0I&HE@80_-]T$,2)(S&% !)=ZC8>'[RWR
MGD7'^CV?V2VEC)MY7"&.&V65%S#-Y0C)4JH,6=J$2NE/P[I-S8W\-]K#VG]K
M.D BLA:.8]*54@C>*SB!;Y"LI629'V*=F5(# 6-#T6Y4G4-2CN["XD>",V=I
M([1Z:J21-%;VX$>#$Z!!.RG82AZ $IJ O86<(NEL;?['LL[=A:MY%O<L1% \
M,>P,5=9PK8DPF-@8_.U $E@%L;>TMK..2"*S2*UC@4--]B0BW'D3(DK;I2IR
M),$(I))QDR8>H>(GCO+72M-N9[:^AE@MYI9U:<:8CBW*1W*^:?/DE=EC5P>
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MQ[0 8PH 7%U;^%;.XNKG]S;Z?:-,+:VB,L]L%,+RPVQ>,>9;-E 6PHCQC*@
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M(!B9IB@\Q2K$L'P"QT2>[WS^+)IXYKZ+^R4L4GED^RPOY;?9D)4_:&D0$S7
M.1L.T@(67I)+:;4'AMK^./<7\BXD:U,Y=9%,LMNK&)4$&%B3S"#O *G;( U
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M=ZKN>6UM;KH\TTELI1%A:R"Q-&4$"JUO"@8^0';YO,)"]&#1MP#3&=+<)')
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M[MH+Q.\F6<E%H C,KZGJ-U9Z,WEZ;92K?S7=O UPENSF>=GMI 0TEQ*DT+%
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MTR0 QCKZ/HL%C92RZK/'-J,B31W<FK&68V:;)U?<S'<]BS1%HTF901EBY<J
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M[BGCL=4MTAN7O L=OYET5BVQR!'5XH\[G+J0RJ%5+"6.J>*);6XU"SV6@NQ
ML%]8\:E;HQ4-=C8&5E5;F5$*)'OG@Y+ BMRRA8V]E!+IEW.D]N-.E.H*KM/&
M@4-]K;RR=X_TC;@F)\GY_P!ZE %RWM_-\C_1_/\ .\N?_28/+^T[?(_TB?\
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M!LE$TA<P!EW%Y  Y.!8N+J&RLGNI;62X14BNG^T6XA%UA$<7$[-"J13H+=\
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M1*#:P;Q:*S1*+>$B'#0L8FWDX9!M)"@J4IBS4NT %W;20I;VVVUMV1--5E7
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M,BQY4D&UHAF%O+ +*&4"=RFU-\K@!HGAZXNM<N=9\0MM\32X-G"P$XTT-O=
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M(=H.T#(.!'CZEXF^R0?Z/<_VXVJ[HM/^PW6&O\O<?N8O+<"#R08M]Q_='/S
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M8&0]?2M&%SK-WJFIB.^NKE#?1K:/&(=0\MK=H)+7,I:,*((=X8A7>1<LRJF
M"/PE8F]\C7+_ %#[??ZA+]MFM[6>$QF5?(C\RW*2G;' I>%R"6D!8-N!13TB
M:Q;.]G%_;LDH9XX8);39/]K)6&3,A6+:CE68[5('E,\@P!F,M'9;>W,M])>Q
M7-PGE3),J->G$;QR1%90H18T8R(J@2;9&" ':_-ZGXGU3^V+/3M!G^V7D\MO
M+<7%K^_M7@D6)6F53NV;&,):)7YBN-^[<_F1@%C4]4N-.U;3](TJ" :F(DC-
MM!;ASIT326J$QY1-]H/FWX^9B,*4V,8K'A[PX_AVUM=CYNO-B34I4MV9DE:*
MW4BV)C(%N3$BLH4*JDD-'Y(44]!\,PZ#;LS:==_VE]HLXKZ_M% D>0"T^6#Y
M ?L>0=ZY4($=57& NYM^R7D:1F"V6S\U1;PV^9HK5!$P6V BR\9"Q!T56PTN
M%D!C4$ #+!IWE"18+-K6(;EC:*/['"OV8R) 9(T#VP&#(^<C&!\VU4Y>TEGU
M>6]BBTZ^LK#3I3%>/8K*2JHT49@T^4"-A"OV9C,JKN)!5 Q92-"REE\2010P
M+]G\-Q^5&QLF2:,R!T58K4Q1Y$:&-7$X8%!(XPCIF#0TI \5JWV.!?L4J65V
MUF)@B2A8,BT*DD6ZR1K&\>%7Y'+XV,' )&MFTVW;3S<7<?FO$L<-BBHR$"VB
M$MJ@<^7;QL<NCAA\S9RIP^?K&IVFG:6UY';R2W8N)%BATQ79S>+LGDM(62#+
MQ2/#)YKGN&#<Y"6)=2CT3P_!=NL<UA$D,DD>E"<K-DJEK]DVG;AS&BF ';^]
MR6(R9<_0_#U[;:I%>:[;1M>0/#&8;5)?LMDO"1-8%03&AVA)HSC(RS8C $@
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MZSC8P.JH8PY+,?F"J_2:8/+BAMXYH)K63R9;:&P;RA-&JVP$L'[\A;=3G<@
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M<^4N;=O*V#NS"51M:()6IIWAC3-$$4'V6[NX+A&L)=2NXY+F[F+7,DCQ2QF
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M<\8&7?@D(<<@", CA^Q_:K=OW!F>4CR;3"[)WE5I8X9QY>]0]O-)*AW.V"6
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M6@NKJT,\DIM(1YV]E"-^\B95(B0JH0#=MR@C7FY;27Q7+<S7%ALT"VEENK.
MZ<EU%)+NEQ=  #SH75&(10TK-=,V0/*DJ..VF\46XU+5([NRT#8;Z*RL;4SY
MEE#HDT+1Q9FBE6:1Y(Y4WA@-Z['(/6317!W.MK]@6WEGFD1+83-"A^T@7%L5
MC(:XD)5F4[L*Q!7+?. 2?85LK=H$ADA2T1Y%,2-.UL")Q]HA9H6,MP^?G4EC
M\QSNW?O,_7M3ATA)XHK>-M01P\-G:J&>!IFN0MS"/(8M*V':0 /M59&PV"),
MOQ9XA?P_:ZA!;6OF:T\LHTFPM+!F:.5HI6^T0DQ8FD)?=*0=J*Q4Y;_6W+#1
M;ZS2&\UD1OK423///IUAYD5FDC73^9:AE!\UBR*^%D9MJ!E.[?0!3\.^&]1M
M)9]=\0QP?V[+:%Y3:V*DZ6K-=.?LK+$PED)D 9/F8G)+.&4'4FFN7L+J\CMI
M-/38TEM&-+>:2R>1[E5NT18R9)9-\;/$0"@9MY&XAK%RL+ZI<6I@DMY=.0ZA
M_HF&%OYOVQ!/$JQDRSM\VY&4KELC<0=W-ZC>R^)]1N-/\.WGV6PMK2>ZN+_3
MXTGC@:0S".6UVQ^9)<.?,#E&VJ/-0$R'< "QXCU"ZFO+JPLKG[&NF>?>WVI7
M$,]S'IA0&1&A;:N^9TG4F/>45%9-K*2&V(="BT+0WTO2(/L,=C%*]MB)[L6.
M[[1MGAW1EI9CN&Z+=P#@<$>81Z1;^'=)N+?3M.GCAL8FFBMK4&8VP$<R+):^
M9&0UPX #1YQER3DN3*:] FGZ=<2W8G@M1]KN)#9!1]AB8;7N8I!$")@':0KN
MW'S9\>;M5: ([^XLK.]B>[L([&[5[CRF1(F>SC=YE^TV_P"[)DEF<P!HUW',
MT8*Y/SY>EQ7'B6#^U=1M?L=E:RS7=K806P+VK[[G%T5$;A[L$[6ARVQLNPWL
MJB2/2+G6K\:QJEO)9V-JAO;#38;=PUF9$=S=.AB99KS?G]U@B/<3\S,"VQ>+
M#)9&&\@DTQYTE<0PX\VU9TN6,MLR1G?=%2Q=$9L<D$YS( 2:A:[)XS]BGC^S
MRRW&ZR7*V6Y+H?:8QY7[Z9]V&CP^&<'!^\_+^)]:\[_B1:4F-0O\W=H^C_OO
ML=F_F[]15A!_K&W,K(K%FW (P9\G0U;4I;:ZGL=)B\^^F^T7<)@A26'3524P
M33PXA!EN,S%WA)9B=ZY&5#V-(T;_ (1R*]1T@2Z3.I7FIW@S:BX=9T>Z3(!$
MC!5,D09$17PK=2X!7L],O-(EUK5+B^\S5S+=W$7VR^(BLX2UQY#3[9!FVVHN
MU2I*,TI&,MLU-2C6.RU:-?+)*37#6^IW;/% 62=?-N,S$?97"@",+A>3M!!V
M$L"QI))=3QV]Y @FFN/-:,P%&N&$\^+C<UJS;BD)8A02#P#LY_7]1U+5+K4]
M!TC4I+'[%<,]_=O(T+Z5"\4K>:\K2L)0^0Z(J@(HP3$P5D )-:\17$^L7FCZ
M5<WVFMI4HEOK^51+'8F9;C#R@RDRQD-&ZJ $B&UG("&,;D4:Z,GV.S\NSL[1
M)[EFNKMG>T=FG/VBXS-F6"0[VPS @@$C.3%773+'10L=A:6EHEK<2WTDEY/N
MDLW:.Y4WL[&4F9'P% 8@@$DD;<(:E=PZ)I>K":YCT6*U>:X2>.42_9VF\]A=
M.I<&1'=]JQ%/]:I"A@%8 %>;7[;3$FU#48X])G1)WE::Z2=[,HSE?M.V?=*C
M"YB*0(&"&4 $90C/$,VO7[ZQ>S26,>G.MU8Z?J\19=.WH96N[I&E4N21(D>U
MBL73 97"7)/]-WZ[JW]N:;IEO:-<QV<_S?9-WF3&ZF5MRO(K( D(\SRL(=B[
ML)L7,MQ]CO8Y+K^S)H?M$J2&Y$IL03<A;J;=( \+  K&5PA&.BY0 I_O+>W:
MWMVN]%@CLGDCCEE@*Z,0)P)I@)B'B8'"1_-&ODC[N/EIZCXN\B"U73X]MW<6
MDFI6T=Y=[H[12Y0SW,D4LFZW;SE**H*J$))15W1GBG6KC299;:RNITOI8I)8
M;>6<$Z>-TT9OI3N;?;[YH?D;A$4L%_=LJV+"T?3-1U*1[R^N-4\H7,P>%I?(
M)-WMEVK(6DMVP1';*S%,*<!V9@ %IIO]D7EQ<RRP?;/](O+J^NIL/:R.'7S9
M$\[FT984"Q[@5\F/.6!:.Y?3,89IA;QP75@C7MLNI7*D6<KPSDS3LLS'R,N\
M6 /E*/MRH5EDOIMOV^S>Y@M;FVB>ZCNG'G_V;YGVD+=-),0"I"D;%'R<KDH<
MCDWGU+Q9=?;+26[L],LG-W:E&:6XC9XKIXKY5^_+ ZR1J(,<L&3 6-U< L7S
M'QF\PM9]2LM,TNX:Z@DA\QKJ24K.?M *R;WLW4E$$7SN20I15K<+V\=G =+E
M@M]/AB,B$WQ$=E!F61+E@DVV2W9H8E1!MVH77(7<BW,+IMNT$$<FGVEDCO"9
M@P@M!B<>9(WFA'@P%Q$IS&"F0@V[,/Q%KUYI3V\!LMMVUVTEE$X,\GF?:'5<
M2OE5CG1A#N&#;FXC!!5QM +GB/Q"NAVLL69&D+F5;,2M+=QDRR>7*$67=+%)
M-Y$:Q H )-K$+E5S]+T*:TO;G5M3BC&K0/<7%M9P9NDTK>]V3.JJRR2I,&&5
M W,P  4*JQ7-)T.?0-'BMKR2>\O++;=VQC@EE@TT_9&A"1KN5IHQLD 1<R'S
M5+#<?,-R_MUTNPNY5:.PBM'EOI9FC:=;-&>X>2XA+1_-.ZLP*9(3<.&'RR !
MJLS6EOJ<YU.[LDM[>68 LLS:><7)-VZ^83+$W&R(@@;%PJX.SG_$6K7TFO7N
MCZ2D<@BLI6OTU.[S:V:-(SE[@D.NR15 $9W-Y;';]G"DO)J6HW&MRWVDZ7<;
MO)^UIJ*[AJ"6 +3JDC('#3-(H<?9B'"9C^5?+"R:BV\VCV"Q6EO=V4=I<2W$
M@N-1(@BC#W+^?).ZL9!,0-ZDN8Q(K85E#$ IVNBW%E%J0L[6>ZFU:6:*2?5(
M!(]U.JW*_P"F87"VF$A$8C"_> QAB#J:I$=E]=3_ &22W9"BR7\$D8DV-<&6
M*Y*J%%N(V*H[AE!;>0Y*[J]_/:(^N-=6T<5O:V[&X:Y5YG1=MTQDG3?^_M2K
M?NXU+8+.N$*'9SY>3Q7K>IWQU:.'1[)_+D262!EGA"7+K-=!"C_9<R)Y:%R)
M$4LRXD+@ &(\9W$^J7D<;>'8$^T1P7CQV[7\:F62&>[. R6:L&6-2K%OON"
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M2SP1M!^9CRP0(HBU)Y[B.SN);74)XIK*6ZN53491&(B3=@27)W9-H2!Y849
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M"."V$PTN[[Q!>6MKI\]\VD-*#=W4IN8)KME!B*!U1/LS(T$S.JA5+"(9'GL
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M8AOU\1ZI#;6YCTS0[5(-.\VR9EEEG.R;R;)XU218"@C+R8VM&H*A5#25U$,
MAN+6VFTV..2-%$$-O<QHT$:FVW+;[0C-;JV"^[:3L V,K*H *::9]FB:WAL/
M[,AM(B[BQM\&V5U23_0WCC_>+YL1W1.FYR<L-NQ'-9DM]-TYY6MIX&MLV5M;
MZ;&?.C5094%H!$#*S!(=T>3$!&P;(C?='JNLZ;IN@QZJYC1'=1#'8HLA%U-&
M[;[$F+_2)9&FQG[I!8G&'!R[*UO8YVU77[?[%JJ2R&SM+2TCD^QQ7",TGV5N
MDUQE&DD)#L?+D"Q[74N &E:1>7^=?U-H$>6(WL46G0E_[+C??(K6LJ(RS3.V
MXS  B7>N04"K)TDUM-"\P\N.**%Y[MO)M3(]KO5PLMLPBP\IQ(SQE6;,Y^8C
M:KD,$-G<6J-%'ILZ(J)!;J)VVYME86_4I;@A8W'EIV?Y,;CS>H7#W4YT?28M
MD[1+:%X@WDZ62C0&2R95&_R&9E?:@(,Z!Y(U0JH!)K&KPW#C1K*..&^D?,WV
M8ADLPRSFYN+62./>]P2+B,+Q(61FV!0Y;0L]&70;>Z"V4GF[/M5Q+8QM*T<Y
M!A^U0B5&+2M$&:1=[L-H&V0R%G-'TY=+TN6*&&2>>\>9K^73W9A=3GSS(JR*
MZ"*<, K3,L:DA5 3Y5CL7+65H9+B6>T6U9YH&F@\J!0KR3-<"*02*Z2KL629
MLG/DDJH;.T DOK-+/9%*?LT<<7DVLMFBPM!&OF2A+:-0\DD@$,.^,C8ZH"%(
M#(>?E-OXFNH+V&?['H$4MP8Y;&8EKN597=FL_*(D\QPDPE8J6*[A$2'>0U_*
M3Q==?VL-.GAT*PY9-/=93=F27SI&ADA=2&1U@DD9"Y:2)DC)(<R] \FZ)=.M
M)/)CBB%K)]A?R1=&)7_<6:[_ "XF)696^<2((L' V2* 6#8-%%!%=VD CL[0
MI.EE'<*(D"RI'):!<[)-N]3''\X$BC>0J;Z>I:JUI96SSQ275_->F"*7346Y
M,EP4EA/V<2/MMW18R[[P44>8I+DLU5[_ %"TLM-TR)H+2:\N[?;IEKI\C^5/
M^ZFV1VC(V82JNH:YV*NQA]T$!*^CZ1"DMY?:M)'J'B"XN)&EFA 19',#QM!I
M\GF*(G41&-F)$A\DE\ HP (].\,6<":CJ.HWD OIY9K2VN+2(/)9VZ6[K]EL
M"A)5HCYHR(U=C&^8^AKH-1BM[?[1YNG;)(HI[L6]FY>2=!YP8VRJZ-'<'SE+
MN%Y,P7<QPRV+<Q7C22'6?.CU"7RE*EXDDA,3.B6K*X^;:P<RJ6)VO]T*HCY>
M_OY?%.IO'IMW/]EC\R/^T+61(Q=;HY6C&G,^]#<*OF1R2!DP"^1]TQ $>LWM
MWKFMWFCZ/?2/Y=PPN[^(H#!,J/\ Z-8^8W%TT/RNP8(@#-A6=A6Y):P6NDHF
MF75C96OE/+IDMKI\4L*L\=PRM:Q(Q9I@C!FX*NH.U1O;$:1:98Z7;P?9[13
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MLO*EN+CR;&3SI[?S'N3]I9=Q\Q9/O)'Y;;7.,-M^3G]4\1:=I-G%]GM8'O\
M_3-4TJWA=ITC9C<8O)Y5?:MO+YJ\MA4\P\X4E #4U[6=-TQ)S=F.X>X<6S1S
MHJO<*S7(\NX!B^2U11(XEYRL;GYN?,S]%TBYL1<:[K-Y)!J;7$\@O;A'98"(
MY5EA?."+%70S1Y= =R9PP!>33=*^P3R:A=7_ /Q,[??*][<3;C9P[)HQ%,)
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M+:M;64T0FT^1HX6%C'(JA463:!N9T.YH]I!9-H 007%G*)+33YXF2(0QL(A
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MTVU5"7&4+11Q%5R?-..VQ86']D:9*EI:7TTIU"9W5(_LQU"7S!*TS,.0V$9
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M4;7P@(CC6VBFEO[[49I[J]N?,C^S:?=N9/D:%3':.DJF.-7 25B$W/\ ,^Q
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MI\PR$'H$T.TTRRM[.UM)+.WTI&DMX[0.XM%V7"":+]T?.G97^:-MV"<\G!D
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M!3OCD,/21Z5::'I<UE:/'8II[_;)4BG>*))'P?M 3[2-EJ&$Y:%B VQL=,L
M2:7_ &/H&BVEAI\/V?0EB:ZMECO$!2-)PSSF4SY>%A(DG' 0,&Y=8ZIZOXC6
MT$<)FN[I;NW-PTNDEI)YI1'&T,ML@=P(F\N4>6<[BC,5:,2O4>N:OK$=Y-;V
MR^7)YMN)K2&9WN6NB(WC:WWNJRVQV.LB_N>(IVW9#5<TW2[O2M2;4[Y([SQ1
MJMP5D,<J3"TL5E'R1AS$?*163<5!8R.&*OP* (].\/7%KK%UKVKM8W/BV^BC
M2VCC FCL4C41,\ D*/Y>Z4R2 $</M&3R^A:W$5Q=6D(N)[EUB$ZFWG=4O%DE
MB<W$+&8J84;(*$LRJ0H^1U$L=JA8:?$D\E]&7MYXVAU&1&G5(U5[B/,[&2#+
MQ9C8C^-CYC,N['UG7IB"NA6D>M>(F13 D<AB$VZ.&07,;F;*6>8PK*#MDD 0
MG))8 L:GK.I!TM-'FM-3U"^2"6"%)F1&;:K?;=RSL8[,;-IC"_.V5RWF9:30
M+:#3X+2*VMYY_M<N[?#/$K30HZ/'- 1<?)91[]HA&X[9 "O+;Z^D:+IFC[M3
MN]1_M&:?9?SW\TD*273)LS>12+(-ENB3,C)G;LX PQ\W8CNTA@2>XU/S;,Q+
M<G9<*B3 /'*]W$YFW+;KYI#HS,-JJJC;Q( "WVS-U=:C!)8R1171,4WE^?L\
MDO=1.;@A+905W)CGYB2^_P"?E[6>\\9:C.W]J>;I@W-!:PQE8]1D4_9I)F!G
M*R6B,I8PHZE@_P ZG<AEN26LWC$F*]NKL:/<(!]EM;@P2:DRR)'+<)^^.+/R
M\80'YA*S8+&-FZ"*_A4>9>WL;VTZ1W?VF*Y$4;+%&KR7*$SDBWSY2E ."26W
M+(6H KV-K#'I<.GV%U(L4Z++$;*X&9/]1B>U#S,([>/=S%@KC "D$"3+UWQ)
MIUG%$KS_ -H:J\2W]E!91-<2W4@6)5N+9%GRL.#)NCW NHE.2H<O<UK5IM(-
MJ)6N[G5+I)#%H\+F(W]Q') JR1MYC"&( ;C'N(\N1V<':XJGH=BYO/,FU">\
MU-HB8;BRG:55MG$<44T)DE=4C*9=TEWF62-F&_RER 5].TV<13:UJDL%YJLN
M;RS^S32WHC7;!F6SS,'^S[F=GC4*SAQ&-RJGF=)'=W=T\QMKF.-+U]\ MY4G
M>6':$^TP,[[ @$D#$>7@%9.)/,5B65\MY<64!FDE>[074AA=E64(5"3Q,)B!
M ?+7,:%S^_CW@;FW<W+-/XLTZVT+3[F>^6YBM[F^U9Q+ HP+9UFA9"1#,0=Z
MP%5^;YV 7'F@!=:U<>(Y8-%TN+[5=O\ 8K[490X*6P+6[)-$PEDC1@ [+"20
MWEL_S+@3:FB6UMH&EVEO87$DQNG@FFN+5$DEU1S]F1KM?G8"(@_O3C/S%P0<
M,\?AB'2[+3M.L[6+[<NH11Z@TDEO\^HR*+4&^&]\)@LK,K#>6!8 D9?0L;[R
MOL%K)J\\\US$DQNHH?-^W[?LRF:+:72*$F0*R[1]]G!4 N0",PLJ(C:9=VXL
M[BVMU^Q*H, +6K>7;D1J7M20?,8X.(W&, !>;BB?QI%;26UK/IV@VL47V:=;
M9MD[R+$HMHXO+1Y+#&#)O"[^,%53BOY<OB66TL+J.>+18K2.V=-,1(A>[VM4
MD2U!02_8$P"\@8;A)P2JBNPM52VO([62;[/-9[+:)8=/5"R8M=PM@-Q6VR0K
MY#;2WWU$8- !'%<+$\<-K_9TUILM895MA*EL66W(B@58P9+8GAV)0C8WW0 8
MZ>H:M;: ^G6[6DGV^1UM;2RL(D,L9"P,\%MOB16M]JDO(2H7&,@X"5[W4X?#
MU_86BV<GVG>+*&&SM@)[F0):N1:)(Q2.UV*PDY4*4Z[OF-/0].^QK!/<7<%Q
M=3_9F#:-!Y1*F6W(6W  !M$0P+)(-[2)@,R^4JT 2>'M :SF$FH+)_;\KI',
M;5EMS!!#-"4@M(S\ILPK N0VX@X8%VVIT%AY+V]I<6ZQI B11QR640D6W5A;
MD0VY$.)+=P,M)VQ_#M_=Y=IJ%G8Z=:W<I@MFMXH5D>RC#1M&1:;Y+5G8A+)0
M5$A"@  ME67+9<QOK[4-*TW1C':QRI-'+<VL/E3VAM+NWAE^SJ[LBP/L7]UT
MV@L?,;Y& *9UN75-1L_#^E7$"7=G%:?;+C2D3=9QN;)E^Q#'SVS?-OW9"J,M
ME0B/T&DZ79:)Y=A:V7V1K>6.-+,O(2@/V/S#:RJ-[6X;!DW)AY"QD*C<3)HV
MG6FCZ-%IVF7L<5M*D<MFD*O)'(P6W"S0+'*7^S[SF16)W&1BS[22U>Y\1V.E
M^'QJ,+Z;'I,5OYVRWU3]VSQ&W1?L[(>+=&+(ZA 20 (V+[7 -"ZFB\.V]M)?
M".WB@>*UCN(8X8O+3$!=((R&VV^V.1Y-S;D6)B,A59>3T%'\0Q6=YK%GG1&\
MEM/TJW# SN5AMI+B*+*M'9*K']VP.Y)G9QAE6I-*T-O$>I:9K%ZTEM9P)$=*
MTVQF5%N8DEMG%XB,_P"[@*I%FW(.S&1^\8$]A8>2EO:6]NT;P.D4D<=E*(UN
M%46X$UN!-B.W0'#1]\_Q;OW@ 0R27-Q:W'VV.YG=%:&2WC@W30DVQD>W)<D6
M^>7#;G.X;6XCW<W/J/V?4['3M'M(+B_OK0S64,$_F16BB.V\MXY(RFRPW1$.
M#M:1A\J,#BI+C6+'2K^RMH1:73M9++;K:?N8XXD2)C<B83,+:Q_=HI3;\Q4X
M$G.Z3P]IJ&"UDGO)[W6F\I[C4$D4S7H+V\[-;2EE'V)3)M9%4 @D ;OO@%?0
M;;1]'8WTRP/J5WY;$V42(]RJ16SXL60JTEI&B\Q@.S;2/F/#['V?2VL[2*6U
M@O+>:*.%(K1,BYB8VJF2W42GR[0?)YD>-I R<CF2.UOK:?2[:#2YI)#]GMKZ
M.RTYT@EN8AY!22".2;$-OA61HV SEAG/+\WJ$UQXHG.E1ZMYEKJ,JPRW-G,!
M#JH5&+""-[K*6\8,8F\DEY"64;=K&@"Q+/>^)]16*U,%U!/F&>ZB,<\-P%,1
M:2V#2JWV8XC6YC!89Q&NYB\E=!H::=#IVCM93^5#]DA%J\<+/)/"1:C= KM(
M\5N0$612,@G<64C>U?R[<>1;V\.+6YBM4DETW*-?1?NT1[1HKC?!;Q-(&88*
MA7;&=S,U.\UT6UO:W@\21DZG<>2]SIS1R?:0@&'LXI;B15"D['5$DD=LX3)4
MT 2:GXEM?#%GI\M[IL]K<&)(XK*U$#3P/FU!LK5"J^=&V[YF0G&P@$$*%S_"
M/AF_W66KZS) UO9RQPZ;%:K)-&D!BMT1[5TE9DC9T^9I-VY 25C#R GAKPO.
M^DVVK:I#YS1Q6?\ 9]G%=RR6R,D<!A\EHVD*0A\"3=YBN84E. H%=A+;_:-1
M6[O+?]]:796&X6#S9+;<8E5(28>8Y$)\QP3L+.N["Y0 C1KXZIYEY%)G>!]H
MMX-QLR?LN;9"T>Z6*1M[-*  H4@[2H*\OJOB"^TF_31-,TR-]>9XX;"WAM_W
M>GP%+7=\RQDM9[]P:3"-E=B@;=Z6-6U"?2[C3])TR*2;4W1;,I8>43I08AP$
M/V8CR!^Y20D92/R&V%G!8\-^&;31+=K2\2.WU>Y18;J>R+F=(T%M&L-N_DB0
MV^SRPSY)C)Y<L"Z@$?@3PU!H5JMTDT]Q<-%9V\VII#%)YFV*V"K;,L.Y[9EP
MK,Q^7RR>#N<:FG6<\%ND":?)HZ,F$:PM(MVDO(+8M;1_NV65'<R.TH7:-ISC
M;E;"6;&ZLY&T^.V&FW$=NH6T5S:AHH?ELW$>3 3F-R54X9SN01@5R]Y;#QG;
MVJV,<:^'84^QO<Z=:QS2(TH%K);V;/$ MN@R[S '(R%P%(4 +N=O$@.F)!)I
M&@QI#8W-\D2CY+B/R6LK0-;_ '!,(@Y;:RL""%V@+TD6FN);:633(+*:*6*V
MFEL2P>TB1HFB@@86ZF6W8@;\D*NZ09PN%L66E6]C>-=QV?V6X_<V\LD$1<VH
M @"VUOF'FV."688"DN?E.2F'=WK>'+5$BLK339XG%K!;6=JK!)YY8?*AM7DC
MA26)]CO, P8$_>7:" "36%L],T[4&U$^3FT6UBM;&W$DD$>+=/LMK%)$4GC>
M23:S[0,M&C#Y!LIZ+X=OKC5!KNK6$>FZE:7%M;VL<%MO33X%V;;>$(O[Q&CN
M)DDE)"HPR%Q&&!IFD+I>J1ZKJ-O':SVZ(;33K*W;.F1-M>>.W@2)Q,2TD223
MIU$CX\O9AN@:*&%XV;2I/-TE(W'V6S#&Q#+$&BM&:%1+$463?L/F ?*JY*JH
M!733VL;>2T^QZE'%:64%M##:%7:%"(U\FUF\L.4<H5=Y'5D\M7^0%7&'<:A<
M7NK:3IVF6D$<T$4<IN]/M!<C2X)9((HOL<KP*C1R1^;N.#M D.2(@ADEU&[D
MU3^R/#ME)#<17$$-[?0LDD6DPMY"-': Q'?$S02QG"@))&[.% R-31O#UGH=
MG8Z/:I.DT'E$K'<!9HMAM#(L):-!);L0'F9<;F9AM+-M4 KZ%X/BT."&",?9
M85M$L;K[' _F02,\3F.VF*>:;=VDE+LSL4)!5HRK%=">YL]"WWE]<?8H;*T7
M=#! '^Q1Q^09$ME%N'DMV!42/T7:N-A!V5[?^SH=.@GN;Z"U_P")?'NGL)&6
M.U*B F2T!0YMN8BYR8@(UWJ<R&L?1[BXUZ72=5GBGM_#\L5J]CH<( =2K6V)
M$0*A-O'(X+%AE?)5E;RY2A #1+2X\3:C8Z[<Z9!I>E6GV>.T6SMP[RH"C0*A
M,.7MF$F\DA-C(F%C:%G;H#%K%C:Z:UO+8V\UIL@N(GE>VLU9HHE6WA3ROGC9
M\!7SNC8X&\;HB16F/L6G:B+%<6GV:XMH++.S/V56AME,9W6AR1(3G;N7YEV_
M+3U#7)M"O8I[BUDDO7N/L[(\9GFDDE>T^2U8F-%MP'\LNVP>8L98,Y.\ DO]
M=_X1N);NXGGDA7;#';O+Y\\$A6VVV1B60F>XD'F.)"Q*YR25)SEZ'X<NP3J6
MN:K)#K4EO!IDDRW2/]@MQ)$PM'D#*SW$P?)E R&?*;?EW2:';WD%U<ZUJM[!
M::GYMGIDJX-P^GQ^;"\5F'92TS2K/^\F+X#,I .W(Z2VF;[1&DD\EG;VJ0Q>
M9)>*9(7<PD6TH+R"25L<N<'$J!"Q9GH KZ5 MM;Z85LH[6XL;>*R6*+=<_V<
MCBVWVLFV3+N< B7;A5 9N/OX<FHBZBM[#1;C[%IAVV]Y>JTQ>U%VL)1$='9)
M[F224/YX9A'N);.[+U[^XUC6V72;&ROM+O[>)=.N=50O.^DK-%;2% =Q^TLS
M#:905:/&\X'SMN:0+3P];_8K>2.T@LKB&S$,*.]O9-*+7-OU5IG=I"RS%3M,
MC;L<JP!8M!8V-Q;LL<=E+ Z6L+RCS/(-P8Y)8)F65LSNR*?,? +31X,A8[ZX
MN+'PXEO=;;33;"SMX;*6>63<;! UN([6<+(0[D2R%92<1AL\AF+R0WO]F:<N
MHZQJGV"WM_(CG5KSS6TYG%L!;RDAEEW-N+3/AE63@@,6'-Z'I.I:E<:??7NG
MW>FZ?:):QZ;9RPM(VFJIM2T+KC,XE()$C;O)\D,=C@J@!8TBSU+6KW2]7UY)
M+"&Q2".SCO(V78Q=0R3B20F1YLVTB'<_ERQA22Z-YO469:U<',EC CQ1013P
MK%!9(RVR_9MJN%E=CN".N\*S,H/&UH[5=WV22S,$$-I*+68VMOYOV;'E*UK;
MD1#,)=1O<_=V,,*1F+B]5\3:G!*FDZ3:QZ=K*O'9Q$VT<EOHQE@M0EN[1HQ\
MIW=BCX4&2)5(**: +&I>+M5-QI>D^'UDEU:-(Q=I;K)J"Z<,Q[K:X<2;'E9H
MYE$KLI&,'8':4;&E:0OAJU0SWEV+_P"T6\,VJ7*-</EY;?,!D?:93(7$8F1%
M 5$#8,*U'I&DVNBSWUP9+Z5K2[$]W<I<SWUW#<2)!NM57R=TUN8O*^8DG@'
M9 RZ@B6QO;>YN8H[""T2&RBD@9L6[RO;C[+"GD!7@8K&/-SD$L!LQ\H !FTI
MVD>*/2[.!+<75Q# K) D:K_HR$QH?(!?=YN'"@S@^40".7L9+GQQ=0^9#)::
M'8VZZ?=NI>XGN1<10%[4/EB\6=C-=8!92I0A=TAIS3_\)?$D\Z7UMH=C%%97
M0%UYD]W)<+;_ .@PR9&Z%F\DM.YS)O\ E<1DM7:*UW;V\#0:/)!/ _V14C5
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M7>V'KFH?V?''86JSV5Q/J$BQ16U_N\BY:[7:[A/F"S+="1O,WQQYB!C<LJ.
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MP &:!6_A#)8GNG_LP^;+.LUI*99"9&@-LXDF#74RM<J6M&*%ECW'Y%P,C&P
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M28V$DFX2G?".@T_2K2TLK(:+I,;6\CH$-Y;O!++Y*3>3'.&MRZI&4A"2-AN
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MG ,=/Q9K]QX9T?4&L[CS=42*6\6P6Y$S1Q(TLGG$.N[RVPJN"RJJ_)$V\('
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M:Q-%/8+9>>P@M2CN)B)HI+U_(B,4]VVS88AN$>2>2P6@ @TJWU/7+[4)[/[
MD.+]-/AB+/$3]I$6H^483NN7P0(B"5V@ON<(J](;%;-+A$ADA$3S77[I&F-L
M9&N&,\!:%B\[%_FCY"AL $$"2..WEN)[;[/;SQ++++.-L"1K8K,DFVX3S(03
M,2IW(<LK7+[]R[:Q]:USR98].TBSSJ\T37\<$=OSIMN[3*U^J/$&>;]X-T/W
MR25 Y8L &KW]Q#XA71+)8(-5DWRV\$"":.SBE=T_M$C[/DS;W*M&&*X<EB%W
M.+&@^'WL-."V<>^_NY5O;NYF5H=DLHD1[R(20MMN&7!: X5,[> 27-*T:STO
M3KVYM[N >9+)JTFHAP(&:X WW:.\;JC(@E"(K,NPKO)W[A'JL>FZ5X?M[^[A
MM+6!7>^N+FXMUCV-E0+TYMB/MF"A6,JN6=U^;:, &Q*C7=UI\L-C)#)>O/*T
MT4*@VX\K8ERQEBR)POEQA#@@2."'6,D<?/JUWXCNKG3]'U".RTN!XYM2U^*9
M$E:'RIHVN Z$1.7\G9D B+"MC>"L%QHO$'B+2Y!_9U]ITT^MHT\MN[6K"'[,
MNR48>)Y(PWEHX8^85#X6)@J1:&D:!%H>F6&FZ/9SBUCM,:?++O\ -BS)$[22
M K&5W.Y:2(R#<L("H<LJ@$FFVPLM.L+#1S'';W%N\\$%J(UA$@N$;[1&%G#^
M0QEWF,,P,>U?D)V21ZUXE_LFUL#'#/JUWJDJBTM[&;;]OF$4<BS1-YQ\JV&P
MAQ@CYLG*DES5=7>U2RD74<R7LL<MO/:EI?.*VY+S16ZR.TUNV8T,2@%<O)NS
MB0&BZ;!HZC6]?A@AU63S;M+%KB*1-,C:5FF>-WVD<3@S.&(.,+\H1: #PSX;
METBZ&I>(9(-2\37<LDXCA9&2V4RE7>W\P*X41RQJY)9MJ(@R%1:T-+C1U$MM
M<^<D_E7,]I9R*@9VE^6[BVRG9#)M>1DW-O&>-YD#QV<Q=(%L[N26]F1[Q TD
MDB3L["(7$>;C8;=03(80QVAXS\K[0V7JGB&*=+BRT^[_ +0U)K22;%C<.RO(
MUO&$F"0SF2.WVN[;0I)8 J?,,?F@$FI:Y,+VRM-/NY+Z^O$BF,5L2T4BL]LJ
MWP"RETMT.X&($>9N?.5#25)X>L-EK:_;4@N[N:6*_-Q;WGFR7TWE6ZO>0L77
MRX5W.A0#!3  "ML:/1=%AL72.*YDOTU!'N)[F*\$4UVSK$&G@\N08MPUQ<2L
MI/RR2;HQRN="+56^S_:KIXS;RO'</(+U8?,BC"[[R$B9Q]GYA)C)7"ERV\N%
M8 !>,UD+J[U".$LCW'VBTNUV3)LC3[9%YDA18$1]S1NK -R-Y"M)S\2W/BUX
M%$MV-+F1"8Q.\,M\&5F:YCCED=&M1]JB/E,,_P #Y\I8GD$EYXE^UW6HR3VF
MB64L-W%<P.8_M4B93[6#([0I;(4\Y8LL3L61@0X$FHS0I91QV\$;I;V\=Y9R
MVJ"1)65(D$UI$EQO6"-3AXE WB3:I;>0X!<M;]Y[R.WE?S_M6RZA:SF;%ZB"
MUS<1'S-L4*LY#19;>,D;LL&S]4\1OIT4*Q)_:UWJ/E365O:W#0F^=%C+20,)
M'40EFAS&2N$69SYBYW5_%/B"WTG3H=1ED@NVGN_.L%B8R37+L(U@DM$$V750
MZI)&"GF!I&X#;9(]!TE8]934-2NY-2U34TBO%6WE9X (V3][:2-*2D"_:W#*
MQRX9MJA#L8 /"VD0L;;5+B2.\GNDBDM4M@(%:WCDS;S6R&0-#$D-SY<D>,GD
M?-N)ET+>XL6=KN]6T!9UU1IHI-GGA5BA^V1R&39'$$5MR*SGRG3=@R%&L17+
M:M;XL]7CG2Z>-Q-82J6F*!4EGMR9V58D<Q;D((^21663S03GQ>(;G5;_ $V#
M13'J"3/!=Z@QE>#S(BD!$MOF4F,+O1V@*G*YW8\Q#* 4]2UG6-3O+S1]*>=9
M+2[ADU/4;0N0D:")FE@0E_O-#<0>0BR NK;R#D/J6EA8FWM]-MQ:-O1+Z.33
MURUX["-1>[I&*2%&+.0YF/\ J7)+%0QH6C:;I]E86\ CO79X[TW$;J)=0F"0
M(U]&PEX3:Q$G=][?>W?O))KB"'0TEO[C^UHXXHKYW$\49OFA^SN+J$F98XX5
M(#,O"Y.>A_> $>HZI%I]E+J#7]HD=Q;K.98VAABN942-DNE;ST8Q,QCA*NYW
M9B7*IEGY]-+;Q&9+S4M0U)M)U)((XK*RVPS:K%YD:B]D$;@A#%,(Y5('R*&(
M0A$0\-VU]XBN+2_U&XDET\W$=[#'$GV6?6I8S%&+V2)G^2!%$+!%(W$!RO*(
M>PL4$20O;WL;RWCK=9T^6-OMZLT&^X(EW$(N=F%=ML3*%)/EA0"-+86<L4AT
MK$,/V>W,5EYV^UE+0 K"Q"AK; C+A BCR6W*Q9@O/WWB6WL;6"PTEOM4GFQ0
MP6FF2&)KVY2*UFC%L-SI%:>43YF>%4]RQ+2-J]CIEU8LMG),+ITALK.Q?<[O
MY5HZK8N-B_8PJ$R%MJDKR,'!N:5I]U<+:ZC>ZC]I>38T]U8"=@CO+!,D=J6W
M9MFRWF-DY&!E4C"Q@%/2=*M+<VVI27,<NJ7*6D;#1XG55A22V*):;FP+-0X,
MI4$-O8DKC8-R35;>WBMY;J\\R&XVW#2P2E4G"+"QN8V\XB*V0 [U8X;./F+@
M2EL4%G97MHN88_L\$<>GVJR"%)#;?+;RE%#6V!EV"G(R04,84<G%#?>++J[T
M6Q,EAH\3^7=P))N2)UBGM7MUCRA:S)B4ADP=Q;;M;<8 "..?6?&^IW&E(;Z#
M3GW'4I)2BB.=8YK62W:'S23;.8PP,;-\X<!PV6B[2QAM+=(;?2X+MM,E=9X5
M@F=T==T!5X9?-V1P*&(\GC<%;8I4$.6MFULBZ99V^I+86%[SB58BX9DD1(^
M#;H)2,!E($'EX<$J:?V^WAL[35=5>!IFBCEEFM)BPD!-KOGMW\S*6BG:9 0
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MR[(!(^YP5._+94E\O3OM;LM-O+&XNM5S_:'ER%8I)&&HA!#M>S G*HNZ0$Q
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M&PW .$^7FP3K-_J%J+.[L_#M@GV;4&@LI+CS]R+;R65EB+<MNK0_O&10Q89
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M-N#+;%U"?9A'-)YLB 8#L>&+586]LXHK"5[RQMM-MXEN5$,8<6VU;=0;9O+
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M)> R+%;GY@LKR.K&1O,223^+*T %MNT6SLHCY%E:V7V?3T0?:'2'>;9%B4'
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MD)AE##&1S]SJ?V'^R-+T*'RO$-O]EL&L@WVI]'AD^RM(K( /,M]B?-,6R&(
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M +G5/[!TZ?499;Z9;;RXUML?:9+;<+91:.J2DRW$A.5D;=@R'+;3\^?I>G7
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M1OYXM;DL9(?W5G-I5_<"9+" 3DP^>AGD$MS.#%M<@8VDY)&UP"OJ4+Z[J/\
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MD[?M#&12R-NXWX!R2W/V>AWVK7%CXAU)+O29[.WDNK>VM(]\ED+DR22N!]F
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M"[9+J:=T6*TN',(\J-4V;_M*2K(3G890KF)'/EC8MI;AK.R\VZ_LZXA^SQ2
MW(G%J2;8M:S,TA\V:3)59-N</D<D;P"/4I+NW>Y>"ZDB2-))&BN+](C8?+='
M[4[DR;HG;8%1E94"AMOR%1AP7Q\1-J+6,G]FZ99[]0MM9*PH-,NVB&^-HSE9
ME9)I)C-DHPF.UN%>HX;N;Q-K-JUE<R:?H]C;K:27\DI6YCEE:VWZ?+O<MYI
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MV"?V?>?Z,3 6)E,^G1R+;J8XMJ1J9@> D.%+-D@%-Y[SQI/;6.F6GV33H?\
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ME[2<EE=<O4KU]'BM-*TB"";68)5DMM-<M(EH\BK$"O[G?]D02RL904V[?*!
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M2U5]/T_49KK3-0UD?8KZUQ&DMQ(LT>G;I8 +>-Y%#323Q,(VFW/APX4C=MH
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M!U*ZN1EK?[4B_P!J*)6*S2SJ5G4KE+0F-&3:VZ18T106VHX!<UW4[;3]$O\
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MW%%^>/<?*W!JT'_$RCGU+S\7;V)D6[BC^U,WFLEK;[9QY5PF]$+,%9MH]F4
ML,[_ &R_/F^?#=[HP\%\P-TZBX5K:W0S 03((T+.I&XAR0I&5Q_$&NWEW>2:
M1HL_VBZN93:75W;RE410)V-O 1(0EZJ*3N8*O"ERN46J^IZK<7^HWNEZ/>7U
M[?K++8W5[#*(841C)*;: &94^UQQ  2!'P5&\J"Q70TC2$T;3H[:._\ M4CQ
M26]W):,L/]K3@2AMG[[<EVOEG?)N&?FR<J#$ &E6<4/AR'3C?3WC)OMI9[>5
M[1]0FA><ND0\]2EQO1FDD)Q)R22#E+&NZM_9\$U]/J5B+%M]M.SW?V9;C#R@
M0P2&<"*XC ;<2!O8*-R;28Q]6T>&SEEBU*Q-K=Q7$RO:7:0I>1J9WD6W/G@)
M,I8-)-P#G)(_Y9\_>:;+XUO+E]9EOGT,R[(],\Y(1J$T8N ]JJK-PT3(IW%@
M'=)#EHQ&8P FC?QUJ+7M_#.NAQ^?:P6K[K>;4Y%-RKQ1H;@>4P50"S*CN!(#
MMC++787%QYOG_P"D>?YWF0?Z-/Y?VG;Y_P#H\'[X>7<)M^9^,[>V/W<<WDO<
M75PK1S3W2-:/):RB-KM8S<E;:$^<"D\9W%GX_BZ8_=Y>M^(+>VU%K6/4_MFI
M744MO%IUI,1]M.9PJ)L=GMY(VC*O/A4'S9Y5?* (]:\3K!>O9PW4=[/=7"6*
MQZ=(TDMP0\OFP1QK.OV>6*-HV><L -P) PH$>EV-[NFN]5U">[U.666.62WG
MC$5T#%('LK']Z&@V/&I9CL=FARQXRL>A:&VG7%]?7S6EYJ>H(Z375E,L?G.3
M<-+8V8#H82CH'+DY=B[-A@2O27%QYOG_ .D>?YWF0?Z-/Y?VG;Y_^CP?OAY=
MPFWYGXSM[8_=@$<WDO<75PK1S3W2-:/):RB-KM8S<E;:$^<"D\9W%GX_BZ8_
M=\WJ4VJ:MJVHR:5!]GN(,12ZV+#SC:"&2ZV^3&6=;AMA:)@FUU,W())CBKS:
MK+XP^WZ=I>J?;=)F^TVESJ$+H/M;?OC]@@A=E42"&4,+A25;R@6W $#I+6#3
M8K>YBTN*T\C3WE1IM-52MBP$_$-NOF#[0HD <;%W^9W_ -6 "/2M*LM)T.&T
MTVSGL[&TB>>",122O9H_GD30^9"7:X8-AHFSMW8QVD+RXTNQ^U7\MU!:1Q^<
M2\3[X[4I]K+S6X,15[D_O/,09( .<@?/<UF2RT@2S3F.QLXTDG6X(B'D2>7<
M/++;IL9GGQN+!A@J21D[P>?^S3:K?M<ZO''I>GV]P]WI5G':EY'8I.1.(VB!
M^U9#R[/WF WS1!P'(!7BM)O$VI3W]W;26VCV+S7%I!;1$^6WFLRW2 (2UX)8
M)"\3+\JSA2-QD1]CQ19!]&OK6>QC$$J3!;6 1LTV];GS3:G:'^U-&S.0RLIY
M4'YG<:EQ;^5Y_P#H_D>3YD_^C0>9]FW>?_I$'[D^9</N^9.<;N^?WG'^-M>T
MZVT/5]/LCOOK^*\TW[!:.QBDD?S2CKE IF+[P0&4NWG(#*\06@#E_A8#_P +
M<,GD6,*S>%+:8)9PPQ#+K;NY9(P,,79S\P!P5Q\NVJ_[0?\ R]?]PS_W(U8^
M%NFW&F_&&?[5>6-Q)<>&H9@EE('2V0^0$AR&;.U54!MS;EVL22U5_P!H/_EZ
M_P"X9_[D: / **** /I/5?$&H67PN\702RQQB*XO[*1YM*N%BGEENI=TD<JL
MRA"I= "/EDVAFP1NR_@S"]SXANKF\DGGDBTK3X[*,7#"0P;UWM&3.1Y*2(=Z
MC/.5VH<Q'O/%$Q/P=\4O/?QW'SZB@E>ZDA _TF55CW$9)7A GW6*A,E6S6/X
M!N%36;*Q*W>^?POHUP(1(VZ41L094?S $B3> \9 +_,0IR=X!VD,:7NT7-S_
M &E'=RP7J1I(H68Q_9BL]M^]^6W1AO93N)9CC((#\O)XNU'6]6M]%\/Q_:VN
M95:[U&UNUV(L<D*RSPD2NBJ%*$099F\S,B <37-6US4KS7K7PYH5W'+J9=+S
M4) 6"&..2*)I(CYI"()597@."PCF&Y6*L]S18/*T[2Y-/NY[_P"U16TTIDF\
MF35,"S7[:"7+JJ1K\T9QO)(8'(+ $GAKR1I>G+"UW=?;+>"[DN'E"3ZBR>3$
M+D9FW*@2.-W0CE94!RV]#H0WLQ>$B^CD2\>"42VY+&=0J!YH$W2_N&9H4*X3
M8&D<N<AC'-J/E6:7)NH)XW\JZE<7GDI/&IM]]U"WFMLMT4L60\-T)PV7Y^9;
M_P 7WEM]MOOLNB2[H)8;?S#+J\2CR3)'&KNJ6SM<MEL%@JQ/OP5:, L01SZ]
M*(H8_P"S]%LI182R6:2K.DBM"K6]H\:(5M@\>UY#DG:XPBJ&&P=.W^5!/:P1
MV,<0M)X([/S/(W_9@+> F(![9@&$C$<>J;"$"?[-B%Q/#!8VMCY,3S1K@649
M5#)%%F  V^4BW/D !I"3'Y0 KW%ZFD6%Q<SP0:;_ &=$R1%RJ(@2"&9H+8B$
ML]NRQON8+O'EMM7Y1L +%Q-;Z-9W&J7L?V*&SW37<UO;F0VQ8PR2QQ8@S)"Y
MW-))USD\$?N^;M/#M]=:S+K&I6$8_L]Q;Z9826V([$!K=[=80JR( 02LTP!*
M%2$(6/<9+#1]1O-1OM5U+1X+6&VE@@TC36@7=9^44\D$I$Z,KEV)==_V=6<(
MP)DV]1!;_9Y0!;_9H[646T36\&3;QEH0D,0\D9A=54R$$A#D!L)N0 CAFTT7
M%JMA/&( BBT>WA4M'#FVQ';J(B'MV!3?("0F1R,#R^;U+6=1OM1?3K"YG;5K
M2*:2[U+3K195LTRL02)9(3YJNZ&1XE<N&AD0.Y0*8[O5;Z=]/\.Z28Q?VJ(U
MW=V%AYL.DOM6V5;4-'L9/,:7=EB5CCN%R" %Z#1M#M-!MXK>SM)+..%XXR(0
M\WV5F%OF& M%EX'*[I)./FW,<-DH 1Z5I%OX:TRUM-/TZ>&&UE2'9;@S/:F6
M2!GCB>2,&2W8EGDD)R,'&"H$>I;*;2WC@A@DL8T>%)TM?,D6&0"$+%"K1[3
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MQB QM(5GQ)N92Q)J3:9<&6>ZC@T^T<6IGN9E*V2 H3]I=KG]X\J[#&VW<OF
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M8R6[^>C6C*T2[ WV0NC_ "..,!F(VJ(>L^P0O;K;W%E&D"(EI)'%;"1;=6$
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M#;R]Y+=^,=6U);?59+7P[8.TUM?QWB*UM(T-V&NQ,LQ:2 ,=NW*#^#Y1#(K
M$E]X@?Q#+=Z7:Q?9-/E^TF[N;K4V>&XMHVD<J<HXCAECD!\U60QJ\?5?($O4
M065G8;-#BA^8VC6]O875L#]IMX_/58Y9@K@VX#)CC>FY-Y+2[6&N["/3A9:;
MJ<&G1K:2W-D4N(V^QQ8F NV7SMLEMRFQ,;5^7@ ?NY-1O;*VTL:K=WTAT&=)
M@]I.8IHKK=YA4^<[%$BD#<!W"_ZE08_F1P"OK.I6EA97FK7\D9TMK=EG;4+)
MX6ERCR1P3$PG,&V;:/E#*Z[#YCR,M<WHVAW'B6\L/$VL6'[ZY^T0Z<DB"[%L
M)!=^8+EQM$ULP9/+P0,%%7@L[R1^'M5\4O\ VSK D,F^<Z59744@3SRLZL+@
M&(21VY01)MRJRA SIOD*5UEPL$^J?.9Y_P!["LK+;Q-,,7+M$98VBW"%'C*1
MR+GB1WXV^: "O=;+B*2:]C@>:&)Y+U9KE8D*;;I?*N=T2DVBDL$?:V[[^T@,
MS9_B;4GL9;R"PLX)WNHBFV_C9$9 UR)WNI)EYM(]P8!#QN51A)4W1ZCKC:+<
M:=8VBV@U!+*Y,,)A5%L$4L&,SLB;;%6$8#J(V;R$(\W<=IX2\,0^'A$D%S&_
MB"=&^V7<EL&:.3R_+6(((D9;/= Y3YHQ^Z15)#8H N1Z5Y,5PTVESW-U)=LE
MY*R;!?R.LRA9P%<M: 2QA,&4H"H8#RGK0:*XN;R_6:U\U)-UJL=U; &[(%PW
ME32+&R_9MDD91AR"65LN60UWTS;$L+V&U5B%BR16_F0*TBOL22-8XC-;1"4(
MNTE?WC%PI0NO-F2Y\7N;BRAD.D17J++/;%W34WVR;K=IB2TEFLSLI?RBI$F%
M15C9R 2,K^-( B7VJCP[+YICMY-PFN3</,$FG5'67[$.%C0;21RV$3=727,U
M]:0W16>.*ZMDENVCN[S=!;.\)*R,X=7-J'$RX="=W*A%C7!=V5I:Z-<6X\R+
M2XW=K>.X=XX$V+()8)0T15+4JC ,^Y<2?)MVQ47EW#HQ?6;@ZDL%K>M \+VH
MGG/GR1(JQ/RQ@+,LFU-S9VJ-OE^50!)J]\-*@75Y)+Y=+L)7<00K-)<WES([
MQ"+8W6/<XV#D,3&041!NY_3]&U'5M>&MZRD%YJ,4K7-GIL@7RK-'B7R6!E'F
MQJ6A 9O*#^:IVJJB3S,^"V376%]JT-C;V]G: VMAO7R+&)HH955)TC*FVE2*
M:.65EV\-$F1N+]A?SRV$6M/;) MY:?Z8D]Q=)$':1602SJA7_1XU 7+DL1 V
M 6168 C:"%WCFTYY+EU2.33T^W O=QA8@SB=G=_L^3;EPH!)C)(E\S:_-OXH
MO]=UQ?#GA34H)KN"(375](DB);M)O+3HKS%IX]K#RXPC1CS(F\S:%%&LZYJF
MJZY=>%_"U_.;B;4-MQJKOD6#Q>7*^T#*R1[-L)C 3:XQ(29@6W-!TW2-,L+&
M/2+.[&D17#16XC0NT*R/'(CQS*VY[=V56;F3/F .56-U4 /#ME;:;I=E#I*R
M*)7BO8Q-,DMQ>E]OVBYD=)]LPVS $G(5E#*''EBK%Y-#/IKR3W=I-'+;M.S2
M2!K>Y4Q1(UPJ&XV_9461B\;'D_,/FVLY:3-*EA*=3N[F22X6XG>U97)#L4BD
M"+(RK:NJ,H7:YPX<E71Y!S^E2WWB^]M[B_ENWT61/M$=LB_9AJY+^4TOE/.S
MK:I&8F,9VB0R%BK;@I ,^V,/C2XN=8U6.2WT*9X[A[2Y<1M<K ;5A.IE"![%
M0TI*L/\ EHSXWNJQ]0NJ+]H@OS/)//,FV&.SL6DGN7!B+/ [2/&EK(JPYQA5
M+@M(KYQ8M'5TL&@OKN:::X6YD6UF:4R%V(68;I72.U=(YB$.1@C9ME4 Y^K>
M+ET>R>[^VQR%T#1+&S;]6N=ELT2V2$R P.'9&V@E2V0<Y<@$FI:NGAVSM+5;
M#S-8&VUTRSLU42R.2LDEO$6A51;*@B5I0.%4YPZ#-/PUI$+:E/JMYY;:E97
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M)FN+C4Y[/[#%&JIJ-P573S)$0&N#YRK<QEE5027/F>9A^OE\O\FN0>;)>_\
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M:IYC,0PR"=XQA2US3[IY?L\E_<>8U[%!.PL[MGCEE7R?WMLJ9?[.6D <LRJ
MH)7$CLW)_:[GQA;K;OJ,DVCW=PBZDM@[EKYU$$$J6F0"MBKMF20$D_.!@'+
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M."H"JHASN0V,L,%N]OIV]3F_:V2%(SJ,@=<RS[[=1'< "*11NC)DW*<+'NH
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M_P 1&_\ $]Y?^'O#5O LTD5Q!J<]\T@EM PNEC#XDS)'*79HUPPC4A]A#(%
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M$/M=O?+J"#4X#B5+*>ZBN"L2DRLOD*%FW1W 5U4L-I+.A&<!%Q_$'BJXTF>
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M KEG2#+E7W(&RY<E22[ %C0K*QTO2[#3-,6/['LCDBBLYMHN0/(_TB#]^2L
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M;C'CW=[?:I<'0M#:T.J.D,UY<7$._P"SACF.[N(S @%P$AA*194[G.5V1AJ
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M(EVAA&Y(;=B.Y_Q+;6X6XN%M!/<6Z7<DE[$L+74,!@)N;@F$%)8BV53@#/\
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M[4O[+TF2VEFGM;:WQ"B0V_V-Y)$C'E+8*<A\R0N! ^XMNSDQ[!)EZ9I\VIW
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M3B>+RY9]AE)AMI'E&5"%@664LI<NH!),C>+M+":1Y<.D0(L"W-FJLCOQ&UC
M3;G-KYD<3/-M96 *[2H8)TEOI<4$$$/E3VRV\L:YMB[-:,7@?[/ WE O;,1A
MCD*JC;A57$<8TA8[(6RV\<<<:/;-%);M<Q0&9(U^SHIB#26NY@S$,@7RPN51
M2J1ZAK<&C7EA<:Q<>3=12F&1$2*9V6<;\B0 &.VC$<I+,J,WV7<3\I#@%?6+
MF+2-'@O_ "9[2:SB86JVEH\GV>0-# +2)!$GFPR/@ .5+?*R8"J\5?2]"O)M
M<&KZO!]D6QEBM]/LK6(L-,V?N]L)$>)89TD)=MJ[ %!P8\QY]EX:O+[3HM1U
M_2MURWE0VEA;DB#3F 2.6$*8R5MY#!&KLHD79,X V;Y9.P46]OJUO*+B=BTM
MPRK,I:< R)&\:*T9<V_F%9"P8!<1X/EX"@%>TTZX6+3O,M]MU8>5&YL%$*6Q
M*P!X8%= )+8C<S98D;0%RZKY?)ZMJ/\ ;,+Z/HDUI9BUMP+R]C2UN+73[1H;
M8F- Z!9+=U<MEC&2('(W!!&:^K:A;:VC^'=$O--MI+>R#:E>83;9P;K8H\$;
MR&-K62)-SQAMH0C=ESL?I-(T2R\+RV&BV^G^7"GRVX@ED::5RT4DTD>Z5C#;
M*54NK,=[';@DKYP >'=$L_#EY;Z7;+!:R2Y<B&V F2;$4DX1Q"JO;OA S[4"
M-M1<$QI%(A6TTM-3@DM(;6UMXF6>W+1HI'S1Q>:L6R6S"3E=^S$85GY;+1B:
MA8VFEV=U'>26]G \<@^R#RTF1/)B:>*-I"J6:JS;@5( /F*<A7?'TZ%O%FLZ
M?JET;M=/@=+RSL&D7S;EW:&1I4E8J[V:%H9 IP=_#*/+CB  65K-XH>2Z&F6
MEIX<5(XK$/8F1Y?EVV^T(JDV9BGW,I*LI>:-B(]X/06UW"!)J37MH;E+>2]2
M::\'ERJT:M(B2-$ +50;8^9$.2H+C<&WUX=2T_3DTZ)]1M,6UN'^T6L-N"MH
M[1N)8U5B8[/*^4?E) "L6 0R'/U37+Z%[&VTN:2XO+Q_M-O%!=?:@CRJFR7Y
M3N;3]S3*[NN02OEA0$V@!K.H7=C$;6*"[N?$"7"RP01R(;B1?/A9O+"L[16<
MK1N&:5_W8PN& 5!8\.Z6+6XAN)DM+R>ZMX&BDLY8XV2-3 2MH5*DV*EE.PX/
MRG(E\T4>$O#(L;?^U9H;2ZO+MXFDN=-BCB5HR(/*6VD5P1:QJ@!1LF383@@A
M6V!>E4MVN/M;O<O#(T,:21RSMNMU\Z.,R[X8$+?O(V'][=U/F $=I>7%S9VM
M[ WVVX?S;6WOCIX(D,A5_-3#C;;+M;ACF01IM=B4:3FSJK:]<6NDZ;<W=KH\
M#V[3#2=NVY0F&,164\>TFWB<DS. &7[HP#@&G73>+KA!OCN[>1\7TR;2MT5-
MLDT=B7<$V8=/WQ8$/DJNXMD;FDSV5GH^GVEJ9W@3R(DM[8R%I@C6\<<\!\UO
M]&"E'8 N-K_.=V]6 (]/W.\5E974C69>"8"T=81((ULRK6:EBOV/:6\P9)RS
M*I)/,B:C;Z7I,5\FJ0:=I-G+;QS3FV/V2Z#QP*A@^<B.WP^!M.%<;B2%<21_
M;]/OBNH'4XQ!:HDM]?1)-'(#YD!1H=VX+9R"%][*3&P4G<<.U<OI%[<^-?$&
MC^(]7:[L+%G5]*L(X7:?)$!D$J& K);[T1UG! 0LI)#%1& 6-)M-2\8V]MJ&
MH6T=CX:*6AL-+$32JBN+8M')"J>5-$0&V29/E>8Q(#+B+K+6*XM;R..2U\F&
M+9%')9VPQ8#%J/LL68\R0N=Y:0* H4@[2@*U],L_L[0V\5SY,>E2PVGEV<7F
MO9J8K;%H&>)FDA;(D:7*,/ER0%)7#FUQM&&C:586,<.H%[;3[>T$JSSV+B."
M66V_U>3;^4J;YPTA4N#M.T  %S6M=3PG:J\\,'VP?NM/LK5%B: +%;N]O$[Q
MA3;?(S23G:$7 P&4;9/#^FS66I2WES#(9R_V075O8&+[!"DL7E6,2M&#+ 3)
M)F=54%5R2-JE33O#USICG4R(UUI4AMYVLXGC@0*L8BLX%>*0I:DMEY$P0P)X
MP52Q%:K9I:+IR2+/I3V^FNEONN#9([69>W0,B^9$8P&:5B609([JH!'8GR]%
MT2?3H9[?RXH8K>.)?/6+=#"5M1,()-ULVT%YP>&4?-V7G[Z_NI=D%BOV:RTV
M7RY]1=)X8[8'S$FLH)(;= +=3 JM.^1&"K??1-LDT=WKJ#3+6&[BL;*]6VGN
M[.W3?;1LPB^SV;-;(-D-Q&K-(.46%&#%OE3<TK24T9;6W3[#:ZL-BS2VVGJI
MB3S8'DM[9%B4M;$RL#(2?++Y8D@E0 L+&+2-,2YMHYX9+'R[22<Z>\\]O#')
M$?LD $"R3VY&\"7DC[V6.2LEW=PZ#I::KK$D>BVFEN$F:TC$J6\9\E4MHLVP
M+P/\I8K@JPV@X7Y8[S6+?1=#EUN3[#:Z996D/DW4+$I"6\G%O"5MCNMGPF95
MW'D@*-HVX>F^&YM6OXI-9L[O38](2VBTBU6 S2:2Q2)/DD,;Q7(9E)+DOY01
M6.UF/E@%?2/"S:GXETO4=8L(]-.AI EMIJ;;FXL@"L<,>[RB)8& >0REB4;(
M4QF*1FZ06.-.M?M.G3_:&B:S6TDAW1VGFB!S9#RK<QM;$)L:8@[0" V2=NA:
MQ7$=Y'_HOV&WLMEJ1#;!S$6%J5BMF$?-L<.KLR@@KD;0GR\GK%\'O8M!T.&-
M]0D>%9XDCCN[:UMR\%O<0)&R*6M1M^?;L.\<?=E\H DU;4Y8]:TW3-&L=VLI
MY:Q(;%&CT6-)K>&4Q*T<<CV[K(X,BG!"';M 8H>$/#=GX9\/6>B3Q[FCM&?5
M8FL1/<I)*D4C1+LB(>W<0S(6.XL55%;<H"ZFA^&&\.BV6UEN]_VT/?W#!7DC
M+QPJ+>$"U :W.V($IY801CD;"JZEI%<0:B$:U^RVMK%;PQM;6P/V5V,6ZW@/
MEY>W(5-S;5V_WN"(0"N[OIN \D%K);^7Y4-I8--):P+]D\VWMT6/=-"W(:50
M-A91MROR\?;6EQK.HK<W>F3KHMMLAMVTVW#/>')9;.-Q#&'TXIC)E54+$?O&
M4;JL:9/_ ,)3!I-Q/:3V^GQQ);BWMH?*:Z1GM%=8(&3G3CA&9F^?:=ORKE6Z
MB2TVWEO%BQM;JVB5;%%LO-?3Y,0HZ0#RU,EL0Z*[KL*98%AD>4 2,+FU>.&*
MVCLBB1VMM-;VKSBSE*Q$P(BP*#:D(NZ0NO.5RA5=E.\UJWT6PTS4(6L8X>((
M4BMC,&!@CD%I8E5C#K((\JY8@NJKM)(5(]6U"?1X;5K?2[M+R"X2RL[.SCB
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MBN 927E8G*S<J%;=DJ<R<GI<-_XMU&*^U22^TK1;*7[''9WEQ(GVE"80D-[
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MM2L+@Q&ZV-;+))92>8ZQQQ[SO4@[B"BY8NZ[FFVL-K9:39V%U(UO&D)2"WN
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M7:(%DSEB8Q\DC#)H7AE/#,4JM93_ &F2)I[J\A"W<UM+ME F25K=7N)'!E+
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M(#/!_H[;YVC>5F7YOF"K@B0N<_4!HN@&%9;:TTY[9&6T2TM0[6:2R/&);51
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MIF, IZ/9W&HZCI6L:I%/;06_EP6UC>7(G_L]Y##*PNVDE$DDTC[!$O.S$3%
MW Z@7-OIMG"TE]]AL;+8\TFH7ID-I*2"\5Q(9SO9DG 0'<JD!LM^[%2/=F%W
MFAN8[;R[>5YQ>RR.NGL5\V0S%7,;$%X,1EDVIO*/MXK#UC6GL%2'0HH(-;OI
M4N(K7479#',TODR-<D2[GC*MMC(!CS$@1F)A4@!JOB9]+G%A87L#:NMH/L]E
M<EI/[-B"(\LFH/\ :-I483]X?F&X[?,R<V-%TA/#'V]_M^^Z6)@][J#*UQ%%
M^\*W%ZXF FCS%B,X5D3*\?.13T6V70;*:X>XDEURX<W][>Z@C0$,B,I2ZV.0
MD1"7 C8 PH%!&]@IDW/M7V.ZGLY;V>%H8KK4%FO6W):_O9 &G9)0#"PDS'&V
M,+"V2&3Y0".358;2RAN4U:TM4MD\J0WEP)!91LA0?:2;C#N+B'9ORQ)W(.KR
M5AV\MQXQU.2TM+KS=$TO_5V3W(!O0(V11=.)'D:&4E9(W*XD02;T8%&:G)<S
M>+[\I:R7=IH>GW TZ*6[NC+;W3;$*M.GFQM-%*)4"?-+YAV$[%+K+UDMI%=R
MMIM_!!?0?N[>'3;L/*4AW',MP=\JR;O(+QNZJ<C:6#,U %AH'O(K.V03M8M%
MM%I<AF2[MBL:M]I,L3.LBAVQ&6!?'S'[VS+UC6+'P_I<5_?PR7 G>%H8'ML2
MZC+^X"NZ>2"+H%?DCXSMR=H4F*2[N+?3HK>YO#.\-S+;S*);(XN2BH/,G"VV
M8[@DILCX+/#"J;266N;T'PWJ6N/:^(_$#79O9W1;&UG1M]HX4YGF)@5/-C'F
M>6IC6('D9>4N0#0\,:'J5Y>V_B+Q#:1G5KJW3RK,AA$D(>W?S9_W0 O%V)T"
MAO*4 *$RNY:P^5]DBE2>^:\E$RO=6FW[1CRG$UP4MU$,T83:BMMSL4$[ON'V
M>S34?M"V\$EQJ<7GP?;(!"UY.A\R-)CY.Y&B55V9)?;YA*DQEJY_5-5,7VCP
M_8S_ &V_O)9+6ZGNXX5CRWEJ&O<0CRI'4-%!\CI(-A(<$  !KL5Q?P#0-(M?
MMUY=Q0+(^I6PF\BP=\QSSB:-=\D3"54A9RQY=@[;L;&EZ%%;>4(8-ZRW?V^,
M21/']J5O):26Z#1[1<"4F1 %1AY:JNQ0X$>EV,NFV[R7$,EZDR1ZA++,DS->
M2J(?,G>%H6,$J;%,4*-S@@*NW*V)!8V-P;JYMHR\C@3W5S:[%N%MRA-S<R"
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M21$8L3A8[K5K144:NT=S;S/#>0FV=Y!>^6UIMN(1YA$:+*X A&YI#@KN+$.
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MN7?#OP6Q(HY7;YFQ,ZQ[O-@@L/*EGEFQ-;C^S(S]IQ?#<I^:7ONR!N;/23<
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M"9!&HD*[$81G<,ERII_Q \-_V38277B6"XDGM(;B4->1Q33W(C5@N!-MM_\
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M1;PR27DE[]DT]#Y<TT5]([87S'D81F2*4LA*[8TSN!!6(@$GBS7'T#2;F?\
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MRUC.9(3'%M<2V\ZHAC=5(:59<*LDA4+L79G4'DW;QQ"&0W=S<"X$-Q:#?:7
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M\UC(7<.T0 7@>5F,YR2^3<)/!.T:^1>NT#W4HD2VN"R^2LR^<3(6>421I\H
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MRR;86!!5N&^3$>*PXA/XP34--M[:2*V@> 7-U=VL30ZH6;8[LKP<SQ1Q+\N
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M2Z\M+=HKD[9-UM$)AD#<598I1AW=*D\.67V*S>YM7_M:ZU**+4VO6G\FYU8
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M*SC?#]F^> W#8\A!C<5!.6R")0<QZ0$M-.B6V@GFM;'[%9V5W:0JV^)Q!O\
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M%9HY489E/W>I(P LEW?Z;X=MY-;O98[.VT]%A7]PKKI4+BU#6C1PN278@,K
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MN^6PO_L5Y)+BXO+QEGEC+^6T5K<MYQ\V3=(BHQR1%E%96<2, 6-#TVST-?\
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MJ!*Q8KYBL@=@8_$NKS:2EYHNFQVD^IA&D5V)9%PUND,TI>.1Y;J,O!B,,S.
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MWIL($9O/9W@F%M* "86,AE:X4*X4OAB6980"G>;M;U2^T[1+62T@TN]GCO\
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MU@EC@$UM/A602XE)3&6:.)$\SRQBN@TA5WP1V=W(T\-O%;M-<Q-++/$BPO\
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MW8W?>#DU6\M!87E[?Q20P7UO%:W'^AN[+#(\J0[5:W+22LTBAH6!";N1R?,
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M3Y1D4!8HY"L<@&>D@#OJ*1(V%AE:9[>6Z;SHPQG'F'#L'C<XV1L%"@$]4"*
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M.)<*N5+R+)'N^8YF(G'RC<?+ )+]+U+>[07L>G"!)9Q=R2RLMKO%QB8N^$F
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M#2\P%HU*!=K)M*Y52ZJ 5[2Y+V\L=E))?3NXN%4W4D:WLA%N_GV[M*Q6U4R
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M9%E;=.6*E),$)D'..9"!KO9-#J4]IJZ3(\+NNP)?L&N2]I% TFQ'0!068G<
M0WW2R\NLDOC"RDN+5I+G0#;R6MDG]HS1'7T"2D0 /*&A=&3#R,"T@4G(0LI
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MV0[-M ^3<=@CDO?$VR%8=#TUI]FZ8R:FRQ EB J,(2S' !;<B ;@ 6YQN44
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M@'&1P>A&",@@U)_PD.J?]"9KG_?ZR_\ DBN@HH Y_P#X2'5/^A,US_O]9?\
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M_98UEMT>)#Y"[;1MK SG@8R@<J%634+Y?#UUIUM:VD?]HWMPMM#:I(P-N1%
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M'&J'&%!PV-N'!HFI>*[VSNO$/EFW6W\ZW\/S1LKM,[R2!KM_WKQ0.8E81DE
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MZ<3"X03JEO<(L(Q;AG1(PA+R%P%# DOCP>&HM2UA/%.I:5?7=W\T-I;WA?\
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M.MJC?9@88@$4RQD)DS,3L8$G@,J@!I-K]ET[3U^Q3V'V6*"W\L+YTECD6_\
MHT;>4?-A./GDW'!!.1C,>?KVM6'A^*X^RMY7V+-G;O#;1N]O.5MFBL880JM(
MLJD,0K<;2-R84I'JNH6G@_1K N)+4V[PV-M'#;/=2JP6%OL5L3&#*DJQ,OF,
MPP^.XPE?PWI5S%?M)=RR6LVC7"Z9''I[O-';VY2V:.V571O,1E9&DG(C<%<9
M"#( #P]X>FT_7AK%W;7=O<2VZ6H6W0E-+B\R&1;-%(;SD9I7#3+\B",JOE!<
M+L6<)TI[&S^R26]O;I!9PR6\<EP]JVV(FW0FWYMRL:[IF;KD':5&V2QM?[.^
MP6<=E/!#:1);B:)?-^QX^S 6T3-%ODA<9+2=MC9*D#9S>JR3PW$.G:5Y=E=P
MO;V=SJBVD4L6C2L<P11*84\X,MR81@_NT8,P4LQ8 $UB^OKW^RM$ACMY[:X%
MK/=6UMN31HE>U22VA=8724OAG&[;L&-ZILP-3PYI5OX6\+V,*6=]:QV$2B4"
M(W5S;.YADDACV0GSHW;<7=>ASMP%'ER:9X7T_2;"WLK:WN[*"V1K7_19IF:U
M\]X'DBA8Q[I(G8$M,3N3YL%,'RY$B2SLXM5>U@T6:"*WBN96ME<V$2F!FM8V
M6,!K?!DW2;ML9R>BD( 1W3V/AW1K9+JYDT:WMDBL%O8T\S^SB5@"Q1R20$-
MVWYI9.-V 3G 3#L;>7Q3/83ZCI/V71K;9:2:-]D222QD9+:14D&S!MR!@IAB
MA=';:5 MZ_AZRU'Q5K%KX@OX9]+T33Y8H-.TV*V5O+PMOPA162:V>3+!\?+Y
M,;HR -CL-)M?LNG:>OV*>P^RQ06_EA?.DL<BW_T:-O*/FPG'SR;C@@G(QF,
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M!M"9]S7,\<D=H^S*1D2Q&:5"67*#>H'R 'H<=LOB9YK5[.2WT6S?^SI##;L
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M7US$\MN[+%_H+R?,R&1O()?]\6W/T/E&@"Q^YFMUM[AHQ $2TDCO91*L*N(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVRQH-K:0+9V-M (X;E79T$ZY;:L+0["823(JAD(VNRS@&?I/A_\ X3'4=/\
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M'(\>82\CJTK2^9D8!17"J=S1+NDFU&QT*WFN;J;3=/32K=#<^8F181,(OW,
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M@O1,5MM]R8)F\M0(W> -(CH[!Y3R@9E# +\ECS[2"ZMF$LEC_9:+;SQPL_\
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M-QJ_B6\TV\LM)TR'&J2Q"*U-],9(;;(@!BN2LS;YMSQ'>Q'RRC89'.R630=
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MMGE^VRL\6C)@2M]K>.8;]R6[$;BWS;@TFR8"C7M>N+7.D6-]!8R6N[?J-W=
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M@@N)@5T]2)@9IB)@9+=RI8*Q+!B22, 17+R%;MS9L9'*O*ZZ9-(SB8NMRO\
MI+ R 6\@R4!4!2@')Q&(]5U6WT:SNKJZO/L4-GOG)N)3(;8L9PLTJB;,D+G
MCB SG  !'[OF]7TN7Q0D]OK^H1V7A\)+<QZ;)YQ<EFF:.:];>&2 "(R*A,0!
M/EG!C&0"Q*LWC*WLY[B"[O\ 0[BX:2TMY<I#=LHFEA>;$:LEOCRUPZON=8\
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MP\@L@#!GSE_)C#&-+9O% DG@TB.UT*W>!+16B427)6.,1P#9 P%G^]G1G1I
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M381LL+M;%1(3/<2.5"N%!8%2=Q"K( 1S7-O9V:7>L0V-K;_9(K/49+F<W M
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MO@(254L[#=N:?Y%G:R6]I^X:P\JUM4N/*C_L_P#=6I6Q>4[RWFDIEE#_ 'L
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M!64HSRY)9"V2<;74 KQ7#VFDVUW=1?V/#9^5'/!$&2.QB,<3,GW6CF4, AE
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MRXS][F];NYI;C_A$])N9!.CO%.VH2F>"QAF/EJURSNYN)9"7\F%F (E7>@V
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MR2L 2UO)P^%X#LQ( 5V(!3\.V45WK#^-=;>"QOKJ*:?2([J=[G^S@JR).[2
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M/F($B#)49'KGA[_D.>+/^PK'_P"D5K0!T%%%% !1110 4444 %%%% !1110
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M',0$ W2/Y?EF$KYL2LX!1G\NMR1&M(8;5K&2.."W\T/9PK(-+;R2BBV!B D
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M!N%SP[9+X<L(9KN]NY-0=X(+JXOKIKV2W>1X,6LQ60;WW2GRV"!4#EL?,QD
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MWOR)# !);'-ZP89NYMT3I&>$(#89Q0!<L=,N?$!5K^.TEPD$!TRYB>6/RHY
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M5=F50QV@KNW-(L5TFW^PZ;92,[W$,MY$;EC</*!:[Y;B9#Y:2A27>(;O.'S
MG<P(!8T;2[32K>*WTU)+BSNWCN_M%O*[R7K 6Z_:9)@412<%G09\T989)=2:
ME?VVD&0ZJ=-$JO;SSJ[);P7 ,D"&Z8RKP\3+PH=B!Y8)RZ8CN=3L--TZ?4M0
M: Z;%Y=S]MF\MH;]%%L1=L\<1 F!^6-!C>4&T8VE,^ST._U;5K:_U'S_ +/Y
MOVB"RE,D)N#');JEU</$B+YFR)76"1"06(W #;& 5].MKS7[S1M0O9I[RR7R
MYH8#=F!]0VBW(U$1++M$:NJ$0%1MWLYR[!#U%K_I\%I,?],:YQ.RO\UI-L>(
M"X0CS1'PHDB0.,[B3\VYECABFFN+4V_VL1R(LLWGP&V:]8&V(GDDC4%'50R^
M4ZIO^92H1<US]SJMH7L++3+:/6[O67M]3BB,KQO.J+;E+V=PH%NB^5C8$.\A
M0 "66@"YJ%Y>I:R0:;I7VW59XFN;**^6.);\Q16["[G&Q2DB/LC"?*=V.%4;
MHY+/P]IOVT7S6T>KRWSQ7/\ :2HKSW2H]LT4C3((XXT0J#Y2YWK&&&3O!K^&
M/#S6%Q<3SB[O[N^>&>:?4(E5;TJ87^T,/*+P/&79(X&8 >5P =SC4M[H3:=!
M>)_Q,["XBCOHWGBFE>X1! 1, L>V*089EA5/G8!EVG?@ )KH6]FE[J7[U)/*
MN/+EBF$4I!MP'\MXW:&8/_JX%.68]W)*9<,][KFLVMN\MI-ITKK>QC=*GVYK
M=K;-Q&3O"0!GW+&,;VC1@[)*QK/%M<^)79;>SC;1;Q+=;@6UN]J-5@D59)91
M)A6A0-=LY0R.TAC=1M_>;^HLT:X<*UC(X=XY5:[A5!>A5MC]IEQ%F.=""%0[
M23'T  * $>DP6\VG:>+$?:["6*">T64$0RQ*+?;,1Y6V"1<;DB3:I.6P#DIS
M_B?7TTVPFM;4>;J$EI]L9Y8%#H@@W1ZC<QM""&BDM@I51\N5^4L8XZS]7\5Q
M06MMI%X-5O-8GEA_T<1O'-*PB$D5\(3$Y15DMLF.,,J!F,B%\QUT'A_P;%HF
MM3ZM=PP7NOWDKR!]K_9[6/SFWF!F5VA9UG9VCWD,Y8 A02 "/0?"*Z?JZ:E>
M64<VKFXFGB:16 B)GF$TB2J&V))'<!DMR< @\EM\@V+ KJ%O:7$,DFHV]VD5
MU UR6,=P@%N1.^8L0RK@LD:[0QRV 22E>UF,EJMU)8R2Q%/M#B:TD5[IHI44
MSRI]F5A.J1QLB@#<20HPBN.;L;NZ\3ZCI=A93^5=6WF75QKUN8/+NG0BW\^%
M=C+-(\.5."4A$P#;G55 !(;B^\4:P;+P])&D=C<(T^N&WVSPW)M)$WNC*J22
M\I')'MS&I'1F_<=!9V*Z=:V-CIFE1G1XT@^PZ:(&0!/-B9YYFD3*2H6+K&<,
M2CL2S']V6FG&VL+?2M'TVTM=-BMT?389XY&CX>-S+.C1!DEC;YE0R!G)8DJ1
MN2OJD-I9V%_J4MI')) @N)IKB-[?[9]D>)A/<21V^X.C(Q15!5UR0"I^0 L7
M9@")+?R7<EK<7 OD^UF5(D2-H9A)*WE 6QB$9"QL5#[?G)9F*\_I< \87#W&
MHQ27/A^X>.2SLI5CAFU7RS"OVZ:,;"R*>=K95D,?[M2J[S3]'FUGQ!-#J$$D
MUJCK?0I?,8KNYE8)$+V0Q*!;E(@R11[4=F1F.UDW+N1W%P98+BVBGN+>2)Y7
MM5 M-0U"6-K95G=)%AV[=KJPR%*E."&"@ +>]2]\@PZQ/>K?W<<J-I\BLLQB
M\C>\)$C".V!1UD5LDL[*#EE#Y]_K2:-H]NUO%.ZR6@>SM].=7%Y*C1K&UK;)
M*6:%4C$A19$7RY/F#%FV6-7UZWM=.D%X+Z]CNXHY8ETJ<B;5'(BR]D$N/,6-
M "SJ,9#;LD;BT>C65]=F+4=6O8Y=6O'CF']F76Z-X%DMV#6A>3Y+<J%\X;=T
MA8X)'EA@"/3;676=1_M'4KCS;[[6MQ:QVKHZI&#;GS+*9]K&W,3(L^!AV+A0
MN</J00P_:-(MH8+2ZLQ;QWD3VDPCS(IBC5[5/-_=P)&6+J."LJ@;R[@EEJ%C
M,;(QZI'>?;'"Q_9[_P#X_G219'EM\W!Q$C/*'3DE5"\JJJW%ZQK6J7C)X2T:
M+2KFYNHDMHGB?R;*>V\KS$DA7S71?*+IYD!5S+$4."AP #4U'4[[4KJWT;2Y
M(]1U2[N([R:[AEW6]M;F+RFDMGW QD*T,CQJV_;='8_S"1=SP_IMGI=G';VD
MOVEKZ47]Q-!,%?4IF,!>\CQ-A8<GYT P<X (($E?PW;6=CIT,&E30:A;R1/=
M3W%K=@3ZK=0BW4SQ%9=NUF5EDW,,N1NR&):GXAOS9>&)[JZO=->"2R:XE,US
M)+;7JF0['C!G#+$&D1I$"ON25(E,F%! .@L[M@EBK:C(QNK>"Y>:%UNC=.6B
M0F(@8$0&-Y6)%Q.'!0[C7+VUXWBN]TNYN-0C&FS7"2V]K;W:I+>W<#VY:5%,
MC*8(RDRM$I8?(9%,A=&$9AEUG0]=N?$]A?6EA=2B\LM)DO4%VMNNWSI3)++^
MZ5UEV/&&01IN4<N2W6&\:>](8R,#>I LL5PJ)=!'D;9$HGRKQ$'S<@%Q$Z[&
M& H!7M?LCPK9HT@AAN/L!CM)7MDGF$*(QML3 +%&GG9C7)5HF(^>/+9\WB*T
MAM0MG/)JTUZBP+%9W;@ZAOE DELW\Y@@CWS[E!#($3+(BHQ+CQ#-&]A'++)J
MDNKI]F2+3D-J\NQ;AI1&LET# \>$#L0&!PN22!%3T/[0\OV^_P!;L=3U._S/
M:R6EV'2Y"-&[VUD/-38J>4RN#D/F-Y&.&C !)X=T8:<\M[>B.XU9G6#SK5XX
MXIEB5W%A8A95,:1O'AE<#?L?<""2NPIL97LDN+F.ZDO4(M]EUA[IF4,US:$S
MDQHJSS9V_/MP%.U4#1W$UFMG';1OYL-U%Y5A9:9=BU>\A0K)&UJ1<*%5$<AR
M-I?;GA0JGG[C6[S6]8O-.TC4-L-S:()+ZWO2CZG(%^<:8'=XDV*'WD9.XA24
M/[T %>^U>]\5ZGJ&C:'J/VC3)+LR7>I(8V#.L<<D-OIS-(5\X)&2S'[C[I!M
M^45UFG65CI-K%IUDL8LYD:T9+&;R4DG:60RBW'GYB,9\]F51N VA6)BVU3L+
M6+3-%N-&TN2"'RHC96\=M&Z1W!6&3<L!^T ";SA,6.]9 $PY&%EJQ?>)-+C@
M2XDU>">#4/W4<EG<_P#'W%OD39;*LV[SH]Z%V0%FP H+;50 CU;Q)::5HQOM
M7O(R)K)I&;3YW?[?"JR'-HBR!HW 9)&< A58 NP7>N/I-H?'9'B+6A(=%D=?
ML5I:74DZ^=YD:I<QNF'C*^7UQ&5WR!DCVR/+GZ;HMSXMOVU[Q8;N6(.7TJRL
M[YX(+R14#Q2P+]H^2=528'#>6P(=&89=NPNY+9Q<:Q>PQA]+MW236U*,L(6.
M3SI+6/,I5U<%65@"<8)?8 0 _LUHK>*TM;6/2K>W>"-!80J?L4[!S(]NK6Q#
M ^:B,_W=K2$^64;=7U;4ET2]6<6$B%7G7RK*W9Y6(<3%;<?9\2O."ID&\ ;'
M(),;N*>IW,'A?RK?3H?)U"XNS9Z;IUG:1'R5XD8P*8H]\;XB:;,@5?FQ(K(,
MGA[P]%I$1>ZM,:EITN]I8;=Y!:6P4B.*V=H/W[&)(XG8#S&'!;*QJ "/0]$F
MTYV^VR1S7VGV\B/Y;&5]*B*R&-K*,V_SEU.&P F8]B+MC$2[EQ#]DL[@A)[&
M.TW6\4VGVGG36D>8=D=O']G.^-E56? 8(P*@D+E">RN%LS'*WV:XM\W,DNGV
M@(A),Q:>W5H7W32Y(>/+%0YP22#)S^M7-Y>ZC?Z?IL,^EPV4KV^I7UE:&:2"
M.0I,?LNR+>TTXE0R'D1F,M@G:[@$FI+-J5PMMI4%W8QV5D+&[OM-R8]/CR6F
MCLP(P9W)MUB)7F,^7M7=O4:EOIT7ANSD@@M?LMK:1?9[9=/LWF>SMW+ /&?*
M<S3.ZHTBG@84L#MW220V<VDZ6?LNEVEI=VB-,+>S0F*WA.6,,#K;9<2/"I=0
MA<>82.1&#'K-_;^'X'GOE@M88+LWH=4+>2"YW>3MMSO9HEN9),9==[Y8*PD4
M -2_XD<$USYWV+R/*@MQ'9^='90L^R-(%2 -)YKQPB2(-E0?E9<(3GZ7IFHS
MWDVN:S8?V?=1Q2R6]E#;K*^D+*)/-DAD2-EN9I7C5RI&Y=Y'.[#F@Z=>7,L7
MB#7+7[-=1Q/?V]M;69SIJ2LKM"@,1,LT@1_-;[X+855WY.H--FMQ;FXAM!)I
M]O+MEM; EK*-HRB-9_NV&2(LM#AR/, W%557 +$=A#8$0Q64=E9Z>AN8X;&V
M#K!B1\&%1!\SRQF02*I++D!1E]YYO7KR6\G/A:SL8$O[F5I)W$23QZ>9$C$D
MD:^0RRJ6N&#K)LD(G+';&X=9-8U"[DU1M"T01Q7RWLC231VR.-,9]FV:/='^
M])6;,BA&P;EMTL2X8Z%CH$.B6$OV&QCA-NCLYCB!:RD9WE;[+_HY,H5;J<+P
M1\H3:"\A  :%HUIH\SR6T-W!+*XDNI/)>1TF>9494=X 9$?R@LDA()6*.4\N
M938-G;:;9&ZG$=M);HELTBVZ9LCLD\L6A\@&8@W B08P02,%RZO)J)^P?:)Y
MX8+.QM(I[N>>-<_8<^<1<0 P$23.&8R*3\N>C;B7Y>/29?%^R2YC^P:+:[;>
MV-E DVQCY:A;4O:C=:.C?O&.5;! Q$"7 )(H;[Q1?_9F@CM_!]C>QFW:&SW?
M:4V+''# -G_'N5):27&"LK1J3&K.=R*"WTG3FMDMIX%L<%H[33BR6#RB4[[/
M9;8F8&4(< X498 [P]RW\ETM9+98X(CID4,,NGQ"5+3S6"K]F;R<.AP"Q)VJ
M(HF* $FLO5K^ST%H+5+6<WEQ=_9+#3[,!W@*Q,HFM%EC"#$3Q[^1$GSC);<)
M  \1ZNGAVSNHQ8>?J+>?=:?9V:JT_FN2@:V!AP[$-)+*?G:/>V0ZL*CTK1;F
M&]M]3UZ>.+5(+CI 7CTNVE=\$0QL4,DLRW+#S&\S]X6&> A-%\.S0WLVL:U!
M:+KCH;5[G3[0E+&1G8JUJ'A)(?[0[R2,6 ;(.5#!;CV]OHUK#*DL&AP6'F,Y
M<F+3K5WB0>6%#0B53)('#,K<B1<HQ&T N&_AL+*2>>]CLDM;<Q":]N0R6#,D
M.V.ZS.?,E+,&#9Z$C<-VY\._UO43J.E6.C-]DNX=D-S'J-RLJV",0O\ I6V9
MO-DES#Y*@ARP8E]I=:S]6U-[&6#2='$%I?V<7F2W1A8IX?MYF;(F*R.K?(8P
ML.?+7RO,.V-%V]!I5BFA:<8X]0GDCLKLM>7>H3J\R%0Y>6ZD650ZM 8P@8$H
M#$S*0N$ (]*TB'0K2XNHY+N*0(C3WFJ &6"1+=B7NIA(HN8@&' 9@KE@K!5'
ME7)[[[%%?7-SJ,%K:VUVZQO<38%C(RO\URQN,21L9$*1_*5$D8VC *"ZK;V.
M3<WG]GK8Q1>8VH2D+:Q/Y/R3%IL2R.1(JS#<H977)(8/S\MQ+XLU-KV]N)[3
M1;7RY)+2:=(XEMS&7:2;RYBES;RJ64/NPK1 ;'7SL@%=KRX\2/)=W-U/IF@6
MNS4+59L22),+A62:X*3OOMBR.4QMC*!SE!'&YZ@2)I_FV5O'_9]KI\1FB,LJ
M^7: _:1YDJB<$V^$&V/"A05QC:?*L(VR)HX[WR5M93!&U[>;S;S[4BA1U5LR
MJX?S,22;R9$[D;,OQ%JJVFEWL-N\CWF^6&UL_MK+*MR^Y5,C),&\IVN+<*HP
M8_-C8[!@Q@!KFNG0K6X:W-VMQ86\444#P27;J))7C1W43CSS*T*HG/F*6RQ
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MO<Z@_B2ZAMM%U&"UCBM(;>2^>Z9;NR@N)8E,?F,762:3R3Y;C=OWJP=0$:<
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MS/<2;X63).UH8G.&8H=S38[2S>VAC%I:RZ2D>FJ^7:*S5UM2;8L[J97?*;)
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MJ;"R#Y6Y^1:Y.T=O&Y2ZG>0>$PEI!;6M[<J/,)DLY1]H#[G,I.Y5W;A*K<%
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ML[8\SRG0 X(C-,T"VL+"=+RYCUG4+URMY?KLBDU*6-[AUBBQ,/+GA8<-QM"
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M:42<B52\8W@NKACL),TKR=A]N:2X6=YH[=U=(V$KKMM2Y@/V>95FPT[[OD8
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MY#GOM*\OI.F:CXSM8-;OIO["TEOL\=GIEPJM;0IY0$4<:@A)8YC,H9L(X >
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MV (H5%0Z@LS93://$\@^S7$]G#)'I\@"0O,,6YA1,+$$C4"8E0#%&WS*[ @
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MD@(F^;<(P6SPS<_HXN?% AN%MHTT&&W-K86GV5XUOC)&LQ1I# ICLUVI$N$
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MY=H^;O)D\0VMSHR2_9_#5E%:2ZE)8W"I!Y3Q FUBD*1C[.J;)GD#;MC;0/F
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MN#YS+,JM 3;Q8P,<2A5C5RL0!)X=T.ST6\U/4);R!=7AWB427 =-%AQ,T<;
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MV+ ;U9CODVZ$JM?ZS'+'81V:2NLZ2Q,L5_<H&LV+[6VE8A@QRHWS%8T '(%
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M@M 5X$BE][81>@NK1+#[7+;Z9Y4GFFYE^PVZLT!?S4^UQ$P_O;@J1O3+$+P
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M^ZKNXN:1X<TJQTO[#;V-VT^R74X433HU!E.%AF4O!'#%<*B*!'A-I9BP;EZ
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MXO)Y+_4+)$LSJ/V$(\7[XNB01^6P6(I<M&[(P5%0 ;=I*2:#X5TO3X);E/\
M2;.\EMIGDAAW)<2J\;V\D!C9F2W3(01ME56,'A0[27$MUM]4LXPT=B8TC5[>
MTC8.A3R52*+$:B6U432AF92$,N04*_( 7(+?R91*;?[/(LH$KV\&XP22M"[Q
M1'R1YD,C;FDD/(.22"/W?)RQ0^+WM--'F+X9B39+]A@$MO(Q6",16<\*@K$N
MZ6-W8+E9)E PK&*G9/%XJO-*M-*@@?0HMLTBK,X=X7$1DAM2RHLEHKD++&^2
M.4\M"L2UV&D26]M%80:8/DD_TF:*"\,HF++$&>-IE'FP_OA(\J%27&2&=W!
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M,RH@8+@OL7E[8:1H=R;J"Q3R;3RI+1S'$DH_TA4M92\*K';!@4BD;:']\GS
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M-Y>6SYBH"&82[;%AI5AHNCZ@_P!CV1W$MTUY<:E%'&VH.&N2_P!K982J6_\
M$LG]UE& /E< CT71;$Z69;..[O([RXN)!+>29&INWVG*S[(RBVK;S(A VDR!
MMNX_/L7DJES#]HU+S[QY;>#SI&MTN7"W+>2"J[H@H5CYJJI8+$0\G0T]2CN'
ML[Z:ZD@CM[B*[@DFFB"DA#/L69W@*BW",6#,N%*CF82'/+ZC?:IXQ:=XK>^@
M\.:CE;.*6Y\J76@D3NEO&H ^S0OY<K-(_P [JRC(4A5 "]GE\6P:DH2=X;:6
M>UOIENDM&NV#@Q:5)SPV^41^8NY=H(5\SN%Z2*QA1+M+98[K:_V&2"*S&)88
MVG=;*2!@J1(L4@"2%E#ED)RI"O<AB^RV;VMNT]W ?-MU^PKL0QJ;C;;1>7(J
MV\D>%0R-M!VJN=V-E?7=12&"9[BX@FAN=]DAW+)#>3L\L45H+=G(9@6/F'=%
MDHN3M#", CU>XL;*UG>_6TN["X>59)8I-\MZZ2S,M@JM)N9]S;0F75L3(4C!
M //VFD7-P[ZMXGL)(I+FW.F>2LCNTMLZS1_V>TDC+\_F)&_VEB!(\H56VE2;
M%GIL^K:E)XAU&>.ZN)7GLH["YMXFBFA26YS:JAD4&Z1/-C,N?+V.P'F#<YW/
M/LOW1B,\TDGGZ8DT)D22\$?VC_1U<RAA-'Y)/G2'&2Y1@9#@ CUVYAO;*_C$
M<=U,[R6,]LD(A?4LI.([+)8R1E0ZR&3 7:3(,(S%<?Q=K@?Q%=Z%H=K)>Z]<
MH;>1YXXVM458#<"UE4E=XD5&"E^@GF*/\KH#Q+KFO7%_!I'AJ[M-2U2X<V]W
M) 72WA")M=) )=T9#222%XF\Q"L$; [T)N:#X=T[PMI-OI,$7VNZO(AI\T^I
MPLJZHT<=R1"1R450K8=D9?*V*I?Y2 "YI.D6GABU2UL+B[>[NG-M;W=_,_GW
MDT<MS<-'+F(A4.9?WH4EE<D<A";D<J&"VN=.:QACTZ66TA=H%MX91OD@6S5B
M6>/$J0995PQ1=H(.U8Y+DE+Q)[K4C*UQ):+-,LEE!.S--Y4 ;!,87>B^>@&]
MA%AW/R5CPO-XHN(=5%E=OHLR.(R8CYVL0DRND+K^[6*)2@*&7(=)%4L/,D5@
M#/>*?Q+<//;V\D6AVUO+;Z?IDL<5J-366RP;.&56SY2F/?YBDHQ.5RL*O766
ML-N]UIUSI]U8P"*6:PC98RB[(I6!M8X6Z?*C[G1ERT$;89!M$:P0VENMI#<V
MC&Y>6RLWM&%OYVP7)6T9HT)B2%00'4A@R-P#D/EZIXFEL-6L[:$_VAJ4FH/:
M6-PD*8GWR2-- PQN6&%%A#S)NPZJ6#%'0@%/5=4MM*2.RMM/CNK^]1=..GV^
MQVG,+.WV+RW1%C@59@?.,9!A+$X)B9KEEHKV:6KW\L%WJ5]NLY/MZ-)]J(MY
M0]DKO%OCM@T0D5VWE\,3N+Y<TOP^EG9WFHWVF3RWUS$EO<VRPJYMXLQF/3X$
M*>4UOM<H\@*KD,Q(Y,>X;12YM98I&@A=+6[DDL6F%_ RR+' S.6=PGFHSR'*
MD[^1F0* 5[\-);WUTMM=ZOY+W,/V>[M5C:4N%46BY@&ZW9B"9<X&Q2S,H;&'
M?RW_ (LU&YL](U',%AJ#P-J"))#,SJ2\NGET0-%'^[3-PI''EKB1LDUV%_XN
MUB\@BN()[*+S].OF"R%I)2K-)I^_R\10@CYKA45G7R5&77<>DL=/T\6MH+:"
MTNM,A272) T$TI6%)3"L"QL6P-P DE)PPA!(*X,8 '2K:TN+BSM=-CBM)'BB
MNIQIZ,MRF0@MI(U12T2Q2JJ.I8+L;>0$8/3O=<M[#3M2O]4O[YX+2*=[N1'(
MA ("R6MO*GE R))Y:J[C?DNJG=YFROJUWIWA?29;O6Y_L<4<36D;6I:%X5$:
MS_9+=BBH595D02IY3'9$F3(H9<^Q\/:IK-YI]WXB:"VMXI0FG:$!]F@LSB1&
M6)T(>2XCCCWJ^W8/F\LX821@%?3+>X\0RK?7EK]BAB^33M,V! T"M+BWB*RH
M(KE1;ABNX^6X5VR4C6W[ W-O-9S6=M??:IK;?8HT%Z<S')9[8?OPWVE8HA^\
M=@5+;P0"ZB-M76[AM;A;B.2"]1UO#!<,7CB\EYHXH4AE8FX*R(VZ/.Y49@1^
M[%8>N^*7M%M6,/GZWJ/G6D5A'J36\4J>:ZB%9!+Y:7*C&YU#8:,IN4R19 -#
MQ!X@>&62PL)/MNK7F8H8(F:-+Q%:??#"_G*(9HPA\R7^'Y/E)*((_#VF#3=+
MDDGN)+O4]01DO9T:.![R0?:&-M"L<X2&=&+EBI )WMDL69:^BZ%-INEPRW6H
M1ZGX@EMQ97>I>:7>\5/-WVELWG(8I5V'+_+DKO8%@Q7<N)$MH)Q:Q_:%N)9(
M3'I\JP_:27G+QPYG4)<(=SR2<%MK8Y&$ (Y;V&'2]/,]Q($D2>S"_;0CNQ^5
M;4.;CFZW*%\S<W,4O*;ZYO5IKC6KS5](T>6#9;RRPS&TN! )Y\/<QQV_F(R+
M=K(I\R13\H.\_/M$,>JR7/B9'T;3X9+6UNGN/MEW;EX$G1FN&^RV\4I5'NG1
MI/-+#$;!BWS(NSI)YTL)3%$9Y;&:(V,<6GE4A8QM,JVUNJRAXK@ C?)C8%@)
M)CVDH 6)XT%F;6TN?+AYMHUT^18A.D1F_P!$MP9<13*$VNX"\ X*E08N7\:Z
MJ@\)>(IS>:5!?3:?+97MXLJRP,Z+,5L4!F5Q< 2M\Q3GDE1D(NIK>L6FG:)=
MSQ3R0VES<3V4LMBKQRS2,]RGE6D6X_Z4)MNYRH#\MG PO/\ BK3YKKPKK6JW
M)M(9_L][]D@6Y*V\'R79E41)(5EO-ID$C'"J6)7=Y;!@#F/A'I+7OQ(N=9B?
M1FVZ/:2JUI:+Y<3R+$) %C.R*7"3(02IRQ8(5RH];\$:;9V%GJ\MA'!#:W.J
MW!2W@M1;I#Y1%N5"AF!Y@+;N,[L[5Z5Q?@"[MM0^,?BVZAU'3;W_ $= DELZ
M-N1I"R['PSR@*4#MO4(Q"!2JQE>\\&_\@.Y_["NI?^ELU '04444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>/
M_M'?\D\T_P#["L?_ **EKV"O'_VCO^2>:?\ ]A6/_P!%2T ?,%%%% 'W_111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0^#9))[M9+<?9YK;RT4@HT;18:!DV+@(3N\Q][,56K'_  KKQEY_G_V)\/\
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MX+ J=^SS  2:3IMOI=Y%)8Z3/.MS*MRTMQ"8Y6D8-YMV<_(LA-P%*%8GVI(
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M[ZZCUC5[J2ZN-02TNX=/BN$*0,D4*O-:L)CB(-+*)#_&&"X(_P!;J6]X][/
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MOSR$Y&#DC;^[IS:KI>C1))=3P67V.6*P*6T?F/;2LMNZV=L@AW21NN"<#=Z
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MN]7C5%'D1I_JP2%;"*"OR.8Y(K"QB2.:UVZ2V^UFE:VC1!!&MP3%.K1J$MD
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MHHH **** "BBB@ KQ_\ :._Y)YI__85C_P#14M>P5X_^T=_R3S3_ /L*Q_\
MHJ6@#Y@HHHH ^_Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#'_X1JRCU'[=:S7UI,9?-*07D@A8DY?,
M))B^?+;CMSEBP(;YJK_\(;I?_/UKG_@]O?\ X]7044 <V?!.G&X24:AX@"*C
M*8AKMYM8DC#'][G(P0,$#YCD'C$G_"&Z7_S]:Y_X/;W_ ./5T%% '/\ _"&Z
M7_S]:Y_X/;W_ ./4?\(;I?\ S]:Y_P"#V]_^/5T%% '/_P#"&Z7_ ,_6N?\
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MS:VEK;Q6\4*1VC *B! <O 22=N3SU)Q@8 Z2B@#G_P#A'M4_Z'/7/^_-E_\
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MSB ^4A^Q^5)$LC(V6\M%4MC=*:>9/%DUJ8H[2+P^$,,-K:/ TLPBFBBFCB.
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M87FFQ/=:K=3W>M+=O>S $SFRA=<2)&BR;VMW:%_*7!()C)0M&<;%Q<>1Y_\
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MO^E\96-G\R!LVQ*0%8U:6WWE#(Y.T'AOERJ  IO+33C!:P^1Y/E(((E(C@D
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MMRIBDW:XAB17:3RH(SM0-M2-D_TA8QE0N&KK+&UE1(;=4D\P.H=D\Z%;HQ-
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M]^%#>73U7Q)#IZ7#7:W=X[V_V3R=,<&74)5;;(;2-9RZ&(M)YG <?+\Q\OD
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MB8A]IR\;O("-FW(VF2Y>>0;.75M0_P!.M9HH8'NHO*=)8G,.4MX3O#0REGW
MDRM@*N_]UMKQ:S;P>3>W>K7SV#Q7-U*C1E9 EKY(:>4JWR;6C(:%%7)N,-$"
MLE9=CIVM>)KV&^\2PQVEO.BR6VEP.4NYD+P+*TZR.52 JBE[=2PQ+AMTBJ2
M>27%S<:AXTTG5;/3M#\G_A*X[6T>*Z&_,(@01*Z(H:VP$VL(B5[\M\_T/>?\
ME#T;_L%7_P#Z-M*\,UH33>)]#FMY-->>7QD7CO50JK,\=FP=(04+Q,?G)^;H
MO[UMV^3W.\_Y*'HW_8*O_P#T;:4 =!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI8W%I/(UO>(+S[/;8@%ZSM;N;J-6DWQQ*68O'_$9&W!BPWR:5!9V=G:V=@D
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MJ#&LAB8 2>:Q4\1N=T9P([^\_L.S6<V/V=;2)8E>&+*6LA-LJ6<.V N\,K$
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M<JD*IF([+ES-;%XMLEPZABZ$X ))R"3)R\$-SKVKS7UQ!)!:VCO=V=O!9N\
M"SW*FY7Y&"WRB3<865B6 W+N/[@ DTZPN/%M@^KZND\6G21)>VD44(%R@,#H
ME\SQ1D2W9 7;&G$8*'!8(*["XD^Q^>OF6-E]G\RYQ$^([7=YY^TW WQ[XWQD
MKCA]QW-C>L=]Y-I=31,L=L@=I+8Q1!GC9HIW>:!?).^X+&7=&"_RC<?O%6S_
M !-XB7PU;S:B-+DN+N.X<FPL=RRW<I$<4,A8E/-3;)$C )+M=T R8Z *_B37
MU\/W"K(VLO+<.PM--M5:6ZWYN=\T/WDF&&1O*<[8E5"0"40Y_A+P]<P7\7B+
M78([KQ!J%ZUXMHL[Q_8XMGD-+"DK%R&5XBZL5PI0;0T:(9/#>@7MAJ,EUJ\_
MG^)S$3! 8HVMHRQ$<EU"A"[,L6>58Y 7#AF5&D2->@M(1#IVHBUNM]J8HKZV
MN8(YI?/<C>9CY6Q7WNFYH8<;N6.?.P "2VF:Y2U2WGDO@CQ2S_9[Q569)6$B
MW,?SL_E!U90A=04$@ <*BMS?]HC7D_L;PS<?Z5<Q?:;NZMVFMX[<7-OE;M '
M(7)9B+=\.SMYGRX,C2>(-2FU:_BMM#6[$ZI_:,ET09XH(626..Z@,9<E\P*5
MA7 E29PRG<Y34L[:PTJS,EO#!<Z9YJZA=7+/'Y=R)")/MSNT:H9$D0MM1P%3
M# ?ZM  2:;IUM!I+6MM8W:I?N;K=)9(MP9S,"UW(S_NP^6CE5&564(0$^7RT
M#<PG24BU*ZDCG^SM>.I4*JJ9@PNA]J&4,) D,9)\K<%(;]WFO?F'0K?48Y;F
M.$VR+J$<_P!G$LZ+C9=7:A@L0?#.66-3M+;RKF81G#L])3Q9>&[U738)]#N=
M06]TO2!.H$L6!G4-I.6W&52T)V* [%E>1AN +FG6U[XON-/U+5;6-K..X2_L
M(MTHCN60PA+X."WDCRV8K:L!DEBQ)RR[DS:G-9IY5M!=S77E3H)[>;9N!MQY
MY20@0>6=[^1G<VS(8-OJ2V-M<7$<$,EI?O(D-WG*,MVF80MW*R1864>6WE@$
M!MG&-O[O'U/49XG2STJVCU#5+M('@L[V"*)I'VJPU"Z PZHGEHH^1"'0J <Q
ME0"/5]:G@M9(-+3^U]2_=R+:WWFMG$43BXDB$&8Y(BBL88]G^L4X$DL:FYHW
MA^&%+.8S1ZG=RNMXM_'B-+KYD9IMT<>(B/-FVQ*VV022%BQDD81^'_#CZ?+'
M,[_VC<7^+J\GOK=E>]<- RS.3'_H[0_O!';_ $Y!#%=""WEOK,1&WGBGGQ)Y
MLT"*+C:8=EVY,/RW"*%*QNJ_.C+M*H' !8MXD/D&2UGNEG\N8!K95:Y(\@"X
MN T:".9" 0N0=J$A25"IP<MX?&EQ!';/)#X?M'AU"^U1I)+6/4E0J1.+F.-5
M$L2Q1AD8#EG4;#"L@&N_^$P>.TL=-CGT6&XCU:\U=(;I'O6"Q/YEI(JNR2JV
M^(Q$[PJB-&7!V=A8:=9:;86EOI&FVES9R/%-$EK'$L%TN^WS=R,L0194Y=54
M_,%RO(&P DTK2;.QL[6SL--@CM6V3I";00)/@P$W$RB!1'<*02J<9QVQ^[P_
M$VN0Z396^HR6L=V[O%-!<Z=&"MW<2(B0RQKE7EE)5E\I)2#!OWL=R*9->UNP
ML+"5?[0@VR1).]^D4=P6#0,T%^T:Q#S9%>T.%C) 1=YPJC9)X>\-7-MJ\.N:
MI:1_VK,DDMOIYD=X-,$D[/<%)0I4RLLJYR,LR.%81\( $VBW-YJ46LZ['=N\
M;O=?V.9'N;>W>&6$+/!)''NW[(RZQD9<RNH"YDSL6<C,XC:&0"5XI5R5AN[\
M*MM_I+@&,H$)*2(5R0H& "$:O9:29;>!;E9+N>Z>WO)GD22!;N2(6O\ I$B^
M7F"53&-L((#8.?XMF/J&J0R/IS:,\=YJEW;K=VKPQ 3W4;K D=S=%1&T<'F"
M/S$0$LL:_P ".@ /,/$4H;Q%9V3?V;>2MXM@O"^GSQQW%PL\$#*;;:RE$;!+
M,3]YHOWKD,]>YWG_ "4/1O\ L%7_ /Z-M*\ O]-\S6K.2]CT.\U*X\2V$"VZ
MVOEPS6_D(42&56=/LP5U7 0OM:-GP2JU[_>?\E#T;_L%7_\ Z-M* .@HHHH
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MY8==L3X8'=''4E[<2P74J17$]EY44LK3S3I(EDOFNYEN%>;YH9/+P@50R*'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ_\
M:._Y)YI__85C_P#14M>P5X_^T=_R3S3_ /L*Q_\ HJ6@#Y@HHHH ^_Z*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "N?\ '/\ R(VM;_\ CW^R/]JQ]_[/C]]L[>9Y>_9GC=MSQFN@KE_B
M/;?:OAKXCCVP-C3YI,3Q>8OR*6X&1AN/E;^%L'!Q@@'F_P ?84N/$/@2&6Z@
MM(Y+N9&N+B-9(X@7@!=U?Y64=2&X('/%=QH$]Y'X5^WR)!:00^9,KFZ+E+@S
M3K/-<9,*F/YA*8R$*G>NU610.7^.+E-1\$;+R#3Y!JH*ZA*83]E(*?/L<;F4
M<,<,$&T!@24(V-#UA)?#EW+X=3[3J4VMRPO<6\2OL@DU"8I,V>9;<!I.4)ZR
M ,A#.@!<\8:W+;D>'=&M[N^OI7,L]O%-,MPB-(F)4;S(SY0>49(D PAC&U0[
MPR6&DOX92XN;V7??W,I:XUEH66-Y4MY&^T7'[\XMPN$$9V*K@E0H92IIF@-8
MQ:M-?6<%[>7?EM>$_:"+J\D5U>-B5.ZT598T0;65 '+#<I-= (XH=8N[M(YX
MOWL,<TJ([O.Q4J(R&0XA7S$?=&VT,9"VW$FX KSW]OI\I>Y>=$@E,OD&8EX0
MS3;IYG\PJ+<H&90^ NS &\*B\O!%_P )1.BW+3RV[2M%%;NOVFTN_DG9;R>%
MI&(MFD#^4H9<[(SN8>7Y990/XGBL;B'3\^'D\]=,6:)K5[I"O[N&01J0MD0I
M/SA=^V$,C8S+T%U9?9OM:I#/J*S2FWF2XML^;YGFN(YI&5BUL#.BCRT/EX.X
ME1(  23336[S$W<=LEN\]P1<2$FU5E?9/.?M W0%EF(7CAHP!'Y1(IZKK%QI
M\\-E;VLZ:E=W<T.DVUS< ^9*$E=YY")R6M@&'R8W)@87.P+'K^H0V 99A'=_
MVHXLDCFM@D\K?:=@BDS&0;7]]L+E?E5@5,C2J:-'T*72WEO \EQJEU>S7$ET
MJS0"]G"SHL,RLKF.W1=H0[BI(4@<C> 1Z)&]O%8S2W/G:QK&^9)TD:X0.%F8
MR9$OSV0\Q!''QM\Q,X=\KN*URSR?9K2[8P7$@BAN)7C EVRMO>3>P>!@Z!55
M6V$CY<KMCCEMA+%<PM#/>V\\LOV>"\>8(TI659(I1Y9Q;G!*E]ZG>-HP(@<M
M-3N]2\07>G:?;W<,8N'LKK6]J)<12(//2(1M RM%MEVJ[X!&[DLR-( 9^K^(
MFO\ 68])T*_DBTRU0WVHZF+E1M5FCD!B>1L2(B2B1@/D56B!W+^XDV(89O#V
MFPJLTEE&SOYDCQ&2&.58I2]Q.7E8K Y1),!E?><NQ:1ZC\/:6-"L&L+&RG2&
M"7;9(7FA@>=8"C@( QCMR4+!I"^Z1V;YB8V>2_O+3P[87>JW%_)9P*\N=0O(
M'E9FWW#"*5=@;R$9AY>'&[*JI^8>8 1ZEJ]OX<T[?J&HSQ+;;F\ZZ)E>!R+C
M%Q<".0!H9"N$C 7YBJJ =JQY>@:=?:U?V_B+5X9(=;*//8V%P_F-HPF21=\J
MATWHZQHH0*I&WD;_ #9"6=G<W$W_  D&OV\D4=F]X=.M=0E=3"YF>1C=2*&0
M1+Y$31O]U 0!O98W/03VIDMQ9EKN\@N[BYBC^UV\CK%(PN"_GJ6426^"$12,
M?<P3E64 %::]N%2RGN[>2WN)76";):-B;F/S9U:3=);NP!C1<?=4@A1\G)ZM
MK$4B_9](O/\ 3[V*ZN[6\N;EX7MEBEF9;B>1-RO9?.WE*XVGY!A@[&/4\3ZO
M,UU8:+:QR:A=WEQ.D4-R2B-NBNEQ=1^6H:W&T;1NW2!&9=YC^>YINDW6GSR3
M1W,\\DUV]UEO/B^U7NR:.19LJ_EVP58A'U V)RYV[@"31]*AT=)=/M;F1;V2
MXFN@9H@TK7$C3_Z1<B!E1HG ^0,$'R 9#[0MRXL]_GK_ &;_ ,?/F1;+EO-^
MV?Z\^5.VR3R[?YMRG/&_;M7[C%Q]ENO/LE_TS/F;+"Y\\;G;SPWGD[O]'?#*
MNY-GR_+N^0#C[Z_@\77EV=#N_P"TK Q7-G<3))%"=1D42/\ V<'.-RE7!654
MRB(^V1C([* 6+F.\\6WE[;11SC3UN[BUDN70P/?;!<QFRD9$8?9P2Y$_;>J@
M&4,PZ3[!"ENUO;V4;P.CVD<<ML(UN%43@6TP$&([= <(_?(^]N_>5_(M[>P:
MUABM+XR.]G$B+;0P7<>^=5LFZG9 N[< N<(Q 8[THU#6--MDNOM4\EU%)<#3
MYH+M5/VJ1VE"6D<190K_ #H=S)AXBA+,/G4 S]8U#3=+T0-:"TEBGN/[*M8'
MMEQ?R*\\?]GNHC 2(89$?. >6R,^8:3I%]<O=:QK5O'<ZEJ*/;QP3V^T1Q;9
M2;"8B)AY"MD^>/\ 6G;U 0/7TS2OMM_/K/B.VM-0OIT*VR_Z*[8*7 DTQ<\,
M8OWFZ0%2^<,=J,*W)H3<;D^U6-Y)/+/"[3QPK'J*?Z3ML21N8>5GYCM/"-P2
M7  )#8KLN$2&2Z%R\T?^F(Q-V2UPQMYRT)*6ZEOD;D$$ 9! DY?6-9N];O[W
M0?#YM)[R[>XM&U"5$E55C2?=#<QF(?(DC!%"E\;XV<D2*DQK&LMK1O?#VD7L
M>J:A<O<6MRT\BI;!/,G3[+)&'#JZJQ.Y=C.D+2*TGE^6VYINCV^A:=):VSSS
MK<;X7FN93'?W[J)BT:']T$;(WK(#\VZ5S@L96 #2]+TZUT?[!I,7VNQ'G6,8
MN2TGVCRVN5-K.S1,5MXSE58D^G.<26-3D2.*8FV^VS7GG6T$$\:QOJ3JMRWV
M23=$ L( 8HY/S=22"3)8NH$D@NYI1!)')FW)O@L7VPEY8UMI=T7^I#2*$89+
M;OX@3YG)CS_%,5U=7EK'=Z>7N$M;2X2*WDUF6*>9X;:577?&(3$V%.=X?<^,
M2)0!)86O_"6SW&KS64\VD74I.GPWR_+JN$D*&X7RF\JV7(\H$#YOWC!G=<]1
M<6_G^?\ Z/\ :?M'F0?Z3!M^UX\__1Y_W)V6ZY^5^=V?XMW[R.:.*XN+H":T
MNTN$:W03B$+?.#<[K21P&)1.?E" KM8DR9<#/U_5[+3WCA\N/5[C4WFM(+>(
MQ.]^R+<%K:8>7\L$;$)OYVEOGP-Y8 -<U!H+@6=KI<FK7VH).J6\T:Q?:XHC
M+YD4[-#A(%\Q%C;/SM(N3M9G8L=(:S$L4EO)J=WJ2.M]?W%NL2ZC/'&\7E7"
M>4?*@V@%&4%3@Y)+#SJ^GZ&+8&[O+JTU.>X>6"17DCN9;F,1RJVFQO*%.Q#&
MC$LV7=)6<+EJV+XVVR:1Y+2ZCN7:T\R4H4NW+3J+2=EB(2)6;8IY)8[3EB1(
M 1S2)>[C;6W]I1W<L]D\CQJ%F,?VD-!<_NOEMT8;%8;B689R"2_/W$0\903V
M=M:^=I4\LB7-S<6TT3WKJ\[BS?S8W>*.-B,S C:WRQA6.$L:G/\ \)'K%[IM
MF^VQNO-MIIYT\G[>T2R))IZN8<B,$LYD!9N91'G:QCV&M[.+&G06\#>?%+!!
M;2P"/[5''YRFWE40_);1[U"N,@[EZ[AY@ &"W;4;H0#[1=22K.89P5\Z5#/Y
M?G)Y1$4:F)0DX&Y_*0;FVKOC^V6-M8,J:A=RV[N]@KW-WLDNG5YX_LT#-(A6
M=7&/,/+@+EV/SJ:S?6,%O+-?WNFJEZ\EC',EMYXNW N +66( EPG/RJX+R;E
M 7=M;EWMU\47\?B[5A)<Z7"D[:39K:-'-=($D:-K<&02)<85VR.'3R7 5TS&
M 26%JGBR\;Q'>^1+IUQ*TFFVEI*H%\\8N5CF0^8K1W8B" Y/RA 3AE'D=1<.
M]W/.T\OF+YLD4!LKYH_M@5)P8(U$RA+A#N#$Y!V!LJ5'DW+[SHWF2=I&>X1H
MPL4IB-TNV=EA@S,-DX4 M)QD#/&/W>'K^K/IL%VVG_\ $UU+4)?)CLXM0:+[
M6 [Q-';_ +TF&2$%6DD50/E).TY,8 :KK<5G>75G:M/J.J:CO6*VAN7C2[VB
M=3# YFVP21>6#*ZXQQQO=0*_AG0_[&LW:\O/[0UK6)1%JNHPW&#>2 S*T4)\
MU3&T !R54'9&0J[AA+%EI?V*629KR"]FN/M<<\EL/)-U([2LUO9_Z0!;R*8\
MN<9<J&9MRLRZE_?+';W<[S27",DL;"R=MUT$%P?L]NJS96X3;\S  G;QC'[L
M CDO;BYB20+N^U[X9XUNQ$[A5N#]G@VS%5N495#L&4':Q#?* F7JFL3:S:P)
MHL]IJ$&K)<PO<;28IHH92I@A21C$9VC>4AVRC^025*<IGZN]]K=[JFDPO=F.
M\2>VO9;>YVP7*[V5+>U\_*BX$*2&0H @975B&(>+I(8;>RLWM;63S(7\V "W
MN"INR#<%H8F,X*W(()DE)!8@DD$?NP".S^R16$EO9-(T#//:XBE>)KMD>YW1
M0EY@PN REGF.-^"V>Z&LZY::;;RW%Y=R21W#R6@-F7_TI@+C%M %ES'< KM+
M\;F 48; 236M4BTO[9_:,LZYB"GR@\?VQ7^T>7;VO[T8N>!DK\S?+@#*[,/2
M;6;4!!J]_=7<H=)HK&Q-P581F-U6!2TP9;Y!&Y>4D$>;*FX@;D +EG!+=SWF
MJ:HD$MW=RO';QP.BR+'&EPBVD,@F&VY3,K/(#@&1U#;5W)H3:I%/NQ+//]KE
MGLE^SAXOM+1_:<P0YE'E3+Y9S*=JMM&#RNP(S/=7$DT%S<742VCRV;>2UWY2
M3[K>$^?E)ED\UMW&U3MR2I=>?UWQ7>+K$VB:0\&KZG>2O 5MY3 D=NJRAT0F
MX"FYB9D9PK1NRNOW<;D *?B3Q--<ZW?Z3X9>.?Q.SBUD=0?LUS"J73K;M(DV
M8)4_><Y1RZ@X"$E=C3-#MO#UA/%IS1W]W=N;>YO/.2"?4@KW&8E='7_2HUW%
MI" 7*\LIRT=S3[%-,L[J$:A/J4UW+.)[KSU26_?-Q^YB*RH$N(PJJ7 7Y8U
MVA!Y=@7$2^;8QW$]QB(P!HYW'VI5^T@6\$C3<7*>6?,?.[Y<G'!0 #<6=SJ-
MTT-Q!<7$\JZ;=36DX1G53.1 F)@T<T*N9'8?,5W%1G 3#M-3F\6.]Y]ICFT=
MW*QPQQF-[V1%F9;>%FFV"6)E#FXB.'*KM91$31<W%WXHNKJ--0CGT&5Y;=S:
M!%&KQ^466UMR\S(3AIA+*HC)*!05V,5Z#]S#;M;V[1F H]I''92B)9E03@6U
MN!,!%.@7#/\ +]WMM_=@&79Z19Z'IUXNDQP75]<Q/;R7"3B"35I(Q<8B\U9
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M-)=YN0ID(CCFC*@J,Y9-S[F#,M/P]X>N5U2?6M2DTV?Q%)<3/"MK(\\22C;
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M&,BR$12J8T,MM&9D 9#DY;?M"R$\_'_:?BK44#^?;>&8)5,\D?G3#4FE,;-
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M:1;-)8][7%Y&\P#CB5(PIQ%N((RK+'TDUUOW2Q7L]BME+/,R738\C_CY0S7
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MH9&VGE#)<[1G=@X(?C:,9ZMD!0#8HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\?_:._Y)YI_P#V%8__
M $5+7L%>/_M'?\D\T_\ ["L?_HJ6@#Y@HHHH ^_Z*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N?\=_\
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M6?)4[ "1+:STB5+>WM_L\=E%<SQS7DXF&GL[2EKJ??<;G63#;2!N \T%E#,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7C_ .T=_P D
M\T__ +"L?_HJ6O8*\?\ VCO^2>:?_P!A6/\ ]%2T ?,%%%% 'W_1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN4NKN[R\\'=]XC'RN#H&SMK)+A#/:68@>:[DS<(QL%D:X;[6ADC)#N6;(;Y
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M_ %*J45<1W-/6'3-+TXSP2:6ELEM9A7Q(]DS_9E6UB<QGS8F;"M)N//?C]V
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MCZ='Y:!U@;$,K2#&%!1O+P50 C!B\;10V=G#Y7AV"5+6[GLU<"2$J$>UM'2
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MC;R?P*%.P(<[2H"6)9YY(KF'3TVWD,LJVHGNI90MT5E8"X$9.V$JR.H9NCH
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M\JL<B,(: (]5N8!9W5Q'<3ZBU]=O:6\(@B+WTD9G#6#YMR%MP4?]XQ)&YR6
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(8YY);B.Y@BCB$\?F-#;QQ31['<* %8MU&6!+.L,<I #P=X56R>+7-6FDO\
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MUM_(@TBUM//GM$A$,)L=JS))=8WE#&5E7 V':9 7')V1V&E?V/X:_LG1K:.
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M.V.6/P]IVFIIMT;?4;36+K47(N[JZE53JUQY4F89%,;;(!&4= F1Y?(!7)D
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M;H5B?<AA+M<D6T4GFKMF5Y6B2X.U&1HUCQYA)CT'PQ.MO)J.HVNFVFJ:F\L
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M[H]ZKYDB31L-Q+.2"%*!X[&!;?2X=/:>.T@@1;)%25HQ91-Y 2UEVW!)N"K
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MW=Y=FZE;4F?]U<?,Z.X*9\IOD7ER :&B:,IO+G5M=2QN]7OY1IL[68MS#?H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7%Y-(CSV<,FV.*(E_,\V2=E\Q264C;$75C\DES1O[-TRUL[+3&M+"WMD6..
M2J4M%:5(VAF59B'G>5)E63G#!QR<^9YW?^!M'BLWD/P;OGCM8I-@CUA-[J#*
MPR$F+.Q_=_WF^=@,B-0Y)\.='&_R_@[?-C=LW:^BY_UFW/[\XSB+/7&]^NP;
MP#T!-4T?1-,:[,MC96MA$9"\@24Z= 9$5[9MLK'<SQRHHC^0&(( ?+4-EZ?!
M;3:C:Z[JFK6DHLW+:3--<HR:? ;>)Y(I")=TD[PF1BY>1<()!@':W-Q>!M,6
M50WP;G$<7F01M_;$+%H68#>P,W,FUY3R25*1@-C#)&?!.FK;I"WP<D4M;M"
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M.5.P8("CR_,_%OPQ\'Z7)J0TK0)+F[@32VALC=2(KF:\>-E$C2'F15V'(PN
M0<DXICP[X=M&GMX(OB/HT=Q*+RVT2PADPJI%$XE_Y:!F\P(,E@R.R*P4+NH
M]D2VA=+,Q1R7+W"1W$HN[41"=E:']_*?*^6=%52JG9DC&!MRG+BTF\27%A;V
M$MV=$"178F*FWCO-QCE:8%(%*SDRLY.=N0"@64,]OP$?AOP? \V=5^)5M!8O
MMFN&MY%2V"*&#-B'* +!;,.,@&$X&T[*X\,>"]'MW$-S\2K46MNM]-%';-']
MGW OEOW0"G=;(-V=NY4(8A&9 #V>PL(8;>TM[>RC,!2*2..6V$2S*@MP)I@(
M (IT"X2/Y?NCIM_=QS36]E9I=74?F0OY4Y-Q;E3=D&W"S2J( 5N00!'$ "Q
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M>*&RUW3<; TQN=)SOF(_>.HBEC"AVRY!#'<[?-C $GV/QA_T'=#_ /!--_\
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M',W_ ,BUT%% '/\ VSQA_P! +0__  <S?_(M'VSQA_T M#_\',W_ ,BUT%%
M'/\ VSQA_P! +0__  <S?_(M'VSQA_T M#_\',W_ ,BUT%% '/\ VSQA_P!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW-Y%=:'<E?+\B:-2$>+YSYDD?RJ"1RV,*2(_LWP\_P"A*_\ +1N/_D>O0**
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)0!\P4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>atxs-20211231xex10d19006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 atxs-20211231xex10d19006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ; !P$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBO/_#OAZPU[6O%UUXE\/:5<7R:V\4;36L<I\A8(/*Y;=U3:Q&>K'@=* /0
M*CCGAF>9(I8W>%]DJJP)1MH;#>AVLIP>Q![UA_\ "">#_P#H5-#_ /!=#_\
M$T?\()X/_P"A4T/_ ,%T/_Q- '05'#/#<H7@ECE0.R%D8, RL58<=PP(([$$
M5A_\()X/_P"A4T/_ ,%T/_Q-</>Z=H'A_P 6+?6/AF"\==;CT];6RTR!9(V^
MR+-&8R3MVJS,[/\ (V2,MLB < ]4AGAN4+P2QRH'9"R,& 96*L..X8$$=B"*
MCFO[.W^T>?=P1?9HA//OD"^5&=V';/W5^1N3Q\I]#7%MK>E6D,<D/P]UEBJ1
MO$D6DQA@!#%+Q\P"E!' F#@EXU5-Q3Y2;6=/L'"Q?#C67$**P:WTVWPI50=J
M_O 25-J@&."8XMI(:(L =I<7]G:2QQ7-W!#)+_JTDD"E_F5. >OS.B_5U'4B
MHWU;38T=WU"T5$25V8S* JQ-ME)YX",<,?X3P<5Q9UVQMXIHA\,M<$8B>!TC
MTZV(:/:49,"7YE*VRK@9#!8@,AH\R?\ "26]M<-<+\-_$"SQ.[^9'86Q;<#.
M201+DDGSSD=?-XSYJ[@#M);^S@E:*6[@CD7R]R/( 1YC%(\C_:8%1ZD8'-6*
M\_37M.CE:Q7X<ZK&[Q&'R/LEFIDB+) P"^=\T?[N)6QE0@C)PA4UCRW/PBU&
MZ6YETG[3/-*9O,.C7;-,\LL4N2?+^?<TD.,Y^655'RO@@'K%%>3P:9\)G_T:
M#PU/(TL4T(4:)>NY5-D4A!\O.Y2J@L/F5BQR&=B;$1^'']K+&_@2>*XN(I"%
MD\,2D;(9 H8((S][S0=RKTVARIVK0!ZA17D>AV.AW>JVC6>A26%I+KIM7LKN
M*5"(CID\QC:&0E4 >YF^5 $(;C(.3UB?"OP-'>6MT/#-B9+6(0QAE)1E (RZ
M$[9&Y/S,"W0YR!0!V%%<W!\/O!MM;Q0)X5T8I&@13)91NQ &.68$L?<DD]ZD
M_P"$$\'_ /0J:'_X+H?_ (F@#H**X?Q%X3\-I)X?L8/#^E1^;J$P@7[%&84D
M:TF):2, ;U_=KE05)*H=WR@5S?AC_A")?"NARS?#N[V36\<9GET 7+95"2[N
MD>7!PA#A</YH(Z2! #U@3PM</;K+&9T17>,,-RJQ(4D=0"58 ]]I]*DKS>6+
MP5%*R?\ "LYW5/+9G3PVI 1V*[Q\N6P-C%%!<!^5RL@22*V\$2S01#X=2*;A
MT6)G\- *0TS1;F.S$8 7S#OVG8RG!)P #T2HYIX;9 \\L<2%U0,[!069@JCG
MN6( '<D"O)_$MKX5F\"ZO<6?P[DM)WTR9XI)-%B@:%O*)!)."A4B0Y_Z9<9W
MP^9L>.O"WA72/"S7\'A+37>&]LB8[338C+*OVJ(,B@ ;BRDKCOG'>@#O/M]G
MY_D?:X/.\WR/+\P;O,V>9LQ_>V?-CKMYZ58KS.\N?#4]U/<2_"?4KN5T2XFF
M.AVY9VDB,Q!+L"SC#*V,_/\ +R67,<@\,Q;]WP=OCLW9VZ+9MG;YF<8DY_U3
M8QURF,[TW 'HAU;35MTN&U"T$#V[722&9=K0J 6D!S@H RDMT&X>M2-?V:>9
MNNX%\J5(),R ;)'V[4/HQWI@=3N7U%>;R#PS%OW?!V^.S=G;HMFV=OF9QB3G
M_5-C'7*8SO3<+?\ PU?5M-M]/\/V,=XVH0HC_P!E/8O%()&VE9&C0;A)"PV%
M@6V2*-S#8P!ZA17!^$?"6E:AX*\+7D[:D+B/1X422+5+F(JKJKL!LD'!;''H
MJCHJ@;%GX#\/6+P-%;7<B06[VL<-QJ%Q/$(74*T?ENY0H0J_*1CY5]!@ Z2B
ML>T\+:-8:=#86EGY%K!%Y4"1RNODC#@LA!RDA$KYD7#G=R3Q0/"NA+>0WB:9
M EU!L$$R J\"H %CC8<QQX&"BX4[FR#N;(!L45Y'97/AOP?=V4E[I%W+;MI@
MN+>6 37Z11K<*7D,@S&T2*MJT<F/,$<*!L'RU.HGB+X?V<5JEOIE\T.EX+RI
MI%UBU2-2@>9BF653;*OS;L/"AQF/<H!Z117E[W'@98E<?#&^=FB$A0>%#E6*
MNQ0Y3&X%54X.W,BX)&XK<'B'P>FI.#X-U*.]EN%O 3X;D$DSI*4,X^3)*;PY
M8\@2C'SDJ #T2BO-_P"VO!-_IWFQ^![Z\M9HO-39X9D=)A"-D&T^7@[D8^6<
MX"D@E,XJY+'X'OK_ 'OX*DN)[AY))IY?"\HQA&D9W9X06)*X &69F  .: .\
MHKSN"+X?36\4K^!)('= S12>$IBR$C[IVPD9'3@D>A-2?8O WWO^$ _=?>W_
M /"-'[G3?M\O=]_Y=F-_\6WR_GH ] HKS^(>&K;S8K3P/JNER2[X99M/TQK:
M0"/RG<>; 0VWYCC:2)#"X3>2@?/\(>'SJT&DZE+K'B.:QO;2YFV3ZG?1OC?"
M("2& #; [-SAFD8IN0+M /4**Y.3PYX%6X,-[8Z-=7@<([ZB4N;AF)0 ,\I9
MV/[V( $G >,#@J*N?\()X/\ ^A4T/_P70_\ Q- &Y#/#<H7@ECE0.R%D8, R
ML58<=PP(([$$40SPW*%X)8Y4#LA9&# ,K%6''<,"".Q!%8?_  @G@_\ Z%30
M_P#P70__ !-4]'T^QTKQU?6&E:+IMA:1:9!,\EHODL[R2R@!D4;' $/#'E<L
M!D.< '64444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"=L4L6Y/+)BW/#WAJP\1> ="DU:XU6Y:ZTJ'[0&U:Z F\Q-S[P) &R7;KGC
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MVU/NKQ@#:, '045S</P^\&P(43PKHQ!=G^>RC<Y9BQY8$XR>!T P!@ "I/\
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M0_+[L/<DU-(8K>::?S[>?;<S3P72QI(B+"QNXRUQ\ELO1T&[.[H027 .#O\
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M 'F<'P6TVUN(KBW\6^+H9XK<6L<D>HJK)"#D1@A,A >=O2KG_"K/^I]\<_\
M@X_^PKT"B@#SL_"2%KA+AO&_C4SHC(DAU8;E5B"P!V9 )521WVCTJ-/@[9QQ
M6L4?C+QDD=IC[,BZF (<*4&P;/E^4E>.Q(Z5Z110!X__ ,,X^#_^@EKG_?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KQ_]H[_DGFG_ /85C_\ 14M>P5X_^T=_R3S3_P#L*Q_^
MBI: /F"BBB@#[_HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+6-2T/XH:QIUA9W=AH>HQQZ>]JOG)/ONH<02LTAEQMD9HDC^;9(&9V 4+YB
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M_M!>.2=H4%NSJFY/E/D1'. N;B,\*3LT%UWXR2>7Y6A^'&\V)YH\QW"95=V
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M$+1P-FWD6+E\;@2JA0^$2Q;.TUQ'*;Z2[2Z2&416\RJMP5,.;FW_ 'I*P#<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5X_P#M'?\ )/-/_P"PK'_Z*EKV"O'_ -H[_DGFG_\ 85C_ /14M 'S
M!1110!]_T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5R_A^:X?4/&4D5KMN%U7$<4\@4.19VP4EEW85L YP2 >
M1G(KJ*P]"@FAUCQ.\L4B)-J:/$S*0'7[);KE?4;E89'<$=J /!/@2N=6M_)B
M@N)&^U?:$@D\FYCC$ED5=F##?'N_@.T8$WWR=A]SAN9F>&:*2.^EF>">%8;H
MQ)<*52.:XC'FN# J2J1&1]Y2?F+JU>*?!%;.]O\ 3%$7FR6<5TYMHI )4F,]
MIFZW%@55HV6,J."L#@!B[*?0YX!XF2\^U126FB2I]KO+J58TM=3DC:.,W(+>
M:(XHTA22-&($P89RBN6 +!$WBTW&FB2.73G2*>*/54+?VDT<@0W VG8UN-D4
M@CC";V*EMB2@R=!;>3/<1VZK'<3ND-V\=Q$$:=<PA;FX'D@QSJ8V")QGRSTV
M_NQ(K2VM;-W\L_:WCN9(9X'M[9YFEA_>;9%8PR[SN2+(+.S9RV77'U/Q)I6D
M6$%R_EZC+<N'@M,1I/J3Q/;H\C*T:8NHV&%B!!)7  ( C (]9\66?AF*WNY$
M^UM-+&]FMJX,^MY6VB,ZF+:CL%F8>45._8C+M"@BOH/A2X9CJGB,_P!I:W>^
M7/#/!8@"W/E6T?G!9TVPS(REL#:7 R4)140\*:%>0ZBFH^(IX+WQ#JD23FV8
M$6[1Q&V5KA5> /#, (24X#.J_=VCR^DL[0AQLMH[A+UX[R1KV*0/.R+;*)I,
MH$AE4)D1;!N**04P^ "..?S8GN9;2"YC.RZ\RVAWP:@JK;L;H;$D82+@B--Q
M9M@P2 &3G]7O;J\GDT[2[R"#9%'<W]]<1P!H?DBD2\N5>/\ =S)Y( B95W+(
MK*R^6WE5YM136=<3P_HB3W$UU+%=WM_+*H3,/V=OM650H\GEK:M&L9*'SLRQ
MJ!@['A;2(K31])BL&@OK&XB6]:26%S_:,C-;R&\ED="8Y@?,98R26^7YEV?(
M 6-$TJRT_;865G/(LOE7S?;(I MT?W -S,[PX2Y4QEO+!!+?,P!;*1R:E92:
M:;;4)H[Z.2R%Y>0_;XG^TQ+$C>>K&2-1;DHT;#8B.SY*JA8M)#'OTY6U6/Y8
M_(NYKJX3[)'>^4+9VNYL)F&1"I B8C(C((VC*8]G=?\ "=Q$B]G.E2[65+9O
M+DOY HBEF5))63[(JRQL82"=X974L"C@%.YF'C0QR7MW&OAJWN([R<^9'MU5
MK>1HIW4/<,J6:%8G92ISG(RQ!/607-O:V8EEOO-MY,7TDHO2!< &%FN86:<^
M7;)N.Z/.,' !! DKM=)-9G4998(KCRGE2ZDD7$J*;?-U"1<_):#:CO'N&X8S
MR?GR_$6OM9/J>FP:M(VL&W5I8XG4):2JL6V](\PM!;AG3S(VW9 +;2HD9P#0
MU;7#9V5JT5W'<W=\Z2V\<1D8:BT:12M) (Y6:. (C[E ;)/W9"P6:/2H;@WE
MKJ&H2?VEJ.H;&9K"X B6("!O-M=TX*VP(42  M*S E=NU3)+9-%-/JFKWLEG
M?RV[I(L5TJF%(9E'VN#S)"L,17RY)8SN! C#!B")+#7UCI-A<SS31BWA>2ZO
M!:/M\YXGB,\\2K,2D2/O\R/!+,6R&+?O "-KP+!)Y%U//.;1+I7A\Z5+H;UD
M%Q;J)_FA1I'WQ*2[+L3E?+#\O/JMQXHU%_#'A6\\JR,JS:QJ^G2B/S')@9S8
MGSB!RY,O7;O).YW >2\N]2\2>'[6'PS<QV=K<7'GZ_-9RL+F%<AVEM!"\JXD
M,4HPADR[$'+>:1T%A9Z;IWA^TL@D=Y9QI%>".RC4?;&C-N_VJWBCDPL2M\S1
MHOS,> 2P\P DTZ.WBB@T^PN9PQB%RDMK(2+HR*B&[A:25D:-2[NZ/O)=E<@L
MRM(2ZK9:= MS=WD\T/V0WTDEO+(R7$4;Q2O<PD3,$A4SMF/EG7"@,J*&-3UO
M^S=);4Y&^W6J1?;[D6MSL>ZCCCB8W%J/.($(. T9(#;B<MG$N'91S>(+C^V/
M$0DGM[.]:ZL=,MB6:5H##']M2/?YL90F4/;\XW!2ADR9 "3P_%J.KQ1ZC<-!
M$EUB[LM-B56@N)"L!^WK&TBOY:RR2.8R5)RCE5FY;I-/EFE>U@N/M?\ I#F4
M^;.5FF6-8BD^W=&8TX59(A&/WDF"NTEGKI<PQ"2XADM)(Y7@O=1N8[H0QR+Y
M<96[#"5BD&V!TV$'>5P2$WN<NXU9XKR/1M&MIY-9FB_M*:U^:TB9&"L;I8V;
M<O[Y-GV<R1[FDD\S@F2@"2?Q#<W)6RT<QZEJUT]O<"W,KVP"1R1K<3-F4O#$
M"/+\HKN$B2920%ZK^'M(ALM&TZVL9([\WB?VG:WI 5Y)-MNB3B+S(C%$BN4,
M,8(\I0I8%MCV- TQM,21HI(]4O-0N(;F6^^UJD^JH&MR;E&1@$@B$CJ(0""H
M49PYWZDMU!-:J+J]@-O<Q&Y>\#1-'\D43B\A$DKJD*,%XVMAV5CQEF +#!]3
M@D$<$\:W^R>%+N%@\!1U'G N)$1@OER1Q,BG<I+ $OLY/2;F;QWJ5CJ-O'(N
MAQO'>*R0FVCU6ZBE$;S.RL[*D8C1HXI-K.0,DK'D5VF7QL-*N[D6EMHBH-5U
M.VNHVMUU%!'"$GF&&\M%83;4D9A)]G7!9/G3I(+G_3+I9X?,C2*"[CAN;3;-
MJ"J(2]VRK%N,T>U5$2HK*RKN $D>P N:=:64 T^S6VC\B5$>* Q11M*L<<)6
MYFB*(R/&R1H @^7<F0. F7J'B(6>AW%^USYK2>7(BQ+,7GE78J2VR)*WG0R.
M]J!&KJO[Q@[[F9:-8UC^QO(B@MY[W4;F5A!9QR?9I]3>+R4,SD1)\RNJ@@$(
M82[_ #*H49?A[3+F\\01ZKJ\D=_<;VFMXX+MV6(N+0M-9.[ O;G<QDYPN?*0
M$%O, -#1[.YNM2AU#5/+N9IG-Q9BQU5VVQ&56W0MO7S;?;,AD#!?FC "NGDJ
MFA#?S75E"AO;0ZA=)!(5M[DR)-,R(R30?OU/V<>5,3'P9!'(1GG?);W%Y=P0
M?Z1 \UQ+'/\ Z-.76\C5X/\ 2(/WR[(=A^9.1N;_ ): _OL>XUZXU'5CH.DW
MT%W=W,5O=RW%I= &(+):AYHU\UPL;1S;D1L F)\K*LG(!3USQ#-J%TMAI6HV
MD5V4CU&YEBU,LEG$(HU:X5A* T2^?"XBD1$D$,Q()=372:7#;VT$4-K)YT=W
M+]N(MK@C[6[O#(]S!F<[+<-(Q:/G.[@$']Y'HUG:6-O%#:2R7 NWCNY'CO'>
M2_8"W'VF-WN&;R%& R$G(P.00))#JUG%$);K4H'C;R9Y7CNQ&)\JCK<1$S_N
M[<+%,S(?O".0_,,[P",SK;Z7)(FI1D2H;W[0]RS),?W+&ZBW7.4M4+9:+< 1
MP."/,P[4OXX^R2:C;^=H4THNDM'9HI-2,?E(+@0R2$"TRY?RCSE(V^<R;33M
M99O&MQIDVN>6NBW5P\EOI9G,;:PT9B"7(BE;(MPNZ4P=MH8^;O%=9 UQ+9B.
M+4OM=Q=8N8Y0XQ<',)6>%5G7%M'N :/.7'4L6)E "*ZN)+RV_>_;K>\\J4"S
MD"&4J(BUU$QN>+8916C5226).X/\V/J?B9[>>SM[2]@OY]4N[>VA2U+-NGV1
M2M=+LN"5MECVLT6!NSRVV3<9-7UV:WA\K3#:7FH72172K8P$FYVPEA=MY4YD
M^S[DB3HS$(8P)/,2K&@Z>UL4N+O5)-8U"]2)I+R*18FOHHY$:*6%5FV)!&)B
M'4#Y\DX.X!P"OH.AVT%[!JKM'<:I?H;BZEMID9[XN]L_FPS%PXM8ON"/@%<9
M5LC?L0W,TKP@21WJ7;P3@V]T8C,JJF^X@'FMF#<T(,?R\>83YF\!XXKBSN+R
MVE>X@N;J3RBKP3A7N/,$3B6W/G$I;D02,T?._P ISAL'?R\I_P"$L5M)TF[Q
MIL\L=S-<62>2+J02E9KFT8S'"QRHK%0%(<K)NE#[)@"P+VX\7WD-I"OFZ6MV
MCW<T=V,:H% 25K9!,R&V4^4)$;<&$KC E7YNDL;)=+2'3%63.]9'BCF97N7#
M0;[B/=.66(,Q,BMDN68G<6/F26KNT%I&B03VLV+E7TI61+@EXG,^\,%12[R,
M8RSF1<D%OF4Y>IZY8V6DP37-S)"^H()6ETJVS-<N)K>%+F,H[@I\\1V-YA9&
M52#M9" &K:XVFZ-/>;Y+Y[A(9K8V4BGSW"I^_B0W(+P%VA3R5(+,Q'S^;DY>
MG6FLZE>0:E>W/G3/A]-@^VHX,9"8O]J, S -#')'&R)CSRI83!6-.C2ZUJ#7
M]>N?M-R^)K.W@D5S;(T".)+<1RLY606L@:-1)N.]5W()))>@&H1-/:I,8+V&
M>)K^0B-YEN5B2!A<6JJTF%#F,"/ABS;U)*YD )'CFG>XN5M8W2=UO;>V6P.;
MA46W(,WF!-EP&0JFYUP-I(/EG;S]YJ$TE_:Z+H4\=_).F_9%.8,0R(-^HEHA
M$'!:X;*(Q#L R,CH^)+N75GUC3M%TM;&W>TNY4N[RY:(Y:1=_FPA8\?:VC:9
MRN JYDWJR/&Q-%TFRT'0Y-+BN8%\R)=3O+J\\SSF<^3F]E,RLL$@9)76-P=S
M1@Y7:^ #4TK3QY-O''/)=S7">>=5\N,K))Y.&O(6"R#>WFJ@1V "(0B[$PQ<
M:M8V**]U:1I9LC:C/;O%L2V@1I9OM01HE=Y2XBWH,LC.AX/S/)=W4%MJ,S7=
MO B&7[7/;3)%"/)0HHNV=LK*T;1(V0Z%(W3<N\(&YO1;>Y\06J72B[>P>X>Z
ML6EM'1[^598C%?3L)$!1!C;"=N]8]R* $CC +%G:WWBRX>[G22#3[A+6ZL&M
M_P!PMW*A0M?/M1\$*8O*AF9L^5\R\97I+.6>YO#.NG?9VFE6XB7;+")E "-+
M*X'+>4Z 0RHK!XF&2%#K76QMY;RPFMH_M%C\MQ;FU8RM<'%NB7+W)QAE3>I7
M>QEC)^]RE8^N3WD,#/:6GGZGJ5HDD<=O"0TLBO:HMV;:9-J21-+NP\@.V- S
M'&8@ UO6H--L[;2;5/MFI7,1GL]-7RHKFY9BC+=-&\ 6.99R6(("@"60@E"B
MW-$TY9;A[BZ-IJ6IRW!GE<VS1+AC:N"ZLC-;RQHD(2(ME_+5V^;+)G^'/#&I
M0VL4VHW,=SJ=];B2646S1)N\V.7S@K1;(I8V=RL;H=S+O'EL\^=P1M-9PW%S
M'/.UELOE 2X0OO(9Y%#(TJ2+B=1;JS?(P1N' 4 DTV&8I8%K2,O&[SVP>,J)
M%9DWW$I^SKY-P5DE/EC&2[@YY*8;7%QK-U;Z+X?,YLE\J>]OKJR$*JZRL[M#
MFV,9N?-(:17 VLN%"OO9*<\+>,-6ETC3[B.?1Y;<F[U46RNMT3#Y#213+"(S
M/M9T8!\+MB*Y"RPG<L-'L[*ST6WL='\L&7[0JP0"U1<%1]IE*Q(4F,8VF, ;
MO,=""@9E #2-,M],L["PT[P]!;V,DOF16L:$1&)3$RW-P9(@ZW"A1A.6+'DG
M:7CIZS=VUEX?.I:FEW;)"ZSO<2*D8F&846\DS$!Y\:,K+"Z F1"JHVQ&!?3V
MVA>&)[V\@CM+=W^TR2K$B>:#)!_ILV^W4+=+G>(MI+," &(&VOI^AW>O7$.K
M:E:7=I/,D<UI:703<DD1,8OIB(C&EUY4HVQ$8^10<[1Y0 :?8'4]1M=;UNRN
MV^R.;N&TDMI 1MMXL7,R) !+><J@0':HW!,M&U:EI9V<?DK_ &+]MF/_ !,S
M')8B/=(N_;<!F@C07<A,>Y&9"O)& I+%M!97<"S0">XC79$I421[S*YCDG.R
M(>1<JSW(<1[2-W[PH"-F'/=M%>Z9X9L--COM4NTBU.Z=85M$(WPG^T+B(JC>
M:)DSY*MD@'<1P  27LLL&HKHVC6L[37\4=S+,UB@CMVD*[-0N(_LX8W)F4XC
M^[B(LWEA25T/#WA]['3E58_+O[N66]-RJL/-ED$:27C"6$_9[C:SD0?=^9EY
M&2IH^@V6CP6\QL?M5U=2K=22R6LG^DRRO:F6XD4Q,;>0.H81 A1LR<;28P6=
MG:P6L\]G!;W$LK7$16U!DO5#P3/+(/LH9;EEAW>2JAB5.#E T8!<GG6+1I;F
M^@CL+&2W-]((XF9;0(OG/<!7MQ^_\YP=D@R=F\ ,'6N?<3^,3>3:J+NQT&9X
M%%@TT4HGE>1$C=O.3;$\3KA[<,V9$(*'/[['C\.V7BF_%W?P1V_A]$.H/?-:
M16ZWY".R7<I\DJ75958JS>7)YA8JACEAKM'N2GDS033O!/:27(FLDA:[N'39
M#]K^239,IB=7"")_NKP&V1D DCELKF_M[>'[)J$F^VO5=)XH[J9=@0WRF-@'
M0@I&>$RJR ;U*HU/4?%FG:-%Y^I:E!-!)]FNI6M[ED+1A03=1!97Q;EEC78=
MH8AP#*TBJ]/4]=6RU31('2358[AUFA\EFS(_^N>[M6#.[1",W"M$&8X$4879
M)ES^R=3N?$$NK:LDCZM DZ:79Q&/:A0)NNT!N-^R0QP(8PR!?,*."'>1@"OI
M %R_]K:M>6EC.J2W]K96=['FWBD41-J&TRM$H.Z:1@?-0!A@ES(9>@:^L97C
MEO)HYA"D>H^>K[$E&V)3=6\C3;8X$4N)$!)(<YR)!YI<Z@K$#[9=RI._]H1_
MV>&=KF".2W8/$1(P\H(RHZ !I<N47G#8^N:^9'73+"^CDU"2WCOIY_-D2V^R
MNL<<EZCK<*%@5#+B,-NW[7'3>P!)J?B2\A5M.M)+&YUV:7_5B^*0%EEBA6XW
M>;F*$.-C6X!9Y-R#< SMH:/';V7V>T2YGOI]0VW\US'(=VHNOV4-=1N)=J0C
M<H,7=1A5*C#U[>)]%U&[AD6^D8RB[N8EG9YKP J#=HP ,FT)"K6\80*"XVR!
MH@V@MVD>;VYU/S;66**Y<1W"QQS!/)+7<#>=E+<!OWB$D$#@'<?- *]K?V\>
MG6EW \ L+K&H7#K,;3SD(BD:[A4R?)"&;,D;8SO<G<3B7#CO6\21 744>I^&
M]YE>&*99CJ!AG<2RQQ'<_E)*$;R@[AHVB"D$-#)3L%U'QE/;&\BGETEHD-O<
MRR+%<:CE!#->);R,4CA!\H^64&Y)6Y82/%+U$&HQ7M@+V\NL64\0NEEAO'MS
M<PM!"KW2!I5,$*"5]R')!"N#OQN )+(LILDB6.7[6XO)!I]ZJ07*M(I-Q$I.
M_ (B=T#!"+A^9F/S9>KZG!#9V4/D_;+V\E$MFMHT33:FRF!$O$< 1,T<;B0I
M(FT-&&&$B#DU_4TA7R%$%]J-S+']FL[6%5%]=P2P"2X!$F6\DA/W3.A AD#,
M5 =*_AC1;R2#3M:O[F#6=0OXH[EKA;,M'*K/:L9@#Y:Q,$CC4 Y8B!)%4-YB
M, 6/#>F3W5U)J=U-]MN[N[-P[!9882T4H198\$FWD6%_)>%P&<Q%&.U79]"T
MN9;S[+<V+>?;W/DS1J)4@FU2,_9#]M8J%9?+4LK1[<.,*0 56H[03:A;Z+>1
MR7>J@I#<B5T,*W3$6RF[C;)\@+&TN8/E\S=*-I&2<N>^O?$T[Z3X<U/S2LJR
M2:G,T=S#)&B0;;E!Y;(L@F!"HH5&,-QRC@,@!&UY-K\K:/H5I)<VVIO%<7FL
M29&(_(MBMT' "Q7&T )$$R&"2D(HPVIH[6"P6YL;'[1)JDJZBL3>6([]-]KF
M_.4&R15:-RF$R^_"L=KU'HWAZQTG2X=,TS1+L68N+6:*)V\H703[)_I<OR Q
M2H5)\H[2YC<E23Q)?7#V]G<WNI17UQID'V>[47 9#*D1MY)+N3Y1Y31XR+=5
M3<8Y3M;?\@!'/J%IX>TN2_U427'R6M[>3W%L\,5S_P >T9N7#QXBG3R\K;HV
MX[1\I9AMP['5XO%G]EZSJBP?V-+%(TGES.CW,B8CN'P[X33@%#,C["S(FY27
M"O<T_2E\3:I:ZAJLL=Q'<(;K2+17:$SQ)Y43:C,\:#-P8WC*+A?+!4#:V63<
MM;C_ (F-I!#<7UZMQBYE6WG_ '=SO,3BZA=YB5MT*E3"C'B490JREP M];S:
MP2WK;]WESWDEM<[(7VQ02-=0223+_HB9"L%!W%N1RV[+U/Q3>VNFP+#''=ZI
M?(!;P6TLK+?7PBMY(WMCO ^Q@%_,)*KP<YW-NKZGKU]#:0 7=W<7VH.##;:=
M-C[;=_9[=D-FS!@+-<N[NW&Y3NW*S(QX;T^:SN&U*Y,FMZI+;KOE@N2LL\:&
MVDB6R>20![51(1(S-F1Q\V[.* +&@PPKJ5UK-_-=ZCJEW<+$)TB"--;^; T3
MVGERL!9H)59^6+9)<\%3N+>W#9=5^WQRQ174:V-V%DU!U\G,L :8+';KE<J6
M.\N<\',M=-6@33KG4O[2_M.W;_2R+6[B19_*$"O);L9PL=NC*V]'8Y9FR<'#
MY>GPS:^]K9/!';:.7+V;6LQB=I+98A'>0Q&5D%KN'RQ;7&?*<AA(2H!7376\
M1:I9Z9;ZCIM_:C4XWO;B"=4-Y+%Y,R?8D:9QLC C,P]-Q7+$UL:4=,TRR1(;
MF06=M;VX.VZDCBFBA2W87-N7G*K;HK_O,9W<ABQ&'-&M;3^R],33+J[6WEM[
M-X4@N'0W$,7V<K+"DLS>5 %8K(A&]@W))P7IW6O_ -BZ9]MFF^TQW4J2V]FM
MYB?4I!)&6FLV-R^82IRMN "WW>CX(!8G\0_V? \MW=P:E^Z6^DBTZXV3WF7@
M$$EK$9V_<GYD*[AYCC 5M^&P_"]A>ZRFE>)=7M(VU:X>*\M[:WU.51)$[1DW
M";I-P2-+F16A;<F<A-@E;S*^A:==ZT]AKNNWMI]KU9([W3]**H5:ZVP.MVG[
MU&<1(JJ4 5@BNN7+,\O:1#[5>6USYT%U)+Y4J/ V'N8\1>;+;MYYV6^[[.63
MH?+<$2&130!79K.?8B"QO9KV[L[J5$N!']MD_<LEU#^];;&J6\C!""7\@X)
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MDO=*G=!-;HMNZ&8V]N"C)+L+':J[EWA&CE;#I(F&],KE],B>>[\;11+OD?4
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MX%3>;\*--3[3!+Y4LZ;(AAH?WC-M?DY;G=T7Y67CN0#TBBBB@ HHHH ****
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MK'_Z*EH ^8**** /O^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSGW.S, >DO[[^SY7EEU&"PM;?S'87LV3;22-*L<\S?: &MV.52+&<E<;=F$
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M_O)6:3(C2ND%N8$<G2Y+=[.XN;RV"PR7 @E=KK-PQ5QYPD5L^2F70R =U*@
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MM#*@011AAM1C( @2.@"GXEU/4[W6]1\-:5)(D<-O/>WEUJ,L;VNGADF0)/\
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M:?>P0-I]I<O#:ZDWDO$T9E074VV51]D)& JQ[1N0J%"@+)J$[(\I@LK2VO\
M3WGO%BN9UCM;$,MXL=X[* 6$I!WKDE0^[ ()/'W-S/XVFNE6\D?PEIM[+(6E
MN(I#<.)BXN)PY57T]"LB*J/DB+U7Y "Y>74_B;7!%8WL^G:!97;:I-<7C2R&
M22++QS%GE\O[ Q",H4@L8VVA0K.G2*ECIJ27%C;26YLWD$:7#X.G(6EC:9U>
M=1]C(A5EB3 Q&&49 V%H]M"[W&F_9+"PMK<F*1V1@D6V9HKEW2XPUGAI D1
MP>1L"Y7F_$'B:XLKG2XX(+[4;Z;S;C3X((P3,5MKII+NUEWR(58RQA8G+E$
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MM]I5I%)F"FYI/A;^Q[QH88IVGENYY?-B?$.GQR"9898A(A1I%BC@@V#(1<8
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MW*A67C_.UCQ=>:Q&;F>V\.P^>88H@\TS,1,8[ED))NK24,2J#*LR)&$*([,
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M(FTMN7<[J7?G)3J)O/.Z2XL9XYK*6>YM28Y;K[.Q^TJ)B0X\U70C$"99-ZC
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\?\ VCO^2>:?_P!A6/\
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M67#NY=2U47&F:7'(EK96[S7=ZB-#<03-'(X,2_905N)EF1I"BL4#2*$5BI<
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M_N#7-ZMXJM-.TA;73M5DGU5;*><M!,]P+?9 %2\E_?2!;?9B38WF,YD1@K2
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M<RA/^6B8R]%TR\N=8TWQ-K5A/ EE%<2:?8FW(FAC=?WUQ,(8]KW,K,O[D;0
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M\N3=,S<H%#'RB%4)N#+& 1ZAJ&KZYK.JZ1IL\>A:5:)(UW?03A/L;%KX-.I
M59 Y2,OECY;;AQ(K/'N/;0:7]ITS2E@TRWM8GF19HHMFC;_MA^VJ22K*[# C
M!&U>H4$K4=D(;/2Q8:3))IMNEE(^EP6*"X2"-?M"B\&T_P"E!U:%C$-Y#/&2
M,ONJYJ6IZ=ILNHOJU_?6UA;1":>)KAD-JLC72^<95DW.LF-J1J2R%8\*IQM
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M)M3F[V>'5+_^PK*6[L8[=%U*^U21A!/IV])EDF(_U<;S19.PK&R&?S=C-O\
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M8XDO7-Q;6\$ZRQS'S(V6\B*R(?*_>*9H^ QSC.XM, 1VMJCV<%M8^1?6\,4
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MY5Q'FX!RL: &1U+8V(D@P\2%EK#TOPM<:E?VFJZK#_IT5HT-BCP!$0^>'EU
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M*)$(\L%W(*A'*N9-)TFWLI8FMV^VM>7:WQFM[PPO<!F:1YHMLIWVRO<*/);
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MQ*WDGY24F9,AA,G20/<6T0%I+/JSW\HNXT%\$20[86\Z%S,6CM _#(!(?WF
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M$E'B[Q"F@V&H6FV>=YY;A+>SORKI=NT"N5 <<VB^8[R.SKY?EE0=F%!\$O\
MDD.A?]O'_I1)0!Z!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!Y?XW_Y+1\/O(^W?:/\ 2M_E?<V;!T\S]WTW
M[]OS[<=_+KL/&7_(#MO^PKIO_I;#7%_$5;Z3XL_#A+>PM+I!<7# 3-NX'EF5
MMIP 40;U.XG<.G W=IXR_P"0';?]A73?_2V&@#H**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\?\ VCO^2>:?
M_P!A6/\ ]%2U[!7C_P"T=_R3S3_^PK'_ .BI: /F"BBB@#[_ **** "BBB@
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MT%TS2P;D#OG$DNX @9"OT$ES#J=P=/,EIJ4%ZXN)[9+H!I[5B@CGB7S6!@
M212%63]XP'.R2-=0\Z*XDN-6Q LL-TTUN?($\:+:NT\3R3,OV89;S-O!#D<L
M"TG)^(+W5]6O;[P;X:^R?:)D,FI'8(C!-O0F80R2G-O*P=7C"DX8R'S!*OF
M'02:ZVH/9:=#J,=I=7J6UU=2M.H94D5/+GM\3.FPR)Y/E@N"\@9@ZD^;)HNF
M_8K.1-/E@22^VW"K;3>8EY(IA OD/G+(T9!0RHS$MC +%BTUC3;"WL=.^S:0
MT DO-MWYD+EOMTN+<?;%_P!(W-"./,4L6DYR6+9DL3ZCO@>Z^U006\DJW>1>
M>8L]NCP'[1&_FH$A$?WUQC<Q.'!_>@%>:_M].TQ+B75X([>66*[DN)KP[+D&
M2W+30,US^[MQO*[,D?,,*P(67E[(WGB?RM>UR[@2PCBBU*PM)T,6VX781?%&
MFPL,<<D>Z-)G0Y8G;(2E&DW4^M75M?ZQ>SIHB2OJMM%NE@_M#RY8\W;B:5O(
MMHM\;K%O&[!?;C"5UD$S7L45LFIW;/<VXF5;9E!<F?\ X^[>1I&!B^;<8BT@
M$9B4J,[) "Q=@OX@-K+;1W!^T0WD$8N)%FC4#RWF1F(7 )57B0C",Q8L9A&>
M?U#6ES#:VTDFHZF+)M1MH5C:5%E\Q_+ND:.1I! X\W**S_N]L8VLZQRV+[6%
MT^WBMM+$=Y=W+I?-#8[B+@825KI%CF+Q6[%)%.%<M(_W9"Q$L:6<&FV#7IOO
M[0N'B.H"]EEB FDB@1A=QXG0+#EFC8$Y(E6,LL*K@ DTC3H=+L)+P7LE[J6I
M6XGDOU4/-<^0\D@N"D,H,L!,D2K'&-VQT1L@X2YJ%U;G+17$$L:[=0M)I;LL
MD,1W%KM'.S<JM)M>-9=HAV@8#A'L/J3B6ZD:/SH3=ES!:7C23%(6"O+$%;+*
MI\E7A"KAA*/WI90_+K?7GC%X[33M1OH[2/>PEMYC"+R07#))<PR+<%I+='7:
M8-R%8Y@5;=Y0H N7%L?&NLW0TV2--(CN(3=-%-)$;K:T$B31R1J '(C(RQ9O
M+BB,9C6<2'H-.BF:XTIHOM<=KLEE,,T!MV=B6WSR[%VEW+JPB81_?D<J60*D
M:+!]G:/3HH'C;-QI@MY(MZ0+:H@DM%=GCX+A!Q&@\PY!!S)EZOK>FZ;:_P!J
M7'V3[%;W$5S%;6LBL6624O\ ;86B_>8,1N&D4J=XCD .P.T@!'J^JSZ;X>5)
M["^O)Y=XT]GAEDN69D<O."I1UD,<F!"JQ,A$@!6)3)&:'H5[>:M_:OB+18(M
M1$IDL]/;RYK2U0R1R--'((24N,R-N^;]ZZ$CY0I2/0_#K3ZO;ZUK=A)<S!Y9
M+&S-LNR-GG1GN\.H%NY'EL(MV]0KDF25I#6Q:3V]K96$QEM+U-/1;BYN5:VB
M219D);4% SM!8S9^9,@S$;\*& ([W3_+@NM$MA]JN)MLDEL\F8Y5D>)7N)U5
M45?F$S&%659@)>"6;;GZEKMPT\>G::\]YJNL;+J*WMKT&.!-D/\ I,<X!"6R
ME7X>,^:Y("E20:\VH7BZQ>^%M'.E7.OP16\K07L9DA<QK"1>2N&,BMD>6$9I
M),K XPNYC8T#0[.U^R:O')?7\]S=_P"FZPL \[4&.PHX96W):!U"A$&TA4/,
M6YG -#0]-L]/7_1I?M4E_*;R26&8*]YNECE\V$B;Y;9&F?,?.=Q^\6)EDN[E
MIK)+F;5XV"(+R&5)5BB<*D/^D)LG4M:H79G21F)W<' 3=3^WVZV<=W-?^;>R
M>:ZW<L9 P#%)Y\;+*%6R5%C9E#X8%59C*65\.[=O'GB Z8SR)I(2&YNX$N5:
M2\)'E.UH7VNMKM?#S+@2 $1C+N7 !Y6\?W%I%YLEQH::FC7$,2J/[2>W.R65
M!).4^PAO))50Y+9X#?,>D@ND33LI+!91S^=>-<>8JPR% DGVU ES\ML6P60'
M+&4%L!G9KB%;Q[-VN9+@N\=TOV2Z:,7A"PKY\0$^!;J'.Z,Y#$YPQ(,E/4=4
MGM=)^T1R_:I+Z6V%I);B5DGD$8DDGB6.5B81'&6\D;2_E.N7,H) #5M;_LF5
M;69OM-_)+!OMX[GRC)([0QQ3J/.9XK;S?W;*%8DL3M8;B^'X8T2^DLK?4-6O
M8]0UJX1+FP+OYIMD*6X!MV%R2T$98B4@AI@?F+9&^YX>L;VYGM=:U+4)YM4O
M/*NHXH9XVV1,EOYBV^)3&;92SA_EW-\C99TC=MB)OM.HV4^(+OSHO-\^"XVR
M7'-J?-MAYIVVW&9$S\Q5>'W9< DAUC33=%UOXWLH7:X607RD*OE&62=V\X[H
M-L\0"E?D)1@-A1EY/4-4U'7+H^&+"7'VFT7[>]X%S!-+*SH4@>7>V^-9I&MY
M&PL2H"IPT3QW&NWVOZV^A:#J,DM^'BNKRY2?:+4LB+%/;Q"8++;[4\QHR[@&
MYC)#D-'70>&M*M-(TN#2M%>-]/A>VN/)M9W8RJ^6,\3-<L4@9\':<Y$4PQ)O
M!H DTZQBL],@M-+N-[2Q"2)EN7D%TQD24W<8-SDPAYW,@+;G!"[B-H>/4-7T
MJV,-_<W$DFGQ(U\J&XCD>(B1W6XC<2^84>(7#;%W!HHV4!<-&\DNJ6:3K<2W
MOVETM#>S+;7XB6>,)$XN8U:YVI;EHO+PP(+.<D(TC/S=C'!XHFAO]:\Q_#\S
MJUI97-W+&=4E>: &Z,,LV%MU;9Y<)W<29QEE5@"/1[=-:GLO$5[+]GLXXIKJ
MTCU$JZ2SJBEM5ERT3/&N1&@*#:IC91$I 7L+A[>VO'MXDOK.9_M-Y-Y*F2=C
MAD%P#N83*  !%MD*^9;@H@514EC>->)"SF1S<.LNV*X4&\"M !<P;9V"6X!R
MR=6#<@EB).?N=:LS906NF222W>H6[:@L5I'<)YR2I&'O%CBDW1Q 22MY3;6D
ME'RGS,,P!)J^JRG;:Z1!]IN+O>UMI^FW2 /')O;[>'22)O+*N^X.0&E"!&4X
MD8T7P_!8:3;6NEW']HW4<L=VUR98@KM)&JQ7<<<; K"H0Q")7C4Q+*H#\;BR
MTJSM[.YO)S]HO+V5]0DN;-A<37N"GE7,"ECNAA60%861]K!-N]@K2;D=_#'+
M:75Q>QM R-=R7"W(2&55@3-R@,Y"VX#;2F&^=U?C&]@".2Z@DG?4+>W@@AEB
M:]34+M(GM8]B21_:0\>=S%#%P[IF(C:05D6N7U2Y3QJUW')#/'X6:)99KQ9U
MSO:(QS/'<;WB6.)70,JE=Y$^#(%D22G<W\WC&)(OMLD&BV]O'>FX^TF'SKA9
MV,UPKB<[H()$56C$@ 63<CG; 6ZQ;:6VBO+"1<1I+]HN/+B2YF'RR.MVJ X5
MGDC1@JPG]\DN%<-Y@ )/LT-J&DG-I!<VKO>LS +'9S&.='NW3S\""0!B$!SE
MF9CN+,F7XLUNS\.Z=J$9A\I[GS;IQY N;BWD02LET0699,M#%Y:':52-CD)$
MPCL:CJENGV62X/[OS9+O3YK>X,\FQ\QFZA8[EE_X_(E6%E&"6""4",'#TC0A
M?/=^)/$L4=O?;UU".U?RR^E+(OR7 :5N"BF3>95Y-N@10L$88 T--T OK:^)
M-=L8YG9YKVVM!%)<+:1E(6:4%K<2M<>9&@5&(*I\J#]WMK<73+>R\LW9\N.R
ME>^NII9C'&I.[%R'$:J)#Y9,D:%$Q/*6#!ANIR!4O[MM3CM+2^"+=)<$-&B-
M"CJUZX\T#8?E0HC%Q&T:RMM?:G/W&HW-UXBL/#V@6TD<\+^8CO \B:6'@N"+
MN5S\WGR"9?W4ZY+1OD_.LA #5]>G=[VTTUY(YX[=;K4+F]M8G2RBC566^N(U
MB#?:F$8,<.>BHS*F-HU+72_[ T[4-)TZ+&HV_P#I*7&?MDD/F"9?[0D)B#R7
M#A9%,:[\E40;58D&B6]OX8T>"599U@L;1M0OS.3#)*Y8B6[N5#/*S2()'CC9
M>"C*^&">7<O3;:387MM+))OMD-[?D%'2%&=F6](:+ E'V9Y D:8\UB2ISY@
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M,J" 1Z='/XNN$US5/M8NQ;_;-.TFUNXA<R(YMBEXB--L2(-"KB&3> ^XEG)
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M=:= TGV6:UB:'RK>)2R!I;=O+A'D O;J"L9D7:%7&[YANCQ]6UU/#&F03>3
MUQ!%Y%O:0(L4\#^8S&$,\:JMH4@<>:RIB.WW@N2"LFNZ]-X?TV2XN+?4O/CO
M<Q1"[.U[@Q+*T:2.FUK7:TY>27 CV-M VILDTK17TN\M;ZZM<ZG\EE<W.FP,
MD5FA$!6"&-U.ZV.P L"=C.[#9N<Q@%-M#FT^RO;BZ;3?MKZ8+)YI[,I:VOEH
M9C;@^5L^PD%E+'# #:79ROER?!+_ ))#H7_;Q_Z425J26E[!8%+>VM%GM+<0
M6O[J5?LUPSHZ1*T2*9+7)B5BH4!8?GW9;9E_!+_DD.A?]O'_ *424 >@4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M ,5OM#Y0Y4'(&]1B70AFFN'A(NX[E+AX+@"WD(-TJJF^> _:#M@#-"2O/"R
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M=(/WIB926&&10!'N+\_K.I3VQ.EZ:T<5W?6ZZA.UU:Q+;V062%I-0$4LH>$
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MDG^QR7\,2*AN=K'<EI&["18B^<RO(2241@ T.34?&>IZ!?:G)]LTI)8M1L8
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MC5M,UC75WV$MI&\6G0W((NSYEH[W*1NW_'LVT!HGY 56V^9)P 2:3:7/BWQ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+B[&P1VL<R7H6[C?A9EG1@7YP@8X.\L\8!)J=M#XJU/5(HY(X=%-QOU2]BF
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M\J@[6.4=&#OYFUQ]'M]/M=5:5X%U2?S;N[FO92T=TYBN4472#?Y=D%7,89^
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MUEZ]XA\83ZU<6OAZSL4^S_:XX)I=6F8PS&;8KR;B(7\PG9%$=X20,N5\IT4
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MU%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)W KY^  -N#DYR>!CD'B/6OM#JW@G61 $4HXN;(L6R=P*^?@ #;@Y.<G@8Y
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ_\
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MC2W$;-=KLW?8H]Z[64?,0<L0Y8V--T^\T_S-1(U6[NY=0=FDFD*;Y/WT0C9
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M99B=&FNI$F'FPOY"';DX*CD*BB*Y-YT&J33RM:1):I/+%-<2GS=/5]_[R?\
M??O;>1D9@H*;=D8V_+NBD&H[_-G@NH([&.(W<$\EYYGD;_M)-Q.!* ]LP"F-
M0>/1-@*<?!8?V_>0WMRD%MHME:3I+%>7GVQ+E<%HKJY,K@SV@<3^5NVM\JNN
M%<[  T>&XUJUM+N23^R= M(H=2@MI+@%2YB,D=U/'YY\FT1H\1VZ/]Y<G 4X
M[2]=@?(COI+&5+A6B\V97:%WDF57F!E_>02MA$C !&0%VD Q1O+<0RRRR77V
M+[/]HE>&XN1*EJ-T_E74I\Q&,+J&_=DL!\@79Y;-6'K_ (M'A]XS)]KAO;FW
MFN+73KJXC<V<B+<.\]P$F+O 5).U0X40@* ^U: #Q3XD6UL(X+*&TU#^T$?[
M%:W5XS+++,\B1F0AV26"8.=D9(QMZ!5=H*]AX>N;GQ+>:W?"[O+O4[(VZB:)
MU@0,5F-FZR1?+!Y:H@D$>2S7&_;(44:&E>'FCN+^74H(]5UBX>;?%<SJ?+B<
MS*JNVXD6<FP%(2LFQF).\KE;EU \.CZE)(($:7[6HGU$-)', UTPBNBT0*6R
MA@0<XP=H8C!D +EY8K>.7:&2X+O+&OG(T8O"%N5^SW($.!;J'.QCD,2#\Q(,
MG+Z]K3:C>SZ7I\$8N8[@+J>H:@%"6ELKW)*W4:@!X&B601AC@B4,Q1BC/)XA
MU2\U36+KPUX>\B?4;B*6*\O+JU+^0I6X,<5PGD;/)SPA+[CN5MLBEO,W--T6
M#13&VE1W9=7N$A>XDEW73M)/(T=PS1L1$KG*2G).XX)WGS0"/3])L[&SNM-L
M[7SE\V>&2.ZE$[W+.;B7R;IPDA2$B4.K,2Q\P!ADD.:Q);VTLEY<VT]Q$T4\
M,LUQ&4ADBW2 QW0,6U;=&9-LF&;:SM_J_-9H]2.F65E<O<R23QV-O(TOVHR%
M[B)4NE\J['E,QMP ^QVW;R,_,W,G/Q:7-XS?^U?LD<ND[YWTB/5K0S'49F6=
MHY;@[28[5/-D$2'!PP.02H(!)8Q?V[%'KU[+?'1;*4W.D2ZA+Y1O&53*TUPZ
MQ9AMB\22(#A<@$KM\J->H^QI)+=V!.+BX\P-]K1;MY4=KHHEPBCBV&6,>77/
MW"5.0Q-+LW:K*L]LUO+/MFNF\CS_ "_M("7#)&0ELH.]'8G.5)^;[^/XCU.W
ML[--#L6@DN(8I9;:RNLP0>0#)#)]J01!5M(D<%22/,\L $D L 5];\16_GM:
MQ6GVK4;R*4M#J=N;?R+8).1-=D;5>T'G(H1P",OG=*K*MC3=*3P_/(]QJDZZ
MH^^\OM2N$4[Y529%>Z"2?+;%<M$GR*GDX+!R!4FFV%SHEO'=WM]=W=\CW$]Q
M>7#/!'(8A.I-Q*XQ';_O%*1(A"'+KYBAGJY<RO92WK6NHP0I:Q7$]M%<(T")
M<NURS2W01%Q;C80KG ;YV)=]C4 6)+2(0/+)!! LVH,T;3ARJ70>1(YIO,=#
M*I(@5$ ^5@FPE0C+Q>J:B?%6NW6G6NI21^';9YEN+Q))"J+);/(XN5:4![60
M-F.8;<>640J&22K&H2S>*;_5;2V\O3M'M+B2&_O)YSYDL(2^243[V!-OYN H
M4X +;71E81= ZSZ-9?9[:62&VT>W,\4;3Q;P0ETN^X3S$3[.VU#&BE I &(U
M3" %A[A=)?[%$L=A9VR%K8-(S"R.VZ)EN%60*+4K&OEJ2 #A<(57;7U758-)
M1]02*2&Y=[A((ITE:ZD>)KA0=H?]_$TDB"*-BB@S)M8,T:U7\1:I=^&K":[D
MNY$$#SW%C'=W:!I)F>=,3_, ;7=-:JF#E-R%]H4D<_I6AWUR+_7-::,.EO,V
MFZ7JDV5L+9XYA'+J#.YD<$&5=K,X3S)  ,L$ -#1-'OAJEWXFUV:..\A1A&L
MUSO71W_TJ5OM(6;9*BI<JJ,"#L<?+&,FJ>J:H;;XJZ-9IJOD?8[35)I7O;V'
M-N9"9 9E$NZ2$*(V2+"%4"MN.Q@G4:R;>&*^'V>#[1+%*I2^8ND0VW;+)>.)
M#FT;YPJL,+G  /"<?XFU>_'Q*LM-TK48+>Z@M+YI);@R-_9$3M&SW$["1DD4
MJC-'&VQ4WQ;@,** -#7-?UE]<O=,T:""#[#*WG76IRHYT\-\SWD7F$!MD<S;
MD#D*DML/ES)&-RQM(?#EA+;6\<=M) CWMQ*9 -DS.Z/=7.ZYW21."T@5V)"P
MMEMX11Q_@+Q+I264ME%J=H;J.]N98O[3O(YC:(J7'^F$^:QD=RI\P1N@PY8*
MJMODV/$/B>'1M+TR31M:M%B@U.VA;[9J0G,,<_FCSIV,Q::)D=9$3<I 4.3A
M2J@&?\30'LUTV2\DC$][#,WVR]C*Z;";I$:>6$RXN(&;841U(3<^60;4619[
MCQ5Y?B60^1I%C$^IZ79W!!N(7;<XN;I)I1'Y>89$BVGA)LJT>W<N7X[NYM8T
MZVUDW,EMX9M+B"X,$TIN!<0SW$+I=7,&_+VYQ,J18#J5&  2L?>7Y^S6;RW-
MW]EO[:*11>*F][%I3*&N9%,S9MF9598VRJ; 6P$S& 2/ MJEY"9X[*""XDOH
MT\UHS9DM,[7%R5N!YL$D@9@GRC!P1\I*9_B36%TAX01'+?Q7$]Q96TVYWLRZ
MO&MW<,)B5M06FW-C"K(B@*4P8_%&M7FC07D5G?>3J<^]+*)U,S6,;NV^[N09
MV7[/N0%9"H$2L%VGE*-"TC^R(I=0O9_)U58FED>[DYL%*RKYL_\ I3EX6$:<
M%V8F-<L%C00@$EHBV%E<1ZIJ-W-=6Z0W\MQ?QL3I]T452Y"2Y$#$L2L9\I0M
MRID"Y5=07MQ'YJ7*_89+:(W3M+=B6.U=OM.Z64^<K26_R_*I5< KC!4B&.^U
M*V6UFE368[".VN&;SI;I&%J_FSH7G+38>!V7RUCX*G@;&4&+C]3FOO$MTNGZ
M;/=Z3I^F7%TUYJTEYN>Q,45U:K(#,^YT<*I+*%"E9/G9R[( &I:EK6KO?V&C
M75WH]KI:)>W%W-,9;B!T5T$99[D0R)_HL@<EV7=( ZAED<=1;Z=;:$Z06,-I
M8V>G6\I@\YT5M+3:Z^9(%<&6WE,1<AFW;P"<GF&O"MCH%O#H6ERQZ'8Z>[F)
M9Y\-;.!++YD@>3$]O(@D. <KM;HRL8([[5-.T"SNYQ+8V,FFQ7+:=;W8:%[*
M,&2,O*/-+R6SRK&$2-,<Q!5RJE0 U34[?0+ ZK=SP:?=012_9H=5NB\UL6@V
MQ>:RW#F2-S;N2D88NVUMN^-F-.VMFE)\1:I<7=A<;_.MX[A%:XTF"62X_?7
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M3?M5B,#<-R]NX;:XO;=GN[:=+@WJ1SZD-T*@L&O)!]J!-GG:/*^7&UOEY^4
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M?W"!M;>MP-W06^C6^DQ216VGXL7_ .)?%#]F+G4 %:-([O\ T8ND,8&Q)-S
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M:[33TV[\56,MGK6J^&)_M*RS1M=7-[%$T 5I=ZW,P4YM-A,H( 'FQ_*H1H@
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MY3EG 095>H$S/:QK%J=W:R/<"> WC*);=II9O+,Z-("T$A*Q)$5#C@?*XS&
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MZ+)KGC"ST27[9=64\,\6%LXYG#74#S-(LLDP:91]D$GE("7";D&T[1$]<O\
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M;9)F,LVH2[U:6YG>/S08Y#Y2F5XU:,,?N[U );*WEB:0:;Y$P\O3EBCT\E&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+M'-D[ST+9_>&I.D$NHK*D$,,D021+A5N'*,UUN>ZW-@6@!,BC>GW708)$9
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M*ZJIW*P12$R@JGX@\5VGV=HX#)/!);W-Y;VS[YE>,"Y26>[&2#8D-&R!3EN
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M&0ABC$D.QR : MV\41/J=VTD'A.6X61#?QKYFHQ).;DR3NT;>5:HHD$2-MW
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M+6BWCL2RE+.,KR]DES'(S/\ *AVE$VHA8=P#%;V$-]##_9YCB1LE7M8K?RH
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MD*Q*6LF+1,TBDN/E8*B;)5 "^O;SQ/=7^CZ6D[6\43QW,U[ 7F$ES+<J]H[
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MRF69CYA9H[$TZZ.9M3U:]CL[2)T66XEW.UG++)$7BCEDC^>W=BH+?+LVD @
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MJ%WJ*&QM;,.L*V[J\RM8EMFP'<TD N2<MYI";"P+ZGP2_P"20Z%_V\?^E$E
M'H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %?(FFQZQ#\>KF+2)KN?4$UBZ4RQB 3N@:3S6'F 1;S'O/( ST
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M%%IG *B4]18VDMK=.T8GM+:"7[(!%9(D@C$L9@CPL;!X0'E =2H1)"&&]6=
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M1."N];3S$A"F,9Q%DDHI:L?4,:[K%P;>3[-H=I+/'=W-U;3%;AX5F,@GE:5
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M))$@$ :&.<R*0 L<CC8WEFNHTW3H=+==/ACCTKRWF\F.R E>'SEA+K"KV_,
MFFWEAE5*)NPN8XZ_A[1U\.Z6--THQN-+1+8)\TDMM<OY,KPB7R26@E+HSOL!
M3)(P,"+0N+F'1A927 M-/@A=;>23(3[$HCB<P6V8,20$1Y=LKM57;*^7A ".
M"6ST^47-XO\ 9,EO$(F3<"+2&)H<I;KY>TVS;@7EX*@J&VE (N;\.64VN/I&
MO75C=VVDH\9TZRA!<V*RK;2@,"I6: NGRE?]2"O"E?\ 1X]&M9_%*V.J1V4]
MGH%E=Q?8K5EE5RWFVDBO"_E;FM.'VHRA1M4G8 GD=98PM_9<,MC<1J0BI;74
M5LLR6@D\AD@@"0H);4C 9P00%Y8$9C ([I$M8MTCP:3-ID2.DD;+(EBC+&H1
M8T52UHQ20,9-F/*+#:%5X\_6-7.DSP:=I]A/)J\=HR0V6FK#OM2R0QI%'OAX
MMBQWF8C8K0A6SQ'4EWJRZ0=)TY'NTO976.STZ -$@E61U\M,6ZA[=4WAW(.R
M..)PN]U8Q^&]#O-.TY+HW6[4'M+:!KU]+*R6TF(<01QB)/\ 1#D94!#&1(2P
M8L8P"QI6D2^&[6:[C:"*^DEA;4/+A2..618HHX[.W#)&##ABL9W@J^T$OEUK
M0=HFBNDMKV=X(\V22->/#$S*HB6!YF9G,C2RM^]B&[<@1B63#&FP)9?OUT^Q
MTF195MY#-$H6$G[/&(H"JIYD<BHH5RV0PC4KE?+3DTN;[7+^2PL;R33-J06>
MJZF;C<U@"D:_8(YB2+BX\TO^];)C\Y@/F;% %B:>Y\2^(YK6RNKN&WMW2/4[
MZ&!Q-&3/$ZV'F6\H#.F90T@#")'P3EG9MBTMH=&M[<6LD<$D2)8P+),$DMN(
MY(+*X9%D0CED$C?,HD4+N>0NUC3['3;&RM=,BM[2TTF%#:2V4A4I LJ1?Z-,
M/.*O.[R*P<JV067J^YZ=[J/V+15:^NI[-FBCAGM;>\\ZX1EA5Q9([2Y:YD+M
MB1%W,G&0VQZ #7-1L]'\/1W-[ID 6WBDLX=.^S"-[AI47RK!$V2!U8% QB;;
MNA'!4,JY^B:>\_BJQUK5-1S-%=O8:=;N&G$*"&8O!N.X>=A$:2<.^7C>+("G
M=';Z5/KOB6YUG6)8[F=DGLM-LY'B%K 00SVI#(^Z5HT*R2QF08\]/E\I2>H5
MIIK*2Y,]W=?;'DB-M%GS454E)@#Q2"**59-R>;E?NJA8L ] &'K%I]J\#:Q:
M8_U-I<6.-,LO-NK+<(_]%CB\L>9&>S8CS&(F[^:#X)?\DAT+_MX_]*)*Q];U
M2XN;.[\(Z ;&[U:?R+3:+@?8K $R,;<JF [1B*<D&) T2*L@<@))L?!+_DD.
MA?\ ;Q_Z424 >@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIMV2(@N=JKM5%V[46,#6^C6<XB,%M-IT0=T:0XL0YB80QN821:,4<-)C"!"
M%$>(BZ2WT.+^VY(H-/73HDCNY8K$RB"!5CS;1;85=[<!G?>"-CJ"05#(O/\
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ML$4>U'(;=N74GNKV$2QR+)'<V[FYAM[:XE=F98_-F+,Z[I8"TJPA8XGV[E(
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MAF']R<MGJ&0>68U4%K8_9-3@NUTZ"W:W\BTD-O#DQ1F/'V>(BW!>W5S$^X,
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M V((V0"/8K)N:-;6Z16)CAGLYM,BBL)((W,SZ<76T;[*N(R)8R A:4DE>2&
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MOW".\>Z2!P"7E/W=C%F4@;.;T"QEU[[)>/IW]D:#!^Z%C:PI)&S2[ T406W
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M_P#V%8__ $5+0!\P4444 ??]%%% !1110 4444 %%%% !1110 4444 %%%%
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MT#!T1E+(P+ACM0!DKWVOWBZE%H/AZVD;4[=$MY);?[/MTZ(RID6^8<R0;_\
M1W<*?*^SAF0LOS[&EZ7IOABP?2;=)+&"S>-Y9DE6W8QQ/#,YB,A+/:AII3(7
MD8KND0;MPP 2>']%_P"$?T..WLK&>*ZM<0%[AO,E$@\A5C640,7MY B[I,91
M0!M39MBCU35-(L+!M1BU&TBTNVMTEM'C4P-:JC@I&&2-B+6<VV,X^;&$,F]
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M565?F'5^(4FU?PK/%H&GR->2V[:,RP:>89[5F0R"V=I+<$6NV1 K;(\%8]S
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M,D2R1F7%HC21HJQ[A+(9B&/EF0G9F$DT#0KS0KR:_N8/M.K^4D+3V\1CMH^
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M'.5N!I]_<R+<W"1R0QKY=H\GD!I8FF\SS&<L/+:0LRF9%%.^N;_Q5+)I-A-
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M!\VX[1Y1&UHQP:3X9ET/3H[9!NUD^7.Z1S)&TTB"S$A@?.8[3,2K(FS.WA5
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MHHH **** "BBB@ KQ_\ :._Y)YI__85C_P#14M>P5X_^T=_R3S3_ /L*Q_\
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M.TI!5BVU0<X.@;0NEPIMH[C[2\T.)8I +OYK@^1/YB.4@7=\K@[23\JA65'
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MBMY(3;D"!1<\R#YEVD/G:] $=]]O>!&>R@D:[_T><RP23?:'WR VLJK;@BV
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M*H,9)&Y-9V5I;W5M"EI96R6[1SPW$<4BPVX%SM:XW29-J3DI&NTK@CY5W*@
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M\FLZI>HX^Q-$%>YA#S(8[C]R?+MU9PL<AX8L,G9O<EGHBI<74<UQ'J%^]O\
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MRH<>?',HS&YKL&,5M;SZ:DD=Q9!_+2SNC#!&B.)84MY(S$"MN7151E#LY/\
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M*Y>RFUKQDZWDHC$$Z2"UMQ&5%Z&6X>![S:%?["N'C12 922S*-VV@"Y!$_Q
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M5[< 2;8R0'C#JQ<L >CW4?@^XU&"^B^+%]:S1[698?$4)CE<')=HWW)R>J*
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M.Y\XV[YSO8R '<6<_A2YN+J+0O'%W%<6MO\ :;B6+63>*D&3DG[098P 5!)
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M@.#4Y;C0]&OM&FM+>X>>XU5-/E@^PQ>1)- LDCL<P.QEQ("_RK$2[ HHZO\
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M$L#!IHMJ%?+:,.KA53/2++;Z; \%C=?9[JQBO)+.TU"Y,"6J!YAYTT:R -:
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M3+NE<&1V:W(!(1$RH R5174<OI$>I:I?S^(?$+265W$[W=M97MPRR:6I2&1
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M80("TD178N!]]5\I,J+--!:R327\D<MDDEQ(DUT66&2664,\JN(BUO%A]A+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&:.PU*T5)7C.5=MZL=Q&U6Y^9452"!BHY-3T&5X7;XOR Q/O7;?Z<H)VE?F
MAPPPQX.1G!Z@$>6:=^SW>7^O:M9_\)#!'8Z?*MO]H^RDR22&**7_ %>[ 7$N
M,[R<KTYXU_\ AF7_ *F[_P IO_VV@#N&O?#S>9GXP3_O)4F;&I:>,,NW &(O
ME7Y!E1A3EL@[FS))J>@RO"[?%^0&)]Z[;_3E!.TK\P$.&&&/!R,X/4 C@_\
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M&O4'\,^)BCA/'NI!RDH4FPM" Q;]T2/*Y"KPPXW'D%.E>&?\,X^,/^@EH?\
MW_F_^-5H:5^SYK]I]M_M%=#O_.M)(K?_ $^>+[/,<;9>(OFV\_*>#F@#V-M+
MOHGO9I?B#J2VEH@$V8K$&W8*78R-Y& -C(<$# YR0PQ)_P (WX@\_/\ PG6J
M^3YN=OV.SW>7LQMSY/WM_P V[&-OR[<_-7E^F? V:UT[38;_ ,/Z'?75O*[W
M=Q_;5U%]K0APJ;1#A,%HSD=?+_VC5?3_ (#WUO\ V/\ ;=)T.\^R^?\ ;_\
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M+9)+46;PRW5C9RQCS68(!(NTH$@W+*S*L<?F-&Y"X++)7MH8;>RM;/1IH[>
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M W& %V(T=CH7E0;]1@@O]9\J.U86D7DQP0EYE%J8#&2+(D%-Y60N&,F (U9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"/3K2*RDCM<1M$]SFUN6NI)%VPRO-#('\QX2ZJK@(6E=U9EPQ+9^M>+K?2[
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M:'RPQ0,$&0=P!8T'2--T&U@:.234;B\N#=R7D(7S[^2:6V+W,1CD^2W#%-Z
M8*J,Y R]S[59Z?YNJW=[YZW?D3230,%\Z-/LX$T+++E+2,N[NK%A^\<D[3\]
MA[KS_L49O9V^VRPRI-:-A+UD\A]\+F5E2$HK[HOO.HD*YP6;D[+61XQ,EQ!-
M=W^DQ7L?FVZ31H-6F-MAH(4,X"0! L[12%BQ9U8 JP(!)>6MYXA^QZ1!<?8O
M#DFQ9_LCE4U2 ?9T)MX5W216^0\;!61 LJR;W4D'<@BF_M1!!Y<+V+I:EK2
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M:HPDFOYOL^FSPZG)'/>N9(UB0O%J$JA%0(_[Y88'4&0JH+["7R-DF>3UI/\
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MV<B"",$2!W0N,&6' CTC2K'PMX<0Z7+)>2Q):^1=P/LDU!T@R4'R,9H/*W.
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MBQS-Y*QG,<IV<Y6@"/P_X<33XH[/4G_TJYP-33[.H>X>-8($2*..,))9>6[
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %>=_'$3'X2:N8I(U0/ 90R%BR^<G"G(VG=M.3G@$8YR/1*Y
M/XEPV-Q\/-7CU$Q^04C*K+)Y:22B13$CMD;4:0(K-E< D[E^\ #@_P!G>Z^S
M_#S5VDMY_)AU"24R(GF;_P!U'E55<N6 4<;>=P R<@8_Q3_Y-Z\%?]N/_I(]
M=1\(IM.M_$?C#1/#5S!-X:LKN.>W8!G=I)4 8+(3@QJ8F ^4EL@[CU/+_%?C
MX$>&T3FUCU"..S<]9+58YEMW;_::(1L>!RQX7H #P"BBB@#[#U29F^'WC76+
M 1PW$[WSR)=1K<1YMP;8X4@ ADMP<-N +'.X#!\X^"VGPS6<T49N[:>YT<H!
M!<A9V\ZZEBEN8,R;4"+#"&.S=F)<=A)W^O3F;X2>+TOY;MYH7U)&56D,J?OI
M&A#;?F";&B.#\OED$_(:\\^",MAHMM<R75U]F6_M+>Z:*:YCB>8QW-P#+$WF
M+B&-(R9%8$G#?PX#@'J=_J\,&E[M5UN-/[1MS;I<V#B$SQMM(NK8&9PB1)*[
M.^"<)O/RHH.7:6MQXUV7?B'][IMW$_V'3()1&TT,OD W*.)%81JC,AW 2%9)
M,A1*(5S],TQ_&$%E=W*[-*DT^);313N2VN)T>-6NUMS*A:T0+"5C;&02=@9@
M7ZBWN;>2\^U2S3W\TDL6QH$(,H<6>9;0B3(M 2C2#+ DMDD## %B"\?49W5;
MKSUFBAA<6^Z+[7%L!DN+9O/PL8-S&2ZY8;&7+G9MY?5?$GVAQHWAN.QU2[OK
M0-,L"[K2</<(K7&T&1!;F22Y68#,IXYVCS!8UG5+R">/PMX9E@;6[>6V,]G$
M#'&JA$9)1B4_9[8>5M>/:68,% 4RK(TFEVMOH!>Z-U=ZE/=I'<SW:W%M')KD
MS20^7)$_G*5BC+",1':A$P4;\_, %EH\-M?^:+Z[U"\UNR:V;58YPURZE(3Y
MUH0Q6"W!>:1LXPY0*"#&IN/?0"*ZCEU& SZA:%[R[TN:*W)MRH":A&'N&V1H
MI*%\,[%$Q\J*#8MK^WCEEFO=7@N)GBCO)_L]X8DE@5HREU$C7+"*W4%A)_ST
MVGJ,!\/['-XN2VM)9=2BTFY1;FYB6\*OJ9=D68Q#[03';QY *@M&ZS'RP3Y<
MA "*YN?'+P2I>1M8.B)'/IMP\%Q*P5@UU;[SA$07$8=5 <-YD;.X0)+N6IM[
MR>TMHK>":UCM!"AMF,&\;(@MQ9+YF$A5+J56=#O'RJ"V!F2,MJ5Q:.]S=R1S
MV[2-':W2QK>%RD/VB$K.62)$_>;0<?OT89E%4Y?$B&"QGAN/MJW<H80V4RO)
MJ4J.(\VN+K$<:F-9)%.5V.=V#YE %/5?$4SV]A=VPCN-2O$A?2%BB+&^&(=U
MQ#'(VV$!;F=70D2-&"?,0+N!I/ARTTB(7>NB.UCM462>VAM76V@;SXW1XF4E
M(XED@9R%"Y1HVG&Y2QD\,V45]+'KVJ7_ -OO[J*TN)# CX&YF:WDMU#&2*$"
M::)MZKO".S #S"]S2XC9PV-X;>.U_P!''VHV6DR*\4HAMW\J%3#N\ADA93N!
M?(1 0RA5 -"6ZFF,$D]K=R21W$,C>5;EC:RM(L!6$O"H>(@3EY,AQ&Q8?*ZX
MX_4=2NY-4NO#?AJUCL=4LWMGN9H-.2=-.E?['"AA.Q59/(DN!EP'Q&WW4 %2
M:I/+=P7N@:+:>1JQ\NUNAY*7<>DQN]G$8HXRFTV\D):4 [01&Y(4A@FAX>T#
M3M)TZU;3[/8MY=Q7-U=:3N\N"9Q;N5M\KEK20QJ&*D@ X.%#&, DM/"]CINF
MRH-'CANYG$<\VDV_E-87,\5O [V>4&V+;EV<-E=ISN.0NA&L-JDVH7D$FEPP
M7'GW(;$B6MQN&^2$F,CRI4D??*"H4%B0CF4K(L%OIEJ9KD?8[6TEBFD(!>/3
MW6*&/R[?=%@6Y0N&D&W:&D^[EMG)PZ=?>(Q:W%V9$T2S1;!(-)MMBS/+';(7
MA+(/,L0S2-M;<K>4&/F)A$ #3)YO$5K'J>II'IWA];=+F6XCL3"[RO*I=X7*
M$I:N\?G%R5F4A9"R+M-=)9Z9]E8QV=A]ADMI52WM%M\6T<XB$O[B01E8X6WS
MQO*8][&1@""J+5P6DV\2O+=P3*[I)-&IG>WDF6/]U"TD!+P;V\POP%,:@C8I
M1.;OM6L].M8/L=E/+?7,L2Z9:V-R/WK+%:R>39OL ^Q$(/-<[5&UN#N& "QK
MOB%+74XKFQ6>_:YE7^SK12KO=W(CB99+5F#*ENT,DB2R<!<$KABQ:OI6@BVT
MQ-6N(O[=U-_."3VLTT4-O)>2(Y^RD XA_?,6N%)=54]<;$DT7P]-IAFN]0MK
MN35!<6MK/=6"&)88Q) \=O:1XP+-0[+(<@GRW)!_AV+:TF-KI<$MM(MQ&B!F
MT^(VZVOE2VZR0P[D7%NS(6(9MSH/D#C&T ,K*ESI\1NX)[A&L[@6$+0/O=G)
MNXE+D0)N^TG>XS(5&UGPF_FX=5N-5\0Z7+I,D"V5G=JNI0PV@6X:XWLLC11,
MSB-<W2O,=JR(DFUG+AD2G>@^)KJTT;3I+0:.+B&VOI[))$>2V$4?FQ0QD[TM
MY";4'RCL571]\@=_+ZRUL426.V6.=)EE01F%EMG1(6M4D6VA;E+0F/YUW<_P
MAPZ&@"OI&EI8^%V\/Z#/^Z,2.+FUN%^[*4V211A\K;D>:"?,60^6[*SR-YIC
MUC5=/T[1IM9GMK3[&+<%5M)9CON959WE@=5&$6.:5WGB5G92YX,6UI-:U.+0
MI9-5U"&>YD&&EL[9G>Z69FLT6.S)$>^W+;2X'#,P!&25KF_"MG-JMQIGB+7[
M"2&2%T_LK3;*<_Z/S!;R2VZQN!]EP%=L[E*OP HWS@$FDZ%<>*IX+SQ'-B-I
M;>]M]&TUQ#&LH0,]S!,LB[X]UVTCLOS;P%#N%&_J#/<7=F);K4)_.U/3X;5D
MTJ4.&+% ;RT.XE8U-R=SL"<(AX"C?)9S6T^J -/'J-Y,D=VLD-XB/Y1^S#S+
M9 Y9;5F0LX+\E",2!A6'J_B6_EU.RTOP^WVW6)\7"NDDB02'RX,7(^9U%D4:
M52O):3A/G!D !3UG79;OQ 8=%234]8ELEMGDL6FAM) PA\NXDD5@0D?VV1MD
M1E.V179E*J5U/#^G:7I*QR(\^I7TDH,E^L6)[\RRP3&:!D<8M%>?+HHV<MG/
MS;[FA:=!HEE80"YU+48[QXY9+^UGEN%O'V0 7,KG+("R*H1792C$D% Y2YIM
MU]K_ 'HO9[Q;N59E1&\KS]GV=#-; R@K; @LRG=OWD@LK+Y@!7LWL[C^SQ%:
M?:6DNS<LMMB+,GR$WD!,V!;D/EA&7+?:,-\QD5N?L?$5UX@OX[3PY+_9-E-*
M9+FZM)H)C-=&<I(D"3<-"R17$OFHOS%6;&]9$:Q+J-QXKUA=%L[C[1HDL1.K
MSV[!6OG*Q1O%#',^8[?RY8Y3)'NRKC8VYLMH:7)%;^'K.TBDGC2TBMI&BTUW
ME^TK$EJQDM"[EGM@IV,JJ6?<P'SGYP \/06>B:/8:-I:3SVHB>[AM+5PN]0P
M99()3-\T+NI)0O(W^DQARB'%1ZWXAL=,&FW%Z8[[S7%Y&89=AN"D<0-Q:,92
MD<2AR'1F4&-I7)*AO,-=\3KI^FR)9W4>H:Q<V_VFSL[61F;4)5B61)H56<E+
M?]U)N3^/# ;BW[R/0]/MQXM_M::[@O=3>(RQ);W9>26"5HP9HB9_^/3^/RG5
MMC[]C-\NX CLM)OM+?4=0UB[M+/5]XN('M9<01IMC-S(L4DH M]TF95.&9D,
MF=S1"/I+V_MX-1NK=GG:2/;=R644Q>YE0&(":)%DW"%=K!D"_.0P"DG$E/3I
M5@.GZ9!+'+9/;I-:PV2LGGA9(6:>*3SR%MU\Y1Y)YV@A=R84\/?:K-XCN(O#
MFA:M'IMDB)YUU97!MV# I;PS6>VX,;V[.0IB'W?+<'$K)D T+[Q5=ZUJEWHN
MC:K'##';Q7]YK<4R*B[<*9K97F97@#JOF+PJB*927>05N:78:=H^F6EO8)/%
MI%INN+*PT^\:8W$8D#_:8V5Q)+'B?]Y&P<$A0@.%,L=E9:5I^DV4,*QV=C"X
MU5)+>:-$8B9?,GMRT["&WV%F=!QY=P #N+*:^O\ BJ;3M!:^CGC'SB>=PQF,
MJK'YD=Q!%%<Y\A_L[CR]PR&9WPJ2;@ UWQ-#86DERUW'J8E3:EM8WPMVN)C;
MJ6G1_M/[NW$<BDKM)3/G<@;S8T;2IM(FBUOQ3J4EQK$:3N(_M9B2VA:8F<HI
MEV-;J'B8%P7 5<\[(T/"6F7UKJ4^NZ]:1PZYJ+RF'3(I]\EK TJ+(2QE*2@
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M8QN<*(BGE@%0P!7!U+Q+JC7 N8[/3+FWMY_L<=NP_P"$A'R@2N,2>3 6,:.
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MEOW+><T<FQ@\:R(N?+V2C'UC47TZ>#2;#2(+O5;_ '0P:;AI8;6 I#;.)$,
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MD#Q.5WA8E(!)H.G7B.->\1:G.\T,2S-9/<F.2SC-Q(1,TA>+$+H-\D;H 3$
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MAA)(2"?G4 CC3_A*=FEB?[3X<2[4/)80^5]LQY=JT5E'N9HK2-6'FR*QW;Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT5O]'T?3;"TFU2:W09LS)Y,*[+5OM$!#@"Q 4@H"OFN@0 Y<T 2:IK]Y)/\
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M;_L_26U6=KZ^FDE^TVEG;W/EB^D6.)$> Q3,%MF//ER;BSS*,%F17L:GKO\
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MZP*DC(!-:\2VUM;ZO)_;\D7F(LD31,@";@AMKJ'?,,P;FCA?GRGD!)$:^:2
M2>)O$?\ 8^BG6!J&8;;R[JYN;:3S%??"!#-'#YS9MY'4Q>4<99RX=2GF$T+0
M[B;6K/Q)XE@G&N_O38Z1]M$O]GHTSI*Z'S,2*4EB+9SMP H V1K'X8T^[N=9
M?6O$ACEUI;AFLM&2Y26325+,LF',AW@QW,;OTP#& O$:C8MY5UFWLY&ECO+>
M\>TODC"LC7(01L;B%6GS'$KM Q0C(V."',@- $>F-%J?V*[D'VI9/*NK-DN'
M$ERI\MS=1))+F&-3<2HZ<L4*IDKM1L>^UJ>\ET2RT:^GN[^_\F\@CVRB+RRR
MR/>L%G61;?$DB>3*Q#,L:JH"G='K?B"]$K6]E#::CJ6^VO;)E\UHI08&S<QN
MLA*(2C@6\>^1TBF^5Q*S+<TK3M+L8)K6X>?69]4\F>^NO*W2:L'>)5F1D?;]
MFCWE6BP0J$9&U@90 T#1OLEK:,\O]H:AJ?[_ %*]AO\ 9-?;HD4W$#HZYMXO
M.*A"%V@AEPRKYEB36;>*UCUC4-0\N-8K>ZFACN3NE0Q>8\L:I<LOE_N=VT!L
MK!<!?,$A)U!?PA+=Y[V.1+IX9 T5R(Q=L6MU6:#,YVP!F :/G<6Q\V[]YQ<,
M$OCN\N8I$@30I;M9R]JZ,^LS1#[-)<*C3,JV\3K"^QE<-L0G<6VD (T?X@:Q
MI\NI6?VG0HI8[V"SF#1-J1"^4;Q8Y20MNIVD0!@2LF]\ET23L-/EN$L["T-U
M_:BR>3*)TN1'+= %7DNHR)#NAWR1@Q_*%7<!O4HC1V1@N#9(+F[GED<:@4AN
MI1]I)D5!/$WGE/LX&7,(9P%DCRH)"MEZE?V^F01K9O/<:AK&R2,:?,1)J+AX
M2;FW9I'0*BRL2DF=R1JI/E1T &IZ[9^'='BU*2?:DN=2C2QE"_:FC8>>\<8D
MD#QRQL90@7:OS/(Z.V]:=KX<FE26XU^QM(H+1+J"&*8DVND+N+[E8E#-;R1+
M$&&X;0&C 5&=(Y-!L;)KR+Q#K-Q]ONM0WWL7DVTC+<H@62*>&%26C41>2C*Z
MG,D,'5U1I-BSLI;>6S4PWT,MI+'9@V5LD(EVLS ,H4H+9(F;9F1L"1E(\]5-
M %P17O\ :SSP^7:W-RBQSN()9P+A8250LR@/;@.6!4Q 2*1DM*P''ZWJ4VH7
M5CX5\/K&&O;>&25;0&6"TB:+R]ZB4B*:U,9/"H4W1[2%DF1HZ]W?7>O72:1X
M<AM#%?Z.&,2QHL,,8BA,2J^Q2\2O<(QBD"D1F;=&XEB4=1I.G+H46H7$\,@A
M-PT]_<R.UM(LHG,Q=6+[/LN)&?8'^4!U82.[@ %/0-*TG3K.;2V/]J1:G*A5
MHVED>\4D3RR%Y&P;8&?[NYUY8,\DDQ0ZDNKK:I]JO;B.2P=(+DSVUPV;D[H
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M90EDHC4&-EPW3,@D0/N275R;C3I&>['F/'/(L.])YW)MX]Z6[NVRW"RR"5'
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M+,200<D%20#TRBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCI^CF2^U?4+?[1'"LN+60[T"WC.DKM#;J(=WE@XE$X7YFWXN:%I"6/DN+_\
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MGCD\YO+LU41$ID$K'&&SRLECPYH<.BVL4-K=7=[:7#BXB:SD!6\S+&_VJ:;
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6DY4_*JQUH27:3Z=<R-J>(Q%%<W%U:W"KPPCV7<1:9ECMQLD)1@0^Q^'&?,
M(X903:WFFV\G]FQ.MM%]GMHVDBC>2V$8MV52AM60%W8$D C!4IM3E]0N9M>O
MQX>\)W4=K<BRB-[>::I*Z;&R1"!(9 (TFB*2W#J&.1EG3#(J&OK/B!O$_C$^
M$]/M8WE9UAU>ZM;A;B6S/[EY%C$@"&W(B,3C&"_WH\E5FZ3PQHMOI^G:=;VB
MV(8Q1RQ10W)$;)BU,KVDBL7^S[EW,K@^:[#<0&RP!)H>F:?H?A^VTG1[B."V
M9!-;>4TTZW$A,)6>%5G9Q;AW^="<'<26"DL^7KOBA+'3A US?*EQ+!<M-I]\
MLTR&4>9"MGE#]HCDEBDCVM@@$_*(L;;FO>(FM_#^IR+J5W<31V]M+$^FVJNS
MO.8TMY;8+( T1E60F)V8MR"=FT/'H^C7ME>/J^J6D$GB35)7FM;13'.-)0C:
MTF7=7DP'C65D;D>6B@(B4 2:+H5W Z:OJ\5HOB:X1YK33X]DD6FM(L27$D:E
ME+ OB23#?QLJDEBTFHLOVR\L+M+>"62XVRMY-]O=XR+<F6VDW#-NK",.FU _
MWL$D++):%7-N5N9+KST23]Q=-_I8$D<GVB#,YVP*TS!EY)7:O*A%?E]4\2:O
MJ;C1?#BR2ZI<HUQ->*X,2K&L!$\!$Y3#!DVV[,-WFJTFU"3( 2:IK]YJ6IPZ
M%HEY/]OF\J>:\3,<$N^./RY[=G9E>,8DD\A2/,^SRY; 82ZFE6D5G96]OISR
M7FU_[0O7T]H8WU.61/,6Y+>:-L4DBNNWC<0JY$2MN-!L]-TFW2R"1SSWEQ%>
M74=S&L<][=2!'%TL4DF8@#%,QC*A@86V@;/F+C4[2!WU&[N8Y4M[>*^DN(8W
MS/;A4,TULXF.(-RP,\:Y.(SE7\Y"0"OKFH+X?\)W>KQWD:1A!?K+9!GM;DEH
M&:4*9(PA9BV(EFQ('8D2LS"H].AO+K7(/$GB*VV7)E!TG2+<F66!7V027)+A
M9 I$BED 147#.ADZ9^G>&)M?GNM0U2PGL)'\N6WMK;3[9,&X0)/<-YD9^9U+
M+)!(TA7:QRY,1'83WJ2;YK-9[R.;;=0V]M=KYEX%\@K+ QF55A7(#*<!B?1O
MW@!3%P&M[#34U"T@MKBWBBL(]-$<$D[*(V-Q;$S%3 BG)C*MPISO4@-AW.OS
MZ;!#:6ZP2ZCJ,4-W;VEA'+Y=[<,\1EGMI?-"-""Q=H3L+ .[D*Y<R>(_$,UO
M;PV^FW-W=ZQ>)'-;6]JYCBU/(A'G6LI+K&$.'*$LNP2%T97\RCPAX6&EF/4=
M8DCU#6=019Y8$BCB65C)$[W(@D1&B=&,8?;C=Y4;LOF$* "/3M%>WO(-<UN]
M^W36N+O;->M'+8Q3A"\Q\P(44&#!3$:[1<';AQ G0++>3W1CCOX)MTL1>.(G
M?-)%+"L\L7^D_)"O*-'C(8-D2;MKQC%[JFF.[27J,GVM&MY8PD\@^S*+F#,Q
M>.)5=P47A@\@;=N7S.?U;6M:U&]M=#TA8[B?5$2>:1;@QA($>)6OHVBN]P@8
M$;(5*LQ#DL>0P!8U+61>O#:":.ZM[JWEDU F:,VNU5B_TDCSSM@51"S0;UWQ
MW>3N(<5L:=:PZ.YT^:ZDGOI[B&6\)N D]]<%8\3H/.^2(+#+F+&"L3A5*KAZ
M=A#;V,2%I+Z]SY>IRW=M<$OJLNV)6N(ECG+&%%QNAV%3N0(IP T=_P"(=(T.
MRQ+JEI;).AO9)X,M$S%%D6[5$GW+;M(C(4'^MDD R=Y+@$D^NZ=;Z/\ VCJ,
M\$]IITL-U/*96CDBWLY%U"QD??#)N 1%;[GF1@NP,59>AZ3?7MQ8:[XF2[O[
MZ1YKRRT20^7]D"%C'*(I+@@.=_.XN8VFB4&-8ZCBM;VXU9=5UGS[?7K>*2^T
M[2XY8[R724:01S$@2![F.4'=M"_(JLD95M@/4+<6=G!9V]G<00Z298&M(4G
M:>,NOSPR></W(>:!0F,;5*!6$B"@"NE_/<Q,3=[;H1&\$EI)*ZW495$%S:@>
M8&54+'R"CCS&3/59),NY\2P1&.+3]3M-0N)TCN=ZWDH@:**1I)KC>LKK%!O;
MR\.5P$=<3!$B:/5/%;Q10G3+O[;?:E:17L<<KM!;(BK&_P!N9O,+V]L!E6C?
M[Y7:!R[/8TO2;>+3M0OI89[FZE^SW?\ :EE&9+JX<!D^UH^63:5W,MO'NVQG
M!4^;Y5 %RR\/S:4\Z*]W=ZI</YTE]-"29)MMJK2JZRKY<&Z,%H"P+A&5!L0
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M&;[.$?RP+0$87F%7D@#2 >0$\N0R%FKZO=V^C3VUJ;.=+F\\FP@L--F(F0[
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[9'OX38/--'=",0JMQ&J3#, 612UOR7).W>1NDR_$/BNXM+P6FCC^T-9U?\
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MC^PW32HL1L+>-YB[/<&/[,7@(EN)2[!HR?E$KMD9+/'>3:5X?%K*XCL; /\
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M5 "OJ#)!JUQINA6\$$VD2QF=K6S60Z+%)(AQ:QK:LSR3Q%V8?,J$')P!FO\
ML_VOV'P;K-G]H@N/(UN>+SK=]\<FV.(;D;NIQD'N*ZC1O#]OX8TRUTFPCGA6
MUB^R1S*IF>WCEDD_?1N83ND=Q&TB'Y$P"0%4;^?^!T,5OX>\1006WV6&/Q!<
MHD&7/E*$C 7,@5^!Q\P#<<@'B@#U"BBB@ HHHH **** "BBB@ HHHH ****
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M$*EG\TJ,HBNNR1* ([R]E\.VMG936'GZS)LFL;&U= C3QQ6\31V:NI$=OAY
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MM]D+1XAVR7$,BJ(I@C1%HL@%8HVV.\88=(-06X>W87EW,#<0R2+9A@-0)6W
MG@S(Q%JAE4N%XR#DD;Q(9AC"O%J-I]OU=TGMOLEP-E_((X!]H$9=6V((P3&D
MA#1YSN+8'/ZMXAN[G5'\/Z!JDE[JFJW N$GM]DL5C"/LS)/\L^4B$1)VL,32
M%N C!6 )+_Q7>2ZU;^'=,> ZS<RAI1-*=K&*:-&GB5;C A AN-T ?S"R_,A!
MD)D\-:59>'_#4:QZE=QQ73Q:K=327<7FW+ 6K2W D\U@(.&\T$MG>VTX*;I/
M"VGV&CZ=&FEW<^L"ZW322VMW&/MKPA")(%6=8XX5(%N8U4?\LU;Y%R9+SQ-I
MMM87VHMXFM'C6WCN'\JX5XV97C074*K/O$ ?*/%N^<H54%F/F@$AUK3EB&K_
M &Z JUI#J-\8U99[JU549)XE\_?%;HQ<M&RMN_> *2Y+Y>C:1?:E>V>MZU81
MK,;A;O3O#YD\D1$NBS7TD;,P$H#F3RP2$+=3*Y:J^GO=ZK?S:]XIBCBN[)%O
MM-T&ZNTA6-0B(;^9&D<Q '/R\^5M? >0[F[ 7C,XC!DO9&=VECM+A4:>6!8]
MSQ S_NXA(OE-&?XW^;"EF8 KK>PV5O [W$EQ;7#_ &R:>.] 610(I&NHV>XS
M':H3AHQG[P !4_/CW^OW.EV4%GI\<FKWDKVSVT%G=/.]ZFR$K<Y,^Z"W+))&
MS,7!+!VWAF#R2ZJ]K]AT?3[R?5];O+0212"5FCG*XE6]8I-B&V\QW5E RXPB
MAE10:_A+1X%6QU":XGU.\OLZB]X\<4,]^QE58IU_>[XXXH3@QC"F.XV[=Q:.
M@"GX>TYK9!<2W-I<:QJ[HL=_'.L5U<A6A#-:N^7>W@CC#?O-YG*EB-K R=9!
M>W%S+8A%^T)=;+F5H[L(;@*R*)[<"9L0C;&[1]&2<<L^Y'KV]W;W/AZ"2\U.
M>XM;FTCN9KH7!M)+I D&Z[C(F4P0J"2Z +R3QS^\Y.74]2\=WMI9:;<R#1KQ
M/,N9O+:-[AHW@_TJR83'RQ&QB.QBNPE\K*X9% +EU<:CXPE_LRWN/,L)94N9
M;BUG6,W:JT<(FM)!-*$6&1&G8#:P(A0J3(S-L:98Z7%+#81:98^3<>3=0#3E
MVI>)"UM(MQ%B3;#"DLKMY63NRS#<6;?'8VMLUK#964,<,%ZBWUCI\<*&!"DL
M$D=Q'Y<VT)&98_,0.!(R,R ;CYDD^N_V?H]K?^?/JUI<11WVZ.7R;F\4L@B,
M$9D7YA^Y$D05%D,_RC<QB8 COM4L=.LK9M2UZ[:26R>87EO-M-X(TMF>[@42
M&((@!<Q;"6 DVJREQ)AV.FW'B&^L/$NHV/VIII4U.QTNWNA"LY6&V*WI4R9$
MBA3%Y9+(&=!D O,\F@:<NN:S9:UJ\,C_ &U$O['3XG8I. UK(M^=SGRY4:5D
M*[B1&!&F]4^?J-*O3>6^F0I?27DEY;Q7@FE,D'VU4%MNN(]C$1)A^82J[V8@
MX4LS $:_OYRMM#Y[7OE7,LUK>?9UU#>D,$ES 4G++'%$<E2.6\LJVX!CAZSK
MDU\386]W:3FYMUN+I)B1;F$20I//-&\J/ D7E3(UOG#F3!W$2A2ZUJYOTBT+
M2Y(]:UITM;PI>1O C-$P5KIB)!Y*).D>Z *'#12*4._>NAHB&W2T:VO9-2?5
MD@U!?+EDA>^^:V$UX[-_JPJLFVW4A=H*X;=MC (_#=I!8W4+VFJ7UWJ&H;YK
MVX:WB$VHLDMNKR$O_J8X=[Q& A64,X5=R@G8T^*SB^SS6LL \R*"4"QE%Q]D
MC?R42*!1%Q;2>2Q+84?*6&.J20SS27%K<+J5WY$Z*[R6EL9H+QB;8++&V9!%
M%C<NS(R'D?/R^97'MK%MK:1F!I+#0[%XU-YI\Z(7B5HHYX;5@B.+.-Q$\DX(
MX4@?+C: $MHWBV]TB&RNI%\/Z>Z)>365JL:2C?&(8[*6)7*Q"6V21]LF4#@,
MP*8CW/#UG9:?9Z+:1&Q^SQ6B[4L$D!5R;5O]%=0&DMF<[Y'8MDL-[8# 6-/L
M[BQO+.$F!;I8E$\%L@4P$"S5TLQ* !:8!+XR<D8._@5[W4]+L=,LKF1O+A3[
M-Y(TSYGB0R6@$5J%B4S6S%DWE<YSM )(5 "/5;]=,MTN=1-VMW9O&+G8S/=W
M3@6K8M"% >)Y?)A=%2-69R3L(PV7HNE2W']EZUK)\N[/V9]/T_2V21+6,_8T
M=K5E8XMS@"7@@*S!3M)>:3P_;&_?3=6U2UM(KZ!(4L[&U:3RH49;3?+:/&6S
M%M95?:OE_P &X+YLDNI;Q:<T7E;I[B-_*AA%@K0EHV6S7S+)HY T=HN49PI(
MSG)P,, 20SK9V4]O;74A'VV*QACB@81?:52!1]F1)01;QE)#)%DGY)@3A6!P
M]9U>>&6ZT'PLOFZE++]G:*&:5(HK=&CB1HT5V$4*&41R21[7W0R!54@R0FNZ
M_?S2Q:1I4$%QXLDB5IY[>61T@):*%I8FRVRW2X0>8AR3Y!#1%7:1;&AV5AH-
MA]DMI_[1N+C*(R"."YU(/!&TKV3^<BI"$^S@"/ 06Y R=K  DT/2=/T[2[>;
M3[N34I+R]EGDU*TEMUEU&Y.RXD,3^:%6)S;M$T0&3MYPJESH-*T21V5G+)%!
M:O&[QZ>JDWSPM$ACM5$Y\B)9%6.174* YRRY9ZDFU5(-1N$EO)Y6FNP8+>&5
M3]M:(L#';*LV]61A$LN_$?R.2JAW8<O:FX\5106T$_D>'H?($JZ?,(TU*]MU
MW>3IQ<J8X08AEPP!\KY-O[QR 1ZG<P^,M4DABDDNM'DN'_U%T$EU=H]R-#9+
M-*%2)(W(FEC*^9\P'!-=8D6G)*VGBZVQW<IM(;2SOFMS(L+( ;8+<#REA7<L
MJH%9BC':!A6CMKEFL+9-/N;34K=[(QF+1BL*W42NT8%H/M0$)BW+O;G.4 8$
M +AZMXLETW299#J7]H-?RM+;7=C<I&ERZ1J +4>:XAAC,>^9YB4&'RKB3"@%
MC4?$.W29W>[GUJZO<_9%TNX\E-16*-W9+/RIR\6QES([99N4&[,:K)H^GM,\
MNL7>J6FLSZ@\Q%S:R+BY"K.L,%BXF7R'2/S"W4YD?]X<,P-.L&1[C6-2@DNM
M7O7DBF33KM81-.%\AHK4_:!M"QV[.X;#,0C?*T01+$>HPW($AO)-1N;MR8VT
M[41%'J:K&Z.+-#>8C,8<%R2.4+ %MK* 7$U"XFE2&[OH'N)XKF"2"W<0O?F)
MI5VVH%T?*D3&68\_,F2A4A.;U#Q%/KU_#I>E7EIJ5XR,DVH:>T7EXV.?]%/V
MMC;W'E/,JEE)<J2<1HQ4U#Q'/J_B";2= OI+B+4$D$]_8ZC$/-"@,L=GOG=4
ME6/<)"(\EMC'RPXD74M;:RMM#\R.[@U/3IHGDE^PM)*-0E3S'5;,&Y8QW"F,
MNS#+._S;@P)4 T-+B33+.9;#3IX89(I4O=1L760FXC,BM*L.^4O(2C%BV^0E
MHE8.0_EV(+![+[+%*FR2"6W)2UA9H+<#?$KVZM&VS>H5'C#8C1V;<#EWIM>0
M0">XO+B2YN_M'D/?VT4K*DXCE3_0K9C-F5%X?:-O,A8DHZ#FS8W'C"\FEEMO
ML>CVF^:26UMQ*<N"S&R9K/\ TB&;GS.29"Q ^3 E *^G0)XDO---J(+7P]IT
M4MS'<:2%@DN 1&S_ &)$B,ZQ\ 2JK*^^X>/>VP ]A:V_]G1?V?+;V-@T43W<
M-G80;S8+MD1Y+4^2!,V63*;-RF9LE@Z*9!";&&-)[22UE" B&RCDNHM/VPS(
MLEJ3;D;]B!3'@*,CC+XES[_4+;1TBTW3]+CAN"EPFF6%M&D)BG5IE22!9(0"
M7!;S&&]8PR,5,;M(0"GK-XV@6KH+&=[Y(C:PQZ?%<1[)5B,D2V0\AQMD$"&2
M/<8D\L!@^6WQZ7X0FM=4OKK5HI)=6O4\NYU&WC,8L/.WA3IX6)B!OE<.S,K
MJ9'&&R2/0K&SN-1U6]>.[UB^>2V:XTQ=GV-,W"LUB"K$3\222Q*[-N\QL,=J
MON.+>&\EEAN((H7EN'*0*9S#/B<&6T)C(:X(23S(0&P2QZ[O. ([@PQ.NJ26
M<=E;Z>[:K+>2V0S;VLBREU@)B#K*YB5IE9=P$S@,3M(Y^\U&>\NK[2K>:1X[
M5YVO;K2TB4P7(BE9H=/!3<UU*"SR LYC#.H?<<U)=WNHZU='1+9/[-%O]HGO
MK^T@4[/+EE25[!5#.UQ*)/G(+^3OVG,A(.Q/ FB6YCM=/^P>1F465O$L@5S:
MS%CIH*[3,6!!0@9"NQ0>9N< N:=I"Z-I<6F_9X[:#3;)FC-C;LXMG'F*LMNK
M1,6E=6D+*6<J=HP^\LV?>;=+LITU&UNX6@1'M8-,1G,4ZH1$M@FT[CY8='4E
M5Q$6:)4E<DUJ[MO#PU'4[Y+NT6W>:1(X5210&CE99[1?*(:?_7%PV"/,E,A:
M-8R<.VT;^U=8@U[7$@MKNWED,%I$/.CLF*W+N;38"D]SYBH9 Z,P>"1@-ICH
M U+?29M1UF]U*^6,Z?9:FUW;V=NAF6W$+2@2QA(RCSR2?:#)'AI!YJ'<CQJ&
MV(],E@N!'=QQLDCEKJ.VBF"Q2REXQ<6SJI,;OD^8@;Y/,+[Q\S2R77E7/VNY
M/GW>V4[K>UWSX;][;C[/,-GDS'@/AML>&SMW-(>'\1>)42<Z/H[07VNSVGGO
M'I<BE(HG2Z+7=FNX$7)$JR,@8LRN &89D !H:SXA^RZBFB66FV.IZQ+:7!N(
M8++SK186-R)I?E&\;IXXO.C)<]%02/R=2QT2TT&66WN?,E:5WFO)WC>.2XG>
M!V>>S\K)\TD7 9%_>@-PP1(E:GHF@Q>'[/4 !/KL@^TW^IWUNCH]Q<.9U)M0
MCE4N%VM$RIL/SH=P*[3N7[0V]A=O;SR("\KAM+P&N)$>XD,5O'YA'VA64F3*
MD288,I&0@!'+*ABN9]2NH)FBBEN)?)N5",8EE@E:V9I%>VD ,8<EMB;MH;<S
MR5S8C;QY;VZ)-:?V"4ENY+73PL<M^^"[I;,X4A#]I\J:4LI9PRE8MSYL:G$/
M'NJ2(EQ(^CQHYDBM;F-QJ:Q;@!9N67:&6X\N=_EYVQ!L;VK<O+FW+7-S--/?
M0R1?;(/LZ%A<!HK@*EBXDW+<>4@W;&P1\RJID8@ L/9V1EEO+8_Z1;?:-]WI
MZ2*($9I]WEQ@.DLWF#]XF#N=59ERL:T:I-;Z5!+-=1_9(XY<@VUN9?LSS/-&
MDT&(#YEQ(TBADYQOYR#^\KZCJ]AI^K0W-[J,$DTLHCM6)C>)3%).'6&'S/,:
MXVOY+% 26>/"D!E'/Z-H]Y+/;ZUJ-G?0^1Y\NGP+;%)]&MY4G!E)^?[5<2[(
MRZ-O=7DR1S@@!HNG/JNL-XDU6WGT[4HK3[5;Z7&K&31HIEN \J*J%9YIG4L5
M9-P/!R0 >L5&1);K[#)I\XMY&D2&%9'M$D:5V>(K$PDG=EC+Q@L,@'YN#)36
MT^RQ7EI8BQLCIDOFP6EK9;A8Q[9&66.,1[IFERRL$VC#2(C;T9GR]?U68WL>
ME:&D:W;/-.]Q90&X32\/<9N !;,'EDVS(\98,6RB\LST 1^(-5ELI;&TL;"?
M3M2BM%VM#"DL6CV[LT2':I02R2$(HMU9QNB!57,:^9H:7H6G:5%-''! NI6/
MFR7$T,32SP-*LA:[A\R-Y9))?D!!9U^0H&8QD-7LM(BT#0YDTN'[)#Y0GA:/
M27EEM9I//07:HL(+S,&B#0A5$2@CA< W+R:'24OFCAC6TL'GN;R2&42/IK2-
M*YN(M\1#2E)6=XRWR*0%5PP#@$E\/["TY)!:>5#I]I]ME;?OCM)5$CLXE>$O
M)Y@\U)'&Z4!E;8#(S5S?P'DAE\*Z]);F-H'UVX:,Q@!2I2+& $0 8_V$_P!U
M>@CMK74?$.W6KBRGM]$LM/2?3].L%4NF,R12VCK$OF*?)@(MY<?,<N@"1AK'
MP49SIWBH+8P6=K_PD%R8X8MR^6<)F/8R(551M R >H*KCD ]0HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *Y_P =_P#)//$O_8*NO_135T%<O\1[;[5\-?$<>V!L:?-)B>+S%^12
MW R,-Q\K?PM@X.,$ \<^ _@VQNM4\21>)= CDO+)+9%@U&VR8A)O8_NW& 2%
M0@D9QTX)S)\3K&WTSX(:?86<?EVMKXENX84W$[46:["C)Y. !UKH_@[=ZG/X
MW\:?VKJ-IK-W(EDTVIZ>\;6[D(P505"Y.TXX7&4;)!QG ^*L;0_!BTB>:2=T
M\47BM+(%#.1/>?,=H R>O  ] * / Z*** /M.TCFE?QU';B1IWO=L8C)#%C8
M6V,$.A!S_MI_O+U'A'P6N[FYUF;2M%M9(KB2R/VUOM3I'.BM*2[,&S&?WD,:
MF-2RG]X#@/')[6NHQ6UWXWMVTR?46?4$4VPMG>.16L8,AF",-N$;< &;& %9
MG16\@^!%PD]YJ6EP19\VT;[1:RA7BU!R'"K*2K-%"JDC*H<LYW.=T<9 /6["
MRL=.LH8()8[V"YN)K.;=#YDVK/$ETKV\@D^53E"Y?<%DD\TX7S"6T+^[:(7<
MD\MW# [RP)/=WRVBS;8[AV!& 8HEZ"6,>:VP,=R)O8UN\AL;*[N+IY+B*9)X
MH[>]D$27C(ER[02*\8CCB"J2)>-X5=S, -_)PV6H^.+Q[V]AGN/#]YYJ6<4]
MLL*:E&!<-%YY13+%&/.3RG.1^Y+E5>2/(!<:SU+Q+?SZ[?Z/(U@UOY=KH\]L
MT3ZG(B2R1I=+)N6%(S(Z G :0!\X\I:W+^V>>*UM[J:"::XE-LLLT#6\VH/$
MMRR1NRIF'85659DZLK,BJ&4&._LC?W]W;R>6YU%);7RYGD634+=$N 8I (A]
MGB228 3+N+#9DDNN[/\ $>I16=[+I]C!)J6KZFY9;.6XACEOD1Y%>VD2:,[+
M<1B0JRC#[7^8,X:4 CU[6[(+*MK:?VE=ZGLN+:&!I+2+4 LK1*3*Z&.-D#0%
M9E</(RP[<*8PTFC>%#9)J$=X+O5+[47#7FH3^9"FJ3(UQB":/#^3 BJ@W* C
MAE4;E.QI-$T>=&N;R2V^WR:O$([J\O$EA?4Y(XG01W%LUOMMH>7 8<G:F=Y?
M#27\EM>)$UQY>LG4$N!:VCVB(FHO&TTJ6EQOA(B,(&%W.I+"0LN5((!<D-PV
M^\O%@\B^W6GV;4K4(TQ;S MM.ZH0JK)E4D!9'64KM=F21^/:]NO&D\FD:-!.
M^A?)"]]<F>*;58@BS+;R3"$M!"J3'YGRTH("L2[M6I<O?>+M9N8]+N8VTF)Q
M%)<%,_VFX9;A+:8B#*6XB,BAP65UN$.9"S*=2*UTZTL[!+>RG^P/:-86[7ZM
M"DZY=([.Z1XMRQ\J(W968\C.9,3 $D-FVD6\MG86\DD4J);EY95LYK\H)D>*
M%$$2QRI'&A60* Z*@W *)%I^)]7M=(L?L\"^;-J%V8($M)I[6&[F\Z4_9TEA
M=O(N-Y^=V"B0A@<#=Y<EW>VVD66LR"RCU0[/(O)[FU3S]4G"3!;601QJ$./)
M",R%76954,74G#TSPHB_;-?\76GVN?S;A(M,V+.UXL/FK%$4EC!N)$CC+QS9
M$CK(P;Y1R 'AWP[<3:C'XTURV^U:O<11Q6EI.PM)K@@^:R31&)%>XBV$(W".
M(D;$>T..D$JWEE'*+V35!J3@276EWS0Q7)C29A'; W68G!B4,5.&R<\;S'))
M;3KOLUFOM2TZ7=''-:7<IF_<^8?LYD65?+D#C'G$_,%,<IW!6>GK/B*[^VWF
MFZ;!)J6H7"-;+':3HN8][CSE N08Q#B2-V(C,DNQ0R8& "3Q)K=P);2RTY?,
MU/4KO[+;BWU(*C"%IBS*Q/[MHM@:3]TX.1$1)GY<O3+-8#=7-SK%W?/JKRRW
M,K3M;2SA)%\JVM<W*O;!)9S'L8$[]RL4RN;&AZ6UJ;RXN-0DNM7NW2+4[FVV
MQ'5)8[:16MH7WH \;!F#HL> @4DLDC#8%XPN+JTN=0CNI;E[A+<07:I)>Q(9
MB8(%$B>5/$S!&<=0JDL#GRP".[DVSWLMG)YEW=_:H?L\#^3'J31H=JI*KGRK
MA,",N2&(BD.S:B&/G_,_X376KVWLY-WAZZW17LMH_DMJVR:-2807'[N)-L<L
MP/[Q2453A-L>^Y\9/<Q?;I)M#E=HKNXM)GA&N2QJY^S6<<DI6.+:K"1U8>85
M8 A0S#J+56C=;6WEC,=LGF+;:?.JI>>2J(R0H9 8#'+&JE-QBQ)AMS.VP II
M863V%K!<-]I\_$EO'9/)#;7J10$Q"T47!CA8!E*Y89,+2 #:LB&NZO;PQ6_V
MU_[534+2%H;?3T+/?&-997>U'G_(R_NY X&1A0'=RFPN6_LV*5XA/-'+=K:X
MTVXWRZFNV2$1Y>4,EQ%@&27=N*P E@ 5CR]'L%N]4-_K(CNKG64PXM%9(GF'
MD*1$9&5[>6#[.S,F1(VS>/FB\N( T+*TGUBWLM0UIX[S4+K3!<-:VS1>7(A"
MOLM&$NY'200L9M^&+J=W$?DZEU=I%+/</J>^&#S[R9(KA42X6)L%$+3 QM$8
MXE?)6(^8^Y<N=D=W%]HLDGO[>[NEF03RI!'=9DCV0[G6(L/L\J2!'5 6D 1R
M@+LV.3U:[U3QUXAN=+T#4[Z&RMHD,VJ:;<;(Y1(\@A>'$V&\LAEDQQ(%F&%>
M.$4 23ZIK7C77KFUT"_DM[6S>-I+ZW8@L#),();?;.T,\0P1*K %A&PQN"I'
MV$DC3ZR4AADMT:X$K11%8WOE5DC:4@F.0&)D3)^9'B8 ;]ZA([5=.T>ZT[3M
M(B@73A+,;>TL)&+F8RL)RP#!%AB+MN#9&YE4!65%>.SVBXND>ZCDU:1\.+EV
MM9+N5"7B$>UB\=N#'.H0JVX*[?."S2 &?+JVGZ180:IND<:A>PP2E7FB:\N0
MZNSHOF,R% LR&!AO?REAZ*BMG^&_#DUU>Z;XL\1V.I/J4B)9V-@Q+&"WW^<A
MN<GYGB;=AW;)"1DJ)B!5C0M-NT1]=U6SCN+V^<?V;87R);S>:[+-(TN6?!#1
M1E5^=XH;5 ,N&%:CV,4T2PW$GVB\U2(7(4[[8W<J*Y!>,1EK98\P 2@^:"L2
MLQ95#@%RR$VHZ;]LM9([J/4[)IUEM4-E%.S10JC2-EIE<X.UE^ZG!RRJ3CZA
MXCEEN(=-T>:.^U/4G:Z@C0S#R@A=09T+J;>)'2%7Y)D;SE\H,2*R]5UI[V?4
M=#T31I[J_N-UXMNRLNR38S1O>3$[H&;:AA0%73R8@6C!"IN6.FS17$K;H]1D
MDN'D:X<F:.\N$+NL3.0YM8H95DPF"%/EX<N71@ TFUATRX"3M=W>J7]PJW=R
M;<6]Q?R0F,>>-C*([>,!E*L,,",;_,'G7+O<\$QOO(DMXXOMLCW/VBWC:ZMG
M3YMS96WA#1*P&6WAF8 A6+@BLTBG?S8)[75KL7#22RAX+Z&18H=KMY10?*Z*
MD:G,GEIECNDKD[Q1X]-]%<P78T-$CDG*>6\FHQK)'/Y3M#&S((0[>6BG,XD#
M(Y4ER 2(C^-M1L5=Y[C0)+22]M[/4F:)]7GA,2+-( I5;8[HV"!4W,Q<QL*Z
MBS\^YTFSDBOI[]I/+D2[226)+ZXCC8'< C""W8Q(X9#L?=T8/B2-[%KBXU.,
M0W>S47:U:21%\JX5BP9W0PD*\:(Z*679*GDAG?*[*^KZD+#1/[;N](N[F7[;
M$HMFAC^T3*KDK&^8]H,3LYB"L=[)%MD8R_, &JW$.FI<2&PN[^;4;WR#9! /
M[1CW>4ZNKQK&"BNQ'(,D5NC&0HK%<?0M/FOGL-0U:>TU+4-0LH[JW>*,Q17L
MBK!*DF57S(0C0('9D(?S(<]$ACDT;PS<7FR^\0V7VRZO)0DL-V ZR$X\Y9D%
MOL78L$ 5U.R1K:-E,?FMOV+_ .T26;ZB+*>;S8I(I;*[@&;H9E+07 CMY&$<
M:[O+*$B0MC+;PS@%QX]0EN+0B:0Q/<(9]@N(?/G0[7X(;R8 L1<*#ME8J"P#
M$R\W=W-_J\!CT*T\UM:EN%GN;E9%A9(GEB>*=&MB(Y A15+)\QBVNT@C"RUY
M8$\:ZY?V.EB=K2*57O\ 4&"HI<[,1;'BPMPD;21N-K9B BE)9P8NDATM;=S'
M8V$<%FEPS00%6(U"Y52?,NB\#.A5X@5F#L7.UB6)4$ KZ;HVFZ,;2PMX8Y))
M[A6:YOH5CGU&6*1R_G-Y #.@_>QMG?(4+9VAG,>HWMOI&CWVKW$'DQM+_:<X
MU4F-7EC81F.0K"ZIY>V#RC'EI&C!4L,N\E]]KLM+U*XG6.]3[/):">_B3-VB
M[V<W*^3&B)&!*$RZQR!^67>&KGX+&^\17\5]>PR:G8R(!I*7B;(]6@*;R]\8
MH7C5%+EH%948'.5W$F@"2UTF\U^7_B9QWRVM[*ZQ1W$!S>^6TD9N+R,VHBC9
M8S&\2,HWE(PY;:NSK(["$7LUW]BCFENKWRV,ML%,_EN&624B $&'9(L1)VL
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M("@\\O;[5=S&X(PAS8AN)IK^U1M0DN3=.MTD=H"L5W"J6P::-O..Q%D93MW
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M*[6RTC)<T#3X;-Y'!CN[B_>&XEO8+D>?JVU;?_2E/F#9 C.X,0RNT@*,-M<
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M-N_E7#K<VL<D1#;P'#X9]A.T"0D[X_@;ILVFZ-XEANVC-Y%KL]O/Y!*P;D5
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M98WWB,OLR[=H\WEW]U+$\^HR2YE^SV=WM,S13A L2O<!4\K 68857+C/.4H
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M?+!;#1?N.PU.&&Z-Q(L%I?7-VZVF\3");CRY)S'$C"4M'+ V7>15+#8Q52P
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MC1O(9BJY^9OF! Q8U&\AU/6=0L[)Y++3[-WCU+4;.0,MI,6F"I:#RR3>2FX
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM1MO)9C+N6K373VUA?3QZDDSVUY#)'EC?K"L!>Z0B01PH)7A;RQU$;D!_,X
M+D#?;KP7$P@EDN+06Z36%QY;ZA;L(2;B/$HV1QM+)CEG7=E&!?#\_J.J7FK2
M_8]#E@.KZWI5MMO[<%3]C+ &Z"-*K0^7YTY"?,S%X\,=CA:>O>(9KP1PZ-<Q
MW6I7%E%J:2W+FU@M(S&%&I1,Y8QQ DH\#9+#/RX+F7I-(T)-"E6TCFG::>5K
MJ]CC=8WU*Y+6Y>\7]YE(U.0T8P#N(VD;0P!32ST:\T:34+F[D:34],@%Y>IY
M%O\ VC"BQG[8T;G 2,2G<K  J61D==@-S7;Q[#3KQ;N]GANH/*OIY+.=H]\"
MA$EF19%<*L9!D,*%L[4#9\XJTBW[+;P7=Y<QLCO]HF:#452">!1$?MD66)6)
M<1[H]RKAY<^;E3)R=BC^,-6C@N+/_B01W9FDTPAK<ZE*LACFN6BD)"PI,H)M
M]P;+&23+,BR %B#[1XQUA[DZG!>:5=6D,*P640M)9%VC=.ZRL7=4:;<8) 8C
M%/&P\QCM;H#%/'9B:UA^S-'I\*PK%ILL".L11]Y6,F7:F\A+4E&;]ZIW!MRD
M%RFH:CIUO/JL&K-;[IK<66WS)@#;E;AW!41LB3X95.)4E)"X;RQ7_M/1K'2;
M'5+X;K&]N[>XM)K>%X@T[Q^9)<I^\/DPE"[.K;<!9RV_S#N )-<UJVM+U91!
M::L-:MXX+73H DCZA 'CW.KD!<*MQ*QC9F4J P9!YE9?A;2)X=)BUS5=0GUF
M_OO+U4SP+*L,BK'"/,1$A!CD6,L@08:92P8$';'8TK2+S3IYKWQ)=6)U']S<
MW+M=&&.9H$B5[R+!_=;4=XI!M"R!$SY:N0=R&VFEN+5ECCF@F19W2ZM2C7;*
M;;;<3-Y0$4Z!6VQX&["_=V?( 1F*SU246S2P7LD]I"R2F4(;ZW#(1<>:D0_>
M1L791$V%,BME#(I7E]5O+CQ'</IVERSA&T^&34;V>V NDBANG >(Q1-BX_=S
MXB8*R,4**CK(HL-J&H^)+R#3-"EGDM9/(NI=6N'61#&!9R+($:!D2X*E]L7R
M!<&0K\RFM#PM!HECH^DZ;IVG_P"BRQ+<6L,<416^B5K?;>N2JD2*&B8YVMNW
MX5]J-0!H:7I=G:Z=%I^GQ07&F7,64A4AK2Z@80B25ML7EQL07(C3"2;F;'S,
M4KW^JZ780--J\\ CEM((93J,?E?;+61XX_,GS",,C22 QC"KYHW[!(-M?5;N
MPT^U%[J5M]HLVB#LE]91QM=#RD%Q<R';GS%MRX\K:CE8YAM9<;,?2;2X\4_V
M?KFH:+.T;7<%[8V[R!6N43[.L5],\9\M9E1YB8\#>N%P1$I !):Z*OBNXT_4
M=;$>L6\EO;I;QS6#1Q72 K(EW(RJP5_W=T1&3@),B$1F5P_06ML;VXT\7L<E
MY?Q6]O,9I;62WCNU4KB6;]UA)49IF2 L<$AB <,DBP^5F\D2>ZADBBN##+:?
M\?'E^23<RJMN'6Y  "Q]_+7 4@[,/4]6TK3+>"TMDDUN6\N!+8VEE=QM]NNE
M%O.LKA0ODG=^]8H/*VLSODR*I )/$/B"#3XA9Q6_]IZUJ6G^1;VD\40-U&5
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ML$$QQN3F+D,2JE"HE*JH,?-VNCS>)M77[5!)<:&B;($NF)-_"DZ?N[MMK$/
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M]:UNSL;6PGG:#4+Z[E63384N1%_:%UY4>R2VD:8B&$@LK*?O;R/FWXE "_\
M$B:+9Q:C=V>+B;R;A(!MLI;QP3%/*4:4DJD.R0I*!Y:A=[ J?+S]+L-1B_M
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M)4L(S<DOK.VL[>ZUC4;&2SBE6[M[CSA$7W&'-Q%*]P<0AII%*YY218P"N/-
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M.TDDC8W!OGY^QCMM>U&'5=<\NXN;I%NK70;2[2/^TB]O ANUC>924*I.FR3
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,R(58J\C+UEA8K!;VEO9PR11%(GC54:U\]$%N/,FV0KY<JJNT1<!E!4C&1&
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M83.Q /[Q8AL.UG%<_JEX;J\AT/398+G4_-BNIM3U*VAQ9&01K#<3H8DQ=_\
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MUL[=Y>.UTU$@GO[N\GN[JXW7<<]I(MQ-( ^Y+JS)8LL*)<,IAPXP=H#[V,X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>KNV7/J4NH3VNCZ9%NOM0M([PWDD*31H"B>5=SM'"T9N%:%O+0,(V$7WQ^[
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M"M+GQ1K-IJFNO)-:!+74=+TI&<;R65Q>AGEX*-/(KP@L$7RU^<"(M'I&E_\
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MGYVS)X?T5-+LXX85@U.:?4!J8NOM*I+J#R&#S;V(HP$<:"613& =Z[1G#G>
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MJK3!HI41X%1@OE_P8W,LGF+OT+.^L8$@5YHX8)T?4;F2)_)B8*P;[5&XF*K
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M6TH3<KHD@<99V>+H+#3AI)CL8;61))+V2>XCCO(TDO<R1LUX2H5F(8H'3Y%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5 AN-1:-[7-Q(#&FV:+ ;82J[$.["@^7'X>TS59KT:CKD<=[?W*(P6>*00!
M\,N^$,I-L4+[/+8!I6MHW.TAC4=EIPCE:_UJ:>\U;48H=0DMMTVPQ6[02?NX
MQ"'C\F1VV1<L^_YRQ8[-1T6Y,-N+&[NW=[6[(>%K?[2!);XN9W\I L\?ED^2
M""53!7D!0".PT=_L>EVAB@>W6*"5HUM&M!=/$;4I<2;8QY$B>6P6 _>  ) 4
MA>7D%Y\0Y;>QL+2"X\&W>V2\OYG,,NK^6T(:3Y(1Y4B-%L*MMWJ3LP%#)32<
M>.M4\C3DCN=#O' NIGL8X9==MX_LL;.TCH"#"\DI)4(>%6/YLLG:01V]TUU;
MVTD\MQ<2P-*\D1):4Q0E;B4- 5AN(T@W+'@+GR]P4R+@ -!M;.6(S6%EYMK?
MRQWZ23*!%J&5MF-X^(L13 @E4PFYE9L#.Y*;30Z5I<>J7-C)->WR1RC^T+0(
M]RR^4\7VIH;8^7/&Q,<: '<< ;G(VV-3O;;3K>"YG:25]@OEM'A19=4""W3S
M)5: %;A7:,1QJ5)<1C(Z)A^&]$U@^3J^N+YFO:GODM8;BV>2&!6^SN)+G;"H
M6XC$$0"YC5C"H7:Q9Z #1-%O;R*\U+4I9]1U-Y7NK:T*1J\!*P&.696B\J._
M2+RU53M3CC&Z1ZZAXT'V*663;')+#,?M42Q+?']PBR7!: >7<*Q79&"I9D4<
M $))A8[=9WMI+A&1+IA+:MNN@@@/GS*L&5N$V_)& "=HP!C]WS][)J=TC:1H
M7F7=_,\<T]_>6D>V(,UN5GG7R8U^U1*04AR#L0,V3L4@$EWJ4M]J(T718OM>
MH+]FN[N26%%"J3!LGNE:%<7 V$B$%&,:,0481A;&A^';>PTS^Q(;:^N+2?-Y
M]HO6*/=F22-WFFD$0DCN8S]P':3\IW;E)BDTS25T+2XX;'2Y+NS=TN(4F9FN
M+^=MLKSW/F1 QSJ8SL+.%+$*2AV[;$OV2P3^TKI9'BE2"65[J)U294:#_2KA
M?) AG3)/1>$!8J(_W0!&LEO=0&2YMIULT\J]>ZOHS:)<F%X=T\Y\I6CFC\G(
M4A4=<8RN?+Y^TM;/QG!9:KK%EOT2Y^RW%E;:FH@:YN%<0M<W)2+;YC(T:QQ[
MBDB]@#\AI^EOXK\0Z9K<XGO-(XO-.BEMVM1)+"\"?;;ATQNF9=QC0IM:-1]S
M+"NDLX6G00VUQ'>SFXCGE:]ME!E :V<O<!(4\JX2,@1H<' 1B#@[ "Q;/,;B
M.'[%=O!,D-S]I2(PS7; PKYDS#RQ&ZA?GB9?G3 7.UXQS]_KEI8:7]@VQW6H
M:FYDMM.T>\>-]1D?:Z7$#I+FW@;;(TA/&=YW-]Z634=0N+-OLEO<SW-]JDML
MT$%K"(KL1^4%6[N0%5HOWRJKNT;H$1$\OEA1H\S7-Y<ZM=7/VV>>**]MY$%Q
M$)[/%N^^UC!=HU&UA)" S2/Y>\JKHM %C3;:\>Z_M*ZF@U+4;R56B^SW9CCD
MM1+;XFM?WI\N$)M>5,'S'X)*[-VA:-Y<6G6UD()K63RG*6MQY0FC58-L]JHE
M(6W4[0T7 (8GYLXE(6^[)9B"YFOY8+J8V]QY7V['V96NH2)6Q"B8RASOP!G#
M9?CSJ6J>+91I&A:M?3VD?DQZEJ5M-]G>\.Y(Y+BV?YEA5&B^Z,)-NN F60M0
M!8FU:X\:RIIV@ZU/]DN8HI+N^TVY$;N=UN7>%6<M%L4;3%G*^:[.N[RA/N>'
M]%L=+T;1M,LX)+NTM4BEAG@7"SN%A7[3%()-D2$/(63@R;I2 P+>9)H^FP6.
MG:59V<?VJT7RY7$-K$;2\XA/VF(!MD&)"L@4$9Q*51V(<1C5[&S\-6^L:G?R
M75F+>&[EN[V/9;70 MS]I5=KF)P<%(1L+/NPI/S@ D%_;Z?:WVI7CP"UDVZA
M--93'=?)'%;;KN,"3*PH 5:,;]RJ/O;MK\_IFBZIJ-U9:MK2SW$]O:126NE7
M%SY4]VR2QSO=?>'E-ND"M;']V'CB!;:L;*:%I^LZMK&F:IXHMI[AX_*GLM.N
M)DC8$*(WO7A+$"8'RV,0VI$LN5+RD@])IUE<VIT]3+=W,4]NEQ<R)"\$UY<F
M2'=-*6V^4$4#]T6RR,R!,1!2 <_8>-Y]4UF.TM-$UG44E>2;[39744=M=I T
M<;3Q%Y?E FC"^2' *2%VW;\'/N/&T^M7%EI-IH6LW=[JNF+?_9WCB$+!C%Y=
MVK"Y)@">4[+&'0EV7YE<AZ\HTBP;Q)XJUK1P)-9<W%_+>ZA9*L7F1.\0%R0C
M$W"*Z^:MN@'S8P6W$#TOX?>#_"VH^%= DNM#TJ>_NK02JC887$<4T9DE=L/M
MD1I&78' <$*X4?)$ :'A6_2RNK&"7PCKEO/J,KW4MW) L=Q<2F6U6:X=1-O@
MC,NTO$%963:WW0PK0T/Q0GB6QDC5;Z!CI\>H?9KZV7S'#3,?M=LFZ9_E96*Q
MLKC(@"[0<MP^J_#_ ,-7?]E6%M:P!;;2I[B6\0-:K<&/[+ TDS. (60^>S("
MYC9=S(Y9HW@\ Z)9^+?$(C.A06NGKHEN;ZT*B+[;)*[%Y7,:'RU^=Y(X]R%O
M+MV4!54H =G/)#XFN+?SC'<Z +@3.2!)'KLEN9$=@84!9U5$<QLC"4PA8P$1
MI&Z2Q>WO)["S-YI6J77R7;R0DK]M>-+8&Y?RQL5E6566,AL_N65EVY7+MOAU
MX9>XCE&@6DR7"0R)%/9+$LBH8=TTF+=3#+U'D A'PV5&Y]O/ZIX?\"Z9;MNT
M*/49(D14TZ*V2*>?S0"\KGRD9)P)B!#O"@M;A51Y(@ #H-1\26VC^'],NF^R
M:SJ&II;R6-OA+;^V92;55N&W1_NY59E*KDX49_A^0T/P^=3N#KU]-'?76JW$
M%_";?S([5[>,Q;' :,M [!8)&BWDNT"#=M#!<?P[\+M%E)U#5="CFO;ZW>$V
M\T0B@\@R)F7"0J(9PC;5 $;.%W%8W:0)J6O@KPG>6MHUIX9L;^UU2(,L_P!F
M2-9(&BBS<.PB4P28R%CBVY9RV!\S1@&II%U;7]_YBO:7+RI#=6DD.R*_O+9T
MM<73D.A";T8.NP!EC1=ORA6SYM:5KBS\-:'))]ME2">-K2-EMV2,VI$T>)"$
MM=A<>6,"0I(@=7.7Y_4= T"[UNWT?PVLEIKL=O'(1IK-9RQQLGEK=W*+Y2(\
M?GRL8@OF-NC&51F6I-"^'7@G38(;^R\^_5;1$9]/O9-]Z8GB+W4(BGSM5S\R
M?,=T:; "!Y@!U'AW0[/2[.W@AO)[Z2YNSJDL\-P(GU*9S$6ND$<JK]G7S,-&
M00<+P3@R"RV<&?(O]*3R-/BF@\HA-L?[G-S%BY&RR&Q=T0VAO+;ELC=AP^%_
M#=O>P[KV26SBTR"26./79HP8HG1HKJ%?M!*VZ%Y2=[':8UV#))?/T7PEI_B?
M3DBNFUE]&N'>6&W?5)E?50UQ%(]UY$DG[N!69L9+2,L@8G?M+ %R#2O^$NO
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MQNF!VC<\#;DJV9LVMK V*QF*.()=VXC25"3ML;A?*'DJ%N8Q&I^?Y\E& 8.
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MVK&2YEC47S;[91=P#>51%+!M@49D*[<%@7CL9/,@>YM)/MUS+^\=-_V2>_\
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M+WFL1Z9IMQ]IU>]B007%M V8@RPN]]'(9F5;083]UC$LB%<MEC6AX8TJPTV
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ME5VGE1]I.X[MHP<<$G/&" =)17/_ &/QA_T'=#_\$TW_ ,E4?8_&'_0=T/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KG_'?_)//$O_ &"KK_T4U=!7/^._^2>>)?\ L%77_HIJ
M /-_A_=6J?'GQ79V5O.UO+I\4J3:@DYNTV+""NZ?]X%)<DANNU,< 5C_ !<_
MY)#!_P!C7??^E%Y76>"8]3L_C7XXM&FDOK/[/9M<7MP(Q+YOE+Y:X0*N"K2]
M%_@7)SUY/XN?\DA@_P"QKOO_ $HO* / **** /L^/S_)\?\ V7_CX^UGRO\
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MRT7S$2.:L>(=5ATU"&TV[U2XU!WM+>V%H ^H,&F!MIBT01($#EE<M\RJ[?,
MQ>GI/AN\MHI[V^CL=0UK4(OLUS<7%B0+MPJK-%*?*!2'%N5C<80B0$QR, 9
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MV-RK.S%6*(9#( 9?P$DMFT;Q(EMJD=X@UB1E2.%(%V%5VRB( &,/@_*>!LP
M,-GO+34-8UW3+B>P-CITD6H7%LC3QO="2.&1XBQ4-%M8LA.,L /4GCA_@6WD
M:=XIT[S8)/LVMRG*Q_9Y#D!<M;[1Y*G9P/7<N!LY[CP;_P @.Y_["NI?^ELU
M !]C\8?]!W0__!--_P#)5'V/QA_T'=#_ /!--_\ )5=!10!S_P!C\8?]!W0_
M_!--_P#)5'V/QA_T'=#_ /!--_\ )5=!10!S_P!C\8?]!W0__!--_P#)5'V/
MQA_T'=#_ /!--_\ )5=!10!S_P!C\8?]!W0__!--_P#)5'V/QA_T'=#_ /!-
M-_\ )5=!10!S_P!C\8?]!W0__!--_P#)5'V/QA_T'=#_ /!--_\ )5=!10!S
M_P!C\8?]!W0__!--_P#)59>K^$=>\0/:+J>NZ:8(78LEOI;J75EVL/GG=,X/
M4J>"RD,CR(_:44 %%%% !1110 5Y_IB7&B?$?Q[J4MG/<1W%I:7<45J \C)%
M"R@!<C+.RR*H'>)L[04+>@5Y_P"-+:\BE\67RKFS/AH-DQ' FA:=T#,2%93O
M.8\.& (?:I D -C^U/&O]G?:?^$6TKSO*\S[)_;3>9NQG9G[/LW9X^]MSWQS
M4@U#QD;AXCX<T8(J*PE.M2;6))RH_P!&SD8!.0!\PP3SCI** .;DU#QDCPJO
MAS1I [[69=:DQ&-I.YLVP.,@#C)RPXQDB3[9XP_Z 6A_^#F;_P"1:Z"B@#G_
M +9XP_Z 6A_^#F;_ .1:/MGC#_H!:'_X.9O_ )%KH** .;FNO&S(!!HWA]'W
MJ27U:9AMW#<,"V')7(![$@X.,'S?4)-2E_:9\*MJEI:6T_\ 9D@5+6Y:=2NR
MYY+-&A!SGC'8<\\>V5X_XA_Y.A\)_P#8*D_]!NJ .\\1R,/$GA"(0R%&U.5C
M*"NU2+.XPIYSDY)& 1\IR1QGI*Y?Q);;O%G@VZVP?N]0GCRT69!NM)S\KY^5
M?DY7!R0IR-O/44 1S00W*!)XHY4#JX5U# ,K!E//<, 0>Q -1Q6%G!*LL5I!
M'(OF;72, CS&#R8/^TP#'U(R>:L44 1S00W*!)XHY4#JX5U# ,K!E//<, 0>
MQ -2444 <_\ \>GQ#_O?VEI7T\O[-+^N[[7[8\OONXZ"L/Q!&MF]MXB\Z.$:
M6DK73.&(:T9095X!((*1R# ))B"Y <FMR@ KR?5/'.L>.]<N_"'@>*>SCBVI
MJ.NSQO&;1>0ZI&P#"3C:,X;(;  &\&N>,?$'C/Q;>^"_!/\ HEO:[H=5UN1&
MS;'=AA%R,-PRCNQR5VA=]=YX8\*:;X4L'M[(233RNSW-[<;6N+EB[-F60 %R
M"Y )[4 >;_$#P=X0\-?#ZS.M:/=WQ%PBW^L6"*+WS&#%IV=\[@\GRE7; \P8
MY517&?!7X;6?BC2=1UB_G@DM9//TQ[:2T$CIF-&$T4A.$D!88.T]#Z\>S_$*
M[2"PTFVN;O2K6QO-0\FZ?5K=9K8H()I '5F7^.-,?,.0.O0\?^SC_P D\U#_
M +"LG_HJ*@ \._ >ST73M:L[S4+'4_[1M&AAFGTH>9:288+)&QD.,;B2!@DA
M>1CG'\:?".S\->'(-7L+S2A:^']UTD.H60WWV75C'<3!@),D%478/O!>^ZO>
M*Y_QM,D?A"^AEM9[J.]\NP:*WD5)&%Q(L!V%_EW#S,C=@9') YH Y?3/AOX?
MUFSMM5DMM#FAO/LMPALM&6VC:!"95"HS,59RP#DYW( FT'YJN0?"O08DLP^G
M:-(]O<?:6)TM,2L[2>:C#/\ JMLF(T_Y9F-"2^,5L>"HVT_1IM!DFDG?1+AK
M%97"_-$%62$9 &2(9(E)P/F5NO4[E_?6^F:=<W]Y)Y=K:Q/-,^TG:B@EC@<G
M !Z4 ?,'C"'1]+@\9:';6WAR3^S(K"SM+I2D5VVUR795 ;S9OFV2L"GW,D?P
MBO\ $3POI?@[P#X9M=-E@U+^UI9=0;5'M?*F9 D8C1?XECVR9*L3\PSQTK8^
M(FDZSX?MO$WV#3=MCK=I9:GKPN9TD>QGDN92L<;*5W+O!7.UNF<BM#]HO['_
M &=X-_L[R/L/E7'V?[/CR_+Q#MV8XVXQC'&* /H."9;FWBG02!)$#J)(V1@"
M,\JP!4^Q ([U)4<$C36\4KPR0.Z!FBD*ED)'W3M)&1TX)'H34E !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %4]2TG3=9MUM]4T^TOH%<.L=U"LJAL$9 8$9P2,^YJY10!S_\ P@G@
M_P#Z%30__!=#_P#$T?\ "">#_P#H5-#_ /!=#_\ $UT%% '/_P#"">#_ /H5
M-#_\%T/_ ,35BQ\)^&],O([RP\/Z5:74>=DT%E'&ZY!!PP&1D$C\:V** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^69N7E<]7<]V.!^0    &Q110!YO\;]&_MSX?I:Q)/)??VA;BRCB'RO,[>6
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;&]U.[M$O8Q:S+%!=Y,*B\E97\Q8XRA7RP7\Q'4!FPX234=?OF2WLM'CCO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#:Z5.TUW%$;NR$99-1C:#;LE>6!1'L"2JD0\I!\BL(Q(%&A>SZ=I^W4-5?\
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MCEB15E<&-]K&0;8ROS.T>G:?+YKO<-_:NK:CIZ02MJU@D<IA+.CRA/E#0DF
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M;\8ARKA&0 ?)H36OC6?[1]J\2^'!Y^GB*[^U:0R8L!NQ=3[P-DWS28@?$?\
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M-/:QK-&HBN#Y;!C$S/<1[976)58*^Y6Y9&/-ZI?3:[=W^A6-Q:1F:]":GJ,
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!S>I:EKUSXE;1=%73;=+>WANKF\O0\I"R&951(E*Y.Z(98R# /
M0T/'XV:PM%2[\/QW@1#=.UM,\;L7^<(OF J$7H23O/41BI+/_DH>L_\ 8*L/
M_1MW5C6=)U+4-[Z=XCOM+D\HHBPP6\L8?G#L)(RQZC(##('8\T 9_P!F\>>1
MG^U?#GG>;C;_ &9/M\O?C=GS_O;/FVXQN^7=CYJD%YKVEZMI<&J7FFWL&H7#
M6JBULGMVB80R2[R6FD##$17;@?>!SQ@U_!L&JWV@Z)K=_P")-2NGNK**XEMG
MBMEB+/&"1\D(< %LCYNPSGG-SQ'\FJ^%YV^6&+53YDAX5-]K<1KD]LNZ*/5F
M4=2* .@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*.?3+BX9Y[NV*6\MZL)")=QR*H^>.10K%=V7@M\+'%,370(D-C;R6]O+IMO
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M1HH7VPJN\*LF8R554[RP\/6-D8\"-;[47D>WGEB\MIR\D<[3NLD3".Z7!8(
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M-$Z,_F*RNSBW9V^01X,;A5D +FN>(K;3M& N-2D9[NRGN( +5+A3+&LMPMY
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M -*(ZL>#M.M]0AU9-5M_MTD,MO;[M04S2!/L$&58R(K?\MIL@JN3+)E0684
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M0 N0[;/,S'O*% -@7W<P6\?E7]R,QK$+AWO 88YT7[,6N;D>4%CN(_+^13C
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M/A=RF.OK.L6V@)+<7\-W-']H@,2-;)G5)XV$9^40AOM&X(R*,*PAB9&5!)M
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M  BZ[0(4*X=EHT_C(66JZM9236E^@DT^U>.+:B&-4-_=D(8GN#&5V1[6"Y
MP'9 "Q$E]KFL_P!J:O8QV,*/'JUGI+0XN%$;*GVB0")S+.8MRF-3F(>2O#NK
MIT#64V^UL)_LEM<6UP[V<JN5>:2174W ;REB,_EFZ=H0CC)4DJ.:+F[::WN9
M9=-CL[2]<7"SS0K$UND04M>3O(I1' 6,QQLI8;%+8&\14]2U?R?+MXK6"[U:
MYB2^:VBM?O(OD@WTT#@2AHV7"1*Q=MH49(S& <W^S\S3^%=<NS?W=VDVL2D-
M<JH9SL0F1NIWMN&X%F' QW)]<KQ_X":E;KX2UL76K07-Q_;;F2=YCF4R+&J.
M=^&_>."!N )/&,Y%>J1ZMILMP+>/4+1YRY01K,I8L"X(QG.<Q2C'_3-_[IP
M<7\;?^20Z[_V[_\ I1'6A\.I;>30I5M6@,<?V50+> QQJ/L-L0$9CYDBX((:
M3#X.T\**YOXUZSI5W\*[^*VURT,DKP-%##<1L;D;XGV@<D@+(DGRX.-ISM.#
MN?#&X2[TG4+F*+RHY9;218\*-@.G6A ^157C_951Z #B@#N*Y_P;_P @.Y_[
M"NI?^ELU=!7/^#?^0'<_]A74O_2V:@#H**** *<VDZ;<WHO9]/M);L(J"=X5
M9PJN)%&XC. X# =B >M1QZ%H\6SR]*L4\O;LVVZ#;M\O;CCC'DQ8]/+3^Z,:
M%% &?_86C_9?LO\ 95C]G_YY?9TV?ZKRNF,?ZOY/]WY>G%2#2=-4N5T^T!=U
M=R(5^9ED,JD\<D2,S@]F8GJ<U<HH SX]"T>+9Y>E6*>7MV;;=!MV^7MQQQCR
M8L>GEI_=&./\5:/9Z;%K[16?V+3;CPU<QRRV5L,#RU"C<!L!8(P"*Q;(5@IB
M"MYGH%<?XOC^U_VM;>7]L_XI^[7[':IBY^? P'V/CS-F%''*,=LN/W8!R_@D
M/;_&_P 7VLK;)%T^QW1?:FFY6&('YG<-)C.-[1D\\LA;#^L5Y'\.I%;XM^+Q
M##&(!96*QR6Q9+<HL*!61$+Q!'&&3<^Y5X .7V^N4 %%%% !1110!EZWI6BW
M]O\ :M9MK1DLT>1+J;"M:C&6=).#&1M!W*01M!R,57\,7.M7-@[:O;QH@=A:
MS,Y$\\6]@CRQ;%$3E A*CNQRJ8VB2&'^W?L]Y>6T\%M#*9;:UE./-QM*2RQD
M JP(8JA)QE68!P!'L4 %4]4OUTVP:X8Q[RZ0Q+(S*K2R.$C4E58J"[*,X.,Y
MQQ5RL_6],_MC1Y[)9O(F;;)!/MW>3,C!XY-N1NVNJMM/!Q@\$T 5Y=.UFZB:
M.;7OLO\ JRDFG6:(^0I#AO.,JE68Y "@K@#+<DQQZ)JL:31'Q3J4B2ICS)+>
MV\V)@P(*%8@F"-P8,C9R,%<')/XECT^XEM]1T_4HY%<^6UI83W<<D>?E8/%&
M0#C@JV""#U7:S1_\)EI?_/KKG_@BO?\ XS0!Y'\<M-U_3O L U3Q#'JUH^L*
MT(DL%AGC!BDVJ71@C  '^ $DYR!Q7OE>!_'CQ1!K/@K3[6'3-9MR-3WF2\TZ
M6W0!%D4?,X )<'<H&3@'=M(Q7OE 'S9X_B6/]I?1F6WDB,E[I[,[1LHE.]!N
M4EB&& %R HRI&,@LWL\&D:5XCUW7VUO2--U![*]2UMGNK..1HXOLT$FP,5SC
M?(YY_O&O&/']Y#<_M+Z-#%:1P/:WNGQ2R+C,[%T?>W YVNJ<YX0<]A[GX>_Y
M#GBS_L*Q_P#I%:T '_"">#_^A4T/_P %T/\ \35B'PGX;M[.YLX?#^E1VMUM
M^T0I91A)=IRNY0,-@\C/2MBB@#/L="T?3(HXK#2K&TCCE,Z)!;I&%D*E"X '
M#%25SUP<=*S_ /A!/!__ $*FA_\ @NA_^)KH** ,^QT+1],BCBL-*L;2..4S
MHD%ND860J4+@ <,5)7/7!QTJ.'PUH-MJAU2#1--BU NSF[2U192S9W'>!G)R
M<G/.36I10!72PLXXK6*.T@2.TQ]F18P!#A2@V#^'Y25X[$CI7-KIL.G?$O3G
MLVDA@GT*:W-I&0L"K!-#Y1" 8! GD'L#@8YSUE<_>?\ )0]&_P"P5?\ _HVT
MH Z"O'_CM\GA^^0?(T^GK(7B^4NL5W I23.0ZYN%9<!60HV"1(PKV"O&_C[!
M#)H3'RHUD%D\[2A06;R[FV15.>, 7,A!QN&2 0KNK@'KE@+==.MA9P>1:B)!
M##Y)B\M,#:NP@%,# VD#'3 JQ4<$C36\4KPR0.Z!FBD*ED)'W3M)&1TX)'H3
M4E '/^#?^0'<_P#85U+_ -+9JC\$F8Z/?"6.-4&L:B(BKEBR_:Y>6&!M.[<,
M#/ !SS@2>#?^0'<_]A74O_2V:CP;_P @.Y_["NI?^ELU '04444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XWKHF'[4
MGA@RR1LATQS$%0J57R[CACD[CNW'(QP0,<9/LE>/^(?^3H?"?_8*D_\ 0;J@
M#G_VFO\ F5O^WO\ ]HU[PEA9QQ6L4=I D=IC[,BQ@"'"E!L'\/RDKQV)'2O!
M_P!IK_F5O^WO_P!HU[!_P@G@_P#Z%30__!=#_P#$T 6-3\*>']:U&*_U71;&
M^NHHC"CW,"R80D'&",'!'&>F6QC<<YZ_#CP4OEX\+Z5^[E>9<VRG+-NR#D?,
MOSG"G*C"X VKBQ_PA6@Q\6=K/IT?4PZ9>364;'^\4A=5+=!N(S@ 9P!6/?6_
M@_3[R2RFUW57OTQFQ@UZ^FN3D \0I*9#P=W"\#GIS0!H3?#CP5/]HW^%]*'G
MQ"%]ELJ84;N5P!L;YC\RX;IS\HQ\H?$72;?0_B!K&F6>F_V=:V\H2&W\\S?)
MM4J^XDGYP0^">-V.U>_R^'+[7O!;0^$+'Q'X;NE\N.U?6-9N8!%&I(.V)99"
M,!-NUE48<$$XKR3XM?#R'P*FCS-JMWJ>H:D]R]Y<S@ .RLA! Y()WG)+-D\\
M=* /I/\ X03P?_T*FA_^"Z'_ .)J.?X?>#;FWE@?PKHP21"C&.RC1@",<,H!
M4^X(([5)_P (;I?_ #]:Y_X/;W_X]1_PANE_\_6N?^#V]_\ CU !_P ()X/_
M .A4T/\ \%T/_P 31_P@G@__ *%30_\ P70__$U&/ VBK</<++K(G=%1Y!K=
M[N95)*@GS<D LQ [;CZU'<_#[P_>;OM0U6?=$\!\W6;QLQOC>G,OW6VKD=#@
M9Z4 >$'2-,LOVDIM-A\,?:+!97(TD+"P?-L6RJN_EA23O )&!@8!&T>M_ XS
M'X2:0)8XU0/.(BKEBR^<_+# VG=N&!G@ YYP/#+3P_%H?QTN-%EL8%M8;NX\
MFWGL'U)/),;M%F%#ND^0H>N1U/0U[?\  J5Y/A1IJNV5CEG5!Y#1[1YC'&XG
M$G))W+@<[>JF@#TBO-_%EQ+'XSN($LIY8Y?[!WSH4"0XU&4C<"P8YZ#:&]\#
MFO2*\_\ $W_(SZA_W+W_ *<I: .D\1S-H]E+K\ C46*&>_41KON;:-)"8PQ&
M05+EU'0D;<J'+"GX6U:W\;6=IXHCMMEC\XTZ.;/FH06221P&*!B057&2%W?-
M^\95T+Y'UB\DTN2SSID>/MCSAE$Y(!$2 $;EY!<G*$9CPVY]D<&GP^'+B)=.
M@DCTN=Q$UE;0 QV\A/$B $%$)X<*I&6#X3]XS 'SI^T,V[XE1CS9WVZ?$-LL
M>U4^9SA#M&Y><YRWS%AGC:/J>OFSX_ZRUOXOGTUM*M&%UIELJW=Q$K2QA)I7
MW0,&R@)8JV0"=IXQ@GZ3H **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q]3MM4CU&+4-,A
ML;N18C 8+Q_)\L$ABR2K&[#.U0R$$':A!4J=]?[9XP_Z 6A_^#F;_P"1:Z"B
M@#FX[KQL'F,NC>'V0OF(+JTRE5VCAC]F.X[MQR,<$#'&37N;#Q-K&K:)+>6V
MFZ?;Z?>F[DDM-0:>1QY,L>P*]NHP?,P3G(&<8.".LHH **** "BBB@ HHHH
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MP\FG7D F:?5=6DB0W\UT% WQBT(%R5,@-Q&!OB [%N22TK7%F5K@*1:3N]Q
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MU)&9FV9+@HQ2.\NK31+>.\N+6[NUOKB"4B6W=OM# 6RB>8>2!#.@0;(AMWL
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M_$^O:E%ITL]KIEC*][<:A:1RO)',T4L30 %1*;GRI0V1N$)2*+R_E^>QB_\
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MI^FO,00<*@\YR&4@DD[5(*@#()-6+/P]K^FWADTJ;0[..YB4W4ES;3WER9%
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M#_\ H5-#_P#!=#_\30!\N?$*W.IBW\4KK>FS07:0I#I:ZU)?W=HICW$.9!N
M#;LC/#/BOL.L.#P7X5M;B*XM_#6C0SQ.'CDCL(E9&!R""%R"#SFMR@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MAO,C4A<C[P!4/6?JE_9^'].NM<U"UGDMC%;N);D!([N0!62:X3RP8)D,?)"
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MBE@GW]P#;3AZ/IMWK-_9:YXB:T@,#V\D-FY1EM[HI -]V,1%KQU<*@V;8\#
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MG\<Z+:V\MQ<1:S#!$A>2231+U510,DDF+  '.:Z2B@#G_P#A,M+_ .?77/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF !C!=3S>LZU>O/<:/HS07-_)Y$\EQ-;1I]G#) (9KE9%0&]:1"L464'*%@
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M&W/E*%WLP.4.2H!3TBQM['0U&@6<$>DF)KVW\RQ,J7Q;[/*MXRQH"LB$N%@
M4MM 78%&VQJMS9V>DS:GJ,,$$=ILNX;S5;0%)F$< %W*JQ!DN%W%%BRC-M(
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M S;]A?!QDKNVYZ 8& #M**P]%\.-HUO:PG7=9O\ [,\A$E]<+(TB..4<[1N
M8!@Q^8= VTE3):Z!]DB@1=7U60P^00TMSO+M&NQBV1SYB\,/NY^=0K_-0!L4
M5CVVBW%AM^R:S?,OFH[)>,)U*#(*9(W#*%1G=]Z-6.XF3S"YTO5FM6BM?$$\
M3^4X$TMM$[B0Q!$;A57:&W2%<9+$ ,J#80#8HK+ETW4'N-R:[=QP%) R"&$L
M&);:58I@!0_0@Y\N/)^_YD<FDZE- Z-XCOH9&E9U>V@MUVIOD*IAXWZ*Z*3W
M\I3P2V0#8KB_%&EPZCXJ2WD2[E%[X<U*VDC@E 9E+VPQ&'.Q7.\C<<9^7<<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?#_34R -TYS]YMN.@^9'Y/0>L5X_^SY<I<^'M?<:K/>2/JKR,MQM$A#(N)G
M)8,^#G+,,IQR&)]@H XOXM;O^%5^(-EK)<G[./W:(K$#>N7PRL,*/F)QD!20
M5(#"/X7?;$\+01W?GF-K2QFM2^2GDFR@7"GH/WB2Y4<C.2,,"9/BT[)\*_$!
M1Y$/V<#*7*P'!=01N;@@C@IU<$J.6%5_A;;&T\.6JBUDBCDTRPF69FD/G;H!
MD\EE)!!7((8*$0H$2-G .\HHKGWU/Q)/>70T_0K%K.*4Q137NH26[S8 W,(Q
M V%W;E!)^;;N'RD$@'045S<EUXV+PF+1O#ZH'S*&U:9BR[3PI^S#:=VTY.>
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M@+'E=PVJ65B00 #S?P1>/<_'F^B<6(6U\-6\2?V>[&V(*V[_ +H$D"/+G:%
M&,'&22?:*\C\-P31_M#:E<744D5W=>'(IK@,I4>9F!3M'( ^7&%>49!^<G(7
MUR@ HHHH *CGC::WEB2:2!W0JLL84LA(^\-P(R.O((]0:DHH \G\)^/OL?@W
M0[7[9X-7R=/MX\7'B3RI!B-1\Z>0=K<<KDX/&36Q_P +'_Z?O W_ (57_P!S
MUZ!10!XWXG\3:EXCTE-..N_#5(#<++.MQK+3+*J3+)&A78HQA KYSNR<!>E8
M<9O)=3\6:C?^)?AQ-=>(M/\ L3R0ZN8S;_N_+!0E&.TC!9?XBJ\C%?0%% '%
MZ;XOUB]#2V^BVFLVYN"IGT+4X)XH4\L':SR-&6EW\D;5 1U.200;DOB3Q )6
M$7@757C_ '>UGO+-2<L1)D><<87!'/S'@[1\QU-2\-:#K-PMQJFB:;?3J@19
M+JU25@N2< L"<9)./<U3_P"$$\'_ /0J:'_X+H?_ (F@#S_XKV6O>,_ ,\<F
M@3Z1_9DLFI227ES"Z211)( J^4[MYC*P."H488;C@$^P5XW\:/A_9-X%^T>&
M_#FFV\]I<?:;J2U@B@9;=(I"Y)X)&=IVC)/''%>R4 ?.GQ2F:V_:$\-3SB[,
M4;V+J#&KY03DGRUC!=AG=PP+%MV.-M?1=?.'Q.;[/^T/X?FBMO-D$MB_EPV_
ME/*PEX&YR%D8X #Y"CA3@H37N=_KNH6>LR64'AO4K^!;>.47-J\*KN9I 4/F
MN@R BGY2?O#('&0#<HK+74M0;5+*W_L*[6TGMS+-=/-#BVDXQ&RAR6/W@2N0
M#MP2"2M>'6]5G<C_ (1;4H$1&=C<7%L"^%.%0)*V7+;1\VQ<9)88 (!N45CW
M&K:E'IUI=P>'+Z:264I/:>?;K-"F&P_,GEMR%& _1\]015=-9UYK.UD;PK.M
MQ<1#=%]MA(MI<D$2MN_U?W2'0.Q&[**0 P!T%%9_VO46NO+32]L)Z2RW"C&)
M=K9"[NJ8=,9SRK>6<9KW&HZR-.O)K70?,NHXDEMK>:\2/SB1EHV8!@DBD,.Z
M'*8?EM@!L45CW%]KL<4;P:)!*R?\?*&^"EOE5CY'R8DY+*/,,7*\X!S5?1O$
M-Y=ZY?:)JNE?8K^VBCN%:"8W$$L+Y 82;%VMN5QM903MR-PR0 =!7C?QZ@A;
M1Y',49<Z9(Y8J,[DN[-4/U59I@#V$K@?>.?9*\G^.7VP:"63SUL1I]SYKG)M
MTD,ML$\Q>0S$&14R"5=@PV[2Z@'I&A(\?A[3$E>=Y%M(@S7#,TC'8,ERZJQ;
MU+*ISU /%:%8_A.W2T\&Z';12^;'%I]O&LF5.\"-0#\C,O/^RS#T)'-;% &'
MX5A:VTZ\@8QN%U.]=98I%='#W$DG!!R"I<HP(!#(PY&"8[/_ )*'K/\ V"K#
M_P!&W='@W_D!W/\ V%=2_P#2V:H]/D9_B-KZM#)&$TRP568KB0>9='<N"3C)
M(YP<J>,8) .DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%9KB1I41E5P5,JX.6!DY,7">//#YNA%]BT<W<WV4(%,&JI]K>1V%MM=WF2.
M2*"HWR,X*%"P8 CU35;OQ9XE%MH]M)9VD%PPO-LJ*;ZXB,!FM&4J ETB1@QS
M)(0!&=K@;FCZ2TL+#2].AL(+S%K#%]E*1K'-O> .(YT/V<F:[46JYC&=FS[I
MVKNL)I=EHMK-;W(@MK"S\L1B&WDW&(Q/!$8Y!^\%R04BRKR,51-H0R@ N+RW
MT26"ZU0:59_9I8[B^D+GR;<3M<(AB7.5D\R0*\S(@=6<G&"J !>ZG!I2WTNH
MPV-Q/)J$$2VT31!)K@R_N57(WFY$(MV._"?*A#(H9EY_1M%34$34M26>XC?
MLK:>Y5IK@I;A #\T>S44:W<M)U0,R;R%S'7TG3);YI_$?BRPGG$MIN@L'MT#
MWV8E:2VDM9(UWW"-:!Q(H7S/EQA%"+V%S?NMG>W%T_F[OM$173YF8W21FYVP
M6X$@9;E54%R!U! /RY0 /,_>ZA<-'!?1B[21H+.R\P7#*S)'AN MPLB1HS,[
M*@@5B(@WR\O<W5QKTL6DZ?<3RVD,4D3W#78D=RS22+ @D\MEOXE@A93)DQ;G
M,A+ ,YK6J7&M:C>6-I>SBZANQ:375B@=(B#<;8;,N1MO6BD597^Y&NXEEVUT
M%MI4MIX<O-'T<^58+%+;VITID B5'(95+,&6Y;<Z;B[*'BWMM)*$ DL+%;:U
MG@L6N[J-$N8IX;>];#H99BI27:H-P&!5CO5@7)D=V5&-?6/$4&FV%[>:C?VF
MR)+AKU;>YE3=:1O.B+;G<%%P':%'VD$,P!(S'4FNW-OI\\UWK,TY9M\=O"J%
M?/"I+M6T(DS'<L+@1YW!Y/*;:H'S##M4U_6=9N=?NM1CMMKRVFEV,4:O]QIQ
M($624(+Y0CH9,&(*#CS%8[0"QJ33WOB>[CO[31KCP\UPSQVPEBW:@Z1I"WF*
MS@22BX:&) V%&UM^&$)K4O+JSTBSN;F>]\V Q?8MT+#SKO8;@+;0R>;YS7(.
M 2S'+ [0K,Q6Y,[/<74IOI+A+A&MA%;S+&LY0W.8;?\ >@I<# #N2 ?+&-N#
MLKW=TQU*XDM'CU+5EMWGL(#M^SL8)9$D2,[SY4^V80O(2!EE.TA70 &?XM\7
MZ;H)EMYY;2^U0NI$,DBI;QM')YL,<GF2[()60LRR-C<8BP#;4C./X;T9K.RF
MG\1W\FH:C<V\$;^=J*N\PB1(S;QXE14GBO.DF"095^?>[,LFC:?;P(FJZW=S
MMK0Q9N)+LPS!Y+<*VG1/YZEF#H)$:3.1('5F9C+767TTTR3""[CD>9V@)BD(
M%TJ-/NMX +A?+N%52&DXY&?X<( 5[^Z9["[GNWCE</*(_L6VX\\PO<-'';QN
MY NH_+1F)0@LF.=OR<O?O#XYO]1@LHM-_L@7"QW-S;78EDU29$W^3;$21JCM
M;$QR2$YPQ3E8]U2:K!+XXO%E6[^T>'7E,0\B9(SJ?EBZW16F7)1L?NY'ROFH
M&*E$7Y^HEWQP11VE[YK1RI&C"=G^UB%Y6^S1YN ?M $>'=SAL'<" 50 ()$_
MLY(XH_)CDB:V6UMI5BWA!/BT@"3[8[B/;AG4@'9P0!^[R]:\1"%+:9IY&>>X
MBMKJTMKN-)95F:YACMXU$Q"3I+C?(K)GRF(8["JR:MJ.G:2L&^Z@N+J3_B76
MY^V,)KJ,RM$T%NQE+K<*WE;Y#@,RKN9,;HL_2=)N-4O-/NM=;R+YO,@MIH;P
M3"TB *O91R&7>;G$3&2<)NQYBAAA2H!8MKNWNKR\U;4=3@GN_-ETM4M[@PA"
MP(>P@+3(?M'F1*_G,JEPR[<+C9N3%7>9Q<R3F9YX_P#1[ID%R=KJ;> >> DZ
M"!<MP 1(1M+.5IRZM*L5S<ZA)MM9XI2SQSI %6-9<VJM]JPMRA#EI5PN(R"1
MM!7'O]9>]U:]33[CS&DNTLKW4+6!H@(HY)@MBK--\MRS[E\P^6N)D((9HMP!
M)J>KZG?7^J:9I-Q)<227'V2>ZCN(T")LD8P6@$N%N$19"S/\PDV%E\I@8MBU
M@6QM[FUAGCFMY'EAA6UE9&N !.6@C9KC/VH.'9YCM+=^5+)7L=(LM*TV#3[6
M2.YMD3[)+&!$RZLL44\0MMK2;?/58TWOA=WE '"@JAJCV-G;I+-?2#:DEHM[
M#-EI8HQ-(]LDKRGR90L $LS%=VP?,K!3& &J>(H=.TN^U;6)X[73_LY61UNP
MKS,/M&ZTB59L)<)A075CO((&-HVX;6W]M0"^UF;[-:)YMAI4?VO=).V^986C
M\^7]U?KL3!8;E)<,2S%82ZT)/%VN2:YJDT[Z=+$]E%I2.L::HB?:B(V1I 5N
M$)# -C9Y>X[&++#UEY?+O*--)<&\>6U7[([*+@HMRWD1$3 0SH$.Z0[02N,@
MX$8!EZ796]IIDUCI[?:=,@\T33+:$/:F"21(3"AA?[1-'Y*1Y9B?W$; '=\U
M/Q-JC:?I-^MYI\DVK7-P9X--L=J33F&9_L\\/R-YTH6.V:126"(H)0#Y'N:U
MXC2"ZO(P_P#:$]K$)(?L<:M)'*TMQ$!;)LD+W CCG#[B%S$,A5:0I3TW29K>
MPU35=06/4-4=));F+2T,MO:,CR-_H*R1E3.TT*,Z$_ZQ0S=%# &?9>$9I-&U
M2YNKJ.ZGU.X@U*273\F.TC"LHN;1A;LLETZJ69D1"2X*[/E)ZRZGLY/M>YX%
M^T2DR?9T$N)(O-VRP_N3YUROV=,Q_,4\H<?*-\=SILSF1;R&T\BW>:[,=O8%
M_LS&29H;FW)C8/<8^^F&^9@PQTEY?7;C4]1-WIEM))9VD-Q="\2SMXPS%)&N
M(_LB,N]KR103N+ +M,H4AXG8 DO]7EU37+VVT^UL=1DT?4$O=6-K:I.8?+\Y
MHA"K %[EXXHX7;<=A*A!G<5W(=+AT.WETZ1XT@D1&/[@23O,@F<7:MY)%S=,
M(HG9-I*F/=\W&Z2/2;/P_%%;0VO]GVL,7DV:PRB40;5NB)+:,HS/<E&RX*G<
M&ZR;6#&N-%HT5Q.TMC:M!%<W7GM&\81MMPZ>0I5T$VUIFDD578A3F,AQM (]
M8N;;37U:\U"WDM!*\9G;>C)LB61TNX R%9)U5%9T(W*+<8#!(_,QSI>I>)(?
M$L^LVDEOIFH)$Z:<]HV];5X5#2Y13NN@R*0C)(T9A"*0LBO4=MH46OM>7US!
M]GTJ&65[*ULHG1[)$B-O'/&(XP&N086_=.'>+,8&QDV/T&IHD]G,D3P6T+2S
M(C6K*Q#DW*S/:LB^8+L*7=AL;D%!R7< &/\  VX>[^&<%Q-%_I$MW</-<,&+
MW3ER3([,HW-SMR"WW1\V057TBO+_ ( R;_A? OF;MEW,N-^[9R#C&]MO7.,)
MUSM.=[^H4 >;_'.YGM?A?>O;M.C-+'&SPRRIM5CM;=L!#*02I5R%^;KN"@])
MX*MA::--"EK';01W#1PHK1NRQHJHJ.Z$AW0)Y1)Y'E[27V^8_)_'Y$;X7SEW
M@5ENX2@E90S')&$!4DM@DX4J=H8YP"K=9X0GAN1K4L,L<H?4W?>C!MRM'&\9
MW#.08V0@[W^4KC8 (HP#I*Y_P;?)JF@M?I)!.TMW<(;N%5'VH12M"DK%>&9D
MB3)&!Z # '05R?PWCOH?!446J31SZ@E[?+=2QC"O*+N;>PX'!;)Z#Z"@#K**
M** "BBB@ HHHH *\[\3SPRZOXM\F6-IK33-,8NK FUF6>XD1V'0%,I)ARJ$
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZKY;;6SN.<J6&/FR #U"BBB@ KQ_]H[_ ))YI_\ V%8__14M>P5X_P#M'?\
M)/-/_P"PK'_Z*EH ^8**** /O^BBB@ K#UB-;KQ%X=@6:-9[>XFOC&P;+Q+
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M<D,GQ-^);0&,H+V!24  W S!NB)SN!SP><_,_P!]O5*\K^&<2Q?$WXEJEO)
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MI>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ!1$1P/O'D]O0[2Y^T?"'P8]FT$\/FZ-',XE^YMN(%;& <L'4*5)&/FYR,$
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MWDRJSH/.VY97B4&1\-4>I>)XK.QFO[X3QGS8HO+B9_.^T)-O6S^SK)_KF1E
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M=I!/R%!N4A3EF#[5U*** "N?U&^32?$R7NI201:8=/<"\G58TLW65 RF4_\
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M18>("V8*K*RALQ^8L9\M%D!*NK,P -$@U&\:R6^O5NHI_M3V\ZQI,5+)M1T
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MLM2U&;78UM(7>&8VURH'[I/FM,>:"+AM\C*T>Q@53=D( ^.8;OQ&\FN:M!)
MBW!$&FW,R,;>,K#Y,97S8_(OG9RT<@)*";:Q^X  5[339M>O;#6-=CNWTZ%U
MBL81>D10JSF&/S0\PD74(VD(9_FQM*KF3;CI$N(+&>&YN[C,T'DP16EW/$["
M8I,8[>(O,=MV4E0.[,1(N,<,2MPS6UUJ27BZG:3O;7#6[RAD>W@E$H58RADW
M)<%)GC#*1DL=P/R)7+ZOXY71-->-(+N>]M[>ZCB$%RVZ%$BWXD+^9&TZF-UW
M$R _9[@ABX:$@%SQ)XGG\,Z/''I]G?:AJ=Y:#[%")98YI858C]W'()6:XC62
M-GWH"PRQSL*KGZ%X?ET^\U'4M;AL9-2>6079L2B(EQ(#@6SF5&@FF2XMDR0I
M;R"6)+HY-+T"WO\ 5KR^UZ>"XU"65&>X:(I!"7DC$)57"2VMVT1CC"HY*[(F
M?+%-VY#=VALBJ:C&DI=K(K<ZJZAIG0JMIO6=REPGEP[G 8Y+L@S(V #0F>";
M5-6MFOI(BKPQO,9I5B03^6A@!$H G(C!4J%*>?&0"78OQ]YJ[>-8GB2XDCTF
MZ1EF:.X6-;Z..>(?98U,J_O2TC0--&[1-N RQ95BU(]3N/$DOVU)YX=(\V"%
MKJWNA$)B[,HCB9;AHVP)PDD@P=\1$>Y]AAU-.C46^E:<GEVNG_9Y;*+RKME9
M0H93:X68XGC6-?WJM(?W4_\ J\@D CAELI'MTANH+:UN+0VUN\5S);1I$MPL
M;0?9O,4QS /'&)%^97R"$PJ-3O\ 56TNR\N=[N60H;6*&2]6,F65%$5B'28N
M+C_5.9FWX!D8,JM\MC7O$*Z9HU]>W9D^T%%MVLXY662:619&BLXQ%*QCN!OB
MW2*#D$,. "E?3/[0&KOK-^TESJ$J3P6(66$Q1Q"=I&LP@F :ZV1[6?&P>2N6
M;8Q< KV,#7PEN;B>TN;Z"X>VM4\U9I[>(1N&LHI?M 9+S8NZ27=U?JZH"NI<
MWTHLY9Y-1V+>2K"BSS(KR9,@:RB,=PBK<J^]1(,?P ERA86+K>_D6UI>[X/-
M6RB<3LS2Q'Y)X@_VA6-PGDNYE/S*NX*&;?GD]3U_4O$+R6_AR^CDOKZW=!>0
MRM]G@A*L3;1E+@Q/J"??!RH*@G*J,T 6-<UFYN[_ %:PT2]N[N[#OISW:2.B
M0F1'(@@57"274;$/NVJ%C7$DB$%ZV/[,AL+6Y-M<1W5BKM;E+AA+%=1O*XDM
M=IG6-K@RY7S9%R=ZJQ=MYJ2.Q2RL[BUL=0G>%I62 13KFZ ,QEME;S5/V@'S
MB908WR$+M(8WS'JFN::@O]2FU.-+9D%M#<+J*Q0/&8XI?+7_ $E5$\BNY27"
M$  GY0I< CU'6-.TRPADN]8GM[48MY"\[1&X4P3O';%I90UO<!&C=I'*,QV<
MC.%Y^RGU3Q1JTVKZYJ'V?2!@66DP2^0;MXI)X60K*R.DR3R0;9/DR?))5'P(
MX[87/B^W.H>)([N30V?[+:VTH>"6^(%Q$T%S%YHACG$RQE9,("_E@%6(5.TN
M[KRIS9W-[/=W!EN+<"W;RVF\Q)9UMDV2J(YDC2,B1\?+T(,A( +#W'V2\NKH
MW'FR6TI68+/A)6E $=NB/-MCFXM^6 4^82H!E;&'KNL2Z9I:6^F"[U&\FN#I
MGD)YV]RFXK#EI@\,IC8N;DY!5#(<@Q@FK:Y,)380W<ESK%R[6L=O;DVJW#10
M2/+%M:4O"3RPF7;CSK8YD4',ECH_V.\OM1O[B>_U>_\ ,MWN6C^RO-&HFQ:6
M:F56AV^6'W9(;[^XYW( 1V5C#I:7=[=327M]J%Q,DCVT@=Y&D:0-9VKJZ.KQ
MF- TK ?+$N2JQ@0ZEP[F\<^;]IAN?M,8>UOF0S. RM;1H9E$<P$2$.I.#'.2
M(BV3)=Z@T5Q%+#>227$MP8H?LX5X;LQFX9K8*TF$E5$<,Y* NJ9) ,8XNX;_
M (2G6-3T>V$XT>**;2+Z]BN-ESJ$T*R-'9Q>;+NW(LKNTC<2%&#83.0"342?
M%)>*&YNS9WUQ]FN+G[/);SZDL,ES*=-6)PGEA8]ZM,67)&TY.X+U"SVD%NL-
MG+))9SO+IT$,+/')(T0N=UO"J^6D!3R\++GY@F"<A7J.&*S@B>QTUOLL,$LM
MN]E8J+47'RW#"VB0R*8I@&64R#9O 5@=I^6/5]7:W>>YN[B1; /+!YEG<*&U
M!E68"UA3S=R3[G #(0[O X(0!,@%C5]1AA'VNXUBT6"V>9Y+C[.#]F5([H%K
M8E7#7"A=KKEOEC<[%W8//K;KK5^NJW+1V=G'>RR6EE'&S[0B7)6XCC,9#7WF
M^:[1X8JN-Z>8JFBW@U?Q-JB:IJ<4DB0I*]O96R@I;3P[T!1I,QFZBE:6/+;8
MY 8Y%_U1 W+BYMX?/%Q8SR6IM)+RW2"V-M(TLGGOLMDP)#<F+S?,^=6!VD*N
M]L $>K64-G;W(F^UK.4NV6*S<"3]X+ET>T_=!3=;?,&$(;#DNTF%8T_&-[+:
MQ:E:6EANU>YB,L:VCH98\K-%]H@.T.UR(5SY;,NY8V6-CL<U7\5ZUJ.A0/9Z
M=IT%[K?FO<06MK&JK KO<L)(MT;$W,D*S$YRNZ-^"6"2R6>DKX/TVZN]>NY+
MK4)T\F6[65O-OP(C$D-KF4.EPZP0.V,EGX!.%,8!'I'AF#29YK[$%]J&I2M]
MOFCFBC:>9$NP4M60Q[;E=VQWQ&"H9OE8OCI+R6^MG,27$@O)WE5AYF7>+;<O
M"MMO583.,*2"#A5^<L K'/O@#I=Z9I(U0/=F :4D;.TG^E[A:'(=;S;RY.1D
M,%'+D8=_?7&MWCM9V\">&;:6243:=<CS[Z=1+,?[/:,*QD=<K*=W.Z5%(*N[
M $DE]-XFN)8=':2PT9WE4W&G7AC;5&S=D?8WRJ+*)$WOD#?DY9HU!DW)XHH8
MB"UC+:Q2F&V%LKQA(469'AMECD=EN8T$N6C12P&P 8)22"SLK%)K>U2TET^5
M'M5TZ".);6XVM<EK>&,R +/VD+?*P3HOS;*^N:G8Z%X?N=2U222\TG3T,?VB
M*7+1',T.(7#-*;CYDB=F=1\Q8,IWK0!A_ 6XN&^'4EA=13Q3:;J$]JT4P *'
MY7*[=H*X+G(;<<YYQA1ZA7E?P AOK;X?7-M?F17AU.:-()),M  $#(4SF,[]
MYVD \YQ\V3ZI0!YG\>1"?A7>&62T5Q<0F(3H&=FWCB(Y&U]NXY&?E#C'.1UG
MAC_CYUXGY&;4%D:!^98&>V@<I(W(9@6.,,ZA2J@X4*O+_'65X_A1J2HV%DE@
M5QY#2;AYBG&X'$?(!W-D<;>K"N@\$2[K*^M]LZ?99;>'RY6^5/\ 0[=MJ)Y<
M?EK\WW-B_-N.%SM !U%<_P"#?^0'<_\ 85U+_P!+9JZ"N?\ !O\ R [G_L*Z
ME_Z6S4 =!1110 4444 %%%% !7!^-Y6AL/&+ZA<7<&DC0H I618U=R]R'C1G
M5D#N/+0D*3\R]]M=Y7%^*YS:V_C2XM98X;R+PXKK)"TBSI@790Y^Z #DJ5^;
M.[/&V@#G_AG$L7Q-^):I;R0 WL#;'C:,DDS$MAF8X8G<#G!!! 4$*/5*\O\
M /D3?%SXBSV?[B!);6-X(_**/)M<,Y*Y^;<KGJ#\[;QNX7U"@ HHHH ****
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MR?-\[=_PC.H>9NQC'F??VX_ASMSSC/- 'O%8]]H GO)-0M+^^M=0X,;&[F>
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MBP+;<O1E90[C(( 12&61L=IJNFPZOI=Q83M(B3)@21$!XFZJZ$@[75@&4]B
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M!(H?/O+N7[/:P%M@DDVL_P S8.U0J.Q."<*<!FPI ,N#P3IT-O%$^H>()W1
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#QOXPZ/I&J^// L.M7T=II\KW/VJ2XG*1>7&$
M?;RP"%^4W#!^9>NT"N@\7>'O"D(T2Z@@M(+S3-8L;6RA@G,:0.]S%(Z+"K!-
M[(Q<_+DC!Z $<?\ 'V'15\0>$I]>.I?V>Z7:3BQD!DPH0KL5SL!W,,G&2/7
MQJ>'?#OA^'X5^%=5M='TI;\W>F,;R!5EDWF\A#DRE=P8Y8,O\)R@R!0![!11
M10 5X_\ M'?\D\T__L*Q_P#HJ6O8*\?_ &CO^2>:?_V%8_\ T5+0!\P4444
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M]G>*QO=5N)\-;IB!9K<RJ[H]\6=-K[<?.ZJ=RL:V+&T;2K*%=/>TLI+5UC6
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MP_Z 6A_^#F;_ .1: .@HKG_MGC#_ * 6A_\ @YF_^1:/MGC#_H!:'_X.9O\
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M+<:IHFFWTZH$62ZM4E8+DG + G&23CW- &I49GA6X2W:6,3NC.D98;F52 Q
MZD LH)[;AZU']@L_/\_[)!YWF^?YGEC=YFSR]^?[VSY<]=O'2L__ (1/PW_9
MW]G?\(_I7V'S?/\ LWV*/R_,QMW[<8W8XSUQ0!H?;[/R//\ M<'D^;Y'F>8-
MOF;_ "]F?[V_Y<==W'6AK^S3S-UW OE2I!)F0#9(^W:A]&.],#J=R^HH^P6?
MG^?]D@\[S?/\SRQN\S9Y>_/][9\N>NWCI49TG36MTMVT^T,"6[6J1F%=JPL
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M<Y0&1(W+JK8Y 8@$C/? SZ"I* /F#P;_ ,G0W/\ V%=2_P#09J^GZ^</!O\
M8_\ PT!<_P#']_;?_"0:E_<^S?9_*F_X%YF_\,>]?1] !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%9]GKNCZA9F\LM5L;FU$JP&:&X1T$C$!4W
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MC8LRZFFV$&C6MM$E]'#/IEQ'9373M+<2I+<2VLLD+%AB8S,^3-A-F]<*,-@
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M??*)-QD<Y+!WPC9 *?A_PS;^$8M/@MA/]H\V.UNKY[,W-R!MC9;=9E@7=;\
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M/6?^P58?^C;N@#H**** "BBB@ HHHH *Y_Q#_P ASPG_ -A63_TBNJZ"N?\
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M_P#A=OP\_P"AA_\ )*X_^-T?\+M^'G_0P_\ DE<?_&ZZ#_A!/!__ $*FA_\
M@NA_^)H_X03P?_T*FA_^"Z'_ .)H Y__ (7;\//^AA_\DKC_ .-T?\+M^'G_
M $,/_DE<?_&ZZ#_A!/!__0J:'_X+H?\ XFC_ (03P?\ ]"IH?_@NA_\ B: .
M?_X7;\//^AA_\DKC_P"-U)!\9_A]<W$4">(HP\CA%,EM,B@DXY9D 4>Y( [U
MN?\ "">#_P#H5-#_ /!=#_\ $UY/\?O#VB:+X-TZ32O#UC922:@H>ZM+6*+
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M@ KQ_P#:._Y)YI__ &%8_P#T5+7L%>/_ +1W_)/-/_["L?\ Z*EH ^8****
M/O\ HHHH *Y?7[ZWT;Q;HNJ7\GDV)M+NS,Q4L%E=H)%W8SM79!*Q<X50A+$5
MU%<WXAL;34?$7A^&YFNX'C>YEC:.1T23,#1M'N5UQ*5E+J0"P$4F".30!P?Q
MYU_3I?A_<:=!>>9<&[@5UAW,HRTPPQ#!>&MY00=^&3E0<,O:.;*PN+>^N(Y-
M(L[.W,9N;EXK>/3U)M2+51C8Z/M +@MM*LJL"0%\@^(<4UYX5\96][<:E<7.
MB:Q!Y%M=7)F6UM71%BE#!E#%P"/F\UER<@,[R'N[-K/Q)%)XA>7[-X-LM/81
MHL80I"5LYG@"(K*\(\B1'Y)):2/;A 2 9^A:;>>)9=(N]3A_LCP_:1?9(K(W
M!!M_F@C-C(3@3K(8X\[MV"9H77>%*=H4FL$1Y9;2P2&XMK:)H[0D6:NUJOV2
M']V/,BD8,#(-NTE1CY/ECL;?[+IU@CV/]F6]A:(TTMS+\NF+&+9VMDD&QI(V
M56)DW,NZ,AMP^09^LZK9Z7%;R6(^R7_FQZ):0NH4V$TZVS"V544Q[=BAS(3(
M$(X$@_=T &K^(X- \FWMK#S]0AVVD5M9&(?99C]DVVD;-&,6[^8FZ4C"Y R&
M,:B31=#.B.E_J322:JB/#-<V%G($MXPL4HM+>(1,&MPD14-UW;@N))"!'X:T
M.WTF_66?SXM9,2S3*A,KZ?!<3KY5E& C(;=3"Z$@C9M9EV!\KJ110V%E'JM[
MYEBFE61$\BP"(6<82WDDABB571HF$7)#N5(*HQ_A "UM+:!+: /'!9VB6UM#
M9W+(\5@5:!EAD'FDO<,2NQ\L%PN.23+S>I:G>745IX?TS7?LLYB6P&HW5V<P
M,RK'+!,R$QRWH.)$".K9#9VJ#YUC5;Z_DQH']D6-E)#$)&9Y9%LM*L%V?OG*
M,@:3S()##M*,JJ&/E$.*V-+L(-"\KRKK[%]GM/M-Y]H,0PK>3OEO-LG[RX;R
M9L3#Y1^\SNQ\P!'8+;:/=/*LMII$".^Y'G0J"8K>647?[S+W6U)6$@9@$RS%
ML_,)J(T:R^VZAJ5W:VFCVX@GFOI(Y0JE+5V%P(Y27N#E@K #EF^5@5,D:7O_
M  C.F137LT%K/%]G^T37MSN,<#R00!KLHW[RX=8VQ+MV*49=VU2SY:PS:U?P
M'69I+32(+?[?#9:E$6DM;54BC9;Q_-P#(!.1NRQ D#.5\V%@".&%]<O]'NM<
MD@T[^SM0DM;6*ZN&W@K/&T=O,//W27#+#!*C[I$;+$H<(S=!9ZI]GL[9TEOI
M)!%NB2['SVZL;=A9W&Z55-RWF*L9<[N>2QW&22TNYG%O<27,FG06MNETJW4I
M+0V;1Q[DO$D?<)2RS%9.=OE'+'YU?'U/Q-<V5A8_8A(E[-<6EO8V\T[F2*)W
ML]\5Z&+E93YA!D*MM#+\P>0!P UW6YHKBQT*UCC^TW*);B/4E-S!'"YMTF@N
M<7&&G E1PS\,'"*6:3+1^&]#O-.V2:G>02W$DMM)>2:A<&[^RR'R6^P_-+G<
MLC*\#DR%?,;C+;I+FA:!;:'I;VVHW,<]RUD)=2N-0V86!MID2YC$Q4EB+@J^
M"H/FDEV:1I=#3[EE2UFEU>-#8V1^T[Y5,5N@:)9!< SNQEW07 63<P7$@8L5
MRX 6V(]9CN%:2T,%O#:/)<2QNJ;FA*VUP?.+R7 RQ1_NC[0?OEOFY^QU)?$%
M["ELT=O8!%LKN[O;5I!-$'@=;5V:5DF,J7*HLK%LD3-'N$P(RY[G_A*X+6RT
ME;[2?#/A^TCDOXI1Y<BM"Z2+:>:;@*LFR-6+?>A( 9U+NH[#2S;Z)*-+M;>#
M2;'3=/BNE5V(2S@=OWB3CS-C2$Q2D2AFQ\^[UF )-/B;3;*UM;2\CM8[1#:Q
M+=E76R#I$(K654F >4,\>UN24&W=N?S'IW_B!/"^G6\]S)?7++*+:.,LL\T!
M<1R"TD19LS7##Y4<!B 0S$C>[EUK">%_#GVA;7^STTNT01VEU<*!:6V^.-4F
M"SOO9_+D*2*'( 8!6?*25]-L+B:6[N/$K0*L43/'::@XF33K(,T?[X&X97DE
MA$A\X@D9E#,RX2@"OI5AJ+:QIVJZTD$=_9RK KM>+<1Z:DJJJVC;WW/,R[2T
MPPY>:(#S(RP'06\%G%IT&G;((+&&*.Q^S7+B2.VC80+]EG7SB))G#85N0 W?
M/[R-[I1<6]O)=QVT5K;F:5KC4&$EFD1M7:*<"8^8Y5B3*20H8!MP<[\>^U-K
MX1>&Y9)+.[FLDMKB195NUTIYHT,4-T)69+@R-'*N\C)W*O!E#L 4[CQ//J]Y
M'I>B"^@CM9?L,M_<-*B6EP NVUED,A$DQDBQYVV5!O1-LHE.[8T:UL/#=G:X
M^W?:[;]S*_FQM)<RS&25;>X8R,OG;I%;<S(I>8!&"RE#)IT4.E(=)L[C3=*M
M]'MX9)1:7(=+*/=')+%.CL,EU1RL[*#AG)"D9DD36-+LHFOI-9@L]L1L(Y;W
M4=\-G*JH?(N%-P5DN-V]BP^8JI!;H6 +&JW^D^$<7^H7<$$S1"TLY;J25$=1
ML"1SS'?N;>68.PW*K2$# D8^?Q:#<>/-375]5B^Q07'F1)82S",W<GEAI;6X
M.-I8,B!9(D9U2V(DVRQKL-&TRZ\<72>(=>7^S]"LXA#+:7/GJKBVE#&.]\V4
M"7RR9=L@!!;<TFTJ8CZ!$E^^ZPCC_>-IX,B2W\BR(A\T1Q.5D=HI.1FX3S-Y
MBDZ%4H +:Y-[>2ZQIL/VEY+2-]\<\,A08CD-JRHZJ6*-NC=G< RR'*H0'P_$
M&H0^&])_L6S@CO"4M["WM()!*KJLR*+66*5F$8:*>)&G.<^9E@#Y2O<\1:\=
M.L[6UOY?-N]4NXHET^>&$Q8G/EI:S*I9@K*)"9 6&Z*0C*[86S]'TM]'B?4O
M$L^[4$TIY]3N_M#--9VS+S;+L?S%53$K)+F0LR3G*L^6 )/#VE7>G(-1U.>.
M7Q!]G2*2\DO4Q:RNT)73F+;R$.(0&_>.Q>5\JS@OL2W"V&FYF6.PM%MY(9[8
MR-:,J)$TD<%N/,$2NL;'=,CX_<D< 9B$F:V>+6-1MXX]4M[*:[OHOM*L+6%U
M7]P-\P5"3"G[S'EL8)3\F^L=KF^UF:]TJPU>33]/@<:;=ZH)=SQ.DQ5;>,M.
M_P"_DCEC_>[<@C!RY"0@%/5-6O/%6IZGI=G=;--26XTJX98B3J-PD<LGV2.-
MG C54)\R7=&9" %9!@CI!8+IMD-)C$=S9P(]E;6MRK RQ;(W^RJCLL=P3$LB
MB4M\@7#;R)28XY$T'1T,@GLX],M%WV<-XLK6T2M&B(H*[6A?R9#YTQ5D4N24
M!;RZ^LW^CZ)%/82O D2^7;-;K9HT]Y'MFDCLTCV*GEE08T/S!OWD8Q)\U $F
MI75E%:PPE8[E)WEL(OM=Q%*Z@2Q0>2QVR,T$LBHDC'?(IE7<!_RSQ[711J6J
M77B/4]+U*=W1FC@EM8]ZK/Y(6W\IHPK.8UV22G;L63RS(_EEX[ T0ZG<//J'
MERZA BZ<L<D<EW_9MK,2,$-YB273(R"5R2JJRLVY!^]U)-1?38O,G2!YM$T^
M>:\N5E9T@&U62V>5T>1\KM=F7YSY2,R@2*I +B+-:6\DTL%V\]FD$47DYN)P
MQ$9D@CDEC!>)BL>968Y+.6:/R\KQ^N:AJ4=Q#X=T,1OJZ(UF6MK9O(TI9#;2
M"&62*,2+$R!T25/+X49&Y#(DFMZB96MO#&D^1_:<TIT\0R6,+'3()HDD:&5<
M>4T:Q;V7:PW&"-,2[9#6IX>T=?#-E/' 8[C5+-)KZ_'S,[33(K&-&,+320.Z
MDB3+29A5<OM*J 1Z'X9LO#NF65J\\\$,T2Z>]X\D@N4E$F#&)2BCRW"K$L@6
M)B(H0I8F+9L?/IZ>>MEY<EC%Y=O;V\#-&A^S[GMD9;?<+?Y(V#KDLXVX!41F
M2119VYFA@CL!:60G3[3Y<"V4>$/V82+&R"(^2WF$,Q3@C@H5Y.XTVXU_6+RQ
MCDGTS0M)M$AU"UCLQY]P'7S/LI\E2KPI;S21JL;;U=@V&.QF +$%BGB34786
M?D^&()85MY([%5DE"$11V\8"-OM"K2N9 0"EUMR%$@K8LY+?3EM@;:>RMXI?
MLQG,9Q9RM+;J+2#S(@SV\CD@.!M 7 *@($N'R=*M[BXO5CT^#3;**X\RWB#K
M:0@ RP1'R0#%B $@9<[NB8CJG)?)H%G97M_I\]G:Z?%*\[PP+(;.V<MY<1\N
M+!C 1=XB)*&.+<73,E !;*F@V<4LE]I6G_996_M&8;5M;=&,>RW(#QCS!&84
MCE9#\L?*C>%.7I[7>J"'4$@CM-/%Q'+9Z?=(DEQ>R11E629C<9:Z0P';O.$
M4N&=/W,<.CW5SJ<9\0W$%O9Z;:174=CY<"6-C 8Y()8Y8Q+D^9'YC L&2(JR
MK)(H8/T#1HGF?:+GR%AT])O*U"19H[()M:)[@-*2TBNLK"1&4,$8,Q*(U $<
MUXHMYK9C=QO#;I$B&X;<H<1!K9Y1/C[4<IL=F4_OE*E\.3AZMJ=Y/J.E6=C?
MSM<7,MO;:C<27!1;2U)9720Q2>4+F26&6(21J-K'8"AV%B_U6_CGM[&PO/[,
MU>24:49[R62>VM $C;:2\P6:X?S!)$^PNX^5U7#E=30[*;1[>VC748Q(EP%N
M[B])DD&\0@07!^T$/=,#&%DPR@#:JJK*& )-$MO[*V@S;9OW2W5Y=W>]_.;R
M$$-Q&)=OVAH5@574L"Q9@%#!9([?6X=/LK6>XU_3;9$>*TNYKN<,D+1(-]LV
MZZ;;<%FD;?E^%PV[:K-)/K']EQ32P7.&L8H'O;:5_M,MK %&V&7-QA)G+NWG
MGY-JDN2%#'DYYF\8W&N6.HV]W'X9TBW16@N+E1YZQE3*DI:96WB2*51-N*%H
M>' 643 &?;PGXA:HDVHP2#0]+26".TU":2-)I7WV\5O<[I7,5TCDGS%#NPD0
MG8Q4'TA2KB"&:YD@MT3[+,)+IA);B2.(+!)(LY)N&=T99!N.,@$%PS27DEQ9
MRWFL2QSQ^3%(1YDH$*01,I960SB/S) )&64A=JD!\;<-S_BSQ5_PB6G*;.]L
M;J^L=ULZ3WN GFC_ $9)%>;)D)$3&1S_ *N.=LKD @&/^S_]L_X0W6?[1\_[
M=_;<_P!H^T9\SS/+BW;\\[LYSGG->L5Y'\ X)M'T'7O#NH126^K6&IE[FV=3
ME%>- AST(/EM@@G( /0@GUR@#SOXXF8?"35Q%'&R%X!*6<J57SDY48.X[MHP
M<<$G/&#L?#Y%_P"$>\V!(TLYDM9+15MFA(B^QVX ;.2QR#SODP,+O)4@9_QG
M@FN?A)KR0122N$B<JBEB%69&8\=@H))[ $U7^#VI6FK>&;Z[LEC2 W%O'Y<8
M<+&R6-JC(-Y+85E*Y).<9R>M 'HE<_X-_P"0'<_]A74O_2V:N@KG_!O_ " [
MG_L*ZE_Z6S4 =!1110 4444 %%%% !7'^.%W:=J]N;GR(;KP_?"5Y;C]VFP*
M%?R@"YP)7RR#I@,&)CQV%<WKD=W)K+1PB-S)H]VL C*+.LFZ+.#O1R&RGW'C
M"E?F;+(4 .3\'A)_C?XWNY8)X+K[)8@1/"K>6&A0LK2*&"L"%&T/AN3AMH*^
MH5X_X(@32/C'J45Z(+6;4-$LGL8G"H\J)$BN%7RD*X,;97$7W<^60 4]@H *
M*** "BBB@ HHHH *Y^\_Y*'HW_8*O_\ T;:5T%<_J/[CQSH-S)\L,MI>62-U
MS,YAE5<>Z02G/3Y<9R0" 20^()[YS)IVC7=U8!&D2]\R)$N%"G A!;<Q9L %
M@B$98.1MW;$,\-RA>"6.5 [(61@P#*Q5AQW# @CL016'X%^7P#X?B/$D.GP0
M2H>L<B($=&'9E964@\@@@\BI- @FMM1\1(T4D5N=3WVRE2J%6MX6<IVP93*2
M1U8N3SF@#SO]H[_DGFG_ /85C_\ 14M>P5Y/^T-8W%W\-8YH(]\=IJ$4TYW
M;$*O&#SU^9U''KZ9KU"POK?4].MK^SD\RUNHDFA?:1N1@"IP>1D$=: /G#QU
M=?:/VFM+B^SP1?9M0TZ+?$FUI<F-]SG^)OGVY_NJH[5[O9_\E#UG_L%6'_HV
M[KPCXHS6^C?M!:3J=Y:_8K5);*ZFN/,,GGHC@-+M&2N A3:!SY>?XJ]WL_\
MDH>L_P#8*L/_ $;=T =!1110 4444 %%%% !7-^(X(6\2>$+AHHS.FIRHDA4
M;E5K.X+ 'J 2JDCOM'I725S_ (A_Y#GA/_L*R?\ I%=4 =!7S_\ M(W-Y;2Z
M+%&WEVMW%*DA$I)DV,C;2N,*N2K'!^<A=P_=H:^@*^?_ -I33;QO[#U40_Z#
M'OMVE^T$XD;Y@OE'A>$8[ADG&&QM7(![Q8(D>G6T<5G]BC6) MKA1Y( &$PA
M*C'3Y21QP<58K/T.^LM2T.RN]-DGEL9(E,$DZR!W0<!CYGSG(&=S?>SG)SFM
M"@#XH^(]K]C^)7B.+[1!/NU":7? ^Y1O8OM)_O+NVL.S CM7TO\ !+_DD.A?
M]O'_ *425\P>._\ DH?B7_L*W7_HUJ^A_A!X3\-ZG\+=&O+_ ,/Z5=W4GG[Y
MI[*.1VQ/(!EB,G  'X4 >L5&)X6N'MUEC,Z(KO&&&Y58D*2.H!*L >^T^E8?
M_"">#_\ H5-#_P#!=#_\31_P@G@__H5-#_\ !=#_ /$T =!7RY^T5&R?$:U9
MII) ^F1,JL%Q&/,D&U< '&03SDY8\XP!]!_\()X/_P"A4T/_ ,%T/_Q-?.GQ
M]TG3=&\=6-OI>GVEC VF1NT=K"L2EO-E&2% &< #/L* /H/X<&W/PU\.&UG\
MZ/\ L^$%O.,N'VC>N23C#;EV_P .-H  P.DAGAN4+P2QRH'9"R,& 96*L..X
M8$$=B"*X/P+X3\'ZGX!\/WA\/Z'=R2:?!YLQLH9"T@0!]S8Y8,&!SSD'/-=!
M_P ()X/_ .A4T/\ \%T/_P 30!N23PPO"DLL:/,^R)68 NVTMA?4[58X'8$]
MJDKG_P#A!/!__0J:'_X+H?\ XFL_4M ^'>CP33:CH?ARWCA\HRE[&']V)7\M
M&;Y?E4MD;CQP>< X /)/BE<PZC^T)X:M+6ZDCGMWL;>62-1NAD,Y<$;@5)"R
M(W0CG!SR*[?X/&&/6?'MJ;F.>\BUV7SG:W"SNNY@K.Z@*P)5\*JC:=QZ, .$
M^(7A*WTSXG:#K6GZ!/IOAY]0M;262U4Q&6<2'<88HSYB_*F 55=Q7<N=P9NO
M^"EU$_B'Q]9P6^V&+5?-2:9'%RZN\H"R-)\YP$SAOF!9\\F@#V"BBB@ HHHH
M *YOQ5!JYNM#OM+TV._33[TW$\(N1%*RM$\.(PPV$@3,_P S+]S'\7'244 9
M>FZ]::E<-:>5=VMXB%FMKNW>)N" VTD;9 I(!:,LOS+SAE)U*P]8C77!-I=G
M-&EQ X6>Z4-YEF)(V!:)@,"?8V!R"HD#$$$*^I8PW%O9QQ75U]JF3(,QC"%Q
MD[2P'&[&,D  G) 4': "Q116/KEX\5SI%@!^YU.[>TG979'5/LTTF492"K9C
M7D=,G&#@@ CG\:>%;6XEM[CQ+HT,\3E)(Y+^)61@<$$%L@@\8J/_ (3OP?\
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ME,9QQ]O+;_$S3H'-UY7A*.6.V59[DO\ :T(@S!<@R"1+@38\N0,<X;((=3(
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MA74O_2V:@#H**** "BBB@ HHHH *X?QK;?:-1N;5%G_TWPUJ<<HM8O,DEVF
M)A,CS&7S9-JDCEV (W&NXKD_%UJQN);_ &1R10Z%J431R;55BY@(!>1&B4?N
MS_K..<[6 ; !R_A:[AU'X^>*[E;F.Y1-,M5LY!*' A9(W/E_/]PL0W",,G.Y
M<X?U2O(_ 3%/C/XKA,\CDZ98$^9YD;/B"(;C')(7SS_&KL,X+J20_KE !111
M0 4444 %%%% !7/WW[SQ]HD3_-&FGWTZH>0L@>V0.!_>"R2*#UP[#H3705S]
MY_R4/1O^P5?_ /HVTH L7VC7]W>23P^)M5LHVQB"".U*)@ <%X6;GKR3U].*
MT+&QM].LX[6UC\N%,D L6)))+,S')9B226)))))))K#@O->UZWBU+1[S3;+3
M9T#VPN[)[B2:,C*RG;-&$# Y"$$@8)()*+N6MXEWYX4;)()6BDC+JS(1R,[2
M<;E*N >=KKD \4 >5_M%3S0_#FU2*61$FU.))55B Z^7(V&]1N53@]P#VKUB
M""&UMXK>WBCA@B0)''&H544#   X  XQ7D?[1W_)/-/_ .PK'_Z*EKV"@#YH
M^(UK]H_:.TJ"]N(+ZUN+NP46S/YHBC+(K1.IX7)W-MZ$2 _Q5[O9_P#)0]9_
M[!5A_P"C;NO$/B';^3^TGH$GV'[-Y]WI\GF^;O\ M/[Q5\S'\&-NS;_TSW?Q
M5[?9_P#)0]9_[!5A_P"C;N@#H**** "BBB@ HHHH *Y_Q#_R'/"?_85D_P#2
M*ZKH*Y_Q#_R'/"?_ &%9/_2*ZH Z"O _VF9YEM_#5NLL@@=[EWC#':S*(@I(
MZ$@,P![;CZU[Y7SY^TS!"MQX:N%BC$[I<H\@4;F53$5!/4@%F(';<?6@#W?2
M;:&RT:QM+>UDM((+>...VD8,T*JH 0D%@2 ,9R>G4]:L3F9;>5K>..2<(3&D
MCE%9L< L 2!GO@X]#4=@B1Z=;1Q6?V*-8D"VN%'D@ 83"$J,=/E)''!Q5B@#
MX(O[K[=J-S>?9X+?SY7E\FW39''N).U%[*,X ["OKOP7X3TZY\"^'IWN=9#R
M:9;.PCUJ\103$IX590%'L  .U?'E?8?@O0M1F\"^'I4\6:S CZ9;,L4<5F50
M&)?E&Z G Z<DGU)H W/^$-TO_GZUS_P>WO\ \>H_X0W2_P#GZUS_ ,'M[_\
M'J/^$>U3_H<]<_[\V7_R/1_PCVJ?]#GKG_?FR_\ D>@ _P"$-TO_ )^M<_\
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M8J%;^%L,<@5X1^S]-?Q_$#9#:WTUA+$R7#PR2+#"^UC&\H7Y6Z.JAN[Y'(H
M^IZ*** "BBB@ HHHH *\?_:._P"2>:?_ -A6/_T5+7L%>/\ [1W_ "3S3_\
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M$;L*!RN4 +&B:9;6]E::3:QQPBT2!6@FB2X+&)+8AKDHH5+A5"A,.1C#@,%
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MQ#:SW,\M]%K<SSB[&RY^9$ :5"258E6SDGD,,G!KUB@#@_C/&LOPDUY7FCA
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M/G(C!91M15PX88&.F16I0!X_^T=_R3S3_P#L*Q_^BI:]@KQ_]H[_ ))YI_\
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M25Z!0 4444 %%%% !116?J>NZ/HGE?VMJMC8>=GR_M=PD6_&,XW$9QD=/44
M?&'CO_DH?B7_ +"MU_Z-:OL/P7/-=>!?#UQ<2R33RZ9;/))(Q9G8Q*223R23
MSFOCCQI/#=>.O$-Q;RQS02ZG<O')&P974RL001P01SFOK?X<:MINH>!=#M[+
M4+2YGM-,M4N8X9E=H6\H##@'*G*D8/H?2@#K**** "BBB@ HHHH **** "BB
MB@ HHHH X/XSP37/PDUY((I)7"1.512Q"K,C,>.P4$D]@":\$^!E_>6_Q2TN
MSANYX[6Z\W[1"DA"2[8)"NY1PV#R,]*]S^+6OZ*O@/Q!I#^);2QU+[.!Y"3@
MSL<JPC\M3NPX^4G& KDGC-?/GP@O[/3/BEHUY?W<%I:Q^?OFGD$:+F"0#+'@
M9) _&@#['HK+TCQ)HOB![M-'U2TOC:.J3?9Y0X4LNX<C@@CN.,AAU4@:E !1
M110 4444 %>/_M'?\D\T_P#["L?_ **EKV"O)_VAKK[/\-8XOL\$OVG4(HM\
MJ;FBPKON0_PM\FW/]UF'>@#UBBHX)&FMXI7AD@=T#-%(5+(2/NG:2,CIP2/0
MFI* /GSX+:)#HOQ&B\G[6/MOA=+QTN8PI5GDBSM8<.AQN!'0-M;YE:OH.OFS
M]G_5;[4_'[I?7,DXLM">UM]_)2(3QL$SU(!8XST& .  /I.@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_VA&5=9
M\$,]_)IZ"XG+7L:LS6XW0?O %Y)7K@<\<5N:2OG_ +.FK>3JT]VIM-3<7Y3#
MW*B:<[F#@D;P.<_,-QY!Y'/_ +2]KOT[P[>?:(%\J6>+R6?$C[PAW*O=1LP3
MV++ZUL>#?^37KG_L%:E_Z%-0![!1110 5X_^T=_R3S3_ /L*Q_\ HJ6O8*\?
M_:._Y)YI_P#V%8__ $5+0!\P4444 ??]%%% !6'K A_X2+PZ[R202_:)ECD5
M 1-F!R8&(.0&QYO0KFW&<'96Y7-^(X5;Q)X0G)DWIJ<J "1@N&L[@G*YP3\H
MP2,CG&,G(!XY\2IM^B_$*7[3!+YFMV4/FP#8K[(5_=DY&]DQAEW2X8%O*B^_
M7?WNHSW%G#HFBW4]K/=VA1KF\O)3-HRSF#:MRK2EFN&WR>5DA@P55&W>U<)\
M2K9;?3?B3_I$D*-J>G,@F1O](<Q*S1I+O!D(W;O+8,L:J"JC=E/4].N-.T73
M()%N/[+M5B%XPU*=@;2.>1&9;D239,TC^=M<Y"D,.Q#@%?3@FCSZM%IS6,5T
MFH*D=O)=*/+61(@&NMKY:29XCLD822?OE)!^=!H3:FFF12/+/]FAM?-M!=W5
MTK0V(VQ[#=;KC,C.=C*?O[9 #L+,3'J%_::=8 :E>R6$"6\2.T]R^ZSAE>*,
M).RSEC*S"0+..$VL=W!+\W"H\7:M9W>J">STF&68V^GZA',K12O) K)=DS >
M9()I4BB(*^7+T(^0@!IBIXEU:'4;J^GL4TZ6%;*RU#;Y]DADMAY5VCN6:29X
M28BP;&=^XOY87I+06-J+>!(X]/\ [%MT9#<#;]@M?+C#12MYO[P,JR8<%HPT
M7.6BYD-U]BB$\E[/%9VGDO(+AO..GL%17BG9)<ONCDW[GWJA#2,Q4(!S^M:U
M_9-F=%TB^@L]2;RDTZR1?,?3)9BL86Y59V!CS.-OR>5'M4 .1&K !JFLW%C+
M#H6E:?8PRCRC!#?3"=$G=HY-UR,9\Y9&0[EE;_6AR6D>!):]EX'>TM8+G4))
MXKJZM)GNX+>%B+")HHF*6_EAE\Z*>.+RCRWEJ%&_RD*Z'AOPS>:3Y,UV+Z;Q
M#?VCL;V:8R?V=&WV?S;<2N9-^U][Q*P8':P)Y9FT+.&)_P"SU@2^>&:[,B1W
M=HX^TJFS#W326^^.2()^[+,&?RHR78G( -">)[NZ?[+:P(TEVLA2>V;RYQ%+
M 'FD)C!690C"+YB&"JPW ?)QYU"XUB\&C^$KF"2&2*&>2]OH1<%3*$E@N' 4
MMYD<4.V/S2"Q4&0@B(S6+W53J$ZZ5ID^\7LL<.IRW<<,7EQ%%B,EU%)"K"XF
MWJL<97:_E1L/DWHVI9Z7#IVEBT5XX;>Y>)[>6: 1O,S?9E%S<M)"1]L$N60,
M!O. 1D$J 1Z/I%OH.CVFG6:?V?ILT4**H<VQG!8PEY7$"M'<.DD# ;E=I%"C
M:%9FL7NI6>EZ==7.JQ;-,:T66YN+Z$)'?1L(HW>=1"&6X"C:(BH#A@HZ$1&H
MZE9Z,MU>ZE%ML%EENIKBZA"0MY<L"AY#Y(;SDQMA"[O,6)3N)*E<?3M.N-0U
MBWUGQ%;^4L,L#:?:W:B*.67;#&]Y,ZH UP2^R)'2-@$ "(22@ >'X_\ A+;S
M3]=N=-G>U7R[W3%O(/(,S8CB>YN2F4:X55W1#:J['4J3R8MRP@.F"TE-S(H+
MQ"":X:2)KN%H[>$F[+I@W!;&T$*YVJH(!D%%KIUS&EM;VQCN8'2VG1[^V??.
M$: /)<DIG[0JQ@HQ*DEL%/W6ZLN\U*+3OL>GV<7G75[=HULFJPND<ZK]G<2W
M$CPAUD0&."-LNV]HPVYP0@!'?W;0V]IH>B))>:G<HAB:X569S$+,M<7;/%NA
MN$1@REE8<*2K,4CJYHVGV=AOF(@NVEEMTN+N\D"O,R_9A;FY$BF1+E5(*( %
M9LL=C2*%KZ#HMQ MG<-:SW&IZE%#=7EUJ4  F$<L,A,Z!?W-PGFS+$BD@",9
M8[%"Z"M$8KB=Y;&5HI8;AY[R-XP(46U>62[4*J)<A5W)N52H"8  ? !8MKU+
M:<R1ZAB/RC<W=U-9K$BA$MMQNS\I2X,9)7A %)RA"#/#Z3>R^*=1C2RL/L^@
MZ?Y=A?7VKNBSZA<,;-9(+@;1()-H*$ [)'5%;<ORF2+4!XY,MK&)+?2%O;1+
MTZE;1I]LN()+7S8[D>6 DK"01A!N$C0@*452).LL-"BM+/2[;38,1PQ0"%+N
M)]EQ"AM<S7"^6NVY18L1AN1C/0,$ )-+L(52RLDBDD>R0(UK<SB0%BUO,\MT
M41D%TK'>O)W%F8-\Q*T]4U^RTC3OM=Y!]NM8)88+& RR-,Q(MG2*2*0EWNRV
MYT!7("C<T>YF-.;7M-T71K-[F*[(*0'RKBW6YN+JX5;5HTN% 5A?$$! &( 4
MN<A0%CT&W>XUC3]:UB7R[^.(1V:7!:6/38I%M,VTWF,&6[;S&4.3N<.201MC
M !8T+3]1748?$GB ;]1?9;1?:)%ACMUS%&$<;?GN \ET$DC7;()& *+(BKJ1
MEGN(FNUC-O:O%;Q6]S>JRPEC:,JW))<M=!\F,C(.1\P+AC'I?D/IUF#^ZA'V
M;SFU+RI)'FQ:F/[6#M=;LC"K@L =K')V+6'//,[R>&+:6T%V$M6N9-08L859
M;9(WNI8\%KXNK",)(N0 V[(3( /+<W-O#H^FW%W8O<V]J+C5+B1X+BW1Q;I)
M'<-M:-KYE$80G# .?N84R[F@V]OI412UE@BA66-1=RDJ[F1;;<+R,LA-W*2<
M,5R,KGEMKQZ3:Z;:6 LK:ZC@,B*MQ,;A5E5G>.%Q<F*8;[J22.51,O1U8 Y!
M#D.LK964^OZG>R6T%O;Q"2>[D;-O%L@=H[FW5U5;IS(^"B< J.<A6 ))[QX-
M'?[9/!9QVVVWFN+G4V1;:!V@+1SL)21<^6Y"N&;++NWJ)-IY^RBO/%6HQ7FH
MM]E\-P>5:PZ5JZEV#9162\C:0%KART9B+&10N&*[V4F.&.'Q386LK"."SND7
MRDN2&C*N]LJM>9>19+HPO%Y*R;\E=[<L$CZRUEN%O(Y)+K[)#:[+6..:Y$HB
M#BU/E7.9"6N22X1@S##Y.XL P!';WEM:(T]F8Q.J*6C^T([J=T4/DSDSXEN'
M:%XDE8D H5).#OY_4/$\VARV-I86UHOB"9X$>QFN2Z[G@!:WGG\W!N"( L<T
MBG=N55##S&636_%,^G0:6-(EG_M:ZB2WL;*^25H[?S'LE*WV'9Q,HE!#$C D
M(.21OL>$?"TMIOFU&?\ M#69/(2[N;G9)Y2P^2T<<Z(X#7&"760AV3=C>X53
M( 4_"6AZ5X8M_P"U4OH[F]@MXK&ZO#%&[0&,0(UJZ0R$M.VU415W!=B\,[,9
MNLM87N9[0123I)98 5[AG^S#9%NAN0LY\V8JS,KG<%R&Y."\ECYTCPI TBO;
MHL9664RFU7; S0SXF.^<J25DYP#GG/[S@]<UJ7Q!J-IX;T;4I[>TDEB@FFGE
M1EAMXS"6D$DBF5+WS9$B5&+.K88JK,K4 7-=U:^O=9L?"D*1VUI+;HDSW%WO
MEM1NM_WCRD'%TC.BQJCR$O,DC$ +NN:5;?\ ")Z2TL<UC%(D0DU"\OKOR42Z
M,=J"ERHE=?.EP6\T9V9!PY<F23P[;-X<L(6N+B.WN&>"VOBB+(K3L\"J;E5<
MG[5+YA)=?E'F#>9 B,UB37;;P_I>^ZU&1Y-+MX$F^TSI)+ K^0HCN@)@IGD.
M[;*<(N6)(7)< CO-=L_#44MU)!/"R^3&H4B>629EA'V21%G+3W;(@VR$$*I!
MW$!MU.QLF75(=8\07MI;216ZVZ6=U=+<Q:<$\B=XI)'D!DG*Q><) N5PS,TB
MK'4FA1W%YJ,.N7MS/:1Q[(+6QU"02?V>"8D59LRY-S+&^5;&]?/=7+C8M:%O
M,^E6L%U=:M!:K;>6+^:]F9H[8>5 &AD#73!9F.UE?+@ G.XN6D +%G/;RRVU
MV#Y$UI_H*R7I)>T#-;A[:;=+EYI"JE)!D'*D%@09,>_N[C[+;Z!9ZG.+\6@M
MYII[@>99H\4:JES(LV%N9)"OERA).2VU&&XDU+4[BXGCT6RGGM+J+9%)YUT#
MY$+)"1#<2K<,4FE<^6DNUI!\Y13_ *QM#0DL],@A@MK_ &L-GF-=70D,3.\4
M3I.JS;6N))8Y@'4;?,\SJQ;S "/P_IPT.RMK>&]CMO)>W@F9EC 152..*WN5
M$K W#)(H$D>W<5CSE0J-8&I-;V0NI;J/2H[-'@=]3F61;,%(PB7!%R0\K,4D
M#DD["5RK/N:2$2IMQJD]MY<L$:_:)4D^Q*?LV;2;,A\R:3G$AW,/-.&Y7?P=
MV)O'26M_-)''X7LGM!IMM>(97N9G:U*QWF\NZEBY19%4G:[L248>: 6#90>*
M-;DEDEN],TJ.X.F RPRI+.&2%)(;OS,/F>/:%D8L3B#!CD7;+WCWKZOY,MG!
M!=P-YCPPS%EC8Q["K2$PDQ3).H382"!O;!9-JEE;7%I%I5I90SV%O:Q*D-@7
M#HT 6)2)I/+?;(FYMJK)\^W.XC=MS]0O/[-L[6Z:Q^V1SRP,R3Q>4]VQ-ND<
MT@\@!+D2>6J(QC7N2H3]V 4]:URVT8V\]ZL<]QJE[!-9:9'"D#7H$D2*S+,F
M5G3S8C@N#_HZ$&,;U6GHVEW[727]Z+Z;5]4B"">:WDMEM[224,5E,.T"[,$8
M4NH 5H(E)7Y3(>%="G6>TU76()[C4YXK=88+F*7;'"R0/FX8QE6N8VM6)D."
MS",'9NC5-RSM)M2L@MY;2%+](YQ%-$;>5U"6P,MRZ)\ETC!M@0K]T8QLW( 6
M%1@('%C)>I(GVEDDA5)+LI'$4FD#1(J7 =$549D &6_@VIR^J7L^KZLV@Z/9
M1WEQ#;I=ZA-<VL1,L,L(B)<-&HBOB@94CD C,9.[CY5#JMWK=Q<6.@I)=R1/
M%+>W'D( 9(B =QDME3[84:W94+ ))%AMBQD2[&AZ/:>'O#]M9V]A&UG"@N(X
MEL73[1&AA83S*(2PND X7@NRDX4\1@!INE6>EI86MO;6B"[O7NHDNOM -TC,
MDI>3S,D72$*PW[F(A;'E@MY9J^I&QMXWGO+N,WED8K>2Y>2-;O:(R%=45'AN
MGWRA%B4MP6VL45%CNAI?AFSWRW%B+32]BWLMTOFF=$,<GF32+'E;D22F1%Y\
MPNQ W/NCR]'TR^\1ZM#JFJ1Q[$<A=(NHL$HT*Q237AC78+IXI$*Q,,"/*@#)
M= #/_9^DMCX5UR+3X;L:>NL2M;2W)3<R%$VJVT_?"A2W 'S#!/./7*\K^!LC
M'1O$L1AU((NNSL)=1*^>Q*IE9.<^:, OD 9;@GG'JE ''_%23ROA?XA;S/+S
M:%<[]F<D#&=Z=<XQDYSC:^=C1_#5V;PO8 /(T:Z98# N5E17^S(2-OWHGP5)
M3[I!1A\SO1\6G9/A7X@*/(A^S@92Y6 X+J"-S<$$<%.K@E1RPKF_#6L/X5T#
M29&N-#1=1TJQG4ZIJ36  6W2/:O[IDE8%<L^=X#HK#:L>0#UBN#T_P#X2'PM
M?^);6T\.:EJUG<7KWVG3"^MPI:5 \D1#NIC02[\$*WWB<$C+9=G\7/MG]G\>
M%(/MEH;K]]XDV^1C9^[D_<?+)^\^[_L/Z40_%SSK72Y\>%(_[0V_NW\28>VS
M$TG[X>1\F-NT]?F8#O0!W$VHZR+6XEM]!WR)$)8H9;Q$:0F)CY>0&"R"0!#S
MLVL&#L<J)!>ZN+AU?2(_(2X6+>EV"SQDG]XJE0, &/()!_UF VU/,X^?XBS-
M;RK;ZEX#CG*$1O)XG+JK8X)40 D9[9&?45U$]UXJ6XE6WT;1I( Y$;R:M*C,
MN>"5%L0#CMDX]30 #7+ZW0?VAH5VDFQY"+,_:%5$:-6)( ))+LRJ 69$)VA_
MW8)?$;1' T+69,O(B[+=?F*2-'W;@,P0@M@%95;[JR,E-]:\21Q74LFF^'$C
MM,_:7;79 (<*'.\_9OE^4AN>Q!Z5)<^*;FR%SYV@7<PLD!O)[6\M#!"WEK(P
M+231L  P.61>,'&"* +@U_*PD:1JNY]@D4VV#"S2B+#'.&P=S$H64(A;.&0O
M&/$;; [Z%K*#8[MFW5BH1HU?A6))!D; &2XB<IO&PO3F\77\'VC?X*\1GR(A
M,^Q;5\J=W"XG.]OE/RKENG'S#,D/BF^N4+P>$M9E0.R%DN+%@&5BK#BYZA@0
M1V((H L1>(VE.#H6LQX>-&WVZ_*7D6/LW(5BY)7("Q,WW6C9\_4I+S4+>XOY
M]*CT](M,O86CUI+=X"6$14RO'(Y6([6W*."%);&U,ZB:S?O+:H?#.JHLV/,=
MI+7%O\Q7Y\39.  WRAN".^0,^^U[4;G29)(?"^JM#<6@V!IE@F,DD8*)A&+Q
MX8['<[3&Q#<J&= #C_!XN)/CIXG/D>3;VVE6D)CGA#SJ3'$RAYP&W,/G!W2$
MMA<;PF5]8KR?PQ8O9?'?48;BXWW$'A^-79K9H1=.TB-+/&H+)M,FXMMV?.Y^
M5B'<^L4 %%%% !7+Z@VLZIXMETFRUC^R[&SM+>ZF>"V22>8R-<)M#R;D508E
M/W"3ZBNHK'U/PU9:MJ,5[/-?0R)$8F%G>26WFC(*[VB*LVWYMH)P/,?C)H K
MVNAZW#!/#<>+;ZX\W=B;[);+)#\^4V8CV_<RK;E;<<%=G0D.AZVNG6]M/XMO
MGF7+SW:6ELLCMA0 H,918\AC@JS9(^? ()%X1M8[-;1M4UR2 2R3$/JL^]F8
MC:#(&$FU -H7=MYRP9OFJO;>!;"#;YFK^([C$21GS=<NAEESE_E<?,V1G^'Y
M1@#G(!8_X1[5/^ASUS_OS9?_ "/6>?!%_/J-IJ-WXSUQ[ZT\Y()(8[6)1'(1
ME640D/PJ9W9&Y=P"\ :'_"&Z7_S]:Y_X/;W_ ./5'/X)TZ:WEB34/$$#NA59
M8]=O"R$C[PW2D9'7D$>H- $G]G>*8/W=MXBL981]U[_2S),?7<T4L2'GIA%X
MQG)R3S_BS4_B!H-K8?V2^AZO?7MW]FCM?L$EO_RRDD+;VN2.!&>#BN@_X0W2
M_P#GZUS_ ,'M[_\ 'JYN\AU?0Y?#$,L%WJ MM=O!'%YPEGN(W@N7A*RRRCA(
MV*,'Y)3@X +@' >-=+^,/CS1H=+U3PGIL,$5PMPK6MQ&K%@K+@[IV&,.>WI7
MT'7+W_B^[TS3KF_O/".N1VMK$\TS^99G:B@EC@7&3@ ]*$\7W<FHS6"^$=<-
MU#%'-(GF6?RHY<*<_:,<F-_R]Q0!Y!\2_-_X:,\*^9Y^WS;#R_-V;=OGG[FW
MG;G/W_FW;OX=M>OZA/<:'XMEU,Z9?7UI?VEO:[[&,2&W,+7$C-(N0VTK(,;0
MQ)4KC<5#?/GQ#\2B'XZVVK7^DR6":9<6;RP!8S.ZILD)<H[(SD' .[[H0'&#
M7I?_  T=X/\ ^@;KG_?B'_X[0!Z!:^)KJXGGAE\+ZY:M'N53,D!65PF\(K)*
MPY' =B$W#:6#<58EUV7RF>UT/5;MAY;*B1I$61U+!QYSH!@@J4)#J>J@$$^;
M_P##1W@__H&ZY_WXA_\ CM'_  T=X/\ ^@;KG_?B'_X[0!Z)-K]XKC[+X8UF
M[@9%=)D-O$&#*#]R69'4C."&4$$&L\^-+Q;=)SX)\3['MVN0!%;EMB@$@KYV
M0_S#"$;CS@'!QQ?_  T=X/\ ^@;KG_?B'_X[1_PT=X/_ .@;KG_?B'_X[0!Z
M1#K=U+9W,A\/:K'=0[2+-_(WRJQP"KB7RCC#9!<,,<CYEW5_^$AU3_H3-<_[
M_67_ ,D5Y_\ \-'>#_\ H&ZY_P!^(?\ X[1_PT=X/_Z!NN?]^(?_ ([0!Z!_
MPD.J?]"9KG_?ZR_^2*ISSZKK.NZ S>&]2L8+*]>XFGNI;8J%-M/& !',S$EI
M%[>M<7_PT=X/_P"@;KG_ 'XA_P#CM1Q_M(>%2\PETK650/B(K'$Q9=HY8;QM
M.[<,#/ !SS@ 'LE?/_[37_,K?]O?_M&N@_X:.\'_ /0-US_OQ#_\=K@/BKXR
MT?XF:/;ZCI,WV+^Q-WF6VHLD<USYS(H\E59M^W82V<8!'6@#Z'\)PV]OX-T.
M&SNOM=K'I]ND-QY9C\U!&H5]IY7(P<'IFMBO/_!?B26'P1X0LX].\^2\T]+>
MVN8KE&MO.CA=A'(W^L5L0G=B-@IR,L16>OQ8U%KS3=,C\*?:=7U?3X=0TVVM
MM14I)&X9F$DDB)Y;*J$X 8'ID4 ?/'BR+2X-1UR*5;Y-?36[A67S_.MA "P(
M\QP)'DW_ ,3#D<GFOIOP7XLTZV\"^'H'MM9+QZ9;(QCT6\=21$HX98B&'N"0
M>U?+&K:QIFI6]\R:/)%J%SJ<EVM[)?23,L# _N"&^^0QSYA^8]Z^H_ OCKPF
MG@'P_%+XDTJ":'3X(9(I[M(G1T0*P*L01R#VYZC((- '0?\ "9:7_P ^NN?^
M"*]_^,T?\)EI?_/KKG_@BO?_ (S1_P )WX/_ .AKT/\ \&,/_P 51_PG?@__
M *&O0_\ P8P__%4 '_"9:7_SZZY_X(KW_P",U\P?&3Q*_B;Q]+))IL]A]AB%
MHB3AE>1 [NLA1E5DW*X.TCCUKZ?_ .$[\'_]#7H?_@QA_P#BJ^9/C5JN@:U\
M09+_ $"YCND>W1+N:/<5:="R'!/!&Q8^5^4]1GDT ?0_AKQMITWA72)7T_4H
M'>RA9HK/0KPP(2@^6/;$1L'08)&,8)K4_P"$RTO_ )]=<_\ !%>__&:Q_"GC
MKP.GA+28K3Q)8P6\-I'#'%?W<44Z!%"XD4D8;CG P>HR"#6Q_P )WX/_ .AK
MT/\ \&,/_P 50 ?\)EI?_/KKG_@BO?\ XS4</C;3I4+/I_B"$AV7:^A7A) 8
M@-\L1&"!D=\$9 .0)/\ A._!_P#T->A_^#&'_P"*J./X@^#97F1?%6C Q/L;
M=>QJ"=H;Y23AAAAR,C.1U!  /#/$6M:7XB_: MY)[*QTFUAB:":37[+]W,1$
MY666)RAY!0+N8' 0_P"R.W_9Q_Y)YJ'_ &%9/_145<AJ>JZ6_P"T-IOB+2/$
MVE+:W]H+C[9<KNAMC]G>/9(/,0[B$!P2I!< CCGK_P!G'_DGFH?]A63_ -%1
M4 >P4444 %%%% !1110 4444 %8?B&18[K01+#&T#ZFJO.Q93;GRI"C*X(VE
MI D?/#"4I@[\5N5CZV;A+[0GMY]JKJ&)8!,$:X0PRKM ) ?:2)"O]V)B 2 "
M 1^'##>'4]66.19[F]F@?S'#[5MY&@55. 0A,;2;><-*_K4?_'CX^CBAXCU/
M3Y9[A.WF0/$BN /XF6?:Q.21'&. O,ES8:EI]_<WVAQ6DYO7#W5K=SM"ID"*
M@E614<@[452FW!PI!4AM]RSL7-X=2OHX/MS1+$HB9F$"8!=%9NN7!)8*FX!
M1\@H X_Q-_R,^H?]R]_Z<I:S_BY:SW./(B\SRO#^JR/_ *=+;;5'V?)_=@^9
M_P!<VPK=SQ5SQ=/#:Z_JMQ<2QPP1)H#R22,%5%&HRDDD\  <YJ/XHV45YYWF
MO.OD^&M7F7R9WBRP^S8#;"-R\\JV5/<&@#TBBBB@ J.>"&ZMY;>XBCF@E0I)
M'(H974C!!!X((XQ4E% ')QQ:UI^J33?9XY[QD\V?[+&8K?4$&%R S,(;A!M
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M8!.YQE?E'4\C@=1UJQ6/XLL;C4_!NN6%G'YEU=:?<0PIN W.T;!1D\#)(ZT
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M#O>%S: QRJV/DQM>,G//FXP<C !Z!1110 4444 %%%% !1110 4444 %%%%
M'F_B;S?^$1^*'D^?N\UL^1LW;?L%MNSOXVXSNQ\VW.WYL5)X?@AMO"GPN2"*
M.)"\;E44*"S:=<,QX[EB23W))K+\?VOVSP'\2XOM$$&W4()=\[[5.RVLWV@_
MWFV[5'=B!WK4\/F9O"GPN,\<:/OC ".6&W^SKC:<D#DK@D=B2,G&2 =)9_\
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M/VFXR9$EN2T&Z)P(HSN/"LY3;E(\@$FC>'[?3=.33[*.>2SN\3217JEOMR,
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M2,@EVNS!HR>HM[KR-1@4WL\6(HX5CN6\R.SY@S#.PE.^YD\U=K%FXY4'YC*
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M9=P!'X8-QXJ_LZZGMX-/\,65I'I]H)6$;3(WV7=#<0F1VVRX4QXDY4#>)%D
M?M)?LD2>9*TEN[I!ITDOFN\MNKM JV\[),7:<F5BDH)V;RV>29""YAMGMKF_
MDM+*[LDDM!+<70E6VC"PR2Q.[2AI'=(C*LC*"$ 9U!!#9>H^+O[!_LZW>/?J
M+W<-C'9K=^>]LLFQDBN,R_-<2)&^R0@J&."^W=(X!'J>IPZ9J5C']AC4R7%I
M;K;O="Y8R-+9AGNT&2)XU\O9+O<<C+ N@8\*^'KYKB'6];$EWJ=Z@N$M[J+8
ML:,;5F:8B+ N(_*C50-@;R58*K%V%SP_I46C2QZG?7\&I:O)BS2\EF<K#"&@
MA>W:?!#R"1,@$(7D9\*FY\6([??L;5K>QGM[G:T?VN#R_/W^7;E[@M" +@QL
M J#9N\UHMN$WT 26ME:6*6SOYDB3);*K:B[@76QH%2>??%\ET&.%7AG(4'[H
M\KG]99M=OSX?T2*.;5)K=?MU_/ H^SP2)"?-NE\M#Y[^2%%OPKJ 9%V *)+^
M\>ZUAK#1I?,NDB@N]6DFMFD80*L929HA%B._R"8TV'*Q@LORQJMS2/#QTH6N
MGV5M)-MN)I6GNTD,5SMN;=I)KC<,FZ^5O*?)5MA==JD*H!<T?2GLH+2UM;.!
MK6;R;EUNXF+W!1SNGE;R5*7)!@D._<69&4!=IDH>Z0X$?D/&GEW5W<WL2K&1
M']D=I;K]VAAN1&2T:\ !0QP  L=W?:186\FK7]Q&8+1%DN6N0467BU;SKE!"
M ETH">7&0&/ 7&?DQ[:TOM4O=+U76M.CM2+A+FQCOTV#(>WA\Z\*$(;QT)\E
M H"'(Y(^4 I^&_MFK+I>M7'GPV$_DMI\.HY5)5CE@B^T7CC'FW<J[3"#E1L4
M@D\UU$,UN)=,MY)9[N&UBC@1[^X.QCNM"K709 4N\L&C0C)YY4M\LEM%#:6\
M=F_F75G<6\*S/J4 A6X600P#[2\B[I;A@K@* ,Y".%)1CCZOJ\GV>.PTR..X
MURZ0S6\,A@=;BZ@$;#[6R1E8Y\V\R*%(4^0X#HRJ8P#F_@A?7$4OBNV32-<E
MA_M4O]KO91O)9@I2568 3*/G<KDGH>0@;U"/5-6>= WA^>.%I5!9KF+<D92,
MEB Q^8.[*5!(VQ.P8DHK^=_ 2.9-&\2&X&I//_;$BR3WQ*M(P5<[HR[%)03E
M_7<HW-MX]<H \S^+.H:A/\-]:AD\.R+;26\;>=<W4*B)@R.=X$H.02 FTOND
M4@KMVE]#X6K"OARU8P6D=X^F6#3M'CS67R L>?W:%DVJ"&+/AVE0'$=7/BI)
MY7PO\0MYGEYM"N=^S.2!C.].N<8R<YQM?.QL_P"%*Q1:!%#%%@+I]@SR>8[%
MV:W5B&RS+N&0,Y5MGEJ4")$S@'H%%%% '-_$&1HOASXD9(9)B=,N%VH5! ,9
M!;YB!@ Y/? . 3@'D_$?@FZ\8^--7GM]<^RBVBM;?RKK3X+V#($CG]VR[=P\
MQ2"Q\Q=\G 21">L^(,;2_#GQ(J320D:9<-N0*20(R2OS C! P>^"<$'!$FC?
M-XJ\2N/G59;>,R'YBK"%6,8)P0H#JX0 J#*S!R79(P#SN'X:Q:.AM;[2KNZM
MX781WEAIVES@6X8A#(LD F:4(!N"K(6/())VC4L_ WP]UZ\+:7=V)N9HEODM
MH;>SWQ*X!63RFB)"^6Z*%8;>0Q7S#OKTB\O[/3XA+>W<%M&=V'FD" [5+MR?
M159CZ!2>@KF]>AT7Q);WUK_PCL>NNCK!<;HA&,*),[)G #.F95&QLK(^&,>6
M90#/E^$/A*4_\>,:(7D+(EM ,I)(SNF?+R!\RJ&!#(L:A&7+%J^L?#/P<MDW
M]I7,=JC6\ENDTB6L8B4HCN8P8]B$"&63Y0-IEG88SD$7@GQ>]O/"GC:[TNUN
M$F#6D9:^DC9@P4BZFP^!E>%5,!<9W9D.HEI?Z5*TFJZ+!K*F4R)=6LDDLPE9
MD=0L$Q;R8]\<8^64JK*CD(NXH <V_A/PXIC&D:?J5_=Q)/ 9+#2;&'D220RL
MSR0QQ,?OQ&,D@J0P0D"05Y/@U/J8,&I:Q'#8QN!#;PVT4V (TA+*\D>Z,&%
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M'W@V5X7;PKHP,3[UVV4:@G:5^8 8888\'(S@]0".DHH YN;X?>#9T"/X5T8
M.K_)91H<JP8<J <9'(Z$9!R"14G_  @G@_\ Z%30_P#P70__ !-=!10!S_\
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M4/\ "VTX8$@X(SD$"/0#"VH^(BL<B7']IXN07#)N^SP["AP#@Q>42#T8N 2
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M_P"TPP0>:Y_2Y<0_"&+^SO,W6A;[=M_U.+!OW><<;\[L9&?*Z'' !ZA1110
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M 4444 %%%% !1110 4444 %%%% !1110 4444 >-_M(1L? NF2B:0(NIJIB
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MABC@ 9(VY8*I5B >B/X8\6&\NFC^(-\MJT1%M&VFVA>.3 PSML =<Y^4*IY
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M[QH+L;+F9Y(&FN+A"JO%+M*,D90G%RJ_NPK8[#[3-!;JUO)&D\")!&E[=$K
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M*-N :/+@OL1FYN>_U'6]1M=)T:U\O5Y;2.>]GN@KK9;RA2XNX1&JF["00F-
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MY@61$S&'D8$Y).!V%=)X/\8:7XST.WU#3[F!IFB1[FU27<]LYSE&& 1R& )
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MXXS7-_'_ , S7!?QK:2VD<%O;QQ7D)0K)(WF!%<$##'#@'.,!!R>@W/V<?\
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MV"M'W50) 0S%2E6-,EOQYMKJ;02W46&$UM!)''(C9P<,6"L"&!4.W 5CC>%
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MADF)TRX7:A4$ QD%OF(& #D]\ X!. 0#I**** "BBB@ HHHH **** "BBB@
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M3AU.QR0=D=<_%I-CXA^)NB2P:)&; 64MW:3R7^;RYC8Q*+N>0EI0@5R(1GS
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M]@PA=ALQY\K#8IX9\ #- 'JE%%% !1110 4444 %%%% !1110 4444 %%%%
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M;S;>"T<BL",D H,8P%7Z/H **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEA,K&0/MR"/,4GIN62YUF&U,C/-)8P0O,YGOY@BV<GF31K+.'G5G@E;_ %2
M8^48*_+LIWEXFCZ9<ZK<77]FW$7^D3/J6V::T1I+@KYXBG'FPG>T<4:D[6(X
M8@[<N33F\1W$M[XAACM[*R>6XM]-U%UE6Q.;M&GO$=\21-M5D*G"X"H0BL[
M!9P+=I!J&L64>E6>F(]WI.GS[I5TY78+%/=Q>9D$'S"B@!(460%E*@KT@OMD
M^I)_:,$?V*5Y=DDV6T[<DK>;=?Z1\\+?>1,+M4KP-N4ISW$UDES=R-'8WD;Q
MR--/$96MHG:9P]P$N27@7S'C )"(Z.X C *5]?UZYT:9K6"XC%X;@74$$P=S
M96QF\J>ZN2+C#P8D+(ORA1CY0(V* $>MWUU%J-]I-IHGVF^O[2XCBM_MT#R3
M19=M\XD1S''GS%A^_%F78XCR ([+0VFLI)9DM-7O[YXVOX;J-0EW*4WI%=C[
M,6B$,(B*';'N8Y9%+X-S0_"W]CVL@EBGGFU26..^BOG^U/<;(FBD\VXV-NA*
M+YB*RI\QVDH)/+6Y+.SV_P!MN-)NWE9Y)4\ZV5V<PAI(X9]D3,H20OY;1AP?
M*5@[&0*X "PF\JZ$-E:9NWN+?RI[8F.[S/,Y2?$"E$V[PKDLI,[$B4[6DX?6
M$OO'5_-X;L/,O=+5!#J.K7"[&NG"-+';2[+=3#+$_((.U,XD5W;RS<UNTGUN
M\?PWI20+&+MX;B\O)I8I[U4$#2V4LAA#KOA*%9%:1I([<$EAN(Z"TL-+BTX:
M3LL;C2WEMW:*[A\OS2PB4Q72O&520>9"\<8$9.(XU5$CR0"QI^E:7I-G;Z+:
M6<$-O++):0PSQ;!>6RE]\4A:'G;YDS(N29 F\N0TC57OKA-/LY-=U&+;:-=B
MXB6Z"VQF!(P+@,OEJRB*)H9)#&^1%&Q1MQ>36+N'3[>:XO9(W$J"S9M3C$-O
M=Q1!D?[5-]F(B#-*Y4?<<JFS D8'#TCPYJ.LZYIOB?7=/\F02QM:6CQJDEPR
M^:!<7P2$A9E@V%!NVJX(!C+[0 6-#T"\UF\LM8UVSG):T5+/2;_),4)&V4W4
MH4^;(JSRI&DG)0DM\[2,NY'#?7R3,8(Y3=67EQKJ-GL-Y$K ,MUM3"$AF*?=
MP+A\PDQD$CA:YN+2=],NP\]ZTK"=556*E#BX58R \?E_NG 8'[/'B8>9\V7]
MOS_Q*]$M?MFH2_.D.HC?Y4H^>&:^VQEX]L<,/E%V\U\@, REU "\N[R\8:3I
MH^T-K$3122W-@8GB5HC&US>1-#@L#!M0-Y:R[RFW$8:K&CZ=;Z6L;2V^5G\@
M-)JJD3SRI+&F;F9D??,C\PE7"OOP@VHKT:5I$5OYT6F-!>S&*&42:A"[S7$D
M?E2 7LC(72905:,D@J)3B(B(9D\R&UMU$!C>U6X26::_ =451!-NNR4$D4Z0
MJ1&S_P!Q#(Q9EH $6:'2[-X8(XOM+QW"Q:UD%_\ 4F(3OY9*W"N(X$R[-CYS
MYK)MKF[0'Q<XGB@L8O# EMX7-]#"CZJ_VB*3S+@ *R;_ #FDBC"C>S[GPKA&
ML6MO+XO>TC@TGRM'?#7 OK1%.HM#<1-,+H*@,4B2/<[8Q\LD@D)PG#[B20VM
MO8V]N8Y8S<6L3SWX#^;(!;,KW>4$D=T4!$>>-VS<0S(H -"&Q6:XM9S#).[H
ML@%PC1K= &V)N+A?) 2X3RQL4@'Y3C;SLY_5O$,WA:RM7-S=W=W%;I865I(Y
MEE>9DB9UN0I\M[A57S$ D0R^8R*,D.TFIZQ9Z6NGS75ONU6\E2"UT^_D$!OI
MO-M8C-.%B*^=$ZJ5*!AL4LA*GY<_P1X<N+1EUPO WB9]/B@\IK<0QQQ>5:NU
MO.L4:K%(K;@F06".I(D";0 &@:"FF745WJ$4%QK\OD1W-WJ$RSK"!+:GR9I%
M _TG:T2Q]0[0K(-ID<'K+.T)<*MM');S/'/;Q312 R1HML!+<O(C/]H0J=@8
M@D 9Y4LE/[-;VT48DAG-C)%+<33WSE89K0K$KK>>9'_K%1L*'!<K;X:0;I <
MN[^TZYK,FB6%K)^XN%6_OIT>+STC:U+2LR*$6X(1E0;0P4+*CQJ4W@$=YXE,
M.HV>FZ0WGZK>2I'>W?F0Q?8DS;PS-.0QAFNU8HJJH.W<HV[<"2-O#=CJW@AM
M*N/+7^T7B?4)IC]D9)YGMI)//C$A_P!*9FW1C:57Y4^Z</J>'[&PL])M(+:/
M[+:#[()%U!HY")5CLUB6X0[6BN=JJJ*F5!PQ!8JM6+F_M] TZ?4]\%G':^6U
MY)=3$_9DQ;!X[C;(YFN3&/D;#?PKG#9< Y>Q\-)+/'=W7B'7'GU"6UOKF*>5
M;>&WNU2W51,I$FRX+2K*D/W&*(A&U%-8=IX);QF]Q)#J_B"?2+QX08M0U%5:
M[@VJBWDD*JA4;8&$18.TCK&S *K;NHT>V:^UFRO]1N+N&&&WM[>V@U%%+(8V
M@*_;RK_-=.TVZ)&)"9W[=Y(K8TL"UMWTZYDC@M=,2.YD%^D;;$Q#*9;DDC=.
M9%N")HR8]RN6+,N* .;/A?3-+\0Q>(+W59YKN*47-R^MR0O;6C%[;>LS#*QW
M.QT\LQ;%Q%&.54E[&L>()=)U/^S-)^779XBL%FEVA,2F.U&;UV9P+DE?*AD;
M>I+H#N!-6-2UG[%%;IHSSVVJZC:-%;I<':+221;.-&OLF1WN%:2$*=I.),-A
M<O5S1=%ATYV$MS)L%Q$9#J%X+HF9ELMHN@TA_P!*W)B,Q_(H(('(# $GA^RM
M]#EC5Y_^)G/C[5>W +%"6@/V:X?SFWS?OML.YF*H0 7P3)<L9KZW>'S9XXS'
M<+;2BYO/,2R3; ODD[]T\LK -&\@# 39.#^[>2PN4AU-+*VF^RS/Y?F13(KD
M/Y<1\J:3S"TMSY4<A!5CM3!<, A?AXOM'C'4[;3SJ<]KHFF116MZFL1!;QC)
M'$GDR(S!EDF661/M YRK*@4%FF )/E\;!7TZZN]-T1[=(93.[0_:1=1P0E;A
MF9C+.(BWE$Y+,8R0$\MI^L,UGI%KIIW_ -GV.F;(=TEV$ATV/RHAY-T/M $D
MC X1L.%+J<'[ST[-]%LGL;NSOH]%L].LH&GM+B81"U+K$BK>KYH9I3"JI'O!
M"E6)+'8*CU?Q);^%K.RM8;B?^T[F46EA:S3&[ECED,#&&96NAYDGS[@Y<*BD
M#=RHD (]9\1V/A8&XAFD&H%%MDL$/GR+/+'#Y:7*([O-<%87\MB55@"A=<AS
M'X1TN]T[47U+69]NJF*"U>66XCEAM 3"OV>0AU:6[D182TI7!/EA<J K1^&=
M(:'64U37-4CDUZW<@6]Q>K=1Z3%.T"Q6QW.&\]D4JLJ@;RS[M_R[MR 7$<0$
M+0:;-)*()YS="1[0,L*HLVYV$UVX\H*S A=V,N !, 26&HPV>C6EW<:E)!!:
MV\227.JR!6ME*VY,5V#* ;AP<A\?+NZ<XDP[?6]1U35DTFTU""P6UM+9+NY2
M]69],D>14-JQ=W6YN'>)D#,BE,YRY?!KW6NQ7NI_9;&?^S;!=/1-0UZXE=1:
MV[QQF. 7'F&.:YS*'64L0@D.-Y9MW0:,TMC9P6T8^R+!%);^=?7",]O<.8=B
MW,<<I6::5W,NX%3\X'!D)(!)80PZ0+2/3X+2RMD>*TD1IANL\QVX2*=1+MEE
M955%DW%EWQ *ZEB<][N#0M+E87T>EP:190_-.DKP:>%W!()E6XQ+*8I5&U22
M657).Z%:DENM.T6SO[B6]GTJ2TM%\^[NV:::T@8HP20O*_GR%FF$3@.BL'09
M(97Q],L7NKJRU'6XX+&STV[BAL=(1FN(-.N&EC7$H.UFF/G;8MJ^5$FUERI4
MD L:+8:IK&N6VI7&@_V-8KY<L5G<G?<:B(]JI->3;6PT:.&2)R7,BDEODR-Q
M+-O.LX[/3XV,Z1SF>YM%5)T2:&5GG C1H[C=+.\:# W%V(!X6.+2_P#19;9/
M#^7^>2*UU6X\Y+K?%$KR3S[)F615DDA"EFW*K 93!7/U2]2QU/3/LT$^HWU[
M+ [V!*QO?(L>Y9YDDA"17"F-V5=T6[R,;CY810"/4M<MO#Z66F6MC)JVHSV\
M5Q;6EU*D;WA5K9(Y[MY(PT4^X80MPQ3&=Y15CT70;<6MW>ZR?[:U*[B235(Y
M8"\<P$5JS"2);<%9(P,Q0LN\AV/!=MAX?\/OHT4>HW\=C/J6H8GF>56M8;F5
ME@*-,/) 687("QKM5@LCMAI-^=A)]]Y%+*]C>*9;>%GNT\A_+ @>-K@^3\MR
MLLI:.']V#YN0 1P "K>1N1<FQ"O=Q;7N[<JMPT=Q#$9)B8E'VC$:&(J55F<!
M598U<\^]TGCS&D:+Y%]HD_EOJ6HR1*T=Z%^R%TDVQJ8[GRV.".%"X&&'[BO!
MJO\ ;TMOH6EB>WLH?LIU/4-17F:0-:+Y,LH4%+\#*Y5B5(4#YR##TECI<%A#
MIMII]A)+'!;QQP172RQI< 0HT,UQ^XPLZM:JG/* @_>9$(!)H=DEKIVCV%MH
M\Z6K6D,J)>1JN1$+4*]R?+RMR@'R*,@^4<D8&RGJNJ6.G65W?3K'/!'92?:V
MO7\FWN R6H)O5$.4N"K )'L)*Y&!N"K<F6+3-,2;.+4RQ71?4+=W#PB2WS+<
M,8@R31(-J%VR @>0G:Q3'MK'^U;RRU?4I(%NH+NWEM[2\^5$8BV7S;L+&H%^
M4DPB$[5W($!P6H S_@C>)=?\)@6%\+IM;EED%ZZK( W3?"IQ')D-N(103P"=
MF%]8KR?X+AVU'QQ*;B^FC?6Y-K72M'N.6)8QF-520Y&X YX4%$ 7=ZQ0!S_C
MO_DGGB7_ +!5U_Z*:H_"8FAN-=LI9(REG>PP1)"ACBC465L=L:9.Q-Q8A03C
M)Z]:L>-#"O@7Q"UQ')) -,N3(D;A&9?*;(#$$ X[X./0U7\)SPW%UXD:"6-T
M36)$*A@[HPBB#!W&=QW9(&X[5*)\NS8@!)XL_P!%M;#6VYAT:[^VSK_TQ,4D
M4C9_V$E:3 !+>7M RP(U)M5L8-+&IM<QM9LBNDL7[P2!L;-FW)<L2 H7)8D
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M%_'$-VQMT>2QUORBZ75LCA-\Q3<(R 5)9B  PWD'EP#TRBBB@ HHHH ****
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M9%1LD; A)->@:K,W_"3^'[:(1RNSSS2121J?+B6,J9E8C(</)%'P>5F?@]5
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M)U <;;!$.0"1U4]ZWXH$B_:$\&2G3_L5W/I4DM\C1*CM<[+D2,Y555V+*?G
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M4^8@8.S)]V0J'"C:A"\ "@#TBBBB@ HHHH **** "BBB@ HHHH **** .?\
M'?\ R3SQ+_V"KK_T4U?+GP8D:+XMZ"R0R3$O*NU"H(!A<%OF(& #D]\ X!.
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M+_9XGFNO NJ7%Q+)-/+K$KR22,69V,41))/))/.:]<KR/]G@PMX%U1K>.2.
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MS\CP;;^?$\7G6_AC9)'N!&Y&^T<,,Y![&@#J/^$[\'_]#7H?_@QA_P#BJ/\
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M#11';;O.\%6@D>*W\K;Q%\[LQ_>_="[D!QE5Q\C$9'Q>F\SP5K4:W,$\,/C
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M"P65>2RLSR-X%@FTZ2TN8M#E\W9OE_L6+<NT*J;025_=H9D3<K;59 =VUO,
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MLRA6+1QNJ$L!R<<]\T 2?\)UX37B7Q)I4$@X:&XNTBDC/=71R&1AT*L 0>"
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M-B0;2-K9<G&2#Q@Y4<XR#)_PI+X>?]"]_P"3MQ_\<H Z#_A._!__ $->A_\
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M !'@9J-]=T>.\NK.35;%+JTB,]S"UP@>&, $NZYRJX(.3QR*\O\ ^&<?!_\
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M, L512Q R0,X'J*\ ^).@ZK_ ,+2T*XO/+TE/$[IIMXNEZC)(TR!XT?<6C0
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M$$5K'I4<$R7T+QI<;(PDJ1AU GP05(3=U [C/)_'>#Q#HW@ZV5?$EW?:7>W
MM[R"[BMPQ;_61E3'"I !C;//]WWK0C_9[TV72]-LM1\3ZS<I9O(=BLJQ*K;B
M1$C!O+);82<MG:>!D%0#N!XR\ M?OC7_  _]H1UNC*;F(?.R&(.'S@OL4J<'
M(7 . 1F-?'/P_33H[Y=>T-88M][&HEC$B,X8LPC^^)"'?(QN)9AC)(KBQ^S?
MX5^T.S:KK)@**$021!@V3N);9@@C;@8&,'DYX(?V;_"JH1/JNLN^]B"DD2C;
MN.T8*'D+@$]R"<#.  ;A^+WPP:SFLSJT!M9M_FPG3IMDF\DON7R\'<68G/7)
MSUK4'Q-\ 7=O;WK>(--81I+<P^;Q)'L!1B%8;E<AR N S G:",UR?_#./@__
M *"6N?\ ?^'_ .-5')^S?X5+PF+5=95 ^90TD3%EVGA3L&T[MIR<\ C'.0 =
MI_PM+P:^L?V3;:S]MOC]V*PM9KK?\NX[3$C!L#DX)Q@YZ&J\'Q/\$:W _P!G
MNY[^&&6'?Y>E7,JI(7'E9Q$<,7 V]]P&.:Y^Q_9_\-Z9>1WEAKGB.TNH\[)H
M+N.-UR"#AA'D9!(_&I++X#Z#IJ2)8>(O$]JDCQNZP7J(&9&W(3B/DJW(/8\B
M@#J'^)7A)4=AJ<CO&DKSPQ6<[RVZQ-MD,T:H7B /=PM4_P#A;W@C^SO[1_M:
M?[#YOD?:?[.N?+\S&[9N\O&['..N*PT^ ^@QW%W<)XB\3K/>HZ74BWJ!IU<Y
M<.?+RP8\D'.>]1_\,_\ AO\ L[^SO[<\1_8?-\_[-]KC\OS,;=^WR\;L<9ZX
MH Z"^^+W@C3+R2SO]6GM+J/&^&?3KF-UR 1E3'D9!!_&J^N?%SP1I\5[8W^H
MWT5TD3![065S;SG*Y 4E5*,01@Y7&0<CK6/??L_^&]3O)+R_USQ'=W4F-\T]
MW'([8  RQCR<  ?A67JOP1T&^\:V=O?:UX@NWO+*XN)KBXNDDE+1-;H@W&/I
MMD(YST7&,<@'*?L]V%Y8_$.Y^V6D]OY^B-/#YT93S(VEBVNN>JG!P1P:^EZ^
M;/#6CWNA_&G5-"O3K.K6>FV1A22TU*5)[:SS&\9&QD9PH908D[L2JL0 ?<_^
M$-TO_GZUS_P>WO\ \>H Z"BO,WDT^+6;RTETCQ<MG:WL&GO>CQ%,5$TK(%RG
MVK=LQ+"P(!/SD%5*\]1XFA73[,W]H9(KNZU/38YIED;<R?:HDV9SPFUG^48'
MSN<99B0#I**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHJ.>>&UMY;BXECA@B0O))(P544#)))X  YS0!X/\)YYIOBV
M4EED=(?"5DD2LQ(1?)M&POH-S,<#N2>]1_&W_D6-=_[&NW_]-L=6/A7-;R?%
M>-(+7R9(O!]DD[^86\Y_+M2'P?N_*57 _N9ZDU4^,XF7PIKPGDC=_P#A+8B"
MB%1M_LY-HP2>0N 3W()P,X !X'1110!]A^(I)O\ A7/CCRC:7-P$O5E?!@<K
MY?\ RT79D.D155SGS%2-MP#\>?\ P6U&&ST>YNI]2M+=+;1XXQ=2R!;>S9KN
MZVI.IE&]RS!E.%^4XRN[+])XD7Q'+I?C33;:^OKNP66YA&[[*! DEM',1)+,
MZXC#2[5P&VQB0'DQLGGGP=U6^Q>6>B11VMX+*&,ZC*FRU287+LD<XWXD,H=8
ME< 2*.%4@%B >KWNHS:;>VFBZ+;QI+I[PVMJ#=DQ:?"SQP_Z7&)U$A9"'A!)
M=MV-JE"6T/#VDVWA] (;N02;TCDFOI4=X"[0NUO<%9?WD\DDLKJWS!3.VWY6
M"O'I-B=(B\F'4+Y'^UVPENKR>&5XBZP[X;@^:?,F?RE4/@E?M*"/Y!P7^J16
ML2W+2P6"Z7M@-_J >0Z>\BVP6WGQ+F?>)MQ??L4HA;)3=0!<_M,PA?*N9+8V
MKI8DW4<D_P!FDEC@$4,V)OWLIDEB;S!N&W>NY22YX^P\[QC<6D@:2W\*6[Q(
M(-6E,K2-*;>8";?-(LY=9$6(,/D\US\KQQA[ W>--4MV%U);^&]/>&$-=NKE
MI?\ 1SY#;F;SA-',Z><&.\':OR,QN.HL+2VL;BTEA>.U2RMXM/MXIF1ET]&-
MOFVDQ*2T\GR -E@-J8')\T +!H8!:6UG/)IT&EO%9^3+CRX%:.WQ:S9D(DE8
M2*4D3.#@9/S+)CZKK;:9;V$AMY$UZ-(;6V@29;AHC((7DM9I#(Q)=TAC,[*
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M;1@$*ZE#T%FD5J]BQAC06*06BQW%U"J6[E8E4.B+MBN-L\BJL0VN" 6 :,*
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MT5A%<W5WJ<&I:Y/C3;J^^TN8HVVN%L8IE<R6^U_+S(X+.SJ?FD<!;'AC2/[
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M?!Q"WA_3+N[U+3K)?$-G/*(UM9+5HVC:1P9%DP$EDPN VX#@CJ 8?@5+B/\
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M;&RMOBJ9(-"CBE/B-LZDD42@[M*+M%D'S,EB7/R[223G->J5Y?+;SVWBZ_\
M$,EC?7#6/B55N(;&66<+;MIR1+)Y P&8&5"Q5"X&X L!R 9_[1W_ "3S3_\
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M_P!"IH?_ (+H?_B:Z"B@#G_^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\
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ME7522<$;<>^UFYL[>S46$D^H:G<6;V=I>:<Z_:"1 6DNY$B*)<1B&9OE.$5
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M'F;P5;]T^QI=I%X<T:UM=,>2"*Q2&(VY:'@A4Q;3#S0GVB5IV8.FP%BFXL
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X_P#M
M'?\ )/-/_P"PK'_Z*EKV"O'_ -H[_DGFG_\ 85C_ /14M>P4 %%%% !1110
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M9DE5C!W/@Q(LOPDT%DACA 25=J%B"1,X+?,2<DC)[9)P ,  '>4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X_^T=_
MR3S3_P#L*Q_^BI:]@KQ_]H[_ ))YI_\ V%8__14M>P4 %%%% !1110 4444
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MU)'S-@>9M?0-Q+:1">"XGC:#R8W@DG24IA4"VDIDF(-Q(9B5D4C)\O<S  .
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M%XXI,H95W.9)&X$LE7+!!=2H@?[9Y?EHEO,TQ01(T4L;S"56:*Y19 0"0TF
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M#L JY>GZ==WFJ6NIZIILESFX+6UM)&B_NU\I%OI@8E NOE4A24*1%@J[E92
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M4(G2VC=H&DMKB,2.'DD#-F3!"J[,3U9[EC";%(5L;"/3;2%UB6U2UD46_F-
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M5\$L-I?)V)6YI[0SZ7IPGGD=(4MD#:I@O W^C,L5RAD&ZZ9B&5]ORDCCG]X
M"6T,5E9V<!M+2WLDCMXH;L"5+)MD/D02J)\/.)3$ZL,\#:""X=N?U&9O%;RZ
M'8ZG=V.GVZ+IVI3S,KI&DRQJUJ9&D<37FY0F\9""9@<OC=)<7[ZCKD>EZ8_V
M.%K3[)?ZN\S,]HAVQBS,JR,KWHE<D,[?)OX#EFW7-'M;;2-)LK)X8[73[)[>
MTAM[B%)&MI3-!@7 BF9'GE9DD20(/+W%CUPP!8T>V&B.1$8X_M%[^].(U2Q\
MQ8/W-R//)FN'PH$IWL6DS]TX:/5M<M],TZ\>XN?+M=.T\M=J;\FYLT80[8)
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M7)!*M67?ZHFG:&NIWL'V6$VBZA)+J=NH25X_LVTW6Q 8[G/R($#8VY"L55
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M3S9FE6+$*3+)!(BG<_E;(_F.X*QH>AIHDOV7_CZAN+LI$UZ5B-T\;1L99E*
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MSQSJ1B.(L6.U1DD?( 1ZC?V^DV"7ETL#0O$]V3?(8C=F&!)%FE M\K<*8AA
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MI5609-XI$8$4H=@98'RH,H.YH_AI]$TR.Q"P76HSRP37$D\;-!*(9(P\YPH
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MAJ0%S;K:QW-@@:,R>?,@M[91)N-X1N4D9"F-&8*!MH L:IJ%C8:7?6JWDEM
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M\,C.6:7YW90!( 20Z=;Z7%<Z=)-/)<2Q+<SF5C<S,(%\M+N/="?-N/W=MN0
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MMN2Y/FDA!AF,2@;09  "1;>/[/!>RZ?)"=_]IK;0&<JK$1&60?N0\<HW2@1
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M8;^+BUVY\07MIHOAA+NT*);N]S"SVZ>0KV;/);QLSQ*GDM$5B.6Q(^X(<K.
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M> 328+A?LU]J\'EPW$KV,.F6=V'6RE;RX5%IY9&WRXA,)6R&1HI6C"JS;MR
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M^([JWT25+F32\W8\U+);*U,TT4LC2,SVQ%NP,TD:RNX8[0R(&^5RY /-_CO
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MNQV2L5D4J4 8@*RIGZG)#96\%N-,CFOXD M+&" -Y4D8MW6" F# MRRH&G;
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M_?(1%+,4P;FI,P>YDDBC^Q[)!<7&H0*J7B!;K-M,?+S%!&=K"5@0P; W%B6
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M6.5-C)GAPFY.MA<2S64NHP3[Y8/. FC03E6$'FRR)$#'<>9P@5@2]L@0IAP
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M6R6D7S-N['037W^F6RIJ,$\=YNOH8H9L/J(4;HX[8FX&W:J1E^/+??GY0SX
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY\MPK2PJTARK-Y8 !.%Y^=+SQ?+<:SK<\Y\.K]JMTT&*$YU3R6NU4*C,LB7
M"[BFWK&C9!7$=-[I?B%<:AJU\^I#0;=%DT86FZ.2]EB-X1+;+ORMPFT  D[@
MFYHQN3R^\N)[>QTZ<1'?:I%);K#IQ*^>D8GQ;6J)*"EP@3!90,[<#&/W8!3O
MQ#);W<U[>1QSW-Q+!#/;WH.^3%Q#'%:>;*%AN@N Q"@%BPYY*T_$/B*(2P);
M6O\ :M_<2W$5O#&[P--Y;30,EL2_[J:-I$$DORYC+NN0N$N>)/$*Z4+N!3)J
M&IRI)$EC9RLDER%CED\J(++NAE1&C=Y=N6#)M!9D5:=O8?8_M^KZO=?VGJ$W
MFH[V9SY_E?; L-DHD#PW"QL0P!/1@"6+O0!7MM%@T^";4;W48(]8U"*:RN;O
M3Y(HEN)I7E/V:S+R Q31R#KP'8EG#.2T?07LB7-XHDC^V;O.6.>"54#N@G7[
M/;YG#17(4N&D &0C@E> D=W.HN+B&#4HWN[]W_=K<M_I:1&19(+5#<KY4Z*%
M#2+M 8[B,Y"<OJ6I+XNFO[>QM9+BPO'2T>_MBT9U:*"9W>UM]TJ)@([AI3(-
MX$NQ&"G8 27=_<>+8'TN!Y[FPO=DES>"8(EU%OGE.GV^R01M,$58FD1V4J)-
M[ H >DC:'3;>QLTGDN0KBUA-KB-;HP"=UMXU214BE7RL.2%C;&P@ [4KZ>ML
MJ2RV,MI=V=U;_9[:ZL)TC-Y$K7;)9VX215C>%2 ) >1NS@KE:=YXEL[&S$JW
M_P!KL)(FMX!;78DFU5 2JK9M]JW>='OVNV-\C ;>=H !<N=;L;"RNE>\DG@@
M>73Y&@O-[SLB$QVT/^D%Q='S,;OON8FR%S&1EV,MQJFH1ZMK%UY\UQF.RL;"
MY$D:B6S,OD1LL@$=R@60BXRH9)N" ZB.OI%[>:[Y?B75YO.BN/,AL;33[DR(
M6;S8C!!AEQ<1^66-T"%*S2X(C4.O275S=HES%#))J4MPERB2+=) EPRM.4LX
MBLH,4Z]#*$/$1W'(&T L7UVUPDURB27!MW8;K-5F-H T\1F@+1$/.!P\625
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M*,@(186W%=SH)#$1MKZ/IDOB+6-*U+6IIYU,L>H65M"J)_:1A6&--08@J(U
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MOLSQ:&FZ+]A\R(V,][->1/:S7=VV_P#M#R?.2..\S ,*48$2A3NV[2S#9YH
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MNA:+$+[U<+\Y89=@4 )!?6,A>_LIH[Q+EUNY9=,?=]KBBD*YC1)LL\7[D2,
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M;&1\K& C)H:EKD.GII]U=+)>07R6T<=Y97@B2YN"Q:%(8C+R'8')W8(= Q=
M[1X?AX7NK75AXAUAKZ._EE>".W^U1B/RI)1+]GB"O&PD@\E?-WKN81S*1(-N
MT DT/21JFI'Q'K5O'+J6JI!(EE'=1S".&*6*2)[:0.#Y2%D:4<AY!E1@J'Z
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M+.T74+A(T2PL4CNH6MYF0W$L*EF7#O./.EVDB,,HSD2OU#WRA+\2327,<CW
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M+K.DF2)'5#O_ 'JT[S5$\8?VY'I][NTII3I3ZO"BF2[#_.UG&,B+^(I'<2X
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MM 9#M9P7]S#';R:A?74DVBR/&&E"B\BU&WF$B)"L2#Y2))D&51BZ+'EFRP4
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MM%M(HK"_R^J%XF9HX=USY"&$!-Y0,',,O.UG2NHO;8:E<7MOF-+:_N#:W$D
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M;F#;OW>6"#:5X_5M0_M+5M7T70#Y5Y#%+#-J>FQ_/&SR.SPP1EL><))+4RR
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M8R"TV7*F>4AE*':106Y\_39!LC\JW@N[&(&6.W0[%2&*$Q;6MWS*K2X' 89
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M'=W6J:@A@6RMIU1W<JS+;C9.3!*BRQO). 5VC.>8P*^DV%H79[G6M-GU"X>
M/>_:GE1K<*8HX[8F?S893'<1L9,L=UWP7WC  6&ELMO=PWFH23:G<H[R/8;4
M@^TL+P/'IY=P(KA?F#L>2%#. SNPZ"\87#F99XY;@/*EO-#Y;%Y%6Y416RR2
M%$N$&0[LN& ((QD1UY9KN[22Y2[D5[M! UMYB 2;&N"]O!LN!LN@HVO)OVYC
M!'W3MY^^U5=1O9K;2HH_LMMJ;6]U?P(T06</.9+:%6=1#<2"5(_M&55S,V&#
M;%(!(=1N-77RM#N/*M[W[6DEU8,$@N8S+<X6U+NO^F_NV8N/D^9G8L!'6HUK
MINFV\,9NHVLX473[*);A45F07,2P6K-,&CN@&",Y8;MN!M.=A:VD-O96]H\<
M=T\;W$(FMI @N9427<MONN2\=P3),&D)WDQ2[R/E:B;6(=$-[<F>,QQW$RQI
M$HCS,9 [VBVQ9"\\B@/&Y+EVD=AM1E5P"3Q!J?V:SDN'O_W$DI@FDM;C8]RJ
MF?%K:KYA_P!)W*L;$!6;)VD,JA.7TFTN+NZBU[Q!<_9U66YBM-/MKT01M<RR
MW:/;Q@-&#=J25\_HX<X!(\VKEG9C6[J"_P!3EDNXHT>"RL([R.5"HB$T!1S<
M%A?%'!\\,.$?& 4E;I GE>:J7\]U#)$;-(X[K_CX\O[3^Z@8S!UN0 /,D9N?
M+S\I!* %-KFRNK*U6&UCF>R=[2.SL9HHGC9D<-;1!;@+'<0Q@;GSPN_9C>0N
M'XI\77[2RZ'HTD%UKEW+);2?9;F14\A6F'EPN"1'=H&AWG;\OF*[#RT)0\6>
M)-8EGU#P_P"'I_M.MW_FV]O<Q1/';Q*B2MY6[S_DN!MDQ,%"L\90@&-O+U-"
MT.VT>P?<T=UJ%T]U]IN8)D$EY+(\[RP0.KQ[9U9%#2;4R(EX78/* *^BV$UJ
M+A3K4=Y=27$\>K-9W1+:I<+'*JQ1;IQ]FG6-4=U4*!A K!4..@,9OTN+J^$<
MJ6[S;I[,R2CRU:XC"P!'WQW"JP#LJY))09XV1WMS;P^;<7%]F"266*:=+TQ1
MLAWK(D>9QY<D*P!W8#@)*4 9F Y?6@GB:6/3-,@GBA\UKIM0AA6W'FAII!!;
M1W (-W@R[Y%,;(Z[F8%3& "/61?>*+J\TZQMI+'3[-VDGGAM?,-H\D3SQ7$4
M;P++]J)9=ZHQ*"8;<NQ>/J+?1H='LDLK2&2UM-/25X8;>$2BTC9'1)8"8"9)
M_D8E,L<SR;BX* B6-CH5E;Z9!#'806J,MI%"GF&W&RXQ+;9A)EN&4$NGS$#)
MYR?,KZN8=*M9YM0LXVE#R^6+*R#>3OEFEB:$M$5:X=XX,JS;3*$(Y90X 7T[
M:%93?;H),P.WV>2UB61][I/B>,_9UC^U2N2IC)VY=0#F0*^7:Z)>:Q>?V[KB
MSQ&+?>164=L2;5B)%2Y'[G_2;@+'&J(Z*T:;=RE_O1P6@9]3U;5K:TEN&N)9
M-/M;&*-GME19I%$0V-'/?+*DQ92S["SD$!F#]1=VTT1N'CCC@%NCSB*"U+^2
MSR2 W$#^4<SF-I2T>U\LRC@,6D "[AFA-QY=I'$($>X!@C+?9F:20&>#_1VW
MSM&\K,OS?,%7!$A<X>LZE>?VG?:3HD5B+^TBENF$4)N!I[/'=E)\+#Q-(S0D
MIF1F#OA",N].]NM3N-9GL]"?35N$>X#7<?ES06TX:Z9([:)G4&^9'9I2S!0!
MELAJV+.PTW2K>2VTN*,2/<3O&(IUED^T8N0989IDQ+=,%*NCN0@4@G:/G )+
M738M%B_L\?;FDAB>X,YC>Y,.%D0W,3F JUS)E2\8ZEG8!B6,EB>'^S;,K,DY
M:WRYEM[3SGA9S,OVJ();D/<.7S(H&U=Q.,']Y'?W=M96%WJ:I']GTQY;V5;-
M498A&]P9&B9HL-/)ADD3<"N]OF!.Y^771)/$Z22:QY;Z2KR1Z7IXC@WW4RM*
MSS%6V*+QGB+LCH$16D1E)>78 1K9:CXHM8]:O(9X='@T][E-,T^V7_2_/B:7
M[2@*LIF9BR-;DG&6W.Z2%9>TO;::(^;#'' ;.X6\>"*U,BB,R3;WA81$^?(K
M-O4!CR5&TR"4QS2P+N8+!!#YL_DR6K12^5,/M/F/;J(V=[G .]"N.6 W$.&P
M_%>M6F@W\6EQ6$=_J\Z7%W%8VA>*26/9<DF *Y,4^7^>7"F0%]FY@$4 K^)]
M7&BBWL;*.2_URV>:6WL[8QAGF\N8O(C",#[0T4QF=3'(@P%VAI8V?0T31%L4
MN[ZXN([W5 C)=:A:0M(8TB:ZCBDBS'(9;A5;RF5F=L##%O\ EIE^'=$AT[47
MN[B[@U?7TNYA+JENMJ=SH9&^Q0(77R)G4EY!MYWRY?)#KTFJW3([WN^.Z$:7
M"QRVNUI?-1;C:MI&SNIN$59$<%1OW9SA#'0!)=V#M%J-M<)Y<*>;*DMA"R/;
M)(L^9X,1L3<DNRL%8YX?"E]C<_J%U<:YJ,<.A_N+'3-0EEU&XLXA)]F=#=!O
M)41AVN&;!<<_ZR/Y94D?='JDXU_5+[P_82R+;VMP6>]TQH[9TNO](E>"U9O^
M7HJ8_,;<5*F7/E$D-J)IFEVNG'1--7R8[>*2&U>R^3)Q=IY=J[R[5NTP_F2'
MD\EL _( 6--L+>QTZ2&V2!8[/>JO8PF7[*D8F@CDB8QN9;D1HD3J2V-N,8(5
MX]7OXM/M_M:FT@MTN)A']G:&1FG(NE(M 5!:\9RH9'!7YF4;CN)CU76+!HEU
MJ:7[78SYA@:RNXYDE*K=*HM&$B.MRX(4[ 3\RHN<,ZY\=O>ZC>17%_+YM\O[
MI7A,<4KQ*+H>1'*K;&O<QLLA!58UDD\LIN9V )--TLZCX@CU]TN[*>YN+B"S
M;4I9"]O$1."UK%.24G8QQR$&-4$1"@':Y;8$$TR.]E%:/<0W%R\C62DA%W72
MH;?S/W(NM[8D)[EP_!6C4;>>(ZA9PQW=B^H6[QPM9W$0C9Q),[" ,R,MU(C.
MY8C:"H)9MAW<_P"(]0FN=4_L/0(+1;Z9+@R/#(2(=_VQ1+;2%D1+H,DI=,!F
M+$%PL;NH!)K>HROJTVD>'M,@FU*X^:9X+9)H+=5DO&282; OV@3QAMDI"^8<
M @EY!<@TRV\/V4UY#'=S272/=K+Y21SR3LES(9(('4DWA5@KAE12N  %0QBO
MHVGV5A$&N3&L][<,\RBYB#/(\\T+R(RR*8[I3<1K,Z9'2.,?= N7MY9VMFM[
M=6T$=JWG,1#*%F>X8SC[-;(DI N\O(KR*P+-P,[OW0!J7BBW<PK!'%<%Y7MX
M8?+4I(RW+"6V:2,(]PXR71FPH)).,F3CQ?KXYM[K4-.L=2LO#]@EQ=6MQIZM
M'<7K,)E=[<*<"5I0QY < 8.Y;EU626"7Q5+<FUN_*\.S2RK"VG3)&=1FC:66
M,V@+CRYEE,C/(3B0V\;#Y&<#H)((%O$BC3S[41/!;):O%%"K1"X06]J/.5HK
MD(Q5G&%VQ$?)_" 7+LK9B*SDDDLK1$,7V*S+(I@$=QM$!2(.TI558QQL&38"
M#@?O,O4]5BLM.M$N;"";][<RR#2H7=GD(G62*U:,[OM*NV&8["5,SC;M<)7O
M=:?2=#5O*@GOKJ*8S6=F[0O=N//+Q6T4,LK+<+,R"61<XRS%CM^6O8::;6>X
MU?Q'>6-U?W,IMH&@DA7+[)(#!;3!HF%VVQ?,DPF<*BA0@V !I5C=!H=<U:2!
M=5GWI+,OD7#V[)%.C+:^7'E[L"*/S?D*ML*J"J!%W-5A:RM]38F[LDN;>5!!
MI\BLTQQ<R'[(N5*W39$C$J0< #=@L"\N1=(9Y;62ZE^T2V\20S1J\VUKF/9;
M'[0!%.J;F=P58J", C;'R]UJ#>()8+/0KRT5V2\\^[TP*\'VDP2LL=K(TBC[
M0/M(=G 0R@.2Z;&0 %S7-7O-0O)[.W6"9H/M*W5_8S&5XMHN EO9IOXOS$6+
M$8V]PP*BM"WL/[.T,:1I:06MJWVBQ3^SKS:6C7[5MCMMSX%VI5#(S  G>2QV
M_+)96>D060M["6.\B5Y'B:*\,CSM*EQ,$@=[C<EP4FWM+D;E?((&/+N:H)["
M*[U'4YIY%BM%BD^QM+$+A64KY4$8G^6X,N"KXW8D1%).6 !'?7,)O]6O+NZD
MM1I=N)+B95%Q%:J$N</#D?)<>6Z.X*M\C(N&#!JXN[M9?%UYJ-JEQ]GTZ266
M[AL'=)'U"8B<6\ZEL+<0_P"C*Z0NP!PV3Y4<0:QJ5G+XS^2?38!H\>H-/860
M9(OMC#[1BXA9D:.9G&^78Y"OE2VU%+W&X9;;[$=TL<$B7"0^7=JD,[SLDGF0
M1A9XUCO',DC><@5669"N]?F !(/L$?FZ?IVH6.DV$TITF1;.^C2.%S]IPML%
MQLNRSQ,X*], ;BN:+_Q5%9:8]Q?V\]S/<>9%=V^F7#O);0^9+'"H",0+AI"D
M)V,"7WD,5B)63Q3XE71[>Y:SNY+K4+])8;.*PC:>9!$-C&.$L8Y98Y9,LOR$
MH#G/E<X]E8:G>7LFOZI?1C5([B.WMY2T<J6$%R_$<,<@A,-P%DBW-*CL1L #
M[C& "2RT+[)>3>+O$<$%CJ5MB^=;:+":7:@3NT:.(R)Y'+R^;SSYFX8*QD[E
MXL&GVZ2:C=W:W&CV]UJ"7,\4MQ "0Z^?(ZH@9PC.?)1E #L%7"HPCB0(R_NI
MXF\J2_:6WL9@$,D0#3Q1R0OY=QOWCR V2)79@[,17/W7B*XUS4_L6BV\'G2R
MI)>;  BSQ1QN8T,UNH>[ 8E49AL^R1E]H#I0!8UZZN-3US4=.TG_ $?4+;%W
M<*8A<0VX7:J74B11EI;DJ,PPLY!6-'(5E5:N:/H-C%80Z3!;QBX1S?Q&<^=.
MQ=U OYVEM\QW7^L*JPP2&7D*=AHELNEZII]JEM&@D3S;<7(93<N< W+R-:JW
MVQH?/+IOSA>1AF9+$L\"VN=4@D #P7A+12H+P++ (II66W4BZ!C4"W7DG"X(
M(V@%>6Y.FZ7.6%I%L1]2=;\R%&A&US>M#Y"GST= [01[ &D)8AG4UCZ3I[>)
M-2$5]9VBZ#>(M[::>Y5/[7*2QE]1G,4:C)22(^0XPS=0NW(C?3?^$NO%M]8\
MB:UN+L-96\L?DEFA#Q-=RR" I+=[8S_HK!55%(=?E.WJ&C_M&S+VT?\ :-K-
M$[21*GE37LD9MU\Z24(@@N8RCJJ94[E',>P[ "1+&YOTLUEACQ)<1W3K(CJ;
MQ(VA*3S,(8S%<*40B,C!"LF,?-'AS7WF7"""W@U/4F\J:TD2V\M[Q?M5O'(]
MP6MF$4D1CB5PIW#:6*1E4V%_JB)J:V=E!8ZGKUSM6R%Q;JA#F.VD62^^0/%,
M!"\JJ FY(, ;E3&IHFAS6U[/=7#1ZC+J+QW)DN;,PO<*CQE))SY6(Y8DVK'$
M F2CN>6/E &?H.B,2FKZC9R:QJUS<1,9+FS6#S$BD2-;AU>WC\F6-7E9$R6*
MD@/( I30>WF>WMX=2L8]3LY[(SWWFZ:0M\R"U'G31^662< 2;(0K;MH&5*@"
M.S1((K:-(OM'E?Z;?FWL51+N55MW:6YB$)DCN<OYJ1+\S;!DCHO)WD*^,)KK
M38C)#X?MG+ZM>7TC;;TI-;23?:&4I]GG6-%V@@@([)^Y*,B !>+?>)K^/1[6
M[M)-&>X@'B"]N8ML>I2[+:.2)U9,VUP/W02-.I8_,KQD5U&E:3-:6^F6Z:?)
M<1P/%,P>$P_VE*1;;KZ<D925"TK>5)EV9-P^9%*R6=F^E>'M(M+:UL8%$5OM
MCOMWES%$MUC:5S I6XWJD2 [3@[]C%!&L>M1Z;9Z7#)<PVCI<H EK?6ZQIJW
MW9 +@?9BRS^9)*ZPHNYFW$+RP4 +J\CT.UN)WBDNHF2WNHH[RSGS=S/+$JRS
MR"W8K.'V*D*+E HX VB+'TC3XM1>R\8ZK9R2E[=KRS%Z88T(C5FBO+V6*-4#
M[&C1%PYC!+ ,=Y231O#G]J7D&L:OI]]<M>2R?8H[V/RWM PAWRS,(5ECN3Y+
ME&7]VNU8T=08R>@CDW;O]*L9-UW;-_I=ML\W_CT^>Z^1=EWS^[3Y/O1_+\OR
M@$;VPC>XN)XXT2[MUN#J4MK' ?*A6WQ/=,\7RW$;&5XU*A,*00N,KGZGJLT]
M_96.B)'<:I?W$UXEI?P&%6C1/DN;M#;>8@CEC2./!4MM0[SSBO-KS7%U;Z9;
MO&+^YN+.6875JJFV#Q1/%+?8B*"X\R'RUB5HR0Z!2I"LMS2M,M=)EM;8F>68
M2HUW/J,T$SSN&@,:7DWEL1<1F<>2BMSL7YL$8 ,_PSIAA@%_.L^HZO<6DGVB
MZL?)@?5$9SN^RDRIY4*-+N9U6+S6,<@8[OGZ@;[YH0;W[0ESLE M)VC-TAB$
M<D\!%Q\L(\V-L<[2C, SNCU7B5YK-89KB?43>1229TZ\: W2 B9)K<FZ)2/,
MGE'!Y+QCY8P*YLRW/BR],&G2VC!W2>35;-7@^V,CR0F:U GRHB(2*9@P>2)\
M*RCRMP!&NKW_ (AS_9K^9!>2Q22WFDI)!)JR1^2^8%,Z^1M4O#+*[=5C0$MA
M$ZC28(+;R+6S3>K_ &>1)[5XHDU"W3 22)(YE \L- )'V .JA0A4HJFG6]O9
MQ06=M+ 8M0B$$<T1-LE[$JILEB>%BB2+ 6'RJC2>4"NR.,8IZAJVGIHPU-VD
M:/5+>*3-J\UFVIN%B96MRDF4E*LRK$V))-BKG8F: (]3U^ST;P]%=:OJF\/:
M&59Y-0%M_:,FP1&6$Q3';'L'FE$1C^]1D!D!4Y\%J^MZX/$&H^?=++*'TO1Y
M96C0O%Y,@909&2*[C*W$;)E-_EOD(OF,31]!GUS6K3Q-KX\V^N?)DCTTI+;L
MJPS';)]GF?,4D1:-F=792LDJ!&W[Y.HL[I[^(EKC<E[MA5UNVMTN7*A9MB',
MT$T0AF/E*1CDEM^XQ@%=I+CRK..'5YYYKN7=!.5#0WPVQM'*I250-H"LR*R"
M54N"(B&!7'UW6?MD$.CV;SZO?:S*8P"?(C6$O<,$<$D0M$$8.)(F,HB9"CX<
M1FH:S/=RW&F:*\#ZUJ]I&2UL983*H9(IIVY)LY(@)E_>*S$K$H9VC,0N0:%"
MFJ7ES>1223ZI<1PW<IQ%_:#)N"M$C,CP/ 8V=2A;,2A@TKD,@!)HH\BS$WG3
MWD][=RSRW"-]G-[(A:588XVG#1R+GRB'YV6K)( H7%BWD_M:SDBN9/[1,L7G
M#:_EO=+&6++#$70VTT4[*N6RRXC#.7Y0N;Z6]BBO;2/SQ=RR6C+!LM)KM%61
MU0.TGF(T8,R[/D?SER?*0.:PY3;>/$DO8S'+H=Z@B+K"BOKB1M<.EM$LKYB,
M9W9<A68@LIC50U %/-QXTLY+F"?S]'NO*MA=QS"WG\101F5F@4$KY+)^]W?*
MOFX.#$AX[!(TMY;6&UN?]$^UB)8+214AE*L5$40\T,C0K "ZKA&42_NV9B$+
MJ&<?:[F*VGGFNY3$QMC+!+<*GFJ8LN#Y2H@W(ZNBO*<@QB3+5];\0PZ/NDU1
M9VM;SS8'FA-S R11>>TA5<85D0!MX=6E579 =B*0 M=4$6G3S:C>SW%E=[E\
M^W28S7$K#:T<,2'S8&B\N4&(*64 .7WB6L/['J>J:I;>(=1GC^T7UDKZ586M
MQ&YMG&QV^SW)C">;L#M@MMF#%&_=PES8@6^UR_BO_$=A)YD5P);71IVV>1+&
MF]#;2_(LTN^"3=OQ\K$JPB.Z?<@M9X($2TN(+O,K*)87EC6>:-YW*R"'Y(&\
MP+YDN")&WH4&56@#/EB2VO+FTV_;M+U&[E$<*3KF2Y EF/D,@7R9D>%P0Q49
M"2"02^8&P_$6I-KE[>Z)H#2-=7CRI=7MM:JB">!VV1HTLH5;I%C!X4LX6-@T
M2A9([FN:GK>K:G_9'AIKX-/A;F_N?-A1$:.21K?Y8C]FF5+B!DD*<X"L69"K
M6-,MK#2M)6'2X9Y6OY?LL=V7C@NM5F\N4N+B1(P\?EC>2YVS!HG^4M@2 %C1
M-$3PG%<V%I=WWVE[L3LTRJ7U(;7DVQ,[[&F<JWF.WSG:W$:>24T)(4_LYYUB
M^W6#2M>I+86Z\13"12;8QN)!( _F-(-S/YC[,E@J1RM:/;ZD8;N2UCNGGL95
ML9W'ELHGD:6U41YDN"6)<+G#(PRS1D'D[J27QG]KO+Z2>#29HC8DV#I*][&_
MFN4MF5S\T:&-IMF\2M;E%#",AP"Q<S7'C&=O[2E@70AOMY;C3K@-]N38)FAM
M65&EE4[6CF52N_R%*;2)(ZZAX+RWTE=*=YTD& 8-+M2B&%8W"Q02858-_E9.
MYR8]^T."T;BO<W"2ZC'%</!>23?:EB07ZB:4H9QMM"&3;-&I,;_*I D&96,9
MW9>MZO;:3:P/<>8]W<O)$EKH%NDLLQ,LCW,5LRD2AP53SI3M!V J$D;Y0"QX
MJ\10Z38#5P)+Z>-[>:R:VB#)?>:\RPPVVYF42E3B1T4L8V) Y79GZ3H:VU_!
M/J#1ZGJ"6\T(-M,T$$#.CH;73?G"(\8MF1A\KX;>77!4V-/T[4\FYU"YM/M=
MRDL4HTF>-(V=9)7DMK+=M=)9"A:9W;.5X((W1;#R7<B7@:ZD=[JXD6(V5^BC
M?$TVQ+<.3F<+#&)(WVQ9#GG]X& "1%LK^XBNDC2)GN02ELT$ICF0RD6CQ9=W
MS$Y=,^8SYD&T"-6Y_5KUKLG2K2*-)4=EO=5TB96^SS>9(9%M83D_:FB:X>0+
M^\16ZRD(&KW'B2&ZNKK1O#FLQR6\MO+;M/8QC9!&(CY:6*I*/,EA5EDD"*Q(
M/#*1'%721QV\=G<6%C<SPO'*T<;6TA!NBIFD"P,\I0W D5_-,F2YC?S%V,I
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M\K^;*,,3U&TLT.QI6@6FDV%_"MW)<SZG>S7-W-973V_VZXWS.T-N!< PRH4
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M,@4$J.K*2B^8?D +&KW5JFF7]]J%[.--A_X^[NQ:?'EI)*-B"&4O')&VWS'
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MWQ$K2?8?,!4MN-RI5W'EB( H$8D@$EM80^'M&MM*L[*[,>FH88_(M@[6RJK
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M51#@A,%B"S&0^_V")'IUM'%9_8HUB0+:X4>2 !A,(2HQT^4D<<'% %BBBB@
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M://J!%G$[-<2ZBX@N"RK,-O^B?/,R*X;>I;A4=4KJ$6XMKQKG^S<WR9:2Y1
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M3*SOQ))\W&X2;+RWNO[1DM?-OKG]Q'=^46FBD$N?LF5M,K:90_OGYPV[NK4
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M N;H!;C9B7S]JCR^ZCD %S4+M(;._FN-3\R%?.6&<7"PATRS36ZE9D'G((9
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MKMU>>)M8U/0[&]\V$^;8WUW;,8T\O:7-C!')*8I;LJ&W2X4(O7!X  3ZO?\
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M0 [BJH-KEMR8!97+72X+C36CAL)!;S)%#:M*LL$MR88G"+,OD*;-$==Z&/:
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MDMRTD$H-VT+2&-I9DA7[,RL$D20';F238K$(]8^O7]YJ&IWGA[2[6#5KJ_\
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M%O%^]7RKB-C)N;.."<J<B( +N;]^2CSW?VF6XA9K6[V++\DH,,0-PNR9/LZ
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M9UCW/(Z[SY=O'N1U<0@ L:YJQU47-AX>:1KS47(N+NV>2UWR)',Z6R$29BO
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M^Z:&-(9YHC>29N0MK"0VU+@,JJ60LY(.47Y,6-2N+,_Z3>W$$D(E:,W*SB-
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M#M);W?205T:Q4R22$6\8+R)(C-\HY*R$N#[.2P[DG- %RBBB@ HHHH ****
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M #O8*>=QD1[D-B9+B%+E8Y[:[1[>\)LY-UQ(IEW(XD#G[.2\A0%E"X559UD
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MO<NCS7$(6Y2P5DFQ!,4\Y))5W)\H^;/R( 7'UC4M3U>\TNRGNWMP\BS:EM:
MW+1SS$V%LCM&OFB-74W",>$R<$*RZFF0:=I=FNF:6GE0V4OD):P.T!F:,RRK
M;QHTP(FP$=W8;9D;)RK92O964NEZ<UC:/!<6\<LEM:I:SI:K<QD-YL,2Q%%2
MY1HG<D@C=OVM$'80V-1UZWMKJ[CNKZ"2.3R[4?9;HB2Y>26YB2WB02CRI@RJ
M#+D;BKYV"/* !J.JV6D:9/%+>3R;XC;PRQ2R.+D1R.IMHCYV[[7MRF[<'=\,
M-VQE3G]/M;WQ/=/>^(?/>UGN[BQALI)8U#Q&6\ADA""3 FC3#M,AW&-"BY^<
MN#3[CQ*DOB#5+:"2ZO+0P6^F+,(TN4^SW.ZR)9LQW*/)*KR@#"K@!=TJCK+[
MR=02:TN6CO+>_=K"81RA4N(RTZM#&/.&V6-<M(P&6", ,@! ".YOW$4LMV^W
MSMMK-!#,RS*[K(R6_P LGEV\V)(0)?,^=F &W,9K/\1>(;?PEJ,DTB_VCK4\
M4C6EN2;:2XASE85;'ESR+*P"K_K%20X#,3YL>H^+%L+^">*"[O=6EMY]MG;L
MSQL$2XD$#*DKI'.&@V&3:Q8JP0$!O+IZ;I::?YESJ<]]<W[2O&;5;A2QEF\Y
M@D,<+HD%WY4D;22J H4NP;#224 1Z-HT.EVXDU::TU22%VTVX0VP/VJ0"8(K
M+(%$,L@EW>8[D2M>2+DJ\1K<<".)96:!99(AIRS)=3%)#M=/LS72OO\ ,6=2
M!,Z CS-BCS':K&HW$4'VX27$\EPTOD,T$[B,M+@BW $P$,QC2)5=BB[YE9>9
M&4\O<R?\)I+J26LGG:1)+]E74%?RI=6C5C+)90!719%&R1!.2 %:10&S)(0
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MP"^<R\O;>'[[Q=<6VL:]:R26A0QVEC?V/V>YNG0LR)>LD9\N -&'V_,KN^[
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M\=\\ MHM\VX3AL!I3PX&[( S&>(-4FLK+4M1>[C:TM[>9B;>[,8OO+2[W6J
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MMO1E."VYP"O+<6]Q%<W-O%!J<VIQ2O! @(&IQQK*HA82*P2W :/$@8(SR;@
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M+,[ EOGCU6X&F6^IW$UA)!!I]O+?F2W2,K#D7),UN6CPUPPP75OE'F#DY.\
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M,O;OG9(SXV^6<!0,KCW>MW=O?Z9H>DZ5'!K\UDTB6[!-NE*J6_[D%8L-;LV
MSAAG8X1BZH@+N^U"&_TRTTJ&.VU?[$T2Z2(X3_9[,ENZ?-L!-FIA='="<LX5
M?F"A+'A/05T#2X/L-_'=&>XC?4-6@LF#W:G9Y$<* ,@@".J[D)1%5@H4DM&
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M8IXOLTMO#MT]=K6F7MCY,)\I=]L=N9&S]U6&.-J  ^_3DAGBLMDEG%)&MO#
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M"T67@<KNDDX^;<QPV2@!'I=A;^'+.TM0D&GV%A$T9F2$YM#D7$B"9HPKV[(
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M8(3AG*^;&0M=A:1/%I.G.+6<0F**ZG6_MFGGF2..!O-G58\F[!1450_JXWE
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M?#6SE(YF#!RHWV@A=]T;-O8&*1.)<,QI.F-::1=3VL<FM3W[O-<WDT2LNO\
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M:9LRXMIU$&1:@\A]XW;4^]NRXZ3BRO%:QN]3D"26RM=PQ(^K%4F/DRXB"QP
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MYERPV[R1M."0EC7]8^QV-W.ES]H8_+(EH^7N85F>)X;=!<(4N$,B*SCDLR@
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MU<$';Y=.\\6Z<\HA@N)]0GOMT4<-@65KJ,,1L@S,OER(L\,K2\!XR'7*@&,
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M8.$(8?.. $Q8U:_MS/))</!-'!YC2W)F,"%%2\'EVKF0*ERFPB1MR87<25
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MYY%3+QAL\<9./,]$\)BX7P;H8O(/(NAI]N)H?)$7EOY:[EV  )@Y&T 8Z8%
M&Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW[JYOPKXFNK+PAI,,4$[M%:3ZI<7=W'/&MM 9+C_ $NX^=C.TH^=8%/+!F#
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M<6SI+'<?;8(X%:-!<$I<2.N3;@L I5"1]XEU=C0!32Q\JUFN]+C_ 'UOY?\
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MB,+\V=C2="NX;VZ\1ZSJ$EIKQ1Y5,LJ$Z1:L\LOESXFV3V^Y653@-CH4V@Q
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M;\*=[;>?UC6X+6S3P[I#>;KL\26L-MIUS% ABA.)7BC,P$:J3*FT,DI\M@&
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M<[SN)W'98M%6_MTEMK"2_M+ZXM+Y9Y&96O@HLRMV7&U(B@!/DE09/*R !N!
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MFTR7"!MP9IR(]@5'7A[WP1X_&CRZ99:)8I )95!.MW+-):!G,5J3YB[HPJ%
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M8+<@@N HL6*C3O/N9+[;?-++)=7%_P"<K0%?M0$KJ'(^R94^5&[(@7+;RY%
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M8L?^$IUBU%Y\^F7%VU]+91P;4UKRE@@\\YE91;HWE2*"W[Q2/W;;0\A<R?\
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MYE_$GV0QWJC(6.3Y'P@2-<S[6V!V9@ T2+_A*9=-UB_:>YM3MN+"WE7R;JY
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MFG1)"[6VLD2IO7;HMXQ W%?F BRIRIX.#C!Z$$@&Y17/_P#"9:7_ ,^NN?\
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M(5<=['5_% C_ .$EMY+?37>?S='<A6U281R1")0TQ$940>>NUMG[U2"3&96
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M.!S#YWEH#"Q%M+&R)NE" ;@H4!MJH 1VMF5B^QDZ5-#Y3V2 )"D.I%5D M2
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MR6,DEM%>L%NE,%N/M&%G3:Q;+'&U2<$*8\?Q+KT,UE<V:O'J5WJ+K!I\>F7
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MIO<+-&0-[%"&VXVGH@!3O;>STCP_>R7L=WIFE6CE9A:W%Q)_HREG1H?)8/"
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M4LE\H8L4VDA@NX!V7R>LU2Q\^>73HI(++S9<6X7]VP\U)O-FMY/+&RY^:9B
M9/EC!.SS"PKR"WM;-(K*X@B^SRNL2*IN"I!N%DD@D,;,]WM$CNI$ARC*1\YD
M.?XFU^XTQS%I^B07NJW]W&\&G3XC2[,-P$>2,F,,9E00L2_R*H5T9UC8D S_
M !#X@_L^4)I=OYFNWDN-)TZWBP"SL&D<AU/D7*Q322LSHB@7 #"4)FC1/"S^
M'/(UVXOI[G7]0M&MKC4Y5822P)DILA8%_M/DK&^TQR9-LRG!8N3PSH TE!-J
MD\^JZU?>9&\[136DUTD=N?)*-*!BY$3E?E>+AYMQ9HF:N@M8]VHVANH_-FN,
M21BX3[/'<<Q%))@R+YEV$MFD"JB^6%*':-KL  M8H9[NP6XL1:6=W#%'$[NC
M0K,A5F%Q]Y;MWF<YW,S*T?W6E+G#U34IM=N&T^QO)'LUMTBNKZ1R[2,I#E8X
M54-%J"!9Y J)\NR/<I+((I([N75G2UTV>!+&*5;;49;PI]GF5[B,R1M&$4"Y
MG#N'5TW1NI4*OG"1MRQT]83I-G#9W=Q;QVYDA:Z+".4>9;.T]R&C!6ZW[W4$
M9)$A)4L=H!7@TO2-/,5CIZ1KIML@MH!'*8+>WW2>00)<LWVK<]R-T>UB6VR$
M$HQCO]6M['=JUYJ7FQZ;%!*EQJ$!CCMT/EB?>J %;MHY/E#(G$JJBX,N9)9(
M+%_M^H>9-&7@:(26DL8N0ZP%9;A1#@W2M;L$4 $$QIA6=:R])LM1U+4](U?6
MX8+>2Y\J2VTG4+90QD6-/-N))%7;]K&W,8V@B.-AM0ES& 1Z=I5S]KT_4-2M
MHX$=TDTZSO-YM;:(W$+!YQ)DC4F\Z0!@3N;/)Y)Z"*U$)TVWN6D@@M;>!8X[
MJWC6WCS) $20(PC>XWQ,$,7RQEON\IOCL D5GI<4T$]O#<103>;J<*R&9U-J
MJ&Z)"E;LGY$PQY7=\Q4*,>^UI[!K&#3K+=JTOERH)K)GBMG:*%%:>68QR/,Z
MB6&)R8][$QO@JQ !8O;V>WEAT_3DL;O6K^(WL=A/!*!/(6@(O+C>"]NL3*X6
M-F)(5$5@RJJQ^']*BE"W4LLFKW&KW%M>_:YGAM_ML4<=LZW6Q$61$B9=JQ<_
M,_S\/N6/PMI%FG]DWMZT&KZAJ<2ZH\K0B62\D_T<"Z#R(GDK!YKJD8P=CY W
M96MC3X-MY9P2/]HNKN);NYCO;7R1?R1BS4W8&&,+1@ "(A27/0;=] !:!]>^
MRW'D026=QY-X&CA:&/4"OV21+LL 6B9-K*L3DEPHR=JY'%WTC>.KC^Q]!ADU
M'0[NXM;C5KURIBU"(&T#-YB%?(N$6,@P[5RFYL!BHJY--/XUO$L/#]S ]I>>
M5J&H7T8ECAN&46_ERJ<^9#(KP[1&#M95E'FK*C;.DTI=-MK#3+?2X([Z.]2*
M]@1]H:_CWVV^^G9HP?/0L'ZY;K][&P +/2;2 Z;I=NL?D2HMZ+>X1XY[YHY+
M1C=SOY899T;.4(_>%AN(Y"US-!;>&DU6Y$>I6<Z6VJW-VL<L9N1$+4_:VP L
M)14+^0 2X08YW"K$MRNDV5[J<MOJ0@#Q7D\KNT1NHD2U\RZEVH#$Z*K#R!MW
MB-QL.>,/1]&O-8OK=_$29N+G;?0V4P,#SLD-K$U\S("T%PBR.OE A0VS;@IY
MI )-.T6;5]9T_6]:TN2*>Y=&M[.>U*R-Y+0M'=W4L4>V.X"K+A&PN'$8VYDW
M;%E%)<7NGH+Z.X29Y;T1SI QU2-'@5;IY(HMBF,%3&JX+ 1$LN&"V+.Y.H7&
MFRV]U:,-0MUO@ELLEO\ ;U4VF;EFQNC* E1$2V]656; .WG]5UIKNXL-.T6"
M/5+O4;>&_M X5%NB#"T=_=,@1XA$8<%=N)-R*O(*H 23ZK]H_L/3[,0:SJ%_
M%!J6U%\A+]4^SE;N<JNZW8.H9<AU98F3!9D532-+BA=FEBGU/4[Z)+E9+DO:
MRZC)!<(_G3QO$I@6&210H!8F(XVOM1:L:?8&RGMY;A)[[5+Z[@DE:6&&-]51
M4A/VF6,Q[H%M\G:F4PR*"2\@SJ0)??9[@O8QW=V;TJ@N(?(@OI5$;^>^V)WB
M$9B9(RV<B-/F<LC4 5_L*_V:MM=PVFI7>JHCF#44:"#4Y5B@!DE1H6\F4+$2
ML0!X5CC()3DY;.?QA.L-K9_;=$O<B>>^M9;637MJ121/++%:KY$<>Y@C9^<I
MM ()-6'6#QUJ,,6DF!]'O=/DGEN[BWB2379H"B(7_=$HL,A0DNN&+;1&Z9KJ
M$M+"TB:WL],@>:^B,ZV8MXX7O[)%1#%*&A4+Y8G")&Q!^1 S@%\ $=G]B.EP
M16:QZG+J=N]S 'BBC.J6K8+&X_<JJ('NRQ4 L1EL,6="74L-A;Z5<:I;Z;J$
M>R"[FDFMA%>SW("1?:4@*@AU)B78,O\ O JX9%2234;^STK3)[C67^V 1&%U
M2S'VK5%61X1"T!3YEW31892%9I,@(C8;E])T[_A/[R?5M7T^"^LF_?Z=&>;.
M_:$*D4K2 N\/S-,#;N"H$I^1G65B 5]/T'6_$VJV_BC6HH+B\CNX)+/3GFE>
MS#"UAD6:"XC#>4N[S"W#QNP5#E@KUUAABL@CB"2\U#4D9H)KBSA$EX\<8FA>
MX4I#B6-E*I&&!QECC:S1EK;MJVFZ?<;I+J*1+>ZCG6-8(]8N5B65)I@D;/"@
M,4>#E3D%"I 0/CW>N:KJGB<^'_"ZQK<1WL-_J-Y<0R)L@:/<JW"A(B'YA5$5
MF9EB*R$ ." 2:GK+IJ,7ACPW<;KXRF1(K6!A"@B($8W>=B&WC,4<<NU2)"SJ
M@#[PMC0]/L-'L_\ A'3=SS_:I2'GCNX[>6_G4QK(UOY4ZM%' L91H@HPJA1G
M!#5_#VF_V1H<,;RSSZK/]EO;K4;*;SY=:";,"%VF9_+#&)'9PL>UVP$5]R[D
M;0VME,+>>22QG3=':V.,2680+YEHL<F] JR0ABAY,9*1AI 6 *]S.TUE!'=:
ME)=R7KM-'!I=RML^J@)&5:V+7.8XD4Y8*ZEBI;.UB),,7D_BJ^M7_M+_ (E,
M^Z46^V6VFUO;# [106]P^S[.Q7+-QD%DX#/)))]HMO$J7,5LMW/X;C1M-BM=
M.D2VBU<AG(C@WR+A(8U8,R,HEPPY2,*>@B6%K?\ LO9(MFSQV@:QN1;K/,H5
M6%KLN-T*1"&3?%@'Y6QN(;< 1V^H06T26=K%]HC2*VDAAL+B*(7K%5,9M5-S
M^[A"P2$QG"L%;!8!]V?J&JV[RD,D]]-/+9/%&A+)JDJ-!*)+&-KD!8T!W.?N
M\AF9PC!J^N^(?LMK>7%E=SWEW)%$1%I]QYDFHS")'0V48G?R53>DD@,3!D8$
MAUY,F@:9=PZI=WU[<1WNK3/)<W;6[(!=-'Y:F&RQ.IC2-XXHY/-7]X0H<XQ@
M K^'H(I=9@U;4-6CO]6U!UQ<V=S"([Q%8$P6A\W>+> [FD7:&D*Y)891M2"\
MLVTD6L-Y!>VMWA+*UT>Z%L]WY4<(8VC"Z 2-"DFY 5].Q:6274E;2]46_NI+
MLP/*;H64S633F+R=TEN[W($<40.R0;P-X?.#D-S_ (GU6?7M4N_"EH\EQ;7#
MSK?/:7L2/<$;%^SVZO-]](]QE3,8!4.P*OY<H 3ZNWC&]U'PWIEQ)JEG,\#Z
ME>17"QP3 /9K-':E92WE>29C(N20T@&[+@-T%I>1:;;V]FIDO7N$2YB:VN(8
M6UB?$;O-; 3J%089Y$P%;>3\V6WQV.E6%O%:06T'^@SW=M<?NI(_L^I2[8W2
M2V!F+QK$($8)G;Y:,JH_!%PZA8V)0WNJ1_,[+)_I_E_:'BD$DLL6ZX.R*)FF
M$B')VIM.5158 CO]6@T^S75;O4O,M1$L[QPW<4*7S9MMMQ"TDX$<*D[2A8*W
MF'.[<"_-Z?!<^*C-K6I3ZE>V-RBO9Z3:RO9-?&&1"E]"CW ,*#>!L+ -M20_
M,R@4]/-_XGEL/$FO6\]S;PRPWECIE@T@?49T98UNHXII/W-NGFKC[F_/F28!
M5:[#$MU%&TDWVVZNHI7%QIK)')<PE8GW6S/.QBA8*D3;2"7=7!3[] !8QD3N
M\5S/<R3_ /$RD>"2%4U<A(\-;[90R*FR"/YB$*MA_,+^8,O5]>FTBTN9+2TC
MNKS44>]@FM)"L%XT-O;L+MY#,JP6ZE1&R%CO&WD@G<:YX@ANW72+:&[U&XOK
MV.:WGLL2Q'"QR12AA))Y"1,UHSLZ%6W%A$P<XL:#IEM%J27\EI'+J=Y;Q32W
M5I.FV[#2I*S6I$H*V\;R$N"@,FY2QD8G> 5]"T:VTR9[;4]2M-7O-0O0\LQ"
M176H7,$ROYB'SR!%  %,04%3$^!@[6V+6^:)+:&>:[U 2);2?:H'7.H.6@3[
M1"L<V8X$)!D7:%(?/(+;Q=8AN+>![6_M+^2Z?S(HX+X1_P!HR1"(NUJ1,P5%
M".#$>&;(8A2S-R]Y>'Q9;WPFUN[A\/\ VB.,7FFVLADU"Z01L39C=(ZB)[<M
MN12K!Y.,H92 6/L6IWVI+YMI'!I]FZ/!I>CZQ'/]I>VE@_U4<J1I'$C*JN,J
M0T>%V[W\WJ+#R4M[2WMVC>!TBDCCLI1&MPJBW FMP)L1VZ X:/OG^+=^\KVE
MK8Z-<6]DEM'IKW3H$TNVO=JRNAC=GME\Q (DW2&11&IDP25/1\/5/$EY/]EM
M]&CU74+[4=/^VVZ6RFVANV_T8K/'+(7$"J-_[IQM8DAP=Z^8 6+[Q)%=1:7:
M6,GVW4=5E<P>5?/%!?;%:&<Q2Q2OY*HH$V#GM@&7)0TG3M ,]M?2ZG_:NK:A
MOA^VPW,$3:FVR.-[B(1N-ODIO0;"&13+@,7W-)X9\,VVE%+J],>H:K?.;F4I
M ELU\#) PN);9@NQX6QP,E<LV/,D(K4L;JXFWI/+]L9XOMT;V<@C742OEE#;
M W+%(U 175L([2 YPS;@ MK][ZSLKBU?[7]M^SW043-;FZ3-MNN(09"T<**Q
M+1$?,>#][+\7JWB.^UF]M=)TZ:.[LYK)+[5-2O#Y-L]N'BD'EQ[]JHJW&98I
M KO#M4N2RN37]7OO$=Q<:/X:N(]2>[MT>]N;2X\V*<1F-7\A7E:! #*F^!CF
M5"X<IF-Y.D\.:?I>B6=K8V=W]I>;R'FDCN\2ZG*Y$HNU/G_=;;.6!!9UB*C<
MD:A@"QH&FV>D0-I]G+]HWW;23-%,%GO9(WA1K@L)N=F LP(!=PQVC=M>-M=M
MM)LHVU349)X/L\=TUXLZ*=2*)$SSVZI-D1(J,\D:IA@QVALD.27#7]N9;A9+
M^SN4"+;V\BQM>W.$YB$TBO;2PF"9C&&!7[V[S%8#+B;4?$5Y;:G=">;2H_*U
M"QTZTN%CFU>11%BYV22XBMT)C98=P.X[G^8A2 5]%BO/%>K6VL7S;--:6.YM
MK6T4VCZNT4BA;QX7D)6&,-&0,EGVHS9 CCKJ+6>W^V1QQGSIM1V7TCV9*B^*
M"U3[3$XE(2%04#1DDN <!AG?)]IFEMU>WDCOI)42[$<-T8_M^P0$RVQ\U@D0
M!(\LX5F8!F"L6?#UO5_LC6T6GK]IU76XBT L)O(.H211)(MQ ^]XE49"L)>7
M0 9D5%20 -4\2OI&DPVJM/?7US%%<1:H\C"UN2D<8-S^Y9O*MU<PF16,:;7<
MC?DAK&AVB:7+LO+S^TM3O[LI=:A#"L#ZA+"T87#))M18D5U:$_,_E2D*</OD
MT33(;:]GU![B.^U#5GCGGN;1A";^-'C,,L0$Y"P1))L8<EP.=V0'D_M#S/#W
MVF/5O[0\^T^PB\MCO^VRJF3/ D,PQM_?EDCQ*WEX4_(NX T+>X\_R/\ 2/M/
MVCRY_P#1I]OVO'D?Z1!^^.RW7/S)SNS_ !;OWG)I>-XL2SL+#4(]7L(;B,ZE
M<)=K$^H2Q-"C26^R3= D3$3,%"[B(]FX2EC8-S-XBUFXATN2/^S;BXB:ZO=/
MNC#)J$:,,O;%9<8B!@BFD'+@LJ[3&BG8L+N'^QK1["*2Y@EMXKF"TLF%NUVJ
MK;[9+='G B@4$!HFQG.#G/[P IV\M@NCZ9I]M=6.L1M%#- L5S'$M_-;M'DV
MH63:GE^1N,041EF4%E&\U<FN[20V<.HW-I=QWSP7D/D2OMN622U"31LS[(D6
M1E/E!GWY4@LQ96KW^NVVGOYU_J,B1PN9;@QSILOC$J^<UN@F,J"$Q9>/H1YB
ME)&;-9>E27FN:M:ZGK4DZVMULCMM)1R$EN(Y()#.=SXADC,1#6Q+%?)F*[\N
M6 ([N6Y\9^);R*&XN[73-/N%L[F:TD=W\T&ZB5K=E7=#*K/&9<@94C)\H9FZ
M"';';VNH:=:QBWBMU4KIZ-,V]A;&.*T9U$?V=E7:S*%7@-E"'9;GV?R[7S6M
M_*:VN_M<ZPP;OLS&+?(+?]SF;>692P&X^=+A@P"C'US5TT/RX$L//U*;4)'T
MZPME42//\K?NBT('ENCR--,2?+,DBAF., !JFKIH44,-K8>=JT?E6MMI]DJA
MXG98V6WA9H0/LSB&0O*<;?+;'*A4-$T--(U%9&_>:U)%%;RO$51X8(C!B*W1
MT5#;A7S(\87+$[5#%4C/#FEO!*^LS7WGW%[Y1FET^-C;0N[1N5M$9&S#-OS+
M*&Y*[OE()34AN5ATN$Q6\DU@EO!="/3'8I GR!$MRB()H@$=R 2Q&!L82*@
M*]E':16\%Y!927$#/;JOV&1V6UWBU"I:L$0-:X57<J0ORME3EE7EXC=^*GCT
MNUN;O3;+2W.GZCJ&D6Z1F*X5;=3:6; >;'!YGSNS)C$8&[9TL7$VH>(=>>TM
M!=K:Q7$4.H:Q%'<1J-DB)+#:@ 2(9)8MLFQVB1(PY.YFKI-*TJWT:SM;6UL_
ML4-GL@ MXC(;8L8"T,3&',D+G)DE)SG))!'[L CTFTTR,@6VG1QQ6#K8M<6"
M20Q^:)(W8011E@L1E9A*=PYB*ON"DK7M=4-EINGK=O&+0);DQZ?%(8I/W2LG
MV$P M+$&BDS$P+;"S$B,*'IZCJ-O9:=?:M>W<Z,]IY\-X+@R(KL!*HM)(X6+
M0XC^<;?NVP=XF#L[1V6BW=P?[<\1:7&US:7#7$-E9VJ/_9FZ2&5A$&CQ<.PR
MTDJDMN#+$-Q- $GAZPGO;72=9U2TL2\?D)'#91R[+!3%%L%K(F5:,L3YA7Y2
MLA5I&2'#;#17B^997^HSPW=W*EPTEJQ?(&V(?9T!+1JKB"1PZO&/-96+JS$$
M]I/->3/=I/!-/Y$<K6LTLA@CD #^3)Y.5WO&J.JE0J*LN8V.3S]]JEXL%KX;
MLO(BU](K:6(6UJ0-.4O]DEEMXW@*F%&R0&;<T<DA#*H4D KZ]K-QJ6HPV&BB
M=[_4OL\=U=6-T)OL-M(;?SIK63RS\I62,,,H5Q'*(\,7.AX.\._V/H>FQ6<5
MC,OFB\O+G3X=HDNI/)Q+;^;^[\DPM(KF/'&1&%.5%CP]X<?P]:VNU]UX98EU
M6Y6W9I&G:*W#M"YC.^.1HE\PD<EW<NC1D5H3BWM+JZGC@^S7B17$1BLH3).$
M:5':>!7 5L>:'D"(^YRJY=D"L &FW3O\U_<><-0E6\C-K=LZX'V<)]G5,LUN
M-P#NVT%MS% DG&'81ZEXNO[35)Q=G0K>XBN%@C+0_P!H3;+=HKH!W(6W 9G\
MH,"&CRP=R46.:S3Q?JUM/ ?*\.65VWFFT1;B"_>23/[DH.5?S&$[LO'SQJVU
MIF/26FFK;B61=.D9X$!\B"9D^S.L=N1;6I*Q@P-Y8)^95+ AARP4 KZ9<S'0
M;3]W(\4-Q91LFG0D6[*T<.#:,C*?LZNZL6;=\JRJ01C&?KGB5M/LE\B[NYI[
MI(Y<Z9&LD]\"D?[VP21I$9!M.^+&0K&3(^4RQWWB.WTFPL;R_>?4]0O)8[B*
M'2XS<.\X@AWBQ1T(:W,9D+2!N-[ '<WRR:3IITR_U;7?$+2+=.\/V^YC,D5O
M#(J0$-;  MY! 02NS@$V_P R[00H!7TW3VCUF+6]<LY-,>V2VM+.%"KP:89&
MB06T \O#E\[9)@ %#+&C':S+L0V\ZV4*SM'HT[) D?EQQ(=*BD1%^S0R-&T<
MI,T0!7CAUZ83-RWM_(\C_1_LWV?RX/\ 1H-WV3/D?Z/!^Y&^W;'S/QMQ_#M_
M=\??W%U=WB^'M"LKZ!K"5;N<$P"\M9 +:0BW=VV3,RS2B5G=CF5BS,&1) "G
MJ%U)KM_8Z2NGR:=!"\%N9K*6!;K3)'0(\%DZ'<R!D82-M 5;>Y&6P%CZRWT=
M-$@_LRSBGM8X;2:Y:_T^T7_0R[HS0V\;1R961EE<H"Y7"CH8\:%O ^G+)80B
M>TM_*V!K<-,8G>5E256:(^9(^XO(79MA4%@0S.<_4M6M=&M7O6MH$AMO.OY8
MY?(:2SG6)99+=(T89FDB>X?=O."6)+*P% %R?R;:WEN+M8]/@MT+3211 K8W
M3C+30EH<.")Y"\K?*-IRHS)C@XK&\\37T6L7>G?8_"-K]D:&WM82\TJK"=HB
M2.W+2VCK<NAC;Y@"Y/E_-'5BRM_^$JNK74;;R+#P7IT32P72W.QX7265U>-F
M0@P@+;2-$V$C:.->L+QUU@2VTW2XR]C'HMM;H)/*CA39IBOYRB>-EB9/-^?]
MX,E$!9B2N3( <'\2-'T;4/$>C6_B&*^ATF'^U9[@6-H\BP I"1+N2-3MRXE9
M\2 2,RDD9QS&I>$_A9816EE*NJG4)HE$D=M+(TWFE5 2%7B!ED,D4B<HJJSR
MAS&PC0>OZUJEAHD%X;B"<3V^)4@TVWCF>V>=[A(IXPR#,TK$H1\V&89&TL[4
M]&T)K.W%_>Z='87T=NSI:V<"O'HT3"8_Z)MA(><Y'F 9W'G[NQ6 /++3P3\-
M[6UA?7)+Y)KJT^V2/9K=R0PJ\3O&82;?F,H))/G8LI@VDL!)7-^*O"6@0Z)K
MFI^'K622.U>VDFC>];?IPE>38,&,)-$Z&+!1V((!#NAW-]#K8:;;O)':V5I:
M2Z4DBI%:6RE]/B=96$]LOD$L\GR@J 4)5E&XHP;Q#XHV\[ZSXZ$6CQS16KV3
M2W0>(#3P[,P5 RER)BX=]FPB1FR6&2X!Z/J'P@^%^BV\-QJL<=G +AOWEWJ3
M1+)N#D1$E@, '(QAOW8R3\V<^/P3\#T>9FU#1I [[E5M=.(QM VKB4'&03SD
MY8\XP!Z9>"XD\6Z5&8/,L4M+J9G,(81SAH4C(?'RMLDG P1D%NN*V* /$[7P
M7\#XKAH'U73;AX[>(,9M8(5CEQOW*Z@NV/F4' PN%7=\US_A#?@9_P _6A_^
M#UO_ (]7L%% 'C8\$_ \7#RG4-&*,BJ(CKIVJ03EA^]SDY .21\HP!SF,>"/
M@S%9PI:>(K&SOH=ACU&#75$ZNI!WC+E Q([+QG@#C'M%% 'A\WAWP/<WDD-_
M\7]5N?.BE2+=KL1"P$1B2-W(*G<V#CY=P ^4[":&\*^#W@D#?&2^::6[2XD8
MZ]"5?8ZE21GF0(B*'SPRJV, +7N%% 'A=WX/^&J6]Q/<?%'4I$".\H77()&<
M$2%OE"DL3YLW !)\Q^NXYDD\$_#B7?YGQ2OG\S=OW>(+<[MWF;L_+SGSI<^O
MF/\ WCGW"B@#YTU3PGX92YM-3TSQ]K+QSI9W7GS7BEC;/?!9G,G!C*RR))\Z
M@!U8_,V[R^[;X.Z/8?9YV\9>*[;R/*@@D.IHGE_>CC13LX_UK*H'_/0@?>.?
M1+K2=-OG9[O3[2X=TV,TT*N2NUUP<CIMDD&/1V'\1SE_\()X/_Z%30__  70
M_P#Q- ')P_#/3;9S:P?$+Q=$YN&0PIK2J3,RF9A@)]\J3(1U();WJN_PST&/
M2WLG^(7B==/2WE1H#K2")88OW<H*[,!$SM8=%Z'%>@:EX:T'6;A;C5-$TV^G
M5 BR75JDK!<DX!8$XR2<>YJG_P ()X/_ .A4T/\ \%T/_P 30!Q<_P )-!D>
M\>X\;^)V=W^RW32:LA+-*L:^6^4Y+J(1M/WAL'/%22_"S1Y[-M5E\>^*Y+5H
MHYVO'UA"ACC)DC<OLQM4DN#G SD5V'_"">#_ /H5-#_\%T/_ ,35R'PUH-MJ
MAU2#1--BU NSF[2U192S9W'>!G)R<G/.30!P\_PPT6TN)9]2\;>)W<VYE?[7
MK 7"0G<LI.T'$3N'!)PK$$]<$N?A;X<DM[F%_%?B",!Q:RG^U\[&E"^9&0P(
MS.SQNRD?,Q7& <'M/^$3\-_V=_9W_"/Z5]A\WS_LWV*/R_,QMW[<8W8XSUQ5
M?_A!/!__ $*FA_\ @NA_^)H Y./X8:*B37C>-O$\A>XVK=-K S'<[A!N5@H'
MFX!AYR<,5QG&./\ %?PS\,Z:9(IO&6LA+;3)%F%Y>*\:10R6[+;LRKE ?.3:
M@1^61@#M"O[)8^$_#>F7D=Y8>']*M+J/.R:"RCC=<@@X8#(R"1^-7!I.FK;O
M;KI]H('MUM7C$*[6A4$+&1C!0!F 7H-Q]: /.[WX:>%K;^TKN]\8:Y#8Q^?!
M<13:R%AM_M&&9&)&1DO&^'8[CL+;L\EM\-_#6LV=Y>^'?%NJO<-+*8;ZUU=I
MQ;2L2X VMSM\R7@G<1<29)+!AWE_X:T'57WZCHFFWCER^ZXM4D.XJJD_,#SM
M1!GT51V%$GAK09GA>71--=X;?[+$S6J$I#M*^6O'";68;1Q@D=Z .'D^&.BW
M]U>?VSXMUG4=0NKB2 EM0$90F*8K"L:\ B*=FVXQC)"A&93G_P#")?#34[AK
M>'QG)+/=NZ+''XA#L[2&<8 +$L<W+C!SGOG?)O\ 4$TJQ5$5K:.4JD2>9/\
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MMN! ._UC4[RX63P]I=_/&RVD\UQK%Q<$#3\2R1232R)($;<OGF.,8\MXAE5
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M,<;NR*NYE!)+*B9>M:BT%O963B/Q ^JV_P#HJ1W*I_::QAY!&5WK&@*LC/*
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MI"JJ!228WC#C:J$&H],T"?2_MBPM/>3:E+<-<:C+)+!<W<P\U8XI2L1\J%$
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M>^CFDSYDDC2*IC888[0^]HP#VB+"M[9SVMI';_9+>.S6*. 2&PWO"SP.L4F
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>/_M'?\D\T_\
M["L?_HJ6O8*\?_:._P"2>:?_ -A6/_T5+0!\P4444 ??]%%% !1110 4444
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MRH5EY\6</C"]CM;))+;1XD&HVT3QAC++<O,_VJ7,GS6\BB6/R>'(F<,J *P
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M7B63))(?L]RPDMH3" +D%W5D"L2B%F0-(0=2QTJYT.66YU'48Y-<O'?[;?)
M^YXA ZH;2/:R>>1;0R/&H;.TY!41@7&1%MK^1G@DWRLACM658(G%S<&%X?-4
MQ-=F4QAPS#]X%)QA0P 6DSO=0VLEKI1DFN]\@CD9K1BLKR%$W8'VE)!,Y*JQ
M;[/E_*+ILYN\FOO$^K/I^B"273XD8W^H1Q[)YI4ABRC*0B)>;F@*,P7RC#PQ
M^>))+]KSQ7=7,%C+]EM(M\VHZAI\9?Y?-)6/R2N\7Z1V]L 2"T>]\ ,(P=S3
M[:TTQ-(L[2UTVUM[)PEO(C.]K;98131*V<27'FY0.XC;$S8#$2JP 6JV=O9+
M::7826T%O;[9T@:XRUOL1=I*8D2Z6$6[@.F_!V(>6=:^JW-EIAMXY[J2:U+O
M#%+ L05YFD4NX0!DFO(YXC(%VH3ODV)(R,IDUC4XM+@TNXN89WA>+-O!=,\J
MLL3J\:*D@5Y+V4"/8KG<K(Y!)5A)EZ383WA'BC5Q'<.SJ;6!UB\O>DD:QF>)
MF0+J1^:'>I"H5V\8"D -#L)];N+;7/$8C@GAO1-%;SK$L4,K&$1M<1*P873(
M^V(,S^6AC!+.,ON0_/ L\WV%II;N#9)=<J^Q[:.7[08OW)NQ(C*F.C*H7@-4
MEC':;X;K%I$\5POESREV,.Y8(T6<2.LANI(F4*S+N0/L.[_EKS;ZS>6B66G:
M.^S4[GR4::\)\RWC>W@ _M!@2L=V[+MC=HY 2H4*=S4 &K>)S'*NF:-/I5]K
M,TL"RPW_ )*I%=%H50W3)\CW"F"7"Q.&&U0L3A=RZEG:6VF((B]W-);)&[1W
MK).9YV:V/EW#F7:UX"D8C9F10)D"!E0XK^$[&;2+(78FCDOIWM(YKS4)"DH5
MDM T5TN\N;AB\IC5B^S>%#*K!3J:-,_E6,6FVLXNS%$9IKZ1F?8%M/,%X%P!
M=F-OE#!ON9R%)6@ TJ*"[EM5AA_>31)/.+C38@8F5H)]EUM(VW.Z:21<;5!D
M=MK%03Q]]KC_ !$>#0/#%_/'I$?E,;E78S744=Q:EI8Y7PT4T/[PL)"6(:-@
MK^8&6Q)?V?B=;#1-#NY_[*7['<7FKW4@07^V6U"'S4Q*+AMI0.=N7BD0 LN8
MMBRTFPAVZ7=PP+9G"/!<QQRP9/V+]W=J#Y8N23MA"?(J8"J5 6@"32M,6UM]
M,TR6.-(&>)XTFB:W_M&5!;2BXX7,+Q^7*%MCC*QXPJ)\LFI:K:PZ/'J&JB>2
M%Y4N3%(L]LDGD-"\DWERKOB:,122+ K'>J.V'))6N=:2R_X1N6Z:"^L]8\G_
M $LVRQQWLY^R^5<297='-PVR)0^0 2R+&2F7X=T^Y\2V\.OW5G)=32I!=V5O
M=E[>"ZGC$&;YV6-O)E*JB+& 5PDFTNDC/0!)I>EW%_J-G>:Y93S7\WV:[M["
M5Q%YSQFU674'&/W4R*8E,.>-DBJ7$A-=)IMNL;VT%PT=W?WR1WKK<1M$+PQ+
M:H]T\;1DPRH0NV($#.,X.2D=C97D^HV$DT/GJ+1'F>XMC NH3YMBUTZ!2(I(
MQ&-BOARVX (J;CES:G=XTVSM[>/6I-30IB%4B@U95C2*>YN]T!$42C9L*,WF
M!D W*0* *YU9M1LM$2UM+O5+J]N(IX=L2V<6JB%+=C?7!,1>%$<+M Y;:@ =
M6 %S3;&S6SL;N23^U[S6I;2Y^U'%N=1V&!UF;]VOEM$JNZ0!OF1')#,6*R:7
MX<6RL'\V&[U:]U5XYKNXF#0270+PYG<E ;=X=S&*%6! 4X^?)70U"WFNTNEE
MT^2\2>X$$0R8WO%5I3Y5S^Y7R[=&+8(+;U'\?F;)  L[&Y9YOW,<\&H64LLT
M%VCXOY=L<2-.3"! ?*2,&,+R9)/D/EY;DYB_Q 6VMT7[=H%_:-YM\;5H1JDL
M4OF)$'1"UK#&ZN@,IW$2,%#M^\J,HOCN_1+6QCN/#-];L);UX61O$$L2 1^?
M)%$&MA'(C?,V-W158' ZBQLA<B6X2WNYA=(\$CZA91P-J[>6^!=J+?='$@&Q
M6(7/(*L"OF  D$.JV^F)(8]4L-31;@EK$"'45(7#W0\A@CI$L14[DWN-NU
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MFP-'/JMX[0B W;0QO +B2#B2.1_L[JS+F0@,Y 11YF$CCTC1;/2=VLZKJ_\
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MEQ+&%0IL(EBY,(1FZ#1=%ATC2YM)T^YD:XV&:6\M+P-/J4T>X2R*KR82<7!
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M\J<;<?P[?W8!7U._?3HII@_DPV?G74_GS-(]FFVY/VB1%D)FA8JH2(8QVP4
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M&&$.TC%76,)LC1 J; *HD=JES)/',XL?,CNFS,@:93'&S3[EGB W22?>8(V
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M,K;DCJ.Q\+Z79RWU[<B#5-6U&63[5?(VU[QU:9Q;6VZ?,,D1B3N,>4O.5W(
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M_P"2>:?_ -A6/_T5+0!\P4444 ??]%%% !1110 4444 %%%% !1110 4444
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M&R6+$-GZ]=Z=I4&H-=3_ &G?GR89BRW%R^^[=H+C<A46A02*C.-BH';<-JN
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M=P2,/MPS$*:SJ,-K;RWUWJ4B6:O)%<36\@CAG4"X00!S+BWE5M@:4E-SA%W
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MT!B/E$;SY62))446X!7M+6;Q>([WQ4TFH:;<.UMIVE/;E&G>..Z#"0%D$5X
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M9)9B5;0EN-+\JYN_M4%S#J,4LPDO'^2\B190T<N8B([1 R%9%^4[P3N,F90
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M]YR_B'5);+[5HNE>>_B!99;B&.&U1_L*O]HD6[4& >8K9$<FT.PWE06D/[P
ML>)M:ET[[18Z1IWVG5D\Z5(;*-)?L+'S"UQ&IC&^X*3!VC)"_,%+ RIYUBRT
M%/#MG,8['==)AY7L+50+1"9U66U0Q$;@'),(+;0S']X[DS&C>%K?PW9W$<<.
MVX7S+B66W@+BU#&Y*O:*8F^;]X0( 6"!S]XL3+L7$"0^>91!8QP>9<-, JQV
M0;S\W,;O%M,S;LNK'"AB3D']X 1W_DV+Q),L=J\SW$D"V\0D,#!9F::#]R=]
MPZR9,9SD>85W;7W\^MRNN:I(;:WDT_3[5Y))&B=M]R@\UIGMH@GFI.IE2.1E
M"MF>9,EXT89^I0S>/K>73Q:7>C:+8W%R^HM9QDR2[A*K+%_HYW3^8)%D\IBN
M'90TOF';UD=HEG%<6L.F?V=;V&YH5M;=62W0K-BXM0L)W3-NVM&1QSP0090
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M3/RJ00NT':N#L-->WO;.S;2TOK>QU#SKRUE@4@Q&0RLUP[,Q1E<RHR1,I(+
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M;AI%;S5RVY,L"0^;GV/2K=+FZO=/CM].LT:R-S/:1@S6Q9U:%E$>4M4++@\
MB,LWR#?( %U)ID%OJ>N:E]K.GBW1;R2>TD9IX")7\J2 P_ZI%N!\RC=PPD/R
M-GC[R^N_%=U/)<PZE:Z/=6227=I;1H]QJ/E1&1K:U>-%=K?,A#3,Q5VD5(RH
M?+6(UU[QK<-JE[!'!I=M<2PQVXWM]KW& (B2I'F2SD*%GD965EE8&/\ =I(.
ML33K?2=.FM+6WOC:V<4=FGV52MS<)AQ';A]BGRXQ*FV42#!W%W7:Y8 KF:ST
M>S@TZ)\6'E&PADANQ&DNPRQQV<):X#)<C@%_XMAR5(&RGXD\3'1;#5KN9Y-0
M+.MO!%8B2+[5O>:)+6%A,<7"2 F1T&X*!\F0-MC6M272Q=7FH74EU+&D=E)#
M83-";AGCR888C<C;<;L2 XW^6RHNX\UGV$#&XN;[4)[1?$UPEE!JY253]EBF
M.S[+!BX#P$$A]V3O9MRAR0J@!IT#7&HW%SJT]IJ^J.\B--8RJ$MI1;[)+&T+
M7&^&?Y3(S@+D9W;< KT$Q5WF<7,DYF>>/_1[ID%R=KJ;> >> DZ"!<MP 1(1
MM+.5C,MQ/$$GNL>5Y-K<-<W(@<"=45HF:"3:+D,4<,$ _>*B8WEQS=UJUWJE
MQJTM@TD1L'*:A>2ND3?9U,4LUF)8I/*$L8ED42N4*9*J23+,H!7U/6KO6;BX
MTRVU2[M9([A8KG4$NDA82.9V&G0+Y@A:Z5'C3<"P_B8AXXZZ"&!;40Z<8I!+
M&CB9+'4&"R2F.5_LR$SHYN"LOF&5U&_&\[3M*2:;9)X1L4TJPG@$>GVD*>6P
M4&<-,PB55,RJLSXD4N5422.K9PA02->VEH9X;G5K1--BM_*NKTZBX\J,22Q)
M&Q:7=%+N('G L7:*0'852@"34KVWL/[7O]4UCR;"WB6*^=9"D<:?O2J1A)/,
MCN,2P[F_C'E[ "1MY?.HZ]KE]J6H:?NDBBN+*RT^21;=F8?O5@8_:&\NYW11
MRK+&NWRU#YR4\NY8HVI7ZZY>VTEM9Z>D$5MI]RZ_:)B4!BBN2T^#<+*4>,2<
M*)@>9')CW$AM]+TZ:P@DQ:V44=BR0W!3*$.(;:,F<&*XQ)#^\;&_<F#R-@!'
MJ&JPNET(M6M&<W LI3'<!1.VZ7_1(1]H7RKK:5!<XR2IQQA,?Q-K]S/J3Z#I
M,<FH:A.@>:2"Z>WB\H2SJL<3+.O^D(R,S+N3S$@E!9< +'X@UW6+F\U#2?#\
M\&HZE+YB!K65XD14$A$!(D8)(I&V64;&'FP)\AD62*2RT.+PU;ZDM@TES<(D
MMI=2&:&V^V$@-:0;T<&"4?:$B1@JC:I&T#R2 "/P]X;TO2+74DM-1_M*34)4
M>6\M;GR;C4 (GEBA61)U_P!("[9&DP@D1\D$LSC<N76)]4OIK[30;A'M_M7G
M-:I)%$MP1;B1969)8F\QGE"C SA<J=L>NZC%IEKJ=S+=>;-'YJ.BWCQ)*SQ%
ME@3$I\B142%VE*A54O(-H9RN/'I3Z]+<:YKL=]%H\-VSZ?I<]VRO<N6FA"R)
M,J;%D\SY(RW/F[')0(B !8V-QXBU'^V]9COK:PO98X+33)F%M=72*9MT5W&<
M*T<>^5U1#\\8)<2$ 5T#W5Q=*MR)</)C;"L@!FECE>3[-&%N=HF1(Y$D_A8D
M$DHC)4FIW,R6^J-')'<3QIY$B+=&W69G$GDVZ-YN8)R9(<R8&[>N.HV9_BG7
M['0;*]U'5M6D@MK9_*NA:O@W(9)C';1J)-T<X$D3EQM) 4Y"YV %?6M5L= M
M7>)X[R_NT338$CO=DNH!998H[>.1IMZRQ/*OF2G)&6/7A(TTUQJ-[>:S>0:J
M=1NYK:RBMY&=P(S/(((3N58)E\F(F0,H+0@$!U\UH]%L[O%[K&O2W;:IL^S3
M0O>(K0K+&B"TB,=P(XYV=()/,"Q[O-7 3.$Z"Y=KNXN;::^DM4%P+:ZNHIE1
M2A*M%"@\TF*5_M"*7"AFVG&S,1 !7O)%^Q&&*&[TXZJDL<2VA9'G+I<R@1!R
M@@N,#S&:1 ,G:68@%:>LZT]SK#^'M+NO,UN64QS3).T$=F(U-Q"I4LV9'5@N
M55@X61F5EB:*J]SKUY/?V%GH-E]CU!99C>Q@&6*RWSH/]*@3!+2!VD5E/WE)
M#M$9)#<TFR@T;2VBN+V18Y7@M;Z::ZEENWEERB)(4D(CG EMP958Y&  B+&5
M *^AZ5#IUDQ#R2RSI)!N6<)<77R2;K?>MSM-TCQN[R#:NYY2NTO(PN:QXDTN
MUBDEOM7@\F.6>QDE@N?*21V61OLP83 17"B-/WDA7&<*5+D+'J6M6R!9KJ22
MVE-P+34!!&D<[AHRT5H&$F]I56Y60&$N28Y F"P4X>EZ9>>)M4_MK6[Z^T_3
M(;N:!+%KXB&5OM-S$L;KYC$7"2>2ZR*VT$HL:C8&H CLH;[Q?JBZ_K!DCM8W
MD@L;&WD\HW93[0'A59"DD<Z2QK()-R!A%$Q2-H_W?420F>XNUFOI+B._O5B#
M6EW)#N5"ZF&+_2<I+&8R\C(%W*K#86SB,K>7^AS0:C%]KNKR)X-2M#(6C@\S
M)CM&,3$QL!<(#,J-E(RS8RI%?7-8N&BSIDO]IS7F(K<:==A4N3MDE%NV9!Y+
M&W<2"=&!.P,1@1QR %?7?$+Q2VJVMO/>ZWJ44T%OI\=ZT"7"*S^;"KI,T<-Q
M"-I:4]=I5#DX2.*R6/2]2&V37KS5GNK2[DEF:!+PI]L/V2$23EH0C!DRH88.
M1D;G2Q9>&ELDU&'5+R.\N=506FMZG<VK6Z7AW1I%&H$JA28I6C!C!!;DG<NQ
MMC4+1M0MX4U5Y+>TOD:*_BD95C>)P\<=L1YIV2EIU^>/.\Q8R 4% !>7R[RC
M327!O'EM5^R.RBX*+<MY$1$P$,Z!#ND.T$KC(.!'S>HW[^(_MVF7+[[ R_9+
MV03-8M?"'"O#:1O(0VZX?RG<E 5D$89R XKW9G\5QS"[N[ZSTG[7_9VH3722
MI]HWW:;;2&.*;9\I9K>2?!SC@L-Q'46,:06<=K+<^1"V;:Y42+"+-&)\BT41
M2@13 7$2AT!W",<Y*&@"G96LT-O%:BZCGGV7.GQR17!L[28*&98(8XIF,+H<
MIO"-(JVTF<?*3)=:\FA:=!=7 G>2RVVYM1.KS3&0;EM@K7!WW*J(F+,6+@ML
MR9"!7OO$7]CZ.FNSVL UN_B^S^7$_F1O-"TCK8Y5SF;F:,.HP74Y&=D9S]-T
M'R-8AO\ 4YYW=Y9;.0->[_[/A=?]'BDD:<R"YS,=LB%R/M$B#Y"C  CTW06#
MZ7+?I'*M@EW::?':72AT"K+']EB?S5/FJH8+*"I=4/FHCQHR](T:-="1[G[5
M-<2RV374$BPM/$TLW[A"DJGS+<*26(+!5DV_,SXKV\J:K9R6VKW4#)J$7E:A
M;O<JPMDD+1"U+)(H\SSGDC$BI\PAV-EU#'+UK7[FZ<VVCQR7'B.XM[FW>REN
MGMDMP%=TBD43@).1@K(@)D$;E62,[T *^OZYJ2C2]*T19)]2EM[F)(FO& ;]
MW,%@E=97*RH8#F4N&:2(JC -*T6A;P6.AHD$^K7>I7<R2VIO&N?WUZ@9XU@5
MEE41RQL(D\Q@H\R0@$23-5C2/#UIH*?97O+N1F>6VO-2N&>!IED8>5&&#IF4
MM*F)45LOYY^625B;#ZI=P6]IJ>H7=IIS(Z+JQ:[0PV7&]8)%9MN=LNTR(RL7
M\EMK(2J@!%:37;P(;:1GN$2=YIXC$9%VM"THE1$DANC$\9(91P-B8P[KQ\\D
M_C&XET71_M:V^F.7N[C[)%\TH/F&2V8PH([YO, ?>T?E,[X5B"PL1Z=?>/W\
MFT,FG:%ICS_9KR>V\NXGO]L\3SM%L3:ZR/YH9"N&SD;R1#TFF6%NEKINFZ*D
M%E:VV]5A6$LU@@B?;(A>/,=RPN(699<_*7X;YF8 DLM&A@M[*'3H9+<);@6>
M(1$J*0H:X,9@V07 \Z;"!1OW$,,#$=._N[?P[H[7UQ;6,&E&6"X*FR,4<-M&
MT>V0QLJE;A08HPC/G$*LB;E,1CFU(Z?%:W-[I$D9NGNF:U:&1;6.2.<R0;PL
M<F+AI&4!DXD9F*F0B$&O8^'+G7+];_6H9%2]2"6WB8/'- D2#-Q+A!&MXY:.
M,[0C(BGRW^0T 5[;1[N\O9[[5;"2%+9%GL(TL4WH\;R"6XE9(6WW0:6618PA
MB8OF/S,EUZ1%N%5LZ;]L=<R-&R!3>RPRHGG2%H$59@D<;1_,JL20/D19!3@(
M>WBU1HXPT=P$UJ&^>,*GDC<MQ/PJI.JI&P9%*G* $H(Y4R_$^N7FD75O;6%G
M!?[I;:>=KFW*/+)'*8F>XVQ'#-LB,)55+M"=F_"12 !K%]*UK=V'ASR-2N]8
MT^;(NIT5YKKRA%NGA>+:K!+=E$>5W,L@:,*CO'8TK1M.MH)A=7?VZXN?)MIK
MFZ=H))T#Q-;M<-Y8:*[C695095W.UC@X\NY#ILUG##9%H]6OFUB![BX8ED$B
MPH\DLZ(!L.U6,:,7"LT&"%"!(Y]02S6:2]N;&"%+N#S3J<*Q&0I*(S<7&U<*
MQ%JQAERB,71=H*KD L6[(]U!->6,\+?NP3J&V*.ZE\V",R3;4V_:4>)1'CY7
M!7RV()\OE[;4Y?'BV46F0SKI$_V>ZN))&2WN=3VRVRF=70+LD@:*19-O81A/
M]9&R5XYKWQFSWPM8!X9@B2YGEU*2.&/4"(K>7_38UY613$N&"A"CAANC4)-V
M 1(;R>YNG@N%MI09A.RVX\I1%F]NU91F17M)/+=5VD;<87+* 5]'L$L])TEY
MT^R^=]EGE@N(5@BN7$=M$K2H8V6WF1@OEPQL,L@P>NVG>RPZ;H-HUU;QR_;;
M>%+&#5;8-/<W$D<<!%SE</<!"0!YB!U>16VK&9 7^M6VGOY6H023W%S>FS%H
MX2)]0B95M]URA'EL\KQ,8L!=RJO*1B8K7\/:3=P./$?B-9+J^E1)W-ZB6\5G
M:NL,I:?]VJ&>%K8KN4;CB+=L7:8P"3PYH6HSZC8ZQK<$]SJ=W$MPHFB6..*$
M&%BEP!'M^TJS)AE52XLHN8\,*V(!;Q6=O;V]Q!)LEM5=M14L;@@VF)+DF-62
M[VE1&K$$DH<'&$C6-K"RNHEFM)Q9NCDZ@%4ND2(!=7K. X??:R*DR C!1]KA
M>.?\32W=FXT_3[>.&:\>2U>_N;9$1K-5)O+FZB*B)T220NK'R]S2MM4H3YP!
M<N([R[BCTC0XYXM;2TRSZFAD"855CN[KY-DEP)K01H59^#YB[U&*U-!T:TT^
MW2QL)HYK-KB*4_:+9YIY+A@D[O=AAN6?"!ED9D ,J@IE$W1VFBV'AFSO8X5^
MT?V?FX:&[N8U%P9#$_VRZ=F8EEDAD/FE5*A7"HVU<R7,]I8W%R6MHYI)=3#1
M1;79CDJP>=9710[36SQ02$[5_<A/ER* )+8V^K2RF2W@GAOHHQ,(6,,UU-&T
M:O<)&9 8/))"L3^^#(J\&*/?S?VF'Q2]LT<<<EE>NM[=:9<0B(Z\R*BI*BNS
M>0FVW#Q(S#S@CA@$5G-AKL^*H8[N[,DWA]KB,?8FM9,Z_,88I$,44V##$KIN
M #,C!9&<A0S'4C2_TRUT_3W?[.MO+&)I-TD-O<3"+$%LC*N(X\B+=(BI&S@(
M(R97C4 L:9;>1>0K%-YT%Q%#<[K.[W'4F MD%R&>7S%6,1C<NYU=)%)9V8K6
M7?:MIMG97=M=-'J5^SQ:=?6SNML^HWFP>2S1B3Y$E9&C.4.]=I.84W&/Q!K6
MG:-+<K-IVJW*S:K#<KF-HCJ%U&W,2;HU'[M(H6CVD><4"AG._=8L]#O[U=3U
M?6_/N7NI3'!8RF10L?FR*MM(H1]D9_<>8\7R2",%@Z*SR@$=GILUY=W4_B%K
MM[G5KC990Y*26T<=P6,2[QLC<(L;,\3 N(=\8+1B5]0+%>M.D\5C(VIQ P21
MR/'#J<L<44D<\<B,P@8'>!C=*5B5U8B(5'<LL5Q<W@BDFL[U!#<'4X&5;IYB
MJPVSJT8>- 9HU4JKJ-TXD7S,L:^HZI-I3RV.DO)J&O7%PMI=21Q&,L0L861P
M RHZ1W$+O,(FC(C"$+F-0 2:SX@O(+RQM=$MX+_79?,CNQ%$;=Y/LP#F-BZL
M(8V,GRLY/^N0+Q+YJ4]$T+3=,TWS+&*._-ZB6\)^6"#4X_*\H0,)&<O%&L1=
M6"D^5RIE+2F0TSPS8Z=;WM]KID6*-(8VE>#RFM(B/,^SJ5#"."*602+)%(=F
MU5+X@R=1Y;QHEN+I?LEY=1"TFMI&(EGFD5Y%@6:*,,%AWC;-&7 7SBPW*7 !
M8N(XH9YT6.";^UI9+<Q7Z.HOI%2<F)D"!44(B@3%7+QH 0V$8\>;&X\9:G!J
MCQ[O#UY=DVUKJ#"-]9*1RR0F3H8[9"H,<:HY;YI'0[BU%HVG>/=1U%[F6>[\
M,W$L5I.D,;3275SG>(I9(E_=0P?+M,9\MB^\RL6<'I!=SR6#ZEK.FR6\#HMK
M=6LT,4D]]+(Y1;7.U5,"/,8U8XWD[BP3+2@$AN_M;0&*?*W<1LX+DGR9M2D6
M*4B*61$#VS1LMP6 0%6*[2#OCJGK&OKL%QIK1WUY>)]GBA@5H#J$;M.8E65-
MTL118I&68XB8,[ @-NCI^(M2%LUQ87EG]JU;4\03:=:QS9U,/%*OV:.610%A
MB#H[3(V ?,)2,OAJ=EI5S<:C=MK4MIJ&HZJ\VGS7,;N(+@"WD+:>AV;K>)6R
M?,C\PLT+[RKX2@#<@T;S)]5F9(-0N-0E2*:[(V+<RPI(0BF $VRQ2 !97+RA
ME*\E8V-R207EZT8-I<?:DNH/(G$;O?>6\J^5,T:,([>/=C)!;,BJVUMRRQWD
M44ZW)UNX\_2X9?,O/MEBYAFA\VX5(S&Z^6BQDQ,9E)++&&?:FUCR^H7VL^)M
M5.GV\EC!!?2K::BC*C[G6U9Y=+,Z988_>,90IQYS@%6CV2 %CQ-?_P#"2RWG
MA_3;N^GAGE-K<SI)M%PRM<F:Q0?*(ID12ZL1M<)&LI*L"^H=*MM-M[]!+K,$
M+O+!;2PNC7$@D$GG>5O02AUV>:=FXR"".0&1WDW:%IIITTC3@VI/9[YH[BYA
M,B??DS%'C!9CBY):X0AMT&9'SD#/>\&G0ZOJFLVDFFHUDD]V8?+CNKJ80SR2
M6PE4*91%%Y>QT(.4/SG#@ %C5Y(=(M]8NIKV[LH($:5_LT8A60H)[G_1E9\-
M/AE:1B&CDV$$??"<NL+>(=974[XQC2;6]E2WTNPD7=/<[KGR\1Y#P76V82N2
M4,>Q7;G=Y%?3H!X](U37'CT/P_<7"'15AOHT\^X:2Y99H]CYCN@9$R"6#,KY
M4G'E]H^I_P!KQ+ E_P#8Y+N(1ZD3<?9Y]/CF5_L\8C,C>5<EI8P&QAMC="(U
MH C6XL9K!;P+:7,4]Q*+9]*DWK=%WN0JVQ60>7<;7+22@ <OEL*62GKOB"\T
MG3IGB_XF&L7V][:RM+LM&UQ )69(5#"1_+,4:RJ3&C#.%WNT;4]<\6,;BYL[
M2XN[G4+^W-D+*RF59%GS-B&(JSI%/$'#3S%BJ!(SM^<;;FD6*6FHW(;4(-0-
MQ=S1:EJ:3K!#:F4E3:6R)*7@F,IA9N[DEF<OM  *>C^%UTM)9)I8]0O[NXFA
MFN[:]:%Y8D:=Q:VC"0.DH>)7D#M\Q:4N[D$C<NXY;[[4]S)YTT_G6ML]E>HG
MELGVM1]EW]+L(=LA)51SAL(16>;RWF^U72B"-8[1;B>SE<P26LL_GF*-(HBT
ML%R_GX>0 LQVA%8L=F7KETNL^)5T3?)I$D[QO?:A\UH\=R3'Y-O!,'>,77V>
M5@Y4,9%4("JGY  U'6+OQ3<:A:V\]W_8MVCZ=<20JA^W*3,8AIYW21,Y!99G
M<C:J@GR]IV]!##:1"&QM(([FSLD>PA5)GA8LD<H2.T=I?]>D>^-W!7.XGS%,
M3(*\$\-G81+IMM)!!<VX6;38U%E':*7W+ -K@6]XXO(^I_>&/_EGD,L>OZ_I
MT5K=WRWG]I7#_P"CV@AW+"9A$\T<4#*V];B:WN"@F0D$@< XC8 -<U7^RXKB
M;3[#[;=++<QV\=G#@R3E;AP]L29(A,N+A)<J'8AB1_JXY(])L9H-4NKO49H]
M2UB]MWCO+R"0QA_]:!86#;UV%&B=F)8,"H9N6W1R6/A/3$U2ZU/4GL;Y-0N[
MF&Z:=(9;41_:<0VR@[2DGF%2<!@TGF[\N8V&I/<W=S82O=R26T[N8[N.TND#
M(N_,%J"90L5Q(LT0+KUY 9<Q, "2XEN+K1_MLMUY;310R"XT^Y'ES%F<PQ6[
M/(%\S>T0+NH24%05PVU.?USQ)_:\O]DZ/)/J$][@O<:;??9P]J&DV&UE\TQB
MX!WD@D>8+6;< H2L_P 2ZW<3W47AS1K'?>:E%(\Z11 + [2SLGE.)C$EW$\<
MLC9(\QH6Q(K*HK<T[1+30KB_T^+59(Y-0O7N;R_A+ILFS'Y:OF4QI<.\T38"
M!)%!7R]N!0!'HWAJSTFSU6WLKKSM7U2*:34;^P<1S7[J94?R%:8B&9)'7<V
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M#L4NY,B^:N\;0_WANS)7@LU@$44 NS+?.);.62W;]RYC_?7)S!LMYV$DAV,
MKL.BF22N/U#Q#%JFFV+>#)]-TQ+AX)Q>/!"T.GQ)$%E.2H1;I8F8&(NV(8&(
MVY (!N:]K#OJ8TBQEGC^SRR27\DEVR)IZ/'<GS;F1)"QC9?GCC!CV[4R\>4
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MD?;N C 9X5)8*5,D=H8M-%G:6T=N'0PXLXI+-;F9(GB*OA&:"("./9(K$\(
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M!(J&/!=G'\3.YI%I8Z9:P;WM'U":]BMI+C5FV2EUEA98;C=*QGN@H9HG V\
MIM1ANT+::VT1[>6?4Y+406X6[GO60HA"V:E;V02;6NF7 1\@88\, -P!&9Q#
M!INI7NF>4LD2/MO(YI'2V1XO*BF8EB]WO<2("K'<)(U.29&Y^SA/C.^-S)=?
M9O#D,MGY8O(X9C=HT-K)';7/F99_^/B79\S_ +R4MD%$WU]&_P"*N^RRR_\
M(N)]EW0:C\DE]GRD'VYCE7N&:."6+9G<F%?:LRYZRZ=K>*VNKR^M([2P2*.:
M/49E\FU/GP28N&,KEK@1>7Y;=-X9BV)%  "P99892+2TBL[][>&Y&H2LSQQ&
M&$"&YC=R6NG,FSGJNS<6*JC9^M>(K:PM]+>ZTN2XOM62VL-EWL\V6&4!O+NH
M04"ROMN43Y3&KALLBLXJ35/$%QIL%JUK)/!J0_T*VL+IA<>66>V7;<!)F+S$
M,"DC.J#SE$C*7!:OH>ARV.O:=K>KWD]W?++)"ZW-PDT>D++%"([;+2Y\[.Q1
M*BEI!(V\?.K  R])T</X?&M^(+Z2&34+=;:2^DGC":1&AC7]Z[LC->%HHP9M
MI*RQH-H5 #UDE[ ^L7-M=W-C:V]]Y44UG<VL00S2+&#!._F$37#1J0JIPJ\L
M'!CS7MEN(M#BT]+B^AF^:Q-UJ-X)7LR_E\7)2Z!>:0D&-HR"OFH %'WL/6]<
MN]2?4+/3KN.VLH7^SWU[J)0VFG>>I\^&<R2NES*K% J( L9*H6V%E8 L7FO-
MJE[8Z#8W$=N94EMKA;\+<I:QH\"&*X/VAHYY7?$90$R 7*DE"#YEBPAMK#2'
ME<VEGIK6[QW3ZG(B*IF@MSNU&(D>;=-)P1E04=LL"0&L:=##H:7%O!?22)H:
M23M'+=@RQY;=*UT?M(21YP7DC9U58\DG&,57O=3M/!]E'+<7-W)%IKR)%%%&
M[R_(F^=KGRYA'-+*O[Q=RAE\PR,N%D90"35-:^R6=W:WW^BR?V>J66GZA%]J
M>56)5H9%6Z*W$TGE?NP2K'<P!<B4#+TSP]::Z]MK6M6$>I([R6NAZ=JERY-M
MA9G?[2))I=TI8%& #L@B0[5VLJ26.GW&F:MI^M^([N"TN;2(%8YKL7$6DP22
M296:6>?>\DH81B6,##0A>4!5MAY'C9=+,?G6B8WV>I2MF(RQ.JQ7,TD[&99)
M) BE4E0%&7!905 )#-'>:68;Z>[G2[='/VV&>TBNYG\Q!;R*\1\F M&@"@DM
ME0X?S/WU/5]92TVW+6T^I2:OOM;33)85BN+\+OQ%)');JR0KYTFYF;"I%&WS
M&1PU?7]3LK/3KN[N]-^UPZE+O@MK^*2)-0,8<E+E'MMEOL4 J[8++ A=PJ$U
M'::#-<G5M;UG1[2?4KZW9W@NK(S*\<<B,;:0) #F,J$1U:0R_P"LVN$1% *>
MDZ3>3WE[J^J202W\MW!+%#/<F!'91:JD=P?)/D2;D@D4+Y;393?$H78G6&Q@
MU)#-'#=O!J5PC.9TEMGD96DSO3R083&JH8Y1M=C%$I<84L+!,'DM+DR:F]TD
MD,<MU8F,W:HLJM!=LL!18@S%D<!=P; 5L$R<GK,NH^(M^BZ%)!J5Q-$8GU#4
M+5987VY?R[U1:;8IHF8F.+(P<F0 D(X!<O=3FU:_O=)\/6\D]SJ#EKFZNE*V
M\D.QE:.9# PCE +1J6CP3;JKN[1O#6II&@V]KIT9LS?7L=W%)%*VJP$3:HY$
MN$O2]OYBQH %1CC(;;@C:&IV/A6'3+"71[32H[N"YN'=KW4H1.VIR([NR7N8
M0RC<7,<HWCY5;)RJ27)9K<1-=B.QCOIO+O;J:>W)0R1*9O)NY/(7R%C1HC')
M)M<84E3M*N 2374NFBZ\0/<R#RT:2>>>RFB\^!8[F>."1?+/E)&LJ?O0"S,K
M(1N^4\GJ>B?VY=1-.MB=)7-KH[I;?9X[Y3*&B6680NB6\99%BC8%9W16PP90
M;EGHR^+KA-2^Q2+X;*+#IMC-&T2ZF(C+) 9PB8AM4W,(U*Y?Y2^X[%/275F#
MIUW9W%K/<6MQG3HG?SGFO4(E3R;EQ 7BA5G.V;<V1ARQW'> 1W*7-\)-3AL9
M+I)$FBB@N(7234XC',WV:XC>)%@17P$=]W&1G]ZV[G_$%^TJ"QTPR:M<ZI;Q
M6<]W>LL:3QNUU%Y5UL5/LPCD?C"K)(P,0!8,5N:E?K<ZYJFF:9:P:OXC??&B
M7@MP%LV^1X[@>6LBVZ.X<)AFE!0J[AGV2:7I%IHMNIEN(]2-BC_;=0OYGCDN
M+Z(&1&N_W1*Q1J"T;NY50R$*Y\MZ -"TTZ70(7O[4R37DKF34+I[:9I=4GCA
MF1E==CM!%N1&0IN7^%%PR[R[TNQ2WN);BPM(;>V1[>TN77R&,48D<12N( ;:
M"-T5HY$8_P"KC8,21OL:DELMQ+>7-C',C6]S$U]>PI&LB*92UM<,8LQV_1E<
M AMG).5\WE]7MIO%MQ!HT$=W?681!>7M[:F"6ZES,ZVURHB3RHA&'^;;O1Y[
M>11GE@ U/4-2\2"XT711'J)LD6QUR_-LT+:G)''/YED/W>V,,1S)Y@$?G#;D
ML >H@TZ&V2:PM=-DDMW1XEDNHQB^8M<EH+@F)G$2D[O-;.\R [G+-OCATO3H
M97L[2+SY!%+"8;@MF[5VN"8[I3$?W.Y6*SMN9R7^9B[>;7O!86NF7,VM0>=I
M@_T:*UOX8Y+S49(I+C; 1(/WRG]VT.#O8\L3N.0 UJXTNVT[5-1UN*^6UNHK
MFTF1QB:]BA%X[0[ H"1A-[QN&5F&W<W][#%GJ_C;6;J^U-+N+3;=+@:?:V\8
M/G-&TR1W$4AD MKI1*%*2J/F7. 4_=1_99_'6K2:E?7$X6R\JV2UM7E,-O))
M)*AE7&3'=Q!U/SH"BA&=8C)B#I)[%;&WE:&'4A]JN#%<7EDC&_U%U&T+*3"/
M+1F,H$@>-458RCJK * :%S--(4=+N.:39'&Q@D*K>7$,C.\4"_: $<"*8,K<
M'<H9F6-EKD]0\27EYJA\-^%9/M^IP[<SB^(2);>Y9&2=7E,B;28M[A6:=2X&
M.&636/.NO$8M=,:TU*_U9[2_\Z&4A8K.&=7AFPTS!DC;[RHL?G>=E""KD7+3
M1+"/1=8TS[7/J%YJ?FV^J:DRQK-JDQAE#PVY9PJM'CA<&- K+]X2%0"06%CI
M]N]I;W$=[JVI.LE[<I??9[C5I(05F2!UE#QO&4SLXC4'9\H9F2YJDJ7%U+"U
MU!?R7?R1V7VE8EN!!+,66V'F;DN8\H6?@;HTYC.6CDOIYIKAIH1)<R2//9?N
MKXP1W,:DDQ0J)\+<*-XWE0<V\@)B4JPYMY7\3ZC?7NCW4\5G-=QPR7]M<M"^
MK" RR?9[3=)PJJK(S(T8=G=PP5&5P U:ZNO$L%S:66M[;3[6CC48YH,ZA"'D
M80V:,Q021R36L0GRI\S&3N0 [D[:;IVEZA86D\>GVB6\R>98;;:(K_I1,5L6
MD$<=Q&49G?\ V<L ,;)!%9Z=/*EJW[F^S9K!IZB*.=HDN0(H2D@\JX5(U1I&
M(7$2*-I&$CU2]FMK=(DOKN_NG22!3 2BZDR":,6ZNC$03JS*SR*$_P!6S<+&
MPC #4M?L?#M_+J=SJTC^8ER[01/YL=TL"2LT<,9D/E2Q+$ [#:C%B"-S+Y>'
MI&B_O;>76'^T73Q7,-O:VO$3J&#M#&YG.V]66 2M(SEBQDPS^7OCL6$-_JLK
M:O<R86XW?8;9KB0OAFN3+;QHTZ^5>JGRM+NPG**JJC$[BZ@KVZL;R[O/[1>6
M*-HPT+3C%RXMHP)%\B>-5VL[A2=@!.[[@ +*MP\MY:RQM!J"2+,L*M!+>N%E
M"119G4Q7$:Q[79E!.T#*;,)S^KZNNK74]EX;N(Y[R_24M?V%PT22'RIDC,0\
MT))*J9^<G#M %&!&[VU/5]=GNKQO#>ESZK=:G>7:P7-]YLL D@B%QN-N5D$<
M-P#:NG(C21U+;3&3C<M-"AM/#3Z5)J$E_<3H8I[^.4>;?W$8FQY/F3-LNHVC
M4EVX'EJ!@(!$ &FVVBVMO'%I^HQW;W[W%T);.]$;:L^)_,$6R=1YZ[U+O@+P
MF FQ/*L:CJ36X@^V:S:,Y2?[8UO=+:K>111W >.W5IB8Y8W,9=]R8P,O\NU=
M!W8O>,U])=BZ>2)5AF6,2A5F'V:VQ*I2=2A+N>2<\@*!%Q;1OX^T<.ESO\-3
M12P6D$LC.VLF-IO*7;)*KQR1M"'+!P9E(+%,%4 )+6:Y\9);R+/(_A.6WN+;
MRX[QU?7 K2^5#&)'61'5$)D=F4R$,#NC&X=!<3P7=JOV74I+RVU%V6"6RN96
M%VZRRS^5#(MR/+=8XY5+$JI)09"IY8N7$$4\$\)2?48999 QA=Y%D97G<11L
M9OW$T;JH\PE5#!%4J0HCQ_%&I16,%XK?\39-5WV<EC%(Y6\9G:W6*,^>5MMC
M,BRR; I9UZ.0H *_B7Q+9:5_:45Q=?:KRZE!BM[+5)$:XC3S!M7$P^R>6T9\
MZ7&PK&Q/S,42QI.DZB\4^I:I>_:M5M8MLFJI;+=*D@58Y18QJ[&-@$E5P8P7
MD8':57RZDTW3YHM4FUC4C:7>K7*1(]S9W) GDB\TO8VH:0&,(\*NVXD2$R!@
M "$T+NWM'MXEDOY,6[E8+R%WFD+1"X 2!3([&X0*?,)5O, 965@2J $=L+"/
MSK;2F@M[6'SK%]/TRZC$<[CS7\J'#H8;E0-[$;<!R"6VAX\N745U.X_L^P$E
MS]CN)+7[0;EEDF: L&@MV=V,=P(GD#2.8WD"DJ0I\V&.]U2X\174NF1'[5'Y
M4MCJHM[@107;I*ZM;0K)REPT:3.0#PA +D-'-'N65K#IFEBP@NI+I-DEL9([
M@*]\R_:"T<9$R[;H,"TDOR[B&/&/W8!'9V?]FV<5E;7WVJU\J:VD*2[9K^0&
M8[(G$ZA+D%7:63:"[<Y7:=ES4KY;?2]6U.>:2:SMK>9KN6T=@)(H_/S%%B;,
M<Z$ ,_&2,<$#RZ]U<:8B7,NI:Q'<&V2YNIYMD@,=NC3HP@,; )+$)/+=TR^
M P!=2.+CMY?'VIQ:_?\ _'B\6+"UAN4<R-Y=TI^S2,BHZNH!>"4*Q*_O0J1J
MC@%B[@N/B!>66J7H\C3UM!]@MX %EGE<2NSV\D\2B57CC$;0R!592[L-HC:3
ML"FS4;J\6_GN?M$J@0Q76(YWA,Y$%NIF&R8;%$F<(X0Y49?;7MY/M%F#')Y+
M-+<03QV#^2FHR(;I9(H [J8IBX,K,,'@#S' +C+\5ZDL(N-)T^UM-1U/7TNH
M/(4LD5Z(XYD* B4!98_W*R.S(612%)951  UK6VM7.EZ->2:CJ,MO<V$$$5X
MK)/+&KE8B3<"6.>)2K22Y&X9R=[1!;%AHBV-[/?RWL>I7]XES;W-VCLLMV2\
MSBTM&:YS;F(JV5''R@Y!5BLEGIUOHT]Y+(]]=ZEK$KP7%VT1@FU$QI<>7#'M
M=!%(B1C][A$< $'+97082\;]4GO<Q2VC^5*D?V]E\[]W%B1?+N4V'<Z[%/S<
M#:/* (]1U2:%+R?9)>1.EQ;E;6<QM<>6V[9;[9F83JAN%P%#.\)RT85<\_<7
M<WC.XOD@N9+CP[._V*0QRF#^T_+,\IBL\N!G 6*1R=LJA]I01Y)::A?>)=4>
MZAO(Y--1#;-?V(^R/JT\?G-Y-IF3)0*T@9W=ER"T?EE3(.D#>5YMK (#8^4;
M6 6-QY7VC9]I!M8$$JB&:,(N7!&<$878-@!':6XFLG33;^2[M($.Y=.>-$FM
MV29H;:';(!"Z)+ 1(-A8",[L'Y8];U>W@W1OJ,[W5QYJQ16!+F]2'SS+;Q1K
M)N69$!!D4I^\\ODX\L5_%>N65EH=U<3_ /$QN'NVLA81B2)Y94\R2&*,%_W,
MP^1Q*!N?:I0$M$ )IOGZQ>ZMJ,L%Y=RRS6]H;2;9NA19U6VA/G+BY7$C-(0"
MOFR(I"Y*@%>RG2^U.;5]0,%W-J<0L4L;<K+#/;^7/<1VQ E*&X\LAVD?]WM<
M*APQ8[F5CMV@2YDN$9'M5,5TVZZ""<>1"S3Y6X3;\\A()VG)&/W<<=U/?17&
MV]@FDGW6:MNEM([B2-9DDBB_>L\<@E21S(JD[-H&\IN')ZWXFF\1W"6/AYX]
M1CN+@1?;8@7M96C-T_D!3,ACG18UD66-AN81$M&C(: +'BCQ1+>W#:!I%I'K
M%]J#R6UU#,)H+>6V4W@>%'W8CG_T=TWG 8X895?DN:1X:M=#O+VY@U*>^FGB
M,-O*3 \C7,0G4"W+M@7 !N&EWC#O(S?*/,6I+/2[;P_821PZA=W"7-[.;NZ@
MV)_:$LCW(\G<CJL,X=D4R_N\LL: CA5Z"2SO=42\3[7);17"26SW$/FQ2A0T
MRCRT8XC==T9$PW>9@G:!L( (]56STZ*ZN"?LMK:1/=RS"W %EE9R]Q#^Z8/,
M2S;E)/!R1\V'Y._2^\6:E=Z=IUC'%H=B\KW$T$.R<7:RW W63RQ*@GW+^\D+
M$*9/E8,"[$\X\6W CTZ62TT:-[EXI+!HT:^N,W 4V,_R%921,TA8X^10-T;N
M[])]CL[;3HH8=-@AMQ+/!:Z?;L+5D91<9>VRD;":12<X95"EF5L LX 0V]G#
M9O%86\%O:V7FE$T^ .EE@W"&6W A(>X)RKQ\[<D8.?WE/7-1&E7 LXK*,ZA<
M)/)86MLT89;@F7;+"7BP7<.WFM\XBW*64HSN3Q1J4UG>VPC6,ZL[C[-:Q@S2
MOAW6.2!9"D;$*S"95*LL<A)D4(A8LK5=+TN[NK9)+BZ@MYE(T[=*+&+]Y_H]
MGO0H[K)&%*''(7(55BB !7T?2[2R>XU /)/K#)=17>H6D#M]G4*AD6';"8Y7
M$H5BNT;I6N&"@[XQH7>CPBXN&-A:0P*[WLZ06(E:*;,GEW<#>21)<$*-R$,1
ME<'C][)J<B:?%,3;>7,GG3006L:LZN5N6\RUW18DN7&XM&2<9).029,O7KR;
M3[AX?#]I:7?B69Y39V!S+:V[1%Y))G("^5+)'<J"21EIHQDKEB 'B74H=.NX
M-,@TBTO]7+G4K;3A")H8%CN,O<DI'YD<KI*[!MK?.A5=S'$EC3O#<^GB\N9I
MI+S7G03W=VEG$9)W6.:*-X'9$CCEV[1L)94'!!\QI'KZ7H=IIT)>2ZU*[N[M
M%?9>R.)[G$,Z1F%V$/E730A0Y&&58\-R?,.A>S16=O/-&(YT1[A[<V,<(99P
M+HO]EC(<R7757#84_,1CYUH CU.Y^R:3-JJ0_9;6TBFU"9%M,/!&8[EO.@\R
M)0+EBRET?(7+ CYLOAZ^DWB/6=5\.?V3)!H6G/YEPT<9DAO69K>:<,L8WK*(
MYI-BX;>[[P5>,$9YA;QC=1:FYCL/#HN))+=;:19'EE6*\#/:K&6S<)([2,P4
M[R%*%A$))>P,@#W%Q<&T5Y;B;9<V8C<K(BW"!H%V/))=+%&B.I&,*0N=K*0"
M-/#UG9>'IM#EM/,L8[2..X1K<3_NXD=(IU'D$3W!$4.8R"%VK@<#?)>S166I
M?V>HC.H!UOK&W2.&W68F69IA 7#%IS$6$AR =ZG,7F%AEZYJ<6@RW$4FE^=K
M4T5S]FM; .AO87:XD*0.&!CFPB23.H))V ;F,>)-*\.7>GWNIW%P))=89#<2
M7%K:H(FR]YY8M!(=D4X$N7W;E^?YMQD9R 5[/0I]4O[K7[W3I/M<J?:+>W\B
M))HD9"T$C&2$(]Y&RF-59L1(W))):3<OI8+;3I+R)8&Q+=>1#8-%)(DR"X+O
M;*8_GN6^8,AX!W]<-O)MK[C;^1%B6?[,MK]GDWW'^DA_LY?;MN3RS[PR#YEY
M^=JYN]G'B!((/#TLEM:.GE075FT9A6*%KJ/R[ OL"W3HK*6 V)'R&("E@"QJ
MEWJ%]K*6&B&.RCM[B1Y)H[6%U:8-,S+9R2[5:Z=1(),JZ)N?+!E;?<^PZ=HV
MAW;:9)!I]KIMI(L<J;KB#35B^U+]HB!CQ)<9)$J9W=F)XWR6%O!HVEPZ?:QV
MEMIJ/-:,+*XE(>!/M1$=NJ,7^U+M4R$#<3OP6*C;<UJ]BTS[9J&HW,%K_9\0
MN3?W=J[VR*WVA(UB7S/]<NX!ROS.&"C&]0@!'<W$]D^J20K';+9(]XD#R10I
M"I6X!E9%D'FF20,Y\UHTPRG*O&YK#MY7U647&G-]BL8;2XU*S6W@:YFBENFN
MO+OF!(WJR!BL"AFW3D,HVJ03"XUG6+B%X+ZTTBVE%\+**$1SQ!E:6*]VH"7S
M/#)BW=&<NY=Q]U%Z"Y;[#9WMQ<2SZ?!:?:+J=H8_)2WC)N3YZ!5=9I&R&9')
M'W7*(Q"D C1H=.N+BTMYY+&"PMQ+';38$&GKFZ GD(D >!@N!%GY B?*G5,_
M7-=L?#)%H$N[=-\][-%:-NN+*)I)5EO64,ZR1%Y48(R_*"S;3L*I3\8^)3X>
MTR>.TTW_ (G;?:)+2PMA#*]J6DEACO57;DM+)-$"I))\QL E9,V-+\.Q:9K&
MKWMY=>?K\NZ\O);9'?[+&ZS1Q2VZ,DC/(5BVB-F<)F0)A6*N 4]&\.3:>E[J
MFL3VEIXAV74OFQS&:#1O-:8M=(DTI"Q2>6K?=#;F<$A25CZB\"JYEFCD@%B\
MMU#/>AF2S<K<J9Y)#*%>(J2!&IR@9<A01LCN4N)+.]VO]FOH/M$J+(PO9;$$
MW*QW42!6=V<'B/( 7*+C:5;C[N[E\8:\1H4\]OX=TR6X^V7.EE'9)'BE83V[
M1H=TS;I%=5,A"SQL%64MY8 :O>77C#4[_2=+%]:Z=8?OGU!7G>:,21RR"1(2
M?WK+<1^5Y97?"T9"88_N>D>*VT3P_?6\-O::-%8)=7$ AC2X;2P3<D7FTMRC
MJ"5C5<C<R<C.V2UM;/0KRRT^RLL6NE1%VT^V42)9PL+CR[I?W7FR3/Y;1E58
MG]XW#?>:GJUS#X=\.ZE8S75I"EJ@NIYYE$KVS33S,EX=P6.5S*JR>2H7:58+
MN_=J0"YJFJQ:$NJW=]JGD+81)<B!G>5+?S9;A%F=F9#*K _Z@$[?*"H"=F?+
M/'6FKJ<WB>YNM.DM9FTQKG3[2&9K<M$9C)YDA9<,["WEG-N=NT*Q"M*TCQ]W
M-8/J=]<>*-?3^S["UB&H06HA96LP86Q=RAHRLUVOEJHC.1$H'WB1NX_XCQ7"
MGQ5;S:=A(]*DN(T=Q';1B6]C_>'Y^)I/)WA P#&+=L9YGC0 [C1?^18^%O\
MVP_]-L]>@5Y_HO\ R+'PM_[8?^FV>O0* "BBB@ HHHH **** "BBB@ HHHH
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M.X$DTGF 8Q&[NX8*$!X7\+KHUK<ZKJ#R:KJDSF^NFDL&AB=&E1ED2(0Y2<+
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M\J.-?O+)Y4;%I!Y>ZY!!!XKUPS7#^;IIEC$<<]K$\MU&OVS#[HQE+9PX",Y
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MNYP^YF*#+:EW90V,,D2V\E[;VZ7$*02V0V",PAA:*([<YMRJC+#)W1HGSD[
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MVQ?8HI#(I2*497[5O1Q(R2I\TK;F(2*@ T*W6.WOKZYCC@U;5W?[78V=PQ&
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M,6&GFRPD9G$L0N$E2)7DNY045@K;@6&TY(\R2\OM-T:W>XU:XM/(M':34Y)
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M;Y4EM@X\C9Y!\JVD^S-^]).3PF?DP 6+)+=YXOLT4]M OE163BQ,;VZ%$D>
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MWV)F, _T7R78"?;\WG1E2Q+!Z^I17?C74I=-M?[2M-*=[FSO=1:!/]+DBEE
MM7"*K^0N"1(KJ&5FC)\QR1T MF@TN-!I$<D;H+.2%(EV,/WR"WE!@#?949E5
M7522&W$;-[, 20:5;V>G)86=GYMJ(FL84N8C_I*()PMM.3"2MNHQMD.=V>K;
MOWG)^(]>M+>]ETV:*[O[W5K<K-_H[P[[0O(4@GC(5XT"W2QI)$&D:4%=K.OE
M/H:SK%E:1'1H;&,S1W"Z; LL$3;5>>'=;.BKB.W>*6W42 -A6 8>:%5[GACP
MY=:)%#JE^GVK7KFT\J(3R3R/ [KYLD$EP7E_<AT 0[?EQU=G)8 C\.^'CX;T
MBRO=0MI+G6)$BBM+<I(Z6+>0J+!OC$FV)&$@$K [1*^6)=R^A<PK<WMU.D%W
M-(R2V7VF*S:WOLJYE,"2LBKY#+\BR;D *C#L[AEL-#-=B>:>TC>2\3R&@DC)
MCF98Y5:WD8V^X6X;<ZR-]XR''RLJOG^)-773DAM[3S)M4U1YX(UDMVCGNUC9
MS]G1HRCQ ;VV3X9$4%V)W!F *>J:MI.C1&RM9I_$=]>2RV,=DLEO,\YC7;]B
MF<C?Y:"5G9WR5PQ=SN"O'HFC7HNKZZU*&/4-0OWFCO'EAEB@DF\K:;98W@8+
M:[(X\SALR-&@.[A:DMO#+R7EYJ-]/!K.I7LLL O$D81%$!Q9M$$D2*W)$Z.&
M+_,%;)D91'T%Q;^?Y_\ H_VG[1YD'^DP;?M>//\ ]'G_ ')V6ZY^5^=V?XMW
M[P KW6F_:_M8E\^\6[E**MQ'Y7G[/-(M9BD *VP(R&8MOWD$LK;9.?O+^\\0
M:G<Z1I5K!)?0_N;S60"PMYC'<%K:*=(U*21APJRE2%$C;AO(20OXG\12OI^B
MK]MTNZ\PRZT\[2)>$M*[6)>,<0[)9$$IWI'G:H\T#&Y;:6NF123Z?81B6)Y+
M>"]=6^U2 SJPBD)@+>4TC2!I#N.T"7<Q<NH!3AT32]#TX)!I5C%86T5U:)+<
MQ[/,@ 9O)N&,!V6^[S27).=D;%I#*0;&MRW$.Z2'39]0CG\V&17LPS7Q'GJM
MG+^['E0[I%*3$,FU6W$!@TE?7+FS\-Q?VI:0P6TYQI^G/):! FU9%,,G[H-'
M:1^7YY</T5B#M"AJ=CX?#RP:C?:%'/=7*?9;6VFMHPMC&()PUG(?*PMNK;@)
MD&9/,0'<H!< KZ/X=%U>K=:K!:2:A(D=O%9-:1@Z?:EWW6I'DL!$J)<1K*-J
MSB1ER,1L-A[19TEM?L-H(1;PI+8Q.R'*LT4=JR+;A_L>\2,)#P1O^4Q%A5R\
ML4,0C@L_]"^:QMU:Q5T@1E,31/"45OLV^.)LJQW9!)6)<US^MZEJ.MSMH&E1
M02ZSY4L-U=3PK-'8^<DY,,RM"I,+&*,(P'S!4=P1M68 I^)M1GU.7Q#X?TZ:
M3SI4E@OM2ODB2.T@:"X*I,%176 $-Y;D[LL7)*%!/T&EZ)8V+WUM8V<DL%W>
M^3<F[L]C70VN)(Y6-OF2)5)9969C(YVF3GYBSTNTL[>32M.M+MH)[B>UDN+V
MT>;S687,K+<>:JM);JTGRNKG>S[=W+%I)W\^SOKB]'EGRGM[HW,.R&9E+RM%
M+(]L/]&10T:S8VLLK\;]I( 7H^PVJW5]:>:NG^6-]P_FQP-Y2L5>:2'>;<2)
M YG7>V\;FVK&P&':Z4WB")IG2-]#@O8K>"!;)56\@6=Q$I00LK6ZQS?*075M
MJ2!H&#FJ]SI#>)-4NM=UVWD318'E%G#JENMN]V$S(!<NL0:&S1D)5) 2QPSY
M^13V#0WT1N;U;B2\<W$@M)9K;RIK<&2)1;<0L3 [HVZ7&0FUOFP' !3M_P#0
M_L<44WEW<>^&.-;/S?L._P#=I"(T@1OLF^)F$A,>[R4^8J>,/6KV'1K6&S&G
M22;D$5OI\8#&1I)5A>R4SV^T6;.%S)N& T0 "M$IL:W<M8V%Y8:;ITFH2E);
M33K>2R59 =\8:V6(P(GV' C#S%\8.-V=A$FE:-IVE:B=2O+OR=0&6FF1VC73
MK>,OY=LL9C"K:;(YAYCA0[*''S%"@!)H.B+8I>VFIW$=S?W"6\6I1V\+>5#%
MN AMH+=HV7[+M>5"_M(200WEW%L[BUTXVTMK.T=I:16HDL<+<HY$(:W@VP1J
M(7VKF4,NTD_ZL(#');HT-[:VZ>7!)IR102QVZJSP),X;9&OV<$P QQQ!UV@K
MYA8AX<CF[Z2XU^632M-MH%T^VB%E=)#&,1EF$,EFG[I9%M"8'5IT4D.RL,+"
MX4 L/XEGU.>'3]$AG,,,LFGW5Q>S2PQVN$16MI)A,6:Y,QB59E#X$A*;RKYD
MT:RM-,TZS"ZC'<107JP7#7)>Z$4C7",(9D6X9?MAFE#&8*0I!X4;<Z%Q#ING
M(4@@NT>-YK"%5F7%HLC1'[,A25?*,RHAB+,-A=%RF4C)=:B/#UK+J%SJ5V;?
M37DMB)Y(W5%:6#9',?-&Z5E(\N5R-J29EYR6 )-0N4L])N+B6^GM+>WBC2X6
M2]4&%!&@^S2R-/\ +</YQ*RJR\^669@HWX=I+J6K:I8:KKGF:+H\*+>VD-Y.
MP1ICF2XANHYF5V>,QN\+*H1 N\9"A:KV]C-J^J6LFJS7=G8VCQ:;#Y\A-Q)(
MF!MU!D?_ %I8^9;R(P :17SN=%?I+6=+2>\O(C.UU;^3:E+@KO@&RW9;-W:4
M":9S(Q20LP5I6&[DAP"OI;VZ6>F13I]DAA^SV,=A,IE@TV6,Q-Y,A+ O,Q \
MN9AMXC*\N/.S]2\56^B>7(B>5J]S*FE:="X,]QD>3^YN4:=/,D#22,LA<H$8
M,'_>CS#6_%-QX7BMM-AF^T:F^=-TIKJ<3/).JH0EU&LHW-+B-EF_A^T#>L?/
MF6-(TO[!J:ZA><:D=0:-YQ=;HK%6CMXA!*3.&F:5(HBC,I8LZ.R(?EH IZ';
MVD9-YJU_(^NBW@TJXED=S/80O)$BVLFR0.TLCEV6Y"@$DN,)M4]);:FANE,<
M^QO-3)ENED6V$TI#Q2K]H.Z3S87B4@81G5$#!7J.VF:4QR0:G=V<43PVY6\9
M6:T<20A[:7=)^\>5=H1R'(WNRR,)$!Y>\U.YUMY]/ADDL=-L'2+5K^25[I+2
M$*4^S,&9XIIR)&,SL&CB!&XN8U>@"2SUB\UC5CI-CK'EPVDJB[NYIRCZ:ID$
M4=GM\UO.N3+ 29)"RG<>'60*VYH]E;:9IL-PBR63V5P3=M/,BM$/*4RRWWE3
M^7-*ZKN\PY*^:C%>&)(/)TNPN+/3VN[*YMD,L44TH9HI)WC<12^;,5G>68NH
MD#8_UB+(C L:^NZG#H=O)?&YD$]F_P!EL!-&+N>.;"K]GPDRR3F=-DBHQ)!&
M]V&$"@%?4]1.EZ7)8^9K/V@6[QQPVYDFNH6DW3*CAKAGG+*HC#Q$[3%.5DB
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MJP6W>%53]Z"I8QA201Q)%)Y6CW,.G2?:O^/BTMX5?[&EQY;7(6TM\.ODR1[
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M&+[1&IGS:0NTQ47 ,3B1UVD+C[A 9 "Q?333),(+N.1YG: F*0@72HT^ZW@
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M_)/-/_["L?\ Z*EH ^8**** /O\ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH P]?A9]1\.SH8R;?4]_E&15>
M0-;S1G8&(#%0^\C.=J.1D@ ^9_%+4XM-^*7AV>:_@M5ATJ_97GN'1(V:"55)
M\N3>N6P,HBL<85G( 3U#75W3Z./*@E_XF"':TFR481SF$[E^8=6&>8A*,-G:
M?)_BND#?%?P^+B?;#)I5VDJQPQ,VTQR@ASN#^6P)4EC&JKO99%.]D -#3KSQ
M/+8Z5J;^'\Z=']F1;*?4H%CA:.9(0@C B0W&=Y6,A%1\9+,L<4/06^O>)8/(
M(\-P P>7:LMUKZJ+8R>0HBE8&3S9BQ+AB 3&R8R\C(;$CZM+%;W\>OSQ,EHL
M5S%''$29F6'RXG$Q0)<,99"A$<0)>/S%P@1^3BU;Q3?7\]G9^+Y'UNRN)M(C
MA-M;/!)+L9_-E"/P64>8IV_NQ;RQE9')$@!)JGQ$UW1+K0[*/0-]Q<W<UA&W
M]H"Y\N-I6BA651+M-QNBR=[X/ER ."TGE])X:MK;2#//-J\=YJT]Z(+S4B4E
MC\UY,FU<Q;,NBJ$1I57:95" !O*'+^(M'AT7P'>>=?7=SKUR]HDUVLXCNY;B
M,VK);-Y;2;K@JA,95&"C))^9I)/2#,T%[)OU..0QW!C\Z1E"0"1X2+>1%D4-
M*P?$;;<@%<Y)/F &>UW#&\9>*0W&GI&;5;AA*8F98E:W=S.4-TP<*KNPR)QM
M+CS,\_=Z@OBRRO\ 3M/O+N#3;)&L+II@P>=)4$0M 99-K7#'#^8Y#1EXD926
ME%:%Q?S7MQ96,5[)IFGEUM&O+FY(8MF(/8JWGYEN&*R SKNV895)?<PU+&YM
M]+^P6-O#Y,=O$EM%#).4CL4_T9?(G8.ZM<'S 8^/F'R@@$LP 03V^GV8DTX_
MN8,"-"2A4R&%S#,DLJEKF4N2KN 09/FY)\S+UC7= T"ROY6U&,0(DT<D]O.V
M2T20+);R2><"]XRJ1&Q(<!3_ '3NN7OB"WT2*$RR3K-%$4A@9C,ZD+ QM)/W
MQ$MW("3&<DG)(W#<7IQ63$_VAJRQW5Q9O&EM9RS+-'9%)%:&-Q)/@WTB2J!+
MG )&#CF0 CTS39;Z4ZCX@EVZE'+):QR3S)FP5VBC"$QS?)<SQ&,YBVJI;Y54
ML?-W%N9H! \,D:FW3R/*O+H_NF:.(1V\[B5\SM(R$2;7^4D#)<,XTMIINJ1@
MZK&C[X]/B:XO'9$_U3"!T>;Y[AU+,K[=V",YP-^/J&JW+W T2P>.&X%O% \M
MW>N?[/28Q+LG\N;+SG#;'WJQ:1 A8>:Z@$>HZ[>+K&G:'I$_DW:>2E])=2EO
M[,M9510LKF1TDNVD \O(?.3D%26>QH,-AX8LXK2"3;=P[YKF.>XC,]Y+,5)C
M?]_M:YW/:@R-E3YJA-JR84T*VB\.V,.^:>%TE2V<SW;W7E-+-$VRX42[3<RM
M,7\Q5VIOQDHH+W+:_N[2WC682-/9V\,9<RIM61A#FU=6NB6N'.-CL2!YJ_,V
M3O +&GRWLKVHL_+G2V<QEI)Y05MV6)@DR.Q=;@*RL"ZN2$;)C\WY>+U2^?QU
M:IIVGV^?"MO+:P?VC+<LDE]%<Q-"6AGD'$D3/AT)9I#E&(RR/(-1OO%:,L0D
M_P"$.5[<PR&Y\J[E,;*T*!W=9$GEE$+*SG#Q2QD-&^2_4:>;;1[*UO4,<%G&
MACF:.%,@JD4/D.D#['N/,154HC !#$H!(+ $D%K]LO ?L4ZVHNQ>6=M,OE02
M*1"[2N!%E9%=Y66.4[C)N;C"F.GJ=Y#I]DEXT5V92\'EW LPLLC3(L7VE]UO
MA;A$651&!\V40KF1$%C4KF'1K=6OA:-('#3?:R$BN9 "89WD6#!E46Z,VT 1
M)N<Y5$-8^C:3-J>LV^H:TL;WA2WO;73;E#%NVLR"[E'EX^U)%(J,B?*K+'D@
M-%Y8 :5ITUS=6]SJ&FW=QY;_ -JVFG2QE0A\K F<F)8EO&D+;H0Z1J7+X+ N
MVXNGRW.=DL[?:XHI$\VW1-[)Y/\ I<N;;Y+E>-L;?*?+7Y5P=DEM;3/<1MY<
M=S!=)#/LN[4HTS1F'_2)&$2B.<#_ )9L#GRH]OE[7QS=[<7D<MMHNA:= VI7
M>R^<S6YCB9BSR)=7G^B@)(3;(-HVMND<#:41Z )+S6&OKV?3=*AD22%TGO+0
M6RO%:0,YN!>!/)+_ &HX^6%_F\P[MC*N]K&A^&3I=OI,%NDER-Z73O.9(#+)
MA#+>2,83*MPQ=D\EY,-&64\!@+%AH<.G6$8M[2[OR;B35$BF B:]D=XW:6?]
MTBK.I=A'&Y ^52<%-T5BZN8;"WMKN[%H+.1XI[BXU(BV650( +B8F !+A6"*
MD9*9Z\%0$ *]Y>0VEH]^\5VL=LC3S7ILQ',%^SQ*UXP>W"^>BMMV#JGF *S)
MY2\>FJMXE\6:YIM[HVI?V?8/M&FVMLOE103*TOVZ6-@1-.6V,('3<NXD)(ZM
MC<T[3+SQ/JT%_J=A/'9VUV)K2TO+<P/=302(@U&61(U*2&,D+ Z@-M&/E&5/
M!]@__"1^)_+3[3#)=VEQ+!=0M'%OV1,LO,:!;G ,TB"/[SPC<I4F@"O;^.8'
M\CS/"^N2^;=QH_G641^T,OD9N)/+4[KB/9)^ZBW,OD/N5-OR4[[Q[/;V\5K>
M>$?&K7=RZ!!)9Q2B1\(Z3+D%5G2.+S?*50JR;PPR"PW-=UFXT?[,;71Y]9FN
M;22]BLOLH62_>'[*1/.?+!AF0;MJ[.2% VML2J_A/10^F6=YJ$O]JZGJ7V6Z
MGO8TFCAO1YGVF*5V\KY&BVR*BY *B-7V[T5 "OH%Y>V]_!<ZAX;\1W.M>;%;
MRRWD,9AV>>\1N%==VS;OG?8IX6X8#="JNFAX4UJSUF\OM*BTZ^@O+.6&XN+'
M5(PH?S!!*+F39&T<4V=[B-2N7WL0K$E)$O87\5:9I[Z=:7%Y-;K<O-=@1-(I
M==LCYMP1<;;5'6(;?]5)G:(48\7X>2\\1>-O%.C65WBQCNX+AGBS;R1L\'ER
MW*RI"IBN\JFZ,A5):="#R0 =(]U=^);^\T;3K74A9L\!N=3:W2+[1A$1ID)A
M4"X1CA@71HFMD*JQ5XJV-/T=K?2[73]/TRTM()G,@$<2PAD'E%;MU-J%2Z4A
M2L1"C.>3L^4TO1K:*W>PTN"2UMV2,QP_V>EO&S@0N;M@;4!;A=PVIRI,>,*5
M8(2SV,^E_P!JZA>V@TW4+>"=I#_HEK*/W'^E-(8]\,XRHC4RDX1,$$$H 2:G
M=65EI+:MK/D6\(B^TRW BDM0X:.*)YR?+,D-P%9TCC#[R#MSG[F7HVBW>MZI
M9Z[KNEQB5'6XTVSN[5$E3;LC>ZN94CP+ADVD1#"C8HQE-T9HVEZOK%U9ZGK%
MI&J&]74+2POK0+*%2)(?/N)(U"+<8^=4(XRR_P *M#T%LC37$<1L9)DD2&Y$
MMU"J+>$&',TW[H&.XCV JA"@_+C[I\H II<06VG6/EW'V:V-I).);2>*.-%0
M10BXB5IF1;=8W,H3:Z@;2</@/'K&L7-I9,EF)+Z_F>0 6V]T>>%$)F"I,7CM
MT=#')$ 69FVX8M^\R[[7Y;?2;&QLIIQ>7%I'>><UXCHGEQPNEQ*YN7:.T/EN
MDA&_?\^&+,&DT+73'TSSY]07S-=GB:5KI=T\BE?WTAB E$KVBR&*-8%"G/!#
M"0M0!'HED88LQZC)>ZO>6Z.+@F0^?#'/BWEC/V@JT$:MN= Y=UD4N=SX?4;6
M8/WEU(DXL;B5+B,B]B7]S'M+78?[1C[-CRLJH!Y8LK>8:N17,-U?[8Y));:^
M>.XMS%=#YU1%8SH1+DP$^2A55'S$E@RR$UQ]EKDWBRUDCT^[U(:2B1RWEW 2
M'DQ+YQDMU24SB*0)-"5R60[$508Y0 "-[RX\4>3I>GW4\@6[DEEGX$J-\FV>
MV83AEMFW.6 D:7RIT50J2QL.DTQ842.#34DAT^6X2:VM1<AWFA5ES- RW!"V
MXW0'8  %5EV'S% CLK:SMXM*M;>W^V0M*MQ!]FG&/NQ?Z3;;K@F*V4.4,:9X
MDV@%2=\>J:[IECIK7VI:C));A$DF-C/)NN!+$%%Q L<Q9( BSN5P3^Z>1>4W
M, %YK2Z9I<^ISZQ:?8[&W2Y\T%G#O-G%R/\ 2<M;Y=PL)Y)CQ&253.'8_:M2
MBCU_Q%#B9Y3>Z;:3WD%Q!8*%.;TE9T2:%5>+HJLF,@%G:5Y-)LI]4OQXK\27
ML9^RNM[;64-U$/LD+)'&MUYBR?NXG6*=VB$DD;*W\3*=W6>7<-_H7VF?[5;?
M-*;>0>8SS<"X17E8"%2T^(Y W,?R@^6NX DFAAEUF9E@D>>%T+H)AY^UVBVR
M(WF@QP9A;?'@>88VX/\ 'R>I^*0D\6CP3?:I)HC-]JCGFACC1T#2WQ<2\V@6
M=MH+KM>((A)PT9-KSC43IND7WVNZ$MK<RW<=TQABDG*J)3OE=#;NLA"VVY7R
MH* [UE2QX3TU-)T>WT:WO)Y;K]Y>&^@D5I-1,S!?MJR%@DBJLA+(ZR%3Y?WL
M1M( 1Z9I$.FV][>IK,=W.4AO[K4FD"27,C#Y+IVCN$4V:+O @( Q$V"W!;4U
MN\M]%T>>;6KJ")K+;=032YW"7</,N$!GWF$-.J>4"&V[HQO#HIC;4K:-(]7U
M*ZM((]\;B>29(S/%NB5YX)/M)$=NS?9F*9Y"L&5VD%8=G8_VTQU/4O\ B6/8
M2KJ$-K/!Y264CQ!VN[F"25EVL\<@41G*>9(2PEWO& 20:'?:[KUY?7K7=O-8
MW$=S8:1/-]H-I.\C#[1*KN4D0HJE1&X5 9DC E3>>D74[,W4;&_G33Y8GO&6
M2X&Q8UE:07*SB3F$X 9 7 62$%8U+!I+"XL5.G6NFK(MO&C7%M:12?ZR)I-B
MRQN)/+:!5<MY8W;5>+"H0BG+36XM)TG3KF9IYYKO[*MC";EV%Q,\:1&1G6:8
M"WS+&"3N <%LR,Z%@"QJFM/HVDPW.I13QW=Y+%##:,[1F\OS'&T4<;)+(L$9
M9&1E.5)R22I)DR]'\.0WGB66XUVQCU/4 \RS"Y(9[".0SE$7) FM6261 <9R
M,,OR[((]+LEO6&L>)W@>ZO;2*4W0GM]B68B\R>(J"5DM \A0L=S'S5)_U<<I
MV+^Y>WLWM;V&"Z:.*2>>UO)VMXW0F5)IBS/(CV^70F(D^4C D%O+2@#02!Y5
MM;V<3Q7'F@7%Q"&\T.LI58=HB7S;<>9*H=@,+B0<GS%XOQ'X@U>_UN7PY:)&
M6L;<S:I>74P:QM9)4DF$-PGE*9(#$C1[\@ 2AF!D5:IW^KZWXMUBYT[PS)A)
MK1S=75S!;%+F%U+VR)YD89XU6[C:960E%  )=\R]19>&=+\-:<VEZ1H?FV<4
MLD.'BW><;@,6CF9HBQM^;=3(F\_( _RQ/D DT'1K;PY;I96=EJ216]Q%:I>2
M1I+<*,(K9.SYH'6*#YE+%0^TB(0XCT+?R;%+6&Z6.Q:!XK2&>*(8B9V$AMD8
MPJ@@PL42N,;CA>) ,R6\21ZQ=W#6L\;6]V$-W]F4R79F5<K\L>?)4&W7>"#F
M#YSB,EN'TM?^$EL+2YN#/!IMI:,MG:K;^89H_( #20PQ([6DC0R%8SY0<Q@%
M6$B1Q &AI4#^*_[.U*XT_P"R^%4B5+:V2)EDD+;8O+544%K!AM?$BJ6*AF41
M@"N@N%VZ=/>ZB8#YT4D5Q'<V^V-]@G+13S&+_CV7<0KE%X7.7\S!DN89KBWU
M1KBTC:>=+>"1/++K(V!FW+&WRUOE^9,-CS9ON;>,/6-:O-%O$L]'TZ^GU>ZE
M2TM%N(S("D8\LO/((V8VR>='+O\ ,9R\K*2F'  +'B?6KS2M1M8+!(+G5I97
MMM/-UD22R2$,Z%5@YMHT9)&D1P<PJK'.233-!2WGE6>Q\^:2464AN+54C:#8
M0]NBK$XCM BK(BASN<['8-NR6^@IIT4DYL?[1>?_ $,L]JL:;-K1&U,9B+16
M0=(R-F_[V]LH&9M"_MK>65Y]0FQITGF+/<30&-\1M*6BFRFQ[8QM*H,@ '#!
MG:174 +H[+6[DU&&#=Y12Z:X7]S/^ZED,$TI@ %L@DXE[G(;YMROS=_]N\7Z
ME=Z;!:W8T:1Y;:YO63R)+R6"6X!LGD125MSE<2J. &0DO(0(]5%_XQU.ZL=/
MN(($$3PWN5D(GG$<\7V-F6-&^R*ZSDS,/F=BL95Q\O40:/\ :?M5K'9P16T4
M4EHHNK;9C;O$:,D>U+BV\N8[4R-N,'+EO+ *9T^QMM$N%-G):VL;S1QM>'RU
M=(WN"8)\1LB6>PL$+9 208"L$)L:Y>V.F6%S?ZDT?V25S:O->P[%N"SS(L%P
M?(/EVZLXVR'@[LDD',F?XD\1QZ-HTGBB\@DME@MX6;R89XY6N I=('9HL/ X
MF9-SHHC<G^,_N\?2-,NY_$%MK>IZ1';:II2);V&F0; UBL@N%5)GC3$EN0T0
M5T5O+VD$?),S &IX;-_)YGB:_P!#G359\VUO!,D@DM4FQ+Y<C\DP[S&,A7\L
MESB-2T4.Q/!;W,M]:(/M4TN\0QW8+NH=G,D+[XF,=M(;<@.VX-DA,!8Q4D/D
MP7$-O8+&9[-'CM(S$(F"L90(7 AS#;YA0)(/O^4OWL#?S^M7NIVB/HWA.RD@
MUPNEM!(UK&$A@W2[3,5CV);HC9B(8LS J5++*I +FM7OV.\CM]-L(+[4M0NV
MMB9'^RW)603;RSJJM%&J6J[90':00  $A7JOI&@SVOEZG>B^N[ZZM)+29U26
M*[^3S=MN&=W$<>,8D65-TD2.9)/-R+%GX:%OJ-Y>2+_:,EU$]C$UY',7F13<
M?Z-,9%DV6X7ROWB@>8R[F+EP&Q_'S7$D]A%IYGN[J>[:W>W206]S,2EX8MV(
M246)X]T,ARF078_+YE '4+>WDFIB\LT@O([C9';W%K 8UF_=W$J":4A_]'"O
M"%DCS^\9N "4KEYI?^$STRVTO1-._P")(\30C4'78"%DW2:<K0 >7"5C6,SH
M7C(7;\[8-9>H^']5U:]O#:>(=2E\.P/<0ZG+?7DD4$R1OS:_.04B18-CW*;V
M=IFSN&_;<NO!FG:/IB"^UW56LYO(T@Q>>T4NHQQR3)'9K&=JIG,2^8I =5D;
M]VKN[ '81Z79VVF7&GVT4 CN-UO;K>$1M<[9)G-H5>(XMPNY5VAOW;,5  #-
M'+J-CH4TD\TUWN>X$<;RIB>^EDFN EJ#(B@HK,3'M?A<$E4^9^+\;Z8/#>BW
M'B&;Q)JL\4,J,JZA?S02RSI._F1Q!4PGFQLZ!HE3:L8P3')(:V-.TOQ!J=XE
M]XA'VN8^;'#;3V[):R B[4P/%\XB8 Q@W'S!E*QJ7#,TH!)HNXA/$5U:VEH@
MLH#:1HBQ6]H8H[L&VF.US"8=[J\OR DA JX9'Z#[!"ENUO;V4;P.CVD<<ML(
MUN%43@6TP$&([= <(_?(^]N_>1RP^9J-[;?9H&\Z+9]DG/FR7.3=?+<OB39;
M-UCZ8.Y<#_5GC_$DNH^(KS5/#'AY9XKR_P#.AU+4+AE9[9<3B*&6/RSMMY%1
MO+9&##>'(W/^] +&KZG<:YK"Z1X4:#4!+ODFO;K%Q';)*KO]GE1HBQMI_)R&
M5^C(1\GE*VQH^A:=HEG_ &!I4$$EG%:"W6VN(F,UTV;K>MTS1MMMV;<RL %+
M;]N58*URWT&T@1-.@21=)N+B7<GV=U<R!G#12*4V/;F(&)=X 58XPI8M&4DD
MNXM.ELM5U.>"PLT\V.6:8N3#,S-YD9FE3_CW9@"K?NAF*(+N5U4 %?4KVSM9
M=1EO[RQ-JT0B<7\8A,N6NE$5TQC(2VSA8WQ\Q!Y?=A\^*RE\5SM>W4.[3+O"
MVBW=LDRSLJ2NAF6-=LEN&F<*"X7=;1NCOYP:J<%C?:LEG)JFE7<$-HGV>'2X
MH/(B!+20^7,41C]E8P0OY:-*%\S,F^((1TEQ;6[WCVD,V7U/[2K+>P&4N$#+
MY3HR;GM@\DCY+J 715;9(JT 1HUS<(E^(KL792)Q(L#Q$2[MRV\CF,-)!BXV
M F$^6%D9B)!E<_5;JRT^:/2K.UDNY;E%LDL(;>)7:'SG $\9AREFF#$) &&V
M9C@G:YIZY<.DOV.&+[1J>H87[& UPZ.S2(1.&56.G*YE!9E?/GYC\O:E2:=H
MTT-Q>27TT=_J%Z@CN6DMC<M TQF22)DD"R?V?YJ(8U4C.&8MLW, "QIFAS+8
M7MUJ5I)=ZDUO#IQN+D&3S@'^>W4-$SBU+DJ99 TC*6=B0J.=2V9YHHKFS/GW
M$VYXI_,:5(W=8YS#%.86S;2;3F3M\JJ 0JH&P>5IH63$UYOBNO/A:ZB#F(N(
M"6C4RVP,DK9+IAOW8(#;%Y>Y:X\5V<JZ,9Y+&[E59[VVD$HN)5,F^T626$YM
M$?<YE8,I#-$BMN\L $FL3PZP)K'3TDM="AMQ#)>-8A(XX7C9);0;DC$<""%9
M)F\Q74KY0VOM"[EK'_8[VEHL>&BQ&D5NF^XM]]Q$TD<)= )+11+&A957RTB
MY;'EB6,5OYT&ER?93'=QJB+O,D4 WK"K1K&LGV<7&\A-X38&(D$>8ZDGGMM&
M2&]N[W3=.L+%$MKDQ;&.GN[6P2WC;RP%@8#YBX!PR,"H V@%>?6+2UTF62_O
MX[6SL[(^?<F^=GMXS-L:&54F+&?$9C656<F1)<8/ROCVUO?>([A]2U^.,0Q/
M);'1M0N/W"RDKLAN0&\MG,LB^2XB;,05FW.\94L=/O?$-PMYJ)U*WL%>!;>R
M:YEEEM "%$5U&DF?-99(KA9<>9$YR[XC7=U$VILJ"[NI)%D#K%"=/E5XFEW
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MMP0HDR "5^5NHU)?,_< P,VH2M:J;RWQ)>[/M$AM7S%A(0%(#D/N1GP-S*[
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MJY+'YNHM](73[)-)@MX[J.-);+$UNR)-$J.UO:R,8GW0+'(5,N[[R ?,SLM
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MM&*6T$J3&**\M# NR,,NV,X;:IWN=KE9@"2[UI=>UZ\\.:9!)J\^IVZB[U5
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MPU2=+&[O987\I5:%HI+U]\@^S.K1!'M\2[ YWJ [.2"GF5P?C#6M6U/4Y8-
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MD:'8)8631VMM9W"VD=O'*;?SY%>5X[:-7F4B<DQLSMQ,K _,K?))=:W;Z;!
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M@Z3;6:(SW<DMYK+S1W]]-*BSS%&F*VY:*4!9XP[KNC! 6!A\H";0"GX?T/\
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M6P?8Z'C+HB9!<&O-_B7%._Q7\'^3J/V+_1+S?-*TL4<""-C(_F9V_<SD)L<
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MGC"JP9_,!<'<&9#MVGQ/U*"]L(TL/$\EIICK#(TFCM)-<QNYA$4V;C;YN^/
MEQEI-RA5 =9 #U"Q=K5(5>^D!A=8MUY,KFU#M 1;3[9<23D-A'^8@$9+%B9<
M?6/$>F>#K*+4+J:.R#W$-O(TQDE,)*0%XKGRW=I;@PHQ20@@!0"V#E_-(?B;
MXPCL;>"*TU4W$41MYI6T29WMFDF6,*-UR5E9621$:1=Q:+:<EY"(]*\<ZU8:
ME9ZKJ,'B>:6*WE6X9]'+K;6\,L1FAAW3<C<K))/+N<;8\X.30!Z/H&BWU]>Z
M9J^L:/:+.]NLT5I(.(COBD,TQ%LH^U!I;AARH!9@H^:1QT$-FTSPL!),)W@N
M=MQ;J@N1&J S3_N 8YP64A.#FWCQL <#R"+XXVD%QY%UI^FWX%Q'YMRLSI'=
M-E2ERX-IN+Q")%) 7)Y5" H0E^,UI<6\"QR:;%/,D,LQN [K]H4*RS3E;7,C
M@PHA6-4"[@4=L@P '?ZCF]NI?#NGK=F]U:W6YFO)HI%$68HTBNY<0CRKA6@;
M9&#&N8R24<J!L:+I:VMJD*6$>+BX>]V2JV+HF6)S=3EH%,=P#\RQ< $8& H,
M?E&G?%C0].M;B.*737B=Y+QEFMY2\T[R^8LTBB+#W"[4R@>*,'&V0@J(;<WQ
MATVXO+:.>[T.*WN;MFO9;1;AR@QF*?;):<S1>7$%.6!(Y4#!C /3+J]L=+TN
MXU/46C2SMTM[J>6^A\H7(/E;9Y?W (N%,1"QKSD("%+)LQ[/3&\2ZI8ZK)'(
M]M&\$L5M>1*IEEB\KS;F5X5Q'=(P6((W:"5  LC%//+;XK:;JFL+J>L2:&JV
M<J/'8,EPL=Q=HI7[>)%MF8?)M1(W!(')*E%S?M_C)I*_V8US<:5<0F6%M2WQ
MRB:Y;]VHN&C%ML6:,HCX65E 4JI8[&4 ]0L+'+VQ_LZ!O-B27,L.PW&VX$GF
MS?Z.OES+N\U4^7,DLHP-N\<'I5_#H_C/7+&.SCNM8U-UO+/2[J$6WV_RXH9(
MYRYM1ME+)<,0654E!&W)+CG)_C4+?[+"%T._D:*,7=QB;RY[OY EW(IME;]U
MY )5>2)$VDE/ES_"OCO1M#US5]4N-6L=0;5/L\\T5Y ]NAE3YED(BM7_ 'P<
M,Q"X5=P.^9LLH!Z/<>&;AO#.M>:)[_6]4T^6=[ZZLPB2DQ" -B.#S8Y$BR1#
MMS^_D4&0[F6OHGA?6=5\+P7-OXKURTNM5B:^MQ%*@AC2<F1R^V  2*;J3Y0R
M^845@8]H\J3PAXLF\2ZOI5FL6FW<5SIAU&=V!1[J2.>"%;B5?) CE7RI,*C.
M,J!N "/4EI)<>*ETZWT6V@%A<113WFJI&#%=A)8)9%$@BC9+@/+<,KJ% ;?@
M+)N\@ Y.RTR[USXFSV6E:E)=Z==V7VA]3E1()4AD-K,1"1;!5G5V2;H0/.R/
M+D9G/<>&0LWBSQ+;6]M(]J;V&\6"XM6BB=W6"9I7)@PDZ!EVKN!.T%E#;I6T
M/#VB6-I8:=;65G)+:6R;+&*^L_*VQ*]OOD?=;JT<OF1F0*3^\;YLXQY?-Z7?
MV5KXJ\1W=ROF:@_D;X+Q)%2[2&&!K><_Z.2+GS)HD,2!=N\81F"E@#H)+^RT
M>PMTD7S$^58_[421'U"5((7BDD+6Y9[G>J*%7+'#D!GCV)GVVB?VM+%K^NZ?
M/)(+1GMK:>R\J=5W1^9=2-"C%+ORUB5%0AOW7RA"Q6*/3-(GUJ]T_6UMXY8Y
MK**\L(Y;>*-,AVF\V:18G!N&9ESA$$8N)C$78,QZ2UT[9]D2SM8/)FE%W,EQ
M9^7]L_U3-<38B7RKE7PP4CYMIX!YB ""WEEU%X#;SRJ)893)<0(D=XT)$;RR
M'R05F!",HX5A%"8V"[]N7J6IMHL.FR/''>:I?7#&R_T11+*/)&Z[FAVK)YL4
M*NA2/!?(7"[U6,\17 TVX:UL;"TU7Q+]G,MM!(D;-/@P*MU<;8P4(EBC4;2%
M.U22JH6AL:9I-[;WL<Y6/4O[1=+BX.H)*I"JZRATWQL83&\C!+9B<!58,K"0
ML 1^'H/LGV5+J[GU#4=1BBNIIHIM_P!JV?9]TD$P==MLKRNWE$#/F/L7;\K6
M+9[<12SRRP+:6TL>H2/8WQB2X$BQG[7@3!8[?=]H+1MN#[&?YFSNN)?*EO)=
M7<TDUI(D%U]JMW:.!P@C,DZR&8HD&"A\LD$B.4XD#'/+S7-WXNO1964DD$,B
M*9=6L;I!/=1EQ'+)8N)76*)7@A,D9))63D!\>8 5SJ=[XSEN$L[F.70HDBNI
M[J".63[6WD AE@\[<;=F22)X-C996 )<NT72:=9^1%!;V5]^XEB$L!LY<R7$
MC*BR7D1DG=6A'F[F1U8E\N=[,"T<45M!HVV&\M)(+!([R"0%/*MPZKLN(2)@
M4M1B?*,V2@=%.P!6DU:_&E2KJ&JO/;_O8-]G;333/*6:%&:$+("T8D:W7'E
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MYJE]K*P)8 @X^E:7/)%:^(]7B_L:/394EL86,KC28)%@,L6UHDRKJTJNQ)2
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MHHH **** "BBB@ KQ_\ :._Y)YI__85C_P#14M>P5X_^T=_R3S3_ /L*Q_\
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M$7S;&!5F.Q 5L(HIWCNXDL[<1LMM8,YMAY^/(MU6V!DB;9L)&"(XHG &[S*
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M#)]Y&&\ATG3O#^@/;:K:P6K6OFW$SW\K7<,TC6]QYER&"(UW(R%Q)&VTA4)
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MF";EKHEH;5=.L(;2+1Y[C[5!IUO</*EU$TJ&25")T4VYCE^:'9L#$D"0;0X
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M[;8G?96L>4NI;IO*=9;+YD).XP _,Y9Y1M)X"GF]/T'4M6N(9]6N(_)MKB.
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MR_\ D>C^P-7C^>+QAJKR+RJW%O:-&Q[!PD*L5]0K*<="#S0!XY(_Q.#PW?\
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MM\,;B0;1(45BDB!@WM_V/QA_T'=#_P#!--_\E4?8_&'_ $'=#_\ !--_\E4
M>/NWQ#N+9\>$M<W2RVUTLCZA;ABSW,4@DD7R0&F!A"#("PQ[04 !+5-:T[QK
MJMOJDU[\/[N\NY[>Z6.:]GMYO*.(8Y)MB1KF?;$JQE-H*@%4<[V?VO['XP_Z
M#NA_^":;_P"2J/L?C#_H.Z'_ .":;_Y*H Q]#TDZ9X-\&V%QIOV&^LI84\A9
MX4D641NLKH 623<IE9AG=L9V'SJ!7<5SXTG6[R6&/6=1TJ[L4E29H8-.E@<O
M&P>,A_M#8PZJ>5.<8[UT% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 2>'+)["S>Z,\\UW/+$]S=,&F$LS&.*='CCF=1(K0D9 $<08 957S8GU4Z?
M]_>7FQ895$SW,L*)8)(\!:&<"94,@5SM<9PH_C)_>DEW9Z?%;W$\\\2P[8&=
MR+FZLV*PN+4E4D)\P*-Q9RS,R!2Q=-O-Z=!-JU_I]_JD5IIMK:7J6EC81*9)
M+9E2'?;)Y>8ID\V$N7PWE"$GY&!, !)IUK?ZUJ.E:QJ?V[2+*UBMEBL+Z60Q
MB7*?N[A9),32$NC12J P?B0;XPIZ"UC2&UM-+L;G^S6CB%E:IYBNUD!%$Y@=
M#*PDN-BLZMA@J@DY&?,DTZ950I&)+<1/#:O%I\;-'9&-HP(#&PSAC(Q\Q8D!
MB*L2H",<?5?$1T>XL-+QJ4FK[X88;>QBDN,+F%GB=YF59"ZI-MG<+A4FY#(X
M8 CU+5+#0=,B^QP03>;J%M%;Z?\ 9XT,Q:2U**ZE(Q%<1QD")&8$(BLV=IV&
MG>%GGU&WUR]A@N=;N/(FW7$#>2T49A_>.OE)MN8U,H1F 8EF.%7]W%'HF@7.
MFO::AKRVDFI2O J_;6=PD&VV79)(/W;70F2,B0@M*8U"[1CRMA3($<-':%WN
M+(7!OW@(696@R9A&!BZ97 0+N3,41!7(! "'[)OGNU62\<)%)<1O$[&;RU@<
M331+#^[NE5@5C #. G]U?*QYKV?5?$$VA:*TEUY=P@O]16&)H8Y81%EY6, 0
MW&&RJH6V/;PY55+J*>HZC>>(+S^RM-U#:HEME?7),H;>' BDB!(VP:BSS2#:
M(U.QU!P0 .@TY[(2P1HD$'V*4/!)*LA2W$S( DOF,K-=RJ[')7>GG$-G?F8
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MW17DD5G,;8W)(?+[B(V]RMM(\^(8?*A5+R8RQ0$2Q/$)4D*2?:9%:(KO#%&
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M\RNV=RAFQ]4\3"SEL[6Q@OI=0N=]W;631S/-;Q;I!)=3H'W-#M<%(2%;<%0
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M(&DC7)6ZS\V]%8J^P@DN;</'$H9I>@T\P6T-K)&9#9P6YN$-C#*T%P%AB4-
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MY;MHUM4\\&27=&B HKQR'>V#PW._+U7Q3>1:B-'T*7[=K$F#<M&A,:R I$9
MK.Q6W615255&0))"K[XI<9^I:_N^TZ#X3O/M-_Q<WEZO[ZY/_'K(+T"-E$L8
MCD(" ?.52-$,:L!<T31SIUK:64T$<TM^\&HC3HFDB4LDML9)LR*#$D&8EC@X
M^2/#;BV$ +&CZ%#IEO9)%%)?71>WF076+:<J@@5I8!NW001B68F J.970!5;
M#:%E%!96\"V%O'Y%R]O*SV4<J07)46L:RQ-$SB.(( /*;A@IR0@=S')>#2-)
MM[O4I9SF);JXN8[::W%R(HX7DN+C9%NAD"QL!$3AP-ASG"8?]AS>)=4MIO$%
MIJ36YN%6TLKH%HKR)-A:XN'6+]R'41O]F;RT,D(R"6.  72QXE,%L4DAT66W
M\CRK66.&2\C22*.1K9"6,5BZA"P60%@L>T#<3+N:.B1_9Q \$LS[3$]DRA4@
M'V5<6J2+C[,R!'D",VUB54NV"([1EAMT@AOY)+>2XM'@BTM6&]%%FH>W4\):
MC)\Q5,@VR-\X.5K/N=:M-*>P2WL([QW>WM;"*Q+QO?$K;N[VGSE8[5(T4LN[
MRV*E6*X+2 %C4-<MM$LM.%@L>HW\R+;Z9#80I"93L@?RK8%&46K*NYY-[!!P
M&)"A:^@Z&VR ZBUI>R7%N8X$L9E^SBR=K9I([>&5W5[?+,&<[7"A510OE@2>
M%+#R=DMW=?;;Y]FQ;0^5"(?]&=?L'[Q0+2,,BO@$R%?FS@*9(;R*PTB$3:A'
M'&4@NGAT^[ACB C@25?LQ>10EJPM9DVL,MESE4#-0!H+:M=V\%W$D<$$[Y%Q
M8[7:(S"*3S+62-/GB,PRXE0!\L[?(H5N;EU0WVL6VGZ%!!"T/V=9KNSMX9FM
M$VVPC%DQ0"6$)=3!F*_NUE9N 41Y-5;4M9U"SAT.>2WU.]2XCN=2^8O;-:7=
MO$[00O(46)V!+Q[AN4 G>R[&N:-#I>GZ*EGI,D]Y8#"V\&FW'E1W4C0B-OLD
MOGA=H\NX=HV=G#[I,@A68 - T>PL-.;3],>=UBM&-I+;2QQ.Y AEWV0;(:%B
M\:MO<H6C7>'+R.VI/=6\5O;WBK:)&EN-5'V>XMO*&!(\\ENSJ"Q8R*CN^Q=D
MP8,K%LU[V>QMKJ/4;C4K1S=Z9)(\HN=AO4$6YQ9,UR!;@!%=R.""A+Y4L.;T
MJXO/'FHWM[+<3S>&7EDO=.M4G,,^HM$0@:';,K0K&\<6 _RL\A<A"RB, CEM
MXO%PL]5N!&-#A=GLI+&TA$E\\D<PN#"@D=\9+S21.&,@4(8BR/YG4$6,=O<3
M*)(-B16<*:9-O:VG0 S):AD7<B+%&61-ROY#J8MP=7N7$MQ>:=/%+=;;JXBD
MM&FTZY ^TN@G!2U#R 17 *[SN!VXVEFV;EQ]=\4V=C/-]EE_M;4-0M'%O;Z:
M@#7D:)+*(XY8WWQR+'-$Y9B058&)-SD  L:]?V=K9@QVL\\GVN0V\&D ,\<R
MFY=I8&,85[@^6_F1LV/O*0Q;;+EZ9HK17$[:C/'>ZA(Y>-K K#%;NYN'N;>Q
MDD+,9WD242'?&0C*04V "/1-*3[9<W&I:I!KOB98A!<WRHN?-P^ZSLW62,0R
M+&DVX#:V95D8@96NDU!Y]ET8;Z[N5N[@1F*RFB4SE6E5X+=GE!CE58QYAR!A
M'9 CEBH!')% +-(I9<1QRN8KJVEB+BX0W!>6!8XMSW)VDRQ[=AW.H#@.K8=_
MK,]S<7=CI<L<<NFWLLDT]A9Q2JC@W$K0V@<9>^>(@2<,JY<\$X:GJ>J)KD%[
MIFCWN-(U.66&ZU%46"&8,\@^QV*R$1RW$I\S=-DC+%L_<5.H'^A69L].A\Z.
M26:V_=WGEBZ52[,D3>>6%S\\I:0X9W@DWE 5=0"O:Z;9Z1!(NDQSM::-$LL<
M-C:B6,K&]T#%;[F;_23S'*QRS X^5FRMCR4T^SN]5-U D.GQ22/=2QK=0*\9
MNA),J1>65N"7+3849R4&3EA'JE]8J][JM[JMI)IMBYAO[CS]J6@"W"[8 CEX
M[H>;$CG@L"-H!^4<?J/E>,$%SK]K)H?AJW>:[CM&2$E98VDE-QPK!YV G62U
M*MM"R,Y#; P!J7.GZCXTQ/?"^TW0;?%]'#'(MU-)N^T_O$=5E2:.2-U4V_/!
MP,*%$VY=&YTO2[F(&33H[:WN;Z>_$+A+:5O/+SA=[B<.S>8L!SL RQ#>6M%[
M;7SB=A9R6DL%Q<36QM[?>NG@QW2K=A5'^DRR,26B&2/-3*@@L^'XU\2)H<2R
M6MM!)<1RSSV<=E.N(G1;PW$R[HU5I-@(<%I-CR E&( F +'B_6].\,6;1B&>
MUNHOM6H64:0-)/%(QG66YCRQBGQYPD,)92D99CC 44X/#LNG7^KZ_KNJ6@\2
M067VN:XC\Z>/2$*7:B6W$@)=#DDP$@ JQ'&Q:N6/A=] NI[V[;S]2DEEN);J
M*Y:)8I9);H6_V5)E,1D;[4Z&-I-JLRDABVYMAC%9P"80_9+$^;=>8ZN9+22=
MYMDD"R0$O<2&4AHB<H650IW8< D>"]TE_)LXI$M+9"T5O"LLD5DNVZ*R #:;
M@-^Z3[,O^K^7;P%-8]_JNJW^LW>G:)<R0IIZ2O<7,?F7(MGD:XQ($.#=$>4R
M>4ORQ2-C$NP"//DF&OZ]K.F:=8QV=C;/--?W%O:1S)GS'C>1(I+;?-<2K'<0
MMC=&!G!D;Y:Z"VTAO#VFZ7IR6\BQ6Z7&W^S[=7CL46(KY\0:)G,I/2,L[$W,
MN3*%R  CL8]'M]1TG3IKNVGB22\4PR3WKVK2BX"W#^8^9@Q3/DJK8DR?FR'$
M>NW5KH7G->6\%K:+*^HR2ND[VMHP\W;.Q^5)6:00'[.N&$CEP6;#U8O+VR\/
M6UY_:D$%G8VDLE\RR&26V='N5D\YI6AXN Y=EA5CRP _A*\_::7>7/DW-]9>
M7C_B:1P+8&-XV.\?;9"MLRO?A'4>1RNY2PZJ% )(+35?$VJ6<FJ:==P0?:/[
M0TRQNDD*Z>5\QDNKB3(WRF0JOV59 $1QQ\N5ZB/_ $1YKN"UD2UD?^T(((TN
ME8@J!.[H%(#D2$K;[,LZE_O,QCCN(8O-COH].@: ?Z3'!)8.Q$.Y997 $6^.
MX,K(_EG<7,"X"L69,/4I5T>XDTC0;.TOM61+>,6D@80,$,")<RK'#L66)GB)
M1"I\K8Q( C"@!JVKRVMQI]F/,U#4)D6]M[:.WF:2V (9[UD)$L*#?,GV<LQ<
M!(E*Y=:N>%=#NM+E\V;]Y?3>6\N#/&DDR,PNI2Y085GGD:.''EG;YB8WL5CT
MGP_"EN+-UDN;^9UU,W<VGB%9)G$:F[PUN4AN$P^V(<GJ^2Q86-AF>VENM/CF
M>V==183Z?)(;J-51%N&86Z^7>*J\1*"<97'*L@!8@.I&WL%MX]2:='E9'N78
MK*K@;;B5<(25,HS;L8L?O=BMY4=<OJ5WJ'C2WNX_#VHZE9:&$:XAU.![AFF.
M$<M T8WY4S2*T+Y!\I4C",':(%G-K@>PM7N[3PU$BO.\&GF"XD:WC*!HS$G$
MZ2);/MP,A5C"(T$J-UEI9II^HPVRVMC91V\NS3].CVI;$.7)F1O(!%QY8GS&
MC$ =2 ^Z@ MK6>WO--32;*"UTI/WEM8Q++:(L; >9+(!%CS 9,+ VT'YG)+
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M%3[.R9EN&=9 9+?;<$)M9"LL*[<HK&, L:CJ]\?%4>D:'9QC5HK>[FC%^^<
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M53YB).D$=LXM[:WFCO4NK>6.);H)-_:D C+1AYE#G[.GG,I9UW%BN6;=^]T
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MGM+>ZLH_(MD:TGC6V#J%E" 6R#R 'MP'4%UVX\E=V</C'NK>^\17K6MVT?\
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MQZFNDKF_ T$-KX;DM[>*.&"+4]02..-0JHHO)@  .  .,5TE !1110 4444
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MYB8V@ OYE;FE*=+L[6UBOO)A@V12BY\EBDKF E+EE?+7,A=R&4A29<D,=NX
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M%T^1?D1=JQ@%/0M-@T6U>W2UNY( @OO(GAEF%T/-5S=S2-;!_MG&?)R2"J@
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M:4^9YAC^8JK, A9\. %S;3:;<2-Y=W+):V4T^RTM2[;@9O\ 2(V,7DFZ??\
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M7HN]1D^TPB4R[H[J1$YC(;A(T0,3M55&X%%(KTBO,]<,*_!;Q69X[1T^T:J
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MV:-+E G[W>$92%8$ (PW+.&&RL)+2W@M((&>>WCM]+F$4<ZJ]R1!;@2H(K@
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MWW$L8\MB+H%PNP!B5NU8@[\H 7-9O+R35KK3M/L8&9_])U&=(C,EIY4D91T
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MX&2TD6."NYM"WTN'3K>]ATYXUO+2X:\NIA +DQS,)7,V%A!DGE5D#Q*5*QR
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M0ARQ)'+8^@Z3K$,NKW6HWOD:J(I;F&R2V=QI*RM=8N8XE>59II'!8KN+*&9
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M#_N25M9'P6)VQR*KJY5EN:3!H^BV<]U;^)IY;K5/W0U2W"7=YJ2PE1&T2J9
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MQM97E/R*$:@"24?\)->7,]W- /#MGYMQ:K=-DAF$H^US'S\O:$+*J*-JNDK
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MMA&\B!&9?*7!*@D X[9./4UN5S_@3_DGGAK_ +!5K_Z*6N@H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ_]H[_D
MGFG_ /85C_\ 14M>P5X_^T=_R3S3_P#L*Q_^BI: /F"BBB@#[_HHHH ****
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M-M;I?V]TD>JSZPEQ%J-["4C74"&N,6<8-QN25 S*"<@)$5+#:-DFDZ5;Z/\
MVE<7.J?:IM2ED^UW-LA190OV@M;6D<4A>.2-O,=L!G9BYR6)*=!=13M]K4M/
M/-Y1\Z.W66+S83YOEI"QD5$FR1EPV> 3M!0J 4[^^6.WNYWFDN$9)8V%D[;K
MH(+@_9[=5FRMPFWYF !.WC&/W?-ZH+SQ9/+#'JD%UX>GE\N0Z?*86U.-4F?[
M)"S2%"P*@22(5$BLR[D\E@2]O[SQ/=2V45WJMG#)%*LEUITAMO/997>"WM_.
MVXN0B-YI'RKM='&=IBZBPTRWB@6RTU8([!_/AF.GYAAB17D'EHJ2CRIMTAW2
M*.3&V=IV;0"G'BS3[!"TEQ;R)/ CVLL<*.J-/LL[=5F3RYXUXWA1Q$=S @;*
M_B76VTRRDO8M2D$[/+!!]E"LE[*J77EVL88R".=65<L4^=E5<'.Q;%_J9T_3
M9+G6;F2.>:WC62UBCDADFS%)B"W(F*?:#('(\MBV-B\_*]9]E;S.ZZGJ5_)"
M\:26]DD;FZ,*HMP-D:F23S+Y5!\Q]KY"LBAOG) (].T=[>\_M#5XISK)BN;N
M-H;1B-(AF!9XX=D;PS7 DR"V/,D#$D$85N@O8[AYY9;B2<-;^;,/*B$OV9&1
MT22 ^02\P"']WDX\]P=XV QGR9$N'@6-4MWFD+6<0E%JVZX5IH,0G?<%B0\?
M."2.<_O,/Q;<7$,$^FZ3HT%YJ\?^FQPB$/#IH9Y]E\"83OF+?,8QN<D-M!PS
M, 'BG4+BPEEM-,M)QJ-M%)?^796@N$M@[31+,@\@E[B0RE_+RH/EON=5W&2Y
M'H<.@6^HW%O:7<MTJ27<Q@ ED,A%Q_I, ,01[J3=M9.  57[H4-);:"FD^<8
MC/&T?G75PT<"RMYLGF_Z8A^SDR7+ ;3&ORJK[0I&T-H1V=Q+>7%N;6"TV2M)
M T&&%N'$W^DQEH-OVAF9@Z$L #DD[B' "2PN);Q(;=(+39*\K[80PMPXN )X
M',>W[0S,I<-N !;@[LOP>O)+XUFNK33K&[7PXB.\RO#-%;W1BF$MQ&8UB65+
MAIE1-P\P;6F*CS RDU6[;7(I- T+3=-?PQ:V\MS=6^FPK<0WD GA8)"55=D[
M*+@+M!7>&"N71FBZBVTB'1!;6$/VN,65D>8K43;%CC:&.Y206Q\RZ,:HACS]
MTD!6 &X L1V4.F 62V\D<D%N9?.M[(-Y*QQO"L\12WV-<,GEJ8NRC"J5&'IZ
M_K-OX>@NS?6WV>?S=VFPV<)EW/([J9(6-OM^UOYLA\K+9QDD*SM5C7=0M]#@
MFDGM)XVCWS1I8VAE\EY'EC22!C!M:YE>9 8V;^,GD;B^?INE[M1DU;58OL^O
MPVCSO:6I\U=(AG,QWVZ"(K+<.R8<D,68-CY2$8 DL]$U6VU&^U;5;B.35)DB
MDNY;:&25+6)+>=5-DC1MB42.X*Y?<"6*KY@2M@^3(EP\"QJEN\TA:SB$HM6W
M7"M-!B$[[@L2'CYP21SG]X/#,CW@EM([9+=Y)XC:1F4P*RS?Z1$/L_S7#LS!
MHQOP#GG=A\/6)[S4KG6]/L;3[/=)*ZW&H6L)F%A_HQVW"X2.22Y>)TCV1L^P
M;.?X7 *>MW=]J=UJ&C:8D=K)IB?:M4_LU?-GM"\1D(M=T2$W$YEF3?D@*N["
MN^VN@LM(71M+&GQ6\=O!IZ2- MG;LXLXO]($<L&Z)S+<%2H=23R2<?-B2,:7
MIWAS3I?+B_LZQTVT+#RRTD=A"@N<7$&Z(AKA@Q\P<G!Y+<>98NC]BM;NYOH8
M-/ALXC=R26Z^8EGNBE:6XA)@^>8NT@*\Y7#$ N48 CU"^FT'2]1:>XM+-]ES
M*!&##%&O^DRK)&3"_F3E5#2+AL;6?:>CX=O'%K$HU"_C@MX$N[B2T@B1R8V1
MKHQ7$,10J;OF4R0E7;(1V",FPEIIO_"0P0ZG=^>-,MXOM5DD,>6.7>5-14)!
MM>YD9$/D@?*KON!\TH=S78EM]+OVEBCM(($DGGDB9HQ91-Y_F74$BP$FX*LQ
M91T)Z_-EP"Y<6_E>?_H_D>3YD_\ HT'F?9MWG_Z1!^Y/F7#[OF3G&[OG]YS>
MO:U;--/HEA!(]^[B0+I@27['$\UREQ=1E0)!.$64-@-B5XT 8L=TGBS6I=!G
MM[6ST[S=0F^TW%M9VL:%MP2X/F6[-'_Q\-N#/D.JJ&&"TB"6QI?AJW\-_:KL
M+8V]XD7F2SRQE+*S1?M.R6%-JJO^L8/&'&%8EG9B7D #1M$3PW9W#WUW8SZR
M/,N;F]=5,5J2;EENW1W#QJX9]R(VP,TFP*"[5H33&WW/]EL;.2"6>9UGDA:/
M3D_TG;?$#:Q\W'S#<.';D$.3)---;O,3=QVR6[SW!%Q(2;565]D\Y^T#= 66
M8A>.&C $?E$C+\4:T]FL>C6-U]DOKCSIY!/.QEM(A+G[:7#,@A0Y;RI"JNOR
M97:8R 5_$FJ/.]SX>LC 9[;-[?3/<,Z:8/M"O!<-*^%W)@S?9VP"J$!@JJ)+
MFD:3;>']-DM&NY+:5$$]]=K*D<J2B*2)KZ;=*R%)!$& 96^<%F!.XI'9:0FE
M--<75_YE]%B]GFO&7%M<B*>%KZ5?.XAD10JQ@@*%& N&*;%Q<>1Y_P#I'V;[
M/YD_^DS[OLF?/_TB?]\-]NV/E3C;C^';^[ *>KZM#H=E/<2M:6$-K<2W$C,X
MC%G&Z3!9Y8DD_?B28,0HVEC(. Z$UAV:ZC?:G%K][%!I,%MYUQ::;-(L8TR.
M6.8F^O(PR[Y'8,NS("!WYW;R"QN4\0S_ -K7DWEV$,4>JZ;:7Z*Z:>)$F9+V
MY9I/F^82A8T?"+LX4\IT%S&EK9WMO:W/]E>7]HN0YD4FQ>0W):[F!EVO"S99
M4(X(Y Q^[ +%Q<>1Y_\ I'V;[/YD_P#I,^[[)GS_ /2)_P!\-]NV/E3C;C^'
M;^[P]:U6?3]4.GZ?%IL5^R7.HP+?I$EOIL4>\/<R[7WDS/(PW C"N25!20/8
MU_69M+>."SFC6]#S3QVMU,6,*[;C-S<,)QMM=VP\@[0 H7>4$9IFF0Z!;S@7
M$<-S$AEDEF8*MHH%P$D=!/@68&1%"#\G)/S;F0 -.T6VT6RB$T^I))#;M/+J
M=Z4^U6QD23>\]P3Y4H41Q)LPX4QQ%@5"LNA=W-M#;W$]S>6EE:6EPZR7%Y<(
M9M/E<2?O5=S(F6$L6Q&"[4DYX(CJ.[NO[.WN][/!#:1(D<4[>;]CQYZ"ZN"L
MN^2%QM^\>-F]MI#LG%ZC<#Q\'M+?4)-/TNQ?^TGNW$<OV;?'<IB21IGBG@+"
M3<$.U5Q$0<N8@".[)\37FHVZ6\]GX9TN66^W*T,4_FN)VE9EFD*F-F\Q#Y@5
M1YDL3Q95GA[BZVPWDA'D6EK'OED4_9XWTO(NBU\"=P/FG &1W8G^-:+B>WT7
M3IQ$?L-KIL4DZPDE_L2 3XFD1)<O;D+A(E'RX  &W]W'K6LPZ#:O>W,TD-O9
MW"33)),'>WC>656FD_?C?$ZY$: $J=N$8J$4 N1W5G!KD6FSV]BDXE\Z"")!
MF%I/M1\[>VW<TBQR95%+*2^2RDL/._#>FCQ6FF^(=6:.'3].TQ%M)\QQPVT2
MMN2Z3:&BCN%DMB9(A\BQR1JQ.QE;I-+MM1D_XF_B*;['J-OYUU%837:RPZ+O
M^TCSY")5\V-D ').T[PFQ<A-R:]A@N+JWB\O3S:(UVP= D=MO-S_ *3.5E59
M(G*,VS[P/S-@G* $>J373SRRM<P0-!+YP:X$&-+A1)@+EP22RRE&0X9#Y;X&
MQE=CC^+M;L]'O-+6VA\F^M9;J^:T\@.D$.)%EOI1&P(4!W8#.9/,9=N\AH[G
M]NVUCXG;3T23[/#</<7H5DBCTH-'.WF3-&V&2787"N,J7+.03&HKZ'90^&;)
MAJUQ:7OBF1)-2OI+C4P41E21?M.'"^3%MQ%NCC^4%5.X+F@ L;./P_#JUY=7
M=I+J%JGVO4;JZ\^4Q2+#*!>)&3@AT"KLB"!0LB!VV!1L,!;W$\QDTVUCM;C[
M4T-TD:_8H<R^9<#:22\I\WYRR@*Q)7<KJ\C7GG:B+"#4O-OOWLL$4J[)(,&9
M#++&'C,MN"510%Y(5MS9#KQ]Y<6_B*"(:9% /" \^\G^W ^3=7)>.['GAE,D
M$)!D<.V 21E&0HLH!(=3N=;=;J"..S\.JEQ=PK):/'97Z2*Q)NF9051E$[;B
MN-[@LK!8FN.@OHQ]H:*,6EA.'G%M-F,-I\LY*1SM"7*2&602[7X?]YLV_-*1
M(P33,0VK?8H+2*61Q<72E;,CSMMS,H<-+'+^\9B\A)95.T-O9,/QGJ]SI-O<
M1V=Q)Y[I)+]CFN'+642BY,MY(8I1(T# JH /[OY"BEPL= !KVM6UIJ5J+"2T
M$L=PTZ0>6CKIH66>"XOI!'(N]&:8*P9@5^=R,HZB32_#2:59S7*K!%KR2RW]
MR[1K<RP.YDW3QHJEW\X1HC*GE;U4E%B;*"2U@;3KC57N]6CLM<N[>=VD>Y63
M[%$I<"Z*22G_ $?<B.D9#>4TLB[MK-MV+Y;;9,999(9+9VNE^USHRZ>0T[+=
M,1('$3X9=H?&SY-J+Y@ !7N;DZ6^J%KJTM4L4?4I(PLFRTC=;@>:1&%\\.R%
MVB/(8R'>W[O')W[OJ%_JFEB\^Q^'=/\ /O\ 4;FW+)-9N)[IR\7$BRL[;3D,
MWEM ^$BE"!9+S5)M;O\ 4M!\.W<>E:/:(UW?:M'=D26K7"7<OG [MDD3YB?.
M[Y1)D!6 :+K(8+/1;-[.P2#2[6S\V=(2X5++<;@FXF43 -;L<E4XQ_L[?W8!
M7@MK#2-FDP0P:='9VC7UP4>/R-(,GGYEA:2/EF9I0 0$"(<A!A7C\0ZW#X?L
M)[U?+L)(;)KY;6ZD$4<,SN5+LL?$PW3$RA7<@B,JK/(I-S4Y[>UBFNK@^5_9
MGG7R&<F9[$E;D&YD42[GA9=P2-1D=,#'[OC]+L;B2#^W_$,?V*"SBFU:VTJ=
MA/\ V5+*]S,UU<QC8TO3$8 #+N9=H96DH L)IR1ZC>ZEJ#SZ;?V_G3Z9;&)9
MGT8W1G0S':Y%RT\B9$0WE69448.:Z1_[/NG^VK=1V]G$AO(# ]NHL2ZW0:_+
M;BK)*KG&X,,_,5SOVT[BW31+74Q:R_V-#:133.+<K,ML/*D\J\*A@S1A%,?D
MLK -$BH L6YJ_BG5M1T^66STB?&I2123Q6UY?+$-.C#3+)?RN2X>',L96)N
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M0%5?>6#=!!IMNMK=6=I8_:HQ+)'+;7-T79I?*<;KN0R.9(WC,(565V560E<
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M8U235+N2.ST_3WDN+%+Q")85;S2T]ZDQ#B#S80\2HR_=0D#RP4Z2XN/(\_\
MTC[-]G\R?_29]WV3/G_Z1/\ OAOMVQ\J<;<?P[?W<E\ZV;S*E]&@MT:YW2S,
M19EEG)FGW2J7@)&%3HI7C 4&/G_$VN0^'2\MLMHFKRN!#'?7@C\E3).OVBZD
M\TDVH,AV(1PS*H 9E" !XFUR&TM+JSA6TNIP]S&;"]O ?)D-O=S!KC]Z5:"1
M4&V-]H53GC: ERSTCROMD-Q'_:>H7&][B&ZGVYW?: OF_O'Q:-DK'%M?9DDA
MFW%<_1M-_L^6XU/4-1^TZO;Q21-J-]%Y,MM&K7),LZ^< ULTF\HJA1M$><[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%!0;2GW0%&R0W5Q9V<WVV7[+<6V^6(SR!0Q!(FNBIN3NME\Y6\MF!0+CKLP
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M>7&CL<?0/#+:1<7.K:S=1C5HGFND6XN5FATDL;H-='YX_P!U,N&=5507!.U
M,1 $F@Z"=*\[4]:BL8-?GEN)]2N+>:%8]+1OM %Y"K@[?,5(T)(^8("X)5\]
M1<1_9?/D\NQM/LWF7.^=/]&M-WG_ .DJVQ=TC;OWB[Q@,?F&<R1QK?27NR.6
M2"='G(M))_/$!9YQ#<OB16:)P&_='< =@79Y;&L,:B^I7ATGPC<01;99II9
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M',3]G<$8C*$ ,I(55(7C]1U.ZUZ\GT#1&OI88;LIJ6J#SY('O&#QRVAAEBF
MA(Y)R8HMRMR0%>34M?;6[>72_#+:E]M-Q<Q?VG<*JO(L@EN/LUK.<A3(D<;(
M^"B1&-B=X13J:1X5T[P_8QR:;IE\RP7<D%BD@:&:WQ-*0CRQ_.]HTFT@,LF
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MBMW2)E9@WSL@&YBZL3L(CD +D)6P!F:.[B@L4:)/L]@SO!$+DA(H46V!9'5
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M[?-VD\" Y.]45;ET$L)9/+LH(8;*5[V$O,I>REE:Z$MW.IF4&W(8L &W<N,
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MO=!_%NL7<>FW'VC2C$;2>YVM&U\7664VCLL9 M]CPE;@+D*Y",S2D@ (I/\
MA,;YGTZ."[T=91=O'>67V>:]:2&78[L=K+;%?+A#B-VD".C;DW%NH>S%Q9RV
M3F>>&:6X$,EZDTH,KF?>DT6%!MU!PFYMK#: 00C-']@A2W:WM[*-X'1[2..6
MV$:W"J)P+:8"#$=N@.$?OD?>W?O,O6-9TZP@N+^]N8+FQO)6TV%'M&>2]N ]
MTC6DH2%B85. FU2<JV2V[YP"QK^LV^E+#=7NLSVJ1RN;;SG,(EE\TH5F A.R
MW7*1B4Y7$P8_.(W-/3-!EO;B?5=5M(Q?:C;FVB2XAFF^S.3<&2WE&0)+<;A@
ME@LC<J57R%3/T31KN^U2[U378;275+Q&;^RWA3$;'[5&(KAE@R8O*5(UF8-D
MK($8I(5DZRXM_/\ /_T?[3]H\R#_ $F#;]KQY_\ H\_[D[+=<_*_.[/\6[]X
M 1W-PPN))QK$@2T2:0K<(L2VI)F GN%W1EX%V%$ P#@N2_$B9^H:E>WLR:7H
MBW=IJ$=ZDBRW0ED$2F:X$CS)G!@=()!&-QYDCP(\(PIZ[J%Q>ZC-H>CVD]SJ
M5SO22XNK0+"44RGR;O=!G[,0S+&R9\PAU#J0SG0TWP_;Z7ITEI;QSW[7&^&6
MYU)2\VI.HF'EW;F$D0@8"R<Y&T#(($@ :;I46@:=(UN?)M[;>J:A=L_F;E$S
M27%XSM&9(S))(0@RN6W@@,#'H7]R^E6;WTL,ZV\,LC(LT[ 1.3*#+-('?_1V
MW)@;3Y0(8J O[LN%LQY\^HG_ $&3S(KB>YMP/.C7SRT4X,0"VZ DJY(#9ZG=
MF3E[*.\\9?9=9FCG33)XF6*TD0Q_VG)^]91/*B;OL2JQ$8D12^[+J<J' +GV
M1O%=PUQ-%&VDRN\=LUY8K-]O=3.8VE\L[&LU#AHPVTLP5MP)4OTD#9U%(,3_
M +N5I?(-QF2'<9QYLA\T[H7QA$P=I X&W$=>XM_/\_\ T?[3]H\R#_28-OVO
M'G_Z//\ N3LMUS\K\[L_Q;OWF?XPUJ\BTXP:?IW]H37/F00V#1EFNFQ)$PEB
M:/\ X]U=H2S[T4JV=V-JR %C5-8?2);,6Z7TZW=V\%K!Y39DN2TFY97?<ZPX
M)D#(F%2!B"5*(U?1=%O-*TZ_U75=1\K4)=US--=R%X[:11(& 82#=:#<7CB8
M@J"22&/R1VOAY8KBYO;@2:I?7:2VIEO(F"S#,[/:LK1,8;7>=RMEBV47<RA
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M[2N7OK7[3H'B^PO+B=;-_/17O'\E(XY+=&?;,V_]V&=SO((3YE"[4 H \O\
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MV9;Z=M69H(EV6J;8<V\9:#FV.-SR KMV=5"D)Q=AHTGBC7O],AM++2[.X%E
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M]YEH\I(7#!]FM;%-ECIO]E[KGR)7\Y-.S%<IYQ;SD_T<YP@VC"@C:G_++/\
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MX]CI-O>ZG;>(-6A@N[EY;C3;*V>,SS201QW"-8OYI*>8#&SM.7.]C(F[806
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRZ*LJH68.<;?DW7+&&XBO([V]D\[48<P6=D;@2BV" R+"RO/\U[);NV9<D
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ML@\H_>41H?(PP!41E/N@$@'%W?QN\*VEK-+:ZS/J%[;?NK;S+26-;A!$CL7
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MS6<;)"OV-Y!(',\AD#^='M+N$)^4(AI^#_#=OIUKI@O[FQN]5\J"V60P&..
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MV  ([=V%_8JE]) Z)]F2VGF63RR4@D:&<>:6DN-B2,K@D!68G=U?#U76;R6
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MV&3[1]_[7<X_UOW?.?;_ *SYONXZ?+_<^3;6A0 4444 %%%% !1110 4444
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MV?W_ #GSI<^OF/\ WCF2;5+Y7%Q!\/M2>X^T+,6>6Q4[MHC:3<)R=XBRH]0
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MT01(U[IE1*3@8KU22^UT:<]S'HD#3")I$M&O@LA;$A5"=A0,2(@?F*@N_)"
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@_14M>P5X_P#M'?\ )/-/_P"PK'_Z*EH ^8**** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>atxs-20211231xex10d19008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 atxs-20211231xex10d19008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *- TX# 2(  A$! Q$!_\0
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MZ%6T_P#!L/\ XU0!TM%<U_:WBW_H5;3_ ,&P_P#C5']K>+?^A5M/_!L/_C5
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M58YG0$;5'.%&:$#T.FHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH *Y'XA_\ (*T?_L.:?_Z4)775R/Q#_P"05H__ &'-/_\ 2A*
M.NHHHH **** .:^'_P#R(VF?[K_^C&KI:YKX?_\ (C:9_NO_ .C&KI: "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI4CJD>IV3.Q"JJW"DDDX '/K5Z@ HHHH **** "BBB@ HHHH **** "BBB@
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M9ZKK^B7-NKB0(U^HPP! /##U-=5_9EA_SXVW_?I?\*/[,L/^?&V_[]+_ (4
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M-?#_ /Y$;3/]U_\ T8U=+0 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ KD?B'_P @K1_^PYI__I0E==7(_$/_ )!6C_\
M8<T__P!*$H ZZBBB@ HHHH YKX?_ /(C:9_NO_Z,:NEKFOA__P B-IG^Z_\
MZ,:NEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$;3/]U__ $8U=+7-?#__ )$;3/\ =?\ ]&-72T %%%% !1110 4444 %%%%
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MU=K7#^$O^1S\0'()(0G'U:@#N**** "BBB@ HHHH **** "BBB@#%N]6N_\
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MY:19VEE418$H,110>3@J22#[D=\UU-%PT"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@/"&?^$RUCG/^F7_
M $/'W[>N_K@?"'/B_6.#D7E^#G_?@Z>U '?4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5R/Q#_P"05H__ &'-/_\
M2A*ZZN1^(?\ R"M'_P"PYI__ *4)0!UU%%% !1110!S7P_\ ^1&TS_=?_P!&
M-72US7P__P"1&TS_ '7_ /1C5TM !1110 4444 %%%% !1110 4444 %%%%
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M:^'_ /R(VF?[K_\ HQJZ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*XZ35Q#<007.H72W%Y<7B0YE2- L4K#;G:<?+CGV]:[&N&TS3K76/&>MVVHP
MI<PZ+= V:2*" ;B(22;AC#?,QQGH* +]AJD^IJ392ZK*BJK;U:UP0<@8)'/0
M_E5:;_A,8]4E:".YFL&B3RUDGMHY%?+;\X0@@C9CZ&NATC0[/1(S'9AECV+&
M%)& %+$8P/\ :/Z5I4 <:9/&8 Q9R-W(:]@_+_54@?QF?^7.4?6]@X_\@UV=
M% '*Z7'XB_LV$:F^I_;<'S3$UH4SDXQ\H[8["KF-4R!_Q.,>NZT_PK>HH P,
M:IA3_P 3GW&ZS_PK*;4(M,BBO[B?4["Q:UA@B=;83NQ#/]_8C[?O*.<9)KM*
MR;_0(K_2X-.-Y=PP1%3^Y90S[2"N25/0@'C'2@ T.[ENC?I)/+,L-PJ1O+&(
MWVM#&^",#!RYZ@&M:JEE8+9&X832RO/())'DVY+!%3L .B _4GZ5;H ****
M"BBB@ HHHH **** /+/&BAOB]X;W*K#R?NNC./N7'9>:Z86\1&XV]KDG_GSN
M.OTKE_'#>7\6O#C;Q'^YQO:X\D#Y+C^/!QV[5T8N8@!G5(,#O_;K?_$4 >>^
M'HI;SQ'>V*RI%"9;V1E%K(P)%P!QC$B'#'D$?CTKL8Y9()/L\NFPL@X\R:"1
M68GIM.%5_IA6]%/6N4\#9O/'.H1VDRS2H+[?Y=\RX!N$()<*2V?<#->DR:3?
MS1O'-$[QLN"K:I(0?P\N@#%^#\,EMX(6&:)XI8Y=KHZE2I"KP0>E=_7GWP=D
M>7P3OD),C3$L6.2257J>]>@T %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1<ZO+#=3Q
MC[#%'$XCW7-R8RQVJQQ\I[-ZUB:=<O;RH5<0W:M=[XVLYI RM.6#*0!E>G/H
MP]:T-9\/3ZKYBK)9(K7<5R#/;&8_)Y9 'S+C)C(/7@]JU1:2#4H;DLFQ+=HB
MJ\<DJ>!Z?*>] &8-7O<\RI_X++C\J/[5O<-^]3C'_,+N:Z"B@#C;SQ1K-MJ2
M6T6ESW4#0ES<PV$H"MNQL(=E[<YSVH_X2K6,9_L74!G_ *AYX]C^]KLJ* .-
M_P"$JUC QHVH;NX_LT__ !VIM+\0:O?6TDUU9O8LLK((I=.G9BHZ-P<<^GZG
MK7644 <X-<G82%;N(B/._P#XEEQE0/7GBM'3M1FN[J:"5("JPQ3QRPR%@ZN7
M'0@8^Y^M8.I^!5U>\U:>?4;B 7MO);JMN[*%# <M@C=_NGBG?#ZZ75?#=AJ\
M*E+::PAMT1S\P:)Y58GM@Y&.: .NHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N1^(?_(*T?_L.:?\ ^E"5UU<C\0_^05H__8<T_P#]*$H ZZBB
MB@ HHHH YKX?_P#(C:9_NO\ ^C&KI:YKX?\ _(C:9_NO_P"C&KI: "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KD?#/_(^>-_\ KYM/_29*ZZN1\,_\
MCYXW_P"OFT_])DH ZZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?_(*T?\ [#FG_P#I0E '74444 %%%% '-?#_ /Y$;3/]U_\ T8U=+7-?#_\
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M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7(_$/_D%:/_V'-/\
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M7_\ 1C5TM<U\/_\ D1M,_P!U_P#T8U=+0 4444 %%%% !1110 4444 %%%%
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MHH **** "BBB@ KD?B'_ ,@K1_\ L.:?_P"E"5UU<C\0_P#D%:/_ -AS3_\
MTH2@#KJ*** "BBB@#FOA_P#\B-IG^Z__ *,:NEKFOA__ ,B-IG^Z_P#Z,:NE
MH **** "BBB@ HHHH **** "BBB@!LD4<T9CE171NJL,@_A5>R2W"R&WMXX?
MWC*VQ0,E3C/%664.I5AD$8(ID%O%;1"*"-40$D*ON<F@"2BBB@ HHHH YKP'
M_P BP_\ V$M0_P#2R:NEK \'%CH$F[/_ "$;_&?3[7+C]*WZ "BBB@ HHHH
M**** "BBB@ HHHH **** .:\>?\ (JM_U_67_I5%72US7CS_ )%5O^OZR_\
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M' R2>E;%<_X$_P"2>>&O^P5:_P#HI:Z"@ HHHH **** "BBB@ HHHH ****
M.1^&W_(HM_V$;[_TJEKKJY'X;?\ (HM_V$;[_P!*I:ZZ@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "N1^(?\ R"M'_P"PYI__ *4)775R/Q#_
M .05H_\ V'-/_P#2A* .NHHHH **** .:^'_ /R(VF?[K_\ HQJZ6N:^'_\
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MAXML[32I+Z!3<>6T0*Y* AWV!@Q&",@]/3WS69+<^(9-%U"._M0;9K"4^:^
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M&DM)"6*HQ.QMQ50=P4GCIWKHJX_P=:/8:MJ=D[!FM[:UA+ 8R5\T9'MQ784
M%>0?M'?\D\L/^PK'_P"BI:]?KR#]H[_DGEA_V%8__14M &7^S5_R!->_Z^8O
M_037N=?*?PG^*&F?#_3]2M[^QN[EKJ5'4P;<  $<Y(]:]$_X:2\.?] 75?\
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M*T?_ +#FG_\ I0E==7(_$/\ Y!6C_P#8<T__ -*$H ZZBBB@ HHHH YKX?\
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M'>R['6=B#P1GIT/%=G7G?B+5M6T_XJV=KH]E!=7%[I8BQ.Y18\/(V\D=ACD
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M )%.Z_["E[_Z.:@#MZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME:CX=T[5+V.\N!=I<QQF)9+:]FMSL)S@^6ZY&1WJM_PB&F?\_.M>O_(;O/\
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M/_@.G^%']A:1_P! JQ_\!T_PK0HH S_["TC_ *!5C_X#I_A1_86D?] JQ_\
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M/]U__1C5TM<U\/\ _D1M,_W7_P#1C5TM !1110 4444 %%%% !1110 4444
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M:^'_ /R(VF?[K_\ HQJZ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*Y'P?_R,?C3_ +"R_P#I-#775Y[X9\0:;8^,?%=I>7"6QN+XW$4DS*B,$2.)
MADG[VY2<>A![T >A457M+^SOT9[.[@N%4X9H9 X!]#BK% !1110 4444 %%%
M49-9TN&22.74K..2,X=6G4%3[C/% %ZBH;:[MKQ&>UN(IT5MI:)PP!]..]34
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_NO_ .C&KI:YKX?_ /(C:9_NO_Z,:NEH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N$O(=4^WZ-=:>\D4<-[J/GR+ \JA6D< ,BD%LG!ZXR >W/=U1
M_LBQ#,RQ,A=V<[)&4%B22< ]223^)H YSPS=W=O+<2ZLE\\\B!?,^PS8;$\Y
M&!@X&UTP"3@<=JT[GQGH%E=FUN[YH+@()#%+!(K;22 <%>AP?RK0_LFV_P">
MEY_X&3?_ !51IH5A'<R7*+<+/*JK)(+J7<P7.T$[N0,G'ID^IH SSX[\,C&=
M5CYZ?(_^%'_"=^&?^@M%_P!\/_A6I_9-MM(\R\/UO)B?SW4X:9;C'SW7'K=2
MG_V;F@"M:>(]-O[:.YM&NIX) 2DD=G,5;''!V^U3_P!K6W_/.]_\ IO_ (FF
MVNB6-E$(K59XHAG")<R!1DY.!NP.?ZU,VGP,,%[G\+J0?^S4 1?VO;?\\KW_
M , IO_B*Y#5([K4?#][8Z?9:J^HBZFFC$,SV117E<JY+,FX$=N?H*[$Z5;D
M>9><?]/DW_Q58^E6ZWEZKSO-Y@T^VRRSNK'YY>I!!/XT 6O#ZA+C5%"31XGC
M!2:3>Z'R(^&;)W'WR?K6W4%K9P6:R"%2/,?>[,Y9F; &2223P /H!4] !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_$/_ )!6C_\ 8<T__P!*$KKJY'XA_P#(*T?_ +#FG_\ I0E '74444 %%%%
M'-?#_P#Y$;3/]U__ $8U=+7-?#__ )$;3/\ =?\ ]&-72T %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SOATN;A2W>PA_
M1Y?_ *U=%7!^ X%@U_7]C3%3Y!"R2NX3*EL+N)P,N>!@<T =Y1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7-:
M2=VMH2.0VH <=O/BKI:X3PU/>R^/=6AFF1K2!KD01K$ 5W/$6RV><D4 =W11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7(_$/_ )!6C_\ 8<T__P!*$KKJY'XA_P#(*T?_ +#FG_\ I0E '74444 %
M%%% '-?#_P#Y$;3/]U__ $8U=+7-?#__ )$;3/\ =?\ ]&-72T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5PW@HJ?$VO
ME< %;<@#CC97<UP/@:YAG\6^)%ADW[/)5OE(Y *GD]>5(_"@#OJ*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X
M/PXH7XB:T.<_O#^;)7>5PF@G'Q+UH?[+=\_W/\XH [NBBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N1^(?_(*T?_L.
M:?\ ^E"5UU<C\0_^05H__8<T_P#]*$H ZZBBB@ HHHH YKX?_P#(C:9_NO\
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MH/4 @YP?3I6G10!0_L:SQC_2>F/^/J7_ .*J2#3+2WN%N$1S*JE SRL^ <9
MR3Z#\JMT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %<C\0_^05H_P#V'-/_ /2A*ZZN1^(?_(*T?_L.:?\ ^E"4
M ==1110 4444 <U\/_\ D1M,_P!U_P#T8U=+7-?#_P#Y$;3/]U__ $8U=+0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !5+5>;'83P\L4;?1I%!_0FKM4M4_X\E//$\)X_ZZ+0!A_#
ME<> ]-;<7+B1BQ/7YV _0"NIKFOA\I7P+I8))^1N2>3\[5TM !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 <7XK(D\6:)"W01S8QU^8!#G\#Q7:5Q?BC/\ PF6A
M<'!CDP<\=5_S^-=I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M *%30_\ P70__$T?\()X/_Z%30__  70_P#Q- '045S_ /P@G@__ *%30_\
MP70__$T?\()X/_Z%30__  70_P#Q- '045S_ /P@G@__ *%30_\ P70__$T?
M\()X/_Z%30__  70_P#Q- '05G:WI%OK>G&UN9+I(PP<&UN'A?(S_$A![]*H
M?\()X/\ ^A4T/_P70_\ Q-'_  @G@_\ Z%30_P#P70__ !-)[ 8NE?#[3+C2
M+.:ZN=>2XD@1I5;5KI2K$ D8+\<]JN?\*XT7_G[US_P<7/\ \75[_A!/!_\
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M"3\[=\5T7_".:'_T!M._\!4_PH F_MG2_P#H)6?_ '_7_&C^V=+_ .@E9_\
M?]?\:A_X1S0_^@-IW_@*G^%'_".:'_T!M._\!4_PH F_MG2_^@E9_P#?]?\
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M_P !4_PH F_MG2_^@E9_]_U_QH_MG2_^@E9_]_U_QJ'_ (1S0_\ H#:=_P"
MJ?X4?\(YH?\ T!M._P# 5/\ "@";^V=+_P"@E9_]_P!?\:/[9TO_ *"5G_W_
M %_QJ'_A'-#_ .@-IW_@*G^%'_".:'_T!M._\!4_PH F_MG2_P#H)6?_ '_7
M_&C^V=+_ .@E9_\ ?]?\:A_X1S0_^@-IW_@*G^%'_".:'_T!M._\!4_PH F_
MMG2_^@E9_P#?]?\ &C^V=+_Z"5G_ -_U_P :A_X1S0_^@-IW_@*G^%'_  CF
MA_\ 0&T[_P !4_PH F_MG2_^@E9_]_U_QH_MG2_^@E9_]_U_QJ'_ (1S0_\
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M_P#O^O\ C1_;.E_]!*S_ ._Z_P"-0_\ ".:'_P! ;3O_  %3_"C_ (1S0_\
MH#:=_P" J?X4 3?VSI?_ $$K/_O^O^-']LZ7_P!!*S_[_K_C4/\ PCFA_P#0
M&T[_ ,!4_P */^$<T/\ Z VG?^ J?X4 3?VSI?\ T$K/_O\ K_C1_;.E_P#0
M2L_^_P"O^-0_\(YH?_0&T[_P%3_"C_A'-#_Z VG?^ J?X4 3?VSI?_02L_\
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MY!&T?.?6B.UW_6G_  _WA+LOZU_RL=E9V=KI]JEK9V\5O;IG9%$@55R<G '
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MAQUS_OW9_P#R/1_PCNI?]#CKG_?NS_\ D>@#H**Y_P#X1W4O^AQUS_OW9_\
MR/1_PCNI?]#CKG_?NS_^1Z .@HKG_P#A'=2_Z''7/^_=G_\ (]'_  CNI?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
%HH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>atxs-20211231xex10d19009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 atxs-20211231xex10d19009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !P ,L# 2(  A$! Q$!_\0
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M3QC-7RR6C_0B\7JC*O/">K7DA<^*[^')SB %!^0:JW_"#ZI_T.6K_P#?QO\
MXJKD/B.0C3FNKNVM4O;-;I6D& "=OR=>3\WZ5:N=9GL=5MK:Y,8BEMYIR_3
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D;+=P26*,1&C1G>D>?E0-G' P.1VK8HHJ6VW=C2L%%%%(9__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>atxs-20211231xex10d19010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 atxs-20211231xex10d19010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  V &(# 2(  A$! Q$!_\0
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D9I#!"<9B0X.>5'7UHHH &@A?.Z*-L]<J#FI*** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673396299912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 04, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Astria Therapeutics,&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-3687168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 High Street <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Floor 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">349-1971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATXS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,016,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,863,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001454789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst&#160;& Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673397029608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 86,508<span></span>
</td>
<td class="nump">$ 24,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,567<span></span>
</td>
<td class="nump">1,395<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">127,075<span></span>
</td>
<td class="nump">46,325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">127,514<span></span>
</td>
<td class="nump">47,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,557<span></span>
</td>
<td class="nump">1,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,281<span></span>
</td>
<td class="nump">4,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">649<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,203<span></span>
</td>
<td class="nump">6,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">397<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">5,203<span></span>
</td>
<td class="nump">6,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share, 150,000,000 shares authorized; 13,016,955 and 3,347,386 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">481,709<span></span>
</td>
<td class="nump">301,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(455,809)<span></span>
</td>
<td class="num">(260,897)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">122,311<span></span>
</td>
<td class="nump">40,669<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">127,514<span></span>
</td>
<td class="nump">$ 47,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember', window );">Series X redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="nump">$ 96,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673393640904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">13,016,955<span></span>
</td>
<td class="nump">3,347,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">13,016,955<span></span>
</td>
<td class="nump">3,347,386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonredeemablePreferredStockMember', window );">Preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">4,908,620<span></span>
</td>
<td class="nump">4,908,620<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember', window );">Series X redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">91,380<span></span>
</td>
<td class="nump">91,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">31,455<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">31,455<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonredeemablePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonredeemablePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673393653464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 15,552<span></span>
</td>
<td class="nump">$ 25,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">14,807<span></span>
</td>
<td class="nump">11,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">164,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">194,976<span></span>
</td>
<td class="nump">37,435<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(194,976)<span></span>
</td>
<td class="num">(37,435)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest and investment income</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(58)<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(194,912)<span></span>
</td>
<td class="num">(37,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts', window );">Dividend on convertible preferred stock related to beneficial conversion feature and issuance costs</a></td>
<td class="num">(24,437)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders</a></td>
<td class="num">$ (219,349)<span></span>
</td>
<td class="num">$ (37,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic</a></td>
<td class="num">$ (24.58)<span></span>
</td>
<td class="num">$ (12.20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted</a></td>
<td class="num">$ (24.58)<span></span>
</td>
<td class="num">$ (12.20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding used in net loss per share - basic</a></td>
<td class="nump">8,925,173<span></span>
</td>
<td class="nump">3,058,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding used in net loss per share - diluted</a></td>
<td class="nump">8,925,173<span></span>
</td>
<td class="nump">3,058,578<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of dividend on convertible preferred stock related to beneficial conversion feature and issuance costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673392530824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Consolidated Statements Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (194,912)<span></span>
</td>
<td class="num">$ (37,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Gain on short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (194,912)<span></span>
</td>
<td class="num">$ (37,300)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673389250968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Preferred Stock </div>
<div>Series X Preferred Stock</div>
</th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Deficit Accumulated</div></th>
<th class="th"><div>Series X Preferred Stock</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 259,315<span></span>
</td>
<td class="num">$ (223,597)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,720<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, beginning of period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,072,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">24,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings', window );">Issuance of common stock for at-the-market offerings, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings', window );">Issuance of common stock for at-the-market offerings, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from exercises of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Proceeds from exercises of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,300)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">301,562<span></span>
</td>
<td class="num">(260,897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,669<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, end of period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,347,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,347,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance costs</a></td>
<td class="nump">$ 84,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance costs (in shares)</a></td>
<td class="nump">35,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of preferred stock and common stock upon acquisition of Quellis</a></td>
<td class="nump">$ 156,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock upon acquisition of Quellis (in shares)</a></td>
<td class="nump">50,504<span></span>
</td>
<td class="nump">555,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon the conversion of preferred stock</a></td>
<td class="num">$ (168,920)<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">168,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon the conversion of preferred stock (in shares)</a></td>
<td class="num">(54,622)<span></span>
</td>
<td class="nump">9,103,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,103,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Fair value adjustment to acquired Quellis warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount', window );">Accretion of preferred stock discount</a></td>
<td class="nump">$ 24,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,437)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from exercises of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Proceeds from exercises of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax', window );">Reclassification of equity classified warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Fractional shares eliminated pursuant to reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(194,912)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(194,912)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Dec. 31, 2021</a></td>
<td class="nump">$ 96,398<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 481,709<span></span>
</td>
<td class="num">$ (455,809)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,311<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, end of period (in shares) at Dec. 31, 2021</a></td>
<td class="nump">31,455<span></span>
</td>
<td class="nump">13,016,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,016,955<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued in At-the-Market offerings during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued in At-the-Market offerings during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accretion of the preferred stock redemption discount during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockAccretionOfRedemptionDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673394554552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atxs_PublicOfferingCommonStockAndWarrantsMember', window );">Issuance of common stock and warrants in public offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atxs_AtMarketOfferingMember', window );">ATM</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=atxs_PublicOfferingCommonStockAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=atxs_PublicOfferingCommonStockAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=atxs_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=atxs_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673397032104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (194,912)<span></span>
</td>
<td class="num">$ (37,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Reconciliation of net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_NonCashPortionOfAcquiredResearchAndDevelopment', window );">Non-cash portion of acquired in-process research and development</a></td>
<td class="nump">164,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,362<span></span>
</td>
<td class="nump">1,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_GainLossOnWarrantInherited', window );">Net gain on warrants inherited in acquisiton of Quellis</a></td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_IncreaseDecreaseInRightOfUseAssetOperating', window );">Right-of-use asset-operating</a></td>
<td class="num">(109)<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,965)<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(1,316)<span></span>
</td>
<td class="nump">1,587<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(30,151)<span></span>
</td>
<td class="num">(32,485)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(78,000)<span></span>
</td>
<td class="num">(62,777)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Sales and maturities of short-term investments</a></td>
<td class="nump">59,000<span></span>
</td>
<td class="nump">69,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired in acquisition of Quellis</a></td>
<td class="nump">6,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="num">(12,555)<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from underwritten public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private offering of public equity, net of issuance costs</a></td>
<td class="nump">104,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_ProceedsFromIssuanceOfAtMarketOffering', window );">Proceeds from at-the-market offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">104,284<span></span>
</td>
<td class="nump">40,860<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">61,578<span></span>
</td>
<td class="nump">14,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">25,051<span></span>
</td>
<td class="nump">10,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">86,629<span></span>
</td>
<td class="nump">$ 25,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Series X Preferred Stock into common stock</a></td>
<td class="nump">168,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts', window );">Non-cash dividend on convertible preferred stock</a></td>
<td class="nump">24,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_ReclassificationOfEquityClassifiedWarrants', window );">Reclassification of warrant liability to additional paid-in capital</a></td>
<td class="nump">$ 3,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of dividend on convertible preferred stock related to beneficial conversion feature and issuance costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_GainLossOnWarrantInherited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on warrant inherited during acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_GainLossOnWarrantInherited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_IncreaseDecreaseInRightOfUseAssetOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of right-of-use-asset-operating.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_IncreaseDecreaseInRightOfUseAssetOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_NonCashPortionOfAcquiredResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-cash portion of acquired IP R&amp;D.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_NonCashPortionOfAcquiredResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_ProceedsFromIssuanceOfAtMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's At-the-market offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_ProceedsFromIssuanceOfAtMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_ReclassificationOfEquityClassifiedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from reclassification of equity classified warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_ReclassificationOfEquityClassifiedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673397161512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Operations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">Astria Therapeutics, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">Notes to Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">1.</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Organization and Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The Company</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Astria Therapeutics, Inc. (the &#8220;Company&#8221;), formerly known as Catabasis Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics. Its mission is to bring hope with life-changing therapies to patients and families that are affected by rare and niche allergic and immunological diseases. On October 26, 2020, the Company announced that the Phase 3 PolarisDMD trial of the Company&#8217;s previous lead product candidate, edasalonexent, for the treatment of Duchenne Muscular Dystrophy (&#8220;DMD&#8221;) did not meet its primary and secondary endpoints. Based on these results, the Company announced that it was stopping activities related to the development of edasalonexent, including the Company&#8217;s ongoing open-label extension trial. On January 28, 2021, the Company acquired Quellis Biosciences, Inc. (&#8220;Quellis&#8221;). The Company&#8217;s lead product candidate, which was acquired in the Quellis acquisition, is STAR-0215 (formerly known as QLS-215), a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema, or HAE, a rare, debilitating and potentially life-threatening disease. The Company was incorporated in the State of Delaware on June 26, 2008.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Reverse Stock Split</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">On August 19, 2021, the Company effected a reverse stock split of its outstanding shares of common stock at a ratio of <span style="-sec-ix-hidden:Hidden_dLw7GAoMFEC93XKwCZhThQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-for-six (1:6) pursuant to a Certificate of Amendment to its Certificate of Incorporation filed with the Secretary of State of the State of Delaware. Pursuant to the reverse stock split, every six shares of the Company&#8217;s issued and outstanding shares of common stock were automatically combined into one issued and outstanding share of common stock, without any change in the par value per share of the common stock. Amounts of common stock resulting from the reverse stock split were rounded down to the nearest whole share and any resulting fractional shares were cancelled for cash. The number of authorized shares of the Company&#8217;s common stock remained unchanged. The reverse stock split affected all issued and outstanding shares of the Company&#8217;s common stock, and the respective numbers of shares of common stock underlying the Company&#8217;s outstanding Series X Preferred Stock, outstanding stock options, outstanding warrants and the Company&#8217;s equity incentive plans were proportionately adjusted. All share and per share amounts of the common stock included in the accompanying consolidated financial statements have been retrospectively adjusted to give effect to the reverse stock split for all periods presented, including reclassifying an amount equal to the reduction in par value to additional paid-in capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:6pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Agreement and Plan of Merger</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">On January 28, 2021, the Company acquired Quellis (the &#8220;Quellis Acquisition&#8221;). &#160;Under the terms of that certain agreement and plan of merger, dated January 28, 2021 (the &#8220;Merger Agreement&#8221;), the Company issued to the stockholders of Quellis 555,444 shares of the Company&#8217;s common stock, par value $0.001 per share, and 50,504 shares of newly designated Series X redeemable convertible preferred stock (&#8220;Series X Preferred Stock&#8221;) (as described below). The Series X Preferred Stock had a conversion value on the closing date of $122.7 million. In addition, the Company assumed options granted under the Quellis stock option plan, which became options to purchase 55,414 shares of the Company&#8217;s common stock, a warrant to purchase 2,805 shares of Series X Preferred Stock at an exercise price of $341.70 per share, and a warrant to purchase 30,856 shares of the Company&#8217;s common stock at an exercise price of $2.10 per share, which warrants are exercisable until December 14, 2030. Upon stockholder approval of the Conversion Proposal (as defined below) on June 2, 2021, the warrant to purchase Series X Preferred Stock was converted into the right to purchase 467,500 shares of the Company&#8217;s common stock, at a per share exercise price of $2.10 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:6pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Purchase Agreement and Series X Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Concurrent with the Quellis Acquisition, the Company entered into a Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain institutional and accredited investors. Pursuant to the Purchase Agreement, the Company sold an aggregate of 35,573 shares of Series X Preferred Stock for gross proceeds of approximately $110.0 million, and net proceeds of $104.3 million (the &#8220;February 2021 Financing&#8221;). Each share of Series X Preferred Stock is convertible into </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">166.67 shares of common stock. In accounting for the Purchase Agreement, the Company recorded a beneficial conversion feature of $19.6 million and issuance costs of $5.7 million. The combined total was treated as a discount to the value of Series X Preferred Stock, See Note 2 &#8211; &#8220;Summary of Significant Accounting Policies&#8221; for further discussion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">As a result of the Quellis Acquisition and the February 2021 Financing, the Company issued the following Series X Preferred Stock or warrants to purchase Series X Preferred Stock:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series&#160;X</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;Preferred&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock at</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Shares issued in merger</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,504</p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Shares issued in February 2021 Financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,573</p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Warrants assumed in merger</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,805</p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,882</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">At its 2021 Annual Meeting of Stockholders on June 2, 2021, the Company&#8217;s stockholders approved the conversion of the Company&#8217;s Series X Preferred Stock into shares of the Company&#8217;s common stock in accordance with Nasdaq Listing Rule 5635(a) (the &#8220;Conversion Proposal&#8221;). Following stockholder approval of the Conversion Proposal, each share of Series X Preferred Stock then outstanding automatically converted into 166.67 shares of the Company&#8217;s common stock, subject to certain beneficial ownership limitations, including that a holder of Series X Preferred Stock is prohibited from converting shares of Series X Preferred Stock into shares of the Company&#8217;s common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (as of December 31, 2021, these percentages are set at 4.99% to 9.99% and can be adjusted by the holder to a number between 4.99% and 19.99%) of the total number of shares of the Company&#8217;s common stock issued and outstanding immediately after giving effect to such conversion. As of December 31, 2021, 54,622 shares of Series X Preferred Stock were converted into 9,103,664 shares of common stock and 31,455 shares of Series X Preferred Stock remained outstanding. Each share of Series X Preferred Stock is convertible into 166.67 shares of common stock. At December 31, 2021, the number of shares of common stock issuable upon conversion of the remaining outstanding shares of Series X Preferred Stock is 5,242,501. Outstanding shares of Series X Preferred Stock are subject to conversion at the option of the holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Prior to stockholder approval of the Conversion Proposal, the terms of the Series X Preferred Stock included a cash redemption feature. This cash redemption feature resulted in substantial doubt about the Company&#8217;s ability to continue as a going concern as disclosed in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2020 (the &#8220;2020 Annual Report on Form 10-K&#8221;). Upon stockholder approval of the Conversion Proposal, the cash redemption feature was eliminated and, consequently, there is no longer substantial doubt about the Company&#8217;s ability to continue as a going concern for at least twelve months subsequent to the issuance of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Holders of Series X Preferred Stock are entitled to receive dividends, subject to certain beneficial ownership limitations, on shares of Series X Preferred Stock equal, on an as-if-converted-to-common-stock basis, and in the same form as dividends actually paid on shares of the Company&#8217;s common stock. Except as otherwise required by law, the Series X Preferred Stock does not have voting rights. However, as long as any shares of Series X Preferred Stock are outstanding, the Company may not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series X Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to the Series X Preferred Stock or alter or amend the Certificate of Designation that authorized the Series X Preferred Stock, amend or repeal any provision of, or add any provision to, the Company&#8217;s Certificate of Incorporation or bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of preferred stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series X Preferred Stock, (ii) issue further shares of Series X Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series X Preferred Stock, or (iii) enter into any agreement with respect to any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">January 2020 Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">On January 30, 2020, the Company entered into an underwriting agreement with Oppenheimer &amp; Co. Inc. relating to an underwritten public offering (the &#8220;January 2020 Financing&#8221;) of 881,666 shares of common stock at a price to the public of $30.00 per share, including 115,000 shares issued upon the exercise in full by Oppenheimer &amp; Co. Inc. of its overallotment option. This resulted in gross proceeds of $26.5 million, and net proceeds of $24.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company has entered into various sales agreements with Cowen and Company LLC (&#8220;Cowen&#8221;), pursuant to which the Company could issue and sell shares of common stock under at-the-market offering programs. On May 20, 2021, the Company terminated its sales agreement with Cowen. On June 30, 2021, the Company entered into an Open Market Sale Agreement<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> with Jefferies LLC (&#8220;Jefferies&#8221;), pursuant to which the Company can issue and sell shares of common stock of up to $25.0 million under at-the-market offering programs (collectively, with the Cowen at-the-market offering program, the &#8220;ATM Programs&#8221;). The Company pays the sales agent commissions of 3% of the gross proceeds from any common stock sold through the ATM Programs. As of December 31, 2021, the Company has not sold any shares of common stock pursuant to the Jefferies agreement and, as a result, $25.0 million of common stock remains available for sale under the Jefferies agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">During the year ended December 31, 2020, the Company sold an aggregate of 392,288 shares of common stock pursuant to the ATM Programs, at an average price of $42.76 per share, for net proceeds of $16.3 million after deducting sales commissions and offering expenses. There was no activity from the ATM Programs during the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">As of December 31, 2021, the Company had an accumulated deficit of $455.8 million and had available cash, cash equivalents and short-term investments $125.5 million. The Company has been primarily involved with research and development activities and has incurred operating losses and negative cash flows from operations since its inception. The Company has not generated any product revenues and has financed its operations primarily through public offerings and private placements of its equity securities. There can be no assurance that the Company will be able to obtain additional debt, equity or other financing or generate product revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company&#8217;s business, results of operations, and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company is subject to a number of risks similar to other life science companies, including, but not limited to, successful discovery and development of its drug candidates, raising additional capital, development by its competitors of new technological innovations, protection of proprietary technology and regulatory approval and market acceptance of the Company&#8217;s products. The Company has been primarily involved with research and development activities and has incurred operating losses and negative cash flows from operations since its inception. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673505835288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">2. &#160;&#160;&#160;Summary of Significant Accounting Policies&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation and Principles of Consolidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Astria Securities Corporation and Quellis Biosciences, LLC, successor in interest to Quellis. All intercompany balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company utilizes certain estimates to record expenses relating to research and development contracts. These contract estimates, which are primarily related to the length of service of each contract and the amount of service provided as of each measurement date, are determined by the Company based on input from internal project management, as well as from service providers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Off-Balance Sheet Risk and Concentrations of Credit Risk </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company has no off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements. Financial instruments that subject the Company to credit risk primarily consist of cash, cash equivalents, short-term investments and restricted cash. The primary objectives for the Company&#8217;s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company&#8217;s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents and Restricted Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The reconciliation of cash, cash equivalents and restricted cash reported within the applicable balance sheet that sum to the total of the same such amount shown in the statement of cash flows is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 86,508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,930</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Restricted cash (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 121</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 86,629</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,051</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-left:46.8pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:46.8pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Included in prepaid expenses and other current assets at December 31, 2021 and other long-term assets at December 31, 2020.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Short-Term Investments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company classifies all corporate debt securities with a remaining maturity of greater than three months and reverse repurchase agreements with a remaining maturity of greater than one business day at the time of purchase as short-term investments. Short-term investments are recorded at fair value, with the unrealized gains and losses reported in other comprehensive loss. The amortized cost of debt securities is adjusted for the amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest and investment income. Realized gains and losses, interest, dividends and declines in value judged to be other-than-temporary are included in interest and investment income. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The cost of securities sold is based on the specific identification method for purposes of recording realized gains and losses. To determine whether an other-than-temporary impairment exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the investment outweighs evidence to the contrary. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three broad levels as follows: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3 inputs are unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The carrying amounts reflected in the balance sheets for cash equivalents, restricted cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values at December 31, 2021 and 2020, due to their short-term nature. There have been no changes to the valuation methods during the years ended December 31, 2021 and 2020. The Company evaluates transfers between levels at the end of each reporting period. There were no <span style="-sec-ix-hidden:Hidden_Q8KxfYwEQ06Q-XDWVRjAVA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">transfers</span></span> <span style="-sec-ix-hidden:Hidden_h7pU9TMEukuhqRukKT1nSg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span></span> <span style="-sec-ix-hidden:Hidden_Spms05oTPUG_D656yLZ_hg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assets</span></span> or liabilities between levels during the years ended December 31, 2021 and 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company&#8217;s investment portfolio may include fixed income securities that do not always trade on a daily basis. As a result, the pricing services used by the Company apply other available information as applicable through processes such as benchmark yields, benchmarking of like securities, sector groupings and matrix pricing to prepare valuations. The Company validates the prices provided by its third party pricing services by obtaining market values from other pricing sources and analyzing pricing data in certain instances. The Company also invests in certain reverse repurchase agreements which are collateralized by deposits in the form of United States Government Securities and Obligations for an amount no less than 102% of their value. The Company does not record an asset or liability for the collateral as the Company is not permitted to sell or re-pledge the collateral. The collateral has at least the prevailing credit rating of United States Government Treasuries and Agencies. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the reverse repurchase agreements on a daily basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company accounted for warrants to purchase its stock pursuant to Accounting Standards Codification (&#8220;ASC&#8221;) Topic 470, Debt, and ASC Topic 480, Distinguishing Liabilities from Equity, and classifies warrants for common stock and preferred stock as liabilities or equity. The warrants classified as liabilities are reported at their estimated fair value and any changes in fair value are reflected in research and development expense. The warrants classified as equity are reported at their estimated fair value with no subsequent remeasurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. The Company has not recognized any significant impairment charges from inception through December&#160;31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Research and development costs are expensed as incurred. Research and development costs include salaries and personnel-related costs, stock-based compensation, consulting fees, fees paid for contract research services, the costs of laboratory equipment and facilities and other external costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred. The deferred amounts are expensed as the related goods are delivered or the services are performed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company accounts for its stock-based compensation awards in accordance with ASC Topic&#160;718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation (</i>&#8220;ASC&#160;718&#8221;). ASC&#160;718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statements of operations based on their grant date fair values. For granted stock options, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model.&#160; The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Company&#8217;s common stock consistent with the expected term of the option, risk-free interest rates and expected dividend yields of the Company&#8217;s common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">For awards subject to service-based vesting conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company expenses restricted stock awards based on the fair value of the award on a straight-line basis over the associated service period of the award. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">During the years ended December 31, 2021 and 2020, the Company recorded stock-based compensation expense for employee and non-employee stock options and restricted stock, which was allocated as follows in the statements of operations (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,132</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 599</p></td></tr><tr><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 791</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,390</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">No related tax benefits were recognized for the years ended December 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss Per Share </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Basic net loss per share is calculated by dividing net loss by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the Company&#8217;s dilutive net loss per share calculation, stock options and warrants to purchase the Company&#8217;s common stock were considered to be common stock equivalents but were excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive; therefore, basic and diluted net loss per share were the same for all periods presented. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,346,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 227,945</p></td></tr><tr><td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,530,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,032,292</p></td></tr><tr><td style="vertical-align:bottom;width:72.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Series X Preferred Stock (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,242,501</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,119,614</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,260,236</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-left:46.8pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:46.8pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Shown as common stock equivalents</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company provides deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company&#8217;s financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. A valuation allowance is provided to reduce the deferred tax assets to the amount that will more likely than not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC Topic&#160;740, <i style="font-style:italic;">Expenses&#8212;Income Taxes</i>. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company did not have any uncertain tax positions for any periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Company assesses the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where it has operations to determine the potential effect its business and any assumptions it has made about its future taxable income. The Company cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on its business if they were to be enacted. Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the currently available option to deduct research and development expenditures and requires taxpayers to amortize them over five years. The U.S. Congress is considering legislation that would defer the amortization requirement to future periods, however, the Company has no assurance that the provision will be repealed or otherwise modified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Segment Information </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, the Company&#8217;s chief executive officer, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business in one operating segment. The Company operates in one geographic segment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company determines if an arrangement is a lease at inception. Operating leases are included in&#160;right-of-use&#160;(&#8220;ROU&#8221;) lease assets, current portion of lease obligations, and long-term lease obligations on the Company&#8217;s balance sheets. The Company does not currently hold any financing leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">ROU lease assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease obligations represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s facility leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company&#8217;s ROU lease assets also include any lease payments made and excludes lease incentives. If the Company&#8217;s facility lease includes options to terminate the lease which would affect the lease period when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments under facility leases are recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Acquired In-Process Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire in-process research and development (&#8220;IPR&amp;D&#8221;) with no alternative future use is charged to expense at the acquisition date. Refer to Note 3, &#8220;Acquisition of Quellis&#8221; for a more detailed description of the accounting policy utilized for the recent asset acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times';line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Preferred Stock Discount</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">As discussed above, in February 2021, the Company issued Series X Preferred Stock in a private placement transaction. It was determined that this transaction resulted in recognition of a beneficial conversion feature, which was valued based on the difference between the price of the shares of common stock on the date of commitment and the conversion price on the closing date, resulting in a total value of $19.6 million. Additionally, the Company incurred total issuance costs of $5.7 million related to the private placement. Both of these features were recorded as a discount on Series X Preferred Stock recognized at the close of the transaction. These features are analogous to preferred dividends and are recorded as a non-cash return to holders of Series X Preferred Stock through additional paid in capital. The discount related to the beneficial conversion feature is recognized through the earliest possible date of conversion, which occurred upon the shareholder approval of the conversion in June 2021. The issuance costs are recognized as a dividend at the time of conversion to common shares. As of December 31, 2021, $24.4 million of the above amounts were accounted for as a non-cash dividend related to shares of Series X Preferred Stock, and $0.9 million remained to be recognized upon future conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times';line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements -Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">In December 2019, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740)</i>. This standard includes amendments within the scope of Topic 740 to reduce complexity and improve areas of U.S. GAAP. This amendment was effective for annual reporting periods beginning after December 15, 2020. Adoption of the standard did not have a material impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements - Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">In June 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, <i style="font-style:italic;">Financial Instruments-Credit Losses</i> (Topic 326). This standard requires a financial asset to be presented at amortized cost basis at the net amount expected to be collected. It also requires that credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. In November 2019, the FASB issued an amendment making this ASU effective for annual reporting periods beginning after December 15, 2022 for smaller reporting companies. Early adoption is permitted. The Company is currently evaluating the impact that this standard will have on its consolidated financial statements as well as the timing of when this standard will be adopted.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673393456616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Quellis<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Acquisition of Quellis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisition of Quellis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3. &#160;&#160;&#160;Acquisition of Quellis</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">On January 28, 2021, the Company completed the Quellis Acquisition in accordance with the terms of the Merger Agreement as discussed in Note 1, &#8220;Organization and Operations&#8221;. Under the terms of the Merger Agreement, the Company issued 555,444 shares of common stock and 50,504 shares of Series X Preferred Stock. Each share of Series X Preferred Stock is convertible into 166.67 shares of Common Stock, subject to certain conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company concluded that the Quellis Acquisition was not the acquisition of a business, as substantially all of the fair value of the non-monetary assets acquired was concentrated in a single identifiable asset, STAR-0215.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company determined that the cost to acquire the Quellis assets was $170.7 million, based on the fair value of the equity consideration issued and including direct costs of the acquisition of $1.8 million. The net assets acquired in connection with the Quellis Acquisition were recorded at their estimated fair values as of January 28, 2021, which is the date the Quellis Acquisition was completed. The following table summarizes the net assets acquired based on their estimated fair values as of January 28, 2021 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Acquired IPR&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164,612</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,307</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 136</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (1,974)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (400)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net acquired tangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 170,681</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:28.8pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">In the estimation of fair value of the asset purchase consideration, the Company used the carrying value of the cash and cash equivalents, prepaid expenses, accounts payable and accrued liabilities as the most reliable indicator of fair value based on the associated short-term nature of the balances. The remaining fair value was attributable to the acquired IPR&amp;D. As STAR-0215 had not, at the time of the Quellis Acquisition, received regulatory approval in any territory, the cost attributable to the IPR&amp;D was expensed in the Company&#8217;s consolidated statements of operations and comprehensive loss for the year ended December 31, 2021 as the acquired IPR&amp;D had no alternative future use, as determined by the Company in accordance with U.S. GAAP.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673393505848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">4. &#160;&#160;&#160;Financial Instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The following tables present information about the Company&#8217;s financial assets and liabilities that have been measured at fair value, and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value. Below is a summary of assets and liabilities measured at fair value on a recurring basis (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">in&#160;Active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,853 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,853 </p></td></tr><tr><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Reverse repurchase agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 5.75pt;">Short-term investments:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Reverse repurchase agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">39,000 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">39,000 </p></td></tr><tr><td style="vertical-align:bottom;width:58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Total </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,853 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">39,000 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">40,853 </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">in&#160;Active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,999</p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Short-term investments:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Reverse repurchase agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,000</p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,999</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2021 and 2020, cash equivalents approximated their fair value due to their short-term nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">In connection with the Quellis Acquisition, the Company issued a warrant to purchase 2,805 shares of Series X Preferred Stock at an exercise price of $341.70 per share. Upon stockholder approval of the Conversion Proposal, and reflecting the reverse stock split, the warrant became a warrant to purchase 467,500 shares of common stock at a purchase price of $2.10. This was originally accounted for as a liability until stockholder approval of the Conversion Proposal on June 2, 2021, at which point the warrant was reclassified to permanent equity. The warrant liability was valued based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The Company estimated the fair value of the warrant liability using Black-Scholes option-pricing models and assumptions that are based on the individual characteristics of the warrants on the valuation date, as well as assumptions including the fair value per share of the underlying security, the remaining contractual term of the warrant, risk-free interest rate, expected dividend yield and expected volatility of the price of the underlying security (in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times';line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Balance at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:80.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Issuance of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,332</p></td></tr><tr><td style="vertical-align:bottom;width:80.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">(Decrease) increase in the fair value of the warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (864)</p></td></tr><tr><td style="vertical-align:bottom;width:80.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Reclassification of warrant liability to additional paid in-capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (3,468)</p></td></tr><tr><td style="vertical-align:bottom;width:80.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><span style="font-family:'Times';line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The fair value of the warrants was based on the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times';line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Weighted-average expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">89.1-89.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">9.54-9.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1.064-1.725</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times';font-size:1pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673393582760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-Term Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_ShortTermInvestmentsTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">5.&#160;&#160;&#160;&#160;Short-Term Investments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The following tables summarize the short-term investments held at December 31, 2021 and 2020 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Reverse repurchase agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,000</p></td></tr><tr><td style="vertical-align:bottom;width:47.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Reverse repurchase agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The contractual maturities of all short-term investments held at December 31, 2021 and 2020 were one year or less. There were no short-term investments in an unrealized loss position at December 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Gross realized gains and losses on the sales of short-term investments are included in other income, net. Unrealized holding gains or losses for the period that have been included in accumulated other comprehensive income, as well as gains and losses reclassified out of accumulated other comprehensive income into other income, net were not material to the Company&#8217;s consolidated results of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">During the years ended December 31, 2021 and 2020 all proceeds included in the Company&#8217;s cash flows related to maturities of underlying securities. The gains on proceeds of maturities of short-term investments were not material to the Company&#8217;s consolidated results of operations for the years ended December 31, 2021 and 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_ShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the short-term investments. Short-term investments may include current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_ShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673393586632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">6.&#160;&#160;&#160;&#160;Accrued Expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Accrued expenses consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,958 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,719</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued contracted costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">760 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,726</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">295 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">268 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 356</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued severance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 396</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3,281 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">4,197 </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673393471464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">7. &#160;&#160;&#160;Commitments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">In November 2019, the Company entered into a sublease for office space which was classified as an operating lease. At inception of the lease, the Company recognized a lease <span style="-sec-ix-hidden:Hidden_HFiUTo3gw02FAUw2F3J6Qg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liability</span></span> and right-of-use asset of approximately $1.7 million. The lease liability represents the present value of the remaining lease payments, discounted using the Company&#8217;s estimated incremental borrowing rate of 7.49%. The ROU asset represents the lease liability adjusted for any prepaid and accrued rent payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The lease is scheduled to expire in 2022. Future minimum payments required under the non-cancelable operating leases as of December 31, 2021 are $0.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Rent expense was $0.7 million and $0.8 million for the years ended December 31, 2021 and 2020, respectively. Lease payments were $0.7 million and $1.5 million for the years ended December 31, 2021 and 2020, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673397163800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">8.&#160;&#160;&#160;Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times';font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Preferred Stock </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Under the Company&#8217;s amended and restated certificate of incorporation, the Company has 5,000,000 shares of preferred stock authorized for issuance, with a $0.001 par value per share. Preferred stock may be issued from time to time in one or more series, each series to have such terms as stated or expressed in the resolutions providing for the issue of such series adopted by the board of directors of the Company. Preferred stock which may be redeemed, purchased or acquired by the Company may be reissued except as otherwise provided by law. As of December 31, 2021, the Company had 31,455 shares of Series X Preferred Stock outstanding. Each share of Series X Preferred Stock is convertible into 166.67 shares of common stock and therefore the number of shares of underlying common stock issuable upon conversion of the Series X Preferred Stock is 5,242,501. Refer to Note 1 &#8211; &#8220;Organization and Operations&#8221; regarding the Company&#8217;s issuance of Series X Preferred Stock in January 2021 and February 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Outstanding Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The following table presents information about warrants that are issued and outstanding at December 31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Year Issued</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity&#160;Instrument</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants&#160;Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date&#160;of&#160;Expiration</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 204</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 732.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3/30/2022</p></td></tr><tr><td style="vertical-align:bottom;width:32.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 699,962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">6/21/2023</p></td></tr><tr><td style="vertical-align:bottom;width:32.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 331,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2/7/2024</p></td></tr><tr><td style="vertical-align:bottom;width:32.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 498,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">12/14/2030</p></td></tr><tr><td style="vertical-align:bottom;width:32.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,530,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:32.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Weighted average exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:32.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Weighted average life in years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.05</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">As of December 31, 2021, the Company had 150,000,000 shares of common stock authorized for issuance, $0.001 par value per share, with 13,016,955 shares issued and <span style="-sec-ix-hidden:Hidden_0h6_9E_LE0OXUd1tw9ln2A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>. &#160;The voting, dividend and liquidation rights of holders of common stock are subject to and qualified by the rights, powers and preferences of the holders of any outstanding preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Reserved for Future Issuance</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Company has reserved for future issuance the following shares of common stock:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;"> December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;"> December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Series X Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,242,501</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Warrants for the purchase of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,530,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,032,291</p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Options outstanding to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,346,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 227,846</p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Options available for future issuance to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,633,736</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 322,695</p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Shares reserved for the employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,904</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,825</p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,784,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,607,657</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">As of December 31, 2021, the Company also had 31,455 shares of Series X Preferred Stock outstanding. Each share of Series X Preferred Stock outstanding is convertible into 166.67 shares of the Company&#8217;s common stock, subject to certain beneficial ownership limitations at the holder&#8217;s option. See Note 1 &#8211; &#8220;Organization and Operations&#8221; for additional detail.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673393521432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Incentive Plans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">9. Stock Incentive Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Prior to the Company&#8217;s initial public offering in June 2015 (the &#8220;IPO&#8221;), the Company granted awards to eligible participants under its 2008 Equity Incentive Plan. In May 2015, the Company&#8217;s board of directors adopted and, in June 2015, the Company&#8217;s stockholders approved the 2015 Stock Incentive Plan, as amended and amended and restated since the IPO (&#8220;2015 Plan&#8221;), which became effective immediately prior to the effectiveness of the IPO. Subsequent to the IPO, option grants have been awarded to eligible participants only under the 2015 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The 2015 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units, stock appreciation rights and other stock-based awards. The Company&#8217;s employees, officers, directors and consultants and advisors are eligible to receive awards under the 2015 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Terms of stock option agreements, including vesting requirements, are determined by the Company&#8217;s board of directors, subject to the provisions of the applicable stock incentive plan. Options granted by the Company generally vest ratably over four years, with a one-year cliff, and options are exercisable from the date of grant for a period of ten years. For options granted through December 31, 2021, the exercise price or purchase price, as applicable, equaled the estimated fair value of the common stock as determined by the Company&#8217;s board of directors on the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">A summary of the Company&#8217;s stock option activity and related information for employees and non-employees follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average&#160;Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term&#160;(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outstanding at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 227,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,156,646 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">15.91 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Assumed in Quellis Acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">55,414 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1.73 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(10,470)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2.10 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Cancelled or forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(81,196)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">48.13 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(1,507)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">100.85 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,346,733 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">22.25 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">9.02 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">168,181 </p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vested and exercisable at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">135,412 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">72.76 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">7.19 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">77,798 </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The total intrinsic value of options exercised in the years ended December 31, 2021 and 2020 was $45 thousand and $29 thousand, respectively. The weighted-average grant date fair value of options granted to employees and non-employees for the years ended December 31, 2021 and 2020 was $9.82 and $3.81, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">At December 31, 2021, the total unrecognized compensation expense related to unvested stock option awards was $10.8 million. The Company expects to recognize that cost over a weighted-average period of approximately 2.9 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The fair value of stock options granted to employees and non-employees was estimated using the Black-Scholes option-pricing model based on the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:36.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Weighted-average expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">69.28-71.32%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">75.51-82.08%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">5-6.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">5.50-6.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0.42-1.36%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0.37-1.51%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Volatility</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Due to the lack of company-specific historical and implied volatility data of its common stock, the Company does not have relevant historical data to support its expected volatility. As such, the Company has used a weighted average of expected volatility based on the volatilities of a representative group of publicly traded biopharmaceutical companies. For purposes of identifying representative companies, the Company considered characteristics such as number of product candidates in early stages of product development, area of therapeutic focus, and length of trading history. The expected volatility was determined using an average of the historical volatilities of the representative group of companies for a period equal to the expected term of the option grant. The Company intends to continue to consistently apply this process using the same representative companies until a sufficient amount of historical information regarding the volatility of the Company&#8217;s own share price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Expected Term</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company uses the &#8220;simplified method&#8221; to estimate the expected term of stock option grants. Under this approach, the weighted-average expected life is presumed to be the average of the contractual term (ten years) and the vesting term (generally four years) of the Company&#8217;s stock options, taking into consideration multiple vesting tranches. The Company utilizes this method due to lack of historical exercise data and the plain-vanilla nature of the Company&#8217;s share-based awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Risk-Free Rate</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The risk-free rate was based on the yield curve of United States Treasury securities with periods commensurate with the expected term of the options being valued.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673393579544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">10. &#160;&#160;&#160;Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">For the years ended December 31, 2021 and 2020, the Company did not record a provision for federal or state income taxes as it has incurred cumulative net operating losses since inception.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">A reconciliation of the U.S. statutory income tax rate to the Company&#8217;s effective tax rate is as follows for the years ended December 31, 2021 and 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Federal income tax (benefit) at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">21.00 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(0.25)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(0.41)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Federal research and development credits and adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0.44 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2.78 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Nondeductible research costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(17.75)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">State income tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0.82 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">6.03 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0.37 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(4.27)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(29.77)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company&#8217;s deferred tax assets consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Deferred tax assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">75,849 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">65,373 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">10,063 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">9,273 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Capitalized research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">139 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">482 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Capitalized legal expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,048 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,070 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">99 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">284 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,977 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,648 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">89,175 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">78,130 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Deferred tax liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">ROU asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(107)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(262)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(89,068)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(77,868)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company recorded an increase to the valuation allowance of $11.2 million during the year ended December 31, 2021 due primarily to the federal and state net operating losses and tax credits generated. The Company recorded an increase to the valuation allowance of $11.1 million during the year ended December 31, 2020 which was also primarily due to the federal and state net operating losses and tax credits generated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences representing net future deductible amounts become deductible. Due to the Company&#8217;s history of losses and expectation of future losses, the deferred tax assets were fully offset by a valuation allowance at December 31, 2021 and 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">As of December 31, 2021, the Company had approximately $279.4 million of federal and $271.8 million of state net operating loss respectively, which may be available to offset future taxable income. Federal net operating loss carryforwards of $150.6 million and state net operating loss carryforwards of $271.8 million will expire at various dates from 2028 through 2041. Federal net operating loss carryforwards of $128.8 million can be carried forward indefinitely. The Company had approximately $8.1 million of federal and $2.4 million of state tax credit carryforwards available to reduce future tax liabilities as of December 31, 2021, which will expire at varying times through the year 2041.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), provides for a limitation of the annual use of net operating losses and other tax attributes (such as research and development tax credit carryforwards) following certain ownership changes (as defined by the Code) that could limit the Company&#8217;s ability to utilize these carryforwards. At this time, the Company has not completed a study to assess whether an ownership change under Section 382 of the Code has occurred, or whether there have been multiple ownership changes since the Company&#8217;s formation, due to the costs and complexities associated with such a study. The Company may have experienced various ownership changes, as defined by the Code, as a result of past financing transactions. Accordingly, the Company&#8217;s ability to utilize the aforementioned carryforwards may be limited. Additionally, U.S. tax laws limit the time during which these carryforwards may be applied against future taxes. Therefore, the Company may not be able to take full advantage of these carryforwards for federal or state income tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">As of December 31, 2021 and 2020, the Company did not have any significant unrecognized tax benefits. The Company had not accrued interest or penalties related to uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The federal and state income tax returns are generally subject to tax examinations for the tax years ended December 31, 2018 through December 31, 2021. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state taxing authorities to the extent utilized in a future period. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673393521432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Defined Contribution Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock', window );">Defined Contribution Benefit Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">11.&#160;&#160; Defined Contribution Benefit Plan </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company sponsors a 401(k) retirement plan, in which substantially all of its employees are eligible to participate. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company did not provide any contributions to this plan during the years ended December 31, 2021 or 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673393582760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">12.&#160;&#160; Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Operating Lease </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">On January 28, 2022, the Company entered into a sublease agreement (the &#8220;Sublease&#8221;) with Grant Thornton LLP (the &#8220;Sublandlord&#8221;), for office space. &#160;The Sublease will commence on the latest to occur of (i) May 1, 2022, (ii) the receipt of the landlord&#8217;s consent to the Sublease and (iii) the date on which the Sublandlord delivers full and exclusive possession of the premises to the Company as set forth in the Sublease and will end on July 31, 2024. The Sublease will increase the future minimum payments described in Note 7 from approximately $0.4 million to approximately $1.8 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673396364008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Polices (Polices)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation and Principles of Consolidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Astria Securities Corporation and Quellis Biosciences, LLC, successor in interest to Quellis. All intercompany balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented.&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company utilizes certain estimates to record expenses relating to research and development contracts. These contract estimates, which are primarily related to the length of service of each contract and the amount of service provided as of each measurement date, are determined by the Company based on input from internal project management, as well as from service providers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock', window );">Off-Balance Sheet Risk and Concentrations of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Off-Balance Sheet Risk and Concentrations of Credit Risk </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company has no off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements. Financial instruments that subject the Company to credit risk primarily consist of cash, cash equivalents, short-term investments and restricted cash. The primary objectives for the Company&#8217;s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company&#8217;s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents and Restricted Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The reconciliation of cash, cash equivalents and restricted cash reported within the applicable balance sheet that sum to the total of the same such amount shown in the statement of cash flows is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 86,508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,930</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Restricted cash (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 121</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 86,629</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,051</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-left:46.8pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:46.8pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Included in prepaid expenses and other current assets at December 31, 2021 and other long-term assets at December 31, 2020.</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Short-Term Investments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company classifies all corporate debt securities with a remaining maturity of greater than three months and reverse repurchase agreements with a remaining maturity of greater than one business day at the time of purchase as short-term investments. Short-term investments are recorded at fair value, with the unrealized gains and losses reported in other comprehensive loss. The amortized cost of debt securities is adjusted for the amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest and investment income. Realized gains and losses, interest, dividends and declines in value judged to be other-than-temporary are included in interest and investment income. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The cost of securities sold is based on the specific identification method for purposes of recording realized gains and losses. To determine whether an other-than-temporary impairment exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the investment outweighs evidence to the contrary. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three broad levels as follows: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3 inputs are unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The carrying amounts reflected in the balance sheets for cash equivalents, restricted cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values at December 31, 2021 and 2020, due to their short-term nature. There have been no changes to the valuation methods during the years ended December 31, 2021 and 2020. The Company evaluates transfers between levels at the end of each reporting period. There were no <span style="-sec-ix-hidden:Hidden_Q8KxfYwEQ06Q-XDWVRjAVA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">transfers</span></span> <span style="-sec-ix-hidden:Hidden_h7pU9TMEukuhqRukKT1nSg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span></span> <span style="-sec-ix-hidden:Hidden_Spms05oTPUG_D656yLZ_hg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assets</span></span> or liabilities between levels during the years ended December 31, 2021 and 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company&#8217;s investment portfolio may include fixed income securities that do not always trade on a daily basis. As a result, the pricing services used by the Company apply other available information as applicable through processes such as benchmark yields, benchmarking of like securities, sector groupings and matrix pricing to prepare valuations. The Company validates the prices provided by its third party pricing services by obtaining market values from other pricing sources and analyzing pricing data in certain instances. The Company also invests in certain reverse repurchase agreements which are collateralized by deposits in the form of United States Government Securities and Obligations for an amount no less than 102% of their value. The Company does not record an asset or liability for the collateral as the Company is not permitted to sell or re-pledge the collateral. The collateral has at least the prevailing credit rating of United States Government Treasuries and Agencies. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the reverse repurchase agreements on a daily basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company accounted for warrants to purchase its stock pursuant to Accounting Standards Codification (&#8220;ASC&#8221;) Topic 470, Debt, and ASC Topic 480, Distinguishing Liabilities from Equity, and classifies warrants for common stock and preferred stock as liabilities or equity. The warrants classified as liabilities are reported at their estimated fair value and any changes in fair value are reflected in research and development expense. The warrants classified as equity are reported at their estimated fair value with no subsequent remeasurement.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. The Company has not recognized any significant impairment charges from inception through December&#160;31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Research and development costs are expensed as incurred. Research and development costs include salaries and personnel-related costs, stock-based compensation, consulting fees, fees paid for contract research services, the costs of laboratory equipment and facilities and other external costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred. The deferred amounts are expensed as the related goods are delivered or the services are performed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company accounts for its stock-based compensation awards in accordance with ASC Topic&#160;718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation (</i>&#8220;ASC&#160;718&#8221;). ASC&#160;718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statements of operations based on their grant date fair values. For granted stock options, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model.&#160; The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Company&#8217;s common stock consistent with the expected term of the option, risk-free interest rates and expected dividend yields of the Company&#8217;s common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">For awards subject to service-based vesting conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company expenses restricted stock awards based on the fair value of the award on a straight-line basis over the associated service period of the award. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">During the years ended December 31, 2021 and 2020, the Company recorded stock-based compensation expense for employee and non-employee stock options and restricted stock, which was allocated as follows in the statements of operations (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,132</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 599</p></td></tr><tr><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 791</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,390</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">No related tax benefits were recognized for the years ended December 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss Per Share </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Basic net loss per share is calculated by dividing net loss by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the Company&#8217;s dilutive net loss per share calculation, stock options and warrants to purchase the Company&#8217;s common stock were considered to be common stock equivalents but were excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive; therefore, basic and diluted net loss per share were the same for all periods presented. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,346,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 227,945</p></td></tr><tr><td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,530,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,032,292</p></td></tr><tr><td style="vertical-align:bottom;width:72.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Series X Preferred Stock (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,242,501</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,119,614</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,260,236</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-left:46.8pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:46.8pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Shown as common stock equivalents</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company provides deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company&#8217;s financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. A valuation allowance is provided to reduce the deferred tax assets to the amount that will more likely than not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC Topic&#160;740, <i style="font-style:italic;">Expenses&#8212;Income Taxes</i>. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company did not have any uncertain tax positions for any periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The Company assesses the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where it has operations to determine the potential effect its business and any assumptions it has made about its future taxable income. The Company cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on its business if they were to be enacted. Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the currently available option to deduct research and development expenditures and requires taxpayers to amortize them over five years. The U.S. Congress is considering legislation that would defer the amortization requirement to future periods, however, the Company has no assurance that the provision will be repealed or otherwise modified.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Segment Information </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, the Company&#8217;s chief executive officer, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business in one operating segment. The Company operates in one geographic segment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company determines if an arrangement is a lease at inception. Operating leases are included in&#160;right-of-use&#160;(&#8220;ROU&#8221;) lease assets, current portion of lease obligations, and long-term lease obligations on the Company&#8217;s balance sheets. The Company does not currently hold any financing leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">ROU lease assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease obligations represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s facility leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company&#8217;s ROU lease assets also include any lease payments made and excludes lease incentives. If the Company&#8217;s facility lease includes options to terminate the lease which would affect the lease period when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments under facility leases are recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired In-Process Research and Development</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Acquired In-Process Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire in-process research and development (&#8220;IPR&amp;D&#8221;) with no alternative future use is charged to expense at the acquisition date. Refer to Note 3, &#8220;Acquisition of Quellis&#8221; for a more detailed description of the accounting policy utilized for the recent asset acquisition.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_PreferredStockDiscountPolicyTextBlock', window );">Preferred Stock Discount</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Preferred Stock Discount</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">As discussed above, in February 2021, the Company issued Series X Preferred Stock in a private placement transaction. It was determined that this transaction resulted in recognition of a beneficial conversion feature, which was valued based on the difference between the price of the shares of common stock on the date of commitment and the conversion price on the closing date, resulting in a total value of $19.6 million. Additionally, the Company incurred total issuance costs of $5.7 million related to the private placement. Both of these features were recorded as a discount on Series X Preferred Stock recognized at the close of the transaction. These features are analogous to preferred dividends and are recorded as a non-cash return to holders of Series X Preferred Stock through additional paid in capital. The discount related to the beneficial conversion feature is recognized through the earliest possible date of conversion, which occurred upon the shareholder approval of the conversion in June 2021. The issuance costs are recognized as a dividend at the time of conversion to common shares. As of December 31, 2021, $24.4 million of the above amounts were accounted for as a non-cash dividend related to shares of Series X Preferred Stock, and $0.9 million remained to be recognized upon future conversion.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements -Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">In December 2019, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740)</i>. This standard includes amendments within the scope of Topic 740 to reduce complexity and improve areas of U.S. GAAP. This amendment was effective for annual reporting periods beginning after December 15, 2020. Adoption of the standard did not have a material impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements - Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">In June 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, <i style="font-style:italic;">Financial Instruments-Credit Losses</i> (Topic 326). This standard requires a financial asset to be presented at amortized cost basis at the net amount expected to be collected. It also requires that credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. In November 2019, the FASB issued an amendment making this ASU effective for annual reporting periods beginning after December 15, 2022 for smaller reporting companies. Early adoption is permitted. The Company is currently evaluating the impact that this standard will have on its consolidated financial statements as well as the timing of when this standard will be adopted.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for off-balance sheet risk and concentrations of credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_PreferredStockDiscountPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for preferred stock discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_PreferredStockDiscountPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673393516152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_ScheduleOfPreferredStockOrWarrantsToPurchasePreferredStockTableTextBlock', window );">Schedule of common stock warrants outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series&#160;X</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;Preferred&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock at</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Shares issued in merger</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,504</p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Shares issued in February 2021 Financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,573</p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Warrants assumed in merger</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,805</p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,882</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_ScheduleOfPreferredStockOrWarrantsToPurchasePreferredStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure preferred stock or warrants to purchase preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_ScheduleOfPreferredStockOrWarrantsToPurchasePreferredStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673398100008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of reconciliation of cash, cash equivalents and restricted cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The reconciliation of cash, cash equivalents and restricted cash reported within the applicable balance sheet that sum to the total of the same such amount shown in the statement of cash flows is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 86,508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,930</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Restricted cash (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 121</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 86,629</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,051</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-left:46.8pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:46.8pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Included in prepaid expenses and other current assets at December 31, 2021 and other long-term assets at December 31, 2020.</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">During the years ended December 31, 2021 and 2020, the Company recorded stock-based compensation expense for employee and non-employee stock options and restricted stock, which was allocated as follows in the statements of operations (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,132</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 599</p></td></tr><tr><td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 791</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,390</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti-dilutive common stock equivalents excluded from calculation of diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,346,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 227,945</p></td></tr><tr><td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,530,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,032,292</p></td></tr><tr><td style="vertical-align:bottom;width:72.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Series X Preferred Stock (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,242,501</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,119,614</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,260,236</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673393629688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Quellis (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Acquisition of Quellis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of net assets acquired</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Acquired IPR&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164,612</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,307</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 136</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (1,974)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (400)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net acquired tangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 170,681</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673484112520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of assets and liabilities measured fair value on recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">in&#160;Active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,853 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,853 </p></td></tr><tr><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Reverse repurchase agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 5.75pt;">Short-term investments:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Reverse repurchase agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">39,000 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">39,000 </p></td></tr><tr><td style="vertical-align:bottom;width:58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Total </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,853 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">39,000 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">40,853 </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">in&#160;Active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,999</p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Short-term investments:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Reverse repurchase agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,000</p></td></tr><tr><td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,999</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of warrant liability was valued based on significant inputs not observable in the market, which represents a Level 3</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times';line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Balance at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:80.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Issuance of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,332</p></td></tr><tr><td style="vertical-align:bottom;width:80.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">(Decrease) increase in the fair value of the warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (864)</p></td></tr><tr><td style="vertical-align:bottom;width:80.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Reclassification of warrant liability to additional paid in-capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (3,468)</p></td></tr><tr><td style="vertical-align:bottom;width:80.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of fair value of the warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-family:'Times';line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Weighted-average expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">89.1-89.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">9.54-9.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1.064-1.725</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673393463320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-Term Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of short term investments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The following tables summarize the short-term investments held at December 31, 2021 and 2020 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Reverse repurchase agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,000</p></td></tr><tr><td style="vertical-align:bottom;width:47.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Reverse repurchase agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673397164360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Accrued expenses consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,958 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,719</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued contracted costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">760 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,726</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">295 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">268 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 356</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued severance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 396</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3,281 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">4,197 </p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673394446824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_CommonStockReservedForFutureIssuanceAbstract', window );"><strong>Reserved for Future Issuance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of common stock reserved for future issuance</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;"> December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;"> December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Series X Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,242,501</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Warrants for the purchase of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,530,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,032,291</p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Options outstanding to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,346,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 227,846</p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Options available for future issuance to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,633,736</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 322,695</p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Shares reserved for the employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,904</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,825</p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,784,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,607,657</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Series X preferred stock or warrants to purchase</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The following table presents information about warrants that are issued and outstanding at December 31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Year Issued</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity&#160;Instrument</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants&#160;Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date&#160;of&#160;Expiration</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 204</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 732.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3/30/2022</p></td></tr><tr><td style="vertical-align:bottom;width:32.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 699,962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">6/21/2023</p></td></tr><tr><td style="vertical-align:bottom;width:32.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 331,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2/7/2024</p></td></tr><tr><td style="vertical-align:bottom;width:32.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 498,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">12/14/2030</p></td></tr><tr><td style="vertical-align:bottom;width:32.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,530,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:32.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Weighted average exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:32.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Weighted average life in years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.05</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_CommonStockReservedForFutureIssuanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_CommonStockReservedForFutureIssuanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673394442648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average&#160;Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term&#160;(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outstanding at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 227,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,156,646 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">15.91 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Assumed in Quellis Acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">55,414 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1.73 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(10,470)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2.10 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Cancelled or forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(81,196)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">48.13 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(1,507)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">100.85 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,346,733 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">22.25 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">9.02 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">168,181 </p></td></tr><tr><td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vested and exercisable at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">135,412 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">72.76 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">7.19 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">77,798 </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions made based on the Black-Scholes option pricing model</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:36.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Weighted-average expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">69.28-71.32%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">75.51-82.08%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">5-6.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">5.50-6.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0.42-1.36%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0.37-1.51%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673393599704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of U.S. statutory income tax rate to effective tax rate</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Federal income tax (benefit) at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">21.00 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(0.25)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(0.41)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Federal research and development credits and adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0.44 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2.78 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Nondeductible research costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(17.75)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">State income tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0.82 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">6.03 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0.37 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(4.27)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(29.77)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of components of deferred tax assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">The Company&#8217;s deferred tax assets consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Deferred tax assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">75,849 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">65,373 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">10,063 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">9,273 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Capitalized research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">139 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">482 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Capitalized legal expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,048 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,070 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">99 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">284 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,977 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,648 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">89,175 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">78,130 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Deferred tax liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">ROU asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(107)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(262)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(89,068)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(77,868)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673389432696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations - Reverse Stock Split, Agreement and Plan of Merger (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 19, 2021</div></th>
<th class="th"><div>Jan. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 02, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Reverse stock split ratio</a></td>
<td class="text">0.1667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_AgreementAndPlanOfMergerAbstract', window );"><strong>Agreement and Plan of Merger</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross', window );">Number of options assumed in Quellis Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_AgreementAndPlanOfMergerAbstract', window );"><strong>Agreement and Plan of Merger</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock upon acquisition of Quellis (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">555,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember', window );">Quellis Biosciences, Inc | Series X redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_AgreementAndPlanOfMergerAbstract', window );"><strong>Agreement and Plan of Merger</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues', window );">Issuance of preferred stock upon acquisition of Quellis (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_TemporaryEquityConversionValue', window );">Conversion value on closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 341.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember', window );">Quellis Biosciences, Inc | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_AgreementAndPlanOfMergerAbstract', window );"><strong>Agreement and Plan of Merger</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock upon acquisition of Quellis (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">555,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross', window );">Number of options assumed in Quellis Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_AgreementAndPlanOfMergerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_AgreementAndPlanOfMergerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) assumed in acquisition during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_TemporaryEquityConversionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The conversion value of temporary equity shares on the merger closing date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_TemporaryEquityConversionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new shares classified as temporary equity issued in an acquisition during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673395098728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations - Stock Purchase Agreement and Series X Preferred Stock (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Jan. 28, 2021</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract', window );"><strong>Stock Purchase Agreement and Series X Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from issuance of private placement | $</a></td>
<td class="nump">$ 104,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Number of shares of common stock into which each share of Series X Preferred Stock may be converted</a></td>
<td class="nump">166.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract', window );"><strong>Stock Purchase Agreement and Series X Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially', window );">Common stock, percentage of beneficial ownership initially, after conversion</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter', window );">Common stock, percentage of beneficial ownership thereafter, after conversion</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract', window );"><strong>Stock Purchase Agreement and Series X Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially', window );">Common stock, percentage of beneficial ownership initially, after conversion</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter', window );">Common stock, percentage of beneficial ownership thereafter, after conversion</a></td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember', window );">Series X redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract', window );"><strong>Stock Purchase Agreement and Series X Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Series X Preferred Stock at Transaction Date</a></td>
<td class="nump">88,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Number of shares of common stock into which each share of Series X Preferred Stock may be converted</a></td>
<td class="nump">166.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_StockIssuedDuringPeriodSharesIncreaseDecreaseDueToConversionOfPreferredSharesIntoCommonShares', window );">Number of Series X preferred shares converted during period</a></td>
<td class="nump">54,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of common shares issued from conversion of Series X preferred shares</a></td>
<td class="nump">9,103,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of common shares issuable upon conversion of preferred stock (in shares)</a></td>
<td class="nump">5,242,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">31,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember', window );">Series X redeemable convertible preferred stock | Shares issued in merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract', window );"><strong>Stock Purchase Agreement and Series X Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Series X redeemable convertible preferred stock, shares issued</a></td>
<td class="nump">50,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember', window );">Series X redeemable convertible preferred stock | Shares issued in February 2021 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract', window );"><strong>Stock Purchase Agreement and Series X Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Series X redeemable convertible preferred stock, shares issued</a></td>
<td class="nump">35,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember', window );">Series X redeemable convertible preferred stock | Warrants assumed in merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract', window );"><strong>Stock Purchase Agreement and Series X Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Series X Preferred Stock at Transaction Date</a></td>
<td class="nump">2,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember', window );">Series X redeemable convertible preferred stock | Quellis Biosciences, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract', window );"><strong>Stock Purchase Agreement and Series X Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Number of shares of common stock into which each share of Series X Preferred Stock may be converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember', window );">Series X redeemable convertible preferred stock | Quellis Biosciences, Inc | Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract', window );"><strong>Stock Purchase Agreement and Series X Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodSharesNewIssues', window );">Issuance of preferred stock in a private offering of public equity, net of issuance costs (in shares)</a></td>
<td class="nump">35,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodGrossValue', window );">Gross proceeds from issuance of preferred stock in a private offering | $</a></td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from issuance of private placement | $</a></td>
<td class="nump">104,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature | $</a></td>
<td class="nump">19,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs | $</a></td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Number of shares of common stock into which each share of Series X Preferred Stock may be converted</a></td>
<td class="nump">166.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of beneficial ownership common stock issued and outstanding immediately after giving effect to such conversion initially considered for prohibiting from converting shares of Series X Preferred Stock into shares of the Company's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of beneficial ownership common stock issued and outstanding immediately after giving effect to such conversion thereafter considered for prohibiting from converting shares of Series X Preferred Stock into shares of the Company's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_StockIssuedDuringPeriodSharesIncreaseDecreaseDueToConversionOfPreferredSharesIntoCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in number of shares issued during the period upon the conversion of preferred shares into common shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_StockIssuedDuringPeriodSharesIncreaseDecreaseDueToConversionOfPreferredSharesIntoCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodGrossValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross value of new stock classified as temporary equity issued in a private offering during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodGrossValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new shares classified as temporary equity issued in a private offering during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e34017-109320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=atxs_SharesIssuedInMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=atxs_SharesIssuedInMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=atxs_SharesIssuedIn2021FinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=atxs_SharesIssuedIn2021FinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=atxs_WarrantsAssumedInMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=atxs_WarrantsAssumedInMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673389240888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations - January 2020 Financing (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_January2020FinancingAbstract', window );"><strong>January 2020 Financing</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atxs_UnderwritingPublicOffering2020Member', window );">January 2020 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_January2020FinancingAbstract', window );"><strong>January 2020 Financing</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds from sale of stock in public offering</a></td>
<td class="nump">$ 26.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering, net of issuance costs</a></td>
<td class="nump">$ 24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atxs_UnderwritingPublicOffering2020Member', window );">January 2020 Financing | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_January2020FinancingAbstract', window );"><strong>January 2020 Financing</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance costs (in shares)</a></td>
<td class="nump">881,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atxs_UnderwritingPublicOffering2020Member', window );">January 2020 Financing | Oppenheimer &amp; Co. Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_January2020FinancingAbstract', window );"><strong>January 2020 Financing</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance costs (in shares)</a></td>
<td class="nump">115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_January2020FinancingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_January2020FinancingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=atxs_UnderwritingPublicOffering2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=atxs_UnderwritingPublicOffering2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=atxs_OppenheimerCo.IncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=atxs_OppenheimerCo.IncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673392482680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations - Liquidity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 455,809<span></span>
</td>
<td class="nump">$ 260,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, Cash Equivalents, and Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=atxs_JefferiesMember', window );">Jefferies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_RemainingAvailableUnderCurrentSalesAgreement', window );">Remaining available under sales agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=atxs_JefferiesMember', window );">Jefferies | ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_CommonStockSaleAgreementValue', window );">Maximum aggregate value of common shares which can be issued under the agreement</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_PercentageOfCommissionPaidToUnderwriterBasedOnProceedsFromOffering', window );">Percentage of commission paid to underwriter based on proceeds from common stock</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings', window );">Issuance of common stock for at-the-market offerings, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings', window );">Issuance of common stock for at-the-market offerings, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings', window );">Issuance of common stock for at-the-market offerings, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_CommonStockSaleAgreementValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of common stock authorized to be issued under the terms of an open market sale agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_CommonStockSaleAgreementValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_PercentageOfCommissionPaidToUnderwriterBasedOnProceedsFromOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission paid to underwriters based on proceeds from offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_PercentageOfCommissionPaidToUnderwriterBasedOnProceedsFromOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_RemainingAvailableUnderCurrentSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of remaining available under its current sales agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_RemainingAvailableUnderCurrentSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued in At-the-Market offerings during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=atxs_JefferiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=atxs_JefferiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=atxs_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=atxs_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673394399224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Polices - Cash and Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 86,508<span></span>
</td>
<td class="nump">$ 24,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total</a></td>
<td class="nump">$ 86,629<span></span>
</td>
<td class="nump">$ 25,051<span></span>
</td>
<td class="nump">$ 10,376<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673392558168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Polices - Fair Value of Financial Instruments (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract', window );"><strong>Fair Value of Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Fair value assets, transfers from Level 1 to Level 2</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Fair value assets, transfers from Level 2 to Level 1</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount', window );">Fair value liabilities, transfers from Level 1 to Level 2</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount', window );">Fair value liabilities, transfers from Level 2 to Level 1</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=atxs_ReverseRepurchaseAgreementsMember', window );">Reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract', window );"><strong>Fair Value of Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_PercentageOfInvestmentAmountToCollateralizedDepositsValue', window );">Percentage of investment amount to collateralized deposits value</a></td>
<td class="nump">102.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=atxs_ReverseRepurchaseAgreementsMember', window );">Reverse repurchase agreements | Government Securities and Obligations | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract', window );"><strong>Fair Value of Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_PercentageOfInvestmentAmountToCollateralizedDepositsValue', window );">Percentage of investment amount to collateralized deposits value</a></td>
<td class="nump">102.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_PercentageOfInvestmentAmountToCollateralizedDepositsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of investment in reverse repurchase agreements which are collateralized by deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_PercentageOfInvestmentAmountToCollateralizedDepositsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=atxs_ReverseRepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=atxs_ReverseRepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAxis=us-gaap_CollateralPledgedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAxis=us-gaap_CollateralPledgedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673392489864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,362<span></span>
</td>
<td class="nump">$ 1,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefits recognized from stock-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,132<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,230<span></span>
</td>
<td class="nump">$ 791<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673397010232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive common stock equivalents excluded from computation of diluted net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">8,119,614<span></span>
</td>
<td class="nump">1,260,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive common stock equivalents excluded from computation of diluted net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">1,346,733<span></span>
</td>
<td class="nump">227,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atxs_CommonStockWarrantsMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive common stock equivalents excluded from computation of diluted net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">1,530,380<span></span>
</td>
<td class="nump">1,032,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atxs_SeriesXPreferredStockMember', window );">Series X Preferred Stock (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive common stock equivalents excluded from computation of diluted net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">5,242,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atxs_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atxs_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atxs_SeriesXPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atxs_SeriesXPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673393542040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673395039656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Preferred Stock Discount (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Series X Preferred Stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember', window );">Series X redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Series X Preferred Stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Series X redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature</a></td>
<td class="nump">$ 19,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_NonCashReturnRelatedToCommonStock', window );">Non cash return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_NonCashReturnRelatedToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of Non Cash Return Related To Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_NonCashReturnRelatedToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e34017-109320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673396112936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Quellis (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 28, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition of Quellis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Number of shares of common stock into which each share of Series X Preferred Stock may be converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166.67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition of Quellis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock upon acquisition of Quellis (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">555,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember', window );">Quellis Biosciences, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition of Quellis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities', window );">Cost to acquire the assets | $</a></td>
<td class="nump">$ 170,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquisitionCosts', window );">Acquisition costs | $</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember', window );">Quellis Biosciences, Inc | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition of Quellis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock upon acquisition of Quellis (in shares)</a></td>
<td class="nump">555,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember', window );">Series X redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition of Quellis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Number of shares of common stock into which each share of Series X Preferred Stock may be converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166.67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember', window );">Series X redeemable convertible preferred stock | Quellis Biosciences, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition of Quellis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues', window );">Issuance of preferred stock upon acquisition of Quellis (in shares)</a></td>
<td class="nump">50,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Number of shares of common stock into which each share of Series X Preferred Stock may be converted</a></td>
<td class="nump">166.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember', window );">Series X redeemable convertible preferred stock | Quellis Biosciences, Inc | Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition of Quellis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Number of shares of common stock into which each share of Series X Preferred Stock may be converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166.67<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired other than intangible assets in excess of (less than) the aggregate liabilities assumed other than deferred tax liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new shares classified as temporary equity issued in an acquisition during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquisitionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(7)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=123726172&amp;loc=d3e511914-122862<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(3)(ii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=123726172&amp;loc=d3e511914-122862<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquisitionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673389125528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisition of Quellis - Net assets acquired based on their estimated fair values (Details) - Quellis Biosciences, Inc<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jan. 28, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition of Quellis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment', window );">Acquired IPR&amp;D</a></td>
<td class="nump">$ 164,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">8,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,974)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(400)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities', window );">Net acquired tangible assets</a></td>
<td class="nump">$ 170,681<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Acquired Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired other than intangible assets in excess of (less than) the aggregate liabilities assumed other than deferred tax liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673389060600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Summary of assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">$ 40,853<span></span>
</td>
<td class="nump">$ 42,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Summary of assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">1,853<span></span>
</td>
<td class="nump">22,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Summary of assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Summary of assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">1,853<span></span>
</td>
<td class="nump">22,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Summary of assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">1,853<span></span>
</td>
<td class="nump">22,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Summary of assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Reverse repurchase agreements | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Summary of assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">$ 39,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=atxs_ReverseRepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=atxs_ReverseRepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673392647736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Warrant liability (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 02, 2021</div></th>
<th class="th"><div>Jan. 28, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Derivative warrant liability was valued based on significant inputs not observable in the market, which represents a Level 3</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuance of warrant</a></td>
<td class="nump">4,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Decrease) increase in the fair value of the warrants</a></td>
<td class="num">(864)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_ReclassificationOfEquityClassifiedWarrants', window );">Reclassification of warrant liability to additional paid-in capital</a></td>
<td class="num">(3,468)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares which may be purchased with warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember', window );">Quellis Biosciences, Inc | Series X redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares which may be purchased with warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 341.70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember', window );">Quellis Biosciences, Inc | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares which may be purchased with warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_ReclassificationOfEquityClassifiedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from reclassification of equity classified warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_ReclassificationOfEquityClassifiedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673389042536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Fair value of warrants (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>item </div>
<div>Y</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=atxs_WeightedAverageExpectedVolatilityMember', window );">Weighted-average expected volatility | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">0.891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=atxs_WeightedAverageExpectedVolatilityMember', window );">Weighted-average expected volatility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">0.893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (in years) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input | Y</a></td>
<td class="nump">9.54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (in years) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input | Y</a></td>
<td class="nump">9.88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">0.01064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">0.01725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=atxs_WeightedAverageExpectedVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=atxs_WeightedAverageExpectedVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673389039256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Investments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>instrument</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Short-Term Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of short term investments in unrealized loss position | instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Short-Term Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 39,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue', window );">Fair Value</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=atxs_ReverseRepurchaseAgreementsMember', window );">Reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Short-Term Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue', window );">Fair Value</a></td>
<td class="nump">$ 39,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=SL120269820-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=atxs_ReverseRepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=atxs_ReverseRepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673397086296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 1,958<span></span>
</td>
<td class="nump">$ 1,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_AccruedContractedResearchCostsCurrent', window );">Accrued contracted costs</a></td>
<td class="nump">760<span></span>
</td>
<td class="nump">1,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_AccruedSeveranceCurrent', window );">Accrued severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 3,281<span></span>
</td>
<td class="nump">$ 4,197<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_AccruedContractedResearchCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date for contracted research costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_AccruedContractedResearchCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_AccruedSeveranceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for severance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_AccruedSeveranceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673389242264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">$ 966<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Estimated incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.49%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future minimum payments</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payments</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673394967848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Preferred Stock (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>series </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_NumberOfPreferredStockSeries', window );">Minimum number of series used to issue preferred stock | series</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Number of shares of common stock into which each share of Series X Preferred Stock may be converted</a></td>
<td class="nump">166.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember', window );">Series X redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">91,380<span></span>
</td>
<td class="nump">91,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">31,455<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">31,455<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Number of shares of common stock into which each share of Series X Preferred Stock may be converted</a></td>
<td class="nump">166.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of common shares issuable upon conversion of preferred stock (in shares)</a></td>
<td class="nump">5,242,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_NumberOfPreferredStockSeries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of series that may be used to issue preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_NumberOfPreferredStockSeries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673389251624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock Warrants (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Common Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted average life (in years)</a></td>
<td class="text">4 years 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atxs_CommonStockWarrantsMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Common Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding (in shares) | shares</a></td>
<td class="nump">1,530,380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atxs_CommonStockWarrantsMember', window );">Common stock warrants | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Common Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 41.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atxs_WarrantsIssuedIn2015Member', window );">Warrants Issued in 2015 | Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Common Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding (in shares) | shares</a></td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 732.72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atxs_WarrantsIssuedIn2018Member', window );">Warrants Issued in 2018 | Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Common Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding (in shares) | shares</a></td>
<td class="nump">699,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 72.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atxs_WarrantsIssuedIn2019Member', window );">Warrants Issued in 2019 | Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Common Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding (in shares) | shares</a></td>
<td class="nump">331,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 37.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atxs_WarrantsIssuedIn2021Member', window );">Warrants Issued In 2021 | Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Common Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding (in shares) | shares</a></td>
<td class="nump">498,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual life of warrant, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atxs_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atxs_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=atxs_WarrantsIssuedIn2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=atxs_WarrantsIssuedIn2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=atxs_WarrantsIssuedIn2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=atxs_WarrantsIssuedIn2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=atxs_WarrantsIssuedIn2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=atxs_WarrantsIssuedIn2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=atxs_WarrantsIssuedIn2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=atxs_WarrantsIssuedIn2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673389289768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value of common stock (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">13,016,955<span></span>
</td>
<td class="nump">3,347,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, outstanding (in shares)</a></td>
<td class="nump">13,016,955<span></span>
</td>
<td class="nump">3,347,386<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673388971240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Shares Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance</a></td>
<td class="nump">9,784,254<span></span>
</td>
<td class="nump">1,607,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember', window );">Series X Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance</a></td>
<td class="nump">5,242,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember', window );">Warrants for the purchase of common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance</a></td>
<td class="nump">1,530,380<span></span>
</td>
<td class="nump">1,032,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atxs_CommonStockOptionsOutstandingMember', window );">Options outstanding to purchase common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance</a></td>
<td class="nump">1,346,733<span></span>
</td>
<td class="nump">227,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atxs_CommonStockOptionsReservedMember', window );">Options available for future issuance to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance</a></td>
<td class="nump">1,633,736<span></span>
</td>
<td class="nump">322,695<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atxs_EmployeeStockPurchasePlan2015Member', window );">Shares reserved for the employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance</a></td>
<td class="nump">30,904<span></span>
</td>
<td class="nump">24,825<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atxs_SeriesXRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atxs_CommonStockOptionsOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atxs_CommonStockOptionsOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atxs_CommonStockOptionsReservedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atxs_CommonStockOptionsReservedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atxs_EmployeeStockPurchasePlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atxs_EmployeeStockPurchasePlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673394367208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Summary of Plans (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Cliff period for vesting</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673389314696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Stock option activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">227,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,156,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross', window );">Assumed in Quellis Acquisition (in shares)</a></td>
<td class="nump">55,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(10,470)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled or forfeited (in shares)</a></td>
<td class="num">(81,196)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(1,507)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">1,346,733<span></span>
</td>
<td class="nump">227,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and exercisable (in shares)</a></td>
<td class="nump">135,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning of period (in dollars per share)</a></td>
<td class="nump">$ 68.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">15.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageExercisePrice', window );">Assumed in Quellis Acquisition (in dollars per share)</a></td>
<td class="nump">1.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled or forfeited (in dollars per share)</a></td>
<td class="nump">48.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">100.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of year (in dollars per share)</a></td>
<td class="nump">22.25<span></span>
</td>
<td class="nump">$ 68.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and Exercisable (in dollars per share)</a></td>
<td class="nump">$ 72.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">9 years 7 days<span></span>
</td>
<td class="text">8 years 1 month 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and Exercisable</a></td>
<td class="text">7 years 2 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 168,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested and Exercisable</a></td>
<td class="nump">77,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 9.82<span></span>
</td>
<td class="nump">$ 3.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested stock option awards</a></td>
<td class="nump">$ 10,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average amortization period over which cost is expected to be recognized</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) assumed in acquisition during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise per share of share options assumed in acquisition during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673389277640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Stock-Based Compensation Expense (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to calculate fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to calculate fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted-average expected volatility</a></td>
<td class="nump">69.28%<span></span>
</td>
<td class="nump">75.51%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.42%<span></span>
</td>
<td class="nump">0.37%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to calculate fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted-average expected volatility</a></td>
<td class="nump">71.32%<span></span>
</td>
<td class="nump">82.08%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.36%<span></span>
</td>
<td class="nump">1.51%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673396114424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of the U.S. statutory income tax rate to the Company's effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax (benefit) at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Permanent differences</a></td>
<td class="num">(0.25%)<span></span>
</td>
<td class="num">(0.41%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Federal research and development credits and adjustments</a></td>
<td class="nump">0.44%<span></span>
</td>
<td class="nump">2.78%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Nondeductible research costs</a></td>
<td class="num">(17.75%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="nump">0.82%<span></span>
</td>
<td class="nump">6.03%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.01%<span></span>
</td>
<td class="nump">0.37%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(4.27%)<span></span>
</td>
<td class="num">(29.77%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673389040248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Deferred tax assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 75,849<span></span>
</td>
<td class="nump">$ 65,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness', window );">Tax credit carryforwards</a></td>
<td class="nump">10,063<span></span>
</td>
<td class="nump">9,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Capitalized research and development</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements', window );">Capitalized legal expenses</a></td>
<td class="nump">1,048<span></span>
</td>
<td class="nump">1,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other differences</a></td>
<td class="nump">1,977<span></span>
</td>
<td class="nump">1,648<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">89,175<span></span>
</td>
<td class="nump">78,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atxs_DeferredTaxLiabilitiesRightOfUseAsset', window );">ROU asset</a></td>
<td class="num">(107)<span></span>
</td>
<td class="num">(262)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(89,068)<span></span>
</td>
<td class="num">(77,868)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 11,200<span></span>
</td>
<td class="nump">$ 11,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atxs_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to right of use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atxs_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atxs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the estimated loss from legal settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673395026744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Operating Loss Carryforwards (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 279.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">8.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Tax Years 2023 through 2039</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">150.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | No expiration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">128.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">271.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Tax Years 2023 through 2039</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 271.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=atxs_TaxYears2023Through2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=atxs_TaxYears2023Through2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=atxs_IndefiniteTaxYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=atxs_IndefiniteTaxYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140673392452264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 28, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingSubleaseDescriptionAbstract', window );"><strong>Sublease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingSubleaseDescriptionAbstract', window );"><strong>Sublease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingSubleaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingSubleaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>atxs-20211231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:atxs="http://astria.com/20211231"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="atxs-20211231.xsd" xlink:type="simple"/>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_u1VQyUC_pkKu65bhuNk4jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_sf3s1jFkZ0aGtBYOQC3ukQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_atxs_WeightedAverageExpectedVolatilityMember_nIDhOwmhF0mlBky65Ot7_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">atxs:WeightedAverageExpectedVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_BS6PVDaxDkyvam1jdK_ZbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_Ts_1LVNTNk69yxGtcPF9Zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_atxs_WeightedAverageExpectedVolatilityMember_RP6DX7K3TUWlKsT4sun6pQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">atxs:WeightedAverageExpectedVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_Ulx_E0qOrUKkre8jvxb7rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_StatementScenarioAxis_atxs_WarrantsAssumedInMergerMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_iJkNUaamoUSxxm1X7f0uqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">atxs:WarrantsAssumedInMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_StatementScenarioAxis_atxs_SharesIssuedInMergerMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_VaYAgt65X062dsLicMLsSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">atxs:SharesIssuedInMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_StatementScenarioAxis_atxs_SharesIssuedIn2021FinancingMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_r3IXNsELnUOmAyLBZVInLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">atxs:SharesIssuedIn2021FinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_30_2020_To_1_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_UnderwritingPublicOffering2020Member__qJWTgwHU0y6BreieN-tEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:UnderwritingPublicOffering2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-30</startDate>
            <endDate>2020-01-30</endDate>
        </period>
    </context>
    <context id="Duration_1_30_2020_To_1_30_2020_srt_CounterpartyNameAxis_atxs_OppenheimerCo.IncMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_UnderwritingPublicOffering2020Member_ps7Jmy_qxEGruAZux02SWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atxs:OppenheimerCo.IncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:UnderwritingPublicOffering2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-30</startDate>
            <endDate>2020-01-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u8JhPH-1RUqa-roQlJ-Ngw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_19_2021_To_8_19_2021_8Dfl9PCzRU-S7OwH_sgU5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
        </entity>
        <period>
            <startDate>2021-08-19</startDate>
            <endDate>2021-08-19</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_m9ULvgi4IE-US35BpN7rWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__NFtVVnk7EGtmJVTvFdECA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VJIc1ZjzpUal4qapZMqgqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kD4Wl26uSEaueUAirWvXnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_N1dQ51RP6UuuD2JViSzVmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3YdF7rgdCkqzCRGFJN0xrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember_GQ8u_bZ2vk2rapCqnMoYiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_UnderwritingPublicOffering2020Member_c40JqESgcEiBixt1r0S-6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:UnderwritingPublicOffering2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Xk2KOEZoqU-rq0ONLV8kug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dRehDxBmQEyeX74Fi2n2Og">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember__jh8k2B4zk-VJ3ifpBRqMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pMusOm4pFUy12JHZQXtkNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_o2nWgMXB4EmLCnwUmgGn8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_30_2020_To_1_30_2020_us-gaap_SubsidiarySaleOfStockAxis_atxs_UnderwritingPublicOffering2020Member_AJ3obUkYbkW3WPPRYNkRqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:UnderwritingPublicOffering2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-30</startDate>
            <endDate>2020-01-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_NonredeemablePreferredStockMember_h2GakjGikkGGLKMSx_TpBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonredeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_NonredeemablePreferredStockMember_c0KfkkESqEyr8mt4ZudgVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonredeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_Bn4szbYkh0yrrFWsgmb0bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember_a9otGjsdyEWhX3Pzq_Pbxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">atxs:AgreementAndPlanOfMergerQuellisBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_jf1HFRlRWE2wdm5GzthVPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_atxs_PublicOfferingCommonStockAndWarrantsMember_S4V25J-LO0yw2cDuPVRuDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:PublicOfferingCommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember_FsZU2jcCL0ag97BH1_5Ixw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxPeriodAxis_atxs_TaxYears2023Through2039Member_PESuIbi88Em2aHygNgW-mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">atxs:TaxYears2023Through2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_atxs_TaxYears2023Through2039Member_nyPtDfbQzUmCkbPiwwfF7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">atxs:TaxYears2023Through2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_atxs_IndefiniteTaxYearsMember_lPRNGMy2XEaPTJLtd05Mcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">atxs:IndefiniteTaxYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_5XqYaukrUUaJdZ71ko0png">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_elNRkz91iE-s8vhvuVnSvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_28_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dDqegR-RH0S_9dr4Q4C-Mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-28</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2019_KyDCpKfGVkmxJYefd9nrVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xuUxeI6afE2LnVQerSEWkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_t8Fc6FbRA0iGWOKhF-GZew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember_hXCdIxgZCEKI8TXwJzmvOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atxs:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember__UO0W7ZwwECRTisRxchBwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atxs:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember_vZQWF0XPxEqvnvbV5-zrbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atxs:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember_xAFJqmrv7kOgE5MRCew76A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atxs:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_DpksmxD47kGvcyVVnTBAsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N1cnyjsfXUyGLlzflAry7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_phPEO_62_0ef87zim7j66g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember_U49V0Lt_9kyE9hrhO0s63A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atxs:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_FkRLjZQMv0avRCk8lVRJrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember_Cc8ygbB1FkS65q1Hq4bUmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">atxs:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_3t5AteWmBk6sQ6YdA-0C-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vK3sQCnrnUaOL4SPp0j-GA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VkwrOZo6Skee0mxwt5XNmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cNQZPiUZ_UeK1Pbzt5CTIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember_aICBK5MKZkuZVxp05YnVBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_EmployeeStockPurchasePlan2015Member_qvrFhdUehU6nDMNnX5A56A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:EmployeeStockPurchasePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_CommonStockOptionsReservedMember_wmV-DoZ1iEel9yGD2br-TA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:CommonStockOptionsReservedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_CommonStockOptionsOutstandingMember_7Vl-PK_cx0mTb1TT5TzDIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:CommonStockOptionsOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember_kmFzwlwoEUWBR8fU7IbkTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_EmployeeStockPurchasePlan2015Member_5SuvAJwIjkuX5pWVQNdilA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:EmployeeStockPurchasePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_CommonStockOptionsReservedMember_TAf-v0nKi0qS_WfrM_WRtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:CommonStockOptionsReservedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_CommonStockOptionsOutstandingMember_Yjog7Avv4UWNzFd78N6wtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:CommonStockOptionsOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_LGPUGn5hf0Wh2Qca8q1eow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_5FuYIQyMO0KrQWYAQrHRTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_atxs_WarrantsIssuedIn2021Member_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_yasr1KjcWk2xnQzdAy_KxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atxs:WarrantsIssuedIn2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_atxs_WarrantsIssuedIn2019Member_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_kZt19R6SjEmokrt5Mie7PA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atxs:WarrantsIssuedIn2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_atxs_WarrantsIssuedIn2018Member_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_-DDXhDsqjEaom3XeTK93Aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atxs:WarrantsIssuedIn2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_atxs_WarrantsIssuedIn2015Member_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_okImnMTN40m3e7LsnREh1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atxs:WarrantsIssuedIn2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_2_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BiFXZ622XUu96mNlkBimYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-02</instant>
        </period>
    </context>
    <context id="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_By6IRPDdpEuZ5F3lwOK5ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">atxs:AgreementAndPlanOfMergerQuellisBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-28</instant>
        </period>
    </context>
    <context id="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_uWtVDAckP0qWnkjhGrfdWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">atxs:AgreementAndPlanOfMergerQuellisBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-28</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_IIoZrvHZ90SylTKjxv1ZnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_rPxgg34LwEO0WW2sJngFGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_pkomaENPeEK2hWjtfDxw1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_kwexEh1NbUCeMgI-knFDkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_ADdWV8SUt0GFgLe1JLOiEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Ds6LSP_EK0qTg90-h5fSyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_nIJM4yXrw0GzaRxtnzccAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ar5rUSj2SE2rATotgrqFBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_OSaVkTaBE0adbR5AtRVk7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_EQBCa0WuakeegbdgZGvTIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_x-MiuZtIH0yax5u7pxoruw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_2fwTF9OAO0KdmBRB8Fzb2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_atxs_SeriesXPreferredStockMember_9HMukFq3bkmw6Lq9raeXDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atxs:SeriesXPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_atxs_CommonStockWarrantsMember_eZiUsBdsv0CpnkEmFJMYiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atxs:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_q91ttEudQ0mAGYdugRr9ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_atxs_CommonStockWarrantsMember_n7ERVEbeHkmVQE0vpdaYVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atxs:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9rTkA9cmjESbAdI_CIGCcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_P4mw2Fw8x0WkHCAyeJfKmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_CpiCowz5gUmCO8VqNzzcCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_8dpBZ3kAYkmlo-2evH5QBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ekfbhdx9h0WtXJ92zEMKrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2021_To_2_28_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_nDMEtpbiBUq1iy12eCKFQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_28_2021_To_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_yxGtZ11D_EqlCL7qM9oOug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">atxs:AgreementAndPlanOfMergerQuellisBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-28</startDate>
            <endDate>2021-01-28</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_pvhZzT4yNEGZB0AEHw1BHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_4_2022_KOiL2_gOU0--dFQOFVb1-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
        </entity>
        <period>
            <instant>2022-03-04</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_WeightedAverageMember_Q8_JfLkSZkujoq1ijmIZaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember_VoS4WBR9UkK6OOydZ60sAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">atxs:AgreementAndPlanOfMergerQuellisBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_28_2021_To_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_MBblrX_TzUq0Y8HTkRLDIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">atxs:AgreementAndPlanOfMergerQuellisBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-28</startDate>
            <endDate>2021-01-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2-DGee-q5EegQ2k0m7z03g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_atxs_JefferiesMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember_SsM7_C8YNk-Wd6_cC-Nh_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atxs:JefferiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember_BsZDsx3vsEuRWOxqvJFk-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zp2xevi_xEmHwwPp0gd3NQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_Q0-uw695P0e1UfMQTMe-mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_28_2021_To_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yGEdHdBZkEuZlEVGeuF7Gg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">atxs:AgreementAndPlanOfMergerQuellisBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-28</startDate>
            <endDate>2021-01-28</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_atxs_JefferiesMember_V_6BHty4gE2XeCiNbcgUQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atxs:JefferiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_uO-Pfxl910eVDz5-n8_42g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_DHwk8E2QikOhwrNFkk342g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_CollateralAxis_us-gaap_CollateralPledgedMember_us-gaap_InvestmentTypeAxis_atxs_ReverseRepurchaseAgreementsMember_eiP--rMiZU-1gbUFnuyFRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:CollateralPledgedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">atxs:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_InvestmentTypeAxis_atxs_ReverseRepurchaseAgreementsMember_aL_h_TEmN0mRrvtYQElzYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">atxs:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_30_2021_To_6_30_2021_srt_CounterpartyNameAxis_atxs_JefferiesMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember_oBnDRsRG00CrcvXjnale3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atxs:JefferiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-30</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mm2r7tKTwEKwrvs2FxtSqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atxs:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_srt_CounterpartyNameAxis_atxs_JefferiesMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember__zmdZLIxRES1KpnGo6-lqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atxs:JefferiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atxs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_stYiOzYUG0mKnmIJCrQu3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">atxs:AgreementAndPlanOfMergerQuellisBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-28</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001454789</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <unit id="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_series_lxqxSSbLPkuOU9DD2aDsAA">
        <measure>atxs:series</measure>
    </unit>
    <unit id="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_instrument_UhpnDIC4ZkS1xbkw5nvJeQ">
        <measure>atxs:instrument</measure>
    </unit>
    <unit id="Unit_Standard_segment_VaIUUonErEmKwL0Ka000VA">
        <measure>atxs:segment</measure>
    </unit>
    <unit id="Unit_Standard_item_r9qJ3cWOSk6WrNQbeKvS6w">
        <measure>atxs:item</measure>
    </unit>
    <unit id="Unit_Standard_Y_7dFwAQRg-k-TRf_n8MTBtg">
        <measure>atxs:Y</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      id="Hidden_juG4ut0hekGfoUSdZJmpGw"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      id="Hidden_tc6QGG0HtUmKZEu4MT14KA"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      id="Hidden_5kAH2yohTU6HuCucgbOHZw"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      id="Hidden_M6aGybrk0kCZ6fzfhotz1g"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ"
      xsi:nil="true"/>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      id="Hidden_Z8KsiGkTJUyr-8iQxbhdkw"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ"
      xsi:nil="true"/>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      id="Hidden_0JRGWDpqhUmL33rExGbsHA"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="2"
      id="Hidden_8asCuAWAkUShdS5MbDUCCQ"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">-24.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="2"
      id="Hidden_yKFj6vewikWA4NmcagA9rg"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">-12.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="0"
      id="Hidden_JnG-Fi9RzU2i2IWCBQbMGQ"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">8925173</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="0"
      id="Hidden_Aew1gIv4ckO-S3lSCxJoeA"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">3058578</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="INF"
      id="Hidden_0h6_9E_LE0OXUd1tw9ln2A"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">13016955</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww"
      decimals="INF"
      id="Hidden_EaPdklywJU--bluP72dbOw"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">31455</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="INF"
      id="Hidden_BLlqcGRUw0yW9_W_BgHGVA"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">3347386</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="INF"
      id="Hidden_28JKwy45H0aXmXOk1zkCAQ"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">13016955</us-gaap:CommonStockSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tc_CDu0k5ax3kKqXcnnJrfoCA_2_1">0001454789</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tc_86DV3SgFiEWJnuiyotif0g_3_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tc__45avv7UGUqaWv-qS9pxxQ_4_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tc_2W1VK_W7vE-aL1bEraS3kQ_5_1">false</dei:AmendmentFlag>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_11_30_2019_KyDCpKfGVkmxJYefd9nrVQ"
      decimals="-5"
      id="Hidden_HFiUTo3gw02FAUw2F3J6Qg"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Hidden_Q8KxfYwEQ06Q-XDWVRjAVA"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Hidden_h7pU9TMEukuhqRukKT1nSg"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Hidden_Spms05oTPUG_D656yLZ_hg"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_Bn4szbYkh0yrrFWsgmb0bw"
      decimals="INF"
      id="Hidden_olLejnU3yUWT4pjn9P3eRQ"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:StockholdersEquityNoteStockSplit
      contextRef="Duration_8_19_2021_To_8_19_2021_8Dfl9PCzRU-S7OwH_sgU5g"
      id="Hidden_dLw7GAoMFEC93XKwCZhThQ">0.1667</us-gaap:StockholdersEquityNoteStockSplit>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="INF"
      id="Hidden_CW-XStj-10mcG6SC9sfguw"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="INF"
      id="Hidden_POM-32zJNUucIU9QC11d1A"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">0</us-gaap:PreferredStockSharesOutstanding>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Narr_8tZKma1dPES08Lq9t0avuA">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tc_i_esSVN1ukOMQaCRNvjqRg_1_0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Narr_ia79y4Fs9EKelD3A1wnnsQ">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Narr_i4p9ZM1Tmk-BYF14Hsz4lw">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tc_g8c6GptXWU-6cPbOOErdqg_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Narr_u_3p1XSeG0qZL-3MBKIIwQ">001-37467</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Narr_Y-k60w7220Os08YYAx1glw">Astria Therapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tc__X3qYDZstk6t218MaiJ1NA_0_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tc_d5lqHRAqn0iirHjaG0pyHA_0_2">26-3687168</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Narr_3b_gbn9fEE6RA7MH3gZQbQ">100 High Street </dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Narr_2E5ZD2CV5EivTaUc8MrxBA">Floor 28</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Narr_-Awlm5ppOEusDZavmo03iw">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Narr_9iRiPmdoWUev0-kRNsEn0Q">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tc_ND8ZTFSOsk2HPxrY6HDGzQ_4_2">02110</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Narr_cknEF3aXmUmyvoS64O1GFg">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Narr_E7LOJv5h3k-hWquPhNZtHQ">349-1971</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tc_pkmf3q3dqUKgSwkiJQXhLA_3_0">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tc_AqbGliVgzk-GSP2trlcbNg_3_2">ATXS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Narr_N0pyATb2oU6xLSuLtbW-4A">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Narr_Sw5h8oiuX0GN_kwr4u4ltA">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Narr_nIBRPIcXIU-gYW6osmkmoA">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Narr__FsznA16XUaOdGM5v84bxQ">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Narr_noZzfUQwMku0E2Nk6L0W8g">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Narr_vNWHLWNFz0OIwvklw2SJBw">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Narr_QZFmNb5OjEO9M3OX4D8y9g">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Narr_N-1PHKfTaEKDFXDAnSkZgg">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Narr_W88Pw2ZlikeA6pKZ5l70CA">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Narr_u_2VGF5O10WpY7ZOiErj_A">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2021_pvhZzT4yNEGZB0AEHw1BHA"
      decimals="0"
      id="Narr_9T0qxuTTKk6SFgyFROQtOw"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">129863570</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_4_2022_KOiL2_gOU0--dFQOFVb1-A"
      decimals="INF"
      id="Narr_E-MJA07B006OQ4VAqJo7jQ"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">13016955</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Narr_MCCE0FylsUSMcDrwov5Ing">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Narr_03pRYAv_-E-zvMASyERCKw">Ernst&#160;&amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Narr_bVuGvl8DDkaz-7rqWaXlsA">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_8SklCD2Pbk28nq6G28nFxg_5_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">86508000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_SfPw4_SFwkqrxWnsksSGxg_5_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">24930000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_BwYHxPMpBUup-dv3GBjEHg_6_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">39000000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_D7tMGG-4Qkq068U4i6vkOg_6_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">20000000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_6gi7Jh1ziUSbUAbZwHUpGQ_7_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1567000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_iXx0RzSbkU6CChy8tscjkQ_7_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1395000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_Z_9t1O_7qUaCrkWk0QfntQ_8_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">127075000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_Wwk2G2ISd0OXMqZtGXrkng_8_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">46325000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_Y7YdnUV5iUmbGsXoQ6K8lw_9_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">394000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_zr-QKpxmo0mx-g8TbMczDQ_9_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">966000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_Y5P5B1hff0CT-GyUGA-4cw_10_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">45000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_tDa-L6E1o06K8LSmjYZv1Q_10_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">165000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_30OrE6_YlUmsn9xBGBtp2w_11_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">127514000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_cAZVlB53b0aN0cZle_nhEg_11_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">47456000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_wkJ6o3E6oEyfIwokCCkh_A_14_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1557000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_vsQzU1xYDE6g-vIByBex2w_14_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1544000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_lFiMHVtLEkuw5WdvZFioJQ_15_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">3281000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_3BHI5onhOEaGKFwBDsrkJg_15_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">4197000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_fvmexcAz8UuyfkU-x3WePw_16_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">365000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_FaYprY1FckGBEabTXn1x7w_16_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">649000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_np0RJv0KgUOL-nujAxnsGg_17_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">5203000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_08xyQzbZ3km1-RtStVcvSw_17_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">6390000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_sK146jJxr02P4w8b-G8Sjw_18_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">397000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_CZ4IJX1k_EyOeppZ0DIcaA_19_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">5203000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_Rk-lixB14kK9RpSeg5pzXQ_19_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">6787000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="INF"
      id="Narr_nKRKj1T3TUKfxsDgDsZLlg"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="INF"
      id="Narr_LT7fQGS6-Uqe1hKNX8rHPg"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_NonredeemablePreferredStockMember_c0KfkkESqEyr8mt4ZudgVg"
      decimals="INF"
      id="Narr_H_FjblRHiUCeom9e34GgOg"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">4908620</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_NonredeemablePreferredStockMember_h2GakjGikkGGLKMSx_TpBQ"
      decimals="INF"
      id="Narr_rLGxlpjoZEOV_O8TAp6IGg"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">4908620</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="INF"
      id="Narr_NgFRpMrXVk6aDc5Tlz7Xlw"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="INF"
      id="Narr_ZNhExe4CCki4ow62CFcTvw"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_Bn4szbYkh0yrrFWsgmb0bw"
      decimals="INF"
      id="Narr_8ZZWdHwMRkqW2CxitoJ2Mw"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww"
      decimals="INF"
      id="Narr__NmbzgfFcECPj_yUTbwccA"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_Bn4szbYkh0yrrFWsgmb0bw"
      decimals="INF"
      id="Narr_2tuszKKYY0WjL1-xnSNoFQ"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">91380</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww"
      decimals="INF"
      id="Narr_lsmcQuV3QEK6swr4RMiktA"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">91380</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww"
      decimals="INF"
      id="Narr_PTQ5NUjvQU66jn0XCZs8QA"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">31455</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_Bn4szbYkh0yrrFWsgmb0bw"
      decimals="INF"
      id="Narr_WsVXJ8wtU0yu2mo48nExnA"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww"
      decimals="-3"
      id="Tc_Y-3DJja1lEikWubbsJluvg_23_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">96398000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="INF"
      id="Narr_cKq37aKUUUyKCKG0qwznkQ"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="INF"
      id="Narr_VNIDz_M44EGdYacMwGRQLw"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="INF"
      id="Narr_Vg9zD-XNwkS0eURHz9Pi-g"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="INF"
      id="Narr_gzmldISqVEyDX-j3B4vpsg"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="INF"
      id="Narr_8qSO6XnBskCT9fZbtUX7gg"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">13016955</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="INF"
      id="Narr_4NUUlSW-j0S-EbEBa1jUpw"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">3347386</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_CPUIFNpYg06OyGko7Rqhxg_24_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">13000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_3HWJiLfUkEmbSeGEICk-jw_24_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_yKrb7B-X5EaSCYkH5E2Skg_25_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">481709000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_Fn2O_1wa5UOPFW7gy1hpTg_25_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">301562000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_ptVcob1pYEyvN3txKSRu1A_27_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-455809000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_ABjJj30NwkWnDSqd1QGvog_27_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-260897000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_1faM2BXhhE6Q-RR1JPffWw_28_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">122311000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_qI-GFEhHTUK3D_je3LZEfA_28_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">40669000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_GsZ07QBWmUGRIuKz5to3ZQ_29_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">127514000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_IcpTfSa_BEaS_GHGswgvvQ_29_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">47456000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_QRgZ7mXCF0uXNgdluRp9Fw_4_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">15552000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_hCT1Dd01Rk29OrgN3OBQng_4_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">25590000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_rMa50_FR70enpFpTaJ2c3w_5_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">14807000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_D4XcUtkTCkWo69sfYTQNIA_5_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">11845000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_UDNyzKYP9UOmOQKw0d1uWA_6_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">164617000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_mOYn3Y-f_062X6k4snIFhg_7_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">194976000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_Mpiev2xzXU-9K79xxJJAag_7_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">37435000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_0jYk4WwI5UOeBGghwyr2Mw_8_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-194976000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_ogyCpfpM9U6ZCeZx1IcBdw_8_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-37435000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_vtr_JNfMPEaSYH9KM0xG5w_10_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">122000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_ge23q-2oD0W7P1RXxqsb2A_10_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">236000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_Bwx8AjzB90yF3aMGuTpiJg_11_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-58000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_4c3W3QOHwkqdLm_Kz44BAg_11_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-101000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_ZLtREk79KkuQurNSd78wPg_12_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">64000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_JQXO9r25TkyiP67yAvoeFg_12_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">135000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_uIGxt2VNj0aP_xHa0jjIFQ_13_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-194912000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_-QivLC38WkmpYzbodX0x8Q_13_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-37300000</us-gaap:NetIncomeLoss>
    <atxs:DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_eBD-UgsPkEeUl4Z-FHK4xA_14_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">24437000</atxs:DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_ebymizkxHki5Ckt08mf97A_15_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-219349000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_D_xw5DwTakSTwVFq4b0rYw_15_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-37300000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="2"
      id="Tc_dXBdT-jPP02rz6cVjNOkmg_16_3"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">-24.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="2"
      id="Tc_msxw68r_Ik2eHgQl0eqsXQ_16_6"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">-12.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="0"
      id="Tc_v4FE-eP840e1O3yrafwGFw_17_3"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">8925173</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="0"
      id="Tc_nuRL9EypKU-EjlrFG2hjKQ_17_6"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">3058578</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_-P4ZQm3zSkaSxVHilxbxTQ_3_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-194912000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_gqCKgIj8206uxzaTjVFbkA_3_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-37300000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_F8gXkWZ1NEGDFxlAL_MJrw_5_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_jtjgUzGs8kmW45YqsCZdpw_5_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_FBqQOxCpkECbwh53bF1nPg_6_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_T-bd-Wvj9Em8nFdyuuu4lg_6_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_d3N2dRXhMEeJYbsECXMLpA_7_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-194912000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_w9HtmgYzOkixK2eakqeVKA_7_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-37300000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cNQZPiUZ_UeK1Pbzt5CTIg"
      decimals="INF"
      id="Tc_iM0EdfLpvkGeLi62u6KP4Q_4_8"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">2072266</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cNQZPiUZ_UeK1Pbzt5CTIg"
      decimals="-3"
      id="Tc_YTS2afuq4EuMi3MgRDDuSQ_4_11"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3YdF7rgdCkqzCRGFJN0xrQ"
      decimals="-3"
      id="Tc_xzR-f8pDkkiCHlZeJWohXQ_4_14"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">259315000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_N1dQ51RP6UuuD2JViSzVmw"
      decimals="-3"
      id="Tc_nzjKoVCNRkOLlfilb1wWBw_4_17"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-223597000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_IIoZrvHZ90SylTKjxv1ZnQ"
      decimals="-3"
      id="Tc_Z_mErjdq9Ealhh0CjBuPCw_4_23"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">35720000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_atxs_PublicOfferingCommonStockAndWarrantsMember_S4V25J-LO0yw2cDuPVRuDA"
      decimals="-5"
      id="Narr_5cI0MkgtekqWvrgGP5DQJA"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zp2xevi_xEmHwwPp0gd3NQ"
      decimals="INF"
      id="Tc_2r18L8EnRU-44Yy0ticvHA_5_8"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">881666</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zp2xevi_xEmHwwPp0gd3NQ"
      decimals="-3"
      id="Tc_shdWlvdCm0GB6OazWgALPg_5_11"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2-DGee-q5EegQ2k0m7z03g"
      decimals="-3"
      id="Tc_R9TSoYieAUSZZw-x2hnPtw_5_14"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">24558000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_TJ0QhMgbwE6lXAkoF8uwFQ_5_23"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">24559000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember_FsZU2jcCL0ag97BH1_5Ixw"
      decimals="-5"
      id="Narr_72wbelq5ykqUoRu8r1JDrw"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">500000</us-gaap:PaymentsOfStockIssuanceCosts>
    <atxs:StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zp2xevi_xEmHwwPp0gd3NQ"
      decimals="INF"
      id="Tc_leVB_jwHxkyxOdwmW0aTpA_6_8"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">392288</atxs:StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings>
    <atxs:StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2-DGee-q5EegQ2k0m7z03g"
      decimals="-3"
      id="Tc_3BdI1nVucE2nf1m_VR4kww_6_14"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">16268000</atxs:StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings>
    <atxs:StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_rv1W76V-UUecaN95z7_dSw_6_23"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">16268000</atxs:StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zp2xevi_xEmHwwPp0gd3NQ"
      decimals="INF"
      id="Tc_zL7SpuWGZEydqJM0lk4Fvg_7_8"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">1166</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zp2xevi_xEmHwwPp0gd3NQ"
      decimals="-3"
      id="Tc_saF8FfmIbUarjF-5KqsqwA_7_11"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2-DGee-q5EegQ2k0m7z03g"
      decimals="-3"
      id="Tc_JJL8wKDnr0m5tyw37im3qg_7_14"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">31000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_TXs8XHssN0uDk65KDt13XA_7_23"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">32000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2-DGee-q5EegQ2k0m7z03g"
      decimals="-3"
      id="Tc_2ZEac2x24067P_52e51YxQ_8_14"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1390000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_ObdJdvVIvkeXzmZt9q9oNw_8_23"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1390000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_t8Fc6FbRA0iGWOKhF-GZew"
      decimals="-3"
      id="Tc_NW81FoRTkk-2em_vD21r4w_9_17"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-37300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_P-oBIQrzkUygAdN1eYLy9Q_9_23"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-37300000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VkwrOZo6Skee0mxwt5XNmg"
      decimals="INF"
      id="Tc_boiMt74q30WpPFyW1477cA_10_8"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">3347386</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VkwrOZo6Skee0mxwt5XNmg"
      decimals="-3"
      id="Tc_3XrCVwYFXEmTcPUkc4bvuw_10_11"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kD4Wl26uSEaueUAirWvXnQ"
      decimals="-3"
      id="Tc_t6drCvPq8E-7LINBTnMWng_10_14"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">301562000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VJIc1ZjzpUal4qapZMqgqQ"
      decimals="-3"
      id="Tc_N7xvfAS-NEmuFs5hEccUaQ_10_17"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-260897000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_CuWBixH3yk6cj2Ykkcl6Zg_10_23"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">40669000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_jf1HFRlRWE2wdm5GzthVPQ"
      decimals="INF"
      id="Tc_U5if2hxUskW80GB4n80yIA_11_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">35573</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_jf1HFRlRWE2wdm5GzthVPQ"
      decimals="-3"
      id="Tc_GrXInVdWxE2LUBI2pcNkNA_11_5"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">84696000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ekfbhdx9h0WtXJ92zEMKrQ"
      decimals="-3"
      id="Tc_dcDADuXgdUaEKQ8rKCZJDA_11_14"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">19565000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_fZ0kZJ9CTkWNEc8ElFwe7Q_11_23"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">104261000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_jf1HFRlRWE2wdm5GzthVPQ"
      decimals="INF"
      id="Tc_bWWDdcc5C0yseXsT8tTmDQ_12_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">50504</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_jf1HFRlRWE2wdm5GzthVPQ"
      decimals="-3"
      id="Tc_tR-6L4vqlUu2nkHjHe4ymA_12_5"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">156185000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u8JhPH-1RUqa-roQlJ-Ngw"
      decimals="INF"
      id="Tc_p-asHhdwRUiAHl1fXFjsDQ_12_8"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">555444</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ekfbhdx9h0WtXJ92zEMKrQ"
      decimals="-3"
      id="Tc_TT1RpKNwrEST-DFxniOzSQ_12_14"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">8098000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_1PGvEuH4okmVlEq1Ujpfzw_12_23"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">164283000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_jf1HFRlRWE2wdm5GzthVPQ"
      decimals="INF"
      id="Tc_QeHjqhCnw0Sgh-QrJqcPiw_13_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">-54622</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_jf1HFRlRWE2wdm5GzthVPQ"
      decimals="-3"
      id="Tc_QgjLYI-pv0iFkkcS42hlvA_13_5"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-168920000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u8JhPH-1RUqa-roQlJ-Ngw"
      decimals="INF"
      id="Tc_0_ZIz4FJkEG-DA8ADAXxAg_13_8"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">9103664</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u8JhPH-1RUqa-roQlJ-Ngw"
      decimals="-3"
      id="Tc_4dzl5_BwtECydhwABeJ_fQ_13_11"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">9000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ekfbhdx9h0WtXJ92zEMKrQ"
      decimals="-3"
      id="Tc_zgJpIhBoS0SdXPE-QPJODw_13_14"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">168911000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ekfbhdx9h0WtXJ92zEMKrQ"
      decimals="-3"
      id="Tc_08AVlAGcPkuVcy0cbFPR0Q_14_14"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1157000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_KEbGNqzLHEuKyjVhSxa5CA_14_23"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1157000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:PreferredStockAccretionOfRedemptionDiscount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_jf1HFRlRWE2wdm5GzthVPQ"
      decimals="-3"
      id="Tc_yA5_kH2Pw02McNfT1jjLXQ_15_5"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-24437000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
    <us-gaap:PreferredStockAccretionOfRedemptionDiscount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ekfbhdx9h0WtXJ92zEMKrQ"
      decimals="-3"
      id="Tc_Ubth5HGxtUK12q2x2WUoPg_15_14"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">24437000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u8JhPH-1RUqa-roQlJ-Ngw"
      decimals="INF"
      id="Tc_fYEeaxYxu0i5EJTSykirLA_16_8"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">10470</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ekfbhdx9h0WtXJ92zEMKrQ"
      decimals="-3"
      id="Tc_njtipbpsc02h9IU1cCZMOg_16_14"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">23000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_fw3PwtniH0uFNHHh8_MyTg_16_23"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">23000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ekfbhdx9h0WtXJ92zEMKrQ"
      decimals="-3"
      id="Tc_foockEwQpU6QE7L7ztbEDA_17_14"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">3468000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_TdhySrQSekW65BISCTF-9Q_17_23"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">3468000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u8JhPH-1RUqa-roQlJ-Ngw"
      decimals="INF"
      id="Tc_k65bfwycvEymQcvrxJpSyg_18_8"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">-9</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ekfbhdx9h0WtXJ92zEMKrQ"
      decimals="-3"
      id="Tc_3e-uICOteU-RMQPvQ1ipgg_19_14"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">3362000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_bo8g_ueT6k6K9qGKWZSeXg_19_23"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">3362000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xuUxeI6afE2LnVQerSEWkg"
      decimals="-3"
      id="Tc_ENABGel5ckaCNZroE5ORJA_20_17"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-194912000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_Uok--MSZmUW1WTmbaXzcXQ_20_23"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-194912000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_3t5AteWmBk6sQ6YdA-0C-w"
      decimals="INF"
      id="Tc_anrkw_BYWEObKXucXGouHQ_21_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">31455</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_3t5AteWmBk6sQ6YdA-0C-w"
      decimals="-3"
      id="Tc_enBZh9zpP0a3DupZDJltwQ_21_5"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">96398000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vK3sQCnrnUaOL4SPp0j-GA"
      decimals="INF"
      id="Tc_afXn0AJ7eE6WQamZIQsr4Q_21_8"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">13016955</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vK3sQCnrnUaOL4SPp0j-GA"
      decimals="-3"
      id="Tc_MKWL0-WHikGwRTomVEl_Zw_21_11"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__NFtVVnk7EGtmJVTvFdECA"
      decimals="-3"
      id="Tc_v3mMpOv1D0GZYPVOapepcg_21_14"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">481709000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_m9ULvgi4IE-US35BpN7rWA"
      decimals="-3"
      id="Tc_uDb65a6B6kCYnHAmuvUOXQ_21_17"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-455809000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_8sL4AkZUX0O7gPohPXldew_21_23"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">122311000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_-JgXfnqG7US_fm3F0e0eTw_4_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-194912000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_mOTs1mpWH0Kt4dqT-pMR0A_4_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-37300000</us-gaap:ProfitLoss>
    <atxs:NonCashPortionOfAcquiredResearchAndDevelopment
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_qd5FTp6vmkubrzpjfZAmTg_6_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">164612000</atxs:NonCashPortionOfAcquiredResearchAndDevelopment>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_OJPnER9C7E2MwSa9TV3dqA_7_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">3362000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_GHQwHp716kmuBYoP1-RQjQ_7_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1390000</us-gaap:ShareBasedCompensation>
    <atxs:GainLossOnWarrantInherited
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_vl8wdIKjbk2DVcZLr0oLqA_8_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">71000</atxs:GainLossOnWarrantInherited>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_QaQ2-eZwrk6z8IsP7tli3g_9_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-21000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_aoR8905VVUOj1UAKbERtSQ_9_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-58000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_fFzycP32XUisroI7BWzFuw_11_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-85000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_8d00lj2oI0GzovVmQoZGiA_11_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-1257000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <atxs:IncreaseDecreaseInRightOfUseAssetOperating
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_oaOkpsOTIki_4TZ8Um-hUA_12_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-109000</atxs:IncreaseDecreaseInRightOfUseAssetOperating>
    <atxs:IncreaseDecreaseInRightOfUseAssetOperating
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc__Wlvs1w6kUaT-sdlaDgByw_12_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">176000</atxs:IncreaseDecreaseInRightOfUseAssetOperating>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_MroKQyMscUOJKIeDhyLgQw_13_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-1965000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_awgXwsPWeUi5eyR3YRF3-g_13_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">347000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_57Fx8xDnpEW3FMZPvVsTrg_14_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-1316000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_CqyXMNy870q_2YN0QO3_qA_14_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1587000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_-gKQBFoqxUO4dcVfxPwKQA_15_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-30151000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_6Z2OMKATs0yz2jABtoi28Q_15_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-32485000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_5FBnl1fX0EOcrgJM2SqaIg_17_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">78000000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_JUPSMeRN00-hQrhgPS1Jnw_17_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">62777000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_9JrlSEGxoUOkQk3UL9BE9w_18_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">59000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_8K0Ar24DE0C1vgDoUxpAAQ_18_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">69110000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc__k28kJONs0CJav6d7zEXIQ_19_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">6466000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_qKYdE-TqcE6UNlAi9wbVLQ_20_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">21000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_SYdzmOS9pketve1Bb8VWig_20_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">33000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_6gbu7frBW0qOjOpmHb_a5w_21_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-12555000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_37t2EAd15k2Fyp_r44wwBQ_21_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">6300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_lUfcMDXe70Ci-uB_0496_A_23_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">24559000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_TDIPq0he1EyRZwE4ThAT9Q_24_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">104261000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <atxs:ProceedsFromIssuanceOfAtMarketOffering
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_ewL8w1z7e06L6oVYU7eDDw_25_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">16270000</atxs:ProceedsFromIssuanceOfAtMarketOffering>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_UNLH3EDSLEmN1OFEuOGy3g_26_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">23000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_51zeycRB8UqQCQ1jklhd7Q_26_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">31000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_3jyHuRrS-0WAgT9dPyfmsQ_27_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">104284000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_wD1Gj5m5DkyoJ-nJVLf2Ww_27_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">40860000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_EqOTzhM36Uujl839b1C5jQ_28_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">61578000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_8stb1wmju0ilbi9RGxHcQA_28_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">14675000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_5k_0sYvK70a4k0O1mrsJyg_29_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">25051000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_IIoZrvHZ90SylTKjxv1ZnQ"
      decimals="-3"
      id="Tc_z-sK_YQK8UKLY5ixhVQsbA_29_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">10376000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_FQ1i6NrQBUyJEVlVC4B5uw_30_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">86629000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_GpQL-z4jGkC2Zbwd7vcomA_30_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">25051000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_wzKnysDu8EOSbjvoGKNuRQ_32_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">168920000</us-gaap:ConversionOfStockAmountConverted1>
    <atxs:DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_7EJCQjgS30OVV_HH3UvCtg_33_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">24437000</atxs:DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts>
    <atxs:ReclassificationOfEquityClassifiedWarrants
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_j84Gx0lF5U6JsTu6q8RYFQ_34_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">3468000</atxs:ReclassificationOfEquityClassifiedWarrants>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_omThe7HkL0iPjuyHVr0WGQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Times New Roman Bold';font-weight:bold;"&gt;Astria Therapeutics, Inc.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-family:'Times New Roman Bold';font-weight:bold;"&gt;Notes to Consolidated Financial Statements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1.&lt;/b&gt;&#160;&#160;&#160;&#160;&lt;b style="font-weight:bold;"&gt;Organization and Operations&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;The Company&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Astria Therapeutics, Inc. (the &#x201c;Company&#x201d;), formerly known as Catabasis Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics. Its mission is to bring hope with life-changing therapies to patients and families that are affected by rare and niche allergic and immunological diseases. On October 26, 2020, the Company announced that the Phase 3 PolarisDMD trial of the Company&#x2019;s previous lead product candidate, edasalonexent, for the treatment of Duchenne Muscular Dystrophy (&#x201c;DMD&#x201d;) did not meet its primary and secondary endpoints. Based on these results, the Company announced that it was stopping activities related to the development of edasalonexent, including the Company&#x2019;s ongoing open-label extension trial. On January 28, 2021, the Company acquired Quellis Biosciences, Inc. (&#x201c;Quellis&#x201d;). The Company&#x2019;s lead product candidate, which was acquired in the Quellis acquisition, is STAR-0215 (formerly known as QLS-215), a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema, or HAE, a rare, debilitating and potentially life-threatening disease. The Company was incorporated in the State of Delaware on June 26, 2008.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;On August 19, 2021, the Company effected a reverse stock split of its outstanding shares of common stock at a ratio of &lt;span style="-sec-ix-hidden:Hidden_dLw7GAoMFEC93XKwCZhThQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;-for-six (1:6) pursuant to a Certificate of Amendment to its Certificate of Incorporation filed with the Secretary of State of the State of Delaware. Pursuant to the reverse stock split, every six shares of the Company&#x2019;s issued and outstanding shares of common stock were automatically combined into one issued and outstanding share of common stock, without any change in the par value per share of the common stock. Amounts of common stock resulting from the reverse stock split were rounded down to the nearest whole share and any resulting fractional shares were cancelled for cash. The number of authorized shares of the Company&#x2019;s common stock remained unchanged. The reverse stock split affected all issued and outstanding shares of the Company&#x2019;s common stock, and the respective numbers of shares of common stock underlying the Company&#x2019;s outstanding Series X Preferred Stock, outstanding stock options, outstanding warrants and the Company&#x2019;s equity incentive plans were proportionately adjusted. All share and per share amounts of the common stock included in the accompanying consolidated financial statements have been retrospectively adjusted to give effect to the reverse stock split for all periods presented, including reclassifying an amount equal to the reduction in par value to additional paid-in capital.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:6pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Agreement and Plan of Merger&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;On January 28, 2021, the Company acquired Quellis (the &#x201c;Quellis Acquisition&#x201d;). &#160;Under the terms of that certain agreement and plan of merger, dated January 28, 2021 (the &#x201c;Merger Agreement&#x201d;), the Company issued to the stockholders of Quellis 555,444 shares of the Company&#x2019;s common stock, par value $0.001 per share, and 50,504 shares of newly designated Series X redeemable convertible preferred stock (&#x201c;Series X Preferred Stock&#x201d;) (as described below). The Series X Preferred Stock had a conversion value on the closing date of $122.7 million. In addition, the Company assumed options granted under the Quellis stock option plan, which became options to purchase 55,414 shares of the Company&#x2019;s common stock, a warrant to purchase 2,805 shares of Series X Preferred Stock at an exercise price of $341.70 per share, and a warrant to purchase 30,856 shares of the Company&#x2019;s common stock at an exercise price of $2.10 per share, which warrants are exercisable until December 14, 2030. Upon stockholder approval of the Conversion Proposal (as defined below) on June 2, 2021, the warrant to purchase Series X Preferred Stock was converted into the right to purchase 467,500 shares of the Company&#x2019;s common stock, at a per share exercise price of $2.10 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:6pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock Purchase Agreement and Series X Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Concurrent with the Quellis Acquisition, the Company entered into a Stock Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with certain institutional and accredited investors. Pursuant to the Purchase Agreement, the Company sold an aggregate of 35,573 shares of Series X Preferred Stock for gross proceeds of approximately $110.0 million, and net proceeds of $104.3 million (the &#x201c;February 2021 Financing&#x201d;). Each share of Series X Preferred Stock is convertible into &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;166.67 shares of common stock. In accounting for the Purchase Agreement, the Company recorded a beneficial conversion feature of $19.6 million and issuance costs of $5.7 million. The combined total was treated as a discount to the value of Series X Preferred Stock, See Note 2 &#x2013; &#x201c;Summary of Significant Accounting Policies&#x201d; for further discussion. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;As a result of the Quellis Acquisition and the February 2021 Financing, the Company issued the following Series X Preferred Stock or warrants to purchase Series X Preferred Stock:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series&#160;X&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;Preferred&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Transaction&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Shares issued in merger&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,504&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Shares issued in February 2021 Financing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,573&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Warrants assumed in merger&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,805&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88,882&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;At its 2021 Annual Meeting of Stockholders on June 2, 2021, the Company&#x2019;s stockholders approved the conversion of the Company&#x2019;s Series X Preferred Stock into shares of the Company&#x2019;s common stock in accordance with Nasdaq Listing Rule 5635(a) (the &#x201c;Conversion Proposal&#x201d;). Following stockholder approval of the Conversion Proposal, each share of Series X Preferred Stock then outstanding automatically converted into 166.67 shares of the Company&#x2019;s common stock, subject to certain beneficial ownership limitations, including that a holder of Series X Preferred Stock is prohibited from converting shares of Series X Preferred Stock into shares of the Company&#x2019;s common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (as of December 31, 2021, these percentages are set at 4.99% to 9.99% and can be adjusted by the holder to a number between 4.99% and 19.99%) of the total number of shares of the Company&#x2019;s common stock issued and outstanding immediately after giving effect to such conversion. As of December 31, 2021, 54,622 shares of Series X Preferred Stock were converted into 9,103,664 shares of common stock and 31,455 shares of Series X Preferred Stock remained outstanding. Each share of Series X Preferred Stock is convertible into 166.67 shares of common stock. At December 31, 2021, the number of shares of common stock issuable upon conversion of the remaining outstanding shares of Series X Preferred Stock is 5,242,501. Outstanding shares of Series X Preferred Stock are subject to conversion at the option of the holder.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Prior to stockholder approval of the Conversion Proposal, the terms of the Series X Preferred Stock included a cash redemption feature. This cash redemption feature resulted in substantial doubt about the Company&#x2019;s ability to continue as a going concern as disclosed in the Company&#x2019;s annual report on Form 10-K for the year ended December 31, 2020 (the &#x201c;2020 Annual Report on Form 10-K&#x201d;). Upon stockholder approval of the Conversion Proposal, the cash redemption feature was eliminated and, consequently, there is no longer substantial doubt about the Company&#x2019;s ability to continue as a going concern for at least twelve months subsequent to the issuance of these financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Holders of Series X Preferred Stock are entitled to receive dividends, subject to certain beneficial ownership limitations, on shares of Series X Preferred Stock equal, on an as-if-converted-to-common-stock basis, and in the same form as dividends actually paid on shares of the Company&#x2019;s common stock. Except as otherwise required by law, the Series X Preferred Stock does not have voting rights. However, as long as any shares of Series X Preferred Stock are outstanding, the Company may not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series X Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to the Series X Preferred Stock or alter or amend the Certificate of Designation that authorized the Series X Preferred Stock, amend or repeal any provision of, or add any provision to, the Company&#x2019;s Certificate of Incorporation or bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of preferred stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series X Preferred Stock, (ii) issue further shares of Series X Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series X Preferred Stock, or (iii) enter into any agreement with respect to any of the foregoing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;January 2020 Financing&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;On January 30, 2020, the Company entered into an underwriting agreement with Oppenheimer &amp;amp; Co. Inc. relating to an underwritten public offering (the &#x201c;January 2020 Financing&#x201d;) of 881,666 shares of common stock at a price to the public of $30.00 per share, including 115,000 shares issued upon the exercise in full by Oppenheimer &amp;amp; Co. Inc. of its overallotment option. This resulted in gross proceeds of $26.5 million, and net proceeds of $24.6 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company has entered into various sales agreements with Cowen and Company LLC (&#x201c;Cowen&#x201d;), pursuant to which the Company could issue and sell shares of common stock under at-the-market offering programs. On May 20, 2021, the Company terminated its sales agreement with Cowen. On June 30, 2021, the Company entered into an Open Market Sale Agreement&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; with Jefferies LLC (&#x201c;Jefferies&#x201d;), pursuant to which the Company can issue and sell shares of common stock of up to $25.0 million under at-the-market offering programs (collectively, with the Cowen at-the-market offering program, the &#x201c;ATM Programs&#x201d;). The Company pays the sales agent commissions of 3% of the gross proceeds from any common stock sold through the ATM Programs. As of December 31, 2021, the Company has not sold any shares of common stock pursuant to the Jefferies agreement and, as a result, $25.0 million of common stock remains available for sale under the Jefferies agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;During the year ended December 31, 2020, the Company sold an aggregate of 392,288 shares of common stock pursuant to the ATM Programs, at an average price of $42.76 per share, for net proceeds of $16.3 million after deducting sales commissions and offering expenses. There was no activity from the ATM Programs during the year ended December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;As of December 31, 2021, the Company had an accumulated deficit of $455.8 million and had available cash, cash equivalents and short-term investments $125.5 million. The Company has been primarily involved with research and development activities and has incurred operating losses and negative cash flows from operations since its inception. The Company has not generated any product revenues and has financed its operations primarily through public offerings and private placements of its equity securities. There can be no assurance that the Company will be able to obtain additional debt, equity or other financing or generate product revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company&#x2019;s business, results of operations, and financial condition.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company is subject to a number of risks similar to other life science companies, including, but not limited to, successful discovery and development of its drug candidates, raising additional capital, development by its competitors of new technological innovations, protection of proprietary technology and regulatory approval and market acceptance of the Company&#x2019;s products. The Company has been primarily involved with research and development activities and has incurred operating losses and negative cash flows from operations since its inception. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="Duration_1_28_2021_To_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yGEdHdBZkEuZlEVGeuF7Gg"
      decimals="INF"
      id="Narr_cF-apuP8qk2wQCZ5iJ2jqA"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">555444</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_By6IRPDdpEuZ5F3lwOK5ig"
      decimals="INF"
      id="Narr_FILZA6BnHEWa-kW85NPNnA"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <atxs:TemporaryEquityStockIssuedInAcquisitionSharesNewIssues
      contextRef="Duration_1_28_2021_To_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_MBblrX_TzUq0Y8HTkRLDIA"
      decimals="INF"
      id="Narr_skVMU9iyr0uc-8HLZX-Iww"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">50504</atxs:TemporaryEquityStockIssuedInAcquisitionSharesNewIssues>
    <atxs:TemporaryEquityConversionValue
      contextRef="Duration_1_28_2021_To_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_MBblrX_TzUq0Y8HTkRLDIA"
      decimals="-5"
      id="Narr_uymKsIOe5kOGwXyppKEyLw"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">122700000</atxs:TemporaryEquityConversionValue>
    <atxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross
      contextRef="Duration_1_28_2021_To_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yGEdHdBZkEuZlEVGeuF7Gg"
      decimals="INF"
      id="Narr_GHTODk-Yr0Gi73QnRbi3Wg"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">55414</atxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_uWtVDAckP0qWnkjhGrfdWg"
      decimals="INF"
      id="Narr_dj-Z-zs4KEaJsO5dcwRwpg"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">2805</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_uWtVDAckP0qWnkjhGrfdWg"
      decimals="2"
      id="Narr_KdSlEYlBkk6oh9JkNhGiJQ"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">341.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_By6IRPDdpEuZ5F3lwOK5ig"
      decimals="INF"
      id="Narr_UrYtbt85A0SkGfe71B1ZQg"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">30856</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_By6IRPDdpEuZ5F3lwOK5ig"
      decimals="2"
      id="Narr_wJhTyXWopE6Qn85bPc-3Zw"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">2.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_6_2_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BiFXZ622XUu96mNlkBimYA"
      decimals="INF"
      id="Narr_4qrEwP84002O8zWIFd0_OA"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">467500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_2_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BiFXZ622XUu96mNlkBimYA"
      decimals="2"
      id="Narr__qfE3knn30mCmGjeVDAJFA"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">2.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <atxs:TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember_VoS4WBR9UkK6OOydZ60sAw"
      decimals="INF"
      id="Narr_meOgCrIHGkmLyo0ZnRlvNw"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">35573</atxs:TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodSharesNewIssues>
    <atxs:TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodGrossValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember_VoS4WBR9UkK6OOydZ60sAw"
      decimals="-5"
      id="Narr_EORrffLbHEeI4K6bz6AGgw"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">110000000.0</atxs:TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodGrossValue>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember_VoS4WBR9UkK6OOydZ60sAw"
      decimals="-5"
      id="Narr_x-ifgQsUP0muqCLrlWSfgw"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">104300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_12_31_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember_a9otGjsdyEWhX3Pzq_Pbxw"
      decimals="2"
      id="Narr_DsFRiYw_SUiZxRlhFaVZTw"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">166.67</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember_VoS4WBR9UkK6OOydZ60sAw"
      decimals="-5"
      id="Narr_MRamrd18J0uMFNvSwLqABQ"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">19600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember_VoS4WBR9UkK6OOydZ60sAw"
      decimals="-5"
      id="Narr_36BL7ys9dUujIT1WZsHv8g"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">5700000</us-gaap:PaymentsOfStockIssuanceCosts>
    <atxs:ScheduleOfPreferredStockOrWarrantsToPurchasePreferredStockTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_b0LO9163dEuJX_aNe2qHAA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series&#160;X&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;Preferred&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Transaction&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Shares issued in merger&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,504&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Shares issued in February 2021 Financing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,573&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Warrants assumed in merger&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,805&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88,882&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</atxs:ScheduleOfPreferredStockOrWarrantsToPurchasePreferredStockTableTextBlock>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_srt_StatementScenarioAxis_atxs_SharesIssuedInMergerMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_VaYAgt65X062dsLicMLsSw"
      decimals="INF"
      id="Tc_RC1_ER7vG0WT-LtXJZb1dw_6_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">50504</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_srt_StatementScenarioAxis_atxs_SharesIssuedIn2021FinancingMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_r3IXNsELnUOmAyLBZVInLA"
      decimals="INF"
      id="Tc_ht-QvX50wE-wf5Ftw2f7Rw_7_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">35573</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_srt_StatementScenarioAxis_atxs_WarrantsAssumedInMergerMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_iJkNUaamoUSxxm1X7f0uqw"
      decimals="INF"
      id="Tc_gCVrFOdQYEm9xUuFJ9ZgUg_8_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">2805</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww"
      decimals="INF"
      id="Tc_B02xcma4s0GpSFOo6RCOQA_9_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">88882</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww"
      decimals="2"
      id="Narr_CrmQNCtCOEK5xAJRMPfW-w"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">166.67</us-gaap:PreferredStockConvertibleConversionRatio>
    <atxs:PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_uO-Pfxl910eVDz5-n8_42g"
      decimals="4"
      id="Narr_KlWtm--hFES-zc66Oikq_w"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.0499</atxs:PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially>
    <atxs:PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_DHwk8E2QikOhwrNFkk342g"
      decimals="4"
      id="Narr_nqrIficQ1kydrcOHXgrNeQ"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.0999</atxs:PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially>
    <atxs:PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_uO-Pfxl910eVDz5-n8_42g"
      decimals="4"
      id="Narr_FsKh0P7drkqwZKgfPOFWjQ"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.0499</atxs:PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter>
    <atxs:PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_DHwk8E2QikOhwrNFkk342g"
      decimals="4"
      id="Narr_LjThl_ir_UOkRkTAqs5FLQ"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.1999</atxs:PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter>
    <atxs:StockIssuedDuringPeriodSharesIncreaseDecreaseDueToConversionOfPreferredSharesIntoCommonShares
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_Q0-uw695P0e1UfMQTMe-mg"
      decimals="INF"
      id="Narr_Mx_iXg5irUKNHwrzPVlgIA"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">54622</atxs:StockIssuedDuringPeriodSharesIncreaseDecreaseDueToConversionOfPreferredSharesIntoCommonShares>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_Q0-uw695P0e1UfMQTMe-mg"
      decimals="INF"
      id="Narr_dhyRg_UTDkCOSAD9eyQQgQ"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">9103664</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww"
      decimals="INF"
      id="Narr_fDgNXeQj8kyyxA794AuKXQ"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">31455</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww"
      decimals="2"
      id="Narr_eNMA6ngkX0KGxkjxXQSUPg"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">166.67</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww"
      decimals="INF"
      id="Narr_D8qkl3qj1068AqMtqB5kNQ"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">5242501</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_30_2020_To_1_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_UnderwritingPublicOffering2020Member__qJWTgwHU0y6BreieN-tEA"
      decimals="INF"
      id="Narr_ME42qQhStUWK4xCwOqRJhg"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">881666</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_1_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_UnderwritingPublicOffering2020Member_c40JqESgcEiBixt1r0S-6w"
      decimals="2"
      id="Narr_-Q2blSzO-Ea5cCPJ2G2D4A"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">30.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_30_2020_To_1_30_2020_srt_CounterpartyNameAxis_atxs_OppenheimerCo.IncMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_UnderwritingPublicOffering2020Member_ps7Jmy_qxEGruAZux02SWA"
      decimals="INF"
      id="Narr_ieNYXzWoNUeadRwl5GhGIA"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">115000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_1_30_2020_To_1_30_2020_us-gaap_SubsidiarySaleOfStockAxis_atxs_UnderwritingPublicOffering2020Member_AJ3obUkYbkW3WPPRYNkRqg"
      decimals="-5"
      id="Narr_ssdR-fS3XEamBSWmsbF2Tw"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">26500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_30_2020_To_1_30_2020_us-gaap_SubsidiarySaleOfStockAxis_atxs_UnderwritingPublicOffering2020Member_AJ3obUkYbkW3WPPRYNkRqg"
      decimals="-5"
      id="Narr_gE57oynMOkmInEMDYTSP-A"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">24600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <atxs:CommonStockSaleAgreementValue
      contextRef="As_Of_6_30_2021_srt_CounterpartyNameAxis_atxs_JefferiesMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember__zmdZLIxRES1KpnGo6-lqg"
      decimals="-5"
      id="Narr_yoSW5gQgbkCtAmn_hy3qOQ"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">25000000.0</atxs:CommonStockSaleAgreementValue>
    <atxs:PercentageOfCommissionPaidToUnderwriterBasedOnProceedsFromOffering
      contextRef="Duration_6_30_2021_To_6_30_2021_srt_CounterpartyNameAxis_atxs_JefferiesMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember_oBnDRsRG00CrcvXjnale3w"
      decimals="INF"
      id="Narr_PnT4nyjsUUiOuc9Lrx63bQ"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.03</atxs:PercentageOfCommissionPaidToUnderwriterBasedOnProceedsFromOffering>
    <atxs:StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_atxs_JefferiesMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember_SsM7_C8YNk-Wd6_cC-Nh_w"
      decimals="0"
      id="Narr_SMCw0KLcZUKx1sBODcB6ow"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">0</atxs:StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings>
    <atxs:RemainingAvailableUnderCurrentSalesAgreement
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_atxs_JefferiesMember_V_6BHty4gE2XeCiNbcgUQg"
      decimals="-5"
      id="Narr_w24dkpw46USzFqXTkKGD2w"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">25000000.0</atxs:RemainingAvailableUnderCurrentSalesAgreement>
    <atxs:StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember_BsZDsx3vsEuRWOxqvJFk-g"
      decimals="INF"
      id="Narr_a4SbFcW6ekW-x0c12dLjlQ"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">392288</atxs:StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember_GQ8u_bZ2vk2rapCqnMoYiQ"
      decimals="2"
      id="Narr_k1USilPPaUCCn9Qmgfrsbg"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">42.76</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_atxs_AtMarketOfferingMember_BsZDsx3vsEuRWOxqvJFk-g"
      decimals="-5"
      id="Narr_i_k2IgrWDkeOL__GxTmrSQ"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">16300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-5"
      id="Narr_J3U-Xzs3BkWpCekbvK7eGw"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-455800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-5"
      id="Narr_Dsvw2oLR1UaOJ6_mD9eXrg"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">125500000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_XNOl5AW4M0S-sbmIjF14kg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2. &#160;&#160;&#160;Summary of Significant Accounting Policies&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Astria Securities Corporation and Quellis Biosciences, LLC, successor in interest to Quellis. All intercompany balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;U.S.&#160;GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented.&#160;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company utilizes certain estimates to record expenses relating to research and development contracts. These contract estimates, which are primarily related to the length of service of each contract and the amount of service provided as of each measurement date, are determined by the Company based on input from internal project management, as well as from service providers.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Off-Balance Sheet Risk and Concentrations of Credit Risk &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company has no off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements. Financial instruments that subject the Company to credit risk primarily consist of cash, cash equivalents, short-term investments and restricted cash. The primary objectives for the Company&#x2019;s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company&#x2019;s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The reconciliation of cash, cash equivalents and restricted cash reported within the applicable balance sheet that sum to the total of the same such amount shown in the statement of cash flows is as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 86,508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,930&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Restricted cash (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 121&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 86,629&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,051&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-left:46.8pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:46.8pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Included in prepaid expenses and other current assets at December 31, 2021 and other long-term assets at December 31, 2020.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Short-Term Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company classifies all corporate debt securities with a remaining maturity of greater than three months and reverse repurchase agreements with a remaining maturity of greater than one business day at the time of purchase as short-term investments. Short-term investments are recorded at fair value, with the unrealized gains and losses reported in other comprehensive loss. The amortized cost of debt securities is adjusted for the amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest and investment income. Realized gains and losses, interest, dividends and declines in value judged to be other-than-temporary are included in interest and investment income. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The cost of securities sold is based on the specific identification method for purposes of recording realized gains and losses. To determine whether an other-than-temporary impairment exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the investment outweighs evidence to the contrary. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three broad levels as follows: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3 inputs are unobservable inputs that reflect the Company&#x2019;s own assumptions about the assumptions &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The carrying amounts reflected in the balance sheets for cash equivalents, restricted cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values at December 31, 2021 and 2020, due to their short-term nature. There have been no changes to the valuation methods during the years ended December 31, 2021 and 2020. The Company evaluates transfers between levels at the end of each reporting period. There were no &lt;span style="-sec-ix-hidden:Hidden_Q8KxfYwEQ06Q-XDWVRjAVA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;transfers&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_h7pU9TMEukuhqRukKT1nSg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;of&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_Spms05oTPUG_D656yLZ_hg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;assets&lt;/span&gt;&lt;/span&gt; or liabilities between levels during the years ended December 31, 2021 and 2020. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s investment portfolio may include fixed income securities that do not always trade on a daily basis. As a result, the pricing services used by the Company apply other available information as applicable through processes such as benchmark yields, benchmarking of like securities, sector groupings and matrix pricing to prepare valuations. The Company validates the prices provided by its third party pricing services by obtaining market values from other pricing sources and analyzing pricing data in certain instances. The Company also invests in certain reverse repurchase agreements which are collateralized by deposits in the form of United States Government Securities and Obligations for an amount no less than 102% of their value. The Company does not record an asset or liability for the collateral as the Company is not permitted to sell or re-pledge the collateral. The collateral has at least the prevailing credit rating of United States Government Treasuries and Agencies. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the reverse repurchase agreements on a daily basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company accounted for warrants to purchase its stock pursuant to Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 470, Debt, and ASC Topic 480, Distinguishing Liabilities from Equity, and classifies warrants for common stock and preferred stock as liabilities or equity. The warrants classified as liabilities are reported at their estimated fair value and any changes in fair value are reflected in research and development expense. The warrants classified as equity are reported at their estimated fair value with no subsequent remeasurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. The Company has not recognized any significant impairment charges from inception through December&#160;31, 2021. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development Expenses &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Research and development costs are expensed as incurred. Research and development costs include salaries and personnel-related costs, stock-based compensation, consulting fees, fees paid for contract research services, the costs of laboratory equipment and facilities and other external costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred. The deferred amounts are expensed as the related goods are delivered or the services are performed. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company accounts for its stock-based compensation awards in accordance with ASC Topic&#160;718, &lt;i style="font-style:italic;"&gt;Compensation&#x2014;Stock Compensation (&lt;/i&gt;&#x201c;ASC&#160;718&#x201d;). ASC&#160;718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statements of operations based on their grant date fair values. For granted stock options, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model.&#160; The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Company&#x2019;s common stock consistent with the expected term of the option, risk-free interest rates and expected dividend yields of the Company&#x2019;s common stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;For awards subject to service-based vesting conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company expenses restricted stock awards based on the fair value of the award on a straight-line basis over the associated service period of the award. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;During the years ended December 31, 2021 and 2020, the Company recorded stock-based compensation expense for employee and non-employee stock options and restricted stock, which was allocated as follows in the statements of operations (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,132&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 599&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,230&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 791&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,390&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;No related tax benefits were recognized for the years ended December 31, 2021 and 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Net Loss Per Share &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Basic net loss per share is calculated by dividing net loss by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the Company&#x2019;s dilutive net loss per share calculation, stock options and warrants to purchase the Company&#x2019;s common stock were considered to be common stock equivalents but were excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive; therefore, basic and diluted net loss per share were the same for all periods presented. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,346,733&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 227,945&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,530,380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,032,292&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Series X Preferred Stock (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,242,501&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,119,614&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,260,236&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-left:46.8pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:46.8pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Shown as common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company provides deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company&#x2019;s financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. A valuation allowance is provided to reduce the deferred tax assets to the amount that will more likely than not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC Topic&#160;740, &lt;i style="font-style:italic;"&gt;Expenses&#x2014;Income Taxes&lt;/i&gt;. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company did not have any uncertain tax positions for any periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;The Company assesses the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where it has operations to determine the potential effect its business and any assumptions it has made about its future taxable income. The Company cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on its business if they were to be enacted. Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the currently available option to deduct research and development expenditures and requires taxpayers to amortize them over five years. The U.S. Congress is considering legislation that would defer the amortization requirement to future periods, however, the Company has no assurance that the provision will be repealed or otherwise modified.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segment Information &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, the Company&#x2019;s chief executive officer, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business in one operating segment. The Company operates in one geographic segment. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in&#160;right-of-use&#160;(&#x201c;ROU&#x201d;) lease assets, current portion of lease obligations, and long-term lease obligations on the Company&#x2019;s balance sheets. The Company does not currently hold any financing leases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;ROU lease assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease obligations represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s facility leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company&#x2019;s ROU lease assets also include any lease payments made and excludes lease incentives. If the Company&#x2019;s facility lease includes options to terminate the lease which would affect the lease period when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments under facility leases are recognized on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Acquired In-Process Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) with no alternative future use is charged to expense at the acquisition date. Refer to Note 3, &#x201c;Acquisition of Quellis&#x201d; for a more detailed description of the accounting policy utilized for the recent asset acquisition.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times';line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Preferred Stock Discount&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;As discussed above, in February 2021, the Company issued Series X Preferred Stock in a private placement transaction. It was determined that this transaction resulted in recognition of a beneficial conversion feature, which was valued based on the difference between the price of the shares of common stock on the date of commitment and the conversion price on the closing date, resulting in a total value of $19.6 million. Additionally, the Company incurred total issuance costs of $5.7 million related to the private placement. Both of these features were recorded as a discount on Series X Preferred Stock recognized at the close of the transaction. These features are analogous to preferred dividends and are recorded as a non-cash return to holders of Series X Preferred Stock through additional paid in capital. The discount related to the beneficial conversion feature is recognized through the earliest possible date of conversion, which occurred upon the shareholder approval of the conversion in June 2021. The issuance costs are recognized as a dividend at the time of conversion to common shares. As of December 31, 2021, $24.4 million of the above amounts were accounted for as a non-cash dividend related to shares of Series X Preferred Stock, and $0.9 million remained to be recognized upon future conversion.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times';line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements -Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;In December 2019, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2019-12, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740)&lt;/i&gt;. This standard includes amendments within the scope of Topic 740 to reduce complexity and improve areas of U.S. GAAP. This amendment was effective for annual reporting periods beginning after December 15, 2020. Adoption of the standard did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;In June 2016, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments-Credit Losses&lt;/i&gt; (Topic 326). This standard requires a financial asset to be presented at amortized cost basis at the net amount expected to be collected. It also requires that credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. In November 2019, the FASB issued an amendment making this ASU effective for annual reporting periods beginning after December 15, 2022 for smaller reporting companies. Early adoption is permitted. The Company is currently evaluating the impact that this standard will have on its consolidated financial statements as well as the timing of when this standard will be adopted.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_2aFOwgm1oU2yoosU0Si8RQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Astria Securities Corporation and Quellis Biosciences, LLC, successor in interest to Quellis. All intercompany balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;U.S.&#160;GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented.&#160;&#160;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_a9YwEaCsAUOFIZj6Wa529A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company utilizes certain estimates to record expenses relating to research and development contracts. These contract estimates, which are primarily related to the length of service of each contract and the amount of service provided as of each measurement date, are determined by the Company based on input from internal project management, as well as from service providers.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <atxs:OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb__dLt46hV50y59pgBNb8u9Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Off-Balance Sheet Risk and Concentrations of Credit Risk &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company has no off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements. Financial instruments that subject the Company to credit risk primarily consist of cash, cash equivalents, short-term investments and restricted cash. The primary objectives for the Company&#x2019;s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company&#x2019;s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</atxs:OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_9s2treraRkCYGUV9veShSg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The reconciliation of cash, cash equivalents and restricted cash reported within the applicable balance sheet that sum to the total of the same such amount shown in the statement of cash flows is as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 86,508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,930&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Restricted cash (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 121&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 86,629&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,051&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-left:46.8pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:46.8pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Included in prepaid expenses and other current assets at December 31, 2021 and other long-term assets at December 31, 2020.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_C8VbTGmc2kKI0MZERkOPHg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The reconciliation of cash, cash equivalents and restricted cash reported within the applicable balance sheet that sum to the total of the same such amount shown in the statement of cash flows is as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 86,508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,930&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Restricted cash (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 121&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 86,629&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,051&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-left:46.8pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:46.8pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Included in prepaid expenses and other current assets at December 31, 2021 and other long-term assets at December 31, 2020.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_Op00F5IuAkuW_wOi-2m3Hw_3_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">86508000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_V0FR3b535U6dQOSHPHuZxg_3_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">24930000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_KwDvCtkuwEGeRjEmCeX6TA_4_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">121000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_pbbkK7M240C2oVrnX3fsKQ_4_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">121000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_folvLW4v4ESd-eNInbWmww_5_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">86629000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_tJvPt1GjXEui07spbfWbCQ_5_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">25051000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_5tkIViyfqUO-VEmT-ckqRA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Short-Term Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company classifies all corporate debt securities with a remaining maturity of greater than three months and reverse repurchase agreements with a remaining maturity of greater than one business day at the time of purchase as short-term investments. Short-term investments are recorded at fair value, with the unrealized gains and losses reported in other comprehensive loss. The amortized cost of debt securities is adjusted for the amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest and investment income. Realized gains and losses, interest, dividends and declines in value judged to be other-than-temporary are included in interest and investment income. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The cost of securities sold is based on the specific identification method for purposes of recording realized gains and losses. To determine whether an other-than-temporary impairment exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the investment outweighs evidence to the contrary. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_keduC77Ed0Kzz1_oiYvpJA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three broad levels as follows: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3 inputs are unobservable inputs that reflect the Company&#x2019;s own assumptions about the assumptions &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The carrying amounts reflected in the balance sheets for cash equivalents, restricted cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values at December 31, 2021 and 2020, due to their short-term nature. There have been no changes to the valuation methods during the years ended December 31, 2021 and 2020. The Company evaluates transfers between levels at the end of each reporting period. There were no &lt;span style="-sec-ix-hidden:Hidden_Q8KxfYwEQ06Q-XDWVRjAVA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;transfers&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_h7pU9TMEukuhqRukKT1nSg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;of&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_Spms05oTPUG_D656yLZ_hg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;assets&lt;/span&gt;&lt;/span&gt; or liabilities between levels during the years ended December 31, 2021 and 2020. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s investment portfolio may include fixed income securities that do not always trade on a daily basis. As a result, the pricing services used by the Company apply other available information as applicable through processes such as benchmark yields, benchmarking of like securities, sector groupings and matrix pricing to prepare valuations. The Company validates the prices provided by its third party pricing services by obtaining market values from other pricing sources and analyzing pricing data in certain instances. The Company also invests in certain reverse repurchase agreements which are collateralized by deposits in the form of United States Government Securities and Obligations for an amount no less than 102% of their value. The Company does not record an asset or liability for the collateral as the Company is not permitted to sell or re-pledge the collateral. The collateral has at least the prevailing credit rating of United States Government Treasuries and Agencies. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the reverse repurchase agreements on a daily basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company accounted for warrants to purchase its stock pursuant to Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 470, Debt, and ASC Topic 480, Distinguishing Liabilities from Equity, and classifies warrants for common stock and preferred stock as liabilities or equity. The warrants classified as liabilities are reported at their estimated fair value and any changes in fair value are reflected in research and development expense. The warrants classified as equity are reported at their estimated fair value with no subsequent remeasurement.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Narr_cpm_Y0z3Tku9kakWzI4rgA"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <atxs:PercentageOfInvestmentAmountToCollateralizedDepositsValue
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_CollateralAxis_us-gaap_CollateralPledgedMember_us-gaap_InvestmentTypeAxis_atxs_ReverseRepurchaseAgreementsMember_eiP--rMiZU-1gbUFnuyFRA"
      decimals="INF"
      id="Narr_WPKuU23ffECqScEd-M8OEw"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">1.02</atxs:PercentageOfInvestmentAmountToCollateralizedDepositsValue>
    <atxs:PercentageOfInvestmentAmountToCollateralizedDepositsValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_InvestmentTypeAxis_atxs_ReverseRepurchaseAgreementsMember_aL_h_TEmN0mRrvtYQElzYg"
      decimals="INF"
      id="Narr_mKhzV9vTQUq-rihj2lmbgg"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">1.02</atxs:PercentageOfInvestmentAmountToCollateralizedDepositsValue>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_vtY94lv_Tky0gwv1vWpNcQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. The Company has not recognized any significant impairment charges from inception through December&#160;31, 2021. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_aQrqDkvMkkC9CW34JKqyDQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development Expenses &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Research and development costs are expensed as incurred. Research and development costs include salaries and personnel-related costs, stock-based compensation, consulting fees, fees paid for contract research services, the costs of laboratory equipment and facilities and other external costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred. The deferred amounts are expensed as the related goods are delivered or the services are performed. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_qGllelNhLUqJtlHoaCbUUA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company accounts for its stock-based compensation awards in accordance with ASC Topic&#160;718, &lt;i style="font-style:italic;"&gt;Compensation&#x2014;Stock Compensation (&lt;/i&gt;&#x201c;ASC&#160;718&#x201d;). ASC&#160;718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statements of operations based on their grant date fair values. For granted stock options, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model.&#160; The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Company&#x2019;s common stock consistent with the expected term of the option, risk-free interest rates and expected dividend yields of the Company&#x2019;s common stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;For awards subject to service-based vesting conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company expenses restricted stock awards based on the fair value of the award on a straight-line basis over the associated service period of the award. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;During the years ended December 31, 2021 and 2020, the Company recorded stock-based compensation expense for employee and non-employee stock options and restricted stock, which was allocated as follows in the statements of operations (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,132&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 599&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,230&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 791&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,390&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;No related tax benefits were recognized for the years ended December 31, 2021 and 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_t_7n1zQIL0mXkjbzPpiMsQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;During the years ended December 31, 2021 and 2020, the Company recorded stock-based compensation expense for employee and non-employee stock options and restricted stock, which was allocated as follows in the statements of operations (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,132&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 599&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,230&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 791&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,390&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9rTkA9cmjESbAdI_CIGCcg"
      decimals="-3"
      id="Tc_57sGiVkc2U26T6oTtNiO8Q_3_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1132000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_CpiCowz5gUmCO8VqNzzcCQ"
      decimals="-3"
      id="Tc_KxqfeGS160a8PUTqAm4OCg_3_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">599000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_P4mw2Fw8x0WkHCAyeJfKmg"
      decimals="-3"
      id="Tc_va6m5FcqjUOU_4lnE9SbGA_4_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">2230000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_8dpBZ3kAYkmlo-2evH5QBw"
      decimals="-3"
      id="Tc_-PrV82bb3UagpP9IfGT-7Q_4_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">791000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_BJ9zZ41_-UqtgahpfBqEHg_5_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">3362000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Tc_fq3Hj-7mYUeVRRHD_FZwPg_5_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1390000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-3"
      id="Narr_pzSSX6DYAUGda0mTD0gUrQ"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Narr_smveeqB4IUSglVnaukMO-w"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_IB3cf1SSX0y0v_8g-5QPbg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Net Loss Per Share &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Basic net loss per share is calculated by dividing net loss by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the Company&#x2019;s dilutive net loss per share calculation, stock options and warrants to purchase the Company&#x2019;s common stock were considered to be common stock equivalents but were excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive; therefore, basic and diluted net loss per share were the same for all periods presented. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,346,733&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 227,945&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,530,380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,032,292&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Series X Preferred Stock (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,242,501&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,119,614&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,260,236&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-left:46.8pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:46.8pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Shown as common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_2rlqik4AUUyDiUMeSsUEcg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,346,733&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 227,945&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,530,380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,032,292&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Series X Preferred Stock (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,242,501&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,119,614&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,260,236&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_2fwTF9OAO0KdmBRB8Fzb2g"
      decimals="INF"
      id="Tc_xX0SDGKV00WjtrUhGYo05A_3_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">1346733</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_q91ttEudQ0mAGYdugRr9ow"
      decimals="INF"
      id="Tc_5unntZQ0ZUC6HnSR3zMNxg_3_4"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">227945</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_atxs_CommonStockWarrantsMember_eZiUsBdsv0CpnkEmFJMYiw"
      decimals="INF"
      id="Tc_da3HGjYW-EeimZAk3JnZGQ_4_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">1530380</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_atxs_CommonStockWarrantsMember_n7ERVEbeHkmVQE0vpdaYVw"
      decimals="INF"
      id="Tc_XOmSq_t4xkSzlk7hxk-WEQ_4_4"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">1032292</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_atxs_SeriesXPreferredStockMember_9HMukFq3bkmw6Lq9raeXDQ"
      decimals="INF"
      id="Tc_vf9ygsner06i_9Jwk1Qdzg_5_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">5242501</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="INF"
      id="Tc_YgNW9CiW_EOgIIZsAK7Xqw_6_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">8119614</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="INF"
      id="Tc_o4jUrW6t2UK8-fdFIRbm7A_6_4"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">1260236</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_2dke4P9CW0-WY71-T39wbQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company provides deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company&#x2019;s financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. A valuation allowance is provided to reduce the deferred tax assets to the amount that will more likely than not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC Topic&#160;740, &lt;i style="font-style:italic;"&gt;Expenses&#x2014;Income Taxes&lt;/i&gt;. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company did not have any uncertain tax positions for any periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;The Company assesses the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where it has operations to determine the potential effect its business and any assumptions it has made about its future taxable income. The Company cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on its business if they were to be enacted. Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the currently available option to deduct research and development expenditures and requires taxpayers to amortize them over five years. The U.S. Congress is considering legislation that would defer the amortization requirement to future periods, however, the Company has no assurance that the provision will be repealed or otherwise modified.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_lRELF4dtlEOY1iwoYCKr7Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segment Information &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, the Company&#x2019;s chief executive officer, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business in one operating segment. The Company operates in one geographic segment. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="INF"
      id="Narr_kIEla1ZcF0a3HNDTKwpKMg"
      unitRef="Unit_Standard_segment_VaIUUonErEmKwL0Ka000VA">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_RZAZO9amh0SXkSTfEsI6Xw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. &lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_msrhB4QCzUqfaHNydBtAEA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in&#160;right-of-use&#160;(&#x201c;ROU&#x201d;) lease assets, current portion of lease obligations, and long-term lease obligations on the Company&#x2019;s balance sheets. The Company does not currently hold any financing leases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;ROU lease assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease obligations represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s facility leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company&#x2019;s ROU lease assets also include any lease payments made and excludes lease incentives. If the Company&#x2019;s facility lease includes options to terminate the lease which would affect the lease period when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments under facility leases are recognized on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_cQhALg56A0qGWTEMYWpBtg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Acquired In-Process Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) with no alternative future use is charged to expense at the acquisition date. Refer to Note 3, &#x201c;Acquisition of Quellis&#x201d; for a more detailed description of the accounting policy utilized for the recent asset acquisition.&lt;/p&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <atxs:PreferredStockDiscountPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_iWihsg4s9EeksuuncSuWIw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Preferred Stock Discount&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;As discussed above, in February 2021, the Company issued Series X Preferred Stock in a private placement transaction. It was determined that this transaction resulted in recognition of a beneficial conversion feature, which was valued based on the difference between the price of the shares of common stock on the date of commitment and the conversion price on the closing date, resulting in a total value of $19.6 million. Additionally, the Company incurred total issuance costs of $5.7 million related to the private placement. Both of these features were recorded as a discount on Series X Preferred Stock recognized at the close of the transaction. These features are analogous to preferred dividends and are recorded as a non-cash return to holders of Series X Preferred Stock through additional paid in capital. The discount related to the beneficial conversion feature is recognized through the earliest possible date of conversion, which occurred upon the shareholder approval of the conversion in June 2021. The issuance costs are recognized as a dividend at the time of conversion to common shares. As of December 31, 2021, $24.4 million of the above amounts were accounted for as a non-cash dividend related to shares of Series X Preferred Stock, and $0.9 million remained to be recognized upon future conversion.&lt;/p&gt;</atxs:PreferredStockDiscountPolicyTextBlock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_nDMEtpbiBUq1iy12eCKFQQ"
      decimals="-5"
      id="Narr_Ol9eLdZV4E6xlGzF6vC60g"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">19600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_nDMEtpbiBUq1iy12eCKFQQ"
      decimals="-5"
      id="Narr_iRpmWfCJrkK-DCxIlI0qZg"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">5700000</us-gaap:PaymentsOfStockIssuanceCosts>
    <atxs:NonCashReturnRelatedToCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_mm2r7tKTwEKwrvs2FxtSqQ"
      decimals="-5"
      id="Narr_IGta-22iOkqSyccf3YC5zg"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">24400000</atxs:NonCashReturnRelatedToCommonStock>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_Q0-uw695P0e1UfMQTMe-mg"
      decimals="-5"
      id="Narr_QpOwa5HYxU2PCGEcFMOUIg"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">900000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_YsYI9FreWkOsx94MQTA7Fw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements -Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;In December 2019, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2019-12, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740)&lt;/i&gt;. This standard includes amendments within the scope of Topic 740 to reduce complexity and improve areas of U.S. GAAP. This amendment was effective for annual reporting periods beginning after December 15, 2020. Adoption of the standard did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;In June 2016, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments-Credit Losses&lt;/i&gt; (Topic 326). This standard requires a financial asset to be presented at amortized cost basis at the net amount expected to be collected. It also requires that credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. In November 2019, the FASB issued an amendment making this ASU effective for annual reporting periods beginning after December 15, 2022 for smaller reporting companies. Early adoption is permitted. The Company is currently evaluating the impact that this standard will have on its consolidated financial statements as well as the timing of when this standard will be adopted.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_QSMmwgFlXUaiMUf8GgvhXw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;3. &#160;&#160;&#160;Acquisition of Quellis&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;On January 28, 2021, the Company completed the Quellis Acquisition in accordance with the terms of the Merger Agreement as discussed in Note 1, &#x201c;Organization and Operations&#x201d;. Under the terms of the Merger Agreement, the Company issued 555,444 shares of common stock and 50,504 shares of Series X Preferred Stock. Each share of Series X Preferred Stock is convertible into 166.67 shares of Common Stock, subject to certain conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company concluded that the Quellis Acquisition was not the acquisition of a business, as substantially all of the fair value of the non-monetary assets acquired was concentrated in a single identifiable asset, STAR-0215.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company determined that the cost to acquire the Quellis assets was $170.7 million, based on the fair value of the equity consideration issued and including direct costs of the acquisition of $1.8 million. The net assets acquired in connection with the Quellis Acquisition were recorded at their estimated fair values as of January 28, 2021, which is the date the Quellis Acquisition was completed. The following table summarizes the net assets acquired based on their estimated fair values as of January 28, 2021 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Acquired IPR&amp;amp;D&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164,612&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,307&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Prepaid expenses and other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 136&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (1,974)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (400)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Net acquired tangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 170,681&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:28.8pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;In the estimation of fair value of the asset purchase consideration, the Company used the carrying value of the cash and cash equivalents, prepaid expenses, accounts payable and accrued liabilities as the most reliable indicator of fair value based on the associated short-term nature of the balances. The remaining fair value was attributable to the acquired IPR&amp;amp;D. As STAR-0215 had not, at the time of the Quellis Acquisition, received regulatory approval in any territory, the cost attributable to the IPR&amp;amp;D was expensed in the Company&#x2019;s consolidated statements of operations and comprehensive loss for the year ended December 31, 2021 as the acquired IPR&amp;amp;D had no alternative future use, as determined by the Company in accordance with U.S. GAAP.&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="Duration_1_28_2021_To_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yGEdHdBZkEuZlEVGeuF7Gg"
      decimals="INF"
      id="Narr__K29DFoW_EazfC9Tj0ejOg"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">555444</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <atxs:TemporaryEquityStockIssuedInAcquisitionSharesNewIssues
      contextRef="Duration_1_28_2021_To_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_MBblrX_TzUq0Y8HTkRLDIA"
      decimals="INF"
      id="Narr_HUV7JeOLnk272oldScYk9Q"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">50504</atxs:TemporaryEquityStockIssuedInAcquisitionSharesNewIssues>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_uWtVDAckP0qWnkjhGrfdWg"
      decimals="2"
      id="Narr_yxQYHCwUGUyma5FzJodDZw"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">166.67</us-gaap:PreferredStockConvertibleConversionRatio>
    <atxs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities
      contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_stYiOzYUG0mKnmIJCrQu3Q"
      decimals="-5"
      id="Narr_-LX6AvP3ikSaOzvDjx8Psg"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">170700000</atxs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities>
    <us-gaap:AcquisitionCosts
      contextRef="Duration_1_28_2021_To_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_yxGtZ11D_EqlCL7qM9oOug"
      decimals="-5"
      id="Narr_szYGpOnEmUmL9-aVhA4nZA"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1800000</us-gaap:AcquisitionCosts>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_IJpduOBHd0SDedudTGK3Pw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Acquired IPR&amp;amp;D&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164,612&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,307&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Prepaid expenses and other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 136&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (1,974)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (400)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Net acquired tangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 170,681&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <atxs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment
      contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_stYiOzYUG0mKnmIJCrQu3Q"
      decimals="-3"
      id="Tc_bs2fy1NNDkKhxBJU3w4H7w_1_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">164612000</atxs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_stYiOzYUG0mKnmIJCrQu3Q"
      decimals="-3"
      id="Tc_siMFJ3l90kqVZ4GJpzP5PA_2_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">8307000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_stYiOzYUG0mKnmIJCrQu3Q"
      decimals="-3"
      id="Tc_u8q6Ln9HT0GgTF0iAMtyFA_3_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">136000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_stYiOzYUG0mKnmIJCrQu3Q"
      decimals="-3"
      id="Tc_PCNZs7b_K0S4HHodSkqFSw_4_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1974000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <atxs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities
      contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_stYiOzYUG0mKnmIJCrQu3Q"
      decimals="-3"
      id="Tc_ko33URsVF0-Mo9NRV_pjNw_5_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">400000</atxs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities>
    <atxs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities
      contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_stYiOzYUG0mKnmIJCrQu3Q"
      decimals="-3"
      id="Tc_VYIArfWoR0mrneO0K580oQ_6_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">170681000</atxs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_dW5D1xkJ20OZBpPfClEVGQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;4. &#160;&#160;&#160;Financial Instruments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities that have been measured at fair value, and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value. Below is a summary of assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in&#160;Active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Cash and cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,853 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,853 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Reverse repurchase agreements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 5.75pt;"&gt;Short-term investments:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Reverse repurchase agreements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;39,000 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;39,000 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Total &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,853 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;39,000 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;40,853 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in&#160;Active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Cash and cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,999&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Short-term investments:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Reverse repurchase agreements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,999&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At December 31, 2021 and 2020, cash equivalents approximated their fair value due to their short-term nature.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;In connection with the Quellis Acquisition, the Company issued a warrant to purchase 2,805 shares of Series X Preferred Stock at an exercise price of $341.70 per share. Upon stockholder approval of the Conversion Proposal, and reflecting the reverse stock split, the warrant became a warrant to purchase 467,500 shares of common stock at a purchase price of $2.10. This was originally accounted for as a liability until stockholder approval of the Conversion Proposal on June 2, 2021, at which point the warrant was reclassified to permanent equity. The warrant liability was valued based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The Company estimated the fair value of the warrant liability using Black-Scholes option-pricing models and assumptions that are based on the individual characteristics of the warrants on the valuation date, as well as assumptions including the fair value per share of the underlying security, the remaining contractual term of the warrant, risk-free interest rate, expected dividend yield and expected volatility of the price of the underlying security (in thousands).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times';line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Balance at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Issuance of warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,332&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;(Decrease) increase in the fair value of the warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (864)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Reclassification of warrant liability to additional paid in-capital&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (3,468)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"&gt;&lt;span style="font-family:'Times';line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;The fair value of the warrants was based on the following assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times';line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;Ended&#160;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Weighted-average expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;89.1-89.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;9.54-9.88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.064-1.725&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times';font-size:1pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_gNuAENhEjEOCFEgrpyQDBw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in&#160;Active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Cash and cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,853 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,853 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Reverse repurchase agreements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 5.75pt;"&gt;Short-term investments:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Reverse repurchase agreements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;39,000 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;39,000 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Total &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,853 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;39,000 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;40,853 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in&#160;Active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Cash and cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,999&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Short-term investments:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Reverse repurchase agreements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,999&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_rPxgg34LwEO0WW2sJngFGg"
      decimals="-3"
      id="Tc_ejJF7_pGLU6rG7cu8qWdKg_8_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1853000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_pkomaENPeEK2hWjtfDxw1g"
      decimals="-3"
      id="Tc_iF8NY5Z2gk2MCXG-ghsoPQ_8_12"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1853000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember_hXCdIxgZCEKI8TXwJzmvOw"
      decimals="-3"
      id="Tc_QYrg_AegckOb_7S9W7y34A_11_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">39000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember__UO0W7ZwwECRTisRxchBwQ"
      decimals="-3"
      id="Tc_fHVUb9RCeUOcDUZwdB8dsQ_11_12"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">39000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_nIJM4yXrw0GzaRxtnzccAQ"
      decimals="-3"
      id="Tc_LCGmWgRFoUuYSC8yisHDyw_12_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1853000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Ds6LSP_EK0qTg90-h5fSyA"
      decimals="-3"
      id="Tc_B8lipiEYf0ORqEy0OaA50w_12_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">39000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ar5rUSj2SE2rATotgrqFBg"
      decimals="-3"
      id="Tc_nnjtR_VoEEmqj07bE3027Q_12_12"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">40853000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_kwexEh1NbUCeMgI-knFDkQ"
      decimals="-3"
      id="Tc_TAA908MwTEeX4F1UXCrQHw_8_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">22999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_ADdWV8SUt0GFgLe1JLOiEQ"
      decimals="-3"
      id="Tc_cgtD6ezwDUOgsEE_qMwPPw_8_12"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">22999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember_vZQWF0XPxEqvnvbV5-zrbw"
      decimals="-3"
      id="Tc_vLy2BWpIbkW2jYh6Mj9ZhA_10_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">20000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember_xAFJqmrv7kOgE5MRCew76A"
      decimals="-3"
      id="Tc_MR8G242zn0G_VTIPast7ww_10_12"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">20000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_EQBCa0WuakeegbdgZGvTIA"
      decimals="-3"
      id="Tc_ZapNEft3wUKY3XvvCeTUbQ_11_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">22999000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_OSaVkTaBE0adbR5AtRVk7Q"
      decimals="-3"
      id="Tc_z4y6lNLy70WdhunU-yzAWA_11_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">20000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_x-MiuZtIH0yax5u7pxoruw"
      decimals="-3"
      id="Tc_mzgi4BwW8EOPd55KzWkQvw_11_12"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">42999000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_uWtVDAckP0qWnkjhGrfdWg"
      decimals="INF"
      id="Narr_kqFTwJKg-E6TqmemqWZ1Sg"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">2805</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_uWtVDAckP0qWnkjhGrfdWg"
      decimals="2"
      id="Narr_UaUA36OAn0O9BR4C_5Esqg"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">341.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_6_2_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BiFXZ622XUu96mNlkBimYA"
      decimals="INF"
      id="Narr_zv6xCPpmmE-p0NhwgYEztg"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">467500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_2_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BiFXZ622XUu96mNlkBimYA"
      decimals="2"
      id="Narr_RDH3PNrMsUmerFC7K5YQXA"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">2.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_e4noWd8WK0m4TP9tN3av7g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times';line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Balance at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Issuance of warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,332&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;(Decrease) increase in the fair value of the warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (864)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Reclassification of warrant liability to additional paid in-capital&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (3,468)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_3hVszi-haEizFq7jk2_Y4Q_2_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_a2losiSOoUGmSA5Qzb1lbw_3_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">4332000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_6OgQNsnRtUmOaj1_lLDaHg_4_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">-864000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <atxs:ReclassificationOfEquityClassifiedWarrants
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-3"
      id="Tc_T_KDhAqSuUazQWywSK6rAA_5_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">3468000</atxs:ReclassificationOfEquityClassifiedWarrants>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_yFRWEiOGbkugLExjZR-Feg_6_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_WzZMD00xoUq6XxErY881LA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times';line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;Ended&#160;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Weighted-average expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;89.1-89.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;9.54-9.88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.064-1.725&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_atxs_WeightedAverageExpectedVolatilityMember_nIDhOwmhF0mlBky65Ot7_w"
      decimals="3"
      id="Narr_LGGHwD3AFkCO5XLWhpPIfQ"
      unitRef="Unit_Standard_item_r9qJ3cWOSk6WrNQbeKvS6w">0.891</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_atxs_WeightedAverageExpectedVolatilityMember_RP6DX7K3TUWlKsT4sun6pQ"
      decimals="3"
      id="Narr_6lzpd1dkt0uQBPgi3yoWhQ"
      unitRef="Unit_Standard_item_r9qJ3cWOSk6WrNQbeKvS6w">0.893</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_sf3s1jFkZ0aGtBYOQC3ukQ"
      decimals="2"
      id="Narr_HWx4v47bZkawkc1KJfnhzg"
      unitRef="Unit_Standard_Y_7dFwAQRg-k-TRf_n8MTBtg">9.54</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_Ts_1LVNTNk69yxGtcPF9Zw"
      decimals="2"
      id="Narr_H8QbXoc-Y027gPdINytjTw"
      unitRef="Unit_Standard_Y_7dFwAQRg-k-TRf_n8MTBtg">9.88</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_u1VQyUC_pkKu65bhuNk4jw"
      decimals="5"
      id="Narr_G0hIeSwk-k6wn8BDEL31Ow"
      unitRef="Unit_Standard_item_r9qJ3cWOSk6WrNQbeKvS6w">0.01064</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_BS6PVDaxDkyvam1jdK_ZbA"
      decimals="5"
      id="Narr_r0eJlpQIYUKmtyXwanhpaQ"
      unitRef="Unit_Standard_item_r9qJ3cWOSk6WrNQbeKvS6w">0.01725</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_Ulx_E0qOrUKkre8jvxb7rg"
      decimals="2"
      id="Tc_16B_KM6l5EOZChoowa2_7w_7_2"
      unitRef="Unit_Standard_item_r9qJ3cWOSk6WrNQbeKvS6w">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <atxs:ShortTermInvestmentsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_fZH0JJ6350-IXvXS8eLFzA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;5.&#160;&#160;&#160;&#160;Short-Term Investments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;The following tables summarize the short-term investments held at December 31, 2021 and 2020 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Reverse repurchase agreements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Reverse repurchase agreements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;The contractual maturities of all short-term investments held at December 31, 2021 and 2020 were one year or less. There were no short-term investments in an unrealized loss position at December 31, 2021 and 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Gross realized gains and losses on the sales of short-term investments are included in other income, net. Unrealized holding gains or losses for the period that have been included in accumulated other comprehensive income, as well as gains and losses reclassified out of accumulated other comprehensive income into other income, net were not material to the Company&#x2019;s consolidated results of operations. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;During the years ended December 31, 2021 and 2020 all proceeds included in the Company&#x2019;s cash flows related to maturities of underlying securities. The gains on proceeds of maturities of short-term investments were not material to the Company&#x2019;s consolidated results of operations for the years ended December 31, 2021 and 2020.&lt;/p&gt;</atxs:ShortTermInvestmentsTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_xZBYd1Mrk0GQAZld0K48EA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;The following tables summarize the short-term investments held at December 31, 2021 and 2020 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Reverse repurchase agreements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Reverse repurchase agreements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember_U49V0Lt_9kyE9hrhO0s63A"
      decimals="-3"
      id="Tc_ZiCiOP_NikOXty0xxV4v6g_5_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">39000000</us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember_U49V0Lt_9kyE9hrhO0s63A"
      decimals="-3"
      id="Tc_EKZJdoRNdUe4YRaitH0Dfg_5_12"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">39000000</us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_phPEO_62_0ef87zim7j66g"
      decimals="-3"
      id="Tc_GLfrKW7X3kyogkP8ErxHOA_6_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">39000000</us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_phPEO_62_0ef87zim7j66g"
      decimals="-3"
      id="Tc_QmAGBkQErUKAp9OSR7tFjA_6_12"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">39000000</us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember_Cc8ygbB1FkS65q1Hq4bUmQ"
      decimals="-3"
      id="Tc_0N91ntOmT06PlNqn6pHn7Q_5_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">20000000</us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_atxs_ReverseRepurchaseAgreementsMember_Cc8ygbB1FkS65q1Hq4bUmQ"
      decimals="-3"
      id="Tc_y0O2YW6go0WzCfy3oo_uNw_5_12"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">20000000</us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_FkRLjZQMv0avRCk8lVRJrQ"
      decimals="-3"
      id="Tc_--DA5f8I_UWWRAzkkMVZ6w_6_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">20000000</us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_ShortTermInvestmentsMember_FkRLjZQMv0avRCk8lVRJrQ"
      decimals="-3"
      id="Tc_u56POnmy1EOGWwrUtAKwUw_6_12"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">20000000</us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="INF"
      id="Narr_urGYfoEq6EGZVuwUlyjYPg"
      unitRef="Unit_Standard_instrument_UhpnDIC4ZkS1xbkw5nvJeQ">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_MWC_N256qka_GUQYr2fZ_A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;6.&#160;&#160;&#160;&#160;Accrued Expenses&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,958 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,719&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Accrued contracted costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;760 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,726&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Accrued other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;295 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;268 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 356&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Accrued severance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 396&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3,281 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4,197 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_qHDeEq9_H02g6GmrZr5-wg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,958 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,719&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Accrued contracted costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;760 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,726&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Accrued other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;295 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;268 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 356&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Accrued severance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 396&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3,281 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4,197 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_7-sYNR-UX0mIiwPwmgmaDA_3_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1958000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_A4D6-tvhN0W7WfJOq03pqQ_3_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1719000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <atxs:AccruedContractedResearchCostsCurrent
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_uZfoqA5h0E6i7FKDYZbnGg_4_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">760000</atxs:AccruedContractedResearchCostsCurrent>
    <atxs:AccruedContractedResearchCostsCurrent
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_Vq9S68l-lEiv8XaY3GxkKw_4_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1726000</atxs:AccruedContractedResearchCostsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_WQ88vFa7yUa2RN8EQh59Eg_5_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">295000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_yprTyGRWGkqgsVSIgO2jpQ_6_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">268000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_ouu2A80PfkyC3QUsphgBFA_6_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">356000</us-gaap:AccruedProfessionalFeesCurrent>
    <atxs:AccruedSeveranceCurrent
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_3Pl_FifSR0q2j3Ghlqxsdw_7_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">396000</atxs:AccruedSeveranceCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_1BadB2SqyEqzPteTBN5GpA_8_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">3281000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_b2Jk5XUK-E-LNnF7bNiJbQ_8_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">4197000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_OxpZi-t0dkWe-tk9LhLadg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;7. &#160;&#160;&#160;Commitments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;In November 2019, the Company entered into a sublease for office space which was classified as an operating lease. At inception of the lease, the Company recognized a lease &lt;span style="-sec-ix-hidden:Hidden_HFiUTo3gw02FAUw2F3J6Qg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;liability&lt;/span&gt;&lt;/span&gt; and right-of-use asset of approximately $1.7 million. The lease liability represents the present value of the remaining lease payments, discounted using the Company&#x2019;s estimated incremental borrowing rate of 7.49%. The ROU asset represents the lease liability adjusted for any prepaid and accrued rent payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The lease is scheduled to expire in 2022. Future minimum payments required under the non-cancelable operating leases as of December 31, 2021 are $0.4 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Rent expense was $0.7 million and $0.8 million for the years ended December 31, 2021 and 2020, respectively. Lease payments were $0.7 million and $1.5 million for the years ended December 31, 2021 and 2020, respectively.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_11_30_2019_KyDCpKfGVkmxJYefd9nrVQ"
      decimals="-5"
      id="Narr_aa7Pa0pgUkiFWP_SL3wViQ"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_11_30_2019_KyDCpKfGVkmxJYefd9nrVQ"
      decimals="4"
      id="Narr_k2VgQLfT8UeSzC3VpP4ptw"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.0749</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-5"
      id="Narr_10rDyaujUU2y5gQdXXXv3Q"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-5"
      id="Narr__V7l6r4jSEidArxRgwDxdA"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-5"
      id="Narr_2mHHxODVEUqzfYAMDZvAjA"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-5"
      id="Narr_w0JrIsEVnE-iPx6hVuMZMQ"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">700000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-5"
      id="Narr_hWblTa2wjESO2g-HP_XIhg"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1500000</us-gaap:OperatingLeasePayments>
    <us-gaap:PreferredStockTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_r8gybHFNBk-Xj2mWRk9EWA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;8.&#160;&#160;&#160;Stockholders&#x2019; Equity&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Times';font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Preferred Stock &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Under the Company&#x2019;s amended and restated certificate of incorporation, the Company has 5,000,000 shares of preferred stock authorized for issuance, with a $0.001 par value per share. Preferred stock may be issued from time to time in one or more series, each series to have such terms as stated or expressed in the resolutions providing for the issue of such series adopted by the board of directors of the Company. Preferred stock which may be redeemed, purchased or acquired by the Company may be reissued except as otherwise provided by law. As of December 31, 2021, the Company had 31,455 shares of Series X Preferred Stock outstanding. Each share of Series X Preferred Stock is convertible into 166.67 shares of common stock and therefore the number of shares of underlying common stock issuable upon conversion of the Series X Preferred Stock is 5,242,501. Refer to Note 1 &#x2013; &#x201c;Organization and Operations&#x201d; regarding the Company&#x2019;s issuance of Series X Preferred Stock in January 2021 and February 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Outstanding Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The following table presents information about warrants that are issued and outstanding at December 31, 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:32.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:32.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Issued&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Equity&#160;Instrument&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&#160;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&#160;of&#160;Expiration&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:32.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Common Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 204&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 732.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3/30/2022&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:32.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Common Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 699,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6/21/2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:32.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Common Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 331,858&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2/7/2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:32.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Common Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 498,356&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12/14/2030&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:32.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,530,380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:32.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Weighted average exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:32.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Weighted average life in years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.05&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;As of December 31, 2021, the Company had 150,000,000 shares of common stock authorized for issuance, $0.001 par value per share, with 13,016,955 shares issued and &lt;span style="-sec-ix-hidden:Hidden_0h6_9E_LE0OXUd1tw9ln2A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;outstanding&lt;/span&gt;&lt;/span&gt;. &#160;The voting, dividend and liquidation rights of holders of common stock are subject to and qualified by the rights, powers and preferences of the holders of any outstanding preferred stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Reserved for Future Issuance&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;The Company has reserved for future issuance the following shares of common stock:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Series X Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,242,501&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Warrants for the purchase of common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,530,380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,032,291&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Options outstanding to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,346,733&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 227,846&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Options available for future issuance to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,633,736&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 322,695&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Shares reserved for the employee stock purchase plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,904&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,825&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,784,254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,607,657&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;As of December 31, 2021, the Company also had 31,455 shares of Series X Preferred Stock outstanding. Each share of Series X Preferred Stock outstanding is convertible into 166.67 shares of the Company&#x2019;s common stock, subject to certain beneficial ownership limitations at the holder&#x2019;s option. See Note 1 &#x2013; &#x201c;Organization and Operations&#x201d; for additional detail.&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="INF"
      id="Narr_ht1zfOOlGkaWh4B4VCN9xQ"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="INF"
      id="Narr_UZaVqo1RbkWELvZv9bqrZQ"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <atxs:NumberOfPreferredStockSeries
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="INF"
      id="Narr__VP5Fv7C_k2f8CTLTn0B8Q"
      unitRef="Unit_Standard_series_lxqxSSbLPkuOU9DD2aDsAA">1</atxs:NumberOfPreferredStockSeries>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww"
      decimals="INF"
      id="Narr_DkObyfSIekiIQkY2Gfmm_Q"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">31455</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="2"
      id="Narr_quxm002mV0SdG3Yrnk30oA"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">166.67</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww"
      decimals="INF"
      id="Narr_qDkLaGbwxUezfxf64fcSjA"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">5242501</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_9DI--S7A0E-X9D3zNHpn_g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The following table presents information about warrants that are issued and outstanding at December 31, 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:32.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:32.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Issued&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Equity&#160;Instrument&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&#160;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&#160;of&#160;Expiration&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:32.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Common Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 204&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 732.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3/30/2022&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:32.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Common Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 699,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6/21/2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:32.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Common Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 331,858&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2/7/2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:32.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Common Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 498,356&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12/14/2030&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:32.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,530,380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:32.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Weighted average exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:32.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Weighted average life in years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.05&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_atxs_WarrantsIssuedIn2015Member_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_okImnMTN40m3e7LsnREh1Q"
      decimals="INF"
      id="Tc_gV_bFvbyUEqYKg6DlUsPJg_2_4"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">204</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_atxs_WarrantsIssuedIn2015Member_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_okImnMTN40m3e7LsnREh1Q"
      decimals="2"
      id="Tc_8Yz-SQutBUqrvGq5EIcpog_2_7"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">732.72</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_atxs_WarrantsIssuedIn2018Member_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_-DDXhDsqjEaom3XeTK93Aw"
      decimals="INF"
      id="Tc_gZt7OXdwMEeeNAy_w1tYwg_3_4"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">699962</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_atxs_WarrantsIssuedIn2018Member_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_-DDXhDsqjEaom3XeTK93Aw"
      decimals="2"
      id="Tc_Q71mjZejsUuW9KFCsqY3pw_3_7"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">72.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_atxs_WarrantsIssuedIn2019Member_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_kZt19R6SjEmokrt5Mie7PA"
      decimals="INF"
      id="Tc_71yxC1uUakesH_JFBfcO7g_4_4"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">331858</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_atxs_WarrantsIssuedIn2019Member_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_kZt19R6SjEmokrt5Mie7PA"
      decimals="2"
      id="Tc_r9N6YD1JgECI28ijMMxhSQ_4_7"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">37.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_atxs_WarrantsIssuedIn2021Member_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_yasr1KjcWk2xnQzdAy_KxA"
      decimals="INF"
      id="Tc__nDvxvT1DEi-pa_5Z4GW3w_5_4"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">498356</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_atxs_WarrantsIssuedIn2021Member_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_yasr1KjcWk2xnQzdAy_KxA"
      decimals="2"
      id="Tc_a9zXd_PX9UGp4LwXkHiBbA_5_7"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">2.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_LGPUGn5hf0Wh2Qca8q1eow"
      decimals="INF"
      id="Tc__uUi08ce6ka0hCa86yRJfA_6_4"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">1530380</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_StatementClassOfStockAxis_atxs_CommonStockWarrantsMember_5FuYIQyMO0KrQWYAQrHRTw"
      decimals="2"
      id="Tc_KOPk6Z_30EWLmNOx9cFvbw_7_7"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">41.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <atxs:WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_WeightedAverageMember_Q8_JfLkSZkujoq1ijmIZaA"
      id="Tc_rQqVVEZYakWm2c6Z6TfV1w_8_9">P4Y18D</atxs:WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="INF"
      id="Narr_HJcLDxCdRUK4jLT42a52Uw"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="INF"
      id="Narr_DYdxQbnyH0ipkchEJ7G6RA"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="INF"
      id="Narr_yAKTLf2PZEa0bs9MJHV7bA"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">13016955</us-gaap:CommonStockSharesIssued>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_b4y9nCTj0E6QWTMWD7-EiQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Series X Preferred Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,242,501&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Warrants for the purchase of common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,530,380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,032,291&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Options outstanding to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,346,733&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 227,846&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Options available for future issuance to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,633,736&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 322,695&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Shares reserved for the employee stock purchase plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,904&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,825&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,784,254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,607,657&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww"
      decimals="INF"
      id="Tc_sOm9n5DduUa0agj5wT8qrQ_3_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">5242501</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember_aICBK5MKZkuZVxp05YnVBw"
      decimals="INF"
      id="Tc_-ew7vdgHJE6fdJ3BAawYuw_4_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">1530380</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember_kmFzwlwoEUWBR8fU7IbkTQ"
      decimals="INF"
      id="Tc_yepDWw5EFUWHR9xQ1OM7ew_4_4"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">1032291</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_CommonStockOptionsOutstandingMember_7Vl-PK_cx0mTb1TT5TzDIQ"
      decimals="INF"
      id="Tc_yfaTcXNE9EGntfvKdgEYxw_5_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">1346733</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_CommonStockOptionsOutstandingMember_Yjog7Avv4UWNzFd78N6wtA"
      decimals="INF"
      id="Tc_RY2WKxVa5kGcF6dKW-xp5w_5_4"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">227846</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_CommonStockOptionsReservedMember_wmV-DoZ1iEel9yGD2br-TA"
      decimals="INF"
      id="Tc_vBvSGetEJ0-1K1nFDgo9Ag_6_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">1633736</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_CommonStockOptionsReservedMember_TAf-v0nKi0qS_WfrM_WRtg"
      decimals="INF"
      id="Tc_zCvOQQef306byqTZ_Fp4Wg_6_4"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">322695</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_EmployeeStockPurchasePlan2015Member_qvrFhdUehU6nDMNnX5A56A"
      decimals="INF"
      id="Tc_BwR9lmsmoESRIAL-2OMWZQ_7_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">30904</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_atxs_EmployeeStockPurchasePlan2015Member_5SuvAJwIjkuX5pWVQNdilA"
      decimals="INF"
      id="Tc_frt5etSUyk-1ELBmu9nS-w_7_4"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">24825</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="INF"
      id="Tc_ikORBBzrWkie8M1Z05Ur7w_8_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">9784254</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="INF"
      id="Tc_q4-LSgTTvUuD-HF9bNOEOw_8_4"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">1607657</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww"
      decimals="INF"
      id="Narr_YWuoWZBz6EWMy_n8Iwuseg"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">31455</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_C8qVETjSOE2CA-izSeZMww"
      decimals="2"
      id="Narr_tqLNaUdHBEOImNMAxeR7ew"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">166.67</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_rkV1KwPrMEqiMsFjXsyF5w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;9. Stock Incentive Plans&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Prior to the Company&#x2019;s initial public offering in June 2015 (the &#x201c;IPO&#x201d;), the Company granted awards to eligible participants under its 2008 Equity Incentive Plan. In May 2015, the Company&#x2019;s board of directors adopted and, in June 2015, the Company&#x2019;s stockholders approved the 2015 Stock Incentive Plan, as amended and amended and restated since the IPO (&#x201c;2015 Plan&#x201d;), which became effective immediately prior to the effectiveness of the IPO. Subsequent to the IPO, option grants have been awarded to eligible participants only under the 2015 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The 2015 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units, stock appreciation rights and other stock-based awards. The Company&#x2019;s employees, officers, directors and consultants and advisors are eligible to receive awards under the 2015 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Terms of stock option agreements, including vesting requirements, are determined by the Company&#x2019;s board of directors, subject to the provisions of the applicable stock incentive plan. Options granted by the Company generally vest ratably over four years, with a one-year cliff, and options are exercisable from the date of grant for a period of ten years. For options granted through December 31, 2021, the exercise price or purchase price, as applicable, equaled the estimated fair value of the common stock as determined by the Company&#x2019;s board of directors on the date of grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;A summary of the Company&#x2019;s stock option activity and related information for employees and non-employees follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&#160;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&#160;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 227,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 68.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,156,646 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;15.91 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Assumed in Quellis Acquisition&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;55,414 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.73 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(10,470)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2.10 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Cancelled or forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(81,196)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;48.13 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(1,507)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;100.85 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,346,733 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;22.25 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;9.02 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;168,181 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Vested and exercisable at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;135,412 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;72.76 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7.19 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;77,798 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The total intrinsic value of options exercised in the years ended December 31, 2021 and 2020 was $45 thousand and $29 thousand, respectively. The weighted-average grant date fair value of options granted to employees and non-employees for the years ended December 31, 2021 and 2020 was $9.82 and $3.81, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;At December 31, 2021, the total unrecognized compensation expense related to unvested stock option awards was $10.8 million. The Company expects to recognize that cost over a weighted-average period of approximately 2.9 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The fair value of stock options granted to employees and non-employees was estimated using the Black-Scholes option-pricing model based on the following assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:36.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Weighted-average expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;69.28-71.32%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;75.51-82.08%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5-6.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.50-6.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.42-1.36%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.37-1.51%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Volatility&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Due to the lack of company-specific historical and implied volatility data of its common stock, the Company does not have relevant historical data to support its expected volatility. As such, the Company has used a weighted average of expected volatility based on the volatilities of a representative group of publicly traded biopharmaceutical companies. For purposes of identifying representative companies, the Company considered characteristics such as number of product candidates in early stages of product development, area of therapeutic focus, and length of trading history. The expected volatility was determined using an average of the historical volatilities of the representative group of companies for a period equal to the expected term of the option grant. The Company intends to continue to consistently apply this process using the same representative companies until a sufficient amount of historical information regarding the volatility of the Company&#x2019;s own share price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Term&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company uses the &#x201c;simplified method&#x201d; to estimate the expected term of stock option grants. Under this approach, the weighted-average expected life is presumed to be the average of the contractual term (ten years) and the vesting term (generally four years) of the Company&#x2019;s stock options, taking into consideration multiple vesting tranches. The Company utilizes this method due to lack of historical exercise data and the plain-vanilla nature of the Company&#x2019;s share-based awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk-Free Rate&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The risk-free rate was based on the yield curve of United States Treasury securities with periods commensurate with the expected term of the options being valued.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N1cnyjsfXUyGLlzflAry7w"
      id="Narr_GWxU2cDCLEWvrL1DD0VDCw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N1cnyjsfXUyGLlzflAry7w"
      id="Narr_vnCmuenM60WRthxZZbR2pg">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N1cnyjsfXUyGLlzflAry7w"
      id="Narr_aRNejPiA2UmsISTYyWmj_Q">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_C5PeJ1Y27kWED6OHJrd4nA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&#160;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&#160;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 227,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 68.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,156,646 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;15.91 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Assumed in Quellis Acquisition&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;55,414 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.73 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(10,470)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2.10 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Cancelled or forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(81,196)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;48.13 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(1,507)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;100.85 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,346,733 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;22.25 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;9.02 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;168,181 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Vested and exercisable at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;135,412 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;72.76 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7.19 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;77,798 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="INF"
      id="Tc_SKqAPrO9S0O0MRYJ79uomQ_6_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">227846</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="2"
      id="Tc_wgO8-DkfyESxjf0UWhyrLg_6_5"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">68.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      id="Tc_ciNtMqhPUUmBUQEgziSZvA_6_7">P8Y1M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="INF"
      id="Tc_MTFEmDDjl0uTmB8aFkmDAA_7_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">1156646</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="2"
      id="Tc_frNfIIa3v0eUUf8vuGACDg_7_5"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">15.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <atxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="INF"
      id="Tc_5iYJVk_2sEeH8oLWfE6Ufw_8_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">55414</atxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross>
    <atxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="2"
      id="Tc_52ZHvgIXFkuhE71vIrrtgw_8_5"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">1.73</atxs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="INF"
      id="Tc_7qWynpdfc0OMgYJNAJDBPw_9_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">10470</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="2"
      id="Tc_N5VpfHuVp0aBhIYDcQQHzw_9_5"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">2.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="INF"
      id="Tc_HlJ0BD5puUqatd2hpBxqZg_10_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">81196</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="2"
      id="Tc_QgO8m0hLwUWFtyiFJ7o12A_10_5"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">48.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="INF"
      id="Tc_yXE24xwskke41sO_Uy1pZA_11_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">1507</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="2"
      id="Tc_AnQFkNFTY0eWGPOiul4SHw_11_5"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">100.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="INF"
      id="Tc_YRMy9ncmB0S7DTpWAyw4sg_12_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">1346733</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="2"
      id="Tc_RwCENR2lNEyCMiUeg0l8mA_12_5"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">22.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tc_k3uOuouF3kGBUTqnV_VJoQ_12_7">P9Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_3DsDo4bPr0KD4qxW23NH_g_12_10"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">168181000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="INF"
      id="Tc_OvlDYshhPEqPY1fGOptC8w_13_2"
      unitRef="Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA">135412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="2"
      id="Tc_UnAtTxzunkqtEU7Bn6Meiw_13_5"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">72.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tc_RQHPa57lbUyEeE4VbMdvKw_13_7">P7Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_dQhEyfob_EmZY6X_JedUTg_13_10"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">77798000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N1cnyjsfXUyGLlzflAry7w"
      decimals="-3"
      id="Narr_FyHiYLX9w0Cj2NeRy89t5g"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">45000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Xk2KOEZoqU-rq0ONLV8kug"
      decimals="-3"
      id="Narr_cAl_bb3vv0uoaCVFBWKc2A"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">29000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N1cnyjsfXUyGLlzflAry7w"
      decimals="2"
      id="Narr_TI2np-E0Wk62_44U0kPLSw"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">9.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Xk2KOEZoqU-rq0ONLV8kug"
      decimals="2"
      id="Narr_9RsKgG6m3EWu38mVghVtjQ"
      unitRef="Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA">3.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_DpksmxD47kGvcyVVnTBAsA"
      decimals="-5"
      id="Narr_kvw1OZ1yxkWuVPe43tCJdg"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">10800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N1cnyjsfXUyGLlzflAry7w"
      id="Narr_4D7PnAu4t0qMbl-ZIr2rqw">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_G7FDm3TvqkyRcZxbuUQdyw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:36.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Weighted-average expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;69.28-71.32%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;75.51-82.08%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5-6.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.50-6.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.42-1.36%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.37-1.51%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dRehDxBmQEyeX74Fi2n2Og"
      decimals="4"
      id="Narr_5NdYP56XFka0neb55rFuAA"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.6928</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember__jh8k2B4zk-VJ3ifpBRqMA"
      decimals="4"
      id="Narr_qQXuc5ibPkKhdxfayKB2bg"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.7132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pMusOm4pFUy12JHZQXtkNQ"
      decimals="4"
      id="Narr_TZ6nP6p23k6d_Qh9RwkICA"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.7551</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_o2nWgMXB4EmLCnwUmgGn8g"
      decimals="4"
      id="Narr_ktgD588EFU-k7H4UXJt43Q"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.8208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dRehDxBmQEyeX74Fi2n2Og"
      id="Narr_i0_6qWIEFESbAmQK6d9y4Q">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember__jh8k2B4zk-VJ3ifpBRqMA"
      id="Narr_n37L2Ybt80qNGm-RINaOow">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pMusOm4pFUy12JHZQXtkNQ"
      id="Narr_Xetajwq_sE28wqnQT6vo6Q">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_o2nWgMXB4EmLCnwUmgGn8g"
      id="Narr_5qvgreZDgEyCVGa35erR7g">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dRehDxBmQEyeX74Fi2n2Og"
      decimals="4"
      id="Narr_t0XYB6ANzUyQskJWFvhRyQ"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.0042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember__jh8k2B4zk-VJ3ifpBRqMA"
      decimals="4"
      id="Narr_lwgDdkn2NUuxvwm2Lei6Vg"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.0136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pMusOm4pFUy12JHZQXtkNQ"
      decimals="4"
      id="Narr_MdXr8TFEEU-4fMzuiIE2jQ"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.0037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_o2nWgMXB4EmLCnwUmgGn8g"
      decimals="4"
      id="Narr_xMK5EhArDUartqXfCyWx2A"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.0151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="2"
      id="Tc_cJ3CgYnDGUi3QmsEwhi6Lw_6_2"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="2"
      id="Tc_wfihcv0fTUWjIJtbt_xWvw_6_4"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_H_D1Lyi1hUKAbrtKuyJ4Aw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;10. &#160;&#160;&#160;Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;For the years ended December 31, 2021 and 2020, the Company did not record a provision for federal or state income taxes as it has incurred cumulative net operating losses since inception.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;A reconciliation of the U.S. statutory income tax rate to the Company&#x2019;s effective tax rate is as follows for the years ended December 31, 2021 and 2020:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Federal income tax (benefit) at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;21.00 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(0.25)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(0.41)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Federal research and development credits and adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.44 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2.78 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Nondeductible research costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(17.75)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;State income tax, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.82 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.03 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.37 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(4.27)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(29.77)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s deferred tax assets consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;75,849 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;65,373 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Tax credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;10,063 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;9,273 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Capitalized research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;139 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;482 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Capitalized legal expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,048 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,070 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;99 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;284 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,977 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,648 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;89,175 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;78,130 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;ROU asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(107)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(262)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(89,068)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(77,868)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company recorded an increase to the valuation allowance of $11.2 million during the year ended December 31, 2021 due primarily to the federal and state net operating losses and tax credits generated. The Company recorded an increase to the valuation allowance of $11.1 million during the year ended December 31, 2020 which was also primarily due to the federal and state net operating losses and tax credits generated.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences representing net future deductible amounts become deductible. Due to the Company&#x2019;s history of losses and expectation of future losses, the deferred tax assets were fully offset by a valuation allowance at December 31, 2021 and 2020. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;As of December 31, 2021, the Company had approximately $279.4 million of federal and $271.8 million of state net operating loss respectively, which may be available to offset future taxable income. Federal net operating loss carryforwards of $150.6 million and state net operating loss carryforwards of $271.8 million will expire at various dates from 2028 through 2041. Federal net operating loss carryforwards of $128.8 million can be carried forward indefinitely. The Company had approximately $8.1 million of federal and $2.4 million of state tax credit carryforwards available to reduce future tax liabilities as of December 31, 2021, which will expire at varying times through the year 2041.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;), provides for a limitation of the annual use of net operating losses and other tax attributes (such as research and development tax credit carryforwards) following certain ownership changes (as defined by the Code) that could limit the Company&#x2019;s ability to utilize these carryforwards. At this time, the Company has not completed a study to assess whether an ownership change under Section 382 of the Code has occurred, or whether there have been multiple ownership changes since the Company&#x2019;s formation, due to the costs and complexities associated with such a study. The Company may have experienced various ownership changes, as defined by the Code, as a result of past financing transactions. Accordingly, the Company&#x2019;s ability to utilize the aforementioned carryforwards may be limited. Additionally, U.S. tax laws limit the time during which these carryforwards may be applied against future taxes. Therefore, the Company may not be able to take full advantage of these carryforwards for federal or state income tax purposes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;As of December 31, 2021 and 2020, the Company did not have any significant unrecognized tax benefits. The Company had not accrued interest or penalties related to uncertain tax positions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The federal and state income tax returns are generally subject to tax examinations for the tax years ended December 31, 2018 through December 31, 2021. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state taxing authorities to the extent utilized in a future period. &lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_7-KzmH_j3UWicq4y118wcQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Federal income tax (benefit) at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;21.00 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(0.25)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(0.41)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Federal research and development credits and adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.44 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2.78 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Nondeductible research costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(17.75)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;State income tax, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.82 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.03 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.37 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(4.27)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(29.77)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="4"
      id="Tc_rRZfHuBxmE-gnfp2UX3eOg_3_2"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="4"
      id="Tc_aSHxo3oh8kiqVzW4MOIRCA_3_4"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="4"
      id="Tc_D4PKRzo8ZUahr3V1ZzuA_A_4_2"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.0025</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="4"
      id="Tc_MrrMCWAcvEOO81iK46Fedg_4_4"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.0041</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="4"
      id="Tc_YAl9cOvVG0y1FjxPYnW2lA_5_2"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.0044</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="4"
      id="Tc_HdeRVCpLREakzRr-mpP_fQ_5_4"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.0278</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="4"
      id="Tc_i-Aw0NLFSkCU5BZNp2a4Ow_6_2"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.1775</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="4"
      id="Tc_iRsgKDPP4kWsovvlY65Tvg_7_2"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.0082</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="4"
      id="Tc_pRKf_QXkOU-IRXfqiwIZ5g_7_4"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.0603</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="4"
      id="Tc_2bsHNZB6XEq34D_K77sGZg_8_2"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.0001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="4"
      id="Tc_EdeoR-ezc0uNT1oL9aTeow_8_4"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0.0037</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="4"
      id="Tc_WG8qs2YXrE2cGp2oQCWzdA_9_2"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">-0.0427</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="4"
      id="Tc_tsFI4XdyCEOobcRBlVaQDA_9_4"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">-0.2977</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="4"
      id="Tc_RrMRTlfmqkeMM3RabdkXxQ_10_2"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="4"
      id="Tc_xrARKlLLLUaD348LW_mTFA_10_4"
      unitRef="Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_PwtgeIJO_0WUy40UUhmsag">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s deferred tax assets consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;75,849 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;65,373 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Tax credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;10,063 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;9,273 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Capitalized research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;139 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;482 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Capitalized legal expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,048 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,070 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;99 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;284 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,977 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1,648 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;89,175 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;78,130 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;ROU asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(107)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(262)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(89,068)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(77,868)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_thAZGxdCq0-F7b4qWd81ng_4_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">75849000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_4BuPfKhy1UynbDs5LeEFdQ_4_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">65373000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_QPH2tcUZDEO-USnNLMztYQ_5_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">10063000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_s2TxZ7OpbEemZsB26kjunw_5_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">9273000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_UYndZ5WxEUeh_mn4cnrcUQ_6_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">139000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_7hnq8ZTku0SjqF80243G9g_6_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">482000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_MNyT-wB5AUys2pKnQ3KjaA_7_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1048000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_HQPrAwB4dE6DtFH2pPW8QA_7_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1070000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements>
    <atxs:DeferredTaxAssetsLeaseLiability
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_K2FUREceh0qKtbbJEGTYYQ_8_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">99000</atxs:DeferredTaxAssetsLeaseLiability>
    <atxs:DeferredTaxAssetsLeaseLiability
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_fftcyLR-6U6NeCCdzaNn9Q_8_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">284000</atxs:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_MXj9c2J3hkeQy1jN03eJpg_9_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1977000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_GTGgrpQxkUuZA4ySbsgYAg_9_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1648000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_8XWHXBt5JEypgtfGdsu-BA_10_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">89175000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_A_aY-CmUPUO4q8H-w-ZU7w_10_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">78130000</us-gaap:DeferredTaxAssetsGross>
    <atxs:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_1gMwyyBFV0-421eIqQul8w_12_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">107000</atxs:DeferredTaxLiabilitiesRightOfUseAsset>
    <atxs:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_IOu6E2adlkCzTA5vxMG51Q_12_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">262000</atxs:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_fAcJf82DPUGxW7J7YMDavA_13_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">89068000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_FdRifXvQsUW3oQbgeiigiw_13_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">77868000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-3"
      id="Tc_AvR4MZrHpUmDD7K56v71vg_14_3"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A"
      decimals="-3"
      id="Tc_FOOv3DCSV0eqD7xmcy6SRA_14_6"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      decimals="-5"
      id="Narr_512XCHamW0OCe5mCN-3tDg"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">11200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_Qx7cidZ2kkSH445SGB2-MQ"
      decimals="-5"
      id="Narr_LuTL3tD2UEGwWeAuMTswaw"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">11100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_elNRkz91iE-s8vhvuVnSvw"
      decimals="-5"
      id="Narr_ixncRcg-S0ykui3-70teBg"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">279400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_5XqYaukrUUaJdZ71ko0png"
      decimals="-5"
      id="Narr_oks06ihO6UO7l2arv_4aow"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">271800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_atxs_TaxYears2023Through2039Member_nyPtDfbQzUmCkbPiwwfF7A"
      decimals="-5"
      id="Narr_3xq4aA-JPUeAI0gYY9Tpew"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">150600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxPeriodAxis_atxs_TaxYears2023Through2039Member_PESuIbi88Em2aHygNgW-mg"
      decimals="-5"
      id="Narr_BjI-a79Ki06fhB8TP2brRg"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">271800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_atxs_IndefiniteTaxYearsMember_lPRNGMy2XEaPTJLtd05Mcg"
      decimals="-5"
      id="Narr_5_Kg20_0e0aFbZbaKMn0Rg"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">128800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_elNRkz91iE-s8vhvuVnSvw"
      decimals="-5"
      id="Narr_DzsAPy4Dok6qjCQ3pC5RUw"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">8100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_5XqYaukrUUaJdZ71ko0png"
      decimals="-5"
      id="Narr_zVA7Z0kAEEu9FufMink6aQ"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">2400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_8GTh2ocIyEagXeEtp2L5sQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;11.&#160;&#160; Defined Contribution Benefit Plan &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company sponsors a 401(k) retirement plan, in which substantially all of its employees are eligible to participate. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company did not provide any contributions to this plan during the years ended December 31, 2021 or 2020.&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g"
      id="Tb_2VIRgvmNX0OImU0En7cMAA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;12.&#160;&#160; Subsequent Events&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Operating Lease &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"&gt;On January 28, 2022, the Company entered into a sublease agreement (the &#x201c;Sublease&#x201d;) with Grant Thornton LLP (the &#x201c;Sublandlord&#x201d;), for office space. &#160;The Sublease will commence on the latest to occur of (i) May 1, 2022, (ii) the receipt of the landlord&#x2019;s consent to the Sublease and (iii) the date on which the Sublandlord delivers full and exclusive possession of the premises to the Company as set forth in the Sublease and will end on July 31, 2024. The Sublease will increase the future minimum payments described in Note 7 from approximately $0.4 million to approximately $1.8 million.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ"
      decimals="-5"
      id="Narr_7e7qdCjybEKUxSl2FPkQ9g"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_1_28_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dDqegR-RH0S_9dr4Q4C-Mw"
      decimals="-5"
      id="Narr_gpfraDknvEGcQm0ZlwmtiQ"
      unitRef="Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ">1800000</us-gaap:OperatingLeaseLiability>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>84
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MYBSDTKP OR^%T-L;4\#N>]7%OU!+ P04    " "0A6I4]]+RL$@%  #@%
M&    'AL+W=O<FMS:&5E=',O<VAE970R+GAM;*U8;6_;-A#^*X118"W@Q"3U
MZLPQT+H85F O0=UN^\I(=$Q4$EV2<I+]^AUE1;(E2G;7?DA,27?'YX[B/0^U
M>)3JB]YR;M!3GA7Z=K(U9G<SF^EDRW.FK^6.%_!D(U7.#%RJAYG>*<[2RBG/
M9A3C<)8S44R6B^K>G5HN9&DR4? [A729YTP]O^.9?+R=D,G+C8_B86OLC=ER
ML6,/?,W-Y]V=@JM9$R45.2^TD 52?',[>4MN5C2V#I7%7X(_ZJ,QLJG<2_G%
M7GQ(;R?8(N(93XP-P>!GSU<\RVPDP/&U#CIIYK2.Q^.7Z+]4R4,R]TSSE<S^
M%JG9WD[B"4KYAI69^2@??^5U0H&-E\A,5__18VV+)R@IM9%Y[0P(<E$<?ME3
M78@C!^(/.-#:@5[JX-4.7I7H 5F5UGMFV'*AY"-2UAJBV4%5F\H;LA&%7<:U
M4?!4@)]9KF2A92929GB*WK&,%0E':QM.HROT>?T>O7[U!KU"HD"?MK+4K$CU
M8F9@9NL_2^I9WAUFH0.SO.?)-?+(%%%,B<-]=;D[/G6?0;Y-TK1)FE;QO*&D
M2Z5X81#3&O*\&8GH-1&]*J(_%)'I+8+:H,0.^-=2[%D&4SAK=0@55J'L-MLO
MXS# \6*V/RY)WXKZ<P\W5B<X_0:G/XISO97*7!FN<EC1/=<F'P)YB!,<3>_-
M,<8=D'TKZ!]X &30@ Q&0=XIOF,B1?P)FI7FNBJL-%NN8$<<KYP+=]!#1((P
MZL!V&'GSP(TZ;%"'HZ@_2<.R"P"&_;EIA*.@ [%OYH<>'< 8-1BC48Q5E[Z2
MFZM2\P-$%\+(L?1^!U[?9AZ&;G!Q RX>!?=GM<+#A8O[%>D6K6]"PH&2S1M4
M\PN6=1C5W+6< >G6JV_F1WXP4#&"V^Z-+^IDF6#W(A-&\-%V1HYH@8RF_39)
M9 FM >W8,[O/N+/G$\=>"[I[S6GE^P.9MRV<T', 5<G;)N$$2/MO,HU)%V#?
MRB?S: !@RPCD#"742[.#CFL%B]P@$%^*&5$\H(R#]#A>-2=\KP\_[+[R#J/0
MGP^ ;VF"C//$:3,[A[// @'%7A=HWRH$2AE VG(%&2>+WV3Q<""T_UWH%>GS
M@3?X K1\0"XAA'.UZ_=Y5^WZ5F$4#R%LV8",T\%*YKDX2 #T^@]I.(K>.$&.
MAK$GC1N]8PF_G<!10G.UYY,E<A;Z^P.=IMIR"XE'&^7:R.3+5F8I5_JG2J"9
MY]%.V?(#&2<(4"L;#OLD1=4<SOJ-1OB6^GU_H%/!W!(-Q6=?%=A;VJ8X1:_P
M-<8$N$$AT+DE1[#?D-XRQ:>(!'@*$M#^'6Z!?BL-Z$[Q+T]_1L2;8A).YT%0
MR3IOZOG1U(O#%UNAM6WKE>0KC38PL/N8&02G )[?PT0O!XG*J'L73^%TJ7>\
M.AYFSZ[EJ%,]E7^='>>P&: LVG(J/<.I:2ILAX*N8/7M%9RI$K83T"6<*/N\
MZ<<DPO,NTKZ=AT'ST@&X1X>DLPQ;YF56G0QK]2US>*^V]A"_AZ8JM;.EC8?]
MAK?]!P0Z3;WE;CK.W<>IIWPC$N$4RK3/O5=^$,3]-7(8TA#'0R1#6Z*FEQ"U
M=G0W)^ ^!Q-*/=*51 X['X?A@*R@+5G3<;+N46*UA2]&[SBVN;1V;7=\=!X1
MV[0E=#I.Z&NN+.1_H,&DG.=6%L.6@&,TZ X[WC5,H/M,<#IG2]$T^J&\15M&
MI./'K0MXJXYP7,@Y:+:X4\C9T><G^^WO=Z8>1*%!>VW #U]'L![J\#GM<&'D
MKOHB=2^-D7DUW'(&*5H#>+Z1H$7J"_N1J_FHN?P/4$L#!!0    ( )"%:E1U
M_DK6-0,  &0-   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULM9??;YLP
M$,?_%0OMH96Z@"&0I$HBK:FF[6%2U&@_7EVX!*L&,]M)MOWULX&2$)( JY:'
M8)N[\^=K#I^9[KEXD3& 0K\2ELJ9%2N5W=NV#&-(B!SP#%)]9\U%0I3NBHTM
M,P$DRIT29KN.$]@)H:DUG^9C2S&?\JUB-(6E0'*;)$3\?@#&]S,+6Z\#3W03
M*S-@SZ<9V< *U-=L*73/KJ)$-(%44IXB >N9]0'?+W!@''*+;Q3V\JB-C)1G
MSE],YW,TLQQ#! Q"94(0?=G! A@SD33'SS*H5<UI'(_;K]$_YN*UF&<B8<'9
M=QJI>&:-+13!FFR9>N+[3U *\DV\D#.9_Z-]8>N/+!1NI>))Z:P)$IH65_*K
M7(@C!SR\X."6#FY7!Z]T\'*A!5DNZY$H,I\*OD?"6.MHII&O3>ZMU=#4/,:5
M$OHNU7YJON"IY(Q&1$&$'@@C:0AH9<))=+,D E(5@Z(A8;?H/7J';"1C/2JG
MMM*SFQAV6,[T4,SD7ICI$<(!\O =<AT7GW%?='=WZNZVUEP)=ROA;AYO>"'>
M4J<+"*%5ZS4.7^Y01@3:$;8%=$-3%''&B) H U$HOCVGN)ABE$]A7IC=W!DX
MCE:W.Q;69E7C]RI^KQ\_V:J8"_I'CQ@!Q6,Z2UT$]H]X?"?_G2<:5D3#?D14
MRFT[S;!!XYRLWS6+&JE?D?K]2/7^)A5)(YINVG#]5MQK%C7<H,(-KN(N>)+H
M'>\->1ITRM,VJQK\J((?]8#OGJ2CQBKB,DM/U[N+90U]7*&/>Z!WR^9Q$\9S
M<##Q_1/JIJ'G#4?>.#C//*F8)SV8>^3UI"MXT_ J.'8.E<CI^E:>*3'UH$?E
M#?^O;;*,?*QT.''&@7N:@!T,Z_2'&H6O%ZD5" H2_= 'I@CT^>V9 0IYN@.A
MJ&EG=7775NQ05W#/PO(O&TXY1]N.TVI6UW"H1+AG*>KQU)O59H*]<>.9MYG5
MR0^5"?<L3=VV'=PL.AX>-M[=,V:7B _%"5^O3F\IIF7H5NRFV2FV?70$-M\?
M7XC8T%0B!FOMXPQ&VED41_JBHWB6GXJ?N=)G[+P9Z\\@$,9 WU]SKEX[YJ!=
M?5C-_P)02P,$%     @ D(5J5,#\Q2YA!   00\  !@   !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6R]EUEOXS@,@/^*$,S###"-+1]Q4J0!>NPQP,YNT<[L
M/"LV$PNUK8PD)]U_OY3L.&DL&]V7?4E\D/1'BB+%Y4'(%Y4#:/):%I6ZF>1:
M[ZX]3Z4YE$Q-Q0XJ?+,1LF0:;^764SL)++-*9>$%OC_S2L:KR6IIGSW*U5+4
MNN 5/$JBZK)D\I\[*,3A9D(GQP=/?)MK\\!;+7=L"\^@O^\>)=YYG96,EU I
M+BHB87,SN:77]W1A%*S$WQP.ZNR:&%?60KR8FR_9S<0W1%! JHT)AG][N(>B
M,):0XV=K=-)]TRB>7Q^M_VJ=1V?63,&]*'[P3.<WD_F$9+!A=:&?Q.%W:!V*
MC;U4%,K^DD,KZT](6BLMRE89"4I>-?_LM0W$F0*=#2@$K4)PJ1 -*(2M0F@=
M;<BL6P],L]52B@.11AJMF0L;&ZN-WO#*+..SEOB6HYY>W8M*B8)G3$-&GC7^
MX1II1<2&_+4#R4RL%;DBWY\?R,</G\@'PBOR+1>U8E6FEIY&!F/)2]OOW37?
M"P:^1P/R550Z5^27*H/LK0$/X3L/@J,'=\&HQ0=(IR2DGTG@!]0!=/]^=7\$
M)^P"&EI[X8"]-FK5EL K[C4%ZGK$:M19C:S5:,#J$RA@,LT)1AVS=(_;;V<6
MRK4 C:69M61V\7Y%XS@.EM[^/"I]J2".%WXG]08S[C#C4<S?H$+O"TO),DQ7
MKK2)QAY<H(VM^!PTFOO)!:A#BLZCV TZZT!GHZ"WZ<^:2TQY7EWMI$A!*2Q*
M[X_QK \UBV8T<5,E'54R2O5-: R>Z&60BR#I$RRB13*[B%Y?+$RB<"!Z\XYS
M/LKYA\!P;:0HCZQ8(UR,\]['KYR0#KD1RD5'N1C?B3H'B0N<BA+(QS:6G\9V
M(_5/5=,?C<"72@/FB[:YPJL]7II4:;_F+(M^?\&"RTWI$ K"F3L,]*S$TU'8
M)A!M #Z3"IPIW1IYLPKQ_!+0(41].D 8G B#]R3^V8(-8P8]@EET2=F7H4/9
M1$^%G8:CD'_BH:K S'=2A>Y4I[T5=@B&2>@/%%YZ:A!TO$,\\#W/ +,1ST:I
MP(R4FJ\+('BXVX TI0[/$ND+5KG"]GHMR!JK]8:G'$/?:-BSV0:8KB4TF:U4
MS:H4\+W2;L>COC]!%(4#E9">.@D=;R7':!.FM>3K6C/C#5)C=I2(J7(F(1=%
MAMA.L+C7X*X"N@BCQ>6*. 3'5N348NAXC^D\P!K9X.(Y"H^</'7R-L;F;P,Y
M[>] AQP-IL$ [:GUT/'>XZ3->%'KRU-:RYN\D]<A-\)[:D%TO ?]L =TR*X8
M)BX.'&_R L^OM58:4]BTT5K91F\JRG]9D'Y7FB^"F";AI8=]P="/YW$R'_#Q
MU,#HXG_Q<6P9%^_ULB_H]M([&T9*D%L[HRE$KRO=G.J[I]T<>&NGGXOG=V8^
MM$/.R4PS7'YE<LMQ+"E@@R;]:8)4LIG7FALM=G;D60N- Y2]S''&!6D$\/U&
M"'V\,1_HIN;5OU!+ P04    " "0A6I4YA"0;Y4"  !K!P  &    'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;*55V6[;,!#\%4+(0PLTUN4K@2P@=GH!31O$
M2?O,2&M+"$6ZY-I._[Y+2E;MU%8#]$4BJ9W9F16Y3+9*/YD" -ES):29> 7B
MZM+W359 Q4U/K4#2EX72%4>:ZJ5O5AIX[D"5\*,@&/H5+Z67)F[M5J>)6J,H
M)=QJ9M95Q?6O*0BUG7BAMUNX*Y<%V@4_359\"7/ A]6MIIG?LN1E!=*42C(-
MBXEW%5[.QC;>!7PO86OVQLPZ>53JR4X^YQ,OL() 0(:6@=-K S,0PA*1C)\-
MI]>FM,#]\8[]@_-.7AZY@9D2/\H<BXDW]E@."[X6>*>VGZ#Q,[!\F1+&/=FV
MCAU2<+8VJ*H&3 JJ4M9O_MS480\0#D\ H@80O03T3P#B!A [H[4R9^N:(T\3
MK;9,VVABLP-7&X<F-Z6T?W&.FKZ6A,-TIJ11HLPY0L[F2"_Z16C83%6T*PK[
MNS; OBACV#E[F%^S-V=OV1DK);LOU-IPF9O$1Q)BZ?RL23JMDT8GDH81NU$2
M"\/>RQSR0P*?'+0VHIV-:=3)> U9C\7A.Q8%47A$T.SU\*!#3MQ6-79\\7]7
MM2-9OTW6=\GZ)Y)]I;,N_J*JJU8CAPYI#_0F/0\O^A=AE/B;_?(<B8M'<1"T
M80?*!JVR06<9OF$!FF4'IDM)<[CL\#ULV8>=OC]2CV+4"4RA-)XCZ(K(-V#0
MU?I8-6J^P9[+X$4=NB(.1(Y:D:-.D?<*N6#JM86H=8[^J;,KXD#GN-4Y[M1Y
MN#-/;:?Q*[?3D;ACV\G?ZUL5Z*5KYX;JM)98G_UVM;TQKERC?+$^I9ND;OQ_
M:.IKZ(;K92D-$[ @RJ WHIKINK77$U0KUQT?%5*O=<.";D/0-H"^+Y3"W<0F
M:._7]#=02P,$%     @ D(5J5)M_U3E>!@  I!P  !@   !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6R]65MOVS84_BN$46 M4-<BJ6N1!$CL).O#AJQIM[TR
M$AUSD417I.+TWX^4%<LB*=E-BKXDDGS.X;F1WW>DDPVO'L2*4@F>BKP4IY.5
ME.N/LYE(5[0@X@-?TU+]LN150:2ZK>YG8EU1DC5*13Y#GA?."L+*R=E)\^RF
M.COAM<Q926\J(.JB(-7W"YKSS>D$3IX??&;W*ZD?S,Y.UN2>WE+Y=7U3J;O9
MSDK&"EH*QDM0T>7IY!Q^O,:-0B/Q-Z,;L7<-="AWG#_HFT_9Z<33'M&<IE*;
M(.K?(YW3/->6E!_?6J.3W9I:<?_ZV?I5$[P*YHX(.N?Y/RR3J]-)/ $979(Z
MEY_YYG?:!A1H>RG/1?,7;%I9;P+26DA>M,K*@X*5V__DJ4W$GH(_I(!:!60H
M0#R@@%L%;"B@:$#!;Q5\4V'(I:!5"$R%8$ A;!7"8V.(6H6H*=8VNTUI%D22
MLY.*;T"EI94U?='4M]%6%6&E;L5;6:E?F=*39W->"IZSC$B:@5NI_JD^DP+P
MI;KCZ<.*YQFMQ&_@\EO-Y'<P!5]O%^#MFW?@#6 E^++BM2!E)DYF4GFC;<[2
M=N6+[<IH8.4;U7.TJIIEU4*WM&)4@'^!\=QA>#YN>,Z+0C6Y&-!>C&N?9QG3
MFX3DX(:P;*J"G),UDR1WV+H<M[6@2Y8R"<[3M"[J7.?88>1JW,@/).9ZW-(7
M;D4Q4^VRZQFTZQG4V/$'[%R0G)0I?0_NZ#TK2U;>ZW99*S]Y!H@$"YI^ !B^
M!\B#B:M^6_-A8UZ?E8]GZ&3VN%\CAT208!CTQ2YML2E".$BBOMRU+8>#"'D[
MJ5X:\"X-^.5I>*OZ1JQ(1<6[HU*R72K8#]B+$ I#MX_^SD>_4<0#/GXJ4P50
M@H*WRH/FZIW>MK?:,V-KCS1&L%LM&,W()R%JG1*=AV;[O0>E0E-UQYY_2;F0
MKL-B'E@E@D9/!':*_""(C5*[I1)W&L-=8.%/"6R_[*X@0\NY.(;A4)&CG7?1
MT=ZE>X<?4$Q%-=]4KNA4\8R'QF-UA*A.%<=79A%93L,0A6;>#TGU(HMWD<6_
M*K)#I8DM_W&"4#P00+(+(!D-X*;B*:69 ,N*%X ^T2IE@C;PRM<:9IQ[(3FX
M%Q+;6T/DVB&"W,% KR,+WBO#.93F=H%>G\"A#0#W6 P<=:Q!Q*GFI)EN%$74
M!6FH+GW2U]3) Z#M"DX\(XV'I/H.=Q *QS'T3]6C.1>N\E^VJOM+3G&$/<NU
M@W)]YSI@@T<B&RVS06C7\.FH+[9ZUS=Z%]I8AST8A 8'N'3(35'HQ1:ZN];T
MPG#@S(<==D+_)6D8AO:!E/AVO-B/<!R:<1P6[$?2X3(,?@$-@!U<PI^#E\ZI
M(;2J&?MA$II=9&,I3((P,'-J6X.>CT(XD-(.<^'QH/L*2G !;>#$01#A ?\Z
MY(3'0^=Z-SELT5,-;'TXK=?-6P'5 *(9?K327S7-<^8N46PG-0AA')@ULD$U
M]A*3.3BD8.BC>"@%'?;"<? =9 \CX1XLEPVK@1=XQADW=XD%@>_[[IA0A\!H
M'(''8U)\2#TM']5^;L,R2N\*J5VQ-T7!,$Z0@3=SAV!B5!PYX%V9@@/;#74
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MO&@N5Y2H*4P+J-^7G,OG&_V19_=A\NQ_4$L#!!0    ( )"%:E0'^U!12 (
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M& ]P&>[X H\3ABMICZJ"EKS$1?;"?8: 6F @P9".(TCP_JL -0K$AGES+N:
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MD"P*4Q4)=N ]Z144ZY28BAN32:O=V_=O!1DO(_D[2\E*XZ?/G0".;[2IG,B
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M(8-<9 I[%+ _X@E_(UB6RI+V@W%K2&C6W30?L-,U</L8[HQ]$JL7E(RH#(_
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M^3[,_K0V,*K*;;9ENR/Z51QFZF)IVQ(DRJ;PH&M@Q[TO0+09:E/T.G6@AUB
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MJ!#;R[O4RTX2X)-?F*#"@IR)<]%ZFD25^32!*GBD,K*/26%YU&1_6.9ZZ?I
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M2%TZ&H#OEPXP3#_0 O%/S;S\?U!+ P04    " "0A6I4,O0>Q%\%   W#0
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M1$IK6>?N6F]_IR:>*>,E.K?^5VR#[&C<$TEMG2X:97A0J#)<Y=>&ASV%1?R
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M[S)@,RTQB(2:,\>G$BS#.+2XB@E5A:?'^11CCSE<?JGS@JL5<1@>O;!LUF[
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M@VTHUKU:BI('A(0EQJ!'1&<[H1)9I@V6.ZJUH=)L@ D>C%S14DMM&*H9U %
M-T8TCI'O2#82TV>%3=D"AC+?]F>84G%?7(!V9<9+!W<%AA3JZ]4$M,E*@$R]
M==JYA9;<5?:M&;<!L4/ >PUB^.0CX6'FO. 2.V^@&)@"!IU7'"58 3=;TO(5
MVMJOQR6MBYIEXV TBMD>;F(0FK!/WO!O["$T[[NY+48FA^-]/+J:D$LJIZ^W
MZZ 28Y&GJ<^^Z*&""VK^^PDO1+> W1L%X\/)/EW_5)UVI?#N(^?=XY)26&^
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M>] N .=SI6QKN 6Z/\CJ#U!+ P04    " "0A6I4>1\JO=0"  !\!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6RM5=MNVS ,_17"&_;4^99TS;HD
M0-.N6(%U*-I=GA6;MH7JXDKRW.SK1\F)EQ9M@0U[L26*Y_"0INAYK\VM;1 =
MW$NA[")JG&N/D\06#4IF8]VBHI-*&\D<;4V=V-8@*P-(BB1/TW>)9%Q%RWFP
M79GE7'=.<(57!FPG)3.;%0K=+Z(LVAFN>=TX;TB6\Y;5>(/N6WME:)>,+"67
MJ"S7"@Q6B^@D.UY-O7]P^,ZQMWMK\)FLM;[UFXMR$:5>$ HLG&=@]/J)IRB$
M)R(9=UO.: SI@?OK'?MYR)UR63.+IUK\X*5K%M$L@A(KU@EWK?M/N,WGT/,5
M6MCPA'[PS281%)UU6F[!I$!R-;S9_;8.>X!9^@P@WP+RH'L(%%2>,<>6<Z-[
M,-Z;V/PBI!K0)(XK_U%NG*%33CBW/-52<D=5=G:>."+TYJ38@E<#.'\&G.5P
MJ95K+'Q4)98/"1)2,LK)=W)6^8N,9UC$,,D.($_S[ 6^R9C>)/!-_C:]!VS3
MD6T:V*;_5JR7P4<Q[.'AS:M9GDX^P(6"+_HGRC4:2CI[?P"N0>_9,K4!<D6#
M)7#E-#"Z.FN!U(- MQ%T5?$"P;:,GGW#BP9Z9J$0S%I><4+1CBF@"VR8XZJ&
M@(WAQ!%?@6VX%KH* </1P]@&"UTK_LL3#><@.%MSP=UFE/]UAP5NP8^,LA,$
M(+5XWW)#9N6_91[#>><ZVE,/<]E):-EF*(3!NX[['#OJ(1,4**W>%HPD"D;Y
M/D[ ^KQ(-O7*4+9=OP C_M=I/*4@0E!R\2CSFD)Y131-,%2)W(YV;E2DTAMF
MH\&7UPO9(#.6/@(U]U/A"$:+](!RL"V&^2(V,7P.]1@3['&0]2A>%A_^GWA/
M-7:R-Q$DFCK,/>H-W2DW#(?1.H[6DV&B_'$?YO(E,S57EFI?$932.(S #+-N
MV#C=AOFRUHZF55@V]'M XQWHO-+:[38^P/C#6?X&4$L#!!0    ( )"%:E1"
MK>&$W@4  ,,/   9    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;+U76V_;
M-A3^*X17;"^"1%&2+\T%:-H4RX N0=*NVR,MT197B51)RH[[ZW<.)<MR<T'7
M#GM(9%Z^C^=^R-.M-I]L*80C]W6E[-FD=*YY&44V+T7-;:@;H6!EI4W-'0S-
M.K*-$;SPH+J*&*73J.923<Y/_=R-.3_5K:ND$C>&V+:NN=E=B$IOSR;Q9#]Q
M*]>EPXGH_+3A:W$GW(?FQL H&E@*60MEI5;$B-79Y%7\\B+%_7[#'U)L[>@W
M04V66G_"P55Q-J$HD*A$[I"!PV<C7HNJ0B(0XW//.1F.1.#X]Y[]K=<==%ER
M*U[KZJ,L7'DVF4]((5:\K=RMWOXJ>GTRY,MU9?U_LNWV,C@Q;ZW3=0^&<2U5
M]^7WO1U&@#E] L!Z /-R=P=Y*=]PQ\]/C=X2@[N!#7]X53T:A),*G7+G#*Q*
MP+GS.Z?S3Z6N"F'L+^3R<RO=[C1RP(SK4=ZS7'0L[ F6F)%W6KG2DDM5B.*8
M( *1!KG87JX+]BSC&Y&')(D#PBB+G^%+!CT3SY=\MYY'M.E FWK:] ?-]SS+
M/"1CHI]_FK-X=M+3$1S2Y(3<0+P*8T31;1[F/X#)#7&E(*]UW7"UZ_&6<,@>
M< ?AJH $LHX[&.3".+F2.0R(7A&I<FT:;3@F23"F(26W) LHI?A';,F! R'-
M((CU@O#6E=K(+S !58)(:UNN<A% *+N2</*"AI3&I.&&;'C5"M* O)XN'"G5
M<=5\1Y;"<R"=T35Q4 2(T]U7*J(5"&Y(K8T@5A@I;$ $S\M^@%M+OH&U%N:<
M,#48PI)>>P"*>U# 6A@ &>H+(UVUJ+\%W?1&%E*MO2JXZD5!M3U??P8O=(-T
MRYW?L]3<%+BGD ;*C3;>3B-;/E1T6TJ@Z]6%:2%J402D:4T.=N\DY3E$@#D<
MLW?,@.K-).YST3C44L,VLY56](ITV(IO0_+*RP1Y)>HEV'^?6U^[O,"5-,M&
M_K[K=/[S001"D0>S*C172"Z]"Q#T+$9:DFNUP2!<5NA/<%<\G8;3V>C$7-<U
ME.P^O"!Z42VQ0H^CM*KU*J!/!DB+65#MT'-':!^->%+;P%QWM.\HO8.>$S0+
M6,J"C,8AN<5%#*W?->1-[),OCD_\E]&3:[/F2G[A7:<!@:\AQOW(9S.#G4:L
M(4A0OL=2=9\TS]M.D=^X:J%Y>M?Y@]Z*I1EFPJ$H7!]<0SYR8[AREKR'@U>Z
M@D;LQ?!FP5P0N"A5U^*]!DMP+=GN<:[D$%UF2$L\=^1[ JL/XNKE(,I__?U+
M0"&YZB3I2^25LLZT4.W<0=FQ!2[OA<DQ*VZ,!!N_Z6O?Y7TC.R^!R'&&3L'
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MWH'62TU==A.?8/B1+?X"4$L#!!0    ( )"%:E3#52N"!1D  %)/   9
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MR3!%G '3M0OT G,#AA6F#]K/,FF0<Y*]8?A!:5/*3X:EW^$_L.I$"T:(U W
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MAS@4K!SBJ6;36(F%V2![OEMBJ/.L,9B4R+J9T]38UA:%C$+I9)\EZ"A6UL2
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M+C]R(\Q%:6;=5!9O&FP@>+,(IY)T!3)!HF-[6;<)=ZY03GE[W+-_FR[#9LN
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ME@:@^[;O#:L:WVIK9:EQ_;:B28G:!9!_HY3=&2[!,'OGOP%02P,$%     @
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MCOOSCO[%YTZYK)G!2R5^\=P6LV 20(X;5@M[IW;7V.9SYGB9$L9_8=?8IDD
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M<FMS:&5E=',O<VAE970R-2YX;6SM6&UOVS80_BN$UPXV8%MOMFNGCH$D;=$
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MN  I'1"&\7V#.>A<.L/^>(O^F]\[[N6.&[A0\ILH[?)TD ]("7/>2'NMUG_
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M0F_ ]9QSM1?T ;;A7OX+4$L#!!0    ( )"%:E088<U$5@0  $ 1   9
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M>!"FH8GT;$3&AW6AYQL2YIMOX,+)[KI,DC'M<:$G$A(FDJ]WX4>F@<FM00S
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M@):PHB4WSW+S%6I!78>72J[]%6WJV"A ::F-S.MDRR!GHKK3][H0>PDXN9!
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M HQW<.>UUG@V/,'T^A2_ 5!+ P04    " "0A6I4[#[F9C4#  #Y"0  &0
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MZIH.AZ[?&?7$JKUOU5MEJ?'[84%O,]3.@/9SI>SCQ!&TK[W%#U!+ P04
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M=(98YRJ_9^43(W?NJK*2!B\^;ACAW12478#O-U*:AXF]_92WW>EW4$L#!!0
M   ( )"%:E1+-CH1IP(  *$&   9    >&PO=V]R:W-H965T<R]S:&5E=#0R
M+GAM;)55[V_:,!#]5ZRHFEJI;7X (>L@4BF:QJ1-K%VWSR8YB%7'3FT'VO]^
M9R=$;*14^P*V<_?>N^?+9;*3ZDD7 (:\E%SHJ5<84]WXOLX***F^EA4(?+*6
MJJ0&MVKCZTH!S5U2R?TH"&*_I$QXZ<2=+54ZD;7A3,!2$5V7)56O,^!R-_5"
M;W]PSS:%L0=^.JGH!A[ /%9+A3N_0\E9"4(S*8B"]=2[#6]FB8UW ;\8[/3!
MFMA*5E(^V<TBGWJ!%00<,F,1*/YMX0XXMT HX[G%]#I*FWBXWJ-_=K5C+2NJ
MX4[RWRPWQ=1+/)+#FM;<W,O=%VCK&5F\3'+M?LFNC0T\DM7:R+)-1@4E$\T_
M?6E].$B(PC<2HC8A<KH;(J=R3@U-)TKNB++1B&87KE27C>*8L)?R8!0^99AG
MTMOLN6::.8?DFORHT1^FR17YC@U!M0:CT3F,49"[\G."D:8 I@AHP] 7/%I3
MW&XIKT&3\SD8RKB^0) ]W(Q)G3$0&>A+LA 9.2-,D)^%K#45N9[X!DNQ@ORL
ME3UK9$=OR/Y*Q36)DDL2!5'X^# GYV<7?Z/X:$3G1M2Y$3G8P7^Y<0)XT $/
M'/#P%+"U<+&\_T#+ZM.\K^8&(W88]FW:IF$\C,-HXF][N(<=]_ D]QW5!4&;
M2687@$+PID"87ML;J-&!A&00C/L%C#H!HY,"E@HJRG("+SA*-+:(%2.QAU3;
M87U"1D="PD'<KR/N=,3O7$(F:ZR;5/25KCCTT<9'M%?AQ_&PGWC<$8_?(U8U
M7CYG=,4XMA?TECP^YAX&03]UTE$G)ZG=:[QO/D/%AF'A)VQ/CEMP',1)^(\*
M_V#BV.']C:H-$YIP6&-B<#W&*E0S$)N-D94;0BMI<*2Y98'?$% V )^OI33[
MC9UKW5<I_0-02P,$%     @ D(5J5'WM".(^ P  C T  !D   !X;"]W;W)K
M<VAE971S+W-H965T-#,N>&ULQ5?;;J,P$/T5"_6AE78+=NY5$FF;JMI*6ZE*
MVMUGETR"5<"I;9)6VH_?,1 @&T(CM5)>$AOFS.6,.0S#C50O.@ PY"T*8SUR
M F-65ZZK_0 BKB_E"F*\LY JX@:W:NGJE0(^3T%1Z#+/Z[H1%[$S'J;7'M1X
M*!,3BA@>%-%)%''U?@VAW(P<ZFPO3,4R,/:".QZN^!)F8)Y6#PIW;N%E+B*(
MM9 Q4; 8.3_HU82E@-3BMX"-KJR)+>59RA>[N9N/',]F!"'XQKK@^+>&"82A
M]81YO.9.G2*F!5;76^^W:?%8S#/7,)'A'S$WP<CI.V0."YZ$9BHW/R$OJ&/]
M^3+4Z2_99+;=@4/\1!L9Y6#,(!)Q]L_?<B(J -H^ & Y@!T+:.6 5EIHEEE:
MU@TW?#Q4<D.4M49O=I%RDZ*Q&A';-LZ,PKL"<69\*V(>^X*'Y"[61B78(:/)
M^0T8+D)]0;Z3*?B)4B)>XOII=D/.SR[(&1$Q>0QDHGD\UT/78";6G^OG4:^S
MJ.Q U!OP+TF+?B/,8[0&/CD>[NW"7:R_(($5)+#47^N OUEVAHE<$*XU( $1
M<)THF!-NR((+1=8\3(#8<X>'=TL(GA^A&^*WBOBM-'[[0/Q':; !6>@Z,C-T
M-T7;YW(];GO]3FOHKJN<U5BQP6!06.VDUBY2:S>F]@O6$!+:4&2G\-0Y"<G=
M(G[W4R1GZ$Z%/KK/\;X1.\QQK\BL=P3'K*'&?N&I?Q*.!T7\P:<X'NS1UQIX
MGO<?R?M6^%*J6.VD1KU2Z;S&Y.YE#.^HG>H%WXZ+9$^X=MU6!)2>A'-:JA=E
MC85-N X("C'Q[0)>$X$!K8[7"C,[YIS76#4<=%H*'6U6NOT>D+_D8XVAI5S1
M]FFZ4<H<[7QA-SI'=6/?JJD;I2+29DF<(O%* ]*P2I0?X#1$^%(!1/OI[D8H
ME8WV3M..4A%IO['&62"5^6Y 13BSK$&;FN+R7O2/4J<:LR9Y*J63-FMG8S.*
MIZ3I+<%**63>2=K"2M5D](O:DCOJ?M"6&K.ZMKB54=E^I]QSM12Q)B$L$.==
M]K"O*AO]LXV1JW1Z?I8&9_%T&>#G$BAK@/<74IKMQ@[DQ0?8^!]02P,$%
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M%#2V?)F@ROVB71T['7DHJY06K $;!8SP^HH?&R,Z@"C< X@:0/0/(-X'B!M
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MYS9[6^I)F0BS0;]?<ZX."Y.@G;U7_P!02P,$%     @ D(5J5& >:KQA @
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M _[L=LI8X<A2LA:$9E(0!=4J>(COUZF-=P&O#'I]=2>VDH.41VL\E:L@LH*
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MQ_V^H6]YYX^?+X1EXV=*8_AHM 9A% =!JZDF24]#UYR"'59#I_;O1)JJ:?6
MU.,)/^7DHF[8HUN/:#0@!UDYR,FP']4:2;(/-\]$Z#4?' 8YN!<T)0ZX08M)
M&/Q_O&4\S[&0YE&=B/X\U)Z23AZB9(IF VFP (9N G=9-U));=",$UN2V70.
M!Z18ZD(W=D> ;Z3"68_":1P,"+1@AFXR'V-PI);H7 N:#N7* AFZB>Q XDA=
M\;FN,)G"H2195D,WK+N '"DEZ2F7[T^3H<%M60W=L.[,/X#5 9BO!(NWR)OW
M5!!UIUX#SOE;9BBRS$=NYG>X^>F$F^,":.QWA<5H&D>^_1L8C\C"'<%1- 4'
MFGXEYC/,)'ZEM\)";\)+G(-O1!3@RA3@E/;'?BW%$1I;X=[0W;WGU5B0( 89
M?NW;Z*\N&$@: Q 49L,/8)^EX]#LXH'<BT=_W7NC=!N*&Y&H%BE!<E&D73Y0
MZ*S[S68CR 8KHK_"E*#Z SD%WW%>NM9/9%<$Y%X1+E6W[AUUN1$E,!D:S1;T
MR WZ-Z3^?+\=Q_$\&5!@^8[<?.]^P3HK9;F,$G>ELJQ:1_4LS*A,<RY+]S<<
MLIA%;LS:TC^;TAO&-LH/.[W3C^ F>?.S^H6G5.UI@^;]V0TL4@,W4EM:X896
M&[,+TK-"C^,UIN(\CLV;MTG!.77GTP2=A-?3*I@.#># XCAP[[4?F2 IWS#Z
M6VM.>;$C3.)J%T5>S#4!@N38!*0X*-ES/=[ET;')'HO^PX_&]]&T\Q-_X",O
ML"P/W#!M=^2'JN"""T5_U\*;'3/7[\!^2].MCDLJ0&454MK$\F0B.T3>*]ZM
M 1V [A]@B<)!6GJ=DZN"B$UUH">UKI*I^FRG?=H>&MY41V4GSV_AQU5]]&?-
MU">17[#07PT2Y&2M3?K36)-&U(=[]8WBN^I\[(DKQ8OJ<DMP1H1IH-^O.5>'
M&^.@/6)=_@=02P,$%     @ D(5J5%7F;0 O P  " P  !D   !X;"]W;W)K
M<VAE971S+W-H965T-34N>&ULO59M:]LP$/XKAV'0P>K7O+4D@2;MV#X42LO6
MSZI]241D*9/D)(7]^$FRXZ3%<5JV]8LMR7J>N^?.)]UP(^12+1 U;'/&U<A;
M:+VZ# *5+C GRA<KY.;+3,B<:#.5\T"M))+,@7(6Q&'8"W)"N3<>NK4[.1Z*
M0C/*\4Z"*O*<R.<),K$9>9&W6[BG\X6V"\%XN")S?$#]8W4GS2RH63*:(U=4
M<) X&WE7T>4TZEB V_&3XD8=C,%*>1)B:2??LY$76H^08:HM!3&O-4Z1,<MD
M_/A5D7JU30L\'._8OSKQ1LP343@5[)%F>C'R!AYD.",%T_=B\PTK05W+EPJF
MW!,VY=Y>WX.T4%KD%=AXD%->OLFV"L0!(#H&B"M _%9 4@$2)[3TS,FZ)IJ,
MAU)L0-K=ALT.7&P<VJBAW*;Q04OSE1J<'C]HD2[A.T^1VWC"'2-<P3FX]?.)
M"5 &4Y&;OT81%_>;K1TCG%VC)I2IS\- &S\L6Y!6-B>ES?B(S2B&6\'U0L$-
MSS![21 8 ;6*>*=B$K<R7F/J0Q)]@3B,HP:'IF^'ARWN)'50$\>7'.&[4J8J
M5C9<"@H;02T@)2PM&-$(,T(EK DK$,0,E$N *'>WV.[4MCO.=N>(;9N?5!N;
M&5W3#'D&SQ19UI2E=J+0#\-/3;%\-^R%CFZMH]O*\W 8%_@-MY33O,A;F'LU
M<^_#L].O;?=;53VZ8P6S<[)&:8Y)P%VZUL*8IXSJYZ94M;/V+OQXT)BK=ER_
MZW>CMF0-:EF#M_UT&F4.9Y3#,Q+9?#:T,W5+9).6-P&A![D[6UI47=2J+EHI
M[ZE:GL\D(E!NA*'2(,TOTB2JG2CT.W%C>D[!DGY;=J)P?\B'[RLFLCU13-'!
M!1)]>#E%\=YZ_%\*Z@1M/_*3YI2=  YB/WQ=BB^E[2^1*/EG176"JE<51])8
M')6POZ%X*7%_5T7ME\4[*NP$D\E7KSE?IW!'3L#@H*?*4<Y=JZD@%07796-2
MK];M[)5KXEZM3VR;ZWJU/4W9(]\2.:>F:AC.#&7H]\V-*,NVLYQHL7*=VY/0
MI@]TPX5IU5':#>;[3 B]FU@#=?,__@-02P,$%     @ D(5J5'27;%9* P
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M]UB8QA2D76#>YT+HS<!NT+2ZD_]02P,$%     @ D(5J5 4Z[$N7 P  [PL
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M]241B43G,U"$,GF!SA#-T1UE3 LKQY[2B1@X+ZY)KRK2X #I#&(7A?@#"OP
M/RYFZ/SL8A?%TV4TM01-+8&%[1V O8%$9\\ZD,(&*;1(X0&D5@9F9(BW9>B
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M"OQKTYKL+I,NT*)VQVLEM#FL;EB:^Q>D33#K&R'T/K G=KC1LS]02P,$%
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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MPWMHSV21W3A1?[0[S4E:;QBMJJ(X@[9K<V5EOOMYV.ZG;9__ 5!+ P04
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M<',O87!P+GAM;%!+ 0(4 Q0    ( )"%:E3'_CVD[@   "L"   1
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M965T,BYX;6Q02P$"% ,4    " "0A6I4=?Y*UC4#  !D#0  &
M    @('[$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
MD(5J5,#\Q2YA!   00\  !@              ("!9A<  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( )"%:E3F$)!OE0(  &L'   8
M          " @?T;  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    " "0A6I4FW_5.5X&  "D'   &               @('('@  >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ D(5J5 ?[4%%( @  204
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( )"%:E34M0!&D@8  *L6   9
M      " @=E<  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ D(5J5!2SC;7= P  ? T  !D              ("!HF,  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " "0A6I493L.DWP"  !-!@
M&0              @(&V9P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( )"%:E1Y'RJ]U (  'P&   9              " @6EJ  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ D(5J5$*MX83>
M!0  PP\  !D              ("!=&T  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    " "0A6I4G5 IJPH*  #6&P  &0
M@(&)<P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( )"%
M:E3_9%(+O@@  *(9   9              " @<I]  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ D(5J5-Z/I[Z= @  [04  !D
M         ("!OX8  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    " "0A6I4L/TWI1(#  #4!@  &0              @(&3B0  >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( )"%:E3#52N"!1D  %)/
M   9              " @=R,  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ D(5J5%-%??AG @  AP4  !D              ("!&*8
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " "0A6I4T8QG
MA3\$  "?"P  &0              @(&VJ   >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    ( )"%:E2^]7)#;P(  &(%   9
M  " @2RM  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
MD(5J5&*&"81?!   BQ$  !D              ("!TJ\  'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    " "0A6I4(["_NKX"  ";"0  &0
M            @(%HM   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( )"%:E1,%*,(FP(  %P&   9              " @5VW  !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ D(5J5'.^@J34 P
M8PD  !D              ("!+[H  'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    " "0A6I4&&9/1_0#   ^"P  &0              @($Z
MO@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( )"%:E3"
M3#I&%00  'P+   9              " @67"  !X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ D(5J5!AAS416!   0!$  !D
M     ("!L<8  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )"%:E1#<]:S!@,  ,X)   9              "
M@4_;  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ D(5J
M5-[<T9O@ @  TP@  !D              ("!C-X  'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    " "0A6I4DF6G"AH#  !:"P  &0
M        @(&CX0  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   ( )"%:E2CZ9X,# (  (D$   9              " @?3D  !X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ D(5J5.P^YF8U P  ^0D
M !D              ("!-^<  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    " "0A6I4448$;7P#  #Y#@  &0              @(&CZ@
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( )"%:E1+-CH1
MIP(  *$&   9              " @5;N  !X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L! A0#%     @ D(5J5'WM".(^ P  C T  !D
M ("!-/$  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " "0
MA6I4(YZ,N"@$   &#@  &0              @(&I]   >&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( )"%:E3@_T79/P,  /4-   9
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M970T.2YX;6Q02P$"% ,4    " "0A6I4$!&VE8X#  "'#P  &0
M    @(&]" $ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    (
M )"%:E1@'FJ\80(  )T&   9              " @8(, 0!X;"]W;W)K<VAE
M971S+W-H965T-3$N>&UL4$L! A0#%     @ D(5J5 45S*0Q P  '0P  !D
M             ("!&@\! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"
M% ,4    " "0A6I4&@B4^B@"  "/!0  &0              @(&"$@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( )"%:E0Q*0L%:P4
M &X5   9              " @>$4 0!X;"]W;W)K<VAE971S+W-H965T-30N
M>&UL4$L! A0#%     @ D(5J5%7F;0 O P  " P  !D              ("!
M@QH! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " "0A6I4
M=)=L5DH#  #V"@  &0              @('I'0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4V+GAM;%!+ 0(4 Q0    ( )"%:E0%.NQ+EP,  .\+   9
M      " @6HA 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%
M  @ D(5J5*C!^=#) @  '0H  !D              ("!."4! 'AL+W=O<FMS
M:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " "0A6I4O9*D]3$"  #=!0
M&0              @($X* $ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+
M 0(4 Q0    ( )"%:E21;!QB00,  -04   -              "  : J 0!X
M;"]S='EL97,N>&UL4$L! A0#%     @ D(5J5)>*NQS     $P(   L
M         ( !#"X! %]R96QS+RYR96QS4$L! A0#%     @ D(5J5*@<^=>A
M!   7B<   \              ( !]2X! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( )"%:E19=@'X]0$  #@C   :              "  <,S 0!X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( )"%:E07R,P;VP$
M -$B   3              "  ? U 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@    !# $, 3!(  /PW 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>123</ContextCount>
  <ElementCount>367</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>52</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Consolidated Statements Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/StatementConsolidatedStatementsComprehensiveLoss</Role>
      <ShortName>Consolidated Statements Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00405 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00500 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Organization and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureOrganizationAndOperations</Role>
      <ShortName>Organization and Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Acquisition of Quellis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureAcquisitionOfQuellis</Role>
      <ShortName>Acquisition of Quellis</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureFinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Short-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureShortTermInvestments</Role>
      <ShortName>Short-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureCommitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Stock Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureStockIncentivePlans</Role>
      <ShortName>Stock Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Defined Contribution Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureDefinedContributionBenefitPlan</Role>
      <ShortName>Defined Contribution Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Polices (Polices)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices</Role>
      <ShortName>Summary of Significant Accounting Polices (Polices)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30103 - Disclosure - Organization and Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureOrganizationAndOperationsTables</Role>
      <ShortName>Organization and Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://astria.com/role/DisclosureOrganizationAndOperations</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Acquisition of Quellis (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureAcquisitionOfQuellisTables</Role>
      <ShortName>Acquisition of Quellis (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://astria.com/role/DisclosureAcquisitionOfQuellis</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureFinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://astria.com/role/DisclosureFinancialInstruments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Short-Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureShortTermInvestmentsTables</Role>
      <ShortName>Short-Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://astria.com/role/DisclosureShortTermInvestments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://astria.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://astria.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Stock Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureStockIncentivePlansTables</Role>
      <ShortName>Stock Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://astria.com/role/DisclosureStockIncentivePlans</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://astria.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Organization and Operations - Reverse Stock Split, Agreement and Plan of Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails</Role>
      <ShortName>Organization and Operations - Reverse Stock Split, Agreement and Plan of Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40102 - Disclosure - Organization and Operations - Stock Purchase Agreement and Series X Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails</Role>
      <ShortName>Organization and Operations - Stock Purchase Agreement and Series X Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40103 - Disclosure - Organization and Operations - January 2020 Financing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureOrganizationAndOperationsJanuary2020FinancingDetails</Role>
      <ShortName>Organization and Operations - January 2020 Financing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40104 - Disclosure - Organization and Operations - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails</Role>
      <ShortName>Organization and Operations - Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Polices - Cash and Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesCashAndCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Polices - Cash and Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary of Significant Accounting Polices - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails</Role>
      <ShortName>Summary of Significant Accounting Polices - Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40203 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40204 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40205 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40206 - Disclosure - Summary of Significant Accounting Policies - Preferred Stock Discount (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreferredStockDiscountDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Preferred Stock Discount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Acquisition of Quellis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureAcquisitionOfQuellisDetails</Role>
      <ShortName>Acquisition of Quellis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://astria.com/role/DisclosureAcquisitionOfQuellisTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Acquisition of Quellis - Net assets acquired based on their estimated fair values (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails</Role>
      <ShortName>Acquisition of Quellis - Net assets acquired based on their estimated fair values (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureFinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://astria.com/role/DisclosureFinancialInstrumentsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Financial Instruments - Warrant liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails</Role>
      <ShortName>Financial Instruments - Warrant liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40403 - Disclosure - Financial Instruments - Fair value of warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureFinancialInstrumentsFairValueOfWarrantsDetails</Role>
      <ShortName>Financial Instruments - Fair value of warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Short-Term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureShortTermInvestmentsDetails</Role>
      <ShortName>Short-Term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://astria.com/role/DisclosureShortTermInvestmentsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://astria.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureCommitmentsDetails</Role>
      <ShortName>Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://astria.com/role/DisclosureCommitments</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Stockholders' Equity - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureStockholdersEquityPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Stockholders' Equity - Common Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Common Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40803 - Disclosure - Stockholders' Equity - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureStockholdersEquityCommonStockDetails</Role>
      <ShortName>Stockholders' Equity - Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40804 - Disclosure - Stockholders' Equity - Shares Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Shares Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Stock Incentive Plans - Summary of Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureStockIncentivePlansSummaryOfPlansDetails</Role>
      <ShortName>Stock Incentive Plans - Summary of Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Stock Incentive Plans - Stock option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails</Role>
      <ShortName>Stock Incentive Plans - Stock option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Stock Incentive Plans - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureStockIncentivePlansStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Incentive Plans - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Income Taxes - Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureIncomeTaxesReconciliationDetails</Role>
      <ShortName>Income Taxes - Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Income Taxes - Deferred tax assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Deferred tax assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41003 - Disclosure - Income Taxes - Operating Loss Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Operating Loss Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="atxs-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://astria.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://astria.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="atxs-20211231x10k.htm">atxs-20211231x10k.htm</File>
    <File>atxs-20211231.xsd</File>
    <File>atxs-20211231_cal.xml</File>
    <File>atxs-20211231_def.xml</File>
    <File>atxs-20211231_lab.xml</File>
    <File>atxs-20211231_pre.xml</File>
    <File>atxs-20211231xex10d19.htm</File>
    <File>atxs-20211231xex21d1.htm</File>
    <File>atxs-20211231xex23d1.htm</File>
    <File>atxs-20211231xex31d1.htm</File>
    <File>atxs-20211231xex31d2.htm</File>
    <File>atxs-20211231xex32d1.htm</File>
    <File>atxs-20211231xex32d2.htm</File>
    <File>atxs-20211231xex4d3.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="472">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>90
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "atxs-20211231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 20,
   "contextCount": 123,
   "dts": {
    "calculationLink": {
     "local": [
      "atxs-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "atxs-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "atxs-20211231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "atxs-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "atxs-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "atxs-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 450,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 22,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 26
   },
   "keyCustom": 35,
   "keyStandard": 332,
   "memberCustom": 25,
   "memberStandard": 24,
   "nsprefix": "atxs",
   "nsuri": "http://astria.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://astria.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Acquisition of Quellis",
     "role": "http://astria.com/role/DisclosureAcquisitionOfQuellis",
     "shortName": "Acquisition of Quellis",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Financial Instruments",
     "role": "http://astria.com/role/DisclosureFinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atxs:ShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Short-Term Investments",
     "role": "http://astria.com/role/DisclosureShortTermInvestments",
     "shortName": "Short-Term Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atxs:ShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Accrued Expenses",
     "role": "http://astria.com/role/DisclosureAccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Commitments",
     "role": "http://astria.com/role/DisclosureCommitments",
     "shortName": "Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Stockholders' Equity",
     "role": "http://astria.com/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Stock Incentive Plans",
     "role": "http://astria.com/role/DisclosureStockIncentivePlans",
     "shortName": "Stock Incentive Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Income Taxes",
     "role": "http://astria.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Defined Contribution Benefit Plan",
     "role": "http://astria.com/role/DisclosureDefinedContributionBenefitPlan",
     "shortName": "Defined Contribution Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Consolidated Balance Sheets",
     "role": "http://astria.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Subsequent Events",
     "role": "http://astria.com/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Polices (Polices)",
     "role": "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices",
     "shortName": "Summary of Significant Accounting Polices (Polices)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atxs:ScheduleOfPreferredStockOrWarrantsToPurchasePreferredStockTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30103 - Disclosure - Organization and Operations (Tables)",
     "role": "http://astria.com/role/DisclosureOrganizationAndOperationsTables",
     "shortName": "Organization and Operations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atxs:ScheduleOfPreferredStockOrWarrantsToPurchasePreferredStockTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Acquisition of Quellis (Tables)",
     "role": "http://astria.com/role/DisclosureAcquisitionOfQuellisTables",
     "shortName": "Acquisition of Quellis (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Financial Instruments (Tables)",
     "role": "http://astria.com/role/DisclosureFinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "atxs:ShortTermInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Short-Term Investments (Tables)",
     "role": "http://astria.com/role/DisclosureShortTermInvestmentsTables",
     "shortName": "Short-Term Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "atxs:ShortTermInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://astria.com/role/DisclosureAccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://astria.com/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - Stock Incentive Plans (Tables)",
     "role": "http://astria.com/role/DisclosureStockIncentivePlansTables",
     "shortName": "Stock Incentive Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://astria.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_NonredeemablePreferredStockMember_h2GakjGikkGGLKMSx_TpBQ",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Income Taxes (Tables)",
     "role": "http://astria.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_YPa1WFrrbkuiWuIeOmYjeA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Organization and Operations - Reverse Stock Split, Agreement and Plan of Merger (Details)",
     "role": "http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails",
     "shortName": "Organization and Operations - Reverse Stock Split, Agreement and Plan of Merger (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_28_2021_To_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_MBblrX_TzUq0Y8HTkRLDIA",
      "decimals": "-5",
      "lang": null,
      "name": "atxs:TemporaryEquityConversionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40102 - Disclosure - Organization and Operations - Stock Purchase Agreement and Series X Preferred Stock (Details)",
     "role": "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails",
     "shortName": "Organization and Operations - Stock Purchase Agreement and Series X Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_uO-Pfxl910eVDz5-n8_42g",
      "decimals": "4",
      "lang": null,
      "name": "atxs:PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zp2xevi_xEmHwwPp0gd3NQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40103 - Disclosure - Organization and Operations - January 2020 Financing (Details)",
     "role": "http://astria.com/role/DisclosureOrganizationAndOperationsJanuary2020FinancingDetails",
     "shortName": "Organization and Operations - January 2020 Financing (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_30_2020_To_1_30_2020_us-gaap_SubsidiarySaleOfStockAxis_atxs_UnderwritingPublicOffering2020Member_AJ3obUkYbkW3WPPRYNkRqg",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40104 - Disclosure - Organization and Operations - Liquidity (Details)",
     "role": "http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails",
     "shortName": "Organization and Operations - Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Summary of Significant Accounting Polices - Cash and Cash Equivalents and Restricted Cash (Details)",
     "role": "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesCashAndCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Polices - Cash and Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - Summary of Significant Accounting Polices - Fair Value of Financial Instruments (Details)",
     "role": "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails",
     "shortName": "Summary of Significant Accounting Polices - Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40203 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation (Details)",
     "role": "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails",
     "shortName": "Summary of Significant Accounting Policies - Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40204 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Share (Details)",
     "role": "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_VaIUUonErEmKwL0Ka000VA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40205 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)",
     "role": "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Segment Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_VaIUUonErEmKwL0Ka000VA",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Consolidated Statements of Operations",
     "role": "http://astria.com/role/StatementConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConversionOfStockAmountConverted1",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40206 - Disclosure - Summary of Significant Accounting Policies - Preferred Stock Discount (Details)",
     "role": "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreferredStockDiscountDetails",
     "shortName": "Summary of Significant Accounting Policies - Preferred Stock Discount (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "atxs:PreferredStockDiscountPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_atxs_SeriesXRedeemableConvertiblePreferredStockMember_Q0-uw695P0e1UfMQTMe-mg",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ConversionOfStockAmountConverted1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockConvertibleConversionRatio",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Acquisition of Quellis (Details)",
     "role": "http://astria.com/role/DisclosureAcquisitionOfQuellisDetails",
     "shortName": "Acquisition of Quellis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_28_2021_To_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_yxGtZ11D_EqlCL7qM9oOug",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AcquisitionCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_stYiOzYUG0mKnmIJCrQu3Q",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "atxs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - Acquisition of Quellis - Net assets acquired based on their estimated fair values (Details)",
     "role": "http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails",
     "shortName": "Acquisition of Quellis - Net assets acquired based on their estimated fair values (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_1_28_2021_us-gaap_BusinessAcquisitionAxis_atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember_stYiOzYUG0mKnmIJCrQu3Q",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "atxs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ar5rUSj2SE2rATotgrqFBg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Financial Instruments (Details)",
     "role": "http://astria.com/role/DisclosureFinancialInstrumentsDetails",
     "shortName": "Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ar5rUSj2SE2rATotgrqFBg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - Financial Instruments - Warrant liability (Details)",
     "role": "http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails",
     "shortName": "Financial Instruments - Warrant liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_atxs_WeightedAverageExpectedVolatilityMember_nIDhOwmhF0mlBky65Ot7_w",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_r9qJ3cWOSk6WrNQbeKvS6w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40403 - Disclosure - Financial Instruments - Fair value of warrants (Details)",
     "role": "http://astria.com/role/DisclosureFinancialInstrumentsFairValueOfWarrantsDetails",
     "shortName": "Financial Instruments - Fair value of warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_atxs_WeightedAverageExpectedVolatilityMember_nIDhOwmhF0mlBky65Ot7_w",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_r9qJ3cWOSk6WrNQbeKvS6w",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "atxs:ShortTermInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_instrument_UhpnDIC4ZkS1xbkw5nvJeQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Short-Term Investments (Details)",
     "role": "http://astria.com/role/DisclosureShortTermInvestmentsDetails",
     "shortName": "Short-Term Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "atxs:ShortTermInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_instrument_UhpnDIC4ZkS1xbkw5nvJeQ",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Accrued Expenses (Details)",
     "role": "http://astria.com/role/DisclosureAccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Commitments (Details)",
     "role": "http://astria.com/role/DisclosureCommitmentsDetails",
     "shortName": "Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_11_30_2019_KyDCpKfGVkmxJYefd9nrVQ",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Stockholders' Equity - Preferred Stock (Details)",
     "role": "http://astria.com/role/DisclosureStockholdersEquityPreferredStockDetails",
     "shortName": "Stockholders' Equity - Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ",
      "decimals": "INF",
      "lang": null,
      "name": "atxs:NumberOfPreferredStockSeries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_series_lxqxSSbLPkuOU9DD2aDsAA",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Consolidated Statements Comprehensive Loss",
     "role": "http://astria.com/role/StatementConsolidatedStatementsComprehensiveLoss",
     "shortName": "Consolidated Statements Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_WeightedAverageMember_Q8_JfLkSZkujoq1ijmIZaA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atxs:WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - Stockholders' Equity - Common Stock Warrants (Details)",
     "role": "http://astria.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails",
     "shortName": "Stockholders' Equity - Common Stock Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_WeightedAverageMember_Q8_JfLkSZkujoq1ijmIZaA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atxs:WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40803 - Disclosure - Stockholders' Equity - Common Stock (Details)",
     "role": "http://astria.com/role/DisclosureStockholdersEquityCommonStockDetails",
     "shortName": "Stockholders' Equity - Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40804 - Disclosure - Stockholders' Equity - Shares Reserved for Future Issuance (Details)",
     "role": "http://astria.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails",
     "shortName": "Stockholders' Equity - Shares Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N1cnyjsfXUyGLlzflAry7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Stock Incentive Plans - Summary of Plans (Details)",
     "role": "http://astria.com/role/DisclosureStockIncentivePlansSummaryOfPlansDetails",
     "shortName": "Stock Incentive Plans - Summary of Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N1cnyjsfXUyGLlzflAry7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_E9ZXeeq0fkKyLTAwEIZ_-A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - Stock Incentive Plans - Stock option activity (Details)",
     "role": "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails",
     "shortName": "Stock Incentive Plans - Stock option activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_aY05QXMC00-i7_yMf_WgYA",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40903 - Disclosure - Stock Incentive Plans - Stock-Based Compensation Expense (Details)",
     "role": "http://astria.com/role/DisclosureStockIncentivePlansStockBasedCompensationExpenseDetails",
     "shortName": "Stock Incentive Plans - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Income Taxes - Reconciliation (Details)",
     "role": "http://astria.com/role/DisclosureIncomeTaxesReconciliationDetails",
     "shortName": "Income Taxes - Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_4rUkkI2I-kerhPgym3qUdw",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - Income Taxes - Deferred tax assets (Details)",
     "role": "http://astria.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Deferred tax assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_elNRkz91iE-s8vhvuVnSvw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41003 - Disclosure - Income Taxes - Operating Loss Carryforwards (Details)",
     "role": "http://astria.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails",
     "shortName": "Income Taxes - Operating Loss Carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_elNRkz91iE-s8vhvuVnSvw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_UYDiqNG1uUW_c0UxbapazQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Subsequent Events (Details)",
     "role": "http://astria.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_1_28_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dDqegR-RH0S_9dr4Q4C-Mw",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cNQZPiUZ_UeK1Pbzt5CTIg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cNQZPiUZ_UeK1Pbzt5CTIg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_atxs_PublicOfferingCommonStockAndWarrantsMember_S4V25J-LO0yw2cDuPVRuDA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00405 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_atxs_PublicOfferingCommonStockAndWarrantsMember_S4V25J-LO0yw2cDuPVRuDA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00500 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_IvEsE-rmfkONP8Yy95pJLQ",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Organization and Operations",
     "role": "http://astria.com/role/DisclosureOrganizationAndOperations",
     "shortName": "Organization and Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atxs-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_REvSPkhU9UWOc6hLVddV7g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 52,
   "tag": {
    "atxs_AccruedContractedResearchCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://astria.com/role/DisclosureAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date for contracted research costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Contracted Research Costs, Current",
        "terseLabel": "Accrued contracted costs"
       }
      }
     },
     "localname": "AccruedContractedResearchCostsCurrent",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atxs_AccruedSeveranceCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://astria.com/role/DisclosureAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for severance.",
        "label": "Accrued Severance, Current",
        "terseLabel": "Accrued severance"
       }
      }
     },
     "localname": "AccruedSeveranceCurrent",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atxs_AgreementAndPlanOfMergerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Agreement and Plan of Merger [Abstract]",
        "terseLabel": "Agreement and Plan of Merger"
       }
      }
     },
     "localname": "AgreementAndPlanOfMergerAbstract",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atxs_AgreementAndPlanOfMergerQuellisBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to acquisition of Quellis Biosciences, Inc, pursuant to agreement and plan of merger.",
        "label": "Quellis Biosciences, Inc"
       }
      }
     },
     "localname": "AgreementAndPlanOfMergerQuellisBiosciencesIncMember",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisDetails",
      "http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails",
      "http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atxs_AtMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to At-the-Market Offering.",
        "label": "ATM"
       }
      }
     },
     "localname": "AtMarketOfferingMember",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails",
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails": {
       "order": 4.0,
       "parentTag": "atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities",
        "negatedLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails": {
       "order": 5.0,
       "parentTag": "atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Acquired Research and Development",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Acquired Research and Development",
        "terseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAcquiredResearchAndDevelopment",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired other than intangible assets in excess of (less than) the aggregate liabilities assumed other than deferred tax liabilities.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other than Intangible Assets And Deferred Tax Liabilities",
        "terseLabel": "Cost to acquire the assets",
        "totalLabel": "Net acquired tangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisDetails",
      "http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atxs_CommonStockOptionsOutstandingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the options outstanding to purchase common stock that has been reserved for future issuance.",
        "label": "Options outstanding to purchase common Stock"
       }
      }
     },
     "localname": "CommonStockOptionsOutstandingMember",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atxs_CommonStockOptionsReservedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the options reserved to purchase common stock that has been reserved for future issuance.",
        "label": "Options available for future issuance to purchase common stock"
       }
      }
     },
     "localname": "CommonStockOptionsReservedMember",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atxs_CommonStockReservedForFutureIssuanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Reserved for Future Issuance"
       }
      }
     },
     "localname": "CommonStockReservedForFutureIssuanceAbstract",
     "nsuri": "http://astria.com/20211231",
     "xbrltype": "stringItemType"
    },
    "atxs_CommonStockSaleAgreementValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of common stock authorized to be issued under the terms of an open market sale agreement.",
        "label": "Common Stock, Sale Agreement, Value",
        "terseLabel": "Maximum aggregate value of common shares which can be issued under the agreement"
       }
      }
     },
     "localname": "CommonStockSaleAgreementValue",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atxs_CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of common stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Common stock warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsMember",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails",
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atxs_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to lease liability.",
        "label": "Deferred Tax Assets, Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atxs_DeferredTaxLiabilitiesRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to right of use asset.",
        "label": "Deferred Tax Liabilities, Right of Use Asset",
        "negatedLabel": "ROU asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atxs_DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of dividend on convertible preferred stock related to beneficial conversion feature and issuance costs",
        "label": "Dividend On Convertible Preferred Stock Related To Beneficial Conversion Feature And Issuance Costs",
        "negatedLabel": "Dividend on convertible preferred stock related to beneficial conversion feature and issuance costs",
        "terseLabel": "Non-cash dividend on convertible preferred stock"
       }
      }
     },
     "localname": "DividendOnConvertiblePreferredStockRelatedToBeneficialConversionFeatureAndIssuanceCosts",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atxs_EmployeeStockPurchasePlan2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the 2015 Employee Stock Purchase Plan (\"2015 ESPP\").",
        "label": "Shares reserved for the employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlan2015Member",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atxs_GainLossOnWarrantInherited": {
     "auth_ref": [],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on warrant inherited during acquisition.",
        "label": "Gain Loss On Warrant Inherited",
        "terseLabel": "Net gain on warrants inherited in acquisiton of Quellis"
       }
      }
     },
     "localname": "GainLossOnWarrantInherited",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atxs_IncreaseDecreaseInRightOfUseAssetOperating": {
     "auth_ref": [],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of right-of-use-asset-operating.",
        "label": "Increase Decrease In Right Of Use Asset Operating",
        "terseLabel": "Right-of-use asset-operating"
       }
      }
     },
     "localname": "IncreaseDecreaseInRightOfUseAssetOperating",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atxs_IndefiniteTaxYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No expiration date.",
        "label": "No expiration"
       }
      }
     },
     "localname": "IndefiniteTaxYearsMember",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atxs_January2020FinancingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "January 2020 Financing [Abstract]",
        "terseLabel": "January 2020 Financing"
       }
      }
     },
     "localname": "January2020FinancingAbstract",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsJanuary2020FinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atxs_JefferiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Jefferies.",
        "label": "Jefferies"
       }
      }
     },
     "localname": "JefferiesMember",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atxs_NonCashPortionOfAcquiredResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of non-cash portion of acquired IP R&amp;D.",
        "label": "Non-cash Portion of Acquired Research and Development",
        "terseLabel": "Non-cash portion of acquired in-process research and development"
       }
      }
     },
     "localname": "NonCashPortionOfAcquiredResearchAndDevelopment",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atxs_NonCashReturnRelatedToCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of Non Cash Return Related To Common Stock",
        "label": "Non Cash Return Related To Common Stock",
        "terseLabel": "Non cash return"
       }
      }
     },
     "localname": "NonCashReturnRelatedToCommonStock",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreferredStockDiscountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atxs_NumberOfPreferredStockSeries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of series that may be used to issue preferred stock.",
        "label": "Number Of Preferred Stock Series",
        "terseLabel": "Minimum number of series used to issue preferred stock"
       }
      }
     },
     "localname": "NumberOfPreferredStockSeries",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "atxs_OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for off-balance sheet risk and concentrations of credit risk.",
        "label": "Off-Balance Sheet Risk and Concentrations of Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Off-Balance Sheet Risk and Concentrations of Credit Risk"
       }
      }
     },
     "localname": "OffBalanceSheetRiskAndConcentrationsOfCreditRiskPolicyPolicyTextBlock",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atxs_OppenheimerCo.IncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Oppenheimer &amp; Co. Inc.",
        "label": "Oppenheimer &amp; Co. Inc"
       }
      }
     },
     "localname": "OppenheimerCo.IncMember",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsJanuary2020FinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atxs_PercentageOfCommissionPaidToUnderwriterBasedOnProceedsFromOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of commission paid to underwriters based on proceeds from offering.",
        "label": "Percentage of Commission Paid to Underwriter based on Proceeds from Offering",
        "terseLabel": "Percentage of commission paid to underwriter based on proceeds from common stock"
       }
      }
     },
     "localname": "PercentageOfCommissionPaidToUnderwriterBasedOnProceedsFromOffering",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "atxs_PercentageOfInvestmentAmountToCollateralizedDepositsValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of investment in reverse repurchase agreements which are collateralized by deposits.",
        "label": "Percentage Of Investment Amount To Collateralized Deposits Value",
        "terseLabel": "Percentage of investment amount to collateralized deposits value"
       }
      }
     },
     "localname": "PercentageOfInvestmentAmountToCollateralizedDepositsValue",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of beneficial ownership common stock issued and outstanding immediately after giving effect to such conversion initially considered for prohibiting from converting shares of Series X Preferred Stock into shares of the Company's common stock.",
        "label": "Percentage of Ownership on Common Stock Issued and Outstanding Immediately After Conversion, Initially",
        "terseLabel": "Common stock, percentage of beneficial ownership initially, after conversion"
       }
      }
     },
     "localname": "PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionInitially",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "atxs_PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of beneficial ownership common stock issued and outstanding immediately after giving effect to such conversion thereafter considered for prohibiting from converting shares of Series X Preferred Stock into shares of the Company's common stock.",
        "label": "Percentage of Ownership on Common Stock Issued and Outstanding Immediately After Conversion, Thereafter",
        "verboseLabel": "Common stock, percentage of beneficial ownership thereafter, after conversion"
       }
      }
     },
     "localname": "PercentageOfOwnershipOnCommonStockIssuedAndOutstandingImmediatelyAfterConversionThereafter",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "atxs_PreferredStockDiscountPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for preferred stock discount",
        "label": "Preferred Stock Discount Policy Text Block",
        "terseLabel": "Preferred Stock Discount"
       }
      }
     },
     "localname": "PreferredStockDiscountPolicyTextBlock",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atxs_ProceedsFromIssuanceOfAtMarketOffering": {
     "auth_ref": [],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's At-the-market offering of stock to the public.",
        "label": "Proceeds from Issuance of At the Market Offering",
        "terseLabel": "Proceeds from at-the-market offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfAtMarketOffering",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atxs_PublicOfferingCommonStockAndWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to a public offering of common stock and warrants.",
        "label": "Issuance of common stock and warrants in public offering"
       }
      }
     },
     "localname": "PublicOfferingCommonStockAndWarrantsMember",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "atxs_ReclassificationOfEquityClassifiedWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from reclassification of equity classified warrants.",
        "label": "Reclassification Of Equity Classified Warrants",
        "negatedLabel": "Reclassification of warrant liability to additional paid-in capital",
        "verboseLabel": "Reclassification of warrant liability to additional paid-in capital"
       }
      }
     },
     "localname": "ReclassificationOfEquityClassifiedWarrants",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails",
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atxs_RemainingAvailableUnderCurrentSalesAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of remaining available under its current sales agreement.",
        "label": "Remaining Available Under Current Sales Agreement",
        "terseLabel": "Remaining available under sales agreement"
       }
      }
     },
     "localname": "RemainingAvailableUnderCurrentSalesAgreement",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atxs_ReverseRepurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments represented by an agreement between the entity and another party for the reverse repurchase transactions of identical or substantially the same securities at a date certain for a specified price. Such agreements are generally short-term in nature.",
        "label": "Reverse repurchase agreements"
       }
      }
     },
     "localname": "ReverseRepurchaseAgreementsMember",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsDetails",
      "http://astria.com/role/DisclosureShortTermInvestmentsDetails",
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atxs_ScheduleOfPreferredStockOrWarrantsToPurchasePreferredStockTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure preferred stock or warrants to purchase preferred stock.",
        "label": "Schedule Of Preferred Stock Or Warrants To Purchase Preferred Stock [Table Text Block]",
        "terseLabel": "Schedule of common stock warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfPreferredStockOrWarrantsToPurchasePreferredStockTableTextBlock",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atxs_SeriesXPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to series X preferred stock.",
        "label": "Series X Preferred Stock",
        "terseLabel": "Series X Preferred Stock (1)"
       }
      }
     },
     "localname": "SeriesXPreferredStockMember",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atxs_SeriesXRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding redeemable convertible Series X preferred stock.",
        "label": "Series X redeemable convertible preferred stock",
        "terseLabel": "Series X Preferred Stock"
       }
      }
     },
     "localname": "SeriesXRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisDetails",
      "http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails",
      "http://astria.com/role/DisclosureStockholdersEquityPreferredStockDetails",
      "http://astria.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails",
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreferredStockDiscountDetails",
      "http://astria.com/role/StatementConsolidatedBalanceSheets",
      "http://astria.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) assumed in acquisition during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Assumed in Acquisition, Gross",
        "terseLabel": "Number of options assumed in Quellis Acquisition",
        "verboseLabel": "Assumed in Quellis Acquisition (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionGross",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails",
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise per share of share options assumed in acquisition during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Assumed in Acquisition, Weighted Average Exercise Price",
        "terseLabel": "Assumed in Quellis Acquisition (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInAcquisitionWeightedAverageExercisePrice",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Outstanding Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atxs_SharesIssuedIn2021FinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to shares issued in 2020 financing.",
        "label": "Shares issued in February 2021 Financing"
       }
      }
     },
     "localname": "SharesIssuedIn2021FinancingMember",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atxs_SharesIssuedInMergerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to shares issued in merger.",
        "label": "Shares issued in merger"
       }
      }
     },
     "localname": "SharesIssuedInMergerMember",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atxs_SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to shares reserved for warrants issued for the purchase of common stock.",
        "label": "Warrants for the purchase of common Stock"
       }
      }
     },
     "localname": "SharesReservedForFutureIssuanceWarrantsForPurchaseOfCommonStockMember",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atxs_ShortTermInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the short-term investments. Short-term investments may include current marketable securities.",
        "label": "Short-term Investments [Text Block]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsTextBlock",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureShortTermInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atxs_StockIssuedDuringPeriodSharesIncreaseDecreaseDueToConversionOfPreferredSharesIntoCommonShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in number of shares issued during the period upon the conversion of preferred shares into common shares.",
        "label": "Stock Issued During Period, Shares, Increase (Decrease) Due to Conversion of Preferred Shares into Common Shares",
        "terseLabel": "Number of Series X preferred shares converted during period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIncreaseDecreaseDueToConversionOfPreferredSharesIntoCommonShares",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "atxs_StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued in At-the-Market offerings during the period.",
        "label": "Stock Issued During Period, Shares, New Issues, At the Market Offerings",
        "terseLabel": "Issuance of common stock for at-the-market offerings, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssuesAtMarketOfferings",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails",
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "atxs_StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued in At-the-Market offerings during the period.",
        "label": "Stock Issued During Period, Value, New Issues, At the Market Offerings",
        "terseLabel": "Issuance of common stock for at-the-market offerings, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssuesAtMarketOfferings",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atxs_StockPurchaseAgreementAndSeriesXPreferredStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Stock Purchase Agreement and Series X Preferred Stock [Abstract]",
        "terseLabel": "Stock Purchase Agreement and Series X Preferred Stock"
       }
      }
     },
     "localname": "StockPurchaseAgreementAndSeriesXPreferredStockAbstract",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atxs_StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to stock purchase agreement with institutional and accredited investors.",
        "label": "Stock Purchase Agreement"
       }
      }
     },
     "localname": "StockPurchaseAgreementInstitutionalAndAccreditedInvestorsMember",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atxs_SummaryOfSignificantAccountingPolicesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Summary of Significant Accounting Polices [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPolicesLineItems",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atxs_SummaryOfSignificantAccountingPolicesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about significant accounting policies.",
        "label": "Summary of Significant Accounting Polices [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPolicesTable",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atxs_TaxYears2023Through2039Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax years 2023 through 2039.",
        "label": "Tax Years 2023 through 2039"
       }
      }
     },
     "localname": "TaxYears2023Through2039Member",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atxs_TemporaryEquityConversionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The conversion value of temporary equity shares on the merger closing date.",
        "label": "Temporary Equity, Conversion Value",
        "terseLabel": "Conversion value on closing date"
       }
      }
     },
     "localname": "TemporaryEquityConversionValue",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atxs_TemporaryEquityStockIssuedInAcquisitionSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new shares classified as temporary equity issued in an acquisition during the period.",
        "label": "Temporary Equity, Stock Issued in an Acquisition, Shares, New Issues",
        "terseLabel": "Issuance of preferred stock upon acquisition of Quellis (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedInAcquisitionSharesNewIssues",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodGrossValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross value of new stock classified as temporary equity issued in a private offering during the period.",
        "label": "Temporary Equity, Stock Issued In Private Offering During Period, Gross Value",
        "terseLabel": "Gross proceeds from issuance of preferred stock in a private offering"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodGrossValue",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atxs_TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new shares classified as temporary equity issued in a private offering during the period.",
        "label": "Temporary Equity, Stock Issued in a Private Offering During Period, Shares, New Issues",
        "verboseLabel": "Issuance of preferred stock in a private offering of public equity, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedInPrivateOfferingDuringPeriodSharesNewIssues",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "atxs_UnderwritingPublicOffering2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents sale of stock by a underwritten public offering.",
        "label": "January 2020 Financing"
       }
      }
     },
     "localname": "UnderwritingPublicOffering2020Member",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsJanuary2020FinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atxs_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual life of warrant, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants And Rights Outstanding Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted average life (in years)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "atxs_WarrantsAssumedInMergerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to warrants assumed in merger.",
        "label": "Warrants assumed in merger"
       }
      }
     },
     "localname": "WarrantsAssumedInMergerMember",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atxs_WarrantsIssuedIn2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to warrants issued in 2015.",
        "label": "Warrants Issued in 2015"
       }
      }
     },
     "localname": "WarrantsIssuedIn2015Member",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atxs_WarrantsIssuedIn2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to warrants issued in 2018.",
        "label": "Warrants Issued in 2018"
       }
      }
     },
     "localname": "WarrantsIssuedIn2018Member",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atxs_WarrantsIssuedIn2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to warrants issued in 2019.",
        "label": "Warrants Issued in 2019"
       }
      }
     },
     "localname": "WarrantsIssuedIn2019Member",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atxs_WarrantsIssuedIn2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to warrants issued in 2021.",
        "label": "Warrants Issued In 2021"
       }
      }
     },
     "localname": "WarrantsIssuedIn2021Member",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atxs_WeightedAverageExpectedVolatilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Weighted-average expected volatility.",
        "label": "Weighted-average expected volatility"
       }
      }
     },
     "localname": "WeightedAverageExpectedVolatilityMember",
     "nsuri": "http://astria.com/20211231",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsFairValueOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://astria.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r36",
      "r38",
      "r84",
      "r85",
      "r195",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsJanuary2020FinancingDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r194",
      "r208",
      "r238",
      "r241",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r400",
      "r425",
      "r426",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsFairValueOfWarrantsDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails",
      "http://astria.com/role/DisclosureStockIncentivePlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r194",
      "r208",
      "r238",
      "r241",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r400",
      "r425",
      "r426",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsFairValueOfWarrantsDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails",
      "http://astria.com/role/DisclosureStockIncentivePlansStockBasedCompensationExpenseDetails",
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r194",
      "r208",
      "r228",
      "r238",
      "r241",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r400",
      "r425",
      "r426",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsFairValueOfWarrantsDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails",
      "http://astria.com/role/DisclosureStockIncentivePlansStockBasedCompensationExpenseDetails",
      "http://astria.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails",
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r194",
      "r208",
      "r228",
      "r238",
      "r241",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r400",
      "r425",
      "r426",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsFairValueOfWarrantsDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails",
      "http://astria.com/role/DisclosureStockIncentivePlansStockBasedCompensationExpenseDetails",
      "http://astria.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails",
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r37",
      "r38",
      "r84",
      "r85",
      "r195",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsJanuary2020FinancingDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r95",
      "r100",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r95",
      "r100",
      "r180",
      "r239",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r376",
      "r378",
      "r381",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r25",
      "r365"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://astria.com/role/DisclosureAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://astria.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAccruedExpensesDetails",
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r28"
     ],
     "calculation": {
      "http://astria.com/role/DisclosureAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r16",
      "r41",
      "r43",
      "r44",
      "r417",
      "r431",
      "r432"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquisitionCosts": {
     "auth_ref": [
      "r402",
      "r403"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.",
        "label": "Acquisition Costs, Period Cost",
        "terseLabel": "Acquisition costs"
       }
      }
     },
     "localname": "AcquisitionCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r14",
      "r277",
      "r365"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r274",
      "r275",
      "r276",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": {
     "auth_ref": [
      "r214",
      "r222",
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.",
        "label": "Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature",
        "verboseLabel": "Beneficial conversion feature"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails",
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreferredStockDiscountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r243",
      "r245",
      "r280",
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r193",
      "r214",
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Fair value adjustment to acquired Quellis warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Reconciliation of net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r245",
      "r270",
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share",
        "verboseLabel": "Antidilutive common stock equivalents excluded from computation of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails",
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreferredStockDiscountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r82",
      "r131",
      "r139",
      "r143",
      "r159",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r318",
      "r323",
      "r345",
      "r363",
      "r365",
      "r405",
      "r415"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r35",
      "r82",
      "r159",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r318",
      "r323",
      "r345",
      "r363",
      "r365"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://astria.com/role/DisclosureFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r246",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockBasedCompensationExpenseDetails",
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails",
      "http://astria.com/role/DisclosureStockIncentivePlansSummaryOfPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r237",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisDetails",
      "http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails",
      "http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r237",
      "r240",
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisDetails",
      "http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails",
      "http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Acquisition of Quellis"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisDetails",
      "http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisition of Quellis"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellis"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r313"
     ],
     "calculation": {
      "http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails": {
       "order": 2.0,
       "parentTag": "atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r313"
     ],
     "calculation": {
      "http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails": {
       "order": 1.0,
       "parentTag": "atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r313"
     ],
     "calculation": {
      "http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails": {
       "order": 3.0,
       "parentTag": "atxs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherThanIntangibleAssetsAndDeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition of Quellis"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash acquired in acquisition of Quellis"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r22",
      "r74"
     ],
     "calculation": {
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://astria.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://astria.com/role/DisclosureFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r8",
      "r75",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r22"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r70",
      "r74",
      "r79"
     ],
     "calculation": {
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r70",
      "r346"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r81",
      "r82",
      "r104",
      "r105",
      "r106",
      "r109",
      "r111",
      "r117",
      "r118",
      "r119",
      "r159",
      "r182",
      "r186",
      "r187",
      "r188",
      "r191",
      "r192",
      "r205",
      "r206",
      "r210",
      "r211",
      "r345",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisDetails",
      "http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails",
      "http://astria.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails",
      "http://astria.com/role/DisclosureStockholdersEquityPreferredStockDetails",
      "http://astria.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails",
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreferredStockDiscountDetails",
      "http://astria.com/role/StatementConsolidatedBalanceSheets",
      "http://astria.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsJanuary2020FinancingDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails",
      "http://astria.com/role/DisclosureStockholdersEquityPreferredStockDetails",
      "http://astria.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r224",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise Price (in dollars per share)",
        "verboseLabel": "Exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails",
      "http://astria.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares which may be purchased with warrants",
        "verboseLabel": "Warrants to purchase number of shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants Outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r224",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralAxis": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of collateral or no collateral, from lender's perspective.",
        "label": "Collateral Held [Axis]"
       }
      }
     },
     "localname": "CollateralAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of collateral or no collateral, from lender's perspective.",
        "label": "Collateral Held [Domain]"
       }
      }
     },
     "localname": "CollateralDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollateralPledgedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pledge of specific property to serve as protection against default.",
        "label": "Government Securities and Obligations"
       }
      }
     },
     "localname": "CollateralPledgedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r30",
      "r179",
      "r409",
      "r420"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r181",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r87",
      "r88",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisDetails",
      "http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsJanuary2020FinancingDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails",
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value of common stock (in dollars per share)",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails",
      "http://astria.com/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://astria.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (in shares)",
        "verboseLabel": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://astria.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Balance, end of period (in shares)",
        "periodStartLabel": "Balance, beginning of period (in shares)",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://astria.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r13",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, outstanding (in shares)",
        "verboseLabel": "Common Stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://astria.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r13",
      "r365"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.001 par value per share, 150,000,000 shares authorized; 13,016,955 and 3,347,386 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock": {
     "auth_ref": [
      "r226",
      "r227",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]",
        "terseLabel": "Defined Contribution Benefit Plan"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureDefinedContributionBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Benefit Plan"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r47",
      "r49",
      "r50",
      "r56",
      "r411",
      "r422"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r76",
      "r77",
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "verboseLabel": "Conversion of Series X Preferred Stock into common stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreferredStockDiscountDetails",
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r11",
      "r12",
      "r212",
      "r215",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Number of common shares issuable upon conversion of preferred stock (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails",
      "http://astria.com/role/DisclosureStockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss": {
     "auth_ref": [
      "r147",
      "r149"
     ],
     "calculation": {
      "http://astria.com/role/DisclosureShortTermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale and Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue": {
     "auth_ref": [
      "r148",
      "r151"
     ],
     "calculation": {
      "http://astria.com/role/DisclosureShortTermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale and Held-to-Maturity, Fair Value",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r153",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of short term investments in unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureShortTermInvestmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r299",
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r299",
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other differences"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness": {
     "auth_ref": [
      "r297",
      "r299",
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, General Business",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r297",
      "r299",
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Capitalized research and development"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements": {
     "auth_ref": [
      "r299",
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the estimated loss from legal settlements.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal Settlements",
        "terseLabel": "Capitalized legal expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock Incentive Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Incentive Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r57",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r101",
      "r104",
      "r109",
      "r110",
      "r111",
      "r114",
      "r115",
      "r329",
      "r330",
      "r412",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share - basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r57",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r104",
      "r109",
      "r110",
      "r111",
      "r114",
      "r115",
      "r329",
      "r330",
      "r412",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share - diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r112",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://astria.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Reconciliation of the U.S. statutory income tax rate to the Company's effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r83",
      "r287",
      "r306"
     ],
     "calculation": {
      "http://astria.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal income tax (benefit) at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r287",
      "r306"
     ],
     "calculation": {
      "http://astria.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": {
     "auth_ref": [
      "r287",
      "r306"
     ],
     "calculation": {
      "http://astria.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Percent",
        "negatedLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r287",
      "r306"
     ],
     "calculation": {
      "http://astria.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "negatedLabel": "Nondeductible research costs"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r287",
      "r306"
     ],
     "calculation": {
      "http://astria.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation Other Adjustments",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r287",
      "r306"
     ],
     "calculation": {
      "http://astria.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income tax, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r287",
      "r306"
     ],
     "calculation": {
      "http://astria.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Federal research and development credits and adjustments"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://astria.com/role/DisclosureAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average amortization period over which cost is expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options",
        "terseLabel": "Unrecognized compensation expense related to unvested stock option awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Tax Benefit from Compensation Expense",
        "terseLabel": "Tax benefits recognized from stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockBasedCompensationExpenseDetails",
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails",
      "http://astria.com/role/DisclosureStockIncentivePlansSummaryOfPlansDetails",
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r52",
      "r53",
      "r54",
      "r87",
      "r88",
      "r89",
      "r91",
      "r97",
      "r99",
      "r116",
      "r160",
      "r214",
      "r222",
      "r274",
      "r275",
      "r276",
      "r303",
      "r304",
      "r328",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r427",
      "r428",
      "r429",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisDetails",
      "http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsJanuary2020FinancingDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails",
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "verboseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsFairValueOfWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsFairValueOfWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of fair value of the warrants"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount",
        "terseLabel": "Fair value assets, transfers from Level 1 to Level 2"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value, Assets, Level 2 to Level 1 Transfers, Amount",
        "terseLabel": "Fair value assets, transfers from Level 2 to Level 1"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r196",
      "r199",
      "r200",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r332",
      "r373",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value, Hierarchy [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r331",
      "r332",
      "r335",
      "r336",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Financial Instruments.",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r196",
      "r229",
      "r230",
      "r235",
      "r236",
      "r332",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r196",
      "r199",
      "r200",
      "r229",
      "r230",
      "r235",
      "r236",
      "r332",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r333"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount",
        "terseLabel": "Fair value liabilities, transfers from Level 1 to Level 2"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r333"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount",
        "terseLabel": "Fair value liabilities, transfers from Level 2 to Level 1"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "verboseLabel": "Derivative warrant liability was valued based on significant inputs not observable in the market, which represents a Level 3"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r337",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r337",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "verboseLabel": "Summary of warrant liability was valued based on significant inputs not observable in the market, which represents a Level 3"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "verboseLabel": "(Decrease) increase in the fair value of the warrants"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Issuance of warrant"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r337"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r196",
      "r199",
      "r200",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r373",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r340",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Net Asset (Liability) [Abstract]",
        "terseLabel": "Summary of assets measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "FairValueNetAssetLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Transfers Between Level 1 and Level 2, Description and Policy [Abstract]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r150",
      "r152",
      "r155",
      "r156",
      "r157",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r168",
      "r169",
      "r170",
      "r171",
      "r198",
      "r213",
      "r327",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsDetails",
      "http://astria.com/role/DisclosureShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r172",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r23",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "Acquired In-Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r173",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r83",
      "r288",
      "r290",
      "r296",
      "r305",
      "r307",
      "r308",
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r51",
      "r285",
      "r286",
      "r290",
      "r291",
      "r295",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r60",
      "r130"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest and investment income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r158",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://astria.com/role/DisclosureFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description [Abstract]",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "terseLabel": "Future minimum payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingSubleaseDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Sublease, Description [Abstract]",
        "terseLabel": "Sublease"
       }
      }
     },
     "localname": "LesseeOperatingSubleaseDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r27",
      "r82",
      "r140",
      "r159",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r319",
      "r323",
      "r324",
      "r345",
      "r363",
      "r364"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r82",
      "r159",
      "r345",
      "r365",
      "r406",
      "r419"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r29",
      "r82",
      "r159",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r319",
      "r323",
      "r324",
      "r345",
      "r363",
      "r364",
      "r365"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of short term investments"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureShortTermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Expected dividend yield"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsFairValueOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Expected term (in years)"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsFairValueOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsFairValueOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsFairValueOfWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsFairValueOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r120",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization and Operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r70",
      "r71",
      "r73"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r45",
      "r48",
      "r54",
      "r55",
      "r73",
      "r82",
      "r90",
      "r92",
      "r93",
      "r94",
      "r95",
      "r98",
      "r99",
      "r107",
      "r131",
      "r138",
      "r141",
      "r142",
      "r144",
      "r159",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r330",
      "r345",
      "r410",
      "r421"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsComprehensiveLoss",
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations",
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r95",
      "r101",
      "r102",
      "r108",
      "r111",
      "r131",
      "r138",
      "r141",
      "r142",
      "r144"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income Expense",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonredeemablePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares that are not redeemable before liquidation of the entity. Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred shares",
        "terseLabel": "Preferred shares"
       }
      }
     },
     "localname": "NonredeemablePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r131",
      "r138",
      "r141",
      "r142",
      "r144"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureCommitmentsDetails",
      "http://astria.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r357",
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Lease payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureCommitmentsDetails",
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r360",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Estimated incremental borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "verboseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Operations"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r28"
     ],
     "calculation": {
      "http://astria.com/role/DisclosureAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax",
        "terseLabel": "Gain on short-term investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "verboseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r46",
      "r49",
      "r316",
      "r317",
      "r322"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Total other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax": {
     "auth_ref": [
      "r42",
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax",
        "terseLabel": "Reclassification of equity classified warrants"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other non-cash items"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails",
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreferredStockDiscountDetails",
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockAccretionOfRedemptionDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of accretion of the preferred stock redemption discount during the period.",
        "label": "Preferred Stock, Accretion of Redemption Discount",
        "negatedLabel": "Accretion of preferred stock discount"
       }
      }
     },
     "localname": "PreferredStockAccretionOfRedemptionDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted.",
        "label": "Preferred Stock, Convertible, Conversion Ratio",
        "terseLabel": "Number of shares of common stock into which each share of Series X Preferred Stock may be converted"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionRatio",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails",
      "http://astria.com/role/DisclosureStockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquityPreferredStockDetails",
      "http://astria.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquityPreferredStockDetails",
      "http://astria.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r12",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquityPreferredStockDetails",
      "http://astria.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (in shares)",
        "verboseLabel": "Preferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails",
      "http://astria.com/role/DisclosureStockholdersEquityPreferredStockDetails",
      "http://astria.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockTextBlock": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.",
        "label": "Preferred Stock [Text Block]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "PreferredStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r12",
      "r365"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r20",
      "r21"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreferredStockDiscountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "verboseLabel": "Proceeds from underwritten public offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from public offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsJanuary2020FinancingDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Net proceeds from issuance of private placement",
        "verboseLabel": "Proceeds from private offering of public equity, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails",
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale, Maturity and Collection of Short-term Investments",
        "terseLabel": "Sales and maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r67",
      "r273"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of common stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r45",
      "r48",
      "r54",
      "r69",
      "r82",
      "r90",
      "r98",
      "r99",
      "r131",
      "r138",
      "r141",
      "r142",
      "r144",
      "r159",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r316",
      "r320",
      "r321",
      "r325",
      "r326",
      "r330",
      "r345",
      "r413"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r8",
      "r74",
      "r79",
      "r404",
      "r416"
     ],
     "calculation": {
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesCashAndCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r15",
      "r222",
      "r277",
      "r365",
      "r418",
      "r430",
      "r432"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails",
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r87",
      "r88",
      "r89",
      "r91",
      "r97",
      "r99",
      "r160",
      "r274",
      "r275",
      "r276",
      "r303",
      "r304",
      "r328",
      "r427",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Deficit Accumulated"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Gross proceeds from sale of stock in public offering"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsJanuary2020FinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsJanuary2020FinancingDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails",
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreferredStockDiscountDetails",
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails",
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreferredStockDiscountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of anti-dilutive common stock equivalents excluded from calculation of diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisDetails",
      "http://astria.com/role/DisclosureAcquisitionOfQuellisNetAssetsAcquiredBasedOnTheirEstimatedFairValuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of components of deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of U.S. statutory income tax rate to effective tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r245",
      "r269",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "verboseLabel": "Schedule of stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of assets and liabilities measured fair value on recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Investments [Line Items]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.",
        "label": "Schedule of Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of net assets acquired"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r8",
      "r79",
      "r404",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r246",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockBasedCompensationExpenseDetails",
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails",
      "http://astria.com/role/DisclosureStockIncentivePlansSummaryOfPlansDetails",
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r251",
      "r257",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions made based on the Black-Scholes option pricing model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r31",
      "r81",
      "r117",
      "r118",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsJanuary2020FinancingDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails",
      "http://astria.com/role/DisclosureStockholdersEquityPreferredStockDetails",
      "http://astria.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r202",
      "r203",
      "r204",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of common stock reserved for future issuance"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r224",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Summary of Series X preferred stock or warrants to purchase"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Cliff period for vesting"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansSummaryOfPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansSummaryOfPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Assumptions used to calculate fair value of stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Weighted-average expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Stock Incentive Plans",
        "verboseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockBasedCompensationExpenseDetails",
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails",
      "http://astria.com/role/DisclosureStockIncentivePlansSummaryOfPlansDetails",
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Additional disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r259"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Cancelled or forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled or forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r253",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, end of period (in shares)",
        "periodStartLabel": "Outstanding, beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of year (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Vested and Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Vested and exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested and Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r244",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockBasedCompensationExpenseDetails",
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails",
      "http://astria.com/role/DisclosureStockIncentivePlansSummaryOfPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r246",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansSummaryOfPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r264",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsJanuary2020FinancingDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r9",
      "r407",
      "r408",
      "r414"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments.",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r445",
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r80",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r81",
      "r82",
      "r104",
      "r105",
      "r106",
      "r109",
      "r111",
      "r117",
      "r118",
      "r119",
      "r159",
      "r182",
      "r186",
      "r187",
      "r188",
      "r191",
      "r192",
      "r205",
      "r206",
      "r210",
      "r211",
      "r214",
      "r345",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisDetails",
      "http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails",
      "http://astria.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails",
      "http://astria.com/role/DisclosureStockholdersEquityPreferredStockDetails",
      "http://astria.com/role/DisclosureStockholdersEquitySharesReservedForFutureIssuanceDetails",
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreferredStockDiscountDetails",
      "http://astria.com/role/StatementConsolidatedBalanceSheets",
      "http://astria.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r34",
      "r52",
      "r53",
      "r54",
      "r87",
      "r88",
      "r89",
      "r91",
      "r97",
      "r99",
      "r116",
      "r160",
      "r214",
      "r222",
      "r274",
      "r275",
      "r276",
      "r303",
      "r304",
      "r328",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r427",
      "r428",
      "r429",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisDetails",
      "http://astria.com/role/DisclosureFinancialInstrumentsWarrantLiabilityDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsJanuary2020FinancingDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails",
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheets",
      "http://astria.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements Comprehensive Loss"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Stockholders' Equity"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r116",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheets",
      "http://astria.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r12",
      "r13",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Issuance of common stock upon acquisition of Quellis (in shares)",
        "verboseLabel": "Issuance of common stock upon acquisition of Quellis (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails",
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r33",
      "r197",
      "r214",
      "r215",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities.",
        "terseLabel": "Issuance of common stock upon the conversion of preferred stock (in shares)",
        "verboseLabel": "Number of common shares issued from conversion of Series X preferred shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails",
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r214",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsJanuary2020FinancingDetails",
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.",
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits",
        "terseLabel": "Fractional shares eliminated pursuant to reverse stock split"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r12",
      "r13",
      "r214",
      "r222",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Proceeds from exercises of options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureStockIncentivePlansStockOptionActivityDetails",
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r34",
      "r214",
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Issuance of preferred stock and common stock upon acquisition of Quellis"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r34",
      "r214",
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon the conversion of preferred stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r214",
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r34",
      "r214",
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Proceeds from exercises of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r13",
      "r17",
      "r18",
      "r82",
      "r146",
      "r159",
      "r345",
      "r365"
     ],
     "calculation": {
      "http://astria.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheets",
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplit": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.",
        "label": "Stockholders' Equity Note, Stock Split",
        "terseLabel": "Reverse stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsReverseStockSplitAgreementAndPlanOfMergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r353",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r353",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r353",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r353",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r366",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureAcquisitionOfQuellisDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsJanuary2020FinancingDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsLiquidityDetails",
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails",
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreferredStockDiscountDetails",
      "http://astria.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "Supplemental disclosure of non-cash transactions:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "verboseLabel": "Series X redeemable convertible preferred stock, shares issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "terseLabel": "Series X Preferred Stock at Transaction Date"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureOrganizationAndOperationsStockPurchaseAgreementAndSeriesXPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r150",
      "r152",
      "r155",
      "r156",
      "r157",
      "r198",
      "r213",
      "r327",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsDetails",
      "http://astria.com/role/DisclosureShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureSummaryOfSignificantAccountingPolicesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrants and rights outstanding, measurement input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/DisclosureFinancialInstrumentsFairValueOfWarrantsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r103",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding used in net loss per share - diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r101",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding used in net loss per share - basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://astria.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "51",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e34017-109320"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r452": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r453": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r454": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r455": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r456": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r457": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r458": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r459": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r460": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r461": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r462": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r463": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r464": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r465": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r466": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r467": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>91
<FILENAME>0001104659-22-032475-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-22-032475-xbrl.zip
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ML'OH<WPJ_(O0OTID'*TN7KB\CE:4AQD \H!PJ+MN67+!M&@^F_.0*S6@/YW
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MSP+4(C'<0WM^R'X,KK4=O#8/]#'8UG>3Y;5!? P0'V_OP2$_I&4,$#N[<LR
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MDK4FY$!R0&C&5+-*TZ"GYY'_H-CZ2;K*^]T N5@LA.JV;O#.KE!R3\69O2$
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MF(*%7,!Y[HP))1#C@;U><0@UQ4=R>NV.'Q0!:FP")MFI%\ZK-1\L>NT.UT6
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M!X2V9;!,4F!8\P*<20F>[D/Y(B->AYB\2+UQ;RNK?">L3W0NB6>9U]!^?/Y
M%I57,P\Q"/JW"M<5W2P65)-D.2_2V+!.1R!^9;'TB3G$1ZB;<Q^KTX X\25)
M>$RC$P0WL[YTE8Y[2LP@K)NKT&>6%7%\B3:K-[(?QV]!D]61@L4-^?/E>\V
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M 8#2 (ZB#Y!HCH; :G *4IQGCB)$J;&DV]PUV_K"=7H3_HV)*M\I;M03@J=
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MHX[(<<-<>14J^GLA1H<!PH^^CIZS( 4/\D8-@IS-R6[Q--5_DJI']!&8= '
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M^61#<L;Y@. &TY<WT$>/)7GBA%<R!U.)A38@3+'$_BSYNL2:^LW.K>\G-!,
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MO,VBE&=>>.HQHQF - ':Y#JJRH05Y!W,)V;4%5:VXF-77SE5/C.K*G!C>==
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MVQ99@WHC18N19BAW1<R[8M\E&:')E(,:5H)!4(*!\GPM#P+8FN?_)1^R!:"
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M)3/,;MDMY>,($,R9D)*+^VGE$LK3G.[)NY;QH?64 .7>^.3M/OPH,-P8X_;
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MHB*1@=E.>ZP(@C7JZJ"VT7QED*J3?LH[DGY)4ZD'U<3+'%7S]%RY=4S@V4D
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MCO8G26WV,^!M%,B'FOYZ4UQI$PV[ZA",IH34_2R8I^>@MX\,]L731*W67=_
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M),O!3;:\2>C!8T%>3HZW%WM*\K<E/M\ 6;XF !_ZB6;#=5-!OA:X'VP/;*-
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ML*ZY0R:Y7,;3J]Y.2-%ZF-+JQ*J[!^)9E:'@8SU:D">%7RL,' 7S0FH7"L?
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M8EUCET\GJI7[_O<Q86G 1+WX3N_L[X7<3PW5KCTZV-T%L>^:2CZI2*-#'^9
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M09F::_AE6.K[#\.-\'('5QNF,Z?[)E-)S/9AJ>+!QE;;PG9;IOSE1J&NEE%
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M&2!7F0N1I\':LF,='[YBGOLA&([(3R-Y.3PY/1OWD2TBTDLZSV911M^1"%9
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M5C1P79U>0-]<4@5G92UPEVDE2$0HLFXB<M\OR9<4Q[#D?47T)3EG?3#D:4X
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M^<XQID)6VX2FD_'X='1^CK<XP_'X\K1_818 ME3JP&H1>5&_@-;MEU3LB 9
M#%&P6CFBX0,NV1$]GDR&N@$6AJ>1(SJ5%)@[4XXC&@"*_ @(.Z+W@=Q^0RH
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M1\E-(&90?'U%,-@+HE4',[>L:H/$YH@D8$<5 :V,T-S:2L!!X]9]Z7BOB=S
MHL@\AWB!?<-AF.!B(3!HJC&_',+N[PI$"SR90;F[Q<!@*H ""SJ&5%#'WY.#
MK#=DU5P:JRP-&#T&$"S\ZL73?W=L;KAOM MCF]_ 0"/76-;+R'&50=*U>WZP
M*L?6SJ]@ *M7<04<H ?,-]NU5]&*BD+A=W@X<"T,^>10NXCG&N4/E"L##5H
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M152<"2TYRI@C"Z$58>2UY[XC/[3Q/P6/?[C; (<D)Q+5IT#MQ(9EMCMYP .
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M(_+3\&SR/[D0[8KS5 KEN.O#99X8"\IT:J<"I:S2E58C21^X$J,2NU)_^=-
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M1?&^9K?/1S;.W$UFO32$&40+I-Y.8]:WOG/7#]0EL%\V%6PB,E2(B"#;1A
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M4+HIY,SFJ#-X![Z7V,KWGF^QCDB<8V3MOWTPVVXQ7QX(VG,C0\!S1/U%1#V
M$!'7$CR'F6D)-+(&OANZ4UDVG4N?P^13C4P-@&^2O5E@>27G1-4-$YF*AG2P
MZD*/ 'C8<9&I(EMU!"B'J*G;0C/C?Z&_-UE<#]]L3/M#8.CS/9#__E<J(2?3
MOVC$ [>_0RH1V-N1ZV(H@@EW2ZX9^M>0]:,!#04(:G(AQR&2.7SE7SU^GN,)
M)GZ>HQM3_YS)"^?!.C0@^R:!4B#!MJ4+D,X?;,8'X84[P2-(L0B,2HB)4-&B
M)K)[B P>J\UT/*>A&7])2:%]V#S,'PII.045COZ&(UV<'P]/[NF$2800Q5^
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M,U#L69J#%OG>H\D>3:*))MD\S61Q )950NK1P,8,E"&A)4?+(+P!3;*' I\
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M[T HSK#B49='K>\7_53\6)2\7YU&.(&RI&"2VENA=@JWGA::Y!W"CB>R^Z0
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M8\FW-*W4SP%5L:/86@]BIGL6H0-$80DD; 32]0!3HD;-8-2:1B;U\W?['L1
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MAVR#@*-T<72(4/J%C1_I-^9:1(+E\>0'RZ=(T08J[^G]&%"[@Z4QZ(EZ=L
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M;F$Y7PI7.UU$H.4"8A=M]KG94@1MAA[F!A>S0-^$*N94G3'( 3#;#U-D!<H
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M*"3O2R'Y5[I)+\"X>%9NB-=IOWVC4]B@9]7<T>0]/BXB>]-UN9B=?#TC1_8
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M$OLA[G+JN*V%A#CR4E&C;H^N[+A?I@=/!E@'O[\F./8]($JY;ELZE8C05':
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M01=5M>:% 4* [0JDCP2D.KLNFRN.48==!U]AQD5L P,%>&_JMISU=V'!K94
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MN_G*IBE+NFI:/<(4_!<LEO;^?\W@=SE6@5XAD#B-(?+)2G\1)^8L]R-<'!,
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M:"0#5WB1:B?=EZV@:!0&6!#%GY$Q)61Z23(@(L(XR6W=:2L*AC-&J[AFPI*
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M5M4&OS6)1I.CBQ68GBA.3: NT;X,&Y4<!U,YLKAD%H4OK3N9S7;,^[O]:KC
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M7SK>,)'I>SE)-)FFE<LF>9M.9-66<O(&XC(FW=@XS9==6R[4%;Q%O2Y-88L
MKK]9 OFIDRR#K]WX%;:_YF'7TH\2TV67KA-9\#&/0?.GRS%9ACYK7BN+*3N6
MB2'*[RU, DH7M:Z(_HJS#B%.!Y:]TX(VMY4/J86[9XM%:Q+N8KC0RU0K8(M
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MS/9JZQALPU(M5,!F0+_$MI=2=&[>9!Q>U\NOA0V+N,RJE0K7Y&J+._)@:6'
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MFVB-C(-Y]VTERBO?4NR-E(2_0(I=4 .C68(177GB%_Z-_4*>*-BEFASV175
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MEFLFUE$PL.)_SZ53QZ71:99.Z;A;P&R<T:2<S@=/8*79/]Y?_!6 ?XS:3B_
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M$UA1$@E7C,J:81/CB8KQ0X R+E*#S]!U237LZIML]%B+](&#7[)GLJG:S4K
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M9:;IQG&OTE$!M,ZC]FF\/EN?&W8T.C8\<,D$R( XP? A_XF0V=*+R'F6"Q1
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M8 IW9<@$2/8WRI$%8@_$ >\R#Q:9NW>VTP\0PV 0(DF.@:Y*(VU)/,8X2N)
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M+BO\BL:;23UH0\[MB<5(&$I:%M(@M*W0"],]M&4F#H U[DCCZ,4F+\JTB2=
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M56><;/XY65'@JA"*6F@Z0HP^+93$/52'9\1%-D]:LO&ZH R^$U-RWH-V>\7
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MJYI#/H"+[3H'AB'MZ 4W&8U9?#5(FQ9Z":#J'G")V1UM-!C>!$C,A>(SWA5
M6I, 40#-7I2/YT!A?EX:BY+V%8JI4]CAX!C2/9Z"KXP)19QS'M$!)TA)#HH[
M6*)LWBC[J98IYNRB0?=,U0;XZ?6ZZB=I_8>^RS":)?:A,?:B(S4/V[CH=.#0
MB@LW.P2/N)VN%'!)XD[P#OS]!4K^0);)X\]Q.7NY?,]A+!IZ&P B902;8+[O
M.&I9+&CUE!VB+F/TBSP/&<LN]+C1,R_GF :X="L> W;HPI<E03(79!3=$S.@
MI%YX*JWW<83+P-;!Q%S.OD(\A:VC]L7'4$Q+%D,@UHF/T*.^<E?OCU_OY)L?
MA%V")<1X%SV4>3N&[.'B^*\(^H#D<0D(56*6S)FAPLA&A)J'7<MT ?I(RYZ_
M6G+O!N]GNLD&9KF$4<E&D%\]6G&D%WHW:SSC??*ZMFI#ZJ' '-)TA3DW8UR&
M=_"8C:!RWP4FRD#\QM\?;+W'-MW,H$>2BE+PD<2ZJXIV(PU3.WIA/7OI&LO*
M<A/80)):,07#C#3O)!F:.>^-)FXAH.T *.--SJ4+K8/Q7B16&C^D4<> V^[#
M* (_>S(5@:<B\/]?B\ O3_- "FOA+7#M ^\GC_2O.$QH]U@#X64N>/0FX9G3
M6;?F\#\DR>1@Y#U742KS<DU[HS >(M73'1=6TC.[E:#*702UK(I;8;(1!M \
M=*4=A20KYVAX[E XX1.73H6J^R/0,+[HTX O1Y&W;?#^).SD_B)I*BS*)>)<
MB(Y(=B7V;UC1!;(?A0"Y@Q;(H)/K!5<I5;=D/.2X![*MO-:G QV=8<57'IEB
M<9:T:XQ=:;;GO!5T/J_S6S.QX]Z]/#*]PPWBT5;L& AJ<H)!G)]<"<Y;7HL)
M4MA<MK55-$SD18WV<-3>V2%@S"%W1PV87,?&HK<RSV=->J+;^#J6H 064I<<
M/)V)6'+J>;]?T' H-&%H3.W6\NLE6#\G)4KN.+"_3!P>DP7^#I+0/4Y\<JH
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M*HT" ]CYET,KF7UD+SFKC-62K]:%F9^]>7'R"O3TWY)SU+2\ 6L6I&UN2L5
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M@#'?KR]R[LXD'P=U35,;;P[73!?5-D>#Z \42#4V9C0ZNU+:.+7@Z*Z7"8#
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M>+$>YM?KT^]E\F%PP$DH--.*V,+7AO5%0Y.EI%L+"P]3P1_NEBF+\X?F_1*
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MN-4DN["P&)4/]::_ [.*=NOC+\WOXAV<L2^*8G..-#%%3\9-CG<4<@]VLPV
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M,KSPG[K"<FFMBZ9M-(<-JIO,'*=E+6_1N2'[VG\L;+T"/1]<:M,*O:'9(R!
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M.?5E0+RD.RGE@$UIA?\*)\M6R/:+UF9+HA0&Y$U>B[] E:7Z-,N10TU,YVO
MCOWG!3MVP8Y]'=BQGR/] <:E=9\$H"=IUYE'-:9NU22T<-$:M+1GJD8IUA99
M^"9XF<,4V%Y@&?LD1JCS/^2$UB)*KB6B'&Z*92K((>M3I9/"QFF\BC,9"2K]
MI+1&A5 ^A''>&K@4,3=5(940-T(R8R<X(.G7O3R@9SPL,*O4$,PZ,+"9"R.?
M3("O%'TT2QWI:7PU5)*D2 <=5;KZR-P\HP5##"\;XHA8V9HQ9AOFK<T,GYII
M3J;SY0ML%7WW8,4VK0CI4_2#,H">KPE3-+%K]Q8V-#0$SS6#$,]2I8)RRN!F
M1ZD51WUE@KFZKFTTBYE6 7.<8YY#6,Y[EX^S>B*//&CD+ $3PJ030BBG[4AG
M"M?"5J_<B\>'[WEQ&_PM^""1PN$6MWWXFXX&6>MK$+WRX.H3>B\A@B3&W05H
M)VD_.C9;_B<97P^+0,R6RSC*H8,9G$"OC]-A4LY4E9(V923FV[MM.B7Z3#8H
MEIVOVSIB <U0>=B,OMB'B GY'P6_+7+1I*3JJ^M6G$[J5O9S7.>"UT!C87I3
MP :000&;,L99%&5DE03IGN7[6AK,Q&?H>E&A1ZLMKJY539,,[9^$#;YGM<[8
M19BP AE62PO+O7W/7Q)4H$BXMSL4BH1H@^M(%&[70K-;>B6Q$.BH:[@N@J-"
MG@OQOE 5CL$IT1A4Z?EB<8+*>>G)'>5R(O6%U:$3.80/[E\BY,T_\^CQEO;-
M.%X8R8W_<:C%XKC[<L>R"NM,6X-0'JLVDI%1NPI]@'W'Z%#BG68:-[84U..I
M_0Z>A0R[3*626.&@37JU^*O57&Q,B^J=G)"6"O,^-[WWB2D'.Q1QE>:*:O,^
MP*OX&;-:"M'B9!T2-IQ">U")9=654BLI:5=E)OP!95RI-, ,==3,GK"1$GKW
MI6BVQ@;33&GSP1J-O.ZIJDJX@7 _P[%2%^,ZY;Q/][W4Y F$U&B@4&4]&^&[
MP@K76&U?9GAH!$1BK7FQDH>"I%2'NLR6["J3S.8,8W'-&XRL<-^C:&ZQW6I3
ME,U/+9/"],:Q=NH))X[EX1?WZ7[&S0<670[_^+P)H&7"2TM[*M%X[@[;:YH"
M-?Z?2J1KHC &:PI1ND2I*)\5<F$L\+(-.4S*RG.PDG+"*F0SKIYES7C$TBB8
M'PI?(TD[QW*5KESF'F6^D9G&XV&0?4J ]?)HHGFD$Z3@CK>TL^"FX#-YA#<2
MU6W1T;7Y5,\*W.<T?2F)4&$)Y#@\$92(Z5K1, FE2B&+VOK)%IUS%=E\]ZI'
M'^V*=$/NI(&K;>^60E=J2@3/GJO^E*48IM>0S@T\X2U+O""2;2!C U*$\!4H
M8#0T9(_>2 _L%K8<U^K#X;+=Z3%IUVZZO_='#CR$P=DDIUSC@HL-"MZ1.Q\S
M6G99G' GD*B,+ENTTL7<?A;*Q!=%[_@<I#2;6CB2[D[NRD&4W.86)K>IX"-Y
MHQK>3:K-V>2W,X&\Y93TEZZ'>$.UJ$Q@V,^M8XQUS_@<CN4FR^9MTR7" @;2
M.'48I#$5-Y<SDDJEDURA^Z=]YUA2\E63F0H3NS6K@DQY+2)U:3'^G\*ME''&
M,/51'L9K*T#D$?![IK7(;B0;@K+,YN3#1<*MAQZKS('D/)4)P;IVL#[00Q4-
M5]#PK@$G0G[]6$)I]_%M4ZIC_!]1=>NF-:Q+ DOA<IIG2D[89PURBJ6>[E)G
M9&2VF[96*K%I#S[:WS[<$I$_\;^HG^J'KCF.8N#,*=%.MP7\ 14<&(<:LSK%
M<@5; P&J>/ TWOHD]H('BV:,X3R,<>/X)GVD&MVIWF+J(3.BRTRZ]943E#-.
MBY"8[;B$B,R:(XP9+ "=O809H69;"#BFA<8TB3'N3^FM 5+\124Q/T+-&-C;
M+8=*27[)()%JT5S=7%5XN3Z.][HIF6Q*437%BZ[ PT6!%I\1G :GECJE68AB
M%\CD^CA/!YS4'>4X[V',ZWXIRB-=V1+YY7-/G$UXI%IZ$I1S_@?+H7U\M!H:
M;*;K%S>'&O//"E-BJKN7F1+%KM^;?3Z0C0#@R+?F=U>(^C)R0XSSJ0K?96K_
M,F8RV^H$%E5@DH43_V 2E#GKU$3SJ"1F!O^LT8>F@T4S/S'7]\5C!'YSP0A<
M, */Q@A<'/;%89>FK3FQ86K0)..+XR,L'7@J]8W9(_C -AN=;4WJ5#%)U-A<
MOS77B3[1?*X459SG7__:].LR('[948_;44.S:BBNUPF5HFB&13(07 &CXBIF
MUEH?R3/0R?Y)]1E]-L$(:X4OP92=ZIS=H]42K/7(=T%BX<&.7H2OG/,&N$R:
MGY_][^IR_8EJ]8#(6$\\*TFAOJ:-"RKPD&2'%$VIN#1*?CI;C=*V],F>W5<X
MU_YSD)9QU%PGIO,ZE[PL-/A]B:O2,<B( O<2Y>I87.$M'WMS/.A6-;G7[WTI
M<C0O-[TJFTU$]5"N195E:" !D*R@UVFAZJVDQ099]/5%SPP6(A9]:8G\M8UJ
M=F,+[J9X=M#UJ]+]V?[,$"PS"(\TH;?C[&KQM\8$QIP=40"8FHQ!1Z^/3!DE
M+?X>,9R;G)(N0F*%GDN9UYM+JP2EX<*J#^VV@@$FTF-" (8'ZX]-@VI<1T>F
M]J\9U\JEZB[<[W(/ZN-7[WZDR'9UUS(5LOZCAV0. !H39JT9O%)CAC']FUB!
M(\F:/!L*IL;)$9&G(YW3W#K,'M^>B!=+WIA[N#,N'W](BN7YRP:)SA,BT2$7
M96WFA&4#FB+Q*^AVW0+G=\^SG"YW<.A/+UF9V2:/\=!1@>5-YE.;GYKE 0YK
MWBHY&P']M< !$G8J,>[FU#[W!^;D#L_X=7X'/ &CQ8 YB*/^:!Y2@(LC0!=A
M58IOZ]0]>H1!5>![>!#_MR,(WA*G>S"/Y;(':,FU0F>:B,EP*N; >Y%K$G)S
M"+\SOIB,!@\GO7#SQ@RUW-<?&T\5,;*F%R;*<<6$%2/ZO[SMQ] 6>KR1.0'R
MBBDUP_8P MHR$#2A$$G8'W)M4[F<]]9?B*4)7+\4D'#'EA *D)7EZ%"5R7@:
MS5Q]9--AB$CM2@0.Z:.M%^-:T#9FWA^7@UCD%^ Z,#)+;<X#Y55[&<1U(1*/
MM\2MGU VU/OYCT;-M$8E56V.X:&%B1N0!4<_>4TF>)*$^4";<\M)^':NAO0!
M+ROQ])'H4HI/@GN']W8"#<HD3*_A4R9^8A<O,A<(Y!U8WF2J,WG+)NWAOCT%
M!,2]WW0WA)NC3OQ=NPKIS\@$2/M6J6>()8+NSAXN%TV)37&"XCDY98[G3EQ:
M'RE5]\74J_/\IYZ8115%S7$Z9\MS,W;G*230Q3\(TRCW Z>(#A-\8.E9]\^F
MPSA&'+U#/6%WV&&0Q0YS2 #%$THPSL):#E+H8GZ3V^)I'BR4N +ZZ;4(34%<
MU-;3XI\3:=J,=(X7$B_?/%*ZR4Q7JJ_E'H#O?BZB2MZLK._?FWY'T.%_GK5K
M>'P^_>J6N-VLJ.PTRA^0=$_[F^P]R\+N4598M4<CT(@)Z31H=*_.OQMCISG_
ME!IP7QMHX D:+-<4[DRG4-VUJF^KLXKA^[=-?=?B3-/T;HZ'NQ)(\P&<.1$G
M^F,<G3--Y=8TI:UU?0*#+0B9$7Q:KLU 'Z)K<N0(U9KF)TL#1WZQ@+?SS$N1
M=J[MZ%,XM]VLRUM1TFHP?I$I0IXR1=.)S*MV?V[JV^.3]UMZ#2^WP0"6=3B"
M[K $JD,Y^1S]/66NK#;3ZUYXW^SV#8'/F6/D^=-GSQ0=$WYT *Z+PZ@4',\!
MQZB8^^RG%B8653ML>U(.CQNTI-))MZ<GA%S+GPZ<S/"<"3WI?6T#3Y/)4*)G
MXERQ0IE]30-T[.KK8:\4\9 , [RFL?-&G_%)E,:L(=S'"8CO8=%Y=TMM P6(
M>S8RP_0G%9V[M@9N2GA_1#&3[6@"N$JP4@(IER&+)/@HO'8Z [J1C$\P<\7U
M'H]CL ,VC7I!^,/G3U^LVV'<*X4-_N[9"_DDOW9\X,F^?P*.F_B"*B+<97@H
MN(B(0&C;.(G18'EO*&8PJ_NU0Y26'H+'(3#6N4$*[X?(MY34T;!$GU<G9H]*
MK>]E9,'.YF<M/OBT 7 .JZ*+A3F >=$8)246K+_2, :+9%0L?S/%QE<JM>:A
MDQ.\9.7Y2B+,;9:/[.N@YOCM!79S@=U\'=0<'R9N^?UA1]6NL S4;:/1L>&P
MX:&XD;PD14NQ,Q<\@ PK,5^E>B;3ZYDZP CKH!Q-<[5V6!ZV-$ZS9-#??=@/
M3:>7BYP-?K9Z]%<(*W[0!.^E'$M4:%3V)>3-UTW3(=CK1TI;H5MMG_6A01J[
MVZ#5@Q'3@NE!J5^YZG<X^B6F$5AW1C;I"8F+N=K5(LJ8T^G!E06=MI%QMV"R
M-P/<\?0F=13.#FX[#BS?#T_X1"J1U_U*M$0GH2#XI&@MZ/LB\H>;N*$IK,Z'
MPP)RQG+2M3!FQ^50_ N_W)GLLJ.@(_)N9*MD@YD):X#\=UIQE>NE8J;GF^M\
M1N_VU,RME!VZAK*@>FC1=5T-J-F%DSV"PWD >-2JCR_F8<!T'\ZG\\\4R9&M
MFANAP(@%./,ZU/A91?J!D_/*GC/ ."A/?D,8XJW(5!EF'[6?J<)G&D5158A(
M5O<";$@9Y(MOA,-@A>)K="\3GIO- =.HX2L7D/X%H3./^20G;S5/[7XAJZ'!
M5CD-3%;;8)(U7+/.+N43_?/E[^O#/E[-V*2C+FT<:\Y=>CCPZ=)I[?P"R;P8
M_.,,_A[33*F6CG!03,?U>:#_AH:SZV&/@),C"YN,1CRYUWJ$=%683);8J1NB
M7.#J*T5L2QV6M<S?F3]"0 GTIDG\Q=(OEOXOL_2?8=Y<;BO4F&#)GA%(JTIF
M[!<3OICP9T<G17""5U^H(\-!.L1!A<X#&VJ3X"+\APJTD@\E"1=SOICSX\R9
MZ2$C.:010*:GOG%FA2R=/+$2L.?U><7[1@F@M<IB5Y9Y:H/I($A15G$MY)-^
MB(HD:TZQ!*5$;M*YU";4J,&,ZU)=]LIEKSQ>^M6W.3DPF4"6<CR6DWP% $BK
MLO<H 6?22>E^DZIHYSEM#+1"E?Y.:1$92QY_*9(=%S6 &#-:<[V;H?-_3_A\
MA/WFLDLNN^314IZ>5X88=_L!H) )W<*^X:KY&M.X)?:%/@N)1"C)-L.,:KW$
M:"6.:?Z83M%>K/MBW8_.8#6,,;W3V*Q+C-5JBNS3:PRL7K21+R;WLQPJ>&,Q
MD1V#]23:R-1WC:'Y1#4\4UIE(/-I2@4_S6* ' .2.X;G6?[CRYSK?Z4(3NVO
MV2DX02F(Q(50!NXV+>38D$,IBRV0<:L#\+>K?GG8\CC(]39D:MP#7#?DD8YF
M+*K1!EI"GM^#6@!7@+F/#HB982Q"9M8MT7[7^=CIK=JD!=>;D;(UU(OL *!?
M,P-[_A0,XO?W<OY-WK>D^KAJE_S^F@Y/ ZK"GAD?DQR91P8/.N^RJ]N50CLB
M$(*@M41_D*TW2!0$[C+N,91NNJ>;=HTA"].($^+##\F%U4KT!TZ]77T-$U/S
M(-:2N=5$\%VV,JV-.?"J&Z68EG!UAO=J\;=;U@W$S ,8:($1V8TL4=@2AI_*
M"!"'(%[H@[0P]":(=WZQP;!Q@RHT501P4]NF[GB\'S-XB37JS="Y3)"C49$[
M8.8U= _P)'"!J5'3K44"C/HZK$3?*=21[SYY7V5-%P4T\C RGP2LK\C0;!)(
MZ$>/1%+(0)=B:CR<_VKQE^16F[O8VN3-^_"-UR=O6Z'*%3JLVEP%'@'3217D
M-PX\^T5$[#W3>?: '-O((L?Q]-SA,\NAO6Y$&0E7"B^$1K/=6U[KR+&[.A]?
M&YF%)$EZ$!V36X2D9#AHS7Q'G9%1<9!DIF6*\)EI.3S ()]C*&Q$S1@&IG0$
M7PE2]7<7I.H%J?IU(%4?'_+]C?-'@0%B'$ ]XDU#FDN[6XS?N% J%ZK09F;B
MZSWE4GE"ZV& F7)"I5-?/!*2TB/'8:,'K[J_A;Q1?Y#9E'[8? &T*=^W3!%J
MPPP2HV,\P35&$.05,$5T:&XV"01WN@S1UX<KW+;7+5.A1RZ!>5H M+S+<YOR
MT\Q7+(-<0W/#?TA?+5>@5:U-+Z# *X5$EXGXHTJ31 <SOU@Z)$4;!8VAJ\7W
M;<1$+W+:9(@3$66%7OU7^95)J:9+>%+<M^.FT(Y5*6A+;HZK^A1J4VZ;+ACR
MF?5AC."PB<H%!2\B+[YIM/=EP28%%WS+1+@2XNM]HYJQB+Q6'E<MX\4=%',>
M +#3(]X12GLMXVZ Q!4)^!V.^WPWX(?;- ]TQJ[H;'9U(38:$M!^!(<G8Y-M
MY]4Q[5-7X<!R'1UH:3;37GSX=FGKZ.@[AJ"5RF'Z<EPSAFLK!!RTVDMX-Y5*
MVG.3-#B ?O!CU5/Q 1X(:(:!;CSI)KGCI<"H1*$X?U3^T<]?*8/32# <XHVJ
M)2$HS6;J0&)20TIX'W(BY9D5].TOER_W0^2Z=-![_IJ/KE/QF=,DZW(H.7:5
M.(4'%A4;=W1L&L369+( .Y:$4&*+\]U!;X*+[7GHL#QU':>&FX>/<3T4IAQI
MI!PB,RIM9Y6%&7;W^GXR":.C+'"W\<!4+IG9(9?O#G158S( E'Z>6M]M1?..
M82UQ-(UQC.2!7[M:O%&P J:ZA7VIPVT#-.FG>L//AN-SBW716YC$$0^%9.K7
M=&&33<3U'08[\"1J82G]P/3K\*-UM7@5\FG/<E'RC)4N[;J^DS,EF=5<)[GP
MPYLN4<O3&=4XGBI-0#JA]^PG4YV.9)14=6I3CB8W<?HIMY.(0J%ZI&L<K1#O
MEU[W(9S7PU$\$JT3S"4DJ8V2EL9B""0VMP<;9A8W)C-<J;RO*CIE,TWII;2L
MKIF",C_-:HB4,P .]*0PR#4. 5_*JD509CN*1A#=,S]%0J*<]B3R#(6IROA%
MS1&XG"B!*-L):",*+(R/'/"=]UUT^(<'^L<!"+XYWJUX#/AGQGD@$.J8"!F(
MNA21G.#'\B[F:PM(/*XE(7=<GYP\U%D+<0CN%U- 32EGA1:N#C@]+E#)FQK_
M:R'%&8<2;QW=0O$UN?.J>$Z1HVJPANC[[)T86S6I-I<E[$3@QJME<YZIVF]8
M35$&36E!(V?4]VS4Q(R@&=H]XTBX].P'X1XZF!DQ)3 ISY J9E1V)B9IC.]*
M85G;(OI@DL)G-MU%OBVZ\#W\>Z^:ZPF'3EHWR!3&'_.0.#*B S,>*MM;YVNT
MGUV;NVX2XJY4N-S\?]0?L#9\9#S%K/BL3M=L<YTZ.O1S.$\P3'[;[KB]S@-G
M+&VKG+'DM(L7.O_ZVAL7=3CJVY1>=&RZMO?RE!53!9(3I38FE<KXNR06]RD<
M3.GU/983LETZ?>S^X6KQOK>N*L$92C>[!6>0^9O"?1M!JQ^HU\IM@5N8_LIB
M(^HC&[ENY8<<_5\SN5SGB\92V>/5DEO?(OKS;+3$! 6OCE\O6+/D 0J[FR.!
M#O=EQ+@1A,>E@V#R]_WP4:)\+_8XW6HV73GD:\X[ZB#\K)$K<H8VRZL+)N)W
M>J#/TMSVS%:9TVA>+?X\T;;76?8C!U64UAFC*GM//%725$0M2A- ^R'^(%ZD
M5EOAKNLC;&PBGBAK"-9"BO&%ON*$0^>);E%T16PRXOR12P9;I_LX>0G#==3W
M-4;7P9"44(V*8*]#@#Q:SI,91 W#E,6_1R<CJC==/RC6\CDBFU/]7??>IB\Y
MT2G_M+"&[I(L&:R/\L:CXSBCXQ74#KX-H-'3_K@380X%C,SSF9OZJM"8@QO=
M@@J0T:VTV.A!;;/BY>2WV+5Z_G%F)3<2X]FOII[HT*6OFB]L5PG!Q-?1?__]
MI?]^Z;^?<?]]/FJ,C/6L,% O;Y42_[9'\DET1N(XYD3!]G.Q=%FU*,;_=$2(
MSS^,GF496%@?KL][G3P,\/UE9;_[7XX*'CCPYN_PWW;^%6/H66GZ?^L9>2*]
MO$Y^,<TDW[7CQW'Q+IK(.Z:FHA+R2\H&[Z1-_B/BT#^C@/\J@O'>U/O@2L,>
MOC[C'.[Q";8S-$,NTN:),71(5I;A-I&WC?O#RJ@F]2_W5.&6(OD0%[76117
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M7[^MA&*%2+2BSW!>A354$:^]JKMZ5?/;+I\>4R]@V-S-,3^;%!<;)8]97<Q
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M+]%/.V6(_?E-;U3_@O&-SQM*:9/!G3CN6([ZN8ZS/CT#HCV.O_[WXAOY'N5
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MU!*DFSPU/E6<YCR?X[S0'J+Y'R0:-%@3\FP5V4Q V:WQ0^&A"6Y^4,BEUA^
M^J!Q$*F.\\*O#@WGGS0BQ"E<4BR>M:;BX<U*D- HC;>D([P2TL?9@EB[DT;N
M3HF'_63=U>('562-Y3-;E?@S8$'T 8\S1Q3L?PHA^!Z"F4Q69).UI'8SAO<)
MO*7UE,_8+$K-CBDXG%\]:>2"Q2';#M,AZL^*%J\6KTY?J(S4QQUO=W4[J'=
MOZ7R\ 1)ZE1S4JA!4N"1%(,WB:C&R>;^7-F4?PPMZ[R=-.-0,NQE_G@GJ@U5
MFHQDA>,S-KS'IWH_IIVGM([JFDZOWOW(?2B%#U4.C6(MJ8JZJ2LEGP_9<4><
M_AM7QU>1"NG]$?T+R:IQ$2#VT;1)ZJ'],?PO@1-<N8->YBJX/GWOL1AP?@GB
M#." <<I&0:RA"1,BV#*YI;L^YDW$?^6KK"PSHO(F%?=SV!3+?!3?]]7B37*?
MO"\UH;(H U03K  L/0+>UA,J.-)USF@D7+V+"^ /59-B6\*/WG(+CP_!97#
M3&,7J]<*Y/]64!MVT6Q28]I1]A-=_ED<:BTGNYCAZ"]@._@[U/VNE&TN.E9_
M_Q@-V]?V<%R$MJ(G:;-HIWCE>]B8G8?399V.<#M#Q<2#E:<=I%R\2(0BM^U)
M![5 F-5&,( );.7,\^^9V1C(  ZUL7"5VPS50GD5T:#=K)^LA$@VOAQ:8Q3V
M;-1**IW%G[6V"9]"C$#)QXQ,7E*%(O&'='D8S<#SF>!M7)KED*;)&!)_3%*)
M6&BDL8]W7ESA,SZ3WE-<[SQ5DEO$,I"Y?(E>$[N]CJ@GQEW0$!YRK-0/<9:5
M@UYDST:_.;<SYU34XLD2F\?4[$0ODA:1@FQ4(R4\CS5F*2PII4AXQ(&2)NB2
M+14Q$VMU1"Y,C1F*H;D4XBA[>N6KEEDN&@A)S%X+?6%GA'N3%6A8N4H$.(WA
M@O>.QWP<+1.X5CBFS)*)LA:VT*$CT$C'0W[<-5[)N%7X*X(*: 77D+STK2G-
MR5QO7U\=72WLQ4,+!NDF;!/-<>I/B/A2Q+'#%LCS&@ @:I[%U()7TLW>A*\1
MB&A] "  #6\$(C8,BD8;<A3Y:QX2!H""/*O^9(*!]4DU!=N?"'\]!2RP$#D?
MV ?0H554]12Y^Y6'N;&Z6RFODR1#&80>@Y2RVU*9/R?5$V7^.$F5JX;U.UJ&
M9,UF?('3V+SW<>C6]5W/8G(J<Y94^B=*2)F^6@2AIUSE(AKK!W5=%^4+Z)N4
MR&!<D"K[44<BY%6:2!V_$RRZO W&QG! G#)053S$JI!;%E5R =4,,<3^5A$N
MBIS37U>!WI \2TL]5[-*QMMSG;.D\YBQ,!B9RSYJQ&N-1NF6X>H2U%5J,GJX
M*.EYM9A85<*)WG?,=*-"?:JV]^!.<H>);JCH1B<BFGX)8S,F/MUH'6?>6*JL
MF0MC0CK0__9M,,&0;?)X;T_#TOT]7/S)FZ=(5+EUF&U9ZEFZ3<<#D+1B$T,C
M/L+__="$*W?JTMD_M,,BLJS'FG$&LNG(-;38PCL>%NY/OM-U[S06FY]:E!0A
M,C4C"_>IUR+$E!#,IJU7$>T[,M(6_W%&YP4[#.9Z\4>=T32!3<P-Z>9>]L3Z
MA#?1-?>;8[1 B!#07':NU#9&K='R.H<+L6:Y+3B46RFMT#46T=9(#G.4"? R
M:T]F2(FTBO_.#..2CCT91$70(I2K+%@3%H/NN.EK.F2(/EXATISJF-IMJ@7+
MIZ&><9B&VU'D3'V,\-I&$5*-Z5*T0\%KIYJHQ-920Z:)0W'<P:;I;O:W4#+C
MS"*FDXG:*QRI4]&+P;X(W]:[#(VK.9V+E*X/JYM&Z.99>5;'Z--,@E#)!MG<
M'#74FS<-*@ES?4<4@U52<.R?T &%1 C9$1HN\E]08FN8PEY\%.2$'(:'5EW&
M>_QJ\&VJ\'T&'IV_3:8!.@S2>F*C8)H.F<Z@X[>![(#U%"1%&=AVOHZ6^+-+
M2_S2$O\B6^+-!BPC%"HQ=)[;(>"?A.N!*X<(A(X:RC]4BQ,RW<[14^"4T/21
MKVR[0QK[UE&]&RAO/@LX?=F4G#Z1/CEFMX>#4:;LFM-43=6YQ?%9J5-/7NV>
M-EW& <N'QH05F(=Z7=HB:ZRDMOQKE59XF!)&CC!&4_$)F9""ZJA_/$BX^"U,
M9U*TT(C;& *L.8RC/+T#C@8X/>0(XZ7,<.A[1/#O>F>W+6A2/(6J5.'MC^O9
MMR%#;OUA-Q<8XP3L (G8]BZQL[3;#3P5\K_XL1,JNN<3K>:;\FU8: 8;W_8I
MUE;UK")@;VVK9^4AQRA.0:Y0&T[2 +P$.<Y!(47QEC 9Q>2V,*G?#O'WA1Z'
M?$/EK2&6(C_!'JK3M1:?N;>=W.,,6^/IM$8:3WZ(P+( ?:+1\O>8 LO>R9>0
M'GZRK*MF2;&X[%>\+_4(S5%YU>^$C#:FF.G-*G?6AYF>"27H)!D)E[$\",48
MYOUE0IA'#E#9F&T9A9]H[NGU72W^Z&8_LWJ#R13G3\I%3%:RY#Q*73B;SO4Q
M\OTE+P9FP7EZL(I"]AD=KUO #%<0T02) V)>IE.>1U2XG>PVH5:D2L2#>.&=
M'#5HEH?5@@*S>!QBBER)#\*\"CWX$ZN<5P^EVKY"8L8F'03M!>G(C2, *>\A
M%"GL>FEY@HL>Y=MF G1-W<B.:ADU8):-ZWIL"45"CZ8OV-<5)<>1L:R'RRJF
M<:L)89.63_FDCCO#UR/F.C0\L1G>/C,A4 ]ZSTPB\"!Z.*(T9C\[&F(N/3[&
M1(:W76<J":>VA,T.<@_97CVF<"0!2DQ ^^92M,<=R=UJ.1_VR!8.[T%OMCFG
M8DNA5#LT$7E]W7 <Q$@G',<3CU"LC$Q*+-E^4AEP"A"T. D3T/$6];Q1]!'
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MLINK\XT[]AMN&=-<O^6D?.@I[#=NWSNS'%%9C?[93%4M ML/8V^/27$PL>
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M?B?4S]PN-/*F<IL0G,G=.!T&6U]U!MH2P(04QW=,^7%LAMP0-/&X9UQC6/F
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M(I%X,XM:JY;I"O^"@A,53?#KKR]#!L$292^SWI2< VDN>W@[)(I8!.#<5 =
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M=ANCT*C$OOO,F2REI^_J*IP6#8^A2@[$HM]#<6ENV.'B6P[I1J39,>CFA1_
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MR]"OV*=2-,Z::A++J)"2RZEI#*=GGE"-%:/TR?7B/*8YQ>;Y2L>K70&_*"2
M(=C6N0P7H8/71'-:?!P$%%W%R>4OU=Z<IUF/[:T%-POL?:MR"WO%DZ+DYZ<Z
MI8=!EXW3^_2,NR]-&-QAJCW?232 =>N%4Y4$=YX1$_C5[YAQE;8,F1*M2UVI
M9+[#%:YO88TY23R=5Q:LE<3<!1;GNE;*@+$PM R+7N8P5]EZ+<_CX433Y,^"
M>?G2N6B_1I>&D2HC%\SKR-S6,0K"Q2)L)?(CP53FZ25?]=SD$=L4U&'H2$J1
M\VQ@4WP9ZXEDOO(\7\T88XE.LY8I\P)'PFN#\^;-;%2$Z#Q8NT)+CB,KO9W2
M(1OOED937+(8[O&-EQP&=2:8,4HJH>S"I?^DM&:]@*68)G<.P7O@1%=66R'P
M$^8D&3^4%DW8120G-.&$5GA"BNXAQ5,K3-\G!.THBIFNDE<O%V[9=QV^(3<O
M1WR'AJ:O#A)/LVCEH$KQ^ACEK2[L(-"MBP!$),&?Y>[GP4B9TPUUP VVOXIH
MD?^LBZ2,6:"SF;10,5U%?I"6[*\2EOO^)10\6"KL)\"=K_.T+E%IP?>DVDU;
MW=5F+=IQ;I4< 4<HY&NQ\J6.4O #K2OJEU&ZOK;E6#3URIJ$@0!>XN)T+;$N
M+;2./OT&:TF8T[I7,7DMQX@"9MH987"I="R6I V6L'-M$IV5R6600<%60<:6
M!AT:<\%+.GTL!%MBIJ38[!3%H&Z9!=N_YMO5N]DMU@QV/=\],RTFUS(?'CP\
M'P$3J0YSKDTXRW@&)54:>F9J&:6+D/4Y?QXQ7@3X!.L\DA6N!HL5YTNVR!=)
M7(,0P^W6:)=?,N.*TO>X+C0L1XV#JW6:;Y0J=;FP4_F^S?97+DGS?(T]V@FE
MH-QVNZ8)?"NUJY?E,N7CJ&8][JM9^VK6!UG-NJ44? =U7YG1M-L-Q%&T6$1)
M01A1((DS YG2%+>-RE!;Z-& #6H6;,X*=T5DHOZSCMDFY"=S;K-NUH@L$L0K
M-0U/"W>(M3;815ZU2-_0$[]N&X=C4## ==.JJ,MM8\)],"DC_>1!<&8U++;8
M8NND*+E+C+)QQR>'->;+7*I]MVA*F/P:#J,I@[=X@$NZP >PK?_4,:@R>/"<
MVRP%)4ITL42D!&?8#M'3<-)E/D^,2<G%81?DAS@1!UP9F?RNFF^8:QI: P,2
M-C0A\!I>VZ('Q6OBEDAX V8MLX?$@]G)D1(*H19J( C!!_"1:MV/> ),&DJ.
M5Z2 +>(5!A8J>S=^_BHA%,(S,9XHFV)4+V)6XE+"! !<"QL1U34\$2TN#)8Z
MVDB87+A0O@(+H%JI37JWFTZ>BZQPGE-X2&4(X:R==/SC;N(0QB2)AI(O87D%
M> N<2;F241"^,S^V41\/$8=IQW/EI;S;(PK22U.$VO]=MX=:'#'RO_NXLLWU
M!]8$Z>&]78%(3 %PHL(+$^42_+=F9.=:DFTG+0@EE))N8)RJ%6<MR#Z^C&A$
MEK8$&[C.ADY.9RKU2>E(^5X[8J<Z"I+X#S]]CDZ.AC.P;CY/)HO%Y\/9;/3Y
MY'1\]/GP))[/3^+IY&1Q]!,K3/[&FTJM1G_Z>\820,5@(RX6+VG\:U5^/CH\
M'HX.Y0O=:HW$A0LPS)\&@=U 0#L(]!:ZW03YUUSWG<KY+2;SD\-H./ZLHN'D
M\^%A''^.9J?'GX]/572\F!R=J/AXZ_S&[PN4H<@_GX^FA\/#KI_8>!#8)7?[
MA-!G9U. L;)T) ;$\)] E:(.>PO2%ES'NE15I>'ELQ(<77(F,5CWE68N@Z(:
MC4+P,H+R7S7A;BG".D&XGY2'/?"; LH.&[BTE"&G45@1A!*/2?NE3FT&;4R]
MZ3.5$C2SP;547P7??Q'-49 FLHFRQO<D*+MUGSVB')=7P3<$[^"=4;8#9<H#
M;8O,CFP$W:*FZ3^=V3^10/PSXOV YL\+> ;XK;^^][X#= 5'+=X!.D,RV+[5
M)_IQ.)H<-8GND?JZ4^6A#+#%E=&*6]O07?PH=]#H8SV=HK)D-#P"*X2OFPS=
MVTA(.=*4M"D4AC*8JV1MTB^:!&:FBHX*Z3S=]I*0&9WTA@UDNU%KA[H8(Z9!
M+G#J:=H(PX#+A-BXCN5#7; E1SMJ K M&;JA6IH(9\MQF\$:E-5S67G"E#C$
M(!3^A:Q1<.& KPM>N80HZ2C0P"WS',O.YSIKQ#=DSZ4\(S0%E[:$3\#(XTP)
MFI>C"2VVVN&45QM'&S=%H+Z"&G<-PU96%U0:.M]$C!_<#>--[?H:&O<$[.,;
M$/A%=Z=D%229IU)F1_'X\&AT\GF\.(X_'QZ=SC]'IX>GGX_5R?$\6@R/3H>C
M+94R^15'2+RWX=S/HY/I^/BXXXIE,@AHX8&S\F[KE]?4!"%3=^A_Q7.;J3G.
MY? G:-#D%)[NX8;:2>>PW2H#6K%J0MB>T* PEHDV>&EZ3PV4K)W\0;[MDJ&F
M&4F%)\$NW)E4SKOF.$Z;S%X0!&C_:W?2S+[0A2E^!@U\.V_VPO;H!;HG K6B
MM9HD)!'L9:,CH!*]+;RI5;3INB+RP?M(T)&?'BN^:,I-HY/H"L6EA#-#W*2:
M_%G*1W/(X_P<IP)4BJ<R1"6XTC/X!,^(<>S]*Z$F?2R9#S1F()7DH+/FT*4V
M-AIH9#;]1,&U(YP4VR>,VUO@L"$!7:LJP?PFCS_<-:#+#BYPQMK(X#9/C,R/
M)[&:QC/X809BY'0<?9X='Y]^GL2+:+8XFLVCT71+C!R^A=U^C!:JVKPR(TO*
MS^/AR70ZZK@L.1P$N/J EQ\XZ^^V1/FKA$4X3G1/J#;-#*K%ZWF^3&)8-E4S
MGHR'DQ=N9N[!YQE.^CQ#GV>X<9Y!1.I)/(OCT\GIY^'QXN3SX5@=?SX]G9Q\
M/IHL9D?ST^'I;++P1.K[LP^?WKSY/#T>3D^_LX^_\Q;<5*#BFEF@OGEC!*?5
M$%,>+ ?FZP=!X05ZOR1<C)__58/\^*#2CBN*Z4!/QT/WV6[#^&F\G8#W$S*<
MEZY D[Z#M\XXL#=8/5<@DCKA,I-]P-]U8I'?6P?=DBI"B#<8S5V1"=-M9?DN
M YJN*P=F^I0\T%'HS%2E^ C.#M&5EGEPAF4,$0'\16L:&EZ&PN79?!"VP,(\
M&0Z&PQ&:KSC8I58N/+8.&E@<1QM^+C<KH*WN-3G[]#\?=9.)1!C\.8T?J1Y$
M&!+#; G&4/*=N]S&6(P$"7$ND/#<X;K])CGJ72M]>?;I3V:F;X)>ZR]U)L5U
MXRF^?C1UUL>C&!(T?[E:'=>1Y8VQ#VVHD%W$[?L+IP:ZS?L,'>^ KQ_Z_0*4
MSO1#:>,CMW2]4!B1: <SH@R>+<W=_I8I)-*3[9S:06Z-:D>C7>86V9RJWA2#
MJI<\^93NZ6R#J:4O6J"R4T--X,H,;[QJ;006M;5 /^GCKD.JW/12JH*:=#=Z
M""SVLB3?>2+C+1GUE88)[C:KWA++V>-(#\K9#F^Y/9BS(#;3J# 'S'D+P=FB
MQMJWKJ,MH.\D,VG(-L;?"?G=1;;ZH-!HM/,(,#UG9C7<GQ'SS4RGQS43AKV>
MQT*1)\4&F9.YE=XH@7W:9[A,7!<:K4UJT DX5^>YKP^3=?'H?ZS9>F<G;J:B
M.$6?SIEN'_\='::XAL-)?#@93L>?9_/1_/-A=!1_/CF-9Y^/AO/%XF2H9A.U
MG0<^^@"BH;A0\>>CZ>GTZ.2^_*;]7:6C 3) <(WLX$W<GX=SR^!55]?UX(-J
MIWU0K0^JW3:H-HNBPY/9R>3S8C(\^GP8'\>?3^>SR>?#T^/Q(IZ>'B_F\9;D
M/'YK$B(E!OIK2G.#97=&P/9)F2]>=SP*=8Q1*+T)$WJRFR$[56^'FL5-/>9+
M78])G_E@TW[O]+B2CNOM_TIV=V[]],?_S6MPU&0L8Q2+&:V#.[%/H<BAD#\5
M=>Y1R4F.FJ$N6#=PSDUR9L@\E@[D/,<W;AVQ:HO])"R8$4:"DXPS7TIL5$T[
MI6")I*6ZY!F[V15V1D F1O!1DJ)<$FX?YY4CTU-VTJ5PZ@UN\G(7?-U]=;,
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M4B5SS RJV*LU+4"(84"<#?Z_#SX.@C^?G;WO]MT6.198UQ8;I1O8CVRYZ#9
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MR 5VMI2-\#(M1X7\"UYHTQDG"/S% K0?RJO0S-[4=. @!6?;*-$A0YP7V$8
M(AD-7 35?\HV3HO K6BP@/VH@,^B^54%AX/3T]_B"9S2#ZS-,TINQRB=;*^"
MT)F$BZ VS%1UB?FJ0_/=$3WFF>:L*J^P6LE@/.PBH34J7=<[<:(MS+WG$O!@
M,#\J@O$H/0@^7G^8Z(=81O49.&+K6=>SN!QJ+XFH;?;Z]5;UZ=Z"J<D\:#^[
MZ6%X-![OPZ)D#S?NWVDX&D["HZ/#781'BF_-(MWY"K:6_/C((/AY/T&1&!<Z
M88/N.OF@,X@%U].2P]?"2)0D3LDXW>(ILGNXZ'=+O+=,]KQJ[=-P?#@&WQYE
M;.M,T-T2LE WYZ/!XT@]COK48Y]Z[$KJ\;:-JQ\4 [[R=?ZX!C_U!W1GW0Q-
M[:P^1_"C0Q=?[$]Z[OPK.ZM/F\!HO? N67J6N$L=OVP?@KP5W@W(/:0OP79
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M4FI-%[A:@E-WOMQ61'# 8']%"7(8J);H_+Q0YW J)%L.QT>NDI-G@%UZ@9\
MDP4>ANX&?AB$R$(5R& LY6<*&%3ATV=J'@$'1,&ZGL%-94[,F+)L73>>U_8X
MD=BOU:RHHV+#//TZR4".@GX(09R=@_!6^ 60H4#E[)R6A2] >99G\B#]UJ@Z
M@ <> !6_J,I:7<$9?:V=3LLH!JTWGGHZ,IA'Y3*D_P8*N.8B2HDF^*)R"6KD
M ):U<JX$O.0?K#?F%6PJ$A/]*ZP?5=V-'Q>@1BEK5$<)4J]A^V\WN)J3A(U-
M8,?Q!5.1*-PP<*UQ:ZUN(%9<P]KG\*LDQBL,KA9X9(4BG!8XZ1(XEPP ],U6
M><W/FO,U&@3OFONEAV]MF1Z:Y: .F_M;U*ALLXT^X985Z3T"8]2@Z7+@F6@-
MG[O !;RN"]S)"C@T;! )N# +5A%X@C1))$#!AZ8ZN#7XMA6^%2P">& 9S&O@
MT*P"C5MG7[+\D@S!NF3['_@%'Y,IL7V4 N:+8W*N098L-.^:_> Z0,&>\P';
M-I2@S$'MHK"'E>'R,A5_5YGY;=('>)L/3C:>SZH(;DE9S\H*^"%!>\LA ^Q<
MB(!R(54@")IL2,S19I-8Y@1=2 =35S4Z?%OL$'I7 MQ4..L:WVO)'.IO&U\/
MU%V4\LV#JQ-EI;R6."Y9*R3<  P.LY_P1BM*%L*1*@Z957*,9"P3V+JS7UCY
M'"&/^-HXOR_@<UFMGY1M0J;[#(D'(A6H3TX&6&U*)'3+)0'I XP:Y_1R+9-R
M?(A]$T8@+J(D)<6O/1MY;86Q&) A\WE>X$&F&Y*4'@<(N<D *- ^S;.=-T'O
M'VD\JTN@< F+G_U3H>6*'OY9#"("U47K$S098?UVR70IZ:5SU(?\.[ACL 4\
M)=D".E'T6Z05'9WWU"B^4$6)JX] OY#D!H4 U@)K&G;=* QI] XI'/P(?'$0
MO&5-<Y%C6 T3%D# ;)&*&^291,$BA8.JY?HS^X,J+S+/;,<7OGSW_]Z\.AB=
M@@L!EW,%VA77NHPNFE(X 9T+B\Y9C0IM:!GDXL@M%/.&7EE9>F1B!3)#\T?Q
M/2Z5X2(L\.07\&\Z:+0IM,@'*2I"<:FRD!@#F5Y$)#RFSO1)&69QQ#)1H=*R
M+TA1-O B9\20<R;(*H]!5OFL0PX=V :R*; /:G#:\+A@:W# 5?-%P&$IVMB@
M.C0?N_R[KHNR)A%5DL6"<@-5"=C )7 >AA_%"=5W2U]*N<:+.B5WD*0BT=QJ
M-DU;/"6BO,NPQ,1:5[1*,**N$-?A[!]D7N^(8XN[UF)S:]N./1#?P+N'7-XW
M^G!9\$N4L6EZXIB,E) AZ#JYL>_AABW19SH#2UL9_58"#;8,\,DTG!Y/P.P#
M"X^DRD?8"OST/\%[8QY_)*LV;YC'QNM+\Q*9)":I CQQ7F"C*Z'HJ9A%'>J@
MK\D*/I%BXLZ-6O.ES=A -M]X,AH>V@#P@^$O.1_#7L,.LY?/49.A\<8;' 4D
M '&@BLN"XV2182I*?KQ;@\4/JP!%'OPN6JU?!"]SM%CF U8D6NDZ3ZE A(BC
MIAVI4*LWP^$>\4+DB9.347AT=.3PJN]U5>C_%1@PDWM@WA$\F0#'#0,08_QM
M5(;SM"9)^#B2KD=]TK5/NC[(I.MH- V!$_6U3L"Z =%3KT7?J*_H(7  $ R;
M%(.45\@<(%:"YO$%!M#3G .$.46HT/Y.2G&T2;JUJ*HGXR,;>MFAF\:'-J/Y
M8%33&0>CQ$5XIP-8G5-++;X^^1J>3KJ(BB0'6Y4=3Z.12E9)+_-+T# 4594X
MX*^_OB0-0W\)V<*..,XCP6=T1FNPCXC]V%Q2P&SMNB9D7=8(\&E=YD3Z0,&^
MC5"9.>::\0HX'-/8@K,#^OHO=::T<FXQ]X )WL%=T)[?1WB8M?K^JZS](Z5#
M.AY,FZ>$\@'%)E*\48\(OX9#^/@6^*1>_Y%7]XNBG<*R-5W-;W;1%E.*^U$6
M?@&KQFSG>.I$AO<B>/ 4E%O*?CQ%"7"UY,,R1USY;7*R@K-/;\'RY<<]HRCJ
M&@X0_Z(/"@\)EYQ0KHQV,/FM3M0W! I%1Y !/4N%#'$=/&R^]+KP,%P%C#Z(
M,;_990VYQT!VE3FSR',*?"HWGU*H%;B092,V@Y20 ]GQZ ['#E_5A8Y#7YT%
M!VJW>TRGXW!\<K(/X?%^NV<;DI$*ST/M=*Y<%D2SE?,A@^,CUU!M]ZBP..?$
MJBG6:?BD)&OQI8Z<6AJRYX(8@Q3T!69KEZ$I"J]7YM6]8+(EXA@$9WDWS.%-
M'@[BO8@\NF\VN=-0@@12/G!&8N699UUE_G><"UNAAU67PKTZ?E8HG9HWM1,2
MT&J69\'*:TQ0\"ES,1-^U:UBHI"B_@=Z_A3I1B&;%#&5(VR\S^\LT-*E"&&0
MPAU,G221DW?Q2B1,^01<LZ6*XD'@M%UV\ERNRPA&%%BN5S6?1*PPG%>QP)A.
MK20@A44Z8J;0R3;E?4EVD:<7NF!Q)ZW=(D?X$ST)/.6:PD V@84]C/*1#.4B
M5K-0:FV1YI=;&&=!B4EB/UO<805Q[5D877CS-"I)8S>YJUFS2]G:[AX-)77A
M6RM*SE"H>IE?4D:3+&.F(*7?;DPSSDCI.+C)ECIL#+[CC,ID4"Z",;M:\^_I
MQ##)0(DV>=!ED6/82K*T[%O4)=\"EX-8]A:ZZL-+Q.(73?J7-S<(_J3F4<V%
M>:A>LQJ<8'2%BJ3\PANL,8^#H?_68F5]]\/]\I^S)*_4?)GE:7Z^T?F]DBX#
M<IE-JIAS8:<=,T$V+>^SG=VU59TF81YR5IP^EQ0@\S"E2^*_Q"(?4P0H69V9
MVN1R5)BP*/(T%&HSF3BA047#*TMO)VV58JX=RSI::(ZYY'FRAEWMEV\'IFE/
MI5->5?*T.@/C[IXS.+&"ZTCLY98 .+'*YW0U.5FC WO<"89^3[0NU7/]PXOO
M$8G0,="AN:4'VFVD11VDT2:OJ^>+Y*N*V^ZZ$X_2T4,VO_P^?O[8A$?S-!OF
MOFEC3>\6EX@N[N[&PI.M%KK?_>;TZ/CT17-=C3Z[+8/RMDO>,U9( 6^TOU6)
M5E:RHK YVV9LQ:&+P!9?H_H@7X3Z(TZU^(Z*='#V0'Z2O1<V2G>N*T8P(?=U
MCM',A*Y,6SV$[:O;ZO[KF;]G_FWF)ZTJM0:HBS!$I@-D;ID!_8NNAJ[ <,0W
M<0^<C*[5 <</K"/Z;"$>1U046+$E%H-DWU$E@/8#'DC*9<^Z/>O>6&Z#$8>N
M!AEARZ@ O0]/!,K/2ZZ<V2%2#0=*Q8CP>E)X MNU,WKN[+GSQMP)M&=\39&<
M["N4;$N@#<S6[%8-;,]M/;?=G-L,9VV[HTYT:B&UKU<59T<H^^8*@U.<\B'F
M%>;4>1$@'@49:S![Q5@N.,,B7:-KL 426\;HV+C67O"]M,!NP[<WC)$@62=:
M,L7?0[M"_2,5YJ$I'V/'&#;%4*0? SDI58XG')UMQ&*C-=M!E(NC< =P"OX%
MDVI+U?@X+"HNZG-=.3UG'4*_TNM#[]F+Z3I5P_ [$ NEFO/3L&6ZB"YMM!<\
M9=P#1IO9"><=(ZWINP>P*%JCJ5M,-[I&6S]0#*^6KC+,1U1Y+V1Z(7,C(9-0
M#;&T#+0(!KGD.R5+J*OB;5&\B!FIAG=OB"Z,;W]4S[L][]XS[S8\Y2W)B\TQ
MT3DF_2LM>J6!Q 1_6;6BFC1_ FU<4WL?_+%0D834=;=Y J^?2Q =?\<!7&>%
MI?<T5Y7JD+5N&K$!)R# 7\Y^[F]0?X-N'"G"G/"<4A/G17Y9<;S3R9.0[78%
M9SWX8N'COEBX+Q:^<;%P+U![@7J-S\XP'^3%+I)4!XM K:./R+W/$?G;H.M3
M;1.@QYMDNE=-OE I+D_CJI%*45EG#28._&VML'A(&B&YA&6A.*FJ39<=7Q'7
M<9Y&R:JWOGM6[U.L/?/WS+\W\^L.[\6.QO \:]1,A;9+6BL"].3*%_3/G@5[
M%KRUJ6'+R0@^Q0?^&>QFK78? (L,K??1R>+'-_@A^(XOW5LR'P+FH O\72U3
M*2XI]8JS144E2$90:NJ J^5(N7&%**90O,I"[B\H)11415]4:=&^2A=II5$X
M!\PIY=E2*6@S!+#X" -)6HM*WMH%>&F)>)%2%$ /+Z7R@%!35BI.YB@E;PF6
MXI#^D2&F=+<4^>] O91367AGB.[(W2&*(^EX,XSN A-IAK-,8BN7L?"8J*9,
M$3.=ERW0CI -9M@^J#$3X9)09E+Z.;&L=U99XI?A5EV3QBN9(XD3*JZE:V3K
MG=PR)VHI$'YDT!=I9\,^_ICRIP4A1E(!LT9ZP7XA+\&J.9LQ6]RJ*RG)=?OA
MJ,',V1S5]I)>0RZA#7+2D=.<32 <!.<?';\(\DN@?[E,U@;ZIK0W,4GK"N]W
M X=F(;@K]OG$OFQ8*Z 1@O8)]0L#5H9(&8H(R;'Q)I#/KA6R#SL(7GEGQI=8
MWQ1@$*IG%H P%+YPU#F(#&Q-Y/YFT'WG#I0/KY@Z/MSF6%J;W@F2HTCFW+L!
MH@[>K3^2@F=3-3,%*.0-ZBKE8YF9\ 9$I72)$ X([ 7%YA>WU)OT")QY32US
M6* $/CA_/+E(X,+%U!H455*\;2FH;4Y_-3J7[$JD#DL+QBUBWN<J<<WN^UQ.
MH%?[W=0-KKJC*A%Q8@":6+8G&3 MB!+0ES7)60F=2(>BJ>^GKXM>%/&$ZU'4
MN6@\5]-LF[?676#.)P_@$UDEJU:E11LRO1*B#Q;1!>S=Z .-\.2W%FS)#)^$
M5DHT1)\+5N0B0;F61:S H ^9Y<.=V$UZGQYR86$+09J5*MJ#I]Y-I(2EN#Q"
M[JE&AMQ5V<=7G\3,)1*!1<V.Y\!*X<I<_#BXTQLW4;Y$#?<:F\9^["25FR^<
MH&Z3DI6P ;O]7S)_?[X*)!?/"QN,.]<KBBF$)=J3*9P'&7YT_] .!@&-$A[!
MXYF_L1NZB'5\UFW]:R(&EU=#!FMJ!$\)?95QA\MGS^^'#VXYZ><&T0E>!GKY
ML@),M,PY0>.GLH;6"9=$UG9:JBKT6_5^)+2PUP3,X]'@\/"JT6".:^P\'[MH
M\7 U2?2_:6[3<\[[70(1KDVY.9$5\]%H5N9HB-UW_JW]TM,W,82RY\@RFT#]
MQJE>8QI?UI],]TX&[LRH/YE.GLQP<-2?3!=/II=F73V97IIU]F1Z:?9]3^:&
MX^*O-99_(!E.;D"&[RK(OYD&)S<J992W7C54A=W+[?^::2J:(."F(97^\-/T
MI]L2YV@P/FV.XAVMOR)J6!+?QR3>.Z<>AB^87A3"X!^W/'>?EH_L7FU1Y7%<
MM!L6#7]W,IGK-[[M]1N-!\/1X[I^&!';$E0=9:@.2.Z>=3S6&=Z%7+:E_\]_
M,Y\KM5C\8%']5U5Q?)GZBW"JA:W[,3VA=W9A.K?]VX2G[\)%[!PAGMS%ULC'
MZL+6G*M.L?XK#MW=S;I0Y-G!9X*GDV$XFHZ>W;41T@7R]%>@OP)[78%Q>'@R
MW;X"#]$G,8KNJ6BZ9SKU2G-9&:KR.ZF]_\P+_F-W[4 2?]_(88?O[V@<3J<M
M][=GYYZ=N\/.P<3KGMZ+M8_"R7!X1WJI"]JZ756Y"LJ6>_=^V;T:I3\PC''_
M<N$A[/^.1<EH>!B.3PY[/Z^_4OV5NILK=3@,3X[N2CW_>%V<9/-"13PB[XK!
M![KC P$0X.^]N?UM8L.[(Q.X(W%>8UUP-X3$'0:+.K?1N[;51^'T^*1W0OM;
MT=\*Q^P\#(^.I^TZ4O?2=Y63[[^!*/'+)/!GW3W$.IHZG?XN.<QW)H=YYOC*
M28>:@9H;W"L-2\,!<=3VV$P;U!"05TT!U( %95)6!#.IAY8AFB5-,\1Y8SP[
MZ_1P<&I'&<:X$VRGE[=D>7; @8F\T W2T5R:_=Z\_T"S@E_)3$1GB"^V7>;S
M+P<\WLD;@"<CLGB(^.#0GPS,JW/-+_QW5)9*9GU-[.#%4& OS?AANT^>$HH]
ML>8YT9P "DML\=6X;D_&=E*G?G_C.T7MS.GC?=H5=+@_]B;L-;;3T[;;S:[J
M-AO>@-$FQ^[(3)?/#(^!V%QI&K?RA7LV+EJ)PQV'M^,.@EE+8G_J(?>BR_ J
M]S4C=RM;7$,PYWB.-'D7^VSQF_1%]R(3JD&:2JLW?;ML93H&Y&CAWI&]N8,]
M\ @? (SF20^CV<-HW@Q&<P7$,E.W!Y/I/9F^M[-7T"0)KO[HT[_K9/5[)Q?P
MQB2K'ZQ]TY9O9P4T&EO#X3;V#<)DUL5\&8F*OF)4Z/&)J_$)X8'0?_+% F7T
M;-.8-+Z**@U:<O6#IZ?.T&]:'N[=F$JB%OY6@\1/2CA$Q(](M$7UY,CJK4'0
MF@S:33UW%/4>Q&OJ;,(8O=66CTX'HZ:VO<2)UJUDW?. CL;.[-U.NQ[N]7QM
M4G4/[GI>EW&4*SH\=-ALSV'DABD03Z[BD2L:@61[I+KW!C,$_;6:%36"F=&]
M-W3><4MV;^!PZ+@Y^ZU_Z*[?6H_7[F1\Z(HSO9%?HDSO8^CP"T]\OFJ\/,]^
M;LR]'P3=&?1^517U6QE<PU?&G>S.^_KO++_,R## &6T(+?S.05XR]=>=N$(O
MVN$\RGJ%G/%O%&T(2F4'X?+\7-F7ARC%T,Z"-177"J'Z%(E) J)"L+:MV_1=
M$3QN3(G_()2/Z70P[;NON]GC.SCN3Z:C)S,:]R?3Q9/AL$=_,MT[F5Z:=?=D
M>FG6S9/II5E73Z:79MT]F5Z:=?-D>FG6U9/II5EW3Z:79MT\&9!F_<%T!X#M
MVCCF?R10U'6"_?$"18U&MX7[.1P/CDX>%]S/>T[&R-"EN)8*N-F&_Y?S,K?%
M ]I%QQ]U(V_,?/K-+^%+LR*!-_T%QR+@7O&M458>M![1X[C!/PZ9Z_M81#U7
MW8$KUA4B/G;U^9!A\4X'D^^+O'#GQ/E51A!FP5WA)CYB!NFE<R^='S(1'_'5
MO!/9_7VOZ9T3YVU>*);=DV\"+OW^7DGKUO??Z-,W[F2KAZ*GNF;OW95Y\YBB
M )_R*DI[ANH9ZB[Q_WM^ZOGIKOAI%!P$DX"&8O9L]0/9:ORXV*J%H6YG-'8.
M \T"0Z34G^VV83Q%K.\[ND"=V_C=89I1O*(+^[L!0.X]!B$Z3IE;H;E-[A"\
MJ;\?'>""_G[T]Z._'_W]N)_[@90:C>\\4MT%2O5WY-[O2.<)<Y=7I'.Q^CVN
M@:Z="N" 5!%<J"S.BR Z+Y2T^C\=WYVCU:'RQ7M*THU^;+#AP<B)PX=%IMM(
MC>.CHP>4_NWO4W^?^OO4WZ>.,4I_GQZ:X]??J:XSRP_T#1\0E7Z\H]@%3]I'
M5,.*&P\HC4#]G#3=XPT?_3#!<MU\HBX,7_ H=1=3)G9&6[NW][L>/!&.AW<X
M[:R_3?UMZF]3?YOZV]3?IJYZC/U]^D^_3P]DZ_?I+>HA8PY(RFTW<SK 1?%:
M-3GI-\XT#MB>6K7 M/C8*_N,=W'@8;8?AY-2AH,CI3W=\70P-&-=LCQ3AJ1!
M5%=Y, R&^%X73>4."'(58YO@Q-C2S&!7R[]I%_!/%W6[Y=SCI%RGT>9YDM&[
M9FD^_T)$%Z)B97#+K?CICU3K2DSQ00'#E S!7E=UH0+X?K*J5U(AN_:SN8AI
MSA.:LCF0G$:Y^#6U@P!AT7<\))KE%PIN&3R#YGJE=:R"*-L$='X\&VR%(S,*
M%06K*$&$;WQ3,%\"81!3O8"/1FF@R@HQTJOHJRH']WMNPQ]X;..KCBT%H@"#
M-X]L.P&?+((Y2- (Q]G""E"2VJ^7YBS@=N"H EAJEL$_W^/ CF 4V>]4B.5/
MX/7XN8^?SCX<#,>C*4XOP+$$>(K!2E4MY^/0BZZ!N8&= +1OSC0XHSVV#+3
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M*301Z6O;A 61RK%904AZ$D_AG, S)R)33[9T-" .Y]$YKX(,Q-TD+($3X/X
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MY]\6'!%MO_*0RJ(G=N<>RO6GB()DZB]$)DIX IIV@'9;IK.#4=T,M0]1#,-
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MQB^!LKDAQP351IH3T@#5&*KH^-LO,$3. TW^_?_]S__\S_^/?Z;^_G5 M<A
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M'QW&>5+[02Q0/061?[OACY$.Y6NK<,<V*_>7@_IO.]&_!AOF1\Z7(#@+@B2
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MATMVQI(-_%Q* FFJV39Q"!V6[24'RF%FK[K)[,5GUL#4(-9O5[\]@IS*N'U
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M+-$M6:=Y<\Y5X;^5%<K[9]!5B&=9D@\K/D-*I&YQ*O5?QM']6*DGQ;)P?P?
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MG;*>$ZYTK^W9C:Z:XY>M$9[<CW^X=[R$-T6 1 C%NUH_25ML<A#@G:V>ER#
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M[>,_ #4CP=E+([ 3/'0(RW,=Y+>@!M">@^^80)GO)VGJ)H[V:: AJ76,22#
MVZ?G!M M#<AL^ZY>),F,EA/7]:'8'PW>W.PD7P#=(0CE?0QJ>%,9V,TAAG&G
MN86@$-+WD7S!5LH9T.)9$E!-9FU+PV6ULA0IW)":/Q/H[!F58]*6U"FR?'J)
M8Q((D"AD>;E1^)'(8GJ=:Z&\GEWU,N6)85>J]'ARU4;(@B*99V26/\OFXC[N
MGIGX%SZ:3:[HOS^?*0#U\=B;J;;S6M];TUSX!0757(X!(2G0&H6S7"/ST[1<
M.!T)Y]1!,]0%(W3!ZTRR7<(:$NX8.,AX-7%> L[-&VJF9.*\/+C++D ]11RX
M4Y^ZY(1L#LWO5[OR&YG?F>,CO!:B&?K&L>I%U1;__ O^$SY:,8!D(U@=[SV4
M04\-M I)_M?' .'N;M%LI C8)TLEPT;6@?_]W_\KNIXM]&<4R[#LWR&^1Q8:
MO)S&4#\"&=D&DIZ1AO#5OR5C*:V=8.$\'XF!_M[H"$0:(HL\26+[(R)0C+I3
M:96)T#!0+!D##-W?_K?"C[ *"#^S' T!V&^<WZHM 'KVSE/Q1KG6[ -W:8]3
MF>V>_$LBQC92*O]QTRP>"A\]'P&ZP4DS$$"*2$=AA AX5CJ&;W>)?(AZ$E8E
M(D4!GE=RO$C*PYS(RNI0%!12$!DIIZH*SRA4EOSAO_43H,DO=H\05MZ90T T
MV3)4^,>\X]J:1$" AM8/\*"1Y)P1-5/YUU_R/^>89OZ:BQ$P[FX0N @1W09C
M8#J00.BH43R194>70VS70^PLB+C&E7/R9RJ9GYH)U:'E.="T<7Z=F+8+Q$48
MTCF&%VB1%R199%F2$65!8466EG,L->2R68H-^$8*;;5;:2;K5$>ODO/;J[MK
MB>JJ%6.$K,S82,;P3*JQNBE?&:6Q<W&='5Y3(Y&.C^0FY6)O6KK6>QGIHND6
MLK=F;X!&9O=':ADZM]+YJE)N@HRE/.1R<B_3%AF1W!]9TXMR:U:Y<$G@C<TI
M+4W+ZVLT,O;VR=VZ7K$$RM#IFGQSD9U-%JO^"(Z,O?VANFP,QHN"KD]'I7N'
M,E>9YD5>9.-OY]GR0VXU*5)Z<UQJ7\S:7*9>0E?EQD96&YQ2Y!B'T9N6V,NU
MY@VET4171<9&CJ>-7JEZ9>5[F;',:-5K9U*NM\5<?.2D67= ^4:$M+F?DW:=
M)ZGK&;H")K;V0K,PO##ZRRS9OVC>66M;O2"S2S@R7+N?[A@J7]_)@HK7D&8.
M^!W^$&5AU"<MX%X$W(H/^*'Q@36CY+E6^(&O%_$G.]HSXJ<%8^*:T+7#B87B
MX@O$H]XEU*C'9C-$5%'DX19\X-"PEJ%PA;]GD(OZV[<SEI!(SZKXS=\E&<*=
MYX*_D;;_!&5_\#S(_^9+K<[@WW<]<GSG;8D8W/$=^MX[\UPCTG1G/FMGGNN+
MG.Y,BF;ISJ1H=AH[\USKYW1G_G!GCD^I>&R+$I$*_ AE^!=0YFLEQ_T1#: G
MAS[\]X_LC]?2@SG/<9]:PLB_)GCR5"QJ "2;*)LJ4(D24  ZU/(/,AGJ+#S1
ME%_5FBJ5K,^4K(.,<N"\.O[O89FA7RLS%'F>^]RRWS>7&92WLBL5*1\<Q0=?
MC@W(EX)C+#J7N(2?M&G?MVG,]:YEW$G*13HB+_VDJK2?;+758N_;4^:AJTO=
MU>V%9JSDU0TZ$TJ[\*7"GO;5.[T"ZJ>$?30O7HUJ$\C!G+=ZD&XFMQ59SXMO
MUE;O!8>)'W='M;*3)N'?HO!V]U1_3[CZ;JM.WCV;GT*&E.6_SZJ3=]_DGY#A
MY%WMO4L7JY)F$KA:TK+=C OL:>0NZ=093V]02U"'_<01*CGWC_QY%. !V)8J
M.>.#%Z[M9 @?Z+%4L>PN=!&Z0/%LS=6 DU<GGH\AT*=H#F^DU0$OHL*/[O3^
M/=4H5TN5E9&_%NN7]E+$7=LV)=5IQ6.*2)]-J"]Q^>/)W8CT"8@T<2>CWD/5
MX?5IG\T.YD[Q7ITA1.*.0:23BVM$;X5,HQO?N]'1I[7Z3P)9D@.;GV/(A9#8
M@DX@G$P^TH[[QFI)-D3-0_9;8=YNKHHSO5R4E^,L(U<HLS42N0^QW[Z;Z*2(
M\E6ZE7T+0^QUB'*3D=5,?S$1RE/>K*AKS_-8 R'*>]E?B?,"=VMQTX28M,?/
MNV?,)&_M7SNEY@!B1ES21\_<5:9!JYV[<;T,+@>R4R[>U:]G>3&7)MBDX)'>
M<9 8\'CG%)U7@L=2N'"GH\%#4]=65S20]#FXO4+@<7S"3MH"+&T!%M^<^*H_
M=[O>CHU4S9D9TAK)!-AY#WKV,P1YQ7(.KN;;=";+?I7.9+&V9"_K2493YR@O
M8PI_#=;#4N>Y[$=MVI=H5,;Q @L89B@J@.%1OR5:E-DA#W^E544:L@+-Y8(.
M/$GOV/58H[+S3?W/4XW*K&'TSJ/RW--.9-F/-2J#O!-=$8X(Y?XFT,K<]2?W
M+'MR03L-S<X(L%( I 3N.4O 54J_/GOR,7&.SO]EC<]DH' @QY%0Z"A.9)5L
M5N09GA=50/,2Q:O<4.#V6V7U9;6A&I?3!KEV;IR!M2K>\=?Y0XW/2*?!5X2E
M7"E[+NUP,N^X11&U2,OMCU3(J^M)'<A,+].]>J Z5,-<7**1E+ _E)-5;\5Q
M-J6#SK*8'5.UXKB)7Q][O^%5F!SW(-DZO:IQG=KU6!@9J)U:[/WD19DS,T+N
MO@<N16EZ<5TI>LX2CJ28V%!Y6LJ,:;I7[C9*CE%\J CY7AL-C5&JMQ@8E<Y=
M3NUE@".08]N<-_VGQE9U(8\O)FV&(<N2*=VI T$I33JX1UQL50,;.%-Y=)4E
MKQR3K<X:[*24&QUJZ-:LEX2^=R?>DU= F]3T\L7D\@&5^<2:V6G.FA6*9H?2
MBYQ7O+SDS8<JA6H$8I3*C8VF5RQI(WTJ=N7[59-E>1:]G8IU7\NL[<5#OM7,
MD<6+8K$+]!QH5M%#XT2=7S4STXIH,+IW=W\AYZUBVP'XJ3&B2J4;Z+!-)6@O
M );IR;4+R&=+-#1&U&HK<YVY7(WG9:]DCX;]_$+D:F@"<:+6V2N&\JARJ0QZ
M9M<J4*LR/5L>ZFC7H&3!=&XJI?*\KCFESO3A>B"AD;%GCK,/HUD^5^N5U_2\
MT2#[,V/4&L&1,?*K<X>_>BC*RS)7J-=$>C@O"$P;CHQUWF,[JK.8ZS<&J36X
M*_:^U<BK2_3,./E7Q4S_TKMP\WJ_>=%?S]854!701./D;S<:=U=FK0/*W?DZ
M7R6]J96=HGY^<?+W&W;MTB[Q%-E5I QO&==*K8RF&B>_-V@#WA7DZ][<Z90U
MR^OFYM>84K&YWI85:WWK%JD>M!TJ#[<W$X]4T++B.T7U,]WJ5&ZX>F:283IE
MH^VU+]J'.@I*K'9WD1G-Z![=[D]Z3*/HE$<C.#+VS M-[-S2LW:S##JW(\Z>
M%KNE*4HEB=&_F3>,3E]>\+VY6YQ>@'RUD1FA?H943%+Z?&>H/ CW+-GMWM]P
M]6K;ONJ@B<:7SS/2%2TL^49O?M_S"JHX<-KVP=Z'&;MR59G-R55/>[B_NR/+
M]7%CC Y=8FNZ[/3*9?;.+NG5?,.87@ZFYOP6/3.VIDD/RER&*4[T;H%VFG8_
M5RE;Z)D4M3_T9@1TAS76+CDGA<;]K3582,,E&AI;/B,:N5+>JKHD+0%*O[H8
M\'D##8TOG[K/+$:-YKC= R6C:9/*8)6[SA]JZ%B\YN4>/V(%DFL/%JN5QU/Y
MB^6AAH[UMGYAJ%=KMMSL9X5L;W156FKM2$/'+?;,Q-+\NEDP=.DZ5ZB.2M>]
M10V-C*])O^IVLP]<M];C%DH7R#<]4"GBU\=F:M[JJI3)Y5VR61VO"AXT:L?F
M4N3C:_*NA?+#4NN3ND=F+6M<+D]=.@]'QM9TDUE=<F)]6"2]ZW%5*G?*(\5&
MSSS0H%/EZYV[!ZG7S[)W5R6&R0T;;3B2WQ]984ES='=Q-2+I 3,#VLKM+-8C
M.#*^^>:*O5K;5WJ!K/:%JI(K]$;3#GIHG% /E_:=,P,CKSR_7X&Y.JJPDP9>
M4VSY N-,ZYK8;)/TQ&BT+;-HLOV1*!Q 7J5FY0O+::LLU<G+RT5&$Z\OVW!D
MG/?SF4FY/IE.2*[?ZCI3K2+=0CP3XH2:76?=WJ _S>N>-F)*Q=SUD!JC9\8(
M51CT5?UVMG+)XL.HV&X(WOVTMH0CXX3JE.YN*GVJRI0S#">8W>Y%?YQ'KX]W
MD<U,=4:^9>]+)/1Y*:G4+UTX&;3Z.*$J%#<SY(S9T)LS@<P('B^,]38$_@,]
M7R7 "+?-"H#(1]_WIGPAM^27:&B,5,LB*8\<6>-ZT[+ .X#-9BD'#XW-U>JL
MO46_.BCT^EKF83IHWI?D^@@-C9&U/^/'.6M=O>W-J\W6XN&.FE0%/->XGIJS
M!7Y9*WG-,E>TP6SAJ;W5)7YL7%&5N^O*;>EJV">K#YTIK]W>-SJV/S:FJ<2A
M/NYD,JL\V87^!\A?&]Z5Y<\AIJJN[VZ$*U;K7I3[=P:G56[6R^H2/S>^#^.,
MP8UF,]O4UV26N<OU%.9^Z(^-41<TFT)?K><R/4\HRG>509_C)#@'ZD#_V\LF
MM<Z8U5Y/NY\/1E:#$TJ3/!H:8\7>N#J_H21 Z_-!3KQ]N.'S8X"'QGF15^SK
MU=B=K\I%IN/VQN V5Z7P#.)2:^MUX\+K7K1TS\U1Y>JEF5F:>&R<"O=9=34>
MT[I-5J5A\4X?M2PFVT;!]-A05;T>7-\ZRK GC8O6J')Y1U[+>30T/MU9%:I8
MCG%KO7Y7T=>YVS;?H)=X;&RZM\Q@-IU-%:%W)=R5%ZQ1A'H$3R$^W99765H7
M_X^][VQ.7<D6_?ZJWG]0[9E[WYDJ\)4$"-@S]U011#8YF2\J(34@E$"!].M?
M=TLD@^/&1N">JMG'AK;4O7KEV%XQG7*=D^-T7 ^GT-3Q,PV3U:K5+<5*<Z!F
MLO6FHZWH1*S70$M/MQ#NC]<E:1ZI=5KQA=CE5<9<0'$,UYYN09@Z9K,X;2X[
M;J_<M[-/D3!K>VM/\%R@Y[/&PET^=7I)MV$.I]9,F,/MGM%'T\+36K;,&,WK
M7#LZG(S,)CL;HZ4GV+B(+'KI;GWS2 .V$AVDYK+(*'CI"0%#5KFJ2J6LH[:Z
M16/L*H:R $NT] 0;,U!3Z:36YIC7-Z,6WQXK"[J,EYY>;XYE9#YN).L=0-/%
M\'"26#UU\0Y.85N<:>PZ*8@#WG4[(RV<+"5-_V G0.A(V:<V$VTZJBN4R]58
MJJ2XD3$: 7VRE*\\*=-%-L/Q(,D,5$UO5-@4GA9]>@W-^@(26VH-#8BV6139
M37[-;O"\T9/'CO3'2%?DQ23?FZ_U5F2SW!0&2[3T% J1AE,!A3BHTRTF4\JV
M![%*7?/6GD A6AIN\D\&5^HH:9Y-SNETWN+QV,!3*,P:O4&S%1ZW^)K3KZR[
M;<7@9#R8ZA1@W";?'C=$E2_WLI#/B/'.;(0GS9Q@C32>Z%US7)K1KCL>QE(]
M: ,44FCIJ74R:*OCA".L^9X@%3FUE2N&B_BI)UA3**G#8K=7+?'ER*I<7R[-
M3(O'2T_AQ;6L9N=IT>,ZZU&D5>\Y]=&H[:T]@9?@MOFA:](+-5_AZHS86W,B
M@V%P"J\6,V[7=6B?\2ZGM@LM1JD76_!D9Y0TL9FH=#=\(]Z9QW/%3F-:T9*Y
M,5IZ J\$[[A,UZ7C]%Q+RIG-4'<AK:&E)_ 2\UK1:4G=12?/+\/"4RZ:$2W\
MU%,@N&9=*+F515M=Y\?5:,U11D+96WLBJ=NZ539J=5[O9/+&E*D]YI(J5/^8
M<ZI:8S$.U\UT-L.'G]JY0FVLK:HB7GL*,$XLL?W,>--7R]JJ:Z4X8<C$\=%.
M:2?6&>6MC*BS:F]27O./3&T3[<"+.*/8E>!5A/FG3K'#-@MN,I9-YDHV7GJ"
M-IO$R$IEG.RCVDHLDADMUQ%$)$O.J6%)/9[O\--8DL]PZ909%D2#;>+'GD(A
MF75=HVXWA(["K(M+.V-SFQQ^[BD42K/Y;#R=,.N.TA^M3%G3UI'8$BX\8ZZ%
M:P)8MH1BISQNB96H*F[RW09:>H(VIM7O]1)#!ZKL>2!KY1R(=A?XJ2=HT^7F
MB'R4(:VGH:"<=O(]<X27GL!+FG<JRTRL65#UVJ S=62C1WM//867- FK4:&\
M[*F@_R0M-^PPTC6\M:>Z8/4)U U]'N_T(O5Z*6UT\FILC ]V*J%L;C)^RK@C
MOKS)3A@@#A;6%#[WC!(T:C3TQYDJ0LT9ZE?I6$7A (>7GNQ@W;"B8:-3>U+G
M?5V4&WHF7JZET-)3%5/H=DO124FOT;5"=*(72]/:,NJM/<%;93;N)<-EM\)G
M[,X@GS&6JCUMX+4G*J:4B#]J@VG6I'73SBP?RPV]].BM/5$QL^SL:05,Q^ZL
M)^:*ZW%L/@;PVC,J9CTF)MUH7*?=34.J9 H]-IKQUF[QYBOF$83I!SJ:2,08
MFHD\"Y4=I(2<&T/P0"?_=!(!FWR()\DD@I>B]E?L$$W:$ ?R8F(/,8;<3!!O
MAI!,0"^&?HC'R,T$\6:X!Y8C-Q/$FR',+* 70S\PA)D%\F;B#S$R5"60-\,\
M$)()Y,40S2RH-Q-]B)'978&\&<+, GLQQ#$3R(M)/-#D9@)Y,X27!?1BZ(<$
M<<P$\F:(RRRH-T.866 OALQ4#>;-)!Z2A&8">3.$F07T8J!F1APS@;P9HIE]
M\<V\?\#P^U++KCQ-^+-%W%\:V+UQF.R&T48_/8PV<G=#B5OP#?#E?:IN@1&P
M+-RQP934"PTJ_B$8]>G1\(P72[DGC,J8NFX:WC#HRZ+2JUKGO:#2IR=E)Q^8
M*P_J>F>WL6O+N'M&HZ_QZ%X9*-\"@[<T].O/N0L"IMPW]?PY$V;H!^9KY\)<
M7%ZG),G570TUZ_*$-NX+3X3VM^!+_/6\@.!A"YXYY.'),8H0 YR82U\"D[>*
MFGXD4 BB?#QA-' &T#WKM<%&E?LFGTNH)?&OG=%U<;VDZNI#8'F*B3DBVNN]
M<=E@ ^6MC'CB/+A_<KH!#^[E?0=P?RB8+&I4751D*GS.,B3X\G7.@UO#E^>^
M)H(IQ"WY8AAQ/RF)H GQ1I[-7C@=)W&37LG;"Z)>0?"\'RT\V7+Z[X78B.>1
MO*><C18:96+?2,[/=R'')?@I?6>(DM)-UW (HGR)O^V>$.7"'.5K];;;0938
M0^2^\*0N^D[;KJBYMZ+GWPZ^>"ZE>T(8Q: RX@P-*R7(\B7^I'M"EBP8*9)R
M.7WE)C'ER_#%]RK=$\+\53%M^U]47E0,@C1?Q63N"V6>C2]]I]OII,OY?D;R
M[W]($@"CT?>[H8[ZN\<?T"QF#!G%D"%4?H>]C]X/FK2HB88$*-&ALD "^PA]
MA EY/[ TD[RD-1D$*![!9TM'EW(ZG9[OBK3TX:@T%3D:'$YAGRU["? $\_8_
M,\'^$ND9MX F1X#ZY\4RW6[AZ(1"KDHAS"U2R/<#RNM9? N ^@ ]_4=9P5,:
M.4N44.(*Y1J*TP2C__W5@3\(+4<T9-&2!3S;W1;$)SK6Z#]F:#JLQ(7UXTCH
MC9]2OR@\*F?E_6'*%FHC-&(P@N;V,$G!M<-C49RAAWF3[ST-$06T30/^:J=6
MBKU;Y97+XD#F(]:0!*G:&-25SD#H@#)3'VZ<6*9='/^B9" INJC9__NK6,W]
MHD:FI8O.__Y25LYOP]5ET_$7_*(,48<P]M_P^^ -GE>V:-LND*$"#W$!KJ-_
M[08=/=*\/*K,%FH>5!2.=;ER/8HF.2=^_<V&Z#@;8CGN/_]S#,*+&4F!XTTO
M6T5$3/]IKN0M'/WR;*73R@K%!6_S84L?J;5J/?&T3L9FI4KCZCPE'/D 2SG,
MN_!VLN,FD1TW>6JW6''DSJ.\^ZA$'L?-;-9MX;GP#&0GA(U<Y, W8A->G(MX
M?7MOX>@WRT7VR;THM[=H^&$7GZ-$GN1<W!K+&76^R33SN5*57EF-K^4HJTTS
M/$K,LJJJ9 K: )1ZYJ2/.4H4<I18,A1A8H2O7*PAQ"U0%_$BO%#]0?T5+&[2
M!(X(3R#SHF5 V-@^&ZDR<B/&-.M<QW6S;*FKM#9=?7E9-@(A!!]SAI\8FVG9
M[&:J3;56T4:*-F26O?12\$:/LVPD%$O&3_C)OPA#^93SZ;SW*7!4]06:2O)&
M3+TKN25_&"EX35IO 1^(; V"TEXLF@-K41@DZ=9::Y>GJP4S,+Y8T1X(.F]-
MY7F2%[7)A,Y,TVX]@P0C&_GU=R06BK/T*WKV)Z+?MQ#J1FY3',XV1_#&D(<%
M;@T"DU(,:N8.-46"WXS@ZXUQB#* @];]\\+8D74M$3U'8 2$'BPMM,T=LL#?
M=CJ9.[0561&M=0M>;6V$;QWK8Z*SLH4ZWF[-W^V!NRAER#W1LD2HO?D*6BO:
M96.E<*5&KY>LE'7KW::;31VA7^P#Z%<7UTA5M/TM;6&:,6W'WB$BYR%B%>Y$
MB$E%^E$=.T"=]Q;6.%^/91NEU*^_F8?D"0I2$#DT!&5X(\KVMB3TZ!O(5@]D
M#.A*S7>N%R#]:1<<N'8.]]P4AZ#U]P;Y?]JIWYHR?'VTOGSX_=T:T2<C9YL9
MNP(+15CQ>F&YK,_HL1RI-CX?C=^I/4"&6X>74X= -F4O,@\O 7]EGPG.LQ:3
MJ"1XH]D)1Z-/:QHBQJ*0$F(H.)](,"'N"T/S/XV0?J94#%X7HR^VM:_/.SYN
MNI^R#EPY=\HY]M:\/9%[VD+.Z'0^S=7$36^<JM3'D'.@0#Q#F,;%FB($JT_I
MMQSZK?FYA&?\08R=#6?S (3G,1Z,&ZQ*Z_$-'?G#K)U/\(]FLMTRGQ20ZK0&
M@V5XQ4Z,NK-$_ .%W:.A6"Q!F,B]CF(@]OA7!+Q^V@6_-6;U/D_]U@A3@M8W
M?L%O#=R\SU,'GUM_L\[76,4E11ZPJMHJ1*.Q5C[-AA^_W\YKE^C&Y'$\7/*<
MUD^I9B[A+G,-J*>AJ"W6TTY#9C^Q9OG%0"Z\(4ITPLX$A.$?J#B$ZX5([5U$
M]SBN&. 8;\IYQ&?81GE]FR)G#SKL5,I4:'&<C*<+C! KKI;?%\^-L\LAT.:Q
MM3KOF$TW83&EK+7\]3?]<)JZNXWGDNK'"P=T@P (4@1[=0<W <3+*6F$'GX2
M&KQ8%/[3 /%BT7>0Z>'G1I61IO?.D/)S??!<C%D#W;0P7196ZGI5DY=ZCQ;;
MLY3 H1AS),F&V,37>7J#@'-7YT)$*K]>(QYD+G3O-1%7BJ@2.+Q<[!QD<B!Q
MU]>$\[$S[V79O/?N1=)RD3&ZKL2SQHC1A6XSJBZ74#:C*"S#A5B.R.8O#\P2
M0!"+F=##JQ6]/PT0+];W$GKX26CP8EGO3P/$3<J'VPP87U;!M!9,+\YUPYT.
MD,1J,K:)"W(+*9@H?/RF@GFG1;]URX38*]O4R#)U"JR )2DVP'%?<X9 0$I+
M26DIN6!21',[R5$$K4EI*2DMO:,@X+M*2_&7-4]EX7TUYEP/Z$TEWIJYO?R
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M*T?M<GB@9(> UR?-&1!:XB8CIN#*V/.5FW#;[2Q61JLC,G;>*EA<FZ^,A8A
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M(T2Y.SRA+\%<@]=,[;53UV8 M:TRQAZFH-S'!=1(@7U1D@D>3"Z1&G<)\Y!
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MF9*XX.3XAN\7(8?$;7JY4)1[M0J4, K"*'YP']Y+=?X/4#QG9J&46&>-O1\
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M]&X\?.@%6'F'PKY*N&L9B3L?L 9 0( +)J8&_ V@4Z&M'C[;BT*B8( '-?Q
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MB8:*8#W]#9FK>_XWVZ/Z-N6F\]!Z\-AA/I6J[\H>O&I;[WK@X_S6=]Z^#(!
MACCM5N>!%IF%-KDGK!=4QOTYMP4\NV?,<'3#WCX&R ^'O'VG$'UU[^(OBNT]
MW_KME^XQ-*G=([5[EZG=.X 8A'HDMMTU4CP$.CZ,C$!,$H;)2%*(1AE.2$BL
M*$1I,!(!%V=I3OKE;43<]DM/)!/3<&?.QWB.R71+Z\FD-Y>72%=ZOK+-/1:>
M4N-JGV\Y>@-,ZM/(S!T+[.G*G#E45JX=ZZIK)YZQ^6+)Z=8;<&7L^<JGU&+1
M7#-Z1BV'NWPZ B:C56TL1 3Z^4J&R6T*)='4.IRC"HS6%1_KJQ1<>?+VJ1Y=
M5<5RL\*#7F'2EJ-\AA^@9YZ\O5]AU3*3@B=:/S5S]G*\>4K1*2%Z^O9EA6\N
MZ61K\?_9^Z[FQ+5UP?>IFO] ];UG9N\JXZ- ['-G5XEHC,D(#"\J(0DAE$"!
M].MG!4D(A$.[C2V[575.;PQ+2RM\.;+E3:==6.>XAYG.<-GHR-9L="]KU>Z4
MT,TRS>?(ZEVW*(.1D74^&'>LL*Z,.**^J=\K^R&QS ZV8*2_SB>2-)_7/WY!
M6Z%^7%]P9FVI,Z\"U@!MA78@(//%R;;*EVV&[=0:TV5NS&>I(O-%!&361O@=
M[,KGNY\H ;]BW5]02,;"W+-BTFM$9S@(^GV@N1X+@D"22T$ASJ];8J? I@!;
MU;U:/#JO2@ 6O?M%(A[J\;3"TBLNF.%56H42N8X%<EPSZ5A:Z>7%H9G#JH!A
M0J,6T,0=7(0)V\FQU5U4H ,$V^U0\8E@A9]I(:=SYU<7DD/C!$V^GN0Z  L.
M, # J]5SO&A<W@>(3D$,P$FR])/V6$@WH2_/#JDLZ(OCW#=>3#ZL47.T]Z+9
M<5TA"#":9,@ /F%50<G:>$%!J'5#,"'OU7/!,!<>&E0(P47IT6.ZQ-NNA>$:
M@N$->K\HX?R(8WWN<J"QP<I@D-<8*]?!H(94.FAY!R] [H(CKJ (SRW,)> ]
M>_+98JSK@N:[*QO78H<H3*TSGY>P1CQ82)+35VR5,<0R+!0&+Q?1ELZ\#+17
M!?WXO(V)$Q^<3&XQRA+[;'$EE]JS@EO\*C8F<!1I[RQ2Z#!2<,->KE'X/) @
MC4X$CTBX[%6SPPP3>MG3GN$F9:.K@?Y KYT&C[PWX(V :NZ\VD8!\;OQ*U@&
MWX2\X]Y3"TF4D4,/=JF3O7IV?C$)Y*"S >!BYHC8;."C//5?"Q@FX-)"Y!0R
M7,5&5/%RA,K-4^$IV,V'ZRU!-S=X#CN_\.3[E(F6 52PH__J7!8YSI>"<L <
M(*Z)Z*U7_0G2QD"8\=R8 3V'D=M 7?2]B)J?#WGB@KO\*D@??!.4G9+!<Q*$
M#-OWP\,2<J'R9?"(%<<]5K^:7SQ]S./F:"*8.+[E<8GBXYE%0B=FX+T2/"$=
M-EA /!8GK ,]%H8AX%*)1^Q&YW"\R-M4PBO.(I @?S@-0NH'0'KY=\PN BY1
MM"G'DBR^KY8G=794W #>,Y"_")> 6\,\ 7ZHG@6:'4\"_?X5/!!7]W@*@+ZZ
M,*;W)3")RA/EPF@VK.L"I38;1&M:[:N=[MV'0<J;.!>4U0'A@EV< JKZ9%SB
M&74_*FM0)?04-GZU J"("-TI"_18D>X+ZKBCAT=049%-S!ZQ4 YXS-8(2G#Z
MVIZ_/B_\0K$Q-]707W^AT:9K@Z7:?_^,-13CV##?>(U;;:(PMI4M_?0_A)<!
M-41O!=# *6##Z$G8 .PSYW^!C<KHFQ/;<ZA;IS?F:/#/PQ8LR&;L6/[2_$WC
MC;ZNM6N>OBT\VPXU9+<-S0^CFN"U^N?F_YV&O4E_8F,]3/%[T4;NN3+0B_VA
M_,PV-=>1/MHX_BXA+B&OQV\WJJ4SR<W$\6;(VTP^N9DXWDSQEDIP)I8WDU"S
MN-Y,0LWB>C. FE')S5SQ9E#_<_3_]Q&6/_$8"K]P#%<EY%_K#(#Z!K_\?S^R
M/]YZ'O1M/N<'(/FA6>1JET*NT)0?VW3% RO\4LC6*V*H_1Q3[-BDR9NSJ.@$
M=^**.Q=!X8*S.OKO9:R@WHH5)'&;I[X75D"[Y"D*)'#P&CC(%;\='!#O00J/
M8; __TL0)&D^_V3J&+@?SNW)[P;QL=ORF_QB[Z!MQ>X@_OL=MH:-+W'86@B]
MD>$\' %-GT2KO[80U37+--"_6*8AZMUBG#)O63"@[K0F)_W##[[MK BBEFVX
MC.J.N6U'25,Z?;?E:([^\4\A=Y,EHN4P$JQ/L/[51HHX;"TV6$]PU>+T49+6
MQ%QM[A^&S+;:F')IYL.Q?D34^O0L2V?9G-CK#.ZZ=^YT!U,#<K#L^TV1CA9;
M_-H*7O_,Z?T7^?=7$-?C3+,^3W)_Q:E<T%E^2W:)VV9C0]+>79!Y*6#G C5K
M;BN;LJ.ZVVI=ZB^K>EEZS UA^A(-ZTQ%.Y8GF)]@_JOEE[AM-C:8_^["S!LP
M?S6;J<U\B\H09<H<6<8C/;>;/8#YN9<P_YN89H8P_BY1R#Y (3LE!#0@!*+I
MPOB_>)"]J]IIXK?WV%#!JQAR7@IU/_WB>1(Y-[7-PSBSR50'8EIJ-XS96-_"
M[&ILX,E1Q<3 D]"3C[4 Q6_OL:$G5S$1O2<]<>XW78>L+Q^KKD+D[=5L/IZ5
M>X">0--1]H;(OBAU_1O%S9]$%+WU,HNW\%).J]^$OD'1\IG<+4J:"!4, 3<N
MZ1?"G$YCEUY3F2847A6=#C4WN\U)OA )FY@$%6G  4D!E*5@D'^*2!'_">K0
MX']_(<7@G>G A>/TF[6A1:4U?F^ZSL^YLI/$\,GY%7<POIZ*V'B8=R,_(O3E
MM_9QWD(.8C3L(_<T:2Y$R LR"YZNZ8S^/%\D\A>6&TK\>JZ*3@.G,Z)2"J@,
MA!+*R4?5^E%:J8 [[,#J#!+,\W&B]>!#HS73D''JY]/CB=N "48P-U*:ZF.J
M;'V!HJ-?(3GN6++]J93ZK*,V1LI^OF8[Z5%5'Z8%==W_*E5I4&GZ-*Q-GPH5
MIT_RY:^6+R]H@(HH<P7G1P. Q944)50?/E1]'M><X;WN7##Y'4@P\#>4D2U;
M$JRB#C,,80:@)4DI':QZX2<MXL+J@ *ZEK#@P<?S+JVOFA@PW:#\>DKD]RDO
M<]L!YX6*7P>SVT]DR-^F!D]DSEN25S0%EAYQ<(7##73 A9I1N@98#:RZ(J9D
MW*(,;,XK!QVNFN-1=7#"EK0 Q!Z6K(;#<!8\KX.!:!+!Q%G^YT<-DRI1_458
M<,=+T_>>"G)$P=2ZXNI!\1U+\G]!]<E1)1]4 PB?)=BXE]IYG$4)*G**)]4P
M<2W((#4?C#%UZ3;5?VKO-\&C-^#EL& *K,&/,^\%G,,/ID>'F5JZHHPKQ<PD
M?$YI>+7@0G0(=[ VN27]TK)BA5E?O:"K#Y$A8$2-W@"H!$5U4#KP"N@K<\#@
MX&4[J/(R BE=<A8F!EJ C$"HQD5V,69!W'X2@0!NF,>2/K!; T(BWK@,)0J@
M7HJ% $':*3:LB7':J1DWMK>#B10'E09!J(0OQ0,HQZN6M<"=0</%(5*PC*J&
M6D2@$OFXPQG<#"S_CSL]^/-+".YAZ7E#1*?A=5'R1OOO])*M_7,^>Q\0R1%;
ML8_3>:G:N!B)M4^J2YQ(0S4 !"A,HC,/JJ\TCN4_SLI(J)+HEO/YJD@T#P>2
M,Y7)9G7/1*L-7A[WF;71?UF.@@>30B<#P>Q8F29T.(E0]>[D\R@UI!8*0'H@
MCL#608H)::E?2 85)4/,&8[$=!.UZE#6L%F$:V/^Z!4]"\^)VK=CZ6IFF3P@
MG;!Z6[@"P\_4 _PJ1?IO@=QT[9I0DD#4RT[]Y1J^</$WKB^-6FI@$H?+ F&B
M#CN->!JF"?NF8!(&6,)_O)=0X9=X'['H@Z2UT]<&+-TK5.&O$U<AA-U]9JBR
MD-_O%1%J^/;PRP'-E13T!E$!A-714.<B2''Q7_]!)!E/38=7YQJAZ?T+@&^V
MI+EV5I@I*$\$RU^$"R;R,T"?_84%WUXN]QQIY?$-"D"320%H/&]2 /IW"T ?
MJSW?:2I-9\DL6<B_N6 P]4L%@^D?3[[C6<;_:?7G?>F3MW#G(J0THUJJ@%=@
MTZ(B^/)FE&:&"]/Y%D,H=A\).B*1@2' +_RJP.Z?#J"LSOY4^ >,!NICB/F@
MGE>HRB;NI62?-$WRA-<0"PN5\DP:HKVKYN8%#8?*^"+.=JSC>U(+"C/Z:&'!
ML_I2-Z\W6]\<6WJL^#VB'KYI J!EZ'G8>VR'RLEZ4'8$CV=LW[@#N>CZ&I%B
MA4T\!C1S2'Z'Q&,C#<-,X?J.M@^+1YD+ZZJ1EK?V4SUO@V6<]A.3\(SP#; W
MR!PJG3,)Z''@];Y\AJ4&";7GQ25ML;D(]>A ?3""+KWPG]@%/:1M28".2EA@
MP):,)[4P!D$"DK_(H8G^2PW]4V$08)X[)5&?46&E<Q/B0 ]5MZCRZOC0R%@R
M\^,?PXPV&3U!5+BPM+)+8RS]>8?^P_4*S=U\LJWVB%PO_5@9C_I+9L1\A@,H
M (F ;*#_O&83B_R*+0Y;55=U%^N^JS:'I#&0/V,3YOS75S]8Z3:1-8==MLY5
M<MG<_F'*+3YE]9@ZG>W@5*$YQ]<W4(18\8.OSLM>59)6YX-RL2GDQO8LPF';
M)9))1!-U\\3J!232X '4<U;D%;_E[&V*L9$/ E:JO_%*W6*ARJL%[BGF9Y7&
M8:G%O<<.CWVE%0/33M2.R@[78PQZ <.^\<AOX!<DGDF&L("27FJO2)H(V&GP
M#>K&"XOIJN'-W<#/#NS2"Z9<!0V%P6LM97<4"4V_F=21\YTU\ 3?XRZ4P;8E
M^UB&W>M)"G1V2T0BZ#YZ,K.]UXD7>V^0M.KQ<]R>$YU/\)CI6GX[+=[@M?W!
M:U6%?@4KX5&W Z^L/2SFB]IOG77QU&S3@PL[//P%5U-0O!Y%7SBP=1:R1H,=
MB!)24VQ?7()7"(_]M-]6'1IS#02*H?YC<"N=&8!RK]PWE*U@OW9<2!,((1KT
M6"&KR"MY.UB]Q&4L5E4;5".M2M:B*^]U>LV*VQ^_9$>U+8?K0PF(V2DV^JL%
MRQJ[>@O1,L[CX5PY.! T,/IU5Y.@Z^;LL:.3=KA?X7? *O%<']]#/[@&)K@%
M;P9)Z:;35DN9LFE2GK$UP]W7^B>14HUV[16A4J@H?5>RH 6#EZ7._+@D+'$,
MS?+)95>\BSY-KTM3(7EDW&VZ+$7/Y]7R>B!4Q72KT*EN?_Q#$E1$(/F79\?W
M9=A3.!5-";<3]SHR\,8%#2TP>!VA,N7Y*D)]CN$L*^@><;Q>"S9L68!:<:=7
MZ'+.YL K"<T)'2 \5-QXV_'+>4.BA;KW>16LL>?B.;@?6DB'\^&>D0&=4L[Q
M,VA/P9^0#@'P %-4H)/8]#HP>,6UO3+LX,6XA3><&B@,J. VI.*A;8"CE!38
M7EBQ<<%Q'C6! (,^&KE^'POX!V[!#:MZF]#[UL:9]*K:82+' POTYN(P*FZ&
M/7:=MI3%DM+TF2P_CP6>FN_]\3PUCC#A6 DBWT2(\K5R+Y1@BUH68/=#<">0
MZP&\%%3XE>UZEIM0'UT?<V"G3?'H[?5[2C*#<M!(<FBN%"&5R0-EO2+-'.PD
M!0/\'PKP!\6&T[J*O8"S/X0D<20OP!A6Q_.OAN)3@K4CTX6IZZ;A+1L.!+0,
M*%JP::;WG7TBXH-')#0MIE/!7"&SU]D3."3$B^K *CPTB7FM<,2P50N+,OO
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M[75G\A<I,=66G-2#:=LIL,L4VF927.I]60:@%@ \#7#.L 4P3 ;&M9A@77=
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M!J (TAZI''%#T;G7IFB?IT*'PO_>>O7%6WB%7IQ^*(8P',J?R=VBE)-0.UX
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MDA5Z7D D1($+K?(6S,WU!0@%I73IBN/XQ4".3I-04*^?D>9%$GH$XN@!"8
MT91PXO&+LD6XZ(=G(H*O 70%Q>Q=F![<CT=N+^N*'Y8K^\Y=?K\,I?0*),RS
M15$@<SDN7RS07$8JY+A"(2-P!)4G,\7\G*"*^6/EA*MJMR4O3*I\C)*"#EF
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M H2&$3H)# F R*'?+H/!'3O*WTN=!T.E\A2@L@-AHA9[  R(FRSQ+!0\Y;:
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MJ3E8Y'NT?DZL&/'V)+U' ^@OX1LZZ_A\G8;/Q^82?L?GH&E$:1]\O/,;;:#
M!=0 .C(<1^FB :37Z_G"E%[7"=B@I69):U<RA/WE^4(C[:!#Q?G$?I>18]N7
MD\D0@<#Y!S5('KS'K>Y.ENG,P[;:(<9CRKXWY%I=_N4>U'[##6A'80P1_J=Z
M-*)<:-)SH6.TM+ROY;E5_8'-6?6\X!;68[$)6S_!CM$WA2P=Z1>=2FC<M_<
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M_"[KYE<[TW+?[J/Y%<:I'V0E4]J."]5.5\QFFX>QVMML(>.$]I3,JR+]_^W
MMI#_^,/:K@ZN5O@(B%BZMJ/,]_@KQ0 T (R!=;2?IAK1M?S?U[;]B,5^@C ?
M#^H9)U61! 1'*9J\20%()5%E-@BR-Y'Z;"E^M;+,'0 ;1Q)3#EB'E9H#2$EM
M(*BD1/!_Q_2^MX]I$ ;O /BYQ1=_=LW_%I7-/_\#_O&/1] DWH($9^&M.Z G
M<,D>726(?WT,U3@MFTYE0C8U?(*U-)G#&T,;0?_^[_\5WM#1AIT63,VT?OK4
M,+13[^T4(HRRE)Y9$J^F^3EX]T]>V_)[VR>TQ=L,Z5/:GP%%I=&]$K=4\5^I
MT&=X1I$#UOE=.G2,'B%.:](<;!\_YG]GX3/QOC1M!2+P3TO2>-@4&LY^,B^Z
M+<=<_:0 NX=P!_[T=I8A;S,?=7UGX$X?+^M_^-3"@M3YOX:=\B741I\!? ):
MJ9TT^/&^^O'/$%*KE#E/E2&Q1P%Q'H[S_X3@X"F /CWZ2R?*(^+*9<4L6<P3
M%)>5\C27R1?F7+%8R'*9V8R<B3R5%^G"#_Q6WB?'M>&T72[JZW5U7V^;18M]
MY&9CF0,,Z'QDE=.+]-!N[0E7F3<,@ZRFY=R6HSCB?*0L.*5#.KN3"&DRE_MT
M94,L[F0P,CKG/%MAU/&\I>9VNGTH3*E6(R=S='1.8M\2IML-U5'=J9S?Y4<[
MOI:7N4QTY*:GYBV*G.VJ2DFX)XF)WEXI/2X;'6E9LQYUUWWH5/?;G#/6**:J
M#A@N%QV9Y[=Z/G-73%?3W<)#K9CM*W=@G;GHCO;9AZ(UG9.;JC(:]9P5,1ZN
M[[:7SK/WF!-9RZA2;+UI,AV6KM1RM>VE4RJ(DSEASWM6=:SVYYO,C-5&Z^VE
MO1-5JJYN&UU3!2-[X_R"VQ0M>$J1.=<R=\<^#D5*75>,%IDQV.&P#4?2YR.7
M8Z'96E&V4EVS"OG VOL5L[AXG@VG]##=CMTEP6^&DU+O_GX]&LA@9.3M3F>W
M*VT-MEAMTFNY9]\]S#K#BR<_+_6ZN0F3(]CU0YZO;I;%;-[=7CKYGKK+]JN-
MO%0M%_OWF6II>>C<]\#(R(Z:S4)9M$8%EU5V+;MHI.D,93)</OIVT94+!E\L
M:54]V]S?9]B"P"Y[8*0_)^!,4()3#)='$B!Z;L:)XVR%W*GW%-&9EE;=>5FK
MCNH]#@XE/X0'O4Y.:1A0_C0D++UN%6<!&7&JYTJ:IM@I1@!L').;&_1#V=0!
MW=JG%-MV 3/G4UO>LGC#@1P\B/M]I5!L+WA+LCE^0F1[CZTR0:25/+=OS;FQ
M/&$NRL4<58!B,1F(NB77!D=@VZ%U'CV+@2.1,<2NQAN=>4NR9,GR-E=23%M0
M@/0LV0U#.#-4@44ZZ-FRQMMV9SYP3$$]3CT UR'9CWU)!&^ M!W0=:3\@(]=
MP"LDRY)$](P_[]@951A![1+KL:$N%W5K+H[EL+C=:-=^)=$6+VN,3[]C]2$,
M /$(O LL%LKZX# DN\QKFB26]MXXVQMH!U(Y@:7R-OB=4]>UX?:^*:>KN>%:
ME_3U>$H.Y!__4#<%(AL1R%/X^B!3PZ>1>DP%6T^AO:=X!XB%*6DG68("X&(%
M9#?$!?_[>0BI*!M%E)#2Y,'(I,N3XQJ@UJJKC-V&U-$G2^G/@Q'J=R&DZEU%
M%]Y$\&, %N1%N&!YEJ%S'<8@.L52/U/FLE5[#>""!N)9/FKC3*TD"P/';8I=
MF5!4 GM<F!J0/;$J .1^" 68GL SL2$,="T3B#:\=H-4"7! &J1*AHS&65YV
M 9HK9:^ XH0)DD]_9I( MO_!!"D'>748U@*0@-GOSAY22]. \MZ)@@Z^UDTC
M?/4EI?8XS5'4(^L6<WI;4TN*/F'B11X.F]RNW%WI>C6](MJ+K3RI'AP !IE<
M_B9[P=8=(A "VK!W>9 H'*_F(VC"!U[3YV!HOW)'=]M6RV:!?EPKYYO92>^1
M 93[EHS>RVUJN "L?<N#JP&JFF( (-BG>$$ RB94T,'Z4^ W/J4I/+90@*MP
M%.U7\3@%/M^[AI2BL(7@!M[\=J$(B]3*5""&AM 7KL:2!'@BRER!9@(3TA$@
M!(%K0<8$9P\7?GSBN#KX+#(EB*D9 "D1OM@&(A"82( C%>2/2AFFDS)G0)#:
M(&5,,= "<"W&&V]AEK0"H(6-%BG<*9%.Z4<S&I*0O"=#)HR%[Q7#2_2%) E(
M8('1(SS>.[3H5B"KDE,E#2C_Z8$ SAKBSPI>6QHB"OQ1-T5)LQ&-!(?EZNA7
M&\P'\<J2CD< WP#D/H@W+K@-@&X0 @!3 JL2[+,UV/X3<(%8D!7!RF\@)&P!
M*T00$7J=8@B:*_K4.;2U@/C[+W"!Z&EI>SC4QH1G?^.1=)U7#/@]Q%BX-KA,
M9/HY7=M-"JQ93<\!IP;O!0/ N:8LM#IIMP), NP7;5,"9[)7)$U$IQ/\MC&A
MGHS.UYLX(#I/+##U%[ICT[7!1/;?V 9U8H(ZH3(5UT)'!H0/$A.:H7DTXI)<
MO[H9=-4%6V3''2&W>!B)XB@OGY.#P'CZX($#(-">!5?L&(']ML3;BLT:1TA&
M[E;PLVD(X"FTD"%864D#V/K#5T>DC&&.Q<*X2>B98;?HM&E^ Y<@ 6JR HMP
M+%>ZDEI"YZ]@/HUH/J^TIR*S<6!CPYX'P=0T?F5+/_T/X?U BY3W'FB'$;#]
MQC<R(O,7[SJF_P6V?:%O3DQD(>>%-^9HE\P7;XO8ZN98_M+\K>'3>%WD8(&X
M+3Q;\R1D7@K-;X(YYYJY]<_-_SL-/34_L4UQ"T[J15.>9W%%+_:'\C/;U%Q'
M^F@;WD48PD^N7M]__&B<_4U/%W6;26XFEC?SDHLYN9E/NYG,;3%!FFM>S2]&
MIK_(7S[Q& J_< Q7I>3Q:\G\@?VLR=QM+A*Z\K4;6ON.;J\).GF#/T"Y_K?:
M7'O(%+ODMA*O\090CGAH4@-?(P4-:$I[B;?>#7UBM^ND >4[AG5YC#L.>XM1
M)%>U.'V4I#4Q5YO[AR&SK3:F7/K93(J#9)DB;R^>-!2$XKO&BK.(& 7L4ZN
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M(F7TP%UDF.G(!V? $40CC[XJVQ;ZNF;H/E*,CSVVA:(2#;@XW;"Q.;_RD,;
M"N$[[CW>>PZ<CN4L%H9I>\\[<>8\CF4M.$:8'SY_SEN8@_!BGO&LL.W)=3BY
M$P\ZQ)?9?2XC.!H)/L8$"Y@60<IY]W,QE(DLT%\6SA2*H.IBMLFC2WA3V5A
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M^B[V[<5D7ESVS*S_QV-S$UFO_^FW\B_DUW\J^AG*)[1*ZC_[1TF#CU!?!!2
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M8/KQ,Q2V L, 289S!%NV!]]1V]UFJ>&2(X9O]ZMU6\23#>';^)SD:C,2YW"
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MV"ITE?UN%WU'>@:@:NF]A6B=]J)I20#_@:1"5EUE@P%11(!/E H:BRVU;9V
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MI%&G0C#"@] ODD-38H1)B5C%E!;WZ)D&7X%.%!"0KGSV1=\Z<C'(#"LZ\R#
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MG]GI3>BG0>)&'IX]WF>B-1K=I(U.G;NAG!$K,;HMFSZ=;V5D=)] .5/AP&9
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MKK'U@")3"1)9R@^WGI,?SC-![7I]<69(Q)J,%:H7Z4MI]YKTHQ5$M;G?>J(
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M &(BIT%(U::4*!-[=V@ V=U\8!GR;@B/7\ME54[6;$L>AV29/$#@2>C)6>>
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MBG&%JUI0Q#A]T8OL9!!38EZMA:K)L\@S0_$PL5)DZVYB;^-:[+W M?C(N4N
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M-50P125EF:W-*F-));1KW;S#6&1ZG>/V1?^JU^' XQIM?C3:5$+5_MR]/.Z
MJGW6087)3AFO(+I46+?>K89N_>&JA\TG@+C\]U6WUZDN0]JN+JK4RG6M7+\Z
MY;J+.5$7P'A %SKM]O\0'\Z1RERTN[W+?$"?[>1^+S"/J@ORL>B?BZ.. /IT
MUKW\U#E!*[$6B2JKGK_^$, ]FF"O&JJZQB>-EU7$J6HROMU&4R%*)33V@F^\
M_;'7Z50U$6*KDFX(35<JH;I_.#T'9G=ZWCX1&^)3I_W['^)S^_A3]ZS3^Z.2
M*%-)FZ!&F4JH[4=7W=.3[ME'(__4>/*C\:02^GKGM'/<[W6/0:*N(H9L5](
MJ#%DMPH8TCWK=WJ]JPNM6BF"4DEL*>9LOJ-ZY/]0Q7I7Q4Y!BUG4?(*L.7:?
MC9>HB+RP3#WVGA(6+L.47MUAY"=T&%FITOJOS=2$MJ;VJ>AP#XM^^U^O-%MB
MNU75" [FH/O5, MIQ[P !MH^/CZ_.NLC(RW!L>KAUW:KBNBCS47[U3 7M8\
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M_4_GO;/^^1D@WP6*VZ+KPPT.022=QSX46@,9Q1-O5CV@?"?Z?8Q08^E/PB@
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M$9(F3NPY*(\@Y<I(\F[F1<2HV& V](&U:.8X<HD/D35HB\Q!H&B)-/!1L +
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M?00?HM0WKW#H 1%5T-2$LGIQ37>@[&A*<5 $UB%=RN#M8JQ,D@4#FIW0""D
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M<>P)K@J)?!?("L&A8Q$550\5A;\XLN1&L>+*<D&_''-[B-UN3-3[34ET!*T
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M"$9W5PAV:B)-PXG/[I-,\6_SE'E^8>8&Q]EB?.*!+8AE9<O(4?"^XAT88SN
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M\(,LO4Y<RS_WTP%W*[(/+.3?U4I^FET#<H"B.XN;=GP2=:)Z8O"@99W_B7(
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M*H=2\-('.O"I4_;]#O#J>A>?]T\Q#!A=:P.+&+B^YZ.SOQN#ON'AV3-6,Y^
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M]DRD9\]V)O"+X5Y/SLQB@C .V!(,@P=.E;HU(;=%(72LVZK#.V[M#9P,.,\
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MK3NU 1EL47, !5ZQ-GP2>B55,0.I8"I!W]7G(9-S+G%7&[! 3<#K#JU_B.T
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M]%:1MVWCQ(-Q3S\7?<_'P&]XM;E)M^'E/%X:(]<RK$\+"/]D4&)7NS(KKR[
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ME."?.25(SF$YASR+T2,]-)?2-UW?2<-VGL&UX1<R.9I/V^CVSMFI'F=(9(N
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M=ZYM+NE:=$*-#MC<U.H(J[CUZ4Z1A*,B \G]T'SX)<\7ZDD4V_4EU0A]A82
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MS-J# C5K5U0054VA_A*:X,)?H"GW-#LW#P&!^U(TH\L<4C,C"+\ X!K$,"M
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MS7;$8@(!(HR/5!GF-;(8S(TIB_H$V .1<=O<GO/\QNNMD&(DI6J"#P$GT5
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ME -(X(-"107 7Z:QN!"[].SH1ZW61%G-6$/E_94&=] :G(S-_(,#2_T'9<S
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M=Y66&B<JB643Q(7^4CN_V9E._3O*+^);].G-47+4?U!K:VB@-(FU/PS?$6M
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M]'*5''Q5J?P&_?ZL!D \_*TMY$?!9J<5X>J4>9)H%Z @6W5%1O+%LF2U2GR
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M7$^UNELH"+U\0OB=GH+0#RAE],!5=X?K0<\?ZD'?;3TH;'WKJ\INWONVJNH
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M_@EW^P$?(L%4 ZXN7;"X4$$CS,(RSC Y N<M.5 &$D:>H=^I($'LG,W/6;:
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M3@$%4*MGD[;*>D T23D&3\87$&PDTI<TFV)#6YQ3@I0P']]!UE@./%^7.P
M.P0R$&=0>AV# Q>$P<%*0'\"QL%X!GUT-M2>3LQ!G@ +)ZB/X=L76I=:@C04
M0U3988XM;'Q!UXT!S@A?HQX*@1[CYZGZY#T&AB)K\XR]!G(PC:ORU$HMY4K7
M!Y_.-?,S"TK#G0_R(^14.TQEPH0EJ"]H@S^4AD2),T?F5[Z@XAD+KNHCH#J
M$" ?8 -H2!3*?QL([+[C(WEL/OG2,:V=ONRA>7HH@_:76X<!\USL+V/0VR&2
MXF0E><8(\",:=@_&XQJ0<8BIGW6=LUM'C]6$W%TTA-C]9 ]YW+NR!8:^ K=I
MG%M^S!!V)]E"[NOJO!3ZOK9%4%HS6K:R_'7M?)<:W?\XN5V-[D[4>_3Z]?''
MC\FG]\FO'XY_.7D0[=[-F3C<C 3IIG,7'T[^]O?]5KU>4M1U?7^"E&V,?6+L
M@] ] D>@LV/0_85:CV<(CR KSQ\U.I9DM =# \] .L-3A>!4&3!2NA_1.:Z'
M%AZ%N0>IE>#&#E-]2*@*G9LJEX$B&LR:BO1^U(/$I/Q\-BMN>PD=)4T3"G4R
M^VE)/I&RZ0-OH4*,.HD%/48:QH= 3MTP'R!O:,\UF5>5OVQU9_(NE>2T1!44
MDZ,PA<0Q-PU$<!:<1_=^IBU2V-A^3"+5*WPZ8DEXDEJDL\$Q"6!5C*V@=DN+
MI>*U ; D UX2JE&EQ26-%SZXW*(XH$F99NE<8 &ZLN"O]!Z69=W8]=7_!K%C
MC:?%'530NHRNF\CGX6=GC)C!SN6L\,Y9#UH/Z T)!V3?- Y+%A<I<P=+DMQ%
M];M$-];D\IH+-Z#+1[.R=6_MR3.!9,!0)]0L9MN?R ]K>A HEG[57#YG6!RF
M#+EM@V8_4!QJT!^AJ?,:.EB;P,O;E!\N9LJ=T3H=FWP:3HY[0W#4.ZO!*GQ/
MGB6![+TQ"<[;(3=NECM3XZS'P>%SG01,"E8434Q]<M^MD"E87/1(.F@>WN/=
M&B9ZH=0WN?0)2':+C(FS0F&:;H7XYZR\N/+U.J]RXN83/7#J@"2CINV;-7J8
ML&3<FI':"CN<1($:0-!@54,/:E)DH*.8<C=U5KOU@-G0G@;?:,.W=4"!G\V@
M_Y[>N!M\6Y@*-J[Q&;19XT1'D\?)9.PV1E%'MGF&K22F3B=:T!Q)6CF*2L>B
MWN.N53'1)[,W,Z+)JQMYW3AMQ3UU2TV:PY/LG-A$54VYM HJYYX[YCPOY[J!
MHN=R-B*#=JP_RLM^ IM %*Z/^+9G,J+X8@\-E<YCV0C=$:XQ#?5#XP$?\H'%
MV_1B;V7^/7OEM^R6OS[Z^/GH[:???TR<#_[N^-VGY,W[7XY.WCWXXCOXXD]N
MQ1>75[?7?J%GHQ^Z+4/\R[ZNH1>DL_)0([G3-9(?'FHD]Z)&\O+9?DSI*EFR
M.RPQOMQ:3R^(=0/71WU[S(QC!A)Q1PW^DY*.++;A/+7RD@*TF8O4C"^8.N\)
M'+T#2)-#8_HN;$BO^6I;P6)1*B3PDG)VFYEW@OH\-)P:9_/R@B7R(!'1Z2-1
M33V((T$]-9A%07CY9 9$\%[1;[-F&-L#<[TI.XCX@LT=8=3D14./U5:3&;,>
MP79*&Q<8XE-&4Z5H-I_BE[R(I'2X[[U$'.,B(P8_JO^ ;CUVDPVXA:4KK*'-
M4K+*9/))44+" /";37*;2A9Q:0C#6[F0Z:,(@J&>E]_30;%30/!\]&2S9>V&
MLW%O%:*);VQ)=>ZYCP7EVY;DI70!V.[%$N<H!V=$.U&13A"56R11YRQ 7G2C
M/M2C D6;*J, -&^X>$7=5&X2*^#VIM)>.@-%#QIM[4)U LWSSV(_,U5.5W8+
M2F+Y68I15K'EG9D^4[MKN-^L6A$!QR^BMZ.1ZK%0L*/PNF7B*/@-'M.T475L
M]67M GVN97J9O1H46">26](!YNYD3,.'13+8H%?@U>/_ZQ-@E$>+LG$L"H4I
MJZF'BUX@=1S= ^IAB*[S-36_>\EXIQWC?0K)'15IC[H 8R&US>>9:I>!EI;>
M>'TGR)I#[Z-R=:S::,.-ST$H)_8)PM#L4'U1E;+L[7Z=IVZ%'[ASDC84[<YI
M-H---E ;,VZGIUG3WU6V8Z;$A9,;LYM&9#K1(K!GT.K)[1#\]5@F%MS!9H]T
M+FNZ.V_A] PM5#):6K928"K"UYJX(V@-< /_Q\G)1K,&^SB]9$-:&[&PU9.$
MK9EH]# ;KQ.-MJ&VE@'5#E9/]J[/JNDT6B6;[8AP7?1UE))@@GN]BR4("YHU
MM017@'V_0.QY6J47B)&5(OL53[VS;>@LM:T]XU3V+&%LRBI*_X;U.J^NCOG]
MQP-GL1GZ\R846D-9+N(V--9P&#='=1Y@* >4;*K E82[GV5S=NBA3_42^)G@
M05"ZD#+*;EOF]1DWAR^ &]%%+X2<%MTZ.DEI<U;T!O,:H2U]*7-+2=#IV3_H
MEBZD5A/4TB1Q[OO)M?X2''U\Z*EM&"C^RTY<]-9DVOC7_;,7% ET*C& <Q.9
M34<)B+ Z.Z=?]^AH%<KM>ZVK+9_O3)\(:(RE)IF":D+]Q39C+_Z4/%OWH)(Z
M$D\I@)ZV&Q:O8FU:#%<Q4["1WGO_I4=K(^PM(_&X)FP?4;D+[+/-*->O)P\B
M@KS+TO_<;))XE6Q@H8S:(,9G5/:+"*!OV6S'\B@R"0VK)6*/I*DTN9=<C*YP
M>\RFF)3DLV>&H9?K_U# Q$8O^"O&F).S;-K.)>;G@PX]GK[Z4CRUPW5'8@\I
M=><S2%PZI>'!)K^J#"COD KWIU##AP6%5*++]##/5>(PA!AV?/D@$/!M, (N
MDS@#[AFV8NBA@7*(2Q0YBGQPX1P@/50THLP6B&<K,\!=/7-[E^T>[2G?^'QT
M9XHWFU/3;VGG,&U1]5-_&# !N(/NU7XN*$!$!QRB#XXX=J8M?#EZX1YQ,S=I
M+"$_+KTPR@3=>G>&?<B8"J!'L=D?@6-+183>")EK5=H-'A=0%UT!*^BNEW0'
MIF)[/S=4V\XXC9#+-$Z;";@7"7F)LX<UK2.Q7.,3FBV*AE,H/4G&-$J3F;2'
M>]3HF-*',]F%;[&%J;GIZ4/=[H[7[9X_?JC;W8NZW>-1'^WF%IA6"PPT]1UT
MGSN)^@./L4(KE!LM"-.OL)$E0ZB9$IBCC83ZAT>QP;503</Y\Q3,1:ZEMW6%
MD D(HY:!D0;6LTJ$ 0X1>MH/2FST-6<]^T]4+X#@FS+H/LP3P[,TA9PQ*83;
MAY,$ED=],?4@ SX!"Y?;$R.DSW-G!>-GG8,.7 '8K[+R'.@! Y*CXAN-5&?\
M0%N,)FF=;7@DNZ&7$^%4X#GG<4UU5*;\&3-S=4Y38J 3?K-!;Z7"@+9\>2)
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MW5E_GG9$CD6W-E10LC/;54#F,?2((.MZ: O9\'P>)EP+#YO8Y%PT*@:KI%=
M8:#SO4%D7;H51G\YMZ/_<'>8J!FBO0G<#]-<K0_W-J3GSBF@$(^[%.1U7&7J
M.^;0_:*[I'"!8$F\>\;LFJ';#*<L.35G(L]-Y.@](Q48\[0:RD*$Q+AQ)RM\
M5C$ ^PX,[SDH]V"RI>3@26Q0_-$H*0(/%9"%>Q5&;.@]Q>X7Z[(?5Q:K:W4<
MBKYO#6A=\1$6>=.>%!CP:@N"<:5%;_.* #N^XC& \NAN)OQWGCS^OTKNRF8(
M>8#(IL!&7T&N@V:!<C7JT J@7S;>1ODWV)T'&[[1R4 )<K.TZ!(V<[XV4_IF
M8?T9&LH?JJV1E1,<"::GYMQ9XWZ990V3<8-.SFQ>0A=-- >#)%^ C716#O/2
MN1<0]+:6W*=\8*;\J8>0] 0[O4O(617W0[Z0))SO80??#FM2;BY:<C[\B>6.
MJ6H"?'ITBF:%LPU91LT[IX0>M)K%'(5UKA^T BGRT#K_WGTAE\634K/S<OCJ
ML?5;PCFZJH%HY2T[S?/7.B*<;Y">5NGR#!6E-^IE*: \,8OSBNG<[7^$#N"
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MSF)A0$.*U8LR.7C"E/BK-56(O  O[,G2?*B"KXN8Q7I!,9N C;C Y7;5>68
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M;-(VXH,7EWLG05M5N5M;#OL.BG;WN<OHZ4/9[KLMVUV_I0CBBVQ1".18'%3
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M]]'6L_UX]'BK/ \&53#5C/PRW).=XC@Q!J('&/+:)D=39V]@$1_50DMW@ <
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MZI!>1?8J_DQ2@=4/SJ/TG,*DRSR;XQ46(). RJ*SY'.!>7ZD'W06&4*XMB+
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M?9=!&;^L>[-@P&9.!)/AGB%X@(<&IEO6-GU7:HHIU!Q-)Y-LV0AMB#<)6,Z
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MX8C4>V3S#%NU.HU%(5MM[00:EN"*P]L :Z+ [DN(X:9U@A+PF,.=<5+@&9)
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MDP>J/'^<];3X1]GT&BX::$O.T@6>8T'?=,E1"7>B7 ,*( $+P*&-C)5WT/4
MVV$<<(]-(^P/,9ECT@.'E^ +;D_<U0WWRWLPW!^AM>L$>KP^'?VU6>.]OYKM
M]KBG&F^@#)/V3YDOT<J76!V, U%INM'XZW=J8^39#5BB*_C;YZ@LH^&5"NPK
M(.-@O@G<QDCQT6B_1##X=KVOOMX[2;ZON-[?G9Y\.'X/3N;1I^#XY,/IV><C
M<#BWW8TK5$V7[6ZL^25$:>Z4^4PG&M-,,ZTY8!:31C]C">US%7*U9V/0K</F
M)V9B18^E=-*34-,#'@#^5+L8 LC1Q5'38]1S\Z4 )%!S!7J+L04>I/JI</Q
M>&LQ%-;1N)-IFM\BNP_Y(V!L@'I/_2_\-L._I)A\AX\,0Q#!LIB^E?X%1$":
MB>CFR@G11\H.4E3-;I0>(D@06W:R,=2:=YY9TS4UM[SQ;G!LNU<" 6Z.-C 8
M$**C5F'5@\BL#Y ;8&9]9\ O >1H.<% /"3 *<VC0#=%AT1G]2?1-W"E^#X
M%RGSFB?*&85OB+>T&"R$YAV1LVH6U-N.$70B-0)U(U'6K'_7&@M@_XE3!BRI
MQXFMAZF])985])!P*5B?5#;UA6>HP>\THSFBC:+))BP$9#P&6"0ZJD3MJ_:'
M>AAL_B5>1GL;X3YC)X]V'BQ%)$AD'Y(:\UAAW3S$:-M8=\^-=1;M.]FHT"R$
M6>L:P")&$Q9!M@@M'4@[ \2"(,B(4E V"9E/RC(?)CJ]"$M=?1P*:-2L(GN-
MF$Y:JZ1HL"60;51NG6RR@>#?0.,VR70A33#(']3?57P"J4-3&EL5AW, TBG=
M"DZMKVE."HKHW(VBVQP3?+.!<EE@6:E!5Y$I$$1'U\K2"$DX>K2S09H,[6"W
MWKAL6SD[Y\IH2RM0Q1YQZ1Z_@>O8=S,_A.;Q#-THZR4)0:TM+)ALZ\;^267U
M4YT-P"0\!+,G/JIVTRON&&EMWHAK'A=#?=2C4O+)>IF9IW!JV"#N6P&L/L?J
M*LH#@?WF(S>@=36\4D:W* T>QU1 G\.X>B^19-=8:L6XNCX-?,I%X[$Z2=0Y
M4PKOO1>DI>:66 'U@0\Y#1AI] IFHP3O@T>U32*H#'$*BCS(P"(;%@$":A*)
MM%OY"1.+>)P'MZ31=<84';6-(PP]]IP:2EL!@H^LA/ET"YAOM@7,)U' ?+:'
MNKYW2-,(DOE;'$^;%L0^/S!H$$!/32H,#2,Y'H[!)U%S<SV WK3#3^BPN\'"
M:&&1C_()&LVJJQQ9QM%EF15"\#+H^?*@\$NU89FM4Y.Z^_0:!<W##7BIT'X\
M=C;/EZ_6#-)>+5'4B9-XI331T<G%\;.+_MG9Z=GQ^>=-YD5?W[F#VTZEF"I+
MZ)9?AODU?J.LX??8^<RX8L^7R5P7Q:0A)JAL )F)0CFSR52Y/,J_&7XC<M]2
MNS::@T;Y&$!"(]X&WX9V5U7DNND2O"D=/JC!4YM?JA9F3UU%UU@.D1]C &Z[
M?\RKEV1V^0ZS']A0(V &W:X,%)3(&((>M/IUH>P!\ 6)NJURY% G ASQ]^9W
M,**_PSY1__V%0B!NL#) O@% %O 6 _ZF!$LT%F&0&3B&FJB2Q8J=&DN&:9-0
M,)/%+(T)P'<Y2ZWX(8$.+>R=(>^2A1R$X0A93I2;23D2%2BIO96!GD)<L2I=
MGEKHD4F.(C[$(9VJZY#!+*_,U;[NGN\&%Q!'S@H8&5@A.%\+;P-/B_JSZGLP
M:3?Q0)UH<1A<5=7TU^?/;VYN=B'54.Y>YM?/\W$T?%ZEP7Y0CK+=Z6C,:'P8
M&$OR2:YB1M_^4-^+[+ZN'.+IA.^WH_\SE"7,F:0EKD($W'>74C[]</0N^*0N
M)+UZBP)/:0'ADZY/BGTJ[#BEPX[J?U^S!)8L:H24OCG[3=AC>H$#(85-"Q3=
M(RM[8/X:ZGX3:_&&ZJ0N8DS!(NI6_A4ZF,M0(+EXE!)P2<TS>,/X[]K]Y)NQ
M\SUI:+O#W?7TRH8$KW0J^Y*, F%CCP)P#H=7XCC4K2SSOK*EO74LK95&E9&2
MQ((N7*G877>GD#!*A+).J8=NJ-&7(@RTF>[[1X);:F/1N%Y(X<("J=6D0Q\%
MF68><QMH+ HR(@EFAEDJFH>"DB4Z,OA?94.!N!ZTS6"R$@YM&815VJ5MCQ!9
MR7$OR9_1D)95V0NB@CIW\*'0"FK'JI93=V=->(<EFU";/W-4\H,^1W>0S\M'
MZJ@=[KYZ0(Y:)][UE1RUB_ZG_KO3SY^_GAR_PT+>>?#I^*1_'AR=O _Z__OU
M^,OG_LDF-24>11;Z/FI[MCMJISZQ T-YD,J.@%D,Y7 -==,!-TT 0F66:9E
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M8(\UNM&,J%UK:*R\<@-[8ZE%(/:RI5AF%VSJK2?,=!J5@C-:I_6ZV_#CBG2
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MY6?"H# D;(&Q0X0]1_-.OX R4=B!F@O0%&PRLTR8MBVA3E/?A"2 T6&A<,1
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MGBZ2-UE.I#0@B__ZA?W4'1>XMT8R\K<=(?-N. =97BNI.M(D2B/<"7%40!+
M#C2)5 EJ>&HD"MP!$DXU%RR:^UZP<';JV)..<\--7L.>_BJP16C8A*F/MEIV
M2[K$:H3WVQAD(E7V#NU<2*V1+:\M2033/E8'ROOO0/W+B<U&1;WND5<(8 V
M3 Q.U1S.-ZO=D&"S$GF*RZ3D,"PXHM9S"+#5W(W5^<%)AU8@K$8Y$I^<^NDM
M1=:U)L!-";G8^BV.NBR3BFDC",37-&8ID-^I)1"[<[-F6I W7<OKE60NVN20
MZHL($T!&2V(*]#$9;*-:"LP8JT87C5$ED/5$5;I4>'7UL2AW\6R:QN;<U!R+
MC:.\4--Q=%U<["OUD;D-\[)B1C<FAB<6!N:;J5^;#);FL5?CA63I#B-[&MU
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MJ!=*9AX@T>EM8[W5I&TW,,(JE WZLE66$;W%?!;;*UGPX]A@#V9$J0<\F60
M].(633BM=N3,%GP5]S(\ZU#?(B(7KAFV-5["\B-9#_U6[W.F*(L*T)^ZG6/Q
M>/-$Q%=+%7!GWVJ75QV@N!5P(ROG.V8VCTB]199A[:?9BJ$^AS(*-CG:Z48.
M'/!KRO1C+PMQ/"B7V;H0F/:K.+4&U6)VHB. G5KAV_5UIJY&<?S/+B1>_%C
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MUJ2&KG*0\L14/%[7Q[0W*DP>;I+_^07F7@T103QD[=,: LK':%K&O\I_V',
M0\XK'"8= @PU%>Z2HD5K+ZCFMJ_TCN.KT:S\=S62OU^#.SF,4M[6:COP)5[O
M'OZ7;</X5F+/K!5J71H\R+$Z ,20R;^?W131]%?:73?J_1>N>OUY-"CS5,W[
M;[!1-V77.IGJ92TU__]JU&FX7^SOOGJ]'?#[&_#]E[O[VP&_QP'?FI,U#K8Z
M-,III$Z8@U\6#OQ+95I>;@=_38/_O"HV>:X^S$%8UR'VJ-]NX8GQJ-_N\:[*
MM=K"A_NF;'@>F9&9#S%[PO;G7E_\AYBF]2,*!3[XJY:4;NSQ%QWV^*N'L\?)
M+_C][/3T_WXX[G]Z'WPY._W2/[LX[I\'KP^#\XNCBW[P[G0W^/3IW7;';W?\
MP][Q#^'%G^0R?ZPNS/H&X?':NE_^SU%5Q67UZPKVBW/"7,38WX7T^B@JK^)1
M(*?C@WG?K8G[F4R<<EYNO2O[#B:KMLJGWP'@F#S )?[+_WE>/@_^$0.5;705
M_ [,A,6W)'M"5NN^/32>>\C\;<W;UKP]N9>^NSG$+?&0;>%)-(E_W5K#;;RZ
MM79;:_?XX]5?_L]%4J7*HIW'&?1;_@F=ZE^*&#! T'O['FEJ2(\>4$CJ2;>6
M;FOIMI9N:^D>F:7[V3-S6UOW)&W=^NN.%TAX^-2JCA_/U$L%%W^<GIU<G)X$
MGSY]V>[M[=Y^V'O[7H_T1[BK?_8C?5MLV^[VS3GPA[MO#A[0&+36WA9:K3U\
MD4=6;SN;E66<IL%?"9"6/2&CM?55MM;K)_15I'*TW=?;?;W=UT]I7W,!Y=V'
M4_]N?HX-S](VM>G'6Y;50:A3LES-FT,FL'@4[O#T<*DG2O'P:DOQ\+@I'EJ(
M5&B.=U^^[$RRV/_G'\>_'U\$1_?+^+(L%^3.AS3/B^!+&FE*Y2\ :RGCLO>#
M&&#>/F'&U:-G^UL+\6@MA+M\?02I;]OXM'5KT_G%6;]_@2RIF]I7O@=[Y7^L
MO;W]%_?^+ =M@[1_\/SE\X.]_8.-/1+;\7V_?;Q7-JP5^<;^.YE<!F4Q_)]?
MHNI[^>Q@[V!__^#%_O?X^_[>:/_MWM[A[M_3RU^"**W^YY>/132]2H:_U!T^
MARN/;<?+%Z]V7Q]J6_GR\,7N'M_R'L^#AT=,]K2/I8/ML;0]EA[2L?1RH\_2
MLL</V+CN[S\_>,4GT>:,C=Z$A[LO.SR6O5&6"*$?QVGUZJZGU3[<@,;$;%FV
M+WMX]^;.<]EV7K[8TV+=/^1H>7TG*LYMTF9MA]]6"/SQ'GX=LC:'2R=M?G_@
M29MCE,X]1@DNXCH_)6&L[#+HDRC&9M,WRSXQD*2#A'::3)**)2B;CZP5PO&]
MG$(_$8;2HOZ?7_9^"89QFO(BU?\NI]&0_[VH@ :S@06%JZ2*G\$/@;@;B-RD
MPO1R]_!PLY4%C4.P_B1'T^(AW=^=4S]ZL$]]I.8WENG><67HRHB5TD%8HHJ^
M]XQD>TW$HZ&8%5VB? "IRFC1#:VOC&8'B'3S()Y,T_Q6!(&UR(4CB3=1YKZR
M!.-!MN)&W0(TWJ,T*A*6F28-$:#O5^]#G/KP535ZUPEJOT^CVR)/U<7+?)A$
M:0 JCT4"PMBSS'H05$I5.T-=&MX;?@G2SNHS2XK9NHF62 U!H$^T/09Q%H^3
M"FZKO@GTZ2!-6D[5ADN3__"F*^**%6(#Y3VP2BN<;U/[JK,L 6YV^A0>!89E
MF,+[TM]0[DV9^XP% )D8V&CR&-E:6X]ZSM35U6V!!)@)X0=JD44)WBJZ+&)Z
M>A%?D<%&K1$<TIC^T>6F7I$(2V4P=$11:/Q(O=41G):1@#]GZM)Z4HTNNDFN
MLUBKB-J"Y"'HSH%ZBK4A0GR:NLE$Y:.V38%RQ:C1$,?. (R-]C=<V'Y:TIT5
MJ6[2CX!_&<%V6Y):G5I%Q"JF:J6AR@7++]\&+& C HP]6@X@PS>)AU<1J#JF
M6O5]P7N.(AJ@#+R/H)Q-89)!+#HT:K<TU&HJ0,I=[5=0E@S5"9%_^Q;'L*_#
MX&]UUPI_-8R**9ZZ0'2=*9,5XW_*DY5&TSZ138%R]^I;(E; 8CCJU^JV(Y)Y
MI^?BZ67A05;Q009N6 CJ4^#1!E+LW[1H,(JAA* 5K!4X9/&B[$]:BJ6B'426
MQJ?T&]*O'?N@#6 Y2RI4,52_+- "*MO&DIW.2L1K.#=1<]\"DY5:]O9(KA]N
M!X_R2+ZXBN<9EK%UGDW4&BK40<;BWK/I- 4;,9X5RD8"7)@.[Y%6G=^\(0T7
MV1*04Y>=%NI3"65'S1[2<NLC,7CF^JS8559 =@^"TZ!0FTPCM'I:RL[94HFC
M-LH&2IY<V9Y1XS@8HY#[$$X!&L9H=@EOC[KO@S09HI2Z^J),QG9S+KG,7SSN
MS8EBP);R.?H_>9[:GJCXD%HWV=F,<W?<PEU6/[GHFL.(=*'-*>;>^N\\087S
M;D<8:%YMSZX?L]!>/LKM\1>$'@W;2X>'QT$.HO%8>:MHR.WU9YTV<%R +VNI
M&1:H+$>173I^IJ_.GFY)>BDE"))8HJJW4[P)JYX/;W7<Q!9<W2%#C9603Y#Z
M0QC9Q?C[,,8P=%: :PGYHV#GY7_UX/HJ=BO!!F2S"#,GN25,*;XXW"'&#:(^
M@ MJ64EE$>CTN\&!M ;.TL=L'4,=^,'-)&I6IUTQXZ#9O!*H=E_2,\ 0H0%A
M:4BP(:'WYVE\J5[*V#>UO<<JYE#V2?T9QXCRB6 5&J?V#,>-0WJT$32U*!\X
MF21XG1)'P!<'ZKA2IHD7  3P)#>O/HA1V NU]>C*]-(5!!HXT%;B 8]^U(&K
M^4+T@JW"]AA%@?@YJ^7"P*GU4&*0>^<EL< ^KF>'.WGE%X>[;R0/RD)*S_AO
MGI+8:UV2F6L!?FA-K#,^^&G637[?8ME^2-WD_GV75P_2<<%/#Q^7VX*?(L!V
M-BDYZ..L:Q!!DK.$SML)*C*K\P_L.!\=^CPPHK!7T7^B8E2"'AOY"OA1I9X>
M?P3_J_SH2W5,%7C8@ZYLPO$]W"FI9A6=I9.\J""M%9?BV/^NG'%.2]+!QZ&%
M\;"=P!M.6Q2(O@W4EH)#R [!S3L.03,'S\R<#K "(_RJ*A)U"5S8MBHMOR$+
MAE(<K%P/3GA;0X?!BS6J8Q6J4%(\![5K?5LMC1==8TI[IMYRA**W6K(:Y,:U
M1G9[T-+J>CRXR.,![]Y7CW#W'BM_=T1.($S[15Q,R&<3C<:&OO,D^A:C8#J6
M8JA",DI *I8]?_7+G:CG[$_8 I^B&_4!9_:-2'8H LU4XL&5A(NUF*48CE2D
MHMTCQ6VUA0,5[0]1*1*W1H&Y/G4 JBW#SFDT!07JFJE1VPZ.2?R;2-IB>/)>
M^;1AL#/HF2CI%J^("O?J*NHE9FI;>BJ\L-/4CZH8E27UY[&**89)#&$2&!O<
MG:4GCMD90E&P6<^QHK6_9Z-+BCBB$LMN\(KHTDMZ \Q/,D8+B_$8)=98\UM*
M='4_7-U[9!4D06V;!8R=M Q/:+='Q+F91*,8?I F\8RS/%$B90=)NJ U=&X$
M/X6D?U3@)=4%_CVCE"3\D.HWMW TP$LHTS!19P&\.5]D1$%;E<.*E 03/;QO
MG284SI AQ,D&TR]W]LRS3)WYZ%_*R3'ITD2%RE&)+Q_2@I5X-P8+=Q6G$.$,
M8@$#<,%%_7*UFTDXU7(5%$%5MX%X&SZL71'C7(JK*%W\+!^/,44^:QDX.$,#
MB/3 'WP&?FTPB,JDW V.&M<Q=6NU+0L5(I(I4)XB%>4PHRYBK+Z;S940GZ["
M!S5-9^5<H7 TC;"GT;#$:CV-(^",#&T3X;Z74;TM>6WB4I7?%YQAR/A#R<]C
M8B!7+C9<2WLN9=.I23%P+V$*TD198..ZH#E@1P?R],U,OO:V3"9?%P(RK O"
MK-^J-8%>S*R,Q[.4K0K9C60"FY?L)2X\G1GRS-QO.CED7\FW'JS1M(<PH2I#
M,4)W"&]E_#[U23S%!"H5(M 14@?8$/1_[>P5?!=+.B/9)LHN*XLIM5UT*=7[
MJ0--)U7LM]AZ/IV]B->/T//Y-"\=1WDUY9&GN+[&%$OP:=F"LW J$;6*7R,A
MYBGXM5UW"F>H^356[NC4U"Z6YY?3Z):^!/L<1;BYMD(9W*ILI.;<VMX%('?P
M%\W#)<2<W;0"6P>'G3+AZ%I1AC(>H0'8;I_.2_'-(]P^[["^Y2VRH^LA !18
MXN,90-)NH-Q.-:[X)B9<'!V#'!+#^4![T0!VN"KO*63S$B1O*5?7PMPW_%,#
MY:REW]AV<D2-E7NJ=FOQ+:XP?%>;_SI*9_KDPZ6D\PBR5[ <R.YH'3NT/3BZ
MKZ*WCW#E'^EEJM&!EA^#JY#@#W-/"P^$#=>D=8HT+30$D\G(1=EAH8:67A(W
MK7J]FD=/?J4<>!UBO4M5;!D<625 7NX?$G@.@'J^A_I.,L23@9)IS8G;0,EE
M&2ZBO(+W4Z=C)A!<\(IU0@LS8E$!D!,T&M65O"6G.5H!W! J<MQ&^SU/TQQ*
M9;^NOPCCY.#WJ%75J3'QW[PUIH,%-:;'46%ZPHVIOV\;4[<UIA\/,]E)>H_J
MU)5FBQ'.0XEGIHK6)GEE@C7RX.C *RN[G(. !OI XR1"*-+D11;?EIS1I!!O
MI^6PSN)+=3.#;ZB%9&E<$1A[%$/Y*9[DZK_YC_ YGNA5R- * (@-#,H"TK3J
M_%4+"^.U7L@N)S0T9-8+V2T:)0=SICUACK>1TODF-VW>TWX];H@HHJR,AO0'
MSC;')7:98*!<3KF90;O74EQJ#2^W7O%R6_1Q[E&*"NNE"@<\+0MC,%.[DH$_
M\&]H+E#.*&?M<TY^JC>P,ZM4X9C$6# 8*:=4C<*,P-I4+F: *5ZU%87DM$>9
M+"*L? )I,>@I--<:Q>-8.Y9!&MT H)/W!OQ%UYRMWP K)MZMO%4_';*W/R:G
M&F'A]"-V[:]NI["'Z'O2?]$HO.B,<BTDE?O.LP384Y.44QS605S=Q+&%AY,&
M%]UW%/J_HT,+&P^GGM_[90;>669"#,36("QI$!ZS11!,*/3U44A**$2I'ECU
M!>QOHK]R\=#\@=-%TA_&QZ%\B'=RTD*^^I:R(E.H/U05;1*L)NZ\ZE%3DRY^
M][]?J0BD"G[?KM/EUNGU(UZFF+RQTX<U\[5U:598&8]Y87CSW*-9+-FEZR0G
M"(NOC966CZP>*'X*<!M*C>AC<],).>C@.OBRSMOUMMQZ>YP'IBF\:4<2<I<Q
M^KJXI*93%6;"/^BKT R8%G$T$B"+:9*24KOV@O$7VW6TY#IZG N)EH_%2D%N
M3QBDR1"R!MS2GE$P#VP/RN?O.0%$$6?Y-<<MY*+A?PJT!A,Q4*_0/23FD^ Z
M&H+5(TL&E0O\#_3+Z#C=+L-EE^'C7(>C>*H<*BM[%D'<RQP>@#IPPU@#+8B_
M0]:IA*+:UF'?G,/^_5&N*NFP0Y==>6&VTZ7^6<X&*L9,B-T&#DUI\W/95, <
M7>;Y2&=B=:-<O>*_8]KO".QCMS<:Y+,%;K,Y8&C-OFQ=LSUQ)-5J@FOJ/!<U
M2Y9N8@NA:O['UOU]R@_]?^R]"5/C2IHN_%<R:F;Z@_B,#V:MY79'4."J8IH"
M+G!.=<?$Q$1:3F.=DB6W%BC/K[_ODBFE9!DO8%L&=<2IKK)E*97Y[LOS)G[Z
MUECKX,+[#B67#%(A)Z%LQ*Y&I8G<6B+/QSF;R3AI !%HH*LZ%-+/2>2T<@S^
MGA6D8ET-42+2;IA$<3X(0W=";@+R"(-'(+A!X*N1D>9YZBZ:J>-!FEK@+Y%L
M-].,< EJB<O'M+ C)#.2O'?L8H?*'71 [-I9 \Q8R5%4%( A]Y.DE^GFA BC
M]IS<XA82H&*"20E"-2D.9'>7\T)JBIR3(C>3)/,9ET:^F9W][VX"M 2GW2C+
MQYCFF#1[BN!TA*B3%3RF1-91CDPX.M1S0X7P0'XWBH-PT,ANX$@P.;R8>P#I
M<FHKQ&)%W8]9B$^E)<3PN,[35U-_A17"TG*X.G5@K[IRJ$;UW5Q4WS*D61+)
MTT7,A2G9R*Q_--YT9U-6BZA1)H%%!SK:MV5EPE*LD-*"$7)43 +<(%72/X5\
ME*&56H^Y548F<3_ ML+M'$_5:FU,K;T&O<8ML /5'6'K'^BS) 1C'0LB' 8=
MS;KXL&H#KT#ZR]#U&!<@EI[N\JWS&L\DJ\W,I+&$HEJV'E;^D&4.YK)'!GF6
M8=-V3FIW<&Z-NOA&XAX1#:AJ#>L#$D\QNJ"61^RE]F3BX?5LL%"[N0':K4EM
M/E+;<$K+R3 FJYQ-C9\& P0+2.NC<@3FR4>LJ\*N;J()^C^7FS,RV(+,_.;J
M,6U34W!08Q5@ARH')LDMT)!M-LJ":8Y'E.M'[!IOL(/*[U&R4&R[TZ@'!I34
M@"JPP]IU>U1TIML&,69(& R,K: - @M\@6IJ$^]>APM5J)B!V,.V@!>> E+(
MVGS=)_'\/XG3S)X9Z+P2W$D.HT0CD9A=?731 NID97$RZJ )9/E-WPA9)4@B
M\=UHG321H#TMRG(9.)9,-V4O5VSG?M0N43^]]Q.O_6GB^7''"&QS@,O/.DJH
M$1JU*H$OA ''LK+ -)I<N=;0DOZ47% 8" $1U3"8.P"2 C<N0GM-Y4L2Z&$,
MO8:=YPAK8Y8X,&3D.,G (FVL&%2AP84>!!XYCB5;SK8 1NF2/'KV5%1;W2O.
MOJUG(<G]1E"V:D!PV]3-S11=R_$YY?B&6J*ID!BK@S5S7<4/C)F@*!N[Y#.Z
M3JFLI^ORD1;,$P$Y1;W1^(^##AR]%HPL!V]UZ.:@N:>33(C*]*!-#&!*27,*
MLI7!12</TO6(&&^NOER)VS0'SG'"[&D&5[,F[+D)>U,IVV>8,*(PU.]]&;I\
MOF@8!]C/B5(O".^EKW,S=89N7E=I,W-T-PIS'"JM"_SI^EV[:2$TWU/&378I
M_4906G!;!J,+.?"3,.!1KKS:"COC!M2$M0!A;29=&8/1T)6%TL!(1!A)30>&
MW$>ZZB%R.>UJ&L3-X)-M:U9"BL^0*;\L.XQUK41!Y6@*Z0P>O;1O?YR<9EF^
M% ("K$;L&Z >=//3;T$21L]Y>$WX<Q+^9JI;F[QT,)*\D0RT+P5?T".$MG+9
M/.V&HT?W&"1>5WNXV42MR3?B?C6\2P^!TNG,MQD5=(AU<5XV!X-:#D(LO.@H
M\!1[)7,%$/%!>(D/7A%<!LS9P6;6OJ> S#BA1XB$W!G+7P<=O+WVJ1 SHB$Z
M82"[CN2:8@-<T@ ;!)C"06_8 DFM<4T6Y93-9Q6JSG'^E;B<&RN&\M-A&4[B
M#='2R.J![9[@SI^4*L"+P]@*N>@'V%"/OF2@P9Y WVAO]Q.&BO%G#?IWZQ,B
MZ:75%J;<^($N(9^.0'#AG6'[$$^>@=\8)=0AG!/-AF-@)[T4[*0[!G;2$-_A
MI]+I)Y&*8SMJE ZZ&P,;U85YS.(Y6!=*LQG,%Q.GM(L#*/B&<9*5X-K7R?6=
M@SJY7L-RK%ONDL;83)5AYH@V1 ^AI%4ZO7/28%%3M4U.R"_E)"3#$3?.S VT
MJ[2U+!V+T5$1-IE<]P2T2.6A*(;O0]FUE4@GW[(>&EVRA6#S:%41^JH;:60M
M;\0A/Q#]05JD6AC5..!"UBZHFW"T34L'-?D@/1I&JLF]!/.Y)$^ *8$9![):
M"1$L_+#JMIY*MNBT@X9GY!R*AT"PR']#+/VU<D2LD*Q1+W1&^EC2K2?PU*YZ
M"/1%O-9,J08VN+Y=(%G[7L^1#YN=CR4N89K,.B9T5D</2["1\XK,([[*4,^2
MR#*\]MACAF7$%)=$2U R@@?5,^ER="9+9,#4,LNF&-/P8'Y$87I53:AS$NJ;
MI%/,Q+M>>9AIIA1HUO!KO(,T"&;/$;&?TQ@+GF6!KVR8M(VHFHT^#'0=@7VW
M8AN2SF![H*D\]M<0:K7\SEL:H(?&*#+6Q[:9]I:[R1P_A_7D*OSA( @HR%-9
M0;(IHJBY=%XNW4QKDV%Z]< AZ@K13-K#4E:GCT-G&[DX04BS9QLZ=)>!2TV8
M8U+"!,1X:6>41=3<AYC"5N']^Q(;ZA *:8I9UI==JP'%++TX>M1^$8-EE[^D
M)ORY"7\S*5\+05!%64<U%?/4%LH")+"9-, E,5GK6S8U(\KZW\Q4-)XHULAW
M!E!1?X2 ["%\C9;O?2+UWURZCLSA<>@VXWS6Q#:OW[:9Z>+38B@ 2VA-![Q=
M1-NA<EB$&0^5;BO;<? 4>VYJI^E0S$6[?:;#+PWS6=M7X?U(W,8RC<P$Z0^^
MAJA)OWI!1T7F6WUO7=UJU=O2!#';!-;A^<D_J&=5+$#/FTG.)^3M4&%W:LEQ
M#303.+M?-FP#%813[#^#YO)H(AG-FAI1[!'' 3#-6:&T(FY_?O!$%KXHQ-E0
MK8.#AG5?^#R>'V.:%]*D$@Z 1*G<R"#$](MPXHK^;7XU*U _EOEZ<@24Z*M\
MWF)ZCFB!4]U]Q>FDPSJ=M+&]FA-/.CWDYM&']*RGB9SV/[Z=?SZ_$Z<O/TUA
MZD);NS,O<^O4!)QN,2IJ%&64$_-O30UV)FX8??#(;-@)O"[J%A"SG8JIPSE>
M8/%9BE]Y,%_^[5_4?)I,#(6=WB@"L]CWSR0"XW0T Y^V*C@N::$7P1E*6%B#
MKBF0S\!U&B)V/1J<%Q)<!@BT4/[O_P96)C3Q'^4OC+=[01!FGD?TB&U>/A*S
M-\+:N<\&6?X,M%A#L,N",1,PFQ"U-0*"#AY]>XK#)QRIVL_N'%"=#B:-XOX4
M ZHF[Q>CBKW71-X@/0-/)8.&")-.A_+\T; OO9@(W2+KM(1L-.2*_Y0*MRCT
MK%'3B?:W7Y#FF^*'_,6I*<H:-:P1K8AZ!(\N="GIG%C-$*NBH_W7Q!".#(<J
MK9 .L;V B9F_T#0-[NV#=))DP$E0(-[)5$Y3L$<<?6(8HYHT5W6B!Z^%-+\A
M-:* )+)\=(>**8\".]3?PH7-/9#:!%WQ*Z;>:K[:!ZD*$ARH9B*=+CE:7M-D
M>I2'KX4FSQ(:\(-]]0'-9N<2P2C&*;=#Q3WY080='E*/[.K(Z*>*GZ!"T96#
MH29TN$QA9XL,1[7$7-6A'KT6ZOR!KE(F(WFNLQ. M1O64G#]QW/\6NB,I"!2
M6#<(0LMA(I@3#1+C!<D#DAV6U-'  NGT&[6 6\MY57&,_?,(+U:>&O8#!"NK
M26H=)U'%^? +O<CMHU)#HJEAZ#X04%8LW?!19J"*:K+RK EN91'VW=="<3_R
MGFR',J^,>P2T^-.KI=CJB.K5Y&W.C4_*8,*9@SI05$3M*9!MA#W.E_1E[/3)
M?LN-Y([@E2F:P@% [A0#N6="?CR#6C'J9ZUXUT&RKR87\X<53>;6^[[$%E4$
M&D3/ ;P&4,19)1729^)C[VJD!NX.SR99NK3<*(J:MSCB\ULMCKB0) ZIN\E4
M V[7I1(O7ME91?TZLT^ >02,J*&5YC'!C#@'/-DA:.B?(%!7X+GZUP,W#$G3
M#H-'++F.^LI[H#GNEO%'FMN7 ^51JU'8DWK<F9<2:Z.V$)=Y[E54K3-0JQ,D
MH45W71?H$6< L'N!?6E(:<&CQPF)),29 -C2&0;)/?6[6A3NUM[NJ@^PBL4$
M,R8;*!87N!Y6"8!7L##IO,QKY<J;]X^:>\8TQ>8I/_ZXHS\K%@[#?P=[S:.#
M&=[;KN/&1\Y8*5\#0KU(!?_I3JNNX-] 0*BW*MFK6(LS;^%-%JFD$8W4?L U
MP6!R>!Y/(? C]-BYU0F'.TC'8]NUMBS6>9)5K+N9H3=G,(Q'NIXF#AZ5ER,J
M#D%*/\*F/JZ]X4O386A= AO&T2X:=;BFNI6>7Q7K:::O^HN;V;*Q&T6)$OW
MZSY5.B.V](4<+<\PMZW!+MLUD2WEN*I83#.K:(ND[\8R'&75@K: JZ752H^D
MBL4Q,WK?=B$J%Z&F5:<YC1E3DWQLFJ<PAE@3TU*.I8IE,=-7?=</*!2(4^Q,
M5(=L^[0ABI#%LZ T@>;'RL_E@$4GP=IHX0<,?01$%T6,CD6$AYBJ(Q$_!D2
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M N=GKC0CJRZ8:,<NLD9K@^E60-+A0'JY+=<?674(F%S/FVK\?U-$ &)I,/!
M"J"AR^9=G^9CDI+A69F(5X S<>A=I!@I&3:763#R"H]G;\[C8<R<2+O[.*V
M,)@M\]0+.IV1EM'Y ^Q*=UI$OE;W;TG=(Z^SO9@&X9ENR/843+1F!@&.PC'^
M$%_6T%=GM-?#(0)ZRF^H"N07/[H4N1\3$[75^5('NIFE.M]Q0HS3QXD9MMCZ
MB8!-6'VC_20+C5CW3^/*:@MS<0NS_58M3-![XCK <&%4]\O4T4'Z_I;'1F%H
MA> 1BVAP&*5).AZXNV0!I_-V>""7U8=@@[/7>JZ.^:6K_CLV9-E-S)'5-^HK
MT&J:]*C^3ZZI_Z"NS]_9J^OS-[8^_^"(2/.EQ>$A]=RL0+3L-G</%Q$NZ_9
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M0_#K2-(O"4?AL(R35@?>L2'M?HLMW<QLY5%A&!>*=-U1&,2Z0L<4)V'=2J/
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MHZ$$";_W;CI5@0GY?IWO-J98,VML0J;FE9[:<^5M11W$EY)N53JMF@QK,JS
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MO"(+6.6!>(H%0I%0$9(O9X!S\]'A&3@T6(8.BC^'BV*Y"B\)I=> FSI]Z:/
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MFOAX*8:@6VD*,!</M Z6LY95';*I2)A;1P$A$POH8HRT1-!\KL\J5*"9AZS
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M!@QS2V+M7V^LOF*;SH[04*Z!"2B1>H(I4]KYB;\JQ&IY99CN[2D?Y;+C27>
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ME3^0VL2A0G]=)Y-%[28@1>6*B!%.G:JUM.!ZE*/45DI#7-1118CD.<<!FZ;
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M#VPP8GW";?C'Z_5LRS8=%G#3R7C!T"=+'/'K'KITX>D4OHA=VL(U#/OFF,.
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MP$SY*_)!D*L>37.;J\'G+4A,1V(9!IBX%+G*R:;\[;G>0-I@"S2^+KGBR4V
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M05 EL:#XISM\Y3,=!O6EVY!H#O9TI')<;5F10H\":G\V;4=EL=H3?HT:6@;
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M6_5W#)X!=\-%72QE&\*]/L(&J -B_P0N$42@1FL^ _Z@7'SQ$=1<YGHA[JJ
M(WA_QX,KP(CQ\8V ,Z K^S8!)+P>GL =;H5X%][B@VQYF3);G TA$EI$. @
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M+V"J_O,<7OS(21<BY2E<Q$MK,')0Q&^+33_^C+J/U(YQ(J#6>#!Y,3Y7!BU
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MM^=PZ :#-W%SL;>EM%]?RTW!7_^#,/D*4$L#!!0    ( )"%:E35OBD,/P@
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M2K"TN/(?P:6F>&1:)9:>!D>S5#)XZXCN H\"#(M!"VW,B5B><;+V6,I92HV
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M:;-&/CDP0TEJB8#T1^!#+Q[:$^Z0KMR/3SME25TADY_17=U!'_1-1-.M.>J
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M2P$"% ,4    " "0A6I4)(87/+,-   WO0  %0              @ &F$0
M871X<RTR,#(Q,3(S,5]C86PN>&UL4$L! A0#%     @ D(5J5+^Y; 6M,@
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M,2YH=&U02P$"% ,4    " "0A6I4U;XI##\(   4)@  &
M@ &0<0< 871X<RTR,#(Q,3(S,7AE>#,Q9#$N:'1M4$L! A0#%     @ D(5J
M5#;I1$BQ"   O"P  !@              ( !!7H' &%T>',M,C R,3$R,S%X
M97@S,60R+FAT;5!+ 0(4 Q0    ( )"%:E3\)J)4.@4  )P3   8
M      "  >R"!P!A='AS+3(P,C$Q,C,Q>&5X,S)D,2YH=&U02P$"% ,4
M" "0A6I4IS_PD(L%  #)%@  &               @ %<B < 871X<RTR,#(Q
M,3(S,7AE>#,R9#(N:'1M4$L! A0#%     @ D(5J5/[VHHR:$   U4,  !<
M             ( !'8X' &%T>',M,C R,3$R,S%X97@T9#,N:'1M4$L%!@
0   .  X O@,  .R>!P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
